PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Siponkoski, ST; Wilson, L; von Steinbuchel, N; Sarajuuri, J; Koskinen, S				Siponkoski, Sini-Tuuli; Wilson, Lindsay; von Steinbuechel, Nicole; Sarajuuri, Jaana; Koskinen, Sanna			QUALITY OF LIFE AFTER TRAUMATIC BRAIN INJURY: FINNISH EXPERIENCE OF THE QOLIBRI IN RESIDENTIAL REHABILITATION	JOURNAL OF REHABILITATION MEDICINE			English	Article						health-related quality of life; traumatic brain injury; rehabilitation; outcome assessment; psychometrics	SATISFACTION; HEALTH; OUTCOMES; DISABILITY; DEPRESSION; VALIDITY; ADULTS; SCALE; SF-36	Objective: To evaluate health-related quality of life of traumatic brain injury patients who have received intensive multidisciplinary residential rehabilitation. To examine the psychometric characteristics of the Finnish Quality of Life after Brain Injury (QOLIBRI) questionnaire. Subjects: A total of 157 adults with TBI, up to 15 years post-injury, who had been treated in the Kapyla Rehabilitation Centre, Helsinki, Finland. Methods: Functional status was assessed using the Extended Glasgow Outcome Scale. Emotional state was evaluated using the Hospital Anxiety and Depression Scale. Health-related quality of life was measured using a generic measure (Short Form-36) and the QOLIBRI. Results: Quality of life was related to depression, amount of help needed, anxiety, education level and age at injury. Quality of life was not associated with time since injury, but a paradoxical relationship was found with injury severity. Internal consistency (alpha = 0.79-0.95) and test-retest reliability (rtt = 0.75-0.87) of the Finnish QOLIBRI met standard psychometric criteria. Conclusion: Quality of life remained relatively stable in the long term. Milder injuries were associated with lower life satisfaction, and careful follow-up is recommended to target patients in special need. This study confirms the reliability and validity of the Finnish QOLIBRI.	[Siponkoski, Sini-Tuuli; Sarajuuri, Jaana; Koskinen, Sanna] Kapyla Rehabil Ctr, FIN-00251 Helsinki, Finland; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [von Steinbuechel, Nicole] Univ Gottingen, Dept Med Psychol & Med Sociol, Gottingen, Germany		Siponkoski, ST (corresponding author), Kapyla Rehabil Ctr, Nordenskioldinkatu 18 B,Box 103, FIN-00251 Helsinki, Finland.	stsipo@gmail.com	Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019; Sarajuuri, Jaana/AAD-8665-2019	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Sarajuuri, Jaana/0000-0002-6432-0295; Koskinen, Sanna/0000-0002-3453-5084; Siponkoski, Sini-Tuuli/0000-0001-8078-3620			Anagnostopoulos F, 2009, QUAL LIFE RES, V18, P53, DOI 10.1007/s11136-008-9423-5; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P93; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacobsson LJ, 2011, NEUROPSYCHOL REHABIL, V21, P383, DOI 10.1080/09602011.2011.566711; Jones JM, 2011, PSYCHOL HEALTH, V26, P353, DOI 10.1080/08870440903440699; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kim YJ, 2011, J CLIN NURS, V20, P1518, DOI 10.1111/j.1365-2702.2010.03618.x; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Power M, 2005, QUAL LIFE RES, V14, P2197, DOI 10.1007/s11136-005-7380-9; Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Sasse N, 2012, J HEAD TRAUMA REHABI; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	27	27	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					835	842		10.2340/16501977-1189			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500021	24002322	gold, Green Published, Green Submitted			2022-02-06	
J	Cohen-Yeshurun, A; Willner, D; Trembovler, V; Alexandrovich, A; Mechoulam, R; Shohami, E; Leker, RR				Cohen-Yeshurun, Ayelet; Willner, Dafna; Trembovler, Victoria; Alexandrovich, Alexander; Mechoulam, Raphael; Shohami, Esther; Leker, Ronen R.			N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cannabinoids; immunohistochemistry; neural stem cells; neuroregeneration	CLOSED-HEAD-INJURY; GROWTH-FACTOR; SUBVENTRICULAR ZONE; STIMULATES NEUROGENESIS; CELLULAR PROLIFERATION; CELLS; MIGRATION; PATHOPHYSIOLOGY; ENDOTHELIUM; HIPPOCAMPUS	N-arachidonoyl-L-serine (AraS) is a novel neuroprotective endocannabinoid. We aimed to test the effects of exogenous AraS on neurogenesis after traumatic brain injury (TBI). The effects of AraS on neural progenitor cells (NPC) proliferation, survival, and differentiation were examined in vitro. Next, mice underwent TBI and were treated with AraS or vehicle. Lesion volumes and clinical outcome were evaluated and the effects on neurogenesis were tested using immunohistochemistry. Treatment with AraS led to a dose-dependent increase in neurosphere size without affecting cell survival. These effects were partially reversed by CB1, CB2, or TRPV1 antagonists. AraS significantly reduced the differentiation of NPC in vitro to astrocytes or neurons and led to a 2.5-fold increase in expression of the NPC marker nestin. Similar effects were observed in vivo in mice treated with AraS 7 days after TBI. These effects were accompanied by a reduction in lesion volume and an improvement in neurobehavioral function compared with controls. AraS increases proliferation of NPCs in vitro in cannabinoid-receptor-mediated mechanisms and maintains NPC in an undifferentiated state in vitro and in vivo. Moreover, although given at 7 days post injury, these effects are associated with significant neuroprotective effects leading to an improvement in neurobehavioral functions.	[Cohen-Yeshurun, Ayelet; Trembovler, Victoria; Alexandrovich, Alexander; Mechoulam, Raphael; Shohami, Esther] Hebrew Univ Jerusalem, Fac Med, Inst Drug Res, Jerusalem, Israel; [Cohen-Yeshurun, Ayelet; Leker, Ronen R.] Hadassah Hebrew Univ Med Ctr, Dept Neurol, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Comprehens Stroke Ctr, IL-91120 Jerusalem, Israel; [Willner, Dafna] Hadassah Hebrew Univ Med Ctr, Dept Anesthesiol, IL-91120 Jerusalem, Israel		Leker, RR (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Neurol, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Comprehens Stroke Ctr, POB 12000, IL-91120 Jerusalem, Israel.	leker@hadassah.org.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA-9789]; Brettler Center for Research in Molecular Pharmacology and Therapeutics; HU School of Pharmacy; Peritz and Chantal Scheinberg Cerebrovascular Research Fund; Sol Irwin Juni Trust Fund; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA009789] Funding Source: NIH RePORTER	This study was supported by NIH Grant No. DA-9789, a grant from the Brettler Center for Research in Molecular Pharmacology and Therapeutics, the HU School of Pharmacy, The Peritz and Chantal Scheinberg Cerebrovascular Research Fund and the Sol Irwin Juni Trust Fund. ES is the incumbent of the Dr. Leon and Mina Deutch Chair in Psychopharmacology at the Hebrew University.	Aguado T, 2005, FASEB J, V19, P1704, DOI 10.1096/fj.05-3995fje; Aguado T, 2006, J NEUROSCI, V26, P1551, DOI 10.1523/JNEUROSCI.3101-05.2006; Ben-Hur T, 2008, J NEUROL SCI, V265, P102, DOI 10.1016/j.jns.2007.05.007; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2004, MOL PHARMACOL, V66, P204, DOI 10.1124/mol.66.2.204; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lachyankar MB, 1997, EXP NEUROL, V144, P350, DOI 10.1006/exnr.1997.6434; Leker RR, 2009, J NEURAL TRANSM, V116, P1397, DOI 10.1007/s00702-009-0329-3; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Madhavan L, 2008, STEM CELLS, V26, P254, DOI 10.1634/stemcells.2007-0221; McHugh D, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-44; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Merkle FT, 2006, CURR OPIN CELL BIOL, V18, P704, DOI 10.1016/j.ceb.2006.09.008; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Palazuelos J, 2006, FASEB J, V20, P2405, DOI 10.1096/fj.06-6164fje; Palazuelos J, 2012, J BIOL CHEM, V287, P1198, DOI 10.1074/jbc.M111.291294; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Su HX, 2009, J NEUROTRAUM, V26, P67, DOI 10.1089/neu.2008.0656; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	42	27	29	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2013	33	8					1242	1250		10.1038/jcbfm.2013.75			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	193OQ	WOS:000322570000014	23695434	Bronze, Green Published			2022-02-06	
J	Baykara, B; Aksu, I; Buyuk, E; Kiray, M; Sisman, AR; Baykara, B; Dayi, A; Tas, A; Ozdemir, D; Arda, MN; Uysal, N				Baykara, B.; Aksu, I.; Buyuk, E.; Kiray, M.; Sisman, A. R.; Baykara, B.; Dayi, A.; Tas, A.; Ozdemir, D.; Arda, M. N.; Uysal, N.			Progesterone treatment decreases traumatic brain injury induced anxiety and is correlated with increased serum IGF-1 levels; prefrontal cortex, amygdala, hippocampus neuron density; and reduced serum corticosterone levels in immature rats	BIOTECHNIC & HISTOCHEMISTRY			English	Article						amygdala; anxiety; brain injury; corticosterone; hippocampus; IGF-1; prefrontal cortex	DOPAMINERGIC ACTIVITY; MESSENGER-RNA; BEHAVIOR; MICE; FEAR; DYSFUNCTION; EXPRESSION; MECHANISM; EXERCISE; BDNF	Traumatic brain injury (TBI) may cause neuropsychiatric problems, such as anxiety disorder, that have negative effects on cognitive functions and behavior. We investigated the effects of progesterone on traumatic brain injury induced anxiety in 7-day-old rat pups subjected to contusion injury. Progesterone treatment decreased TBI induced anxiety and serum corticosterone levels, and increased serum IGF-1 levels. Moreover, progesterone treatment increased amygdala, prefrontal cortex and hippocampal neuron density. We found a negative correlation between serum corticosterone levels and anxiety tests, and a positive correlation between serum IGF-1 levels and anxiety tests. In addition, progesterone treatment decreased serum corticosterone compared to the controls and sham. Our results indicate that single dose progesterone may be effective for treating anxiety caused by TBI.	[Baykara, B.] Dokuz Eylul Univ, Fac Med, High Sch Phys Therapy & Rehabil, TR-35340 Izmir, Turkey; [Aksu, I.; Kiray, M.; Sisman, A. R.; Dayi, A.; Tas, A.; Ozdemir, D.; Arda, M. N.; Uysal, N.] Dokuz Eylul Univ, Fac Med, TR-35340 Izmir, Turkey; [Buyuk, E.] Albert Einstein Coll Med, Montefiore Med Ctr, Div Reprod Endocrinol & Infertil, Dept Obstet Gynecol & Womens Hlth, New York, NY USA; [Baykara, B.] Dokuz Eylul Univ, Fac Med, Dept Child & Adolescent Psychiat, TR-35340 Izmir, Turkey		Uysal, N (corresponding author), Dokuz Eylul Univ, Sch Med, Dept Physiol, TR-35340 Izmir, Turkey.	nazan.uysal@deu.edu.tr	dayi, ayfer/O-9503-2019; Baykara, Basak/AAC-6504-2019; Baykara, Huseyin Burak/AAH-4898-2020	dayi, ayfer/0000-0002-4102-1399; Baykara, Basak/0000-0002-4178-2235; Baykara, Huseyin Burak/0000-0002-1530-0159; Uysal, Nazan/0000-0002-2348-7427	Dokuz Eylul University Research FoundationDokuz Eylul University [2012.KB.SAG.070]	This work was supported by Dokuz Eylul University Research Foundation Grant no: 2012.KB.SAG.070.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Aksu I, 2012, NEUROSCI LETT, V531, P176, DOI 10.1016/j.neulet.2012.10.045; Albanidou-Farmaki E, 2008, TOHOKU J EXP MED, V214, P291, DOI 10.1620/tjem.214.291; Baykara B., 2012, TURK NEUROSURG; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Brummelte S, 2010, NEUROSCIENCE, V168, P680, DOI 10.1016/j.neuroscience.2010.04.023; De Bellis MD, 2000, BIOL PSYCHIAT, V48, P51, DOI 10.1016/S0006-3223(00)00835-0; DENENBERG VH, 1969, ANN NY ACAD SCI, V159, P852, DOI 10.1111/j.1749-6632.1969.tb12983.x; El-Bakri NK, 2004, GROWTH HORM IGF RES, V14, P388, DOI 10.1016/j.ghir.2004.04.004; Frye CA, 2004, BRAIN RES, V1004, P116, DOI 10.1016/j.brainres.2004.01.020; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Jahng JW, 2010, NEUROSCIENCE, V171, P144, DOI 10.1016/j.neuroscience.2010.08.063; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Klur S, 2009, HIPPOCAMPUS, V19, P800, DOI 10.1002/hipo.20562; Kroboth PD, 1997, PSYCHOPHARMACOL BULL, V33, P297; LeDoux J, 1998, BIOL PSYCHIAT, V44, P1229, DOI 10.1016/S0006-3223(98)00282-0; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; LUO JM, 1989, ENDOCRINOLOGY, V125, P165, DOI 10.1210/endo-125-1-165; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; Mitschelen M, 2011, NEUROSCIENCE, V185, P50, DOI 10.1016/j.neuroscience.2011.04.032; Offen D, 2001, NEUROSCI LETT, V316, P129, DOI 10.1016/S0304-3940(01)02344-8; Ozdemir D, 2012, NEUROSCI LETT, V507, P84, DOI 10.1016/j.neulet.2011.11.059; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.09.004; Porritt MJ, 2005, EXP NEUROL, V192, P226, DOI 10.1016/j.expneurol.2004.11.030; Rosen JB, 1998, PSYCHOL REV, V105, P325, DOI 10.1037/0033-295X.105.2.325; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; SCHMIDT PJ, 1994, J CLIN ENDOCR METAB, V79, P1256, DOI 10.1210/jc.79.5.1256; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Selman PJ, 1997, J REPROD FERTIL, P345; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; Trejo JL, 2008, MOL CELL NEUROSCI, V37, P402, DOI 10.1016/j.mcn.2007.10.016; Uysal N, 2011, NEUROSCI LETT, V505, P273, DOI 10.1016/j.neulet.2011.10.039; Walter B, 2004, J NEUROTRAUM, V21, P1076, DOI 10.1089/0897715041651024; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	41	27	28	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1052-0295	1473-7760		BIOTECH HISTOCHEM	Biotech. Histochem.	JUL	2013	88	5					250	257		10.3109/10520295.2013.769630			8	Biotechnology & Applied Microbiology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Cell Biology	184PP	WOS:000321904800005	23480228				2022-02-06	
J	Corson, K; Denneson, LM; Bair, MJ; Helmer, DA; Goulet, JL; Dobscha, SK				Corson, Kathryn; Denneson, Lauren M.; Bair, Matthew J.; Helmer, Drew A.; Goulet, Joseph L.; Dobscha, Steven K.			Prevalence and correlates of suicidal ideation among Operation Enduring Freedom and Operation Iraqi Freedom veterans	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Suicidal ideation; Depression; Veterans; Primary health care; Mental health; Screening	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; RISK-FACTORS; COMBAT VETERANS; AFGHANISTAN; CARE; VA; DEPRESSION; VALIDITY	Background: We sought to determine the prevalence and correlates of suicidal ideation (SI) among Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans following the Department of Veterans Affairs' (VA) 2007 implementation of required brief SI assessments for veterans who screen positive for depression and post-traumatic stress disorder. Methods: We retrospectively identified OEF/OIF veterans screened for depression using the Patient Health Questionnaire (PHQ-2) between April 2008 and September 2009 at three geographically-distinct VA Medical Centers' primary care or mental health clinics. Veteran responses to a two-item risk assessment tool (VA Pocket Card) or PHQ-9 9th item, administered following a positive depression screen (PHQ-2 > 3), were determined using manual chart review. Generalized estimating equations were used to calculate adjusted odds ratios for demographic and clinical correlates of positive SI assessments. Results: Of 1340 OEF/OIF veterans with positive depression screens, 32.4% reported SI. In multivariate models, odds of SI were lower for non-Hispanic white veterans (AOR=0.68) and greater for those with PHQ-2 >= 5 (AOR=1.87), depression (AOR=1.45), bipolar disorder/schizophrenia (AOR=2.84), and 2 or >= 3 diagnoses (AORs=1.59 and 2.49, respectively). Limitations: Study findings may not be generalizable to non-veteran patient populations and the study does not address the reliability and validity of tools employed for brief suicidal ideation assessment. Conclusions: SI is common among OEF/OIF veterans who receive VA care, perhaps more so among non-white veterans. Targeting veterans with higher PHQ-2 scores for SI assessment should be considered to reduce patient and administrative burden. Published by Elsevier B.V.	[Corson, Kathryn; Denneson, Lauren M.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Dept Psychiat, Portland, OR 97207 USA; [Bair, Matthew J.] Indiana Univ, Dept Med, Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA; [Helmer, Drew A.] Univ Med & Dent New Jersey, Sch Med, Vet Affairs New Jersey Hlth Care Syst, War Related Illness & Injury Study Ctr, Newark, NJ USA; [Goulet, Joseph L.] Yale Univ, Sch Med, Dept Psychiat, West Haven Vet Affairs Med Ctr, New Haven, CT USA; [Dobscha, Steven K.] Portland VA Med Ctr, Portland, OR USA		Corson, K (corresponding author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Dept Psychiat, POB 1034 P3 DEP PC, Portland, OR 97207 USA.	kathryn.corson@va.gov		Goulet, Joseph/0000-0002-0842-804X	Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service ProjectUS Department of Veterans Affairs [DHI-08-096]	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service Project DHI-08-096. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. The funding source had no role in study design; data collection, analysis, or interpretation; or in writing of the manuscript and submission process.	Basham C, 2011, SUICIDE LIFE-THREAT, V41, P287, DOI 10.1111/j.1943-278X.2011.00028.x; Bauer A. M., JOURNAL OF GENERAL I; Borges G, 2008, J AFFECT DISORDERS, V105, P25, DOI 10.1016/j.jad.2007.01.036; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Britton PC, 2012, PSYCHIAT RES, V200, P395, DOI 10.1016/j.psychres.2012.06.036; Bronisch T, 2008, J AFFECT DISORDERS, V108, P135, DOI 10.1016/j.jad.2007.10.010; Bruce ML, 2010, ANN NY ACAD SCI, V1208, P98, DOI 10.1111/j.1749-6632.2010.05697.x; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Department of Veterans Affairs, 2008, REPORT OF THE BLUE R; Department of Veterans Affairs, 2007, OFFICE OF INSPECTOR; Department of Veterans Affairs, 2007, OFFICE OF INFORMATIO; Department of Veterans Affairs, 2008, SUICIDE RISK ASSESSM; Dobscha S. K., GENERAL HOSPITAL PSY; Epidemiology Program, 2012, EPIDEMIOLOGY PROGRAM; Ganzini L., JOURNAL OF GENERAL I; Gaynes BN, 2004, ANN INTERN MED, V140, P822, DOI 10.7326/0003-4819-140-10-200405180-00015; Gibbons RD, 2012, AM J PUBLIC HEALTH, V102, pS17, DOI 10.2105/AJPH.2011.300491; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; Haney E., 2012, VETERANS AFFAIRS EVI; Hawkins EJ, 2010, DRUG ALCOHOL DEPEN, V109, P147, DOI 10.1016/j.drugalcdep.2009.12.025; Hawton K, 2003, AM J PSYCHIAT, V160, P1494, DOI 10.1176/appi.ajp.160.8.1494; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Ilgen MA, 2010, ARCH GEN PSYCHIAT, V67, P1152, DOI 10.1001/archgenpsychiatry.2010.129; Institute of Medicine, 2010, COMMITTEE ON THE INI; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Kashner TM, 1998, MED CARE, V36, P1324, DOI 10.1097/00005650-199809000-00005; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kessler RC, 2005, JAMA-J AM MED ASSOC, V293, P2487, DOI 10.1001/jama.293.20.2487; Kline A, 2011, J NERV MENT DIS, V199, P914, DOI 10.1097/NMD.0b013e3182392917; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; La Bash HAJ, 2009, J INTERPERS VIOLENCE, V24, P231, DOI 10.1177/0886260508317177; Lambert MT, 1997, J MENT HEALTH ADMIN, V24, P350, DOI 10.1007/BF02832668; Lambert MT, 2002, PSYCHIATR SERV, V53, P92, DOI 10.1176/appi.ps.53.1.92; Lemaire CM, 2011, J AFFECT DISORDERS, V130, P231, DOI 10.1016/j.jad.2010.10.021; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lowe B, 2005, J PSYCHOSOM RES, V58, P163, DOI 10.1016/j.jpsychores.2004.09.006; Mann JJ, 2008, J CLIN PSYCHIAT, V69, P23, DOI 10.4088/JCP.v69n0104; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Martin J., 2009, J MENTAL HEALTH COUN, V31, P101, DOI DOI 10.17744/MEHC.31.2.A6338384R2770383; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mills PD, 2011, SUICIDE LIFE-THREAT, V41, P21, DOI 10.1111/j.1943-278X.2010.00012.x; NIELSEN B, 1990, ACTA PSYCHIAT SCAND, V81, P250, DOI 10.1111/j.1600-0447.1990.tb06490.x; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Quan HD, 2002, MED CARE, V40, P675, DOI 10.1097/00005650-200208000-00007; Ramchand R., 2011, THE WAR WITHIN PREVE; Razykov I, 2012, J PSYCHOSOM RES, V73, P163, DOI 10.1016/j.jpsychores.2012.06.001; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Schell T. L., 2008, SURVEY OF INDIVIDUAL; Schinka JA, 2012, AM J PUBLIC HEALTH, V102, pS147, DOI 10.2105/AJPH.2011.300436; Schulberg HC, 2005, ANN FAM MED, V3, P523, DOI 10.1370/afm.377; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sher L, 2011, MIL MED, V176, P601, DOI 10.7205/MILMED-D-11-00026; Stroupe KT, 2010, J REHABIL RES DEV, V47, P781, DOI 10.1682/JRRD.2009.08.0122; Sundararaman R., 2008, SUICIDE PREVENTION A; SUTKER PB, 1995, J PERS ASSESS, V64, P415, DOI 10.1207/s15327752jpa6403_2; Szanto K, 2003, ARCH GEN PSYCHIAT, V60, P610, DOI 10.1001/archpsyc.60.6.610; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Uebelacker L.A., 2011, PRIMARY CARE COMPANI, V13; VA/DoD Evidence Based Practice Guideline Work Group, 2011, VA DOD CLINICAL PRAC; West AN, 2010, J RURAL HEALTH, V26, P301, DOI 10.1111/j.1748-0361.2010.00298.x; Wittkampf KA, 2007, GEN HOSP PSYCHIAT, V29, P388, DOI 10.1016/j.genhosppsych.2007.06.004; Zivin K, 2007, AM J PUBLIC HEALTH, V97, P2193, DOI 10.2105/AJPH.2007.115477	71	27	27	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	JUL	2013	149	1-3					291	298		10.1016/j.jad.2013.01.043			8	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	166XJ	WOS:000320593000038	23531358				2022-02-06	
J	Harris, NG; Nogueira, MSM; Verley, DR; Sutton, RL				Harris, Neil G.; Nogueira, Marcia S. M.; Verley, Derek R.; Sutton, Richard L.			Chondroitinase Enhances Cortical Map Plasticity and Increases Functionally Active Sprouting Axons after Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal sprouting; c-Fos; cortex; CSPG; perineuronal net; plasticity	SPINAL-CORD-INJURY; C-FOS EXPRESSION; EXTRACELLULAR-MATRIX; PERINEURONAL NETS; IMPACT INJURY; INHIBITORY PROTEOGLYCANS; SULFATE PROTEOGLYCANS; ADULT RATS; IN-VITRO; ABC	The beneficial effect of interventions with chondroitinase ABC enzyme to reduce axon growth-inhibitory chondroitin sulphate side chains after central nervous system injuries has been mainly attributed to enhanced axonal sprouting. After traumatic brain injury (TBI), it is unknown whether newly sprouting axons that occur as a result of interventional strategies are able to functionally contribute to existing circuitry, and it is uncertain whether maladaptive sprouting occurs to increase the well-known risk for seizure activity after TBI. Here, we show that after a controlled cortical impact injury in rats, chondroitinase infusion into injured cortex at 30 min and 3 days reduced c-Fos(+) cell staining resulting from the injury alone at 1 week postinjury, indicating that at baseline, abnormal spontaneous activity is likely to be reduced, not increased, with this type of intervention. c-Fos(+) cell staining elicited by neural activity from stimulation of the affected forelimb 1 week after injury was significantly enhanced by chondroitinase, indicating a widespread effect on cortical map plasticity. Underlying this map plasticity was a larger contribution of neuronal, rather than glial cells and an absence of c-Fos(+) cells surrounded by perineuronal nets that were normally present in stimulated naive rats. After injury, chondroitin sulfate proteoglycan digestion produced the expected increase in growth-associated protein 43-positive axons and perikarya, of which a significantly greater number were double labeled for c-Fos after intervention with chondroitinase, compared to vehicle. These data indicate that chondroitinase produces significant gains in cortical map plasticity after TBI, and that either axonal sprouting and/or changes in perineuronal nets may underlie this effect. Chondroitinase dampens, rather than increases nonspecific c-Fos activity after brain injury, and induction of axonal sprouting is not maladaptive because greater numbers are functionally active and provide a significant contribution to forelimb circuitry after brain injury.	[Harris, Neil G.; Nogueira, Marcia S. M.; Verley, Derek R.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu	Verley, Derek/J-4550-2015	Verley, Derek/0000-0002-2670-6568; Harris, Neil/0000-0002-1965-6750	National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS055910]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH NINDS; award no.: NS055910) and the UCLA Brain Injury Research Center.	Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; Benali A, 2008, J NEUROSCI, V28, P12284, DOI 10.1523/JNEUROSCI.1952-08.2008; Bowes C, 2012, P NATL ACAD SCI USA, V109, P2595, DOI 10.1073/pnas.1121604109; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BULLITT E, 1992, BRAIN RES, V580, P172, DOI 10.1016/0006-8993(92)90941-2; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; Carulli D, 2010, BRAIN, V133, P2331, DOI 10.1093/brain/awq145; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen S., 2002, J NEUROTRAUM, V19, P1300; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Dityatev A, 2007, DEV NEUROBIOL, V67, P570, DOI 10.1002/dneu.20361; Frischknecht R, 2009, NAT NEUROSCI, V12, P897, DOI 10.1038/nn.2338; Garcia-Alias G, 2011, J NEUROSCI, V31, P17788, DOI 10.1523/JNEUROSCI.4308-11.2011; Gentet LJ, 2012, NAT NEUROSCI, V15, P607, DOI 10.1038/nn.3051; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Goldenberg-Cohen N, 2005, INVEST OPHTH VIS SCI, V46, P2716, DOI 10.1167/iovs.04-0547; Grimpe B, 2004, J NEUROSCI, V24, P1393, DOI 10.1523/JNEUROSCI.4986-03.2004; Harris N., 2010, J NEUROTRAUM, V27, P1; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Hermann GE, 2009, BRAIN RES, V1273, P72, DOI 10.1016/j.brainres.2009.03.059; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Hrabetov D.A., 2001, J PHYSL, V587, P4029; Ikegami T, 2005, EUR J NEUROSCI, V22, P3036, DOI 10.1111/j.1460-9568.2005.04492.x; Karetko-Sysa M, 2011, EXP NEUROL, V231, P113, DOI 10.1016/j.expneurol.2011.05.022; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lowe AS, 2007, NEUROIMAGE, V35, P719, DOI 10.1016/j.neuroimage.2006.12.014; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; Mingorance A, 2006, FASEB J, V20, P491, DOI 10.1096/fj.05-5121fje; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Nedergaard M, 2012, GLIA, V60, P1013, DOI 10.1002/glia.22288; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; Pawela CP, 2009, NEUROIMAGE, V46, P1137, DOI 10.1016/j.neuroimage.2009.03.004; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Pyka M, 2011, EUR J NEUROSCI, V33, P2187, DOI 10.1111/j.1460-9568.2011.07690.x; Rolls A, 2006, FASEB J, V20, P547, DOI 10.1096/fj.05-4540fje; Rusakov DA, 2001, BIOPHYS J, V81, P1947, DOI 10.1016/S0006-3495(01)75846-8; Saghatelyan AK, 2001, MOL CELL NEUROSCI, V17, P226, DOI 10.1006/mcne.2000.0922; Soleman S, 2012, BRAIN, V135, P1210, DOI 10.1093/brain/aws027; Steinmetz MP, 2005, J NEUROSCI, V25, P8066, DOI 10.1523/JNEUROSCI.2111-05.2005; Stevens B, 2000, SCIENCE, V287, P2267, DOI 10.1126/science.287.5461.2267; Su CK, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-44; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Verley D., 2011, J NEUROTRAUM, V28, p[A, P220]; Wang DF, 2011, J NEUROSCI, V31, P9332, DOI 10.1523/JNEUROSCI.0983-11.2011; Wegner F, 2003, EXP NEUROL, V184, P705, DOI 10.1016/S0014-4886(03)00313-3; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3; Zhao RR, 2011, J NEUROSCI METH, V201, P228, DOI 10.1016/j.jneumeth.2011.08.003	57	27	27	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1257	1269		10.1089/neu.2012.2737			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100006	23517225	Green Published			2022-02-06	
J	Solaiman, O; Singh, JM				Solaiman, Othman; Singh, Jeffrey M.			Hypocapnia in Aneurysmal Subarachnoid Hemorrhage: Incidence and Association With Poor Clinical Outcomes	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						subarachnoid hemorrhage; mechanical ventilation; hypocapnia; hyperventilation; Glasgow Outcome Scale	TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-FLOW; HEAD-INJURY; HYPERVENTILATION; MANAGEMENT; VASOSPASM; HYPOXIA; METABOLISM; GUIDELINES; ISCHEMIA	Background: The impact of hypocapnia on outcome in aneurysmal subarachnoid hemorrhage (SAH) is unclear, although hypocapnia is associated with poor outcome in other brain injuries. We sought to determine the incidence and impact of hypocapnia in mechanically ventilated patients with aneurysmal SAH.Methods: We assembled a retrospective cohort of 102 consecutive mechanically ventilated patients with aneurysmal SAH admitted to an academic neurosurgical intensive care unit (ICU). Ventilation records, arterial blood gas data, and clinical outcomes were reviewed. The primary outcome was 3-month Glasgow Outcome Scale, with secondary outcomes of ICU and hospital mortality and symptomatic vasospasm.Results: Hypocapnia was common (92% of patients had 1 or more PaCO2 measurements <35 mm Hg), with 68% of these measurements occurring while breathing spontaneously with minimal ventilator support. Median duration of hypocapnia was 4 days (interquartile range, 2 to 12). Forty-eight percent of all PaCO2 measurements on a given day were below 30 mm Hg. Unfavorable outcome (Glasgow Outcome Scale <4) occurred in 52 of 89 patients (58.4%). ICU and hospital mortality was 26.5% and 32.4%, respectively, and 34% developed symptomatic vasospasm. Duration of hypocapnia was associated with unfavorable outcome (adjusted odds ratio 1.33 for each additional day of hypocapnia) and symptomatic vasospasm (adjusted odds ratio 1.25 for each additional day of hypocapnia), but not ICU or hospital mortality. These associations appeared robust in sensitivity analyses to address potential misclassification and ascertainment bias.Conclusions: Hypocapnia is common in ventilated patients with aneurysmal SAH, and a significant proportion of this developed spontaneously despite minimal ventilator support. The duration of hypocapnia is independently associated with poor functional outcomes and symptomatic vasospasm. Further study is warranted to confirm a causal link between hypocapnia and poor outcomes, and to confirm whether tight control of PaCO2 might improve outcomes in aneurysmal SAH.	[Solaiman, Othman] Univ Toronto, Toronto Western Hosp, Neurovasc Therapeut Program, Toronto, ON M5T 2S8, Canada; [Singh, Jeffrey M.] Univ Toronto, Dept Med, Interdept Div Crit Care Med, Toronto, ON, Canada		Singh, JM (corresponding author), Univ Hlth Network, 2nd Floor McLaughlin Wing Room 411K, Toronto, ON M5T 2S8, Canada.	jeff.singh@uhn.ca		Singh, Jeffrey/0000-0003-3499-574X			Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS87; Carrera E, 2010, J NEUROL NEUROSUR PS, V81, P793, DOI 10.1136/jnnp.2009.174425; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Efron B., 1993, INTRO BOOTSTRAP; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Graham EM, 1996, NEUROSCI LETT, V218, P29, DOI 10.1016/0304-3940(96)13114-1; Heran NS, 2004, CAN J NEUROL SCI, V31, P80, DOI 10.1017/S0317167100002870; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Jennett B, 1975, J R Coll Physicians Lond, V9, P231; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knuth T., 2005, GUIDELINES FIELD MAN; LEITCH AG, 1980, J APPL PHYSIOL, V49, P52, DOI 10.1152/jappl.1980.49.1.52; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marshall SA, 2010, NEUROSURG CLIN N AM, V21, P291, DOI 10.1016/j.nec.2009.10.010; MATSUDA M, 1990, ACTA NEUROCHIR, V105, P98, DOI 10.1007/BF01669990; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Neumann JO, 2008, INTENS CARE MED, V34, P1676, DOI 10.1007/s00134-008-1123-7; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V31, P338, DOI 10.1001/archneur.1974.00490410086010; PLUM F, 1972, ANN INTERN MED, V76, P328, DOI 10.7326/0003-4819-76-2-328; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; ROUT MW, 1971, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5765.7; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Vannucci RC, 1997, PEDIATR RES, V42, P24, DOI 10.1203/00006450-199707000-00005	32	27	28	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2013	25	3					254	261		10.1097/ANA.0b013e3182806465			8	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	202LJ	WOS:000323217100005	23295268				2022-02-06	
J	Wilson, AG; Pizzo, MJ; Crystal, JD				Wilson, A. George; Pizzo, Matthew J.; Crystal, Jonathon D.			Event-Based Prospective Memory in the Rat	CURRENT BIOLOGY			English	Article							MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; COMPUTERIZED TASK; TIME; PERFORMANCE; COMPLEXITY; DEFICITS; REMEMBER; DEMANDS	People plan to act in the future when an appropriate event occurs, a capacity known as event-based prospective memory [1]. Prospective memory involves forming a representation of a planned future action, subsequently inactivating the representation, and ultimately reactivating it at an appropriate point in the future. Recent studies suggest that monkeys, chimpanzees, and rats display elements of prospective memory [2-5], but it is uncertain if the full sequence (activation-inactivation-reactivation) that occurs in humans also occurs in nonhumans [6-8]. Here, we asked if rats exhibit event-based prospective memory. Rats completed an ongoing temporal-discrimination task while waiting for a large meal. To promote the use of event-based prospective memory, we created an event (tone pulses) that provided information that the meal could be obtained soon. Event-based prospective memory was suggested by the dramatic decline in ongoing-task performance after the event, with excellent performance at other times. To document that the event initiated memory activation, we arranged for the event to occur at novel times. Finally, multiple, repeated presentations of the event on the same day demonstrate that rats inactivate and reactivate the memory representation in an on-demand, event-based fashion. Development of an animal model of prospective memory may be valuable to probe the biological underpinnings of memory disorders [7, 9].	[Wilson, A. George; Pizzo, Matthew J.; Crystal, Jonathon D.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA; [Wilson, A. George] Virginia Tech Caril Res Inst, Roanoke, VA 24016 USA		Crystal, JD (corresponding author), Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.	jcrystal@indiana.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080052]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080052] Funding Source: NIH RePORTER	All procedures were approved by the Institutional Animal Care and Use Committee at Indiana University, Bloomington, and followed the guidelines of the National Research Council Guide for the Care and Use of Laboratory Animals. This work was supported by National Institute of Mental Health grant R01MH080052 to J.D.C.	Aberle I, 2010, DEV PSYCHOL, V46, P1444, DOI 10.1037/a0020718; Beran MJ, 2012, LEARN MOTIV, V43, P192, DOI 10.1016/j.lmot.2012.05.002; Beran MJ, 2012, J EXP PSYCHOL ANIM B, V38, P233, DOI 10.1037/a0027796; Blanco-Campal A, 2009, J INT NEUROPSYCH SOC, V15, P154, DOI 10.1017/S1355617708090127; Blough DS, 1996, J EXP PSYCHOL ANIM B, V22, P118, DOI 10.1037/0097-7403.22.1.118; Carey CL, 2006, J CLIN EXP NEUROPSYC, V28, P536, DOI 10.1080/13803390590949494; CHURCH RM, 1977, J EXP PSYCHOL ANIM B, V3, P216, DOI 10.1037/0097-7403.3.3.216; Craik FI., 1986, HUMAN MEMORY COGNITI, V5, P409; Crystal JD, 2013, BEHAV PROCESS, V93, P39, DOI 10.1016/j.beproc.2012.11.014; Crystal JD, 2012, LEARN MOTIV, V43, P181, DOI 10.1016/j.lmot.2012.05.006; d'Ydewalle G, 2001, AM J PSYCHOL, V114, P411, DOI 10.2307/1423688; Driscoll I, 2005, NEUROPSYCHOLOGY, V19, P28, DOI 10.1037/0894-4105.19.1.28; Einstein, 2007, PROSPECTIVE MEMORY O; Einstein GO, 1997, PSYCHOL AGING, V12, P479, DOI 10.1037/0882-7974.12.3.479; Evans TA, 2012, COGNITION, V125, P131, DOI 10.1016/j.cognition.2012.07.012; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Jones S, 2006, NEUROPSYCHOLOGY, V20, P144, DOI 10.1037/0894-4105.20.2.144; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5; Raskin SA, 2011, NEUROPSYCHOLOGY, V25, P201, DOI 10.1037/a0020999; Roberts WA, 2002, PSYCHOL BULL, V128, P473, DOI 10.1037//0033-2909.128.3.473; Schmitter-Edgecombe M, 2009, NEUROPSYCHOLOGY, V23, P168, DOI 10.1037/a0014186; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Troyer AK, 2007, J INT NEUROPSYCH SOC, V13, P365, DOI 10.1017/S1355617707070452; Wilson AG, 2012, ANIM COGN, V15, P349, DOI 10.1007/s10071-011-0459-5; Woods SP, 2009, J INT NEUROPSYCH SOC, V15, P42, DOI 10.1017/S1355617708090012	28	27	27	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0960-9822			CURR BIOL	Curr. Biol.	JUN 17	2013	23	12					1089	1093		10.1016/j.cub.2013.04.067			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	168CH	WOS:000320682800023	23727093	Green Accepted, Bronze			2022-02-06	
J	Leunissen, I; Coxon, JP; Geurts, M; Caeyenberghs, K; Michiels, K; Sunaert, S; Swinnen, SP				Leunissen, Inge; Coxon, James P.; Geurts, Monique; Caeyenberghs, Karen; Michiels, Karla; Sunaert, Stefan; Swinnen, Stephan P.			Disturbed cortico-subcortical interactions during motor task switching in traumatic brain injury	HUMAN BRAIN MAPPING			English	Article						bimanual coordination; cognitive control; fMRI; task switching; traumatic brain injury	RESPONSE-INHIBITION; COGNITIVE CONTROL; BASAL GANGLIA; WORKING-MEMORY; WHITE-MATTER; BIMANUAL COORDINATION; EXECUTIVE DYSFUNCTION; REACTION-TIME; NEURAL BASIS; HEAD-INJURY	The ability to suppress and flexibly adapt motor behavior is a fundamental mechanism of cognitive control, which is impaired in traumatic brain injury (TBI). Here, we used a combination of functional magnetic resonance imaging and diffusion weighted imaging tractography to study changes in brain function and structure associated with motor switching performance in TBI. Twenty-three young adults with moderate-severe TBI and twenty-six healthy controls made spatially and temporally coupled bimanual circular movements. A visual cue signaled the right hand to switch or continue its circling direction. The time to initiate the switch (switch response time) was longer and more variable in the TBI group and TBI patients exhibited a higher incidence of complete contralateral (left hand) movement disruptions. Both groups activated the basal ganglia and a previously described network for task-set implementation, including the supplementary motor complex and bilateral inferior frontal cortex (IFC). Relative to controls, patients had significantly increased activation in the presupplementary motor area (preSMA) and left IFC, and showed underactivation of the subthalamic nucleus (STN) region. This altered functional engagement was related to the white matter microstructural properties of the tracts connecting preSMA, IFC, and STN. Both functional activity in preSMA, IFC, and STN, and the integrity of the connections between them were associated with behavioral performance across patients and controls. We suggest that damage to these key pathways within the motor switching network because of TBI, shifts the patients toward the lower end of the existing structure-function-behavior spectrum. Hum Brain Mapp, 2013. (c) 2012 Wiley Periodicals, Inc.	[Leunissen, Inge; Coxon, James P.; Geurts, Monique; Caeyenberghs, Karen; Swinnen, Stephan P.] Katholieke Univ Leuven, Res Ctr Movement Control & Neuroplast, Dept Biomed Kinesiol, Motor Control Lab,Grp Biomed Sci, B-3001 Heverlee, Belgium; [Michiels, Karla] Univ Hosp, Dept Phys Med & Rehabil, Louvain, Belgium; [Sunaert, Stefan] Katholieke Univ Leuven, Univ Hosp, Dept Radiol, B-3001 Heverlee, Belgium		Swinnen, SP (corresponding author), Katholieke Univ Leuven, Ctr Movement Control & Neuroplast, Dept Biomed Kinesiol, Tervuursevest 101, B-3001 Heverlee, Belgium.	Stephan.Swinnen@faber.kuleuven.be	Coxon, James/S-1286-2019	Coxon, James/0000-0003-2351-8489; Leunissen, Inge/0000-0002-3977-3620; Caeyenberghs, Karen/0000-0001-7009-6843	Research Program of the Research Foundation, Flanders (FWO)FWO [G. 0483.10, G. 0482.10, G. A114.11]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P6/29]	Contract grant sponsor: The Research Program of the Research Foundation, Flanders (FWO); Contract grant number: G. 0483.10, Levenslijn G. 0482.10, G. A114.11; Contract grant sponsor: The Interuniversity Attraction Poles program of the Belgian federal government; Contract grant number: P6/29.	Alexander MP, 2005, NEUROLOGY, V65, P572, DOI 10.1212/01.wnl.0000172912.07640.92; Amunts K, 1999, J COMP NEUROL, V412, P319, DOI 10.1002/(SICI)1096-9861(19990920)412:2<319::AID-CNE10>3.0.CO;2-7; Aravamuthan BR, 2007, NEUROIMAGE, V37, P694, DOI 10.1016/j.neuroimage.2007.05.050; Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288; Aron AR, 2007, J NEUROSCI, V27, P3743, DOI 10.1523/JNEUROSCI.0519-07.2007; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Baunez C, 2001, EUR J NEUROSCI, V13, P1609, DOI 10.1046/j.0953-816x.2001.01521.x; Blinkenberg M, 1996, J CEREBR BLOOD F MET, V16, P794, DOI 10.1097/00004647-199609000-00004; Brett M., 2002, NEUROIMAGE, DOI 10.1016/S1053-8119(02)90010-8; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Byblow WD, 2000, EXP BRAIN RES, V131, P366, DOI 10.1007/s002219900271; Byblow WD, 1999, HUM MOVEMENT SCI, V18, P281, DOI 10.1016/S0167-9457(99)00012-3; Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85; Carson RG, 1997, Q J EXP PSYCHOL-A, V50, P664, DOI 10.1080/027249897392062; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Clark L, 2007, BIOL PSYCHIAT, V61, P1395, DOI 10.1016/j.biopsych.2006.07.020; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Coxon JP, 2009, J COGNITIVE NEUROSCI, V21, P1193, DOI 10.1162/jocn.2009.21081; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; De Luca C, 2010, J NEUROSCI, V30, P3167, DOI 10.1523/JNEUROSCI.2673-09.2010; Debaere F, 2004, NEUROIMAGE, V21, P1416, DOI 10.1016/j.neuroimage.2003.12.011; Derrfuss J, 2005, HUM BRAIN MAPP, V25, P22, DOI 10.1002/hbm.20127; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Forstmann BU, 2008, J NEUROSCI, V28, P9790, DOI 10.1523/JNEUROSCI.1465-08.2008; Frank MJ, 2007, PHILOS T R SOC B, V362, P1641, DOI 10.1098/rstb.2007.2058; Frank MJ, 2006, NEURAL NETWORKS, V19, P1120, DOI 10.1016/j.neunet.2006.03.006; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Hikosaka O, 2010, TRENDS COGN SCI, V14, P154, DOI 10.1016/j.tics.2010.01.006; Inase M, 1999, BRAIN RES, V833, P191, DOI 10.1016/S0006-8993(99)01531-0; Isoda M, 2007, NAT NEUROSCI, V10, P240, DOI 10.1038/nn1830; Johansen-Berg H, 2004, P NATL ACAD SCI USA, V101, P13335, DOI 10.1073/pnas.0403743101; KELSO JAS, 1995, CHAOS, V5, P64, DOI 10.1063/1.166087; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kenner NM, 2010, J NEUROSCI, V30, P8512, DOI 10.1523/JNEUROSCI.1096-10.2010; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Li CSR, 2008, NEUROIMAGE, V41, P1352, DOI 10.1016/j.neuroimage.2008.04.023; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mani TM, 2007, NEUROCASE, V13, P229, DOI 10.1080/13554790701594862; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; McAllister TW, 2006, BRAIN COGNITION, V60, P189; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Nachev P, 2008, NAT REV NEUROSCI, V9, P856, DOI 10.1038/nrn2478; Nambu A, 2002, NEUROSCI RES, V43, P111, DOI 10.1016/S0168-0102(02)00027-5; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Nichols T, 2005, NEUROIMAGE, V25, P653, DOI 10.1016/j.neuroimage.2004.12.005; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Prodoehl J, 2008, NEUROIMAGE, V39, P956, DOI 10.1016/j.neuroimage.2007.09.027; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; Rieger M, 2003, NEUROPSYCHOLOGY, V17, P272, DOI 10.1037/0894-4105.17.2.272; Rushworth MFS, 2004, TRENDS COGN SCI, V8, P410, DOI 10.1016/j.tics.2004.07.009; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Sosin DM, 1996, BRAIN INJURY, V10, P47; Swinnen SP, 2002, NAT REV NEUROSCI, V3, P350, DOI 10.1038/nrn807; Swinnen SP, 2004, TRENDS COGN SCI, V8, P18, DOI 10.1016/j.tics.2003.10.017; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P181, DOI 10.1017/S1355617710001414; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Verhagen L, 2006, NEUROIMAGE; Wager TD, 2003, NEUROIMAGE, V18, P293, DOI 10.1016/S1053-8119(02)00046-0; Ward NS, 2004, CURR OPIN NEUROL, V17, P725, DOI 10.1097/00019052-200412000-00013; Wenderoth N, 2009, J NEUROPHYSIOL, V102, P302, DOI 10.1152/jn.91090.2008	91	27	27	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2013	34	6					1254	1271		10.1002/hbm.21508			18	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	129QA	WOS:000317855400002	22287257	Green Accepted, Green Published			2022-02-06	
J	Max, JE; Schachar, RJ; Landis, J; Bigler, ED; Wilde, EA; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Hanten, G; Levin, HS				Max, Jeffrey E.; Schachar, Russell J.; Landis, Julie; Bigler, Erin D.; Wilde, Elisabeth A.; Saunders, Ann E.; Ewing-Cobbs, Linda; Chapman, Sandra B.; Dennis, Maureen; Hanten, Gerri; Levin, Harvey S.			Psychiatric Disorders in Children and Adolescents in the First Six Months After Mild Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							POST-CONCUSSIVE SYMPTOMS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RELIABILITY; VALIDITY; IMPAIRMENT; CHILDHOOD; SCHEDULE; OUTCOMES	The objective was to assess the nature, rate, predictive factors, and neurocognitive correlates of novel psychiatric disorders (NPD) after mild traumatic brain injury (MTBI). Children age 5-14 years with MTBI (N=87) from consecutive admissions to five trauma centers were enrolled and studied with semistructured psychiatric interviews soon after injury (baseline), and 70 of these children were assessed again 6 months post-injury. Injury severity; lesion characteristics; pre-injury variables, including psychiatric disorder, family psychiatric history, family functioning, socioeconomic status, psychosocial adversity, and adaptive functioning; and post-injury neurocognitive and adaptive functioning measures were assessed with standardized instruments. NPD occurred in 25 of 70 participants (36%) in the first 6 months after injury. NPD at 6 months was predicted by the presence of frontal white-matter lesions on MRI at 3 months post-injury, and was associated with concurrent decrements on neurocognitive indices of processing speed, expressive language, and intellectual functioning. NPD was not predicted by other indices of severity, pre-injury psychosocial variables, estimated pre-injury academic functioning, or adaptive and executive function decrements 6 months post-injury. These findings suggest that short-term psychiatric morbidity associated with MTBI in children and adolescents may be more common than previously thought and may have readily identifiable neuroimaging and neurocognitive correlates.	[Max, Jeffrey E.] Rady Childrens Hosp, Dept Psychiat, San Diego, CA USA; [Max, Jeffrey E.] Univ Calif San Diego, San Diego, CA 92103 USA; [Schachar, Russell J.] Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Wilde, Elisabeth A.; Hanten, Gerri; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Saunders, Ann E.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75230 USA		Max, JE (corresponding author), Rady Childrens Hosp, San Diego, CA USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	National institute of Mental health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National institute of Mental health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Costello EJ, 1996, ARCH GEN PSYCHIAT, V53, P1137; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Logan Gordon D., 1994, P189; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Semel E., 1995, CLIN EVALUATION LANG, VThird; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wechsler D, 1991, WISC 3 MANUAL; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D., 1999, WESCHLER ABBREVIATED; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	44	27	27	0	12	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2013	25	3					187	197		10.1176/appi.neuropsych.12010011			11	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	215XC	WOS:000324243300036	24026712				2022-02-06	
J	Guyenet, SJ; Nguyen, HT; Hwang, BH; Schwartz, MW; Baskin, DG; Thaler, JP				Guyenet, Stephan J.; Nguyen, Hong T.; Hwang, Bang H.; Schwartz, Michael W.; Baskin, Denis G.; Thaler, Joshua P.			High-fat diet feeding causes rapid, non-apoptotic cleavage of caspase-3 in astrocytes	BRAIN RESEARCH			English	Article						Glia; Astrocytes; Apoptosis; Obesity; Neuron injury; Hypothalamus	POSTNATAL EXCITOTOXIC DAMAGE; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; CELL-DEATH; KAPPA-B; ACTIVATION; OBESITY; MICE	Astrocytes respond to multiple forms of central nervous system (CNS) injury by entering a reactive state characterized by morphological changes and a specific pattern of altered protein expression. Termed astrogliosis, this response has been shown to strongly influence the injury response and functional recovery of CNS tissues. This pattern of CNS inflammation and injury associated with astrogliosis has recently been found to occur in the energy homeostasis centers of the hypothalamus during diet-induced obesity (DIO) in rodent models, but the characterization of the astrocyte response remains incomplete. Here, we report that astrocytes in the mediobasal hypothalamus respond robustly and rapidly to purified high-fat diet (HFD) feeding by cleaving caspase-3, a protease whose cleavage is often associated with apoptosis. Although obesity develops in HFD-fed rats by day 14, caspase-3 cleavage occurs by day 3, prior to the development of obesity, suggesting the possibility that it could play a causal role in the hypothalamic neuropathology and fat gain observed in DIO. Caspase-3 cleavage is not associated with an increase in the rate of apoptosis, as determined by TUNEL staining, suggesting it plays a non-apoptotic role analogous to the response to excitotoxic neuron injury. Our results indicate that astrocytes in the mediobasal hypothalamus respond rapidly and robustly to HFD feeding, activating caspase-3 in the absence of apoptosis, a process that has the potential to influence the course of DIO. (C) 2013 Elsevier B.V. All rights reserved.	[Guyenet, Stephan J.; Nguyen, Hong T.; Hwang, Bang H.; Schwartz, Michael W.; Baskin, Denis G.; Thaler, Joshua P.] Univ Washington, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr, UW Med South Lake Union,Dept Med, Seattle, WA 98109 USA; [Hwang, Bang H.; Baskin, Denis G.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs Puget Sound Hlth Care Syst, Off Res & Dev, Seattle, WA 98108 USA		Thaler, JP (corresponding author), Univ Washington, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr, UW Med South Lake Union,Dept Med, 850 Republican St,Box 358055, Seattle, WA 98109 USA.	guyenet@uw.edu; hongtng@uw.edu; bhhwang@uw.edu; mschwart@uw.edu; baskindg@uw.edu; jpthaler@uw.edu			National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32DK007247, F32DK091989, DK088872, DK017047, P30DK017047, DK068384, DK083042, DK052989]; Department of Veterans Affairs Senior Research Career Scientist Award at the Veterans Affairs Puget Sound Health Care System; Biomedical Research Core Programs Cellular and Molecular Imaging Core of the University of Washington NIH/NIDDK Diabetes Research Center; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK083042, R01DK052989, P30DK035816, P01DK068384, R01DK090320, T32DK007247, P30DK017047, K08DK088872, F32DK091989] Funding Source: NIH RePORTER	This work was supported by a National Institutes of Health (NIH) Fellowship Training Program Award (T32DK007247), an NIH National Research Service Award (F32DK091989) to S.G., an NIH Career Development Award (DK088872), an NIH-funded Diabetes Research Center Pilot and Feasibility award (DK017047) to J.T., the NIH-funded University of Washington Nutrition Obesity Research Center and Diabetes Research Center (Grant P30DK017047 to D.B.), and NIH Grants DK068384, DK083042, and DK052989 to M.S.; This work was also supported by resources from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, including the Merit Review Research Program and the Research Enhancement Award Program. D.B. is the recipient of a Department of Veterans Affairs Senior Research Career Scientist Award at the Veterans Affairs Puget Sound Health Care System. Additional support came from the Biomedical Research Core Programs Cellular and Molecular Imaging Core of the University of Washington NIH/NIDDK Diabetes Research Center.	Acarin L, 2005, J NEUROTRAUM, V22, P189, DOI 10.1089/neu.2005.22.189; Acarin L, 2007, GLIA, V55, P954, DOI 10.1002/glia.20518; Aras R, 2012, BRAIN RES, V1450, P102, DOI 10.1016/j.brainres.2012.02.056; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; De Souza CT, 2005, ENDOCRINOLOGY, V146, P4192, DOI 10.1210/en.2004-1520; EAMSHAW WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI DOI 10.1146/ANNUREV.BI0CHEM.68.1383; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Horvath TL, 2010, P NATL ACAD SCI USA, V107, P14875, DOI 10.1073/pnas.1004282107; Jeon BT, 2012, DIABETES, V61, P1444, DOI 10.2337/db11-1498; Kleinridders A, 2009, CELL METAB, V10, P249, DOI 10.1016/j.cmet.2009.08.013; Lamkanfi M, 2006, J CELL BIOL, V173, P165, DOI 10.1083/jcb.200509092; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; McNay DEG, 2012, J CLIN INVEST, V122, P142, DOI 10.1172/JCI43134; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Moraes JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005045; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Narkilahti S, 2003, EUR J NEUROSCI, V18, P1486, DOI 10.1046/j.1460-9568.2003.02874.x; Oomman S, 2006, BRAIN RES, V1078, P19, DOI 10.1016/j.brainres.2006.01.041; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Petrilli V, 2004, J CLIN INVEST, V114, P1072, DOI 10.1172/JCI200421854; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rohn TT, 2004, EXP CELL RES, V295, P215, DOI 10.1016/j.yexcr.2003.12.029; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Shu IW, 2003, BRAIN RES, V985, P1, DOI 10.1016/S0006-8993(03)02806-3; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Thaler JP, 2012, J CLIN INVEST, V122, P153, DOI 10.1172/JCI59660; Villapol S, 2008, NEUROSCIENCE, V153, P108, DOI 10.1016/j.neuroscience.2008.01.054; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Zhang XC, 2005, EXP NEUROL, V191, P318, DOI 10.1016/j.expneurol.2004.10.011; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043; Zhao XX, 2006, J BIOL CHEM, V281, P29357, DOI 10.1074/jbc.M513105200	36	27	28	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 28	2013	1512						97	105		10.1016/j.brainres.2013.03.033			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	160AG	WOS:000320087800010	23548599	Green Accepted			2022-02-06	
J	Itoh, T; Tabuchi, M; Mizuguchi, N; Imano, M; Tsubaki, M; Nishida, S; Hashimoto, S; Matsuo, K; Nakayama, T; Ito, A; Munakata, H; Satou, T				Itoh, Tatsuki; Tabuchi, Masaki; Mizuguchi, Nobuyuki; Imano, Motohiro; Tsubaki, Masahiro; Nishida, Shozo; Hashimoto, Shigeo; Matsuo, Kazuhiko; Nakayama, Takashi; Ito, Akihiko; Munakata, Hiroshi; Satou, Takao			Neuroprotective effect of (-)-epigallocatechin-3-gallate in rats when administered pre- or post-traumatic brain injury	JOURNAL OF NEURAL TRANSMISSION			English	Article						(-)-Epigallocatechin gallate; Traumatic brain injury; Apoptosis; Green tea treatment; Cerebral function	GREEN TEA POLYPHENOL; CENTRAL-NERVOUS-SYSTEM; IMPROVES CEREBRAL FUNCTION; NEURONAL CELL-DEATH; NEURAL STEM-CELLS; MITOCHONDRIAL DYSFUNCTION; EXPERIMENTAL-ISCHEMIA; OXYGEN RADICALS; DAMAGE; PROTECTS	Our previous study indicated that consuming (-)-epigallocatechin gallate (EGCG) before or after traumatic brain injury (TBI) eliminated free radical generation in rats, resulting in inhibition of neuronal degeneration and apoptotic death, and improvement of cognitive impairment. Here we investigated the effects of administering EGCG at various times pre- and post-TBI on cerebral function and morphology. Wistar rats were divided into five groups and were allowed access to (1) normal drinking water, (2) EGCG pre-TBI, (3) EGCG pre- and post-TBI, (4) EGCG post-TBI, and (5) sham-operated group with access to normal drinking water. TBI was induced with a pneumatic controlled injury device at 10 weeks of age. Immunohistochemistry and lipid peroxidation studies revealed that at 1, 3, and 7 days post-TBI, the number of 8-Hydroxy-2'-deoxyguanosine-, 4-Hydroxy-2-nonenal- and single-stranded DNA (ssDNA)-positive cells, and levels of malondialdehyde around the damaged area were significantly decreased in all EGCG treatment groups compared with the water group (P < 0.05). Although there was a significant increase in the number of surviving neurons after TBI in each EGCG treatment group compared with the water group (P < 0.05), significant improvement of cognitive impairment after TBI was only observed in the groups with continuous and post-TBI access to EGCG (P < 0.05). These results indicate that EGCG inhibits free radical-induced neuronal degeneration and apoptotic death around the area damaged by TBI. Importantly, continuous and post-TBI access to EGCG improved cerebral function following TBI. In summary, consumption of green tea may be an effective therapy for TBI patients.	[Itoh, Tatsuki; Ito, Akihiko; Satou, Takao] Kinki Univ, Fac Med, Dept Pathol, Osaka 5898511, Japan; [Tabuchi, Masaki; Munakata, Hiroshi] Kinki Univ, Fac Med, Dept Biochem, Osaka 5898511, Japan; [Mizuguchi, Nobuyuki] Kinki Univ, Life Sci Res Inst, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Fac Med, Dept Surg, Osaka 5898511, Japan; [Tsubaki, Masahiro; Nishida, Shozo; Matsuo, Kazuhiko; Nakayama, Takashi] Kinki Univ, Fac Pharmaceut Sci, Osaka 5898511, Japan; [Hashimoto, Shigeo] PL Hosp, Dept Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ Hosp, Fac Med, Div Hosp Pathol, Osaka, Japan		Itoh, T (corresponding author), Kinki Univ, Fac Med, Dept Pathol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			Kao Research Council for the Study of Healthcare Science;  [23500629];  [24501009]	This work was supported by Grants-in-Aid for Scientific Research (23500629 and 24501009) and a 2012 research grant of the Kao Research Council for the Study of Healthcare Science. The authors thank Mari Yachi for technical assistance.	Aktas O, 2004, J IMMUNOL, V173, P5794, DOI 10.4049/jimmunol.173.9.5794; Amemiya S, 2005, EUR J PHARMACOL, V516, P125, DOI 10.1016/j.ejphar.2005.04.036; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; CHAN PH, 1985, PROG BRAIN RES, V63, P227; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Herges K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025456; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hong JT, 2000, BRAIN RES BULL, V53, P743, DOI 10.1016/S0361-9230(00)00348-8; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2012, J NEURAL TRANSM, V119, P877, DOI 10.1007/s00702-011-0764-9; Itoh T, 2011, NEUROMOL MED, V13, P300, DOI 10.1007/s12017-011-8162-x; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Itoh T, 2009, NEUROTOX RES, V16, P378, DOI 10.1007/s12640-009-9081-6; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; Jang S, 2010, BRAIN RES, V1313, P25, DOI 10.1016/j.brainres.2009.12.012; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kim CY, 2009, ARCH PHARM RES, V32, P869, DOI 10.1007/s12272-009-1609-z; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Lee H, 2004, J NEUROSCI RES, V77, P892, DOI 10.1002/jnr.20193; Lee SR, 2000, NEUROSCI LETT, V287, P191, DOI 10.1016/S0304-3940(00)01159-9; Lee SY, 2003, BRAIN RES BULL, V61, P399, DOI 10.1016/S0361-9230(03)00139-4; Lin LC, 2007, J AGR FOOD CHEM, V55, P1517, DOI 10.1021/jf062816a; Loren DJ, 2005, PEDIATR RES, V57, P858, DOI 10.1203/01.PDR.0000157722.07810.15; Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x; Mandel SA, 2005, NEUROSIGNALS, V14, P46, DOI 10.1159/000085385; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Nakagawa K, 1999, J AGR FOOD CHEM, V47, P3967, DOI 10.1021/jf981195l; Park JW, 2009, J NEUROSCI RES, V87, P567, DOI 10.1002/jnr.21847; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Sakurai M, 2003, J VASC SURG, V37, P446, DOI 10.1067/mva.2003.100; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Suganuma M, 1998, CARCINOGENESIS, V19, P1771, DOI 10.1093/carcin/19.10.1771; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; Walton KM, 1998, J NEUROCHEM, V70, P1764; Wang XY, 2001, BIOL NEONATE, V79, P172; Weinreb O, 2009, GENES NUTR, V4, P283, DOI 10.1007/s12263-009-0143-4; Weissman L, 2007, NEUROSCIENCE, V145, P1318, DOI 10.1016/j.neuroscience.2006.08.061; Won MH, 2001, NEUROSCI LETT, V301, P139, DOI 10.1016/S0304-3940(01)01625-1; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Yu JX, 2010, FEBS LETT, V584, P2921, DOI 10.1016/j.febslet.2010.05.011	51	27	28	0	13	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564			J NEURAL TRANSM	J. Neural Transm.	MAY	2013	120	5					767	783		10.1007/s00702-012-0918-4			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	131IH	WOS:000317986000007	23180302				2022-02-06	
J	McDonald, S; English, T; Randall, R; Longman, T; Togher, L; Tate, RL				McDonald, Skye; English, Therese; Randall, Rebekah; Longman, Thea; Togher, Leanne; Tate, Robyn L.			Assessing Social Cognition and Pragmatic Language in Adolescents with Traumatic Brain Injuries	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Emotion; Theory of mind; Pragmatics; Sarcasm; Brain injury; Adolescence	HEAD-INJURY; FRONTOTEMPORAL DEMENTIA; EMOTION RECOGNITION; ASPERGER-SYNDROME; RIGHT-HEMISPHERE; CHILDREN; MIND; SARCASM; PERCEPTION; CHILDHOOD	Traumatic brain injuries (TBI) in children and adolescents can impair social cognition and communication skills but there are few assessment tools suitable for adolescents. The Awareness of Social Inference Test (TASIT) uses professionally enacted audiovisual vignettes of everyday conversational exchanges and is a valid measure of social perception disorders in adults. This study examined its utility for assessing impairments in social cognition in a group of 16 adolescents with TBI, compared to a group of 16 typically developing (TD) adolescents. Adolescents with TBI were, on average, no different to their TD peers on TASIT 1 (emotion recognition) and TASIT 3 (recognizing lies and sarcasm when provided with additional cues) but performed more poorly on TASIT 2 which required them to interpret sarcastic and sincere conversational exchanges with few cues other than the demeanor of the speakers. Within the TBI group, poor performance on TASIT correlated to both relative and self-reported communication difficulties at home. It also correlated with IQ, face recognition and severity of injury as indexed by duration of post-traumatic amnesia. Overall, this study suggests TASIT is a valid measure for adolescents although it raised questions as to how effective normative data is for comparing performance in social cognition during childhood and adolescence.	[McDonald, Skye; English, Therese; Randall, Rebekah; Longman, Thea; Togher, Leanne; Tate, Robyn L.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia	This research was funded by the National Health and Medical Research Council of Australia. We are grateful to the Prince of Wales Children's Hospital, Brain Injury Unit and the John Hunter Pediatric Brain Injury Service for their assistance with recruitment. We are especially indebted to the young people and their families who participated in this research. The Awareness of Social Inference Test (TASIT) is sold commercially by Pearson Assessment and the first author receives royalties for this. Other than this there are no conflicts of interest.	Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Asher S.R., 1986, CHILDREN SCH, V8, P205; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; BERNDT DJ, 1983, J CONSULT CLIN PSYCH, V51, P627, DOI 10.1037/0022-006X.51.4.627; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Blake ML, 2009, J SPEECH LANG HEAR R, V52, P359, DOI 10.1044/1092-4388(2009/07-0012); Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Cohen J., 2013, STAT POWER ANAL BEHA; DeGroot T, 1999, J APPL PSYCHOL, V84, P986, DOI 10.1037/0021-9010.84.6.986; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Faul M, 2010, TRAUMATIC BRAIN INJU; Fournier NM, 2008, EPILEPSY BEHAV, V12, P460, DOI 10.1016/j.yebeh.2007.12.009; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Kern RS, 2009, PSYCHOL MED, V39, P645, DOI 10.1017/S0033291708003966; Kipps CM, 2009, BRAIN, V132, P592, DOI 10.1093/brain/awn314; KOLB B, 1992, BRAIN COGNITION, V20, P74, DOI 10.1016/0278-2626(92)90062-Q; Kosmidis MH, 2008, BEHAV NEUROL, V19, P65, DOI 10.1155/2008/157356; Kovacs M., 1992, CHILDRENS DEPRESSION; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S., 2011, AWARENESS SOCIAL INF; Morse S, 1999, Pediatr Rehabil, V3, P139; Nixon S.J., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [DOI 10.1037/10198-001, https://doi.org/10.1037/10198-001]; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; PLACE KS, 1991, DISCOURSE PROCESS, V14, P227, DOI 10.1080/01638539109544783; Rankin KP, 2009, NEUROIMAGE, V47, P2005, DOI 10.1016/j.neuroimage.2009.05.077; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Sparks A, 2010, SCHIZOPHR RES, V122, P172, DOI 10.1016/j.schres.2010.06.011; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Towne R.L., 1993, LANG SPEECH HEAR SER, V24, P100; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; Vicari S, 2000, CORTEX, V36, P31, DOI 10.1016/S0010-9452(08)70834-7; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Wechsler D., 2011, WECHSLER ABBREVIATED; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	57	27	27	0	45	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2013	19	5					528	538		10.1017/S1355617713000039			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	136OB	WOS:000318370100005	23442218				2022-02-06	
J	Peach, RK				Peach, Richard K.			The Cognitive Basis for Sentence Planning Difficulties in Discourse After Traumatic Brain Injury	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						cognition; language disorders; traumatic brain injury; executive functions; attention	CLOSED-HEAD INJURY; COLORED PROGRESSIVE MATRICES; WORKING-MEMORY; NARRATIVE DISCOURSE; LANGUAGE; INTELLIGENCE; SPEECH; PERFORMANCE; IMPAIRMENT; RETENTION	Purpose: Analyses of language production of individuals with traumatic brain injury (TBI) place increasing emphasis on microlinguistic (i.e., within-sentence) patterns. It is unknown whether the observed problems involve implementation of well-formed sentence frames or represent a fundamental linguistic disturbance in computing sentence structure. This study investigated the cognitive basis for microlinguistic deficits in individuals with TBI. Method: Fifteen nonaphasic individuals with severe TBI and 6 age- and education-matched non brain-injured adults participated in this study. Monologic discourse samples were analyzed for pausing patterns, mazes, errors, and abandoned utterances. Measures of cognitive abilities were correlated with the sentence measures. Results: The speakers with TBI produced more pauses between clauses (but not within clauses) as well as more mazes than did the non brain-injured speakers. Significant regression models were built. Raven's Coloured Progressive Matrices (Raven, 1965), a measure associated with working memory, predicted pause behavior, and Likenesses-Differences (Baker & Leland, 1967), a measure of executive function, predicted maze behavior. Conclusions: Sentence planning impairments following TBI are associated with deficient organization and monitoring of language representations in working memory. These findings suggest that the deficits are due to problems in the recruitment and control of attention for sentence planning. These findings bear on sentence processing models that emphasize the activation, organization, and maintenance of language representations for accurate sentence production.	Rush Univ, Chicago, IL 60612 USA		Peach, RK (corresponding author), Rush Univ, Chicago, IL 60612 USA.	richard_k_peach@rush.edu					Baker H., 1967, DETROIT TESTS LEARNI; Boersma P., 2010, PRAAT DOING PHONETIC; BUTTERWORTH B, 1979, BRAIN LANG, V8, P133, DOI 10.1016/0093-934X(79)90046-4; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; Chapman, 2008, SYSTEMATIC ANAL LANG; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Cohen J., 2013, STAT POWER ANAL BEHA; Colom R, 2004, INTELLIGENCE, V32, P277, DOI 10.1016/j.intell.2003.12.002; Conway ARA, 2002, INTELLIGENCE, V30, P163, DOI 10.1016/S0160-2896(01)00096-4; COOPER WE, 1984, LANG SPEECH, V27, P17, DOI 10.1177/002383098402700102; Copland DA, 2000, J MED SPEECH-LANG PA, V8, P1; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Crosson B., 2012, COGNITION ACQUIRED L, P167; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; DeShon RP, 1995, INTELLIGENCE, V21, P135, DOI 10.1016/0160-2896(95)90023-3; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Ellis C, 2009, NEUROREHABILITATION, V24, P255, DOI 10.3233/NRE-2009-0476; FERREIRA F, 1991, J MEM LANG, V30, P210, DOI 10.1016/0749-596X(91)90004-4; GAINOTTI G, 1986, J CLIN EXP NEUROPSYC, V8, P37, DOI 10.1080/01688638608401295; Gernsbacher M. A., 2006, HDB PSYCHOLINGUISTIC, V2nd, P61, DOI DOI 10.1016/B978-012369374-7/50004-3; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Goldman-Eisler F., 1968, PSYCHOLINGUISTICS EX; Goodglass H., 1972, BOSTON DIAGNOSTIC AP; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heitz R. P., 2005, HDB UNDERSTANDING ME, P61; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P369, DOI 10.1080/026990598122502; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; Holland A., 1980, COMMUNICATIVE ABILIT; Holmes V. M, 1988, LANG COGNITIVE PROC, V3, P323; Hough MS, 2003, APHASIOLOGY, V17, P183, DOI 10.1080/02687030244000608; Jennett B, 1981, MANAGEMENT HEAD INJU; Kaplan E, 1983, BOSTON NAMING TEST; KERTESZ A, 1975, BRAIN LANG, V2, P387, DOI 10.1016/S0093-934X(75)80079-4; Kertesz A., 1982, W APHASIA BATTERY TE; Kircher TTJ, 2004, NEUROIMAGE, V21, P84, DOI 10.1016/j.neuroimage.2003.09.041; Kirsner K., 2002, P 9 AUSTR INT SPEECH, P52; Levelt W.J.M., 1989, SPEAKING INTENTION A; LEVELT WJM, 1983, COGNITION, V14, P41, DOI 10.1016/0010-0277(83)90026-4; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lynn R, 2004, INTELLIGENCE, V32, P411, DOI 10.1016/j.intell.2004.06.007; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Martin RC, 2004, COGN NEUROPSYCHOL, V21, P625, DOI 10.1080/02643290342000302; Martin RC, 2001, MEMORY, V9, P261, DOI 10.1080/09658210143000173; McNeil MR, 2000, SCI PRACT NEUROPSYCH, P221; Navarro-Ruiz MI, 2001, CLIN LINGUIST PHONET, V15, P63, DOI 10.3109/02699200109167632; Peach R., 2012, COGNITION ACQUIRED L, P241; Peach R. K., 1990, ANN CONV AM SPEECH L; Peach R. K., 1986, ANN CONV AM SPEECH L; Peach R. K., 2012, COGNITION ACQUIRED L; Raven J, 2000, COGNITIVE PSYCHOL, V41, P1, DOI 10.1006/cogp.1999.0735; Raven J., 1965, RAVENS COLOURED PROG; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rispoli M, 2008, J SPEECH LANG HEAR R, V51, P953, DOI 10.1044/1092-4388(2008/070); SHALLICE T, 1977, NEUROPSYCHOLOGIA, V15, P729, DOI 10.1016/0028-3932(77)90002-1; Shapiro L. P., 2012, COGNITION ACQUIRED L, P61; Smits CHM, 1997, J CLIN PSYCHOL, V53, P687, DOI 10.1002/(SICI)1097-4679(199711)53:7<687::AID-JCLP6>3.0.CO;2-F; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Spreen O., 1977, NEUROSENSORY CTR COM, VRev; SPSS Inc, 2007, SPSS WIND VERS 16 0; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Thordardottir ET, 2002, BRAIN COGNITION, V48, P587, DOI 10.1006/brcg.2001.1422; WECHSLER D, 1973, INSTRUCTION MANUAL W; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	67	27	28	0	19	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY 1	2013	22	2					S285	S297		10.1044/1058-0360(2013/12-0081)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	156LD	WOS:000319822600007	23695905				2022-02-06	
J	Poropatich, R; Lai, E; McVeigh, F; Bashshur, R				Poropatich, Ronald; Lai, Eva; McVeigh, Francis; Bashshur, Rashid			The U.S. Army Telemedicine and m-Health Program: Making a Difference at Home and Abroad	TELEMEDICINE AND E-HEALTH			English	Article						behavioral health; mobile health; cell phone; teleconsultation; synchronous; asynchronous; telemedicine; telehealth; military	TRAUMATIC BRAIN-INJURY; TELEMENTAL HEALTH; SERVICE DELIVERY; MILITARY; TECHNOLOGY	This article highlights the deployment of telemedicine by the U.S. Army through the various echelons of care and in overseas locations, including range and scope of health services provided by telemedicine in a challenging environment. This is followed by a discussion of technological developments advances in mobile communications likely to change the practice of telemedicine in the military from limited fixed-point access to a highly mobile individual with handheld communication devices.	[Poropatich, Ronald; Lai, Eva; McVeigh, Francis] USA, Telemed & Adv Technol Res Ctr, Med Res & Mat Command, Ft Detrick, MD USA; [Poropatich, Ronald] Univ Pittsburgh, Ctr Mil Med Res, Pittsburgh, PA 15219 USA; [Lai, Eva] Johns Hopkins Univ, Baltimore, MD USA; [Bashshur, Rashid] Univ Michigan, Ann Arbor, MI 48109 USA		Poropatich, R (corresponding author), Univ Pittsburgh, Ctr Mil Med Res Hlth Sci, Bridgeside Point 2,Room 410 450 Technol Dr, Pittsburgh, PA 15219 USA.	rkp19@pitt.edu					[Anonymous], 1995, JOINT PUBLICATION, V4-02; [Anonymous], 2010, TELEBEHAVIORAL HLTH; Blank Elizabeth, 2011, J Surg Orthop Adv, V20, P50; Doarn CR, 2012, TELEMED E-HEALTH, V18, P654, DOI 10.1089/tmj.2012.0123; Doarn CR, 2011, TELEMED E-HEALTH, V17, P501, DOI 10.1089/tmj.2011.0088; Doarn Charles R, 2010, Telemed J E Health, V16, P373, DOI 10.1089/tmj.2010.0009; Girard P, 2007, J REHABIL RES DEV, V44, P1017, DOI 10.1682/JRRD.2006.12.0174; Gros DF, 2011, CONTEMP CLIN TRIALS, V32, P122, DOI 10.1016/j.cct.2010.10.003; Hsu J., 2011, 23KM0DPH11 USACHPPM; Jones MD, 2012, PSYCHOL SERV, V9, P132, DOI 10.1037/a0026709; Kosaraju A, 2010, TELEMED J E-HEALTH, V16, P219, DOI 10.1089/tmj.2009.0095; Lam DM, 2008, TELEMED J E-HEALTH, V14, P946, DOI 10.1089/tmj.2008.0018; Mahnke CB, 2011, TELEMED E-HEALTH, V17, P35, DOI 10.1089/tmj.2010.0089; McManus J, 2008, PREHOSP DISASTER MED, V23, P210, DOI 10.1017/S1049023X0006489X; Mines MJ, 2011, AM J OPHTHALMOL, V152, P126, DOI 10.1016/j.ajo.2011.01.028; Morgan AE, 2009, MIL MED, V174, P1055, DOI 10.7205/MILMED-D-04-6308; Morgan Jeffrey, 2012, Stud Health Technol Inform, V173, P294; Nieves JE, 2009, MIL MED, V174, pXXI; Poropatich RK, 2006, TELEMED J E-HEALTH, V12, P396, DOI 10.1089/tmj.2006.12.396; Rand ER, 2009, MIL MED, V174, P1144, DOI 10.7205/MILMED-D-00-2309; Schmidt T, 2011, MIL MED, V176, P1417, DOI 10.7205/MILMED-D-11-00237; Stetz MC, 2011, J CLIN PSYCHOL MED S, V18, P188, DOI 10.1007/s10880-011-9246-3; Yurkiewicz IR, 2012, NEUROLOGY, V79, P1237, DOI 10.1212/WNL.0b013e31826aac33	23	27	27	1	16	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627			TELEMED E-HEALTH	Telemed. e-Health	MAY	2013	19	5					380	386		10.1089/tmj.2012.0297			7	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services	130FR	WOS:000317899200013	23537383	Green Submitted			2022-02-06	
J	Cusimano, MD; Sharma, B; Lawrence, DW; Ilie, G; Silverberg, S; Jones, R				Cusimano, Michael D.; Sharma, Bhanu; Lawrence, David W.; Ilie, Gabriela; Silverberg, Sarah; Jones, Rochelle			Trends in North American Newspaper Reporting of Brain Injury in Ice Hockey	PLOS ONE			English	Article							CONCUSSION; CHILDREN; IMPACT; HEAD; NHL	The frequency and potential long-term effects of sport-related traumatic brain injuries (TBI) make it a major public health concern. The culture within contact sports, such as ice hockey, encourages aggression that puts youth at risk of TBI such as concussion. Newspaper reports play an important role in conveying and shaping the culture around health-related behaviors. We qualitatively studied reports about sport-related TBI in four major North American newspapers over the last quarter-century. We used the grounded-theory approach to identify major themes and then did a content analysis to compare the frequency of key themes between 1998-2000 and 2009-2011. The major themes were: perceptions of brain injury, aggression, equipment, rules and regulations, and youth hockey. Across the full study period, newspaper articles from Canada and America portrayed violence and aggression that leads to TBI both as integral to hockey and as an unavoidable risk associated with playing the game. They also condemned violence in ice hockey, criticized the administrative response to TBI, and recognized the significance of TBI. In Canada, aggression was reported more often recently and there was a distinctive shift in portraying protective equipment as a solution to TBI in earlier years to a potential contributing factor to TBI later in the study period. American newspapers gave a greater attention to 'perception of risks' and the role of protective equipment, and discussed TBI in a broader context in the recent time period. Newspapers from both countries showed similar recent trends in regards to a need for rule changes to curb youth sport-related TBI. This study provides a rich description of the reporting around TBI in contact sport. Understanding this reporting is important for evaluating whether the dangers of sport-related TBI are being appropriately communicated by the media.	[Cusimano, Michael D.; Sharma, Bhanu; Lawrence, David W.; Ilie, Gabriela; Silverberg, Sarah; Jones, Rochelle] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Div Neurosurg,Dept Surg,Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada		Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Div Neurosurg,Dept Surg,Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Ilie, Gabriela/AAM-9122-2021; Meijer, Anna/K-5118-2016; Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research # TIR-103946, and the Ontario Neurotrauma Foundation. The authors have completed this study on behalf of the Canadian Brain Injury and Violence Research Team. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali SH, 2006, URBAN STUD, V43, P491, DOI 10.1080/00420980500452458; Anderson C. A., 2007, SAGE HDB SOCIAL PSYC, P296; Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Audit Bureau of Circulations, 2011, AV CIRC TOP 25 US DA; BANDURA A, 1978, J COMMUN, V28, P12, DOI 10.1111/j.1460-2466.1978.tb01621.x; Bauer MW, 2000, QUALITATIVE RES TEXT; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Bergeron LR, 2002, FAM SOC-J CONTEMP H, V83, P547, DOI 10.1606/1044-3894.48; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Boxer P, 2009, J YOUTH ADOLESCENCE, V38, P417, DOI 10.1007/s10964-008-9335-2; Cantor J, 2000, J ADOLESCENT HEALTH, V27, P30, DOI 10.1016/S1054-139X(00)00129-4; Chapman S, 2005, MED J AUSTRALIA, V183, P247, DOI 10.5694/j.1326-5377.2005.tb07029.x; Council on Communications and Media, 2011, Pediatrics, V128, P201, DOI 10.1542/peds.2011-1066; Cusimano MD., 2011, OPEN MED-WARSAW, V5, P57; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Faul M, 2010, TRAUMATIC BRAIN INJU; Gee CJ, 2011, BEHAVIORAL SPORT PSYCHOLOGY: EVIDENCE-BASED APPROACHES TO PERFORMANCE ENHANCEMENT, P199, DOI 10.1007/978-1-4614-0070-7_12; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Herman E., 2002, MANUFACTURING CONSEN; Iyengar S, 1991, IS ANYONE RESPONSIBL; Jordan Amy B, 2008, Adolesc Med State Art Rev, V19, P431; KatE Efilow lowarsfold, 1955, PERSONAL INFLUENCE P; Kepner T, 2012, NY TIMES; Kirsh SJ, 2010, MEDIA YOUTH DEV PERS; LordMaes J, 1996, J LEARN DISABIL, V29, P609, DOI 10.1177/002221949602900605; Lupton D, 1998, SOC SCI MED, V46, P947, DOI 10.1016/S0277-9536(97)10013-2; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McGuire W. J., 2001, PUBLIC COMMUNICATION, P22, DOI DOI 10.4135/9781452233260.n2; Morse JM, 1998, QUAL HEALTH RES, V8, P147, DOI 10.1177/104973239800800201; National Center for Injury Prevention & Control, 2003, REP C MILD TRAUM BRA; Newspapers Canada, 2011, DAIL NEWSP CIRC PROV; Patton M. Q., 2002, QUALITATIVE RES EVAL, P688; Putnam J. M., 2007, American Journal of Health Studies, V22, P130; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Sheldon JP, 2001, RES Q EXERCISE SPORT, V72, P304, DOI 10.1080/02701367.2001.10608965; Smith AM, 2000, AM SOC TEST MATER, V1341, P199, DOI 10.1520/STP15240S; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Strauss A., 1998, BASICS QUALITATIVE R, V2nd Edition; Tesch R, 1991, QUALITATIVE HLTH RES, V1, P309, DOI [DOI 10.1177/104973239100100303, 10.1177/104973239100100303]; Ward-Smith Peggy, 2005, J Neurosci Nurs, V37, P92; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; WIDMEYER WN, 1984, J PSYCHOL, V117, P77, DOI 10.1080/00223980.1984.9923661; Youl PH, 2009, INT J CANCER, V124, P1963, DOI 10.1002/ijc.24154	47	27	27	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e61865	10.1371/journal.pone.0061865			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	130IK	WOS:000317907200095	23613957	Green Published, gold			2022-02-06	
J	Bodart, O; Laureys, S; Gosseries, O				Bodart, Olivier; Laureys, Steven; Gosseries, Olivia			Coma and Disorders of Consciousness: Scientific Advances and Practical Considerations for Clinicians	SEMINARS IN NEUROLOGY			English	Article						unresponsive wakefulness syndrome-vegetative state; minimally conscious state; consciousness; functional magnetic resonance imaging (fMRI); neuroimaging	PERSISTENT VEGETATIVE STATE; CORTICAL EFFECTIVE CONNECTIVITY; REGIONAL CEREBRAL METABOLISM; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; RESTING-STATE; UNRESPONSIVE WAKEFULNESS; FUNCTIONAL CONNECTIVITY; COGNITIVE FUNCTION; DEFAULT NETWORK	Recently, neuroscientists and clinicians have seen the rapid evolution of diagnoses in disorders of consciousness. The unresponsive wakefulness syndrome-vegetative state, the minimally conscious state plus and minus, and the functional locked-in syndrome have been defined using new neuroimaging techniques. Diffusion tensor imaging, positron emission tomography, functional magnetic resonance imaging, electroencephalography, and transcranial magnetic stimulation techniques have all promoted important discoveries in the field of disorders of consciousness. This has led to a better understanding of these patients' condition and to the development of new prognosis, therapeutic, and communication tools. However, low sensitivity and artifacts problems need to be solved to bring these new technologies to the single-patient level; they also need to be studied in larger scale and randomized control trials. In addition, new ethics questions have arisen and need to be investigated.	[Bodart, Olivier; Laureys, Steven; Gosseries, Olivia] Univ Liege, Univ Hosp Liege, Cyclotron Res Ctr, Dept Neurol,Coma Sci Grp, B-4031 Liege, Belgium		Laureys, S (corresponding author), Univ Liege, Cyclotron Res Ctr, Sart Tilman B30,Allee 6 Aout 8, B-4031 Liege, Belgium.	steven.laureys@ulg.ac.be	Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/A-3349-2011; Laureys, Steven/AAN-2097-2021	Gosseries, Olivia/0000-0001-9011-7496; Laureys, Steven/0000-0002-3096-3807	Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Fonds Leon Fredericq; Belgian interuniversity attraction poleBelgian Federal Science Policy Office; James S. McDonnell Foundation; Mind Science Foundation; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; Concerted Research Action [ARC 06/11-340]; Public Utility Foundation "Universite Europeenne du Travail"; Fondazione Europea di Ricerca Biomedica; University of LiegeUniversity of Liege	This work was supported by the Belgian National Funds for Scientific Research (FNRS), Fonds Leon Fredericq, Belgian interuniversity attraction pole, James S. McDonnell Foundation, Mind Science Foundation, European Commission (Mindbridge, DISCOS, DECODER & COST), Concerted Research Action (ARC 06/11-340), Public Utility Foundation "Universite Europeenne du Travail," "Fondazione Europea di Ricerca Biomedica," and the University of Liege. We also thank Erik Ziegler and Francisco Gomez for their help with the illustrations.	Bekinschtein TA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00005; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Babiloni C, 2009, CLIN NEUROPHYSIOL, V120, P719, DOI 10.1016/j.clinph.2009.02.157; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Bekinschtein TA, 2009, P NATL ACAD SCI USA, V106, P1672, DOI 10.1073/pnas.0809667106; Beuthien-Baumann B, 2003, NUCL MED COMMUN, V24, P643, DOI 10.1097/00006231-200306000-00005; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Bruno MA, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-35; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Clauss RP, 2000, S AFR MED J, V90, P68; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; Demertzi A, 2011, J NEUROL, V258, P1058, DOI 10.1007/s00415-010-5882-z; Demertzi A, 2009, PROG BRAIN RES, V177, P329, DOI 10.1016/S0079-6123(09)17722-1; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer C, 2006, CRIT CARE MED, V34, P1520, DOI 10.1097/01.CCM.0000215823.36344.99; Friston KJ, 2011, BRAIN CONNECT, V1, P13, DOI 10.1089/brain.2011.0008; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2006, BRAIN INJURY, V20, P1321, DOI 10.1080/02699050601081802; Godbolt AK, 2012, BRAIN INJURY, V26, P188, DOI 10.3109/02699052.2011.648708; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Gosseries O, 2012, COMA DISORDERS CONSC, P121; Gosseries O, 2011, FUNCT NEUROL, V26, P25; Gosseries O, 2009, NEUROLOGY OF CONSCIOUSNESS: COGNITIVE NEUROSCIENCE AND NEUROPATHOLOGY, P191, DOI 10.1016/B978-0-12-374168-4.00015-0; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Karantanas A, 2000, J NEUROSURG, V92, P896; Larriviere D, 2006, NEUROLOGY, V66, P1624, DOI 10.1212/01.wnl.0000217133.21665.55; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Luaute J, 2005, ARCH PHYS MED REHAB, V86, P917, DOI 10.1016/j.apmr.2004.08.011; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Lule D, 2013, CLIN NEUROPHYSIOL, V124, P101, DOI 10.1016/j.clinph.2012.04.030; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Massimini M, 2010, COGN NEUROSCI-UK, V1, P176, DOI 10.1080/17588921003731578; Monti MM, 2013, HUM BRAIN MAPP, V34, P1245, DOI 10.1002/hbm.21507; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Moreno DR, 2010, NEUROLOGY, V75, P1871, DOI 10.1212/WNL.0b013e3181feb259; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Noe E, 2012, ARCH PHYS MED REHAB, V93, P428, DOI 10.1016/j.apmr.2011.08.048; Norton L, 2012, NEUROLOGY, V78, P175, DOI 10.1212/WNL.0b013e31823fcd61; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Owen AM, 2002, NEUROCASE, V8, P394, DOI 10.1076/neur.8.4.394.16184; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Qin PM, 2010, HUM BRAIN MAPP, V31, P1993, DOI 10.1002/hbm.20989; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Rudolf J, 1999, J NEUROSURG ANESTH, V11, P17, DOI 10.1097/00008506-199901000-00004; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Soddu A, 2011, FUNCT NEUROL, V26, P37; Sorger B, 2012, CURR BIOL, V22, P1333, DOI 10.1016/j.cub.2012.05.022; TEASDALE G, 1974, LANCET, V2, P81; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Tshibanda L, 2009, PROG BRAIN RES, V177, P215, DOI 10.1016/S0079-6123(09)17715-4; Vanhaudenhuyse A, 2008, NEUROLOGY, V71, P1374, DOI 10.1212/01.wnl.0000320110.70134.60; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Vanhaudenhuyse A, 2008, NEUROCRIT CARE, V8, P262, DOI 10.1007/s12028-007-9016-0; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	94	27	30	0	39	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	APR	2013	33	2					83	90		10.1055/s-0033-1348965			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	188VS	WOS:000322225300003	23888393	Green Submitted			2022-02-06	
J	Huang, L; Coats, JS; Mohd-Yusof, A; Yin, YF; Assaad, S; Muellner, MJ; Kamper, JE; Hartman, RE; Dulcich, M; Donovan, VM; Oyoyo, U; Obenaus, A				Huang, Lei; Coats, Jacqueline S.; Mohd-Yusof, Alena; Yin, Yufang; Assaad, Sarah; Muellner, Michael J.; Kamper, Joel E.; Hartman, Richard E.; Dulcich, Melissa; Donovan, Virginia M.; Oyoyo, Udo; Obenaus, Andre			Tissue vulnerability is increased following repetitive mild traumatic brain injury in the rat	BRAIN RESEARCH			English	Article						Concussion; Magnetic resonance imaging; Behavior; Cumulative injury; Gliosis; Rat	PROFESSIONAL FOOTBALL PLAYERS; CLOSED-HEAD INJURY; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; AXONAL INJURY; NEUROLOGICAL IMPAIRMENT; COMPUTED-TOMOGRAPHY; MICE; DEFICITS; SPORTS	Repetitive mild traumatic brain injury (rmTBI) is an important medical concern for active sports and military personnel. Multiple mild injuries may exacerbate tissue damage resulting in cumulative brain injury and poor functional recovery. In the present study, we investigated the time course of brain vulnerability to rmTBI in a rat model of mild cortical controlled impact. An initial mild injury was followed by a second injury unilaterally at an interval of 1, 3, or 7 days. RmTBI animals were compared to single mTBI and sham treated animals. Neuropathology was assessed using multi-modal magnetic resonance imaging (MRI), followed by ex vivo tissue immunohistochemistry. Neurological and behavioral outcomes were evaluated in a subset of animals receiving rmTBI 3 days apart and shams. RmTBI 1 or 3 days apart but not 7 days apart revealed significantly exacerbated MRI-definable lesion volumes compared to single mTBI and shams. Increases in cortical tissue damage, extravascular iron and glial activation assessed by histology/immunohistochemistry correlated with in vivo MRI findings where shorter intervals (1 or 3 days apart) resulted in greater tissue pathology. There were no neurological deficits associated with rmTBI 3 day animals. At 1 mo post-injury, animals with rmTBI 3 days apart showed reduced exploratory behaviors and subtle spatial learning memory impairments were observed. Collectively, our findings suggest that the mildly-impacted brain is more vulnerable to repetitive injury when delivered within 3 days following initial mTBI. (c) 2012 Elsevier B.V. All rights reserved.	[Huang, Lei] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92354 USA; [Huang, Lei] Loma Linda Univ, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; [Coats, Jacqueline S.; Mohd-Yusof, Alena; Yin, Yufang; Assaad, Sarah; Muellner, Michael J.; Obenaus, Andre] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92354 USA; [Kamper, Joel E.; Hartman, Richard E.; Dulcich, Melissa] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA; [Donovan, Virginia M.; Obenaus, Andre] Univ Calif Riverside, Dept Cell Mol & Dev Biol, Riverside, CA 92521 USA; [Oyoyo, Udo] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92354 USA; [Obenaus, Andre] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA		Obenaus, A (corresponding author), Loma Linda Univ, Dept Pediat, 1175 Campus St,CSPA1010, Loma Linda, CA 92354 USA.	aobenaus@llu.edu	Hartman, Richard/C-5767-2008; Kamper, Joel/V-2450-2019	Hartman, Richard/0000-0001-9235-3169; Kamper, Joel/0000-0001-5098-5176	Department of Defense (DCMRP) [DR080470]; National Science Foundation (IGERT: Video Bioinformatics Grant) [DGE 0903667]; Walter E. McPherson Scholarship	This study was supported by funding from Department of Defense (DCMRP #DR080470, AO) and in part by a National Science Foundation (IGERT: Video Bioinformatics Grant DGE 0903667; VMD is an IGERT Fellow) as well as a Walter E. McPherson Scholarship (MJM).	Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lee Bruce, 2005, NeuroRx, V2, P372; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; Masdeu J C, 1994, J Neuroimaging, V4, P177; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Recker R, 2009, J CEREBR BLOOD F MET, V29, P1305, DOI 10.1038/jcbfm.2009.56; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Sousa JC, 2004, J NEUROCHEM, V88, P1052, DOI 10.1046/j.1471-4159.2003.02309.x; Theye Fred, 2004, Clin Med Res, V2, P165; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tokutomi T, 1997, ACT NEUR S, V70, P80; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	51	27	27	0	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 7	2013	1499						109	120		10.1016/j.brainres.2012.12.038			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	113ZX	WOS:000316710300010	23276495				2022-02-06	
J	Liegeois, F; Tournier, JD; Pigdon, L; Connelly, A; Morgan, AT				Liegeois, Frederique; Tournier, Jacques-Donald; Pigdon, Lauren; Connelly, Alan; Morgan, Angela T.			Corticobulbar tract changes as predictors of dysarthria in childhood brain injury	NEUROLOGY			English	Article							WHITE-MATTER INTEGRITY; SPHERICAL DECONVOLUTION; DIFFUSION TRACTOGRAPHY; CHILDREN; SPEECH; PLASTICITY; EPIDEMIOLOGY; PERFORMANCE; OUTCOMES; STROKE	Objectives: To identify corticobulbar tract changes that may predict chronic dysarthria in young people who have sustained a traumatic brain injury (TBI) in childhood using diffusion MRI tractography. Methods: We collected diffusion-weighted MRI data from 49 participants. We compared 17 young people (mean age 17 years, 10 months; on average 8 years postinjury) with chronic dysarthria who sustained a TBI in childhood (range 3-16 years) with 2 control groups matched for age and sex: 1 group of young people who sustained a traumatic injury but had no subsequent dysarthria (n = 15), and 1 group of typically developing individuals (n = 17). We performed tractography from spherical seed regions within the precentral gyrus white matter to track: 1) the hand-related corticospinal tract; 2) the dorsal corticobulbar tract, thought to correspond to the lips/larynx motor representation; and 3) the ventral corticobulbar tract, corresponding to the tongue representation. Results: Despite widespread white matter damage, radial (perpendicular) diffusivity within the left dorsal corticobulbar tract was the best predictor of the presence of dysarthria after TBI. Diffusion metrics in this tract also predicted speech and oromotor performance across the whole group of TBI participants, with additional significant contributions from ventral speech tract volume in the right hemisphere. Conclusion: An intact left dorsal corticobulbar tract seems crucial to the normal execution of speech long term after acquired injury. Examining the speech-related motor pathways using diffusion-weighted MRI tractography offers a promising prognostic tool for people with acquired, developmental, or degenerative neurologic conditions likely to affect speech. Neurology (R) 2013;80:926-932	[Liegeois, Frederique] UCL Inst Child Hlth, Dev Cognit Neurosci Unit, London, England; [Tournier, Jacques-Donald; Connelly, Alan; Morgan, Angela T.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Pigdon, Lauren; Morgan, Angela T.] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Morgan, Angela T.] Univ Melbourne, Royal Childrens Hosp, Melbourne, Vic, Australia; [Morgan, Angela T.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia		Liegeois, F (corresponding author), UCL Inst Child Hlth, Dev Cognit Neurosci Unit, London, England.	F.Liegeois@ucl.ac.uk	Connelly, Alan/A-9065-2013; Liegeois, Frederique/A-6351-2009; Morgan, Angela/J-5235-2017	Connelly, Alan/0000-0001-7159-8079; Morgan, Angela/0000-0003-1147-7405; Liegeois, Frederique/0000-0002-8640-6217	Transport Accident Commission, TAC [D131]; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [607315]; Operational Infrastructure Support Program of the State Government of Victoria	This study was supported by grant D131 from Victorian Neurotrauma Initiative, Australia (now Transport Accident Commission, TAC), awarded to A. T. M., F. L., A. C., and J.-D.T.; and National Health and Medical Research Council grant 607315 awarded to A.T.M.; The authors thank all participants and their families for their time and support. The authors also thank Shawna Farquharson and her team of radiographers for scanning participants. J.-D.T. and A. C. are grateful to the Operational Infrastructure Support Program of the State Government of Victoria for their support.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Hayden D., 1999, VERBAL MOTOR PRODUCT; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kim JS, 2003, NEUROLOGY, V60, P1178, DOI 10.1212/01.WNL.0000055930.28954.E9; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lawes INC, 2008, NEUROIMAGE, V39, P62, DOI 10.1016/j.neuroimage.2007.06.041; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Liegeois F, 2004, BRAIN, V127, P1229, DOI 10.1093/brain/awh159; Liegeois F, 2010, BRAIN LANG, V114, P126, DOI 10.1016/j.bandl.2009.12.004; Liegeois FJ, 2012, NEUROSCI BIOBEHAV R, V36, P439, DOI 10.1016/j.neubiorev.2011.07.011; McCauley RJ, 2008, AM J SPEECH-LANG PAT, V17, P81, DOI 10.1044/1058-0360(2008/007); Morgan AT, 2011, BRAIN LANG, V117, P69, DOI 10.1016/j.bandl.2011.01.002; Morgan AT, 2010, CHILD CARE HLTH DEV, V36, P44, DOI 10.1111/j.1365-2214.2009.00961.x; Northam GB, 2012, J PEDIATR-US, V160, P402, DOI 10.1016/j.jpeds.2011.08.055; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Pan C, 2012, AM J NEURORADIOL, V33, P1274, DOI 10.3174/ajnr.A2952; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Terao Y, 2007, J NEUROL, V254, P442, DOI 10.1007/s00415-006-0385-7; Tournier JD, 2008, NEUROIMAGE, V42, P617, DOI 10.1016/j.neuroimage.2008.05.002; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Urban PP, 1997, BRAIN, V120, P1077, DOI 10.1093/brain/120.6.1077; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Yallampalli R, J NEUROIMAGING	34	27	27	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR	2013	80	10					926	932		10.1212/WNL.0b013e3182840c6d			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	101KI	WOS:000315773500015	23390172	hybrid, Green Published			2022-02-06	
J	Sun, YX; Dai, DK; Liu, R; Wang, T; Luo, CL; Bao, HJ; Yang, R; Feng, XY; Qin, ZH; Chen, XP; Tao, LY				Sun, Yu-Xia; Dai, Ding-Kun; Liu, Ran; Wang, Tao; Luo, Cheng-Liang; Bao, Hai-Jun; Yang, Rui; Feng, Xue-Ying; Qin, Zheng-Hong; Chen, Xi-Ping; Tao, Lu-Yang			Therapeutic effect of SN50, an inhibitor of nuclear factor-kappa B, in treatment of TBI in mice	NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; NF-kappa B; Apoptosis; TNF-alpha; Cathepsin B; Caspase-3	TRAUMATIC BRAIN-INJURY; CELL-DEATH MECHANISMS; INDUCED APOPTOSIS; ACTIVATION; MITOCHONDRIA; NEUROPROTECTION; CONTRIBUTES	NF-kappa B upregulation has been demonstrated in neurons and glial cells in response to experimental injury and neuropathological disorders, where it has been related to both neurodegenerative and neuroprotective activities. It has been generally recognized that NF-kappa B plays important roles in the regulation of apoptosis and inflammation as well as innate and adaptive immunity. However, the regulatory mechanism of NF-kappa B in apoptosis remained to be determined. The present study sought to first investigate the effect of a NF-kappa B inhibitor SN50, which inhibits NF-kappa B nuclear translocation, on cell death and behavioral deficits in our mice traumatic brain injury (TBI) models. Additionally, we tried to elucidate the possible mechanisms of the therapeutic effect of SN50 through NF-kappa B regulating apoptotic and inflammatory pathway in vivo. Encouragingly, the results showed that pretreatment with SN50 remarkably attenuated TBI-induced cell death (detected by PI labeling), cumulative loss of cells (detected by lesion volume), and motor and cognitive dysfunction (detected by motor test and Morris water maze). To analyze the mechanism of SN50 on cell apoptotic and inflammatory signaling pathway, we thus assessed expression levels of TNF-alpha, cathepsin B and caspase-3, Bid cleavage and cytochrome c release in SN50-pretreated groups compared with those in saline vehicle groups. The results imply that through NF-kappa B/TNF-alpha/cathepsin networks SN50 may contribute to TBI-induced extrinsic and intrinsic apoptosis, and inflammatory pathways, which partly determined the fate of injured cells in our TBI model.	[Sun, Yu-Xia; Dai, Ding-Kun; Liu, Ran; Wang, Tao; Luo, Cheng-Liang; Bao, Hai-Jun; Yang, Rui; Feng, Xue-Ying; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Dept Forens Med, Suzhou 215123, Peoples R China; [Qin, Zheng-Hong] Soochow Univ, Lab Aging & Nerves Dis, Dept Pharmacol, Suzhou 215123, Peoples R China; [Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Lab Aging & Nerves Dis, Suzhou 215123, Peoples R China; [Chen, Xi-Ping; Tao, Lu-Yang] Minist Justice, Inst Forens Sci, Shanghai Key Lab Forens Med, Shanghai, Peoples R China		Chen, XP (corresponding author), Soochow Univ, Dept Forens Med, 199 Renai Rd, Suzhou 215123, Peoples R China.	luyang.tao@163.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30571909, 30872666, 30870808, 81172911]; Shanghai Forensic Key Lab Foundation [KF0904, KF1005]	The work was supported by the National Science Foundation of China (No. 30571909, 30872666, 30870808, 81172911) and the Shanghai Forensic Key Lab Foundation (No. KF0904, KF1005).	Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ellen Niederberger, 2010, EXPERT REV PROTEOMIC, V7, P189; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferlazzo N, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-62; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Kim R, 2006, CANCER CHEMOTH PHARM, V57, P545, DOI 10.1007/s00280-005-0111-7; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Luo CL, 2010, NEURAL REGEN RES, V5, P706, DOI 10.3969/j.issn.1673-5374.2010.09.012; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Olga Sanz, 2002, J NEUROSCI RES, V67, P772; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Saika S, 2005, AM J PATHOL, V166, P1393, DOI 10.1016/S0002-9440(10)62357-7; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tao LY, 2003, J FORENSIC MED, V19, P4; Tardy C, 2006, BBA-REV CANCER, V1765, P101, DOI 10.1016/j.bbcan.2005.11.003; Uberti D, 2004, BIOCHEM PHARMACOL, V67, P1743, DOI 10.1016/j.bcp.2004.01.012; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	34	27	28	1	10	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAR	2013	34	3					345	355		10.1007/s10072-012-1007-z			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	098RL	WOS:000315566300011	22437493				2022-02-06	
J	Weber, AF; Mihalik, JP; Register-Mihalik, JK; Mays, S; Prentice, WE; Guskiewicz, KM				Weber, Amanda Friedline; Mihalik, Jason P.; Register-Mihalik, Johna K.; Mays, Sally; Prentice, William E.; Guskiewicz, Kevin M.			Dehydration and Performance on Clinical Concussion Measures in Collegiate Wrestlers	JOURNAL OF ATHLETIC TRAINING			English	Article						balance; mild traumatic brain injury; neurocognitive test; SCAT2	POSTURAL STABILITY; HYDRATION STATUS; WEIGHT-LOSS; HIGH-SCHOOL; URINARY INDEXES; INJURIES; EXERCISE; DEPRIVATION; SYMPTOMS; DURATION	Context: The effects of dehydration induced by wrestling-related weight-cutting tactics on clinical concussion outcomes, such as neurocognitive function, balance performance, and symptoms, have not been adequately studied. Objective: To evaluate the effects of dehydration on the outcome of clinical concussion measures in National Collegiate Athletic Association Division I collegiate wrestlers. Design: Repeated-measures design. Setting: Clinical research laboratory. Patients or Other Participants: Thirty-two Division I healthy collegiate male wrestlers (age = 20.0 +/- 1.4 years; height 175.0 +/- 7.5 cm; baseline mass 79.2 +/- 12.6 kg). Intervention(s): Participants completed preseason concussion baseline testing in early September. Weight and urine samples were also collected at this time. All participants reported to prewrestling practice and postwrestling practice for the same test battery and protocol in mid-October. They had begun practicing weight-cutting tactics a day before prepractice and postpractice testing. Differences between these measures permitted us to evaluate how dehydration and weight-cutting tactics affected concussion measures. Main Outcome Measures: Sport Concussion Assessment Tool 2 (SCAT2), Balance Error Scoring System, Graded Symptom Checklist, and Simple Reaction Time scores. The Simple Reaction Time was measured using the Automated Neuropsychological Assessment Metrics. Results: The SCAT2 measurements were lower at prepractice (P = .002) and postpractice (P < .001) when compared with baseline. The BESS error scores were higher at postpractice when compared with baseline (P = .015). The GSC severity scores were higher at prepractice (P = .011) and postpractice (P < .001) than at baseline and at postpractice when than at prepractice (P = .003). The number of Graded Symptom Checklist symptoms reported was also higher at prepractice (P = .036) and postpractice (P < .001) when compared with baseline, and at postpractice when compared with prepractice (P = .003). Conclusions: Our results suggest that it is important for wrestlers to be evaluated in a euhydrated state to ensure that dehydration is not influencing the outcome of the clinical measures.	[Weber, Amanda Friedline; Mihalik, Jason P.; Register-Mihalik, Johna K.; Prentice, William E.; Guskiewicz, Kevin M.] WakeMed Hlth & Hosp, Dept Exercise & Sport Sci, Matthew A Geller Sport Related Traumat Brain Inju, Raleigh, NC USA; [Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Clin Res Unit, Emergency Serv Inst, Raleigh, NC USA; [Mays, Sally] Univ N Carolina, Chapel Hill, NC 27599 USA		Mihalik, JP (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Mihalik, Jason/0000-0001-6085-8322; Register-Mihalik, Johna/0000-0002-4229-4743; Guskiewicz, Kevin/0000-0002-8682-2130			Agel J, 2007, J ATHL TRAINING, V42, P303; Armstrong LE, 1998, INT J SPORT NUTR, V8, P345, DOI 10.1123/ijsn.8.4.345; ARMSTRONG LE, 1994, INT J SPORT NUTR, V4, P265, DOI 10.1123/ijsn.4.3.265; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Choma CW, 1998, MED SCI SPORT EXER, V30, P746, DOI 10.1097/00005768-199805000-00016; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Jarrett GJ, 1998, AM J SPORT MED, V26, P674, DOI 10.1177/03635465980260051301; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2001, BRIT J SPORT MED, V35, P209, DOI 10.1136/bjsm.35.4.209-a; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Oppliger RA, 2003, INT J SPORT NUTR EXE, V13, P29, DOI 10.1123/ijsnem.13.1.29; Oppliger RA, 2005, INT J SPORT NUTR EXE, V15, P236, DOI 10.1123/ijsnem.15.3.236; Patel AV, 2007, J ATHL TRAINING, V42, P66; Petri NM, 2006, CROAT MED J, V47, P855; Popowski LA, 2001, MED SCI SPORT EXER, V33, P747; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Shirreffs SM, 2004, BRIT J NUTR, V91, P951, DOI 10.1079/BJN20041149; Szinnai G, 2005, AM J PHYSIOL-REG I, V289, pR275, DOI 10.1152/ajpregu.00501.2004; Vicente R., 2004, NCAA SPORTS SPONSORS; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Wroble RR, 1998, MED SCI SPORT EXER, V30, P625, DOI 10.1097/00005768-199804000-00022; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	34	27	28	0	36	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAR-APR	2013	48	2					153	160		10.4085/1062-6050-48.1.07			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	211GP	WOS:000323894300002	23672379	Green Submitted, Bronze, Green Published			2022-02-06	
J	Loov, C; Shevchenko, G; Nadadhur, AG; Clausen, F; Hillered, L; Wetterhall, M; Erlandsson, A				Loov, Camilla; Shevchenko, Ganna; Nadadhur, Aishwarya Geeyarpuram; Clausen, Fredrik; Hillered, Lars; Wetterhall, Magnus; Erlandsson, Anna			Identification of Injury Specific Proteins in a Cell Culture Model of Traumatic Brain Injury	PLOS ONE			English	Article							IN-VITRO MODELS; MEMBRANE; ASSOCIATION; EXPRESSION; MIGRATION; CYTOKINES; PATHWAY; BINDING; FUSION; ACTIN	The complicated secondary molecular and cellular mechanisms following traumatic brain injury (TBI) are still not fully understood. In the present study, we have used mass spectrometry to identify injury specific proteins in an in vitro model of TBI. A standardized injury was induced by scalpel cuts through a mixed cell culture of astrocytes, oligodendrocytes and neurons. Twenty-four hours after the injury, cell culture medium and whole-cell fractions were collected for analysis. We found 53 medium proteins and 46 cell fraction proteins that were specifically expressed after injury and the known function of these proteins was elucidated by an extensive literature survey. By using time-lapse microscopy and immunostainings we could link a large proportion of the proteins to specific cellular processes that occur in response to trauma; including cell death, proliferation, lamellipodia formation, axonal regeneration, actin remodeling, migration and inflammation. A high percentage of the proteins uniquely expressed in the medium after injury were actin-related proteins, which normally are situated intracellularly. We show that two of these, ezrin and moesin, are expressed by astrocytes both in the cell culture model and in mouse brain subjected to experimental TBI. Interestingly, we found many inflammation-related proteins, despite the fact that cells were present in the culture. This study contributes with important knowledge about the cellular responses after trauma and identifies several potential cell-specific biomarkers.	[Loov, Camilla; Nadadhur, Aishwarya Geeyarpuram; Clausen, Fredrik; Hillered, Lars; Erlandsson, Anna] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Shevchenko, Ganna; Wetterhall, Magnus] Uppsala Univ, Dept Chem BMC, Uppsala, Sweden		Erlandsson, A (corresponding author), Uppsala Univ, Dept Neurosci, Uppsala, Sweden.	anna.erlandsson@neuro.uu.se		Hillered, Lars/0000-0002-2808-9292; G Nadadhur, Aishwarya/0000-0003-0468-9135; Clausen, Fredrik/0000-0003-3592-4417	Jeanssons Foundation; Tore Nilssons Foundation; Swedish Society of Medicine [SLS-251631]; Magnus Bergvall foundation [24942*1*2011]; Medical Faculty Foundation for Psychological and Neurological Research at Uppsala University; Uppsala University Hospital	This study was supported by grants from Jeanssons Foundation, Tore Nilssons Foundation, the Swedish Society of Medicine (SLS-251631), Magnus Bergvall foundation (24942*1*2011) and the Medical Faculty Foundation for Psychological and Neurological Research at Uppsala University and Uppsala University Hospital. MW further acknowledges Lars Hiertas Minne Foundation (FO2009-0695) and Signe och Olof Wallenius Foundation (R103). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Campbell J.N., 2011, J NEUROTRAUMA; Castoreno AB, 2005, P NATL ACAD SCI USA, V102, P13129, DOI 10.1073/pnas.0506716102; Chastain EML, 2011, BBA-MOL BASIS DIS, V1812, P265, DOI 10.1016/j.bbadis.2010.07.008; Chen XQ, 2005, J CEREBR BLOOD F MET, V25, P338, DOI 10.1038/sj.jcbfm.9600032; Chianale F, 2010, P NATL ACAD SCI USA, V107, P4182, DOI 10.1073/pnas.0908326107; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Fiedler LR, 2009, BIOCHEM SOC T, V37, P1243, DOI 10.1042/BST0371243; Groves E, 2008, CELL MOL LIFE SCI, V65, P1957, DOI 10.1007/s00018-008-7578-4; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hoffman-Kim D, 2010, ANNU REV BIOMED ENG, V12, P203, DOI 10.1146/annurev-bioeng-070909-105351; Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kang CB, 2008, NEUROSIGNALS, V16, P318, DOI 10.1159/000123041; Korobova F, 2008, MOL BIOL CELL, V19, P1561, DOI 10.1091/mbc.E07-09-0964; Kreipke CW, 2006, MICROVASC RES, V71, P197, DOI 10.1016/j.mvr.2006.02.002; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; Lee SH, 2010, MOL CELLS, V29, P311, DOI 10.1007/s10059-010-0053-8; Loov C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033090; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marion S, 2011, TRAFFIC, V12, P421, DOI 10.1111/j.1600-0854.2011.01158.x; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Moon Y, 2011, NEUROREPORT, V22, P304, DOI 10.1097/WNR.0b013e3283460265; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Peri F, 2008, CELL, V133, P916, DOI 10.1016/j.cell.2008.04.037; Qi YX, 2008, CARDIOVASC RES, V80, P114, DOI 10.1093/cvr/cvn158; Rao MS, 1999, ANAT RECORD, V257, P137; Ravin R, 2008, CELL STEM CELL, V3, P670, DOI 10.1016/j.stem.2008.09.012; Riddell JR, 2010, J IMMUNOL, V184, P1022, DOI 10.4049/jimmunol.0901945; Shevchenko G, 2012, J PROTEOME RES, V11, P2441, DOI 10.1021/pr201169q; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Wojciak-Stothard B, 2007, J CELL SCI, V120, P929, DOI 10.1242/jcs.002212; Wolk K, 2005, GENES IMMUN, V6, P452, DOI 10.1038/sj.gene.6364224; Wright KT, 2010, BIOCHEM BIOPH RES CO, V398, P79, DOI 10.1016/j.bbrc.2010.06.039; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Yamaguchi H, 2009, J CELL PHYSIOL, V220, P748, DOI 10.1002/jcp.21822; Zhang W, 2011, P NATL ACAD SCI USA, V108, P4956, DOI 10.1073/pnas.1102527108	43	27	27	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2013	8	2							e55983	10.1371/journal.pone.0055983			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092XV	WOS:000315157200097	23409102	Green Published, Green Submitted, gold			2022-02-06	
J	Kraemer, WJ; Looney, DP; Martin, GJ; Ratamess, NA; Vingren, JL; French, DN; Hatfield, DL; Fragala, MS; Spiering, BA; Howard, RL; Cortis, C; Szivak, TK; Comstock, BA; Dunn-Lewis, C; Hooper, DR; Flanagan, SD; Volek, JS; Anderson, JM; Maresh, CM; Fleck, SJ				Kraemer, William J.; Looney, David P.; Martin, Gerard J.; Ratamess, Nicholas A.; Vingren, Jakob L.; French, Duncan N.; Hatfield, Disa L.; Fragala, Maren S.; Spiering, Barry A.; Howard, Robert L.; Cortis, Cristina; Szivak, Tunde K.; Comstock, Brett A.; Dunn-Lewis, Courtenay; Hooper, David R.; Flanagan, Shawn D.; Volek, Jeff S.; Anderson, Jeffrey M.; Maresh, Carl M.; Fleck, Steven J.			CHANGES IN CREATINE KINASE AND CORTISOL IN NATIONAL COLLEGIATE ATHLETIC ASSOCIATION DIVISION I AMERICAN FOOTBALL PLAYERS DURING A SEASON	JOURNAL OF STRENGTH AND CONDITIONING RESEARCH			English	Article						clinical chemistries; muscle damage; strength training; sports medicine	PREVENTING SUDDEN-DEATH; TRAINING-PROGRAMS; MUSCLE DAMAGE; RESPONSES; EXERCISE; PERFORMANCE; GAME	Kraemer, WJ, Looney, DP, Martin, GJ, Ratamess, NA, Vingren, JL, French, DN, Hatfield, DL, Fragala, MS, Spiering, BA, Howard, RL, Cortis, C, Szivak, TK, Comstock, BA, Dunn-Lewis, C, Hooper, DR, Flanagan, SD, Volek, JS, Anderson, JM, Maresh, CM, and Fleck, SJ. Changes in creatine kinase and cortisol in national collegiate athletic association division I American football players during a season. J Strength Cond Res 27(2): 434-441, 2013-The purpose of this study was to track creatine kinase (CK) and serum cortisol over an American college football season starting with the preseason practice. A secondary purpose was to observe changes in basic clinical chemistries. Twenty-two National Collegiate Athletic Association Division I football players (age: 20.4 +/- 1.1 years, height: 188.27 +/- 8.3 cm, weight: 115.8 +/- 29.7 kg) volunteered to participate in this study. Each of the players had participated in the summer strength and conditioning supervised program. Resting blood samples were obtained just before the start of preseason practice (T-1), 2 weeks later (T-2), and the day after game 2 (T-3), game 4 (T-4), game 6 (T-5), and game 9 (T-6) of a 12-game season. Creatine kinase, a panel of clinical chemistries, cortisol, and testosterone were assayed at each time point. No significant changes in CK concentrations were observed over the season with peak values of each range <= 1,070.0 IU.L-1, but the largest range was observed at T-6 after game 9 (119-2,834 IU.L-1. The analysis of covariance analysis demonstrated that the number of plays in the ninth game (T-6) explained the magnitude of the changes in CK. No changes in serum cortisol concentrations were observed yet, again large variations existed with peak values of each range <= 465.0 nmol.L-1. Clinical chemistries showed various significant changes from T-1, but none were considered clinically relevant changes for any player over the time course of the study. In conclusion, the strength and conditioning program before preseason camp or the structure of summer camp practices and the in-season strength and conditioning appeared to mute muscle damage and the stress response of cortisol. Such data demonstrate that changes in muscle damage and adrenal cortical stress over the season are minimal, yet large individual variations can be observed. Management of these variables appears to be related to optimal strength and conditioning and sports medicine programs. Thus, the greater concerns for student-athlete safety in the sport of American football are related to preventing sudden death, traumatic injury, and managing concussion syndromes.	[Kraemer, William J.; Looney, David P.; Martin, Gerard J.; Ratamess, Nicholas A.; Vingren, Jakob L.; French, Duncan N.; Hatfield, Disa L.; Fragala, Maren S.; Spiering, Barry A.; Howard, Robert L.; Cortis, Cristina; Szivak, Tunde K.; Comstock, Brett A.; Dunn-Lewis, Courtenay; Hooper, David R.; Flanagan, Shawn D.; Volek, Jeff S.; Anderson, Jeffrey M.; Maresh, Carl M.] Univ Connecticut, Dept Kinesiol, Human Performance Lab, Storrs, CT USA; [Fleck, Steven J.] Univ Wisconsin Parkside, Kenosha, WI USA		Kraemer, WJ (corresponding author), Univ Connecticut, Dept Kinesiol, Human Performance Lab, Storrs, CT USA.	william.kraemer@uconn.edu	Flanagan, Shawn/AAC-6018-2021; CORTIS, Cristina/AAB-9960-2020; Dunn-Lewis, Courtenay/G-8524-2017	Flanagan, Shawn/0000-0002-6531-4567; CORTIS, Cristina/0000-0001-9643-5532; Dunn-Lewis, Courtenay/0000-0002-2406-4215	University of Connecticut's Human Performance Laboratory	The investigators want to thank a dedicated group of student-athletes who participated in this investigation. The findings in this study do not reflect any endorsement by the National Strength and Conditioning Association. No conflict of interest exists, and this study was funded by internal funds at the University of Connecticut's Human Performance Laboratory.	BERG K, 1990, RES Q EXERCISE SPORT, V61, P395, DOI 10.1080/02701367.1990.10607504; Casa DJ, 2012, J ATHL TRAINING, V47, P477, DOI 10.4085/1062-6050-47.4.08; Casa DJ, 2012, J ATHL TRAINING, V47, P96; Fragala MS, 2011, SPORTS MED, V41, P621, DOI 10.2165/11590430-000000000-00000; Hoffman JR, 2005, MED SCI SPORT EXER, V37, P1237, DOI 10.1249/01.mss.0000170068.97498.26; Hoffman JR, 2004, J STRENGTH COND RES, V18, P129; Hoffman JR, 2003, J STRENGTH COND RES, V17, P561; Hoffman JR, 2002, MED SCI SPORT EXER, V34, P1845, DOI 10.1097/00005768-200211000-00023; Kraemer W. J., 1992, STRENGTH POWER SPORT, P64; Kraemer WJ, 2009, J STRENGTH COND RES, V23, P2, DOI 10.1519/JSC.0b013e31819306f2; KRAEMER WJ, 1993, J APPL PHYSIOL, V74, P450; Kraemer WJ, 2000, EXERCISE SPORT SCI, P795; Mclellan CP, 2010, J STRENGTH COND RES, V24, P2908, DOI 10.1519/JSC.0b013e3181c1fcb1; Spiering BA, 2008, SPORTS MED, V38, P527, DOI 10.2165/00007256-200838070-00001; Spiering BA, 2008, MED SCI SPORT EXER, V40, P1039, DOI 10.1249/MSS.0b013e31816722bd; Young WB, 2012, J STRENGTH COND RES, V26, P492, DOI 10.1519/JSC.0b013e318225a1c4	16	27	27	2	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1064-8011			J STRENGTH COND RES	J. Strength Cond. Res.	FEB	2013	27	2					434	441		10.1519/JSC.0b013e318281d1b0			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	086WB	WOS:000314718600020	23358319				2022-02-06	
J	Sinclair, KL; Ponsford, JL; Rajaratnam, SMW; Anderson, C				Sinclair, Kelly L.; Ponsford, Jennie L.; Rajaratnam, Shantha M. W.; Anderson, Clare			Sustained attention following traumatic brain injury: Use of the Psychomotor Vigilance Task	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Sustained attention; Psychomotor Vigilance Task; Fatigue; Sleep disturbance; Daytime sleepiness; Information-processing speed	EPWORTH SLEEPINESS SCALE; EXCESSIVE DAYTIME SLEEPINESS; RESPONSE-TIME DISTRIBUTIONS; CLOSED-HEAD INJURY; OBJECTIVE MEASUREMENT; COGNITIVE IMPAIRMENT; SELECTIVE ATTENTION; MENTAL EFFORT; TEST PVT; PERFORMANCE	Objective: Deficits in sustained attention are common following traumatic brain injury (TBI), as a result of primary (i.e., neuropathology) and/or secondary factors (i.e., fatigue, sleep disturbance, depressed mood). The extent to which secondary factors play a role in attention deficits is relatively unexamined. Moreover, the Psychomotor Vigilance Task (PVT) is seldom used in TBI assessment despite its sensitivity to secondary factors observed following injury. The primary aim of the current study was to examine the usefulness of the auditory PVT in identifying attentional difficulties in patients with TBI compared with noninjured controls, and also to explore the impact of fatigue, sleep quality, and daytime sleepiness on sustained attention performances. Method: Participants (n=20 per group) completed the auditory PVT and self-report measures of fatigue, sleep quality, daytime sleepiness, and depression. Results: Compared to controls, patients with TBI had widespread PVT deficits including slower response times, increased response variability and attention lapses, and delayed responding in the slowest 10% of responses. Distribution analyses suggested this was likely due to generalized cognitive slowing. Self-reported secondary factors had varying impacts on aspects of PVT performance, with self-reported fatigue exhibiting a more global impact on attention performance. Conclusions: The auditory PVT is a sensitive measure of sustained attention deficits in patients with TBI, with aspects of performance influenced by fatigue, sleep disturbance, and depression.	[Sinclair, Kelly L.; Ponsford, Jennie L.; Rajaratnam, Shantha M. W.; Anderson, Clare] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia		Anderson, C (corresponding author), Monash Univ, Fac Med Nursing & Hlth Sci, Sch Psychol & Psychiat, Clayton Campus, Clayton, Vic 3800, Australia.	clare.anderson@monash.edu		Anderson, Clare/0000-0002-5086-4865; Rajaratnam, Shantha/0000-0001-7527-8558	Transport Accident Commission; Jack Brockhoff Foundation; NHMRC (National Health and Medical Research Council) Centre for Integrated Research and Understanding of Sleep (CIRUS), The University of Sydney; RACV (Royal Automobile Club of Victoria) Sir Edmund Herring Memorial Scholarship; Psychology Press; Guilford Press; Vanda Pharmaceuticals; Takeda Pharmaceuticals North AmericaTakeda Pharmaceutical Company Ltd; Philips Lighting; Philips Respironics; Cephalon; ResMed Foundation; Sanofi-AventisSanofi-Aventis; VicRoads; Brown Medical School/Rhode Island Hospital; Ausmed	We thank the Monash Epworth Rehabilitation Research Centre for assistance with participant recruitment. This work was supported by funding from the Transport Accident Commission; Jack Brockhoff Foundation; NHMRC (National Health and Medical Research Council) Centre for Integrated Research and Understanding of Sleep (CIRUS), The University of Sydney; and RACV (Royal Automobile Club of Victoria) Sir Edmund Herring Memorial Scholarship. K. L. S. reports no conflicts of interest. J.L.P. reports that she has received royalties from Psychology Press and Guilford Press for textbooks on traumatic brain injury and received an honorarium, travel, and accommodation support to present a lecture on fatigue and sleep disturbance at the TBI Interagency Conference in Washington, DC, May 2011. S. W. R. reports that he has served as a consultant through his institution to Vanda Pharmaceuticals, Philips Respironics, EdanSafe, The Australian Workers' Union, and National Transport Commission and has through his institution received research grants and/or unrestricted educational grants from Vanda Pharmaceuticals, Takeda Pharmaceuticals North America, Philips Lighting, Philips Respironics, Cephalon, and ResMed Foundation, and reimbursements for conference travel expenses from Vanda Pharmaceuticals. His institution has received equipment donations or other support from Optalert (TM), Compumedics, and Tyco Healthcare. He has also served as an expert witness and/or consultant to shift work organizations. C.A. reports receiving a research award/prize from Sanofi-Aventis, contract research support from VicRoads, and lecturing fees from Brown Medical School/Rhode Island Hospital and Ausmed. In addition, she has served as consultant to the Rail, Bus and Tram Union to produce a report on best practice management of fatigue in the rail industry, through an agreement with Monash University.	Ambulatory Monitoring Inc, 2012, REACT VERS 1 1 05; Anderson C, 2012, SLEEP, V35, P1137, DOI 10.5665/sleep.2004; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Balkin TJ, 2008, CHEST, V134, P653, DOI 10.1378/chest.08-1064; Basner M, 2011, ACTA ASTRONAUT, V69, P949, DOI 10.1016/j.actaastro.2011.07.015; Basner M, 2011, SLEEP, V34, P581, DOI 10.1093/sleep/34.5.581; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Blatter K, 2006, BEHAV BRAIN RES, V168, P312, DOI 10.1016/j.bbr.2005.11.018; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dinges DF, 1997, SLEEP, V20, P267; DINGES DF, 1985, BEHAV RES METH INSTR, V17, P652, DOI 10.3758/BF03200977; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Doran SM, 2001, ARCH ITAL BIOL, V139, P253; Dorrian J, 2005, SLEEP DEPRIVATION CL, P39; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Edinger JD, 2008, SLEEP, V31, P599, DOI 10.1093/sleep/31.5.599; Epstein JN, 2010, J INT NEUROPSYCH SOC, V16, P138, DOI 10.1017/S1355617709991111; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Ginstfeldt T, 2010, BRAIN INJURY, V24, P1123, DOI 10.3109/02699052.2010.506853; Hervey AS, 2006, CHILD NEUROPSYCHOL, V12, P125, DOI 10.1080/09297040500499081; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Himanen L, 2009, BRAIN INJURY, V23, P220, DOI 10.1080/02699050902748323; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Jewett ME, 1999, SLEEP, V22, P171, DOI 10.1093/sleep/22.2.171; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Jung CM, 2011, J SLEEP RES, V20, P348, DOI 10.1111/j.1365-2869.2010.00877.x; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kim H, 2007, SLEEP, V30, P1309, DOI 10.1093/sleep/30.10.1309; Kindlon D. J., 1998, CHILD PSYCHOL PSYCHI, V3, P72, DOI [10.1017/S136064179800149X, DOI 10.1017/S136064179800149X]; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lee IS, 2010, J CLIN SLEEP MED, V6, P163; Leth-Steensen C, 2000, ACTA PSYCHOL, V104, P167, DOI 10.1016/S0001-6918(00)00019-6; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lim JL, 2008, ANN NY ACAD SCI, V1129, P305, DOI 10.1196/annals.1417.002; Luce R., 1986, REPONSE TIMES THEIR; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Myerson J, 2007, J EXP ANAL BEHAV, V88, P319, DOI 10.1901/jeab.2007.88-319; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; PARSONS LC, 1982, NURS RES, V31, P260; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Rouder JN, 2005, PSYCHON B REV, V12, P195, DOI 10.3758/BF03257252; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Santhi N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001233; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Short MA, 2012, SLEEP MED, V13, P378, DOI 10.1016/j.sleep.2011.11.005; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Systat Software Inc, 2008, SIGM VERS 11 0; Teicher MH, 1996, J AM ACAD CHILD PSY, V35, P334, DOI 10.1097/00004583-199603000-00015; Thomas M, 2000, J SLEEP RES, V9, P335, DOI 10.1046/j.1365-2869.2000.00225.x; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Verma A, 2007, J CLIN SLEEP MED, V3, P357; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Wyatt JK, 1999, AM J PHYSIOL-REG I, V277, pR1152; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	89	27	27	0	27	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB 1	2013	35	2					210	224		10.1080/13803395.2012.762340			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	092HM	WOS:000315111000009	23391455				2022-02-06	
J	Axelson, HW; Winkler, T; Flygt, J; Djupsjo, A; Hanell, A; Marklund, N				Axelson, Hans W.; Winkler, Tomas; Flygt, Johanna; Djupsjo, Anders; Hanell, Anders; Marklund, Niklas			Plasticity of the contralateral motor cortex following focal traumatic brain injury in the rat	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Traumatic brain injury; motor cortex; mapping; microstimulation; motor evoked potential	FOREBRAIN CHOLINERGIC SYSTEM; PRIMARY SOMATOSENSORY CORTEX; CONTROLLED CORTICAL IMPACT; FUNCTIONAL RECOVERY; ADULT RATS; NOGO-A; BEHAVIORAL RECOVERY; SENSORIMOTOR CORTEX; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA	Purpose: Recovery is limited following traumatic brain injury (TBI) since injured axons regenerate poorly and replacement of lost cells is minimal. Behavioral improvements could instead be due to plasticity of uninjured brain regions. We hypothesized that plasticity of the uninjured hemisphere occurs contralateral to a focal TBI in the adult rat. Thus, we performed cortical mapping of the cortex contralateral to the TBI using intracortical microstimulation (ICMS). Methods: A focal TBI was induced using the weight-drop technique (n = 5) and sham-injured animals were used as controls (n = 4). At five weeks post-injury, ICMS was used to map the motor area contralateral to the injury. Motor responses were detected by visual inspection and electromyography (EMG). Results: In sham-and brain-injured animals, numerous fore- and hindlimb motor responses contralateral to the stimulation (ipsilateral to the injury) were obtained. Compared to sham-injured controls, there was a markedly increased (p < 0.05) number of fore- and hindlimb responses ipsilateral to the stimulation after TBI. Conclusion: Following focal TBI in the rat, our data suggest reorganization of cortical and/or subcortical regions in the uninjured hemisphere contralateral to a focal TBI leading to an altered responsiveness to ICMS. Although we cannot exclude that these changes are maladaptive, it is plausible that this plasticity process positively influences motor recovery after TBI.	[Axelson, Hans W.; Winkler, Tomas; Flygt, Johanna; Djupsjo, Anders; Hanell, Anders; Marklund, Niklas] Uppsala Univ, Dept Neurosci, S-75185 Uppsala, Sweden		Marklund, N (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	niklas.marklund@neuro.uu.se	Hanell, Anders/E-4776-2011; Axelson, Hans/K-2246-2019	Hanell, Anders/0000-0001-9369-3886; Marklund, Niklas/0000-0002-9797-5626	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University	This work was supported by grants from the Swedish Research Council and grants from Uppsala University. We thank Drs Gwendolyn L. Kartje and April J. Emerick for initial methodological advice. The authors thank P-O Fallmar for invaluable engineering assistance.	Abo M, 2001, NEUROREPORT, V12, P1543, DOI 10.1097/00001756-200105250-00048; Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Biernaskie J, 2005, EUR J NEUROSCI, V21, P989, DOI 10.1111/j.1460-9568.2005.03899.x; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; Cramer SC, 2006, EXP BRAIN RES, V168, P25, DOI 10.1007/s00221-005-0082-2; Dancause N, 2006, J NEUROPHYSIOL, V96, P3506, DOI 10.1152/jn.00792.2006; Dijkhuizen RM, 2001, P NATL ACAD SCI USA, V98, P12766, DOI 10.1073/pnas.231235598; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Eisner-Janowicz I, 2008, J NEUROPHYSIOL, V100, P1498, DOI 10.1152/jn.90447.2008; Emerick AJ, 2003, J NEUROSCI, V23, P4826; Emery DL, 2000, J COMP NEUROL, V424, P521; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gaffan D, 2008, CORTEX, V44, P928, DOI 10.1016/j.cortex.2008.03.005; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hanell A, 2010, J NEUROTRAUM, V27, P1297, DOI 10.1089/neu.2009.1255; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; Jones TA, 1999, J NEUROSCI, V19, P10153; JONES TA, 1994, J NEUROSCI, V14, P2140; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; Kaeser M, 2010, J NEUROPHYSIOL, V103, P1630, DOI 10.1152/jn.00459.2009; Kerr AL, 2011, J COMMUN DISORD, V44, P538, DOI 10.1016/j.jcomdis.2011.04.011; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KOLB B, 1989, PROG NEUROBIOL, V32, P235, DOI 10.1016/0301-0082(89)90023-3; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; LEE RG, 1995, CAN J NEUROL SCI, V22, P257, DOI 10.1017/S0317167100039445; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Leocani L, 2006, NEUROL SCI, V27, pS27, DOI 10.1007/s10072-006-0542-x; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Liu Y, 1999, EXP BRAIN RES, V128, P149, DOI 10.1007/s002210050830; MacDonald E, 2007, NEUROREHAB NEURAL RE, V21, P486, DOI 10.1177/1545968307305521; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Napieralski JA, 1996, J COMP NEUROL, V373, P484; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Nishimura Y, 2007, SCIENCE, V318, P1150, DOI 10.1126/science.1147243; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Papadopoulos CM, 2009, STROKE, V40, P294, DOI 10.1161/STROKEAHA.108.519769; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Papathanasiou ES, 2006, EXP NEUROL, V199, P122, DOI 10.1016/j.expneurol.2006.02.115; Plowman EK, 2010, J COMMUN DISORD, V43, P286, DOI 10.1016/j.jcomdis.2010.04.005; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Reinecke S, 2003, EUR J NEUROSCI, V17, P623, DOI 10.1046/j.1460-9568.2003.02459.x; Rema V, 2003, J NEUROSCI, V23, P10378; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shanina EV, 2006, NEUROSCIENCE, V139, P1495, DOI 10.1016/j.neuroscience.2006.01.016; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Ueno M, 2012, BRAIN, V135, P1253, DOI 10.1093/brain/aws053; Uryu K, 2001, NEUROSCIENCE, V105, P307, DOI 10.1016/S0306-4522(01)00203-2; Witte OW, 1997, ADV NEUROL, V73, P207; Xerri C, 2003, NEUROSCIENCE, V118, P161, DOI 10.1016/S0306-4522(02)00911-9; Xerri C, 1998, J NEUROPHYSIOL, V79, P2119, DOI 10.1152/jn.1998.79.4.2119; Zai LL, 2009, J NEUROSCI, V29, P8187, DOI 10.1523/JNEUROSCI.0414-09.2009; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046	81	27	28	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2013	31	1					73	85		10.3233/RNN-2012-120242			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	073JY	WOS:000313740500007	23047494				2022-02-06	
J	Glynn, N; Agha, A				Glynn, Nigel; Agha, Amar			Which patient requires neuroendocrine assessment following traumatic brain injury, when and how?	CLINICAL ENDOCRINOLOGY			English	Article							ANTERIOR-PITUITARY INSUFFICIENCY; HEAD-INJURY; POSTTRAUMATIC HYPOPITUITARISM; ACUTE-PHASE; DYSFUNCTION; HYPONATREMIA; PREVALENCE; SECRETION; HORMONE	Traumatic brain injury (TBI) is an important public health problem, particularly among young adults in industrialized countries. Hypopituitarism is a common occurrence among survivors of TBI and may contribute to the associated morbidity seen in the acute and chronic phases following injury. The available data suggest that survivors of moderate to severe TBI should undergo screening for hypopituitarism particularly in the first year after injury. This requires a close liaison between endocrinologists, neurosurgeons, neuropsychologists, intensive care and rehabilitation physicians. Patients who suffer milder forms of TBI should also be considered for endocrine evaluation if they exhibit any clinical features of pituitary hormone deficiencies.	[Agha, Amar] Beaumont Hosp, Acad Dept Endocrinol, Div Neuroendocrinol, Dublin 9, Ireland; RCSI Med Sch, Dublin, Ireland		Agha, A (corresponding author), Beaumont Hosp, Acad Dept Endocrinol, Div Neuroendocrinol, Beaumont Rd, Dublin 9, Ireland.	amaragha@beaumont.ie		Glynn, Nigel/0000-0002-9248-8191			Agha A, 2006, J CLIN ENDOCR METAB, V91, P43, DOI 10.1210/jc.2005-1131; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Coronado VG, 2011, SURVEILLANCE TRAUMAT; Faul M, 2010, TRAUMATIC BRAIN INJU; Hannon M. J., 2011, ENDOCR REV, V32; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Moro N, 2007, SURG NEUROL, V68, P387, DOI 10.1016/j.surneu.2006.11.052; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; VINGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50, DOI 10.1007/BF01400528	28	27	28	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664			CLIN ENDOCRINOL	Clin. Endocrinol.	JAN	2013	78	1					17	20		10.1111/cen.12010			4	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	053DF	WOS:000312249800003	22891644				2022-02-06	
J	Miller, KJ; Ivins, BJ; Schwab, KA				Miller, Kelly J.; Ivins, Brian J.; Schwab, Karen A.			Self-Reported Mild TBI and Postconcussive Symptoms in a Peacetime Active Duty Military Population: Effect of Multiple TBI History Versus Single Mild TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; military; multiple TBI; postconcussive symptoms; soldier	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; BASE-RATE; CONCUSSION; FOOTBALL; PREVALENCE; EXPECTATION; VETERANS; SEQUELAE	Objective: To investigate the potential cumulative impact of mild traumatic brain injury (MTBI) on postconcussive symptoms. Participants: A total of 224 active duty soldiers reporting MTBI within 1 year of testing. For 101, this MTBI was their only reported traumatic brain injury (TBI); 123 had sustained at least 1 additional MTBI during their lifetime. A No TBI control group (n = 224) was included for comparison. Main Measure: Self-report symptoms data via questionnaire. Within time since injury subgroups (<= 3 months; Post-3 months), symptom endorsement (no symptoms, 1 or 2 symptoms, 3+ symptoms) among soldiers with 1 MTBI was compared with that of soldiers with 2 or more MTBIs. Injured soldiers' symptom endorsement was compared with that of soldiers who had not sustained a TBI. Results: Among the recently injured (<= 3 months), those with 2 or more MTBIs endorsed significantly more symptoms than those with 1 MTBI: 67% of soldiers with 2 or more MTBIs reported 3+ symptoms, versus 29% of One MTBI soldiers. Among Post-3 month soldiers, there were no significant differences between MTBI groups. Overall, soldiers with MTBI endorsed significantly more symptoms than those without TBI. Conclusion: Past experience of MTBI may be a risk factor for increased symptom difficulty for several months postinjury. Clinicians should ascertain lifetime history of brain injury when evaluating patients for MTBI.	[Miller, Kelly J.; Ivins, Brian J.; Schwab, Karen A.] Def & Vet Brain Injury Ctr, Rockville, MD 20852 USA; [Schwab, Karen A.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Miller, KJ (corresponding author), Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Rockville, MD 20852 USA.	kelly.j.miller2.ctr@us.army.mil					Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1993, ICD 10 CLASS MENT BE, P63	41	27	27	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2013	28	1					31	38		10.1097/HTR.0b013e318255ceae			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	070ZW	WOS:000313555400004	22647963				2022-02-06	
J	Moll, LR; Cott, CA				Moll, Laura R.; Cott, Cheryl A.			The paradox of normalization through rehabilitation: growing up and growing older with cerebral palsy	DISABILITY AND REHABILITATION			English	Article						Aging with disability; cerebral palsy (CP); normalization; rehabilitation; the Life Course Perspective	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; HEALTH-CARE; ADULTS; DISABILITY; BODY; PERSPECTIVES; EXPERIENCES; LOCOMOTION; MOBILITY	Purpose: To examine the experience of normalization through rehabilitation for persons growing up & growing older with lifelong physical impairment (cerebral palsy [CP]). Method: A qualitative methodology consisting of narrative inquiry informed by the Life Course Perspective. Multiple (3-4), indepth interviews were completed with each participant in order to co-construct their life stories. Data were systematically compared for themes and categories, as well as the central plot that weaves the participants' experiences together. Results: Nine community-dwelling individuals (three men; six women), aged 26-70, with mild to severe CP participated. Their common narrative involved intensive rehabilitation in childhood that focused on "normalizing" movement, particularly walking. In adolescence they were deemed to have achieved their functional potentials and "nothing further could be done". After transitioning out of pediatric health services many start to lose the gains they achieved in rehabilitation (particularly around walking). In their 30's and 40's they begin to slow down and lose functional abilities but no longer have access to rehabilitation to help them manage their aging bodies. Conclusions: Many of the assumptions that underlie the organization and delivery of rehabilitation services for people with long term impairments may contribute to difficulties encountered in adulthood and old age by focusing on normalizing physical function at the expense of learning to manage their bodies across the life course.	[Moll, Laura R.; Cott, Cheryl A.] Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Cott, Cheryl A.] Univ Toronto, Fac Med, Dept Phys Therapy, Toronto, ON M5G 1V7, Canada		Moll, LR (corresponding author), Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada.	lrmoll@gmail.com			University of TorontoUniversity of Toronto; Toronto Rehabilitation Institute TRI Student Scholarship Fund; TD Grants in Medical Excellence	This study was funded by the University of Toronto (2004-2005), Toronto Rehabilitation Institute TRI Student Scholarship Fund (2005-2006), and TD Grants in Medical Excellence (2006-2011).	Andersson C, 2001, DEV MED CHILD NEUROL, V43, P76, DOI 10.1017/S0012162201; Andren E, 2000, DISABIL REHABIL, V22, P299, DOI 10.1080/096382800296656; BACK KW, 1970, J GERONTOL, V25, P249, DOI 10.1093/geronj/25.3.249; Bauman W, 2004, AGING DISABILITY WHA, P196; Bury M., 1996, EXPLORING DIVIDE ILL, P18; Charlifue S, 2004, ARCH PHYS MED REHAB, V85, P1848, DOI 10.1016/j.apmr.2004.03.017; Clausen J., 1972, AGING SOC SOCIOLOGY, P457; Clinin D.J., 2000, NARRATIVE INQUIRY EX; Colantonio A, 2004, INT J REHABIL RES, V27, P209, DOI 10.1097/00004356-200409000-00006; Davis L. J, 1995, ENFORCING NORMALCY D; De Kleijn-de Vrankrijker MW, 2003, DISABIL REHABIL, V25, P561, DOI 10.1080/09638280110110879; Dean S, 2000, PSYCHOL REP, V86, P653, DOI 10.2466/pr0.2000.86.2.653; Elder Glen H., 1998, METHODS LIFE COURSE, P189; Foucault M., 2003, BIRTH CLIN ARCHEOLOG; Fougeyrollas P, 2002, TOP SPINAL CORD INJU, V7, P56; Frank, 1995, WOUNDED STORYTELLER; FURUMASU J, 1996, TECHNOL DISABIL, V5, P41; Gajdosik Carrie Giller, 2001, Physical and Occupational Therapy in Pediatrics, V21, P49, DOI 10.1300/J006v21n04_04; Giele J.Z., 1998, METHODS LIFE COURSE; Hammel KW., 2006, PERSPECTIVES DISABIL; Harrison Tracie, 2003, J Holist Nurs, V21, P242, DOI 10.1177/0898010103254917; Harrison Tracie C, 2005, Health Care Women Int, V26, P731, DOI 10.1080/07399330500179689; Harrison Tracie Culp, 2006, ANS Adv Nurs Sci, V29, pE1; Hewitt Martin, 1991, BODY SOCIAL PROCESS, P225; Hilberink SR, 2007, J REHABIL MED, V39, P605, DOI 10.2340/16501977-0103; Hughes B, 2009, DISABIL SOC, V24, P399, DOI 10.1080/09687590902876144; Hurst R, 2003, DISABIL REHABIL, V25, P572, DOI 10.1080/0963828031000137072; Jahnsen R, 2004, CLIN REHABIL, V18, P309, DOI 10.1191/0269215504cr735oa; Jahnsen R, 2002, DISABIL REHABIL, V24, P511, DOI 10.1080/09638280110108805; Jahnsen R, 2003, ADV PHYSIOTHER, V5, P21, DOI DOI 10.1080/14038190310005779; JOHNSTONE D, 1998, INTRO DISABILITY STU; Kemp BJ., 2004, AGING DISABILITY WHA; Kemp BJ., 2001, TOP SPINAL CORD INJ, V6, P116, DOI [10.1310/L8TF-65XD-8K1U-UE3M, DOI 10.1310/L8TF-65XD-8K1U-UE3M]; Kielhofner G, 2004, CONCEPTUAL FDN OCCUP; Kohler-Riessman C., 2008, NARRATIVE METHODS HU; Kuzel AJ., 1999, DOING QUALITATIVE RE, V2, P33; Lankasky K., 2004, AGING DISABILITY WHA; Lankasky K., 2004, AGING DISABILITY WHA, P9; Liem NR, 2004, ARCH PHYS MED REHAB, V85, P1567, DOI 10.1016/j.apmr.2003.12.038; Liptak GS, 2008, CURR OPIN NEUROL, V21, P136, DOI 10.1097/WCO.0b013e3282f6a499; Morris J., 2001, HYPATIA, V16, P1, DOI [DOI 10.1111/J.1527-2001.2001.TB00750.X, 10.1353/hyp.2001.0059, DOI 10.1353/HYP.2001.0059]; Neri MT, 2003, DISABIL REHABIL, V25, P85, DOI 10.1080/0963828021000007941; Nicholls David A., 2010, Physiotherapy Theory and Practice, V26, P497, DOI 10.3109/09593981003710316; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Oliver M, 1998, BRIT MED J, V317, P1446, DOI 10.1136/bmj.317.7170.1446; Oliver M., 1996, DEFINING IMPAIRMENT; Oliver M., 1990, POLITICS DISABLEMENT; Opheim A, 2012, PHYS THER, V92, P279, DOI 10.2522/ptj.20100432; Opheim A, 2009, DEV MED CHILD NEUROL, V51, P381, DOI 10.1111/j.1469-8749.2008.03250.x; Patton M., 2002, QUALITATIVE RES EVAL, P223; Perry J, 2004, AGING DISABILITY WHA, P175; Pimm P., 1992, ED CHILD PSYCHOL, V9, P27; Priestley M., 2003, DISABILITY LIFE COUR; Roebroeck ME, 2009, DEV MED CHILD NEUROL, V51, P670, DOI 10.1111/j.1469-8749.2009.03322.x; Sandstrom K, 2007, CLIN REHABIL, V21, P432, DOI 10.1177/0269215507073489; Schanke HK, 1997, DISABIL REHABIL, V19, P108, DOI 10.3109/09638289709166835; Seymour W., 1998, REMAKING BODY REHABI; Shakespeare T., 1999, EXPLORING DISABILITY; Smith B, 2004, DISABIL SOC, V19, P613, DOI 10.1080/0968759042000252533; Strauss D, 2004, NEUROREHABILITATION, V19, P69; Sullivan M., 2005, FOUCAULT GOVT DISABI, P340; Thomas C., 1999, FEMALE FORMS EXPERIE; Thomas C., 2002, DISABILITY STUDIES T; Turner B.S., 1992, REGULATING BODIES ES; VALVANO J, 1991, PEDIATRIC PHYSICAL T, V3, P125, DOI DOI 10.1097/00001577-199100330-00004; Wiart L, 2002, DISABIL REHABIL, V24, P492, DOI 10.1080/09638280110105240; Wilkins S, 1993, AGING CHRONIC ILLNES, P363; Zaffuto-Sforza Celeste D, 2005, Phys Med Rehabil Clin N Am, V16, P235, DOI 10.1016/j.pmr.2004.06.014; [No title captured]	69	27	27	0	25	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2013	35	15					1276	1283		10.3109/09638288.2012.726689			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	169VM	WOS:000320808700004	23066918				2022-02-06	
J	Gu, LX; Chafi, MS; Ganpule, S; Chandra, N				Gu, Linxia; Chafi, Mehdi S.; Ganpule, Shailesh; Chandra, Namas			The influence of heterogeneous meninges on the brain mechanics under primary blast loading	COMPOSITES PART B-ENGINEERING			English	Article						Layered structures; Mechanical properties; Interface/interphase; Finite element analysis; Blast wave	RESPONSES; TISSUE	In the modeling of brain mechanics subjected to primary blast waves, there is currently no consensus on how many biological components to be used in the brain-meninges-skull complex, and what type of constitutive models to be adopted. The objective of this study is to determine the role of layered meninges in damping the dynamic response of the brain under primary blast loadings. A composite structures composed of eight solid relevant layers (including the pia, cerebrospinal fluid (CSF), dura maters) with different mechanical properties are constructed to mimic the heterogeneous human head. A hyper-viscoelastic material model is developed to better represent the mechanical response of the brain tissue over a large strain/high frequency range applicable for blast scenarios. The effect of meninges on the brain response is examined. Results show that heterogeneous composite structures of the head have a major influence on the intracranial pressure, maximum shear stress, and maximum principal strain in the brain, which is associated with traumatic brain injuries. The meninges serving as protective layers are revealed by mitigating the dynamic response of the brain. In addition, appreciable changes of the pressure and maximum shear stress are observed on the material interfaces between layers of tissues. This may be attributed to the alternation of shock wave speed caused by the impedance mismatch. (c) 2012 Elsevier Ltd. All rights reserved.	[Gu, Linxia; Chafi, Mehdi S.; Ganpule, Shailesh; Chandra, Namas] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA; [Gu, Linxia] Nebraska Ctr Mat & Nanosci, Lincoln, NE 68588 USA		Gu, LX (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.	lgu2@unl.edu	gu, linxia/A-5645-2013	gu, linxia/0000-0003-2637-0299	US Army Research Office (ARO) [W911NF-08-1-0483]	This study is supported by the US Army Research Office (ARO), Contract No. W911NF-08-1-0483. The authors are grateful for Mr. Eric Cutler's help with proof reading.	Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; ARBOGAST KB, 1997, P 41 STAPP CAR CRASH, P293; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; BRANDS DWA, 2000, P 44 STAPP CAR CRASH, P249; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Chafi MS, 2009, INT J IMPACT ENG, V36, P1269, DOI 10.1016/j.ijimpeng.2009.03.007; Chen X, 2004, INT J SOLIDS STRUCT, V41, P4635, DOI 10.1016/j.ijsolstr.2004.02.064; Chen X, 2004, COMPOS SCI TECHNOL, V64, P1477, DOI 10.1016/j.compscitech.2003.10.024; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Zaouk A, 2009, INTERACTION BLAST HE; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zoghi-Moghadam M, 2009, COMPUT METHOD BIOMEC, V12, P1, DOI [10.1080/10255840802020420, 10.1080/10255840903064897]	24	27	29	0	24	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1359-8368	1879-1069		COMPOS PART B-ENG	Compos. Pt. B-Eng.	DEC	2012	43	8					3160	3166		10.1016/j.compositesb.2012.04.014			7	Engineering, Multidisciplinary; Materials Science, Composites	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	028DS	WOS:000310403600034		Green Published			2022-02-06	
J	Hu, R; Sun, HD; Zhang, Q; Chen, JY; Wu, N; Meng, H; Cui, GY; Hu, SL; Li, F; Lin, JK; Wan, Q; Feng, H				Hu, Rong; Sun, Haodong; Zhang, Qian; Chen, Jingyu; Wu, Nan; Meng, Hui; Cui, Gaoyu; Hu, Shengli; Li, Fei; Lin, Jiangkai; Wan, Qi; Feng, Hua			G-protein coupled estrogen receptor 1 mediated estrogenic neuroprotection against spinal cord injury	CRITICAL CARE MEDICINE			English	Article						apoptosis; estrogen; functional recovery; G-protein coupled estrogen receptor 1; neuroprotection	MESSENGER-RNA; IMMUNOREACTIVE NEURONS; BRAIN-STEM; ALPHA; RAT; EXPRESSION; 17-BETA-ESTRADIOL; ACTIVATION; BETA; APOPTOSIS	Objective: What underlies the protection of estrogen against spinal cord injury remains largely unclear. Here, we investigated the expression pattern of a new estrogen receptor, G-protein coupled estrogen receptor 1 in the spinal cord and its role in estrogenic protection against spinal cord injury. Design and Settings: Department of Neurosurgery and Key Laboratory of Neurotrauma, Southwest Hospital. Subjects: Male Sprague-Dawley rats. Interventions: The animals subjected to spinal cord injury were divided into six groups and given vehicle solution, 17 beta-estradiol, or G-protein coupled estrogen receptor 1 agonist G-1 at 15 mins and 24 hrs postinjury, or given nuclear estrogen receptor antagonist ICI 182,780 at 1 hr before spinal cord injury followed by 17 beta-estradiol administration at 15 mins and 24 hrs postinjury, or given G-protein coupled estrogen receptor 1 specific antisense or random control oligonucleotide at 4 days before spinal cord injury followed by 17 beta-estradiol administration at 15 mins and 24 hrs postinjury. Measurements: Male Sprague-Dawley rats were subjected to spinal cord injury using a weight-drop injury approach. Immunohistochemical assays were used to observe the distribution and cell-type expression pattern of G-protein coupled estrogen receptor 1. The terminal deoxynucleotidyl transferase dUTP nickend labeling-staining assay and behavior tests were employed to assess the role of G-protein coupled estrogen receptor 1 in mediating estrogenic protection against spinal cord injury. Main Results: We show that G-protein coupled estrogen receptor 1 is mainly distributed in the ventral horn and white matter of the spinal cord, which is totally different from nuclear estrogen receptors. We also show that G-protein coupled estrogen receptor 1 is specifically expressed by neurons, oligodendrocytes, and microglial cells, but not astrocytes. Furthermore, estrogen treatment prevents spinal cord injury-induced apoptotic cell death and enhances functional recovery after spinal cord injury, which can be mimicked by the specific G-protein coupled estrogen receptor 1 agonist G-1 and inhibited by specific knockdown of G-protein coupled estrogen receptor 1 expression, but not pure nuclear ER antagonist ICI 182,780. Finally, we show that estrogen or G-1 up-regulates the protein expression level of G-protein coupled estrogen receptor 1 to intensify estrogenic effects during spinal cord injury. Conclusions: These results reveal that G-protein coupled estrogen receptor 1 may mediate estrogenic neuroprotection against spinal cord injury, and underline the promising potential of estrogen with its new target G-protein coupled estrogen receptor 1 for the treatment of spinal cord injury patients. (Crit Care Med 2012; 40:3230-3237)	[Hu, Rong; Zhang, Qian; Chen, Jingyu; Wu, Nan; Meng, Hui; Cui, Gaoyu; Hu, Shengli; Li, Fei; Lin, Jiangkai; Wan, Qi; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China; [Hu, Rong; Zhang, Qian; Chen, Jingyu; Wu, Nan; Meng, Hui; Cui, Gaoyu; Hu, Shengli; Li, Fei; Lin, Jiangkai; Wan, Qi; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Key Lab Neurotrauma, Chongqing, Peoples R China; [Sun, Haodong] Gen Hosp Chengdu Mil Command, Dept Neurosurg, Chengdu, Sichuan, Peoples R China		Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China.	feng-hua8888@yahoo.com.cn	Feng, Hua/AAX-4121-2021	Feng, Hua/0000-0003-4489-9217; HU, RONG/0000-0002-3916-186X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872735]; "863 Programs (Chinese National Programs for High Technology Research and Development)"National High Technology Research and Development Program of China [2009AA02Z409]; Natural Science Foundation of ChongqingNatural Science Foundation of Chongqing [CSTC2008BB5125]	Supported by grants from the National Natural Science Foundation of China (No. 30872735), from the "863 Programs (Chinese National Programs for High Technology Research and Development)" (No. 2009AA02Z409), and from the Natural Science Foundation of Chongqing (No. CSTC2008BB5125).	Amandusson A, 1996, EUR J NEUROSCI, V8, P2440, DOI 10.1111/j.1460-9568.1996.tb01207.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Brailoiu E, 2007, J ENDOCRINOL, V193, P311, DOI 10.1677/JOE-07-0017; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; Dun SL, 2009, J NEUROSCI RES, V87, P1610, DOI 10.1002/jnr.21980; Fehlings MG, 2010, J NEUROSURG-SPINE, V13, P165, DOI 10.3171/2009.11.SPINE09862; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Fu ES, 2005, CURR OPIN ANESTHESIO, V18, P181, DOI 10.1097/01.aco.0000162838.56344.88; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hebbeler SL, 2001, J NEUROBIOL, V48, P301, DOI 10.1002/neu.1059; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hu R, 2007, NEUROSCIENCE, V144, P1229, DOI 10.1016/j.neuroscience.2006.09.056; Hu R, 2011, ANN SURG, V254, P353, DOI 10.1097/SLA.0b013e31822645b4; Hu R, 2010, J NEUROSURG-SPINE, V13, P169, DOI 10.3171/2010.3.SPINE09190; Isensee J, 2009, ENDOCRINOLOGY, V150, P1722, DOI 10.1210/en.2008-1488; Ismailoglu O, 2010, J CLIN NEUROSCI, V17, P1306, DOI 10.1016/j.jocn.2010.01.049; Kan WH, 2008, ANN SURG, V248, P294, DOI 10.1097/SLA.0b013e318180a3db; Kuo J, 2010, J NEUROSCI, V30, P12950, DOI 10.1523/JNEUROSCI.1158-10.2010; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lu CL, 2009, GASTROENTEROLOGY, V137, P1040, DOI 10.1053/j.gastro.2009.03.047; Macias CA, 2009, ANN SURG, V249, P10, DOI 10.1097/SLA.0b013e31818a1505; Matsuda KI, 2008, NEUROSCI LETT, V441, P94, DOI 10.1016/j.neulet.2008.05.108; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785, DOI 10.1152/jappl.2001.91.6.2785; Merchenthaler I, 2004, J COMP NEUROL, V473, P270, DOI 10.1002/cne.20128; Micevych P, 2009, FRONT NEUROENDOCRIN, V30, P315, DOI 10.1016/j.yfrne.2009.04.011; MOGIL JS, 1993, PAIN, V53, P17, DOI 10.1016/0304-3959(93)90050-Y; Nakamizo T, 2000, NEUROREPORT, V11, P3493, DOI 10.1097/00001756-200011090-00019; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Olde B, 2009, TRENDS ENDOCRIN MET, V20, P409, DOI 10.1016/j.tem.2009.04.006; Papka RE, 2001, CELL TISSUE RES, V304, P193, DOI 10.1007/s004410100363; Platania P, 2005, NEUROBIOL DIS, V20, P461, DOI 10.1016/j.nbd.2005.03.025; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Sakamoto H, 2007, ENDOCRINOLOGY, V148, P5842, DOI 10.1210/en.2007-0436; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Takanami K, 2010, BRAIN RES, V1310, P17, DOI 10.1016/j.brainres.2009.11.004; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Tian DS, 2009, J NEUROCHEM, V109, P1658, DOI 10.1111/j.1471-4159.2009.06077.x; Vanderhorst VGJM, 2009, NEUROSCIENCE, V158, P798, DOI 10.1016/j.neuroscience.2008.10.017; VanderHorst VGJM, 2005, J COMP NEUROL, V488, P152, DOI 10.1002/cne.20569; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; WAKELING AE, 1992, J STEROID BIOCHEM, V43, P173, DOI 10.1016/0960-0760(92)90204-V; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Yu HP, 2007, ANN SURG, V245, P971, DOI 10.1097/01.sla.0000254417.15591.88; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086	54	27	29	3	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2012	40	12					3230	3237		10.1097/CCM.0b013e3182657560			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	041UQ	WOS:000311427100016	22975889				2022-02-06	
J	Liao, CC; Chiu, WT; Yeh, CC; Chang, HC; Chen, TL				Liao, Chien-Chang; Chiu, Wen-Ta; Yeh, Chun-Chieh; Chang, Huai-Chia; Chen, Ta-Liang			Risk and outcomes for traumatic brain injury in patients with mental disorders	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEAD-INJURIES; BIRTH COHORT; HIP FRACTURE; OLDER WOMEN; SCHIZOPHRENIA; HEALTH; FALLS; HOSPITALIZATIONS; DEPRESSION; VIOLENCE	Objective To investigate the risk of traumatic brain injury (TBI) and post-injury mortality in patients with mental disorders. Background Patients with mental disorders are at higher risk of injuries. However, the association between mental disorders and TBI is still not understood. We conducted case-control studies to investigate whether people with pre-existing mental disorders are at higher risk of TBI and post-injury mortality. Methods Using reimbursement claims, we analysed 16 635 patients with TBI and 66 540 controls with adjustment of covariates to study the association of mental disorders and TBI. A nested case-control study was also conducted to analyse contributory factors for post-injury mortality. Results People with mental disorders were at increased risk of TBI (odds ratio (OR) 1.94, 95% confidence interval (CI) 1.86 to 2.02). Men, older age, living in highly urbanised areas and patients on low income had a higher risk of TBI and post-injury mortality. Psychiatric medication intensity and frequency of psychiatric visits was significantly correlated with TBI in a severity dependent relationship (p for trend <0.0001). Patients receiving advanced psychiatric healthcare had an increased risk of TBI (OR 2.98, 95% CI 2.67 to 3.33) and post-injury mortality (OR 1.92, 95% CI 1.34 to 2.77). A history of receiving psychiatric related outpatient care (OR 1.77, 95% CI 1.70 to 1.85), hospitalisation (OR 3.21, 95% CI 2.79 to 3.70) or emergency visits (OR 3.53, 95% CI 3.15 to 3.94) were highly associated with subsequent TBI. Conclusions Patients with mental disorders have an increased risk of TBI. Intensity of psychiatric medication is associated with increased post-injury mortality. Special attention to prevent TBI among this disabled population is mandatory.	[Chen, Ta-Liang] Taipei Med Univ, Coll Med, Sch Med, Taipei Med Univ Hosp,Dept Anaesthesiol, Taipei 11031, Taiwan; [Liao, Chien-Chang; Chang, Huai-Chia; Chen, Ta-Liang] Taipei Med Univ Hosp, Ctr Hlth Policy Res, Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei 11031, Taiwan; [Yeh, Chun-Chieh] China Med Univ Hosp, Trauma & Emergency Ctr, Taichung, Taiwan; [Liao, Chien-Chang; Chang, Huai-Chia; Chen, Ta-Liang] Taipei Med Univ, Sch Med, Taipei 11031, Taiwan		Chen, TL (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Taipei Med Univ Hosp,Dept Anaesthesiol, 250 Wuxing St, Taipei 11031, Taiwan.	tlc@tmu.edu.tw	Yeh, Chun Chieh/I-4893-2019; Yeh, Chun Chieh/Y-3304-2019	Yeh, Chun Chieh/0000-0001-6753-7564; 			Arseneault L, 2000, ARCH GEN PSYCHIAT, V57, P979, DOI 10.1001/archpsyc.57.10.979; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Brennan PA, 2000, ARCH GEN PSYCHIAT, V57, P494, DOI 10.1001/archpsyc.57.5.494; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Coben JH, 2009, AM J PREV MED, V36, P49, DOI 10.1016/j.amepre.2008.10.001; Cooke BK, 2007, AM J SURG, V193, P41, DOI 10.1016/j.amjsurg.2006.06.034; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Cubbin C, 2002, ANNU REV PUBL HEALTH, V23, P349, DOI 10.1146/annurev.publhealth.23.100901.140548; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Daumit GL, 2006, ARCH GEN PSYCHIAT, V63, P267, DOI 10.1001/archpsyc.63.3.267; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Howard L, 2007, BRIT J PSYCHIAT, V190, P129, DOI 10.1192/bjp.bp.106.023671; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Joo JH, 2002, J CLIN PSYCHIAT, V63, P936, DOI 10.4088/JCP.v63n1012; Kerse N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002423; Kudoh A, 2005, ANESTH ANALG, V101, P1867, DOI 10.1213/01.ANE.0000184123.67853.86; Lai SW, 2010, MEDICINE, V89, P295, DOI 10.1097/MD.0b013e3181f15efc; Li Y, 2007, MED CARE, V45, P587, DOI 10.1097/MLR.0b013e31803d3b54; Liao CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031527; Liperoti R, 2007, J CLIN PSYCHIAT, V68, P929, DOI 10.4088/JCP.v68n0616; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; Meaney AM, 2007, SCHIZOPHR RES, V93, P136, DOI 10.1016/j.schres.2007.01.013; Newgard CD, 2011, AM J PUBLIC HEALTH, V101, P669, DOI 10.2105/AJPH.2010.300063; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel V, 2010, JAMA-J AM MED ASSOC, V303, P1976, DOI 10.1001/jama.2010.616; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Shih CC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-191; Thapa PB, 1998, NEW ENGL J MED, V339, P875, DOI 10.1056/NEJM199809243391303; Vassallo JL, 2007, BRAIN INJURY, V21, P567, DOI 10.1080/02699050701426832; Whooley MA, 1999, ARCH INTERN MED, V159, P484, DOI 10.1001/archinte.159.5.484; Wu Q, 2010, OSTEOPOROSIS INT, V21, P1627, DOI 10.1007/s00198-010-1181-x; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Yeh CC, 2012, INJURY, V43, P1903, DOI 10.1016/j.injury.2011.03.016	40	27	27	1	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2012	83	12					1186	1192		10.1136/jnnp-2012-302337			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	037IU	WOS:000311097700015	22773855				2022-02-06	
J	Waid-Ebbs, JK; Wen, PS; Heaton, SC; Donovan, NJ; Velozo, C				Waid-Ebbs, J. Kay; Wen, Pey-Shan; Heaton, Shelley C.; Donovan, Neila J.; Velozo, Craig			The item level psychometrics of the behaviour rating inventory of executive function-adult (BRIEF-A) in a TBI sample	BRAIN INJURY			English	Article						Measurement; Rasch analysis; traumatic brain injury; executive function; BRIEF-A	TRAUMATIC BRAIN-INJURY; CONFIRMATORY FACTOR-ANALYSIS; SELF-REPORT; DYSEXECUTIVE SYMPTOMS; ECOLOGICAL VALIDITY; COMMUNITY SAMPLE; SCALE FRSBE; OUTCOMES; REHABILITATION; CHILDREN	Primary objective: To determine whether the psychometrics of the BRIEF-A are adequate for individuals diagnosed with TBI. Research design: A prospective observational study in which the BRIEF-A was collected as part of a larger study. Methods and procedures: Informant ratings of the 75-item BRIEF-A on 89 individuals diagnosed with TBI were examined to determine items level psychometrics for each of the two BRIEF-A indexes: Behaviour Rating Index (BRI) and Metacognitive Index (MI). Patients were either outpatients or at least 1 year post-injury. Main outcomes and results: Each index measured a latent trait, separating individuals into five-to-six ability levels and demonstrated good reliability (0.94 and 0.96). Four items were identified that did not meet the infit criteria. Conclusions: The results provide support for the use of the BRIEF-A as a supplemental assessment of executive function in TBI populations. However, further validation is needed with other measures of executive function. Recommendations include use of the index scores over the Global Executive Composite score and use of the difficulty hierarchy for setting therapy goals.	[Waid-Ebbs, J. Kay; Velozo, Craig] N Florida S Georgia Vet Hlth Syst, Brain Rehabil Res Ctr Excellence, Gainesville, FL USA; [Wen, Pey-Shan] Univ Florida, Dept Hlth Outcomes & Policy, Gainesville, FL USA; [Heaton, Shelley C.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Donovan, Neila J.] Louisiana State Univ, Dept Commun Sci & Disorders, Baton Rouge, LA 70803 USA; [Velozo, Craig] N Florida S Georgia Vet Hlth Syst, Rehabil Outcome Res Ctr, Res Enhancement Award Program, Gainesville, FL USA; [Velozo, Craig] Univ Florida, Occupat Therapy Dept, Gainesville, FL USA		Waid-Ebbs, JK (corresponding author), 2314 SW 95th Terrace, Gainesville, FL 32607 USA.	julia.waid-ebbs@va.gov		Wen, Pey-Shan/0000-0002-8921-8801	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21HD045869-03]; VA RR&D Pre-Doctoral Fellowship Award; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD045869] Funding Source: NIH RePORTER	This study was conducted using existing data from an NIH funded study entitled 'Developing a Computer Adaptive TBI Cognitive Measure' (NIH R-21: #5R21HD045869-03) and from a VA RR&D Pre-Doctoral Fellowship Award. The study was approved by the Institutional Review Board of the University of Florida and the Research and Development Committee at the North Florida/South Georgia VA Medical Center.; This material is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.	Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; ARRINDELL WA, 1985, APPL PSYCH MEAS, V9, P165, DOI 10.1177/014662168500900205; Bond T, 2001, APPL RASCH MODEL FUN; Brown TA., 2015, CONFIRMATORY FACTOR, V2; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW., 2005, EFFECTIVENESS REHABI; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Crocker L., 1986, INTRO CLASSICAL MODE; Cummings J. L., 2007, HUMAN FRONTAL LOBES; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Donovan NJ, 2011, BRAIN INJURY, V25, P348, DOI 10.3109/02699052.2011.556105; Egeland J, 2010, CHILD NEUROPSYCHOL, V16, P326, DOI 10.1080/09297041003601462; Fuster JM, 2000, EXP BRAIN RES, V133, P66, DOI 10.1007/s002210000401; Garlinghouse MA, 2010, SCHIZOPHR RES, V120, P71, DOI 10.1016/j.schres.2010.02.1067; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2005, PSYCHOL ASSESS RESOU; GRAHAM DI, 1999, REHABILITATION ADULT, P19; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jette AM, 2005, J REHABIL MED, V37, P339, DOI 10.1080/16501970500302793; Johnston MV, 2006, BRAIN INJURY, V20, P391, DOI 10.1080/02699050500487795; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, pS3; Kline P., 1981, PERSONAL STUDY GROUP, V1, P23; Lane-Brown AT, 2009, BRAIN INJURY, V23, P999, DOI 10.3109/02699050903379347; LeJeune B, 2010, CHILD NEUROPSYCHOL, V16, P182, DOI 10.1080/09297040903352556; Levin B, 2008, COGNITIVE NEUROREHAB; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Linacre J, 1994, RASCH MEAS T, V7, P328; Linacre J.M., 2002, RASCH MEAS T, V16; Linacre John M, 2002, J Appl Meas, V3, P85; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; MARSH HW, 1988, PSYCHOL BULL, V103, P391, DOI 10.1037/0033-2909.103.3.391; Massof Robert W, 2010, J Appl Meas, V11, P253; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McMahon Brian T, 2005, Work, V25, P67; MUTHEN BO, 2006, MPLUS USERS GUIDE; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Reid RC, 2010, INT J NEUROSCI, V120, P120, DOI 10.3109/00207450903165577; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; Sohlberg M., 2001, COGNITIVE REHABILITA; Spinella M, 2005, BIOL PSYCHOL, V70, P175, DOI 10.1016/j.biopsycho.2004.01.005; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Velozo CA, 2006, J OCCUP REHABIL, V16, P109, DOI 10.1007/s10926-005-9014-z; Velozo CA, 2011, J REHABIL RES DEV, V48, P1211, DOI 10.1682/JRRD.2010.10.0203; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wright B, 1979, BEST TEST DESIGN; Wright B, 1994, MEASUREMENT T, V8, P370; Wright BD., 1982, RATING SCALE ANAL	58	27	27	0	19	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1646	1657		10.3109/02699052.2012.700087			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700011	22876936				2022-02-06	
J	Koz, ST; Etem, EO; Baydas, G; Yuce, H; Ozercan, HI; Kuloglu, T; Koz, S; Etem, A; Demir, N				Koz, Sema Tulay; Etem, Ebru Onalan; Baydas, Gyasettin; Yuce, Huseyin; Ozercan, Halil Ibrahim; Kuloglu, Tuncay; Koz, Suleyman; Etem, Arzu; Demir, Nevgul			Effects of resveratrol on blood homocysteine level, on homocysteine induced oxidative stress, apoptosis and cognitive dysfunctions in rats	BRAIN RESEARCH			English	Article						Resveratrol; Homocysteine; Oxidative stress; Apoptosis; TUNEL; Cognitive function	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; RED WINE; IN-VITRO; ENDOTHELIAL FUNCTION; PLATELET ACTIVATION; CELL PROLIFERATION; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; HYPERHOMOCYSTEINEMIA	We aimed to examine the protective effects of resveratrol against homocysteine induced oxidative stress, apoptosis and cognitive impairment. Rats were randomly divided into three groups. Control group received standard rat food; homocysteine group (I-Icy group) received daily methionine at a dose of 1 g/kg-body weight dissolved in drinking water for thirty days; third group (Hcy+Res group) received same amount of methionine plus 20 mg/kg/day resveratrol intraperitoneally for thirty days. Cognitive performances of the animals were tested by Morris water maze test. Then all animals were sacrificed to study lipid peroxidation (LPO), DNA fragmentation and p53 mRNA expression in the rat brain. The aortas of the sacrificed rats were processed for histopathological examination. Apoptosis in the aortas was assessed by TUNEL staining. Resveratrol significantly decreased serum levels of homocysteine, reversed Hcy induced LPO increase, decreased DNA fragmentation and p53 mRNA expression in the rat brains, and improved homocysteine induced impairment of long term spatial memory. Resveratrol could inhibit homocysteine induced apoptosis and histopathological deterioration in the rat aortic sections. In conclusion, resveratrol is effective in preventing homocysteine induced vascular and neural defects. In hyperhomocysteinemic rat model, our findings consequently warrant in future studies to reveal the true improvement mechanism of resveratrol. (C) 2012 Elsevier B.V. All rights reserved.	[Koz, Sema Tulay] Malatya State Hosp, Dept Lab, TR-44000 Malatya, Turkey; [Etem, Ebru Onalan; Yuce, Huseyin] Firat Univ, Fac Med, Dept Med Biol & Genet, TR-23119 Elazig, Turkey; [Baydas, Gyasettin] Bingol Univ, TR-12000 Bingol, Turkey; [Ozercan, Halil Ibrahim] Firat Univ, Fac Med, Dept Pathol, TR-23119 Elazig, Turkey; [Kuloglu, Tuncay] Firat Univ, Fac Med, Dept Histol & Embryol, TR-23119 Elazig, Turkey; [Koz, Suleyman] Inonu Univ, Turgut Ozal Med Ctr, Dept Nephrol, TR-44300 Malatya, Turkey; [Demir, Nevgul] Okmeydani Res Hosp, Dept Biochim, Istanbul, Turkey; Kecioren Res Hosp, Dept Family Med, TR-06380 Ankara, Turkey		Koz, ST (corresponding author), Malatya State Hosp, Dept Lab, TR-44000 Malatya, Turkey.	kozsema@hotmail.com	BAYDAS, GIYASETTIN/AAI-4266-2021; onalan, ebru/C-6463-2016; kuloglu, tuncay/W-2310-2018; Koz, Sema T/AAS-3664-2021	onalan, ebru/0000-0001-9968-8201; Koz, Sema T/0000-0002-6342-0200; Baydas, Giyasettin/0000-0002-9206-3177			Akar F, 2011, CARDIOVASC DRUG THER, V25, P119, DOI 10.1007/s10557-010-6255-7; Al-Obaidi MK, 2000, CIRCULATION, V101, P372, DOI 10.1161/01.CIR.101.4.372; Aman M, 2010, J VASC RES, V47, P494, DOI 10.1159/000313877; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bagi Z, 2003, AM J PHYSIOL-HEART C, V285, pH2277, DOI 10.1152/ajpheart.00448.2003; Baydas G, 2005, NEUROSCIENCE, V135, P879, DOI 10.1016/j.neuroscience.2005.05.048; Baydas G, 2005, BRAIN RES, V1046, P187, DOI 10.1016/j.brainres.2005.04.011; Baydas G, 2007, INT J DEV NEUROSCI, V25, P133, DOI 10.1016/j.ijdevneu.2007.03.001; Berrougui H, 2009, ATHEROSCLEROSIS, V207, P420, DOI 10.1016/j.atherosclerosis.2009.05.017; Binienda ZK, 2010, NEUROSCI LETT, V480, P117, DOI 10.1016/j.neulet.2010.06.020; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Dayal S, 2008, ARTERIOSCL THROM VAS, V28, P1596, DOI 10.1161/ATVBAHA.108.166421; Deng WG, 2004, WORLD J GASTROENTERO, V10, P46; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Gatz SA, 2008, CARCINOGENESIS, V29, P321, DOI 10.1093/carcin/bgm276; Ghribi O, 2003, J NEUROSCI RES, V71, P853, DOI 10.1002/jnr.10511; Henning SM, 1997, FREE RADICAL BIO MED, V23, P936, DOI 10.1016/S0891-5849(97)00097-X; Hsieh TC, 1999, CANCER RES, V59, P2596; Hsieh TC, 2010, INT J MOL MED, V26, P741, DOI 10.3892/ijmm_00000521; Huang RFS, 2001, J NUTR, V131, P33, DOI 10.1093/jn/131.1.33; Janicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33; Kaneider NC, 2004, THROMB RES, V114, P185, DOI 10.1016/j.thromres.2004.06.020; Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008; Khan MM, 2010, BRAIN RES, V1328, P139, DOI 10.1016/j.brainres.2010.02.031; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kim DH, 2011, AM J PHYSIOL-RENAL, V301, pF427, DOI 10.1152/ajprenal.00258.2010; Koz S.T., 2011, PHYTOTHER RES; Koz ST, 2010, INT J DEV NEUROSCI, V28, P325, DOI 10.1016/j.ijdevneu.2010.02.006; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Kumar A, 2010, BIOCHEM BIOPH RES CO, V394, P360, DOI 10.1016/j.bbrc.2010.03.014; Lee SJ, 2005, J BIOL CHEM, V280, P5781, DOI 10.1074/jbc.M411224200; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212; Malinowska J, 2011, PLATELETS, V22, P277, DOI 10.3109/09537104.2010.550349; Martinez-Cruz F, 2006, NEUROSCI LETT, V392, P1, DOI 10.1016/j.neulet.2005.02.073; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Mokni M, 2007, NEUROCHEM RES, V32, P981, DOI 10.1007/s11064-006-9255-z; Mokni M, 2007, ARCH BIOCHEM BIOPHYS, V457, P1, DOI 10.1016/j.abb.2006.10.015; Moriya J, 2011, BIOL PHARM BULL, V34, P354, DOI 10.1248/bpb.34.354; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Nicholson SK, 2010, BRIT J NUTR, V103, P1398, DOI 10.1017/S0007114509993485; Noll C, 2009, FOOD CHEM TOXICOL, V47, P230, DOI 10.1016/j.fct.2008.11.005; Okawara M, 2007, BIOCHEM PHARMACOL, V73, P550, DOI 10.1016/j.bcp.2006.11.003; Poussier B, 2005, J VASC SURG, V42, P1190, DOI 10.1016/j.jvs.2005.08.014; Ranney A, 2009, BEHAV PHARMACOL, V20, P330, DOI 10.1097/FBP.0b013e32832f0193; Ridker P.M., 2011, BONOW BRAUNWALDS HEA, P927; Rivera L, 2009, BIOCHEM PHARMACOL, V77, P1053, DOI 10.1016/j.bcp.2008.11.027; Robb EL, 2008, BIOCHEM BIOPH RES CO, V372, P254, DOI 10.1016/j.bbrc.2008.05.028; Ruef J, 2001, CARDIOVASC PATHOL, V10, P311, DOI 10.1016/S1054-8807(01)00095-3; Sakata Y, 2010, EXP NEUROL, V224, P325, DOI 10.1016/j.expneurol.2010.03.032; Schmatz R, 2009, EUR J PHARMACOL, V610, P42, DOI 10.1016/j.ejphar.2009.03.032; Schroecksnadel K, 2005, CLIN CHEM LAB MED, V43, P1084, DOI 10.1515/CCLM.2005.189; Shen MY, 2007, BRIT J HAEMATOL, V139, P475, DOI 10.1111/j.1365-2141.2007.06788.x; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Smith AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012244; Soh UJK, 2010, BRIT J PHARMACOL, V160, P191, DOI 10.1111/j.1476-5381.2010.00705.x; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Streck EL, 2004, BEHAV BRAIN RES, V153, P377, DOI 10.1016/j.bbr.2003.12.013; Streck EL, 2003, METAB BRAIN DIS, V18, P147, DOI 10.1023/A:1023815119931; Tsai SK, 2007, J VASC SURG, V46, P346, DOI 10.1016/j.jvs.2007.04.044; Tyagi N, 2005, AM J PHYSIOL-HEART C, V289, pH2649, DOI 10.1152/ajpheart.00548.2005; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Wang Q, 2004, NEUROCHEM RES, V29, P2105, DOI 10.1007/s11064-004-6883-z; Win W, 2002, MUTAT RES-GEN TOX EN, V513, P113, DOI 10.1016/S1383-5718(01)00303-5; Yang YM, 2008, EUR J PHARMACOL, V583, P148, DOI 10.1016/j.ejphar.2008.01.009; Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068; Zhang C, 2011, CARDIOVASC RES, V90, P538, DOI 10.1093/cvr/cvr022; Zhang HR, 2009, ARTERIOSCL THROM VAS, V29, P1164, DOI 10.1161/ATVBAHA.109.187146; Zhang J, 2011, INT J FOOD SCI NUTR, V62, P814, DOI 10.3109/09637486.2011.581651; Zou JG, 2000, LIFE SCI, V68, P153, DOI 10.1016/S0024-3205(00)00925-5; Zou JG, 2003, INT J MOL MED, V11, P317	76	27	27	2	39	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 12	2012	1484						29	38		10.1016/j.brainres.2012.09.026			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	038LB	WOS:000311175100003	22995369				2022-02-06	
J	Englot, DJ; Rolston, JD; Wang, DD; Hassnain, KH; Gordon, CM; Chang, EF				Englot, Dario J.; Rolston, John D.; Wang, Doris D.; Hassnain, Kevin H.; Gordon, Charles M.; Chang, Edward F.			Efficacy of vagus nerve stimulation in posttraumatic versus nontraumatic epilepsy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						posttraumatic epilepsy; seizure; epilepsy; traumatic brain injury; vagus nerve stimulation	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; TREATMENT-RESISTANT DEPRESSION; PATIENT OUTCOME REGISTRY; TEMPORAL-LOBE EPILEPSY; FAILED CRANIAL SURGERY; INTRACTABLE EPILEPSY; MULTICENTER; THERAPY; VNS	Object. In the US, approximately 500,000 individuals are hospitalized yearly for traumatic brain injury (TBI), and posttraumatic epilepsy (PTE) is a common sequela of TBI. Improved treatment strategies for PTE are critically needed, as patients with the disorder are often resistant to antiepileptic medications and are poor candidates for definitive resection. Vagus nerve stimulation (VNS) is an adjunctive treatment for medically refractory epilepsy that results in a >= 50% reduction in seizure frequency in approximately 50% of patients after 1 year of therapy. The role of VNS in PTE has been poorly studied. The aim of this study was to determine whether patients with PTE attain more favorable seizure outcomes than individuals with nontraumatic epilepsy etiologies. Methods. Using a case-control study design, the authors retrospectively compared seizure outcomes after VNS therapy in patients with PTE versus those with nontraumatic epilepsy (non-PTE) who were part of a large prospectively collected patient registry. Results. After VNS therapy, patients with PTE demonstrated a greater reduction in seizure frequency (50% fewer seizures at the 3-month follow-up; 73% fewer seizures at 24 months) than patients with non-PTE (46% fewer seizures at 3 months; 57% fewer seizures at 24 months). Overall, patients with PTE had a 78% rate of clinical response to VNS therapy at 24 months (that is, >= 50% reduction in seizure frequency) as compared with a 61% response rate among patients with non-PTE (OR 1.32, 95% CI 1.07-1.61), leading to improved outcomes according to the Engel classification (p < 0.0001, Cochran-Mantel-Haenszel statistic). Conclusions. Vagus nerve stimulation should be considered in patients with medically refractory PTE who are not good candidates for resection. A controlled prospective trial is necessary to further examine seizure outcomes as well as neuropsychological outcomes after VNS therapy in patients with intractable PTE. (http://thejns.org/doi/abs/10.3171/2012.8.JN122)	[Englot, Dario J.; Rolston, John D.; Wang, Doris D.; Chang, Edward F.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Englot, Dario J.; Rolston, John D.; Wang, Doris D.; Chang, Edward F.] Univ Calif San Francisco, Comprehens Epilepsy Ctr, San Francisco, CA 94143 USA; [Hassnain, Kevin H.; Gordon, Charles M.] Cyberonics Inc, Houston, TX USA		Englot, DJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Box 0112, San Francisco, CA 94143 USA.	EnglotDJ@neurosurg.ucsf.edu	Rolston, John/AAG-3436-2019; Englot, Dario J./C-3656-2013	Rolston, John/0000-0002-8843-5468; Englot, Dario J./0000-0001-8373-690X; Wang, Doris/0000-0001-6112-3002	Cyberonics, Inc.	Two authors (K.H.H. and C.M.G.) are employees of Cyberonics, Inc., the manufacturer of the VNS Therapy System and sponsor of the VNS Therapy Patient Outcome Registry. They assisted in the statistical analyses.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Amar AP, 2004, NEUROSURGERY, V55, P1086, DOI 10.1227/01.NEU.0000141073.08427.76; Amar AP, 2008, NEUROSURGERY, V62, P506, DOI [10.1227/01.NEU,0000141073.08427.76, 10.1227/01.neu.0000316253.54651.5e]; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Ansari S, 2007, ACTA NEUROCHIR SUPPL, V97, P281; Ben-Menachem E, 2002, LANCET NEUROL, V1, P477, DOI 10.1016/S1474-4422(02)00220-X; Birbeck GL, 2002, EPILEPSIA, V43, P535, DOI 10.1046/j.1528-1157.2002.32201.x; Cecchini AP, 2009, NEUROL SCI, V30, pS101, DOI 10.1007/s10072-009-0073-3; Chang EF, 2010, EPILEPSIA, V51, P87, DOI 10.1111/j.1528-1167.2009.02457.x; CHASE MICHAEL H., 1967, BRAIN RES, V5, P236, DOI 10.1016/0006-8993(67)90089-3; Elliott RE, 2011, EPILEPSY BEHAV, V20, P57, DOI 10.1016/j.yebeh.2010.10.017; Engel, 1987, SURG TREATMENT EPILE, P553; Englot DJ, 2011, J NEUROSURG, V115, P1248, DOI 10.3171/2011.7.JNS11977; Englot DJ, 2011, NEUROSURG CLIN N AM, V22, P443, DOI 10.1016/j.nec.2011.07.002; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; George MS, 2008, BRAIN STIMUL, V1, P112, DOI 10.1016/j.brs.2008.02.001; George MS, 2005, BIOL PSYCHIAT, V58, P364, DOI 10.1016/j.biopsych.2005.07.028; Henry TR, 2002, NEUROLOGY, V59, pS3, DOI 10.1212/WNL.59.6_suppl_4.S3; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hord ED, 2003, J PAIN, V4, P530, DOI 10.1016/j.jpain.2003.08.001; Jabbari B, 2002, BRAIN INJURY, V16, P463, DOI 10.1080/02699050110102086; Klinkenberg S, 2012, CLIN NEUROL NEUROSUR, V114, P336, DOI 10.1016/j.clineuro.2011.11.016; Koo B, 2001, J CLIN NEUROPHYSIOL, V18, P434, DOI 10.1097/00004691-200109000-00008; Lee HO, 2008, J KOREAN NEUROSURG S, V44, P196, DOI 10.3340/jkns.2008.44.4.196; Luoni C, 2011, EPILEPSIA, V52, P2181, DOI 10.1111/j.1528-1167.2011.03325.x; McLachlan RS, 1997, ANN NEUROL, V41, P482, DOI 10.1002/ana.410410411; Neese SL, 2007, BRAIN RES, V1128, P157, DOI 10.1016/j.brainres.2006.09.073; Riggio S, 2010, PSYCHIAT CLIN N AM, V33, P807, DOI 10.1016/j.psc.2010.08.004; Rush AJ, 2000, BIOL PSYCHIAT, V47, P276, DOI 10.1016/S0006-3223(99)00304-2; Rush AJ, 2005, BIOL PSYCHIAT, V58, P355, DOI 10.1016/j.biopsych.2005.05.024; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; von Lehe M, 2006, EPILEPSY BEHAV, V9, P73, DOI 10.1016/j.yebeh.2006.03.014	34	27	28	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2012	117	5					970	977		10.3171/2012.8.JNS122			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	027UW	WOS:000310380300033	22978542	Bronze			2022-02-06	
J	Fang, F; Chen, HL; Feldman, AL; Kamel, F; Ye, WM; Wirdefeldt, K				Fang, Fang; Chen, Honglei; Feldman, Adina L.; Kamel, Freya; Ye, Weimin; Wirdefeldt, Karin			Head injury and Parkinson's disease: A population-based study	MOVEMENT DISORDERS			English	Article						Parkinson disease; head injury; nested case-control study; odds ratio	ENVIRONMENTAL RISK-FACTORS; TRAUMATIC BRAIN-INJURY; HISTORY	Background: The epidemiological evidence on head injury and the risk of Parkinson's disease (PD) has been inconsistent. Methods: We examined the relation between previous hospitalization for head injury and PD using a population-based nested case-control design based on the Swedish National Patient Register from 2001 until 2007, including 18,648 PD cases and 93,240 controls, randomly selected from the general population. Exposure was defined as hospitalization for head injury between 1987 and index date. Results: Overall, previous hospitalization resulting from head injury was associated with an increased risk of PD; this association appeared to be largely explained by head injuries experienced recently, especially within 1 year before PD ascertainment. Conclusions: Our results do not provide convincing evidence for a causal relationship between head injury later in life and PD. (C) 2012 Movement Disorder Society	[Fang, Fang; Feldman, Adina L.; Ye, Weimin; Wirdefeldt, Karin] Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden; [Chen, Honglei; Kamel, Freya] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; [Wirdefeldt, Karin] Karolinska Inst, Dept Clin Neurosci, SE-17177 Stockholm, Sweden		Wirdefeldt, K (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Box 281, SE-17177 Stockholm, Sweden.	karin.wirdefeldt@ki.se	Feldman, Adina/H-3435-2012	Feldman, Adina/0000-0002-9388-6896; Kamel, Freya/0000-0001-5052-6615; Fang, Fang/0000-0002-3310-6456; Chen, Honglei/0000-0003-3446-7779	Swedish Research Council (SIMSAM)Swedish Research Council [80748301]; Swedish Parkinson Foundation; Swedish Medical Society; Swedish Society for Medical Research; Swedish Brain Foundation; National Institutes of Health, the National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01-ES-101986]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ZIAES044007, Z01ES101986, ZIAES101986] Funding Source: NIH RePORTER	The study was supported by the Swedish Research Council (SIMSAM grant no. 80748301), the Swedish Parkinson Foundation, the Swedish Medical Society, the Swedish Society for Medical Research, the Swedish Brain Foundation, and the intramural research program of the National Institutes of Health, the National Institute of Environmental Health Sciences (Z01-ES-101986 and unmet need funding). The funding sources had no role in the design of the study or the decision to submit the manuscript for publication.	Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Carvey PM, 2009, J NEUROCHEM, V111, P291, DOI 10.1111/j.1471-4159.2009.06319.x; Dahl E, 2006, INJURY, V37, P402, DOI 10.1016/j.injury.2005.09.008; Dick FD, 2007, OCCUP ENVIRON MED, V64, P666, DOI 10.1136/oem.2006.027003; Dong JQ, 2003, BIOMED ENVIRON SCI, V16, P173; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; Feldman AL, 2012, NEUROEPIDEMIOLOGY, V38, P186, DOI 10.1159/000336356; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Hawkes CH, 2010, PARKINSONISM RELAT D, V16, P79, DOI 10.1016/j.parkreldis.2009.08.007; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; LACAVA G, 1963, J Sports Med Phys Fitness, V3, P87; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Logroscino G, 2005, ENVIRON HEALTH PERSP, V113, P1234, DOI 10.1289/ehp.7573; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#; Tsai CH, 2002, CLIN NEUROL NEUROSUR, V104, P328, DOI 10.1016/S0303-8467(02)00027-6; Wirdefeldt K, 2008, NEUROBIOL AGING, V29, P1765, DOI 10.1016/j.neurobiolaging.2007.04.009; Wirdefeldt K, 2011, EUR J EPIDEMIOL, V26, pS1, DOI 10.1007/s10654-011-9581-6; Wright JM, 2005, ARCH ENVIRON HEALTH, V60, P32, DOI 10.3200/AEOH.60.1.32-38	22	27	27	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.	NOV	2012	27	13					1632	1635		10.1002/mds.25143			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	045KU	WOS:000311695500013	23143933				2022-02-06	
J	Harrison-Felix, C; Kreider, SED; Arango-Lasprilla, JC; Brown, AW; Dijkers, MP; Hammond, FM; Kolakowsky-Hayner, SA; Hirshson, C; Whiteneck, G; Zasler, ND				Harrison-Felix, Cynthia; Kreider, Scott E. D.; Arango-Lasprilla, Juan C.; Brown, Allen W.; Dijkers, Marcel P.; Hammond, Flora M.; Kolakowsky-Hayner, Stephanie A.; Hirshson, Chari; Whiteneck, Gale; Zasler, Nathan D.			Life Expectancy Following Rehabilitation: A NIDRR Traumatic Brain Injury Model Systems Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; chronic; epidemiology; life expectancy; mortality; rehabilitation; vital statistics	TERM MORTALITY TRENDS; HEAD-INJURY; SURVIVAL; DEATH; RISK; COMA	Objective: To characterize overall and cause-specific mortality and life expectancy among persons who have completed inpatient traumatic brain injury rehabilitation and to assess risk factors for mortality. Design: Prospective cohort study. Setting: The Traumatic Brain Injury Model Systems. Participants: A total of 8573 individuals injured between 1988 and 2009, with survival status per December 31, 2009, determined. Interventions: Not applicable. Main Outcome Measures: Standardized mortality ratio (SMR), life expectancy, cause of death. Results: SMR was 2.25 overall and was significantly elevated for all age groups, both sexes, all race/ethnic groups (except Native Americans), and all injury severity groups. SMR decreased as survival time increased but remained elevated even after 10 years postinjury. SMR was elevated for all cause-of-death categories but especially so for seizures, aspiration pneumonia, sepsis, accidental poisonings, and falls. Life expectancy was shortened an average of 6.7 years. Multivariate Cox regression showed age at injury, sex, race/ethnic group, marital status and employment status at the time of injury year of injury, preinjury drug use, days unconscious, functional independence and disability on rehabilitation discharge, and comorbid spinal cord injury to be independent risk factors for death. Conclusion: There is an increased risk of death after moderate or severe traumatic brain injury. Risk factors and causes of death have been identified that may be amenable to intervention.	[Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Arango-Lasprilla, Juan C.] Univ Deusto Ikerbasque, Basque Fdn Sci, Bilbao, Spain; [Brown, Allen W.] Mayo Clin, Rochester, MN USA; [Dijkers, Marcel P.; Hirshson, Chari] Mt Sinai Sch Med, New York, NY USA; [Hammond, Flora M.] Carolinas HealthCare Syst, Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN USA; [Kolakowsky-Hayner, Stephanie A.] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; [Zasler, Nathan D.] Concuss Care Ctr Virginia Ltd, Richmond, VA USA; [Zasler, Nathan D.] Tree Life Serv Inc, Richmond, VA 23233 USA; [Zasler, Nathan D.] Virginia Commonwealth Univ, Richmond, VA 23284 USA		Harrison-Felix, C (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	charrison-felix@craighospital.org	Heinemann, Allen W/K-6283-2012; Kolakowsky-Hayner, Stephanie A./I-9858-2019	Heinemann, Allen W/0000-0003-2782-7326; Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Dijkers, Marcel/0000-0002-8362-5596; Brown, Allen W./0000-0001-7228-3351	National Institute on Disability and Rehabilitation Research; Office of Special Education Services; Department of EducationUS Department of Education [H133A110006, H133A070022]; Mount Sinai School of Medicine [H133A070033]; Virginia Commonwealth University [H133A070036]; Mayo Clinic [H133A070013]; Santa Clara Valley Medical Center [H133A070038]; Carolinas HealthCare System [H133A070042]	This work was supported, in part, by grants from the National Institute on Disability and Rehabilitation Research, Office of Special Education Services, Department of Education to Craig Hospital (H133A110006, H133A070022), Mount Sinai School of Medicine (H133A070033), Virginia Commonwealth University (H133A070036), Mayo Clinic (H133A070013), Santa Clara Valley Medical Center (H133A070038), and Carolinas HealthCare System (H133A070042). However, the contents of this manuscript do not necessarily represent the policy of the Department of Education and endorsement by the Federal Government should not be assumed.	Baguley I, 2000, BRAIN INJURY, V14, P505; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Baguley IJ, 2008, BRAIN INJURY, V22, P919, DOI 10.1080/02699050802448578; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Egede LE, 2012, AM J PUBLIC HEALTH, V102, pS266, DOI 10.2105/AJPH.2011.300176; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shavelle RM, 2007, BRAIN INJURY MED PRI, P247; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151	38	27	27	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					E69	E80		10.1097/HTR.0b013e3182738010			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200007	23131972				2022-02-06	
J	Homaifar, BY; Brenner, LA; Forster, JE; Nagamoto, H				Homaifar, Beeta Y.; Brenner, Lisa A.; Forster, Jeri E.; Nagamoto, Herbert			Traumatic Brain Injury, Executive Functioning, and Suicidal Behavior: A Brief Report	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; suicide attempt; suicidal ideation; executive functioning; perseveration	DEPRESSION; RUMINATION; IDEATION; ATTEMPTERS; HISTORY; MODEL	Objective: The aim of this pilot study was to explore the relationship between executive dysfunction and suicidal behavior in two groups of participants: (Group 1, n = 18) veterans with traumatic brain injury (TBI) and a history of at least one suicide attempt (SA), and (Group 2, n = 29) veterans with TBI and no history of SA. Controlling for the severity of TBI, it was hypothesized that participants in Group 1 would perform more poorly than those in Group 2 on measures of executive functioning. Design: The primary outcome variable was decision making as assessed by performance on the Iowa Gambling Task (IGT). Secondary outcome variables included laboratory-measured impulsivity as measured by the Immediate and Delayed Memory Test (IMT/DMT), abstract reasoning as measured by the Wisconsin Card Sorting Test (WCST), and aggression as measured by the Lifetime History of Aggression (LHA) scale. Results: Among those in Group 1, time between TBI and first suicide attempt postinjury varied widely (months to nearly 30 years). Only the WCST perseverative errors score differed significantly between individuals with and without histories of one or more suicide attempts (SAs). Conclusion: Suggestions for future study of SA among those with TBI are provided. When working with individuals with TBI, clinicians are encouraged to incorporate suicide risk assessment into their practice. Augmenting this process with a measure of perseveration may be beneficial.	[Homaifar, Beeta Y.; Brenner, Lisa A.] VISN 19 MIRECC, Denver, CO 80220 USA; [Homaifar, Beeta Y.; Brenner, Lisa A.; Nagamoto, Herbert] Univ Colorado Denver, Sch Med, Dept Psychiat, Denver, CO 80210 USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Neurol, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Phys Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Rehabil, Denver, CO USA; [Forster, Jeri E.] Univ Colorado Denver, Sch Med, Dept Pediat, Denver, CO USA; [Nagamoto, Herbert] Eastern Colorado Hlth Care Syst, Vet Affairs Med Ctr, Denver, CO USA		Homaifar, BY (corresponding author), VISN 19 MIRECC, 1055 Clermont St, Denver, CO 80220 USA.	beeta.homaifar@va.gov	Brenner, Lisa A./AAG-2442-2019				Allen LM, 2004, CARB COMPUTERIZED AS; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; Davis RN, 2000, COGNITIVE THER RES, V24, P699, DOI 10.1023/A:1005591412406; Department of Veterans Affairs, 2009, VA DOD CLIN PRACT GU; Dougherty DM, 2004, SUICIDE LIFE-THREAT, V34, P374, DOI 10.1521/suli.34.4.374.53738; Heaton PDRK., 1993, WISCONSIN CARD SORTI; JANOFSKY JS, 1992, HOSP COMMUNITY PSYCH, V43, P132; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Jollant F, 2005, AM J PSYCHIAT, V162, P304, DOI 10.1176/appi.ajp.162.2.304; Keilp JG, 2001, AM J PSYCHIAT, V158, P735, DOI 10.1176/appi.ajp.158.5.735; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Marzuk PM, 2005, ACTA PSYCHIAT SCAND, V112, P294, DOI 10.1111/j.1600-0447.2005.00585.x; O'Connor RC, 2008, BEHAV RES THER, V46, P392, DOI 10.1016/j.brat.2008.01.007; Oquendo M. A., 2003, STANDARDIZED EVALUAT, P103; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Rudd MD, 2006, COGNITION SUICIDE TH, P355, DOI [10.1037/11377-016, DOI 10.1037/11377-016]; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Smith JM, 2006, SUICIDE LIFE-THREAT, V36, P443, DOI 10.1521/suli.2006.36.4.443; Smith JM, 2009, CLIN PSYCHOL REV, V29, P116, DOI 10.1016/j.cpr.2008.10.003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Watkins E, 2008, EMOTION, V8, P364, DOI 10.1037/1528-3542.8.3.364; Wells A, 1996, BEHAV RES THER, V34, P881, DOI 10.1016/S0005-7967(96)00050-2; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	29	27	27	1	16	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2012	57	4					337	341		10.1037/a0030480			5	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	047EG	WOS:000311819900009	23181582				2022-02-06	
J	Tian, Z; Yu, W; Liu, HB; Zhang, N; Li, XB; Zhao, MG; Liu, SB				Tian, Zhen; Yu, Wei; Liu, Hong-bao; Zhang, Nan; Li, Xu-bo; Zhao, Ming-gao; Liu, Shui-bing			Neuroprotective effects of curculigoside against NMDA-induced neuronal excitoxicity in vitro	FOOD AND CHEMICAL TOXICOLOGY			English	Article						Excitotoxicity; NMDA; Curculigoside; Neuroprotection	CELL-LINE; GLUTAMATE; EXCITOTOXICITY; DEATH; CONTRIBUTES; ORCHIOIDES; ANTAGONIST; RECEPTORS; TOXICITY; DISEASE	Glutamate is an important excitatory neurotransmitter in the central nervous system. Excessive accumulation of glutamate can cause excitotoxicity, which plays a key role in spinal cord injury, traumatic brain injury, stroke, and neurodegenerative diseases. Curculigoside (CCGS) is a major bioactive compound isolated from the rhizome of Curculigo orchioides Gaertn. CCGS has an extensive biological effect and has been used in Traditional Chinese Medicine. However, little is known about the neuroprotective effects of CCGS on glutamate-induced excitotoxicity. This study aims to evaluate the neuroprotective effects of CCGS in cultured cortical neurons. The results indicated that treatment with 1 and 10 mu M CCGS evidently prevented N-methyl-D-aspartate (NMDA)-induced neuronal cell loss and reduced the number of apoptotic and necrotic cells in a time- and concentration-dependent manner. The neuroprotective effects of CCGS are related to down regulating the apoptotic protein levels and reducing the production of intracellular reactive oxygen species in cultured cortical neurons. These findings give a new insight into the development of natural anti-excitotoxicity agents. (C) 2012 Elsevier Ltd. All rights reserved.	[Tian, Zhen; Zhang, Nan; Li, Xu-bo; Zhao, Ming-gao; Liu, Shui-bing] Sch Pharm, Dept Pharmacol, Xian 710032, Shaanxi, Peoples R China; [Liu, Hong-bao] Fourth Mil Med Univ, Xijing Hosp, Dept Nephrol, Xian 710032, Shaanxi, Peoples R China; [Yu, Wei] 208th Hosp Peoples Liberat Army, Dept Clin Lab, Changchun 130062, Jilin, Peoples R China		Liu, SB (corresponding author), Sch Pharm, Dept Pharmacol, Xian 710032, Shaanxi, Peoples R China.	liushb1974@yahoo.com.cn		Liu, Hongbao/0000-0002-1283-4956	NSF of ChinaNational Natural Science Foundation of China (NSFC) [31070923, 30900277, 2008ZXJ09004-023, 2009ZX09103-111, 2011ZXJ091 06-01C]; Program for New Century Excellent Talents in UniversityProgram for New Century Excellent Talents in University (NCET)	This research was supported by NSF of China, Nos. 31070923, 30900277, 2008ZXJ09004-023, 2009ZX09103-111, 2011ZXJ091 06-01C, and Program for New Century Excellent Talents in University.	Behbahani H, 2005, J NEUROSCI RES, V82, P432, DOI 10.1002/jnr.20634; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BRORSON JR, 1994, J NEUROSCI, V14, P187; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; Chen J, 2011, NEUROSCI LETT, V499, P181, DOI 10.1016/j.neulet.2011.05.054; Chen L, 2008, NEUROPHARMACOLOGY, V54, P1175, DOI 10.1016/j.neuropharm.2008.03.007; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Gonzalez-Juanatey JR, 2004, J ENDOCRINOL, V180, P325; Hirata Y, 2011, J NEUROCHEM, V119, P839, DOI 10.1111/j.1471-4159.2011.07464.x; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; Jiang W, 2011, NEUROSCIENCE, V192, P572, DOI 10.1016/j.neuroscience.2011.06.079; Jiao L, 2009, PHYTOMEDICINE, V16, P874, DOI 10.1016/j.phymed.2009.01.005; Leaver KR, 2008, CLIN EXP PHARMACOL P, V35, P1388, DOI 10.1111/j.1440-1681.2008.05046.x; Li ST, 2012, CURR DRUG TARGETS, V13, P207, DOI 10.2174/138945012799201630; Ma CJ, 2011, PHYTOTHER RES, V25, P922, DOI 10.1002/ptr.3449; MANEV H, 1989, MOL PHARMACOL, V36, P106; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Shen H., 2008, BRAIN RES B; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tahar AH, 2004, NEUROBIOL DIS, V15, P171, DOI 10.1016/j.nbd.2003.10.007; Tao LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026055; Wang H, 2008, NEURON, V59, P634, DOI 10.1016/j.neuron.2008.06.027; Wang Y, 2012, ACTA BIOCH BIOPH SIN, V44, P431, DOI 10.1093/abbs/gms014; Wang YK, 2010, J ETHNOPHARMACOL, V132, P233, DOI 10.1016/j.jep.2010.08.008; Wu Q, 2005, CHEM PHARM BULL, V53, P1065, DOI 10.1248/cpb.53.1065; Zhang Y., 2012, CHEM-BIOL INTERACT, V53, P1065	30	27	29	1	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-6915			FOOD CHEM TOXICOL	Food Chem. Toxicol.	NOV	2012	50	11					4010	4015		10.1016/j.fct.2012.08.006			6	Food Science & Technology; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Food Science & Technology; Toxicology	031PL	WOS:000310654300019	22902827				2022-02-06	
J	Scalfani, MT; Dhar, R; Zazulia, AR; Videen, TO; Diringer, MN				Scalfani, Michael T.; Dhar, Rajat; Zazulia, Allyson R.; Videen, Tom O.; Diringer, Michael N.			Effect of osmotic agents on regional cerebral blood flow in traumatic brain injury	JOURNAL OF CRITICAL CARE			English	Article						Osmotic agents; Cerebral blood flow; Traumatic brain injury; Intracranial hypertension	HYPERTONIC SALINE; INTRACRANIAL HYPERTENSION; MANNITOL; PRESSURE; 7.5-PERCENT; METABOLISM; MANAGEMENT	Purpose: Cerebral blood flow (CBF) is reduced after severe traumatic brain injury (TBI) with considerable regional variation. Osmotic agents are used to reduce elevated intracranial pressure (ICP), improve cerebral perfusion pressure, and presumably improve CBF. Yet, osmotic agents have other physiologic effects that can influence CBF. We sought to determine the regional effect of osmotic agents on CBF when administered to treat intracranial hypertension. Materials and Methods: In 8 patients with acute TBI, we measured regional CBF with positron emission tomography before and 1 hour after administration of equi-osmolar 20% mannitol (1 g/kg) or 23.4% hypertonic saline (0.686 mL/kg) in regions with focal injury and baseline hypoperfusion (CBF <25 mL per 100 g/min). Results: The ICP fell (22.4 +/- 5.1 to 15.7 +/- 7.2 mm Hg, P = .007), and cerebral perfusion pressure rose (75.7 +/- 5.9 to 81.9 +/- 10.3 mm Hg, P = .03). Global CBF tended to rise (30.9 +/- 3.7 to 33.1 +/- 4.2 mL per 100 g/min, P = .07). In regions with focal injury, baseline flow was 25.7 +/- 9.1 mL per 100 g/min and was unchanged; in hypoperfused regions (15% of regions), flow rose from 18.6 +/- 5.0 to 22.4 +/- 6.4 mL per 100 g/min (P < .001). Osmotic therapy reduced the number of hypoperfused brain regions by 40% (P < .001). Conclusion: Osmotic agents, in addition to lowering ICP, improve CBF to hypoperfused brain regions in patients with intracranial hypertension after TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Scalfani, Michael T.; Dhar, Rajat; Zazulia, Allyson R.; Videen, Tom O.; Diringer, Michael N.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Dhar, Rajat; Diringer, Michael N.] Washington Univ, Sch Med, Neurol Neurosurg Intens Care Unit, St Louis, MO 63110 USA; [Zazulia, Allyson R.; Videen, Tom O.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA		Diringer, MN (corresponding author), Washington Univ, Sch Med, Dept Neurol, Campus Box 8111, St Louis, MO 63110 USA.	diringerm@neuro.wustl.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Dhar, Rajat/0000-0002-5167-5097	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS03596610, UL1 RR024992]; NIH National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024992]; NIH National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P01NS035966]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035966, P50NS035966] Funding Source: NIH RePORTER	Funded by NIH grant number(s): NS03596610 and UL1 RR024992.; The authors thank Angela Shackelford, RN, John Hood, and the cyclotron and NNICU staff for their assistance in conducting this research and caring for these patients. This work was supported by the NIH National Center for Research Resources (UL1 RR024992) and the NIH National Institutes of Neurological Disorders and Stroke (5P01NS035966).	Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; DIRNAGL U, 1990, J CEREBR BLOOD F MET, V10, P327, DOI 10.1038/jcbfm.1990.61; Forsyth LL, 2008, PHARMACOTHERAPY, V28, P469, DOI 10.1592/phco.28.4.469; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; KIESEWETTER H, 1982, BIORHEOLOGY, V19, P737; KLEISER B, 1992, STROKE, V23, P171, DOI 10.1161/01.STR.23.2.171; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	30	27	32	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	OCT	2012	27	5							526.e7	10.1016/j.jcrc.2011.10.008			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	025PP	WOS:000310204300031	22176808	Green Accepted			2022-02-06	
J	DeCuypere, M; Klimo, P				DeCuypere, Michael; Klimo, Paul, Jr.			Spectrum of Traumatic Brain Injury from Mild to Severe	SURGICAL CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Neurotrauma; Cerebral edema; Intracranial pressure monitoring; Craniectomy	SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; TRANSCRANIAL DOPPLER; UNITED-STATES; OPTIC-NERVE; ELDERLY-PATIENTS; US ARMY; MANAGEMENT; IMPACT	Traumatic brain injury (TBI) involves significant damage of the brain parenchyma, and is the leading cause of morbidity and mortality after trauma. It is thus essential for all physicians involved in acute care medicine and surgery to have a thorough understanding of TBI. Management of the patient with TBI is a rapidly advancing field, characterized by an improved understanding of intracranial pathophysiology and decreasing overall mortality largely because of improved neurocritical and surgical care. This article summarizes the classification system, management approaches, and recent controversies in the care of mild, moderate, and severe TBI.	[Klimo, Paul, Jr.] Semmes Murphey Neurol & Spine Inst, Memphis, TN 38120 USA; [DeCuypere, Michael; Klimo, Paul, Jr.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA; [Klimo, Paul, Jr.] LeBonheur Childrens Hosp, Dept Neurosurg, Memphis, TN 38103 USA		Klimo, P (corresponding author), Semmes Murphey Neurol & Spine Inst, 6325 Humphreys Blvd, Memphis, TN 38120 USA.	pklimo@semmes-murphey.com		DeCuypere, Michael/0000-0002-4598-8644			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Agrawal A, 2008, CLIN NEUROL NEUROSUR, V110, P321, DOI 10.1016/j.clineuro.2008.01.013; Ahmad FU, 2011, WORLD NEUROSURG, V75, P451, DOI 10.1016/j.wneu.2010.12.042; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barmparas G, 2011, WORLD J SURG, V35, P1809, DOI 10.1007/s00268-011-1149-9; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; CHESNUT RM, 1993, J TRAUMA, V35, P492, DOI 10.1097/00005373-199309000-00036; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS259; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Eastridge BJ, 2006, J TRAUMA, V61, P1366, DOI 10.1097/01.ta.0000245894.78941.90; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Fodale V, 2007, ACTA ANAESTH SCAND, V51, P839, DOI 10.1111/j.1399-6576.2007.01355.x; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Geeraerts T, 2008, CRIT CARE, V12, DOI [10.1186/cc6893, 10.1186/cc7006]; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Gittleman AM, 2005, AM J NEURORADIOL, V26, P603; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Hutchinson PJ, 2011, BRIT J NEUROSURG, V25, P441, DOI 10.3109/02688697.2011.583366; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jia XF, 2008, RESUSCITATION, V76, P431, DOI 10.1016/j.resuscitation.2007.08.014; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lazaridis C, 2011, J CRIT CARE; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; Lu J, 2005, ACT NEUR S, V95, P281; Marion DW, 2011, LANCET NEUROL, V10, P497, DOI 10.1016/S1474-4422(11)70098-9; Marion DW, 2006, NEUROSURGERY, V58, P655; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Rasulo EA, 2008, EUR J ANAESTH, V25, P167, DOI 10.1017/S0265021507003341; Reynolds FD, 2003, J TRAUMA, V54, P492, DOI 10.1097/01.TA.0000051601.60556.FC; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; Rosenfeld JV, 2007, J NEUROSURG, V106, P195, DOI 10.3171/jns.2007.106.1.195; Rustemeyer J, 2007, BRIT J ORAL MAX SURG, V45, P556, DOI 10.1016/j.bjoms.2007.01.003; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sariego Jack, 2006, Disaster Manag Response, V4, P114, DOI 10.1016/j.dmr.2006.09.001; Schlifka B, 2007, J TRAUMA, V62, pS103, DOI 10.1097/TA.0b013e318065b4e5; Schreckinger M, 2009, NEUROCRIT CARE, V11, P427, DOI 10.1007/s12028-009-9256-2; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Soldatos T, 2009, EMERG MED J, V26, P630, DOI 10.1136/emj.2008.058453; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WISNER DH, 1993, J TRAUMA, V35, P271, DOI 10.1097/00005373-199308000-00017; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048; Zwahlen RA, 2007, J CRANIO MAXILL SURG, V35, P142, DOI 10.1016/j.jcms.2007.01.006	97	27	29	2	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	AUG	2012	92	4					939	+		10.1016/j.suc.2012.04.005			20	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	000IE	WOS:000308379100011	22850156				2022-02-06	
J	Ley, EJ; Clond, MA; Bukur, M; Park, R; Chervonski, M; Dagliyan, G; Margulies, DR; Lyden, PD; Conti, PS; Salim, A				Ley, Eric J.; Clond, Morgan A.; Bukur, Marko; Park, Ryan; Chervonski, Michael; Dagliyan, Grant; Margulies, Dan R.; Lyden, Patrick D.; Conti, Peter S.; Salim, Ali			beta-Adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, and inflammatory response after traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; beta-adrenergic receptor; cerebral glucose metabolism; propranolol; knockout	HEAD-INJURY; BETA(2)-ADRENERGIC RECEPTOR; CELL-CULTURE; PROPRANOLOL; IMPACT; RATS; PERFUSION; ISCHEMIA; SURVIVAL; STATE	BACKGROUND: The purpose of this study was to evaluate how beta-adrenergic receptor inhibition after traumatic brain injury (TBI) alters changes in early cerebral glucose metabolism and motor performance, as well as cerebral cytokine and heat shock protein (HSP) expression. METHODS: Mouse cerebral glucose metabolism was measured by microPET fluorodeoxyglucose uptake and converted into standardized uptake values (SUV). Four groups of C57/Bl6 mice (wild type [WT]) were initially evaluated: sham or TBI, followed by tail vein injection of either saline or a nonselective beta-adrenergic receptor inhibitor (propranolol, 4 mg/kg). Then motor performance, cerebral cytokine, and HSP70 expression were studied at 12 hours and 24 hours after sham injury or TBI in WT mice treated with saline or propranolol and in beta 1-adrenergic/beta 2-adrenergic receptor knockout (BARKO) mice treated with saline. RESULTS: Cerebral glucose metabolism was significantly reduced after TBI (mean SUV TBI, 1.63 vs. sham 1.97, p < 0.01) and propranolol attenuated this reduction (mean SUV propranolol, 1.89 vs. saline 1.63, p < 0.01). Both propranolol and BARKO reduced motor deficits at 24 hours after injury, but only BARKO had an effect at 12 hours after injury. TBI WT mice treated with saline performed worse than propranolol mice at 24 hours after injury on rotarod (23 vs. 44 seconds, p < 0.01) and rearing (130 vs. 338 events, p = 0.01) results. At 24 hours after injury, sham BARKO and TBI BARKO mice were similar on rotarod (21 vs. 19 seconds, p = 0.53), ambulatory testing (2,891 vs. 2,274 events, p = 0.14), and rearing (129 vs. 64 events, p = 0.09) results. Interleukin 1 beta expression was affected by BARKO and propranolol after TBI; attenuation of interleukin 6 and increased HSP70 expression were noted only with BARKO. CONCLUSION: beta-adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, as well as cerebral cytokine and HSP expression after TBI. (J Trauma Acute Care Surg. 2012; 73: 33-40. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Ley, Eric J.; Clond, Morgan A.; Bukur, Marko; Margulies, Dan R.; Lyden, Patrick D.; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Park, Ryan; Chervonski, Michael; Dagliyan, Grant; Conti, Peter S.] Univ So Calif, Dept Radiol, Los Angeles, CA USA		Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	eric.ley@cshs.org		Bukur, Marko/0000-0002-1850-7147; Clond, Morgan/0000-0002-3036-4193	American Association for the Surgery of Trauma Research and Education Foundation	This study was supported in part by a grant from the American Association for the Surgery of Trauma Research and Education Foundation.	AKAIKE N, 1981, BRIT J PHARMACOL, V73, P431, DOI 10.1111/j.1476-5381.1981.tb10439.x; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beiermeister KA, 2010, J TRAUMA, V69, P338, DOI 10.1097/TA.0b013e3181e5d35e; Bracken MB, 2005, NEUROSURGERY, V57, P1300, DOI 10.1227/01.NEU.0000187320.71967.59; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; Faul M, 2010, TRAUMATIC BRAIN INJU; Fonseca RB, 2005, J TRAUMA, V59, P884, DOI 10.1097/01.ta.0000187653.64300.f5; Friese RS, 2008, J TRAUMA, V64, P1061, DOI 10.1097/TA.0b013e3181684cf0; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Han RQ, 2009, ANESTH ANALG, V108, P280, DOI 10.1213/ane.0b013e318187ba6b; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Laureys G, 2010, PROG NEUROBIOL, V91, P189, DOI 10.1016/j.pneurobio.2010.01.011; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mannick JA, 2002, J AM COLL SURGEONS, V194, P104, DOI 10.1016/S1072-7515(01)01123-1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Oberbeck R, 2009, CURR MED CHEM, V16, P1082, DOI 10.2174/092986709787581770; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; RAINBOW TC, 1984, P NATL ACAD SCI-BIOL, V81, P1585, DOI 10.1073/pnas.81.5.1585; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang J, 2010, J NEUROIMMUNOL, V223, P77, DOI 10.1016/j.jneuroim.2010.04.006; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zamah AM, 2002, J BIOL CHEM, V277, P31249, DOI 10.1074/jbc.M202753200	40	27	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2012	73	1					33	40		10.1097/TA.0b013e31825a769b			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	979JU	WOS:000306814100006	22743370				2022-02-06	
J	Nalder, E; Fleming, J; Cornwell, P; Foster, M				Nalder, Emily; Fleming, Jennifer; Cornwell, Petrea; Foster, Michele			Linked Lives: The Experiences of Family Caregivers During the Transition from Hospital to Home Following Traumatic Brain Injury	BRAIN IMPAIRMENT			English	Article						transition; family caregiver; community integration; lived experience	LIFE SATISFACTION; SOCIAL SUPPORT; STROKE; NEEDS; IMPACT; HOPE; INDIVIDUALS; PREDICTORS; DISCHARGE; SYMPTOMS	The transition from hospital to home following traumatic brain injury (TBI) has been identified as the point where responsibility for care shifts from rehabilitation services to informal family caregivers. There has, however, been little research examining the experiences of family members during this important transition that involves adopting or, in some cases, resuming a caring role (e.g., a parent caring for an adult child). The aim of this qualitative investigation was to understand the experiences of family caregivers during the transition from hospital to home, defined as the first six months postdischarge. The sample included 10 family caregivers, of which all were female and either a mother, spouse or ex-partner of an individual with TBI. Semistructured interviews were conducted on average nine months following community reentry and data were analysed thematically using a framework approach. The overarching theme was that caregivers wished to move past the injury. This desire to move forward stemmed from a realisation of how their life had changed and the weight of the care responsibility. Caregivers were also aware of how the life of the individual with a TBI had changed and hoped for a return to normality (by regaining independence, engaging in meaningful occupation and having meaningful relationships). Implications of the findings for research and clinical practice are discussed. There is a need for services to support family caregivers during the transition from hospital to home.	[Nalder, Emily; Fleming, Jennifer] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Fleming, Jennifer] Queensland Hlth, Ctr Functioning & Hlth Res, Brisbane, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Queensland Hlth, Occupat Therapy Dept, Brisbane, Qld, Australia; [Cornwell, Petrea] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia; [Foster, Michele] Univ Queensland, Sch Social Work & Human Serv, Brisbane, Qld 4072, Australia		Nalder, E (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.	e.nalder@uq.edu.au	Cornwell, Petrea/AAE-5547-2019		Australian Research CouncilAustralian Research Council [LP0776294]; Queensland Government Department of Communities (Disability Services); Acquired Brain Injury Outreach Service	The authors wish to acknowledge the funding support provided by way of an Australian Research Council Linkage Grant (LP0776294) and from partner organisations Queensland Government Department of Communities (Disability Services) and the Acquired Brain Injury Outreach Service. Our sincere appreciation goes also to Professor Linda Worrall, Dr Terry Haines, Dr Tamara Ownsworth, Dr Melissa Kendall and Professor Lesley Chenoweth for their contribution to the design and development of this project. The authors are also grateful to Mrs Cassandra Shields for her assistance in the peer-checking process.	Arnaert Antonia, 2006, Holist Nurs Pract, V20, P137; Australian Bureau of Statistics, 1993, DIS AG CAR BRAIN INJ; Backstrom B, 2007, NURS INQ, V14, P243, DOI 10.1111/j.1440-1800.2007.00373.x; Bluvol A, 2004, J ADV NURS, V48, P322, DOI 10.1111/j.1365-2648.2004.03004.x; Borneman T., 2002, J HOSP PALLIAT NURS, V4, P21, DOI DOI 10.1097/00129191-200201000-00012; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; Creswell JW, 2017, DESIGNING CONDUCTING, V3rd; Cross A, 2010, TOP STROKE REHABIL, V17, P484, DOI 10.1310/tsr1706-484; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Elder G.H., 2009, CRAFT LIFE COURSE RE; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fraser C, 1999, J Neurosci Nurs, V31, P9; Gebhardt MC, 2011, REHABIL NURS, V36, P3, DOI 10.1002/j.2048-7940.2011.tb00059.x; Gum A, 2006, PSYCHOL HEALTH, V21, P319, DOI 10.1080/14768320500422907; Johnson B P, 1995, J Neurosci Nurs, V27, P113; Jumisko E, 2007, J FAM NURS, V13, P353, DOI 10.1177/1074840707303842; Keenan Alanna, 2010, Can J Neurosci Nurs, V32, P25; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Leathem J, 1996, BRAIN INJURY, V10, P27; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Michels N, 1988, Home Health Care Serv Q, V9, P29, DOI 10.1300/J027v09n01_03; Minichiello V., 1995, IN DEPTH INTERVIEWIN; Murray HM, 2006, BRAIN INJURY, V20, P575, DOI 10.1080/02699050600664590; Nalder E., 2011, REFLECTIONS LI UNPUB; Nalder E, 2012, J HEAD TRAUMA REHAB, V27, P143, DOI 10.1097/HTR.0b013e3182168fb1; O'Callaghan AM, 2011, INT J SPEECH-LANG PA, V13, P218, DOI 10.3109/17549507.2011.549240; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Patton M.Q., 1990, QUALITATIVE EVALUATI; Peleg G, 2009, BRAIN INJURY, V23, P800, DOI 10.1080/02699050903196696; Penna S, 2010, J HEAD TRAUMA REHAB, V25, P52, DOI 10.1097/HTR.0b013e3181c29952; QSR International, 2010, NVIVO QUAL DAT AN SO, V10; Ritchie J., 2003, QUALITATIVE RES PRAC; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; TATE RL, 2003, 26 ANN BRAIN IMP C S; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Turner B, 2010, BRAIN IMPAIR, V11, P281, DOI 10.1375/brim.11.3.281; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; Turner BJ, 2011, DISABIL REHABIL, V33, P818, DOI 10.3109/09638288.2010.513422; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Willis JW, 2007, FDN QUALITATIVE RES; World Health Organization, 2007, INT CLASS FUNCT DIS	47	27	27	0	30	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	JUL	2012	13	1			SI		108	122		10.1017/BrImp.2012.4			15	Clinical Neurology; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	964VQ	WOS:000305725200010		Green Published			2022-02-06	
J	Zhao, S; Yu, ZY; Zhao, G; Xing, CH; Hayakawa, K; Whalen, MJ; Lok, JM; Lo, EH; Wang, XY				Zhao, Song; Yu, Zhanyang; Zhao, Gang; Xing, Changhong; Hayakawa, Kazuhide; Whalen, Michael J.; Lok, Josephine M.; Lo, Eng H.; Wang, Xiaoying			Neuroglobin-overexpression reduces traumatic brain lesion size in mice	BMC NEUROSCIENCE			English	Article						Neuroglobin; Neuroprotection; Controlled cortical impact; Oxidative stress; Traumatic brain injury	OXIDATIVE STRESS; IN-VIVO; INJURY; EXPRESSION; PROTECTS; OUTCOMES; NEUROPROTECTION; MECHANISMS; ISCHEMIA; PROTEINS	Background: Accumulating evidence has demonstrated that over-expression of Neuroglobin (Ngb) is neuroprotective against hypoxic/ischemic brain injuries. In this study we tested the neuroprotective effects of Ngb over-expression against traumatic brain injury (TBI) in mice. Results: Both Ngb over-expression transgenic (Ngb-Tg) and wild-type (WT) control mice were subjected to TBI induced by a controlled cortical impact (CCI) device. TBI significantly increased Ngb expression in the brains of both WT and Ngb-Tg mice, but Ngb-Tg mice had significantly higher Ngb protein levels at the pre-injury baseline and post-TBI. Production of oxidative tissue damage biomarker 3NT in the brain was significantly reduced in Ngb-Tg mice compared to WT controls at 6 hours after TBI. The traumatic brain lesion volume was significantly reduced in Ngb Tg mice compared to WT mice at 3 weeks after TBI; however, there were no significant differences in the recovery of sensorimotor and spatial memory functional deficits between Ngb-Tg and WT control mice for up to 3 weeks after TBI. Conclusion: Ngb over-expression reduced traumatic lesion volume, which might partially be achieved by decreasing oxidative stress.	[Zhao, Song; Yu, Zhanyang; Xing, Changhong; Hayakawa, Kazuhide; Lok, Josephine M.; Lo, Eng H.; Wang, Xiaoying] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Neurol, Charlestown, MA 02129 USA; [Zhao, Song; Yu, Zhanyang; Xing, Changhong; Hayakawa, Kazuhide; Lok, Josephine M.; Lo, Eng H.; Wang, Xiaoying] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Radiol, Charlestown, MA 02129 USA; [Zhao, Song; Zhao, Gang] Jilin Univ, Bethune Hosp 1, Dept Orthoped, Changchun 130023, Jilin, Peoples R China; [Zhao, Song; Zhao, Gang] Jilin Univ, Bethune Hosp 1, Dept Neurosurg, Changchun 130023, Jilin, Peoples R China; [Whalen, Michael J.; Lok, Josephine M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA		Wang, XY (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Neurol, 149 13th St,Room 2401, Charlestown, MA 02129 USA.	wangxi@helix.mgh.harvard.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS049476]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049476] Funding Source: NIH RePORTER	This work was supported in part by NIH grant R01-NS049476 (to X.W.). We appreciate Ms. Jessica L. Poppe for language editorial assistance.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2004, NEWS PHYSIOL SCI, V19, P110, DOI 10.1152/nips.01513.2003; Chuang PY, 2010, J NEUROTRAUM, V27, P999, DOI 10.1089/neu.2009.1129; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Houdebine LM, 2002, J BIOTECHNOL, V98, P145, DOI 10.1016/S0168-1656(02)00129-3; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jin KL, 2008, NEUROSCI LETT, V430, P135, DOI 10.1016/j.neulet.2007.10.031; Jin KL, 2011, PHARMACOLOGY, V87, P81, DOI 10.1159/000322998; Khan AA, 2008, FASEB J, V22, P1737, DOI 10.1096/fj.07-100784; Khan AA, 2007, P NATL ACAD SCI USA, V104, P19114, DOI 10.1073/pnas.0706167104; Khan AA, 2006, P NATL ACAD SCI USA, V103, P17944, DOI 10.1073/pnas.0607497103; Lin Xin, 2010, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V26, P39; Liu JX, 2009, J NEUROSCI RES, V87, P164, DOI 10.1002/jnr.21826; Liu N, 2012, BIOCHEM J, V443, P153, DOI 10.1042/BJ20111856; Lok J, 2011, J NEUROCHEM, V118, P248, DOI 10.1111/j.1471-4159.2011.07294.x; Shang AJ, 2012, NEUROL SCI, V33, P551, DOI 10.1007/s10072-011-0772-4; Sijen T, 2001, CURR BIOL, V11, P436, DOI 10.1016/S0960-9822(01)00116-6; Sultana R, 2008, METHOD ENZYMOL, V440, P309, DOI 10.1016/S0076-6879(07)00820-8; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang XY, 2008, STROKE, V39, P1869, DOI 10.1161/STROKEAHA.107.506022; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wei X, 2011, AM J PATHOL, V179, P2788, DOI 10.1016/j.ajpath.2011.08.015; Yu Z, 2009, NEUROSCIENCE, V162, P396, DOI 10.1016/j.neuroscience.2009.04.055; Yu ZY, 2009, NEUROL RES, V31, P122, DOI 10.1179/174313209X389866	31	27	32	2	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JUN 15	2012	13								67	10.1186/1471-2202-13-67			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	010PJ	WOS:000309106300001	22703519	gold, Green Published			2022-02-06	
J	Stein, DM; Lindel, AL; Murdock, KR; Kufera, JA; Menaker, J; Scalea, TM				Stein, Deborah M.; Lindel, Allison L.; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Scalea, Thomas M.			USE OF SERUM BIOMARKERS TO PREDICT SECONDARY INSULTS FOLLOWING SEVERE TRAUMATIC BRAIN INJURY	SHOCK			English	Article; Proceedings Paper	25th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN, 2012	Lake Buena Vista, FL	Eastern Assoc Surg Trauma		Traumatic brain injury; neuroinflammation; biomarker; intracranial hypertension; cerebral hypoperfusion	TUMOR-NECROSIS-FACTOR; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL HYPERTENSION; CEREBROSPINAL-FLUID; INTERLEUKIN-8; CYTOKINES; MORTALITY; HYPOPERFUSION; DYSFUNCTION; PLASMA	The management of severe traumatic brain injury (TBI) focuses on prevention and treatment of intracranial hypertension (ICH) and cerebral hypoperfusion (CH). Predicting which patients will develop these secondary insults is currently not possible. This study investigates the systemic manifestation of neuroinflammation and its role in helping to predict clinical deterioration following severe TBI. Patients with head Abbreviated Injury Severity greater than 3, age older than 14 years, "isolated'' TBI, and placement of intracranial pressure monitor were prospectively enrolled. Serum was collected within 24 h and twice daily for 7 days. Measures of moderate and severe ICH (intracranial pressure >20 and >30 mmHg) and moderate and severe CH (cerebral perfusion pressure <60 and <50 mmHg) were compared with interleukin 8 (IL-8) and tumor necrosis factor alpha (TNF-alpha) levels drawn before periods of monitoring. An adjusted mixed-model analysis accounting for longitudinal correlations was applied. Sixty-eight patients were enrolled; 670 12-h periods of monitoring and 845 serum samples were available for analysis. Associations were found between serum levels of IL-8 and moderate and severe CH. Levels of TNF-alpha and severe ICH and CH were also correlated. Specificities of 81% to 95% were found for prediction of ICH and CH for TNF-alpha and CH for IL-8. Interleukin 8 and TNF-alpha demonstrate promise as candidate serum markers of impending ICH and CH. This suggests that we may be able to "predict'' imminent events following TBI before clinical manifestations. Given the morbidity of ICH and CH, minimizing the effects of these secondary insults may have a significant impact on outcome and help guide decisions about timing of interventions.	[Stein, Deborah M.] Univ Maryland, Sch Med, Div Crit Care, Program Trauma,R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Stein, Deborah M.; Lindel, Allison L.; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, Baltimore, MD 21201 USA		Stein, DM (corresponding author), Univ Maryland, Sch Med, Div Crit Care, Program Trauma,R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Bansal V, 2012, INFLAMMATION, V35, P214, DOI 10.1007/s10753-011-9307-7; Bratton S. L., 2007, J NEUROTRAUMA S1, V24, pS37; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Jawa Randeep S, 2006, J Intensive Care Med, V21, P63, DOI 10.1177/0885066605284325; Kahraman S, 2011, J TRAUMA, V70, P547, DOI 10.1097/TA.0b013e31820c768a; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	34	27	28	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUN	2012	37	6					563	568		10.1097/SHK.0b013e3182534f93			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	944LD	WOS:000304202200001	22552017				2022-02-06	
J	Ewing-Cobbs, L; Prasad, MR; Swank, P; Kramer, L; Mendez, D; Treble, A; Payne, C; Bachevalier, J				Ewing-Cobbs, Linda; Prasad, Mary R.; Swank, Paul; Kramer, Larry; Mendez, Donna; Treble, Amery; Payne, Christa; Bachevalier, Jocelyne			Social communication in young children with traumatic brain injury: Relations with corpus callosum morphometry	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Brain injury; Young children; Joint attention; Gesture; Corpus callosum; Social communication	CLOSED-HEAD INJURY; SUPERIOR FRONTAL GYRUS; PROBLEM-SOLVING SKILLS; JOINT ATTENTION; SEX-DIFFERENCES; CHILDHOOD; OUTCOMES; CORTEX; TERM; RECOVERY	The purpose of the present investigation was to characterize the relations of specific social communication behaviors, including joint attention, gestures, and verbalization, with surface area of midsagittal corpus callosum (CC) subregions in children who sustained traumatic brain injury (TBI) before 7 years of age. Participants sustained mild (n = 10) or moderate-severe (n = 26) noninflicted TBI. The mean age at injury was 33.6 months; mean age at MRI was 44.4 months. The CC was divided into seven subregions. Relative to young children with mild TBI, those with moderate-severe TBI had smaller surface area of the isthmus. A semi-structured sequence of social interactions between the child and an examiner was videotaped and coded for specific social initiation and response behaviors. Social responses were similar across severity groups. Even though the complexity of their language was similar, children with moderate-severe TBI used more gestures than those with mild TBI to initiate social overtures; this may indicate a developmental lag or deficit as the use of gestural communication typically diminishes after age 2. After controlling for age at scan and for total brain volume, the correlation of social interaction response and initiation scores with the midsagittal surface area of the CC regions was examined. For the total group, responding to a social overture using joint attention was significantly and positively correlated with surface area of all regions, except the rostrum. Initiating joint attention was specifically and negatively correlated with surface area of the anterior midbody. Use of gestures to initiate a social interaction correlated significantly and positively with surface area of the anterior and posterior midbody. Social response and initiation behaviors were selectively related to regional callosal surface areas in young children with TBI. Specific brainbehavior relations indicate early regional specialization of anterior and posterior CC for social communication. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	[Ewing-Cobbs, Linda; Prasad, Mary R.; Swank, Paul] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda; Prasad, Mary R.; Swank, Paul] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Kramer, Larry] Univ Texas Hlth Sci Ctr Houston, Dept Intervent Radiol, Houston, TX 77030 USA; [Mendez, Donna] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA; [Treble, Amery] Univ Houston, Dept Psychol, Houston, TX 77004 USA; [Payne, Christa; Bachevalier, Jocelyne] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA		Ewing-Cobbs, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat, 7000 Fannin,Suite 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu		Payne, Christa/0000-0002-6281-1269	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2RO1 NS29462]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER	This work was supported in part by NIH 2RO1 NS29462. The authors thank Dr. Giuseppe Colasurdo for facilitating acquisition of the MRI scans. We are grateful to the parents and children who participated in this project.	Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bates E, 1997, DEV NEUROPSYCHOL, V13, P447, DOI 10.1080/87565649709540686; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Butterworth G., 1995, JOINT ATTENTION ITS, P29; Carpenter M, 2002, J AUTISM DEV DISORD, V32, P91, DOI 10.1023/A:1014836521114; Casey BJ, 2005, CURR OPIN NEUROBIOL, V15, P239, DOI 10.1016/j.conb.2005.03.012; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; Cutini S, 2008, NEUROIMAGE, V42, P945, DOI 10.1016/j.neuroimage.2008.05.013; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1988, CLIN NEUROPSYCHOLOGY, P89; du Boisgueheneuc F, 2006, BRAIN, V129, P3315, DOI 10.1093/brain/awl244; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L., 2008, HDB DEV COGNITIVE NE, P399; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Frischen A, 2007, PSYCHOL BULL, V133, P694, DOI 10.1037/0033-2909.133.4.694; Ganesalingam K., 2011, NEUROPSYCHOLOGY; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Goldin-Meadow S, 2010, LANG COGN, V2, P1, DOI 10.1515/LANGCOG.2010.001; Goldman PS, 1974, PLASTICITY RECOVERY; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Grossmann T, 2010, BIOL LETTERS, V6, P540, DOI 10.1098/rsbl.2009.1069; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hasan KM, 2008, BRAIN RES, V1227, P52, DOI 10.1016/j.brainres.2008.06.030; Hasan KM, 2009, BRAIN RES, V1249, P91, DOI 10.1016/j.brainres.2008.10.026; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hirotani M, 2009, NEUROREPORT, V20, P600, DOI 10.1097/WNR.0b013e32832a0a7c; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Kolb B, 2010, BEHAV NEUROSCI, V124, P873, DOI 10.1037/a0021822; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; Laube I, 2011, NEUROIMAGE, V54, P1643, DOI 10.1016/j.neuroimage.2010.08.074; Lebel C, 2010, NEUROIMAGE, V52, P20, DOI 10.1016/j.neuroimage.2010.03.072; LEUNG EHL, 1981, DEV PSYCHOL, V17, P215, DOI 10.1037/0012-1649.17.2.215; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Lindenberg R, 2012, HUM BRAIN MAPP, V33, P812, DOI 10.1002/hbm.21258; Malkova L, 2010, BEHAV NEUROSCI, V124, P742, DOI 10.1037/a0021622; Materna S, 2008, J COGNITIVE NEUROSCI, V20, P108, DOI 10.1162/jocn.2008.20008; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Mundy P, 2003, J CHILD PSYCHOL PSYC, V44, P793, DOI 10.1111/1469-7610.00165; Mundy P, 2010, NEURAL NETWORKS, V23, P985, DOI 10.1016/j.neunet.2010.08.009; Park HJ, 2008, HUM BRAIN MAPP, V29, P503, DOI 10.1002/hbm.20314; Pelphrey KA, 2003, NEUROPSYCHOLOGIA, V41, P156, DOI 10.1016/S0028-3932(02)00146-X; Posner MI, 2009, PHYS LIFE REV, V6, P103, DOI 10.1016/j.plrev.2009.02.001; Rueda MR, 2004, NEUROPSYCHOLOGIA, V42, P1029, DOI 10.1016/j.neuropsychologia.2003.12.012; Saito DN, 2010, FRONT INTEGR NEUROSC, V4, DOI 10.3389/fnint.2010.00127; Sauer E, 2010, CHILD DEV, V81, P528, DOI 10.1111/j.1467-8624.2009.01413.x; SCAIFE M, 1975, NATURE, V253, P265, DOI 10.1038/253265a0; SCHALTEN.G, 1972, CONFIN NEUROL, V34, P169; Schilbach L, 2010, J COGNITIVE NEUROSCI, V22, P2702, DOI 10.1162/jocn.2009.21401; Sheehan EA, 2007, BRAIN LANG, V101, P246, DOI 10.1016/j.bandl.2006.11.008; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Thorndike R. L., 1986, STANFORD BINET INTEL; Tomasello M, 2005, BEHAV BRAIN SCI, V28, P675, DOI 10.1017/S0140525X05000129; Verger K, 2001, BRAIN INJURY, V15, P211; Vygotsky L.S., 1978, MIND SOC; Walzer N, 2010, J CLIN GASTROENTEROL, V44, P361, DOI 10.1097/MCG.0b013e3181c8a4f8; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2009, P NATL ACAD SCI USA, V106, P20664, DOI 10.1073/pnas.0909197106; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zaidel E., 2003, PARALLEL BRAIN COGNI; [No title captured]	94	27	28	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		247	254		10.1016/j.ijdevneu.2011.07.004			8	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800011	21807088	Green Accepted			2022-02-06	
J	Kim, DJ; Czosnyka, Z; Kasprowicz, M; Smieleweski, P; Baledent, O; Guerguerian, AM; Pickard, JD; Czosnyka, M				Kim, Dong-Joo; Czosnyka, Zofia; Kasprowicz, Magdalena; Smieleweski, Piotr; Baledent, Oliver; Guerguerian, Anne-Marie; Pickard, John D.; Czosnyka, Marek			Continuous Monitoring of the Monro-Kellie Doctrine: Is It Possible?	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood volume; cerebral compliance; compensatory mechanism; CSF compartment; traumatic brain injury; vascular compartment	PRESSURE-VOLUME INDEX; CEREBRAL PERFUSION-PRESSURE; FLUID PULSE PRESSURE; INTRACRANIAL-PRESSURE; CEREBROSPINAL-FLUID; HEAD-INJURY; BRAIN; AUTOREGULATION; HYDRODYNAMICS; CATS	The Monro-Kellie doctrine describes the principle of homeostatic intracerebral volume regulation, which stipulates that the total volume of the parenchyma, cerebrospinal fluid, and blood remains constant. Hypothetically, a slow shift (e. g., brain edema development) in the irregular vasomotion-driven exchanges of these compartmental volumes may lead to increased intracranial hypertension. To evaluate this paradigm in a clinical setting and measure the processes involved in the regulation of systemic intracranial volume, we quantified cerebral blood flow velocity (CBFv) in the middle cerebral artery, arterial blood pressure (ABP), and intracranial pressure (ICP), in 238 brain-injured subjects. Relative changes in compartmental compliances C-a (arterial) and C-i (combined venous and CSF compartments) were mathematically estimated using these raw signals through time series analysis; C-a and C-i were used to compute an index of cerebral compliance (ICC) as a moving correlation coefficient between C-a and C-i. Conceptually, a negative ICC would represent a functional Monro-Kellie doctrine by illustrating volumetric compensations between C-a and C-i. Clinical observations show that Lundberg A-waves and arterial hypertension were associated with negative ICC, whereas in refractory intracranial hypertension, a positive ICC was observed. In subjects who died, ICC was significantly greater than in survivors (0.46 +/- 0.027 versus 0.22 +/- 0.017; p < 0.01) over the first 5 days of intensive care. The mortality rate is 5% when ICC is less than 0, and 43% when above 0.7. ICC above 0.7 was associated with terminally elevated ICP (chi-square p = 0.026). We propose that the Monro-Kellie doctrine can be monitored in real time to illustrate the state of intracranial volume regulation.	[Kim, Dong-Joo] Korea Univ, Dept Brain & Cognit Engn, Seoul 136713, South Korea; [Kim, Dong-Joo; Czosnyka, Zofia; Smieleweski, Piotr; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; [Kim, Dong-Joo; Guerguerian, Anne-Marie] Univ Toronto, Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Kasprowicz, Magdalena] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, PL-50370 Wroclaw, Poland; [Baledent, Oliver] Amiens Univ Hosp, Dept Imaging & Biophys, Amiens, France		Kim, DJ (corresponding author), Korea Univ, Dept Brain, Seoul 136713, South Korea.	dongjookim@korea.ac.kr	baledent, olivier/AAQ-4489-2020	baledent, olivier/0000-0001-6028-6440; Kasprowicz, Magdalena/0000-0002-2271-7737	National Institute of Health Research Biomedical Research CentreNational Institute for Health Research (NIHR); Cambridge University Hospital Foundation Trust; Foundation of Polish Science; EC grant INTERREG; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0001237, G0600986] Funding Source: UKRI	The project was supported by the National Institute of Health Research Biomedical Research Centre, Cambridge University Hospital Foundation Trust-Neurosciences Theme and Senior Investigator Award (J.D.P.). M. K. is supported by the Foundation of Polish Science. M. C., Z.C., O.B., P. S., and J.D.P. are supported by EC grant INTERREG, interregional cooperation between the University of Picardie (Amiens) and the University of Cambridge, U.K.	Alperin N, 2005, J NEUROSURG, V103, P46, DOI 10.3171/jns.2005.103.1.0046; Avezaat C, 1984, CEREBROSPINAL FLUID; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Baledent O, 2006, J NEURORADIOLOGY, V33, P292, DOI 10.1016/S0150-9861(06)77287-X; BURTON AC, 1954, PHYSIOL REV, V34, P619, DOI 10.1152/physrev.1954.34.4.619; Carrera E., 2011, J NEUROTRAUMA; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DAVSON H, 1967, PHYSL CEREBROSPINAL; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; GOPINATH SP, 1993, J NEUROSCI METH, V49, P11, DOI 10.1016/0165-0270(93)90104-Y; GRAY WJ, 1987, J NEUROSURG, V67, P369, DOI 10.3171/jns.1987.67.3.0369; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; GREITZ D, 1992, NEURORADIOLOGY, V34, P370, DOI 10.1007/BF00596493; GUINANE JE, 1972, AM J PHYSIOL, V223, P425, DOI 10.1152/ajplegacy.1972.223.2.425; GUINANE JE, 1974, NEUROLOGY, V24, P138, DOI 10.1212/WNL.24.2.138; GUINANE JE, 1975, NEUROLOGY, V25, P559, DOI 10.1212/WNL.25.6.559; Ito U, 1990, Adv Neurol, V52, P459; JENNETT B, 1975, LANCET, V1, P480; Kim DJ, 2009, PHYSIOL MEAS, V30, P647, DOI 10.1088/0967-3334/30/7/009; Kim DJ, 2009, NEUROSURGERY, V64, P494, DOI 10.1227/01.NEU.0000338434.59141.89; Kirkpatrick PJ, 1996, J NEUROL NEUROSUR PS, V60, P131, DOI 10.1136/jnnp.60.2.131; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Luerssen T.G.S.P., 1989, INTRACRANIAL PRESSUR, P35; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Marmarou A., 1973, THEORETICAL EXPT EVA; Marmarou A.T., 1994, INTRACRANIAL PRESSUR, P15; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Miller JD, 1972, INTRACRANIAL PRESSUR, P270; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Monro A., 1783, OBSERVATIONS STRUCTU; Neff S, 1996, J NEUROSURG, V85, P1195; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; OSTERHOLM JL, 1970, J NEUROSURG, V32, P654, DOI 10.3171/jns.1970.32.6.0654; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; PALLET J, 2001, SPSS SURVIVAL MANUAL; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Piper I, 1999, BRIT J NEUROSURG, V13, P581, DOI 10.1080/02688699943097; POLLAY M, 1980, NEUROSURGERY, V6, P675, DOI 10.1227/00006123-198006000-00014; SKLAR FH, 1977, J NEUROSURG, V47, P670, DOI 10.3171/jns.1977.47.5.0670; SULLIVAN HG, 1977, J NEUROSURG, V47, P532, DOI 10.3171/jns.1977.47.4.0532; Toth M, 2000, PFLUG ARCH EUR J PHY, V439, P573, DOI 10.1007/s004240050980; Ursino M, 1997, J APPL PHYSIOL, V82, P1256, DOI 10.1152/jappl.1997.82.4.1256	44	27	27	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1354	1363		10.1089/neu.2011.2018			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600009	21895518	Green Published			2022-02-06	
J	Kutzing, MK; Luo, V; Firestein, BL				Kutzing, Melinda K.; Luo, Vincent; Firestein, Bonnie L.			Protection from Glutamate-Induced Excitotoxicity by Memantine	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Microelectrode array; Memantine; NMDA receptor antagonist; Traumatic brain injury; Glutamate; Excitotoxicity	NMDA RECEPTOR ANTAGONISTS; TRAUMATIC BRAIN-INJURY; SEVERE ALZHEIMERS-DISEASE; SPINAL-CORD NEURONS; MICROELECTRODE ARRAYS; CORTICAL-NEURONS; POSTTRAUMATIC EPILEPSY; SYNCHRONOUS ACTIVITY; ACTIVATED CHANNELS; BLOCK	This study investigates whether the uncompetitive N-methyl-d-aspartic acid receptor antagonist, memantine, is able to protect dissociated cortical neurons from glutamate-induced excitotoxicity (GIE). Treatment with glutamate resulted in a significant loss of synchronization of neuronal activity as well as a significant increase in the duration of synchronized bursting events (SBEs). By administering memantine at the same time as glutamate, we were able to completely prevent these changes to the neuronal activity. Pretreatment with memantine was somewhat effective in preventing changes to the culture synchronization but was unable to fully protect the synchronization of electrical activity between neurons that showed high levels of synchronization prior to injury. Additionally, memantine pretreatment was unable to prevent the increase in the duration of SBEs caused by GIE. Thus, the timing of memantine treatment is important for conferring neuroprotection against glutamate-induced neurotoxicity. Finally, we found that GIE leads to a significant increase in the burst duration. Our data suggest that this may be due to an alteration in the inhibitory function of the neurons.	[Kutzing, Melinda K.; Luo, Vincent; Firestein, Bonnie L.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; [Kutzing, Melinda K.] Rutgers State Univ, Grad Program Biomed Engn, Piscataway, NJ 08854 USA; [Firestein, Bonnie L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA		Firestein, BL (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.	fire-stein@biology.rutgers.edu		Firestein, Bonnie/0000-0002-1679-3565	New Jersey Commission on Brain Injury Research [09-3209-BIR-E-2]; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5T32GM008339]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008339] Funding Source: NIH RePORTER	This work was funded by a grant from the New Jersey Commission on Brain Injury Research, #09-3209-BIR-E-2 to BLF. MLK was supported by Biotechnology Fellowship, Grant 5T32GM008339 from National Institute of General Medical Sciences.	Anitha M, 2011, MED HYPOTHESES, V76, P138, DOI 10.1016/j.mehy.2010.09.003; Bordji K, 2011, REV NEUROSCIENCE, V22, P285, DOI 10.1515/RNS.2011.029; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; Cente M, 2009, CELL MOL NEUROBIOL, V29, P945, DOI 10.1007/s10571-009-9379-1; Chen HSV, 1998, NEUROSCIENCE, V86, P1121, DOI 10.1016/S0306-4522(98)00163-8; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; Chen HSV, 2006, J NEUROCHEM, V97, P1611, DOI 10.1111/j.1471-4159.2006.03991.x; Chiappalone M, 2003, BIOSENS BIOELECTRON, V18, P627, DOI 10.1016/S0956-5663(03)00041-1; Chiappalone M, 2007, INT J NEURAL SYST, V17, P87, DOI 10.1142/S0129065707000968; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Dingledine R, 1999, PHARMACOL REV, V51, P7; Du YZ, 2007, GLIA, V55, P463, DOI 10.1002/glia.20472; Gopal KV, 2003, NEUROTOXICOL TERATOL, V25, P69, DOI 10.1016/S0892-0362(02)00321-5; Hales Chadwick M, 2010, J Vis Exp, DOI 10.3791/2056; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Johnson JW, 2006, CURR OPIN PHARMACOL, V6, P61, DOI 10.1016/j.coph.2005.09.007; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kuszczyk M, 2010, PHARMACOL REP, V62, P1041, DOI 10.1016/S1734-1140(10)70366-2; Kutzing MK, 2011, ANN BIOMED ENG, V39, P2252, DOI 10.1007/s10439-011-0319-0; Leveille F, 2008, FASEB J, V22, P4258, DOI 10.1096/fj.08-107268; Li YL, 2007, BIOSENS BIOELECTRON, V22, P2976, DOI 10.1016/j.bios.2006.12.018; Lin CH, 2008, J NEUROCHEM, V104, P1415, DOI 10.1111/j.1471-4159.2007.05098.x; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 2006, NEURON, V50, P10, DOI 10.1016/j.neuron.2006.03.026; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; Lipton SA, 2007, NAT REV NEUROSCI, V8, P803, DOI 10.1038/nrn2229; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Morefield SI, 2000, BIOSENS BIOELECTRON, V15, P383, DOI 10.1016/S0956-5663(00)00095-6; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Okamoto SI, 2009, NAT MED, V15, P1407, DOI 10.1038/nm.2056; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Rao VLR, 2001, BRAIN RES, V911, P96; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Rogawski MA, 2003, CNS DRUG REV, V9, P275, DOI 10.1111/j.1527-3458.2003.tb00254.x; ROGAWSKI MA, 1993, TRENDS PHARMACOL SCI, V14, P325, DOI 10.1016/0165-6147(93)90005-5; Sattler R, 1998, J NEUROCHEM, V71, P2349; Shew WL, 2010, J NEUROSCI METH, V192, P75, DOI 10.1016/j.jneumeth.2010.07.023; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Tani H, 2007, NEUROBIOL DIS, V25, P230, DOI 10.1016/j.nbd.2006.08.025; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Wilkinson D, 2007, DEMENT GERIATR COGN, V24, P138, DOI 10.1159/000105162; Willmore LJ, 2010, NEUROLOGY, V75, P202, DOI 10.1212/WNL.0b013e3181e8e94f; Wrighton DC, 2008, J PHYSIOL-LONDON, V586, P211, DOI 10.1113/jphysiol.2007.143164; Xia P, 2010, J NEUROSCI, V30, P11246, DOI 10.1523/JNEUROSCI.2488-10.2010; Ye ZC, 1998, GLIA, V22, P237, DOI 10.1002/(SICI)1098-1136(199803)22:3<237::AID-GLIA3>3.0.CO;2-2; ZEEVALK GD, 1992, J NEUROCHEM, V59, P1211, DOI 10.1111/j.1471-4159.1992.tb08430.x	51	27	28	2	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2012	40	5					1170	1181		10.1007/s10439-011-0494-z			12	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	926DZ	WOS:000302812800017	22203191	Green Accepted			2022-02-06	
J	Thau-Zuchman, O; Shohami, E; Alexandrovich, AG; Leker, RR				Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.; Leker, Ronen R.			Combination of Vascular Endothelial and Fibroblast Growth Factor 2 for Induction of Neurogenesis and Angiogenesis after Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Angiogenesis; Neurogenesis; Vascular endothelial growth factor; Fibroblast growth factor 2; Neuroprotection	CLOSED-HEAD INJURY; UP-REGULATION; VEGF; EXPRESSION; MICE; PERMEABILITY; REGENERATION; HIPPOCAMPUS; ASTROCYTES; CONTUSION	Fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) are potent mitogens for endogenous neural stem cells (eNSC) and also induce angiogenesis. We infused the individual factors or their combination into the lateral ventricles of mice for 7 days after traumatic brain injury (TBI) in order to evaluate the effects on functional outcome and on eNSC proliferation and differentiation. The results show that VEGF induced a significant increment in the number of proliferating eNSC in the subventricular zone and in the perilesion cortex and that combination of FGF2 and VEGF did not augment the effects of VEGF alone. Fate analysis showed that most newborn cells differentiated into astrocytes and oligodendroglia while only a few cells differentiated into neurons. Functional outcome was significantly better in mice treated with VEGF, FGF2, or their combination as compared to vehicle. Injury size was significantly reduced only in mice treated with VEGF suggesting additional neuroprotective effects for VEGF. Combination therapy did not have an additive effect on outcome or neuronal differentiation. In conclusion, FGF2-VEGF combination does not augment neurogenesis and angiogenesis or reduce lesion volumes after TBI compared with individual factors. This may suggest the existence of a ceiling effect for brain regeneration.	[Leker, Ronen R.] Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel; [Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ Med Ctr, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Jerusalem, Israel; [Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ Med Ctr, Dept Neurol, Jerusalem, Israel		Leker, RR (corresponding author), Hadassah Univ Hosp, Dept Neurol, POB 12000, IL-91120 Jerusalem, Israel.	leker@cc.huji.ac.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334; Thau-Zuchman, Orli/0000-0003-0403-7962	Sol Irwin Juni Trust; Peritz and Chantal Scheinberg Cerebrovascular Research Fund	This study was supported by the Sol Irwin Juni Trust Fund and by the Peritz and Chantal Scheinberg Cerebrovascular Research Fund	Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Horner PJ, 2003, TRENDS NEUROSCI, V26, P597, DOI 10.1016/j.tins.2003.09.010; Jin KL, 2006, J NEUROBIOL, V66, P236, DOI 10.1002/neu.20215; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kim JH, 2004, J KOREAN MED SCI, V19, P879, DOI 10.3346/jkms.2004.19.6.879; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Lafuente JV, 2006, J NEURAL TRANSM, V113, P487, DOI 10.1007/s00702-005-0407-0; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang WY, 2005, NEUROSCIENCE, V134, P1167, DOI 10.1016/j.neuroscience.2005.04.064; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Xiao ZF, 2007, CELL RES, V17, P73, DOI 10.1038/sj.cr.7310126; Yun YR, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/218142	36	27	31	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	MAY	2012	47	1					166	172		10.1007/s12031-012-9706-8			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	924NQ	WOS:000302699000019	22246995				2022-02-06	
J	Kansu, E				Kansu, Emin			Thrombosis in stem cell transplantation	HEMATOLOGY			English	Article						Thrombosis; Stem cell transplantation; Sinusoidal obstructive syndrome; Transplant-associated thrombotic microangiopathy	HEPATIC VENOOCCLUSIVE DISEASE; BONE-MARROW-TRANSPLANTATION; COMPLICATIONS; MICROANGIOPATHY; CHILDREN	Hemostatic changes and thrombotic events are frequent in patients undergoing stem cell transplantation. Arterial and venous thromboses are major causes of morbidity and mortality. Thrombotic complications can be classified into four groups including: catheter-related thrombosis, venous thromboembolic (VTE) events, sinusoidal obstructive syndrome (SOS)/veno-occlusive disease, and transplant-associated thrombotic microangiopathy (TAM). The incidence of catheter-related thrombosis is 8-20% in patients undergoing autologous hematopoietic stem cell transplantation (HSCT), and the incidence is low in syngeneic and allogeneic transplant patients. Venous duplex Doppler ultrasound, venogram, and computed tomography scan are required to visualize the venous thrombus. The treatment should be aimed at the prevention of pulmonary embolism, the avoidance of thrombus extension, and the preservation of catheter patency. Patients undergoing HSCT may have risk factors for VTE including underlying malignancy, traumatic brain injury, prolonged hospitalization, administration of conditioning regimens, and central venous catheters. Important risk factors are presence of history of VTE and graft-versus-host disease. One-year incidence of symptomatic VTE is 3.7%. SOS, also known as veno-occlusive disease, is a serious liver disease, seen in approximately 50-60% of HSCT patients. The mortality rate from the severe form of SOS is 84.3% and majority of the patients have multi-organ failure. The frequency is quite low after autologous transplantation. Risk factors for SOS include pre-existing hepatic damage, previous high-dose chemotherapy and abdominal irradiation, female gender and donor-recipient human leukocyte antigen disparity. Cyclophosphamide and busulphan are the most common agents with the highest incidence and fatal SOS. Histopathologic features of SOS include dilatation of sinusoids, necrosis of perivenular hepatocytes, and obstruction of small intrahepatic central venules by microthrombi and fibrin deposition. Signs of SOS usually occur within first 30 days after HSCT including hyperbilirubinemia, hepatomegaly, ascites, and weight gain. Symptoms of liver failure, including encephalopathy, coagulopathy, and renal failure will appear in severe form. A hepatic venous pressure gradient above 10 mmHg is highly specific for SOS. Early use of defibrotide has been shown to be effective in the treatment of high-risk SOS. TAM is a distinct, infrequent, and significant life-threatening complication of HSCT. TAM is seen in the range of 0.5-76% and was reported to be 10-25% in patients undergoing allogeneic HSCT with a mortality rate around 50%. It can also be seen after autologous HSCT and mainly affects the glomerular capillaries. There has been no standard therapy for TAM. Few case series reported good response to rituximab and high-dose corticosteroids were used with limited success. Trials with complement inhibitors such as eculizumab are currently underway.	Hacettepe Univ, Inst Oncol, Hematopoiet Stem Cell Transplantat Unit, Ankara, Turkey		Kansu, E (corresponding author), Hacettepe Univ, Inst Oncol, Hematopoiet Stem Cell Transplantat Unit, Ankara, Turkey.	eminkansu47@gmail.com					Batts ED, 2007, BONE MARROW TRANSPL, V40, P709, DOI 10.1038/sj.bmt.1705758; Cho BS, 2010, TRANSPLANTATION, V90, P918, DOI 10.1097/TP.0b013e3181f24e8d; Coppell JA, 2010, BIOL BLOOD MARROW TR, V16, P157, DOI 10.1016/j.bbmt.2009.08.024; Gonsalves A, 2008, J THROMB HAEMOST, V6, P1468, DOI 10.1111/j.1538-7836.2008.03077.x; Graf L, 2012, HAMOSTASEOLOGIE, V32, P1; Hasegawa S, 1998, BONE MARROW TRANSPL, V22, P1191, DOI 10.1038/sj.bmt.1701506; Ho VT, 2008, BONE MARROW TRANSPL, V41, P229, DOI 10.1038/sj.bmt.1705899; Laskin BL, 2011, BLOOD, V118, P1452, DOI 10.1182/blood-2011-02-321315; Miano M, 2008, BONE MARROW TRANSPL, V41, pS39, DOI 10.1038/bmt.2008.53; Nadir Y, 2007, THROMB RES, V120, pS92, DOI 10.1016/S0049-3848(07)70136-6; Paz IB, 2008, THOMASS HEMATOPOIETI, P1244; Pihusch M, 2004, SEMIN HEMATOL, V41, P93, DOI 10.1053/j.seminhematol.2003.11.018; Pihusch R, 2002, TRANSPLANTATION, V74, P1303, DOI 10.1097/00007890-200211150-00018; Pihusch V, 2005, THROMB RES, V116, P233, DOI 10.1016/j.thromres.2004.12.010; Richardson PG, 2010, BIOL BLOOD MARROW TR, V16, P1005, DOI 10.1016/j.bbmt.2010.02.009; Strasser SI, 2008, THOMASS HEMATOPOIETI, P1434; Sullivan K M, 1998, Biol Blood Marrow Transplant, V4, P20; Vassal G, 1996, CANCER CHEMOTH PHARM, V37, P247	18	27	28	0	4	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1024-5332			HEMATOLOGY	Hematology	APR	2012	17			1			S159	S162		10.1179/102453312X13336169156735			4	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	927OA	WOS:000302916200045	22507809				2022-02-06	
J	Tomaiuolo, F; Bivona, U; Lerch, JP; Di Paola, M; Carlesimo, GA; Ciurli, P; Matteis, M; Cecchetti, L; Forcina, A; Silvestro, D; Azicnuda, E; Sabatini, U; Di Giacomo, D; Caltagirone, C; Petrides, M; Formisano, R				Tomaiuolo, Francesco; Bivona, Umberto; Lerch, Jason P.; Di Paola, Margherita; Carlesimo, Giovanni A.; Ciurli, Paola; Matteis, Mariella; Cecchetti, Luca; Forcina, Antonio; Silvestro, Daniela; Azicnuda, Eva; Sabatini, Umberto; Di Giacomo, Dina; Caltagirone, Carlo; Petrides, Michael; Formisano, Rita			Memory and anatomical change in severe non missile traumatic brain injury: similar to 1 vs. similar to 8 years follow-up	BRAIN RESEARCH BULLETIN			English	Article						Craniocerebral trauma; nmTBI; CHI; Coma; Neuroanatomy; Memory	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; HIPPOCAMPAL ATROPHY; LESIONS; FORNIX; MRI; CONSEQUENCES; MORPHOLOGY; SURVIVORS; MATTER	In previous studies, we investigated a group of subjects who had suffered from a severe non missile traumatic brain injury (nmTBI) without macroscopic focal lesions and we found brain atrophy involving the hippocampus, fornix, corpus callosum, optic chiasm, and optic radiations. Memory test scores correlated mainly with fornix volumes [37,38]. In the present study, we re-examined 11 of these nmTBI subjects approximately 8 yr later. High-spatial resolution T1 weighted magnetic resonance images of the brain (1 mm(3)) and standardised memory tests were performed once more in order to compare brain morphology and memory performance originally assessed 3-13 months after head injury (first study) and after 8-10 yr (present study). An overall improvement of memory test performance was demonstrated in the latest assessment, indicating that cognitive recovery in severe nmTBI subjects had not been completed within 3-13 months post-injury. It is notable that the volumes of the fornix and the hippocampus were reduced significantly from normal controls, but these volumes do not differ appreciatively between nmTBI subjects at first (after 1 yr) and at second (after similar to 8yr) scans. On the contrary, a clear reduction in the volume of the corpus callosus can be observed after similar to 1 yr and a further significant reduction is evident after similar to 8yr, indicating that the neural degeneration in severe nmTBI continues long after the head trauma and relates to specific structures and not to the overall brain. (C) 2012 Elsevier Inc. All rights reserved.	[Tomaiuolo, Francesco] Auxilium Vitae Volterra, Unita Cerebroles Acquisite, I-56048 Volterra, PI, Italy; [Tomaiuolo, Francesco; Bivona, Umberto; Di Paola, Margherita; Carlesimo, Giovanni A.; Ciurli, Paola; Matteis, Mariella; Silvestro, Daniela; Azicnuda, Eva; Sabatini, Umberto; Caltagirone, Carlo; Formisano, Rita] IRCCS Fdn Santa Lucia, Rome, Italy; [Tomaiuolo, Francesco; Di Paola, Margherita; Di Giacomo, Dina] Univ Aquila, Dept Internal Med & Publ Hlth, I-67100 Laquila, Italy; [Lerch, Jason P.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Forcina, Antonio] Univ Cassino, Dept Ind Engn, Cassino, Italy; [Carlesimo, Giovanni A.; Caltagirone, Carlo] Univ Rome, Clin Neurol, Tor Vergata, Italy; [Petrides, Michael] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada		Tomaiuolo, F (corresponding author), Auxilium Vitae Volterra, Unita Cerebroles Acquisite, Borgo San Lazzero 5, I-56048 Volterra, PI, Italy.	f.tomaiuolo@riabilitazione-volterra.it	Tomaiuolo, Francesco/AAC-1534-2019; Cecchetti, Luca/K-7060-2016; Di Giacomo, Dina/K-1983-2016; Caltagirone, Carlo/B-4930-2013; Sabatini, Umberto/K-4659-2016; Azicnuda, Eva/K-9010-2016; Di Paola, Margherita/A-8480-2010	Cecchetti, Luca/0000-0001-5184-6477; Di Giacomo, Dina/0000-0001-8189-2052; Sabatini, Umberto/0000-0001-5321-8626; Tomaiuolo, Fancesco/0000-0003-1230-2770			Adams J.H., 1990, HDB CLIN NEUROLOGY, V13, P43; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adams JH, 1994, INTRO NEUROPATHOLOGY; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Azouvi P., 1993, ANN READAPTATION MED, V36, P1; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Capitani E., 1987, J NEUROL SCI S8, P14; Carlesimo G, 2002, NUOVA RIV NEUROLOGIA, V12, P1; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; Rey A, 1968, REATTIVO FIGURA COMP; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wilson JTL, 1990, NEUROPSYCHOLOGY, V4, P261, DOI 10.1037/0894-4105.4.4.261; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328	36	27	27	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	MAR 10	2012	87	4-5					373	382		10.1016/j.brainresbull.2012.01.008			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	922YS	WOS:000302585500002	22289841				2022-02-06	
J	Mbye, LH; Keles, E; Tao, LY; Zhang, J; Chung, J; Larvie, M; Koppula, R; Lo, EH; Whalen, MJ				Mbye, Lamin H.; Keles, Eyup; Tao, Luyang; Zhang, Jimmy; Chung, Joonyong; Larvie, Mykol; Koppula, Rajani; Lo, Eng H.; Whalen, Michael J.			Kollidon VA64, a membrane-resealing agent, reduces histopathology and improves functional outcome after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-brain barrier; edema; Kollidon VA64; mice; plasmalemma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SURFACTANT POLOXAMER-188; MECHANICAL TRAUMA; PRENATAL EXPOSURE; CELL-DEATH; PERMEABILITY; NEURONS; DAMAGE; EPILEPTOGENESIS; RECOVERY	Loss of plasma membrane integrity is a feature of acute cellular injury/death in vitro and in vivo. Plasmalemma-resealing agents are protective in acute central nervous system injury models, but their ability to reseal cell membranes in vivo has not been reported. Using a mouse controlled cortical impact (CCI) model, we found that propidium iodide-positive (PI+) cells pulse labeled at 6, 24, or 48 hours maintained a degenerative phenotype and disappeared from the injured brain by 7 days, suggesting that plasmalemma permeability is a biomarker of fatal cellular injury after CCI. Intravenous or intracerebroventricular administration of Kollidon VA64, poloxamer P188, or polyethylene glycol 8000 resealed injured cell membranes in vivo (P < 0.05 versus vehicle or poloxamer P407). Kollidon VA64 (1 mmol/L, 500 mu L) administered intravenously to mice 1 hour after CCI significantly reduced acute cellular degeneration, chronic brain tissue damage, brain edema, blood-brain barrier damage, and postinjury motor deficits (all P < 0.05 versus vehicle). However, VA64 did not rescue pulse-labeled PI+ cells from eventual demise. We conclude that PI permeability within 48 hours of CCI is a biomarker of eventual cell death/loss. Kollidon VA64 reduces secondary damage after CCI by mechanisms other than or in addition to resealing permeable cells. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 515-524; doi: 10.1038/jcbfm.2011.158; published online 16 November 2011	[Mbye, Lamin H.; Keles, Eyup; Zhang, Jimmy; Chung, Joonyong; Koppula, Rajani; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Mbye, Lamin H.; Keles, Eyup; Zhang, Jimmy; Chung, Joonyong; Koppula, Rajani; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; [Tao, Luyang] Soochow Univ, Inst Forens Sci, Suzhou, Peoples R China; [Larvie, Mykol; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA		Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA 02129 USA.	mwhalen@partners.org		Chung, Joon Yong/0000-0002-3980-2065	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS061255]; Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064545, R01NS061255] Funding Source: NIH RePORTER	This study was supported by NINDS 5RO1NS061255 (MJW) and the Nature Science Foundation of China (LT).	Bassanini S, 2007, NEUROBIOL DIS, V26, P481, DOI 10.1016/j.nbd.2007.02.008; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Curry DJ, 2004, NEUROSURGERY, V55, P943, DOI 10.1227/01.NEU.0000137890.29862.2C; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Frim DM, 2004, NEUROREPORT, V15, P171, DOI 10.1097/00001756-200401190-00033; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Grindel JM, 2002, J PHARM SCI-US, V91, P1936, DOI 10.1002/jps.10190; Hallene KL, 2006, NEUROSCIENCE, V142, P267, DOI 10.1016/j.neuroscience.2006.06.017; Janigro D, 2010, EPILEPSY CURR, V10, P67, DOI 10.1111/j.1535-7511.2010.01359.x; Kilinc D, 2007, P ANN INT IEEE EMBS, P5395, DOI 10.1109/IEMBS.2007.4353562; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Marchi N, 2011, CARDIOVASC PSYCHIAT, P1; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pisetsky DS, 2011, ANTIOXID REDOX SIGN, V15, P2209, DOI 10.1089/ars.2010.3865; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	36	27	28	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2012	32	3					515	524		10.1038/jcbfm.2011.158			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	901FN	WOS:000300948200013	22086196	Bronze, Green Published			2022-02-06	
J	Hu, XB; Feng, Z; Fan, YC; Xiong, ZY; Huang, QW				Hu, Xue-Bin; Feng, Zhe; Fan, Yu-Cong; Xiong, Zhi-Yong; Huang, Qi-Wei			Health-related quality-of-life after traumatic brain injury: A 2-year follow-up study in Wuhan, China	BRAIN INJURY			English	Article						Health-related quality-of-life; traumatic brain injury; SF-36; follow-up	FUNCTIONAL OUTCOMES; HEAD-INJURY; 1ST YEAR; SATISFACTION; ADULTS	Objective: To assess health-related quality-of-life (HRQoL) 2 years after traumatic brain injury (TBI) among a group of Chinese. Methods: A total of 358 adult patients with moderate-to-severe TBI based on Glasgow Coma Scale score were recruited in a large trauma centre in Wuhan, China during May 2005 to April 2008. They were followed up for 2 years and the Medical Outcome Short Form 36 was used to measure HRQoL. Results: After a 2-year follow-up, there were 312 (87.2%) survivors. All domains of HRQoL had the lowest scores at discharge, greatly improved over the first 6 months and showed continued improvement. Patients with TBI still had significantly lower scores in every domain than the reference group 2 years after discharge. Female patients had lower MCS scores than the males (OR = 1.8, 95% CI: 1.1-2.9). Patients older than 30 had lower scores in PCS (OR = 1.7, 95% CI: 1.1-2.6). Patients with severe TBI had lower scores in both PCS (OR = 1.9, 95% CI: 1.2-3.1) and MCS (OR = 1.6, 95% CI: 1.0-2.6) compared with those with moderate TBI. Conclusions: HRQoL of a group of Chinese patients with TBI improved during 2 years after discharge. Age, sex and severity of TBI were significantly associated with physical or mental HRQoL after discharge.	[Hu, Xue-Bin; Fan, Yu-Cong; Xiong, Zhi-Yong; Huang, Qi-Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Union Hosp, Dept Neurosurg, Wuhan 430032, Hubei, Peoples R China; [Feng, Zhe] Huazhong Univ Sci & Technol, Sch Life Sci & Technol, Wuhan 430032, Hubei, Peoples R China		Hu, XB (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Union Hosp, Dept Neurosurg, Wuhan 430032, Hubei, Peoples R China.	huxb7276@163.com					Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bercaw EL, 2011, CLIN NEUROPSYCHOL, V25, P72, DOI 10.1080/13854046.2010.532813; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Centers for Disease Control and Prevention, 2000, MEAS HLTH DAYS POP A; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Faul M, 2010, TRAUMATIC BRAIN INJU; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Johansson U, 2003, BRAIN INJURY, V17, P991, DOI 10.1080/0269905031000110508; Li L, 2003, J EPIDEMIOL COMMUN H, V57, P259, DOI 10.1136/jech.57.4.259; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Novack TA, 2010, BRAIN INJURY, V24, P464, DOI 10.3109/02699051003601713; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803	27	27	28	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2012	26	2					183	187		10.3109/02699052.2011.648707			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	897NP	WOS:000300658200007	22360524				2022-02-06	
J	Osanai, T; Kuroda, S; Sugiyama, T; Kawabori, M; Ito, M; Shichinohe, H; Kuge, Y; Houkin, K; Tamaki, N; Iwasaki, Y				Osanai, Toshiya; Kuroda, Satoshi; Sugiyama, Taku; Kawabori, Masahito; Ito, Masaki; Shichinohe, Hideo; Kuge, Yuji; Houkin, Kiyohiro; Tamaki, Nagara; Iwasaki, Yoshinobu			Therapeutic Effects of Intra-Arterial Delivery of Bone Marrow Stromal Cells in Traumatic Brain Injury of Rats-In Vivo Cell Tracking Study by Near-Infrared Fluorescence Imaging	NEUROSURGERY			English	Article						Bone marrow stromal cell; Clinical application; Intra-arterial transplantation; In vivo optical imaging; Traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MICE CEREBRAL INFARCT; SECONDARY MITOCHONDRIAL DYSFUNCTION; MESENCHYMAL STEM-CELLS; GROWTH-FACTOR; SPINAL-CORD; NEUROTROPHIC FACTORS; FUNCTIONAL RECOVERY; ACID RECEPTOR; AXON GROWTH	BACKGROUND: A noninvasive and effective route of cell delivery should be established to yield maximal therapeutic effects for central nervous system (CNS) disorders. OBJECTIVE: To elucidate whether intra-arterial delivery of bone marrow stromal cells (BMSCs) significantly promotes functional recovery in traumatic brain injury (TBI) in rats. METHODS: Rat BMSCs were transplanted through the ipsilateral internal carotid artery 7 days after the onset of cortical freezing injury. The BMSCs were labeled with fluorescent dye, and in vivo optical imaging was employed to monitor the behaviors of cells for 4 weeks after transplantation. Motor function was assessed for 4 weeks, and the transplanted BMSCs were examined using immunohistochemistry. RESULTS: In vivo optical imaging and histologic analysis clearly demonstrated that the intra-arterially injected BMSCs were engrafted during the first pass without systemic circulation, and the transplanted BMSCs started to migrate from the cerebral capillary bed to the injured CNS tissue within 3 hours. Intra-arterial BMSC transplantation significantly promoted functional recovery after cortical freezing injury. A subgroup of BMSCs expressed the phenotypes of neurons, astrocytes, and endothelial cells around the injured neocortex 4 weeks after transplantation. CONCLUSION: Intra-arterial transplantation may be a valuable option for prompt, noninvasive delivery of BMSCs to the injured CNS tissue, enhancing functional recovery after TBI. In vivo optical imaging may provide important information on the intracerebral behaviors of donor cells by noninvasive, serial visualization.	[Osanai, Toshiya; Kuroda, Satoshi; Sugiyama, Taku; Kawabori, Masahito; Ito, Masaki; Shichinohe, Hideo; Houkin, Kiyohiro; Iwasaki, Yoshinobu] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Sapporo, Hokkaido 0608638, Japan; [Kuge, Yuji; Tamaki, Nagara] Hokkaido Univ, Grad Sch Med, Dept Nucl Med, Sapporo, Hokkaido 0608638, Japan		Kuroda, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Neurosurg, North 15,West 7, Sapporo, Hokkaido 0608638, Japan.	skuroda@med.hokudai.ac.jp	Shichinohe, Hideo/G-5367-2012; Kuge, Yuji/E-1290-2012; Sugiyama, Taku/U-9482-2018; Houkin, Kiyohiro/G-5364-2012; Kawabori, Masahito/AAH-7117-2020; Osanai, Toshiya/AAF-3011-2020; Yasuda, Kazunori/D-4156-2012	Sugiyama, Taku/0000-0003-0398-225X; Kawabori, Masahito/0000-0002-3574-8380; 	Ministry of Education, Science and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [19390371, 20591701, 20390377, 21390400]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23390342, 21390400] Funding Source: KAKEN	This study was supported by Grant-in-aid from the Ministry of Education, Science and Culture of Japan (No. 19390371, No. 20591701, No. 20390377 and No. 21390400). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bliss T, 2007, STROKE, V38, P817, DOI 10.1161/01.STR.0000247888.25985.62; Boddington Sophie, 2008, J Vis Exp, DOI 10.3791/686; Borlongan CV, 2008, REGEN MED, V3, P249, DOI 10.2217/17460751.3.3.249; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chiba Y, 2009, NEUROSURGERY, V64, P991, DOI 10.1227/01.NEU.0000341905.57162.1D; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Gu Y, 2010, J MOL NEUROSCI, V40, P332, DOI 10.1007/s12031-009-9304-6; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Hokari M, 2009, CYTOKINE, V46, P260, DOI 10.1016/j.cyto.2009.02.008; Kamei N, 2007, J NEUROSURG-SPINE, V6, P412, DOI 10.3171/spi.2007.6.5.412; Kuroda S, 2011, J STEM CELLS REGEN, V7, P2; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lacza Z, 2003, BRAIN RES PROTOC, V11, P145, DOI 10.1016/S1385-299X(03)00039-4; Lee JB, 2004, BRAIN RES PROTOC, V14, P37, DOI 10.1016/j.brainresprot.2004.09.004; Lee PH, 2008, CLIN PHARMACOL THER, V83, P723, DOI 10.1038/sj.clpt.6100386; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lundberg J, 2009, NEURORADIOLOGY, V51, P661, DOI 10.1007/s00234-009-0551-6; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A., 2003, NEUROSURGERY, V53, P702; Maruichi K, 2009, NEUROPATHOLOGY, V29, P422, DOI 10.1111/j.1440-1789.2008.00995.x; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Mori K, 2005, J CEREBR BLOOD F MET, V25, P887, DOI 10.1038/sj.jcbfm.9600083; Nakai A, 1997, NEUROBIOL DIS, V4, P288, DOI 10.1006/nbdi.1997.0146; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Orlacchio A, 2010, CURR MED CHEM, V17, P595, DOI 10.2174/092986710790416272; Osanai T, 2010, NEUROSURGERY, V66, P1140, DOI 10.1227/01.NEU.0000369610.76181.CF; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Shichinohe H, 2007, BRAIN RES, V1183, P138, DOI 10.1016/j.brainres.2007.08.091; Shichinohe H, 2006, J NUCL MED, V47, P486; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Sugiyama T, 2011, NEUROSURGERY, V68, P1036, DOI 10.1227/NEU.0b013e318208f891; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Wang Lei, 2002, Hematology, V7, P113; Wechsler L, 2009, STROKE, V40, P510, DOI 10.1161/STROKEAHA.108.526863; Yamaguchi S, 2006, BRAIN RES, V1087, P15, DOI 10.1016/j.brainres.2006.02.127; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Yano S, 2006, J NEUROTRAUM, V23, P1682, DOI 10.1089/neu.2006.23.1682; Yasuda H, 2010, J NEUROSURG, V112, P336, DOI 10.3171/2009.2.JNS08495; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	48	27	29	1	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2012	70	2					435	444		10.1227/NEU.0b013e318230a795			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	879IK	WOS:000299322700052	21822154				2022-02-06	
J	Schneiders, AG; Sullivan, SJ; Handcock, P; Gray, A; McCrory, PR				Schneiders, A. G.; Sullivan, S. J.; Handcock, P.; Gray, A.; McCrory, P. R.			Sports concussion assessment: the effect of exercise on dynamic and static balance	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						athletic injuries; motor performance; brain concussion; exercise; reliability	ERROR SCORING SYSTEM; STABILITY FOLLOWING CONCUSSION; FUNCTIONAL ANKLE INSTABILITY; POSTURAL STABILITY; TREADMILL EXERCISE; PERFORMANCE; FATIGUE; GAIT; EXERTION; DEFICITS	This study determined the effect of exercise on measures of static and dynamic balance used in the assessment of sports-related concussion (SRC). A balanced three-group cross-over randomized design was used with three levels of exercise verified by blood-lactate, heart rate and perceived-exertion: no exercise/rest (NE), moderate-intensity exercise (ME), and high-intensity exercise (HE). Participants performed two timed balance tasks: tandem gait (TG) and single-leg stance (SLS); pre- and post-exercise and 15 min after exercise. Linear mixed-models with adjusted means and contrasts compared exercise effects. Ninety asymptomatic participants (45?:45?) were recruited. When times were contrasted with NE; HE resulted in a significant decrease in SLS (P<0.001) and TG (P<0.001) performance immediately following exercise. Fifteen minutes of recovery improved SLS (P<0.001) and TG (P=0.011) from post-exercise performance. ME caused a significant decrease in performance in SLS (P=0.038) but not TG (P=0.428). No statistically significant change occurred following ME in any tasks after 15-min recovery (SLS P=0.064; TG P=0.495). Testretest reliability was considerably higher for the dynamic task compared with the static task. The reliability of static and dynamic balance tasks, and the change in performance following exercise, have implications for the immediate assessment of SRC, as these measures are utilized in concussion assessment instruments.	[Schneiders, A. G.] Univ Otago, Sch Physiotherapy, Ctr Physiotherapy Res, Dunedin 9054, New Zealand; [Handcock, P.] Univ Otago, Sch Phys Educ, Dunedin 9054, New Zealand; [Gray, A.] Univ Otago, Dept Prevent & Social Med, Dunedin 9054, New Zealand; [McCrory, P. R.] Univ Melbourne, Ctr Hlth & Exercise Sports Med, Melbourne, Vic 3010, Australia		Schneiders, AG (corresponding author), Univ Otago, Sch Physiotherapy, Ctr Physiotherapy Res, POB 56, Dunedin 9054, New Zealand.	tony.schneiders@otago.ac.nz	McCrory, Paul/Q-8688-2019; Gray, Andrew Robert/L-9161-2015; Handcock, Phil/P-2400-2019; Schneiders, Anthony/F-4212-2015	Gray, Andrew Robert/0000-0003-4299-2194; Handcock, Phil/0000-0002-0753-1117; Schneiders, Anthony/0000-0002-1583-3879; McCrory, Paul/0000-0003-4850-0568	University of Otago	This study was funded by a University of Otago Research Grant.	American College of Sports Medicine, 2005, ACSMS HLTH REL PHYS ACSMS HLTH REL PHYS; [Anonymous], 1999, SAS STAT V8 SOFTW US; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Crowell DH, 2001, J ATHL TRAINING, V36, pS; Derave W, 2002, INT J SPORTS MED, V23, P44, DOI 10.1055/s-2002-19374; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hamilton RT, 2008, J ATHL TRAINING, V43, P144, DOI 10.4085/1062-6050-43.2.144; Jankovic J, 2001, ADV NEUROL, V87, P119; Kingma H, 2006, CURR OPIN NEUROL, V19, P21, DOI 10.1097/01.wco.0000199021.48538.d9; Kinzey SJ, 1998, J ORTHOP SPORT PHYS, V27, P356, DOI 10.2519/jospt.1998.27.5.356; Lepers R, 1997, EUR J APPL PHYSIOL, V76, P55, DOI 10.1007/s004210050212; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Nakagawa L, 2004, J SPORT REHABIL, V13, P255, DOI 10.1123/jsr.13.3.255; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; Nardone A, 1998, ARCH PHYS MED REHAB, V79, P920, DOI 10.1016/S0003-9993(98)90088-0; Onate JA, 2007, J ATHL TRAINING, V42, P446; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Schneiders AG, 2008, BRIT J SPORT MED, V42, P1011, DOI 10.1136/bjsm.2007.041665; SELIGA R, 1991, AM IND HYG ASSOC J, V52, P417, DOI 10.1202/0002-8894(1991)052<0417:EOWLAR>2.0.CO;2; Stolze H, 2002, J NEUROL NEUROSUR PS, V73, P310, DOI 10.1136/jnnp.73.3.310; Susco TM, 2004, J ATHL TRAINING, V39, P241; THOMAS JR, 1975, MED SCI SPORT EXER, V7, P203; Warren J, 2006, PHYS THER SPORT, V7, P185, DOI 10.1016/j.ptsp.2006.06.002; Wikstrom EA, 2005, MED SCI SPORT EXER, V37, P169, DOI 10.1249/01.MSS.0000149887.84238.6C; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Yaggie JA, 2002, ARCH PHYS MED REHAB, V83, P224, DOI 10.1053/apmr.2002.28032	33	27	27	4	27	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0905-7188			SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	FEB	2012	22	1					85	90		10.1111/j.1600-0838.2010.01141.x			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	874UT	WOS:000298984300012	20561282				2022-02-06	
J	Fink, EL; Kochanek, PM; Clark, RSB; Bell, MJ				Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.; Bell, Michael J.			Fever control and application of hypothermia using intravenous cold saline	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						brain injury; hypothermia; fever; pediatric; cold saline	TRAUMATIC BRAIN-INJURY; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; AMERICAN-HEART-ASSOCIATION; HOSPITAL CARDIAC-ARREST; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; COMATOSE SURVIVORS; TEMPERATURE; CHILDREN	Objectives: To describe the use and feasibility of cold saline to decrease body temperature in pediatric neurocritical care. Design: Retrospective chart review. Setting: Pediatric tertiary care university hospital. Patients: Children between 1 wk and 17 yrs of age admitted to the pediatric intensive care unit with acute brain injury and having received intravenous cold saline between June and August 2009. Interventions: None. Measurements and Main Results: Eighteen subjects accounted for 20 infusions with mean infusion volume 18 +/- 10 mL/kg. Eight subjects had traumatic brain injury, two had intracranial hemorrhage, six had cardiac arrest, and one each had ischemic stroke and status epilepticus. The mean age was 9.5 +/- 4.8 yrs. Temperature decreased from 38.7 +/- 1.1 degrees C to 37.7 +/- 1.2 degrees C and from 37.0 +/- 2.0 degrees C to 35.3 +/- 1.6 degrees C 1 hr after infusion for fever (n = 14; p < .05) or hypothermia induction (n = 6; p = .05), respectively. Cold saline was not bloused but rather infused over 10-15 mins. Mean arterial blood pressure and oxygenation parameters (PaO(2)/FIO(2) ratio, mean airway pressure) were unchanged, but heart rate decreased in those with hypothermia (121 +/- 4 beats per minute vs. 109 +/- 12 beats per minute; p < .05). Serum sodium concentration and international normalized ratio were significantly increased after cold saline infusion. There were no differences between preinfusion and postinfusion serum glucose and hematocrit, or between cerebral perfusion pressure and intracranial pressure in traumatic brain injury patients. Conclusions: Cold saline was an effective method of reducing temperature in children with acute brain injury. This approach can be considered to treat fever or to induce hypothermia. A prospective study comparing safety and efficacy vs. other cooling measures should be considered. (Pediatr Crit Care Med 2012; 13:80-84)	[Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA		Fink, EL (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	finkel@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Fink, Ericka/AAU-9792-2021	Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K23NS065132, 5K12HD047349, NS052478]; Laerdal Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS052478, K23NS065132] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health grants 1K23NS065132, 5K12HD047349, and NS052478; and The Laerdal Foundation.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS53; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Atkins DL, 2006, PEDIATRICS, V117, pE1005, DOI 10.1542/peds.2006-0346; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; Crowder CM, 1996, J NEUROSURG, V85, P98, DOI 10.3171/jns.1996.85.1.0098; Fink EL, 2010, NEUROCRIT CARE, V12, P414, DOI 10.1007/s12028-010-9334-5; Fink EL, 2010, PEDIATR CRIT CARE ME, V11, P66, DOI 10.1097/PCC.0b013e3181c58237; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Hickey RW, 2000, PEDIATRICS, V106, P118, DOI 10.1542/peds.106.1.118; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Kelly BP, 2010, PEDIATR CARDIOL, V31, P11, DOI 10.1007/s00246-009-9526-y; Kim F, 2005, CIRCULATION, V112, P715, DOI 10.1161/CIRCULATIONAHA.105.544528; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Kim Y, 1996, STROKE, V27, P2281; Kim YM, 2008, RESUSCITATION, V79, P336, DOI 10.1016/j.resuscitation.2008.07.010; Kliegel A, 2005, RESUSCITATION, V64, P347, DOI 10.1016/j.resuscitation.2004.09.002; Kollmar R, 2009, STROKE, V40, P1907, DOI 10.1161/STROKEAHA.108.530410; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Maxton FJC, 2004, J ADV NURS, V45, P214, DOI 10.1046/j.1365-2648.2003.02883.x; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Robinson JL, 1998, J PEDIATR-US, V133, P553, DOI 10.1016/S0022-3476(98)70067-8; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; STONE JG, 1995, ANESTHESIOLOGY, V82, P344, DOI 10.1097/00000542-199502000-00004	31	27	27	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2012	13	1					80	84		10.1097/PCC.0b013e3181fe27c7			5	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	875YT	WOS:000299073000025	21037507	Green Accepted			2022-02-06	
J	Katada, R; Nishitani, Y; Honmou, O; Mizuo, K; Okazaki, S; Tateda, K; Watanabe, S; Matsumoto, H				Katada, Ryuichi; Nishitani, Yoko; Honmou, Osamu; Mizuo, Keisuke; Okazaki, Shunichiro; Tateda, Kenji; Watanabe, Satoshi; Matsumoto, Hiroshi			Expression of Aquaporin-4 Augments Cytotoxic Brain Edema after Traumatic Brain Injury during Acute Ethanol Exposure	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CYTOCHROME-P450 2E1; WATER TRANSPORT; ALCOHOL; RAT; MICE; MORTALITY; INTOXICATION; ASTROCYTES; SEVERITY; LIVER	We previously reported that ethanol consumption affects morbidity and mortality after traumatic brain injury (TBI) by accelerating brain edema via oxidative stress after TBI. Aquaporin-4 (AQP4), a water channel, is involved in brain edema formation. In this study, we found that acute ethanol administration increased AQP4 expression after TBI, leading to severe brain edema in rats. Rats were pretreated with ethanol (3 g/kg) or DL-buthionine-(S, R)-sulfoximine (BSO; 100 mg/kg), an oxidative stressor, before TBI. Acetazolamide, an AQP4 inhibitor, was administered to ethanol-pretreated rats 3 or 12 hours after TBI. Brain edema was increased 24 hours after TBI in both the ethanol- and BSO-pretreated groups. Ethanol pretreatment induced lipid peroxidation 24 hours after TBI. Transcription factors, NE-kappa B and hypoxia-inducible factor-1 alpha, were activated 3 and 24 hours after TBI in the BSO- and ethanol-pretreated groups, respectively. In the ethanol-pretreated group, AQP4 was accumulated, particularly in astrocyte end feet, 24 hours after TBI. Acetazolamide treatment improved the survival rate to 100% and decreased brain edema and AQP4 in ethanol-pretreated rats. These findings suggest that ethanol induces up-regulation of AQP4, leading to brain edema. The accumulation of AQP4 may play an important role in the augmentation of brain edema after TBI under ethanol consumption. (Am J Pathol 2012, 180:17-23; DOL. 10.1016/j.ajpath.2011.09.011)	[Matsumoto, Hiroshi] Sapporo Med Univ, Dept Legal Med & Mol Alcohol, Sch Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; [Honmou, Osamu] Sapporo Med Univ, Dept Neural Repair & Therapeut, Sch Med, Sapporo, Hokkaido 0608556, Japan; [Nishitani, Yoko] Kumamoto Univ, Grad Sch Med Sci, Dept Forens Med, Kumamoto, Japan		Matsumoto, H (corresponding author), Sapporo Med Univ, Dept Legal Med & Mol Alcohol, Sch Med, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	hmatsumo@sapmed.ac.jp		honmou, Osamu/0000-0001-8697-7530	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [22790601, 20390196]	Supported in part by Grants-in-Aid for Young Scientists (B) (22790601 to R.K.) and for Scientific Research (B) (20390196 to H.M.) and grants from the Japan Society for the Promotion of Science.	Allansson L, 2001, J NEUROCHEM, V76, P472, DOI 10.1046/j.1471-4159.2001.00097.x; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Aschner M, 2001, BRAIN RES, V900, P219, DOI 10.1016/S0006-8993(01)02314-9; Blanco AM, 2004, NEUROREPORT, V15, P681, DOI 10.1097/00001756-200403220-00021; Davis RL, 2004, NEUROSCI LETT, V371, P128, DOI 10.1016/j.neulet.2004.08.051; Huber VJ, 2007, BIOORG MED CHEM LETT, V17, P1270, DOI 10.1016/j.bmcl.2006.12.010; Illarionova NB, 2010, NEUROSCIENCE, V168, P915, DOI 10.1016/j.neuroscience.2009.11.062; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; JAMIE YD, 2009, NEUROSCI LETT, V453, P68; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lange RT, 2008, ARCH CLIN NEUROPSYCH, V23, P809, DOI 10.1016/j.acn.2008.07.004; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mansouri A, 2001, J PHARMACOL EXP THER, V298, P737; Matsumoto H, 2002, ALCOHOL CLIN EXP RES, V26, p6S, DOI 10.1097/01.ALC.0000026827.79925.C9; Migliati ER, 2010, NEUROCRIT CARE, V13, P123, DOI 10.1007/s12028-010-9376-8; Nielsen S, 1997, J NEUROSCI, V17, P171; Nishitani Y, 2006, FEBS LETT, V580, P9, DOI 10.1016/j.febslet.2005.11.030; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Rabinstein AA, 2010, CURR TREAT OPTION NE, V12, P129, DOI 10.1007/s11940-010-0062-0; Raza H, 2004, DIABETES, V53, P185, DOI 10.2337/diabetes.53.1.185; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Sripathirathan K, 2009, J NEUROTRAUM, V26, P261, DOI 10.1089/neu.2008.0682; Takata K, 2004, PROG HISTOCHEM CYTO, V39, P1, DOI 10.1016/j.proghi.2004.03.001; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010; Tindberg N, 1996, MOL PHARMACOL, V50, P1065; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verkman AS, 2009, J EXP BIOL, V212, P1707, DOI 10.1242/jeb.024125; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; YANG B, 2008, J BIOL CHEM, V1229, P224; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yuki T, 1980, Adv Exp Med Biol, V132, P689	40	27	36	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2012	180	1					17	23		10.1016/j.ajpath.2011.09.011			7	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	874RO	WOS:000298976000003	22051773	Bronze			2022-02-06	
J	Mellergard, P; Sjogren, F; Hillman, J				Mellergard, Pekka; Sjogren, Florence; Hillman, Jan			The Cerebral Extracellular Release of Glycerol, Glutamate, and FGF2 Is Increased in Older Patients following Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; FGF2; glutamate; glycerol; microdialysis; monitoring; traumatic brain injury	NEUROSURGICAL INTENSIVE-CARE; HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; AGED BRAIN; STROKE; MECHANISMS; MORTALITY; RECOVERY; MODERATE	Old age is associated with a poor recovery from traumatic brain injury (TBI). In a retrospective study we investigated if the biochemical response following TBI is age dependent. Extracellular fluids were continuously sampled by microdialysis in 69 patients admitted to our NSICU following severe TBI. The concentrations of glycerol, glutamate, lactate, pyruvate, and eight different cytokines (IL-1 beta, IL-6, IL-10, IL-8, MIP-1 beta, RANTES, FGF2, and VEGF) were determined by fluorescence multiplex bead technology. Patients in the oldest age group (>= 65 years) had significantly higher microdialysate concentrations of glycerol and glutamate compared to younger patients: the mean microdialysate concentration of glycerol increased from 55.9 mu mol/L (25-44 year) to 252 mu mol/L (>= 65 years; p < 0.0001); similarly glutamate increased from 15.8 mmol/L to 92.2 mmol/L (p < 0.0001). The lactate-pyruvate ratio was also significantly higher in the patients >= 65 years of age (63.9) compared with all the other age groups. The patterns of cytokine responses varied. For some cytokines (IL-1b, IL-10, and IL-8) there were no differences between age groups, while for others (MIP-1b, RANTES, VEGF, and IL-6) some differences were observed, but with no clear correlation with increasing age. For FGF2 the mean microdialysate concentration was 43 pg/mL in patients >= 65 years old, significantly higher compared to all other age groups (p < 0.0001). Increased concentrations of glycerol and glutamate would indicate more extensive damaging processes in the elderly. An increase in concentration of FGF2 could serve a protective function, but could also be related to a dysregulation of the timing in the cellular response in elderly patients.	[Mellergard, Pekka; Hillman, Jan] Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; [Sjogren, Florence] Linkoping Univ Hosp, Dept Dermatol, S-58185 Linkoping, Sweden		Mellergard, P (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	pekka.mellergard@efk.se					Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Fulwyler M J, 1990, Methods Cell Biol, V33, P613; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KEMENY DM, 1992, J IMMUNOL METHODS, V150, P57, DOI 10.1016/0022-1759(92)90065-2; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Mellergard P, 2010, BRIT J NEUROSURG, V24, P261, DOI 10.3109/02688690903521605; Monfils MH, 2005, NEUROSCIENCE, V134, P1, DOI 10.1016/j.neuroscience.2005.04.006; Mudo G, 2009, J NEURAL TRANSM, V116, P995, DOI 10.1007/s00702-009-0207-z; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Petcu EB, 2008, GERONTOLOGY, V54, P6, DOI 10.1159/000112845; Popa-Wagner A, 2007, CURR NEUROVASC RES, V4, P216; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sendroy-Terrill M, 2010, ARCH PHYS MED REHAB, V91, P489, DOI 10.1016/j.apmr.2009.11.011; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Sturnegk P, 2007, BRIT J NEUROSURG, V21, P332, DOI 10.1080/02688690701411574; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	31	27	28	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					112	118		10.1089/neu.2010.1732			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300013	21988111	Green Submitted			2022-02-06	
J	Williamson, DJ; Holsman, M; Chaytor, N; Miller, JW; Drane, DL				Williamson, David J.; Holsman, Maria; Chaytor, Naomi; Miller, John W.; Drane, Daniel L.			Abuse, Not Financial Incentive, Predicts Non-Credible Cognitive Performance in Patients With Psychogenic Non-Epileptic Seizures	CLINICAL NEUROPSYCHOLOGIST			English	Article						Psychogenic seizures; Non-epileptic seizures; Symptom validity testing; Word Memory Test; WMT	DISSOCIATIVE SYMPTOMS; RESPONSE BIAS; IMPAIRMENT; EPILEPSY; MMPI-2	Participants with psychogenic non-epileptic seizures (PNES) who fail symptom validity testing (SVT) perform worse on neuropsychological testing than those who do not, consistent with results found in participants with different clinical presentations (e. g., mild traumatic brain injury). However, little is known about how variables typically associated with SVT failure in other populations (e. g., the presence of financial incentives, exaggerated report of psychopathology) correlate with SVT failure in participants with PNES. Likewise the relationship between SVT failure and reported abuse, one of the most frequently described demographic characteristics of the PNES population, has not been examined. We found that failure on the Word Memory Test (WMT) in 91 participants with PNES was strongly associated with reported abuse but, contrary to expectations, was not associated with the presence of financial incentives or severity of reported psychopathology. These results indicate that the factors driving WMT failure may differ significantly in participants with PNES in ways that are potentially clinically relevant.	[Williamson, David J.] Janssen Sci Affairs LLC, Mobile, AL USA; [Williamson, David J.] Univ S Alabama, Dept Neurol, Mobile, AL 36688 USA; [Holsman, Maria] Puget Sound Vet Affairs, Dept Rehabil Psychol, Seattle, WA USA; [Chaytor, Naomi; Miller, John W.; Drane, Daniel L.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA; [Chaytor, Naomi; Miller, John W.] Harbor Med Ctr, UW Reg Epilepsy Ctr, Seattle, WA USA; [Drane, Daniel L.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA		Williamson, DJ (corresponding author), 100 Mem Hosp Dr,Suite 2A, Mobile, AL 36608 USA.	dj.williamson@alumni.duke.edu	Chaytor, Naomi/L-4315-2019	Chaytor, Naomi/0000-0001-8821-289X			ALPER K, 1993, NEUROLOGY, V43, P1950, DOI 10.1212/WNL.43.10.1950; Betts T, 1992, Seizure, V1, P27, DOI 10.1016/1059-1311(92)90051-2; Binder LM, 1998, ARCH CLIN NEUROPSYCH, V13, P513, DOI 10.1016/S0887-6177(97)00042-5; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bortz JJ, 2003, MAYO CLIN PROC, V78, P781, DOI 10.4065/78.6.781; Bowman ES, 1999, NEUROLOGY, V53, pS84; Butcher JN, 2001, MMPI 2 MANUAL ADM SC; Chafetz MD, 2011, ARCH CLIN NEUROPSYCH, V26, P306, DOI 10.1093/arclin/acr030; CHU JA, 1990, AM J PSYCHIAT, V147, P887; Cragar DE, 2002, NEUROPSYCHOL REV, V12, DOI 10.1023/A:1015491123070; Cragar DE, 2006, CLIN NEUROPSYCHOL, V20, P552, DOI 10.1080/13854040590947380; DePrince AP, 1999, PSYCHOL SCI, V10, P449, DOI 10.1111/1467-9280.00185; DODRILL CB, 2000, NONEPILEPTIC SEIZURE; Drake M E Jr, 1992, Seizure, V1, P11; Drane DL, 2006, EPILEPSIA, V47, P1879, DOI 10.1111/j.1528-1167.2006.00611.x; Drane DL, 2011, LITTLE BLACK BOOK NE; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P., 1996, WORD MEMORY TEST USE; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hill S. K., 2003, J FORENSIC NEUROPSYC, P1, DOI [10.1300/J151v03n03_01, DOI 10.1300/J151V03N03_01]; HOREN SA, 1995, CAN J PSYCHIAT, V40, P185; Hoskins LL, 2010, ARCH CLIN NEUROPSYCH, V25, P591, DOI 10.1093/arclin/acq060; Iverson G., 1999, J COGNITIVE REHABILI, V17, P4; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Locke DEC, 2006, J CLIN EXP NEUROPSYC, V28, P325, DOI 10.1080/13803390490918183; Merckelbach H., 1999, PERSONALITY INDIVIDU, V194, P289; Rossini ED, 1996, J NERV MENT DIS, V184, P289, DOI 10.1097/00005053-199605000-00004; Selkirk M, 2008, EPILEPSIA, V49, P1446, DOI 10.1111/j.1528-1167.2008.01611.x; SPSS Inc., 2006, SPSS BAS 15 0 WIND U; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	35	27	27	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	4					588	598		10.1080/13854046.2012.670266			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	945XW	WOS:000304311100003	22439651				2022-02-06	
J	Jin, W; Kong, J; Lu, TY; Wang, HD; Ni, HB; Wu, J; Dai, YX; Jiang, JA; Liang, WB				Jin, Wei; Kong, Jie; Lu, Tianyu; Wang, Handong; Ni, Hongbin; Wu, Jun; Dai, Yuxiang; Jiang, Jian; Liang, Weibang			Erythropoietin Prevents Secondary Brain Injury Induced by Cortical Lesion in Mice: Possible Involvement of Nrf2 Signaling Pathway	ANNALS OF CLINICAL AND LABORATORY SCIENCE			English	Article							HEME OXYGENASE-1 EXPRESSION; CEREBRAL-ISCHEMIA; NEURONAL APOPTOSIS; NEUROPROTECTION; MODEL; PATHOPHYSIOLOGY; INFLAMMATION; ACTIVATION; RECOVERY	Erythropoietin (EPO) has demonstrated neuroprotective effects against traumatic brain injury (TBI), but the underlying mechanisms remain unclear. The signaling pathway of an antioxidant transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2), has been shown in our previous studies to play an important role in protecting mice from TBI-induced secondary brain injury. The present study explored the effect of recombinant human erythropoietin (rhEPO) on cerebral activation of the Nrf2 signaling pathway and secondary brain injury in mice after TBI. Adult male ICR mice were randomly divided into three groups: (1) Sham group; (2) TBI group; and (3) TBI+rhEPO group (n = 12 per group). Closed head injury was performed using Hall's weight-dropping method. rhEPO was administered at a dose of 5,000 IU/kg at 30 min after TBI. Brain samples were extracted at 24 hr after the trauma. The treatment with rhEPO markedly up-regulated the mRNA expression and activities of Nrf2 and its downstream cytoprotective enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1). Administration of rhEPO also significantly ameliorated the secondary brain injury, as shown by decreased severity of neurological deficit, brain edema, and cortical apoptosis. In summary, post-TBI rhEPO administration induces Nrf2-mediated cytoprotective responses in the injured brain, and this may be a mechanism whereby rhEPO improves the outcome following TBI.	[Jin, Wei; Kong, Jie; Lu, Tianyu; Ni, Hongbin; Wu, Jun; Dai, Yuxiang; Jiang, Jian; Liang, Weibang] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu Prov, Peoples R China; [Wang, Handong] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu Prov, Peoples R China		Liang, WB (corresponding author), Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurosurg, 321 Zhongshan Rd, Nanjing 210008, Jiangsu Prov, Peoples R China.	njneurosurgery@yahoo.com.cn			Drum Tower Hospital of China	This work was supported by grants from the Drum Tower Hospital of China. The authors thank Dr. Lizhi Xu and Dr. Gengbao Feng for their technical assistance.	Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Byts Nadiya, 2009, Exp Transl Stroke Med, V1, P4, DOI 10.1186/2040-7378-1-4; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Genc K, 2010, CELL BIOCHEM FUNCT, V28, P197, DOI 10.1002/cbf.1639; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Katavetin P, 2007, BIOCHEM BIOPH RES CO, V359, P928, DOI 10.1016/j.bbrc.2007.05.207; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kumral A, 2005, BIOL NEONATE, V87, P15, DOI 10.1159/000080490; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhu L, 2009, BRAIN RES, V1289, P96, DOI 10.1016/j.brainres.2009.07.015	31	27	35	0	4	ASSOC CLINICAL SCIENTISTS	MIDDLEBURY	PO BOX 1287, MIDDLEBURY, VT 05753 USA	0091-7370	1550-8080		ANN CLIN LAB SCI	Ann. Clin. Lab. Sci.	WIN	2011	41	1					25	32					8	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	727BC	WOS:000287771300005	21325251				2022-02-06	
J	Jiang, C; Cui, KF; Wang, JP; He, YH				Jiang, Chao; Cui, Kefei; Wang, Jianping; He, Yuanhong			Microglia and cyclooxygenase-2: Possible therapeutic targets of progesterone for stroke	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Progesterone; Microglia; Inflammatory reaction; Cyclooxygenase-2; Cerebral infarction; Mechanism	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MARROW CHIMERIC MICE; INFLAMMATORY RESPONSE; ARTERY OCCLUSION; IN-VITRO; RATS; MACROPHAGES; ACTIVATION; PROTECTS	Previous studies have demonstrated that progesterone (PROG) may be a pleiotropic neuroprotective agent. Although there have been reports about the neurotoxicity of activated microglia and cyclooxygenase-2 (COX-2) in animal models of ischemic stroke, the influence of PROG on the activation of microglia and the expression of COX-2 after stroke has not been examined in detail. In this investigation, we carried out research about the influence of PROG on cultured microglia by detection of the expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) in their supernatant fluid before and after induced with lipopolysaccharide (LPS) or influenced by PROG with Enzyme-Linked Immunosorbent Assay technique in vitro. Moreover, the expression of COX-2 and ionized calcium-binding adapter molecule 1 (Iba1) was also detected in the cortex of rats that underwent permanent middle cerebral artery occlusion and received PROG or vehicle treatment by immunohistochemistry and western blot technique. The results revealed that PROG significantly reduced the expression of INF-alpha and IL-1 beta in cultured microglia after activated with LPS in vitro. In addition, PROG also valuably inhibited the expression of Ibal and COX-2 after stroke in vivo. These observations raised the possibility that PROG can exert its neuroprotective effects by inhibiting the activation of microglia and the over expression of COX-2 after stroke. (C) 2011 Elsevier B.V. All rights reserved.	[Jiang, Chao; Wang, Jianping; He, Yuanhong] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China; [Cui, Kefei] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450052, Henan, Peoples R China; [Cui, Kefei] Zhengzhou Univ, Affiliated Hosp 1, Dept Ultrasound, Zhengzhou 450052, Henan, Peoples R China		Wang, JP (corresponding author), Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China.	wjpwfy666@126.com			Medical Science and Technology Research Programs of Henan Province [WKJ2010-2-016]	This work was supported by grants from Medical Science and Technology Research Programs of Henan Province (WKJ2010-2-016).	Ahmad M, 2009, BRAIN RES, V1279, P168, DOI 10.1016/j.brainres.2009.05.020; Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Benedetto N, 2003, INT IMMUNOPHARMACOL, V3, P825, DOI 10.1016/S1567-5769(03)00047-X; Bianchi R, 2010, NEUROBIOL AGING, V31, P665, DOI 10.1016/j.neurobiolaging.2008.05.017; Candelario-Jalil E, 2008, CURR PHARM DESIGN, V14, P1401, DOI 10.2174/138161208784480216; Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dubal DB, 1999, J NEUROSCI, V19, P6385; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Fillpovic R, 2008, EXP NEUROL, V211, P41, DOI 10.1016/j.expneurol.2007.12.024; Frank MG, 2007, BRAIN BEHAV IMMUN, V21, P47, DOI 10.1016/j.bbi.2006.03.005; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gonzalez-Rey E, 2008, BRAIN BEHAV IMMUN, V22, P35, DOI 10.1016/j.bbi.2007.07.004; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Jiang C, 2009, INFLAMM RES, V58, P619, DOI 10.1007/s00011-009-0032-8; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kim HS, 2008, FREE RADICAL BIO MED, V45, P950, DOI 10.1016/j.freeradbiomed.2008.06.009; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LEVI G, 1993, P NATL ACAD SCI USA, V90, P1541, DOI 10.1073/pnas.90.4.1541; Li SQ, 2009, NEUROCHEM RES, V34, P1451, DOI 10.1007/s11064-009-9932-9; Liang X, 2007, J MOL NEUROSCI, V33, P94, DOI 10.1007/s12031-007-0058-8; Munhoz CD, 2008, BRAZ J MED BIOL RES, V41, P1037, DOI 10.1590/S0100-879X2008001200001; Nicholas RS, 2002, J NEUROIMMUNOL, V124, P36, DOI 10.1016/S0165-5728(02)00011-5; Pang Y, 2010, NEUROSCIENCE, V166, P464, DOI 10.1016/j.neuroscience.2009.12.040; Pola R, 2009, THROMB HAEMOSTASIS, V101, P800, DOI 10.1160/TH09-03-0206; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schilling M, 2005, EXP NEUROL, V196, P290, DOI 10.1016/j.expneurol.2005.08.004; Schilling M, 2003, EXP NEUROL, V183, P25, DOI 10.1016/S0014-4886(03)00082-7; Schilling M, 2009, BRAIN RES, V1289, P79, DOI 10.1016/j.brainres.2009.06.054; Schumacher M, 2002, HORMONES BRAIN BEHAV, P683; Shen J, 2007, EUR J PHARMACOL, V558, P88, DOI 10.1016/j.ejphar.2006.11.059; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Wu D, 2005, ACTA MED OKAYAMA, V59, P121; Yin W, 2002, BRAIN RES, V926, P165, DOI 10.1016/S0006-8993(01)03304-2	42	27	29	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	NOV	2011	11	11					1925	1931		10.1016/j.intimp.2011.08.001			7	Immunology; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Pharmacology & Pharmacy	853MV	WOS:000297431300039	21843661				2022-02-06	
J	Haar, CV; Anderson, GD; Hoane, MR				Haar, Cole Vonder; Anderson, Gail D.; Hoane, Michael R.			Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Vitamin B(3); Treatment; Recovery of function; Rat	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; FUNCTIONAL RECOVERY; CELL-DEATH; CONTUSION INJURY; CLINICAL-TRIALS; NADP(+)/NADPH; MECHANISMS; PRECURSOR; NAD(+)	Previous research has demonstrated considerable preclinical efficacy of nicotinamide (NAM; vitamin B(3)) in animal models of TBI with systemic dosing at 50 and 500 mg/kg yielding improvements on sensory, motor, cognitive and histological measures. The current study aimed to utilize a more specific dosing paradigm in a clinically relevant delivery mechanism: continuously secreting subcutaneous pumps. A bilateral frontal controlled cortical impact (CCI) or sham surgery was performed and rats were treated with NAM (150 mg/kg day) or saline (1 ml/kg) pumps 30 min after CCI, continuing until seven days post-CCI. Rats were given a loading dose of NAM (50 mg/kg) or saline (1 ml/kg) following pump implant. Rats received behavioral testing (bilateral tactile adhesive removal, locomotor placing task and Morris water maze) starting on day two post-CC and were sacrificed at 31 days post-CCI and brains were stained to examine lesion size. NAM-treated rats had reductions in sensory, motor and cognitive behavioral deficits compared to vehicle-treated rats. Specifically, NAM-treated rats significantly improved on the bilateral tactile adhesive removal task, locomotor placing task and the reference memory paradigm of the Morris water maze. Lesion size was also significantly reduced in the NAM-treated group. The results from this study indicate that at the current dose, NAM produces beneficial effects on recovery from a bilateral frontal brain injury and that it may be a relevant compound to be explored in human studies. (C) 2011 Elsevier BM. All rights reserved.	[Haar, Cole Vonder; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA; [Anderson, Gail D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA		Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Vonder Haar, Cole/0000-0001-7949-2068; Hoane, Michael/0000-0001-7779-2657	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647-04]; NIH/NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD061944-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	The authors would like to thank Andrew Vaz for his help with behavioral data collection and scoring and Michael Emery and Kris Martens for assisting in surgical procedures. Funding for this project was provided by ARRA funds from NINDS grant NS045647-04 and NIH/NICHD grant HD061944-01.	CDC, 2010, INJ PREV CONTR TRAUM; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; Komotar RJ, 2007, NAT PROTOC, V2, P2345, DOI 10.1038/nprot.2007.359; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NEAFSEY EJ, 1990, CEREBRAL CORTEX RAT, P197; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Xia WL, 2009, CURR PHARM DESIGN, V15, P12, DOI 10.2174/138161209787185832; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672	25	27	28	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	OCT 31	2011	224	2					311	317		10.1016/j.bbr.2011.06.009			7	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	818ZQ	WOS:000294795600012	21704653	Green Accepted			2022-02-06	
J	Moulaert, VRMP; Verbunt, JA; Bakx, WGM; Gorgels, APM; de Krom, MCFTM; Heuts, PHTG; Wade, DT; van Heugten, CM				Moulaert, Veronique R. M. P.; Verbunt, Jeanine A.; Bakx, Wilbert G. M.; Gorgels, Anton P. M.; de Krom, Marc C. F. T. M.; Heuts, Peter H. T. G.; Wade, Derick T.; van Heugten, Caroline M.			'Stand still ..., and move on', a new early intervention service for cardiac arrest survivors and their caregivers: rationale and description of the intervention	CLINICAL REHABILITATION			English	Article						Heart arrest; hypoxic brain injury; cognitive impairment; rehabilitation interventions; nursing care	TRAUMATIC BRAIN-INJURY; CORONARY-ARTERY-DISEASE; TELEPHONE INTERVENTION; HEAD-INJURY; NURSING INTERVENTIONS; RANDOMIZED-TRIAL; SELF-MANAGEMENT; MILD; REHABILITATION; QUALITY	Objective: To describe a new early intervention service for survivors of cardiac arrest and their caregivers, and to explain the evidence and rationale behind it. Rationale: A cardiac arrest may cause hypoxic-ischaemic brain injury, which often results in cognitive impairments. Survivors of cardiac arrest can also encounter emotional problems, limitations in daily life, reduced participation in society and a decreased quality of life. A new early intervention service was designed based on literature study, expert opinion and patient experiences. Description of the intervention: The early intervention service is an individualized programme, consisting of one to six consultations by a specialized nurse for the patient and their caregiver. The intervention starts soon after discharge from the hospital and can last up to three months. The intervention consists of screening for cognitive and emotional problems, provision of information and support, promotion of self-management strategies and can include referral to further specialized care if indicated. Discussion: This intervention is assumed to reduce future problems related to hypoxic-ischaemic brain injury in the patient and caregiver, and its effectiveness is currently being investigated in a randomized controlled multicentre trial.	[Moulaert, Veronique R. M. P.; Verbunt, Jeanine A.; Bakx, Wilbert G. M.; Wade, Derick T.] Ctr Expertise Rehabil & Audiol, NL-6432 CC Adelante, Hoensbroek, Netherlands; [Moulaert, Veronique R. M. P.; Verbunt, Jeanine A.] Maastricht Univ, Dept Rehabil Med, CAPHRI Sch Publ Hlth & Primary Care, Med Ctr, Maastricht, Netherlands; [Gorgels, Anton P. M.] Maastricht Univ, Dept Cardiol, Med Ctr, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands; [de Krom, Marc C. F. T. M.] Maastricht Univ, Dept Neurol, Med Ctr, Maastricht, Netherlands; [Heuts, Peter H. T. G.] Vrije Univ Amsterdam, Dept Rehabil Med, Med Ctr, Amsterdam, Netherlands; [Heuts, Peter H. T. G.] Ctr Rehabil & Rheumatol, Amsterdam, Netherlands; [Wade, Derick T.] Nuffield Orthopaed Ctr, Oxford Ctr Enablement, Oxford OX3 7LD, England; [van Heugten, Caroline M.] Maastricht Univ, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [van Heugten, Caroline M.] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands		Moulaert, VRMP (corresponding author), Ctr Expertise Rehabil & Audiol, Zandbergsweg 111, NL-6432 CC Adelante, Hoensbroek, Netherlands.	v.moulaert@adelante-zorggroep.nl		Wade, Derick/0000-0002-1188-8442	Netherlands Organization for Health Research and Development (ZON/MW)Netherlands Organization for Health Research and Development; Fonds Nuts Ohra	This study is funded by the Netherlands Organization for Health Research and Development (ZON/MW); and Fonds Nuts Ohra.	Alderson AL, 2003, ARCH PHYS MED REHAB, V84, P668, DOI 10.1016/S0003-9993(03)04842-6; Allen JK, 2010, J CARDIOVASC NURS, V25, P207, DOI 10.1097/JCN.0b013e3181cc79be; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Cowan MJ, 2001, NURS RES, V50, P68, DOI 10.1097/00006199-200103000-00002; de Vos R, 1999, ARCH INTERN MED, V159, P249, DOI 10.1001/archinte.159.3.249; Dougherty CM, 2005, PACE, V28, P1157, DOI 10.1111/j.1540-8159.2005.09500.x; Dougherty CM, 2004, PACE, V27, P1594, DOI 10.1111/j.1540-8159.2004.00691.x; Dougherty CM, 2004, HEART LUNG, V33, P183, DOI 10.1016/j.hrtlng.2004.01.003; Dougherty CM, 2000, HEART LUNG, V29, P79; Dougherty CM, 2001, ADV NURS SCI, V24, P78, DOI 10.1097/00012272-200109000-00009; Dougherty Cynthia M, 2004, J Cardiovasc Nurs, V19, P21; Dusseldorp E, 1999, HEALTH PSYCHOL, V18, P506, DOI 10.1037/0278-6133.18.5.506; Edwards DF, 2006, NEUROREHAB NEURAL RE, V20, P42, DOI 10.1177/1545968305283038; Gorgels APM, 2003, EUR HEART J, V24, P1204, DOI 10.1016/S0195-668X(03)00191-X; Jovicic Aleksandra, 2006, BMC Cardiovasc Disord, V6, P43, DOI 10.1186/1471-2261-6-43; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KOSTER RW, 2009, HART VAATZIEKTEN NED, P49; Linden W, 1996, ARCH INTERN MED, V156, P745, DOI 10.1001/archinte.156.7.745; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Lundgren-Nilsson A, 2005, RESUSCITATION, V66, P285, DOI 10.1016/j.resuscitation.2005.04.001; Moulaert Veronique R M P, 2007, BMC Cardiovasc Disord, V7, P26, DOI 10.1186/1471-2261-7-26; Moulaert VRMP, 2009, RESUSCITATION, V80, P297, DOI 10.1016/j.resuscitation.2008.10.034; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nys GMS, 2005, ARCH CLIN NEUROPSYCH, V20, P623, DOI 10.1016/j.acn.2005.04.001; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Straus SMJM, 2004, J CLIN EPIDEMIOL, V57, P98, DOI 10.1016/S0895-4356(03)00210-5; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Thornton M, 2003, J GERONTOL B-PSYCHOL, V58, pS127, DOI 10.1093/geronb/58.2.S127; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; van Heugten C, 2007, CLIN NEUROL NEUROSUR, V109, P257, DOI 10.1016/j.clineuro.2006.10.002; Wachelder EM, 2009, RESUSCITATION, V80, P517, DOI 10.1016/j.resuscitation.2009.01.020; Wade DT, 2004, BMJ-BRIT MED J, V329, P1398, DOI 10.1136/bmj.329.7479.1398; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; World Health Organization, 2007, INT CLASS FUNCT DIS	42	27	28	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	OCT	2011	25	10					867	879		10.1177/0269215511399937			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	834AH	WOS:000295928500001	21565869	Green Published, hybrid			2022-02-06	
J	Wang, L; Tang, XG; Zhang, HX; Yuan, JS; Ding, H; Wei, YZ				Wang, Lei; Tang, Xingguo; Zhang, Hongxi; Yuan, Jishan; Ding, Hua; Wei, Yongzhong			Elevated leptin expression in rat model of traumatic spinal cord injury and femoral fracture	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Leptin; Fracture; Osteogenesis; Spinal cord injuries; Bone; Callus	SYMPATHETIC NERVOUS-SYSTEM; HETEROTOPIC OSSIFICATION; SERUM LEPTIN; BRAIN-INJURY; BONE; LOCALIZATION; OSTEOBLASTS; RECEPTORS; INCREASES; HUMANS	Background: Few studies have reported a relationship between leptin induced by spinal cord injury (SCI) and healing bone tissue. Objective: To observe serum and callus leptin expression within the setting of fracture and traumatic SCI. Methods: Seventy-two male Sprague Dawley rats were randomized equally into four groups: control, SCI group, fracture group, and fracture/SCI group. Rats were sacrificed at 7, 14, 21, and 28 days post-fracture/SCI. Serum leptin was detected using radioimmunoassay at 1, 7, 14, 21, and 28 days, and callus formation was measured radiologically at 14, 21, and 28 days. Callus leptin was analyzed by means of immunohistochemistry. Results: Serum leptin in the fracture group, SCI group, and combined fracture/SCI group were all significantly increased compared to control group at the 1, 7, 14, and 2-day time points (P < 0.05). Serum leptin in the combined fracture/SCI group was significantly higher than in the fracture group at 7, 14, and 21 days (P < 0.05), and higher than in SCI groups at 14 and 21days after operation (P < 0.05). The percentage of leptin-positive cells in the fracture/SCI callus, and callus volume was significantly higher than in the fracture-only group (P < 0.001). Conclusions: Overall, elevated leptin expression was demonstrated within healing bone especially in the 21 days of a rat model combining fracture and SCI. A close association exists between leptin levels and the degree of callus formation in fractures.	[Wang, Lei; Tang, Xingguo; Zhang, Hongxi; Yuan, Jishan; Ding, Hua] Jiangsu Univ, Affiliated Peoples Hosp, Dept Orthoped, Zhenjiang, Jiangsu Provinc, Peoples R China; [Wei, Yongzhong] Nanjing Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Jiangsu Provinc, Peoples R China		Zhang, HX (corresponding author), Dianli Rd 8, Zhenjiang 212001, Jiangsu Provinc, Peoples R China.	zhanghx-ortho@hotmail.com			Medical Science and Technology Development of Jiangsu Health Bureau, China [H200512]	Supported by funds from the Medical Science and Technology Development of Jiangsu Health Bureau (H200512), China.	Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bonnet N, 2007, BONE, V40, P1209, DOI 10.1016/j.bone.2007.01.006; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; COUSIN B, 1993, ENDOCRINOLOGY, V133, P2255, DOI 10.1210/en.133.5.2255; Desborough JP, 1993, ANAESTHESIA REV, V10, P131; Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013; Faggioni R, 2000, AM J PATHOL, V156, P1781, DOI 10.1016/S0002-9440(10)65049-3; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Freehafer A A, 1966, Med Serv J Can, V22, P471; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Lee YJ, 2002, FEBS LETT, V528, P43, DOI 10.1016/S0014-5793(02)02889-2; Li JL, 2000, J BONE MINER RES, V15, P2042, DOI 10.1359/jbmr.2000.15.10.2042; Li S, 2001, Hua Xi Yi Ke Da Xue Xue Bao, V32, P240; Lin Ji, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P19; Lolmede K, 2003, INT J OBESITY, V27, P1187, DOI 10.1038/sj.ijo.0802407; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P3408, DOI 10.1210/jc.82.10.3408; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Miell JP, 1996, HORM METAB RES, V28, P704, DOI 10.1055/s-2007-979882; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; Patel L, 2002, J PEDIATR ENDOCR MET, V15, P963; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P5214; Rayner DV, 2001, J MOL MED, V79, P8, DOI 10.1007/s001090100198; Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426; Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018; Shahbazian LM, 1999, METABOLISM, V48, P1397, DOI 10.1016/S0026-0495(99)90149-X; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167-0115(00)00152-X; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; Thomas T, 2004, CURR OPIN PHARMACOL, V4, P295, DOI 10.1016/j.coph.2004.01.009; Thomas T, 2002, J BONE MINER RES, V17, P1563, DOI 10.1359/jbmr.2002.17.9.1563; Utriainen T, 1996, DIABETES, V45, P1364, DOI 10.2337/diabetes.45.10.1364; Wang YH, 2005, ARCH PHYS MED REHAB, V86, P1964, DOI 10.1016/j.apmr.2005.04.017; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009	43	27	28	0	13	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	1079-0268			J SPINAL CORD MED	J. Spinal Cord. Med.	SEP	2011	34	5					501	509		10.1179/2045772311Y.0000000034			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	835OS	WOS:000296046300009	22118258	Green Published			2022-02-06	
J	Asgari, S; Bergsneider, M; Hamilton, R; Vespa, P; Hu, X				Asgari, Shadnaz; Bergsneider, Marvin; Hamilton, Robert; Vespa, Paul; Hu, Xiao			Consistent Changes in Intracranial Pressure Waveform Morphology Induced by Acute Hypercapnic Cerebral Vasodilatation	NEUROCRITICAL CARE			English	Article						Intracranial pressure; Hemodynamic signal; Cerebral vasodilation; Hypercapnia; Waveform morphology	TRAUMATIC BRAIN-INJURY; PULSE PRESSURE; BLOOD-FLOW; AUTOREGULATION; ALGORITHM; DYNAMICS; FEATURES	Intracranial pressure (ICP) remains a pivotal physiological signal for managing brain injury and subarachnoid hemorrhage (SAH) patients in neurocritical care units. Given the vascular origin of the ICP, changes in ICP waveform morphology could be used to infer cerebrovascular changes. Clinical validation of this association in the setting of brain trauma, and SAH is challenging due to the multi-factorial influences on, and uncertainty of, the state of the cerebral vasculature. To gain a more controlled setting, in this articel, we study ICP signals recorded in four uninjured patients undergoing a CO2 inhalation challenge in which hypercapnia induced acute cerebral vasodilatation. We apply our morphological clustering and analysis of intracranial pressure (MOCAIP) algorithm to identify six landmarks on individual ICP pulses (based on the three established ICP sub-peaks; P1, P2, and P3) and extract 128 ICP morphological metrics. Then by comparing baseline, test, and post-test data, we assess the consistency and rate of change for each individual metric. Acute vasodilatation causes consistent changes in a total of 72 ICP pulse morphological metrics and the P2 sub-region responds to cerebral vascular changes in the most consistent way with the greatest change as compared to P1 and P3 sub-regions. Since the dilation/constriction of the cerebral vasculature resulted in detectable consistent changes in ICP MOCIAP metrics, by an extended monitoring practice of ICP that includes characterizing ICP pulse morphology, one can potentially detect cerebrovascular changes, continuously, for patients under neurocritical care.	[Asgari, Shadnaz; Bergsneider, Marvin; Hamilton, Robert; Vespa, Paul; Hu, Xiao] Univ Calif Los Angeles, David Geffen Sch Med, Neural Syst & Dynam Lab, Dept Neurosurg, Los Angeles, CA 90095 USA; [Bergsneider, Marvin; Hamilton, Robert; Hu, Xiao] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Biomed Engn Grad Program, Los Angeles, CA 90095 USA; [Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Neurocrit Care Program, Dept Neurosurg, Los Angeles, CA 90095 USA		Hu, X (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Neural Syst & Dynam Lab, Dept Neurosurg, 18-265 Semel,10833 Le Conte Ave,Box 703919, Los Angeles, CA 90095 USA.	xhu@mednet.ucla.edu			R01 award [NS054881, NS066008];  [NS059797]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS059797, R01NS054881, R01NS066008] Funding Source: NIH RePORTER	This work is partially supported by NS059797 and R01 awards NS054881 and NS066008.	Afonso VX, 1999, IEEE T BIO-MED ENG, V46, P192, DOI 10.1109/10.740882; Asgari S, 2010, IEEE T INF TECHNOL B, V14, P166, DOI 10.1109/TITB.2009.2034845; Asgari S, 2009, PHYSIOL MEAS, V30, P1211, DOI 10.1088/0967-3334/30/11/006; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; CZOSNYKA M, 1996, ACTA NEUROCHIR WIEN, V138, P541; Fan JY, 2008, AM J CRIT CARE, V17, P545; Germon K, 1988, J Neurosci Nurs, V20, P344; Hamilton R., 2009, C P IEEE ENG MED BIO, P4331; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hu X, 2008, PHYSIOL MEAS, V29, P459, DOI 10.1088/0967-3334/29/4/004; Hu X, 2010, IEEE T BIO-MED ENG, V57, P1070, DOI 10.1109/TBME.2009.2037607; Hu X, 2010, PHYSIOL MEAS, V31, P679, DOI 10.1088/0967-3334/31/5/006; Hu X, 2009, IEEE T BIO-MED ENG, V56, P696, DOI 10.1109/TBME.2008.2008636; Hu X, 2009, J CEREBR BLOOD F MET, V29, P688, DOI 10.1038/jcbfm.2008.160; Kasprowicz M, 2010, J NEUROSCI METH, V190, P310, DOI 10.1016/j.jneumeth.2010.05.015; Kaufman L., 2005, FINDING GROUPS DATA; Lavinio A, 2009, INTENS CARE MED, V35, P546, DOI 10.1007/s00134-008-1311-5; March K, 1990, J Neurosci Nurs, V22, P375; MILLER J D, 1987, Neurological Research, V9, P193; Muwaswes M, 1985, J Neurosurg Nurs, V17, P238; NORNES H, 1977, ACTA NEUROCHIR, V38, P177, DOI 10.1007/BF01401089; NORTH B, 1997, HEAD INJURY, P209; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; SCALZO F, 2010, ARTIF INTELL M UNPUB; Scalzo F, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-61; Scalzo F, 2009, MED BIOL ENG COMPUT, V47, P967, DOI 10.1007/s11517-009-0505-5; Tsuncda S, 1980, INTRACRANIAL PRESSUR, P188; YOSHIHARA M, 1995, J NEUROSURG, V82, P386, DOI 10.3171/jns.1995.82.3.0386	33	27	29	1	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	AUG	2011	15	1					55	62		10.1007/s12028-010-9463-x			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	789XI	WOS:000292552100009	21052864	Green Accepted			2022-02-06	
J	Berrigan, L; Marshall, S; Mccullagh, S; Velikonja, D; Bayley, M				Berrigan, Lindsay; Marshall, Shawn; Mccullagh, Scott; Velikonja, Diana; Bayley, Mark			Quality of clinical practice guidelines for persons who have sustained mild traumatic brain injury	BRAIN INJURY			English	Article						Mild traumatic brain injury; clinical practice guidelines; evidence-based practice; AGREE instrument; post-concussion syndrome	POST-CONCUSSION SYMPTOMS; POSTCONCUSSION SYNDROME; CHRONIC PAIN; HEAD-INJURY; VALIDATION; INSTRUMENT; PREDICTION; APPRAISAL	Background: Mild TBI is one of the most common neurological disorders occurring today. For individuals who experience persistent symptoms following mild TBI, consequences can include functional disability, stress and time away from one's occupation. The objective of the study was to evaluate the quality of clinical practice guidelines (CPGs) that include recommendations on the care of persons who have sustained mild TBI and associated persistent symptoms. Methods: A minimum of four appraisers used the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument to evaluate seven CPGs found via a systematic search of bibliographic databases and internet resources. Results: High AGREE scores were obtained for the domains Scope and Purpose and Clarity and Presentation. The CPGs fared less well on Rigour of Development, Stakeholder Involvement, Editorial Independence and Applicability. The number of recommendations addressing the care of persistent symptoms following mild TBI was meager, with the exception of military guidelines. Conclusions: There is considerable variability in the quality of guidelines addressing mild TBI and, overall, the CPGs reviewed score lower on Rigour of Development than CPGs for other medical conditions. There is a clear need for clinical guidance on the management of individuals who experience persistent symptoms following mild TBI.	[Berrigan, Lindsay; Marshall, Shawn] Ottawa Gen Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada; [Marshall, Shawn] Univ Ottawa, Ottawa, ON, Canada; [Mccullagh, Scott; Bayley, Mark] Univ Toronto, Toronto, ON, Canada; [Velikonja, Diana] McMaster Univ, Hamilton, ON, Canada		Berrigan, L (corresponding author), Ottawa Gen Hosp, Res Inst, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	lberrigan@Ottawahospital.on.ca		Bayley, Mark/0000-0001-7860-9463	Ontario Neurotrauma Foundation	This work was conducted with funding support from the Ontario Neurotrauma Foundation. The authors report no conflicts of interest.	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Burgers JS, 2004, J CLIN ONCOL, V22, P2000, DOI 10.1200/JCO.2004.06.157; Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18; *DEP LAB EMPL STAT, 2005, TRAUM BRAIN INJ MED; Department of Veterans Affairs/Department of Defense, 2009, VA DOD CLIN PRACT GU; *DVBIC, 2008, UPD MTBI CLIN GUID; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Hurdowar A, 2007, J EVAL CLIN PRACT, V13, P657, DOI 10.1111/j.1365-2753.2007.00708.x; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 1996, NEUROTRAUMA, P13; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lohr KN, 1992, GUIDELINES CLIN PRAC; *MAANSW, 2008, GUID MILD TRAUM BRAI; Martelli M.F., 2007, BRAIN INJURY MED PRI, P1183; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; NICE, 2007, HEAD INJ TRIAG ASS I; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rusnak M, 2008, BRATISL MED J, V109, P374; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spinos P, 2010, J TRAUMA, V69, P789, DOI 10.1097/TA.0b013e3181edea67; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stone MA, 2010, DIABETES RES CLIN PR, V87, P252, DOI 10.1016/j.diabres.2009.10.020; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; *WORKPL SAF INS BO, 2006, MILD TRAUM BRAIN INJ; World Health Organization, 2004, ICD 10 INT STAT CLAS	46	27	27	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2011	25	7-8					742	751		10.3109/02699052.2011.580317			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	769RJ	WOS:000291035600010	21604931				2022-02-06	
J	Curia, G; Levitt, M; Fender, JS; Miller, JW; Ojemann, J; D'Ambrosio, R				Curia, Giulia; Levitt, Michael; Fender, Jason S.; Miller, John W.; Ojemann, Jeffrey; D'Ambrosio, Raimondo			Impact of Injury Location and Severity on Posttraumatic Epilepsy in the Rat: Role of Frontal Neocortex	CEREBRAL CORTEX			English	Article						drug screening; electrocorticography; endophenotype; model; partial seizures; syndrome; trauma	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; COMPLEX PARTIAL SEIZURES; HEAD-INJURY; LOBE EPILEPSY; ELECTRICAL-STIMULATION; TEMPORAL-LOBE; CLINICAL CHARACTERISTICS; INTERNATIONAL-BUREAU; GENE POLYMORPHISMS	Human posttraumatic epilepsy (PTE) is highly heterogeneous, ranging from mild remitting to progressive disabling forms. PTE results in simple partial, complex partial, and secondarily generalized seizures with a wide spectrum of durations and semiologies. PTE variability is thought to depend on the heterogeneity of head injury and patient's age, gender, and genetic background. To better understand the role of these factors, we investigated the seizures resulting from calibrated fluid percussion injury (FPI) to adolescent male Sprague-Dawley rats with video electrocorticography. We show that PTE incidence and the frequency and severity of chronic seizures depend on the location and severity of FPI. The frontal neocortex was more prone to epileptogenesis than the parietal and occipital, generating earlier, longer, and more frequent partial seizures. A prominent limbic focus developed in most animals, regardless of parameters of injury. Remarkably, even with carefully controlled injury parameters, including type, severity, and location, the duration of posttraumatic apnea and the age and gender of outbred rats, there was great subject-to-subject variability in frequency, duration, and rate of progression of seizures, indicating that other factors, likely the subjects' genetic background and physiological states, have critical roles in determining the characteristics of PTE.	[Miller, John W.; Ojemann, Jeffrey; D'Ambrosio, Raimondo] Univ Washington, Harborview Med Ctr, Dept Neurosurg, Seattle, WA 98104 USA; [Curia, Giulia] Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy; [Curia, Giulia; Levitt, Michael; Fender, Jason S.; Miller, John W.; Ojemann, Jeffrey; D'Ambrosio, Raimondo] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [Miller, John W.; Ojemann, Jeffrey; D'Ambrosio, Raimondo] Univ Washington, Sch Med, Reg Epilepsy Ctr, Seattle, WA 98104 USA		D'Ambrosio, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, Box 359915,325 9Th Ave, Seattle, WA 98104 USA.	raid@u.washington.edu	Curia, Giulia/A-8863-2008	Curia, Giulia/0000-0002-8472-350X; Ojemann, Jeffrey/0000-0001-7580-8934	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS053928]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053928] Funding Source: NIH RePORTER	National Institutes of Health (NS053928 to R. D.).	Aarabi B, 2000, NEUROSURG FOCUS, V8, P1, DOI DOI 10.3171/F0C.2000.8.1.155; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Bancaud J, 1992, Adv Neurol, V57, P3; BECKER DP, 1979, ARCH NEUROL-CHICAGO, V36, P750, DOI 10.1001/archneur.1979.00500480024005; Beghi E, 2005, EPILEPSIA, V46, P1698, DOI 10.1111/j.1528-1167.2005.00273_1.x; BEGHI E, 1992, EPILEPSIA, V33, P45; Benbadis SR, 2003, SEIZURE-EUR J EPILEP, V12, P167, DOI 10.1016/S1059-1311(02)00320-5; Berg AT, 2009, ANN NEUROL, V65, P510, DOI 10.1002/ana.21642; Besenski N, 1996, NEURORADIOLOGY, V38, pS36; Binnie CD, 2003, CLINICAL NEUROPHYSIOLOGY, VOL 2, P268; BLACKWOOD DHR, 1982, J NEUROSCI METH, V5, P343, DOI 10.1016/0165-0270(82)90004-8; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Brandt C, 2003, EPILEPSY RES, V55, P83, DOI 10.1016/S0920-1211(03)00114-1; BROWNING RA, 1987, EPILEPSY RETICULAR F, P137; CAVENESS W F, 1954, Clin Neurosurg, V2, P116; CAVENESS WF, 1961, EPILEPSIA, V2, P123; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen J, 2005, EPILEPSIA, V46, P956, DOI 10.1111/j.1528-1167.2005.51204.x; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Costello Daniel J, 2004, Expert Rev Neurother, V4, P541, DOI 10.1586/14737175.4.3.541; Cukiert A, 2001, EPILEPSIA, V42, P889, DOI 10.1046/j.1528-1157.2001.00201.x; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; DEVINSKY O, 1989, NEUROLOGY, V39, P527; DEVINSKY O, 1988, NEUROLOGY, V38, P1347, DOI 10.1212/WNL.38.9.1347; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Eastman CL, 2010, EXP NEUROL, V224, P369, DOI 10.1016/j.expneurol.2010.04.013; Eftekhar B, 2009, J NEUROSURG, V110, P319, DOI 10.3171/2008.4.17519; Engel J, 2006, EPILEPSIA, V47, P1558, DOI 10.1111/j.1528-1167.2006.00215.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Epsztein J, 2008, NEUROSCIENTIST, V14, P78, DOI 10.1177/1073858407301681; Fisher RS, 2008, EPILEPSIA, V49, P7, DOI 10.1111/j.1528-1167.2008.01921.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gale K, 1988, MECHANISMS EPILEPTOG, P111; GEIER S, 1977, NEUROLOGY, V27, P951, DOI 10.1212/WNL.27.10.951; Goggio AF, 1941, J NEUROL PSYCHIATRY, V4, P11, DOI 10.1136/jnnp.4.1.11; Gupta Y K, 2006, Indian J Physiol Pharmacol, V50, P7; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P112; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Hartzfeld P, 2008, BRIT J NEUROSURG, V22, P224, DOI 10.1080/02688690701818901; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Holguin A, 2007, J NEUROSCI METH, V161, P265, DOI 10.1016/j.jneumeth.2006.11.014; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Ikeda A, 2009, EPILEPSIA, V50, P2072, DOI 10.1111/j.1528-1167.2009.02097.x; INOUE M, 1990, PHYSIOL BEHAV, V48, P199, DOI 10.1016/0031-9384(90)90285-C; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JABBARI B, 1986, ELECTROEN CLIN NEURO, V64, P285, DOI 10.1016/0013-4694(86)90151-3; JENNETT W B, 1961, Ann R Coll Surg Engl, V29, P370; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Jobst BC, 2000, EPILEPSIA, V41, P1139, DOI 10.1111/j.1528-1157.2000.tb00319.x; Jyoti A, 2009, NEUROSCI LETT, V453, P86, DOI 10.1016/j.neulet.2009.01.082; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Kanemoto K, 2000, ANN NEUROL, V47, P571, DOI 10.1002/1531-8249(200005)47:5<571::AID-ANA3>3.0.CO;2-A; Kelly KM, 2010, EPILEPSY CURR, V10, P15, DOI 10.1111/j.1535-7511.2009.01341.x; Kerling F, 2006, EPILEPSY BEHAV, V9, P281, DOI 10.1016/j.yebeh.2006.05.010; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Klein PM, 2009, EPILEPSIA, V50, P385; Langendorf F, EPILEPSY COMPREHENSI, P2469; Lee KR, 1997, J NEUROSURG, V87, P73, DOI 10.3171/jns.1997.87.1.0073; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Leppik IE, 1997, CONT DIAGNOSIS MANAG, P8; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; LOSCHER W, 1995, BRAIN RES, V697, P197, DOI 10.1016/0006-8993(95)00843-F; Luders H O, 1992, Adv Neurol, V57, P149; LUDERS HO, 1995, ADV NEUROL, V67, P115; LUDWIG B, 1975, EPILEPSIA, V16, P141, DOI 10.1111/j.1528-1157.1975.tb04731.x; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Muller CJ, 2009, GENES BRAIN BEHAV, V8, P481, DOI 10.1111/j.1601-183X.2009.00490.x; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Noebels JL, 2003, ANNU REV NEUROSCI, V26, P599, DOI 10.1146/annurev.neuro.26.010302.081210; OZTAS B, 1990, MECH AGEING DEV, V51, P149, DOI 10.1016/0047-6374(90)90097-Y; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; Penfield W, 1954, EPILEPSY FUNCTIONAL; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RASMUSSEN T, 1983, EPILEPSIA, V24, P482, DOI 10.1111/j.1528-1157.1983.tb04919.x; Sadrzadeh SMH, 2004, CLIN CHEM, V50, P1095, DOI 10.1373/clinchem.2003.028001; SALANOVA V, 1995, EPILEPSIA, V36, P16, DOI 10.1111/j.1528-1157.1995.tb01659.x; Salanova V, 2002, EPILEPSIA, V43, P170, DOI 10.1046/j.1528-1157.2002.33800.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Shinomoto S, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000433; So NK, 1998, EPILEPSIA, V39, pS49, DOI 10.1111/j.1528-1157.1998.tb05125.x; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sutula TP, 2004, EPILEPSY RES, V60, P161, DOI 10.1016/j.eplepsyres.2004.07.001; SWARTZ BE, 1992, J EPILEPSY, V5, P80, DOI 10.1016/S0896-6974(05)80055-6; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vezzani A, 2008, BRAIN BEHAV IMMUN, V22, P797, DOI 10.1016/j.bbi.2008.03.009; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Virta N, 2002, PEDIATR NEUROL, V26, P192, DOI 10.1016/S0887-8994(01)00380-0; WALKER A E, 1965, J Med Assoc State Ala, V35, P93; WALKER A. EARL, 1962, WORLD NEUROL, V3, P185; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1972, J NEUROSURG, V37, P164, DOI 10.3171/jns.1972.37.2.0164; Williamson P D, 1992, Adv Neurol, V57, P289; WILLIAMSON PD, 1985, ANN NEUROL, V18, P647, DOI 10.1002/ana.410180604; WILLIAMSON PD, 1986, EPILEPSIA, V27, pS46, DOI 10.1111/j.1528-1157.1986.tb05740.x; WILLIAMSON PD, 1985, ANN NEUROL, V18, P497, DOI 10.1002/ana.410180413; WILLIAMSON PD, 1992, ANN NEUROL, V31, P3, DOI 10.1002/ana.410310103; Willmore LJ, 2009, NEUROCHEM RES, V34, P688, DOI 10.1007/s11064-008-9841-3; Winawer MR, 2007, MAMM GENOME, V18, P23, DOI 10.1007/s00335-006-0087-6; Wohlrab G, 1997, EPILEPSIA, V38, P275, DOI 10.1111/j.1528-1157.1997.tb01117.x; Worrell GA, 2008, BRAIN, V131, P928, DOI 10.1093/brain/awn006	132	27	27	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JUL	2011	21	7					1574	1592		10.1093/cercor/bhq218			19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	779AL	WOS:000291750400010	21112931	Green Published, Bronze			2022-02-06	
J	Pappadis, MR; Sander, AM; Struchen, MA; Leung, P; Smith, DW				Pappadis, Monique R.; Sander, Angelle M.; Struchen, Margaret A.; Leung, Patrick; Smith, Dennis W.			Common Misconceptions About Traumatic Brain Injury Among Ethnic Minorities With TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						minorities; misconceptions; recovery; traumatic brain injury	COMMUNITY INTEGRATION; HEAD-INJURY; RECOVERY; REPLICATION; DEPRESSION; AWARENESS; OUTCOMES; IMPACT; RETURN; WORK	Objective: To investigate common TBI misconceptions among ethnic minorities with TBI. Design: Cross-sectional study. Setting: Level I trauma center. Participants: Fifty-eight persons with TBI (28 black and 30 Hispanic) discharged from the neurosurgery unit and living in the community. Main Measure: Forty-item Common Misconceptions about Traumatic Brain Injury Questionnaire (CM-TBI). Results: Participants displayed misconceptions about approximately one-third of the 40 items, most regarding amnesia and recovery. Fewer misconceptions were found in the brain damage/injury and sequelae categories. A greater percentage of TBI misconceptions was associated with having lower education, actively practicing religion, being Spanish-speaking and non-US born. After controlling for education and actively practicing religion, Spanish-speaking Hispanics reported a greater percentage of misconceptions than English-speaking Hispanics and blacks. Conclusions and Implications: Understanding common TBI misconceptions can assist rehabilitation staff in tailoring education programs for racial/ethnic minorities including those who are Spanish-speaking. Educational attainment and cultural factors should be considered when developing educational interventions for persons with TBI from diverse backgrounds. Inaccurate information regarding TBI, especially the recovery process, may hinder treatment planning by rehabilitation professionals and may result in disappointment and the setting of unrealistic goals for persons with injury and their families.	[Pappadis, Monique R.; Sander, Angelle M.; Struchen, Margaret A.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Pappadis, Monique R.; Leung, Patrick] Univ Houston, Grad Coll Social Work, Houston, TX USA; [Smith, Dennis W.] Univ Houston, Dept Hlth & Human Performance, Houston, TX USA; [Sander, Angelle M.; Struchen, Margaret A.] Harris Cty Hosp Dist, Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA		Pappadis, MR (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd,Ste 907, Houston, TX 77019 USA.	monique.pappadis@memorialhermann.org	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	National Institute on Disability and Rehabilitation Research; US Department of EducationUS Department of Education [H133B031117]	This work was supported by a grant from the National Institute on Disability and Rehabilitation Research, US Department of Education ( grant H133B031117, Rehabilitation Research and Training Center on Community Integration in Persons with Traumatic Brain Injury). Special thanks to the patients and staff of Harris County Hospital District, including Drs Shankar Gopinath and Claudia Robertson.	Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Capella ME, 2002, REHABIL COUNS BULL, V45, P143, DOI 10.1177/003435520204500303; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dowswell G, 2000, J CLIN NURS, V9, P507, DOI 10.1046/j.1365-2702.2000.00411.x; Ernst WJ, 2009, J HEAD TRAUMA REHAB, V24, P213, DOI 10.1097/HTR.0b013e3181a7ecd8; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Glover NM, 2007, J REHABIL, V73, P41; GORDON WA, 1999, REHABILITATION ADULT, P312; Gouvier W. D., 1988, ARCH CLIN NEUROPSYCH, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; McGrane SA, 2000, BRAIN INJURY, V14, P975; MCKINLAY W, 1999, REHABILITATION ADULT, P74; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; O'Jile JR., 1997, INT J REHABILITATION, V3, P61, DOI [10.1007/BF02766798, DOI 10.1007/BF02766798]; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	45	27	27	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					301	311		10.1097/HTR.0b013e3181e7832b			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700007	20808242				2022-02-06	
J	Shin, SS; Dixon, CE				Shin, Samuel S.; Dixon, C. Edward			Oral fish oil restores striatal dopamine release after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Fish oil; Omega-3 fatty acid; Docosahexaenoic acid; Eicosapentaenoic acid; Traumatic brain injury; Dopamine	POLYUNSATURATED FATTY-ACID; RAT FRONTAL-CORTEX; SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; EVOKED RELEASE; AXONAL INJURY; DOUBLE-BLIND; MODEL; DEFICIENCY; HIPPOCAMPUS	Omega-3 fatty acid administration can affect the release of neurotransmitters and reduce inflammation and oxidative stress, but its use in traumatic brain injury (TBI) has not been described extensively. We investigated the effect of 7 day oral fish oil treatment in the recovery of potassium evoked dopamine release after TBI. Sham rats and TBI rats were given either olive oil or fish oil by oral gavage and were subject to cerebral microdialysis. Olive oil treated TBI rats showed significant dopamine release deficit compared to sham rats, and this deficit was restored with oral fish oil treatment. There was no effect of fish oil treatment on extracellular levels of dopamine metabolites such as 3,4-dihydroxyphenylacetic acid and homovanillic acid. These results suggest the therapeutic potential of omega-3 fatty acids in restoring dopamine neurotransmission deficits after TBI. Published by Elsevier Ireland Ltd.	[Shin, Samuel S.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Shin, Samuel S.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA		Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F30NS067731-01, 5R01NS060672-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS067731, R01NS060672] Funding Source: NIH RePORTER	Supported by NIH grants: 1F30NS067731-01, 5R01NS060672-02.	Agut J, 2000, ANN NY ACAD SCI, V920, P332; Aid S, 2005, J NUTR, V135, P1008, DOI 10.1093/jn/135.5.1008; Aid S, 2003, J LIPID RES, V44, P1545, DOI 10.1194/jlr.M300079-JLR200; BAILES J, 2011, NEUROSURGERY    0105; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Bousquet M, 2008, FASEB J, V22, P1213, DOI 10.1096/fj.07-9677com; Bousquet M, 2009, PROG NEURO-PSYCHOPH, V33, P1401, DOI 10.1016/j.pnpbp.2009.07.018; Cansev M, 2008, ALZHEIMERS DEMENT, V4, pS153, DOI 10.1016/j.jalz.2007.10.005; Corrigan FM, 1998, INT J BIOCHEM CELL B, V30, P197, DOI 10.1016/S1357-2725(97)00125-8; Dangour AD, 2010, AM J CLIN NUTR, V91, P1725, DOI 10.3945/ajcn.2009.29121; Delattre AM, 2010, NEUROSCI RES, V66, P256, DOI 10.1016/j.neures.2009.11.006; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Favreliere S, 2003, NEUROBIOL AGING, V24, P233, DOI 10.1016/S0197-4580(02)00064-7; GREEN D, 1985, STROKE, V16, P706, DOI 10.1161/01.STR.16.4.706; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; KIMURA M, 1995, NEUROSCI RES, V22, P353, DOI 10.1016/0168-0102(95)00914-F; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Kodas E, 2002, J LIPID RES, V43, P1209, DOI 10.1194/jlr.M200132-JLR200; Korchounov AM, 2008, B EXP BIOL MED+, V146, P14, DOI 10.1007/s10517-008-0197-0; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mura A, 2003, MOVEMENT DISORD, V18, P860, DOI 10.1002/mds.10472; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Peet M, 2003, PROSTAG LEUKOTR ESS, V69, P477, DOI 10.1016/j.plefa.2003.08.020; Sarsilmaz M, 2003, PROSTAG LEUKOTR ESS, V69, P253, DOI 10.1016/S0952-3278(03)00107-8; SHIN SS, 2010, BRAIN RES; Smi CK, 2004, DEV BRAIN RES, V152, P11, DOI [10.1016/j.debrainres.2004.05.004, 10.1016/j.devbrainres.2004.05.004]; Tanriover G, 2010, FOLIA HISTOCHEM CYTO, V48, P434, DOI 10.2478/v10042-010-0047-6; WAINWRIGHT PE, 1992, NEUROSCI BIOBEHAV R, V16, P193, DOI 10.1016/S0149-7634(05)80180-0; Wang L, 2005, J MOL NEUROSCI, V27, P137, DOI 10.1385/JMN:27:1:137; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wurtman RJ, 2009, ANNU REV NUTR, V29, P59, DOI 10.1146/annurev-nutr-080508-141059; Zimmer L, 2000, NEUROSCI LETT, V284, P25, DOI 10.1016/S0304-3940(00)00950-2; Zimmer L, 1998, NEUROSCI LETT, V240, P177, DOI 10.1016/S0304-3940(97)00938-5; Zimmer L, 2002, AM J CLIN NUTR, V75, P662, DOI 10.1093/ajcn/75.4.662	39	27	29	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 8	2011	496	3					168	171		10.1016/j.neulet.2011.04.009			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774TF	WOS:000291408800005	21514362	Green Accepted			2022-02-06	
J	Barber, L; Barrett, R; Lichtwark, G				Barber, Lee; Barrett, Rod; Lichtwark, Glen			Validity and reliability of a simple ultrasound approach to measure medial gastrocnemius muscle length	JOURNAL OF ANATOMY			English	Article						acquired brain injury; cerebral palsy; muscle contracture; muscle length; spasticity; spinal injury; stroke; traumatic brain injury; ultrasound	CHILDREN; MORPHOLOGY; PROGRESSION; VALIDATION; SUPPORT; VOLUME	Fixed shortening of a muscle, or contracture, often develops in individuals with an upper motor neuron disorder. A clinical measure of muscle length would therefore be useful for identifying the presence of muscle contracture, tracking changes over time and evaluating the effect of interventions. This study compared a novel ultrasound-tape length method with a previously validated freehand 3D ultrasound method for measuring muscle length. The ultrasound-tape method intra-session reliability was also assessed. Resting medial gastrocnemius muscle length was measured at three ankle joint angles in 15 typically developed (TD) adults and nine adults with cerebral palsy (CP) using the two methods. The ultrasound-tape method on average overestimated the muscle length in the TD group by < 0.1% (95% CI, 6%) and underestimated in the muscle length in the CP group by 0.1% (95% CI, 6%) compared with the 3D ultrasound method. Intra-session reliability of the ultrasound-tape method was high, with intra-class correlation coefficients > 0.99. The ultrasound-tape method has sufficient accuracy to detect clinically relevant differences and changes in medial gastrocnemius muscle length and may therefore be a useful clinical tool for assessing muscle length changes associated with contracture.	[Barber, Lee; Barrett, Rod] Griffith Univ, Sch Physiotherapy & Exercise Sci, Gold Coast, Qld 4222, Australia; [Lichtwark, Glen] Univ Queensland, Sch Human Movement Studies, Brisbane, Qld, Australia		Barber, L (corresponding author), Griffith Univ, Sch Physiotherapy & Exercise Sci, Gold Coast Campus, Gold Coast, Qld 4222, Australia.	l.barber@griffith.edu.au	Lichtwark, Glen A/B-6002-2008; Barrett, Rod/B-4419-2009; Barber, Lee A/G-3575-2011; Barber, Lee/V-6900-2019	Lichtwark, Glen A/0000-0001-7366-3348; Barber, Lee A/0000-0002-3220-3078; Barber, Lee/0000-0002-3220-3078; Barrett, Rod/0000-0002-1784-1629	National Health and Medical Research Council, AustraliaNational Health and Medical Research Council of Australia [481953]	This work was supported by funding from the National Health and Medical Research Council, Australia (Biomedical Postgraduate Scholarship Grant ID: 481953).	Bache CE, 2003, CURR ORTHOPAED, V17, P88, DOI 10.1054/cuor.2003.0328; Barber L, 2009, J BIOMECH, V42, P1313, DOI 10.1016/j.jbiomech.2009.03.005; Barrett RS, 2010, DEV MED CHILD NEUROL, V52, P794, DOI 10.1111/j.1469-8749.2010.03686.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CAMPBELL RSD, 2002, IMAGING, V14, P229; Fry NR, 2007, J PEDIATR ORTHOPED, V27, P769, DOI 10.1097/BPO.0b013e3181558943; Fry NR, 2004, GAIT POSTURE, V20, P177, DOI 10.1016/j.gaitpost.2003.08.010; Fry NR, 2003, GAIT POSTURE, V17, P119, DOI 10.1016/S0966-6362(02)00059-0; Gao F, 2008, J APPL PHYSIOL, V105, P1802, DOI 10.1152/japplphysiol.90930.2008; Liu MQ, 2008, J BIOMECH, V41, P3243, DOI 10.1016/j.jbiomech.2008.07.031; Maganaris CN, 2003, CLIN ANAT, V16, P215, DOI 10.1002/ca.10064; Malaiya R, 2007, J ELECTROMYOGR KINES, V17, P657, DOI 10.1016/j.jelekin.2007.02.009; McDowell BC, 2000, GAIT POSTURE, V12, P114, DOI 10.1016/S0966-6362(00)00068-0; Mitsiopoulos N, 1998, J APPL PHYSIOL, V85, P115, DOI 10.1152/jappl.1998.85.1.115; Oberhofer K, 2010, CLIN BIOMECH, V25, P88, DOI 10.1016/j.clinbiomech.2009.09.007; Ohata K, 2008, DEV MED CHILD NEUROL, V50, P152, DOI 10.1111/j.1469-8749.2007.02018.x; Palisano RJ, 2008, DEV MED CHILD NEUROL, V50, P744, DOI 10.1111/j.1469-8749.2008.03089.x; Sheean G, 2002, EUR J NEUROL, V9, P3, DOI 10.1046/j.1468-1331.2002.0090s1003.x; Steele KM, 2010, J BIOMECH, V43, P2099, DOI 10.1016/j.jbiomech.2010.04.003; Weller R, 2007, ULTRASOUND MED BIOL, V33, P402, DOI 10.1016/j.ultrasmedbio.2006.08.007; Whittaker JL, 2007, J ORTHOP SPORT PHYS, V37, P434, DOI 10.2519/jospt.2007.2350	21	27	27	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8782	1469-7580		J ANAT	J. Anat.	JUN	2011	218	6					637	642		10.1111/j.1469-7580.2011.01365.x			6	Anatomy & Morphology	Science Citation Index Expanded (SCI-EXPANDED)	Anatomy & Morphology	758PE	WOS:000290176400006	21450014	Green Published, Bronze			2022-02-06	
J	Koike, MA; Garcia, FG; Kitazawa, M; Green, KN; LaFerla, FM				Koike, M. A.; Garcia, F. G.; Kitazawa, M.; Green, K. N.; LaFerla, F. M.			Long term changes in phospho-APP and tau aggregation in the 3xTg-AD mice following cerebral ischemia	NEUROSCIENCE LETTERS			English	Article						Alzheimer's disease; Ischemia; Stroke; Phospho-APP	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; A-BETA; VASCULAR-LESIONS; EXPRESSION; PLAQUES; BACE1; PHOSPHORYLATION; PREVALENCE	The risk of Alzheimer's disease increases following cerebral hypoperfusion. We studied the long-term interaction between low blood flow to the brain and Alzheimer's disease by inducing a transient global ischemic insult in aged 3xTg-AD mice and determining the effects on AD pathology 3-months post injury. We found that global ischemia does not increase the levels of amyloid-beta in these mice. However, the injury did lead to enhanced phosphorylation of the amyloid precursor protein (APP) at the Thr668 site in both the 3xTg-AD mice and wild-type controls. Furthermore, we found an increase in insoluble total tau 3-months post-injury. Together these findings further elucidate the long-term impact of cerebral hypoperfusion on Alzheimer's disease. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Koike, M. A.; Garcia, F. G.; Kitazawa, M.; Green, K. N.; LaFerla, F. M.] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA		Green, KN (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, 3222 Biol Sci 3, Irvine, CA 92697 USA.	kngreen@uci.edu; laferla@uci.edu	Kitazawa, Masashi/AAI-1721-2021	Kitazawa, Masashi/0000-0003-2165-8197	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-021982, 1F31NS063650-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS063650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021982] Funding Source: NIH RePORTER	This work was supported by grants from the NIH AG-021982 to FML and NIH 1F31NS063650-01A1 to MAK. We thank Mr. David Cheng for assistance with the mice.	Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Cai ZY, 2009, NEUROCHEM RES, V34, P1226, DOI 10.1007/s11064-008-9899-y; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Doraiswamy PM, 2002, J GERONTOL A-BIOL, V57, pM173, DOI 10.1093/gerona/57.3.M173; Gentile MT, 2009, NEUROBIOL AGING, V30, P222, DOI 10.1016/j.neurobiolaging.2007.06.005; Goulding JMR, 1999, J NEUROL NEUROSUR PS, V67, P654, DOI 10.1136/jnnp.67.5.654; Hiltunen M, 2009, NEUROBIOL DIS, V35, P103, DOI 10.1016/j.nbd.2009.04.009; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Koike MA, 2010, AM J PATHOL, V177, P300, DOI 10.2353/ajpath.2010.090750; Lee JH, 2000, ARCH NEUROL-CHICAGO, V57, P1474, DOI 10.1001/archneur.57.10.1474; Li ZG, 2007, DIABETES, V56, P1817, DOI 10.2337/db07-0171; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; McLin JP, 2006, EUR J NEUROSCI, V24, P2191, DOI 10.1111/j.1460-9568.2006.05111.x; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Pluta R, 2007, CURR NEUROVASC RES, V4, P121, DOI 10.2174/156720207780637207; Purandare N, 2009, J NEUROL SCI, V283, P17, DOI 10.1016/j.jns.2009.02.306; Riekse RG, 2004, J AM GERIATR SOC, V52, P1442, DOI 10.1111/j.1532-5415.2004.52405.x; Sadowski M, 2004, NEUROCHEM RES, V29, P1257, DOI 10.1023/B:NERE.0000023612.66691.e6; Sheng B, 2007, J AM GERIATR SOC, V55, P918, DOI 10.1111/j.1532-5415.2007.01171.x; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Suzuki T, 2008, J BIOL CHEM, V283, P29633, DOI 10.1074/jbc.R800003200; van Groen T, 2005, STROKE, V36, P1551, DOI 10.1161/01.STR.0000169933.88903.cf; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; Ye JT, 2009, NEUROREPORT, V20, P1456, DOI 10.1097/WNR.0b013e328332024a; Zhang X, 2007, J BIOL CHEM, V282, P10873, DOI 10.1074/jbc.M608856200	31	27	28	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 9	2011	495	1					55	59		10.1016/j.neulet.2011.03.034			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	766YA	WOS:000290821300012	21419194	Green Accepted			2022-02-06	
J	Gabaeff, SC				Gabaeff, Steven C.			Challenging the Pathophysiologic Connection between Subdural Hematoma, Retinal Hemorrhage and Shaken Baby Syndrome	WESTERN JOURNAL OF EMERGENCY MEDICINE			English	Article							CLINICAL CHARACTERISTICS; SUBARACHNOID HEMORRHAGE; CEREBRAL CONCUSSION; HEAD-INJURIES; BRAIN-DAMAGE; INFANTS; PREVALENCE; PRESSURE; FALLS	Child abuse experts use diagnostic findings of subdural hematoma and retinal hemorrhages as near-pathognomonic findings to diagnose shaken baby syndrome. This article reviews the origin of this link and casts serious doubt on the specificity of the pathophysiologic connection. The forces required to cause brain injury were derived from an experiment of high velocity impacts on monkeys, that generated forces far above those which might occur with a shaking mechanism. These forces, if present, would invariably cause neck trauma, which is conspicuously absent in most babies allegedly injured by shaking. Subdural hematoma may also be the result of common birth trauma, complicated by prenatal vitamin D deficiency, which also contributes to the appearance of long bone fractures commonly associated with child abuse. Retinal hemorrhage is a non-specific finding that occurs with many causes of increased intracranial pressure, including infection and hypoxic brain injury. The evidence challenging these connections should prompt emergency physicians and others who care for children to consider a broad differential diagnosis before settling on occult shaking as the de-facto cause. While childhood non-accidental trauma is certainly a serious problem, the wide exposure of this information may have the potential to exonerate some innocent care-givers who have been convicted, or may be accused, of child abuse.	[Gabaeff, Steven C.] Emergency Med & Clin Forens Med, Sacramento, CA 95823 USA		Gabaeff, SC (corresponding author), Emergency Med & Clin Forens Med, Sacramento, CA 95823 USA.	sgabaeff@adnc.com					AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; Barnes PD, 2009, CHILD ABUSE NONACCID; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Binenbaum G, 2007, J AAPOS, V11, P85; Bodnar LM, 2007, J NUTR, V137, P447, DOI 10.1093/jn/137.2.447; CAFFEY J, 1974, PEDIATRICS, V54, P396; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; Chadwick DR, VIRAL MENINGITIS; CHAMBERS SE, 1985, PEDIATR RADIOL, V15, P4, DOI 10.1007/BF02387844; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Cohen MC, 2009, PEDIATR DEVEL PATHOL, V12, P169, DOI 10.2350/08-08-0509.1; Cordner S, 2007, PEDIAT FORENSIC PATH; Donohoe M, 2003, AM J FOREN MED PATH, V24, P239, DOI 10.1097/01.paf.0000083635.85457.97; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Duncan J M, 1874, Br Med J, V2, P763; Duszak RS, 2009, RETINOPATHY VALSALAV; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; FRIEDE RL, 1978, AM J PATHOL, V92, P69; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gilliland MGF, 2003, HISTOPATHOLOGY, V43, P592, DOI 10.1111/j.1365-2559.2003.01762.x; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Hornbein TF, 2001, HIGH ALTITUDE EXPLOR, P744; Keller KA, 2008, PEDIATR RADIOL, V38, P1210, DOI 10.1007/s00247-008-1001-z; King WJ, 2003, CAN MED ASSOC J, V168, P155; KLINICH KD, 2002, STAPP CAR CRASH J, V46; Koto T, 2007, AM J PATHOL, V170, P1389, DOI 10.2353/ajpath.2007.060693; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Lantz PE, 2006, AAFS ANN M SEATT WA; Lashutka MK, 2004, ANN EMERG MED, V43, P585, DOI 10.1016/j.annemergmed.2003.12.006; Leestma JE, 2006, J AM PHYS SURG; Lettau M, 2009, AM J NEURORADIOL, V30, P185, DOI 10.3174/ajnr.A1147; Mack J., 2009, PEDIATR RADIOL, V39, P197; Maxeiner H, 2001, J FORENSIC SCI, V46, P85; Medele RJ, 1998, J NEUROSURG, V88, P851, DOI 10.3171/jns.1998.88.5.0851; Mittal MK, 2009, ANN EMERG MED, V54, P523, DOI 10.1016/j.annemergmed.2008.12.037; Molina DK, 2009, AM J FOREN MED PATH, V30, P89, DOI 10.1097/PAF.0b013e31818737d2; MORIMOTO T, 1995, ACTA NEUROCHIR, V137, P44, DOI 10.1007/BF02188779; MULLER PJ, 1974, J NEUROSURG, V41, P160, DOI 10.3171/jns.1974.41.2.0160; OBI E, 2007, J AAPOS, V11, P99, DOI DOI 10.1016/J.JAAPOS.2007.01.031; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Park E, 1921, B J HOPKINS HOSP, V32, P362; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Reddy AR, 2010, EUR J OPHTHALMOL, V20, P799, DOI 10.1177/112067211002000427; Reece RM, 2003, P C SPONS HHS NIH NI; Rooks VJ, 2008, AM J NEURORADIOL, V29, P1082, DOI 10.3174/ajnr.A1004; Squier W, 2008, DEV MED CHILD NEUROL, V50, P10, DOI 10.1111/j.1469-8749.2007.02004.x; SYROGIANNOPOULOS GA, 1986, PEDIATR INFECT DIS J, V5, P343, DOI 10.1097/00006454-198605000-00014; Talbert DG, 2005, MED HYPOTHESES, V64, P8, DOI 10.1016/j.mehy.2004.07.017; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; TAYLOR AS, 1856, MED JURISPRUDENCE, P366; Terson PDA, 1900, CLIN OPHTHALMOL, V22, P309; The Boston Globe, 2009, BOSTON GLOBE; TILL K, 1968, BRIT MED J, V3, P400, DOI 10.1136/bmj.3.5615.400; Tuerkheimer D., 2009, WASHINGTON U LAW REV, V87; Vezina G., PEDIAT RADIOL; Vinchon M, 2010, CHILDS NERV SYST; WALSH FB, 1951, AM J OPHTHALMOL, V34, P509, DOI 10.1016/0002-9394(51)90294-2; Ziegler EE, 2006, PEDIATRICS, V118, P603, DOI 10.1542/peds.2006-0108	68	27	27	0	1	WESTJEM	ORANGE	C/O SHAHRAM LOTFIPOUR, MD, MPH, 333 CITY BLVD W STE 640, RT 128-01, ORANGE, CA 92868 USA	1936-900X	1936-9018		WEST J EMERG MED	West. J. Emerg. Med.	MAY	2011	12	2					144	158					15	Emergency Medicine	Emerging Sources Citation Index (ESCI)	Emergency Medicine	V9W6R	WOS:000422592000001	21691518				2022-02-06	
J	Nelson, NW; Hoelzle, JB; McGuire, KA; Ferrier-Auerbach, AG; Charlesworth, MJ; Sponheim, SR				Nelson, Nathaniel W.; Hoelzle, James B.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Sponheim, Scott R.			Neuropsychological evaluation of blast-related concussion: Illustrating the challenges and complexities through OEF/OIF case studies	BRAIN INJURY			English	Article						Traumatic brain injury; blast injury; neuropsychological injury	TRAUMATIC BRAIN-INJURY; POSTCONCUSSIVE SYMPTOMS; POSTTRAUMATIC-STRESS; MILITARY TBI; VETERANS; IRAQ; PERFORMANCE; DEPLOYMENT; CONTEXT; METAANALYSIS	Background/objective: Soldiers of Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF) sustain blast-related mild traumatic brain injury (concussion) with alarming regularity. This study discusses factors in addition to concussion, such as co-morbid psychological difficulty (e. g. post-traumatic stress) and symptom validity concerns that may complicate neuropsychological evaluation in the late stage of concussive injury. Case report: The study presents the complexities that accompany neuropsychological evaluation of blast concussion through discussion of three case reports of OEF/OIF personnel. Discussion: The authors emphasize uniform assessment of blast concussion, the importance of determining concussion severity according to acute-injury characteristics and elaborate upon non-concussion-related factors that may impact course of cognitive limitation. The authors conclude with a discussion of the need for future research examining the impact of blast concussion (particularly recurrent concussion) and neuropsychological performance.	[Nelson, Nathaniel W.] Univ St Thomas, GSPP, MOH 217, Minneapolis, MN 55403 USA; [Nelson, Nathaniel W.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Sponheim, Scott R.] Minneapolis VA Med Ctr, Minneapolis, MN USA; [Hoelzle, James B.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; [McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA		Nelson, NW (corresponding author), Univ St Thomas, GSPP, MOH 217, LaSalle Ave, Minneapolis, MN 55403 USA.	nels0600@stthomas.edu	Sponheim, Scott/J-3857-2017	Sponheim, Scott/0000-0002-2782-0856	Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PT074550, W81XWH-08-2-0038]; Minnesota Veterans Research Institute (MVRI)	This study was supported in part by Grants funded by the Congressionally Directed Medical Research Programs (number PT074550, contract W81XWH-08-2-0038) to Scott R. Sponheim, PhD, and the Minnesota Veterans Research Institute (MVRI) to Nathaniel W. Nelson, PhD.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blake D. D., 1990, BEHAV THER, V13, P187, DOI DOI 10.1007/BF02105408; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Butcher J, 1989, MANUAL ADM SCORING M; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Delis D.C., 2000, CALIFORNIA VERBAL LE; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; FIRST MB, 2007, STRUCTURED CLIN INTW; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; General Accounting Office, 2008, VA HLTH CAR MILD TRA; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Golden CJ, 1978, STROOP COLOR WORD TE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 1991, COMPREHENSIVE NORMS; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kaplan E, 1983, BOSTON NAMING TEST; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; KROENKE K, 1993, ARCH INTERN MED, V153, P2474, DOI 10.1001/archinte.153.21.2474; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; MEYERS J, 1995, MEYERS SCORING SYSTE; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; *PSYCH CORP, 1994, VIG W CONT PERF TEST; *PSYCH CORP, 2001, WECHSL TEST AD READ; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Ruff RM, 1999, STUD NEUROPSYCHOL DE, P315; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh T.N., 1996, TEST MEMORY MALINGER; VANDERPLOEG RD, 2009, NEUROPSYCHOLOGY MALI, P41; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	57	27	27	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2011	25	5					511	525		10.3109/02699052.2011.558040			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	745KQ	WOS:000289164700009	21405948	Green Published			2022-02-06	
J	Verlhac, S				Verlhac, Suzanne			Transcranial Doppler in children	PEDIATRIC RADIOLOGY			English	Article						Transcranial Doppler; Mean velocity; Circle of Willis; Sickle cell anaemia; Children	SICKLE-CELL-DISEASE; CEREBRAL-BLOOD-FLOW; BRAIN-DEATH; SONOGRAPHY; STROKE; ULTRASONOGRAPHY; AUTOREGULATION; HEMODYNAMICS; ULTRASOUND; VELOCITIES	Transcranial Doppler US, a non-invasive tool for evaluating the cerebral arteries, has evolved significantly during the last two decades. This review describes the practical procedure, and summarises and illustrates its established and "work-in-progress" indications in children. Indications for a transcranial Doppler US examination include, but are not limited to: (1) evaluation of cerebral blood flow velocities in the circle of Willis in patients with sickle cell anaemia to guide transfusion therapy; (2) diagnosis and follow-up of vasculopathy, such as moyamoya disease; (3) diagnosis and monitoring of acute cerebrovascular disorders in intensive care patients, in particular following traumatic brain injury, and during cardiovascular surgery; and (4) confirmation of a clinical diagnosis of brain death by documentation of cerebral circulatory arrest.	[Verlhac, Suzanne] Hop Robert Debre, Paediat Imaging Dept Sebag G, F-75935 Paris 19, France; [Verlhac, Suzanne] Intercommunal Hosp, Reference Ctr Sickle Cell Dis, Creteil, France		Verlhac, S (corresponding author), Hop Robert Debre, Paediat Imaging Dept Sebag G, 48 Blvd Serurier, F-75935 Paris 19, France.	suzanne.verlhac@rdb.aphp.fr					AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Abboud MR, 2004, BLOOD, V103, P2822, DOI 10.1182/blood-2003-06-1972; ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; Adams RJ, 2004, BLOOD, V103, P3689, DOI 10.1182/blood-2003-08-2733; ADAMS RJ, 1989, J CARDIOVASC TECHNOL, V8, P97; ADAMS RJ, 1992, STROKE, V23, P1073, DOI 10.1161/01.STR.23.8.1073; Bernaudin F, 2000, J CHILD NEUROL, V15, P333, DOI 10.1177/088307380001500510; Bernaudin F, 2011, BLOOD, V117, P1130, DOI 10.1182/blood-2010-06-293514; BODE H, 1988, ARCH DIS CHILD, V63, P1474, DOI 10.1136/adc.63.12.1474; BODE H, 1988, ARCH DIS CHILD, V63, P606, DOI 10.1136/adc.63.6.606; BODE H, 1989, ULTRASCHALL MED, V10, P54, DOI 10.1055/s-2007-1005962; Brouh Y, 2002, ANN FR ANESTH, V21, P676, DOI 10.1016/S0750-7658(02)00698-6; Bulas D, 2005, PEDIATR RADIOL, V35, P235, DOI 10.1007/s00247-005-1417-7; Bulas DI., 2009, ULTRASOUND CLIN, V4, P533; Chabrier S, 1998, J CHILD NEUROL, V13, P27, DOI 10.1177/088307389801300105; CHADDUCK WM, 1989, J CHILD NEUROL, V4, pS77, DOI 10.1177/0883073889004001S12; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Enninful-Eghan H, 2010, J PEDIATR-US, V157, P479, DOI 10.1016/j.jpeds.2010.03.007; FERI M, 1994, CRIT CARE MED, V22, P1120, DOI 10.1097/00003246-199407000-00012; Figaji AA, 2010, CHILD NERV SYST, V26, P431, DOI 10.1007/s00381-009-1036-y; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Fullerton HJ, 2004, BLOOD, V104, P336, DOI 10.1182/blood-2004-02-0636; Galarza M, 2004, NEUROL RES, V26, P409, DOI 10.1179/016164104225016010; Goutorbe Ph, 2001, SFAR R, V451, p266s; Hankins JS, 2008, BRIT J HAEMATOL, V142, P94, DOI 10.1111/j.1365-2141.2008.07167.x; HAS, 2010, SYNDR DREP MAJ ENF A; Hirsch W, 2002, CLIN RADIOL, V57, P492, DOI 10.1053/crad.2002.0949; HOFFMAN WH, 1995, J CLIN ULTRASOUND, V23, P517, DOI 10.1002/jcu.1870230903; Le Moigno S, 2001, SFAR R, V452, p266s; Lee YS, 2004, J NEUROIMAGING, V14, P319, DOI 10.1177/1051228404264958; Lowe LH, 2005, AM J NEURORADIOL, V26, P1698; Lowe LH, 1989, PEDIATR RADIOL, V35, P54; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; McCarville MB, 2008, PEDIATR BLOOD CANCER, V50, P818, DOI 10.1002/pbc.21430; Monteiro LM, 2006, INTENS CARE MED, V32, P1937, DOI 10.1007/s00134-006-0353-9; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; O'Brien NF, 2010, INTENS CARE MED, V36, P680, DOI 10.1007/s00134-009-1747-2; Ohene-Frempong K, 1998, BLOOD, V91, P288; Orliaguet GA, 2004, PEDIATR ANESTH, V14, P407, DOI 10.1111/j.1460-9592.2004.01340.x; Polito Angelo, 2006, Cardiovasc Ultrasound, V4, P47, DOI 10.1186/1476-7120-4-47; Qian S. Y., 1998, SMJ, V39, P247; Rafay MF, 2006, J CHILD NEUROL, V21, P8, DOI 10.1177/08830738060210010101; RAJU TNK, 1992, CRIT CARE CLIN, V8, P93, DOI 10.1016/S0749-0704(18)30269-0; Roberts JS, 2006, CRIT CARE MED, V34, P2217, DOI 10.1097/01.CCM.0000227182.51591.21; Rodriguez Rosendo A., 2002, Pediatr Crit Care Med, V3, P153, DOI 10.1097/00130478-200204000-00012; Rougeot C, 2006, EUR J PAEDIATR NEURO, V10, P152, DOI 10.1016/j.ejpn.2006.04.001; Sadik JC, 2001, J RADIOL, V82; Schatlo B, 2007, REV RECENT CLIN TRIA, V2, P49, DOI 10.2174/157488707779318125; Soetaert AM, 2009, CURR PROBL DIAGN RAD, V38, P218, DOI 10.1067/j.cpradiol.2008.05.004; SOPER R, 1995, J PEDIATR-US, V126, P945, DOI 10.1016/S0022-3476(95)70217-2; Takase K, 1997, CLIN NEUROL NEUROSUR, V99, pS101; The American College of Radiology, 2007, ACR AIUM PRACT GUID; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; U.S. Department of Health and Human Services, 2007, GUID SUMM; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; Vavilala MS, 2004, PED AN M PHOEN AZ US; Verlhac S, 2008, ARCH PEDIATRIE, V15, P636, DOI 10.1016/S0929-693X(08)71858-X; Verlhac S, 2003, J RADIOL, V84, P131; Verlhac S, 1995, PEDIATR RADIOL, V25, pS14; Visocchi M, 2007, ACTA NEUROCHIR, V149, P347, DOI 10.1007/s00701-006-1102-0	64	27	27	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	MAY	2011	41			1			S153	S165		10.1007/s00247-011-2038-y			13	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	V32CS	WOS:000208929900026	21523592	Bronze			2022-02-06	
J	Gura, M; Elmaci, I; Sari, R; Coskun, N				Gura, Melek; Elmaci, Ilhan; Sari, Ramazan; Coskun, Nilufer			Correlation of Pulsatility Index with Intracranial Pressure in Traumatic Brain Injury	TURKISH NEUROSURGERY			English	Article						Intracranial pressure; Pulsatility index; Transcranial doppler ultrasonography; Traumatic brain injury	TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; CEREBRAL-BLOOD-FLOW; HYPERTENSION; CARE; ICP	AIM: In traumatic brain injury (TBI) patients, it is desired to monitor the intracranial pressure (ICP) to assess the cerebral haemodynamics and guide the therapy. The study was designed to see if the pulsatility index (PI) measured by transcranial Doppler ultrasonography (TCD) predicts information about ICP values. MATERIAL and METHODS: In 52 TBI patients with Glasgow Coma Scale (GCS) score < 9, invasive intracranial monitoring and TCD ultrasonography for PI were performed through five days. ICP, cerebral perfusion pressure (CPP), PI values were recorded and calculated. The correlation and regression analysis between ICP, PI and CPP were investigated in the whole group and in patients with a Glasgow Outcome Score (GOS) of 3-5. RESULTS: The decline in ICP and PI values was significant through five days. The correlation between ICP and PI was strongly significant (p < 0.0001) on days 1, 3 and 5. In patients with a GOS of 3-5, correlation of ICP and PI was also observed. The only significant correlation observed between CPP and PI was on days. CONCLUSION: The strong correlation observed between ICP and PI through the management period of TBI patients can lead us to use TCD ultrasonography-derived PI as a guide if invasive monitoring is not available.	[Gura, Melek; Coskun, Nilufer] Goztepe Training Hosp, Dept Anesthesiol & Reanimatol, Istanbul, Turkey; [Elmaci, Ilhan] Acibadem Univ, Fac Med, Dept Neurosurg, Istanbul, Turkey; [Sari, Ramazan] Goztepe Training Hosp, Dept Neurosurg, Istanbul, Turkey		Gura, M (corresponding author), Goztepe Training Hosp, Dept Anesthesiol & Reanimatol, Istanbul, Turkey.	melekgura@gmail.com	SARI, Ramazan/AAJ-9244-2020; Elmaci, Ilhan/AAF-3459-2021	SARI, Ramazan/0000-0001-7866-8113; Elmaci, Ilhan/0000-0001-9433-0307			Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHAN KH, 1992, NEUROSURGERY, V30, P697; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 2001, J NEUROSURG, V94, P685; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Kincaid MS, 2006, CRIT CARE NEURO, V12, P93; Klingerhofer J, 1997, J Mol Med, V65, P542; Lescot T, 2008, CURR OPIN CRIT CARE, V14, P129, DOI 10.1097/MCC.0b013e3282f63c51; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin N A, 1993, Neurosurgery, V33, P761; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; MORENO JA, 2000, NEUROSURG FOCUS, V8; Rincon F, 2007, CURR OPIN CRIT CARE, V13, P115, DOI 10.1097/MCC.0b013e32808255c6; Saqqur M, 2007, CRIT CARE MED, V35, pS216, DOI 10.1097/01.CCM.0000260633.66384.FB; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Sorteberg A, 2007, CONT NEUROSURGERY, V29, P1; Splavski B, 2006, BRIT J NEUROSURG, V20, P386, DOI 10.1080/02688690601048104; Splavski B, 2006, BRAIN INJURY, V20, P1265, DOI 10.1080/02699050601082099; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Stocchetti N, 2008, MINERVA ANESTESIOL, V74, P199; The Brain Trauma Foundation, 2007, J NEUROTRAUM, pS45; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Umamaheswara R, 2008, SAARC J ANAESTH, P58; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y	32	27	29	0	5	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	APR	2011	21	2					210	215					6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	761CC	WOS:000290371700015	21534204	Bronze			2022-02-06	
J	Wang, W; Li, MH; Li, YD; Gu, BX; Wang, J; Zhang, PL; Li, M				Wang, Wu; Li, Ming-Hua; Li, Yong-Dong; Gu, Bin-Xian; Wang, Ju; Zhang, Pei-Lei; Li, Min			Treatment of Traumatic Internal Carotid Artery Pseudoaneurysms With the Willis Covered Stent: A Prospective Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Pseudoaneurysm; Covered stent; Internal carotid artery (ICA)	ANGIOGRAPHIC FOLLOW-UP; INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; GRAFT TREATMENT; ARTERIOVENOUS-FISTULAS; PLACEMENT; INJURY; REPAIR; COILS	Purpose: To evaluate the efficacy of the Willis covered stent in the treatment of traumatic pseudoaneurysms of the internal carotid artery (ICA). Materials: Thirty-eight patients with traumatic head and neck injury underwent angiography. We evaluated 14 delayed pseudoaneurysms in 13 patients who underwent angiography after treatment with the Willis covered stent. Prospective data on the technical success, initial and final angiographic results, mortality, morbidity, and final clinical outcome were analyzed immediately after the procedure, at the time of discharge from the hospital, at 3 months, 6 months, and 12 months after the procedures, and yearly thereafter. Results: The Willis covered stent placement was successful in all 14 pseudoaneurysms. The initial angiographic results showed complete exclusion in 9 patients with 10 aneurysms (71.4% [95% confidence interval {CI}: 44-98%]) and incomplete exclusion in 4 patients. The angiographic follow-up (mean, 15 months [95% CI: 9-20 months]; range, 3-36 months) findings exhibited a complete exclusion in 12 patients with 13 aneurysms (92.9% [95% CI: 77-108%]) and an incomplete exclusion in 1 patient and maintained patency of the ICA in all patients. The clinical follow-up (mean, 20 months [95% CI: 14-27 months]) findings demonstrated full recovery (11 patients), symptom improvement (1 patient), or no change in the symptoms (1 patient). No procedure-related complications or deaths occurred during follow-up. Conclusion: Treatment with the Willis covered stent provides a viable approach for patients with traumatic pseudoaneurysms of the ICA, maintaining patency of the ICA and thus leading to excellent clinical results. An expanded clinical experiences and a larger sample are needed.	[Wang, Wu; Li, Ming-Hua; Li, Yong-Dong; Gu, Bin-Xian; Wang, Ju; Zhang, Pei-Lei; Li, Min] Shanghai Jiao Tong Univ, Dept Diagnost & Intervent Radiol, Affiliated Peoples Hosp 6, Shanghai 200030, Peoples R China		Li, YD (corresponding author), 600 Yi Shan Rd, Shanghai 200233, Peoples R China.	liyongdong2009@tom.com			National Natural Scientific Fund of ChinaNational Natural Science Foundation of China (NSFC) [30570540]; Shanghai Important Subject Fund of Medicine [05 III 023]; Program for Shanghai Outstanding Medical Academic Leader [LJ 06016]	Supported by the National Natural Scientific Fund of China (contract number: 30570540), the Shanghai Important Subject Fund of Medicine (contract number: 05 III 023), and the Program for Shanghai Outstanding Medical Academic Leader (contract number: LJ 06016).	Akiyama Y, 2005, J TRAUMA, V58, P624, DOI 10.1097/01.TA.0000096662.79685.EA; Archondakis E, 2007, AM J NEURORADIOL, V28, P342; Bouthillier A, 1996, NEUROSURGERY, V38, P425, DOI 10.1097/00006123-199603000-00001; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Cohen JE, 2008, NEUROSURGERY, V63, P476, DOI 10.1227/01.NEU.0000324995.57376.79; Coldwell DM, 2000, J TRAUMA, V48, P470, DOI 10.1097/00005373-200003000-00016; Felber S, 2004, NEUROSURGERY, V55, P631, DOI 10.1227/01.NEU.0000134455.02947.1F; Gomez F, 2007, AM J NEURORADIOL, V28, P1762, DOI 10.3174/ajnr.A0636; Hoit DA, 2008, NEUROSURGERY, V62, P380, DOI [10.1227/01.NEU.0000297138.40345.25, 10.1227/01.NEU.0000335088.85470.FC]; Hori Y, 2007, J VASC INTERV RADIOL, V18, P1300, DOI 10.1016/j.jvir.2007.06.032; Kadyrov NA, 2002, J NEUROSURG, V96, P624, DOI 10.3171/jns.2002.96.3.0624; Klein GE, 1997, AM J NEURORADIOL, V18, P1261; Kubaska SM, 2003, J ENDOVASC THER, V10, P182, DOI 10.1583/1545-1550(2003)010<0182:ICAPTW>2.0.CO;2; LARSON JJ, 1995, NEUROSURGERY, V36, P26; Layton KF, 2004, AM J NEURORADIOL, V25, P1760; Li MH, 2008, AM J NEURORADIOL, V29, P1395, DOI 10.3174/ajnr.A1096; Li MH, 2007, AM J NEURORADIOL, V28, P1579, DOI 10.3174/ajnr.A0668; Li MH, 2006, AM J NEURORADIOL, V27, P1107; Li MH, 2009, RADIOLOGY, V253, P470, DOI 10.1148/radiol.2532090037; Li YD, 2010, J NEUROL NEUROSUR PS, V81, P74, DOI 10.1136/jnnp.2009.171967; Maras D, 2006, CARDIOVASC INTER RAD, V29, P958, DOI 10.1007/s00270-005-0367-7; Marotta TR, 1998, NEUROSURGERY, V42, P408, DOI 10.1097/00006123-199802000-00138; Parodi JC, 1999, ANN VASC SURG, V13, P121, DOI 10.1007/s100169900230; Redekop G, 2001, J NEUROSURG, V95, P412, DOI 10.3171/jns.2001.95.3.0412; Reiter BP, 1998, J VASC INTERV RADIOL, V9, P245, DOI 10.1016/S1051-0443(98)70264-7; Saatci I, 2004, AM J NEURORADIOL, V25, P1742; Scavee V, 2001, CARDIOVASC INTER RAD, V24, P283, DOI 10.1007/s00270-001-0012-z; ul Haq Tanveer, 2004, Australas Radiol, V48, P220; Wang Jian B, 2008, Neurosurgery, V62, pE1176, DOI 10.1227/01.neu.0000325886.00033.18	29	27	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2011	70	4					816	822		10.1097/TA.0b013e3181f892af			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	750OV	WOS:000289558700016	21610389				2022-02-06	
J	Li, J; Li, GB; Hu, JL; Fu, XH; Zeng, YJ; Zhou, YG; Xiong, G; Yang, N; Dai, SS; He, FT				Li, Jun; Li, Gongbo; Hu, Jian-Lin; Fu, Xiao-Hong; Zeng, Yi-Jun; Zhou, Yuan-Guo; Xiong, Gang; Yang, Nan; Dai, Shuang-Shuang; He, Feng-Tian			Chronic or high dose acute caffeine treatment protects mice against oleic acid-induced acute lung injury via an adenosine A(2A) receptor-independent mechanism	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Adenosine A(2A) receptor; Caffeine; Acute lung injury; Inflammation	TRAUMATIC BRAIN-INJURY; A(2A)-RECEPTOR ACTIVATION; EXTRACELLULAR ADENOSINE; LIVER-INJURY; INFLAMMATION; HYPOXIA; MOUSE; THERAPY; INACTIVATION; REPERFUSION	The antagonism or genetic deletion of adenosine A(2A) receptors has been shown to exacerbate tissue damage in acute lung injury. Caffeine, a widely consumed behavioral drug, acts as a non-selective antagonist of A(2A) receptor and also has additional pharmacological effects. Thus, the protective vs. deleterious effects of caffeine in acute lung injury should be evaluated. In a murine oleic acid-induced model of acute lung injury, we found that chronic caffeine treatment by drinking water (0.1 g/l or 0.25 g/l for 2 weeks before acute lung injury) or acute caffeine treatment at high dose (i.p. 50 mg/kg, injection, 30 min before acute lung injury) significantly attenuated the lung edema, hemorrhage, neutrophil recruitment as well as the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) expressions in both of the wild type (WT) and A(2A) receptor knockout (KO) mice. This profile was accompanied by increased cAMP levels and up-regulation of A2B receptor mRNAs in the lungs. In contrast, acute caffeine treatment at low dose (i.p. 5 mg/kg or 15 mg/kg, injection, 30 min before acute lung injury) enhanced the inflammation and lung damage in WT mice with decreasing cAMP but not in A(2A) receptor KO mice. These results indicate that caffeine either enhances lung damage by antagonizing A(2A) receptor or exerts protection against lung damage via A(2A) receptor-independent mechanisms, depending on the timing of exposure (chronic vs. acute) and dose of administration (low vs. high). These findings provide new insight of caffeine in acute lung injury and highlight the potential benefit and strategy of caffeine intake or administration for preventing acute lung injury. (C) 2011 Elsevier B.V. All rights reserved.	[Li, Gongbo; Fu, Xiao-Hong; Zeng, Yi-Jun; Dai, Shuang-Shuang; He, Feng-Tian] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China; [Li, Jun; Xiong, Gang] Third Mil Med Univ, SE Hosp, Dept Cardiothorac Surg, Chongqing 400038, Peoples R China; [Zhou, Yuan-Guo; Yang, Nan] Third Mil Med Univ, Inst Surg Res, State Key Lab Trauma Burn & Combined Injury, Ctr Mol Biol, Chongqing 400042, Peoples R China; [Zhou, Yuan-Guo; Yang, Nan] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China; [Hu, Jian-Lin] Third Mil Med Univ, SE Hospital, Dept Resp Dis, Chongqing 400038, Peoples R China		Dai, SS (corresponding author), Third Mil Med Univ, Dept Biochem & Mol Biol, 30 Gaotanyan, Chongqing 400038, Peoples R China.	tmmubiodss@yahoo.com.cn; hefengtian06@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30900587]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [CSTC2009BB5317]; Science Foundation of Third Military Medical University	This work was supported by National Natural Science Foundation of China (No. 30900587) and Natural Science Foundation of Chongqing, China (NO. CSTC2009BB5317) and Science Foundation of Third Military Medical University (to Dai SS).	Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; Day YJ, 2004, AM J PHYSIOL-GASTR L, V286, pG285, DOI 10.1152/ajpgi.00348.2003; Donadieu E, 2007, ACTA HISTOCHEM, V109, P177, DOI 10.1016/j.acthis.2007.01.004; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eckle T, 2008, BLOOD, V111, P2024, DOI 10.1182/blood-2007-10-117044; Eckle T, 2009, PHYSIOLOGY, V24, P298, DOI 10.1152/physiol.00022.2009; Ellman PI, 2008, J SURG RES, V149, P3, DOI 10.1016/j.jss.2007.08.008; Eltzschig HK, 2005, J EXP MED, V202, P1493, DOI 10.1084/jem.20050177; Eltzschig HK, 2003, J EXP MED, V198, P783, DOI 10.1084/jem.20030891; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Fozard JR, 2002, EUR J PHARMACOL, V438, P183, DOI 10.1016/S0014-2999(02)01305-5; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Gantner F, 1997, J PHARMACOL EXP THER, V280, P53; Graham TE, 2001, SPORTS MED, V31, P785, DOI 10.2165/00007256-200131110-00002; Hasko G, 2006, CRIT CARE MED, V34, P1119, DOI 10.1097/01.CCM.0000206467.19509.C6; Hasko G, 2008, J LEUKOCYTE BIOL, V83, P447, DOI 10.1189/jlb.0607359; Johansson B, 1997, BRAIN RES, V762, P153, DOI 10.1016/S0006-8993(97)00378-8; Koshiba M, 1997, J BIOL CHEM, V272, P25881, DOI 10.1074/jbc.272.41.25881; Lappas CM, 2005, J IMMUNOL, V174, P1073, DOI 10.4049/jimmunol.174.2.1073; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Linden J, 2005, MOL PHARMACOL, V67, P1385, DOI 10.1124/mol.105.011783; Link AA, 2000, J IMMUNOL, V164, P436, DOI 10.4049/jimmunol.164.1.436; Morote-Garcia JC, 2009, GASTROENTEROLOGY, V136, P607, DOI 10.1053/j.gastro.2008.10.037; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2007, J IMMUNOL, V179, P7431, DOI 10.4049/jimmunol.179.11.7431; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Riksen NP, 2006, J AM COLL CARDIOL, V48, P700, DOI 10.1016/j.jacc.2006.04.083; Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Schmidt B, 2007, NEW ENGL J MED, V357, P1893, DOI 10.1056/NEJMoa073679; Spicuzza L, 2006, EUR J PHARMACOL, V533, P77, DOI 10.1016/j.ejphar.2005.12.056; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Thong FSL, 2002, CAN J APPL PHYSIOL, V27, P152, DOI 10.1139/h02-011; Ulrich K, 2005, AM J PHYSIOL-LUNG C, V288, pL1179, DOI 10.1152/ajplung.00450.2004; Varani K, 2005, CELL MOL LIFE SCI, V62, P2350, DOI 10.1007/s00018-005-5312-z; Varani K, 2000, CIRCULATION, V102, P285; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wu RQ, 2006, CRIT CARE MED, V34, P1273, DOI 10.1097/01.CCM.0000208437.93725.18; Yang D, 2006, J CLIN INVEST, V116, P1913, DOI 10.1172/JCI27933; Yu LQ, 2004, BRAIN RES, V1000, P156, DOI 10.1016/j.brainres.2003.11.072	43	27	30	4	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 11	2011	654	3					295	303		10.1016/j.ejphar.2010.12.040			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	731YS	WOS:000288147300015	21238452				2022-02-06	
J	Fort, E; Bouffard, E; Charnay, P; Bernard, M; Boisson, D; Laumon, B; Hours, M				Fort, Emmanuel; Bouffard, Emilie; Charnay, Pierrette; Bernard, Marlene; Boisson, Dominique; Laumon, Bernard; Hours, Martine			RETURN TO WORK FOLLOWING ROAD ACCIDENTS: FACTORS ASSOCIATED WITH LATE WORK RESUMPTION	JOURNAL OF REHABILITATION MEDICINE			English	Article						return to work; road traffic accident; cohort; injury	TRAUMATIC BRAIN-INJURY; VOCATIONAL-REHABILITATION; WHIPLASH INJURY; MAJOR TRAUMA; RISK-FACTORS; DISABILITY; COMPENSATION; DETERMINANTS; RECOVERY; CHALLENGES	Objective: To analyse factors associated with late return to work in road accident victims. Materials and methods: The ESPARR cohort comprises road accident victims monitored over time from initiation of hospital care. A total of 608 ESPARR cohort subjects were working at the time of their accident and answered questionnaires at 6 months and/or 1 year. For each level of overall severity of injury (Maximum - Abbreviated Injury Scale (M-AIS) 1, 2,3 and 4-5), a time-off-work threshold was defined, beyond which the subject was deemed to be a late returner; 179 subjects were considered to be late in returning to work, while 402 showed a normal pattern of return. Logistic regression identified factors associated with late return. Results: Type of journey, overall injury severity and intention to press charges emerged as factors predictive of late return to work on the basis of the data collected at inclusion alone. After adjustment, pain (odds ratio (OR): 2.6; 95% confidence interval (95% CI) 1.0-6.7) and physical sequelae (OR: 3.8; 95% CI 1.7-8.3) at 6 months and the fact of pressing charges (OR: 2.6; 95% CI 1.2-5.5) remained significantly linked with late return to work. Conclusion: Impaired health status at 6 months after the initial accident (in the form of persistent pain and physical sequelae) is a determining factor delaying return to work following a road traffic accident.	[Fort, Emmanuel; Bouffard, Emilie; Hours, Martine] Univ Lyon 1, INRETS, UMRESTTE, Univ Lyon, FR-69500 Bron, France; [Charnay, Pierrette; Bernard, Marlene; Laumon, Bernard; Hours, Martine] Univ Lyon 1, INRETS Domaine Rockefeller, Univ Lyon, UMRESTTE, F-69365 Lyon, France; [Boisson, Dominique] Hosp Civils Lyon, Hop Henry Gabrielle, Serv Med Phys & Readaptat, St Genis Laval, France		Hours, M (corresponding author), Univ Lyon 1, INRETS, UMRESTTE, Univ Lyon, 25 Ave Francois Mitterrand, FR-69500 Bron, France.	martine.hours@inrets.fr	Fort, Emmanuel/Q-4570-2019	Fort, Emmanuel/0000-0003-1419-9914	French Ministry of Equipment, Transport, Housing, Tourism and Sea [SU0400066]; French Ministry or Health [PHRC2003, PHRC-N03, PHRC2005, PHRC-N051]	We acknowledge funding from the French Ministry of Equipment, Transport, Housing, Tourism and Sea (Predit 3 Program "New Knowledge in the Field of Road Safety": Number SU0400066) and from the French Ministry or Health (Program PHRC2003: PHRC-N03; and PHRC2005: PHRC-N051).	Adams H, 2007, J OCCUP REHABIL, V17, P305, DOI 10.1007/s10926-007-9082-3; Association for the Advancement of Automotive Medicine (AAAM), 1990, ABBR INJ SCAL 1990 R; BALLABENI P, 2010, J OCCUP REHABIL 0710; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Bruyns CNP, 2003, J HAND SURG-AM, V28A, P28, DOI 10.1053/jhsu.2003.50026; Burnham RS, 1996, SPINE, V21, P1066, DOI 10.1097/00007632-199605010-00015; Chamberlain MA, 2009, J REHABIL MED, V41, P856, DOI 10.2340/16501977-0457; CHEADLE A, 1994, AM J PUBLIC HEALTH, V84, P190, DOI 10.2105/AJPH.84.2.190; Clay FJ, 2010, INJURY, V41, P787, DOI 10.1016/j.injury.2010.04.005; Clay FJ, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-6; *CPAM, CIR772004 CPAM, P15; Crook J, 1998, J RHEUMATOL, V25, P1570; Ferrari R, 2001, MED HYPOTHESES, V56, P372, DOI 10.1054/mehy.2000.1215; Galizzi M, 2003, LABOUR ECON, V10, P311, DOI 10.1016/S0927-5371(03)00014-9; Gun RT, 2005, SPINE, V30, P386, DOI 10.1097/01.brs.0000153399.24457.ee; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Hours M, 2008, ACCIDENT ANAL PREV, V40, P1789, DOI 10.1016/j.aap.2008.06.017; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; JAMES SKP, 2003, ARCH PHYS MED REHAB, V84, P1282; Krause N, 2001, AM J IND MED, V40, P464, DOI 10.1002/ajim.1116; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lenne-Aurier K., 1998, Annales de Readaptation et de Medecine Physique, V41, P5, DOI 10.1016/S0168-6054(97)83589-1; Lidal IB, 2007, DISABIL REHABIL, V29, P1341, DOI 10.1080/09638280701320839; MacEachen E, 2010, J OCCUP REHABIL, V20, P349, DOI 10.1007/s10926-010-9229-5; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Oyeflaten I, 2008, J REHABIL MED, V40, P548, DOI 10.2340/16501977-0202; Ozegovic D, 2009, EUR SPINE J, V18, P893, DOI 10.1007/s00586-009-0954-4; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Rusch MD, 2003, J HAND SURG-AM, V28A, P673, DOI 10.1016/S0363-5023(03)00178-3; Selander J, 2002, DISABIL REHABIL, V24, P704, DOI 10.1080/09638280210124284; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Ventureyra VAG, 2002, PSYCHOTHER PSYCHOSOM, V71, P47, DOI 10.1159/000049343; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wasiak R, 2007, J OCCUP REHABIL, V17, P766, DOI 10.1007/s10926-007-9101-4; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	40	27	28	1	13	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAR	2011	43	4					283	291		10.2340/16501977-0670			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	743ID	WOS:000289011000002	21347505	Green Submitted, gold			2022-02-06	
J	Lee, S; Ueno, M; Yamashita, T				Lee, S.; Ueno, M.; Yamashita, T.			Axonal remodeling for motor recovery after traumatic brain injury requires downregulation of gamma-aminobutyric acid signaling	CELL DEATH & DISEASE			English	Article						axonal sprouting; compensatory recovery; corticospinal tract; GABA type A receptor; plasticity; traumatic brain injury	TEMPORAL-LOBE EPILEPSY; GABA(A) RECEPTOR; SPINAL-CORD; IN-VIVO; CORTICAL CIRCUITS; STROKE RECOVERY; MOUSE MODEL; PLASTICITY; INHIBITION; EXPRESSION	Remodeling of the remnant neuronal network after brain injury possibly mediates spontaneous functional recovery; however, the mechanisms inducing axonal remodeling during spontaneous recovery remain unclear. Here, we show that altered gamma-aminobutyric acid (GABA) signaling is crucial for axonal remodeling of the contralesional cortex after traumatic brain injury. After injury to the sensorimotor cortex in mice, we found a significant decrease in the expression of GABA(A)R-alpha 1 subunits in the intact sensorimotor cortex for 2 weeks. Motor functions, assessed by grid walk and cylinder tests, spontaneously improved in 4 weeks after the injury to the sensorimotor cortex. With motor recovery, corticospinal tract (CST) axons from the contralesional cortex sprouted into the denervated side of the cervical spinal cord at 2 and 4 weeks after the injury. To determine the functional implications of the changes in the expression of GAB(A)AR-alpha 1 subunits, we infused muscimol, a GABA R agonist, into the contralesional cortex for a week after the injury. Compared with the vehicle-treated mice, we noted significantly inhibited recovery in the muscimol-treated mice. Further, muscimol infusion greatly suppressed the axonal sprouting into the denervated side of the cervical spinal cord. In conclusion, recovery of motor function and axonal remodeling of the CST following cortical injury requires suppressed GABA(A)R subunit expression and decreased GABAergic signaling. Cell Death and Disease (2011) 2, e133; doi: 10.1038/cddis.2011.16; published online 17 March 2011	[Lee, S.; Ueno, M.; Yamashita, T.] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Suita, Osaka 5650871, Japan; [Lee, S.; Ueno, M.; Yamashita, T.] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; [Ueno, M.; Yamashita, T.] CREST, JST, Chiyoda Ku, Tokyo 1020075, Japan		Yamashita, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamashita@molneu.med.osaka-u.ac.jp	Lee, Sachiko/I-6252-2014; Ueno, Masaki/J-1216-2019	Yamashita, Toshihide/0000-0003-4559-7018; Ueno, Masaki/0000-0003-1484-9921	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science	This work was supported by a Grant-in-Aid for Young Scientists (S) from the Japan Society for the Promotion of Science.	Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brown CE, 2007, J NEUROSCI, V27, P4101, DOI 10.1523/JNEUROSCI.4295-06.2007; Brown CE, 2009, J NEUROSCI, V29, P1719, DOI 10.1523/JNEUROSCI.4249-08.2009; Cramer SC, 2006, EXP BRAIN RES, V168, P25, DOI 10.1007/s00221-005-0082-2; Devaud LL, 1997, J NEUROCHEM, V69, P126; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hu YH, 2008, J BIOL CHEM, V283, P9328, DOI 10.1074/jbc.M705110200; Hua JY, 2005, NATURE, V434, P1022, DOI 10.1038/nature03409; Hurley LM, 2008, J NEUROPHYSIOL, V100, P1656, DOI 10.1152/jn.90536.2008; Jacob TC, 2008, NAT REV NEUROSCI, V9, P331, DOI 10.1038/nrn2370; Katagiri H, 2007, NEURON, V53, P805, DOI 10.1016/j.neuron.2007.02.026; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Klausberger T, 2002, J NEUROSCI, V22, P2513, DOI 10.1523/JNEUROSCI.22-07-02513.2002; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Lund IV, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162396; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; Martin JH, 1999, EXP BRAIN RES, V125, P184, DOI 10.1007/s002210050673; MONTPIED P, 1993, MOL BRAIN RES, V18, P267, DOI 10.1016/0169-328X(93)90199-Y; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Omoto S, 2010, J NEUROSCI, V30, P13045, DOI 10.1523/JNEUROSCI.3228-10.2010; Ono T, 2003, J NEUROSCI, V23, P5887; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Pronichev I V, 1998, Neurosci Behav Physiol, V28, P80, DOI 10.1007/BF02461916; Redecker C, 2000, J NEUROSCI, V20, P5045; Redecker C, 2002, J CEREBR BLOOD F MET, V22, P1463, DOI 10.1097/01.WCB.0000034149.72481.BD; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; Ruthazer ES, 2003, SCIENCE, V301, P66, DOI 10.1126/science.1082545; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Shen H, 2010, SCIENCE, V327, P1515, DOI 10.1126/science.1184245; Uesaka N, 2005, J NEUROSCI, V25, P1, DOI 10.1523/JNEUROSCI.3855-04.2005; Whiting PJ, 2003, DRUG DISCOV TODAY, V8, P445, DOI 10.1016/S1359-6446(03)02703-X; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008	40	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	MAR	2011	2								e133	10.1038/cddis.2011.16			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	742UE	WOS:000288969700010	21412279	gold, Green Published			2022-02-06	
J	Perez-Barcena, J; Ibanez, J; Brell, M; Crespi, C; Frontera, G; Llompart-Pou, JA; Homar, J; Abadal, JM				Perez-Barcena, Jon; Ibanez, Javier; Brell, Marta; Crespi, Catalina; Frontera, Guiem; Antonio Llompart-Pou, Juan; Homar, Javier; Maria Abadal, Josep			Lack of correlation among intracerebral cytokines, intracranial pressure, and brain tissue oxygenation in patients with traumatic brain injury and diffuse lesions	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; head trauma; microdialysis; cytokines; inflammation	TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; CEREBRAL MICRODIALYSIS; INTERLEUKIN-6 LEVELS; NERVOUS-SYSTEM; MESSENGER-RNA; INFLAMMATION; CATHETERS	Objectives: To determine the evolution of cytokine patterns using microdialysis in patients with traumatic brain injury with diffuse lesions and to study the relationship between cytokines and intracranial pressure, brain tissue oxygenation and lesion type on the computed cranial tomography scan (patients with and without brain swelling). Design: Prospective and observational study. Setting: Third-level university hospital. Patients: Patients between 15 and 65 yrs with severe traumatic brain injury and a diffuse lesion requiring intracranial pressure and brain tissue oxygenation monitoring were eligible. Interventions: Microdialysis catheters with a high-cutoff membrane of 100 kDa were inserted. Results: Sixteen patients were included in the analysis. There was a substantial interindividual variability between cytokine values. The highest concentrations for the interleukin-1 beta, interleukin-6, and interleukin-8 were measured during the first 24 hrs followed by a gradual decline. The average concentration for interleukin-10 did not vary over time. This pattern is the most frequent in patients with traumatic brain injury with diffuse lesions. The intracranial pressure-cytokines correlation coefficients for the 16 patients varied substantially: interleukin-1 beta-intracranial pressure (-0.76 to 0.63); interleukin-6 -intracranial pressure (-0.83 to 0.78); interleukin-8 -intracranial pressure (-0.86 to 0.84); and interleukin-10 -intracranial pressure (-0.36 to 0.65). The brain tissue oxygenation-cytokine correlation coefficients, like with intracranial pressure, also varied between patients: interleukin-1 beta-brain tissue oxygenation (-0.49 to 0.68), interleukin-6-brain tissue oxygenation (-0.99 to 0.84); interleukin-8-brain tissue oxygenation (-0.65 to 0.74); and interleukin-10-brain tissue oxygenation (-0.34 to 0.52). Similarly, we found no difference in the cytokine values inpatient microdialysis with and without swelling in the computed tomographic scan. Conclusions: No clear relationship was found between the temporal pattern of cytokines and the behavior of the intracranial pressure, brain tissue oxygenation, and the presence or absence of swelling in the computed tomography scan. This study demonstrates the feasibility of microdialysis in recovering cytokines for a prolonged time, although there may be some nonresolved methodologic problems with this technique when we try to study the inflammation during traumatic brain injury that could affect the results and make interpretation of microdialysis data prone to difficulties. (Crit Care Med 2011; 39: 533-540)	[Perez-Barcena, Jon; Antonio Llompart-Pou, Juan; Homar, Javier; Maria Abadal, Josep] Son Dureta Univ Hosp, Intens Care Unit Dept, Palma De Mallorca, Spain; [Ibanez, Javier; Brell, Marta] Son Dureta Univ Hosp, Dept Neurosurg, Palma De Mallorca, Spain; [Crespi, Catalina; Frontera, Guiem] Son Dureta Univ Hosp, Invest Unit, Palma De Mallorca, Spain		Perez-Barcena, J (corresponding author), Son Dureta Univ Hosp, Intens Care Unit Dept, Palma De Mallorca, Spain.	juan.perez@ssib.es	Crespi, Catalina/A-5543-2013	Crespi, Catalina/0000-0003-0781-9708; Ibanez, Javier/0000-0003-3735-8332	Spanish government's Fondo de Investigacion SanitariaInstituto de Salud Carlos III [FIS PI070307]	This research was supported by a public grant from the Spanish government's Fondo de Investigacion Sanitaria (FIS PI070307) awarded to J.P.B. This public institution will not gain or lose financially from the publication of this manuscript in any way.	Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bratton S L, 2007, J NEUROTRAUMA S1, V24, pS71, DOI DOI 10.1089/NEU.2007.9985; Cohen D, 1991, J LAB CLIN MED, V118, P225; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; FAN L, 1995, MOL BRAIN RES, V30, P125; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; O'CALLAGHAN J P, 1991, Biomedical and Environmental Sciences, V4, P197; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; Poca MA, 2006, J NEUROTRAUM, V23, P1510, DOI 10.1089/neu.2006.23.1510; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Unterberg AW, 1997, ACT NEUR S, V70, P106; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI, V119, P315; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; [No title captured]	43	27	28	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2011	39	3					533	540		10.1097/CCM.0b013e318205c7a4			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	723BB	WOS:000287480000016	21169825				2022-02-06	
J	Yoshioka, N; Kimura-Kuroda, J; Saito, T; Kawamura, K; Hisanaga, S; Kawano, H				Yoshioka, Nozomu; Kimura-Kuroda, Junko; Saito, Taro; Kawamura, Koki; Hisanaga, Shin-ichi; Kawano, Hitoshi			Small Molecule Inhibitor of Type I Transforming Growth Factor-beta Receptor Kinase Ameliorates the Inhibitory Milieu in Injured Brain and Promotes Regeneration of Nigrostriatal Dopaminergic Axons	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; fibrotic scar; glial scar; chondroitin sulfate proteoglycans; axonal regeneration	SPINAL-CORD-INJURY; CHONDROITIN SULFATE PROTEOGLYCANS; FIBROTIC SCAR FORMATION; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT BRAIN; REACTIVE ASTROCYTES; GENE-EXPRESSION; TGF-BETA; EXTRACELLULAR-MATRIX; CORTICOSPINAL TRACT	Transforming growth factor-beta (TGF-beta), a multifunctional cytokine, plays a crucial role in wound healing in the damaged central nervous system. To examine effects of the TGF-beta signaling inhibition on formation of scar tissue and axonal regeneration, the small molecule inhibitor of type I TGF-beta receptor kinase LY-364947 was continuously infused in the lesion site of mouse brain after a unilateral transection of the nigrostriatal dopaminergic pathway. At 2 weeks after injury, the fibrotic scar comprising extracellular matrix molecules including fibronectin, type IV collagen, and chondroitin sulfate proteoglycans was formed in the lesion center, and reactive astrocytes were increased around the fibrotic scar. In the brain injured and infused with LY-364947, fibrotic scar formation was suppressed and decreased numbers of reactive astrocytes occupied the lesion site. Although leukocytes and serum IgG were observed within the fibrotic scar in the injured brain, they were almost absent in the injured and LY-364947-treated brain. At 2 weeks after injury, tyrosine hydroxylase (TH)-immunoreactive fibers barely extended beyond the fibrotic scar in the injured brain, but numerous TH-immunoreactive fibers regenerated over the lesion site in the LY-364947-treated brain. These results indicate that inhibition of TGF-beta signaling suppresses formation of the fibrotic scar and creates a permissive environment for axonal regeneration. (C) 2010 Wiley-Liss, Inc.	[Yoshioka, Nozomu; Saito, Taro; Hisanaga, Shin-ichi] Tokyo Metropolitan Univ, Dept Biol Sci, Tokyo 158, Japan; [Yoshioka, Nozomu; Kimura-Kuroda, Junko; Kawamura, Koki; Kawano, Hitoshi] Tokyo Metropolitan Inst Neurosci, Dept Dev Morphol, Tokyo, Japan		Kawano, H (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Dev Morphol, Tokyo, Japan.	kawano-ht@igakuken.or.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20500318]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23500422] Funding Source: KAKEN	Contract grant sponsor: Ministry of Education, Science, Sports and Culture of Japan; Contract grant number: 20500318.	Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Asher RA, 2000, J NEUROSCI, V20, P2427; BAGHDASSARIAN D, 1993, GLIA, V7, P193, DOI 10.1002/glia.440070302; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; Boche D, 2003, J CEREBR BLOOD F MET, V23, P1174, DOI 10.1097/01.WCB.0000090080.64176.44; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brazda N, 2009, PROG BRAIN RES, V175, P269, DOI 10.1016/S0079-6123(09)17518-0; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Davies JE, 2004, EUR J NEUROSCI, V19, P1226, DOI 10.1111/j.1460-9568.2004.03184.x; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gris P, 2007, GLIA, V55, P1145, DOI 10.1002/glia.20537; Hamada Y, 1996, NEUROSCI LETT, V203, P97, DOI 10.1016/0304-3940(95)12271-0; Homma A, 2006, J COMP NEUROL, V499, P120, DOI 10.1002/cne.21097; Kano MR, 2007, P NATL ACAD SCI USA, V104, P3460, DOI 10.1073/pnas.0611660104; Kawano H, 2005, J NEUROSCI RES, V80, P191, DOI 10.1002/jnr.20441; KAWANO H, 1995, DEV BRAIN RES, V86, P101, DOI 10.1016/0165-3806(95)00018-9; Kimura-Kuroda J, 2010, MOL CELL NEUROSCI, V43, P177, DOI 10.1016/j.mcn.2009.10.008; King VR, 2004, NEUROSCIENCE, V126, P173, DOI 10.1016/j.neuroscience.2004.03.035; Klapka N, 2005, EUR J NEUROSCI, V22, P3047, DOI 10.1111/j.1460-9568.2005.04495.x; Kohta M, 2009, NEUROSCI RES, V65, P393, DOI 10.1016/j.neures.2009.08.017; Komuta Y, 2010, CELL MOL NEUROBIOL, V30, P101, DOI 10.1007/s10571-009-9435-x; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Li HP, 2007, J NEUROSCI RES, V85, P536, DOI 10.1002/jnr.21141; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liesi P, 2002, EXP NEUROL, V173, P31, DOI 10.1006/exnr.2001.7800; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; McAuliffe JJ, 2008, BRAIN RES, V1190, P175, DOI 10.1016/j.brainres.2007.11.038; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Sawyer JS, 2003, J MED CHEM, V46, P3953, DOI 10.1021/jm0205705; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schiwy N, 2009, EUR J NEUROSCI, V30, P1544, DOI 10.1111/j.1460-9568.2009.06929.x; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; Shearer MC, 2001, CELL TISSUE RES, V305, P267, DOI 10.1007/s004410100384; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Teng X, 2008, J NEUROSCI RES, V86, P3140, DOI 10.1002/jnr.21767; Uemura K, 1996, J BIOL CHEM, V271, P4581; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Wu MH, 2009, AM J PATHOL, V174, P519, DOI 10.2353/ajpath.2009.080574; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yoshioka N, 2010, J COMP NEUROL, V518, P3867, DOI 10.1002/cne.22431	61	27	29	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAR	2011	89	3					381	393		10.1002/jnr.22552			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	717RG	WOS:000287064500011	21259325				2022-02-06	
J	Jin, X; Yang, KH; King, AI				Jin, Xin; Yang, King H.; King, Albert I.			Mechanical properties of bovine pia-arachnoid complex in shear	JOURNAL OF BIOMECHANICS			English	Article						Pia-arachnoid complex (PAC); Mechanical properties; Shear loading; CSF layer; Dynamic loading	HUMAN BRAIN-TISSUE; SUBDURAL SPACE; HUMAN HEAD; BEHAVIOR; ELASTICITY; IMPACT; MATER; MODEL	Traumatic brain injury (TBI) has become a major public health and socioeconomic problem that affects 1.5 million Americans annually. Finite element methods have been widely used to investigate TBI mechanisms. The pia-arachnoid complex (PAC) covering the brain plays an important role in the mechanical response of the brain during impact or inertial loading. Existing finite element brain models have tended to oversimplify the response of the PAC due to a lack of accurately defined material properties of this structure, possibly resulting in a loss of accuracy in the model predictions. The objectives of this study were to experimentally determine the material properties of the PAC under shear loading. Bovine PAC was selected in the current study in view of its availability and comparability with previous studies. Tangential shear tests were conducted at 0.8, 7.3, and 72 s(-1). The mean shear moduli were 11.73, 20.04, and 22.37 kPa at the three strain rates tested. The ultimate stress, at the three strain rates, was 9.21, 17.01, and 22.26 kPa, while the ultimate strain was 1.52, 1.58, and 1.81. Results from the current study provide essential information to properly model the PAC membrane, an important component in the skull/brain interface, in a computational model of the human/animal head. Such an improved representation of the in vivo skull/brain interface will enhance future studies investigating brain injury mechanisms under various loading conditions. (C) 2010 Elsevier Ltd. All rights reserved.	[Jin, Xin; Yang, King H.; King, Albert I.] Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA		Jin, X (corresponding author), Wayne State Univ, Ctr Bioengn, 818 W Hancock, Detroit, MI 48201 USA.	mail.jinxin@gmail.com	Jin, Xin/J-6476-2015				Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; Al-Bsharat AS, 1999, P 43 STAPP CAR CRASH; Arbogast K., 1997, P 41 STAPP CAR CRASH; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; BANDAK FA, 1994, P 37 STAPP CAR CRASG, V37; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands D W, 2000, Stapp Car Crash J, V44, P249; Claessens M., 1997, P 41 STAPP CAR CRASH; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; ESTES MS, 1970, P 4 ASME BIOM C; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; FREDERICKSON RG, 1991, ANAT RECORD, V230, P38, DOI 10.1002/ar.1092300105; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HARRIGAN TP, 1988, J BIOMECH, V21, P269, DOI 10.1016/0021-9290(88)90257-6; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Jin X, 2007, STAPP CAR CRASH JO, V51, P115; KANG HS, 1997, P P 41 STAPP CAR CRA; Killer HE, 2003, BRIT J OPHTHALMOL, V87, P777, DOI 10.1136/bjo.87.6.777; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; King A I, 2003, P INT IRCOBI C BIOM; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MAO H, 2010, J NEUROTRAUMA; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller RT, 1998, P 42 STAPP CAR CRASH; Ozawa H, 2004, J NEUROSURG-SPINE, V1, P122, DOI 10.3171/spi.2004.1.1.0122; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Shreiber D. I., 1997, P 41 STAPP CAR CRASH; Takhounts EG, 2008, STAPP CAR C, V52, P1; THURMAN DL, 2000, TRAUMATIC BRAIN INJU; TROSEILLE X, 1992, P 36 STAPP CAR CRASH; TUNTURI AR, 1978, J NEUROSURG, V48, P975, DOI 10.3171/jns.1978.48.6.0975; TURQUIER F, 1996, P 40 STAPP CAR CRASH; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Zhang L, 2001, Stapp Car Crash J, V45, P369; ZHANG L, 2003, P ASME BIOENG C, P37; ZHOU C, 1994, P 38 STAPP CAR CRASH	47	27	27	1	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	FEB 3	2011	44	3					467	474		10.1016/j.jbiomech.2010.09.035			8	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	724BL	WOS:000287551000018	21087768				2022-02-06	
J	Perkes, I; Schofield, PW; Butler, T; Hollis, SJ				Perkes, Iain; Schofield, Peter W.; Butler, Tony; Hollis, Stephanie J.			Traumatic brain injury rates and sequelae: A comparison of prisoners with a matched community sample in Australia	BRAIN INJURY			English	Article						Prisoners; traumatic brain injury; community comparison; Australia	HEAD-INJURY; PSYCHIATRIC-DISORDERS; SUBSTANCE-ABUSE; UNITED-STATES; POPULATION; PREVALENCE; BEHAVIOR; ILLNESS; COHORT; CRIME	Aim: To compare rates of past reported traumatic brain injury (TBI) in a prisoner sample with those in a control group drawn from the same location of usual residence. Method: The prisoner group comprised a consecutive sample of men (n=200) received into custody and screened by face-to-face interview. The control group comprised men (n=200) matched for location of usual residence screened by telephone interview. Participants were asked about past TBIs and screened for drug and alcohol abuse, impulsivity and dissocial personality disorder. Results: Eighty-two per cent of prisoners and 71.5% of community participants reported at least one past TBI of any severity (i.e. with or without a loss of consciousness (LOG)) and 64.5% of prisoners and 32.2% of community participants reported at least one TBI associated with a LOC. Prisoners were more likely to report persisting side-effects of TBI and were much more likely to screen positive for impulsivity and dissocial personality disorder. Multivariate analyses found no significant association between TBI frequency or severity and custody/community group membership. Conclusions: High reported rates of TBI in prisoner populations may reflect the excess of socio-demographic risk factors for TBI. Results of the current study do not support a role for TBI as causally related to criminal conduct.	[Schofield, Peter W.] Univ Newcastle, Neuropsychiat Serv, Hunter New England Area Hlth, Ctr Brain & Mental Hlth Res, Newcastle, NSW 2300, Australia; [Perkes, Iain] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Butler, Tony] Curtin Univ Technol, Natl Drug Res Inst, Perth, WA, Australia; [Hollis, Stephanie J.] Univ Sydney, Sch Publ Hlth, Sydney Med Sch, Sydney, NSW 2006, Australia		Schofield, PW (corresponding author), Univ Newcastle, Neuropsychiat Serv, Hunter New England Area Hlth, Ctr Brain & Mental Hlth Res, POB 833, Newcastle, NSW 2300, Australia.	peter.schofield@hnehealth.nsw.gov.au	Hollis, Stephanie J/B-5977-2011; Schofield, Peter/J-7133-2013; Butler, Tony/F-4614-2012; Perkes, Iain/J-7001-2017	Butler, Tony/0000-0002-2679-2769; Perkes, Iain/0000-0001-8028-9032; Schofield, Peter/0000-0001-8298-8590	NHMRCNational Health and Medical Research Council of Australia [533554]; NSW Justice Health; Ian Potter Foundation (Melbourne)	Margot Eyeson-Annan and Matt Gorringe from the NSW Health Department's Health Survey Team assisted with developing the community survey component. Dr Nadine Smith provided advice on the statistical analysis. Tony Butler is supported by an NHMRC Career development Award (No 533554). NSW Justice Health and the Ian Potter Foundation (Melbourne) provided financial assistance for this project.	ABS, 2001, CENS POP HOUS; ABS, 2001, CENS POP HOUS SOC IN; Allnutt S, 2008, AUST NZ J PSYCHIAT, V42, P969, DOI 10.1080/00048670802415350; *AUSTR BUR STAT, 2004, PRIS AUSTR; *AUSTR I HLTH WELF, 2008, SER AUSTR I HLTH WEL, V31; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bell N, 2009, CAN J PUBLIC HEALTH, V100, P73, DOI 10.1007/BF03405498; Butler T, 2006, AUST NZ J PSYCHIAT, V40, P272, DOI 10.1111/j.1440-1614.2006.01785.x; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; DIRKMEN SS, 1989, NEUROPSYCHOLOGICAL R; EYSENCK SBG, 1980, PSYCHOL REP, V47, P1299, DOI 10.2466/pr0.1980.47.3f.1299; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; GRONWALL D, 1975, LANCET, V2, P995; HORVATH P, 1993, PERS INDIV DIFFER, V14, P41, DOI 10.1016/0191-8869(93)90173-Z; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3; KRUEGER RF, 1994, J ABNORM PSYCHOL, V103, P328, DOI 10.1037/0021-843X.103.2.328; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Loranger AW, 1997, ICD 10 INT PERSONALI; Lynam DR, 2000, J ABNORM PSYCHOL, V109, P563, DOI 10.1037//0021-843X.109.4.563; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SAMPSON RJ, 1997, SCIENCE, V277, P5328; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; *SPSS INC, 2009, SPSS VERS 17 COMP PR; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Winkleby MA, 2003, J EPIDEMIOL COMMUN H, V57, P444, DOI 10.1136/jech.57.6.444; [No title captured]	39	27	27	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2011	25	2					131	141		10.3109/02699052.2010.536193			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800001	21117917				2022-02-06	
J	Tasker, RC; Fleming, TJ; Young, AE; Morris, KP; Parslow, RC				Tasker, Robert C.; Fleming, Thomas J.; Young, Amber Er; Morris, Kevin P.; Parslow, Roger C.			Severe head injury in children: intensive care unit activity and mortality in England and Wales	BRITISH JOURNAL OF NEUROSURGERY			English	Article							TRAUMATIC-BRAIN-INJURY; PEDIATRIC INDEX; FUNNEL PLOTS; MODEL; EPIDEMIOLOGY; PERFORMANCE; REGRESSION; HYPOXIA; KINGDOM; TESTS	Methods: aEuro integral Analysis of HI cases ((age aEuroS < 16 years)) from the Paediatric Intensive Care Audit Network national cohort of sequential PICU admissions in 27 units in England and Wales, in the 5 years 2004--2008. Risk-adjusted mortality using the Paediatric Index of Mortality ((PIM)) model was compared between PICUs aggregated into quartile groups, first to fourth based on descending number of HI admissions//year: highest volume, medium--higher volume, medium--lower volume, and lowest volume. The effect of category of PICU interventions -- observation only, mechanical ventilation ((MV)) only, and intracranial pressure ((ICP)) monitoring -- on outcome was also examined. Observations were reported in relation to specialist paediatric neurosurgical PICU practice. Results: aEuro integral There were 2575 admissions following acute HI ((4.4%% of non-cardiac surgery PICU admissions in England and Wales)). PICU mortality was 9.3%%. Units in the fourth-quartile ((lowest volume)) group did not have significant specialist paediatric neurosurgical activity on the PICU; the other groups did. Overall, there was no effect of HI admissions by individual PICU on risk-adjusted mortality. However, there were significant effects for both intensive care intervention category ((p < 0.001)) and HI admissions by grouping ((p < 0.005)). Funnel plots and control charts using the PIM model showed a hierarchy in increasing performance from lowest volume ((group IV)), to medium--higher volume ((group II)), to highest volume ((group I)), to medium--lower volume ((group III)) sectors of the health care system. Conclusions: aEuro integral The health care system in England and Wales for critically ill HI children requiring PICU admission performs as expected in relation to the PIM model. However, the lowest-volume sector, comprising 14 PICUs with little or no paediatric neurosurgical activity on the unit, exhibits worse than expected outcome, particularly in those undergoing ICP monitoring. The best outcomes are seen in units in the mid-volume sector. These data do not support the hypothesis that there is a simple relationship between PICU volume and performance.	[Tasker, Robert C.] Univ Cambridge, Sch Clin, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England; [Fleming, Thomas J.] Univ Leeds, Ctr Epidemiol & Biostat, Data Management Grp, Leeds, W Yorkshire, England; [Young, Amber Er] Frenchay Hosp, Dept Anaesthesia, Bristol BS16 1LE, Avon, England; [Young, Amber Er] Birmingham Childrens Hosp, Paediat Intens Care Unit, Birmingham, W Midlands, England; [Parslow, Roger C.] Univ Leeds, Ctr Epidemiol & Biostat, Paediat Epidemiol Grp, Leeds, W Yorkshire, England		Tasker, RC (corresponding author), Univ Cambridge, Sch Clin, Addenbrookes Hosp, Dept Paediat, Box 116,Hills Rd, Cambridge CB2 2QQ, England.	rct31@cam.ac.uk	Tasker, Robert C/R-5837-2019; Parslow, Roger/AAV-1477-2020; Young, Amber/H-2988-2018	Parslow, Roger/0000-0002-3945-5294; Young, Amber/0000-0001-7205-492X; Tasker, Robert/0000-0003-3647-8113	National Clinical Audit and Patient Outcomes Programme via Healthcare Quality Improvement Partnership (HQIP); Health Commission Wales Specialised Services; NHS Lothian/National Service Division NHS Scotland; Royal Belfast Hospital for Sick Children; Evelyn Trust; Pan Thames PICU Commissioning Consortium	We would like to thank all the staff in participating hospitals that have collected data for PICANet. PICANet is funded by the National Clinical Audit and Patient Outcomes Programme via Healthcare Quality Improvement Partnership (HQIP), Health Commission Wales Specialised Services, NHS Lothian/National Service Division NHS Scotland, the Royal Belfast Hospital for Sick Children and the Pan Thames PICU Commissioning Consortium. RCT is supported by the Evelyn Trust.	Baghurst PA, 2008, INTENS CARE MED, V34, P1281, DOI 10.1007/s00134-008-1081-0; Brady AR, 2006, PEDIATRICS, V117, pE733, DOI 10.1542/peds.2005-1853; Brier GW, 1950, MONTHLY WEATHER REV, V75, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:V0FEIT>2.0.C0;2; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Cooke MW, 2007, ARCH DIS CHILD, V92, P6, DOI 10.1136/adc.2006.094920; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kochanek PM, 2009, PEDIATR CRIT CARE ME, V10, P517, DOI 10.1097/PCC.0b013e3181ab88cd; Kunadian B, 2008, BRIT MED J, V336, P931, DOI 10.1136/bmj.39512.529120.BE; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; MurphyFilkins RL, 1996, CRIT CARE MED, V24, P1968, DOI 10.1097/00003246-199612000-00007; *PAED INT CAR AUD, DAT DEF VERS 3 NOV 2; *PAED INT CAR AUD, ANN REP PAED INT CAR; Parslow RC, 2009, ARCH DIS CHILD, V94, P210, DOI 10.1136/adc.2007.134403; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; *ROYAL COLL SURG E, 1999, WORK PART MAN PAT HE; Royal College of Surgeons of England and the British Orthopaedic Society, 2000, BETT CAR SEV INJ; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shann F, 1997, INTENS CARE MED, V23, P201, DOI 10.1007/s001340050317; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; *SOC BRIT NEUR SUR, 1999, SAF NEUR 2000; Spiegelhalter D, 2003, INT J QUAL HEALTH C, V15, P7, DOI 10.1093/intqhc/15.1.7; Spiegelhalter DJ, 2005, STAT MED, V24, P1185, DOI 10.1002/sim.1970; Tasker RC, 2006, EMERG MED J, V23, P519, DOI 10.1136/emj.2005.028779; Tasker RC, 2004, EMERG MED J, V21, P433, DOI 10.1136/emj.2002.004069; Tasker RC, 2009, CURR OPIN PEDIATR, V21, P724, DOI 10.1097/MOP.0b013e328331e813; *UK NAT HLTH SERV, 2008, COMM SAF SUST SPEC P	34	27	28	0	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	FEB	2011	25	1					68	77		10.3109/02688697.2010.538770			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	722BO	WOS:000287405000010	21083365	Green Published			2022-02-06	
J	Matthews, S; Simmons, A; Strigo, I				Matthews, Scott; Simmons, Alan; Strigo, Irina			The effects of loss versus alteration of consciousness on inhibition-related brain activity among individuals with a history of blast-related concussion	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Functional magnetic resonance imaging; Self awareness; Somatic symptoms	COGNITIVE CONTROL; VALIDITY	In this investigation, 27 individuals who experienced blast-related concussion, i.e., brief loss (LOC) or alteration (AOC) of consciousness, performed a stop task during functional magnetic resonance imaging. LOC versus AOC subjects displayed altered ventromedial prefrontal cortex activity, which correlated with somatic symptom severity-findings which may suggest a neural correlate of impaired self awareness after LOC. Published by Elsevier Ireland Ltd.	[Matthews, Scott; Simmons, Alan; Strigo, Irina] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Matthews, Scott; Simmons, Alan] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA		Matthews, S (corresponding author), VASDHS 3350 Jolla Village Dr,Mail Code 116-A, La Jolla, CA 92093 USA.	scmatthews@ucsd.edu	Simmons, Alan N/A-9815-2008	Simmons, Alan N/0000-0003-3963-2112	Veterans AdministrationUS Department of Veterans Affairs; Veterans Affairs San Diego Healthcare SystemUS Department of Veterans Affairs; Center of Excellence for Stress and Mental Health; Veterans Affairs Mental illness Education and Clinical Center (MIRECC)	The authors thank Ryan M. O'Connell, Lindsay E. Reinhardt, Suzanne A. Moseley, Martin P. Paulus, Dean C. Delis and Larry Frank, Ph.D., for their contributions to this research, which was funded by grants from the Veterans Administration and Congressionally Directed Medical Research Program, and supported by the Veterans Affairs San Diego Healthcare System, Center of Excellence for Stress and Mental Health and Veterans Affairs Mental illness Education and Clinical Center (MIRECC).	Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; *CDC, 2006, FACTS TRAUM BRAIN IN; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; First M., 1997, STRUCTURED CLIN INTE; Floden D, 2006, J COGNITIVE NEUROSCI, V18, P1843, DOI 10.1162/jocn.2006.18.11.1843; Gallagher HL, 2002, NEUROIMAGE, V16, P814, DOI 10.1006/nimg.2002.1117; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Matthews SC, 2005, NEUROREPORT, V16, P755, DOI 10.1097/00001756-200505120-00020; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schwab KA, 2006, NEUROLOGY, V66, pA235; Spikman JM, 2010, J NEUROTRAUM, V27, P1195, DOI 10.1089/neu.2010.1277; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	21	27	27	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	JAN 30	2011	191	1					76	79		10.1016/j.pscychresns.2010.09.013			4	Clinical Neurology; Neuroimaging; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	737TM	WOS:000288591100011	21144713				2022-02-06	
J	Bohman, K; Arbogast, KB; Bostrom, O				Bohman, Katarina; Arbogast, Kristy B.; Bostrom, Ola			Head Injury Causation Scenarios for Belted, Rear-Seated Children in Frontal Impacts	TRAFFIC INJURY PREVENTION			English	Article						Head injury; Rear seat; Frontal impact; Child	TRAUMATIC BRAIN-INJURY; SHORT-TERM; PREDICTORS; OUTCOMES	Objectives: Head injuries are the most common serious injuries sustained by children in motor vehicle crashes and are of critical importance with regard to long-term disability. There is a lack of understanding of how seat belt-restrained children sustain head injuries in frontal impacts. The aim of the study was to identify the AIS2+ head injury causation scenarios for rear-seated, belt-restrained children in frontal impacts, including the set of parameters contributing to the injury. Method: In-depth crash investigations from two National Highway Traffic Safety Administration (NHTSA) databases, the National Automotive Sampling System-Crashworthiness Data System (NASS-CDS; 1997-2008) and the Crash Injury Research and Engineering Network (CIREN; 1996-2009), were collected and analyzed in detail. Selection criteria were all frontal impacts with principal direction of force (PDOF) of 11, 12, and 1 o'clock involving rear-seated, three-point belt-restrained, with or without booster cushion, children from 3 to 13 years with an AIS2+ head injury. Cases were analyzed using the BioTab method of injury causation assessment in order to systematically analyze the injury causation scenario for each case. Results: There were 27 cases meeting the inclusion criteria, 19 cases with MAIS2 head injuries and 8 cases with MAIS3+ head injuries, including 2 fatalities. Three major injury causation scenarios were identified, including head contact with seatback (10 cases), head contact with side interior (7 cases,) and no evidence of head contact (9 cases). Conclusions: Head injuries with seatback or side interior contact typically included a PDOF greater than 10 degree (similar to the Insurance Institute for Highway Safety [IIHS] and EuroNCAP offset frontal testing) and vehicle maneuvers. For seatback contact, the vehicle's movements contributed to occupant kinematics inboard the vehicle, causing a less than optimal restraint of the torso and/or torso roll out of the shoulder belt. For side interior contact, the PDOF and/or maneuvers forced the occupant toward the side interior. The cases without evidence of head/face contact were characterized by high crash severity and accompanied by severe injuries to the thorax and spine. These data lead to increased understanding of the injury patterns and causation in this crash restraint scenario so that interventions to mitigate the burden of injury can be advanced.	[Bohman, Katarina] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Arbogast, Kristy B.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Bohman, Katarina; Bostrom, Ola] Autoliv Res, Vargarda, Sweden		Bohman, K (corresponding author), Autoliv Dev AB, Wallentinsvagen 22, S-44783 Vargarda, Sweden.	katarina.bohman@autoliv.com		Arbogast, Kristy/0000-0002-1694-4562	National Science Foundation (NSF) Center for Child Injury Prevention Studies at the Children's Hospital of Philadelphia (CCHIPS)National Science Foundation (NSF); institute FFI	The authors acknowledge the National Science Foundation (NSF) Center for Child Injury Prevention Studies at the Children's Hospital of Philadelphia (CCHIPS) for partially sponsoring this study and its Industry Advisory Board (IAB) members for their support, valuable input, and advice. The views presented are those of the authors and not necessarily the views of CHOP, the NSF, or the IAB members.; The authors also acknowledge the institute FFI for partially funding the project. Ulrich Sander, Autoliv Research, is acknowledged for his contribution in analyzing the PDOF of the cases.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Andersson M., 2010, P 54 ANN AAAM LAS VE; ARBOGAST KB, 2005, P INT RES C BIOM INJ; Arbogast KB, 2010, J TRAUMA, V69, P913, DOI 10.1097/TA.0b013e3181e883f9; BIDEZ MW, 2005, SAE 2005 WORLD C EXH; BOHMAN K, 2007, 20 INT TECHN C ENH S; Bose Dipan, 2008, Ann Adv Automot Med, V52, P61; BOSTROM O, 2008, P 52 ANN AAAM SAN DI, P289; GLASS W, 2002, NAWCADPAXTR2001184 N; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Howard A, 2004, J TRAUMA, V56, P1276, DOI 10.1097/01.TA.0000078883.74947.EB; Huang S, 2006, 2006011142 SAE; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KENT R, 2007, 20 INT TECHN C ENH S; Klinich KD, 2008, UMTRI2008492, VII; Lindquist MO, 2006, J TRAUMA, V61, P1506, DOI 10.1097/01.ta.0000210496.52412.02; LOPEZVALDEZ FJ, 2009, P INT RES C BIOM INJ; Maltese MR, 2007, STAPP CAR CRASH JO, V51, P299; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; *NAT HIGHW TRAFF S, 2008, 810654 DOT HS NAT HI; *NAT HIGHW TRAFF S, 2010, 4 STEPS KIDS BOOST S; PHEASANT S, 1996, BODYSPACE; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Scheidler MG, 2000, J TRAUMA, V49, P864, DOI 10.1097/00005373-200011000-00012; SHERWOOD CP, 2006, P 50 ANN AAAM CHIC I; Swanson J, 2003, 18 INT TECHN C ENH S; Talmor D, 2010, ACCIDENT ANAL PREV, V42, P672, DOI 10.1016/j.aap.2009.10.015; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; THIELMAN CY, 1998, PUBLICATION FEDERAL; TORNVALL F, 2008, THESIS CHALMERS U TE; TYLKO S, 2005, 19 INT TECHN C ENH S; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	36	27	27	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.		2011	12	1					62	70	PII 932649413	10.1080/15389588.2010.526159			9	Public, Environmental & Occupational Health; Transportation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Transportation	717LD	WOS:000287044500009	21259175				2022-02-06	
J	Gordon, SN; Fitzpatrick, PJ; Hilsabeck, RC				Gordon, Shalanda N.; Fitzpatrick, Pamela J.; Hilsabeck, Robin C.			No Effect of PTSD and Other Psychiatric Disorders on Cognitive Functioning in Veterans With Mild TBI	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; mTBI; Post-traumatic stress disorder; PTSD; Cognitive functioning	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; VIETNAM VETERANS; PROCESSING SPEED; TEST-PERFORMANCE; IRAQ-WAR; ATTENTION; SEQUELAE	There has been speculation that post-traumatic stress disorder (PTSD) superimposed on mild traumatic brain injury (mTBI) may have synergistic, negative effects on cognitive functioning. The purpose of this study was to investigate differences in processing speed, executive functioning, and memory of 82 veterans with mTBI and PTSD, mTBI, and another psychiatric condition, or mTBI alone. It was hypothesized that there would be no group differences in cognitive performances. Participants completed the Trail Making Test, Stroop, Rey Complex Figure, and California Verbal Learning Test-2. There were no significant group differences on any cognitive measure. Findings suggest that PTSD and other psychiatric disorders do not necessarily have a negative exacerbating effect on processing speed, executive functioning, or memory in veterans with mTBI.	[Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Psychol Serv 116B, San Antonio, TX 78229 USA; [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Hilsabeck, Robin C.] Univ Calif San Diego, San Diego, CA 92103 USA; [Gordon, Shalanda N.] Cent Texas Vet Hlth Care Syst, Temple, TX USA		Hilsabeck, RC (corresponding author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	Hilsabeck@uthscsa.edu	Hilsabeck, Robin/ABC-5093-2020				American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Baker DG, 2009, MIL MED, V174, P773; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Delis D.C., 2000, CALIFORNIA VERBAL LE; Gabbe BJ, 2003, BRIT J SPORT MED, V37, P545, DOI 10.1136/bjsm.37.6.545; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Golden CJ., 2002, STROOP COLOR WORD TE; Golier J, 1997, INTEGR PHYS BEH SCI, V32, P52, DOI 10.1007/BF02688613; Green P., 1996, WORD MEMORY TEST USE; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Levin H.S., 1989, MILD HEAD INJURY; LEVINE MJ, 1988, COGNITIVE REHABILITA, V6, P14; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ruff RM, 1999, BRAIN INJURY, V13, P943; Sachinvala N, 2000, J NERV MENT DIS, V188, P818, DOI 10.1097/00005053-200012000-00005; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Sattler J.M., 2001, ASSESSMENT CHILDREN; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Spiro A, 2006, J AMBUL CARE MANAG, V29, P71, DOI 10.1097/00004479-200601000-00008; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wechsler D., 2008, WECHSLER ADULT INTEL; WechslerD, 2001, WECHSLER TEST ADULT; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wolfson, 1993, HALSTEAD REITAN NEUR; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	52	27	27	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					337	347	PII 934025482	10.1080/13854046.2010.550634			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100001	21360415				2022-02-06	
J	Lew, HL; Kraft, M; Pogoda, TK; Amick, MM; Woods, P; Cifu, DX				Lew, Henry L.; Kraft, Malissa; Pogoda, Terri K.; Amick, Melissa M.; Woods, Patricia; Cifu, David X.			Prevalence and characteristics of driving difficulties in Operation Iraqi Freedom/Operation Enduring Freedom combat returnees	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						automobiles; combat; concussion; deployment; driving; OIF/OEF; posttraumatic stress disorder; road rage; traumatic brain injury; veterans	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENT; MENTAL-HEALTH PROBLEMS; WAR VETERANS; POSTCONCUSSIVE SYMPTOMS; SLEEP DISTURBANCE; FOLLOW-UP; GULF-WAR; AFGHANISTAN	We studied the prevalence and characteristics of self-reported driving difficulties and examined their association with traumatic brain injury (TBI) and/or posttraumatic stress disorder (PTSD) in Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) veterans who were seen at a Department of Veterans Affairs outpatient polytrauma clinic. In this study, we used a brief driving questionnaire and chart reviews to assess the prevalence and characteristics of driving difficulties in the following four groups of patients: TBI only, PTSD only, TBI + PTSD, and Neither (neither TBI nor PTSD). Compared with before deployment, 93% of OIF/OEF veterans seen in the polytrauma clinic reported more difficulties with driving in at least one domain, with the most common areas of difficulty being (1) problems with anger or impatience (82%), (2) general driving difficulties (65%), and (3) experiences with near misses (57%). Patients with PTSD (with or without TBI) reported the most significant driving impairments, whereas respondents with a history of only TBI endorsed driving difficulties similar to veterans without either diagnosis. Qualitative analysis of veterans' comments also revealed similar patterns. Self-reported driving problems were common among OIF/OEF returnees. Respondents who had a diagnosis of PTSD (with or without TBI) reported the most severe driving difficulties since returning from deployment. The association between PTSD and driving problems warrants further investigation.	[Lew, Henry L.] DVBIC, Richmond, VA USA; [Lew, Henry L.] Univ Manoa, Honolulu, HI USA; [Kraft, Malissa; Pogoda, Terri K.; Amick, Melissa M.; Woods, Patricia] VA Boston Healthcare Syst, Polytrauma & Traumat Brain Injury Res Ctr, Dept Vet Affairs, Boston, MA USA; [Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Amick, Melissa M.] DVBIC, Boston, MA USA; [Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Richmond, VA USA		Lew, HL (corresponding author), Univ Hawaii Manoa, 1410 Lower Campus Rd, Honolulu, HI 96822 USA.	hlew@dvbic.org	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780; Cifu, David/0000-0003-1600-9387	VA Merit Review GrantUS Department of Veterans Affairs [B5009R]	This material was based on work supported by VA Merit Review Grant B5009R.	Amin MM, 2010, MIL MED, V175, P155; Atkinson MP, 2009, MANAGE SCI, V55, P1454, DOI 10.1287/mnsc.1090.1042; Boehmer TKC, 2004, ARCH INTERN MED, V164, P1908, DOI 10.1001/archinte.164.17.1908; Calhoun PS, 2007, J TRAUMA STRESS, V20, P1009, DOI 10.1002/jts.20255; CARDEN MJ, DEP LAUNCH SAFE DRIV; CASTRO CA, 2005, P NATO RES TECHN ORG; Contardi S, 2004, BRAIN RES BULL, V63, P427, DOI 10.1016/j.brainresbull.2003.12.016; *DEP DEF INJ SURV, 1999, MIL MED S, V164; *DEP VET AFF, 2010, VET SAF DRIV IN; Department of Veterans Affairs/Department of Defense, 2009, VA DOD CLIN PRACT GU; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Fear NT, 2008, AM J PREV MED, V35, P230, DOI 10.1016/j.amepre.2008.05.027; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hooper TI, 2005, AM J IND MED, V48, P118, DOI 10.1002/ajim.20190; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kang HK, 2002, OCCUP ENVIRON MED, V59, P794, DOI 10.1136/oem.59.12.794; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Knapik JJ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-231; KORB LJ, 2007, CALL DUTY COMPREHENS; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; Kupchik M, 2007, DEPRESS ANXIETY, V24, P244, DOI 10.1002/da.20189; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2011, J REHABIL RES DEV, V48, P913, DOI 10.1682/JRRD.2010.08.0140; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2010, NEUROREHABILITATION, V26, P271, DOI 10.3233/NRE-2010-0562; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lewis V, 2009, MIL MED, V174, P948, DOI 10.7205/MILMED-D-04-0208; Lincoln Andrew E, 2006, Traffic Inj Prev, V7, P31, DOI 10.1080/15389580500412028; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Maher MJ, 2006, CNS DRUGS, V20, P567, DOI 10.2165/00023210-200620070-00003; Mann RE, 2010, ACCIDENT ANAL PREV, V42, P1538, DOI 10.1016/j.aap.2010.03.010; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Matsuoka Y, 2008, CRIT CARE MED, V36, P74, DOI 10.1097/01.CCM.0000291650.70816.D6; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; Miyata S, 2010, NEUROSCI LETT, V469, P229, DOI 10.1016/j.neulet.2009.12.001; Philip P, 2005, SLEEP, V28, P1511, DOI 10.1093/sleep/28.12.1511; Pietrzak Robert H, 2009, J Spec Oper Med, V9, P74; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Reger MA, 2009, J CLIN PSYCHIAT, V70, P1266, DOI 10.4088/JCP.08m04361; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Schwab KA, 2007, J REHABIL RES DEV, V44, pXIII; Sivak M, 1996, J SAFETY RES, V27, P225, DOI 10.1016/S0022-4375(96)00027-8; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; *W REED ARM I RES, 2007, P COMB STRESS REL DI; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Ware J Catesby, 2006, Behav Sleep Med, V4, P1, DOI 10.1207/s15402010bsm0401_1; Wickens CM, 2008, ACCIDENT ANAL PREV, V40, P1223, DOI 10.1016/j.aap.2008.01.006	59	27	27	0	5	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2011	48	8					913	925		10.1682/JRRD.2010.08.0140			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	847DM	WOS:000296952100004	22068370	Bronze			2022-02-06	
J	Metting, Z; Rodiger, LA; de Jong, BM; Stewart, RE; Kremer, BP; van der Naalt, J				Metting, Zwany; Rodiger, Lars A.; de Jong, Bauke M.; Stewart, Roy E.; Kremer, Berry P.; van der Naalt, Joukje			Acute Cerebral Perfusion CT Abnormalities Associated with Posttraumatic Amnesia in Mild Head Injury	JOURNAL OF NEUROTRAUMA			English	Article						mild head injury; perfusion computed tomography; posttraumatic amnesia	TRANSIENT GLOBAL AMNESIA; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; PREFRONTAL CORTEX; DISSOCIATION; DYSFUNCTION; IMPAIRMENT; METABOLISM; ANATOMY; RETURN	Posttraumatic amnesia (PTA) is a common symptom following traumatic brain injury. Although this transient memory deficit implies specific impairment of higher brain function, the actual pathophysiology of PTA is not well understood. The aim of this study was to assess regional cerebral hemodynamics with perfusion computed tomography (CT) in patients during PTA following mild head injury compared to patients with resolved PTA. A total of 74 patients with mild head injury without structural abnormalities on a non-contrast CT scan were included and compared to 25 healthy controls. Two patient groups were defined: (1) a PTA group that was scanned during the episode of PTA (n = 34), and (2) a post-PTA group scanned after resolution of PTA (n = 40). The PTA group had significantly reduced cerebral blood flow (CBF) in the frontal grey matter (41.78 [SD 7.4] versus 44.44 [SD 6.2] mL . 100 g(-1) . min(-1), p = 0.023), and caudate nucleus (44.59 [SD 6.2] versus 47.85 [SD 7.7] mL . 100 g(-1) . min(-1), p = 0.021), compared to the post-PTA group. Thus in patients with mild head injury, PTA is associated with cerebral perfusion abnormalities in specific cortical and subcortical regions.	[Metting, Zwany; de Jong, Bauke M.; Kremer, Berry P.; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Rodiger, Lars A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, NL-9700 RB Groningen, Netherlands; [Stewart, Roy E.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9700 RB Groningen, Netherlands		Metting, Z (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.	z.metting@neuro.umcg.nl		van der Naalt, Joukje/0000-0001-9873-2418; Stewart, Roy/0000-0001-9227-433X; de Jong, Bauke M./0000-0002-6568-5739	ZonMw, Den Haag, The NetherlandsNetherlands Organization for Health Research and DevelopmentNetherlands Government [39200002]	This study was funded by a grant (number 39200002) from ZonMw, Den Haag, The Netherlands. The authors thank W.G.J. Tukker and M.M. Sprenger for their assistance.	Ahmed S, 2000, BRAIN INJURY, V14, P765; BARON JC, 1994, BRAIN, V117, P545, DOI 10.1093/brain/117.3.545; Bartsch T, 2010, LANCET NEUROL, V9, P205, DOI 10.1016/S1474-4422(09)70344-8; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Blumenfeld RS, 2007, NEUROSCIENTIST, V13, P280, DOI 10.1177/1073858407299290; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Eastwood JD, 2002, RADIOLOGY, V222, P227, DOI 10.1148/radiol.2221010471; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Eustache F, 1997, J NEUROL NEUROSUR PS, V63, P357, DOI 10.1136/jnnp.63.3.357; FAZIO F, 1992, J CEREBR BLOOD F MET, V12, P353, DOI 10.1038/jcbfm.1992.52; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Funahashi S, 2006, NEUROSCIENCE, V139, P251, DOI 10.1016/j.neuroscience.2005.07.003; GOLDBERG E, 1982, Journal of Clinical Neuropsychology, V4, P219, DOI 10.1080/01688638208401131; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Nariai T, 2001, J NEUROTRAUM, V18, P1323, DOI 10.1089/08977150152725623; NISSEN MJ, 1987, NEUROLOGY, V37, P789, DOI 10.1212/WNL.37.5.789; Pantoni L, 2000, ACTA NEUROL SCAND, V102, P275, DOI 10.1034/j.1600-0404.2000.102005275.x; Raichle ME, 1998, P NATL ACAD SCI USA, V95, P765, DOI 10.1073/pnas.95.3.765; RIESE W, 1958, Int Rec Med Gen Pract Clin, V171, P73; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schlosser RGM, 2006, NEUROSCIENCE, V139, P91, DOI 10.1016/j.neuroscience.2005.06.037; Schmidtke K, 1998, J NUCL MED, V39, P155; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Warren JD, 2000, J CLIN NEUROSCI, V7, P57, DOI 10.1054/jocn.1998.0129; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Yamane Y, 2008, J COMPUT ASSIST TOMO, V32, P415, DOI 10.1097/RCT.0b013e3180de5b9b; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	37	27	28	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2183	2189		10.1089/neu.2010.1395			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400008	20939700	Green Submitted			2022-02-06	
J	Filippidis, AS; Papadopoulos, DC; Kapsalaki, EZ; Fountas, KN				Filippidis, Aristotelis S.; Papadopoulos, Dimitrios C.; Kapsalaki, Eftychia Z.; Fountas, Kostas N.			Role of the S100B serum biomarker in the treatment of children suffering from mild traumatic brain injury	NEUROSURGICAL FOCUS			English	Article						biomarker; children; mild traumatic brain injury; S100B biomarker	NEURON-SPECIFIC ENOLASE; PROTEIN; HEAD; EMPHASIS; RELEASE; MARKERS; DAMAGE	Object. The aim of this study was to provide a systematic update of the current literature regarding the clinical role of the S100B serum biomarker in the initial evaluation of children who have sustained a mild traumatic brain injury (TBI). Methods. Searches in MEDLINE were defined with the keywords "mild TBI children S100," "mild TBI pediatric S100," and " children S100 brain injury." From the pool of obtained studies, those that had the inclusion criteria of mild TBI only or mixed types of TBI but including detailed information about groups of children with mild TBI were used. Results. Few studies were identified and fewer included more than 100 cases. The prospective studies showed that the S100B biomarker levels could be influenced by patient age and the time frame between head injury and blood sampling. Moreover, extracranial sources of S100B or additional injuries could influence the measured levels of this biomarker. A normal value of S100B in children with mild TBI could rule out injury-associated abnormalities on CT scans in the majority of reported cases. Conclusions. The vulnerability of S100B serum levels to the influences of patient age, blood sampling time, and extracranial S100B release limits the biomarker's role in the initial evaluation of children with mild TBI. The application of S100B in pediatric mild TBI cases has an elusive role, although it could help in selected cases to avoid unnecessary head CT scans. (DOI: 10.3171/2010.8.FOCUS10185)	[Filippidis, Aristotelis S.; Fountas, Kostas N.] Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Neurosurg, Biopolis, Larissa, Greece; [Papadopoulos, Dimitrios C.] Gen Hosp Larissa, Dept Crit Care Med, Larisa, Greece; [Kapsalaki, Eftychia Z.] Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Diagnost Radiol, Biopolis, Larissa, Greece		Fountas, KN (corresponding author), Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Neurosurg, Build A,3rd Floor,Suite 56, Biopolis, Larissa, Greece.	fountas@med.uth.gr					Akhtar Javed I, 2003, Pediatr Crit Care Med, V4, P322; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Castellani C, 2009, ACTA PAEDIATR, V98, P1607, DOI 10.1111/j.1651-2227.2009.01423.x; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Hatpio R, 2004, CLIN BIOCHEM, V37, P512, DOI 10.1016/j.clinbiochem.2004.05.012; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Unden J, 2007, NEUROCRIT CARE, V6, P94, DOI 10.1007/s12028-007-0005-0; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Whitaker-Azmitia PM, 1997, BRAIN RES, V776, P51, DOI 10.1016/S0006-8993(97)01002-0; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	27	27	28	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E2	10.3171/2010.8.FOCUS10185			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900003	21039136				2022-02-06	
J	Kang, CE; Clarkson, R; Tator, CH; Yeung, IWT; Shoichet, MS				Kang, Catherine E.; Clarkson, Richard; Tator, Charles H.; Yeung, Ivan W. T.; Shoichet, Molly S.			Spinal Cord Blood Flow and Blood Vessel Permeability Measured by Dynamic Computed Tomography Imaging in Rats after Localized Delivery of Fibroblast Growth Factor	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; growth factors; computed tomography scanning; traumatic spinal cord injury	BRAIN-BARRIER; NONINVASIVE MEASUREMENT; ENDOTHELIAL-CELLS; CONTUSION INJURY; PERFUSION CT; ANGIOGENESIS; HYALURONAN; NEOVASCULARIZATION; OLIGOSACCHARIDES; RECOMMENDATIONS	Following spinal cord injury, profound vascular changes lead to ischemia and hypoxia of spinal cord tissue. Since fibroblast growth factor 2 (FGF2) has angiogenic effects, its delivery to the injured spinal cord may attenuate the tissue damage associated with ischemia. To limit systemic mitogenic effects, FGF2 was delivered to the spinal cord via a gel of hyaluronan and methylcellulose (HAMC) injected into the intrathecal space, and compared to controls receiving HAMC alone and artificial cerebrospinal fluid (aCSF) alone. Dynamic perfusion computed tomography (CT) was employed for the first time in small animals to serially measure blood flow and permeability in the injured and uninjured spinal cord. Spinal cord blood flow (SCBF) and permeability-surface area (PS) measurements were obtained near the injury epicenter, and at two regions rostral to the epicenter in animals that received a 26-g clip compression injury. As predicted, SCBF measurements decreased and PS increased after injury. FGF2 delivered via HAMC after injury restored SCBF towards pre-injury values in all regions, and increased blood flow rates at 7 days post-injury compared to pre-injury measurements. PS was stabilized at regions rostral to the epicenter of injury when FGF2 was delivered with HAMC, with significantly lower values than aCSF controls at 7 days in the region farthest from the epicenter. Laminin staining for blood vessels showed a qualitative increase in vessel density after 7 days when FGF2 was locally delivered. Additionally, permeability stains showed that FGF2 moderately decreased permeability at 7 days post-injury. These data demonstrate that localized delivery of FGF2 improves spinal cord hemodynamics following injury, and that perfusion CT is an important technique to serially measure these parameters in small animal models of spinal cord injury.	[Kang, Catherine E.; Shoichet, Molly S.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada; [Yeung, Ivan W. T.] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada; [Shoichet, Molly S.] Univ Toronto, Dept Chem, Toronto, ON M5S 1A1, Canada; [Kang, Catherine E.; Shoichet, Molly S.] Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Clarkson, Richard; Yeung, Ivan W. T.] Princess Margaret Hosp, Univ Hlth Network, Dept Radiat Phys, Toronto, ON M4X 1K9, Canada; [Tator, Charles H.] Univ Toronto, Krembil Neurosci Ctr, Toronto Western Res Inst, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Dept Surg, Toronto, ON, Canada		Shoichet, MS (corresponding author), Donnelly Ctr, 160 Coll St,Room 514, Toronto, ON M5S 3E1, Canada.	molly.shoichet@utoronto.ca			Canadian Institute for Health ResearchCanadian Institutes of Health Research (CIHR)	The authors are indebted to Peter Poon for all of his surgical and technical assistance with these studies. The authors would also like to thank Sunmo Kim and Nicolas Gonzalez for fruitful discussions regarding perfusion CT modeling and measurements. We acknowledge funding from the Canadian Institute for Health Research (to M.S.S. and C.H.T.).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; BECK DW, 1984, J NEUROPATH EXP NEUR, V43, P219, DOI 10.1097/00005072-198405000-00001; Bendfeldt K, 2007, J NEUROSCI, V27, P3260, DOI 10.1523/JNEUROSCI.4033-06.2007; Bisdas S, 2008, EUR RADIOL, V18, P2321, DOI 10.1007/s00330-008-0973-2; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; Fehlings MG, 2001, SPINE, V26, pS56, DOI 10.1097/00007632-200112151-00012; GUHA A, 1989, STROKE, V20, P372, DOI 10.1161/01.STR.20.3.372; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Hamann MCJ, 2003, EXP NEUROL, V182, P300, DOI 10.1016/S0014-4886(03)00040-2; Hawryluk GWJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E14; Hayashi Y, 1997, GLIA, V19, P13, DOI 10.1002/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B; Hebel R., 1986, ANATOMY EMBRYOLOGY L; Jones LL, 2001, MICROSC RES TECHNIQ, V54, P317, DOI 10.1002/jemt.1144; Kang CE, 2009, TISSUE ENG PT A, V15, P595, DOI 10.1089/ten.tea.2007.0349; KANG CE, 2009, J CONTROLLE IN PRESS; KETY SS, 1951, PHARMACOL REV, V3, P1; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Lee TT, 1999, J NEUROTRAUM, V16, P347, DOI 10.1089/neu.1999.16.347; LEES VC, 1995, LAB INVEST, V73, P259; Leggett D A, 1998, Australas Radiol, V42, P335, DOI 10.1111/j.1440-1673.1998.tb00533.x; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Miles KA, 2000, ACAD RADIOL, V7, P840, DOI 10.1016/S1076-6332(00)80632-7; Miles KA, 1998, BRIT J RADIOL, V71, P276, DOI 10.1259/bjr.71.843.9616236; MILES KA, 1991, BRIT J RADIOL, V64, P409, DOI 10.1259/0007-1285-64-761-409; MILES KA, 1993, RADIOLOGY, V188, P405, DOI 10.1148/radiology.188.2.8327686; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; Murakami M, 2008, CURR OPIN HEMATOL, V15, P215, DOI 10.1097/MOH.0b013e3282f97d98; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; PETERS AM, 1987, CARDIOVASC RES, V21, P830, DOI 10.1093/cvr/21.11.830; PETERS AM, 1987, NUCL MED COMMUN, V8, P823, DOI 10.1097/00006231-198710000-00009; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; PRESTI D, 1994, CELL BIOCHEM FUNCT, V12, P281, DOI 10.1002/cbf.290120409; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; *REEV FDN CD, 2009, ON DEGR SEP PAR SPIN; Relf M, 1997, CANCER RES, V57, P963; Reuss B, 2003, J NEUROSCI, V23, P6404; Rivlin A S, 1978, Surg Neurol, V10, P38; SANDLER AN, 1976, BRAIN RES, V118, P181, DOI 10.1016/0006-8993(76)90707-1; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; Tateishi U, 2001, J COMPUT ASSIST TOMO, V25, P23, DOI 10.1097/00004728-200101000-00004; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Toda H, 2008, J PHYSIOL SCI, V58, P263, DOI 10.2170/physiolsci.RP005008; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; Wu XH, 2007, J NEUROTRAUM, V24, P1502, DOI 10.1089/neu.2006.0228; YEUNG WTI, 1994, J NEURO-ONCOL, V18, P53, DOI 10.1007/BF01324604; Yi CA, 2004, RADIOLOGY, V233, P191, DOI 10.1148/radiol.2331031535; Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841	52	27	28	1	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					2041	2053		10.1089/neu.2010.1345			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500011	20799884				2022-02-06	
J	Keenan, HT; Leventhal, JM				Keenan, Heather T.; Leventhal, John M.			A Case-Control Study to Evaluate Utah's Shaken Baby Prevention Program	ACADEMIC PEDIATRICS			English	Article						abusive head trauma; child abuse; prevention	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; INFANTS	OBJECTIVE: Educational programs designed to inform mothers and other child caretakers about the dangers of infant shaking have been widely adopted; however, only one has been evaluated to ascertain its effect on abusive head trauma (AHT). This project's goal was to evaluate whether an educational video delivered on the postpartum ward decreased AHT occurrence. METHODS: A case-control study was conducted in which 77 Utah resident mothers of children aged under 2 years who had AT-IT were drawn from the only pediatric level-one trauma center in Utah and the Medical Examiner's Office from 2001 to 2007. Five control mothers per case matched by birth year were identified through the state's birth certificate registry. Conditional logistic regression was used to calculate the adjusted odds of AHT given maternal exposure to the educational video. An alternate injury and alternate educational exposures were assessed to examine potential confounding. RESULTS: The educational video was associated with nonstatistically significant reductions of both AHT (odds ratio [OR] 0.7, 95% confidence interval [CI], 0.5-1.2) and the alternate injury mechanism, child injury from motor vehicle crash (OR 0.9, 95% Cl, 0.6-1.4). Alternate education about car seat use (OR 0.4, 95% CI, 0.2-0.8), back to sleep (OR 0.3, 95% CI, 0.2-0.5), and setting hot water temperature (OR 0.2, 95% CI, 0.1-0.4) were associated with significant reductions in AHT. CONCLUSIONS: AHT occurrence was not significantly associated with the educational video but was associated with alternate postpartum education provided to mothers. These results suggest that the shaken baby prevention video is not causal at reducing AHT.	[Keenan, Heather T.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA; [Leventhal, John M.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA		Keenan, HT (corresponding author), Univ Utah, Sch Med, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu			Primary Children's Medical Center Foundation	This study was funded by a Primary Children's Medical Center Foundation grant, awarded to Heather Keenan. Partial support for all datasets within the Utah Population Database was provided by the University of Utah's Huntsman Cancer Institute.	Blair PS, 2006, LANCET, V367, P314, DOI 10.1016/S0140-6736(06)67968-3; Colson ER, 2006, PEDIATRICS, V118, pE243, DOI 10.1542/peds.2005-2517; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Joint Commission, 2006, SOURCE, V4, P3; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Midwest Childrens' Resource Center & Junior League of Saint Paul, 1995, PORTR PROM PREV SHAK; *NAT CTR SHAK BAB, 2000, EL STOR; Shapiro ED, 2004, PEDIATR INFECT DIS J, V23, P127, DOI 10.1097/01.inf.0000109248.32907.1d; Shapiro ED, 2008, AM J PREV MED, V34, pS153, DOI 10.1016/j.amepre.2008.01.022; Vazquez M, 2001, NEW ENGL J MED, V344, P955, DOI 10.1056/NEJM200103293441302	12	27	28	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1876-2859			ACAD PEDIATR	Acad. Pediatr.	NOV-DEC	2010	10	6					389	394		10.1016/j.acap.2010.08.005			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	680SD	WOS:000284253800006	21075319				2022-02-06	
J	Bondanelli, M; Ambrosio, MR; Carli, A; Bergonzoni, A; Bertocchi, A; Zatelli, MC; Ceruti, S; Valle, D; Basaglia, N; degli Uberti, E				Bondanelli, Marta; Ambrosio, Maria Rosaria; Carli, Anna; Bergonzoni, Antonella; Bertocchi, Amedeo; Zatelli, Maria Chiara; Ceruti, Stefano; Valle, Domenico; Basaglia, Nino; degli Uberti, Ettore			Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							TRAUMATIC BRAIN-INJURY; ENDOCRINE-SOCIETY; ASSOCIATION; HYPOPITUITARISM; ABNORMALITIES; HYPERGLYCEMIA; RELIABILITY; GUIDELINES; STATEMENT; DIAGNOSIS	Backround: Stroke is a leading cause of death in industrialized countries, representing the main cause of long-term disability. Recent studies indicate that hypopituitarism may be observed after an acute stroke. Objective: The aim was to prospectively investigate incidence and pattern of pituitary dysfunction in patients suffering ischemic stroke and to assess the predictive value of different clinical and radiological parameters for hypopituitarism. Patients and Methods: We assessed endocrine, clinical, radiological, and functional parameters in 56 patients (34 males; mean age, 64.8 +/- 1.3 yr; mean body mass index, 25.8 +/- 0.45 kg/m(2)) at 1-3 months (visit 1) and 12-15 months (visit 2) after an ischemic stroke. Results: At visit 1, hypopituitarism was detected in 20 (35.7%) of 56 stroke patients, with multiple deficits in three and isolated deficits in 17. At visit 2, hypopituitarism was detected in 18 (37.5%) of 48 stroke patients, with multiple deficits in two. Four patients with previously diagnosed isolated GH or LH/FSH deficit exhibited normal pituitary function, whereas GH deficiency was newly diagnosed in three cases. Hypopituitarism was associated with worse outcome. We identified both clinical (preexisting diabetes mellitus, medical complications during hospitalization) and radiological (Alberta Stroke Programme Early CT Score <= 7) parameters as major risk factors for developing hypopituitarism after ischemic stroke. Conclusions: Hypopituitarism may associate with ischemic stroke in one third of cases and persist in a long-term period, aggravating the functional outcome. We identified specific risk factors for hypopituitarism after stroke, which may help to select patients needing an accurate endocrine evaluation to improve stroke outcome. (J Clin Endocrinol Metab 95: 4660-4668, 2010)	[Bondanelli, Marta; Ambrosio, Maria Rosaria; Carli, Anna; Zatelli, Maria Chiara; degli Uberti, Ettore] Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, I-44100 Ferrara, Italy; [Bergonzoni, Antonella; Bertocchi, Amedeo; Basaglia, Nino] Univ Ferrara, Azienda Osped, Dept Rehabil Med, I-44121 Ferrara, Italy; [Ceruti, Stefano] Univ Ferrara, Azienda Osped, Neuroradiol Unit, I-44121 Ferrara, Italy; [Valle, Domenico] Eli Lilly & Co, I-50019 Florence, Italy		degli Uberti, E (corresponding author), Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, Via Savonarola 9, I-44100 Ferrara, Italy.	ti8@unife.it	Zatelli, Maria Chiara/Y-1160-2019; Zatelli, Maria Chiara/U-2649-2018	ambrosio, maria rosaria/0000-0002-7911-9770; Bondanelli, Marta/0000-0001-8071-6559; Zatelli, Maria Chiara/0000-0001-8408-7796; degli Uberti, Ettore/0000-0002-9441-7223	Fondazione Cassa di Risparmio di FerraraFondazione Carife; Associazione Ferrarese dell'Ipertensione Arteriosa; Italian Ministry of University and Scientific and Technological ResearchMinistry of Education, Universities and Research (MIUR)	This work was supported by grants from the Italian Ministry of University and Scientific and Technological Research to the University of Ferrara and FAR 2009, Fondazione Cassa di Risparmio di Ferrara, and Associazione Ferrarese dell'Ipertensione Arteriosa.	Adams HP, 2004, CEREBROVASC DIS, V18, P124, DOI 10.1159/000079260; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aviv RI, 2007, AM J NEURORADIOL, V28, P1975, DOI 10.3174/ajnr.A0689; Baliga Bantwal Suresh, 2006, Curr Cardiol Rep, V8, P23, DOI 10.1007/s11886-006-0006-1; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; BERGER L, 1986, STROKE, V17, P865, DOI 10.1161/01.STR.17.5.865; Bhasin S, 2006, J CLIN ENDOCR METAB, V91, P1995, DOI 10.1210/jc.2005-2847; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2008, J Endocrinol Invest, V31, P16; Bondanelli M, 2008, PITUITARY, V11, P187, DOI 10.1007/s11102-008-0112-8; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Bondanelli M, 2006, J CLIN ENDOCR METAB, V91, P3928, DOI 10.1210/jc.2006-1040; Denti L, 2004, AM J MED, V117, P312, DOI 10.1016/j.amjmed.2004.02.049; Dimopoulou I, 2005, INTENS CARE MED, V31, P1020, DOI 10.1007/s00134-005-2689-y; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; Dimopoulou I, 2004, INTENS CARE MED, V30, P1216, DOI 10.1007/s00134-004-2297-2; GANDOLFO C, 2007, SPREAD STROKE PREVEN, P45; Goldstein LB, 1997, STROKE, V28, P307, DOI 10.1161/01.STR.28.2.307; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Johansson A, 2000, J INTERN MED, V247, P179, DOI 10.1046/j.1365-2796.2000.00600.x; Kelly-Hayes M, 1998, STROKE, V29, P1274, DOI 10.1161/01.STR.29.6.1274; Kissela B, 2009, STROKE, V40, P530, DOI 10.1161/STROKEAHA.108.521906; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Nordborg C, 1996, ACTA NEUROPATHOL, V91, P61; OLSSON T, 1992, STROKE, V23, P1573, DOI 10.1161/01.STR.23.11.1573; Puetz V, 2008, STROKE, V39, P2485, DOI 10.1161/STROKEAHA.107.511162; Qiao M, 2009, INT J DEV NEUROSCI, V27, P691, DOI 10.1016/j.ijdevneu.2009.07.004; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Szczudlik A, 2001, J NEUROL SCI, V189, P105, DOI 10.1016/S0022-510X(01)00566-4; Ustrell-Roig X, 2007, REV ESP CARDIOL, V60, P753, DOI 10.1157/13108281; van Rijn MJE, 2006, J NEUROL NEUROSUR PS, V77, P24, DOI 10.1136/jnnp.2005.067447; Walker AE, 1981, STROKE S1, V12, pI13; Weant KA, 2008, NEUROSURGERY, V63, P645, DOI 10.1227/01.NEU.0000325728.50939.15	35	27	27	0	2	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	OCT	2010	95	10					4660	4668		10.1210/jc.2010-0611			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	659NK	WOS:000282573300024	20660027	Bronze			2022-02-06	
J	Randazzo, C; Nelson, NG; McKenzie, LB				Randazzo, Charles; Nelson, Nicolas G.; McKenzie, Lara B.			Basketball-Related Injuries in School-Aged Children and Adolescents in 1997-2007	PEDIATRICS			English	Article						basketball; injuries; child; adolescent; emergency department; National Electronic Injury Surveillance System; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PATTERNS; SPORTS; RISK; EPIDEMIOLOGY; ASSOCIATION; PLAYERS; SOCCER; MEN	OBJECTIVE: The objective was to determine national patterns of basketball-related injuries treated in emergency departments in the United States among children and adolescents <20 years of age. METHODS: A retrospective analysis was conducted with data from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission, from 1997 to 2007. Sample weights provided by the Consumer Product Safety Commission were used to calculate national estimates of basketball-related injuries. Trend significance of the numbers and rates of basketball-related injuries over time was analyzed by using linear regression. RESULTS: An estimated 4 128 852 pediatric basketball-related injuries were treated in emergency departments. Although the total number of injuries decreased during the study period, the number of traumatic brain injuries (TBIs) increased by 70%. The most common injury was a strain or sprain to the lower extremities (30.3%), especially the ankle (23.8%). Boys were more likely to sustain lacerations and fractures or dislocations. Girls were more likely to sustain TBIs and to injure the knee. Older children (15-19 years of age) were 3 times more likely to injure the lower extremities. Younger children (5-10 years of age) were more likely to injure the upper extremities and to sustain TBIs and fractures or dislocations. CONCLUSIONS: Although the total number of basketball-related injuries decreased during the 11-year study period, the large number of injuries in this popular sport is cause for concern. Pediatrics 2010;126:727-733	[Randazzo, Charles; Nelson, Nicolas G.; McKenzie, Lara B.] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH 43205 USA; [McKenzie, Lara B.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA		McKenzie, LB (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	lara.mckenzie@nationwidechildrens.org	McKenzie, Lara/C-5122-2012	McKenzie, Lara/0000-0003-2889-0001	Dorothy M. Bennett and Clark L. Bennett Medical Research Scholarship	We gratefully acknowledge the Dorothy M. Bennett and Clark L. Bennett Medical Research Scholarship for financial stipend support for Mr Randazzo during this study.	Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Borowski LA, 2008, AM J SPORT MED, V36, P2328, DOI 10.1177/0363546508322893; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; CHANDY T A, 1985, Physician and Sportsmedicine, V13, P106; Damore DT, 2003, PEDIATR EMERG CARE, V19, P65, DOI 10.1097/00006565-200304000-00001; Deitch JR, 2006, AM J SPORT MED, V34, P1077, DOI 10.1177/0363546505285383; Emery CA, 2007, CLIN J SPORT MED, V17, P17, DOI 10.1097/JSM.0b013e31802e9c05; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; Hamming BJ, 2007, CLIN J SPORT MED, V17, P446, DOI 10.1097/JSM.0b013e31815aed13; Harmer Peter A, 2005, Med Sport Sci, V49, P31, DOI 10.1159/000085341; Hickey GJ, 1997, CLIN J SPORT MED, V7, P252, DOI 10.1097/00042752-199710000-00002; LANESE RR, 1990, AM J PUBLIC HEALTH, V80, P1459, DOI 10.2105/AJPH.80.12.1459; McGuine TA, 2006, AM J SPORT MED, V34, P1103, DOI 10.1177/0363546505284191; McQuillan R, 2006, PUBLIC HEALTH, V120, P732, DOI 10.1016/j.puhe.2006.02.011; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; *NAT FED STAT HIGH, 2004, PART SETS REC 6 STRA; *NAT FED STAT HIGH, 2007, 2004 06 HIGH SCH ATH; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Prebble T B, 1999, WMJ, V98, P22; Sallis RE, 2001, INT J SPORTS MED, V22, P420, DOI 10.1055/s-2001-16246; Schroeder T., 2001, NEISS SAMPLE DESIGN; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Taylor BL, 2000, ACAD EMERG MED, V7, P1376, DOI 10.1111/j.1553-2712.2000.tb00495.x; *US BUR CENS, 2008, PUBL US CENS BUR; *US BUR CENS, 2008, INT EST US POP AG SE; US Consumer Product Safety Commission, 2000, NEISS NAT EL INJ SUR; Xiang HY, 2007, BRAIN INJURY, V21, P293, DOI 10.1080/02699050701311034; Yde J, 1990, Br J Sports Med, V24, P51	35	27	29	0	14	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2010	126	4					727	733		10.1542/peds.2009-2497			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	658WW	WOS:000282526100044	20837592				2022-02-06	
J	Wei, CW; Montanera, W; Selchen, D; Lian, J; Stevens, C; de Tilly, LN				Wei, Corie W.; Montanera, Walter; Selchen, Daniel; Lian, Jackie; Stevens, Christopher; de Tilly, Lyne Noel			Blunt Cerebrovascular Injuries: Diagnosis and Management Outcomes	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CAROTID-ARTERY; ARTERIOVENOUS-FISTULAS; ENDOVASCULAR STENTS; VASCULAR INJURIES; NECK INJURIES; TRAUMA; ACCURACY; THERAPY; ANTICOAGULATION	Background: Blunt cerebrovascular injury (BCVI) to the carotid and vertebral arteries is a potentially devastating injury in trauma patients. The optimal management for BCVI has not been standardized. At our institution, 64-slice multi-detector computed tomographic angiography (CTA) has been used as the initial screening exam for BCVI in patients who met predefined screening criteria. The purpose of this study is to review the incidence of CTA-diagnosed BCVI in at-risk patients and to evaluate the treatment and clinical outcome of patients with BCVI. Methods: This study included trauma patients with a positive diagnosis of BCVI on CTA during a 41-month study period. The medical records and relevant radiographic findings were retrospectively reviewed. Results: Twenty seven of 222 blunt trauma patients evaluated with CTA had a positive diagnosis of BCVI, with an occurrence rate of 12.2%. Traumatic brain injury (72.2%) and basal skull fractures (55.6%) were the most frequent associated injuries with carotid trauma while 100% of blunt vertebral injuries occurred in the setting of cervical fractures. Fourteen (51.8%) patients received medical therapy; Eleven (40.7%) patients received conservative treatment. Endovascular treatment was attempted in a single case of vertebral arteriovenous fistula. BCVI-related stroke was found in four patients (14.8%), one of whom developed an infarct while on medical treatment. Conclusions: BCVI is found in a significant portion of blunt trauma patients with identifiable risk factors, and screening CTA has high diagnostic yield in detecting these lesions. Medical therapy is the mainstay of treatment at our institution; however, BCVI-related stroke may occur despite treatment.	[Wei, Corie W.; Montanera, Walter; de Tilly, Lyne Noel] Univ Toronto, St Michaels Hosp, Dept Med Imaging, Toronto, ON M5B 1W8, Canada; [Selchen, Daniel] Univ Toronto, St Michaels Hosp, Dept Neurol, Toronto, ON M5B 1W8, Canada; [Lian, Jackie] McGill Univ, Dept Med Imaging, Montreal, PQ, Canada; [Stevens, Christopher] Univ British Columbia, Dept Med Imaging, Vancouver, BC V5Z 1M9, Canada		de Tilly, LN (corresponding author), Univ Toronto, St Michaels Hosp, Dept Med Imaging, 30 Bond St, Toronto, ON M5B 1W8, Canada.						Anaya C, 2009, SEMIN ULTRASOUND CT, V30, P205, DOI 10.1053/j.sult.2009.02.003; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl Walter L, 2003, Curr Opin Crit Care, V9, P530, DOI 10.1097/00075198-200312000-00011; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 2001, J TRAUMA, V50, P969, DOI 10.1097/00005373-200105000-00039; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; BROMBERG WJ, 2007, BLUNT CEREBROVASCULA; Bush RL, 2001, J ENDOVASC THER, V8, P53, DOI 10.1583/1545-1550(2001)008<0053:ESPACE>2.0.CO;2; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2005, ARCH SURG-CHICAGO, V140, P480, DOI 10.1001/archsurg.140.5.480; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; Cothren CC, 2003, J TRAUMA, V55, P811, DOI 10.1097/01.TA.0000092700.92587.32; COTHREN CC, 2004, ARCH SURG-CHICAGO, V139, P455; Duke BJ, 1997, J NEUROSURG, V87, P825, DOI 10.3171/jns.1997.87.6.0825; Eachempati SR, 1998, J TRAUMA, V45, P997, DOI 10.1097/00005373-199812000-00004; Edwards NM, 2007, J AM COLL SURGEONS, V204, P1007, DOI 10.1016/j.jamcollsurg.2006.12.041; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; Feiz-Erfan I, 2007, J NEUROSURG, V107, P364, DOI 10.3171/JNS-07/08/0364; Goodwin RB, 2009, J TRAUMA, V67, P1046, DOI 10.1097/TA.0b013e3181b83b63; Herrera DA, 2008, AM J NEURORADIOL, V29, P1585, DOI 10.3174/ajnr.A1123; HIGASHIDA RT, 1989, AM J ROENTGENOL, V153, P577, DOI 10.2214/ajr.153.3.577; Kerwin AJ, 2001, J TRAUMA, V51, P308, DOI 10.1097/00005373-200108000-00013; Krings T, 2008, EUR RADIOL, V18, P1531, DOI 10.1007/s00330-008-0915-z; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McGuinness BJ, 2008, INJURY, V39, P1242, DOI 10.1016/j.injury.2008.01.054; Melton S, 2007, J AM COLL SURGEONS, V204, P1014; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; Miller PR, 2001, J TRAUMA, V51, P285; Mutze S, 2005, RADIOLOGY, V237, P884, DOI 10.1148/radiol.2373042189; Redekop G, 2001, J NEUROSURG, V95, P412, DOI 10.3171/jns.2001.95.3.0412; Risgaard O, 2007, ANZ J SURG, V77, P686, DOI 10.1111/j.1445-2197.2007.04187.x; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Sliker CW, 2008, AM J ROENTGENOL, V190, P790, DOI 10.2214/AJR.07.2378; Spain DA, 2006, J TRAUMA, V60, P751; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Utter GH, 2006, J AM COLL SURGEONS, V203, P838, DOI 10.1016/j.jamcollsurg.2006.08.003; Vinchon M, 1994, Cardiovasc Surg, V2, P359; Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012; Waitzman AA, 1996, J OTOLARYNGOL, V25, P322	44	27	31	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	SEP	2010	37	5					574	579		10.1017/S0317167100010726			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	650BH	WOS:000281821800008	21059501	Bronze			2022-02-06	
J	Radyushkin, K; El-Kordi, A; Boretius, S; Castaneda, S; Ronnenberg, A; Reim, K; Bickeboller, H; Frahm, J; Brose, N; Ehrenreich, H				Radyushkin, K.; El-Kordi, A.; Boretius, S.; Castaneda, S.; Ronnenberg, A.; Reim, K.; Bickeboeller, H.; Frahm, J.; Brose, N.; Ehrenreich, H.			Complexin2 null mutation requires a 'second hit' for induction of phenotypic changes relevant to schizophrenia	GENES BRAIN AND BEHAVIOR			English	Article						Animal model; cryolesion; etiology; MK-801; mouse model; neurotrauma; parietal cortex; PPI; schizophrenia	TRAUMATIC BRAIN INJURY; PREPULSE INHIBITION; ANIMAL-MODELS; TRANSGENIC MICE; MOUSE MODEL; KETAMINE; VULNERABILITY; DISORDER; SIGNS; RATS	Schizophrenia is a devastating disease that affects approximately 1% of the population across cultures. Its neurobiological underpinnings are still unknown. Accordingly, animal models of schizophrenia often lack construct validity. As concordance rate in monozygotic twins amounts to only 50%, environmental risk factors (e.g. neurotrauma, drug abuse, psychotrauma) likely act as necessary 'second hit' to trigger/drive the disease process in a genetically predisposed individual. Valid animal models would have to consider this genetic-environmental interaction. Based on this concept, we designed an experimental approach for modeling a schizophrenia-like phenotype in mice. As dysfunction in synaptic transmission plays a key role in schizophrenia, and complexin2 (CPLX2) gene expression is reduced in hippocampus of schizophrenic patients, we developed a mouse model with Cplx2 null mutation as genetic risk factor and a mild parietal neurotrauma, applied during puberty, as environmental 'second hit'. Several months after lesion, Cplx2 null mutants showed reduced pre-pulse inhibition, deficit of spatial learning and loss of inhibition after MK-801 challenge. These abnormalities were largely absent in lesioned wild-type mice and non-lesioned Cplx2 null mutants. Forced alternation in T-maze, object recognition, social interaction and elevated plus maze tests were unaltered in all groups. The previously reported mild motor phenotype of Cplx2 null mutants was accentuated upon lesion. MRI volumetrical analysis showed a decrease of hippocampal volume exclusively in lesioned Cplx2 null mutants. These findings provide suggestive evidence for the 'second hit' hypothesis of schizophrenia and may offer new tools for the development of advanced treatment strategies.	[Reim, K.; Brose, N.] Georg August Univ, Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; [Radyushkin, K.; El-Kordi, A.; Castaneda, S.; Ronnenberg, A.; Ehrenreich, H.] Georg August Univ, Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Boretius, S.; Frahm, J.] Georg August Univ, Max Planck Inst Biophys Chem, Biomed NMR Forsch GmbH, D-37075 Gottingen, Germany; [Bickeboeller, H.] Georg August Univ, Dept Genet Epidemiol, D-37075 Gottingen, Germany; [Radyushkin, K.; El-Kordi, A.; Boretius, S.; Frahm, J.; Brose, N.; Ehrenreich, H.] DFG Ctr Mol Physiol Brain, Gottingen, Germany		Brose, N (corresponding author), Georg August Univ, Max Planck Inst Expt Med, Dept Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.	brose@em.mpg.de; ehrenreich@em.mpg.de	Bickeboller, Heike/V-2318-2018; Boretius, Susann/ABF-4993-2021	Bickeboller, Heike/0000-0002-3361-5488; Boretius, Susann/0000-0003-2792-7423; Ehrenreich, Hannelore/0000-0001-8371-5711	Max Planck SocietyMax Planck SocietyFoundation CELLEX; DFG Center for Molecular Physiology of the Brain (CMPB)German Research Foundation (DFG)	This study was supported by the Max Planck Society and the DFG Center for Molecular Physiology of the Brain (CMPB). The staff of the Transgenic Animal Facility at the Max Planck Institute for Experimental Medicine is gratefully acknowledged for excellent technical assistance.	Adler CM, 1999, AM J PSYCHIAT, V156, P1646, DOI 10.1176/ajp.156.10.1646; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anderson JE, 1998, RESTOR NEUROL NEUROS, V12, P175; Ayhan Y, 2009, BEHAV BRAIN RES, V204, P274, DOI 10.1016/j.bbr.2009.04.010; Bayer TA, 1999, J PSYCHIATR RES, V33, P543, DOI 10.1016/S0022-3956(99)00039-4; BEGEMANN M, 2010, ARCH GEN PS IN PRESS; Blumenthal TD, 2004, PSYCHOPHYSIOLOGY, V41, P326, DOI 10.1111/j.1469-8986.2003.00144.x; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; Brose N, 2008, TRAFFIC, V9, P1403, DOI 10.1111/j.1600-0854.2008.00758.x; Carlsson A, 1999, BRIT J PSYCHIAT, V174, P2, DOI 10.1192/S0007125000293574; Chan RCK, 2008, NEUROSCI BIOBEHAV R, V32, P957, DOI 10.1016/j.neubiorev.2008.01.005; Coyle JT, 2004, BIOCHEM PHARMACOL, V68, P1507, DOI 10.1016/j.bcp.2004.07.034; Csomor PA, 2008, BEHAV NEUROSCI, V122, P885, DOI 10.1037/0735-7044.122.4.885; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; GEYER MA, 1984, NEUROBEH TOXICOL TER, V6, P161; GEYER MA, 2002, PSYCHOPHARMACOLOGY 4, pR42; Glynn D, 2003, HUM MOL GENET, V12, P2431, DOI 10.1093/hmg/ddg249; Glynn D, 2007, BRAIN RES BULL, V72, P108, DOI 10.1016/j.brainresbull.2006.10.017; GOTTESMAN II, 1976, SCHIZOPHRENIA BULL, V2, P360, DOI 10.1093/schbul/2.3.360; Gunduz-Bruce H, 2009, BRAIN RES REV, V60, P279, DOI 10.1016/j.brainresrev.2008.07.006; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harrison PJ, 1998, LANCET, V352, P1669, DOI 10.1016/S0140-6736(98)03341-8; HEINRICHS DW, 1988, AM J PSYCHIAT, V145, P11; HYDE TM, 1990, SEMIN NEUROL, V10, P276, DOI 10.1055/s-2008-1041279; Ison JR, 1997, PSYCHOBIOLOGY, V25, P266; Jamain S, 2008, P NATL ACAD SCI USA, V105, P1710, DOI 10.1073/pnas.0711555105; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; Karl T, 2010, BEHAV BRAIN RES, V207, P434, DOI 10.1016/j.bbr.2009.10.029; Lahti AC, 2001, NEUROPSYCHOPHARMACOL, V25, P455, DOI 10.1016/S0893-133X(01)00243-3; Lee HJ, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-15; Lipska BK, 2004, J PSYCHIATR NEUROSCI, V29, P282; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Malhotra AK, 1997, NEUROPSYCHOPHARMACOL, V17, P141; Malhotra AK, 1996, NEUROPSYCHOPHARMACOL, V14, P301, DOI 10.1016/0893-133X(95)00137-3; McAllister, 1998, Semin Clin Neuropsychiatry, V3, P211; MCIIWAIN KL, 2001, PHYSIOL BEHAV, V73, P705; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Natt O, 2002, J NEUROSCI METH, V120, P203, DOI 10.1016/S0165-0270(02)00211-X; Olney JW, 1999, J PSYCHIAT RES, V33, P523, DOI 10.1016/S0022-3956(99)00029-1; ONEILL SK, 1989, BRAIN RES BULL, V22, P611, DOI 10.1016/0361-9230(89)90078-6; Radyushkin K, 2009, GENES BRAIN BEHAV, V8, P416, DOI 10.1111/j.1601-183X.2009.00487.x; Reim K, 2005, J CELL BIOL, V169, P669, DOI 10.1083/jcb.200502115; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Sawa A, 2002, SCIENCE, V296, P692, DOI 10.1126/science.1070532; Sawada K, 2002, MOL PSYCHIATR, V7, P484, DOI 10.1038/sj.mp.4000978; Shenton ME, 2001, SCHIZOPHR RES, V49, P1, DOI 10.1016/S0920-9964(01)00163-3; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Swerdlow NR, 1998, SCHIZOPHRENIA BULL, V24, P285, DOI 10.1093/oxfordjournals.schbul.a033326; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; van Os J, 2009, LANCET, V374, P635, DOI 10.1016/S0140-6736(09)60995-8; WILLNER P, 1986, PROG NEURO-PSYCHOPH, V10, P677, DOI 10.1016/0278-5846(86)90051-5; Wolfer DP, 1998, NEWS PHYSIOL SCI, V13, P118, DOI 10.1152/physiologyonline.1998.13.3.118; Wong AHC, 2003, NEUROSCI BIOBEHAV R, V27, P269, DOI 10.1016/S0149-7634(03)00035-6; Yamauchi Y, 2005, BRAIN RES, V1056, P59, DOI 10.1016/j.brainres.2005.07.015; Yee BK, 2005, BEHAV BRAIN RES, V163, P265, DOI 10.1016/j.bbr.2005.05.013; Yee BK, 2004, NEUROPSYCHOPHARMACOL, V29, P240, DOI 10.1038/sj.npp.1300323; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0	60	27	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1601-1848	1601-183X		GENES BRAIN BEHAV	Genes Brain Behav.	AUG	2010	9	6					592	602		10.1111/j.1601-183X.2010.00590.x			11	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	640FA	WOS:000281032700005	20412316	Bronze			2022-02-06	
J	Akyuz, M; Ucar, T; Acikbas, C; Kazan, S; Yilmaz, M; Tuncer, R				Akyuz, Mahmut; Ucar, Tanju; Acikbas, Cem; Kazan, Saim; Yilmaz, Murat; Tuncer, Recai			Effect of Early Bilateral Decompressive Craniectomy on Outcome for Severe Traumatic Brain Injury	TURKISH NEUROSURGERY			English	Article						Severe traumatic brain injury; Decompressive craniectomy; Intracranial pressure	CEREBRAL HEMISPHERIC STROKE; SEVERE HEAD-INJURY; SURGICAL DECOMPRESSION; MASS LESION; BLOOD-FLOW; MANAGEMENT; PRESSURE; INFARCTION; EDEMA; HEMORRHAGE	AIM: Debate continues as to whether decompressive craniectomy (DC) is an effective treatment for severe traumatic brain injury (STBI). DC is mostly used as a second tier treatment option. The aim of this study was determined whether early bilateral DC is effective as a first tier treatment option in patients with STBI. MATERIAL and METHODS: The study compared two groups. Group 1 comprised 36 STBI patients for whom control of intracranial pressure (ICP) was not achieved with conservative treatment methods according to radiological and neurological findings. These patients underwent bilateral or unilateral DC as a second tier treatment. Group 2 comprised 40 STBI patients who underwent early bilateral DC as a first tier treatment. RESULTS: Group 2 patients had a mean better outcome than Group 1patients, especially for patients with a GCS 6-8. Postoperative ICP was lower in Group 2 patients than Group 1 patients. CONCLUSION: This study indicates that early bilateral DC can be effective for controlling ICP in STBI patients. It is likely the favorable outcome results for Group 2 patients reflects the relatively short time between trauma and surgery. Therefore, these data indicate early bilateral DC can be considered as a first tier treatment in STBI patients.	[Akyuz, Mahmut; Ucar, Tanju; Acikbas, Cem; Kazan, Saim; Tuncer, Recai] Akdeniz Univ, Fac Med, Dept Neurosurg, TR-07058 Antalya, Turkey; [Yilmaz, Murat] Akdeniz Univ, Fac Med, Anesthesiol & Intens Care Unit, TR-07058 Antalya, Turkey		Akyuz, M (corresponding author), Akdeniz Univ, Fac Med, Dept Neurosurg, TR-07058 Antalya, Turkey.	mahmutakyuz@akdeniz.edu.tr	Yilmaz, Murat/I-6629-2017; Kazan, Saim/G-1782-2016; tuncer, mehmet recai/C-6969-2016		Akdeniz University Research FoundationAkdeniz University	This study was supported by the Akdeniz University Research Foundation.	Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; Engelhorn T, 1999, STROKE, V30, P1456, DOI 10.1161/01.STR.30.7.1456; GAAB MR, 1990, ACT NEUR S, V51, P326; GERL A, 1980, Zentralblatt fuer Neurochirurgie, V41, P125; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; IVAMOTO HS, 1974, STROKE, V5, P365, DOI 10.1161/01.STR.5.3.365; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Kunze E, 1998, ACT NEUR S, V71, P16; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Wolfla CE, 1997, J NEUROSURG, V86, P505, DOI 10.3171/jns.1997.86.3.0505; Wolfla CE, 1996, J NEUROSURG, V84, P642, DOI 10.3171/jns.1996.84.4.0642; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; YONAS H, 1990, J NEUROSURG, V73, P266, DOI 10.3171/jns.1990.73.2.0266; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	32	27	32	1	13	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	JUL	2010	20	3					382	389					8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	634DC	WOS:000280558700015	20669113	Bronze			2022-02-06	
J	Kuypers, NJ; Hoane, MR				Kuypers, Nicholas J.; Hoane, Michael R.			Pyridoxine Administration Improves Behavioral and Anatomical Outcome after Unilateral Contusion Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						B-vitamin; controlled cortical impact; recovery of function; treatment; traumatic brain injury; vita-nutrient; vitamin B-6	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; NICOTINAMIDE TREATMENT; OXIDATIVE STRESS; SENSORIMOTOR FUNCTION; FUNCTIONAL RECOVERY; SENSORY NEUROPATHY; REDUCES EDEMA; HEAD-INJURY; VITAMIN-B-6	The purpose of this project was to evaluate the preclinical efficacy of pyridoxine, or vitamin B-6. Rats received a 3.0mm unilateral controlled cortical impact (CCI) injury of the sensorimotor cortex or sham surgery. Treatment with vitamin B-6 (600 or 300mg/kg IP) or vehicle was administered at 30min and 24 h post-CCI. Somatosensory dysfunction was evaluated with the vibrissae-forelimb placing and bilateral tactile adhesive removal tests. Sensorimotor dysfunction was evaluated with the locomotor placing and the forelimb asymmetry tests. On the forelimb asymmetry test both treatment groups displayed no asymmetry bias on any of the testing days post-CCI and were statistically no different than the shams. Both vitamin B-6 groups displayed a significant improvement in behavioral performance on the locomotor placing test compared to the vehicle-treated group. Administration of 600mg/kg also significantly reduced tactile adhesive removal latencies on days 2, 4, 6, and 12 post-CCI. Both treatment groups were improved in their rate of recovery post-CCI on the vibrissae-forelimb placing test, but only the recovery seen in the 600-mg/kg group was significantly improved compared to vehicle. Finally, the 600-mg/kg dose resulted in significant cortical sparing compared to the vehicle-treated group. In general, the effects of vitamin B-6 on recovery of function were dose-dependent, with the 600-mg/kg dose consistently showing greater recovery than the 300-mg/kg dose. More experimental analyses are warranted to evaluate the potential preclinical efficacy and mechanistic action of vitamin B-6.	[Kuypers, Nicholas J.; Hoane, Michael R.] So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Carbondale, IL 62901 USA		Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	Funding was provided by National Institutes of Health grant NS045647.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; BARTH TM, 1990, STROKE, V21, P153; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Bender DA, 1999, BRIT J NUTR, V81, P7, DOI 10.1017/S0007114599000082; BETZ AL, 1994, ACTA NEUROCHIR, P314; Cabrini L, 1998, BIOCHEM MOL BIOL INT, V46, P689; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chong ZZ, 2008, CURR NEUROVASC RES, V5, P159, DOI 10.2174/156720208785425666; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cuskelly GJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1182, DOI 10.1152/ajpendo.2001.281.6.E1182; Friso S, 2004, AM J CLIN NUTR, V79, P992; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane Michael R, 2004, Clin Calcium, V14, P65; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Hwang IK, 2007, EXP NEUROL, V206, P114, DOI 10.1016/j.expneurol.2007.04.005; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Kelly PJ, 2003, STROKE, V34, pE51, DOI 10.1161/01.STR.0000071109.23410.AB; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; KRINKE G, 1981, NEUROTOXICOLOGY, V2, P13; KRINKE G, 1985, J NEUROPATH EXP NEUR, V44, P117, DOI 10.1097/00005072-198503000-00001; Kruman I, 1997, J NEUROSCI, V17, P5089; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oka T, 2001, NUTR RES REV, V14, P257, DOI 10.1079/NRR200125; OKADA M, 1991, J NUTR SCI VITAMINOL, V37, P349, DOI 10.3177/jnsv.37.349; PARRY GJ, 1985, NEUROLOGY, V35, P1466, DOI 10.1212/WNL.35.10.1466; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Perry TA, 2004, EXP NEUROL, V190, P133, DOI 10.1016/j.expneurol.2004.07.013; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; ROBERTS E, 1964, VITAM HORM, V22, P503, DOI 10.1016/S0083-6729(08)60351-9; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SCHALLERT T, 2005, ORIENTING PLACING BE, P129; Shen J, 2010, AM J CLIN NUTR, V91, P337, DOI 10.3945/ajcn.2009.28571; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van den Heuvel Corinna, 2004, Clin Calcium, V14, P9; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; XU Y, 1989, NEUROLOGY, V39, P1077, DOI 10.1212/WNL.39.8.1077	50	27	29	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1275	1282		10.1089/neu.2010.1327			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100012	20486803	Green Published			2022-02-06	
J	Taylor, AN; Rahman, SU; Tio, DL; Gardner, SM; Kim, CJ; Sutton, RL				Taylor, Anna N.; Rahman, Shayan U.; Tio, Delia L.; Gardner, Stephen M.; Kim, Christine J.; Sutton, Richard L.			Injury Severity Differentially Alters Sensitivity to Dexamethasone after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adrenocorticotropic hormone; corticosterone; corticotropin-releasing hormone; dexamethasone; glucocorticoid negative feedback; rat; stress	CORTICOTROPIN-RELEASING HORMONE; PREFRONTAL CORTEX; HYPOPITUITARISM; NEUROENDOCRINE; STRESS; RECEPTOR; RESPONSES; AXIS; RAT; HIPPOCAMPUS	We have reported differential short-and long-term dysregulation of the neuroendocrine stress response after traumatic brain injury (TBI) produced by controlled cortical impact (CCI). We have now investigated three possible mechanisms for this TBI-induced dysregulation: (1) effects on the sensitivity of negative-feedback systems to glucocorticoids; (2) effects on the sensitivity of pituitary corticotrophs to corticotropin-releasing hormone (CRH); and (3) effects on neuronal loss in the hilar region of the dentate gyrus and in the CA3b layer of the dorsal hippocampus. TBI was induced to the left parietal cortex in adult male rats with a pneumatic piston, at two different impact velocities and compression depths, to produce either moderate or mild CCI. At 7 and 35 days after surgery, the rats were injected SC with the synthetic glucocorticoid analog dexamethasone (DEX; 0.01, 0.10, or 1.00mg/kg) or saline, and 2 h later were subjected to 30min of restraint stress and tail vein blood collection. Whereas all doses of DEX suppressed corticosterone (CORT) and adrenocorticotropic hormone (ACTH) responses to stress on both days, CORT and ACTH were significantly more suppressed after 0.01mg/kg DEX in the moderate TBI group than in the mild TBI or sham groups. At both 7 and 35 days post-TBI, CRH (1.0 and 10.0 mu g/kg IP) stimulated CORT and ACTH in all rats, regardless of injury condition. Hippocampal cell loss was greatest at 48 days after moderate TBI. Enhanced sensitivity to glucocorticoid negative feedback and greater hippocampal cell loss, but not altered pituitary responses to CRH, contribute to the short-and long-term attenuation of the neuroendocrine stress response following moderate TBI. The role of TBI-induced alterations in glucocorticoid receptors in limbic system sites in enhanced glucocorticoid feedback sensitivity requires further investigation.	[Taylor, Anna N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Brain Res Inst, Los Angeles, CA 90095 USA; [Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Taylor, Anna N.] VAGLAHS, W Los Angeles Healthcare Ctr, Los Angeles, CA USA		Taylor, AN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Brain Res Inst, 10833 Le Conte Ave,Box 951763, Los Angeles, CA 90095 USA.	ataylor@mednet.ucla.edu			Department of Veterans Affairs Medical Research ServiceUS Department of Veterans Affairs; UCLA Brain Injury Research Center	We thank Sima Ghavim for her expert assistance with the histological preparations. This research was supported by the Department of Veterans Affairs Medical Research Service, and the UCLA Brain Injury Research Center.	Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Akana SF, 2001, J NEUROENDOCRINOL, V13, P625, DOI 10.1046/j.1365-2826.2001.00676.x; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHILDERS MK, 1998, BRAIN INJURY, V12, P547; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cullinan WE, 2008, BRAIN STRUCT FUNCT, V213, P63, DOI 10.1007/s00429-008-0192-2; de Kloet CS, 2007, PSYCHONEUROENDOCRINO, V32, P215, DOI 10.1016/j.psyneuen.2006.12.009; de Kloet ER, 2000, EUR J PHARMACOL, V405, P187, DOI 10.1016/S0014-2999(00)00552-5; Di S, 2009, J NEUROSCI, V29, P393, DOI 10.1523/JNEUROSCI.4546-08.2009; DIORIO D, 1993, J NEUROSCI, V13, P3839; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Furay AR, 2008, ENDOCRINOLOGY, V149, P5482, DOI 10.1210/en.2008-0642; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Haller J, 2008, FRONT NEUROENDOCRIN, V29, P273, DOI 10.1016/j.yfrne.2007.10.004; HERMAN JP, 1993, CELL MOL NEUROBIOL, V13, P349, DOI 10.1007/BF00711577; HERMAN JP, 1995, J NEUROENDOCRINOL, V7, P475, DOI 10.1111/j.1365-2826.1995.tb00784.x; Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MATHESON GK, 1971, BRAIN RES, V32, P151, DOI 10.1016/0006-8993(71)90160-0; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; Miklos IH, 2002, NEUROSCIENCE, V113, P581, DOI 10.1016/S0306-4522(02)00147-1; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Sullivan RM, 1999, J NEUROSCI, V19, P2834; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tasker JG, 2006, ENDOCRINOLOGY, V147, P5549, DOI 10.1210/en.2006-0981; Taylor AN, 2009, J NEUROTRAUM, V26, pA47; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TAYLOR AN, 2004, 7 INT NEUR S AD AUST; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Urban RJ, 2006, GROWTH HORM IGF RES, V16, pS25, DOI 10.1016/j.ghir.2006.03.017; Walilko T, 2009, J TRAUMA, V67, P1311, DOI 10.1097/TA.0b013e31819adc36; Yehuda R, 2009, ANN NY ACAD SCI, V1179, P56, DOI 10.1111/j.1749-6632.2009.04979.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x	48	27	27	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1081	1089		10.1089/neu.2009.1252			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300011	20560754				2022-02-06	
J	Costa, T; Constantino, LC; Mendonca, BP; Pereira, JG; Herculano, B; Tasca, CI; Boeck, CR				Costa, Tayana; Constantino, Leandra C.; Mendonca, Bruna P.; Pereira, Josimar G.; Herculano, Bruno; Tasca, Carla I.; Boeck, Carina R.			N-Methyl-D-Aspartate Preconditioning Improves Short-Term Motor Deficits Outcome After Mild Traumatic Brain Injury in Mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						NMDA preconditioning; neuroprotection; trauma brain injury; motor behavior	CEREBELLAR GRANULE CELLS; ISCHEMIC TOLERANCE; QUINOLINIC ACID; COGNITIVE DEFICITS; NMDA RECEPTORS; GLUTAMATE; MODEL; NEUROPROTECTION; TOXICITY; SEIZURES	Traumatic brain injury (TBI) causes impairment of fine motor functions in humans and nonhuman mammals that often persists for months after the injury occurs. Neuroprotective strategies for prevention of the seguelae of TBI and understanding the molecular mechanisms and cellular pathways are related to the glutamatergic system. It has been suggested that cellular damage subsequent to TBI is mediated by the excitatory neurotransmitters, glutamate and aspartate, through the excessive activation of the N-methyl-D-aspartate (NMDA) receptors. Thus, preconditioning with a low dose of NMDA was used as a strategy for protection against locomotor deficits observed after TBI in mice. Male adult mice CF-1 were preconditioned with NMDA (75 mg/kg) 24 hr before the TBI induction. Under anesthesia with O-2/N2O (33%: 66%) inhalation, the animals were subjected to the experimental model of trauma that occurs by the impact of a 25 g weight on the skull. Sensorimotor gating was evaluated at 1.5, 6, or 24 hr after TBI induction by using footprint and rotarod tests. Cellular damage also was assessed 24 hr after occurrence of cortical trauma. Mice preconditioned with NMDA were protected against all motor deficits revealed by footprint tests, but not those observed in rotarod tasks. Although mice showed motor deficits after TBI, no cellular damage was observed. These data corroborate the hypothesis that glutamatergic excitotoxicity, especially via NMDA receptors, contributes to severity of trauma. They also point to a putative neuroprotective mechanism induced by a sublethal dose of NMDA to improve motor behavioral deficits after TBI. (C) 2009 Wiley-Liss, Inc.	[Costa, Tayana; Constantino, Leandra C.; Mendonca, Bruna P.; Pereira, Josimar G.; Boeck, Carina R.] Univ Extremo Catarinense, Lab Neurociencias, PPGCS, Unidad Acad Ciencias Saude, BR-88806000 Criciuma, SC, Brazil; [Herculano, Bruno; Tasca, Carla I.] Univ Fed Santa Catarina, Dept Bioquim, Ctr Ciencias Biol, Florianopolis, SC, Brazil		Boeck, CR (corresponding author), Univ Extremo Catarinense, Lab Neurociencias, PPGCS, Unidad Acad Ciencias Saude, BR-88806000 Criciuma, SC, Brazil.	cariboeck@hotmail.com	Tasca, Carla Ines/AAB-8287-2019; Constantino, Leandra/H-8505-2018; Herculano, Bruno/N-4587-2019; Herculano, Bruno/F-8917-2018; Boeck, Carina Rodrigues/E-9472-2011	Tasca, Carla Ines/0000-0002-3414-6150; Constantino, Leandra/0000-0003-0523-4351; Herculano, Bruno/0000-0003-0095-3381; Herculano, Bruno/0000-0003-0095-3381; Boeck, Carina Rodrigues/0000-0002-6828-5634	Brazilian National Council Research [478249/200C-3]; FAPESCFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC) [12348/2007-0]; UNESC	Contract grant sponsor: Brazilian National Council Research (CNN): Contract grant number: 478249/200C-3; Contract grant sponsor: FAPESC; Contract grant number: 12348/2007-0 (to CRIB): Contract grant sponsor: UNESC.	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Billinger M, 1999, J AM COLL CARDIOL, V33, P1027, DOI 10.1016/S0735-1097(98)00674-3; Boeck CR, 2005, NEUROPHARMACOLOGY, V49, P17, DOI 10.1016/j.neuropharm.2005.01.024; Boeck CR, 2004, EPILEPSIA, V45, P745, DOI 10.1111/j.0013-9580.2004.65203.x; Bristow LJ, 1996, J PHARMACOL EXP THER, V277, P578; Carter RJ, 1999, J NEUROSCI, V19, P3248; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHUANG DM, 1992, MOL PHARMACOL, V42, P210; DAMSCHRODERWILLIAMS P, 1995, J NEUROCHEM, V65, P1069; Dietrich MO, 2005, ENVIRON TOXICOL PHAR, V19, P169, DOI 10.1016/j.etap.2004.07.004; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farlow MR, 2008, DRUG SAFETY, V31, P577, DOI 10.2165/00002018-200831070-00003; Ferguson AL, 2008, EUR J NEUROSCI, V28, P2084, DOI 10.1111/j.1460-9568.2008.06490.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GimenezLlort L, 1997, PHARMACOL BIOCHEM BE, V56, P549, DOI 10.1016/S0091-3057(96)00295-X; Grabb MC, 1999, J NEUROSCI, V19, P1657; Grusser-Cornehls U, 2001, PROG NEUROBIOL, V63, P489, DOI 10.1016/S0301-0082(00)00024-1; Jadhav V, 2007, SURG NEUROL, V67, P15, DOI 10.1016/j.surneu.2006.07.014; Jiang XY, 2003, ANN NY ACAD SCI, V993, P134, DOI 10.1111/j.1749-6632.2003.tb07522.x; Jonas W, 2001, NEUROREPORT, V12, P335, DOI 10.1097/00001756-200102120-00031; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; Lin CH, 2008, EUR J PHARMACOL, V589, P85, DOI 10.1016/j.ejphar.2008.05.047; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; Marini AM, 1998, J BIOL CHEM, V273, P29394, DOI 10.1074/jbc.273.45.29394; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Ogita K, 2003, J NEUROCHEM, V85, P1336, DOI 10.1046/j.1471-4159.2003.01778.x; Pagliaro P, 2001, LIFE SCI, V69, P1, DOI 10.1016/S0024-3205(01)01113-4; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rejdak R, 2001, POL J PHARMACOL, V53, P73; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rybnikova E, 2005, BEHAV BRAIN RES, V160, P107, DOI 10.1016/j.bbr.2004.11.023; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saleh MC, 2009, BRAIN RES, V1247, P212, DOI 10.1016/j.brainres.2008.10.014; SASAHIRA M, 1995, NEUROSCI LETT, V185, P95, DOI 10.1016/0304-3940(94)11233-9; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Sei Y, 1998, NEUROSCI LETT, V241, P180, DOI 10.1016/S0304-3940(97)00980-4; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Tauskela JS, 2003, AM J PHYSIOL-CELL PH, V285, pC899, DOI 10.1152/ajpcell.00110.2003; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Vandresen S, 2007, BRAIN RES, V1184, P38, DOI 10.1016/j.brainres.2007.09.091; Vohra HA, 2006, J SURG RES, V134, P138, DOI 10.1016/j.jss.2005.12.009; Willis C, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003986.PUB2; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; YANG GM, 1997, NEUROMETHODS, P47	59	27	27	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2010	88	6					1329	1337		10.1002/jnr.22300			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	575ZK	WOS:000276112600017	19998488				2022-02-06	
J	O'Brien, NF; Reuter-Rice, KE; Khanna, S; Peterson, BM; Quinto, KB				O'Brien, Nicole Fortier; Reuter-Rice, Karin E.; Khanna, Sandeep; Peterson, Bradley M.; Quinto, Kenneth B.			Vasospasm in children with traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Vasospasm; Transcranial doppler ultrasound; Traumatic brain injury; Pediatric	CEREBRAL-BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; HEAD-INJURY; AGE-DEPENDENCE; VELOCITY; SONOGRAPHY; ARTERIES; ULTRASONOGRAPHY; DIAGNOSIS; PERFUSION	To determine the incidence of vasospasm in children who have suffered moderate to severe traumatic brain injury. A prospective observational pilot study in a 24-bed pediatric intensive care unit was performed. Twenty-two children aged 7 months to 14 years with moderate to severe traumatic brain injury as indicated by Glasgow Coma Score a parts per thousand currency sign12 and abnormal head imaging were enrolled. Transcranial Doppler ultrasound was performed to identify and follow vasospasm. Patients with a flow velocity in the middle cerebral artery (MCA) > 120 cm/s were considered to have vasospasm by criterion A. If flow velocity in the MCA was > 120 cm/s and the Lindegaard ratio was > 3, vasospasm was considered to be present by criterion B. Patients with basilar artery (BA) flow velocity > 90 cm/s met criteria for vasospasm in the posterior circulation (criterion C). In the MCA, 45.5% of patients developed vasospasm based on criterion A and 36.3% developed vasospasm based on criterion B. A total of 18.2% of patients developed vasospasm in the BA by criterion C. Typical day of onset of vasospasm was hospital day 2-3. Duration of vasospasm in the anterior circulation was 4 +/- A 2 days based on criteria A and 3 +/- A 1 days based on criteria B. Vasospasm in the posterior circulation persisted for 2 +/- A 1 days. Using the adult criteria outlined above to diagnose vasospasm, a significant proportion of pediatric patients who have suffered moderate to severe traumatic brain injury develop vasospasm during the course of their treatment.	[O'Brien, Nicole Fortier] Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Reuter-Rice, Karin E.; Khanna, Sandeep; Peterson, Bradley M.] Univ Calif San Diego, Rady Childrens Hosp, Dept Pediat Crit Care, San Diego, CA 92103 USA; [Quinto, Kenneth B.] Univ Calif San Diego, Rady Childrens Hosp, Dept Allergy & Immunol, San Diego, CA 92103 USA		O'Brien, NF (corresponding author), Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.	Nicole.Obrien@nationwidechildrens.org; skhanna@rchsd.org; bpeterson@rchsd.org; kbquinto@ucsd.edu	O'brien, Nicole/E-3776-2011	Reuter-Rice, Karin/0000-0003-1501-8994			AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BODE H, 1989, EUR J PEDIATR, V148, P406, DOI 10.1007/BF00595898; BODE H, 1988, ARCH DIS CHILD, V63, P606, DOI 10.1136/adc.63.6.606; BODE H, 1989, J CHILD NEUROL, V4, pS68, DOI 10.1177/0883073889004001S11; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; Philip S, 2009, CRIT CARE MED, V37, P2973, DOI 10.1097/CCM.0b013e3181a963f6; Pietrini D, 2004, Minerva Anestesiol, V70, P549; SCHONING M, 1993, STROKE, V24, P1305, DOI 10.1161/01.STR.24.9.1305; Society of Critical Care Medicine, 2003, Crit Care Med, V31, pS407; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; Wintermark M, 2004, PEDIATRICS, V113, P1642, DOI 10.1542/peds.113.6.1642	21	27	29	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2010	36	4					680	687		10.1007/s00134-009-1747-2			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	568UK	WOS:000275548400014	20091024	hybrid, Green Published, Green Submitted			2022-02-06	
J	Tait, RJ; Anstey, KJ; Butterworth, P				Tait, Robert J.; Anstey, Kaarin J.; Butterworth, Peter			Incidence of self-reported brain injury and the relationship with substance abuse: findings from a longitudinal community survey	BMC PUBLIC HEALTH			English	Article							CLINICALLY IMPORTANT DIFFERENCES; BLOOD-ALCOHOL LEVEL; UNITED-STATES; HEALTH SURVEY; HEAD-INJURY; PREVALENCE; EPIDEMIOLOGY; AUSTRALIA; CANNABIS; OUTCOMES	Background: Traumatic or serious brain injury (BI) has persistent and well documented adverse outcomes, yet 'mild' or 'moderate' BI, which often does not result in hospital treatment, accounts for half the total days of disability attributed to BI. There are currently few data available from community samples on the incidence and correlates of these injuries. Therefore, the study aimed to assess the 1) incidence of self-reported mild (not requiring hospital admission) and moderate (admitted to hospital)) brain injury (BI), 2) causes of injury 3) physical health scores and 4) relationship between BI and problematic alcohol or marijuana use. Methods: An Australian community sequential-cohort study (cohorts aged 20-24, 40-44 and 60-64 years at wave one) used a survey methodology to assess BI and substance use at baseline and four years later. Results: Of the 7485 wave one participants, 89.7% were re-interviewed at wave two. There were 56 mild (230.8/100000 person-years) and 44 moderate BI (180.5/100000 person-years) reported between waves one and two. Males and those in the 20-24 year cohort had increased risk of BI. Sports injury was the most frequent cause of BI (40/100) with traffic accidents being a greater proportion of moderate (27%) than mild (7%) BI. Neither alcohol nor marijuana problems at wave one were predictors of BI. BI was not a predictor of developing substance use problems by wave two. Conclusions: BI were prevalent in this community sample, though the incidence declined with age. Factors associated with BI in community samples differ from those reported in clinical samples (e. g. typically traumatic brain injury with traffic accidents the predominate cause). Further, detailed evaluation of the health consequences of these injuries is warranted.	[Tait, Robert J.; Anstey, Kaarin J.; Butterworth, Peter] Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia		Tait, RJ (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, GPO Box 4, Canberra, ACT 0200, Australia.	Robert.Tait@anu.edu.au	Anstey, Kaarin/A-3852-2008; Tait, Robert/B-8693-2009	Anstey, Kaarin/0000-0002-9706-9316; Tait, Robert/0000-0003-0648-3093; Butterworth, Peter/0000-0002-1531-3881	NHMRCNational Health and Medical Research Council of Australia [179805, 157125, 366756, 366781]	This study was supported by NHMRC Program Grant 179805 and NHMRC Project Grant 157125. The sponsors had no role in the design, conduct or reporting of the research. Anstey and Butterworth are funded by NHMRC Fellowships #366756, #366781.	Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; *CDC, 2002, MMWR-MORBID MORTAL W, V55, P201; *CDC, 2003, MMWR-MORBID MORTAL W, V56, P167; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Fairweather AK, 2007, J NERV MENT DIS, V195, P130, DOI 10.1097/01.nmd.0000254746.15325.fa; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fisk JE, 2008, J PSYCHOPHARMACOL, V22, P727, DOI 10.1177/0269881107084000; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jamieson LM, 2007, INJURY PREV, V13, P243, DOI 10.1136/ip.2007.015354; JENNETT B, 1975, LANCET, V1, P480; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; MILLER LL, 1983, PSYCHOL BULL, V93, P441, DOI 10.1037/0033-2909.93.3.441; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; OCONNOR P, 1999, HOSPITALISATION DUE; ORANCE L, 2007, B AUSTR I HLTH WELFA, V55, P1; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Samsa G, 1999, PHARMACOECONOMICS, V15, P141, DOI 10.2165/00019053-199915020-00003; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-0443.1993.tb00822.x; Schootman M, 2000, BRAIN INJURY, V14, P373; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tate PS, 1999, BRAIN INJURY, V13, P767; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WHO, 2004, GLOB STAT REP ALC 20; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winter, 1995, QUANTIFICATION DRUG; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Wyrwich KW, 2005, HEALTH SERV RES, V40, P577, DOI 10.1111/j.1475-6773.2005.0l374.x	45	27	27	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2458			BMC PUBLIC HEALTH	BMC Public Health	MAR 29	2010	10								171	10.1186/1471-2458-10-171			11	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	588ZY	WOS:000277114700001	20350327	Green Published, gold			2022-02-06	
J	Armstrong, E; Ferguson, A				Armstrong, Elizabeth; Ferguson, Alison			Language, meaning, context, and functional communication	APHASIOLOGY			English	Article						Aphasia; Linguistic context; Discourse; Conversation	TRAUMATIC BRAIN-INJURY; LINGUISTIC PERSPECTIVE; CONVERSATION ANALYSIS; APHASIC CONVERSATION; CONNECTED SPEECH; VERB RETRIEVAL; TURN-TAKING; DISCOURSE; ADULTS; ORGANIZATION	Background : In the 1970s Audrey Holland first emphasised the importance of ofunctional communicationo rather than olinguistic accuracyo for individuals with aphasia, noting that they could often ocommunicateo better than they could otalko. Her approach inspired many to explore why and how this could be so, and to look for avenues that tapped everyday communication skills, rather than the person with aphasia's performance on decontextualised language tests. Aims: This paper addresses the kinds of issues that are involved in ofunctional communicationo and specifically addresses the role of language in this endeavour. It aims to highlight language as a set of omeaning-making resourceso rather than as a set of syntactic/semantic constructs that exist outside of the communicator's everyday environment, that have to be mastered before being put into practice and that exist regardless of specific contexts. Main Contribution: The paper discusses language's role in social life in which speakers not only convey information to each other but also maintain social relationships through communication. A taxonomy of the different kinds of social meanings that speakers use to communicate is proposed for use in aphasia research, based on the work of Halliday (1994)those related to conveying ideas and experiences (e.g., vocabulary related to particular experiences, topics), those related to interpersonal relationships (e.g., speech acts, evaluative language devices, exchange structure), and those related to maintaining continuity and coherence across the speaker's discourse (e.g., cohesion). In addition, the systematic relationship existing between language and context and its clinical implications are explored. Conclusions: Language as information is only one form of language use. The paper argues for further consideration in aphasiology of the importance of multiple language uses and their relation to context. It is proposed that regarding language forms from these different perspectives of use will enable clinicians to further address the different aspects of communication required for meaningful and satisfying interactions in everyday social life.	[Armstrong, Elizabeth] Edith Cowan Univ, Perth, WA, Australia; [Ferguson, Alison] Univ Newcastle, Newcastle, NSW 2308, Australia		Armstrong, E (corresponding author), Edith Cowan Univ, Dept Psychol & Social Sci, Joondalup, WA 6027, Australia.	b.armstrong@ecu.edu.au		Armstrong, Elizabeth/0000-0003-4469-1117			Ahlsen E, 2005, CLIN LINGUIST PHONET, V19, P433, DOI 10.1080/02699200400027205; Ahlsen E, 2003, COPENHAGEN WORKING P, V3, P9; Armstrong E, 2005, APHASIOLOGY, V19, P285, DOI 10.1080/02687030444000750; Armstrong E, 2005, CLIN LINGUIST PHONET, V19, P137, DOI 10.1080/02699200410001698599; Armstrong E, 2001, APHASIOLOGY, V15, P1029, DOI 10.1080/02687040143000375; ARMSTRONG E, 2007, CONTINUING DISCOURSE, P383; ARMSTRONG EM, 1991, CLIN LINGUIST PHONET, V5, P39, DOI 10.3109/02699209108985501; Armstrong L, 2007, APHASIOLOGY, V21, P355, DOI 10.1080/02687030600911310; Avent JR, 2003, APHASIOLOGY, V17, P397, DOI 10.1080/02687030244000743; Bastiaanse R, 1998, APHASIOLOGY, V12, P951, DOI 10.1080/02687039808249463; Beeke S, 2008, CLIN LINGUIST PHONET, V22, P317, DOI 10.1080/02699200801918911; Beeke S, 2007, APHASIOLOGY, V21, P256, DOI 10.1080/02687030600911344; Beeke Suzanne, 2007, Seminars in Speech and Language, V28, P136, DOI 10.1055/s-2007-970571; Bird H, 1996, J NEUROLINGUIST, V9, P187, DOI 10.1016/0911-6044(96)00006-1; Borod JC, 2000, NEUROPSYCHOLOGY, V14, P112, DOI 10.1037/0894-4105.14.1.112; Breedin SD, 1998, BRAIN LANG, V63, P1, DOI 10.1006/brln.1997.1923; Butt D., 2000, USING FUNCTIONAL GRA; CARAMAZZA A, 1990, CORTEX, V26, P95, DOI 10.1016/S0010-9452(13)80077-9; Cherney LR, 2008, AM J SPEECH-LANG PAT, V17, P19, DOI 10.1044/1058-0360(2008/003); COELHO CA, 1994, CLIN APHASIOL, V22, P145; Doyle PJ, 2000, APHASIOLOGY, V14, P537, DOI 10.1080/026870300401306; Dronkers NF, 1998, J NEUROLINGUIST, V11, P179, DOI 10.1016/S0911-6044(98)00012-8; Drummond SS, 1995, J NEUROLINGUIST, V9, P47, DOI 10.1016/0911-6044(95)00005-4; Eggins S., 2004, ANAL CASUAL CONVERSA; Ellis C, 2005, J REHABIL RES DEV, V42, P737, DOI 10.1682/JRRD.2005.02.0026; Fairclough Norman., 2003, NALYSING DISCOURSE T; Ferguson A, 1998, APHASIOLOGY, V12, P1007, DOI 10.1080/02687039808249466; Ferguson A, 2002, J COMMUN DISORD, V35, P11, DOI 10.1016/S0021-9924(01)00071-5; FERGUSON A, 1992, J NEUROLINGUIST, V7, P277, DOI 10.1016/0911-6044(92)90019-S; FERGUSON A, 1994, APHASIOLOGY, V8, P143, DOI 10.1080/02687039408248647; GLINDEMANN R, 1995, TREATMENT APHASIA TH, P90; GOODWIN C, 1995, RES LANG SOC INTERAC, V28, P233, DOI 10.1207/s15327973rlsi2803_4; Goodwin C., 2003, CONVERSATION BRAIN D; Halliday M., 2004, INTRO FUNCTIONAL GRA; Halliday M. K., 1976, COHESION ENGLISH; Halliday Michael Alexander K., 2004, INTRO FUNCTIONAL GRA; Halliday Michael Alexander Kirkwood, 1989, LANGUAGE CONTEXT TEX; Herbert R, 2008, APHASIOLOGY, V22, P184, DOI 10.1080/02687030701262613; HILLIS AE, 1991, BRAIN, V114, P2081, DOI 10.1093/brain/114.5.2081; Holland A., 1982, CLIN APH P C, P345; Holland A., 1980, COMMUNICATIVE ABILIT; Holland A., 1979, RATIONALE ADULT APHA, P167; HOLLAND AL, 1982, J SPEECH HEAR DISORD, V47, P50, DOI 10.1044/jshd.4701.50; Hopper T, 2002, APHASIOLOGY, V16, P745, DOI 10.1080/02687030244000059; Hunston Susan, 2000, EVALUATION TEXT AUTH; Jacobs B, 2004, DISABIL REHABIL, V26, P1231, DOI 10.1080/09638280412331280244; Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Kay J, 1996, APHASIOLOGY, V10, P159, DOI 10.1080/02687039608248403; Kim M, 2000, BRAIN LANG, V74, P1, DOI 10.1006/brln.2000.2315; Klippi A., 2003, CONVERSATION BRAIN D, P117; Laakso M, 1999, APHASIOLOGY, V13, P345, DOI 10.1080/026870399402136; Labov W., 1972, LANGUAGE INNER CITY; Lock S, 2001, INT J LANG COMM DIS, V36, P25, DOI 10.3109/13682820109177853; Martin J. R., 2003, WORKING DISCOURSE ME; Martin J.R, 1997, GENRE I SOCIAL PROCE, V3, P39; Martin James R., 2005, LANGUAGE EVALUATION; Martin N, 2008, APHASIA REHABILITATI; Mayer JF, 2003, APHASIOLOGY, V17, P481, DOI 10.1080/02687030344000148; Mortensen L, 2005, CLIN LINGUIST PHONET, V19, P227, DOI 10.1080/02699200410001698652; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Nickels L, 2002, APHASIOLOGY, V16, P935, DOI 10.1080/02687030244000563; Nickels L., 2002, COGNITIVE NEUROPSYCH; Oelschlaeger ML, 1999, J SPEECH LANG HEAR R, V42, P636, DOI 10.1044/jslhr.4203.636; Perkins L, 1999, APHASIOLOGY, V13, P259, DOI 10.1080/026870399402091; Robson J, 2004, APHASIOLOGY, V18, P917, DOI 10.1080/02687030444000462; Rose S, 2008, IEEE NETWORK, V22, P22, DOI 10.1109/MNET.2008.4476067; SACKS H, 1974, LANGUAGE, V50, P696, DOI 10.2307/412243; Sarno M. T., 1969, FUNCTIONAL COMMUNICA; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SCHEGLOFF EA, 1977, LANGUAGE, V53, P361, DOI 10.2307/413107; Searle J. R., 1969, SPEECH ACTS ESSAY PH; Shadden B., 2007, GROUP TREATMENT NEUR, P111; SHAPIRO LP, 1993, BRAIN LANG, V45, P423, DOI 10.1006/brln.1993.1053; Sherratt S, 2007, APHASIOLOGY, V21, P320, DOI 10.1080/02687030600911401; Simmons-Mackie N, 2007, TOP LANG DISORD, V27, P5, DOI 10.1097/00011363-200701000-00003; Thompson CK, 2003, J SPEECH LANG HEAR R, V46, P591, DOI 10.1044/1092-4388(2003/047); Thompson G., 2000, EVALUATION TEXT AUTH, P1; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Ulatowska H, 2006, BRAIN LANG, V99, P61, DOI 10.1016/j.bandl.2006.06.040; Whitworth A., 1997, CONVERSATION ANAL PR; Wilcox M. J., 1977, CLIN APHASIOLOGY C P, P166; Youmans G, 2005, APHASIOLOGY, V19, P435, DOI 10.1080/02687030444000877	85	27	27	0	23	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology		2010	24	4					480	496	PII 921463867	10.1080/02687030902775157			17	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	598RU	WOS:000277856700005		Green Published			2022-02-06	
J	Erickson, SJ; Montague, EQ; Gerstle, MA				Erickson, Sarah J.; Montague, Erica Q.; Gerstle, Melissa A.			Health-related quality of life in children with moderate-to-severe traumatic brain injury	DEVELOPMENTAL NEUROREHABILITATION			English	Article						children; adolescents; traumatic brain injury; health-related quality of life	GENERIC CORE SCALES; BASIC ISSUES; ADOLESCENTS; RELIABILITY; VALIDITY; RECOMMENDATIONS; PEDSQL(TM); CANCER; MODULE	Objective: To investigate health-related quality of life (HRQOL) in a sample of ethnically diverse children with traumatic brain injury (TBI). Methods: Twenty children with moderate-severe TBI and their parents were recruited from a TBI clinic at a paediatric rehabilitation hospital. Children's self-reported HRQOL was assessed with the Pediatric Quality of Life Inventory. Parents completed a parallel proxy measure. Results: Children reported significantly lower Psychosocial HRQOL compared to their Total HRQOL, driven largely by low School HRQOL scores. Compared to other paediatric populations, children with TBI reported lower or equivalent HRQOL. Compared with children's self-reports, parents reported even lower HRQOL for their children across primary domains, with fair-to-moderate convergence between informants. Conclusions: Results provide preliminary evidence that children who have suffered moderate-severe TBI experience relatively poor HRQOL, particularly in the School domain. Limited convergence between informants suggests that children and parents perceive HRQOL differently, with parents reporting lower HRQOL.	[Erickson, Sarah J.; Montague, Erica Q.; Gerstle, Melissa A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Erickson, SJ (corresponding author), Univ New Mexico, Dept Psychol, 1 UNM,MSC03 2220, Albuquerque, NM 87131 USA.	erickson@unm.edu	Erickson, Sarah/AAH-1620-2020	Erickson, Sarah/0000-0002-4863-0074			Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; Eiser C, 2003, CHILD CARE HLTH DEV, V29, P95, DOI 10.1046/j.1365-2214.2003.00318.x; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fennell EB, 2001, J CHILD NEUROL, V16, P58, DOI 10.1177/088307380101600110; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Ocampo S, 1997, OCCUP THER INT, V4, P161; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Ravens-Sieberer U, 2002, RESTOR NEUROL NEUROS, V20, P151; Souza Ligia Maria Do N, 2007, Dev Neurorehabil, V10, P35, DOI 10.1080/13638490600822239; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; TEASDALE G, 1974, LANCET, V2, P81; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni JW, 2002, ARTHRITIS RHEUM, V46, P714, DOI 10.1002/art.10095; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2005, DEV MED CHILD NEUROL, V47, P592, DOI 10.1017/S0012162205001179; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109	21	27	28	0	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1751-8423			DEV NEUROREHABIL	Dev. Neurorehabil.		2010	13	3					175	181		10.3109/17518420903479867			7	Clinical Neurology; Pediatrics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics; Rehabilitation	686LM	WOS:000284697800005	20450467				2022-02-06	
J	Gao, C; Wang, CL; Wu, P; Liu, Z; Liu, XZ				Gao Cheng; Wang Chunlei; Wu Pei; Liu Zhen; Liu Xiangzhen			Simvastatin activates Akt/glycogen synthase kinase-3 beta signal and inhibits caspase-3 activation after experimental subarachnoid hemorrhage	VASCULAR PHARMACOLOGY			English	Article						Subarachnoid hemorrhage; Acute brain injury; Akt/GSK3 beta; Simvastatin; Apoptosis	NITRIC-OXIDE SYNTHASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; PROTEIN-KINASE-B; CELL-DEATH; STATIN USE; AKT PHOSPHORYLATION; NEURONAL APOPTOSIS; DNA FRAGMENTATION; CYTOCHROME-C	This study was designed to explore the role of simvastatin and its effects on the Akt/GSK3 beta survival signal and apoptosis pathway after experimental subarachnoid hemorrhage (SAH). SAH was induced by blood injection into the cisterna magna in New Zealand white rabbits. Increased expression of phospho-Akt and phospho-GSK3 beta was observed in brain tissue after SAH. Apoptosis and related proteins, including P53, apoptosis-inducing factor (AIF). cytochrome C, and cleaved caspase-3, were also activated. Simvastatin, at both low dose (10 mg/kg) and high dose (40 mg/kg), further increased expression of phospho-Akt and phospho-GSK3 beta decreased activation of caspase-3, and inhibited apoptosis. Preserved blood-brain barrier and attenuated brain edema were observed following simvastatin treatment. In addition, the neuroprotective effects of simvastatin were blocked by wortmannin (2.5 mu g/kg/min), an irreversible PIK3 inhibitor. P53, AIF, and cytochrome C were not affected by simvastatin treatment. Findings from the present study suggest that simvastatin ameliorates acute brain injury after SAH. The potential mechanisms of action include activation of the Akt/GSK3 beta survival signal and inhibition of caspase-dependent apoptosis pathway. (C) 2009 Elsevier Inc. All rights reserved.	[Gao Cheng; Wang Chunlei; Wu Pei; Liu Zhen; Liu Xiangzhen] Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 1, Harbin, Peoples R China		Gao, C (corresponding author), Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 1, 23 Youzheng St, Harbin, Peoples R China.	doctorgaocheng@yahoo.com.cn; wangchunlei@163.com; wupei001@163.com; liuzhen8028@163.com; liuxzhen001@yahoo.com.cn	Gao, C/B-6388-2009	Gao, Cheng/0000-0002-8867-1591	Youth Special Foundation of Heilongjiang Province [QC07C100]; Special Found of The First Affiliated Hospital of Harbin Medical University [2007035]	This research was supported by the Youth Special Foundation of Heilongjiang Province to Gao C (No.QC07C100) and The Special Found of The First Affiliated Hospital of Harbin Medical University (No.2007035).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; Cahill J, 2007, NEUROSURGERY, V60, P531, DOI 10.1227/01.NEU.0000249287.99878.9B; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; ENDO S, 1988, STROKE, V19, P1420, DOI 10.1161/01.STR.19.11.1420; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Gabikian P, 2002, STROKE, V33, P2681, DOI 10.1161/01.STR.0000033931.62992.B1; Gao C, 2008, AUTON NEUROSCI-BASIC, V141, P22, DOI 10.1016/j.autneu.2008.04.007; Hetman M, 2000, J NEUROSCI, V20, P2567; Hutter BO, 2001, J NEUROSURG, V94, P241, DOI 10.3171/jns.2001.94.2.0241; Kramer AH, 2008, NEUROSURGERY, V62, P422, DOI 10.1227/01.neu.0000316009.19012.e3; Kusaka G, 2003, J NEUROSURG, V99, P383, DOI 10.3171/jns.2003.99.2.0383; Madonna R, 2005, J BIOL CHEM, V280, P13503, DOI 10.1074/jbc.M411859200; Matz PG, 2001, STROKE, V32, P506, DOI 10.1161/01.STR.32.2.506; Matz PG, 2000, STROKE, V31, P2450, DOI 10.1161/01.STR.31.10.2450; Matz PG, 2000, BRAIN RES, V858, P312, DOI 10.1016/S0006-8993(99)02454-3; McGirt MJ, 2009, J NEUROSURG, V110, P968, DOI 10.3171/2008.10.JNS08901; McGirt MJ, 2006, NEUROSURGERY, V58, P945, DOI 10.1227/01.NEU.0000210262.67628.7E; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; Miida T, 2007, PHARMACOL THERAPEUT, V113, P378, DOI 10.1016/j.pharmthera.2006.09.003; Nau R, 2002, BRAIN PATHOL, V12, P329; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ogungbo B, 2001, BRIT J NEUROSURG, V15, P388, DOI 10.1080/02688690120082387; Ostrowski RP, 2005, J CEREBR BLOOD F MET, V25, P554, DOI 10.1038/sj.jcbfm.9600048; Park S, 2004, STROKE, V35, P2412, DOI 10.1161/01.STR.0000141162.29864.e9; Parra A, 2005, NEUROSURGERY, V56, P476, DOI 10.1227/01.NEU.0000153925.96889.8A; Prunell GF, 2005, J NEUROSURG, V102, P1046, DOI 10.3171/jns.2005.102.6.1046; Sanada S, 2004, CIRCULATION, V110, P2143, DOI 10.1161/01.CIR.0000143830.59419.73; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Sillberg VAH, 2008, STROKE, V39, P2622, DOI 10.1161/STROKEAHA.107.508341; Sugawara T, 2008, J NEUROSCI RES, V86, P3635, DOI 10.1002/jnr.21807; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Tseng MY, 2006, NEUROSURG FOCUS, V21, pE10, DOI DOI 10.3171/F0C.2006.21.3.10; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Yu FS, 2005, NEUROBIOL DIS, V20, P491, DOI 10.1016/j.nbd.2005.04.004; Zhou ML, 2007, J NEUROSCI METH, V159, P318, DOI 10.1016/j.jneumeth.2006.07.026	42	27	28	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1537-1891	1879-3649		VASC PHARMACOL	Vasc. Pharmacol.	JAN-FEB	2010	52	1-2					77	83		10.1016/j.vph.2009.12.001			7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	563TR	WOS:000275157900010	20004738				2022-02-06	
J	Greve, KW; Bianchini, KJ; Etherton, JL; Meyers, JE; Curtis, KL; Ord, JS				Greve, Kevin W.; Bianchini, Kevin J.; Etherton, Joseph L.; Meyers, John E.; Curtis, Kelly L.; Ord, Jonathan S.			The Reliable Digit Span Test in Chronic Pain: Classification Accuracy in Detecting Malingered Pain-Related Disability	CLINICAL NEUROPSYCHOLOGIST			English	Article						Reliable digit span; Chronic pain; Cognition; Malingered pain-related disability; Criterion groups design; Symptom validity test; Response bias	TRAUMATIC BRAIN-INJURY; MMPI-2 VALIDITY SCALES; NEUROCOGNITIVE DYSFUNCTION; WAIS-III; INDICATORS; SPECIFICITY; SENSITIVITY; DEPRESSION	This study used criterion groups validation (known-groups design) to examine the classification accuracy of the Reliable Digit Span test (RDS) in a large group of chronic pain patients referred for psychological evaluation. The sample consisted of 612 patients classified into one of six groups based on evidence of malingered pain-related disability (MPRD): No-Incentive, Not MPRD; Incentive-Only, Not MPRD; Indeterminate; Possible MPRD; Probable MPRD; Definite MPRD. A total of 30 college student simulators were also included. Lower average RDS scores and higher rates of RDS failure were seen in patients classified as MPRD and in simulators. Consistent with previous literature in a variety of populations, RDS = 6 provided the most accurate differentiation between MPRD and non-MPRD pain patients. Clinical implications are discussed.	[Greve, Kevin W.; Bianchini, Kevin J.; Curtis, Kelly L.; Ord, Jonathan S.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Bianchini, Kevin J.; Etherton, Joseph L.; Curtis, Kelly L.] Jefferson Neurobehav Grp, Metairie, LA USA; [Etherton, Joseph L.] SW Texas State Univ, Dept Psychol, San Marcos, TX 78666 USA; [Meyers, John E.] Ctr Neurosci Orthoped & Spine, Dakota Dunes, SD USA		Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Bianchini K. J., 2004, J FORENSIC NEUROPSYC, V4, P65; Bianchini KJ, 2008, ASSESSMENT, V15, P435, DOI 10.1177/1073191108317341; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAN DIGIT RECOGN; Boone K.B., 2007, ASSESSMENT FEIGNED C; Butters N., 1980, ALCOHOLIC KORSAKOFFS; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Etherton J, 2005, ASSESSMENT, V12, P130, DOI 10.1177/1073191105274859; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Green P., 2005, GREENS WORD MEMORY T, Vrev. ed.; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2007, ASSESSMENT, V14, P12, DOI 10.1177/1073191106295095; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P850, DOI 10.1080/13854040802585055; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; IVERSON GL, 2001, J FORENSIC NEUROPSYC, V2, P19, DOI DOI 10.1300/J151v02n01_02; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2007, ASSESSMENT MALINGERE, P44; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J.A., 2007, ASSESSMENT MALINGERE, P131; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002	42	27	27	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	1					137	152	PII 915733575	10.1080/13854040902927546			16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535MK	WOS:000272972300011	19816837				2022-02-06	
J	Lew, HL; Weihing, J; Myers, PJ; Pogoda, TK; Goodrich, GL				Lew, Henry L.; Weihing, Jeffrey; Myers, Paula J.; Pogoda, Terri K.; Goodrich, Gregory L.			Dual sensory impairment (DSI) in traumatic brain injury (TBI) - An emerging interdisciplinary challenge	NEUROREHABILITATION			English	Article						Dual sensory impairment; DSI; auditory; hearing; visual; military; blast	CLOSED-HEAD-INJURY; INFORMATION-PROCESSING DEFICITS; LOW-VISION REHABILITATION; INTRACEREBRAL POTENTIALS; VISUAL-STIMULI; RARE TARGET; AUDITORY DYSFUNCTION; HEARING IMPAIRMENT; NOISE EXPOSURE; CONCUSSION	The present review characterizes dual sensory impairment (DSI) as co-existing auditory and visual deficits in TBI that can be peripherally or centrally based. Current research investigating DSI in the military population, along with applicable research which focuses on unimodal deficits, is considered. Due to the heterogenous nature of TBI lesions, an important challenge that the clinician faces is ruling out the influence of multiple sensory deficits and/or the influence of cognitive processes on diagnosis and rehabilitation of the patient. Treatment options for DSI involve remediation of the sensory deficits via existing sensory aids or training exercises.	[Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, DVBIC, Richmond, VA 23219 USA; [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Dept PM&R, Richmond, VA 23219 USA; [Lew, Henry L.] Harvard Univ, Sch Med, Dept PM&R, Boston, MA USA; [Weihing, Jeffrey; Pogoda, Terri K.] VA Boston Healthcare Syst, TBI Res Ctr, Boston, MA USA; [Myers, Paula J.] James A Haley Vet Hosp, Audiol Serv, Tampa, FL 33612 USA; [Pogoda, Terri K.] Boston Healthcare Syst, VA, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA; [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Western Blind Rehabil Ctr, Palo Alto, CA USA		Lew, HL (corresponding author), Virginia Commonwealth Univ, Sch Med, DVBIC, 730 E Broad St, Richmond, VA 23219 USA.	hlew@dvbic.org	Goodrich, Gregory L./AAF-7184-2019; Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780			*AM SPEECH LANG HE, AUD PROC DIS; American Speech-Language-Hearing Association, PREF PRACT PATT PROF; Attias J., 2005, Journal of Basic and Clinical Physiology and Pharmacology, V16, P117; Bamiou DE, 2007, BRAIN RES REV, V56, P170, DOI 10.1016/j.brainresrev.2007.07.003; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; Bellis TJ, 2008, BRAIN COGNITION, V66, P280, DOI 10.1016/j.bandc.2007.09.006; Bergemalm PO, 2001, ACTA OTO-LARYNGOL, V121, P724, DOI 10.1080/00016480152583674; BERGMAN M, 1987, EAR HEARING, V8, P87, DOI 10.1097/00003446-198704000-00005; Bertone A, 2007, J CLIN EXP NEUROPSYC, V29, P467, DOI 10.1080/13803390600770793; Bouwmeester L, 2007, J NEUROL NEUROSUR PS, V78, P555, DOI 10.1136/jnnp.2006.103853; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Cacace Anthony T, 2005, Am J Audiol, V14, P112, DOI 10.1044/1059-0889(2005/012); Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; CHANDLER D, 2006, ASHA LEADER, V11, P9; Chermak GD, 2007, HDB CENTRAL AUDITORY, V2; Chisolm Theresa Hnath, 2007, Trends Amplif, V11, P73, DOI 10.1177/1084713807300879; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; COCKERHAM G, 2009, J REHABILIT IN PRESS; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Drake M E Jr, 1996, Electromyogr Clin Neurophysiol, V36, P457; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Duncan CC, 2003, PSYCHOPHYSIOLOGY, V40, P45, DOI 10.1111/1469-8986.00006; Dutton GN, 2003, EYE, V17, P289, DOI 10.1038/sj.eye.6700344; Duvdevany A, 2007, INT J AUDIOL, V46, P119, DOI 10.1080/14992020600937402; Fligor BJ, 2002, ARCH PHYS MED REHAB, V83, P141, DOI 10.1053/apmr.2002.26813; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Gaetz M, 2000, BRAIN INJURY, V14, P815; Giorgi RG, 2009, OPTOMETRY VISION SCI, V86, P492, DOI 10.1097/OPX.0b013e31819f9e4d; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; GRANICK S, 1976, J GERONTOL, V31, P434, DOI 10.1093/geronj/31.4.434; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P229, DOI 10.1016/0013-4694(95)98475-N; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Isaki E, 2000, BRAIN INJURY, V14, P441; Jordan Nikki N., 2009, Seminars in Hearing, V30, P28, DOI 10.1055/s-0028-1111104; KOONS P, EYE BRAIN IN PRESS; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2007, J CLIN NEUROPHYSIOL, V24, P398, DOI 10.1097/WNP.0b013e318150694b; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027; Marshall RS, 2009, NEUROLOGIST, V15, P185, DOI 10.1097/NRL.0b013e3181942894; McBride D, 2001, SCAND AUDIOL, V30, P106, DOI 10.1080/010503901300112211; McFarland DJ, 1997, AUDIOLOGY, V36, P249; MCFARLAND DJ, 1995, PSYCHOL RES-PSYCH FO, V57, P80; McFarland DJ, 1998, J SPEECH LANG HEAR R, V41, P300, DOI 10.1044/jslhr.4102.300; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; MUSIEK FE, 2007, HDB CENTRAL AUDITORY, V1; Musiek Frank E, 2004, J Am Acad Audiol, V15, P117, DOI 10.3766/jaaa.15.2.3; Myers Paula J., 2009, Seminars in Hearing, V30, P5, DOI 10.1055/s-0028-1111103; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Putter-Katz Hanna, 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P301; Rappaport M, 1990, J Neuropsychiatry Clin Neurosci, V2, P399; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Riggs RV, 2007, AM J PHYS MED REHAB, V86, P853, DOI 10.1097/PHM.0b013e318151f907; Schuett S, 2008, NEUROPSYCHOLOGIA, V46, P2445, DOI 10.1016/j.neuropsychologia.2008.04.016; Schuett S, 2009, NEUROPSYCHOLOGIA, V47, P733, DOI 10.1016/j.neuropsychologia.2008.12.004; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Smith SL, 2008, J REHABIL RES DEV, V45, P597, DOI 10.1682/JRRD.2007.02.0023; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; SOUSTIEL JF, 1995, BRAIN INJURY, V9, P805, DOI 10.3109/02699059509008236; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tay T, 2006, GERONTOLOGY, V52, P386, DOI 10.1159/000095129; TEUFERTAUTREY S, 2004, HEARING HLTH, V20, P20; Thach AB, 2008, OPHTHALMOLOGY, V115, P377, DOI 10.1016/j.ophtha.2007.04.032; THOMAS PD, 1983, J GERONTOL, V38, P321, DOI 10.1093/geronj/38.3.321; *US GOV ACC OFF, 2008, GAO08276; Valentijn SAM, 2005, J AM GERIATR SOC, V53, P374, DOI 10.1111/j.1532-5415.2005.53152.x; van Boxtel MPJ, 2000, J CLIN EXP NEUROPSYC, V22, P147, DOI 10.1076/1380-3395(200002)22:1;1-8;FT147; Voyer D, 2003, BRAIN COGNITION, V53, P393, DOI 10.1016/S0278-2626(03)00152-0; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Weihing J., 2007, AUDITORY PROCESSING; WEIHING J, J AM ACAD AUDI UNPUB; WEXLER B, 1980, NEUROPSYCHOLOGIA, V28, P71; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; YOUNG S, 2008, HOME HEALTHCARE NURS, V26, P472	87	27	27	1	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	3					213	222		10.3233/NRE-2010-0557			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300005	20448311				2022-02-06	
J	Makri, G; Lavdas, AA; Katsimpardi, L; Charneau, P; Thomaidou, D; Matsas, R				Makri, Georgia; Lavdas, Alexandros A.; Katsimpardi, Lida; Charneau, Pierre; Thomaidou, Dimitra; Matsas, Rebecca			Transplantation of Embryonic Neural Stem/Precursor Cells Overexpressing BM88/Cend1 Enhances the Generation of Neuronal Cells in the Injured Mouse Cortex	STEM CELLS			English	Article						Neuronal differentiation; Traumatic brain injury; Motor cortex; Neurosphere cultures; Lentiviral vectors; Brain repair	ADULT-RAT BRAIN; SPINAL-CORD-INJURY; EPIDERMAL-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; IN-VITRO MODEL; STEM-CELLS; REACTIVE ASTROCYTES; PRECURSOR CELLS; PROGENITOR CELLS; GLIAL SCAR	The intrinsic inability of the central nervous system to efficiently repair traumatic injuries renders transplantation of neural stem/precursor cells (NPCs) a promising approach towards repair of brain lesions. In this study, NPCs derived from embryonic day 14.5 mouse cortex were genetically modified via transduction with a lentiviral vector to overexpress the neuronal lineage-specific regulator BM88/Cend1 that coordinates cell cycle exit and differentiation of neuronal precursors. BM88/Cend1-overexpressing NPCs exhibiting enhanced differentiation into neurons in vitro were transplanted in a mouse model of acute cortical injury and analyzed in comparison with control NPCs. Immunohistochemical analysis revealed that a smaller proportion of BM88/Cend1-overexpressing NPCs, as compared with control NPCs, expressed the neural stem cell marker nestin 1 day after transplantation, while the percentage of nestin-positive cells was significantly reduced thereafter in both types of cells, being almost extinct 1 week post-grafting. Both types of cells did not proliferate up to 4 weeks in vivo, thus minimizing the risk of tumorigenesis. In comparison with control NPCs, Cend1-overexpressing NPCs generated more neurons and less glial cells 1 month after transplantation in the lesioned cortex whereas the majority of graft-derived neurons were identified as GABAergic interneurons. Furthermore, transplantation of Cend1-overexpressing NPCs resulted in a marked reduction of astrogliosis around the lesioned area as compared to grafts of control NPCs. Our results suggest that transplantation of Cend1-overexpressing NPCs exerts beneficial effects on tissue regeneration by enhancing the number of generated neurons and restricting the formation of astroglial scar, in a mouse model of cortical brain injury. STEM CELLS 2010; 28: 127	[Makri, Georgia; Lavdas, Alexandros A.; Katsimpardi, Lida; Thomaidou, Dimitra; Matsas, Rebecca] Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, Athens 11521, Greece; [Charneau, Pierre] Inst Pasteur, Grp Mol Virol & Vectorol, F-75724 Paris 15, France		Thomaidou, D (corresponding author), Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, 127 Vassilissis Sofias Ave, Athens 11521, Greece.	thomaidou@pasteur.gr; rmatsa@pasteur.gr	Lavdas, Alexandros Alpha./H-3353-2019; CHARNEAU, Pierre/M-1565-2017	Lavdas, Alexandros Alpha./0000-0002-4206-6724; CHARNEAU, Pierre/0000-0003-1184-5773	Hellenic General Secretariat for Research and TechnologyGreek Ministry of Development-GSRT [YB-11, YB26]; Institut Pasteur Paris Grand Programme Horizontal on Stem Cells	This work was supported by the Hellenic General Secretariat for Research and Technology EPAN Grants YB-11 and YB26 and the Institut Pasteur Paris Grand Programme Horizontal on Stem Cells. We thank Dr. M. Gaitanou for providing af. nity purified anti-BM88/Cend1 antibody, Dr. E. Siapati for help with qPCR, and Drs F. Stylianopoulou and I. Kazanis for introducing us to the methodology of brain trauma. L. K. is currently affiliated with Harvard Stem Cell Institute, Harvard University, 7 Divinity Avenue, Sherman Fairchild B-09, Cambridge, MA 02138, USA.	AGULLO L, 1995, BRAIN RES, V686, P160, DOI 10.1016/0006-8993(95)00486-A; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Antony JM, 2004, NAT NEUROSCI, V7, P1088, DOI 10.1038/nn1319; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Bernreuther C, 2006, J NEUROSCI, V26, P11532, DOI 10.1523/JNEUROSCI.2688-06.2006; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Dayer AG, 2007, BRAIN, V130, P2962, DOI 10.1093/brain/awm200; Einstein O, 2006, EXP NEUROL, V198, P275, DOI 10.1016/j.expneurol.2005.11.007; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Fricker-Gates RA, 2002, J NEUROSCI, V22, P4045, DOI 10.1523/JNEUROSCI.22-10-04045.2002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gaillard A, 2007, NAT NEUROSCI, V10, P1294, DOI 10.1038/nn1970; Georgopoulou N, 2006, J BIOL CHEM, V281, P33606, DOI 10.1074/jbc.M602689200; Glaser T, 2007, STEM CELLS, V25, P3016, DOI 10.1634/stemcells.2007-0218; Gritti A, 1999, J NEUROSCI, V19, P3287; Hargus G, 2008, STEM CELLS, V26, P1973, DOI 10.1634/stemcells.2007-0929; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Katsimpardi L, 2008, STEM CELLS, V26, P1796, DOI 10.1634/stemcells.2007-0921; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; Kirik D, 2003, TRENDS NEUROSCI, V26, P386, DOI 10.1016/S0166-2236(03)00164-4; Koutmani Y, 2004, EUR J NEUROSCI, V20, P2509, DOI 10.1111/j.1460-9568.2004.03724.x; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Magavi Sanjay S P, 2002, Methods Mol Biol, V198, P283; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Masgrau R, 2009, NEUROPHARMACOLOGY, V56, P598, DOI 10.1016/j.neuropharm.2008.10.015; McKay R, 2000, NAT MED, V6, P747, DOI 10.1038/77468; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Neufeld AH, 2003, NEUROSCIENTIST, V9, P485, DOI 10.1177/1073858403253460; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Parmar M, 2002, MOL CELL NEUROSCI, V21, P645, DOI 10.1006/mcne.2002.1204; PATSAVOUDI E, 1995, J NEUROSCI RES, V40, P506, DOI 10.1002/jnr.490400410; Pluchino S, 2008, J NEUROL SCI, V265, P105, DOI 10.1016/j.jns.2007.07.020; Politis PK, 2007, P NATL ACAD SCI USA, V104, P17861, DOI 10.1073/pnas.0610973104; Politis PK, 2007, GENE EXPR PATTERNS, V7, P165, DOI 10.1016/j.modgep.2006.06.007; Salmon P, 2007, CURR PROTOC HUM GENE, DOI DOI 10.1002/0471142905.HG0808S52; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Tang BL, 2007, CELL MOL NEUROBIOL, V27, P75, DOI 10.1007/s10571-006-9119-8; Tom VJ, 2004, J NEUROSCI, V24, P6531, DOI 10.1523/JNEUROSCI.0994-04.2004; Tuszynski MH, 2007, NAT NEUROSCI, V10, P1229, DOI 10.1038/nn1007-1229; Vitry S, 2001, MOL CELL NEUROSCI, V17, P983, DOI 10.1006/mcne.2001.0987; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	56	27	31	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	JAN	2010	28	1					127	139		10.1002/stem.258			13	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	555GJ	WOS:000274496600017	19911428	Bronze			2022-02-06	
J	Morgan, AT; Mageandran, SD; Mei, C				Morgan, A. T.; Mageandran, S-D.; Mei, C.			Incidence and clinical presentation of dysarthria and dysphagia in the acute setting following paediatric traumatic brain injury	CHILD CARE HEALTH AND DEVELOPMENT			English	Article						dysarthria; dysphagia; paediatric; speech language pathology; traumatic brain injury	EMERGENCY-MEDICINE RESEARCH; INSTRUMENTAL ANALYSIS; CHILDHOOD; CHILDREN; SPEECH; ELECTROPALATOGRAPHY; DYNAMICS; RECORDS; MOTOR	Background A lack of data on dysarthria and dysphagia outcomes for children following traumatic brain injury (TBI) limits our clinical evidence base, and poses daily challenges for the speech language pathologist (SLP) managing this group. The present study aimed to examine dysarthria and dysphagia incidence and the clinical presentation of children with these disorders in the acute phase following TBI. Methods Incidence and characteristics were determined via a comprehensive retrospective medical chart review of children consecutively referred to a tertiary paediatric hospital over an 8-year period. Cases (n = 22 dysarthria, n = 72 dysphagia) and matched controls were compared across ancillary variables (e.g. age, severity of TBI, motor impairment). Results Incidence across the entire cohort was low [i.e. dysarthria (1.2%, 22/1895), dysphagia (3.8%, 72/1895)], but was markedly higher for the sub-category of children with severe TBI [e.g. dysphagia (76%, 63/83)]. Speech deficits were reported across respiration, phonation, resonance, articulation and prosody. Swallowing deficits included reduced lip closure, delayed swallow initiation, wet voice and coughing. Language and swallowing deficits were often co-morbid with dysarthria. Motor impairment was frequently co-morbid with both dysarthria and dysphagia. Cases had longer periods of hospitalization, ventilation and supplementary feeding compared with controls. Conclusion Despite the low incidence of dysarthria and dysphagia across the entire TBI cohort, this sub-group may place longer-term burden on SLP services, having prolonged periods of ventilation, extended periods of hospitalization and a complex co-morbid clinical presentation compared with controls. The prevalence of co-morbid communication and swallowing impairments suggests a need for integrated rather than single discipline (i.e. dysphagia stream only) SLP services.	[Morgan, A. T.; Mageandran, S-D.; Mei, C.] Murdoch Childrens Res Inst, Language & Literacy Grp, Melbourne, Vic, Australia; [Morgan, A. T.; Mei, C.] Royal Childrens Hosp, Speech Pathol Dept, Parkville, Vic, Australia; [Morgan, A. T.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Morgan, A. T.; Mageandran, S-D.] La Trobe Univ, Melbourne, Vic, Australia		Morgan, AT (corresponding author), 50 Flemington Rd, Parkville, Vic 3052, Australia.	angela.morgan@mcri.edu.au	Morgan, Angela/J-5235-2017	Morgan, Angela/0000-0003-1147-7405; Mei, Cristina/0000-0002-6765-8064			Allison J J, 2000, Jt Comm J Qual Improv, V26, P115; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Burd R S, 2001, Respir Care Clin N Am, V7, P79, DOI 10.1016/S1078-5337(05)70024-1; Cahill LM, 2005, BRAIN INJURY, V19, P41, DOI 10.1080/02699050410001719961; Cahill LM, 2002, BRAIN INJURY, V16, P415, DOI 10.1080/02699050110119871; Cahill LM, 2003, J HEAD TRAUMA REHAB, V18, P268, DOI 10.1097/00001199-200305000-00005; Cahill LM, 2000, J MED SPEECH-LANG PA, V8, P347; CAHILL LM, 2001, ASIA PAC J SPEECH LA, V6, P33; CAHILL LM, 2001, TRAUMATIC BRAIN INJU, P121; Cheng HY, 2005, J MED SPEECH-LANG PA, V13, P15; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DANIELWHITNEY B, 1989, RECENT ADVANCES IN CLINICAL DYSARTHRIA, P129; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Humbert IA, 2007, DYSPHAGIA, V22, P266, DOI 10.1007/s00455-007-9080-9; Jansen ACM, 2005, J CLIN EPIDEMIOL, V58, P269, DOI 10.1016/j.jclinepi.2004.07.006; Kendall KA, 2004, DYSPHAGIA, V19, P65, DOI 10.1007/s00455-003-0500-1; LANDIS JR, 1977, BIOMETRICS, V33, P174; Morgan A, 2005, J MED SPEECH-LANG PA, V13, P109; Morgan A, 2004, J HEAD TRAUMA REHAB, V19, P226, DOI 10.1097/00001199-200405000-00004; Morgan A, 2004, J CLIN NEUROSCI, V11, P182, DOI 10.1016/S0967-5868(03)00195-4; Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Morgan A, 2003, J HEAD TRAUMA REHAB, V18, P239, DOI 10.1097/00001199-200305000-00002; Morgan A, 2002, J HEAD TRAUMA REHAB, V17, P220, DOI 10.1097/00001199-200206000-00004; Morgan AT, 2007, BRAIN INJURY, V21, P1183, DOI 10.1080/02699050701649573; Morgan AT, 2001, ASIA PACIFIC J SPEEC, V6, P9; Murdoch BE, 2003, BRAIN INJURY, V17, P79, DOI 10.1080/0269905021000010203; Murdoch BE, 1997, INT CONGR SER, V1146, P621; Saarinen T, 2006, CEREB CORTEX, V16, P212, DOI 10.1093/cercor/bhi099; SHOUMITRO D, 1999, BRAIN INJURY, V13, P369; Stierwalt JAG, 1996, DISORDERS MOTOR SPEE, P241; Theodoros D G, 1998, Pediatr Rehabil, V2, P107; To T, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-29; WARD EC, 2001, TRAUMATIC BRAIN INJU, P331; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021; Yawn BP, 2005, AM J EPIDEMIOL, V161, P974, DOI 10.1093/aje/kwi122	37	27	28	0	22	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0305-1862			CHILD CARE HLTH DEV	Child Care Health Dev.	JAN	2010	36	1					44	53		10.1111/j.1365-2214.2009.00961.x			10	Psychology, Developmental; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics	536BF	WOS:000273016400005	19320903				2022-02-06	
J	Naunheim, RS; Treaster, M; English, J; Casner, T; Chabot, R				Naunheim, Rosanne S.; Treaster, Matthew; English, Joy; Casner, Teya; Chabot, Robert			Use of brain electrical activity to quantify traumatic brain injury in the emergency department	BRAIN INJURY			English	Article						Electroencephalogram; traumatic brain injury	HEAD-INJURY; EEG; CONCUSSION; MILD; CANCER; QEEG	Primary objective: To validate a QEEG algorithm on traumatic brain injury in an Emergency Department (ED) setting. Methods and procedures: EEG data were collected from 105 patients with head injury (53 CT+ and 52 CT-) and 50 ED controls. Ten minutes of eyes closed resting EEG was collected from five frontal locations. A discriminant index of the probability of belonging to the TBI CT+ group was computed. Analysis of variance was computed comparing this index across the three patient groups. Using ROC curves, the p<0.05 confidence level was determined to compute sensitivity and specificity for the TBI CT+ population. Results: CT+ patients had a mean TBI discriminant index of 80.4, CT- patients 38.9 and controls 24.5; F = 70.2, p<0.0001. Sensitivity was 92.45% for the CT+ group and specificity was 90.00% for the control group. Conclusions: The TBI discriminant index appears to be a sensitive index of brain function. It may be used to suggest whether or not a patient presenting with altered mental status requires a CT scan. This index may aid in the triage of such patients in the ED. Such an easy to use, automated system may greatly enhance the clinical utility of EEG in the ED.	[Naunheim, Rosanne S.; Treaster, Matthew; English, Joy; Casner, Teya] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Chabot, Robert] NYU, Sch Med, Brain Res Labs, New York, NY USA		Naunheim, RS (corresponding author), Washington Univ, Sch Med, 660 So Euclid Box 8072, St Louis, MO 63110 USA.	naunheir@wusm.wustl.edu			BrainScope	Teya Casner, MPH, is funded by BrainScope and responsible for collection of data and data transfer to New York University. Robert Chabot is a scientific consultant to BrainScope, Co. However, BrainScope did not participate in the data analysis or writing of the manuscript.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Chen Xi-Ping, 2006, Neurosci Bull, V22, P165; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Gurdjian ES, 1975, IMPACT HEAD INJURY; JACQUIN A, 2010, IEEE T BIOM IN PRESS; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kondacs A, 1999, CLIN NEUROPHYSIOL, V110, P1708, DOI 10.1016/S1388-2457(99)00122-4; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Malloy, 1998, Semin Clin Neuropsychiatry, V3, P186; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Redberg RF, 2009, ARCH INTERN MED, V169, P2049, DOI 10.1001/archinternmed.2009.453; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; THIRUPPATHY SP, 2004, ACTA NEUOCHIRURGICA, V146, P1083; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	25	27	28	0	4	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	11					1324	1329		10.3109/02699052.2010.506862			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	667MY	WOS:000283198800006	20722504				2022-02-06	
J	Park, KD; Kim, DY; Lee, JK; Nam, HS; Park, YG				Park, Ki Deok; Kim, Deog Young; Lee, Ju Kang; Nam, Hee-Seung; Park, Yoon-Ghil			Anterior pituitary dysfunction in moderate-to-severe chronic traumatic brain injury patients and the influence on functional outcome	BRAIN INJURY			English	Article						Traumatic brain injury; pituitary dysfunction; BMI; functional outcome	GROWTH-HORMONE DEFICIENCY; GH	Objective: The objective of this study is to determine the prevalence of anterior pituitary dysfunction in moderate-to-severe chronic traumatic brain injury (TBI) patients. The investigation of a relationship between pituitary hormonal status and body mass index (BMI) in TBI patients by observing changes in BMI was conducted as well as an assessment of whether there is a difference in functional outcome related to anterior pituitary dysfunction in TBI patients. Methods: Forty-five TBI patients and 30 normal controls underwent a series of standard endocrine tests for anterior pituitary hormone function. It was studied whether changes in BMI correlated with anterior pituitary hormone levels. This study also compared changes in mini-mental state examination (K-MMSE) and functional independence measure (FIM) scores between patients in the hormone-sufficient and -deficient groups. Results: Anterior pituitary dysfunction was found in 31.1% of TBI patients. Changes in BMI statistically correlated with IGF-1 and basal cortisol levels. A meaningful difference was found between the hormone-sufficient and -deficient groups in light of the K-MMSE and FIM score gains. Conclusions: These findings strongly suggest that patients who suffer head trauma should be routinely tested for anterior pituitary hormone deficiency.	[Park, Ki Deok; Lee, Ju Kang] Gachon Univ Med & Sci, Gil Med Ctr, Dept Rehabil Med, Inchon, South Korea; [Kim, Deog Young] Yonsei Univ, Coll Med, Dept & Res Inst Rehabil Med, Seoul, South Korea; [Nam, Hee-Seung] Hallym Univ, Dept Rehabil Med, Coll Med, Seoul, South Korea; [Park, Yoon-Ghil] Yonsei Univ, Coll Med, Dept Rehabil Med & Rehabil, Inst Muscular Dis, Seoul, South Korea		Park, YG (corresponding author), 146-92 Dogok Dong, Seoul 135270, South Korea.	drtlc@yuhs.ac	kim, deog young/Q-8498-2019	Park, Yoon Ghil/0000-0001-9054-5300; kim, deog young/0000-0001-7622-6311			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha Amar, 2005, Am J Med, V118, P1416; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Elovic EP, 2004, J HEAD TRAUMA REHAB, V19, P184, DOI 10.1097/00001199-200403000-00010; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P541, DOI 10.1097/00001199-200311000-00008; FISHER DA, 1998, QUEST DIAGNOSTIC MAN, P312; GUNN IR, 1991, ANN CLIN BIOCHEM, V28, P327, DOI 10.1177/000456329102800402; HO KKY, 1995, METABOLISM, V44, P91, DOI 10.1016/0026-0495(95)90227-9; Kang Y., 1997, J KOREAN NEUROL ASS, V15, P300; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Toogood AA, 1998, CLIN ENDOCRINOL, V48, P569, DOI 10.1046/j.1365-2265.1998.00440.x; VELDHUIS JD, 1991, J CLIN ENDOCR METAB, V72, P51, DOI 10.1210/jcem-72-1-51	17	27	28	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	11					1330	1335		10.3109/02699052.2010.506863			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	667MY	WOS:000283198800007	20828231				2022-02-06	
J	Svoboda, E; Richards, B; Polsinelli, A; Guger, S				Svoboda, Eva; Richards, Brian; Polsinelli, Angelina; Guger, Sharon			A theory-driven training programme in the use of emerging commercial technology: Application to an adolescent with severe memory impairment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Cognitive rehabilitation; Memory intervention; Technology; Adolescent; Amnesia; Suprasellar germinoma	TRAUMATIC BRAIN-INJURY; PAGING SYSTEM; DEVELOPMENTAL AMNESIA; REHABILITATION; AID; CHILDREN; NEUROPAGE; PEOPLE; INDIVIDUALS; PATIENT	We describe a theory-driven memory intervention programme for training individuals with moderate to severe memory impairment in the use of emerging commercial technology. Here we demonstrate the application of the programme to training MK, an 18-year-old woman with severe memory impairment following treatment for a suprasellar germinoma, to autonomously use a smartphone to support her day-to-day memory. A within-subject A1B1A2B2 single-case experimental design was used to evaluate the impact of smartphone use on MK's real-life functioning. Following intervention MK showed increased confidence in dealing with memory-demanding situations and generalised smartphone use across all aspects of her life as quantified by several and varied ecologically valid measures including a phone call schedule, behaviour memory observations and questionnaires. Moreover the intervention also benefited her family as indicated by a sustained reduction in caregiver strain and an increase in reported quality of life. These findings suggest that individuals with severe memory impairment, particularly young adults with potentially life-long dependence on their families, are able to capitalise on emerging commercial technology to function more autonomously. The findings also suggest that the gap between individuals with severe memory impairment and potent emerging technology can be closed by provision of a theory-driven structured training programme.	[Svoboda, Eva; Richards, Brian; Polsinelli, Angelina] Baycrest, Cognit & Behav Hlth Program, Toronto, ON M6A 2E1, Canada; [Guger, Sharon] Hosp Sick Children, Toronto, ON M5G 1X8, Canada		Svoboda, E (corresponding author), Baycrest, Cognit & Behav Hlth Program, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	esvoboda@baycrest.org					BATT RC, 1990, AM J OCCUP THER, V44, P364, DOI 10.5014/ajot.44.4.364; Brizzolara D, 2003, CORTEX, V39, P605, DOI 10.1016/S0010-9452(08)70856-6; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Cullen C. N., 1976, NURS TIMES, V72, P45; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DePompei R, 2008, NEUROREHABILITATION, V23, P487; Emslie H, 2007, NEUROPSYCHOL REHABIL, V17, P567, DOI 10.1080/09602010701381933; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Gadian DG, 2000, BRAIN, V123, P499, DOI 10.1093/brain/123.3.499; Gentry T., 2008, AM J OCCUPATIONAL TH, V62, P8, DOI DOI 10.5014/AJOT.62.1.18; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Gioia GA, 2005, PSYCHOL ASSESS RESOU; GREENE J, 1999, LEARNING USE STAT TE; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; JOHNSON R, 1990, BRIT J CLIN PSYCHOL, V29, P437, DOI 10.1111/j.2044-8260.1990.tb00909.x; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; MCGUIRE BE, 1990, CLIN REHABIL, V4, P319, DOI DOI 10.1177/026921559000400412; Oddy M, 2004, NEUROPSYCHOL REHABIL, V14, P481, DOI 10.1080/09602010343000309; RICHARDS B, 1990, J CLIN EXPT NEUROPSY, V12, P395; Schacter DL, 1995, MEMORY DISTORTION, P1; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SOHLBERG MM, 2001, COGNITIVE REHABILITA, P194; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; Stull D., 1996, J CLIN GEROPSYCHOL, V2, P175; Svoboda E, 2009, J INT NEUROPSYCH SOC, V15, P629, DOI 10.1017/S1355617709090791; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Teasdale TW, 2009, J NEUROL NEUROSUR PS, V80, P781, DOI 10.1136/jnnp.2008.162966; Troyer AK, 2002, J GERONTOL B-PSYCHOL, V57, pP19, DOI 10.1093/geronb/57.1.P19; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; Tulving E., 1972, ORG MEMORY, P381; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Vargha-Khadem F, 2003, P NATL ACAD SCI USA, V100, P10055, DOI 10.1073/pnas.1233756100; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wilson BA, 2009, DEV NEUROREHABIL, V12, P421, DOI 10.3109/17518420903200573; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	55	27	27	0	15	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	4					562	586	PII 921646372	10.1080/09602011003669918			25	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	622BT	WOS:000279634300005	20425664				2022-02-06	
J	Tasker, RC; Westland, AG; White, DK; Williams, GB				Tasker, Robert C.; Westland, Amber Gunn; White, Deborah K.; Williams, Guy B.			Corpus Callosum and Inferior Forebrain White Matter Microstructure Are Related to Functional Outcome from Raised Intracranial Pressure in Child Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Diffusion tensor imaging; Fractional anisotropy; Social interaction; Corpus callosum; Intracranial pressure	PEDIATRIC INTENSIVE-CARE; DIFFUSION-TENSOR MRI; CLOSED-HEAD INJURY; WALLERIAN DEGENERATION; WATER DIFFUSION; NEUROPSYCHOLOGICAL SEQUELAE; NEUROPSYCHOMETRIC TESTS; SEX-DIFFERENCES; ADOLESCENTS; ANISOTROPY	In severe paediatric traumatic brain injury (TBI), a common focus of treatment is raised intracranial pressure (ICP). We have previously reported frontal cerebral vulnerability with executive deficits from raised ICP in paediatric TBI. Now, using diffusion tensor imaging (DTI) in a different population, we have examined fractional anisotropy (FA), and mean, axial and radial diffusivity (MD, AD, RD) in 4 regions of the corpus callosum (CC) and in both inferior frontal regions. Our aim was to examine during the chronic phase of TBI whether the CC cross-sectional area correlated with regional DTI metrics of white matter microstructure, with global outcome ratings of function (Functional Independence Measure and Multiattribute Health Status Classification) and with performance in the Rey-Osterrieth Complex Figure (ROCF) test. We examined 33 paediatric TBI cases who were followed, on average, 4.9 years after severe injury. All cases had received mechanical ventilation during their acute treatment and, a priori, they were assigned to a non-ICP or a raised ICP group. Twenty-two participants had mainly right-sided injury at the time of acute ictus. The findings confirm that severe TBI in childhood, complicated by intracranial hypertension, results in CC vulnerability. In the chronic phase of recovery, it is reduced in the cross-sectional area, it is more compact and thinned, and the anterior region is disproportionately small. Late after raised ICP, we have also found that individuals exhibit regional microstructural abnormality with combined reduced FA and increased MD, AD and RD. Smaller size and such microstructural changes in the anterior CC were associated with similar right-sided (rather than left-sided) frontal microstructural changes in the ICP group. Taken together, this evidence points to an interaction between raised ICP-related brain tissue perturbation and focal frontal extracallosal injury, leading to anterior CC regional vulnerability, most likely wallerian degeneration. At long-term follow-up, this lack of white matter integrity in the anterior CC is correlated with functional outcome, particularly in aspects of social interaction and the copy component of the ROCF test, which suggests that the CC-to-forebrain function warrants further study in chronic TBI. Copyright (C) 2010 S. Karger AG, Basel	[Tasker, Robert C.] Univ Cambridge, Sch Clin, Addenbrookes Hosp, Dept Paediat,Paediat Intens Care Unit, Cambridge CB2 2QQ, England; [Tasker, Robert C.; Westland, Amber Gunn] Univ Cambridge, Sch Clin Med, Dept Paediat, Cambridge CB2 2QQ, England; [Williams, Guy B.] Univ Cambridge, Sch Clin Med, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England		Tasker, RC (corresponding author), Univ Cambridge, Sch Clin, Addenbrookes Hosp, Dept Paediat,Paediat Intens Care Unit, Box 116,Hills Rd, Cambridge CB2 2QQ, England.	rct31@cam.ac.uk	Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390]; Evelyn Trust; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0001237, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	We wish to thank the patients and families who participated in this study, and the staff in the Department of Paediatrics and radiographers at the Wolfson Brain Imaging Centre. The Medical Research Council (G9439390) and the Evelyn Trust supported this study.	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; ALLEN LS, 1991, J NEUROSCI, V11, P933; Barkovich AJ, 2000, AM J NEURORADIOL, V21, P1099; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; Beebe DW, 2004, APPL NEUROPSYCHOL, V11, P91, DOI 10.1207/s15324826an1102_4; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Braga LW, 2007, J CHILD NEUROL, V22, P1084, DOI 10.1177/0883073807306246; Butt AM, 2000, J NEUROSCI RES, V59, P477, DOI 10.1002/(SICI)1097-4547(20000215)59:4<477::AID-JNR2>3.0.CO;2-J; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; *CTR FUNCT ASS RES, 1991, GUID US FUNCT IND ME; *CTR FUNCT ASS RES, 1990, GUID US UN SET MED R; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; GEMKE RJBJ, 1995, ARCH DIS CHILD, V73, P196, DOI 10.1136/adc.73.3.196; Gemke RJBJ, 1996, J CLIN EPIDEMIOL, V49, P327, DOI 10.1016/0895-4356(95)00528-5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Giorgio A, 2008, NEUROIMAGE, V39, P52, DOI 10.1016/j.neuroimage.2007.07.043; Glenn OA, 2003, J MAGN RESON IMAGING, V18, P641, DOI 10.1002/jmri.10420; Green HAL, 2002, STROKE, V33, P1517, DOI 10.1161/01.STR.0000016973.80180.7B; Gupta RK, 2006, J MAGN RESON IMAGING, V24, P549, DOI 10.1002/jmri.20677; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hasan KM, 2009, BRAIN RES, V1249, P91, DOI 10.1016/j.brainres.2008.10.026; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinoshita Y, 1999, ENVIRON RES, V80, P348, DOI 10.1006/enrs.1998.3935; KOLB B, 1990, FUNDAMENTALS HUMAN N, P838; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Morriss MC, 1999, NEURORADIOLOGY, V41, P929, DOI 10.1007/s002340050869; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Pandya DN., 1986, 2 HEMISPHERES ONE BR, P47; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pizzini FB, 2010, BRAIN RES, V1312, P10, DOI 10.1016/j.brainres.2009.11.030; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Qiu DQ, 2008, NEUROIMAGE, V41, P223, DOI 10.1016/j.neuroimage.2008.02.023; Rajapakse JC, 1996, BRAIN DEV-JPN, V18, P379, DOI 10.1016/0387-7604(96)00034-4; RAUCH RA, 1994, BEHAV BRAIN RES, V64, P65, DOI 10.1016/0166-4328(94)90119-8; Robertson Charlene M. T., 2001, Pediatr Crit Care Med, V2, P145, DOI 10.1097/00130478-200104000-00009; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; SCHAEFER GB, 1990, J CHILD NEUROL, V5, P127, DOI 10.1177/088307389000500211; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Slawik H, 2009, J NEUROTRAUM, V26, P1891, DOI 10.1089/neu.2009.0942; Somerville J, 2000, J CLIN EXP NEUROPSYC, V22, P613, DOI 10.1076/1380-3395(200010)22:5;1-9;FT613; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Sperle PA, 1997, AM J OCCUP THER, V51, P35, DOI 10.5014/ajot.51.1.35; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Thomalla G, 2005, J NEUROL NEUROSUR PS, V76, P266, DOI 10.1136/jnnp.2004.046375; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; Ulug AM, 2002, DEVELOPMENTAL SCI, V5, P286, DOI 10.1111/1467-7687.t01-1-00005; Verger K, 2001, BRAIN INJURY, V15, P211; Virta A, 1999, MAGN RESON IMAGING, V17, P1121, DOI 10.1016/S0730-725X(99)00048-X; Waller, 1850, PHILOS T R SOC LOND, VI, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021]; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WIMBERGER DM, 1995, J COMPUT ASSIST TOMO, V19, P28, DOI 10.1097/00004728-199501000-00005; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799	71	27	27	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					374	384		10.1159/000316806			11	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900005	20829579				2022-02-06	
J	Chen, ZY; Tortella, FC; Dave, JR; Marshall, VS; Clarke, DL; Sing, G; Du, F; Lu, XCM				Chen, Zhiyong; Tortella, Frank C.; Dave, Jitendra R.; Marshall, Vivienne S.; Clarke, Diana L.; Sing, George; Du, Fu; Lu, X. -C. May			Human Amnion-Derived Multipotent Progenitor Cell Treatment Alleviates Traumatic Brain Injury-Induced Axonal Degeneration	JOURNAL OF NEUROTRAUMA			English	Article						axon degeneration; human amnion; penetrating ballistic-like brain injury; progenitor cells; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MARROW STROMAL CELLS; EMBRYONIC STEM-CELLS; EPITHELIAL-CELLS; RAT MODEL; PRECURSOR CELLS; SPINAL-CORD; TRANSPLANTATION; NEURONS; NEUROGENESIS	To identify a viable cell source with potential neuroprotective effects, we studied amnion-derived multipotent progenitor (AMP) cells in a rat model of penetrating ballistic-like brain injury (PBBI). AMP cells were labeled with fluorescent dye PKH26 and injected in rats immediately following right hemispheric PBBI or sham PBBI surgery by ipsilateral i.c.v. administration. At 2 weeks post-injury, severe necrosis developed along the PBBI tract and axonal degeneration was prominent along the corpus callosum (cc) and in the ipsilateral thalamus. Injected AMP cells first entered the subventricular zone (SVZ) in both sham and PBBI rats. Further AMP cell migration along the cc only occurred in PBBI animals. No significant difference in injury volume was observed across all treatment groups. In contrast, treatment with AMP cells significantly attenuated axonal degeneration in both the thalamus and the cc. Interestingly, PKH26-labeled AMP cells were detected only in the SVZ and the cc (in parallel with the axonal degeneration), but not in the thalamus. None of the labeled AMP cells appeared to express neural differentiation, as evidenced by the lack of double labeling with nestin, S-100, GFAP, and MAP-2 immunostaining. In conclusion, AMP cell migration was specifically induced by PBBI and requires SVZ homing, yet the neuroprotective effect of intracerebral ventrical treatment using AMP cells was not limited to the area where the cells were present. This suggests that the attenuation of the secondary brain injury following PBBI was likely to be mediated by mechanisms other than cell replacement, possibly through delivery or sustained secretion of neurotrophic factors.	[Chen, Zhiyong; Tortella, Frank C.; Dave, Jitendra R.; Lu, X. -C. May] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Marshall, Vivienne S.; Clarke, Diana L.; Sing, George] Stemnion Inc, Pittsburgh, PA USA; [Du, Fu] FD NeuroTechnol Inc, Ellicott City, MD USA		Chen, ZY (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Zhiyong.chen@amedd.army.mil	Dave, Jitendra R/A-8940-2011				Bantubungi K, 2008, MOL CELL NEUROSCI, V37, P454, DOI 10.1016/j.mcn.2007.11.001; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Ben Menachem-Zidon O, 2008, NEUROPSYCHOPHARMACOL, V33, P2251, DOI 10.1038/sj.npp.1301606; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; CDC, 1999, TRAUM BRAIN INJ US R; DUNNETT SB, 1994, J NEUROL, V242, pS43, DOI 10.1007/BF00939242; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Hentze H, 2007, TRENDS BIOTECHNOL, V25, P24, DOI 10.1016/j.tibtech.2006.10.010; HernitGrant CS, 1996, EXP NEUROL, V139, P131, DOI 10.1006/exnr.1996.0088; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Janardhan Vallabh, 2004, Curr Cardiol Rep, V6, P117, DOI 10.1007/s11886-004-0009-8; Kakishita K, 2000, EXP NEUROL, V165, P27, DOI 10.1006/exnr.2000.7449; Kakishita K, 2003, BRAIN RES, V980, P48, DOI 10.1016/S0006-8993(03)02875-0; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kong XY, 2008, BRAIN RES, V1205, P108, DOI 10.1016/j.brainres.2008.02.040; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood U, 2004, RADIOLOGY, V233, P625, DOI 10.1148/radiol.2333041190; McDonald JW, 2004, J NEUROTRAUM, V21, P383, DOI 10.1089/089771504323004539; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Pierret C, 2007, STEM CELLS DEV, V16, P1017, DOI 10.1089/scd.2007.0012; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Sakuragawa N, 1996, NEUROSCI LETT, V209, P9, DOI 10.1016/0304-3940(96)12599-4; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7; Snyder E Y, 1997, Adv Neurol, V72, P121; SOTELO C, 1991, TRENDS NEUROSCI, V14, P350, DOI 10.1016/0166-2236(91)90161-M; Steed David L, 2008, Eplasty, V8, pe18; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAKAHASHI K, 1970, Development Growth and Differentiation, V12, P65; Uchida S, 2000, J NEUROSCI RES, V62, P585, DOI 10.1002/1097-4547(20001115)62:4<585::AID-JNR13>3.0.CO;2-U; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	38	27	27	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1987	1997		10.1089/neu.2008.0863			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600014	19886807				2022-02-06	
J	Beauchamp, MH; Anderson, VA; Catroppa, C; Maller, JJ; Godfrey, C; Rosenfeld, JV; Kean, M				Beauchamp, Miriam H.; Anderson, Vicki A.; Catroppa, Cathy; Maller, Jerome J.; Godfrey, Celia; Rosenfeld, Jeffery V.; Kean, Michael			Implications of Reduced Callosal Area for Social Skills after Severe Traumatic Brain Injury in Children	JOURNAL OF NEUROTRAUMA			English	Article						behavior; magnetic resonance imaging; pediatric brain injury; recovery; traumatic brain injury	CLOSED-HEAD-INJURY; HUMAN CORPUS-CALLOSUM; INTERHEMISPHERIC COOPERATION; PROCESSING DEFICITS; EARLY-CHILDHOOD; SEX-DIFFERENCES; AUTISM; MRI; AGENESIS; RECOVERY	The corpus callosum has been shown to be particularly vulnerable to the effects of traumatic brain injury (TBI) in childhood, and severe injury frequently results in a smaller corpus callosum post-injury. However, the long-term effects of TBI on the integrity of the callosum, as well as the potential functional significance of callosal injury are poorly understood. Some studies suggest the corpus callosum may be involved in social skills, which are often reduced following TBI. In this study, callosal size was investigated in 37 individuals 10 years post-childhood TBI, and its relationship with social competence was examined. The results indicate that individuals who sustain severe TBI in childhood display reduced callosal size 10 years post-injury. In addition, callosal size correlated significantly with social skills, suggesting that callosal atrophy may be related to poorer social skills after TBI. These findings highlight the persistence of callosal abnormalities, which may be a result of interrupted neural development after childhood TBI. The results further underscore the potential importance of the corpus callosum for social competence after TBI.	[Beauchamp, Miriam H.; Anderson, Vicki A.; Catroppa, Cathy; Godfrey, Celia; Kean, Michael] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Beauchamp, Miriam H.; Anderson, Vicki A.; Catroppa, Cathy] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia; [Beauchamp, Miriam H.; Anderson, Vicki A.; Catroppa, Cathy; Godfrey, Celia; Kean, Michael] Royal Childrens Hosp, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffery V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffery V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia		Beauchamp, MH (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	miriam.beauchamp@mcri.edu.au	Rosenfeld, Jeffrey V/B-7249-2011; Maller, Jerome J/H-4963-2014; Catroppa, Cathy/AAX-9458-2021	Maller, Jerome J/0000-0003-4685-1508; Catroppa, Cathy/0000-0002-9750-0436	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [284518]	This work was supported by the National Health and Medical Research Council ( project grant no. 284518).	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Alexander AL, 2007, NEUROIMAGE, V34, P61, DOI 10.1016/j.neuroimage.2006.08.032; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Badaruddin DH, 2007, CHILD PSYCHIAT HUM D, V38, P287, DOI 10.1007/s10578-007-0065-6; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Bedell J. R., 1997, HDB COMMUNICATION PR; Belmonte MK, 2004, J NEUROSCI, V24, P9228, DOI 10.1523/JNEUROSCI.3340-04.2004; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Boger-Megiddo I, 2006, J AUTISM DEV DISORD, V36, P733, DOI 10.1007/s10803-006-0121-2; Brambilla P, 2003, BRAIN RES BULL, V61, P557, DOI 10.1016/j.brainresbull.2003.06.001; Brown WS, 2005, NEUROPSYCHOLOGIA, V43, P906, DOI 10.1016/j.neuropsychologia.2004.09.008; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Daniel A., 1983, POWER PRIVILEGE PRES; Doron KW, 2008, CORTEX, V44, P1023, DOI 10.1016/j.cortex.2008.03.007; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Geschwind DH, 2007, CURR OPIN NEUROBIOL, V17, P103, DOI 10.1016/j.conb.2007.01.009; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Gresham FM., 1990, SOCIAL SKILLS RATING; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hill EL, 2003, PHILOS T R SOC B, V358, P281, DOI 10.1098/rstb.2002.1209; Hrdlicka M, 2008, NEUROENDOCRINOL LETT, V29, P281; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Paul LK, 2004, ARCH CLIN NEUROPSYCH, V19, P215, DOI 10.1016/S0887-6177(03)00024-6; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; Paul LK, 2006, INT J PSYCHOPHYSIOL, V61, P47, DOI 10.1016/j.ijpsycho.2005.10.017; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Raine A, 2003, ARCH GEN PSYCHIAT, V60, P1134, DOI 10.1001/archpsyc.60.11.1134; Reynolds CR., 1992, BEHAV ASSESSMENT SYS; Schmitz C, 2008, NEUROPATH APPL NEURO, V34, P4, DOI 10.1111/j.1365-2990.2007.00872.x; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Talairach J, 1993, REFERENTIALLY ORIENT; Tamietto M, 2007, NEUROPSYCHOLOGIA, V45, P836, DOI 10.1016/j.neuropsychologia.2006.08.012; Tamietto M, 2006, EXP BRAIN RES, V171, P389, DOI 10.1007/s00221-005-0279-4; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Verger K, 2001, BRAIN INJURY, V15, P211; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1989, WECHSLER PRESCHOOL P; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wildgruber D, 2005, NEUROIMAGE, V24, P1233, DOI 10.1016/j.neuroimage.2004.10.034; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	73	27	27	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2009	26	10					1645	1654		10.1089/neu.2009.0916			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	507CT	WOS:000270829200003	19413462				2022-02-06	
J	McCarthy, MC; Moncrief, H; Sands, JM; Markert, RJ; Hall, LC; Wenker, IC; Anderson, HL; Ekeh, AP; Walusimbi, MS; Woods, RJ; Saxe, JM; Tchorz, KM				McCarthy, Mary C.; Moncrief, Hugh; Sands, Jean M.; Markert, Ronald J.; Hall, Lawrence C.; Wenker, Ian C.; Anderson, Harry L., III; Ekeh, A. Peter; Walusimbi, Mbaga S.; Woods, Randy J.; Saxe, Jonathan M.; Tchorz, Kathryn M.			Neurologic outcomes with cerebral oxygen monitoring in traumatic brain injury	SURGERY			English	Article							TISSUE OXYGENATION; HEAD-INJURY	Background. Optimizing cerebral oxygenation is advocated to Improve outcome in head-injured patients. The purpose of this study was to compare outcomes in brain-injured patients treated with 2 types of monitors. Methods. Patients with traumatic brain injury and a Glasgow Coma Scale score<8 were identified 071 admission. A polarographic cerebral oxygen/pressure monitor (Licox) or fiberoptic intracranial pressure monitor (Camino) was inserted tin. evidence-based algorithm treatment was Implemented Elements from the prehospital and emergency department records and the first 10 days of intensive care unit (ICU) care were collected Glasgow Outcome Scores (GOS) were determined every 3 months after discharge. Results. Over a 3-year period, 145 patient, were entered into the study; 81 patients In. the Lucox group and 64 patients in the Camino group. Mortality, hospital length of stay, and ICU length of stay were equivalent In the 2 groups. More patients In the Lucox group achieved a moderate/recovered GOS at 3 months than in the Camino Group (79% vs 61%, P = 09) Conclusion.. Three-month GOS revealed a clinically meaningful 18% benefit in patients undergoing cerebial oxygen monitoring and optimization. Six-month outcomes were also better Unfortunately, these important differences did-not reach significance Continued study of the benefits of cerebral oxygen. monitoring is warranted. (Surgery 2009:146:585-91)	[Sands, Jean M.] Miami Valley Hosp, Clin Res Ctr, Dayton, OH 45409 USA; [Moncrief, Hugh] Neurosurg Inst Inc, Dayton, OH USA; [Hall, Lawrence C.] Radiol Phys Inc, Dayton, OH USA; [McCarthy, Mary C.; Anderson, Harry L., III; Ekeh, A. Peter; Walusimbi, Mbaga S.; Woods, Randy J.; Saxe, Jonathan M.; Tchorz, Kathryn M.] Wright State Univ, Sch Med, Div Trauma Crit Care & Emergency Gen Surg, Dept Surg, Dayton, OH USA; [Markert, Ronald J.] Wright State Univ, Sch Med, Dept Internal Med & Orthoped, Dayton, OH USA; Wright State Univ, Sch Med, Dept Emergency Med, Dayton, OH USA		McCarthy, MC (corresponding author), Miami Valley Hosp, Clin Res Ctr, 1 Wyoming St,Suite 7000, Dayton, OH 45409 USA.		Wenker, Ian/AAD-5957-2022	Wenker, Ian/0000-0002-0744-6510			DONG HK, 2006, NEUROCRIT CARE, V4, P83; Haitsma IK, 2007, PROG BRAIN RES, V161, P207, DOI 10.1016/S0079-6123(06)61014-5; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; SLICFEL MF, 2006, J NEUROSURG, V105, P568; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815	10	27	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	OCT	2009	146	4					585	591		10.1016/j.surg.2009.06.059			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	507OD	WOS:000270863100007	19789016				2022-02-06	
J	King, DA; Hume, PA; Milburn, P; Gianotti, S				King, D. A.; Hume, P. A.; Milburn, P.; Gianotti, S.			Rugby league injuries in New Zealand: a review of 8 years of Accident Compensation Corporation injury entitlement claims and costs	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS INJURIES; SEASONAL-CHANGE; FOOTBALL; PREVENTION; RATES	Aim: This paper provides an overview of the epidemiology of rugby league injuries and associated costs in New Zealand requiring medical treatment. Method: New Zealand national Accident Compensation Corporation injury data for the period 1999 to 2007 were searched for rugby league injury cases. Data were analysed by demographics, body region, nature/severity of injury, and medical procedure and costs. Results: A total of 5941 injury entitlement claims were recorded over the study period with a significant decrease observed in the injury rate between the 1999-2000 and 2002-2003 reporting years. The total cost of the injuries for the study period was $42 822 048 (equivalent to L15 916 072). The mean (SD) number of injury entitlement claims per year was 743 (271) and yearly cost was $5 352 760 (L1 989 880) ($2 485 535 (L923 994)). The knee was the most commonly reported injury site (225 per 1000 entitlement claims; $8 750 147 (L3 252 020)) and soft tissue injuries were the most common injury types (474 per 1000 entitlement claims; $17 324 214 (L6 438 599)). Accounting for only 1.8% of total injury entitlement claims, concussion/brain injuries accounted for 6.3% of injury entitlement costs and had the highest mean cost per claim ($25 347 (L9420)). The upper and lower arm recorded the highest mean injury site claim cost of $43 096 (L16 016) per claim. The 25-29 age group recorded 27.7% of total injury entitlement claims and 29.6% of total injury entitlement costs, which was slightly more than the 20-24 age group (27.3% claims; 24.7% costs). Nearly 15% of total moderate to serious injury entitlement claims and 20% of total costs were recorded from participants 35 years or older. Discussion: This study identified that the knee was the most common injury site and soft tissue injuries were the most common injury type requiring medical treatment, which is consistent with other international studies on rugby league epidemiology. This study also highlights that the rate of injury and the average age of injured rugby league players increased over time. The high cost of concussion/brain injuries is a cause for concern as it reflects the severity of the injuries. Conclusion: Injury prevention programmes for rugby league should focus on reducing the risk of concussion/brain injury and knee and soft tissue injury, and should target participants in the 20-30 years old age range. More longitudinal epidemiological studies with specific details on injury mechanisms and participation data are warranted to further identify the injury circumstances surrounding participation in rugby league activities.	[King, D. A.] Hutt Valley Dist Hlth Board, Emergency Dept, Lower Hutt, New Zealand; [King, D. A.; Hume, P. A.; Gianotti, S.] Auckland Univ Technol, Inst Sports & Recreat Res New Zealand, Sch Sport & Recreat, Fac Hlth & Environm Sci, Auckland, New Zealand; [Milburn, P.] Griffith Univ, Sch Physiotherapy & Exercise Sci, Gold Coast, Australia; [Gianotti, S.] Accid Compensat Corp, Wellington, New Zealand		King, DA (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	Douglas.King@huttvalleydhb.org.nz	Hume, Patria Anne/P-1084-2017; Hume, Patria/AAN-5514-2021	Hume, Patria Anne/0000-0003-1847-8128; Hume, Patria/0000-0003-1847-8128			Carter AF, 2008, J SCI MED SPORT, V11, P167, DOI 10.1016/j.jsams.2007.01.004; Estell J, 1995, Aust J Sci Med Sport, V27, P95; Gabbett TJ, 2008, J SCI MED SPORT, V11, P323, DOI 10.1016/j.jsams.2007.06.003; Gabbett TJ, 2004, SPORTS MED, V34, P849, DOI 10.2165/00007256-200434120-00004; Gabbett TJ, 2000, BRIT J SPORT MED, V34, P98, DOI 10.1136/bjsm.34.2.98; Gabbett TJ, 2003, BRIT J SPORT MED, V37, P36, DOI 10.1136/bjsm.37.1.36; Gabbett TJ, 2001, J SPORT SCI, V19, P341, DOI 10.1080/02640410152006117; Gianotti S, 2007, J SCI MED SPORT, V10, P436, DOI 10.1016/j.jsams.2006.10.006; GIBBS N, 1994, SPORTS MED, V18, P438, DOI 10.2165/00007256-199418060-00007; GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510; Gissane C, 2003, AM J SPORT MED, V31, P954, DOI 10.1177/03635465030310063501; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Hodgson L, 2006, CLIN J SPORT MED, V16, P305, DOI 10.1097/00042752-200607000-00004; King D, 2006, NZ J SPORTS MED, V34, P21; King D, 2007, NZ J SPORTS MED, V34, P18; King DA, 2006, J SCI MED SPORT, V9, P110, DOI 10.1016/j.jsams.2005.09.001; King DA, 2008, J SCI MED SPORT, V11, P562, DOI 10.1016/j.jsams.2007.04.011; KING DA, 2009, SPORTS MED IN PRESS; KING DA, 2007, INJURIES NZ BARTERCA; KING DA, 2009, NZ J SPORTS IN PRESS; KING DA, 2009, CLIN J SPOR IN PRESS; Lythe M, 1992, NZ J SPORTS MED, V20, P6; Mac Auley DC, 2001, INT J SPORTS MED, V22, P379; MEIR R, 1993, STRENGTH COND, V1, P11; MEIR R, 1993, STRENGTH COND, V1, P24; Meir RA, 1997, BRIT J SPORT MED, V31, P132, DOI 10.1136/bjsm.31.2.132; NORTON R, 1995, NZ J SPORTS MED, V22, P37; ORCHARD J, 2003, SPORTSLINK       SEP, P12; Orchard J., 2004, SPORT HLTH, V22, P11; Phillips LH, 1998, BRIT J SPORT MED, V32, P144, DOI 10.1136/bjsm.32.2.144; Phillips LH, 2000, BRIT J SPORT MED, V34, P133, DOI 10.1136/bjsm.34.2.133; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Raftery M., 1999, INCIDENCE INJURY JUN; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; *STAT NZ, 2006, STAT; Stevens Sean T, 2008, Res Sports Med, V16, P68, DOI 10.1080/15438620701879020; Twellaar M, 1996, AM J SPORT MED, V24, P528, DOI 10.1177/036354659602400419; WALKER RD, 1985, PRACTITIONER, V229, P205	38	27	27	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2009	43	8					595	602		10.1136/bjsm.2009.061481			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	480WN	WOS:000268767800010	19553223	Green Published			2022-02-06	
J	Hattori, N; Swan, M; Stobbe, GA; Uomoto, JM; Minoshima, S; Djang, D; Krishnananthan, R; Lewis, DH				Hattori, Naoya; Swan, Megan; Stobbe, Gary A.; Uomoto, Jay M.; Minoshima, Satoshi; Djang, David; Krishnananthan, Ruben; Lewis, David H.			Differential SPECT Activation Patterns Associated with PASAT Performance May Indicate Frontocerebellar Functional Dissociation in Chronic Mild Traumatic Brain Injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						traumatic brain injury; cognitive fatigue; SPECT; activation study; PASAT	SERIAL ADDITION TEST; WORKING-MEMORY; RECOVERY; MODERATE; DISEASE	Patients with mild traumatic brain injury (TBI) often complain of cognitive fatigue during the chronic recovery phase. The Paced Auditory Serial Addition Test (PASAT) is a complex psychologic measure that may demonstrate subtle deficiencies in higher cognitive functions. The purpose of this study was to investigate the brain activation of regional cerebral blood flow (rCBF) with PASAT in patients with mild TBI to explore mechanisms for the cognitive fatigue. Methods: Two groups consisting of 15 patients with mild TBI and 15 healthy control subjects underwent Tc-99m-ethylene cysteine dimer SPECT at rest and during PASAT on a separate day. Cortical rCBF was extracted using a 3-dimensional stereotactic surface projection and statistically analyzed to identify areas of activation, which were compared with PASAT performance scores. Results: Image analysis demonstrated a difference in the pattern of activation between patients with mild TBI and healthy control subjects. Healthy control subjects activated the superior temporal cortex (Brodmann area [BA] 22) bilaterally, the precentral gyrus (BA 9) on the left, and the precentral gyrus (BA 6) and cerebellum bilaterally. Patients with mild TBI demonstrated a larger area of supratentorial activation (BAs 9, 10, 13, and 46) but a smaller area of activation in the cerebellum, indicating frontocerebellar dissociation. Conclusion: Patients with mild TBI and cognitive fatigue demonstrated a different pattern of activation during PASAT. Frontocerebellar dissociation may explain cognitive impairment and cognitive fatigue in the chronic recovery phase of mild traumatic brain injury.	[Hattori, Naoya; Minoshima, Satoshi; Krishnananthan, Ruben; Lewis, David H.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA; [Swan, Megan] Seattle Pacific Univ, Dept Psychol, Seattle, WA 98119 USA; [Stobbe, Gary A.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; [Uomoto, Jay M.] VA Puget Sound Hlth Care Syst, Ctr Polytrauma Care, Dept Neuropsychol, Seattle, WA USA; [Djang, David] Seattle Nucl Med, Dept Nucl Med, Seattle, WA USA		Hattori, N (corresponding author), Univ Washington, Sch Med, Dept Radiol, Box 356113,1959 NE Pacific St, Seattle, WA 98195 USA.	nhattori@u.washington.edu	Lewis, David H/AAM-7997-2021; Hattori, Naoya/AAR-6405-2020; Hattori, Naoya/G-2298-2012; Uomoto, Jay/AAF-4809-2019	Lewis, David H/0000-0003-1927-1073; Minoshima, Satoshi/0000-0002-0043-3047			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM COLL RAD, 2007, ACR PRACT GUID PERF; Audenaert K, 2002, NUCL MED COMMUN, V23, P907, DOI 10.1097/00006231-200209000-00015; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Desmond JE, 2003, NEUROIMAGE, V19, P1510, DOI 10.1016/S1053-8119(03)00102-2; Fos L A, 2000, Appl Neuropsychol, V7, P140, DOI 10.1207/S15324826AN0703_4; Goethals I, 2005, PSYCHIAT RES-NEUROIM, V139, P31, DOI 10.1016/j.pscychresns.2004.09.007; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; HARRINGTON DE, 1993, ARCH PHYS MED REHAB, V74, P579, DOI 10.1016/0003-9993(93)90155-4; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LANE TJ, 1991, AM J MED, V91, P335, DOI 10.1016/0002-9343(91)90150-V; Lazeron RHC, 2003, J NEUROL SCI, V213, P29, DOI 10.1016/S0022-510X(03)00144-8; Lockwood AH, 2004, J INT NEUROPSYCH SOC, V10, P26, DOI 10.1017/S1355617740410145; Lombardi WJ, 2001, NEUROLOGY, V57, P785, DOI 10.1212/WNL.57.5.785; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; SHIFFRIN RM, 1984, PSYCHOL REV, V91, P269, DOI 10.1037/0033-295X.91.2.269; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289	28	27	27	0	3	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	JUL	2009	50	7					1054	1061		10.2967/jnumed.108.060368			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	529VO	WOS:000272547100015	19525460	Bronze			2022-02-06	
J	Gordan, W; Spivak-David, D; Adornato, V; Dale, B; Brougham, R; Georgeadis, AC; Gassaway, J				Gordan, Wendy; Spivak-David, Dana; Adornato, Viki; Dale, Beverly; Brougham, Rebecca; Georgeadis, Amy C.; Gassaway, Julie			SCIRehab Project Series: The Speech Language Pathology Taxonomy	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries, Rehabilitation, physical; Speech language pathology, Taxonomy; Practice-based evidence; Tracheostomy; Ventilator; Dysphagia; Apraxia; Dysarthria	SPINAL-CORD-INJURY; CLOSED HEAD-INJURY; COGNITIVE REHABILITATION; DYSFUNCTION; STROKE; RISK	Introduction: Outcomes research for speech language pathology (SLP) interventions for acute traumatic spinal cord injury (SCI) rehabilitation in the US is difficult because of the lack of a treatment classification system (taxonomy). Objective: To describe a taxonomy developed by speech language pathologists (SLPs) to examine the effects of SLP interventions on SCI rehabilitation outcomes. Methods: The SCIRehab study uses practice-based evidence, a rigorous observational methodology that examines treatment processes without specifying or requiring specific therapeutic interventions. Speech language pathology lead clinicians and researchers at 6 US SCI centers developed a detailed SLP taxonomy documentation process that is comprehensive of SLP interventions for patients with SCI. Results: The SLP taxonomy consists of 7 intervention categories that address deficits (speech production for patients with artificial airway, motor speech and voice, swallowing, cognitive-communication, and communication) and the associated exercises and tasks that patients perform. Time is recorded for each category, and supplementary information focuses on cueing needs and family involvement that helps to describe and guide intervention selection. The SCIRehab project is enrolling 1,500 patients with acute traumatic SCI at 6 inpatient rehabilitation facilities. Conclusions: Speech language pathology taxonomy information is being captured for the SCIRehab patients who are referred for SLP services; this may be the first attempt to document the many details of the SLP rehabilitation process for patients with SCI in the US.	[Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA; [Gordan, Wendy] Craig Hosp, Englewood, CO USA; [Spivak-David, Dana] Mt Sinai Med Ctr, New York, NY 10029 USA; [Adornato, Viki] Carolinas Rehabil, Charlotte, NC USA; [Dale, Beverly] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Brougham, Rebecca] Shepherd Ctr, Atlanta, GA USA; [Georgeadis, Amy C.] Natl Rehabil Hosp, Washington, DC USA		Gassaway, J (corresponding author), Inst Clin Outcomes Res, 699 E S Temple, Salt Lake City, UT 84102 USA.	jgassaway@isisicor.com			National Institute on Disability and Rehabilitation Research (NIDRR); US Department of EducationUS Department of Education [H133A060103, H133N060005, H133N060027, H133N060028, H133A21943-16, H133N060009, H133N060014]	This work was supported in part by grants from the National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education Services, US Department of Education to Craig Hospital (grants #H133A060103 and #H133N060005), Mount Sinai School of Medicine (grant #H133N060027), National Rehabilitation Hospital (grant #H133N060028), Carolinas Rehabilitation (grant #H133A21943-16), Shepherd Center (#grant H133N060009), and Rehabilitation Institute of Chicago (grant #H133N060014).	Abel R, 2004, DYSPHAGIA, V19, P87, DOI 10.1007/s00455-003-0511-y; Ashley MJ, 1995, TRAUMATIC BRAIN INJU; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DAHLBERG C, 1997, TOP SPINAL CORD INJ, V2, P41; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; FOLKINS JW, 1990, J SPEECH HEAR DISORD, V55, P596, DOI 10.1044/jshd.5504.596; Frempong-Boadu A, 2002, J SPINAL DISORD TECH, V15, P362, DOI 10.1097/00024720-200210000-00004; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; Hatfield B, 2005, ARCH PHYS MED REHAB, V86, pS61, DOI 10.1016/j.apmr.2005.08.111; HOIT JD, 1990, J SPEECH HEAR RES, V33, P798, DOI 10.1044/jshr.3304.798; Holland A., 1984, LANGUAGE DISORDERS A; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; Logemann JA, 1998, EVALUATION TREATMENT; MacBean N, 2006, J MED SPEECH-LANG PA, V14, P167; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; MARTYNOV AI, 1997, KLIN MED MOSCOW, V12, P8; *NAT SPIN CORD INJ, 1999, ANN REP MOD SPIN COR; National Spinal Cord Injury Statistical Center, 2008, SPIN CORD INJ FACTS; PARENTE R., 1996, RETRAINING COGNITION; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Steudel W I, 1988, Acta Neurochir Suppl (Wien), V43, P85; UB Foundation Activities Inc., 2004, IRF PAI TRAIN MAN; Wenke RJ, 2008, BRAIN INJURY, V22, P339, DOI 10.1080/02699050801960987; Whitford DL, 2009, DIABETES CARE, V32, P251, DOI 10.2337/dc08-1200; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; Winslow CP, 1999, AM J OTOLARYNG, V20, P16, DOI 10.1016/S0196-0709(99)90046-7; Wolfe DL, 2004, TOP SPINAL CORD INJ, V10, P41	31	27	27	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	JUN	2009	32	3					307	318		10.1080/10790268.2009.11760784			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	474NF	WOS:000268290100011	19810632	Green Published			2022-02-06	
J	Matsushige, T; Nakaoka, M; Kiya, K; Takeda, T; Kurisu, K				Matsushige, Toshinori; Nakaoka, Mitsuo; Kiya, Katsuzo; Takeda, Tetsuji; Kurisu, Kaoru			Cerebral Sinovenous Thrombosis After Closed Head Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injury; Sinus thrombosis; Cerebral venous infarction; Edema; Diffusion weighted imaging	DURAL SINUS THROMBOSIS; WEIGHTED MAGNETIC-RESONANCE; EMPTY DELTA SIGN; VENOUS THROMBOSIS; MR; PROGNOSIS; RECANALIZATION; THROMBOLYSIS; ANGIOPLASTY; HEMATOMA	Background: Cerebral sinovenous thrombosis (CSVT) after closed head injury is an uncommon but potentially serious complication. The aim of this study was to determine whether diffusion weighted imaging (DWI) provide predictive information regarding prognosis. Methods: We retrospectively reviewed a series of 11 patients with CSVT after closed head injury. Each patient underwent computed tomography and magnetic resonance imaging within 24 hours of onset of symptoms, including DWI, magnetic resonance venography, and conventional sequences. Apparent diffusion coefficient (ADC) values were measured in seven regions of interest in 7 of 11 patients using DWI. Follow-up imaging and clinical outcome were assessed 6 months or later after initial presentation. Results. The most affected sinus was the posterior portion of the superior sagittal sinus. There was a mean time interval of 4.1 days between subsequent venous stroke and the initial insult. Brain edema improved in 6 of 11 patients on follow-up imaging. Six of 11 patients recovered successfully, although high or mixed DWI intensity associated with moderately decreased ADC (0.53-0.57 x 10(-3) mm(2)/s). Two other patients with hematomas developed venous infarction, despite mixed DWI with heterogeneous ADC value (0.55-1.11 X 10(-3) nun/s). The other three patients, with high DWI and strongly decreased ADC values (0.26-0.27 X 10(-3) mm(2)/s), developed severe brain atrophy after superior sagittal sinus thrombosis.. Conclusions. The prospective cutoff point of ADC value may be higher in CSVT after head injury with traumatic hematoma. The territory of venous infarction was found to be larger in infants after treatment failure. In infants, CSVT can demonstrate initially cytotoxic brain edema, which is reversible with anticoagulation therapy.	[Matsushige, Toshinori; Kiya, Katsuzo] Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Minami Ku, Hiroshima 7348551, Japan; [Nakaoka, Mitsuo] Matsue Red Cross Hosp, Dept Neurosurg, Matsue, Shimane, Japan; [Kiya, Katsuzo] Hiroshima Prefectural Hosp, Dept Neurosurg, Minami Ku, Hiroshima, Japan; [Takeda, Tetsuji] Ehime Prefectural Cent Hosp, Dept Neurosurg, Matsuyama, Ehime, Japan		Matsushige, T (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	teruteru728@yahoo.co.jp					BOUSSER MG, 1985, STROKE, V16, P199, DOI 10.1161/01.STR.16.2.199; Canhao P, 2003, CEREBROVASC DIS, V15, P159, DOI 10.1159/000068833; Chahlavi A, 2004, J NEUROSURG, V101, P347, DOI 10.3171/jns.2004.101.2.0347; Chaloupka JC, 1999, NEUROSURGERY, V45, P650, DOI 10.1097/00006123-199909000-00045; Chu K, 2001, ARCH NEUROL-CHICAGO, V58, P1569, DOI 10.1001/archneur.58.10.1569; de Bruijn SFTM, 1999, STROKE, V30, P484, DOI 10.1161/01.STR.30.3.484; Ducreux D, 2001, AM J NEURORADIOL, V22, P261; Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26; Ferro JM, 2002, CEREBROVASC DIS, V13, P272, DOI 10.1159/000057855; Forbes KPN, 2001, AM J NEURORADIOL, V22, P450; HESSELBROCK R, 1985, NEUROSURGERY, V16, P825, DOI 10.1227/00006123-198506000-00017; Hinman JM, 2002, EUR J RADIOL, V41, P147, DOI 10.1016/S0720-048X(01)00365-5; Keller E, 1999, STROKE, V30, P1144, DOI 10.1161/01.STR.30.5.1144; Kim SY, 1997, AM J NEURORADIOL, V18, P639; Lee EJY, 2002, RADIOLOGY, V224, P788, DOI 10.1148/radiol.2243990978; Lovblad KO, 2000, NEURORADIOLOGY, V42, P728, DOI 10.1007/s002340000395; Lovblad KO, 2001, CEREBROVASC DIS, V11, P169, DOI 10.1159/000047634; Manzione J, 2000, AM J NEURORADIOL, V21, P68; Mullins ME, 2004, AM J NEURORADIOL, V25, P1666; Murphy KJ, 2000, NEUROSURGERY, V46, P497, DOI 10.1097/00006123-200002000-00048; Muthukumar N, 2004, J CLIN NEUROSCI, V11, P924, DOI 10.1016/j.jocn.2003.10.032; ONUMA T, 1995, J NEUROSURG, V82, P995, DOI 10.3171/jns.1995.82.6.0995; Owler BK, 2005, CHILD NERV SYST, V21, P262, DOI 10.1007/s00381-004-1014-3; Peeters E, 2001, AM J NEURORADIOL, V22, P1949; Rother J, 1996, J CEREBR BLOOD F MET, V16, P1353; Rottger C, 2005, NEUROSURGERY, V57, P573, DOI 10.1227/01.NEU.0000170438.13677.22; Stolz E, 2004, STROKE, V35, P544, DOI 10.1161/01.STR.0000112972.09096.65; Takitani K, 2002, PEDIATR INT, V44, P680, DOI 10.1046/j.1442-200X.2002.01620.x; TSAI FY, 1995, AM J NEURORADIOL, V16, P1021; VIRAPONGSE C, 1987, RADIOLOGY, V162, P779, DOI 10.1148/radiology.162.3.3809494; Wasay M, 2002, J NEUROIMAGING, V12, P267, DOI 10.1177/10528402012003009; Wasay M, 2001, STROKE, V32, P2310, DOI 10.1161/hs1001.096192; Yoshikawa T, 2002, NEURORADIOLOGY, V44, P481, DOI 10.1007/s00234-002-0772-4	33	27	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2009	66	6					1599	1604		10.1097/TA.0b013e3181a3a8e6			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	457PN	WOS:000266944500013	19509620				2022-02-06	
J	Ernst, WJ; Trice, AD; Gilbert, JL; Potts, H				Ernst, William J.; Trice, Ashton D.; Gilbert, Jennifer L.; Potts, Heather			Misconceptions About Traumatic Brain Injury and Recovery Among Nursing Students	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						healthcare; misconceptions; recovery; traumatic brain injury		Objective: To identify potential misconceptions that nursing students have regarding traumatic brain injury (TBI) and recovery, Design: Descriptive questionnaire. Setting: University. Main Measure: Thirty-item questionnaire addressing knowledge about TBI and recovery. Participants: One hundred eight undergraduate students, 65 in the prenursing program and 43 nursing majors. Results: In general, nursing students had a lower frequency of misconceptions than did university students in a prior study, and the more advanced nursing majors had a lower frequency of misconceptions than did the prenursing students. Substantial misconceptions did exist, though, especially concerning unconsciousness, amnesia, and recovery. Conclusions: Nursing students possess several misconceptions pertaining to TBI and recovery that have the potential to adversely affect assessment, treatment, and education of patients and family members. Education focusing on TBI and recovery should be included in the nursing curriculum and be a part of continuing education at the professional level.	[Ernst, William J.; Trice, Ashton D.] James Madison Univ, Dept Grad Psychol, Harrisonburg, VA 22807 USA; [Gilbert, Jennifer L.] Childrens Natl Med Ctr, Dept Psychiat Psychol, Washington, DC 20010 USA; [Potts, Heather] George Washington Univ, Grad Sch Educ & Human Dev, Washington, DC USA		Ernst, WJ (corresponding author), Neuropsychol Evaluat Serv, 495 Iron Bridge Rd,Ste 8, Freehold, NJ 07728 USA.	william-e@earthlink.net					Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Fletcher JM, 2000, SCI PRACT NEUROPSYCH, P25; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lucas J.A., 2006, CLIN NEUROPSYCHOLOGY, V2nd ed., P351; O'Jile JR., 1997, INT J REHABILITATION, V3, P61, DOI [10.1007/BF02766798, DOI 10.1007/BF02766798]; Semrud-Clikeman M, 2005, HDB SCH NEUROPSYCHOL; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	13	27	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					213	220		10.1097/HTR.0b013e3181a7ecd8			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800007	19461368				2022-02-06	
J	Kim, J; Shin, SD; Im, TH; Lee, KJ; Ko, SB; Park, JO; Ahn, KO; Song, KJ				Kim, Jaiyong; Shin, Sang Do; Im, Tai Ho; Lee, Kug Jong; Ko, Sang Back; Park, Ju Ok; Ahn, Ki Ok; Song, Kyoung Jun			Development and Validation of the Excess Mortality Ratio-adjusted Injury Severity Score Using the International Classification of Diseases 10th Edition	ACADEMIC EMERGENCY MEDICINE			English	Article						Injury Severity Score; excess mortality; International Classification of Diseases; validation study	MYOCARDIAL-INFARCTION; ADMINISTRATIVE DATA; 9TH REVISION; TRAUMA; DIAGNOSIS; SYSTEM; PREDICTORS; ACCURACY; TRISS; DEATH	This study aimed to develop and validate a new method for measuring injury severity, the excess mortality ratio-adjusted Injury Severity Score (EMR-ISS), using the International Classification of Diseases 10th Edition (ICD-10). An injury severity grade similar to the Abbreviated Injury Scale (AIS) was converted from the ICD-10 codes on the basis of quintiles of the EMR for each ICD-10 code. Like the New Injury Severity Score (NISS), the EMR-ISS was calculated from three maximum severity grades using data from the Korean National Injury Database. The EMR-ISS was then validated using the Hosmer-Lemeshow goodness-of-fit chi-square (HL chi-square, with lower values preferable), the area under the receiver operating characteristic curve (AUC-ROC), and the Pearson correlation coefficient to compare it with the International Classification of Diseases 9th Edition-based Injury Severity Score (ICISS). Nationwide hospital discharge abstract data (DAD) from stratified-sample general hospitals (n = 150) in 2004 were used for an external validation. The total number of study subjects was 29,282,531, with five subgroups of particular interest identified for further study: traumatic brain injury (TBI, n = 3,768,670), traumatic chest injury (TCI, n = 1,169,828), poisoning (n = 251,565), burns (n = 869,020), and DAD (n = 26,374). The HL chi-square was lower for EMR-ISS than for ICISS in all groups: 42,410.8 versus 55,721.9 in total injury, 7,139.6 versus 20,653.9 in TBI, 6,603.3 versus 4,531.8 in TCI, 2,741.2 versus 9,112.0 in poisoning, 764.4 versus 4,532.1 in burns, and 28.1 versus 49.4 in DAD. The AUC-ROC for death was greater for EMR-ISS than for ICISS: 0.920 versus 0.728 in total injury, 0.907 versus 0.898 in TBI, 0.675 versus 0.799 in TCI, 0.857 versus 0.900 in poisoning, 0.735 versus 0.682 in burns, and 0.850 versus 0.876 in DAD. The Pearson correlation coefficient between the two scores was -0.68 in total injury, -0.76 in TBI, -0.86 in TCI, -0.69 in poisoning, -0.58 in burns, and -0.75 in DAD. The EMR-ISS showed better calibration and discrimination power for prediction of death than the ICISS in most injury groups. The EMR-ISS appears to be a feasible tool for passive injury surveillance of large data sets, such as insurance data sets or community injury registries containing diagnosis codes. Additional further studies for external validation on prospectively collected data sets should be considered.	[Shin, Sang Do] Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea; [Kim, Jaiyong] Hallym Univ, Dept Social & Prevent Med, Coll Med, Gangwon Do, South Korea; [Im, Tai Ho] Hanyang Univ, Coll Med, Dept Emergency Med, Seoul 133791, South Korea; [Lee, Kug Jong] Ajou Univ Hosp, Dept Emergency Med & Trauma Surg, Kyonggi Do, South Korea; [Ko, Sang Back] Yonsei Univ, Wonju Coll Med, Dept Prevent Med, Gangwon Do, South Korea; [Park, Ju Ok] Jeju Natl Univ, Coll Med, Dept Emergency Med, Jeju Do, South Korea; [Ahn, Ki Ok] Seoul Fire Serv Acad, EMS Educ & Training Ctr, Seoul, South Korea; [Song, Kyoung Jun] Seoul Natl Univ, Borame Hosp, Dept Emergency Med, Seoul, South Korea		Shin, SD (corresponding author), Seoul Natl Univ, Coll Med, Dept Emergency Med, Seoul, South Korea.	shinsangdo@snuh.org	안, 기옥/L-5596-2019; Shin, Sang/J-5523-2012	안, 기옥/0000-0002-8446-3269; 	Korean Center for Disease Control and Prevention	This study was conducted by the Injury Statistics Working Group of Korea, which was composed on the basis of the convention for injury research among the Korean Society of Emergency Medicine, the Korean Society of Traumatology, the Korean Burn Society, and the Health Insurance Review Agency. This study was financially supported by the Korean Center for Disease Control and Prevention in 2006.	Ahn YS, 2004, INJURY PREV, V10, P199, DOI 10.1136/ip.2003.004895; Andel D, 2007, J BURN CARE RES, V28, P163, DOI 10.1097/BCR.0B013E31802C9E8F; *ASS ADV AUT MED, 1990, ABBR INJ SCAL 1990; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bilgin TE, 2005, TOXICOL IND HEALTH, V21, P141, DOI 10.1191/0748233705th222oa; Clark DE, 2006, INJURY PREV, V12, P111, DOI 10.1136/ip.2005.010058; Do Shin S, 2004, BURNS, V30, P820, DOI 10.1016/j.burns.2004.06.005; Ebrahim S, 2006, BMJ-BRIT MED J, V333, P22, DOI 10.1136/bmj.38855.610324.80; EICHELBERGER MR, 1989, ANN EMERG MED, V18, P939, DOI 10.1016/S0196-0644(89)80457-3; Gorelick MH, 2007, ACAD EMERG MED, V14, P646, DOI 10.1197/j.aem.2007.03.1357; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hannan EL, 1999, J TRAUMA, V47, P8, DOI 10.1097/00005373-199907000-00003; Harwood PJ, 2006, J TRAUMA, V60, P334, DOI 10.1097/01.ta.0000197148.86271.13; HAYS WL, 1998, STATISTICS, P484; Henderson T, 2006, MED CARE, V44, P1011, DOI 10.1097/01.mlr.0000228018.48783.34; Hosmer D, 1989, APPL LOGISTIC REGRES; Huang NC, 2006, CLIN TOXICOL, V44, P99, DOI 10.1080/15563650500514251; Hunt PA, 2006, INJURY, V37, P1, DOI 10.1016/j.injury.2005.02.014; Kim Y, 2003, J TRAUMA, V54, P775, DOI 10.1097/01.TA.0000028251.15629.1D; Kim Y, 2000, J TRAUMA, V48, P280, DOI 10.1097/00005373-200002000-00014; Lai DJ, 1996, AM J EPIDEMIOL, V143, P832; Langley J, 2006, INJURY PREV, V12, P58, DOI 10.1136/ip.2005.010173; Lavoie A, 2004, J TRAUMA, V56, P1312, DOI 10.1097/01.TA.0000075342.36072.EF; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; Meinow B, 2004, J GERONTOL B-PSYCHOL, V59, pS181, DOI 10.1093/geronb/59.3.S181; Odongua N, 2007, YONSEI MED J, V48, P192, DOI 10.3349/ymj.2007.48.2.192; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Park HK, 2007, INT J CLIN PRACT, V61, P1086, DOI 10.1111/j.1742-1241.2007.01345.x; Park JH, 2008, INT J CARDIOL, V128, P392, DOI 10.1016/j.ijcard.2007.04.114; Quan H, 2004, MED CARE, V42, P801, DOI 10.1097/01.mlr.0000132391.59713.0d; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Shin SD, 2004, J KOREAN MED SCI, V19, P186, DOI 10.3346/jkms.2004.19.2.186; Song YM, 2003, AM J EPIDEMIOL, V158, P479, DOI 10.1093/aje/kwg173; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Sungurtekin H, 2006, CLIN TOXICOL, V44, P121, DOI 10.1080/15563650500514350; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Virnig BA, 2001, ANNU REV PUBL HEALTH, V22, P213, DOI 10.1146/annurev.publhealth.22.1.213; World Health Organization, INT STAT CLASS DIS R; DISCUSSION DOCUMENT	40	27	27	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	MAY	2009	16	5					454	464		10.1111/j.1553-2712.2009.00412.x			11	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	438IE	WOS:000265548300014	19388920	Bronze			2022-02-06	
J	Makdissi, M				Makdissi, M.			Is the simple versus complex classification of concussion a valid and useful differentiation?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; PROFESSIONAL FOOTBALL; AGREEMENT STATEMENT; AUSTRALIAN RULES; NCAA CONCUSSION; SOCCER PLAYERS; HEAD-INJURY	Background: At the Second International Conference on Concussion in Sport, concussion was classified as "simple" or "complex" based largely on duration of clinical features. The purpose of the classification system was to assist clinicians in identifying higher grades of injury severity and guide injury management. The aim of the current paper is to review the validity and clinical usefulness of the simple versus complex classification system. Study design: Qualitative review of the literature on concussion in sport, with a focus on time course of clinical recovery and prognostic factors. Intervention: Pubmed, Medline and Sport Discus databases were reviewed. Fifty journal articles were included in the review. Results: Prospective studies support the recovery of symptoms, balance deficits and cognitive impairment in the majority of concussed athletes within 10 days of injury. However, clinical factors that predict higher grades of injury severity or poor outcome following concussion remain unclear. At present, concussion severity can only be accurately determined in retrospect after all clinical features have resolved. Conclusion: It is recommended that concussion in sport be considered as a single entity. Clinical factors that have demonstrated to be associated with longer duration of symptoms (for example, post-traumatic amnesia) or poor outcome (for example, repetitive head injury) may serve as "modifying" factors to assist the treating practitioner in identifying potential for higher grades of injury severity or adverse outcomes.	[Makdissi, M.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Makdissi, M.] Olymp Pk Sports Med Ctr, Melbourne, Vic, Australia		Makdissi, M (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	makdissi@unimelb.edu.au		makdissi, michael/0000-0003-0334-7133			*AM AC NEUR, 1997, 1997 AAN NAT PRESS C; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT, 1989, MILD HEAD INJURY, P257; Bland JM, 2002, BRIT MED J, V324, P606, DOI 10.1136/bmj.324.7337.606; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; TEASDALE G, 1974, LANCET, V2, P81; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	50	27	27	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I23	I27		10.1136/bjsm.2009.058206			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	450YO	WOS:000266438100004	19433420				2022-02-06	
J	Schmidt, B; Klingelhofer, J; Perkes, I; Czosnyka, M				Schmidt, Bernhard; Klingelhoefer, Juergen; Perkes, Iain; Czosnyka, Marek			Cerebral Autoregulatory Response Depends on the Direction of Change in Perfusion Pressure	JOURNAL OF NEUROTRAUMA			English	Article						cerebral autoregulation; cerebral blood flow; cerebral perfusion pressure; transcranial Doppler ultrasonography	BLOOD-PRESSURE; SPONTANEOUS FLUCTUATIONS; HEAD-INJURY; HUMANS; FLOW	The purpose of cerebral autoregulation is to keep cerebral blood flow constant during variations of cerebral perfusion pressure (CPP). Recently, the autoregulatory response was reported to be greater during arterial blood pressure (ABP) increase than during decrease following repeated induced changes in ABP in 14 brain-injured subjects. The goal of this study was to further investigate the asymmetry of autoregulation during spontaneous increases and decreases of CPP in a larger group of brain injury patients. Data recordings (N = 727) of CPP and cerebral blood flow velocity (CBFV) in 210 subjects with traumatic brain injury (TBI) were studied. Autoregulation was assessed using moving correlation indices (Mx) between CPP and CBFV. Periods of increasing and decreasing CPP were separately correlated to corresponding CBFV in order to assess autoregulatory responses to upward (upMx) and downward (downMx) changes of CPP. These correlation indices range from -1 to +1; negative or zero values indicate intact autoregulation, whereas positive values indicate impaired autoregulation. Only data with defined strong CPP variations were evaluated. Strong CPP variations were found in 84 recordings of 53 patients. On average (+/- SD) upMx was significantly lower than downMx (0.05 +/- 0.49 versus 0.14 +/- 0.54; p < 0.005). Despite this difference, upMx and downMx were strongly correlated with each other (R = 0.82; p < 0.001). In conclusion, the autoregulatory response was significantly greater during increase than during decrease in CPP. The results may indicate non-linear behavior of cerebral autoregulation.	[Schmidt, Bernhard; Klingelhoefer, Juergen] Chemnitz Med Ctr, Dept Neurol, D-09131 Chemnitz, Germany; [Perkes, Iain] Univ Cambridge, Dept Med, Div Anaesthesia, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Czosnyka, Marek] Addenbrookes Hosp, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England		Schmidt, B (corresponding author), Chemnitz Med Ctr, Dept Neurol, Dresdner Str 178, D-09131 Chemnitz, Germany.	B.Schmidt@skc.de	Perkes, Iain/J-7001-2017	Perkes, Iain/0000-0001-8028-9032	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390, G0001237] Funding Source: UKRI; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aaslid R, 2007, STROKE, V38, P1465, DOI 10.1161/STROKEAHA.106.473462; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; DIEHL RR, 1989, STROKE, V20, P1; Enevoldsen E, 1986, Acta Neurochir Suppl (Wien), V36, P133; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; ENEVOLDSEN EM, 1977, ACTA NEUROL SCAND, V56, P514; Giller CA, 2003, MED ENG PHYS, V25, P633, DOI 10.1016/S1350-4533(03)00028-6; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; LASSEN NA, 1974, CIRC RES, V34, P749, DOI 10.1161/01.RES.34.6.749; LUNDBERG N, 1960, ACTA PSYCHIATRICA  S, V149, P1; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Schmidt B, 2000, J NEUROSURG, V92, P793, DOI 10.3171/jns.2000.92.5.0793; SHIGEMORI M, 1989, Neurological Research, V11, P165; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; ZABOLOTNY W, 1994, INTRACRANIAL PRESSUR, V9, P439; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zhang R, 2000, AM J PHYSIOL-HEART C, V278, pH1848, DOI 10.1152/ajpheart.2000.278.6.H1848	22	27	30	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					651	656		10.1089/neu.2008.0784			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500001	19281414				2022-02-06	
J	Bonatti, E; Kuchukhidze, G; Zamarian, L; Trinka, E; Bodner, T; Benke, T; Delazer, M				Bonatti, Elisabeth; Kuchukhidze, Giorgi; Zamarian, Laura; Trinka, Eugen; Bodner, Thomas; Benke, Thomas; Delazer, Margarete			Decision making in ambiguous and risky situations after unilateral temporal lobe epilepsy surgery	EPILEPSY & BEHAVIOR			English	Article						Decision making; Ambiguity; Risk; Executive functions; Mesial temporal lobe epilepsy; Epilepsy surgery	VENTROMEDIAL PREFRONTAL CORTEX; MILD ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY; GAMBLING TASK; PARKINSONS-DISEASE; HUMAN AMYGDALA; EMOTION; DAMAGE; IMPAIRMENT; RESECTION	Decision making is essential in everyday life. Though the importance of the mesial temporal structures in emotional processing and feedback learning is well established, decision making in patients after mesial temporal lobe surgery has rarely been studied. We studied 23 patients with mesial temporal lobe epilepsy after unilateral temporal lobe surgery and 26 healthy controls using two different gambling tasks. the Iowa Gambling Task (IGT) and the Probability-Associated Gambling (PAG) task. In the IGT, rules for gains and losses are implicit; in the PAG task, winning probabilities are well defined. Compared with healthy controls, patients performed poorly on the IGT (decisions under ambiguity). No group difference was found in the PAG task (decisions under risk. Results of the present investigation indicate that after mesial temporal lobe surgery, patients have difficulties in making decisions under ambiguity, whereas they decide advantageously when information about the decision situation is explicitly given. (C) 2009 Elsevier Inc. All rights reserved.	[Bonatti, Elisabeth; Kuchukhidze, Giorgi; Zamarian, Laura; Trinka, Eugen; Bodner, Thomas; Benke, Thomas; Delazer, Margarete] Innsbruck Med Univ, Dept Clin Neurol, A-6020 Innsbruck, Austria		Bonatti, E (corresponding author), Innsbruck Med Univ, Dept Clin Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	Elisabeth.Bonatti@i-med.ac.at	Zamarian, Laura/J-9575-2018	Zamarian, Laura/0000-0002-1640-4179; Trinka, Eugen/0000-0002-5950-2692; Delazer, Margarete/0000-0001-6482-4445; Kuchukhidze, Giorgi/0000-0001-6899-8506	Austrian Science FundAustrian Science Fund (FWF) [P18896-1305]; Tiroler Wissenschaftsfonds; Medical University Innsbruck; Medizinische Forschungsforderung Innsbruck [PDO-Nr. 12880 (2007-419)]	The present research was supported by Austrian Science Fund (FWF) Grant P18896-1305, by Tiroler Wissenschaftsfonds (TWF), by a predoctoral grant from the Medical University Innsbruck, and by Medizinische Forschungsforderung Innsbruck Grant PDO-Nr. 12880 (2007-419).	Andresen B, 2002, HPI HAMBURGER PERSON; Aschenbrenner S, 2002, REGENSBURGER WORTFLU; Bar-On R, 2003, BRAIN, V126, P1790, DOI 10.1093/brain/awg177; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1999, J NEUROSCI, V19, P5473; Bolla KI, 2004, CEREB CORTEX, V14, P1226, DOI 10.1093/cercor/bhh083; Bonatti E, 2008, COGN BEHAV NEUROL, V21, P164, DOI 10.1097/WNN.0b013e318184e688; Brand M, 2004, BEHAV NEUROL, V15, P77, DOI 10.1155/2004/578354; Brand M, 2005, NEUROPSYCHOLOGY, V19, P267, DOI 10.1037/0894-4105.19.3.267; Brand M., 2002, TEST ZUM KOGNITIVEN; Brand M, 2007, NEUROPSYCHOLOGIA, V45, P1305, DOI 10.1016/j.neuropsychologia.2006.09.021; Brand M, 2006, NEURAL NETWORKS, V19, P1266, DOI 10.1016/j.neunet.2006.03.001; Brand M, 2008, J NEUROPSYCHOL, V2, P431, DOI 10.1348/174866407X220607; Buss U., 1995, HOSP ANXIETY DEPRESS; Butman J, 2007, ACTAS ESP PSIQUIATRI, V35, P8; Cavedini P, 2002, NEUROPSYCHOLOGIA, V40, P205, DOI 10.1016/S0028-3932(01)00077-X; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Cohen MX, 2008, NEUROIMAGE, V39, P1396, DOI 10.1016/j.neuroimage.2007.10.004; Cools R, 2003, NEUROPSYCHOLOGIA, V41, P1431, DOI 10.1016/S0028-3932(03)00117-9; Delazer M, 2007, NEUROPSYCHOLOGIA, V45, P1632, DOI 10.1016/j.neuropsychologia.2007.01.006; Denburg NL, 2007, ANN NY ACAD SCI, V1121, P480, DOI 10.1196/annals.1401.031; Denburg NL, 2005, NEUROPSYCHOLOGIA, V43, P1099, DOI 10.1016/j.neuropsychologia.2004.09.012; Denburg NL, 2001, BRAIN COGNITION, V47, P156; Dunn BD, 2006, NEUROSCI BIOBEHAV R, V30, P239, DOI 10.1016/j.neubiorev.2005.07.001; Fein G, 2007, J INT NEUROPSYCH SOC, V13, P480, DOI 10.1017/S135561770707052X; Fox AM, 2000, CLIN NEUROPHYSIOL, V111, P1045, DOI 10.1016/S1388-2457(00)00257-1; Frank MJ, 2004, SCIENCE, V306, P1940, DOI 10.1126/science.1102941; Harting C, 2000, WMS R WECHSLER GEDAC; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Helmstaedter C, 2008, EPILEPSIA, V49, P88, DOI 10.1111/j.1528-1167.2007.01386.x; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; Huettel SA, 2006, NEURON, V49, P765, DOI 10.1016/j.neuron.2006.01.024; ILMBERGER J, 1988, 30 ANN M TEAP MARB; JACKSON M, 1986, CORTEX, V22, P611, DOI 10.1016/S0010-9452(86)80020-X; KOHLER J, 2000, PLANUNGSTEST KONSTAN; Labudda K, 2009, NEUROPSYCHOLOGIA, V47, P50, DOI 10.1016/j.neuropsychologia.2008.08.014; LEHRL S, 1991, MANUAL ZUM MWT B BAL; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; LEZAK MD, 1998, NEUROPSYCHOLOGICAL A; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Overman WH, 2004, BRAIN COGNITION, V55, P134, DOI 10.1016/s0278-2626(03)00279-3; Phelps EA, 2006, ANNU REV PSYCHOL, V57, P27, DOI 10.1146/annurev.psych.56.091103.070234; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; Phelps EA, 1997, CURR BIOL, V7, pR311, DOI 10.1016/S0960-9822(06)00146-1; Roth M., 2003, Z DIFFER DIAGN PSYCH, V24, P65, DOI [10.1024//0170-1789.24.1.65, DOI 10.1024//0170-1789.24.1.65]; Shaw P, 2007, NEUROPSYCHOLOGIA, V45, P2783, DOI 10.1016/j.neuropsychologia.2007.04.020; Sinz H, 2008, NEUROPSYCHOLOGIA, V46, P2043, DOI 10.1016/j.neuropsychologia.2008.02.002; Stout JC, 2001, J INT NEUROPSYCH SOC, V7, P92, DOI 10.1017/S1355617701711095; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Wieser HG, 2001, EPILEPSIA, V42, P282, DOI 10.1046/j.1528-1157.2001.4220282.x; WYNNE HJ, 2002, MEASURING GAMBLING P; Zamarian L, 2008, NEUROPSYCHOLOGY, V22, P645, DOI 10.1037/0894-4105.22.5.645	54	27	28	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	APR	2009	14	4					665	673		10.1016/j.yebeh.2009.02.015			9	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	435JR	WOS:000265340700017	19233314				2022-02-06	
J	Gawryszewski, VP; Coelho, HMM; Scarpelini, S; Zan, R; Jorge, MHPD; Rodrigues, EMS				Gawryszewski, Vilma Pinheiro; Mendes Coelho, Herlander Manoel; Scarpelini, Sandro; Zan, Renato; Prado de Mello Jorge, Maria Helena; Silveira Rodrigues, Eugenia Maria			Land transport injuries among emergency department visits in the state of Sao Paulo, in 2005	REVISTA DE SAUDE PUBLICA			Portuguese	Article						Traffic Accidents; Risk Factors; First Aid; Emergency Medical Care; External Causes	ROAD	OBJECTIVE: To analyze the characteristics of visits resulting from land transport injuries. METHODS: A total of 5,934 visits in four hospital emergency departments (ED) were analyzed, in the state of Sao Paulo, in 2005. A questionnaire based on the following three models was used to collect data: World Health Organization (WHO), Center for Disease Control and Prevention (CDC), and Pan American Health Organization (PAHO). Variables analyzed were as follows: type of road user (vehicle occupant, pedestrian, motorcyclist, and cyclist), sex, age group, and type of injury suffered. Logistic regression analysis was employed to test associations between variables. Odds ratios with their respective 95% confidence intervals were calculated. RESULTS: The majority of victims were males (74.2%) in the 20-to-29- year age group (35.0%). Vulnerable road users totaled 72.4% of all cases (29.8% were motorcyclists, 24.1% pedestrians, and 18.5% cyclists). Victims aged between zero and 14 years who had suffered injuries were mostly pedestrians and cyclists; motorcyclists predominated among those aged between 15 and 39 years; and pedestrians among those aged over 50 years. About half of the cases suffered minor injuries (strains, dislocations, contusions and cuts), while the other half was comprised by fractures, traumatic brain injuries and internal injuries. Extremities were the most affected body parts, particularly among motorcyclists. The majority of victims were discharged at triage (87.6%). Compared to women, men were 1.5 times more likely to be admitted or transferred, or to die. Pedestrians, vehicle occupants and motorcyclists were, respectively, 2.7, 2.4 and 1.9 times more likely to be admitted or transferred, or to die than cyclists. CONCLUSIONS: Measures aimed to protect vulnerable road users should be among the priorities to reduce land transport-related injuries.	[Gawryszewski, Vilma Pinheiro] SES SP, Ctr Vigilancia Epidemiol, Sao Paulo, Brazil; [Mendes Coelho, Herlander Manoel] Hosp Geral Grajau, SES SP, Sao Paulo, Brazil; [Scarpelini, Sandro] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil; [Zan, Renato] Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil; [Prado de Mello Jorge, Maria Helena] Univ Sao Paulo, Fac Saude Publ, BR-09500900 Sao Paulo, Brazil; [Silveira Rodrigues, Eugenia Maria] Organizacao Pan Amer Saude, Washington, DC USA		Gawryszewski, VP (corresponding author), Av Dr Arnaldo,351 Sala 609 Cerqueira Cesar, BR-01246902 Sao Paulo, SP, Brazil.	gawry@uol.com.br	Scarpelini, Sandro/H-7063-2012	Scarpelini, Sandro/0000-0001-5727-3913			Ameratunga S, 2006, LANCET, V367, P1533, DOI 10.1016/S0140-6736(06)68654-6; Bastos Yara Gerber Lima, 2005, Cad. Saúde Pública, V21, P815, DOI 10.1590/S0102-311X2005000300015; Batista Sandra Elisa Adami, 2006, Rev. Col. Bras. Cir., V33, P6; Bunn F., 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003110, DOI 10.1002/14651858.CD003110]; Diniz Eugênio Paceli Hatem, 2005, Ciênc. saúde coletiva, V10, P905, DOI 10.1590/S1413-81232005000400014; Gaspar Vera L. V., 2004, J. Pediatr. (Rio J.), V80, P447, DOI 10.1590/S0021-75572004000800005; Gawryszewski Vilma Pinheiro, 2006, Sao Paulo Med. J., V124, P208, DOI 10.1590/S1516-31802006000400007; Gawryszewski VP, 2008, CAD SAUDE PUBLICA, V24, P1121, DOI 10.1590/S0102-311X2008000500019; Haileyesus T, 2007, INJURY PREV, V13, P202, DOI 10.1136/ip.2006.014019; Jorge Maria Helena Prado de Mello, 2004, Rev. bras. epidemiol., V7, P228; Kobusingye, 2001, INJURY SURVEILLANCE; Nicaj L, 2006, INJURY PREV, V12, P414, DOI 10.1136/ip.2005.010082; Peden M., 2004, WORLD REPORT ROAD TR; Queiroz Marcos S., 2003, Psicol. Soc., V15, P101, DOI 10.1590/S0102-71822003000200008; Souza Edinilsa Ramos de, 2006, Ciênc. saúde coletiva, V11, P363, DOI 10.1590/S1413-81232006000200014; Veronese Andréa Márian, 2006, Cad. Saúde Pública, V22, P2717, DOI 10.1590/S0102-311X2006001200021; Vyrostek Sara B., 2004, Morbidity and Mortality Weekly Report, V53, P1; [No title captured], DOI DOI 10.1590/S0102-88392001000100007	18	27	38	0	0	REVISTA DE SAUDE PUBLICA	SAO PAULO	FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO, BRAZIL	0034-8910	1518-8787		REV SAUDE PUBL	Rev. Saude Publica	APR	2009	43	2					275	282		10.1590/S0034-89102009000200008			8	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	419FC	WOS:000264203500008	19287873	gold, Green Published			2022-02-06	
J	Lloyd-Williams, M; Morton, J; Peters, S				Lloyd-Williams, Mari; Morton, Juliet; Peters, Sarah			The End-of-Life Care Experiences of Relatives of Brain Dead Intensive Care Patients	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Sudden death; organ donation; palliative care; intensive care	ORGAN DONATION; UNIT; PROFESSIONALS; BREAKING; NEWS	Brain death is a. traumatic and sudden event following a severe injury to the brain. Most patients with brain death spend the last days of life in at? intensive care unit (ICU), where some families will be approached to ask for organ donation, This qualitative study was carried out with relatives of patients who had died of brain death in an ICU; all relatives were interviewed six months after the death. Twenty ICUs were recruited for this study. The next of kin of 130 patients who died during the study period were approached, and 30 (22%) agreed to be interviewed; one later withdrew. This paper focuses on the perceived Palliative care needs of the 29 families. Participants valued the physical care their relatives had received, but communication, and breaking bad news was a cause for concern. The facilities on many ICUs, for examine, cramped relatives' rooms and little privacy to be with the patients at, to say the final goodbye, was a common theme to emerge. Bereavement follow-up did not routinely occur, and this was an identified factor noted by relatives. Families living through. the period of brain death in, a loved one may have particular needs in terms of end-of-life care and should be Offered the support of a palliative care team, through the last days of a. patients life, and into the period of bereavement. Staff training on how to communicate bad news also should be implemented as a matter Of urgency. J Pain Symptom Manage 2009;37:659-664. (C) 2009 U.S. Cancer Pain, Relief Committee. Published by Elsevier Inc. All rights reserved.	[Lloyd-Williams, Mari; Morton, Juliet] Univ Liverpool, Sch Populat Community & Behav Sci, Acad Palliat & Support Care Study Grp, Liverpool L69 3GB, Merseyside, England; [Peters, Sarah] Univ Manchester, Manchester, Lancs, England		Lloyd-Williams, M (corresponding author), Univ Liverpool, Sch Populat Community & Behav, Acad Palliat & Support Care Study Grp, Whelan Bldg, Liverpool L69 3GB, Merseyside, England.	mlw@liv.ac.uk					Byock I, 2006, CRIT CARE MED, V34, pS416, DOI 10.1097/01.CCM.0000237345.62823.82; Floden A, 2006, TRANSPLANT P, V38, P2619, DOI 10.1016/j.transproceed.2006.07.031; Gavrin JR, 2007, CRIT CARE MED, V35, pS85, DOI 10.1097/01.CCM.0000252909.52316.27; Kesselring A, 2007, AM J TRANSPLANT, V7, P211, DOI 10.1111/j.1600-6143.2006.01594.x; Lefebvre H, 2006, BRAIN INJURY, V20, P711, DOI 10.1080/02699050600744244; Levy MM, 2006, CRIT CARE MED, V34, pS306, DOI 10.1097/01.CCM.0000246096.18214.79; Murphy PG, 2007, BRIT J HOSP MED, V68, P298, DOI 10.12968/hmed.2007.68.6.23568; Parle M, 1997, SOC SCI MED, V44, P231, DOI 10.1016/S0277-9536(96)00148-7; Schildmann J, 2005, PALLIATIVE MED, V19, P93, DOI 10.1191/0269216305pm996oa; STRAUSS AC, 1998, BARRIERS QUALITATIVE; Wall RJ, 2007, CRIT CARE MED, V35, P1084, DOI 10.1097/01.CCM.0000259382.36414.06; White DB, 2007, ARCH INTERN MED, V167, P461, DOI 10.1001/archinte.167.5.461; Whitney CM, 2005, NEUROLOGIST, V11, P61, DOI 10.1097/01.nrl.0000149974.25259.6c; Williams G, 1997, BRIT MED J, V314, P1831, DOI 10.1136/bmj.314.7097.1831a	14	27	27	2	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	APR	2009	37	4					659	664		10.1016/j.jpainsymman.2008.04.013			6	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	433SH	WOS:000265225600006	18789640	Green Published, Bronze			2022-02-06	
J	Jiang, JY				Jiang, Ji-Yao			Clinical Study of Mild Hypothermia Treatment for Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			adult brain injury; animal studies; biomarkers; blood-brain barrier dysfunction; clinical management of CNS injury; hypothermia; regeneration; stem cells; traumatic brain injury; traumatic spinal cord injury	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; HOSPITAL CARDIAC-ARREST; COLD INTRAVENOUS FLUID; MODERATE HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; COMATOSE SURVIVORS; LONG; HYPERTENSION	Clinical randomized controlled trials (RCTs) suggest that mild hypothermia may improve the outcome of severe traumatic brain injured patients with intracranial hypertension when cooling is maintained for longer than 48 h. However, the results are not yet conclusive, and more RCTs are required. Mild hypothermia significantly decreases intracranial pressure (ICP) values when refractory intracranial hypertension cannot be controlled by conventional measures in patients with severe traumatic brain injury (TBI). Prolonged mild-to-moderate hypothermia may be associated with high incidence of pneumonia and hypokalemia, which should be prevented.	Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China.	Jiangjyb@online.sh.cn					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hayashi N, 1999, Nihon Geka Gakkai Zasshi, V100, P443; Hayashi N, 1998, Nihon Rinsho, V56, P1627; Hayashi S, 2005, ACT NEUR S, V95, P269; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iida K, 2003, J NEUROSURG, V98, P793, DOI 10.3171/jns.2003.98.4.0793; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 1998, CHINESE MED J-PEKING, V111, P180; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Masaoka Hiroyuki, 2000, Keio Journal of Medicine, V49, pA159; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mrlian A, 2006, Bratisl Lek Listy, V107, P113; Murakami M, 2007, NEUROL MED-CHIR, V47, P116, DOI 10.2176/nmc.47.116; Nara I, 1998, ACT NEUR S, V71, P22; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smrcka M, 2005, ACT NEUR S, V95, P273; Soukup J, 2002, NEUROL RES, V24, P161, DOI 10.1179/016164102101199710; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Sund-Levander M, 2000, J CLIN NURS, V9, P55, DOI 10.1046/j.1365-2702.2000.00352.x; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Zhang Sai, 2002, Chin J Traumatol, V5, P43; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	46	27	32	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					399	406		10.1089/neu.2008.0525			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900014	19260782				2022-02-06	
J	Weaver, FM; Burns, SP; Evans, CT; Rapacki, LM; Goldstein, B; Hammond, MC				Weaver, Frances M.; Burns, Stephen P.; Evans, Charlesnika T.; Rapacki, Lauren M.; Goldstein, Barry; Hammond, Margaret C.			Provider Perspectives on Soldiers With New Spinal Cord Injuries Returning From Iraq and Afghanistan	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Health personnel; Rehabilitation; Spinal cord injuries; Veterans	TRAUMATIC BRAIN-INJURY; COMBAT; WAR; REHABILITATION; CASUALTIES; RISK	Objective: The military conflicts in Iraq and Afghanistan have resulted in many soldiers returning with serious combat injuries, including spinal cord injuries (SCIs). The purpose of this study was to query providers regarding any unique problems or needs in a cohort of these soldiers treated in Veterans Health Administration (VHA) SCI Centers. Design: Semi structured questionnaire. Setting: Seventeen VHA SCI Centers. Participants: Thirty-eight providers, including physicians, nurses, therapists, social workers, and psychologists who volunteered to return completed questionnaires. Interventions: Not applicable. Main Outcome Measures: Identification of medical and psychosocial issues, rehabilitation delays, therapy and vocational needs, social support, and discharge planning. Results: Providers identified several injuries and conditions beyond SCI that were experienced by these soldiers including fractures, pressure ulcers, traumatic brain injuries, posttraumatic stress disorder, and resistant infections. Rehabilitation was often delayed because these problems needed to be addressed first. Soldiers' family and friends provide considerable support. Vocational needs include use of technology, especially computers; education; and participation in sports. Although most return to the community after discharge, many soldiers are still active duty, and some return to military base housing. Conclusions: Combat soldiers returning with SCI often have additional medical and psychosocial problems that require appropriate and timely intervention. They have strong support from family and friends and are motivated to integrate back into the community after discharge.	[Weaver, Frances M.; Evans, Charlesnika T.; Rapacki, Lauren M.] Edward Hines Jr VA Hosp, Ctr Complex Chron Care, Hines, IL 60141 USA; [Weaver, Frances M.; Evans, Charlesnika T.; Rapacki, Lauren M.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA; [Weaver, Frances M.; Evans, Charlesnika T.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA; [Weaver, Frances M.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA; [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA; [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA; [Burns, Stephen P.; Goldstein, Barry; Hammond, Margaret C.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Goldstein, Barry; Hammond, Margaret C.] Dept Vet Affairs, Spinal Cord Injury & Disorders Serv, Seattle, WA USA		Weaver, FM (corresponding author), VA Hosp, 5000 S 5th Ave 151H, Hines, IL 60141 USA.	Frances.Weaver@va.gov	Weaver, Frances/S-1540-2019		Spinal Cord Injury Quality Enhancement Research Initiative (QUERI) in the Department of Veterans Affairs [SC198-001]	Supported by the Spinal Cord Injury Quality Enhancement Research Initiative (QUERI) in the Department of Veterans Affairs (grant no. SC198-001).	Cirillo VJ, 2008, PERSPECT BIOL MED, V51, P121, DOI 10.1353/pbm.2008.0005; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DILLINGHAM TR, 1993, AM J PHYS MED REHAB, V72, P214, DOI 10.1097/00002060-199308000-00008; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Mahmoud A, 1999, TOP SPINAL CORD INJ, V5, P42; Martz E, 2005, ARCH PHYS MED REHAB, V86, P1182, DOI 10.1016/j.apmr.2004.11.036; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; POLLACK P, 2007, ACAD ORTHOPED SU MAR; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Westgren N, 1998, ARCH PHYS MED REHAB, V79, P1433, DOI 10.1016/S0003-9993(98)90240-4	14	27	28	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2009	90	3					517	521		10.1016/j.apmr.2008.09.560			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	421YW	WOS:000264395200023	19254621				2022-02-06	
J	Jaffee, MS; Helmick, KM; Girard, PD; Meyer, KS; Dinegar, K; George, K				Jaffee, Michael S.; Helmick, Kathy M.; Girard, Philip D.; Meyer, Kim S.; Dinegar, Kathy; George, Karyn			Acute clinical care and care coordination for traumatic brain injury within Department of Defense	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cognitive assessment; community reentry; loss of consciousness; medical evacuation; polytrauma; posttraumatic amnesia; rehabilitation; TBI; TBI screening; traumatic brain injury	NEUROPSYCHOLOGICAL STATUS RBANS; REPEATABLE BATTERY; MILITARY; REHABILITATION; RELIABILITY; IMPAIRMENT; VALIDITY	The nature of current combat situations that U.S. military forces encounter and the use of unconventional weaponry have dramatically increased service personnel's risks of sustaining a traumatic brain injury (TBI). Although the true incidence and prevalence of combat-related TBI are unknown, service personnel returning from deployment have reported rates of concussion between 10% and 20%. The Department of Defense has recently released statistics on TBI dating back to before the wars in Iraq and Afghanistan to better elucidate the impact and burden of TBI on America's warriors and veterans. Patients with severe TBI move through a well-established trauma system of care, beginning with triage of initial injury by first-responders in the war zone to acute care to rehabilitation and then returning home and to the community. Mild and moderate TBIs may pose different clinical challenges, especially when initially undetected or if treatment is delayed because more serious injuries are present. To ensure identification and prompt treatment of mild and moderate TBI, the U.S. Congress has mandated that military and Department of Veterans Affairs hospitals screen all service personnel returning from combat. Military health professionals must evaluate them for concussion and then treat the physical, emotional, and cognitive problems that may surface. A new approach to health management and care coordination is needed that will allow medical transitions between networks of care to become more centralized and allow for optimal recovery at all severity levels. This article summarizes the care systems available for the acute management of TBI from point of injury to stateside military treatment facilities. We describe TBI assessment, treatment, and overall coordination of care, including innovative clinical initiatives now used.	[Jaffee, Michael S.; Helmick, Kathy M.; Girard, Philip D.; Meyer, Kim S.; George, Karyn] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Girard, Philip D.] Manchester Dept Vet Affairs Med Ctr, Manchester, NH USA		Girard, PD (corresponding author), Manchester VA Med Ctr, Off Telemed, 718 Smyth Rd, Manchester, NH 03104 USA.	Philip.girard@va.gov					Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Brown AW, 2007, BRAIN INJURY, V21, P673, DOI 10.1080/02699050701468925; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COOPER GJ, 1983, J TRAUMA, V23, P955, DOI 10.1097/00005373-198311000-00001; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; *DEF VET BRAIN INJ, 2009, OCT 2009 ARM FORC SU; Girard P, 2007, J REHABIL RES DEV, V44, P1017, DOI 10.1682/JRRD.2006.12.0174; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Institute of Medicine, 2008, GULF WAR HLTH, V7; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Johnson DR, 2008, ARCH CLIN NEUROPSYCH, V23, P73, DOI 10.1016/j.acn.2007.10.001; Knuth T., 2005, GUIDELINES FIELD MAN; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McCrea M., 1997, STANDARDIZED ASSESSM; Mckay C, 2008, CLIN NEUROPSYCHOL, V22, P228, DOI 10.1080/13854040701260370; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Tanielian TL., 2008, RAND CORPORATION INV; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tsokos M, 2003, AM J RESP CRIT CARE, V168, P549, DOI 10.1164/rccm.200304-528OC; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015	31	27	27	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					655	665		10.1682/JRRD.2008.09.0114			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	531BQ	WOS:000272638100003	20104395	Bronze			2022-02-06	
J	Kaminski, TW; Groff, RM; Glutting, JJ				Kaminski, Thomas W.; Groff, Rachel M.; Glutting, Joseph J.			Examining the stability of Automated Neuropsychological Assessment Metric (ANAM) baseline test scores	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Sport-related concussion; Brain; Cognition; Mental; Memory	SAMPLE-SIZE; RELIABILITY; PERFORMANCE; CONCUSSION; MANAGEMENT	Computerized neuropsychological (NP) testing has evolved into an important tool for clinicians in the assessment of sport-related concussions. The importance of having a reliable baseline test score for comparison post concussion is critical; yet, the stability of these baseline measurements has not been well established. The purpose of this study was to examine the consistency of the measurements derived from the Automated Neuropsychological Assessment Metric (ANAM) test battery over a series of repeated trials, in an attempt to determine at what point the test scores stabilized. A cohort of 25 recreationally active collegiate students, free from mild head injury, volunteered for the study. Throughput score (measures of performance efficiency) stability was assessed for the computerized NP tests using intraclass correlation coefficients (ICCs). Average throughput scores for all five test trials were simple reaction time (SRT) = 235, matching to sample (MSP) = 41, continuous performance test (CPT) = 108, math processing (MTH) = 24, and Sternberg memory (STN) = 89, and these are within the range of those previously reported. Results show that all four of the ICCs were in the excellent range of agreement (i.e., >= .75), and more importantly, the statistical comparisons of the ICCs show that there was no significant difference between the ICCs. Consequently, results serve to show that two time periods are sufficient to obtain stable NP results, and thus clinicians can feel comfortable relying on a two-score baseline test for follow-up comparison.	[Kaminski, Thomas W.; Groff, Rachel M.] Univ Delaware, Dept Hlth Nutr & Exercise Sci, Athlet Training Res Lab, Newark, DE 19716 USA; [Glutting, Joseph J.] Univ Delaware, Sch Educ, Newark, DE 19716 USA		Kaminski, TW (corresponding author), Univ Delaware, Dept Hlth Nutr & Exercise Sci, Human Performance Lab, 159 Fred Rust Ice Arena,541 S Coll Ave, Newark, DE 19716 USA.	kaminski@udel.edu			University of Delaware Research Foundation; University of Delaware Undergraduate Science and Engineering Scholars Program; University of Delaware Alumni Enrichment Award	This study was generously supported by a grant from the University of Delaware Research Foundation, the University of Delaware Undergraduate Science and Engineering Scholars Program, and the University of Delaware Alumni Enrichment Award.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; BANDERET LE, 1988, 30 ANN M MIL TEST AS; BARTKO JJ, 1976, PSYCHOL BULL, V83, P762, DOI 10.1037/0033-2909.83.5.762; BITTNER AC, 1985, BEHAV RES METH INS C, V17, P217, DOI 10.3758/BF03214386; BLEIBERG J, 1994, M INT NEUR SOC CINC; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Cicchetti D, 2006, J NERV MENT DIS, V194, P557, DOI 10.1097/01.nmd.0000230392.83607.c5; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Cohen J., 1983, APPL MULTIPLE REGRES; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Fleiss JL, 1986, RELIABILITY MEASUREM, DOI DOI 10.1002/9781118032923; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Kane R. L., 1997, NEUROPSYCHOLOGY HDB; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; Kenny DA., 2006, DYADIC DATA ANAL; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MARUFF P, 2001, COGSPORT COMPUTER SO; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Randolph C, 2005, J ATHL TRAINING, V40, P139; REEVES D, 2001, AUTOMATED NEUROPSYCH; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; REEVES DL, 1995, AUTOMATED NEUROPSYCH; Salthouse TA, 2002, J CLIN EXP NEUROPSYC, V24, P858, DOI 10.1076/jcen.24.7.858.8392; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sim J, 2005, PHYS THER, V85, P257; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.3.CO;2-5	34	27	27	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	6					689	697		10.1080/13803390802484771			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	482JV	WOS:000268883300006	19110989				2022-02-06	
S	Mataric, M; Tapus, A; Winstein, C; Eriksson, J		Gaggioli, A; Keshner, EA; Weiss, PL; Riva, G		Mataric, Maja; Tapus, Adriana; Winstein, Carolee; Eriksson, Jon			Socially Assistive Robotics for Stroke and Mild TBI Rehabilitation	ADVANCED TECHNOLOGIES IN REHABILITATION: EMPOWERING COGNITIVE, PHYSICAL, SOCIAL AND COMMUNICATIVE SKILLS THROUGH VIRTUAL REALITY, ROBOTS, WEARABLE SYSTEMS AND BRAIN-COMPUTER INTERFACES	Studies in Health Technology and Informatics		English	Article; Book Chapter						Socially-Assistive Robotics (SAR); Human-robot interaction (HRI); Robot-assisted rehabilitation; Technology-assisted therapy	INDUCED MOVEMENT THERAPY; UPPER-EXTREMITY; PERSONALITY; RECOVERY	This paper describes an interdisciplinary research project aimed at developing and evaluating effective and user-friendly non-contact robot-assisted therapy, aimed at in-home use. The approach stems from the emerging field of social cognitive neuroscience that seeks to understand phenomena in terms of interactions between the social, cognitive, and neural levels of analysis. This technology-assisted therapy is designed to be safe and affordable, and relies on novel human-robot interaction methods for accelerated recovery of upper-extremity function after lesion-induced hemiparesis. The work is based on the combined expertise in the science and technology of non-contact socially assistive robotics and the clinical science of neurorehabilitation and motor learning, brought together to study how to best enhance recovery after stroke and mild traumatic brain injury. Our approach is original and promising in that it combines several ingredients that individually have been shown to be important for learning and long-term efficacy in motor neurorehabilitation: (1) intensity of task specific training and (2) engagement and self-management of goal-directed actions. These principles motivate and guide the strategies used to develop novel user activity sensing and provide the rationale for development of socially assistive robotics therapy for monitoring and coaching users toward personalized and optimal rehabilitation programs.	[Mataric, Maja] Univ So Calif, Dept Comp Sci, Robot Res Lab, Ctr Robot & Embedded Syst CRES,Interact Lab, Los Angeles, CA 90089 USA; [Winstein, Carolee] Univ So Calif, Div Biokinesiol & Phys Therapy, Sch Dent, Los Angeles, CA 90089 USA; [Mataric, Maja] Univ So Calif, Viterbi Sch Engn, Los Angeles, CA 90089 USA		Mataric, M (corresponding author), Univ So Calif, Dept Comp Sci, Robot Res Lab, Ctr Robot & Embedded Syst CRES,Interact Lab, Los Angeles, CA 90089 USA.	mataric@usc.edu; adriana.tapus@ieee.org; winstein@usc.edu; je@kth.se	LUO, JINGJING/AAZ-6697-2021	LUO, JINGJING/0000-0002-3222-1276; Winstein, Carolee/0000-0001-9789-4626			Ada L., 1994, INSIGHTS REACH GRASP, VVolume 105, P239; American Heart Association, 2003, HEART DIS STROK STAT; Bandura A., 1969, PRINCIPLES BEHAV MOD; Brewer BR, 2003, P ANN INT IEEE EMBS, V25, P1613, DOI 10.1109/IEMBS.2003.1279676; Broderick JP, 2004, STROKE, V35, P205, DOI 10.1161/01.STR.0000106160.34316.19; Burgar CG, 2000, J REHABIL RES DEV, V37, P663; CARR JH, 1989, PHYSIOTHERAPY, V75, P372; DESROSIERS J, 2003, CLIN REHABIL, P666; Eriksson J, 2005, INT C REHAB ROBOT, P21; EYSENCK HJ, 1991, PERS INDIV DIFFER, V12, P773, DOI 10.1016/0191-8869(91)90144-Z; Feil-Seifer D, 2005, INT C REHAB ROBOT, P465; Fisher BE, 2008, ARCH PHYS MED REHAB, V89, P1221, DOI 10.1016/j.apmr.2008.01.013; Gerkey BP, 2003, PROCEEDINGS OF THE 11TH INTERNATIONAL CONFERENCE ON ADVANCED ROBOTICS 2003, VOL 1-3, P317; Ghahramanlou M, 2001, P AM STROK ASS 26 IN; Hall ET., 1966, HIDDEN DIMENSION; Hellstrom K, 2003, J REHABIL MED, V35, P202, DOI 10.1080/16501970310000836; Hesse S, 2003, CNS DRUGS, V17, P1093, DOI 10.2165/00023210-200317150-00004; Hesse S, 2003, ARCH PHYS MED REHAB, V84, P915, DOI 10.1016/S0003-9993(02)04954-7; Institute of Medicine, 2001, CROSSING QUALITY CHA; *INT LAB, INT LAB HUM ROB INT; Kelly-Hayes M, 1998, STROKE, V29, P1274, DOI 10.1161/01.STR.29.6.1274; MATARIC M, 2007, INT J NEUROENGINEERI, V5; Nakajima H, 2003, IEEE SYS MAN CYBERN, P2381; Nakajima H., 2004, J JAPANESE SOC ARTIF, V19, P184; Nass C, 2001, J EXP PSYCHOL-APPL, V7, P171, DOI 10.1037//1076-898X.7.3.171; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; OLSEN TS, 1990, STROKE, V21, P247, DOI 10.1161/01.STR.21.2.247; REINKENSMEYER DJ, 2000, J REHABILITATION RES, V37; Schaechter JD, 2002, NEUROREHAB NEURAL RE, V16, P326, DOI 10.1177/154596830201600403; SMITS H, 2000, HAND RECOVERY STROKE; Tapus A, 2006, P INT S EXP ROB ISER; TAPUS A, 2006, INT J ROBOTICS SOC J, V24, P14; Tapus A., 2007, P NEUR INF PROC SYST; Tapus A, 2008, INTEL SERV ROBOT, V1, P169, DOI 10.1007/s11370-008-0017-4; TAUB EG, 2003, J MED PHYS, V14, P77; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; WATSON MJ, 2008, PHYSIOTHERAPY, V80, P103; Winstein CJ, 2004, ARCH PHYS MED REHAB, V85, P620, DOI 10.1016/j.apmr.2003.06.027; Winstein CJ, 2008, STROKE RECOVERY REHA, P267; Wolf SL, 2008, LANCET NEUROL, V7, P33, DOI 10.1016/S1474-4422(07)70294-6; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	42	27	27	0	10	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0926-9630	1879-8365	978-1-60750-018-6	STUD HEALTH TECHNOL			2009	145						249	262		10.3233/978-1-60750-018-6-249			14	Computer Science, Cybernetics; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Robotics; Rehabilitation	Book Citation Index – Social Sciences & Humanities (BKCI-SSH); Book Citation Index – Science (BKCI-S)	Computer Science; Engineering; Robotics; Rehabilitation	BMC52	WOS:000271844400017	19592798				2022-02-06	
J	McCarter, RJ; Walton, NH; Brooks, DN; Powell, GE				McCarter, Renee J.; Walton, Nigel H.; Brooks, D. Neil; Powell, Graham E.			Effort Testing in Contemporary UK Neuropsychological Practice	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; Symptom validity; Neuropsychology; Survey	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; WORD MEMORY TEST; PSYCHOGENIC NONEPILEPTIC SEIZURES; MMPI-2 VALIDITY SCALES; NEGATIVE RESPONSE BIAS; RELIABLE DIGIT SPAN; CLASSIFICATION ACCURACY; TEST FAILURE; HEAD-INJURY	A survey of members of the British Psychological Society Division of Neuropsychology (N = 588) was conducted via email to ascertain current practice with respect to the use of symptom validity testing (SVT) in clinical and legal neuropsychological assessments. Replies were received from 130 practicing neuropsychologists. Results showed that 59% frequently use SVT in legal assessments, but a minority (15%) employ them in clinical assessments. Practice in the UK is only moderately different to that in North America with respect to frequency of use of SVT, although methods employed showed greater diversity. Favored tests, respondents' justifications for use of SVT and rationales for not using SVT are reported.	[McCarter, Renee J.; Walton, Nigel H.] NPsych Clin Neurosci Partnership, Bristol BS41 9JQ, Avon, England; [Brooks, D. Neil] Milton Keynes, Rehab Walls, London, England; [Powell, Graham E.] Psychol Serv, London, England		McCarter, RJ (corresponding author), NPsych Clin Neurosci Partnership, 133 Long Ashton Rd, Bristol BS41 9JQ, Avon, England.	rjmccarter@npsych.co.uk					Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; BATT K, 2008, J INT NEUROPSYCHO S1, V14, P139; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bianchini K, 2005, ARCH CLIN NEUROPSYCH, V20, P365, DOI 10.1016/j.acn.2004.09.003; Bianchini KJ, 2008, ASSESSMENT, V15, P435, DOI 10.1177/1073191108317341; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini Kevin J, 2004, Spine J, V4, P718, DOI 10.1016/j.spinee.2004.06.007; Bianchini KJ, 2003, CLIN NEUROPSYCHOL, V17, P574, DOI 10.1076/clin.17.4.574.27946; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Bunnage M., 2008, J INT NEUROPSYCHO S1, V14, P138; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; Derogatis LR., 1977, SCL 90 R SYMPTOM CHE; Dodrill CB, 2008, EPILEPSIA, V49, P691, DOI 10.1111/j.1528-1167.2007.01457.x; Drane DL, 2006, EPILEPSIA, V47, P1879, DOI 10.1111/j.1528-1167.2006.00611.x; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Eysenck HJ., 1991, MANUAL EYSENCK PERSO; FAUST D, 1988, SCIENCE, V241, P31, DOI 10.1126/science.3291114; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; Faust D, 1988, Arch Clin Neuropsychol, V3, P145, DOI 10.1016/0887-6177(88)90060-1; FAUST D, 1995, NEUROL CLIN, V13, P255, DOI 10.1016/S0733-8619(18)30044-6; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick RI, 2007, ASSESSMENT, V14, P3, DOI 10.1177/1073191106292009; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; GIOIA GA, 1996, BRIEF BEHAV RATING I; GOUGH HG, 1947, J ABNORM SOC PSYCH, V42, P215, DOI 10.1037/h0063295; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 1996, WORD MEMORY TEST USE; GREEN P, 2007, GREENS NONVERBAL MED; Greve KW, 2008, ARCH CLIN NEUROPSYCH, V23, P341, DOI 10.1016/j.acn.2007.12.001; Greve KW, 2007, CHILD PSYCHIAT HUM D, V37, P307, DOI 10.1007/s10578-006-0036-3; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Greve KW, 2006, NEUROTOXICOLOGY, V27, P940, DOI 10.1016/j.neuro.2006.06.009; Greve KW, 2007, ASSESSMENT, V14, P12, DOI 10.1177/1073191106295095; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; GREVE KW, 2007, CLIN NEUROPSYCHOL, V21, P1; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Iverson GL, 2003, HANDBOOK OF FORENSIC NEUROPSYCHOLOGY, P137; Kaemmer, 1989, MINNESOTA MULTIPHASI; KAPUR N, 1994, J NEUROL NEUROSUR PS, V57, P385, DOI 10.1136/jnnp.57.3.385; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; LORING DW, 1995, ANN N AM M INT NEUR; Meehl P.E., 1954, CLIN VERSUS STAT PRE; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; POWELL G, 2004, CLIN NEUROPSYCHOLOGY; Powell MR, 2004, CLIN NEUROPSYCHOL, V18, P465, DOI 10.1080/1385404049052409; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; RUOCCO AC, 2007, CLIN NEUROPSYCHOL, V26, P1; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; VANDERWERF SP, 2000, NEUROPSYCHIATRY NEUR, V13; WADDELL G, 1980, SPINE, V5, P117, DOI 10.1097/00007632-198003000-00005; Warrington E, 1984, RECOGNITION MEMORY T, V1; [No title captured]	81	27	28	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	6					1050	1066	PII 908983482	10.1080/13854040802665790			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	473BG	WOS:000268178000009	19235633				2022-02-06	
J	Siegert, RJ; Walkey, FH; Turner-Stokes, L				Siegert, Richard J.; Walkey, Frank H.; Turner-Stokes, Lynne			An examination of the factor structure of the Beck Depression Inventory-II in a neurorehabilitation inpatient sample	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Beck Depression Inventory; BDI-II; Depression; Rehabilitation; Factor analysis; Statistical; Brain injuries	TRAUMATIC BRAIN-INJURY; INTEGRATED CARE PATHWAY; PAIN	The Beck Depression Inventory-II (BDI-II) is widely used for assessing depression in neurorehabilitation. Given the concern that the somatic items might be misleading, we examined its factor structure in 353 inpatients. Exploratory factor analysis was undertaken to compare two- to five-factor solutions. Confirmatory factor analysis was then used to test the best exploratory solutions for goodness of fit on a subsample. Both provided strong support for a general depression factor and two specific factors, one somatic and one cognitive/affective. The BDI-II provides a meaningful score of overall depression, and it can also yield two subscores-one measuring somatic symptoms and the other measuring psychological symptoms of depression. To avoid confusing the common symptoms of neurological disability with depression in neurorehabilitation, clinicians need to consider all three scores carefully. (JINS, 2009, 15, 142-147.)	[Siegert, Richard J.; Turner-Stokes, Lynne] Kings Coll London, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England; [Walkey, Frank H.] Victoria Univ Wellington, Sch Psychol, Wellington, New Zealand; [Turner-Stokes, Lynne] Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, London, England		Siegert, RJ (corresponding author), Guys Kings Coll, Dept Palliat Care Policy & Rehabil, Sch Med, 3rd Floor,Cutcombe Rd,Denmark Hill, London SE5 9RJ, England.	richard.siegert@kcl.ac.uk	Siegert, Richard/C-3241-2009; Turner-Stokes, Lynne/F-4418-2012; Siegert, Richard J./K-2030-2019	Turner-Stokes, Lynne/0000-0002-3302-9462; Siegert, Richard/0000-0002-3074-0929	Dunhill Medical TrustDunhill Medical Trust; Luff Foundation	We are grateful to all the patients on the Regional Rehabilitation Unit, Northwick Park Hospital, who allowed their data to be used and staff who performed the assessments. We are especially grateful to Dr. Frances Clegg for initiating the data set and to Margot Kalmus, Jo Clark, and Heather Williams for assistance with collation and validation of the data set. Financial support for the preparation of this manuscript was provided by the Dunhill Medical Trust and the Luff Foundation. Three anonymous reviewers made suggestions that assisted the authors to substantially improve the original manuscript.	Arnau RC, 2001, HEALTH PSYCHOL, V20, P112, DOI 10.1037//0278-6133.20.2.112; Balos D.L., 2001, NEW DEV TECHNIQUES S, P269, DOI DOI 10.4324/9781410601858; BARRETT PT, 1981, PERS INDIV DIFFER, V2, P311, DOI 10.1016/0191-8869(81)90086-6; Beck A. T., 1966, BECK DEPRESSION INVE; CATTELL RB, 1974, AUST J PSYCHOL, V26, P103, DOI 10.1080/00049537408255223; CHRISTENSEN BK, 1995, J INT NEUROPSYCH SOC, V1, P122; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hassan N, 2002, CLIN REHABIL, V16, P534, DOI 10.1191/0269215502cr523oa; Hau KT, 2004, BRIT J MATH STAT PSY, V57, P327, DOI 10.1111/j.2044-8317.2004.tb00142.x; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Morley S, 2002, PAIN, V99, P289, DOI 10.1016/S0304-3959(02)00137-9; Munoz DJ, 2007, OBES SURG, V17, P1097, DOI 10.1007/s11695-007-9185-0; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; *ROYAL COLL PHYS, 2005, US ANT MED AD UND RE; Thombs BD, 2007, BURNS, V33, P547, DOI 10.1016/j.burns.2006.10.398; Thompson B., 2004, EXPLORATORY CONFIRMA; Turner-Stokes L, 2002, CLIN REHABIL, V16, P231, DOI 10.1191/0269215502cr487oa; Ullman JB., 2001, USING MULTIVARIATE S, V4, P653; Wesley AL, 1999, CLIN J PAIN, V15, P117, DOI 10.1097/00002508-199906000-00008	22	27	27	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					142	147		10.1017/S1355617708090048			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300016	19128538				2022-02-06	
J	Temple, RO; Zgaljardic, DJ; Abreu, BC; Seale, GS; Ostir, GV; Ottenbacher, KJ				Temple, Richard O.; Zgaljardic, Dennis J.; Abreu, Beatriz C.; Seale, Gary S.; Ostir, Glenn V.; Ottenbacher, Kenneth J.			Ecological validity of the neuropsychological assessment battery screening module in post-acute brain injury rehabilitation	BRAIN INJURY			English	Article						Traumatic brain injury; neuropsychological assessment; outcomes assessment; rehabilitation	FUNCTIONAL INDEPENDENCE; STROKE; NAB; PERFORMANCE; IMPAIRMENT; VALIDATION; SAMPLE; SCORES; SCALE	Primary objective: To assess the ecological validity of the Screening Module of the Neuropsychological Assessment Battery (NAB-SM) using the Functional Independence Measure (FIM). Method: Seventy individuals with moderate-to-severe traumatic brain injury at a residential post-acute rehabilitation facility were administered the FIM instrument and the NAB-SM upon admission. Hierarchical regression analysis was used to examine the relationship between the variables from these two assessment measures. Results: Hierarchical models revealed that (1) the NAB-SM Total score was significantly associated with the FIM instrument Total score as well as the Motor and Cognition sub-scale scores, above and beyond the contribution of demographic variables, (2) the NAB-SM Language, Memory and Spatial domain scores were significantly associated with of the FIM instrument Cognition sub-scale score and (3) the NAB-SM Spatial domain score was significantly associated with of the FIM instrument Total and Motor sub-scale scores. Conclusions: The current findings support previous research and provide strong evidence for the ecological validity of the NAB-SM with regard to functional abilities as assessed by the FIM instrument.	[Zgaljardic, Dennis J.] Transit Learning Ctr, Dept Neuropsychol, Galveston, TX 77550 USA; [Temple, Richard O.] CORE Hlth Care, Dripping Springs, TX USA; [Zgaljardic, Dennis J.; Abreu, Beatriz C.; Seale, Gary S.; Ostir, Glenn V.; Ottenbacher, Kenneth J.] Univ Texas Med Branch, Galveston, TX USA		Zgaljardic, DJ (corresponding author), Transit Learning Ctr, Dept Neuropsychol, 1528 PO St, Galveston, TX 77550 USA.	dzgaljardic@tlc-galveston.org		Ottenbacher, Kenneth/0000-0001-5990-3982	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K02-AG019736]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01-HD046682]; Moody Foundation [2005-24]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD046682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K02AG019736, R01AG031178, R01AG024806] Funding Source: NIH RePORTER	This work was supported in part by the National Institute on Aging, Grant K02-AG019736; and by the National Institute of Child Health and Human Development, Grant K01-HD046682 and by the Moody Foundation, Grant #2005-24. We also gratefully acknowledge Jason Levinson, MA, for his assistance with data collection and Renee Pearcy for her research assistance.	Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brown LB, 2005, ARCH CLIN NEUROPSYCH, V20, P209, DOI 10.1016/j.acn.2004.06.003; Chan CHC, 1999, ARCH CLIN NEUROPSYCH, V14, P71, DOI 10.1093/arclin/14.1.71; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; COTE R, 1986, STROKE, V17, P731, DOI 10.1161/01.STR.17.4.731; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Fong KNK, 2001, BRAIN INJURY, V15, P443, DOI 10.1080/02699050010005940; Golding E., 1989, MIDDLESEX ELDERLY AS; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; GOWLAND C, 1993, STROKE, V24, P58, DOI 10.1161/01.STR.24.1.58; Hajek VE, 1997, ARCH PHYS MED REHAB, V78, P1331, DOI 10.1016/S0003-9993(97)90306-3; HAJEK VE, 1989, ARCH PHYS MED REHAB, V70, P114; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Iverson GL, 2007, APPL NEUROPSYCHOL, V14, P178, DOI 10.1080/09084280701508952; Kaplan E.F., 1978, BOSTON NAMING TEST; Kutlay S, 2007, DISABIL REHABIL, V29, P315, DOI 10.1080/09638280600756612; Lynch WJ, 2004, J HEAD TRAUMA REHAB, V19, P180, DOI 10.1097/00001199-200403000-00009; MAHONEY F I, 1965, Md State Med J, V14, P61; NELSON A, 1986, J NERV MENT DIS, V174, P73, DOI 10.1097/00005053-198602000-00002; RAVEN JA, 1947, COLORED PROGRESSIVE; Reitan R, 1985, HALSTEAD REITAN NEUR; SEABY L, 1989, Physiotherapy Canada, V41, P264; SEGAL ME, 1993, PARAPLEGIA, V31, P622, DOI 10.1038/sc.1993.101; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; TEMPLE RO, 2006, ANN M NAT AC NEUR SA; Wechsler D., 1987, MANUAL WECHSLER ADUL; White T, 2003, NEUROPSYCHOLOGICAL A; ZGALJARDIC DJ, 2008, ANN M INT NEUR SOC W	29	27	29	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	1					45	50	PII 906993240	10.1080/02699050802590361			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	399FY	WOS:000262787000009	19096970	Green Accepted			2022-02-06	
J	Wood, RLL; Williams, C; Kalyani, T				Wood, Rodger L. L.; Williams, Claire; Kalyani, Tania			The impact of alexithymia on somatization after traumatic brain injury	BRAIN INJURY			English	Article						TBI; TAS-20; somatization; affective disorder	ORGANIC ALEXITHYMIA; GENERAL-POPULATION; HEAD-INJURY; SCALE; DEPRESSION; SYMPTOMS; ASSOCIATION; DISORDERS; VALIDITY	Introduction: High rates of alexithymia have been reported following traumatic brain injury (TBI). Difficulty modulating emotional states has been shown to increase the risk of affective distress and the tendency to express this distress in the form of physical symptoms. The current study therefore examined relationships between alexithymia, affective distress and somatization in a TBI sample. Method: Eighty-three patients with TBI completed the Toronto Alexithymia Scale (TAS-20) and the Symptom Checklist (SCL-90-R). Results: Alexithymic individuals reported higher ratings of anxiety, low mood and somatic symptoms. Alexithymia accounted for a significant amount of variance in anxiety, depression and somatization ratings. Scores on sub-scale 1 of the TAS-20 (difficulty identifying feelings) made a significant unique contribution to explaining somatization ratings after controlling for the influence of anxiety and depression ratings. Conclusion: Alexithymia after TBI increases the risk of affective disturbance and somatization. It needs to be identified at an early stage to direct rehabilitation interventions and improve prospects for psychosocial outcome.	[Wood, Rodger L. L.; Williams, Claire; Kalyani, Tania] Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales		Wood, RLL (corresponding author), Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X			Bach M, 1996, PSYCHOSOMATICS, V37, P451, DOI 10.1016/S0033-3182(96)71533-5; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; Cohen J., 2013, STAT POWER ANAL BEHA; COX BJ, 1995, COMPR PSYCHIAT, V36, P195, DOI 10.1016/0010-440X(95)90081-6; De Gucht V, 2003, J PSYCHOSOM RES, V54, P425, DOI 10.1016/S0022-3999(02)00467-1; De Gucht V, 2004, PERS INDIV DIFFER, V36, P1655, DOI 10.1016/j.paid.2003.06.012; Derogatis L, 1977, SCL90R J HOPK U SCH; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Honkalampi K, 2000, J PSYCHOSOM RES, V48, P99, DOI 10.1016/S0022-3999(99)00083-5; Hoofien D, 2005, APPL NEUROPSYCHOL, V12, P30, DOI 10.1207/s15324826an1201_6; Jones MP, 2004, PSYCHOSOMATICS, V45, P508, DOI 10.1176/appi.psy.45.6.508; Koh KB, 2005, J CLIN PSYCHIAT, V66, P485, DOI 10.4088/JCP.v66n0411; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Loas G, 2001, J PSYCHOSOM RES, V50, P255, DOI 10.1016/S0022-3999(01)00197-0; Luminet O, 2001, PSYCHOTHER PSYCHOSOM, V70, P254, DOI 10.1159/000056263; Mattila AK, 2008, PSYCHOSOM MED, V70, P716, DOI 10.1097/PSY.0b013e31816ffc39; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Nelson H.E., 1982, NATL ADULT READING T; PARKER JDA, 1993, EUR J PERSONALITY, V7, P221, DOI 10.1002/per.2410070403; Parker JDA, 2001, PERS INDIV DIFFER, V30, P107, DOI 10.1016/S0191-8869(00)00014-3; PASINI A, 1992, COMPR PSYCHIAT, V33, P42, DOI 10.1016/0010-440X(92)90078-5; PENNEBAKER JW, 1995, CANADIAN PSYCHOL, V26, P82; Rasquin S, 2005, CEREBROVASC DIS, V19, P309, DOI 10.1159/000084499; Salminen JK, 1999, J PSYCHOSOM RES, V46, P75, DOI 10.1016/S0022-3999(98)00053-1; Taylor G. J., 1997, DISORDERS AFFECT REG; TAYLOR GJ, 1992, J PSYCHOSOM RES, V36, P417, DOI 10.1016/0022-3999(92)90002-J; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS C, J CLIN EXPT IN PRESS; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518	34	27	27	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					649	654	PII 912684062	10.1080/02699050902970786			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600009	19557568				2022-02-06	
J	Johnstone, B; Glass, BA				Johnstone, Brick; Glass, Bret A.			SUPPORT FOR A NEUROPSYCHOLOGICAL MODEL OF SPIRITUALITY IN PERSONS WITH TRAUMATIC BRAIN INJURY	ZYGON			English	Article						neuropsychology; spirituality; traumatic brain injury	TEMPORAL-LOBE EPILEPSY; CEREBRAL-BLOOD-FLOW; RELIGIOUS-EXPERIENCE; MEDITATION; ATTENTION; DISEASE; SPECT; TASK; MYTH	Recent research suggests that spiritual experiences are related to increased physiological activity of the frontal and temporal lobes and decreased activity of the right parietal lobe. The current study determined if similar relationships exist between self-reported spirituality and neuropsychological abilities associated with those cerebral structures for persons with traumatic brain injury (TBI). Participants included 26 adults with TBI referred for neuropsychological assessment. Measures included the Core Index of Spirituality (INSPIRIT); neuropsychological indices of cerebral structures: temporal lobes (Wechsler Memory Scale-III), right parietal lobe (Judgment of Line Orientation), and frontal lobes (Trail Making Test, Controlled Oral Word Association Test). As hypothesized, spirituality was significantly negatively correlated with a measure of right parietal lobe functioning and positively correlated (nonsignificantly) with measures of left temporal lobe functioning. Contrary to hypotheses, correlations between spirituality and measures of frontal lobe functioning were zero or negative (and nonsignificant). The data support a neuropsychological model that proposes that spiritual experiences are related to decreased activity of the right parietal lobe, which may be associated with decreased awareness of the self (transcendence) and increased activity of the left temporal lobe, which may be associated with the experience of specific religious archetypes (religious figures and symbols).	[Johnstone, Brick] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA; [Glass, Bret A.] Univ Missouri, Dept Educ Sch & Counseling Psychol, Columbia, MO 65212 USA		Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			Aftanas LI, 2001, NEUROSCI LETT, V310, P57, DOI 10.1016/S0304-3940(01)02094-8; Azari NP, 2001, EUR J NEUROSCI, V13, P1649, DOI 10.1046/j.0953-816x.2001.01527.x; BEAR DM, 1979, CORTEX, V15, P357, DOI 10.1016/S0010-9452(79)80064-7; BEAR DM, 1977, ARCH NEUROL-CHICAGO, V34, P454, DOI 10.1001/archneur.1977.00500200014003; BENTON A, 1975, NEUROLOGY, V25, P907, DOI 10.1212/WNL.25.10.907; BENTON AL, 1970, NEUROLOGY, V20, P1084, DOI 10.1212/WNL.20.11.1084; Brozgold A Z, 1998, Appl Neuropsychol, V5, P15, DOI 10.1207/s15324826an0501_2; d'Aquili E. G., 1993, STUDIA LITURGICA, V23, P2; d'Aquili E. G., 1993, ZYGON J RELIG SCI, V33, P177; d'Aquili EG, 2000, ZYGON, V35, P39, DOI 10.1111/0591-2385.00258; d'Aquili EG, 1998, ZYGON, V33, P187, DOI 10.1111/0591-2385.00140; DAQUILI EG, 1978, ZYGON, V13, P257, DOI 10.1111/j.1467-9744.1978.tb00338.x; DAQUILI EG, 1986, ZYGON, V21, P141, DOI 10.1111/j.1467-9744.1986.tb00741.x; FENWICK P, 2003, SPIRITUALITY PSYCHIA, V13; Hamsher K., 1989, MULTILINGUAL APHASIA; HERZOG H, 1991, NEUROPSYCHOBIOLOGY, V23, P182, DOI 10.1159/000119450; Johnstone B., 1995, APPL NEUROPSYCHOL, V2, DOI [10.1207/s15324826an0201_4, DOI 10.1207/S15324826AN0201_4]; Joseph R, 1990, NEUROPSYCHOLOGY NEUR; KANDEL ER, 1993, PRINCIPLES NEURAL SC; KASS JD, 1991, J SCI STUD RELIG, V30, P203, DOI 10.2307/1387214; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Mesulam M.-M., 2000, PRINC BEHAV COGN NEU, V2, P1, DOI [DOI 10.1017/9781108164320.002, 10.1017/9781108164320.002]; Newberg A, 2003, PERCEPT MOTOR SKILL, V97, P625, DOI 10.2466/PMS.97.5.625-630; Newberg A, 2001, PSYCHIAT RES-NEUROIM, V106, P113, DOI 10.1016/S0925-4927(01)00074-9; Newberg A, 1997, J NUCL MED, V38, P77; Newberg AB, 2003, MED HYPOTHESES, V61, P282, DOI 10.1016/S0306-9877(03)00175-0; NEWBERG AB, 2005, FIELD ANAL NEUROSCIE; Newberg Andrew I., 2005, HDB PSYCHOL RELIG SP, P199; NOVELLY RA, 1984, ANN NEUROL, V15, P64, DOI 10.1002/ana.410150112; Portas CM, 1998, J NEUROSCI, V18, P8979; Puri BK, 2001, INT J PSYCHOPHYSIOL, V40, P143, DOI 10.1016/S0167-8760(00)00159-8; Reitan RM, 1992, TRAIL MAKING TEST MA; Saver JL, 1997, J NEUROPSYCH CLIN N, V9, P498; Shimizu T, 2000, NEUROREPORT, V11, P3077, DOI 10.1097/00001756-200009280-00009; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Tranel D., 2002, HDB MEMORY DISORDERS; Wechsler D, 1997, WMS 3 ADM SCORING MA; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wuerfel J, 2004, J NEUROL NEUROSUR PS, V75, P640, DOI 10.1136/jnnp.2003.06973; [No title captured]; [No title captured]	42	27	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0591-2385	1467-9744		ZYGON	Zygon	DEC	2008	43	4					861	874		10.1111/j.1467-9744.2008.00964.x			14	Social Issues; Religion	Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Social Issues; Religion	375JO	WOS:000261110200007					2022-02-06	
J	Benton, RL; Maddie, MA; Worth, CA; Mahoney, ET; Hagg, T; Whittemore, SR				Benton, Richard L.; Maddie, Melissa A.; Worth, Christopher A.; Mahoney, Edward T.; Hagg, Theo; Whittemore, Scott R.			Transcriptomic screening of microvascular endothelial cells implicates novel molecular regulators of vascular dysfunction after spinal cord injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						flow cytometry; PAI-1; spinal cord injury; TSP-1; uPA	PLASMINOGEN-ACTIVATOR RECEPTOR; CONTUSION INJURY; UP-REGULATION; HUMAN BRAIN; RAT; BARRIER; VESSELS; GROWTH; MOUSE; PAI-1	Microvascular dysfunction is a critical pathology that underlies the evolution of secondary injury mechanisms after traumatic spinal cord injury (SCI). However, little is known of the molecular regulation of endothelial cell (EC) plasticity observed acutely after injury. One reason for this is the relative lack of methods to quickly and efficiently obtain highly enriched spinal microvascular ECs for high-throughput molecular and biochemical analyses. Adult C57Bl/6 mice received an intravenous injection of fluorescein isothiocyanate ( FITC)-conjugated Lycopersicon esculentum lectin, and FITC-lectin-bound spinal microvessels were greatly enriched by fluorescence-activated cell sorter (FACS) purification. This technique allows for rapid (< 1.5 h postmortem) isolation of spinal cord microvascular ECs (smvECs). The results from cell counting, reverse-transcription polymerase chain reaction (RT-PCR), and western blot analyses show a high degree of EC enrichment at mRNA and protein levels. Furthermore, a focused EC biology microarray analysis identified multiple mRNAs dramatically increased in the EC compartment 24 h after SCI, which is a time point associated with the pathologic loss of spinal vasculature. These included thrombospondin-1, CCL5/RANTES, and urokinase plasminogen activator, suggesting they may represent targets for therapeutic intervention. Furthermore, these novel methodologic approaches will likely facilitate the discovery of molecular regulators of endothelial dysfunction in a variety of central nervous system (CNS) disorders including stroke and other neurodegenerative diseases having a vascular component.	[Benton, Richard L.; Maddie, Melissa A.; Mahoney, Edward T.; Hagg, Theo; Whittemore, Scott R.] Univ Louisville, Sch Med, Kentucky Spinal Cord Res Ctr, Louisville, KY 40292 USA; [Benton, Richard L.; Maddie, Melissa A.; Mahoney, Edward T.; Hagg, Theo; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; [Benton, Richard L.; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; [Worth, Christopher A.] Univ Louisville, Sch Med, Brown Canc Ctr, Louisville, KY 40292 USA; [Hagg, Theo] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA		Benton, RL (corresponding author), Univ Louisville, Sch Med, Kentucky Spinal Cord Res Ctr, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	rlbent01@louisville.edu			Norton Healthcare [NS045734, RR15576]; Commonwealth of Kentucky Challenge for Excellence; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045734] Funding Source: NIH RePORTER	This research was supported by NS045734, RR15576, Norton Healthcare, and by the Commonwealth of Kentucky Challenge for Excellence (SRW and TH).	Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Albo D, 1999, J SURG RES, V82, P331, DOI 10.1006/jsre.1998.5578; Arai Y, 1998, ACTA NEUROCHIR, V140, P377, DOI 10.1007/s007010050112; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; Beschorner R, 2000, NEUROPATH APPL NEURO, V26, P522, DOI 10.1046/j.0305-1846.2000.287.x; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Casella GTB, 2006, EXP NEUROL, V202, P8, DOI 10.1016/j.expneurol.2006.05.028; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; DIGLIO CA, 1982, LAB INVEST, V46, P554; DUCKER T B, 1969, Surgical Forum (Chicago), V20, P428; Enerson BE, 2006, J CEREBR BLOOD F MET, V26, P959, DOI 10.1038/sj.jcbfm.9600249; Ge SJ, 2006, J NEUROIMMUNOL, V177, P209, DOI 10.1016/j.jneuroim.2006.05.012; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Hamann GF, 2004, STROKE, V35, P764, DOI 10.1161/01.STR.0000116866.60794.21; Hemmings SJ, 1999, MOL CELL BIOCHEM, V202, P119, DOI 10.1023/A:1007069431615; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; JOO F, 1982, J NEUROCHEM, V39, P263, DOI 10.1111/j.1471-4159.1982.tb04731.x; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Lin Y, 2007, J CEREBR BLOOD F MET, V27, P1010, DOI 10.1038/sj.jcbfm.9600412; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Minor KH, 2008, MOL CELL NEUROSCI, V37, P143, DOI 10.1016/j.mcn.2007.09.005; Nagai N, 2008, NEUROSCI LETT, V432, P46, DOI 10.1016/j.neulet.2007.12.004; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Prager GW, 2004, CIRC RES, V94, P1562, DOI 10.1161/01.RES.0000131498.36194.6b; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; Shusta EV, 2002, J CEREBR BLOOD F MET, V22, P245, DOI 10.1097/00004647-200203000-00001; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Wu ZH, 2003, J NEUROSCI METH, V130, P53, DOI 10.1016/S0165-0270(03)00206-1; YANG GY, 1994, J NEUROSURG, V81, P82; Yousif S, 2007, BRAIN RES, V1134, P1, DOI 10.1016/j.brainres.2006.11.089; Zhang XF, 2007, MICROVASC RES, V74, P90, DOI 10.1016/j.mvr.2007.04.007; Zhang ZG, 1999, J NEUROSCI, V19, P10898, DOI 10.1523/JNEUROSCI.19-24-10898.1999	38	27	28	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2008	28	11					1771	1785		10.1038/jcbfm.2008.76			15	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	366IB	WOS:000260472900002	18612314	Green Accepted			2022-02-06	
J	Stranjalis, G; Bouras, T; Korfias, S; Andrianakis, I; Pitaridis, M; Tsamandouraki, K; Alamanos, Y; Sakas, DE; Marmarou, A				Stranjalis, George; Bouras, Triantafyllos; Korfias, Stefanos; Andrianakis, Ilias; Pitaridis, Marinos; Tsamandouraki, Kiki; Alamanos, Yannis; Sakas, Damiabos E.; Marmarou, Anthony			Outcome in 1,000 Head Injury Hospital Admissions: The Athens Head Trauma Registry	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Clinical management of brain injury; Epidemiology; Head trauma; Outcome measures; Traumatic brain injury	BRAIN-INJURY; INTENSIVE-CARE; SUBDURAL HEMATOMAS; MANAGEMENT; EPIDEMIOLOGY; COMA; CONSORTIUM; PRESSURE	Background. The aim of this study was to establish a head trauma registry to (a) examine demographics, etiology, severity, clinical course, and outcome; (b) compare results with previous published series; (c) identify causes of bad outcomes; and (d) propose methods to improve therapy and prognosis. Methods: The following data were collected on 1,000 consecutive victims with head injury over 14 years of age admitted during a 4-year period: demographic characteristics, cause of injury, clinical variables, neuroimaging, therapy data, and outcome in 6 months. Results: Seventy-four percent were men, and mean age was 43 years. Seventy-one percent suffered injuries due to road crashes, 14% due to alcohol, and 2% due to substances. The secondary transfer rate was 49%. For severe injuries, the time intervals from incident to hospital and subsequently to neurosurgical unit were 35 minutes and 4 hours, respectively. In 65% and 72% of cases, there was no record of preresuscitation hypoxia or hypotension, respectively, whereas suspected or definite episodes of hypoxia and hypotension were 27% and 13%, respectively. Most cases were mild trauma (63%), the remaining were severe (26%) and moderate (11%) injuries. Severe systemic trauma coexisted in 18%. Cranial surgery rate was.19% and it increased to 39% in severe trauma. The 6-month overall good outcome was 71%, with lower rates in moderate (58%) and severe (24%) injuries. Conclusions: The organization of Greece's first head injury registry offered an important preliminary core data concerning brain trauma etiology, management, and long-term outcome.	[Stranjalis, George; Bouras, Triantafyllos; Korfias, Stefanos; Sakas, Damiabos E.] Univ Athens, Dept Neurosurg, Evangelismos Hosp, Athens, Greece; [Andrianakis, Ilias; Pitaridis, Marinos] Univ Athens, Dept Intens Care Med, Evangelismos Hosp, Athens, Greece; [Stranjalis, George; Bouras, Triantafyllos; Korfias, Stefanos; Sakas, Damiabos E.] Hellen Neurosurg Res Ctr Prof P Kokkalis, Athens, Greece; [Tsamandouraki, Kiki] Inst Social & Prevent Med, Athens, Greece; [Alamanos, Yannis] Univ Ioannina, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece; [Marmarou, Anthony] Amer Brain Injury Consortium, Richmond, VA USA		Stranjalis, G (corresponding author), 32 Skoufa St, Athens 10673, Greece.	stranjal@otenet.gr					Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Annoni J M, 1992, Disabil Rehabil, V14, P23; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Cruz J, 2001, NEUROSURGERY, V49, P864; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1979, Acta Neurochir Suppl (Wien), V28, P149; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; OBrien DP, 1996, IRISH MED J, V89, P216; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; QUATTROCCHI KB, 1991, SURG NEUROL, V35, P183, DOI 10.1016/0090-3019(91)90069-L; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; SERVADEI F, 1988, ITAL J NEUROL SCI, V9, P449, DOI 10.1007/BF02337162; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Stranjalis G, 1996, SURG NEUROL, V45, P314, DOI 10.1016/0090-3019(95)00435-1; Stranjalis G, 1998, J NEUROSURG, V88, P782, DOI 10.3171/jns.1998.88.4.0782; Stranjalis G, 2000, HEADACHE, V40, P176, DOI 10.1046/j.1526-4610.2000.00024.x; STRANJALIS G, 2000, J RESTOR NEUROSCI NE, V6, P24; TALIAFERI T, 2006, ACTA NEUROCHIR WIEN, V148, P255; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, ACTA NEUROCHIR, V139, P797, DOI 10.1007/BF01411397; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049	44	27	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2008	65	4					789	793		10.1097/TA.0b013e3181469e26			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	361JS	WOS:000260124500009	18849792				2022-02-06	
J	Bonatti, E; Zamarian, L; Wagner, M; Benke, T; Hollosi, P; Strubreither, W; Delazer, M				Bonatti, Elisabeth; Zamarian, Laura; Wagner, Michaela; Benke, Thomas; Hollosi, Pia; Strubreither, Wilhelm; Delazer, Margarete			Making decisions and advising decisions in traumatic brain injury	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						decision-making; risk; ambiguity; executive functions; TBI	ORBITAL PREFRONTAL CORTEX; SOMATIC MARKER HYPOTHESIS; IOWA GAMBLING TASK; HEAD-INJURY; ADVANTAGEOUS DECISIONS; ORBITOFRONTAL CORTEX; COGNITIVE ESTIMATION; MAKING PROCESSES; PERFORMANCE; RISK	Objective and Background: Decision under ambiguity and decision under risk are fundamental in every-day life. Methods: We investigated these 2 types of decision in traumatic brain injury (TBI) patients through the Iowa Gambling Task (IGT), the Probability-Associated Gambling (PAG) task, and a Counsel version of the PAG task. Although in the IGT rules for gain and losses are implicit and probability information is missing, in the PAG task and the counsel task rules are explicit and probabilities are well-defined. Results: In the IGT, TBI patients selected more disadvantageously than healthy controls and failed to develop,in advantageous strategy over time. Patients also made less advantageous choices than controls in the PAG task and the counsel task. Compared with controls, TBI patients gambled more frequently with low probabilities and less frequently With high probabilities. Overall, participants decided more advantageously in the counsel task, which does not provide feedback. than in the PAG task. Importantly, our results indicate that TBI patients' performance oil all decision tasks correlated with executive functions. Conclusions: Our study shows that TBI patients have difficulties in decision under risk and decision Under ambiguity. Difficulties may be attributed to deficient learning from feedback and to reduced risk estimation. but not to impulsive risk taking behavior.	[Bonatti, Elisabeth; Zamarian, Laura; Benke, Thomas; Delazer, Margarete] Innsbruck Med Univ, Dept Clin Neurol, A-6020 Innsbruck, Austria; [Wagner, Michaela] Innsbruck Med Univ, Dept Radiol, A-6020 Innsbruck, Austria; [Hollosi, Pia; Strubreither, Wilhelm] Austrian Workers Compensat Board, Rehabil Ctr Haring, Bad Haring, Austria		Bonatti, E (corresponding author), Innsbruck Med Univ, Dept Clin Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	Elisabeth.Bonatti@i-med.ac.at	Zamarian, Laura/J-9575-2018	Zamarian, Laura/0000-0002-1640-4179; Delazer, Margarete/0000-0001-6482-4445			ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; [Anonymous], 2002, TESTBATTERIE AUFMERK; Aschenbrenner S., 2000, REGENSBURGER WORTFLU; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2005, TRENDS COGN SCI, V9, P159, DOI 10.1016/j.tics.2005.02.002; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bolla KI, 2004, CEREB CORTEX, V14, P1226, DOI 10.1093/cercor/bhh083; BRAND M, 2008, J NEUROPSYC IN PRESS; Brand M., 2002, TEST ZUM KOGNITIVEN; Brand M, 2007, J CLIN EXP NEUROPSYC, V29, P86, DOI 10.1080/13803390500507196; Brand M, 2006, NEURAL NETWORKS, V19, P1266, DOI 10.1016/j.neunet.2006.03.001; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; Damasio H, 1995, HUMAN BRAIN ANATOMY; Denburg NL, 2007, ANN NY ACAD SCI, V1121, P480, DOI 10.1196/annals.1401.031; Denburg NL, 2005, NEUROPSYCHOLOGIA, V43, P1099, DOI 10.1016/j.neuropsychologia.2004.09.012; Denburg NL, 2001, BRAIN COGNITION, V47, P156; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Dunn BD, 2006, NEUROSCI BIOBEHAV R, V30, P239, DOI 10.1016/j.neubiorev.2005.07.001; *ENJOIMESOFT, 2002, PLAN COMP PROGR; Fein G, 2007, J INT NEUROPSYCH SOC, V13, P480, DOI 10.1017/S135561770707052X; FLOWERS KA, 1985, J NEUROL NEUROSUR PS, V48, P517, DOI 10.1136/jnnp.48.6.517; Fox AM, 2000, CLIN NEUROPHYSIOL, V111, P1045, DOI 10.1016/S1388-2457(00)00257-1; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Fukui H, 2005, NEUROIMAGE, V24, P253, DOI 10.1016/j.neuroimage.2004.08.028; Garcia-Molina A, 2007, NEUROLOGIA, V22, P206; Harting C, 2000, WMS R WECHSLER GEDAC; Helmstaedter C., 2001, VLMT VERBALER LERN M; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; JACKSON M, 1986, CORTEX, V22, P611, DOI 10.1016/S0010-9452(86)80020-X; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P615, DOI 10.1017/S1355617707070762; LEHRL S, 1991, MANUAL ZUM MWT B; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; LEZAK MD, 1998, NEUROPSYCHOLOGICAL A; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Overman WH, 2004, BRAIN COGNITION, V55, P134, DOI 10.1016/s0278-2626(03)00279-3; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; Shiv B, 2005, COGNITIVE BRAIN RES, V23, P85, DOI 10.1016/j.cogbrainres.2005.01.006; Silverberg ND, 2007, J INT NEUROPSYCH SOC, V13, P898, DOI 10.1017/S1355617707071135; Sinz H, 2008, NEUROPSYCHOLOGIA, V46, P2043, DOI 10.1016/j.neuropsychologia.2008.02.002; Smith GJ, 2002, MEASURING GAMBLING P; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trepel C, 2005, COGNITIVE BRAIN RES, V23, P34, DOI 10.1016/j.cogbrainres.2005.01.016; Wade D, 1992, MEASUREMENT NEUROLOG; Wiederkehr S, 2005, REV NEUROL-FRANCE, V161, P201, DOI 10.1016/S0035-3787(05)85023-4; Yacubian J, 2007, NEUROIMAGE, V38, P557, DOI 10.1016/j.neuroimage.2007.08.007; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; ZAMARIAN L, 2008, NEUROPSYCHO IN PRESS	59	27	28	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1543-3633			COGN BEHAV NEUROL	Cogn. Behav. Neurol.	SEP	2008	21	3					164	175		10.1097/WNN.0b013e318184e688			12	Behavioral Sciences; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	354UL	WOS:000259664400007	18797259				2022-02-06	
J	Awad, H; Suntres, Z; Heijmans, J; Smeak, D; Bergdall-Costell, V; Christofi, FL; Magro, C; Oglesbee, M				Awad, Hamdy; Suntres, Zacharias; Heijmans, John; Smeak, Daniel; Bergdall-Costell, Valerie; Christofi, Fievos L.; Magro, Cynthia; Oglesbee, Michael			Intracellular and extracellular expression of the major inducible 70kDa heat shock protein in experimental ischemia-reperfusion injury of the spinal cord	EXPERIMENTAL NEUROLOGY			English	Article						spinal cord; ischemia-reperfusion injury; heat shock protein 70	WHOLE-BODY HYPERTHERMIA; TRAUMATIC BRAIN-INJURY; STRESS-RESPONSE; OXIDATIVE STRESS; IN-VITRO; DIABETIC-KETOACIDOSIS; HSP72 INDUCTION; MESSENGER-RNA; BLOOD-VOLUME; GLIAL-CELLS	Inflammatory responses exacerbate ischemia-reperfusion (IR) injury of spinal Cord, although understanding of mediators is incomplete. The major inducible 70kDa heat shock protein (hsp70) is induced by ischemia and extracellular hsp70 (e-hsp70) can modulate inflammatory responses, but there is no published information regarding e-hsp70 levels in the cerebrospinal fluid (CSF) or serum as part of any neurological disease state save trauma. The present work addresses this deficiency by examining e-hsp70 in serum and CSF of dogs in an experimental model of spinal cord IR injury. IR injury of spinal cord caused hind limb paraplegia within 2-3 h that was correlated to lumbosacral poliomalacia with T cell infiltrates at 3 d post-ischemia. In this context, we showed a 5.2-fold elevation of e-hsp70 in CSF that was induced by ischemia and was sustained for the following 3 d observation interval. Plasma e-hsp70 levels were unaffected by IR injury, indicating e-hsp70 release from within the central nervous system. A putative Source of this e-hsp70 was ependymal cells in the ischemic penumbra, based upon elevated i-hsp70 levels detected within these cells. Results warrant further investigation of e-hsp70's potential to modulate spinal cord IR injury. (C) 2008 Elsevier Inc. All rights reserved.	[Oglesbee, Michael] Ohio State Univ, Dept Vet Biosci, Coll Vet Med, Columbus, OH 43212 USA; [Awad, Hamdy; Christofi, Fievos L.] Ohio State Univ, Dept Anesthesiol, Coll Med & Publ Hlth, Columbus, OH 43212 USA; [Magro, Cynthia] Ohio State Univ, Dept Pathol, Coll Med & Publ Hlth, Columbus, OH 43212 USA; [Suntres, Zacharias] Lakehead Univ, No Ontario Sch Med, Thunder Bay, ON P7B 5E1, Canada; [Heijmans, John] Maastricht Univ, Univ Hosp Maastricht, Maastricht, Netherlands; [Smeak, Daniel] Ohio State Univ, Dept Vet Clin Sci, Coll Vet Med, Columbus, OH 43212 USA; [Bergdall-Costell, Valerie] Ohio State Univ, Univ Lab Anim Resources, Columbus, OH 43212 USA		Oglesbee, M (corresponding author), Ohio State Univ, Dept Vet Biosci, Coll Vet Med, 1925 Coffey Rd, Columbus, OH 43212 USA.						ARTRU AA, 1987, J CEREBR BLOOD F MET, V7, P471, DOI 10.1038/jcbfm.1987.90; Asea A, 2005, EXERC IMMUNOL REV, V11, P34; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; *AVMA PAN EUTH AM, 2001, 2000 REP AVMA PAN EU; Batulan Z, 2003, J NEUROSCI, V23, P5789; BERGUER R, 1992, J VASC SURG, V15, P62, DOI 10.1016/0741-5214(92)70014-C; Boros P, 2006, AM J TRANSPLANT, V6, P652, DOI 10.1111/j.1600-6143.2005.01228.x; Calabrese V, 2001, INT J TISSUE REACT, V23, P127; Cizkova D, 2004, EXP NEUROL, V185, P97, DOI 10.1016/j.expneurol.2003.09.020; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; DICESARE S, 1992, IMMUNOLOGY, V76, P341; Diehl KA, 2000, AM J HEMATOL, V64, P262, DOI 10.1002/1096-8652(200008)64:4<262::AID-AJH5>3.0.CO;2-D; Febbraio MA, 2002, J PHYSIOL-LONDON, V544, P957, DOI 10.1113/jphysiol.2002.025148; FINSTERER U, 1973, PFLUG ARCH EUR J PHY, V341, P63, DOI 10.1007/BF00587330; Foster JA, 1997, MOL BRAIN RES, V45, P207, DOI 10.1016/S0169-328X(96)00138-6; Gifondorwa DJ, 2007, J NEUROSCI, V27, P13173, DOI 10.1523/JNEUROSCI.4057-07.2007; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Hoffman WH, 2007, EXP MOL PATHOL, V83, P65, DOI 10.1016/j.yexmp.2007.01.006; Ishikawa M, 2004, J CEREBR BLOOD F MET, V24, P907, DOI 10.1097/01.WCB.0000132690.96836.7F; Johnson JD, 2006, J LEUKOCYTE BIOL, V79, P425, DOI 10.1189/jlb.0905523; Kearns RJ, 1999, CLIN EXP IMMUNOL, V116, P188; Kelly S, 2001, J CEREBR BLOOD F MET, V21, P972, DOI 10.1097/00004647-200108000-00010; Kim BS, 2005, TRANSPLANTATION, V79, P1370, DOI 10.1097/01.TP.0000158355.83327.62; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; LI Y, 1992, ACTA NEUROPATHOL, V84, P94, DOI 10.1007/BF00427221; Manzerra P, 1996, EXP CELL RES, V229, P35, DOI 10.1006/excr.1996.0341; Marcuccilli CJ, 1996, J NEUROSCI, V16, P478; MARINI AM, 1990, J NEUROCHEM, V54, P1509, DOI 10.1111/j.1471-4159.1990.tb01198.x; Marini M, 1996, INT J RADIAT BIOL, V70, P337, DOI 10.1080/095530096145076; Matsuyama K, 1997, ANN THORAC SURG, V63, P1315, DOI 10.1016/S0003-4975(97)00104-5; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Oglesbee MJ, 1999, VET IMMUNOL IMMUNOP, V69, P185, DOI 10.1016/S0165-2427(99)00053-7; Oglesbee MJ, 2005, CLIN BIOCHEM, V38, P900, DOI 10.1016/j.clinbiochem.2005.05.011; Oglesbee MJ, 2002, NEUROSCIENCE, V113, P55, DOI 10.1016/S0306-4522(02)00159-8; Orendacova J, 2004, CELL MOL NEUROBIOL, V24, P477, DOI 10.1023/B:CEMN.0000022775.67975.ed; Peppelenbosch N, 2005, J VASC SURG, V42, P608, DOI 10.1016/j.jvs.2005.06.023; Pockley AG, 2003, HYPERTENSION, V42, P235, DOI 10.1161/01.HYP.0000086522.13672.23; POTTS DG, 1969, AMER J ROENTGENOL RA, V105, P756, DOI 10.2214/ajr.105.4.756; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.3.CO;2-V; Robinson MB, 2008, DEV NEUROBIOL, V68, P1, DOI 10.1002/dneu.20550; Sakurai M, 1996, NEUROSCI LETT, V217, P113, DOI 10.1016/S0304-3940(96)13079-2; Sakurai M, 1998, J VASC SURG, V27, P720, DOI 10.1016/S0741-5214(98)70238-1; SATOH J, 1994, BRAIN RES, V653, P243, DOI 10.1016/0006-8993(94)90396-4; Steensberg A, 2006, BRAIN BEHAV IMMUN, V20, P585, DOI 10.1016/j.bbi.2006.03.002; Su FH, 2005, SHOCK, V23, P516, DOI 10.1097/01.shk.000161390.46688.da; SUNTRES ZE, 1991, J PHARMACOL EXP THER, V258, P797; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Walsh RC, 2001, CELL STRESS CHAPERON, V6, P386, DOI 10.1379/1466-1268(2001)006<0386:EISHIH>2.0.CO;2; Watanabe N, 1998, INT J HYPERTHER, V14, P309, DOI 10.3109/02656739809018235; Weinstein PR, 2004, STROKE, V35, P2666, DOI 10.1161/01.STR.0000144052.10644.ed; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046	55	27	28	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	AUG	2008	212	2					275	284		10.1016/j.expneurol.2008.03.024			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	334WL	WOS:000258252000009	18511046				2022-02-06	
J	Hoane, MR; Pierce, JL; Kaufman, NA; Beare, JE				Hoane, Michael R.; Pierce, Jeremy L.; Kaufman, Nicholas A.; Beare, Jason E.			Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article						traumatic brain injury; therapy; window of opportunity; vitamin; recovery of function	FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; DYSFUNCTION; TRIALS	Previously, we have shown that the window of opportunity for nicotinamide (NAM) therapy (50 mg/kg) following cortical contusion injuries (CCI) extended to 4-8 hrs post-CCI when administered over a six day post-CCI interval. The purpose of the present study was to determine if a more chronic NAM treatment protocol administered following CCI would extend the current window of opportunity for effective treatment onset. Groups of rats received either unilateral CCI's or sham procedures. Initiation of NAM therapy (50 mg/kg, ip) began at either 15-min, 4-hrs, 8-hrs or 24-hrs post-injury. All groups received daily systemic treatments for 12 days post-CCI at 24 hr intervals. Behavioral assessments were conducted for 28 days post injury and included: vibrissae forelimb placing, bilateral tactile adhesive removal, forelimb asymmetry task and locomotor placing testing. Behavioral analysis on both the tactile removal and locomotor placing tests showed that all NAM-treated groups facilitated recovery of function compared to saline treatment. However, on the vibrissae-forelimb placing and forelimb asymmetry tests only the 4-hr and 8-hr NAM-treated groups were significantly different from the saline-treated group. The lesion analysis showed that treatment with NAM out to 8 hrs post-CCI significantly reduced the size of the injury cavity. The window of opportunity for NAM treatment is task-dependent and in some situations can extend to 24 hrs post-CCI. These results suggest that a long term treatment regimen of 50 mg/kg of NAM starting at the clinically relevant time points may prove efficacious in human TBI.	[Hoane, Michael R.; Pierce, Jeremy L.; Kaufman, Nicholas A.; Beare, Jason E.] So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA		Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Ctr Integrat Res Cognit & Neural Sci, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu	Beare, Jason E/D-2870-2016	Beare, Jason E/0000-0003-3988-1223; Hoane, Michael/0000-0001-7779-2657	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	The authors would like to thank Jordan Yearwood for his assistance on this project. Research supported by NINDS (NS045647-03) to M.R.H.	Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; CHOI DW, 1987, J NEUROSCI, V7, P369; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; HOANE MR, 2008, NEUROSCIENC IN PRESS; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; HORSMAN MR, 1993, RADIOTHER ONCOL, V27, P131, DOI 10.1016/0167-8140(93)90133-S; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PAXINOS G, 2005, RAT BRAIN STEREMAXIC; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; Sadanaga-Akiyoshi F, 2003, NEUROCHEM RES, V28, P1227, DOI 10.1023/A:1024236614015; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Schallert T, 2005, BEHAV LAB RAT, P129; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tam D, 2005, ANN NY ACAD SCI, V1053, P258, DOI 10.1196/annals.1344.023; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4	34	27	27	0	8	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.	JUL-AUG	2008	1	1					46	53		10.4161/oxim.1.1.6694			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520QO	WOS:000271861500006	19794908	Green Published, gold			2022-02-06	
J	Mossberg, KA; Masel, BE; Gilkison, CR; Urban, RJ				Mossberg, Kurt A.; Masel, Brent E.; Gilkison, Charles R.; Urban, Randall J.			Aerobic capacity and growth hormone deficiency after traumatic brain injury	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							QUALITY-OF-LIFE; CONSENSUS GUIDELINES; PITUITARY-FUNCTION; MAXIMAL TREADMILL; CHRONIC FATIGUE; GH TREATMENT; ADULTS; HYPOPITUITARISM; EXERCISE; REHABILITATION	Context: GH deficiency occurs in approximately 20% of all individuals who suffer from a moderate to severe traumatic brain injury. Objective: This study determined whether GH deficiency secondary to traumatic brain injury had an effect on aerobic capacity. Design: Subjects were screened for GH deficiency by the glucagon stimulation test and performed a maximal treadmill exercise test. Setting: Patients were studied in the postacute recovery phase after traumatic brain injury. Participants: Thirty-five individuals were studied. Groups were formed as follows: normal GH axis, greater than 8 ng/ml response (n = 12); insufficient, GH 3-8 ng/ml response (n = 11); and deficient, less than 3 ng/ml response (n = 12). Intervention: There was no intervention. Main Outcome Measure: Aerobic capacity was assessed by measuring expired gases during a graded treadmill exercise test. One-way and two-way ANOVAs were carried out on all peak and submaximal cardiorespiratory variables, respectively. Appropriate post hoc comparisons followed as necessary. Results: Significantly higher peak oxygen consumption was found in traumatic brain injury subjects with GH normal vs. GH insufficient and deficient [26.4 +/- 6.9, 20.8 +/- 4.6, and 19.7 +/- 5.0, respectively (P < 0.05)]. Submaximal oxygen consumption was significantly higher in the GH normal group. All other variables were statistically similar. Conclusions: This study shows that individuals with traumatic brain injury with normal GH secretion have below normal aerobic capacity and those patients who have GH insufficiency/deficiency are further deconditioned. Studies of GH replacement in these subjects should be conducted to assess whether GH therapy can improve cardiorespiratory fitness and prevent secondary disability.	[Mossberg, Kurt A.] Univ Texas Galveston, Med Branch, Dept Phys Therapy, Galveston, TX 77555 USA; [Masel, Brent E.] Transit Learning Ctr, Galveston, TX 77550 USA		Mossberg, KA (corresponding author), Univ Texas Galveston, Med Branch, Dept Phys Therapy, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000073] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00073, M01 RR000073] Funding Source: Medline		Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Astrand PO, 2003, TXB WORK PHYSL PHYSL; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Colao A, 2001, CLIN ENDOCRINOL, V54, P137, DOI 10.1046/j.1365-2265.2001.01218.x; Conceicao FL, 2003, J ENDOCRINOL INVEST, V26, P1065, DOI 10.1007/BF03345251; Cummings DE, 2003, ANNU REV MED, V54, P513, DOI 10.1146/annurev.med.54.101601.152147; DANIEL PM, 1961, MOD TRENDS ENDOCRINO, V2, P55; Fellus J, 2007, BRAIN INJURY MED, P545; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Grohar-Murray M E, 1998, J Neurosci Nurs, V30, P191; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31, DOI 10.1152/jappl.1969.26.1.31; Hillier SL, 1997, BRAIN INJURY, V11, P661; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Katz DI, 2007, BRAIN INJURY MED PRI, P3; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P7; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LUKASKI HC, 1989, J SPORT MED PHYS FIT, V29, P223; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Merola B, 1995, EUR J ENDOCRINOL, V133, P680, DOI 10.1530/eje.0.1330680; MOSSBERG K, 2005, ARCH PHYS MED REHAB, V86, pE12; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; TAYLOR HL, 1955, J APPL PHYSIOL, V8, P73, DOI 10.1152/jappl.1955.8.1.73; Taylor RR, 2002, PSYCHOSOM MED, V64, P319, DOI 10.1097/00006842-200203000-00016; Thomas SG, 2003, J CLIN ENDOCR METAB, V88, P5734, DOI 10.1210/jc.2003-030632; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Whaley MH, 2006, ACSMS GUIDELINES EXE; Woodhouse LJ, 2006, ENDOCR REV, V27, P287, DOI 10.1210/er.2004-0022; Woodhouse LJ, 1999, J CLIN ENDOCR METAB, V84, P4570, DOI 10.1210/jc.84.12.4570	43	27	28	0	6	ENDOCRINE SOC	CHEVY CHASE	8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA	0021-972X			J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	JUL 1	2008	93	7					2581	2587		10.1210/jc.2008-0368			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	324JA	WOS:000257513700027	18413421	Green Published, Bronze			2022-02-06	
J	Schubert, GA; Poli, S; Schilling, L; Heiland, S; Thome, C				Schubert, Gerrit Alexander; Poli, Sven; Schilling, Lothar; Heiland, Sabine; Thome, Claudius			Hypothermia reduces cytotoxic edema and metabolic alterations during the acute phase of massive SAH: A diffusion-weighted imaging and spectroscopy study in rats	JOURNAL OF NEUROTRAUMA			English	Article						acute; cytotoxic edema; DWI; hypothermia; metabolism; MR spectroscopy; subarachnoid hemorrhage	ANEURYSMAL SUBARACHNOID HEMORRHAGE; MAGNETIC-RESONANCE SPECTROSCOPY; CEREBRAL-BLOOD-FLOW; ACETYL-L-ASPARTATE; TRAUMATIC BRAIN-INJURY; PROLONGED HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; BEDSIDE MICRODIALYSIS; N-ACETYLASPARTATE; MILD HYPOTHERMIA	Acute changes in cerebral perfusion and metabolism after subarachnoid hemorrhage (SAH) have been shown to contribute significantly to acute brain injury. The purpose of this study was to examine the effects of moderate hypothermia on the acute changes after massive experimental SAH as evaluated by diffusion-weighted imaging (DWI) and magnetic resonance spectroscopy (MRS). SAH in rats was induced by injection of 0.5 mL of arterial blood. Normothermic animals (NT, n = 10) were kept at 37.0 +/- 0.2 degrees C, while temperature was lowered to 32.0 +/- 0.2 degrees C in the primary hypothermia group (pHT, n = 10) prior to SAH and in the secondary hypothermia group (sHT, n = 10) immediately after SAH. DWI and MRS were performed from 30 min prior up to 3 h after injury. The apparent diffusion coefficient (ADC) was measured in cortical and hippocampal regions of interest (ROIs). MRS included lactate, N-acetyl aspartate (NAA), and creatine in a central voxel. DWI showed a generalized, significant decline in ADC after SAH in NT. Significant change in ADC in pHT was absent, and accelerated recovery for animals in sHT was noted. MRS analysis revealed significant lactate accumulation to 204 +/- 40% from baseline only in NT, while sHT was characterized by a transient, less pronounced increase of lactate (159 +/- 11%) and lactate in pHT did not change significantly (117 +/- 11%). NAA did not change significantly when compared to baseline or between groups for NT, pHT, or sHT. Creatine rose significantly to 166 +/- 27% in NT after the insult, indicating increased metabolic stress which was absent in pHT (106 +/- 8%) and sHT (124 +/- 18%). Hypothermia can ameliorate early development of cytotoxic edema, lactate accumulation, and a general metabolic stress response after SAH, even when started after the insult. Our study indicates that a potentially beneficial influence on metabolism and cerebral perfusion in this crucial phase is practicable and might hold the key to further improve outcome in SAH.	[Schubert, Gerrit Alexander; Poli, Sven; Thome, Claudius] Heidelberg Univ, Dept Neurosurg, Univ Hosp Mannheim, D-68167 Mannheim, Germany; [Schilling, Lothar] Heidelberg Univ, Dept Neurosurg Res, Univ Hosp Mannheim, D-68167 Mannheim, Germany; [Heiland, Sabine] Heidelberg Univ, Dept Neuroradiol Res, D-6800 Mannheim, Germany		Schubert, GA (corresponding author), Heidelberg Univ, Dept Neurosurg, Univ Hosp Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	gerrit.schubert@nch.ma.uni-heidelberg.de	Schubert, Gerrit Alexander/Q-9192-2017	Schubert, Gerrit Alexander/0000-0001-9135-6042			Back T, 2004, J NEUROL, V251, P388, DOI 10.1007/s00415-004-0399-y; BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; Baldwin ME, 2004, STROKE, V35, P2506, DOI 10.1161/01.STR.0000144654.79393.cf; Barber PA, 1999, STROKE, V30, P2059, DOI 10.1161/01.STR.30.10.2059; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; Busch E, 1998, STROKE, V29, P2155, DOI 10.1161/01.STR.29.10.2155; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Condette-Auliac S, 2001, STROKE, V32, P1818, DOI 10.1161/01.STR.32.8.1818; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Ebisu T, 1997, RADIOLOGY, V203, P823, DOI 10.1148/radiology.203.3.9169711; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Gabikian P, 2002, STROKE, V33, P2681, DOI 10.1161/01.STR.0000033931.62992.B1; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gee CE, 2006, EUR J NEUROSCI, V23, P2595, DOI 10.1111/j.1460-9568.2006.04786.x; GIDEON P, 1992, STROKE, V23, P1566, DOI 10.1161/01.STR.23.11.1566; Harris NG, 2000, J CEREBR BLOOD F MET, V20, P28, DOI 10.1097/00004647-200001000-00006; HASEGAWA Y, 1994, NEUROLOGY, V44, P1484, DOI 10.1212/WNL.44.8.1484; Higuchi T, 1996, NEUROSURGERY, V38, P121, DOI 10.1097/00006123-199601000-00030; Hoehn-Berlage M, 1999, NMR BIOMED, V12, P45, DOI 10.1002/(SICI)1099-1492(199902)12:1<45::AID-NBM545>3.0.CO;2-6; Iseda K, 2007, J NEUROSURG, V107, P128, DOI 10.3171/JNS-07/07/0128; JAKOBSEN J, 1992, ACTA NEUROL SCAND, V86, P1, DOI 10.1111/j.1600-0404.1992.tb08044.x; Karibe H, 2000, NEUROSURGERY, V47, P594, DOI 10.1097/00006123-200009000-00012; Kawamura Y, 2000, J NEUROTRAUM, V17, P243, DOI 10.1089/neu.2000.17.243; KNIGHT RA, 1994, STROKE, V25, P1252, DOI 10.1161/01.STR.25.6.1252; Kobayashi M, 2001, STROKE, V32, P2237, DOI 10.1161/hs1001.096621; Kollmar R, 2002, ANESTHESIOLOGY, V97, P868, DOI 10.1097/00000542-200210000-00018; Kuroiwa T, 1998, STROKE, V29, P859, DOI 10.1161/01.STR.29.4.859; Leibovici A, 2007, DEV NEUROSCI-BASEL, V29, P268, DOI 10.1159/000097410; MacLellan C, 2002, BRAIN RES, V958, P192, DOI 10.1016/S0006-8993(02)03702-2; MacLellan CL, 2004, J CEREBR BLOOD F MET, V24, P432, DOI 10.1097/00004647-200404000-00008; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Nicoli F, 2003, STROKE, V34, pE82, DOI 10.1161/01.STR.0000078659.43423.0A; Parsons MW, 2000, NEUROLOGY, V55, P498, DOI 10.1212/WNL.55.4.498; PEREZTREPICHIO AD, 1995, STROKE, V26, P667, DOI 10.1161/01.STR.26.4.667; Piepgras A, 2001, NEUROSURGERY, V48, P1128, DOI 10.1097/00006123-200105000-00033; PRICHARD JW, 1993, RES P ARNMD, V71, P153; ROSENSTEIN J, 1984, NEUROSURGERY, V15, P519, DOI 10.1227/00006123-198410000-00008; Rowe J, 1998, J NEUROL NEUROSUR PS, V64, P98, DOI 10.1136/jnnp.64.1.98; Ryba MS, 1999, BRAIN RES, V850, P225, DOI 10.1016/S0006-8993(99)02161-7; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schubert GA, 2008, J NEUROTRAUM, V25, P539, DOI 10.1089/neu.2007.0500; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Thome C, 2001, ACTA NEUROCHIR SUPPL, V77, P255; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009; Valenzuela MJ, 2001, NEUROLOGY, V56, P592, DOI 10.1212/WNL.56.5.592; van Walsum AMV, 1999, AM J OBSTET GYNECOL, V181, P1537, DOI 10.1016/S0002-9378(99)70401-1; VANDERGROND J, 1995, STROKE, V26, P822, DOI 10.1161/01.STR.26.5.822; VANDERSPRENKEL JWB, 1988, STROKE, V19, P1556, DOI 10.1161/01.STR.19.12.1556	59	27	27	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					841	852		10.1089/neu.2007.0443			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000010	18627260				2022-02-06	
J	Bansal, V; Fortlage, D; Lee, J; Kuncir, E; Potenza, B; Coimbra, R				Bansal, Vishal; Fortlage, Dale; Lee, Jeanne; Kuncir, Eric; Potenza, Bruce; Coimbra, Raul			A 21-year history of all-terrain vehicle injuries: has anything changed?	AMERICAN JOURNAL OF SURGERY			English	Article						all-terrain vehicles (ATVs); trauma; helmet use; injury prevention	MOTORCYCLE HELMETS; TRAUMA CENTERS; REGULATIONS; PATTERNS; IMPACT	BACKGROUND: All-terrain vehicle (ATV)-related injuries have increased. The purpose of this study was to determine if the increase in injuries correlates with the expiration of government mandates. METHODS: ATV-injured patients admitted to a level I trauma center were reviewed over the years 1985-1999 and 2000-2005. Several demographic variables and injuries sustained were analyzed. RESULTS: There were a total of 433 injuries, which increased from 164 between 1985 and 1999, to 269 between 2000 and 2005. By comparing the time periods we observed a decrease in closed-head injury (53.6% vs 27.5%; P <.001), spinal cord injury (11.6% vs 5.2%; P <.05), and soft-tissue injury (62.8% vs 45.3%; P <.01), but an increase in long-bone fractures (18.9% vs 33.0%; P <.05). No differences were observed in other injuries. CONCLUSIONS: The number of patients sustaining ATV-related injuries has increased and correlates with the expiration of government mandates. Even though ATVs remain dangerous, injury prevention strategies such as helmet laws may be having a positive impact. (C) 2008 Elsevier Inc. All rights reserved.	[Bansal, Vishal; Fortlage, Dale; Lee, Jeanne; Kuncir, Eric; Potenza, Bruce; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Burns & Crit Care, San Diego, CA 92103 USA		Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Burns & Crit Care, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; Eastridge BJ, 2006, J TRAUMA, V60, P978, DOI 10.1097/01.ta.0000215582.86115.01; Fonseca AH, 2005, AM SURGEON, V71, P937; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; Moore MJ, 1997, INT REV LAW ECON, V17, P379, DOI 10.1016/S0144-8188(97)00022-7; Mullins RJ, 2007, J AM COLL SURGEONS, V204, P216, DOI 10.1016/j.jamcollsurg.2006.10.025; ORSAY EM, 1994, ANN EMERG MED, V23, P802, DOI 10.1016/S0196-0644(94)70317-5; Rodgers GB, 1999, ACCIDENT ANAL PREV, V31, P409, DOI 10.1016/S0001-4575(98)00080-3; Rodgers GB, 2001, AM J EPIDEMIOL, V153, P1112, DOI 10.1093/aje/153.11.1112; RODGERS GB, 1993, ACCIDENT ANAL PREV, V25, P335, DOI 10.1016/0001-4575(93)90027-T; Scutchfield SB, 2003, CLIN ORTHOP RELAT R, P61, DOI 10.1097/01.blo.0000060441.40507.3e; Smith LM, 2005, J TRAUMA, V58, P783, DOI 10.1097/01.TA.0000158252.11002.6E; Upperman JS, 2003, J PEDIATR SURG, V38, P1284, DOI 10.1016/S0022-3468(03)00383-X; US Consumer Product Safety Commission, 1998, FED REGISTER, V63, P48199; 2005, FED REG, V67	15	27	27	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610			AM J SURG	Am. J. Surg.	JUN	2008	195	6					789	792		10.1016/j.amjsurg.2007.05.049			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	311FI	WOS:000256585700011	18367134				2022-02-06	
J	Thornton, KE; Carmody, DP				Thornton, Kirtley E.; Carmody, Dennis P.			Efficacy of traumatic brain injury rehabilitation: Interventions of QEEG-guided biofeedback, computers, strategies, and medications	APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK			English	Article						EEG biofeedback; traumatic brain injury; cognitive rehabilitation; neurocognitive rehabilitation; QEEG; activation QEEG; memory rehabilitation	CLINICAL-NEUROPHYSIOLOGY-SOCIETY; CLOSED-HEAD INJURY; OF-THE-LITERATURE; COGNITIVE REHABILITATION; AMERICAN-ACADEMY; NEUROPSYCHOLOGICAL TESTS; NEUROIMAGING TECHNIQUES; CONTROLLED-TRIAL; MEMORY; EEG	The onset of cognitive rehabilitation brought with it a hope for an effective treatment for the traumatic brain injured subject. This paper reviews the empirical reports of changes in cognitive functioning after treatment and compares the relative effectiveness of several treatments including computer interventions, cognitive strategies, EEG biofeedback, and medications. The cognitive functions that are reviewed include auditory memory, attention and problem solving. The significance of the change in cognitive function is assessed in two ways that include effect size and longevity of effect. These analyses complement the previously published meta-reviews by adding these two criteria and include reports of EEG biofeedback, which is shown to be an effective intervention for auditory memory.	[Thornton, Kirtley E.; Carmody, Dennis P.] Brain Fdn, S Plainfield, NJ 07080 USA; [Carmody, Dennis P.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Inst Study Child Dev, New Brunswick, NJ 08903 USA		Thornton, KE (corresponding author), Brain Fdn, Ste 2A,2509 Pk Ave, S Plainfield, NJ 07080 USA.	ket@chp-neurotherapy.com	Carmody, Dennis P./AAS-7734-2020	thornton, kirtley/0000-0002-3303-4747; Carmody, Dennis/0000-0002-1288-104X			ASHLEY MJ, 1990, J INSURANCE MED, V22, P156; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BENEDICT RHB, 1989, CLIN PSYCHOL REV, V9, P605; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; CHEREK L, 1995, NEUROREHABILITATION, V5, P87, DOI 10.3233/NRE-1995-5108; CHESTNUT RM, 1998, 2 AG HLTH CAR POL RE; Christensen AL., 1975, LURIAS NEUROPSYCHOLO; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COE R, 2000, WHAT IS EFFECT SIZE; Cohen J., 2013, STAT POWER ANAL BEHA; Cohen J, 1969, STAT POWER ANAL BEHA; Delis DC, 1987, CALIFORNIA VERBAL LE; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Glass G.V., 1981, META ANAL SOCIAL RES, V124; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HAMMOND C, 2004, J NEUROTHERAPY, V8, P5, DOI DOI 10.1300/J184V08N01_02; *HARC ASS INC, 1955, WECHSL AD INT SCAL; Harley J. P., 1992, NEUROREHABILITATION, V2, P62; Hedges L.V., 1985, STAT METHODS META AN; Hedges LV., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.2307/1164588]; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; *IVA, 1995, BRAIN TRAIN; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Keller I, 2001, J NEUROTHERAPY, V5, P19; KERNER MJ, 1985, COGNITIVE REHABI NOV, P26; Laatsch L, 2000, NEUROREHABILITATION, V15, P189; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; LUBAR JO, 1984, BIOFEEDBACK SELF-REG, V9, P1, DOI 10.1007/BF00998842; MARKER T, 1996, COGPACK; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McKinlay W W, 1992, Brain Inj, V6, P107, DOI 10.3109/02699059209029649; Milders M, 1998, MEMORY, V6, P21, DOI 10.1080/741941597; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; *NAN, 2002, COGN REH OFF POS NAT; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Olejnik S, 2000, CONTEMP EDUC PSYCHOL, V25, P241, DOI 10.1006/ceps.2000.1040; OTHMER S, 1992, EEG BIOFEEDBACK TRAI; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; *PSYCH ASS RES, 1993, WISC CARD SCOR TEST; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; REITAN R, 1993, H REITAN NEUROPSYCHO; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ricker J H, 1998, Appl Neuropsychol, V5, P184, DOI 10.1207/s15324826an0504_3; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Schoenberger NE, 2001, J HEAD TRAUMA REHAB, V16, P260, DOI 10.1097/00001199-200106000-00005; SIEGMUND K, 1999, NEUROSOFT INTEGRIERT; STEPHENS J, 2006, EFFECTIVENESS EEG BI; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TANSEY MA, 1991, AUST J PSYCHOL, V43, P147, DOI 10.1080/00049539108260139; TANSEY MA, 1993, BIOFEEDBACK SELF-REG, V18, P33, DOI 10.1007/BF00999512; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; Thornton K, 2000, J HEAD TRAUMA REHAB, V15, P1285, DOI 10.1097/00001199-200012000-00008; Thornton KE, 2005, CHILD ADOL PSYCH CL, V14, P137, DOI 10.1016/j.chc.2004.07.001; THORNTON KE, 2007, 20071 BRAIN FDN; THORNTON KE, 2001, Patent No. 6309361; THORNTON KE, J NEUROTHER IN PRESS; THORNTON KE, 2002, CLIN NEUROPSYCHOLOGY, V17, P1, DOI DOI 10.1016/S0887-6177(00)00073-1; Tinius T. P., 2000, J NEUROTHER, V4, P27, DOI [DOI 10.1300/J184v04n02_05, 10.1300/J184v04n02_05]; *TOVA CO, 1992, TEST VAR ATT; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wehman P., 1989, J HEAD TRAUMA REHAB, V4, P66, DOI [10.1097/00001199-198909000-00010, DOI 10.1097/00001199-198909000-00010]; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3	86	27	28	0	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1090-0586	1573-3270		APPL PSYCHOPHYS BIOF	Appl. Psychophysiol. Biofeedback	JUN	2008	33	2					101	124		10.1007/s10484-008-9056-z			24	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	316CO	WOS:000256926700005	18551365				2022-02-06	
J	Desilva, TM; Billiards, SS; Borenstein, NS; Trachtenberg, FL; Volpe, JJ; Kinney, HC; Rosenberg, PA				Desilva, Tara M.; Billiards, Saraid S.; Borenstein, Natalia S.; Trachtenberg, Felicia L.; Volpe, Joseph J.; Kinney, Hannah C.; Rosenberg, Paul A.			Glutamate transporter EAAT2 expression is up-regulated in reactive astrocytes in human periventricular leukomalacia	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						cerebral palsy; reactive astrocytes; inflammation; microglia; oligodendrocytes; prematurity	TRAUMATIC BRAIN-INJURY; CEREBRAL WHITE-MATTER; EXCITATORY AMINO-ACIDS; RAT-BRAIN; NITRIC-OXIDE; VESICULAR RELEASE; NMDA RECEPTORS; MICE LACKING; SPINAL-CORD; IN-VITRO	The major neuropathological correlate of cerebral palsy in premature infants is periventricular leukomalacia (PVL), a disorder of the immature cerebral white matter. Cerebral ischemia leading to excitotoxicity is thought to be important in the pathogenesis of this disorder, implying a critical role for glutamate transporters, the major determinants of extracellular glutamate concentration. Previously, we found that EAAT2 expression is limited primarily to premyelinating oligodendrocytes early in development and is rarely observed in astrocytes until >40 weeks. In this study, we analyzed the expression of EAAT2 in cerebral white matter from PVL and control cases. Western blot analysis suggested an up-regulation of EAAT2 in PVL compared, with control cases. Single- and double-label immunocytochemistry showed a significantly higher percentage of EAAT2-immunopositive astrocytes in PVL (51.8% +/- 5.6%) compared with control white matter (21.4% +/- 5.6%; P = 0.004). Macrophages in the necrotic foci in PVL also expressed EAAT2. Premyelinating oligodendrocytes in both PVL and control cases expressed EAAT2, without qualitative difference in expression. The previously unrecognized up-regulation of EAAT2 in reactive astrocytes and its presence in macrophages in PVL reported here may reflect a response to either hypoxic-ischemic injury or inflammation.	[Desilva, Tara M.; Volpe, Joseph J.; Rosenberg, Paul A.] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Desilva, Tara M.; Billiards, Saraid S.; Borenstein, Natalia S.; Volpe, Joseph J.; Kinney, Hannah C.; Rosenberg, Paul A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Billiards, Saraid S.; Borenstein, Natalia S.; Kinney, Hannah C.] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; [Trachtenberg, Felicia L.] New England Res Inst, Watertown, MA 02472 USA		Rosenberg, PA (corresponding author), Childrens Hosp, Dept Neurol, Enders Res Bldg,Enders 349,300 Longwood Ave, Boston, MA 02115 USA.	paul.rosenberg@childrens.harvard.edu		Rosenberg, Paul/0000-0002-5185-1118	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041883, P01NS038475, T32NS007473, R01NS040753] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD018655, HD18655] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38475, P01 NS038475-10, NS41883, T32NS07473, NS40753, R01 NS041883, NS07473, T32 NS007473, R01 NS040753, P01 NS038475-09, P01 NS038475] Funding Source: Medline		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Back SA, 2007, J CEREBR BLOOD F MET, V27, P334, DOI 10.1038/sj.jcbfm.9600344; BANKER BQ, 1962, ARCH NEUROL-CHICAGO, V7, P386, DOI 10.1001/archneur.1962.04210050022004; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Billiards SS, 2006, J COMP NEUROL, V497, P199, DOI 10.1002/cne.20991; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chen WZ, 2004, J NEUROSCI, V24, P1136, DOI 10.1523/JNEUROSCI.1586-03.2004; Chen WZ, 2002, J NEUROSCI, V22, P2142, DOI 10.1523/JNEUROSCI.22-06-02142.2002; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi JW, 2004, J NEUROSCI RES, V75, P722, DOI 10.1002/jnr.20009; Chretien F, 2004, J NEUROPATH EXP NEUR, V63, P1058, DOI 10.1093/jnen/63.10.1058; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Deng WB, 2003, P NATL ACAD SCI USA, V100, P6801, DOI 10.1073/pnas.1136624100; Desilva TM, 2007, J COMP NEUROL, V501, P879, DOI 10.1002/cne.21289; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fern R, 2000, J NEUROSCI, V20, P34, DOI 10.1523/JNEUROSCI.20-01-00034.2000; Folkerth RD, 2004, BRAIN PATHOL, V14, P265; Follett PL, 2000, J NEUROSCI, V20, P9235; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Furuta A, 1997, J NEUROSCI, V17, P8363; Furuta A, 2005, DEV BRAIN RES, V155, P155, DOI 10.1016/j.devbrainres.2005.01.005; Gibson CL, 2005, GLIA, V50, P417, DOI 10.1002/glia.20143; Halliwell B, 1998, FREE RADICAL BIO MED, P246; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Itoh T, 2002, J NEUROCHEM, V81, P390, DOI 10.1046/j.1471-4159.2002.00866.x; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Maragakis NJ, 2004, GLIA, V45, P133, DOI 10.1002/glia.10310; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Noh KM, 2000, J NEUROSCI, V20; Northington FJ, 1999, J NEUROBIOL, V39, P515; O'Shea RD, 2006, NEUROCHEM INT, V48, P604, DOI 10.1016/j.neuint.2005.12.028; Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Porcheray F, 2006, AM J PHYSIOL-CELL PH, V291, pC618, DOI 10.1152/ajpcell.00021.2006; Pow DV, 2004, DEV BRAIN RES, V153, P1, DOI 10.1016/j.devbrainres.2004.06.019; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; Rimaniol AC, 2000, J IMMUNOL, V164, P5430, DOI 10.4049/jimmunol.164.10.5430; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; Rosenberg PA, 2003, J NEUROSCI RES, V71, P237, DOI 10.1002/jnr.10472; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHSTEIN JD, 1994, BIOCHEM PHARMACOL, V34, P73; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tolias CM, 1999, NEUROSCI LETT, V273, P57, DOI 10.1016/S0304-3940(99)00630-8; Tolias CM, 1999, FREE RADICAL BIO MED, V26, P99, DOI 10.1016/S0891-5849(98)00146-4; TORP R, 1995, EXP BRAIN RES, V103, P51; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Volpe J. J, 2001, NEUROLOGY NEWBORN; Yamada K, 1998, J NEUROSCI, V18, P5706; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; Yoshioka A, 1996, J NEUROSCI RES, V46, P164; Zaheer A, 2004, NEUROCHEM RES, V29, P1473, DOI 10.1023/B:NERE.0000029558.82943.00; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	71	27	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	MAY 10	2008	508	2					238	248		10.1002/cne.21667			11	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	288CK	WOS:000254963600003	18314905	Green Accepted			2022-02-06	
J	Mailer, BJ; McLeod, TCV; Bay, RC				Mailer, Brandy J.; McLeod, Tamara C. Valovich; Bay, R. Curtis			Healthy youth are reliable in reporting symptoms on a graded symptom scale	JOURNAL OF SPORT REHABILITATION			English	Article						concussion; patient-oriented evidence; POEM; outcomes	CONCUSSION ASSESSMENT; VALIDITY; MANAGEMENT; OUTCOMES; TOOLS	Context: Clinicians often rely on the self-report symptoms of patients in making clinical decisions; hence it is important that these scales be reliable. Objective: To determine the test-retest reliability of healthy youth in completing a graded symptom scale (GSS), modified from the Head Injury Scale Self-Report Concussion Symptoms Scale (HIS). Design: Repeated-measures. Setting: Middle school classroom. Patients or Other Participants: 126 middle school students. Intervention: A survey consisting of a demographic and life events questionnaire and a GSS asking about symptom severity and duration. Main Outcomes Measures: Score for each symptom on the severity and duration scale and a total symptom score (TSS) and the total number of symptoms endorsed (TSE) from the severity scale. Responses on a life events questionnaire were also recorded. Results: We found excellent reliability for TSS (ICC = .93) and TSE (ICC = .88) for the severity scale. We found moderate to excellent reliability on the individual symptoms of both the severity (ICC = .65-.89) and duration (ICC = .56-.96) scales. Conclusions: Healthy youth can reliably self-report symptoms using a GSS. This patient-oriented outcome measure should be incorporated into more investigations in this age group.	[Mailer, Brandy J.] Linfield Coll, McMinnville, OR USA; [McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ USA; [Bay, R. Curtis] AT Still Univ, Dept Interdisciplinary Hlth Sci, Mesa, AZ USA		Mailer, BJ (corresponding author), Linfield Coll, McMinnville, OR USA.		Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Bay, Ralph/0000-0003-3525-9269			Barr WB, 2001, J ATHL TRAINING, V36, P297; Binkley JM, 1999, PHYS THER, V79, P371; Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245; Ebell MH, 2004, J AM BOARD FAM PRACT, V17, P59, DOI 10.3122/jabfm.17.1.59; Ferrara Michael S., 2001, J Athl Train, V36, P145; FLANDRY F, 1991, AM J SPORT MED, V19, P112, DOI 10.1177/036354659101900204; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Hurwitz SR, 2000, J BONE JOINT SURG AM, V82A, P888, DOI 10.2106/00004623-200006000-00020; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rhee H., 2005, PEDIAT NURS, V31, P350; Rhee Hyekyun, 2005, Pediatr Nurs, V31, P314; Sackett DL, 1995, J ROY SOC MED, V88, P620; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SNYDER AR, IN PRESS J ATHL TRAI; Snyder AR, 2007, ATHL TRAIN ED J, V2, P1; Swiontkowski MF, 1999, J BONE JOINT SURG AM, V81A, P1245, DOI 10.2106/00004623-199909000-00006; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watkins MP., 2015, FDN CLIN RES APPL PR, V3rd; Wilson JK, 2000, J SPORT REHABIL, V9, P304, DOI 10.1123/jsr.9.4.304	27	27	27	0	3	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1056-6716	1543-3072		J SPORT REHABIL	J. Sport Rehabil.	FEB	2008	17	1					11	20		10.1123/jsr.17.1.11			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	261SG	WOS:000253099700002	18270383				2022-02-06	
J	Quintana, A; Molinero, A; Borup, R; Nielsen, FC; Campbell, IL; Penkowa, M; Hidalgo, J				Quintana, Albert; Molinero, Amalia; Borup, Rehannah; Nielsen, Finn Cilius; Campbell, Iain L.; Penkowa, Milena; Hidalgo, Juan			Effect of astrocyte-targeted production of IL-6 on traumatic brain injury and its impact on the cortical transcriptome	DEVELOPMENTAL NEUROBIOLOGY			English	Article						cryolesion; cytokines; gene expression; micro-array; mouse; neuroinflammation	CENTRAL-NERVOUS-SYSTEM; MICE EXPRESSING INTERLEUKIN-6; DEPENDENT PROTEIN-KINASE; MURINE LEUKEMIA-VIRUS; TUMOR-NECROSIS-FACTOR; I PLUS II; TRANSGENIC MICE; GENE-EXPRESSION; METALLOTHIONEIN-I; CEREBRAL OVEREXPRESSION	Interleukin-6 (IL-6) is one of the key players in the response of the brain cortex to injury. We have described previously that astrocyte-driven production of IL-6 (GFAP-IL6) in transgenic mice, although causing spontaneous neuroinflammation and long term damage, is beneficial after an acute (freeze) injury in the cortex, increasing healing and decreasing oxidative stress and apoptosis. To determine the transcriptional basis for these responses here we analyzed the global gene expression profile of the cortex, at 0 (unlesioned), I or 4 days post lesion (dpl), in both GFAP-IL6 mice and their control littermates. GFAP-IL6 mice showed an increase in genes associated with the inflammatory response both at 1 dpl (Iftm1, Endod1) and 4 dpl (Gfap, C4b), decreased expression of proapoptotic genes (i.e. Gadd45b, Clic4, p21) as well as reduced expression of genes involved in the control of oxidative stress (Atf4). Furthermore, the presence of IL-6 altered the expression of genes involved in hemostasis (Vwt), cell migration and proliferation (Cap2), and synaptic activity (Vamp2). All these changes in gene expression could underlie the phenotype of the GFAP-IL6 mice after injury, but many other possible factors were also identified in this study, highlighting the utility of this approach for deciphering new pathways orchestrated by IL-6. (c) 2007 Wiley Periodicals, Inc.	[Quintana, Albert; Molinero, Amalia; Hidalgo, Juan] Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, Inst Neurosci, Barcelona, Spain; [Quintana, Albert; Molinero, Amalia; Hidalgo, Juan] Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, Dept Cellular Biol Physiol & Immunol, Barcelona, Spain; [Borup, Rehannah; Nielsen, Finn Cilius] Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; [Campbell, Iain L.] Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; [Penkowa, Milena] Univ Copenhagen, Fac Hlth Sci, Sect Neuroprotect, Ctr Inflammat & Metab, Copenhagen, Denmark		Hidalgo, J (corresponding author), Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, Inst Neurosci, Barcelona, Spain.	juan.hidalgo@uab.es	Quintana, Albert/N-5544-2015; Hidalgo, Juan/C-9082-2011; Nielsen, Finn Cilius/AAA-4926-2020; molinero, amalia/K-2147-2014	Quintana, Albert/0000-0003-1674-7160; Hidalgo, Juan/0000-0003-0921-1122; molinero, amalia/0000-0001-8661-8570; Nielsen, Finn Cilius/0000-0002-9829-1031			Abe M, 2003, BIOCHEM BIOPH RES CO, V306, P10, DOI 10.1016/S0006-291X(03)00903-3; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Arce I, 2004, EUR J IMMUNOL, V34, P210, DOI 10.1002/eji.200324230; Armario A, 1998, J NEUROIMMUNOL, V92, P160, DOI 10.1016/S0165-5728(98)00199-4; Balschun D, 2004, FASEB J, V18, P1788, DOI 10.1096/fj.04-1625fje; Banett S., 1996, HUM RESOUR MANAG J, V6, P18; Bauer S, 2007, NAT REV NEUROSCI, V8, P221, DOI 10.1038/nrn2054; Bertling E, 2004, MOL BIOL CELL, V15, P2324, DOI 10.1091/mbc.E04-01-0048; Bhoumik A, 2002, J CLIN INVEST, V110, P643, DOI 10.1172/JCI200216081; Blagoveshchenskaya AD, 2002, MOL BIOL CELL, V13, P1582, DOI 10.1091/mbc.01-09-0462; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; CHURN SB, 1993, STROKE, V24, P271, DOI 10.1161/01.STR.24.2.271; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; Cooper BJ, 2006, J BIOL CHEM, V281, P22471, DOI 10.1074/jbc.M602520200; Cottrell JR, 2004, NEURON, V44, P677, DOI 10.1016/j.neuron.2004.10.025; Coutts AS, 2007, EMBO REP, V8, P84, DOI 10.1038/sj.embor.7400855; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Deak F, 2006, J NEUROSCI, V26, P6668, DOI 10.1523/JNEUROSCI.5272-05.2006; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Gebicke-Haerter PJ, 2005, J NEUROSCI RES, V81, P327, DOI 10.1002/jnr.20479; Giralt M, 2002, NEUROBIOL DIS, V9, P319, DOI 10.1006/nbdi.2002.0480; Gros-Louis F, 2007, NAT GENET, V39, P80, DOI 10.1038/ng1927; Guo L, 2006, NAT BIOTECHNOL, V24, P1162, DOI 10.1038/nbt1238; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harvey J, 2007, J NEUROCHEM, V100, P307, DOI 10.1111/j.1471-4159.2006.04205.x; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Ho YS, 2004, J BIOL CHEM, V279, P32804, DOI 10.1074/jbc.M404800200; Horvath S, 2006, P NATL ACAD SCI USA, V103, P17402, DOI 10.1073/pnas.0608396103; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Johnson MC, 2006, VET IMMUNOL IMMUNOP, V110, P357, DOI 10.1016/j.vetimm.2005.12.007; Kassouf W, 2006, CANCER RES, V66, P412, DOI 10.1158/0008-5472.CAN-05-2755; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kurnellas MP, 2004, FASEB J, V18, P298, DOI 10.1096/fj.04-2549fje; Ladenheim B, 2000, MOL PHARMACOL, V58, P1247, DOI 10.1124/mol.58.6.1247; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liang FY, 1997, J NEUROSCI, V17, P2168; Lu XCM, 2004, J NEUROSCI RES, V77, P843, DOI 10.1002/jnr.20218; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Marx CE, 2001, BIOL PSYCHIAT, V50, P743, DOI 10.1016/S0006-3223(01)01209-4; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Murphy PG, 2000, EUR J NEUROSCI, V12, P1891, DOI 10.1046/j.1460-9568.2000.00074.x; Nelson TE, 2004, EUR J NEUROSCI, V20, P2387, DOI 10.1111/j.1460-9568.2004.03706.x; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; O'Neill EE, 2002, PROTEOMICS, V2, P288, DOI 10.1002/1615-9861(200203)2:3<288::AID-PROT288>3.0.CO;2-0; Otero M, 2005, FEBS LETT, V579, P295, DOI 10.1016/j.febslet.2004.11.024; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Penkowa M, 2006, J NEUROSCI RES, V84, P1452, DOI 10.1002/jnr.21043; PEREZ RP, 1993, CANCER RES, V53, P3771; Peters M, 2003, J NEUROSCI, V23, P9752; PETERSEN R, 1988, GENE, V72, P161, DOI 10.1016/0378-1119(88)90138-2; Pottorf WJ, 2006, J NEUROCHEM, V98, P1646, DOI 10.1111/j.1471-4159.2006.04063.x; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Quintana A, 2007, J NEUROSCI RES, V85, P2668, DOI 10.1002/jnr.21126; Radeke HH, 2002, J BIOL CHEM, V277, P27535, DOI 10.1074/jbc.M200419200; Raivich G, 2003, J NEUROSCI RES, V72, P726, DOI 10.1002/jnr.10621; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sato S, 1997, J IMMUNOL, V159, P3278; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; SHALABY F, 1994, ONCOGENE, V9, P2579; Shibata R, 2006, CLIN CANCER RES, V12, P5363, DOI 10.1158/1078-0432.CCR-05-2245; Shimada A, 1998, J VET MED SCI, V60, P351, DOI 10.1292/jvms.60.351; Simmen T, 2005, EMBO J, V24, P717, DOI 10.1038/sj.emboj.7600559; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; Stein Deborah M, 2004, Curr Opin Crit Care, V10, P520, DOI 10.1097/01.ccx.0000144770.96342.65; Stigliani S, 2006, J NEUROCHEM, V96, P656, DOI 10.1111/j.1471-4159.2005.03631.x; STOYE JP, 1987, J VIROL, V61, P2659, DOI 10.1128/JVI.61.9.2659-2669.1987; Strestik BD, 2001, J GEN VIROL, V82, P1349, DOI 10.1099/0022-1317-82-6-1349; Suh KS, 2004, J BIOL CHEM, V279, P4632, DOI 10.1074/jbc.M311632200; Svechnikova I, 2007, BIOCHEM BIOPH RES CO, V354, P466, DOI 10.1016/j.bbrc.2006.12.222; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Ur E, 2002, NEUROENDOCRINOLOGY, V75, P264, DOI 10.1159/000054718; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Westberg JA, 2007, STROKE, V38, P1025, DOI 10.1161/01.STR.0000258113.67252.fa; Won SJ, 2002, J BIOCHEM MOL BIOL, V35, P67, DOI 10.5483/BMBRep.2002.35.1.067; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yun SJ, 2002, MOL BRAIN RES, V107, P57, DOI 10.1016/S0169-328X(02)00447-3	95	27	27	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-8451	1932-846X		DEV NEUROBIOL	Dev. Neurobiol.	FEB 1	2008	68	2					195	208		10.1002/dneu.20584			14	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	259OL	WOS:000252948500005	18000830				2022-02-06	
J	Sachse, KT; Jackson, EK; Wisniewski, SR; Gillespie, DG; Puccio, AM; Clark, RSB; Dixon, CE; Kochanek, PM				Sachse, Kathleen T.; Jackson, Edwin K.; Wisniewski, Stephen R.; Gillespie, Delbert G.; Puccio, Ava M.; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.			Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						adenosine; alcohol; coffee; head injury; head trauma; theobromine	ADENOSINE RECEPTOR AGONISTS; CEREBRAL-BLOOD-FLOW; PARKINSONS-DISEASE; HEAD-INJURY; RISK; MICE; CONSUMPTION; ANTAGONISTS; ETHANOL; PLASMA	Caffeine, the most widely consumed psychoactive drug and a weak adenosine receptor antagonist, can be neuroprotective or neurotoxic depending on the experimental model or neurologic disorder. However, its contribution to pathophysiology and outcome in traumatic brain injury (TBI) in humans is undefined. We assessed serial cerebrospinal fluid (CSF) concentrations of caffeine and its metabolites (theobromine, paraxanthine, and theophylline) by high-pressure liquid chromatography/ultraviolet in 97 ventricular CSF samples from an established bank, from 30 adults with severe TBI. We prospectively selected a threshold caffeine level of >= 1 mu mol/L (194 ng/mL) as clinically significant. Demographics, Glasgow Coma Scale (GCS) score, admission blood alcohol level, and 6-month dichotomized Glasgow Outcome Scale (GOS) score were assessed. Mean time from injury to initial CSF sampling was 10.77 +/- 3.13 h. On initial sampling, caffeine was detected in 24 of 30 patients, and the threshold was achieved in 9 patients. Favorable GOS was seen more often in patients with CSF caffeine concentration >= versus < the threshold (55.6 versus 11.8%, P = 0.028). Gender, age, admission CGS score, admission blood alcohol level, and admission systolic arterial blood pressure did not differ between patients with CSF caffeine concentration >= versus < the threshold. Increases in CSF concentrations of the caffeine metabolites theobromine and paraxanthine were also associated with favorable outcome (P = 0.018 and 0.056, respectively). Caffeine and its metabolites are commonly detected in CSF in patients with severe TBI and in an exploratory assessment are associated with favorable outcome. We speculate that caffeine may be neuroprotective by long-term upregulation of adenosine A1 receptors or acute inhibition of A2a receptors.	[Sachse, Kathleen T.; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Sachse, Kathleen T.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.; Gillespie, Delbert G.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15260 USA; [Puccio, Ava M.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Puccio, Ava M.; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK068575, DK68575] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038087, NS30318, P01 NS030318, NS38087, P50 NS030318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK068575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, R01NS038087, P01NS030318] Funding Source: NIH RePORTER		Al Moutaery K, 2003, NEUROSURGERY, V53, P704, DOI 10.1227/01.NEU.0000079487.66013.6F; Arendash GW, 2006, NEUROSCIENCE, V142, P941, DOI 10.1016/j.neuroscience.2006.07.021; Ascherio A, 2001, ANN NEUROL, V50, P56, DOI 10.1002/ana.1052; Azam Sonish, 2003, Med Sci Monit, V9, pBR325; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; BOULENGER JP, 1983, LIFE SCI, V32, P1135, DOI 10.1016/0024-3205(83)90119-4; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Conde SV, 2006, J NEUROCHEM, V98, P616, DOI 10.1111/j.1471-4159.2006.03912.x; *CTR SCI PUBL INT, 2007, NUTR ACT NEWSL; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/0897715042441828; Dassesse D, 1999, EUR J NEUROSCI, V11, P3101, DOI 10.1046/j.1460-9568.1999.00725.x; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Evans SM, 1999, J PHARMACOL EXP THER, V289, P285; FREDHOLM BB, 1982, ACTA PHYSIOL SCAND, V115, P283, DOI 10.1111/j.1748-1716.1982.tb07078.x; Frye RF, 1998, J LIQ CHROMATOGR R T, V21, P1161, DOI 10.1080/10826079808006591; George FR, 1993, EXP CLIN PSYCHOPHARM, V1, P7, DOI 10.1037/1064-1297.1.1-4.7; Huang ZL, 2005, NAT NEUROSCI, V8, P858, DOI 10.1038/nn1491; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; JOHANSSON B, 1993, N-S ARCH PHARMACOL, V347, P407, DOI 10.1007/BF00165391; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kochanek PM, 2005, J CEREBR BLOOD F MET, V25, P1596, DOI 10.1038/sj.jcbfm.9600154; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Phillis JW, 2001, NEUROL RES, V23, P183, DOI 10.1179/016164101101198316; Pignataro G, 2007, J CEREBR BLOOD F MET, V27, P1, DOI 10.1038/sj.jcbfm.9600334; Pugliese AM, 2006, BRIT J PHARMACOL, V147, P524, DOI 10.1038/sj.bjp.0706646; RAMKUMAR V, 1988, J CLIN INVEST, V82, P242, DOI 10.1172/JCI113577; Reece TB, 2004, J SURG RES, V121, P130, DOI 10.1016/j.jss.2004.04.006; Ribeiro JA, 2005, CNS NEUROL DISORD-DR, V4, P325, DOI 10.2174/1568007054546090; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Schapira AHV, 2006, NAT REV DRUG DISCOV, V5, P845, DOI 10.1038/nrd2087; Shi D, 1999, CELL MOL NEUROBIOL, V19, P719, DOI 10.1023/A:1006901005925; SOTO J, 1994, THER DRUG MONIT, V16, P108, DOI 10.1097/00007691-199402000-00017; Strong R, 2000, NEUROPHARMACOLOGY, V39, P515, DOI 10.1016/S0028-3908(99)00156-2; SUTHERLAND GR, 1991, NEUROSCIENCE, V42, P171, DOI 10.1016/0306-4522(91)90157-J; Tan EK, 2003, J NEUROL SCI, V216, P163, DOI 10.1016/j.jns.2003.07.006; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103; 1996, J NEUROTRAUMA, V11, P643	43	27	28	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2008	28	2					395	401		10.1038/sj.jcbfm.9600539			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	255MS	WOS:000252662700017	17684518	Green Accepted, Bronze			2022-02-06	
J	Chen, G; Shi, J; Qi, M; Yin, H; Hang, C				Chen, G.; Shi, J.; Qi, M.; Yin, H.; Hang, C.			Glutamine decreases intestinal nuclear factor kappa B activity and pro-inflammatory cytokine expression after traumatic brain injury in rats	INFLAMMATION RESEARCH			English	Article						traumatic brain injury; intestine; nuclear factor kappa B; inflammation; glutamine	COLONIC EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; BACTERIAL TRANSLOCATION; INDUCED APOPTOSIS; MULTIPLE TRAUMA; GENE-EXPRESSION; TNF-ALPHA; HUMAN GUT; ACTIVATION; PERMEABILITY	Objective: To investigate whether glutamine supplementation modulates intestinal nuclear factor kappa B (NF-kappa B) activity and pro-inflammatory cytokine expression after traumatic brain injury (TBI) in rats. Materials and methods: Right parietal cortical contusion in male rats was made by the weight-dropping method. After trauma, the rats were randomly given chow alone or glutamine mixed chow for 5 d. Gut samples were extracted at 5 d postinjury. We measured NF-kappa B binding activity by electrophoretic mobility shift assay; NF-kappa B subunits p50 and p65 expression by immunohistochemistry; the concentrations of interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6 by enzyme-linked immunosorbent assay; intestinal mucosal morphological changes by histopathological study and electron microscopy; and apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining. Results: Administration of glutamine following TBI could decrease NF-kappa B binding activity, NF-kappa B p65 protein expression and concentrations of pro-inflammatory cytokines in the gut. TBI-induced damage of gut structure was ameliorated after glutamine supplementation. Conclusion: The results of the present study suggest that the therapeutic benefit of post-TBI glutamine supplementation might be due to its inhibitory effects on intestinal NF-kappa B activation and pro-inflammatory cytokine expression.	[Chen, G.; Shi, J.; Qi, M.; Yin, H.; Hang, C.] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China		Hang, C (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	nju_neurosurgery@163.com	QI, Meng/F-2802-2012	Chen, Gang/0000-0002-0758-1907			Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bastian L, 2002, BRIT J NUTR, V87, pS133, DOI 10.1079/BJN2001466; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Coeffier M, 2003, CLIN NUTR, V22, P407, DOI 10.1016/S0261-5614(03)00040-2; Coeffier M, 2001, CYTOKINE, V13, P148, DOI 10.1006/cyto.2000.0813; deBlaauw I, 1997, GASTROENTEROLOGY, V112, P118, DOI 10.1016/S0016-5085(97)70226-9; Ellis RD, 1998, INFLAMM RES, V47, P440, DOI 10.1007/s000110050358; Erbil Y, 1999, HEPATO-GASTROENTEROL, V46, P2791; Evans ME, 2005, AM J PHYSIOL-GASTR L, V289, pG388, DOI 10.1152/ajpgi.00072.2005; Evans ME, 2003, J NUTR, V133, P3065, DOI 10.1093/jn/133.10.3065; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FILLMANN H, IN PRESS TOXICOLOGY; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769, DOI 10.1152/ajpgi.1997.273.4.G769; Garcia-de-Lorenzo A, 2003, NUTRITION, V19, P805, DOI 10.1016/S0899-9007(03)00103-5; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Ha WY, 2006, INFLAMM RES, V55, P293, DOI 10.1007/s00011-006-0086-9; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Houdijk APJ, 1998, LANCET, V352, P772, DOI 10.1016/S0140-6736(98)02007-8; Huang Y, 2003, CYTOKINE, V22, P77, DOI 10.1016/S1043-4666(03)00115-7; Li N, 2004, AM J PHYSIOL-GASTR L, V286, pG914, DOI 10.1152/ajpgi.00493.2003; Margaritis VG, 2005, WORLD J SURG, V29, P1329, DOI 10.1007/s00268-005-7721-4; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Novak F, 2002, CRIT CARE MED, V30, P2022, DOI 10.1097/00003246-200209000-00011; Papaconstantinou HT, 2000, J GASTROINTEST SURG, V4, P416, DOI 10.1016/S1091-255X(00)80022-0; Paquette JC, 2005, J CELL PHYSIOL, V202, P912, DOI 10.1002/jcp.20194; Parikh AA, 1997, J SURG RES, V69, P139, DOI 10.1006/jsre.1997.5061; PARK PO, 1990, SURGERY, V107, P574; Paterson RL, 2000, CRIT CARE MED, V28, P1047, DOI 10.1097/00003246-200004000-00022; Pieper GM, 2004, INFLAMM RES, V53, P22, DOI 10.1007/s00011-003-1223-3; SCHRODER J, 1995, JPEN-PARENTER ENTER, V19, P502, DOI 10.1177/0148607195019006502; Suh GJ, 2003, NUTR RES, V23, P131, DOI 10.1016/S0271-5317(02)00479-7; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; VENTE JP, 1989, ANN SURG, V209, P57, DOI 10.1097/00000658-198901000-00009; Wischmeyer PE, 2003, NUTRITION, V19, P1, DOI 10.1016/S0899-9007(02)00839-0	40	27	33	0	1	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1023-3830	1420-908X		INFLAMM RES	Inflamm. Res.	JAN	2008	57	2					57	64		10.1007/s00011-007-7101-7			8	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	267NV	WOS:000253516600003	18288455				2022-02-06	
J	Johnson, DR; Vincent, AS; Johnson, AE; Gilliland, K; Schlegel, RE				Johnson, Dan R.; Vincent, Andrea S.; Johnson, Ashley E.; Gilliland, Kirby; Schlegel, Robert E.			Reliability and construct validity of the Automated Neuropsychological Assessment Metrics (ANAM) mood scale	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mood; construct validity; neuropsychological assessment; traumatic brain injury	TRAUMATIC BRAIN-INJURY; GULF-WAR; DEPRESSION; VALIDATION; VETERANS; FATIGUE	The reliability and construct validity of the Automated Neuropsychological Assessment Metrics (ANAM) mood scale (AMS) were examined using concurrent, well-validated measures of mood and confirmatory factor analysis (CFA) with a sample of 210 volunteer college students. The AMS was given in computerized format with multiple adjectives using a visual analog Likert scale yielding seven dimensions of mood including vigor, restlessness, depression, anger, fatigue, anxiety, and happiness. All seven mood dimensions of the AMS demonstrated excellent test-retest reliability and internal consistency. Also, the AMS anxiety dimension correlated strongly with the Spielberger's State Anxiety Inventory (r=0.67) and the AMS depression dimension correlated strongly with the Beck Depression Inventory-II (r=0.71). CFA revealed that the AMS 7-factor mood model fit the data well and significantly better than an alternative, theoretically plausible model. When concurrent measures of mood were incorporated in the CFA model, the AMS demonstrated both convergent and discriminant validity. The AMS 7-factor model explained 55.12% of the total variance in the items. It was concluded that the AMS provides a brief yet reasonably complete and valid assessment of mood. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	[Johnson, Dan R.; Vincent, Andrea S.; Johnson, Ashley E.; Gilliland, Kirby; Schlegel, Robert E.] Univ Oklahoma, Ctr Study Human Operator Performance, Norman, OK 73019 USA		Johnson, DR (corresponding author), Univ Oklahoma, Ctr Study Human Operator Performance, 455 W Lindsey,DAHT Room 740, Norman, OK 73019 USA.	johnsoda@ou.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anger WK, 2003, OCCUP ENVIRON MED, V60, P531; Anger WK, 1996, NEUROTOXICOL TERATOL, V18, P347, DOI 10.1016/0892-0362(96)00079-7; BIERSNER RJ, 1984, J HUM STRESS, V10, P43, DOI 10.1080/0097840X.1984.9934958; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Browne, 1993, TESTING STRUCTURAL E, DOI [10.1177/0049124192021002005, DOI 10.1177/0049124192021002005]; Browne MW., 1982, TOPICS APPL MULTIVAR, P72, DOI DOI 10.1017/CB09780511897375.003; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Clauw D, 2003, BMJ-BRIT MED J, V327, P1357, DOI 10.1136/bmj.327.7428.1357; David AS, 2002, PSYCHOL MED, V32, P1357, DOI 10.1017/S0033291702006359; Glass JM, 2004, J PSYCHOSOM RES, V57, P391, DOI 10.1016/j.jpsychores.2004.04.002; Jorge R, 2002, NEUROREHABILITATION, V17, P311; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; Matthews G., 1999, PERS PSYCHOL EUR, V7, P335, DOI DOI 10.1177/154193120404801107; Matthews RG, 2002, CHEM REC, V2, P4, DOI 10.1002/tcr.10006; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Montgomery EB, 2000, MOVEMENT DISORD, V15, P467, DOI 10.1002/1531-8257(200005)15:3<467::AID-MDS1007>3.0.CO;2-#; Roebuck-Spencer TM, 2006, ARTHRIT RHEUM-ARTHR, V55, P434, DOI 10.1002/art.21992; RYMAN DH, 1974, PSYCHOL REP, V35, P479, DOI 10.2466/pr0.1974.35.1.479; Storzbach D, 2000, PSYCHOSOM MED, V62, P726, DOI 10.1097/00006842-200009000-00017; Tanaka J. S., 1993, TESTING STRUCTURAL E, P10; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	30	27	28	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2008	23	1					73	85		10.1016/j.acn.2007.10.001			13	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	259ET	WOS:000252922600006	18031982	Bronze			2022-02-06	
J	Pfister, D; Strebel, SP; Steiner, LA				Pfister, D.; Strebel, S. P.; Steiner, L. A.			Effects of catecholamines on cerebral blood vessels in patients with traumatic brain injury	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Brain Annual Meeting	MAY 09-12, 2007	Brescia, ITALY			brain injury; trauma; regional blood flow; brain; catecholamines	CORTICAL IMPACT INJURY; PERFUSION-PRESSURE AUGMENTATION; SEVERE HEAD-INJURY; OVINE MODEL; INDUCED HYPERTENSION; PROPOFOL INFUSION; EDEMA FORMATION; DOPAMINE; NOREPINEPHRINE; FLOW	Data on the cerebrovascular effects of catecholamines after head injury are difficult both to interpret and to compare. Diverse parameters with regard to brain trauma animal models, methods of determining the effects on the cerebral blood flow and metabolism and choice of end-points have been used. Many studies investigate the cerebrovascular effects of catecholamines over a range of cerebral perfusion pressures above the range recommended by current guidelines. The relationship between patient outcome and the use of a specific substance to improve cerebral perfusion has not been investigated. Dopamine, norepinephrine and phenylephrine all seem to increase cerebral blood flow in various animal models and in patients. The data suggest that norepinephrine may be the most predictable. It is associated with an improved restoration of global and regional oxygenation when compared to dopamine. Dopamine has been associated with an increase in brain oedema. There is further evidence that dopamine has many disadvantages in critically ill patients due to its ability to suppress circulating concentrations of most anterior pituitary-dependent hormones. Both aspects would further discourage its use. Data on phenylephrine are scarce. It has been associated with increased intracranial pressure and a failure to improve cerebral oxygenation despite markedly improved cerebral perfusion pressure. For all other catecholamines and related substances there are insufficient data on the cerebrovascular effects after head injury. This suggests that norepinephrine may be the catecholamine that is the most suitable substance to maintain or restore adequate cerebral perfusion. The data, however, are insufficient to formulate a guideline.	[Pfister, D.; Strebel, S. P.; Steiner, L. A.] Univ Basel Hosp, Dept Anesthesia, CH-4031 Basel, Switzerland		Steiner, LA (corresponding author), Univ Basel Hosp, Dept Anesthesia, Spitalstr 21, CH-4031 Basel, Switzerland.	lsteiner@uhbs.ch	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011				Alspaugh DM, 2000, J TRAUMA, V48, P851, DOI 10.1097/00005373-200005000-00008; [Anonymous], 2003, GUIDELINES MANAGEMEN; Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; Beaumont A, 2000, ACT NEUR S, V76, P147; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; CHILLON JM, 2002, CEREBRAL BLOOD FLOW, P395; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Corbett SM, 2006, CRIT CARE MED, V34, P2479, DOI 10.1097/01.CCM.0000230238.72846.B3; Edvinsson L, 2002, CEREBRAL BLOOD FLOW, P384; Edvinsson L, 2002, CEREBRAL BLOOD FLOW, P191; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; Moppett IK, 2004, BRIT J ANAESTH, V92, P39, DOI 10.1093/bja/aeh014; Myburgh JA, 1998, ACT NEUR S, V71, P19; Myburgh JA, 2003, ANAESTH INTENS CARE, V31, P259, DOI 10.1177/0310057X0303100303; Myburgh JA, 2003, INTENS CARE MED, V29, P817, DOI 10.1007/s00134-003-1684-4; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sahuquillo J, 2000, ACT NEUR S, V76, P457; SOKRAB TEO, 1989, ACTA PHYSIOL SCAND, V137, P101, DOI 10.1111/j.1748-1716.1989.tb08725.x; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Steiner LA, 2003, ANESTH ANALG, V97, P572, DOI 10.1213/01.ANE.0000070234.17226.B0; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; Stubbe HD, 2006, CRIT CARE MED, V34, P2651, DOI 10.1097/01.CCM.0000239196.17999.B7; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024	38	27	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.		2008	25			42			98	103		10.1017/S0265021507003407			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Anesthesiology	283AY	WOS:000254610100017	18289425				2022-02-06	
J	Sherer, M; Yablon, SA; Nakase-Richardson, R; Nick, TG				Sherer, Mark; Yablon, Stuart A.; Nakase-Richardson, Risa; Nick, Todd G.			Effect of severity of post-traumatic confusion and its constituent symptoms on outcome after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amnesia; brain injuries; confusion; delirium; psychotic disorders; rehabilitation; treatment outcome	CLOSED-HEAD-INJURY; COGNITIVE TEST; RATING-SCALE; AMNESIA; RECOVERY; ORIENTATION; VALIDATION; PSYCHOSIS; DELIRIUM	Objective: To investigate the prognostic significance of severity of post-traumatic confusion (PTC) and its constituent symptoms for early and late outcome after traumatic brain injury (TBI). Design: Prospective cohort study. Setting: Inpatient brain injury rehabilitation program. Participants: A total of 168 patients meeting study criteria from 195 consecutive Traumatic Brain Injury Model Systems neurorehabilitation admissions. Interventions: Not applicable. Main Outcome Measures: Employability at neurorehabilitation discharge and productivity status at 1 year postinjury. Results: More severely confused patients had poorer outcomes for both employability and productivity. Multivariable logistic regression revealed that after adjustment for all other predictors, time to follow commands, and confusion severity predicted employability at discharge and age and confusion severity predicted productivity status at 1 year. Each symptom showed an unadjusted effect on discharge employability. All symptoms except nighttime sleep disturbance or daytime decreased arousal had effects on productivity at 1 year. Presence of psychotic-type symptoms was associated with especially poor productivity outcomes. Conclusions: PTC constituent symptoms and severity predict outcome after TBI. Presence or absence of psychotic-type symptoms on a single evaluation at approximately 21 days postinjury may have particular prognostic significance for productivity outcome.	[Sherer, Mark] Mem Hermann TIRR, Dept Res, Houston, TX 77030 USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA; [Yablon, Stuart A.; Nakase-Richardson, Risa] Methodist Rehabil Ctr, Jackson, MS USA; [Yablon, Stuart A.; Nakase-Richardson, Risa] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Nick, Todd G.] Cincinnati Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH USA; [Nick, Todd G.] Univ Cincinnati, Coll Med, Cincinnati, OH USA		Sherer, M (corresponding author), Mem Hermann TIRR, Dept Res, 1333 Moursund, Houston, TX 77030 USA.	Mark.Sherer@memorialhermann.org					CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1994, HEAD INJURY, P525; McAllister TW, 2002, NEUROREHABILITATION, V17, P357; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; National Data and Statistical Center, TRAUM BRAIN INJ MOD; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sachdev P, 2001, J NEUROPSYCH CLIN N, V13, P533, DOI 10.1176/appi.neuropsych.13.4.533; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Trzepacz Paula T., 1994, P189; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0	23	27	28	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2008	89	1					42	47		10.1016/j.apmr.2007.08.128			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	249LB	WOS:000252228600008	18164329				2022-02-06	
J	Jiang, Y; Sun, XC; Gui, L; Xia, YX; Tang, WY; Cao, YQ; Gu, YJ				Jiang, Yong; Sun, Xiaochuan; Gui, Li; Xia, Yuxian; Tang, Wenyuan; Cao, Yueqing; Gu, Yingjiang			Correlation between APOE-491AA promoter in epsilon 4 carriers and clinical deterioration in early stage of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						APOE; early response; polymorphism; promoter; traumatic brain injury	APOLIPOPROTEIN-E EPSILON-4; HEAD-INJURY; ALZHEIMERS-DISEASE; REGULATORY REGION; E POLYMORPHISM; APOE GENOTYPE; E4; ASSOCIATION; ALLELE; DEPOSITION	The objective of this work was to investigate the relationship between apolipoprotein E (APOE) promoters (G-219T, C-427T, A-491T) polymorphisms and the clinical deterioration in early stage of traumatic brain injury (TBI) in a cohort of Chinese patients. In this study, we used the cohort of patients which has been reported previously. A total of 110 subjects with TBI (80 males and 30 females, with mean age of 43.87 years) were admitted from December 2003 to May 2004, and demographic and clinical data were collected. The clinical deterioration of patient's condition in acute stage (< 7 days after TBI) was judged by either of the following criteria: decrease of Glasgow Coma Scale (GCS) score (compared with initial admission GCS), increase in hematoma volume or delayed hematoma both detected by repeated computed tomography (CT) scanning compared to that on admission. Venous blood was collected from patients with TBI on admission to determine the APOE promoter polymorphisms. The APOE genotyping was performed by means of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). chi(2) test and logistic regression analyses were done by SPSS. In 110 Chinese patients, the distributions of APOE genotypes and alleles matched Hardy-Weinberg Law, and 19 subjects presented with deteriorated clinical condition in acute stage after hospitalization. chi(2) test showed insignificant differences in association of APOE promoter polymorphisms with clinical deterioration (p > 0.05). But logistic regression analyses, after adjusting patients' age, injury severity and injury mechanism etc, showed that -491AA (OR = 11.681, p = 0.009, 95%, CI 1.824-74.790) and APOE epsilon 4 were all risk factors, with injury severity and alcohol-drinking as other risk factors. In Chinese population, as a significant but not independent risk factor, only APOE -491AA promoter in epsilon 4 carriers is apt to the clinical deterioration and may contribute to the poor outcome after TBI.	[Jiang, Yong; Sun, Xiaochuan; Tang, Wenyuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Jiang, Yong; Gui, Li; Gu, Yingjiang] Luzhou Med Coll, Affiliated Hosp 1, Dept Neurosurg, Luzhou, Peoples R China; [Xia, Yuxian; Cao, Yueqing] Chongqing Univ, Bioengn Coll, Ctr Gene Res, Chongqing 630044, Peoples R China		Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	sunxch1445@gmail.com					Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Corbo RM, 2001, CLIN CHEM LAB MED, V39, P2, DOI 10.1515/CCLM.2001.002; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Ezra Y, 2003, NEUROSCIENCE, V121, P315, DOI 10.1016/S0306-4522(03)00436-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205; Houlden H, 2006, J NEUROL NEUROSUR PS, V77, P1106, DOI 10.1136/jnnp.2006.095513; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Johansson K, 1997, LANCET, V349, P1143, DOI 10.1016/S0140-6736(97)24016-X; Katzman R, 1996, NEUROLOGY, V46, P889; Lambert JC, 2000, HUM MOL GENET, V9, P57, DOI 10.1093/hmg/9.1.57; Lambert JC, 2001, LANCET, V357, P608, DOI 10.1016/S0140-6736(00)04063-0; Laws SM, 2002, MOL PSYCHIATR, V7, P886, DOI 10.1038/sj.mp.4001097; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Michikawa M, 1999, MECH AGEING DEV, V107, P233, DOI 10.1016/S0047-6374(98)00134-1; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pahnke J, 2003, ACTA NEUROPATHOL, V105, P25, DOI 10.1007/s00401-002-0602-0; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655; Yang JD, 2003, NEUROSCI LETT, V350, P25, DOI 10.1016/S0304-3940(03)00815-2	38	27	39	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1802	1810		10.1089/neu.2007.0299			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000002	18159991				2022-02-06	
J	Beis, K; Pieter, W; Abatzides, G				Beis, Konstantinos; Pieter, Willy; Abatzides, George			Taekwondo techniques and competition characteristics involved in time-loss injuries	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						martial arts; taekwondo; time-loss; Greek; injuries	CHAMPIONSHIPS; KARATE; BLOWS; HEAD	The purpose of this study was to assess time-loss injuries in young and adult taekwondo athletes. Participants were 2739 children (11-13 years), Junior (14-17 years) and adult males and females (18 years and older) competing in the national Greek championships. Injury data were collected by project staff with all diagnoses made by the tournament physician. Odds ratios were computed as well as 95% confidence intervals around the injury rates. The female Juniors had a higher time-loss injury rate ( Fisher's Exact Test p = 0.033) than their adult counterparts. However, they were not at a higher risk of incurring a time- loss injury: OR = 0.143, 95% CI: 0.018-1.124. Collapsed over age, the females as a group recorded more time- loss injuries [11.36/1,000 A-E (95% CI: 6.25-16.47) versus 7.40/1,000 A-E (95% CI: 4.44-10.36)], but this was not significant (OR = 0.703, 95% CI: 0.383-1.293). In the Juniors, the boys only incurred time- loss injuries to the head and neck. There was no difference in the Junior girls in the distribution of time- loss injuries across body region, although they were at higher risk of sustaining an injury to the head and neck (OR = 1.510, 95% CI: 0.422-5.402) but this was not statistically significant. Although there were no statistical differences among age groups within gender, the Junior boys and girls (11-13 years) sustained more cerebral concussions. The Junior boys were at a higher risk of incurring a cerebral concussion than the boys (OR = 7.871, 95% CI: 0.917-67.583, Fisher's Exact Test p = 0.036). In the males, there was no difference between the men and Junior boys in injury rate for swing kicks compared to other techniques (OR = 2.000, 95% CI = 0.397-28.416). There also was no difference between the men and boys (OR = 4.800, 95% CI: 0.141-58.013). To help reduce the incidence of time- loss injuries in taekwondo, especially cerebral concussions, it is suggested for coaches to emphasize blocking skills. Educating referees, coaches and athletes plays an important role in helping to reduce taekwondo time- loss injuries.	Univ Sci Malaysia, Sch Hlth Sci, Sports Sci Program, Kubang Kerian 16150, Kelantan, Malaysia; Aristotle Univ Thessaloniki, Dept Phys Educ & Sport Sci, GR-54006 Thessaloniki, Greece		Pieter, W (corresponding author), Univ Sci Malaysia, Sch Hlth Sci, Sports Sci Program, Kubang Kerian 16150, Kelantan, Malaysia.	kostbeis@phed.auth.gr; yshin516@yahoo.com; abi@phed.auth.gr					Arriaza R, 2005, KNEE SURG SPORT TR A, V13, P603, DOI 10.1007/s00167-004-0593-6; Beis K, 2001, EUR J SPORT TRAUMA R, V23, P130; Dah C, 1989, CINESIOLOGIE, V28, P153; GUMMERSON T, 2005, COACHING CHAMPIONS D; Kazemi M, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-22; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; Koh JO, 2001, INT J APPL SPORTS SC, V13, P33; MATSUBAYASHI K, 1993, 1993 ADV BIOENG, P259; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pieter F, 1995, BIOL SPORT, V12, P257; Pieter W, 1997, SPORTS EXERC INJURY, V3, P37; Pieter W, 1997, J TRAUMA, V43, P89, DOI 10.1097/00005373-199707000-00020; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1998, BRIT J SPORT MED, V32, P88; PIETER W, 1998, KINESIOLOGY, V30, P22, DOI DOI 10.1589/JPTS.28.231; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; Pieter W, 1997, COACH SPORT SCI J, V2, P7; Pieter W., 1999, 5 IOC WORLD C SPORT; Pieter W, 1997, ICHPERSD 40 WORLD C, P355; PIETER W, 1990, GENEESK SPORT, V23, P222; PIETER W, 1996, EPIDEMIOLOGY SPORTS, P268; PIETER W, 2004, 1 REG C HUM PERF KUD; Siana J E, 1986, Br J Sports Med, V20, P165; Tuominen Risto, 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P44; WHITING WC, 1988, AM J SPORT MED, V16, P130, DOI 10.1177/036354658801600207; WIRTZ PD, 1988, J AM PODIAT MED ASSN, V78, P474, DOI 10.7547/87507315-78-9-474; ZANDBERGEN A, THESIS TWENTSE AKAD, P1; Zemper E D, 1989, Br J Sports Med, V23, P161; Zemper E. D., 1991, INT C EXP SPORTS MED	31	27	27	0	14	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	OCT	2007	6				2		45	51					7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	215DS	WOS:000249789100009	24198703				2022-02-06	
J	Huh, JW; Raghupathi, R				Huh, Jimmy W.; Raghupathi, Ramesh			Chronic cognitive deficits and long-term histopathological alterations following contusive brain injury in the immature rat	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; children; contusion; head injury; infants; pediatric; traumatic brain injury	TRAUMATIC BRAIN; HEAD-INJURY; FRONTAL LESIONS; CORTICAL IMPACT; AGE; CHILDREN; DAMAGE; VULNERABILITY; MATURATION; RECOVERY	Although diffuse axonal injury is the primary pathology in pediatric brain trauma, the additional presence of focal contusions may contribute to the poor prognosis in brain-injured children younger than 4 years of age. Because existing models of pediatric brain trauma focus on diffuse brain injury, a model of contusive brain trauma was developed using postnatal day (PND) 11 and 17 rats, ages that are neurologically equivalent to a human infant and toddler, respectively. Closed head injury was modeled by subjecting the intact skull over the left parietal cortex of the immature rat to an impact with a metal-tipped indenter. Brain trauma on PND11 or PND17 led to significant spatial learning deficits at 28 days post-injury, compared to age-matched control rats (p < 0.05). Although both groups of rats sustained skull fractures on impact, the histopathologic response of the brain was distinctly age-dependent. At 3 days post-injury in PND11 rats, the cortex below the impact site was contused and hemorrhagic, and contained reactive astrocytes, while the subcortical white matter and thalamus contained injured (swollen) axons. At 14 and 28 days post-injury, the cortex, white matter, and hippocampus were substantially atrophied, and the lateral ventricle was enlarged. In contrast, in PND17 rats, the contused cortex observed at 3 days post-injury matured into a pronounced cavity lined with a glia limitans at 14 days; reactive astrocytes were present in both the hippocampus and thalamus up to 28 days post-injury. No evidence of traumatic axonal injury was observed in any region of the brain-injured PND17 rat. These data suggest that contusive brain trauma in the immature rat is associated with chronic cognitive deficits, but underscore the effect of the age-at-injury on behavioral and histopathologic outcomes.	Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA USA		Raghupathi, R (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA.	rramesh@drexelmed.edu	Raghupathi, Ramesh/AAX-5538-2021		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0-NS41561, K08-NS053651] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS053651, R01NS041561] Funding Source: NIH RePORTER		Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1978, CURRENT CONCEPTS, P1; CAFFEY J, 1974, PEDIATRICS, V54, P396; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chopp M, 1999, BRAIN RES, V828, P197, DOI 10.1016/S0006-8993(99)01354-2; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CROWNE DP, 1989, NEUROPSYCHOLOGIA, V27, P1119, DOI 10.1016/0028-3932(89)90095-X; DIMATTIA BV, 1988, BEHAV NEUROSCI, V102, P397, DOI 10.1037/0735-7044.102.3.397; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobbing J., 1981, SCI F PAEDIATRICS, P744; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1999, EXP TOXICOL PATHOL, V51, P172, DOI 10.1016/S0940-2993(99)80091-8; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; DUHAIME AC, 1996, NEUROLOGICAL SURG, P1777; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; Kolb B, 2000, BRAIN RES, V882, P62, DOI 10.1016/S0006-8993(00)02828-6; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Langfitt T W, 1969, Clin Neurosurg, V16, P436; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POLITIS MJ, 1988, EXP NEUROL, V100, P288, DOI 10.1016/0014-4886(88)90108-2; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Salvati S, 2000, DEV NEUROSCI-BASEL, V22, P481, DOI 10.1159/000017479; SHAPIRA Y, 1989, Neurological Research, V11, P169; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; ZIMMERMAN RA, 1981, J NEURORADIOLOGY, V8, P257	51	27	27	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2007	24	9					1460	1474		10.1089/neu.2006.3787			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	214ZT	WOS:000249777600005	17892408				2022-02-06	
J	Marton, E; Mazzucco, M; Nascimben, E; Martinuzzi, A; Longatti, P				Marton, Elisabetta; Mazzucco, Marina; Nascimben, Ennio; Martinuzzi, Andrea; Longatti, Pierluigi			Severe head injury in early infancy: analysis of causes and possible predictive factors for outcome	CHILDS NERVOUS SYSTEM			English	Article						paediatric head injury; childhood trauma; functional outcome; paediatric coma scales; prognostic factors	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; POSTTRAUMATIC SEIZURES; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC FACTORS; COMA SCALE; IMPACT; AGE; MECHANISMS; EXPERIENCE	Object The aim of this study was to analyse the causes and prognostic factors for outcome in severe traumatic brain injuries (TBI) in early infancy. Materials and methods We present a retrospective study on 16 infants aged less than 12 months observed over the last 20 years in our department for severe brain injury. Infants were evaluated by the Children Coma Scale (CCS). We assessed Glasgow Outcome Scale (GOS) at discharge and at 12 months after discharge. Conclusions The main causes of trauma were domestic accidents followed by car accidents. The highest positive correlation was found between the GOS score at I year and the presence of hypoxia and hypotension at admission, the presence of hyperglycaemia at 24 It and the occurrence of major clotting disorders. A significant but weaker correlation was found with the CCS at admission, the occurrence of early post-traumatic seizures and the length of stay in the intensive care unit.	Univ Padua, Dept Neurosurg, Ca Foncello Hosp, I-31100 Treviso, Italy; Ca Foncello Hosp, Neurosurg Intens Care Unit, Treviso, Italy; Conegliano Res Ctr, E Medea Sci Inst, Conegliano, Italy		Marton, E (corresponding author), Univ Padua, Dept Neurosurg, Ca Foncello Hosp, I-31100 Treviso, Italy.	emarton@libero.it	Martinuzzi, Andrea/AAC-3127-2022; Martinuzzi, Andrea/K-3887-2016	Martinuzzi, Andrea/0000-0002-0319-3579; MARTON, ELISABETTA/0000-0001-9430-6518			Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Chiaretti A, 2002, CHILD NERV SYST, V18, P54, DOI 10.1007/s00381-001-0533-4; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Dias MS, 1999, PEDIATR NEUROSURG, V30, P232, DOI 10.1159/000028803; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; EWINGCOBBS L, 1995, J HEAD TRAUMA REHAB, V10, P13, DOI 10.1097/00001199-199510000-00004; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Vinchon M, 2003, PEDIATR NEUROSURG, V39, P122, DOI 10.1159/000071648	33	27	27	0	3	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	AUG	2007	23	8					873	880		10.1007/s00381-007-0314-9			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	191SD	WOS:000248151400012	17384952				2022-02-06	
J	Redell, JB; Zhao, J; Dash, PK				Redell, John B.; Zhao, Jing; Dash, Pramod K.			Acutely increased cyclophilin A expression after brain injury: A role in blood-brain barrier function and tissue preservation	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						biomarkers; cyclophilin A; cyclosporine A; proteomics; blood-brain barrier	MITOCHONDRIAL PERMEABILITY TRANSITION; CONTROLLED CORTICAL IMPACT; SMOOTH-MUSCLE-CELLS; CYCLOSPORINE-A; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; RAT; DAMAGE; DEATH; IDENTIFICATION	Blood-brain barrier (BBB) compromise is a significant pathologic event that manifests early following traumatic brain injury (TBI). Because many signaling cascades are initiated immediately after the traumatic event, we were interested in examining acute differential protein expression that may be involved in BBB function. At acute time points postinjury, altered protein expression may result from altered translation efficiency or turnover rate rather than from a genomic response. The application of tandem 2-D gel electrophoresis and mass spectrometry analysis is a powerful approach for directly screening differential protein expression following TBI. Using comparative 2-D gel analysis, we selected candidate protein spots with apparent altered expression and identified them by mass spectrometry. Cyclophilin A was selected for further analysis because it has been implicated in endothelial cell activation and inflammation, and studies have suggested cyclosporine A, an inhibitor of all cyclophilin isoforms, might be beneficial after TBI. We examined if altered expression of cyclophilin A in the brain vasculature might play a role in BBB function. We found significantly increased cyclophilin A levels in isolated brain microvessels 30 min following injury. Postinjury administration of cyclosporine A significantly attenuated BBB permeability measured 24 hr postinjury, suggesting cyclophilin activity after TBI may be detrimental. However, direct injection of purified recombinant cyclophilin A attenuated both BBB permeability and tissue damage in a stab wound model of injury. These findings suggest that increased expression of cyclophilin A may play a protective role after TBI, whereas other cyclophilin isoforms may be detrimental. (c) 2007 Wiley-Liss, Inc.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Neurosurg & Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, Neurosurg & Vivian L Smith Ctr Neurol Res, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS049160] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH072933] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049160, NS35457] Funding Source: Medline		Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Adelson PD, 1998, ACT NEUR S, V71, P104; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; Arora K, 2005, J IMMUNOL, V175, P517, DOI 10.4049/jimmunol.175.1.517; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; BOULOS S, 2006, NEUROBIOL DIS; CHEN S, 2006, J CEREB BLOOD FLOW M; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doyle V, 1999, BIOCHEM J, V341, P127, DOI 10.1042/0264-6021:3410127; Glod J, 2006, BLOOD, V107, P940, DOI 10.1182/blood-2004-11-4403; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hamer PW, 2002, J ANAT, V200, P69, DOI 10.1046/j.0021-8782.2001.00008.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Jin ZG, 2004, ARTERIOSCL THROM VAS, V24, P1186, DOI 10.1161/01.ATV.0000130664.51010.28; Kim SH, 2004, AM J PATHOL, V164, P1567, DOI 10.1016/S0002-9440(10)63715-7; Krizbai IA, 2005, CELL MOL NEUROBIOL, V25, P129, DOI 10.1007/s10571-004-1378-7; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Meloni BP, 2005, PROTEOMICS, V5, P4743, DOI 10.1002/pmic.200500107; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; PLATEEL M, 1995, J NEUROCHEM, V65, P2138; ROOTS BI, 1981, J EXP BIOL, V95, P167; Seko Y, 2004, BIOCHEM BIOPH RES CO, V317, P162, DOI 10.1016/j.bbrc.2004.03.021; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Simpson R. J., 2003, PROTEINS PROTEOMICS; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Suzuki J, 2006, CIRC RES, V98, P811, DOI 10.1161/01.RES.0000216405.85080.a6; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Wagnerova J, 2002, J NEUROL SCI, V195, P51, DOI 10.1016/S0022-510X(01)00685-2; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Yang H, 2005, J SURG RES, V123, P312, DOI 10.1016/j.jss.2004.08.026; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200	47	27	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUL	2007	85	9					1980	1988		10.1002/jnr.21324			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	196EE	WOS:000248463700015	17461417				2022-02-06	
J	Rafols, JA; Morgan, R; Kallakuri, S; Kreipke, CW				Rafols, Jose A.; Morgan, Randy; Kallakuri, Srinivas; Kreipke, Christian W.			Extent of nerve cell injury in Marmarou's model compared to other brain trauma models	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; cell death; diffuse axonal injury; diffuse brain injury	AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; CLOSED-HEAD TRAUMA; NEURONAL DEGENERATION; STRETCH-INJURY; FLUORO-JADE; RATS; MARKER; LOCALIZATION; EXPRESSION	Objectives: We sought to determine the extent of nerve cell injury in the Marmarou's acceleration impact model of diffuse brain injury. Methods: Sensitive markers for cell injury including immunostaining for b-amyloid precursor protein (b-APP, a marker for diffuse axonal injury, DAI), Fluoro-Jade (FJ) histochemistry and electron microscopy (EM) were used in sham- operated and traumatized brains. Results: APP immunostaining confirmed and extended previous findings of DAI in association and subcortical fiber systems in the white matter after injury. Increasing FJ labeling of neurons in layers II-III of sensorimotor cortex (smCx) from 4 to 48 hours after trauma and scattered labeled cells were found in the lower cortical layers. EM confirmed the presence of dystrophic pyramidal neurons in layers II-III of smCx 24 and 48 hours post-trauma. Discussion: Taken together, the data revealed significant nerve cell injury without apparent cell death in this model.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA		Rafols, JA (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS039860] Funding Source: Medline		Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Gurevich B, 1998, J NEUROSURG, V88, P1066, DOI 10.3171/jns.1998.88.6.1066; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; *I LAB AN RES COMM, 1996, NIH PUBL; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Ueda Y, 2006, ACTA NEUROPATHOL, V112, P85, DOI 10.1007/s00401-005-0029-5; [No title captured]; [No title captured]	29	27	29	1	10	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	JUN	2007	29	4					348	355		10.1179/016164107X204657			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	192PM	WOS:000248214200003	17626729				2022-02-06	
J	Affonseca, CA; Carvalho, LFA; Guerra, SD; Ferreira, AR; Goulart, EMA				Affonseca, Carolina A.; Carvalho, Luis Fernando A.; Guerra, Sergio D.; Ferreira, Alexandre R.; Goulart, Eugenio M. A.			Coagulation disorder in children and adolescents with moderate to severe traumatic brain injury	JORNAL DE PEDIATRIA			English	Article							SEVERE HEAD-INJURY; COAGULOPATHY; MANAGEMENT; ACTIVATION	Objectives: To describe the epidemiological profile of children and adolescents with moderate to severe traumatic brain injury admitted to an intensive care unit; to describe the frequency of coagulation disorders in these patients; to determine the relationship between coagulopathy and trauma severity; to assess the factors associated with coagulopathy; and to assess the effect of coagulopathy on the mortality of these patients. Methods: Cross-sectional study with 301 patients aged up to 16 years admitted to an intensive care unit due to moderate to severe traumatic brain injury, carried out over a 5-year period. The coagulation profile was associated with clinical, epidemiological and CT findings. Univariate and multivariate analyses were used to check the association between coagulopathy and mortality. Results: Minimum age was 23 days, and maximum age was 16 years (mean of 7.9 years). About 77% of patients had coagulopathy, whose occurrence was directly associated with the severity of the trauma, but not with the rise in mortality. The factors associated with the presence of coagulopathy were the following: severity of the traumatic brain injury (OR = 2.83; 95%CI 1.58-5.07), diagnosis of brain swelling on cranial computed tomography (OR = 2.11; 95%CI 1.13-4.07) and occurrence of chest and/or abdominal injury (OR = 2.07; 95%CI 1.11-4.00). Appi oximately 35% of patients died. The multivariate analysis showed that the factors associated with an increased risk of death were presence of sodium disorders (OR = 5.56; 95%CI 2.90-10.65), hypotension in the intensive care unit (OR = 12.58; 95%CI 4.40-35.00) and acute respiratory distress syndrome (OR = 13.57; 95%CI 1.51-121.66). Conclusion: The development of coagulopathy is a frequent complication in patients with moderate to severe traumatic brain injury. Even though it is not closely associated with death in this study, it may be regarded as a marker of injury severity.	[Affonseca, Carolina A.; Carvalho, Luis Fernando A.; Guerra, Sergio D.; Ferreira, Alexandre R.; Goulart, Eugenio M. A.] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil; [Carvalho, Luis Fernando A.; Guerra, Sergio D.] Hosp Joao XXIII, UTI Pediat, Belo Horizonte, MG, Brazil; [Ferreira, Alexandre R.; Goulart, Eugenio M. A.] Univ Fed Minas Gerais, Fac Med, Dept Pediat, Belo Horizonte, MG, Brazil		Affonseca, CA (corresponding author), Rua Heitor Socrates Cardoso,630 Santa Amelia, BR-31560320 Belo Horizonte, MG, Brazil.	luiscarol@uol.com.br	Ferreira, Alexandre Rodrigues/AAK-2601-2021	Ferreira, Alexandre Rodrigues/0000-0001-6749-8980			*AM COLL SURG, 1999, BAS ADV PREH LIF SUP; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; *COL AM CIR, 1997, SUP AV VID TRAUM PRO; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Guerra S D, 1999, J Pediatr (Rio J), V75 Suppl 2, pS279; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Keller M S, 2001, Semin Pediatr Surg, V10, P12, DOI 10.1053/spsu.2001.19381; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; May AK, 1997, AM SURGEON, V63, P233; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; SORENSEN JV, 1993, SCAND J CLIN LAB INV, V53, P659, DOI 10.3109/00365519309092568; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	24	27	28	0	0	SOC BRASIL PEDIATRIA	RIO DE JANEIRO, RJ	RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL	0021-7557	1678-4782		J PEDIAT-BRAZIL	J. Pediatr.	MAY-JUN	2007	83	3					274	282		10.2223/JPED.1639			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	281OE	WOS:000254506400014	17551658	Bronze			2022-02-06	
J	Nakajima, H; Uchida, K; Kobayashi, S; Inukai, T; Horiuchi, Y; Yayama, T; Sato, R; Baba, H				Nakajima, Hideaki; Uchida, Kenzo; Kobayashi, Shigeru; Inukai, Tomoo; Horiuchi, Yukiko; Yayama, Takafumi; Sato, Ryuichiro; Baba, Hisatoshi			Rescue of rat anterior horn neurons after spinal cord injury by retrograde transfection of adenovirus vector carrying brain-derived neurotrophic factor gene	JOURNAL OF NEUROTRAUMA			English	Article						axonal transport; growth factor; regeneration; spinal cord injury; therapeutic approaches for the treatment of CNS injury; traumatic spinal cord injury	FUNCTIONAL RECOVERY; AXONAL REGENERATION; VIRAL VECTORS; MOTOR-NEURONS; MOUSE TWY/TWY; EXPRESSION; COMPRESSION; SURVIVAL; DELIVERY; BDNF	We investigated the efficacy of retrograde gene delivery via the sternomastoid muscle of recombinant adenovirus vector (AdV) carrying brain-derived neurotrophic factor (BDNF) gene for the rescue of injured rat spinal cord. One hundred-thirty five adult Sprague-Dawley rats were used in the study with a standard weight-compression technique to produce spinal cord injury. AdV-BDNF gene or AdV-beta-galactosidase (AdV-LacZ) gene was injected into the sternomastoid muscle immediately after traumatic C4 segment spinal cord injury. AdV-BDNF was successfully appeared in the injured cervical spinal cord following injection into the sternomastoid muscle. BDNF expression in the anterior horn neurons of the cervical spinal cord reached peak levels at 1-2 weeks; and the expression persisted at significant levels for approximately 4 weeks after injury. AdV-BDNF transfection was associated with increased numbers of intact neurons as confirmed by Nissl, cholineacetyltransferase (ChAT), and acetylcholine esterase (AChE) staining especially from 2 weeks after injury, compared with the AdV-LacZ injected rats. Our results suggest that in vivo targeted retrograde AdV-BDNF-gene delivery may enhance neuronal survival following traumatic injury of the spinal cord.	Univ Fukui, Fac Med Sci, Dept Surg, Div Orthopaed & Rehabil Med, Fukui 9101193, Japan		Nakajima, H (corresponding author), Univ Fukui, Fac Med Sci, Dept Surg, Div Orthopaed & Rehabil Med, 23-3 Matsuokashimoaizuki, Fukui 9101193, Japan.	nhideaki@fmsrsa.fukui-med.ac.jp					Baba H, 1996, J NEUROL, V243, P109, DOI 10.1007/BF02443999; Baba H, 1997, J NEUROL, V244, P222, DOI 10.1007/s004150050076; BLACK P, 1986, NEUROSURGERY, V19, P752, DOI 10.1227/00006123-198611000-00006; Blesch A, 2002, BRAIN RES BULL, V57, P833, DOI 10.1016/S0361-9230(01)00774-2; Blitts B, 2003, NEUROSCIENCE, V118, P271, DOI 10.1016/S0306-4522(02)00970-3; Boulis NM, 2003, NEUROSURGERY, V52, P381, DOI 10.1227/01.NEU.0000044459.24519.3E; Boulis NM, 2002, J NEUROSURG, V96, P212, DOI 10.3171/spi.2002.96.2.0212; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Collazos-Castro JE, 2005, J NEUROTRAUM, V22, P544, DOI 10.1089/neu.2005.22.544; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Emborg ME, 2000, PROG BRAIN RES, V128, P323; Giehl KM, 2001, J NEUROSCI, V21, P3492, DOI 10.1523/JNEUROSCI.21-10-03492.2001; Haase G, 1998, J NEUROL SCI, V160, pS97, DOI 10.1016/S0022-510X(98)00207-X; HEDREEN JC, 1985, J HISTOCHEM CYTOCHEM, V33, P134, DOI 10.1177/33.2.2578498; Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Kaspar BK, 2002, MOL THER, V5, P50, DOI 10.1006/mthe.2001.0520; KEIR SD, 1995, J NEUROVIROL, V1, P259, DOI 10.3109/13550289509114022; Kishino A, 2003, BRAIN RES, V964, P56, DOI 10.1016/S0006-8993(02)04066-0; Kishino A, 1997, EXP NEUROL, V144, P273, DOI 10.1006/exnr.1996.6367; KITAMURA S, 1982, ANAT REC, V202, P527, DOI 10.1002/ar.1092020412; Koda M, 2004, J NEUROTRAUM, V21, P329, DOI 10.1089/089771504322972112; Kuo H, 1995, BRAIN RES, V705, P31, DOI 10.1016/0006-8993(95)01065-3; LIUDMILA N, 2002, J COMP NEUROL, V452, P255; Mannes AJ, 1998, BRAIN RES, V793, P1, DOI 10.1016/S0006-8993(97)01422-4; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nakajima H, 2005, NEUROSCI LETT, V385, P30, DOI 10.1016/j.neulet.2005.05.012; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Nakamura M, 1996, NEUROSCIENCE, V75, P481, DOI 10.1016/0306-4522(96)00220-5; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Novikova L, 1996, NEUROSCI LETT, V220, P203, DOI 10.1016/S0304-3940(96)13267-5; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ruitenberg MJ, 2002, METHODS, V28, P182, DOI 10.1016/S1046-2023(02)00222-0; Thomas CE, 2001, MOL THER, V3, P36, DOI 10.1006/mthe.2000.0224; Uchida K, 2002, SPINE, V27, P480, DOI 10.1097/00007632-200203010-00008; Uchida K, 1998, J NEUROL, V245, P781, DOI 10.1007/s004150050287; Uchida K, 2003, ACTA NEUROPATHOL, V106, P29, DOI 10.1007/s00401-003-0691-4; Xu K, 2006, SPINE, V31, P1867, DOI 10.1097/01.brs.0000228772.53598.cc; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	42	27	34	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					703	712		10.1089/neu.2006.0004			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000011	17439352				2022-02-06	
J	Nursal, TZ; Erdogan, B; Noyan, T; Cekinmez, M; Atalay, B; Bilgin, N				Nursal, Tarik Zafer; Erdogan, Bulent; Noyan, Turgut; Cekinmez, Melih; Atalay, Betul; Bilgin, Nevzat			The effect of metoclopramide on gastric emptying in traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						traumatic brain injury; enteral nutrition; gastric emptying; metoclopramide; gastric residue; paracetamol method	ENTERAL NUTRITION; HEAD-INJURIES; GASTROPARESIS; CISAPRIDE	Objective: Gastric paresis in traumatic brain injury (TBI) hinders the effectiveness of enteral support in this patient group. In this study we have investigated the effect of metoclopramide on gastric emptying in TBI patients. Method: In this prospective, randomized, controlled, double-blind study, 19 TBI patients with Glasgow Coma Scale scores of 3-11 were included. In all patients, enteral nutrition was commenced with a nasogastric feeding tube within 48 hours of trauma. Patients were randomized into two groups. In the metoclopramide (M) group, 10 mg metoclopramide was delivered intravenously three times daily for 5 days. In the control (Q group, an equal volume of saline was administered. Besides demographics, gastric emptying according to a paracetamol absorption test at days 0 and 5, time to reach target nutritional requirements, gastric residues, intolerance to feeding, nutritional complications, and clinical outcomes were recorded for each patient. Results: The gastric residue rates were 2.7 +/- 7.4 mL and 8.1 +/- 17.7 mL per 100 patient days for groups C and M respectively (p = 0.408). Similarly, feeding intolerance and complication rates did not significantly differ between groups C and M, (respectively p = 0.543 and 0.930). Gastric emptying parameters also were similar between the study groups. Conclusion: We were unable to document any advantage to using metoclopramide in TBI patients. Simple intragastric enteral feeding with close monitoring of the possible complications seems to be sufficient with acceptable morbidity rates. (c) 2005 Elsevier Ltd. All rights reserved.	Baskent Univ, Adana Teaching & Med Res Ctr, Dept Gen Surg, TR-01250 Adana, Turkey; Baskent Univ, Adana Teaching & Med Res Ctr, Dept Neurosurg, TR-01250 Adana, Turkey; Baskent Univ, Adana Teaching & Med Res Ctr, Dept Nutr, TR-01250 Adana, Turkey		Nursal, TZ (corresponding author), Baskent Univ, Adana Teaching & Med Res Ctr, Dept Gen Surg, Dadaloglu Mah 39 Sok 6, TR-01250 Adana, Turkey.	tznursal@baskent-adri.edu.tr	Atalay, Betul Gulsen/ABF-8847-2020; Atalay, Betul/S-5609-2019; NOYAN, MUSTAFA TURGUT/AAK-2011-2021	Atalay, Betul Gulsen/0000-0003-0879-5189; NOYAN, MUSTAFA TURGUT/0000-0003-0268-8999; cekinmez, melih/0000-0001-9658-9005			Altmayer T, 1996, ARCH PHYS MED REHAB, V77, P1093, DOI 10.1016/S0003-9993(96)90075-1; Cohen J, 2000, CLIN NUTR, V19, P233, DOI 10.1054/clnu.2000.0097; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; Harbrecht BG, 1998, AM J SURG, V176, P311, DOI 10.1016/S0002-9610(98)00206-2; JACKSON MD, 1989, ARCH PHYS MED REHAB, V70, P553; Jooste CA, 1999, INTENS CARE MED, V25, P464, DOI 10.1007/s001340050881; MacLaren R, 2000, CRIT CARE MED, V28, P438, DOI 10.1097/00003246-200002000-00025; Marino LV, 2003, BRIT J NEUROSURG, V17, P24, DOI 10.1080/026889031000093708; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Minard G, 2000, JPEN-PARENTER ENTER, V24, P145, DOI 10.1177/0148607100024003145; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; Sanaka M, 1998, J GASTROENTEROL, V33, P785, DOI 10.1007/s005350050177; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Suchner U, 1996, NUTRITION, V12, P13, DOI 10.1016/0899-9007(95)00016-X; Thor Piotr J, 2003, Med Sci Monit, V9, pCR392	15	27	31	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2007	14	4					344	348		10.1016/j.jocn.2005.11.011			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	158BP	WOS:000245766200008	17336229				2022-02-06	
J	Dohi, K; Satoh, K; Nakamachi, T; Yofu, S; Hiratsuka, K; Nakamura, S; Ohtaki, H; Yoshikawa, T; Shioda, S; Aruga, T				Dohi, Kenji; Satoh, Kazue; Nakamachi, Tomoya; Yofu, Sachiko; Hiratsuka, Keisuke; Nakamura, Shunsuke; Ohtaki, Hirokazu; Yoshikawa, Toshikazu; Shioda, Seiji; Aruga, Tohru			Does edaravone (MCI-186) act as an antioxidant and a neuroprotector in experimental traumatic brain injury?	ANTIOXIDANTS & REDOX SIGNALING			English	Article							LIPID-PEROXIDATION; OXIDATIVE STRESS; ISCHEMIA; DAMAGE; PROTECTS; INCREASE; EDEMA; RATS	Edaravone (MCI-186) is a novel synthetic free radical scavenger intended to have neuroprotective effect against ischemic insult. It is currently used on patients with cerebral infarction. Here, we note beneficial pharmaceutical effects of edaravone in rat experimental traumatic brain injury. Under specific experimental conditions, edaravone minimized traumatic brain injury by functioning as a synthetic antioxidant. Clinical trials testing the efficacy of edaravone are warranted.	Showa Univ, Sch Med, Dept Emergency & Crit Care Med, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Dept Anat, Tokyo 1428555, Japan; Kyoto Prefectural Univ Med, Dept Med 1, Kyoto, Japan		Dohi, K (corresponding author), Showa Univ, Sch Med, Dept Emergency & Crit Care Med, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	kdop@med.showa-u.ac.jp		dohi, kenji/0000-0002-4451-0382			Araki Y, 2003, INT J MOL MED, V12, P125; Benedetti S, 2004, CLIN BIOCHEM, V37, P312, DOI 10.1016/j.clinbiochem.2003.12.001; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Chang EF, 2003, J NEUROSCI, V23, P3689; Dohi K, 2005, IN VIVO, V19, P855; Dohi K, 2003, ACT NEUR S, V86, P123; DOHI K, IN PRESS J NEUROTRAU; HOUKIN K, 2003, CEREBROVASC DIS, V15, P222; Huh PW, 2000, EUR J PHARMACOL, V389, P79, DOI 10.1016/S0014-2999(99)00768-2; Ikeda Y, 2000, ACT NEUR S, V76, P343; Ito K, 2005, FREE RADICAL BIO MED, V38, P369, DOI 10.1016/j.freeradbiomed.2004.10.029; Juurlink BHJ, 1999, NEUROTOX RES, V1, P119, DOI 10.1007/BF03033276; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Khanna S, 2005, STROKE, V36, pE144, DOI 10.1161/01.STR.0000181082.70763.22; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mihara Y, 2004, HYPOTHERMIA FOR ACUTE BRAIN DAMAGE: PATHOMECHANISM AND PRACTICAL ASPECTS, P94; Nakamura H, 2003, ACT NEUR S, V86, P309; OGAWA T, 2004, NEUROTRAUMATOLOGY, V27, P149; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Satoh K, 2002, REDOX REP, V7, P219, DOI 10.1179/135100002125000587; Scholpp J, 2004, J NEUROTRAUM, V21, P667, DOI 10.1089/0897715041269632; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; WATANABE T, 1988, PROSTAG LEUKOTR ESS, V33, P81, DOI 10.1016/0952-3278(88)90127-5; WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597; Wen J, 2006, BIOL PHARM BULL, V29, P713, DOI 10.1248/bpb.29.713; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; Yamato M, 2003, FREE RADICAL BIO MED, V35, P1619, DOI 10.1016/j.freeradbiomed.2003.09.013	30	27	28	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1523-0864	1557-7716		ANTIOXID REDOX SIGN	Antioxid. Redox Signal.	FEB	2007	9	2					281	287		10.1089/ars.2007.9.281			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	126GJ	WOS:000243500400012	17115943				2022-02-06	
J	Newsome, MR; Scheibel, RS; Hunter, JV; Wang, ZYJ; Chu, ZL; Li, XQ; Levin, HS				Newsome, Mary R.; Scheibel, Randall S.; Hunter, Jill V.; Wang, Zhiyue J.; Chu, Zili; Li, Xiaoqi; Levin, Harvey S.			Brain activation during working memory after traumatic brain injury in children	NEUROCASE			English	Article						fMRI; traumatic brain injury; children; working memory	CLOSED-HEAD INJURY; PREFRONTAL CORTEX; CHILDHOOD; FMRI; ADOLESCENCE; IMPAIRMENT; ATTENTION; MODERATE; SKILLS; TASK	Eight children with moderate to severe traumatic brain injury (TBI) and eight matched, uninjured control children underwent fMRI during an N-back task to test effects of TBI on working memory performance and brain activation. Two patterns in the TBI group were observed. Patients whose criterion performance was reached at lower memory loads than control children demonstrated less extensive frontal and extrafrontal brain activation than controls. Patients who performed the same, highest (3-back) memory load as controls demonstrated more frontal and extrafrontal activation than controls. Our findings of performance and brain activation changes in children after TBI await longitudinal investigation.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Texas Childrens Hosp, Diagnost Imaging Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA		Newsome, MR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mnewsome@bcm.tmc.edu	Wang, Zhiyue J/L-3851-2014	Wang, Zhiyue J/0000-0002-5649-2900	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Bookheimer SY, 2000, MENT RETARD DEV D R, V6, P161, DOI 10.1002/1098-2779(2000)6:3<161::AID-MRDD2>3.0.CO;2-W; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Casey BJ, 1998, NEUROIMAGE, V8, P249, DOI 10.1006/nimg.1998.0360; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Davidson MC, 2003, MENT RETARD DEV D R, V9, P161, DOI 10.1002/mrdd.10076; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Downing P, 2001, NEUROPSYCHOLOGIA, V39, P1329, DOI 10.1016/S0028-3932(01)00121-X; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jones JA, 2003, NEUROREPORT, V14, P1129, DOI 10.1097/00001756-200306110-00006; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Munson S, 2006, PEDIATRICS, V117, P1372, DOI 10.1542/peds.2005-0826; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Poldrack Russell A, 2002, Top Magn Reson Imaging, V13, P61, DOI 10.1097/00002142-200202000-00005; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Schlaggar BL, 2002, SCIENCE, V296, P1476, DOI 10.1126/science.1069464; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wechsler D., 2011, WECHSLER ABBREVIATED; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WOODCOCK RW, 2001, WOODCOCKJOHNSON TEST; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3; [No title captured]	56	27	27	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase	FEB	2007	13	1					16	24		10.1080/13554790601186629			9	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	161KO	WOS:000246014000003	17454685				2022-02-06	
J	Jumisko, E; Lexell, J; Soderberg, S				Jumisko, Eija; Lexell, Jan; Soderberg, Siv			The experiences of treatment from other people as narrated by people with moderate or severe traumatic brain injury and their close relatives	DISABILITY AND REHABILITATION			English	Article						brain injury; traumatic; relatives; treatment; experiences; interviews	QUALITY-OF-CARE; MISCONCEPTIONS; PERCEPTIONS; DIGNITY; SELF	Purpose. The aim of this study was to describe the treatment from other people as experienced by people with moderate or severe traumatic brain injury (TBI) and their close relatives. Method. Twelve people with moderate or severe TBI and eight of their close relatives were interviewed. The interviews were analysed using thematic content analysis. Results. The results were described by the means of two themes: being excluded and missing confirmation. People with TBI and their close relatives had experiences of being avoided, being ruled by the authorities, being met with distrustfulness and being misjudged. They also searched for answers and longed for the right kind of help. People who listened to them, believed them and tried to understand and help them were appreciated. Conclusions. This study showed a lack of treatment which promotes well-being of the people with TBI and their close relatives. They experienced bad treatment also from authorities. Therefore, we emphasize that authorities should continuously reflect on how to make their practice a place which promotes dignity. Treatment of people with TBI and close relatives may be improved by increased knowledge about TBI, living with it and being a close relative to a person with TBI. This is a challenge to health care and rehabilitation professionals.	Lulea Univ Technol, Dept Hlth Sci, Div Nursing, SE-97187 Lulea, Sweden; Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, S-95187 Lulea, Sweden; Univ Lund Hosp, Dept Rehabil, S-22185 Lund, Sweden		Jumisko, E (corresponding author), Lulea Univ Technol, Dept Hlth Sci, Div Nursing, SE-97187 Lulea, Sweden.	Eija.Jumisko@ltu.se		Lexell, Jan/0000-0001-5294-3332			Andersson S, 2002, J Psychiatr Ment Health Nurs, V9, P285, DOI 10.1046/j.1365-2850.2002.00480.x; ASTROM G, 1995, THESIS UMEA U UMEA, P149; Attree M, 2001, J ADV NURS, V33, P456, DOI 10.1046/j.1365-2648.2001.01689.x; Backhouse M, 1999, AUST OCCUP THER J, V46, P99, DOI DOI 10.1046/J.1440-1630.1999.00183.X; Baxter L. A., 1994, STUDYING INTERPERSON, P239; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; Carson P, 1993, J Neurosci Nurs, V25, P165; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; Corring D J, 1999, Can J Occup Ther, V66, P71; CRISHOLM J, 2001, AXON, V23, P12; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; DELEHANTY R, 1998, J COGNITIVE REHABILI, V16, P14; DOLFE A, 2004, HUR MAN UPPNAR GOTT; Downe-Wamboldt B, 1992, Health Care Women Int, V13, P313; Duff Diane, 2002, Axone, V24, P14; EDLUND M, 2002, THESIS ABO AKAD ABO, P153; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Gallagher A, 2004, NURS ETHICS, V11, P587, DOI 10.1191/0969733004ne744oa; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guba EG, 1989, 4 GENERATION EVALUAT, P294; GUERRIERE D, 1997, J SOC PEDIAT NURSES, V2, P110; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; GUSTAFSSON B, 1994, THEOR MED, V15, P409, DOI 10.1007/BF00993798; Gustafsson B, 2000, J NURSING THEORY, V9, P6; HALLDORSDOTTIR S, 1996, THESIS LINKOPING U L, P198; JUMISKO E, 2005, J NEUROSCIENCE NURSI, V36, P20; Kvale S, 1997, KVALITATIVA FORSKNIN, P306; Lincoln YS, 1985, NATURALISTIC INQUIRY, P416; LOSTRUP KE, 1971, ETHICAL DEMAND, P239; Lovgren G, 1996, SCAND J CARING SCI, V10, P151; Lund M.L., 2001, OCCUP THER INT, V8, P151; Lyons R, 1998, PERSPECTIVES LOSS SO, P137; McMillen A., 2002, SCANDINAVIAN J OCCUP, V9, P176, DOI DOI 10.1080/11038120260501208; Naden D., 2000, INT J HUMAN CARING, V4, P23, DOI [10.20467/1091-5710.4.3.23, DOI 10.20467/1091-5710.4.3.23]; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Nordenfelt L, 2004, HEALTH CARE ANAL, V12, P69, DOI 10.1023/B:HCAN.0000041183.78435.4b; Ohlen Joakim, 2004, Res Theory Nurs Pract, V18, P371; Ohman M, 2004, QUAL HEALTH RES, V14, P396, DOI 10.1177/1049732303261692; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Paterson B, 2001, Rehabil Nurs, V26, P48; Paterson J., 2002, REHABIL NURS, V27, P13, DOI DOI 10.1002/J.2048-7940.2002.TB01973.X; POLIT DF, NURSING RES PRINCIPL, P758; REHNSFELDT A, 1999, THESIS ABO AKAD ABO, P216; Robertson-Malt S, 1999, J ADV NURS, V29, P290, DOI 10.1046/j.1365-2648.1999.00830.x; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Schroder A, 2006, J CLIN NURS, V15, P93, DOI 10.1111/j.1365-2702.2005.01241.x; Schroder A, 2004, SCAND J CARING SCI, V18, P204, DOI 10.1111/j.1471-6712.2004.00271.x; SERIO CD, BRAIN INJ, V11, P1; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Smith J E, 2000, Care Manag J, V2, P27; Soderberg S, 2004, DISABIL REHABIL, V26, P419, DOI 10.1080/09638280410001663111; Soderberg S, 1999, QUAL HEALTH RES, V9, P575, DOI 10.1177/104973299129122090; Sundin K, 2000, SCAND J CARING SCI, V14, P16, DOI 10.1111/j.1471-6712.2000.tb00556.x; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; WALLACE CL, 1995, J ADV NURS, V22, P285, DOI 10.1046/j.1365-2648.1995.22020285.x; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; Wiman E, 2004, J CLIN NURS, V13, P422, DOI 10.1111/j.1365-2702.2004.00902.x	58	27	27	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2007	29	19					1535	1543		10.1080/09638280601055816			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	220QL	WOS:000250171800007	17852253				2022-02-06	
J	Lane, K; Penne, RB; Bilyk, JR				Lane, Katherine; Penne, Robert B.; Bilyk, Jurij R.			Evaluation and Management of Pediatric Orbital Fractures in a Primary Care Setting	ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY			English	Article						Pediatric orbital fracture; orbital blowout fracture; white-eyed blowout fracture; orbit trauma		Objective: To review and evaluate the management of whiteeyed blowout fractures (WEBOF) from Emergency Department (ED) triage through surgical repair. Methods: Retrospective chart review of consecutive cases of pediatric orbital blowout fracture requiring surgical repair at a large ophthalmologic referral center. The characteristics of patients withWEBOFand those with conventional orbital blowout fractures were compared, including: mechanism of injury, clinical presentation, ED management and referral patterns, and time to definitive treatment. Results: Sixteen patients comprised theWEBOF study group, and 14 patients with conventional blowout fractures comprised the control group. AllWEBOF had pain with eye movement, limited ductions and diplopia, and 75% had nausea and vomiting. These symptoms were present in significantly lower frequencies in control patients (64%, 64%, 7%, 14%, respectively). Compared to controls, WEBOF patients were younger; had injury more often resulting from sports and play; were less likely to undergo orbital imaging in the ED; were more likely to be diagnosed with concussion in the ED; were less likely to be seen urgently by an ophthalmologist; and were told to follow-up with an ophthalmologist 4-5 days later than control patients. Conclusions: WEBOF is a clinical diagnosis consisting of vertical diplopia, gaze restriction and nausea and/or vomiting in the setting of peri-orbital trauma in the pediatric and young-adult age group. The paucity of external signs of trauma may lead to initialmisdiagnosis and delay in treatment. All patients who meet WEBOF criteria should undergo dedicated orbital CT as part of the ED evaluation. If WEBOF is suspected, a prompt referral to an ophthalmologist should be made.	[Lane, Katherine; Penne, Robert B.; Bilyk, Jurij R.] Wills Eye Inst, 840 Walnut St, Philadelphia, PA 19107 USA		Lane, K (corresponding author), Wills Eye Inst, 840 Walnut St, Philadelphia, PA 19107 USA.	katelane@verizon.net		Lane, Katherine/0000-0002-4110-5058			Baek Se Hyun, 2003, Korean J Ophthalmol, V17, P44; Bansagi ZC, 2000, OPHTHALMOLOGY, V107, P829, DOI 10.1016/S0161-6420(00)00015-4; Burnstein MA, 2002, OPHTHALMOLOGY, V109, P1207; DEMAN K, 1991, INT J ORAL MAX SURG, V20, P330, DOI 10.1016/S0901-5027(05)80260-7; DUTTON JJ, 1991, SURV OPHTHALMOL, V35, P279; Egbert JE, 2000, OPHTHALMOLOGY, V107, P1875, DOI 10.1016/S0161-6420(00)00334-1; Grant JH, 2002, PLAST RECONSTR SURG, V109, P482, DOI 10.1097/00006534-200202000-00011; Hatton MP, 2001, OPHTHALMIC PLAST REC, V17, P174, DOI 10.1097/00002341-200105000-00005; HAWES MJ, 1983, OPHTHALMOLOGY, V90, P1066; ILANKOVAN V, 1991, J CRANIO MAXILL SURG, V19, P348, DOI 10.1016/S1010-5182(05)80277-X; Jordan DR, 1998, OPHTHALMIC PLAST REC, V14, P379, DOI 10.1097/00002341-199811000-00001; Koltai PJ, 1996, PEDIATR CLIN N AM, V43, P1253, DOI 10.1016/S0031-3955(05)70518-6; McCulley TJ, 2004, EUR J OPHTHALMOL, V14, P330, DOI 10.1177/112067210401400409; Rubin PAD, 1999, OPHTHALMIC PLAST REC, V15, P284, DOI 10.1097/00002341-199907000-00010; Sires BS, 1998, ARCH OPHTHALMOL-CHIC, V116, P955; SMITH B, 1984, PLAST RECONSTR SURG, V74, P200, DOI 10.1097/00006534-198408000-00004; Wachler BSB, 1998, OPHTHALMIC PLAST REC, V14, P17	17	27	27	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0167-6830	1744-5108		ORBIT	Orbit		2007	26	3					183	191		10.1080/01676830701519374			9	Ophthalmology	Emerging Sources Citation Index (ESCI)	Ophthalmology	VB4HC	WOS:000415472100006	17891646				2022-02-06	
J	O'Brien, A; Chiaravalloti, N; Arango-Lasprilla, JC; Lengenfelder, J; DeLuca, J				O'Brien, Amanda; Chiaravalloti, Nancy; Arango-Lasprilla, Juan Carlos; Lengenfelder, Jeannie; DeLuca, John			An investigation of the differential effect of self-generation to improve learning and memory in multiple sclerosis and traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEMANTIC-MEMORY; ALZHEIMER-TYPE; RETRIEVAL DEFICIT; EPISODIC MEMORY; FREE-RECALL; WORDS; DEMENTIA; DEPTH; ORGANIZATION; ACQUISITION	The generation effect (GE) is a phenomenon in which material that is produced by an individual is learned and remembered better than information that is provided to that individual. The current study examined the potential benefits of self-generation on learning and memory in individuals with traumatic brain injury (TBI) and multiple sclerosis (MS). The impact of cognitive impairment on the benefits of self-generation was also examined. Subjects consisted of 18 individuals with TBI and 31 individuals with clinically definite MS. Both the TBI and MS groups recalled significantly more words in the selfgenerated condition versus the provided condition. Those impaired in the domains of working memory, episodic memory, or executive functioning demonstrated a significant benefit from self-generation (all ps < .05). Furthermore, although individuals with impairments in multiple cognitive domains recalled fewer words overall compared to those with no or one impaired cognitive domain, this group demonstrated a large effect size in the difference in recall for generated versus provided words. Results demonstrate that people with cognitive impairments can benefit from self-generation to improve learning and memory. Future research should focus on how to amplify the benefit of the GE for impaired groups, apply it to everyday functional tasks, and sustain its effect over time.	KMRREC, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA		DeLuca, J (corresponding author), KMRREC, Neuropsychol & Neurosci Lab, 300 Execut Dr,Suite 10, W Orange, NJ 07052 USA.	jdeluca@kmrrec.org					Andrade VM, 2003, J CLIN EXP NEUROPSYC, V25, P1070, DOI 10.1076/jcen.25.8.1070.16730; [Anonymous], 1993, NEUROPSYCHOLOGY, V7, P364, DOI [DOI 10.1037/0894-4105.7.3.364, 10.1037/0894-4105.7.3.364]; Arnett PA, 1997, NEUROPSYCHOLOGY, V11, P535, DOI 10.1037/0894-4105.11.4.535; Barrett AM, 2000, NEUROLOGY, V54, P1258, DOI 10.1212/WNL.54.6.1258; BEGG I, 1989, J EXP PSYCHOL LEARN, V15, P977, DOI 10.1037/0278-7393.15.5.977; BEGG I, 1991, MEM COGNITION, V19, P487, DOI 10.3758/BF03199571; BOWER GH, 1979, J RES PERS, V13, P420, DOI 10.1016/0092-6566(79)90005-9; BRAINERD CJ, 1995, J MEM LANG, V34, P157, DOI 10.1006/jmla.1995.1008; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Challis BH, 1996, CONSCIOUS COGN, V5, P142, DOI 10.1006/ccog.1996.0009; Chiaravalloti ND, 2005, MULT SCLER, V11, P58, DOI 10.1191/1352458505ms1118oa; Chiaravalloti ND, 2002, ARCH PHYS MED REHAB, V83, P1070, DOI 10.1053/apmr.2002.33729; Chobor KL, 1998, J NEUROLINGUIST, V11, P119, DOI 10.1016/S0911-6044(98)00009-8; CLARK SE, 1995, MEM COGNITION, V23, P442, DOI 10.3758/BF03197245; CRAIK FIM, 1975, J EXP PSYCHOL GEN, V104, P268, DOI 10.1037/0096-3445.104.3.268; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DICK MB, 1989, BRAIN COGNITION, V9, P88, DOI 10.1016/0278-2626(89)90046-8; Duchnick JJ, 2002, J CLIN EXP NEUROPSYC, V24, P840, DOI 10.1076/jcen.24.6.840.8405; Eustache F, 1999, J NEUROL NEUROSUR PS, V66, P148, DOI 10.1136/jnnp.66.2.148; GARDINER JM, 1984, MEM COGNITION, V12, P443, DOI 10.3758/BF03198305; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; Golden CJ, 1978, STROOP COLOR WORD TE; Goverover Y., 2005, J INT NEUROPSYCHO S1, V11, P49; Green S.B., 2003, USING SPSS WINDOWS M, V4th ed.; HODGES JR, 1994, EXPLORING DISORDERS, P77; Hough MS, 1997, BRAIN INJURY, V11, P801; Howe ML, 1998, J EXP CHILD PSYCHOL, V71, P170, DOI 10.1006/jecp.1998.2469; HUNT RR, 1993, J MEM LANG, V32, P421, DOI 10.1006/jmla.1993.1023; Hunt RR, 2003, J MEM LANG, V48, P811, DOI 10.1016/S0749-596X(03)00018-4; Kenealy PM, 2002, J INT NEUROPSYCH SOC, V8, P855, DOI 10.1017/S1355617702860143; KLEIN SB, 1988, J PERS SOC PSYCHOL, V55, P5, DOI 10.1037/0022-3514.55.1.5; KLEIN SB, 1986, J EXP PSYCHOL GEN, V115, P26, DOI 10.1037/0096-3445.115.1.26; Lengenfelder J., 2002, J INT NEUROPSYCH SOC, V8, P173; LENGENFELDER J, 2003, J INT NEUROPSYCH SOC, V9, P320; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LIPINSKA B, 1994, J CLIN EXP NEUROPSYC, V16, P809, DOI 10.1080/01688639408402695; Lokken K, 1999, Appl Neuropsychol, V6, P147, DOI 10.1207/s15324826an0603_2; MCELROY LA, 1982, J VERB LEARN VERB BE, V21, P249, DOI 10.1016/S0022-5371(82)90593-X; McKinlay W, 1999, COGNITIVE BEHAV EFFE, P74; MCMURRAY DW, 1981, AUST J PSYCHOL, V33, P197, DOI 10.1080/00049538108258736; MITCHELL DB, 1986, J GERONTOL, V41, P79, DOI 10.1093/geronj/41.1.79; Multhaup KS, 1997, NEUROPSYCHOLOGY, V11, P382, DOI 10.1037/0894-4105.11.3.382; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PAYNE DG, 1986, MEM COGNITION, V14, P246, DOI 10.3758/BF03197700; Pesta BJ, 1999, MEM COGNITION, V27, P106, DOI 10.3758/BF03201217; POLLMANN S, 1993, DEMENTIA, V4, P102, DOI 10.1159/000107304; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Ricker, 1994, Assessment, V1, P47, DOI 10.1177/1073191194001001007; Ricker JH, 1996, NEUROPSY NEUROPSY BE, V9, P50; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; SCHALLERT DL, 1976, J VERB LEARN VERB BE, V15, P621, DOI 10.1016/0022-5371(76)90055-4; SEAMON JG, 1976, J EXP PSYCHOL-HUM L, V2, P680; SLAMECKA NJ, 1978, J EXP PSYCHOL-HUM L, V4, P592, DOI 10.1037/0278-7393.4.6.592; Souliez L, 1996, CORTEX, V32, P347, DOI 10.1016/S0010-9452(96)80056-6; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Spreen O, 1991, COMPENDIUM NEUROPSYC; Steffens MC, 1998, Q J EXP PSYCHOL-A, V51, P705, DOI 10.1080/027249898391350; Symons CS, 1997, PSYCHOL BULL, V121, P371, DOI 10.1037/0033-2909.121.3.371; Taconnat L, 2004, J EXP PSYCHOL LEARN, V30, P827, DOI 10.1037/0278-7393.30.4.827; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; Thornton AE, 2002, J INT NEUROPSYCH SOC, V8, P395, DOI 10.1017/S1355617702813200; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Westmacott R, 2003, MEM COGNITION, V31, P761, DOI 10.3758/BF03196114; Wilkinson G., 1993, WIDE RANGE ACHIEVEME, V3	71	27	28	0	11	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	3					273	292		10.1080/09602010600751160			20	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	165IQ	WOS:000246298500001	17474057				2022-02-06	
J	Vaccaro, M; Hart, T; Whyte, J; Buchhofer, R				Vaccaro, Monica; Hart, Tessa; Whyte, John; Buchhofer, Regina			Internet use and interest among individuals with traumatic brain injury: A consumer survey	DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY			English	Article						Internet; traumatic brain injury	REHABILITATION; PEOPLE; MEMORY; MAIL	Purpose. To examine experiences among individuals in the USA with traumatic brain injury (TBI) regarding their access to and use of the Internet, problems encountered, and desire for improved Internet access and skills. Method. An in-depth survey was administered as a semi-structured interview to 80 individuals at least 3 months post moderate to severe TBI. Results. Two-thirds of respondents reported having a computer at home, but only half had access to the Internet. Fewer than half were Internet users, as compared to 60% users in the USA population at the time of the survey. However, Internet activities engaged in by users in this sample were comparable to those of the overall population. There was a strong interest in using the Internet among non-users. Most respondents expressed a strong desire for coaching or other training to enhance or develop Internet skills. Reported reasons for Internet non-use in this sample were lack of access and knowledge, versus lack of interest as in the general population. Conclusions. The high interest in using and learning more about the Internet supports the development of interventions to improve Internet skills for people with TBI.	[Vaccaro, Monica; Buchhofer, Regina] Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA; [Hart, Tessa; Whyte, John] Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Dept Rehabil Med, Philadelphia, PA USA		Vaccaro, M (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	mvaccaro@einstein.edu		Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research [H133A70033]	This work was funded by the National Institute on Disability and Rehabilitation Research, Grant # H133A70033. We thank Kimberly Willis, Cynthia Boyer and Dan Keating at Bancroft NeuroHealth, Haddonfield, NJ, for assistance in recruiting participants, and Gemma Baldon for database development and management.	[Anonymous], 2002, NAT ONL AM EXP US IN; Barrera M, 2002, AM J COMMUN PSYCHOL, V30, P637, DOI 10.1023/A:1016369114780; Chen W., 2003, CHARTING BRIDGING DI; Egan J, 2005, BRAIN INJURY, V19, P555, DOI 10.1080/02699050400013659; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Falling through the net: Defining the digital divide, 2000, FALL THROUGH NET DEF; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Kaye HS, 2000, DISABILITY STAT REPO; Kleiner A, INTERNET ACCESS US P; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Schopp LH, 2004, TELEMED J E-HEALTH, V10, P243, DOI 10.1089/1530562041641309; Sohlberg MM, 2005, APHASIOLOGY, V19, P651, DOI 10.1080/02687030544000100; Sohlberg MM, 2003, BRAIN INJURY, V17, P609, DOI 10.1080/0269905031000070189; Sutcliffe A, 2003, INTERACT COMPUT, V15, P577, DOI 10.1016/S0953-5438(03)00051-1; Todis B, 2005, BRAIN INJURY, V19, P389, DOI 10.1080/02699050400003957; Vaccaro MJ, 2002, NEUROREHABILITATION, V17, P169; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willis B, 1999, QUESTION APPRAISAL S; Wright P, 2000, ERGONOMICS, V43, P702, DOI 10.1080/001401300404689; 2003, PEW INTERNET AM LIFE	23	27	27	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1748-3107	1748-3115		DISABIL REHABIL-ASSI	Disabil. Rehabil.-Assist. Technol.		2007	2	2					85	95		10.1080/17483100601167586			11	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V06DY	WOS:000213922100002	19263543				2022-02-06	
J	Van Baalen, B; Ribbers, GM; Medema-Meulepas, D; Pas, MS; Odding, E; Stam, HJ				Van Baalen, B.; Ribbers, G. M.; Medema-Meulepas, D.; Pas, M. S.; Odding, E.; Stam, H. J.			Being restricted in participation after a traumatic brain injury is negatively associated by passive coping style of the caregiver	BRAIN INJURY			English	Article						traumatic brain injury; outcome; caregiver; coping	FRENCHAY ACTIVITIES INDEX; SICKNESS IMPACT PROFILE; FUNCTIONAL STATUS; STROKE PATIENTS; SOCIAL SUPPORT; PREDICTORS; SEVERITY; REHABILITATION; CLASSIFICATION; POPULATION	Purpose: To examine whether the caregivers' coping style is associated with the functional outcome of the traumatic brain injury ( TBI) patient 1 year post- injury. Method: A cross-sectional study among patients with a TBI, including their primary caregivers. The study included 51 patients aged 17-64 years with a moderate-to-severe TBI and 51 caregivers ( 23 parents and 28 partners) aged 23-67 years. The coping preferences of the caregivers were assessed at minimum 6 and maximum 12 months post- injury, by filling out the Utrecht Coping List ( UCL) and were related to limitations in activity, as measured with the Frenchay Activities Index and with restrictions in participation as measured with the Sickness Impact Profile-68 of TBI patients 1 year post-injury. The patients were interviewed at their homes; the caregivers received and returned the UCL by mail. Results: The patients' age and the caregivers' coping style are independently associated with restrictions in participation 1 year post- injury. Conclusions: A passive coping style of the primary caregiver is negatively associated with the patient's functional outcome in terms of participation in society.	Erasmus MC, Dept Rehabil Med, Rotterdam, Netherlands; Rijndam Rehabil Ctr, Rotterdam, Netherlands		Van Baalen, B (corresponding author), Erasmus MC, Dept Rehabil Med, POB 3000 CA, Rotterdam, Netherlands.	j.t.m.vanbaalen@erasmusmc.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; 			DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; GILSON BS, 1975, AM J PUBLIC HEALTH, V65, P1304, DOI 10.2105/AJPH.65.12.1304; Hachisuka K, 1999, J CLIN EPIDEMIOL, V52, P1089, DOI 10.1016/S0895-4356(99)00085-2; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Kosciulek JF, 1997, BRAIN INJURY, V11, P821, DOI 10.1080/026990597123034; KWASNICA CM, 1994, ARCH PHYS MED REHAB, V75, P384, DOI 10.1016/0003-9993(94)90159-7; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Poon WS, 2005, ACT NEUR S, V93, P207; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sanderman R, 1992, GEDRAG GEZONDHEID, V20, P32; Schreurs PJG, 1988, HANDLEIDING UTRECHTS; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Stalenhoef PA, 2000, FAM PRACT, V17, P490, DOI 10.1093/fampra/17.6.490; Toschlog EA, 2003, AM SURGEON, V69, P491; Turnbull JC, 2000, ARCH PHYS MED REHAB, V81, P1034, DOI 10.1053/apmr.2000.7162; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Williams J., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]	29	27	27	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	9					925	931		10.1080/02699050701553197			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	202ZA	WOS:000248942600004	17729045				2022-02-06	
J	Borman, JB; Aharonson-Daniel, L; Savitsky, B; Peleg, K				Borman, J. B.; Aharonson-Daniel, L.; Savitsky, B.; Peleg, K.		Israeli Trauma Grp	Unilateral flail chest is seldom a lethal injury	EMERGENCY MEDICINE JOURNAL			English	Article							MANAGEMENT; STABILIZATION; OUTCOMES; TRAUMA	Background: The chest cage is a common target for traumatic damage. Although relatively rare, it is considered to be a serious condition with significant reported mortalities. As most flail injuries are accompanied by severe extrathoracic injuries, it is often difficult to pinpoint a single injury responsible for the patient's death. Aim: To investigate the factors related to mortality when flail injury is diagnosed. Methods: Data from the Israel National Trauma Registry between 1998 and 2003 included 11 966 chest injuries ( 262 flail chest injuries) out of a total of 118 211 trauma hospitalisations. Mortality figures were analysed to determine which factors, singly or in combination, influenced flail chest mortality. Results: Road crashes accounted for most flail injuries (76%). The total mortality was 54 (20.6%) of 262 patients with flail chest injuries. 13 (20.4%) of the deaths occurred soon after admission to the emergency room and 37 (68.5%) within the first 24 h. Mortality in moderate to severe injuries ( injury severity score (ISS) 9 - 24) was 3.6% and that in critical injuries 28.5% (ISS >24). Mortality increased with age: 17% in those aged <45 years, 22.1% in those between 45 and 64 years and 28.8% in those >65 years. Age remained a risk for inpatient death when adjusted for severity. Mortality in isolated unilateral flail injury was not more than 6%. Total mortality for traumatic brain injury (TBI) and flail was 34%. Flail, TBI and other major injuries increased the mortality to 61.1%. Conclusions: Advanced age is associated with higher mortality. Isolated unilateral bony cage instability infrequently leads to death in patients who make it to the emergency department but rather its combination with additional extrathoracic trauma.	Chaim Sheba Med Ctr, Israel Natl Ctr Trauma & Emergency Med Res, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Tel Hashomer, Israel		Aharonson-Daniel, L (corresponding author), Chaim Sheba Med Ctr, Israel Natl Ctr Trauma & Emergency Med Res, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Tel Hashomer, Israel.	limorad@gertner.health.gov.il	Aharonson-Daniel, Limor/F-1998-2012	Aharonson-Daniel, Limor/0000-0003-4585-6892; Savitsky, Bella/0000-0001-8917-8419			Adegboye V O, 2002, Afr J Med Med Sci, V31, P315; Albaugh G, 2000, AM SURGEON, V66, P978; Athanassiadi K, 2004, EUR J CARDIO-THORAC, V26, P373, DOI 10.1016/j.ejcts.2004.04.011; Balci Akin Eraslan, 2004, Asian Cardiovasc Thorac Ann, V12, P11; Leo Francesco, 2003, Asian Cardiovasc Thorac Ann, V11, P188; Liman ST, 2003, EUR J CARDIO-THORAC, V23, P374, DOI 10.1016/S1010-7940(02)00813-8; Tanaka H, 2002, J TRAUMA, V52, P727, DOI 10.1097/00005373-200204000-00020; TRINKLE JK, 1975, ANN THORAC SURG, V19, P355, DOI 10.1016/S0003-4975(10)64034-9; Velmahos GC, 2002, INT SURG, V87, P240; Voggenreiter G, 1998, J AM COLL SURGEONS, V187, P130, DOI 10.1016/S1072-7515(98)00142-2; Yalcinkaya I, 2000, Ulus Travma Derg, V6, P288	11	27	35	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	DEC	2006	23	12					903	905		10.1136/emj.2006.037945			3	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	109WE	WOS:000242339500005	17130594	Bronze, Green Published, Green Submitted			2022-02-06	
J	Laatsch, L; Kirsky, C				Laatsch, Linda; Kirsky, Christine			Changes in fMRI activation following rehabilitation of reading and visual processing deficits in subjects with traumatic brain injury	BRAIN INJURY			English	Article						cognitive rehabilitation; fMRI; reading; visual perception; traumatic brain injury	WORDS	In this case series fMRI was used to examine activation patterns during presentation of a reading comprehension (RC) task in three adult subjects with a history of severe traumatic brain injury (TBI). These subjects received cognitive rehabilitation therapy (CRT) for visual processing and acquired reading deficits. fMRI and neuropsychological testing occurred pre- and post-rehabilitation. The study's objective was to evaluate the neurobiological changes using fMRI occurring with CRT and to compare these results to repeat fMRI in matched control subjects. While improvements in neuropsychological testing occurred post-CRT, diffuse and variable activation patterns in the subjects with TBI were still demonstrated when compared to the control subjects repeat imaging. Multiple networks exist to accomplish the complex task of sentence reading and rehabilitation of the cognitive components of reading, such as visual processing; in subjects with TBI, can alter the activation pattern demonstrated during reading comprehension in subjects many years post-injury. This is the first demonstration of changes in network activation patterns post-CRT in patients with severe, chronic TBI on an fMRI task shown to have imaging stability in a normal control sample.	Univ Illinois, Coll Med, Dept Rehabil & Neurol, Chicago, IL 60612 USA; Oregon Hlth & Sci Univ, Dept Endocrinol, Portland, OR 97201 USA		Laatsch, L (corresponding author), Univ Illinois, Coll Med, Dept Rehabil & Neurol, MC 888 912 S Wood, Chicago, IL 60612 USA.	llaatsch@uic.edu					BRACY O, 1985, SOFT TOOLS COGNITIVE; Brunswick N, 1999, BRAIN, V122, P1901, DOI 10.1093/brain/122.10.1901; CHAPMAN SB, 1989, BRAIN LANG, V36, P651, DOI 10.1016/0093-934X(89)90092-8; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen L, 2000, BRAIN, V123, P291, DOI 10.1093/brain/123.2.291; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Eddy WF, 1996, P COMP STAT, P39; GIANUTSOS R, 1984, COGNITIVE REHAB TASK; GLADSOJO J, 1999, NORMS LETT CATEGORY; Gold BT, 2000, BRAIN LANG, V73, P456, DOI 10.1006/brln.2000.2317; Grossman M, 2002, BRAIN LANG, V80, P296, DOI 10.1006/brln.2001.2581; Heaton RK, 1991, COMPREHENSIVE NORMS; Joseph J, 2001, J LEARN DISABIL-US, V34, P566, DOI 10.1177/002221940103400609; Laatsch L, 2000, NEUROREHABILITATION, V15, P189; Lewis R. F, 1995, PSYCHOL ASSESSMENT R; MANZEL K, 1995, M MIDW PSYCH ASS CHI; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McGonigle DJ, 2000, NEUROIMAGE, V11, P708, DOI 10.1006/nimg.2000.0562; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Price CJ, 2003, NEUROIMAGE, V20, pS30, DOI 10.1016/j.neuroimage.2003.09.012; Price CJ, 1998, TRENDS COGN SCI, V2, P281, DOI 10.1016/S1364-6613(98)01201-7; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Pugh K. R., 2001, LEARNING DISABILITIE, V16, P240, DOI DOI 10.1111/0938-8982.00024; Reitan R, 1985, HALSTEAD REITAN NEUR; Shaywitz SE, 2003, BIOL PSYCHIAT, V54, P25, DOI 10.1016/S0006-3223(02)01836-X; Small SL, 1998, BRAIN LANG, V62, P298, DOI 10.1006/brln.1998.1951; Talairach J., 1988, COPLANAR STEREOTAXIC; THULBORN K, 1999, MED RADIOLOGY DIAGNO, P337; Thulborn KR, 1999, STROKE, V30, P749, DOI 10.1161/01.STR.30.4.749; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilkinson, 1984, WIDE RANGE ACHIEVEME	33	27	27	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2006	20	13-14					1367	1375		10.1080/02699050600983743			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	130GF	WOS:000243787100006	17378228				2022-02-06	
J	Nakamura, N; Yamaura, A; Shigemori, M; Ogawa, T; Tokutomi, T; Ono, J; Kawamata, T; Sakamoto, T				Nakamura, Norio; Yamaura, Akira; Shigemori, Minoru; Ogawa, Takeki; Tokutomi, Takashi; Ono, Jun-ichi; Kawamata, Tatsurou; Sakamoto, Tetsuya			Final report of the Japan Neurotrauma Data Bank project 1998-2001: 1,002 cases of traumatic brain injury	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						severe brain injury; databank; epidemiology; trauma	COMA	A 4-year study (Japan Neurotrauma Data Bank) of the medical treatment of 1002 cases of traumatic brain injuries in Japan was conducted from 1998 to 2001 at 10 emergency medical centers. Patients with severe head injury were eligible for entry with a Glasgow Coma Scale score of 8 or less at admission. Patients who underwent craniotomy were also included. Children under 5 years old were excluded. An original data sheet with 392 items from multi-focal viewpoints, such as etiology of injury, pre-hospital care, initial treatment including neuro-intensive care unit, and surgical treatment, was created. The results show that the patient's age and mechanism of injury are the most important factors in the outcome.	Jikei Univ, Sch Med, Dept Emergency Med, Minato Ku, Tokyo 1058461, Japan; JNTDB Committee, Japan Soc Neurotraumatol, Japanese Council Traff Sci, Tokyo, Japan		Ogawa, T (corresponding author), Jikei Univ, Sch Med, Dept Emergency Med, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	dem@jikei.ac.jp					KAWAMATA T, 2002, SHINKEI GAISHO, V25, P205; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; OGAWA T, 1998, SHINKEI GAISHO, V21, P125; OGAWA T, 2002, SHINKEI GAISHO, V25, P117; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; 2000, SHINKEI GAISHO, V23, P1	7	27	29	0	3	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	DEC	2006	46	12					567	573		10.2176/nmc.46.567			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	117VM	WOS:000242901400001	17185881	Bronze			2022-02-06	
J	de Guise, E; LeBlanc, J; Feyz, M; Lamoureux, J				de Guise, Elaine; LeBlanc, Joanne; Feyz, Mitra; Lamoureux, Julie			Prediction of outcome at discharge from acute care following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute care; Glasgow Outcome Scale (GOS); traumatic brain injury	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; POSTTRAUMATIC AMNESIA; COGNITIVE RESERVE; MORTALITY; PROGNOSIS; AGE; HEMORRHAGE; RECOVERY; MODERATE	Objective: To compute outcome probabilities for persons with traumatic brain injury at discharge from acute care. Participants: Three hundred thirty-nine patients with traumatic brain injury (239 mild, 48 moderate, 52 severe). Setting: Level I trauma center. Main Measures: Predictor variables considered were age, education, Glasgow Coma Scale score, duration of posttraumatic amnesia, cerebral imaging results, and need for neurosurgical intervention. Outcome measures were Extended Glasgow Outcome Scale and discharge destination. Results: Logistic regressions showed that a shorter posttraumatic amnesia decreased the probability of moderate to severe disability. Moreover, discharge home was less probable for patients with positive cerebral imaging. Conclusion: This model can help predict rehabilitation needs upon discharge from an acute care hospital.	McGill Univ, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ, Canada; Univ Montreal, Dept Prevent & Social Med, Montreal, PQ, Canada		de Guise, E (corresponding author), Montreal Gen Hosp, Local D13-124,1650 Av Cedar, Montreal, PQ H3G 1A4, Canada.	elaine.deguise@muhc.mcgill.ca					Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; de Guise E, 2005, CAN J NEUROL SCI, V32, P186, DOI 10.1017/S0317167100003954; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Harris OA, 2000, J TRAUMA, V49, P1076, DOI 10.1097/00005373-200012000-00017; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1981, MANAGEMENT HEAD INJU, P295; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Khan S, 2002, BRAIN INJURY, V16, P537, DOI 10.1080/02699050110119862; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; Lane PL, 2000, CAN J SURG, V43, P442; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Orient-Lopez F, 2004, REV NEUROLOGIA, V39, P901, DOI 10.33588/rn.3910.2004302; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Vath A, 2001, NEUROL RES, V23, P315, DOI 10.1179/016164101101198677; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	49	27	27	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					527	536		10.1097/00001199-200611000-00007			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400007	17122683				2022-02-06	
J	Shah, SA; Prough, DS; Garcia, JM; DeWitt, DS; Hellmich, HL				Shah, Syed A.; Prough, Donald S.; Garcia, Jeanna M.; DeWitt, Douglas S.; Hellmich, Helen L.			Molecular correlates of age-specific responses to traumatic brain injury in mice	EXPERIMENTAL GERONTOLOGY			English	Article						ribonuclease protection assay; interleukin-1 beta; brain-derived neurotrophic factor; caspase-3; fluid percussion TBI	HIPPOCAMPUS; EXPRESSION; DEFICITS; BDNF	Aged traumatic brain injury (TBI) patients suffer higher rates of mortality and disability than younger patients. Cognitive problems common to TBI patients are associated with damage to the hippocampus, a central locus of learning and memory. To investigate the molecular mechanisms of age-related vulnerability to brain injury in a mouse model of TBI, we studied the effects of TBI on hippocampal gene expression in young and aged mice. Young and aged male C57B1/6 mice were subjected to sham injury or TBI and sacrificed 24 h post-injury. We used laser capture microdissection to obtain pure populations of neurons from the CA1, CA3, and dentate gyrus subfields of the hippocampus. We compared injury-induced gene expression in hippocampal neurons of young and aged mice using quantitative ribonuclease protection assay analysis of linearly amplified mRNA from laser captured neurons. Both increased age and TBI were associated with increased expression of neuroprotective (brain-derived neurotrophic factor), pro-inflammatory (interleukin-1 beta), and proapoptotic (caspase-3) genes in mouse hippocampal neurons. Our data support previous reports that suggested the CA3 subregion is highly susceptible to fluid percussion TBI and that age-related changes in gene expression are one potential mechanism of increased vulnerability of the aged brain to TBI. (c) 2006 Elsevier Inc. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA		Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042849-01A1] Funding Source: Medline		Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Lynch AM, 2002, EUR J NEUROSCI, V15, P1779, DOI 10.1046/j.1460-9568.2002.02012.x; Maher FO, 2004, NEUROBIOL AGING, V25, P795, DOI 10.1016/j.neurobiolaging.2003.08.007; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Murray CA, 1998, J NEUROSCI, V18, P2974; Neatherlin J S, 2000, Crit Care Nurs Q, V23, P49; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Schaaf MJM, 2001, BRAIN RES, V915, P227, DOI 10.1016/S0006-8993(01)02855-4; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Ward MT, 1999, NEUROBIOL AGING, V20, P363, DOI 10.1016/S0197-4580(99)00045-7; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zhao XY, 2001, J COMP NEUROL, V441, P187, DOI 10.1002/cne.1406	21	27	28	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0531-5565	1873-6815		EXP GERONTOL	Exp. Gerontol.	NOV	2006	41	11					1201	1205		10.1016/j.exger.2006.07.006			5	Geriatrics & Gerontology	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology	122IN	WOS:000243219500014	16978820				2022-02-06	
J	Boto, GR; Gomez, PA; De la Cruz, J; Lobato, RD				Boto, G. R.; Gomez, P. A.; De la Cruz, J.; Lobato, R. D.			Severe head injury and the risk of early death	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIALS; SHOW CONVINCING EFFICACY; NEUROPROTECTIVE AGENTS; CLINICAL-TRIALS; THEORETICAL CONSIDERATIONS; COMPUTERIZED-TOMOGRAPHY; PREDICTING SURVIVAL; PRAGMATIC ANALYSIS; PRACTICAL SCALE	Background: Severe head injury (SHI) is one of the most important health, social and economic problems in industrialised countries. Unfortunately, none of the neuroprotection trials for traumatic brain injury have shown efficacy. One of the reasons for this failure could be the inclusion of patients with high probability of early death. A population-based, retrospective study was conducted to develop a prognostic model for identification of these patients. Methods: Between January 1987 and August 1999, a total of 895 patients (>= 15 years of age) with non-missile SHI were studied, in whom a computed tomography scan was carried out within the first 6 h of injury. The association between early death ( first 48 h after injury) and independent prognostic factors was determined by logistic regression analysis. A scoring system was also constructed. Results: The early-death rate was 20%. Independent predictors of early mortality after SHI were non-evacuated mass ( odds ratio ( OR) 65, 95% confidence interval (CI) 11 to 379), diffuse injury IV ( OR 25, 95% CI 5 to 112), diffuse injury III ( OR 8, 95% CI 3 to 22), flaccidity ( OR 7, 95% CI 3 to 15), non-reactive bilaterally mydriasis ( OR 6, 95% CI 3 to 12), evacuated mass ( OR 4, 95% CI 1 to 11), age >= 65 years ( OR 4, 95% CI 1 to 9), decerebration ( OR 3, 95% CI 2 to 7) and shock ( OR 3, 95% CI 2 to 6). The prognostic model correctly identified 93% of the patients. Conclusions: This prognostic model is based on simple clinical and radiological data readily available during the first 6 h after injury and is useful for identification of early death after SHI.			Boto, GR (corresponding author), Avda Doctor Garcia Tapia,159 Portal D Atico B, Madrid 28030, Spain.	grboto@yahoo.es	Rodriguez-Boto, Gregorio/AAR-9035-2021; Gomez, Pedro/N-5051-2019	Rodriguez-Boto, Gregorio/0000-0001-6361-5713; Gomez, Pedro/0000-0002-4185-5238			Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CHOI SC, 1996, NEUROTRAUMA, P779; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/BF01709556; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Contant CF, 1996, NEUROLOGICAL SURG, P1792; Dickerson J, 2002, J NEUROSURG, V97, P811, DOI 10.3171/jns.2002.97.4.0811; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; FELDMAN Z, 1996, NEUROTRAUMA, P805; GIANNOTTA SL, 1987, HEAD INJURY, P464; GIBSON RM, 1989, LANCET, V2, P369; Hukkelhoven CWPM, 2000, BRIT MED J, V321, P704, DOI 10.1136/bmj.321.7262.704; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Imberti R, 2003, NEUROSURGERY, V53, P241, DOI 10.1227/01.NEU.0000072302.16102.A8; Jennett B, 1975, Ciba Found Symp, P309; JENNETT B, 1975, LANCET, V1, P480; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Marshall L F, 1988, Clin Neurosurg, V34, P549; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Sekulovic N, 1979, Acta Neurochir Suppl (Wien), V28, P203; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1993, HEAD INJURY, P553; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; YAMAKI T, 1992, ACTA NEUROCHIR, V119, P153, DOI 10.1007/BF01541800	40	27	36	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2006	77	9					1054	1059		10.1136/jnnp.2005.087056			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	074MS	WOS:000239817100015	16740580	Green Published, Bronze			2022-02-06	
J	Gill, M; Steele, R; Windemuth, R; Green, SM				Gill, Michelle; Steele, Robert; Windemuth, Ryan; Green, Steven M.			A comparison of five simplified scales to the out-of-hospital Glasgow Coma Scale for the prediction of traumatic brain injury outcomes	ACADEMIC EMERGENCY MEDICINE			English	Article						Glasgow Coma Score; traumatic brain injury; prehospital care; out-of-hospital care	PLACEBO-CONTROLLED TRIAL; MINOR HEAD-INJURY; INTERRATER RELIABILITY; EMERGENCY-DEPARTMENT; MOTOR SCORE; MRC CRASH; HYPOTHERMIA; PREVENTION; ADULTS	Background: The 15-point Glasgow Coma Scale (GCS) frequently is used in the initial evaluation of traumatic brain injury (TBI) in out-of-hospital settings. We hypothesized that the GCS might be unnecessarily complex for out-of-hospital use. Objectives: To assess whether a simpler scoring system might demonstrate similar accuracy in the prediction of TBI outcomes. Methods: We performed a retrospective analysis of a trauma registry consisting of patients evaluated at our Level I trauma center from 1990 to 2002. The ability of out-of-hospital GCS scores to predict four clinically relevant TBI outcomes (emergency intubation, neurosurgical intervention, brain injury, and mortality) by using areas under receiver operating characteristic curves (AUROCs) was calculated. The same analyses for five simplified scales were performed, and compared with the predictive accuracies of the total GCS score. Results: In this evaluation of 7,233 trauma patients over a 12-year period of time, the AUROCs for the total GCS score were 0.83 (95% confidence interval [CI] = 0.81 to 0.84) for emergency intubation, 0.86 (95% Cl = 0.85 to 0.88) for neurosurgical intervention, 0.83 (95% Cl = 0.82 to 0.84) for brain injury, and 0.89 (95% CI = 0.88 to 0.90) for mortality. The five simplified scales approached the performance of the total GCS score for all clinical outcomes. Conclusions: In the evaluation of injured patients, five simplified neurological scales approached the performance of the total GCS score for the prediction of four clinically relevant TBI outcomes.	Loma Linda Univ, Med Ctr, Sch Med, Dept Emergency Med, Loma Linda, CA 92354 USA		Gill, M (corresponding author), Loma Linda Univ, Med Ctr, Sch Med, Dept Emergency Med, 11234 Anderson St,POB 2000,Room A-108, Loma Linda, CA 92354 USA.	mgill@ahs.llumc.edu					Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; [Anonymous], 1999, RES OPT CAR INJ PAT; BAXT WG, 1989, ANN EMERG MED, V18, P1, DOI 10.1016/S0196-0644(89)80302-6; *BRAIN TRAUM FDN, GUID PREH MAN TRAUM; Bull MJ, 2002, PEDIATRICS, V109, P542; Bull MJ, 2001, PEDIATRICS, V108, P1030; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Chesnut RM, 1998, CRIT CARE MED, V26, P10, DOI 10.1097/00003246-199801000-00008; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Edwards P, 2005, LANCET, V365, P1957; Gabbe BJ, 2004, ACAD EMERG MED, V11, P181, DOI 10.1197/j.aem.2003.08.019; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; GILL M, IN PRESS ANN EMERG M; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Grmec S, 2001, CRIT CARE, V5, P19; HACKNEY RG, 1994, BRIT MED J, V308, P1356, DOI 10.1136/bmj.308.6940.1356; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hollander JE, 2003, ACAD EMERG MED, V10, P830, DOI 10.1197/aemj.10.8.830; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Mace SE, 2001, ANN EMERG MED, V38, P405, DOI 10.1067/mem.2001.115882; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Mulholland SA, 2005, INJURY, V36, P1298, DOI 10.1016/j.injury.2005.07.010; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2001, NEW ENGL J MED, V344, P602, DOI 10.1056/NEJM200102223440810; Pilkington P, 2005, BMJ-BRIT MED J, V330, P331, DOI 10.1136/bmj.38324.646574.AE; PLANT JR, 1995, ANN EMERG MED, V26, P133, DOI 10.1016/S0196-0644(95)70142-7; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; World Health Organization, 1977, INT CLASS DIS 9 REV	33	27	30	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	SEP	2006	13	9					968	973		10.1197/j.aem.2006.05.019			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	082DK	WOS:000240366700009	16894005				2022-02-06	
J	Macciocchi, SN; Seel, RT; Alderson, A; Godsall, R				Macciocchi, Stephen N.; Seel, Ronald T.; Alderson, Amy; Godsall, Robert			Victoria Symptom Validity Test performance in acute severe traumatic brain injury: Implications for test interpretation	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						symptom validity; Victoria Symptom Validity Test; traumatic brain injury	MEMORY IMPAIRMENT; TEST-SCORES; VALIDATION	Effort testing has become commonplace in clinical practice. Recent research has shown that performance on effort tests is highly correlated with performance on neuropsychological measures. Clinical application of effort testing is highly dependent on research derived interpretive guidelines. The Victoria Symptom Validity Test (VSVT) is one of many measures currently used in clinical practice. The VSVT has recommended interpretive guidelines published in the test manual, but the samples used in developing interpretive guidelines are small and heterogeneous and concern has been expressed regarding high false negative rates. In this study, a homogeneous sample of acute, severely brain injured persons were used to assess the sensitivity of the VSVT. Results confirmed that acute, severely brain injured persons (N = 71) perform very well on the VSVT. The severe brain injury population is 99% likely to have between 44.1 and 46.8 correct VSVT Combined Score responses. While the VSVT was insensitive to memory dysfunction, the presence of severe visual perceptual (Benton Visual Form Discrimination Score < 21) and verbal fluency (Controlled Oral Word Association Score < 15) deficits predicted poor performance on the VSVT. These results provide further evidence that performance expectations currently incorporated in the VSVT manual interpretative criteria are too conservative. Empirically based alternative criteria for interpreting VSVT Combined Scores in the TBI population are presented. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Shepherd Ctr, Atlanta, GA USA		Macciocchi, SN (corresponding author), Shepherd Ctr, 2020 Peachtree Rd, Atlanta, GA USA.	stephen_macciocchi@shepherd.org					Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; Benton A., 1994, CONTRIBUTIONS NEUROP; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; CULLUM CM, 1991, PSYCHOGEMIC FACTORS; Green J, 2000, NEUROPSYCHOLOGICAL E; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Hamsher K., 1989, MULTILINGUAL APHASIA; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lishman W. A., 1997, ORGANIC PSYCHIAT; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; PANKRATZ L, 1990, CLIN NEUROPSYCHOL, V4, DOI DOI 10.1080/13854049008401832; PERNA RB, 2000, J COGNITIVE REHABILI, V18, P10; PORTER JH, 1986, STAT APPL BEHAV SCI; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rey A., 1964, EXAMEN CLIN PSYCHOL; Slick D. J., 1997, MANUAL VICTORIA SYMP; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 2003, CLIN NEUROPSYCHOL, V17, P390, DOI 10.1076/clin.17.3.390.18090; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Tombaugh T.N., 1996, TEST MEMORY MALINGER; Watkins MP., 2015, FDN CLIN RES APPL PR, V3rd; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1981, WAIS R MANUAL; [No title captured]	36	27	27	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2006	21	5					395	404		10.1016/j.acn.2006.06.003			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	084AC	WOS:000240502800003	16889930	Bronze			2022-02-06	
J	Salem, KH; Lindemann, I; Keppler, P				Salem, KH; Lindemann, I; Keppler, P			Flexible intramedullary nailing in pediatric lower limb fractures	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						eSIN nails; pediatric femoral fractures; torsion; malalignment; limb length discrepancy	FEMORAL-SHAFT FRACTURES; FEMUR FRACTURES; LONG BONES; CHILDREN; COMPLICATIONS; FIXATION; ADOLESCENT; HEAD; PLATE	Seventy-three children (48 boys and 25 girls; mean age, 5.7 years) with unilateral femoral or tibial shaft fractures were treated using elastic intramedullary nails at the authors' institution. There were 61 simple type A fractures (84%) and 12 wedge type B fractures (16%). All but 3 children had closed fractures. Associated injuries were seen in one third of the cases. All fractures were reduced by closed manipulation. Union was achieved in all cases without additional intervention. Technical problems Occurred in few patients. Improper nail length was seen in 4 cases. None of the study patients developed deep infection. No angulation greater than 15 degrees was found after femoral fractures. Nine patients had length discrepancy greater than 10 turn. Spiral fractures showed a tendency for shortening whereas transverse fractures were more associated with post-traumatic lengthening. No significant axial malalignment or shortening was seen in tibial fractures. Torsional differences of greater than 15 degrees were detected by computed tomography or navigated ultrasound examination in nearly half of the patients: however, only 4 children had clinically apparent gait changes. The study confirms the satisfactory results of treating pediatric lower limb fractures using elastic nails. Proper surgical technique and intraoperative control of limb alignment can help avoid postoperative deformities.	Univ Ulm, Dept Trauma Hand & Reconstruct Surg, D-89075 Ulm, Germany; Cairo Univ, Fac Med, Dept Orthopaed Surg, Cairo, Egypt		Salem, KH (corresponding author), Univ Ulm, Dept Trauma Hand & Reconstruct Surg, Steinhoevelstr 9, D-89075 Ulm, Germany.	khaled_hamedsalem@hotmail.com					BEATY JH, 1994, J PEDIATR ORTHOPED, V14, P178, DOI 10.1097/01241398-199403000-00009; Buechsenschuetz KE, 2002, J TRAUMA, V53, P914, DOI 10.1097/00005373-200211000-00017; Carey TP, 1996, CLIN ORTHOP RELAT R, P110; Christian C. A., 1998, CAMPBELLS OPERATIVE, P1993; DIETZ HG, 1997, INTRAMEDULLARE OSTEO; Dietz HG, 1993, LANGENBECKS ARCH C S, P946; Ender J, 1970, ACTA CHIR AUSTRIACA, V2, P40; Firica A, 1978, Ital J Orthop Traumatol, V4, P23; Flynn JM, 2001, J PEDIATR ORTHOPED, V21, P4, DOI 10.1097/01241398-200101000-00003; GLENN JN, 1973, J TRAUMA, V13, P958, DOI 10.1097/00005373-197311000-00004; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HANSEN TB, 1992, ACTA ORTHOP SCAND, V63, P50, DOI 10.3109/17453679209154849; Heinrich S D, 1992, J Orthop Trauma, V6, P452, DOI 10.1097/00005131-199212000-00011; HUGHES BF, 1995, J PEDIATR ORTHOPED, V15, P457, DOI 10.1097/01241398-199507000-00009; Kasser James R., 1996, P1195; Knorr P, 1996, UNFALLCHIRURG, V99, P410; KREGOR PJ, 1993, J BONE JOINT SURG AM, V75A, P1774, DOI 10.2106/00004623-199312000-00006; LASCOMBES P, 1988, REV CHIR ORTHOP, V74, P293; Lascombes P, 1993, HEFTE UNFALLCHIRURG, V230, P955; LIGIER JN, 1985, Z KINDERCHIR, V40, P209; LIGIER JN, 1988, J BONE JOINT SURG BR, V70, P74, DOI 10.1302/0301-620X.70B1.3339064; Linhart WE, 1999, J TRAUMA, V47, P372, DOI 10.1097/00005373-199908000-00028; Maier M, 2003, UNFALLCHIRURG, V106, P48, DOI 10.1007/s00113-002-0481-9; Metaizeau JP, 2004, J BONE JOINT SURG BR, V86B, P954, DOI 10.1302/0301-620X.86B7.15620; Narayanan UG, 2004, J PEDIATR ORTHOPED, V24, P363, DOI 10.1097/01241398-200407000-00004; Oh CW, 2002, INT ORTHOP, V26, P52, DOI 10.1007/s00264-001-0304-6; OMALLEY DE, 1995, J PEDIATR ORTHOPED, V15, P21, DOI 10.1097/01241398-199501000-00005; Prevot J, 1993, Chirurgie, V119, P473; PREVOT J, 1995, HEFTE UNFALLCHIR, V249, P77; RANEY EM, 1993, J PEDIATR ORTHOPED, V13, P516, DOI 10.1097/01241398-199307000-00018; Scharli A F, 1989, Z Unfallchir Versicherungsmed Berufskr, V82, P216; SCHMITTENBECHER PP, 1995, OPERAT ORTHOP TRAUMA, V7, P215; SHANNAK AO, 1988, J PEDIATR ORTHOPED, V8, P306, DOI 10.1097/01241398-198805000-00010; THOMETZ JG, 1995, J BONE JOINT SURG AM, V77, P1423, DOI 10.2106/00004623-199509000-00019; Tscherne H, 1984, FRACTURES SOFT TISSU; Vinz H, 1972, Zentralbl Chir, V97, P90; WARD WT, 1992, J PEDIATR ORTHOPED, V12, P626	37	27	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-6798			J PEDIATR ORTHOPED	J. Pediatr. Orthop.	JUL-AUG	2006	26	4					505	509		10.1097/01.bpo.0000217733.31664.a1			5	Orthopedics; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Pediatrics	059NR	WOS:000238740000015	16791070				2022-02-06	
J	McDermott, S; Moran, R; Platt, T; Dasari, S				McDermott, Suzanne; Moran, Robert; Platt, Tan; Dasari, Srikanth			Variation in health conditions among groups of adults with disabilities in primary care	JOURNAL OF COMMUNITY HEALTH			English	Article						sensory; developmental; traumatic; psychiatric disability	TRAUMATIC BRAIN-INJURY; INTELLECTUAL DISABILITY; SECONDARY CONDITIONS; MENTAL-RETARDATION; PREVALENCE; MODERATE; OUTCOMES; EPILEPSY; PEOPLE	The literature on the health of adults with disabilities focuses on one disability compared to a comparison group. This study allows cross disability comparisons with the hypothesis. Adults with disabilities had higher odds of having common health conditions, compared to adults without disability in the same practice. A retrospective record review of 1449 patients with disability and 2084 patients without disability included individuals with sensory impairments (n=117), developmental disabilities (n=692), trauma-related impairments (n=155) and psychiatric impairments (n=485). The only two health conditions with statistically significantly increased odds for all groups with disabilities were dementia and epilepsy. Patients with developmental disabilities were less likely to have coronary artery disease, cancer, and obesity. Those with sensory impairments had increased odds for congestive heart failure, diabetes, transient ischemic attacks and death. Patients with trauma disabilities had increased odds for chronic obstructive pulmonary disease, and depression. Finally, psychiatric patients had increased odds for most of the investigated condition. In conclusion, there were many similarities in the risk for common health conditions such as asthma, cancer, coronary artery disease, depression, hypertension, and obesity, among patients with and without disability. Some of the conditions with increased odds ratios, including depression, seizures, and dementia are secondary to the primary disability.	Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA		McDermott, S (corresponding author), Family Practice Ctr, 3209 Colonial Dr, Columbia, SC 29208 USA.	suzanne.mcdermott@palmettohealth.org			ODCDC CDC HHS [R01/CCR418776] Funding Source: Medline		Albrecht GL, 2001, HDB DISABILITY STUDI, P585; Ashley MJ, 1997, BRAIN INJURY, V11, P677; Bowley C, 2000, J INTELL DISABIL RES, V44, P529, DOI 10.1046/j.1365-2788.2000.00270.x; Charlifue SW, 1999, ARCH PHYS MED REHAB, V80, P1429, DOI 10.1016/S0003-9993(99)90254-X; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; DAY K, 1994, J INTELL DISABIL RES, V38, P241, DOI 10.1111/j.1365-2788.1994.tb00392.x; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Eastgate Gillian, 2003, Aust Fam Physician, V32, P330; Fedeyko HJ, 2003, RES SOC SCI DISABIL, V3, P55, DOI 10.1016/S1479-3547(03)03004-5; Goldzweig CL, 2004, JAMA-J AM MED ASSOC, V291, P1497, DOI 10.1001/jama.291.12.1497; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Jansen DEMC, 2004, J INTELL DISABIL RES, V48, P93, DOI 10.1111/j.1365-2788.2004.00483.x; Kapell D, 1998, MENT RETARD, V36, P269, DOI 10.1352/0047-6765(1998)036<0269:POCMCI>2.0.CO;2; KAYE HS, 1996, TRENDS DISABILITY RA; Kinne S, 2004, AM J PUBLIC HEALTH, V94, P443, DOI 10.2105/AJPH.94.3.443; Kroll Thilo, 2003, Manag Care Q, V11, P11; LARSON CP, 1986, J MENT DEFIC RES, V30, P121; Lollar DJ, 2002, PUBLIC HEALTH REP, V117, P131, DOI 10.1093/phr/117.2.131; McDermott S, 2005, AM J MENT RETARD, V110, P48, DOI 10.1352/0895-8017(2005)110<48:POEIAW>2.0.CO;2; McDermott S, 1997, Fam Med, V29, P429; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; MORGAN C, 2003, AM J MENT DEFIC, V108, P239; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; Phillips A, 2004, J INTELL DISABIL RES, V48, P142, DOI 10.1111/j.1365-2788.2004.00503.x; RUBIN IL, 1987, MENT RETARD, V25, P201; *SAS I, 1999, SAS STAT US GUID VER; *WHO, 2000, INT STAT CLASS DIS; World Health Organization, 2007, INT CLASS FUNCT DIS; ZIRING PR, 1988, JAMA-J AM MED ASSOC, V260, P1439, DOI 10.1001/jama.260.10.1439	30	27	27	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0094-5145	1573-3610		J COMMUN HEALTH	J. Community Health	JUN	2006	31	3					147	159		10.1007/s10900-005-9008-y			13	Health Policy & Services; Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	044KO	WOS:000237671400001	16830504				2022-02-06	
J	Kotil, K; Kuscuoglu, U; Kirali, M; Uzun, H; Akcetin, M; Bilge, T				Kotil, K; Kuscuoglu, U; Kirali, M; Uzun, H; Akcetin, M; Bilge, T			Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo-control trial	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; agmatine; neuroprotection; rat	NITRIC-OXIDE SYNTHASE; CLONIDINE-DISPLACING SUBSTANCE; BRAIN-INJURY; RAT-BRAIN; LIPID-PEROXIDATION; TRAUMATIC INJURY; ARGININE; NEURONS; PATHOPHYSIOLOGY; GLUTAMATE	Object. No definitive treatment for spinal cord injuries (SCIs) exists, and more research is required. The use of agmatine [4-(aminobutyl)-guanidine-NH2-CH2-CH2-CH2-CH2-NH-C(-NH2)(=NH)], a guanidinium Compound formed by decarboxylation Of L-arginine by arginine decarboxylase, is a neurotransmitter-neuromodulator with both N-methyl-D-aspartate receptor (NMDAR)-antagonizing and nitric oxide synthase (NOS)-inhibiting activities. The purpose of this study was to demonstrate the dose-dependent activity of agmatine, an inducible NOS (iNOS) inhibitor and selective NMDAR antagonist, on biochemical and functional recovery in an experimental rat SCI model. Methods. This Study involved 40 Wistar albino male rats. The rats were subjected to sleep-awake cycles for 7 days before surgery. In each group, general anesthesia was induced by a 60-mg/kg ketamine injection. For the surgical SCI model, a Yasargil aneurysm clip was placed in the spinal cord. The study was conducted in the following four main groups: Group I (control group) laminectomy only Group II, trauma-only group and SCI; Group III, laminectomy, SCI and agmatine 50 mg/kg for 10 days; and Group IV, laminectomy, SCI, and agmatine 100 mg/kg, for 10 clays. On Day 1, no statistical difference was observed in any group (p < 0.005, analysis of variance [ANOVA] and the Fisher protected least significant difference [PLSD]). On Day 2, no statistical difference was noted among Groups II, III, and IV (p = 0.27, p = 0.42, and p = 0.76, respectively; ANOVA and Fisher PLSD). Beginning on Day 3, recovery in Groups III and IV differed significantly from that in Group 11 (p < 0.005, ANOVA and Fisher PLSD), and a statistically significant difference between Groups III and IV was observed, which also was present on Days 5, 7, and 10 (p = 0.003 p = 0.0024, and p = 0.0036, respectively; ANOVA and Fisher PLSD). Several observations were noteworthy: motor function scores were reduced significantly in the spinal cord-injured rats compared with the controls (p < 0.005); on Day 1, the agreement of motor function scores in rats in each SCI group indicated that the traumatic event had been replicated equally across all groups (p = 0.59, p = 0.59, and p = 0.28); a statistically significant difference in motor function scores developed on Day 3 between the rats subjected to trauma alone (Group II) and those treated with agmatine (Groups III and TV) (p < 0.005) and no statistically significant intergroup difference in motor function existed at any postinjury interval between the 50- and 100-mg/kg/day agmatine-treated rats (p > 0.005). Conclusions. Agmatine administration following SCI was shown to reduce NO levels significantly. No statistically significant intergroup difference in the reduction of NO levels was found between rats treated with 50- and 100-mg/kg/day doses of agmatine. Administration of a 100-mg/kg/day dose of agmatine reduced the NO levels to those measured in controls. The authors conclude that with additional studies into the role of agmatine, this drug may be helpful in the treatment of patients with SCIs.	Haseki Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey; Univ Istanbul, Dept Biochem, Istanbul, Turkey		Kotil, K (corresponding author), Hasan Ali Yucel Sok Senile, Apt 34-14 Ciftehavuzlar, TR-34728 Istanbul, Turkey.	kadirkotil@superonline.com	Uzun, Hafize/D-4811-2019	Uzun, Hafize/0000-0002-1347-8498			Abe K, 2000, BRAIN RES, V872, P141, DOI 10.1016/S0006-8993(00)02517-8; Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ANDERSON DK, 1992, J NEUROTRAUM, V9, P143, DOI 10.1089/neu.1992.9.143; Ascenzi P, 2002, EUR J BIOCHEM, V269, P884, DOI 10.1046/j.0014-2956.2002.02718.x; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Blantz RC, 2000, ACTA PHYSIOL SCAND, V168, P21; Bradley KJ, 1997, EUR J PHARMACOL, V331, P133, DOI 10.1016/S0014-2999(97)01043-1; Buege J A, 1978, Methods Enzymol, V52, P302; Chabrier PE, 1999, CELL MOL LIFE SCI, V55, P1029, DOI 10.1007/s000180050353; COLLINS WF, 1983, PARAPLEGIA, V21, P204, DOI 10.1038/sc.1983.34; Diaz-Ruiz A, 2002, NEUROSCI LETT, V319, P129, DOI 10.1016/S0304-3940(01)02540-X; Dumont AS, 2002, CURR OPIN NEUROL, V15, P713, DOI 10.1097/00019052-200212000-00009; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P265, DOI 10.1097/00002826-200109000-00003; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; Fairbanks CA, 2000, P NATL ACAD SCI USA, V97, P10584, DOI 10.1073/pnas.97.19.10584; FEHLINGS MG, 1995, SPINE, V20, P2187, DOI 10.1097/00007632-199510001-00002; FEHLINGS MG, 2001, SPINE, V26, P52; Feng YZ, 2002, PEDIATR RES, V52, P606, DOI 10.1203/01.PDR.0000028057.79132.1F; Festoff BW, 2004, J NEUROTRAUM, V21, P907, DOI 10.1089/0897715041526168; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; GILAD GM, 1995, LIFE SCI, V58, pPL41, DOI 10.1016/0024-3205(95)02274-0; Gilad GM, 2000, NEUROSCI LETT, V296, P97, DOI 10.1016/S0304-3940(00)01625-6; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Grillo MA, 2004, AMINO ACIDS, V26, P3, DOI 10.1007/s00726-003-0030-z; GUTIERREZ PA, 1993, UROL CLIN N AM, V20, P373; Horvath G, 1999, EUR J PHARMACOL, V368, P197, DOI 10.1016/S0014-2999(99)00060-6; IADECOLA C, 1992, AM J PHYSIOL, V263, pR1156, DOI 10.1152/ajpregu.1992.263.5.R1156; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; KALRA SP, 1995, NEUROSCI LETT, V194, P165, DOI 10.1016/0304-3940(95)11750-Q; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Kwon BK, 2002, SPINE, V27, P1504, DOI 10.1097/00007632-200207150-00005; Legos JJ, 2002, EXPERT OPIN INV DRUG, V11, P469; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; LIAU LM, 1996, NEUROLOGICAL SURG, P1549; Lortie MJ, 1996, J CLIN INVEST, V97, P413, DOI 10.1172/JCI118430; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; Morrissey JJ, 1997, P ASSOC AM PHYSICIAN, V109, P51; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Otake K, 1998, BRAIN RES, V787, P1, DOI 10.1016/S0006-8993(97)01200-6; PILETZ JE, 1995, J PHARMACOL EXP THER, V272, P581; Pineda J, 1996, NEUROSCI LETT, V219, P103, DOI 10.1016/S0304-3940(96)13180-3; Raasch W, 1995, Ann N Y Acad Sci, V763, P330, DOI 10.1111/j.1749-6632.1995.tb32419.x; Reis DJ, 2000, TRENDS PHARMACOL SCI, V21, P187, DOI 10.1016/S0165-6147(00)01460-7; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Ruiz-Durantez E, 2002, BRIT J PHARMACOL, V135, P1152, DOI 10.1038/sj.bjp.0704556; SAKAMOTO A, 1991, BRAIN RES, V554, P186, DOI 10.1016/0006-8993(91)90187-Z; Sastre M, 1997, J NEUROCHEM, V69, P2421; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Tarlov I.M., 1957, SPINAL CORD COMPRESS; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544; Yu CG, 2000, NEUROREPORT, V11, P3203, DOI 10.1097/00001756-200009280-00031; Zhu MY, 2003, CELL MOL NEUROBIOL, V23, P865, DOI 10.1023/A:1025069407173	60	27	29	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	1547-5654			J NEUROSURG-SPINE	J. Neurosurg.-Spine	MAY	2006	4	5					392	399		10.3171/spi.2006.4.5.392			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	041CG	WOS:000237430100007	16703907				2022-02-06	
J	Rodriguez, SR; Mallonee, S; Archer, A; Gofton, J				Rodriguez, SR; Mallonee, S; Archer, A; Gofton, J			Evaluation of death certificate-based surveillance for traumatic brain injury - Oklahoma 2002	PUBLIC HEALTH REPORTS			English	Article							MEDICAL EXAMINER; NEW-MEXICO; ACCURACY; COMPLETION	Objectives. Death certificate data are used to estimate state and national incidence of traumatic brain injury (TBI)-related deaths. This study evaluated the accuracy of this estimate in Oklahoma and examined the case characteristics of those persons who experienced a TBI-related death but whose death certificate did not reflect a TBI. Methods. Data from Oklahoma's vital statistics multiple-cause-of-death database and from the Oklahoma Injury Surveillance System database were analyzed for TBI deaths that occurred during 2002. Cases were defined using the Centers for Disease Control and Prevention (CDC) ICD-10 code case definition. In multivariate analysis using a logistic regression model, we examined the association of case characteristics and the absence of a death certificate for persons who experienced a TBI-related death. Results. Overall, sensitivity of death certificate-based surveillance was 78%. The majority (62%) of missed cases were due to listing "multiple trauma" as the cause of death. Death certificate surveillance was more likely to miss TBI-related deaths among traffic crashes, falls, and persons aged <= 65 years. After adding missed cases to cases captured by death certificate surveillance, traffic crashes surpassed firearm fatalities as the leading external cause of TBI-related death. Conclusions. Death certificate surveillance underestimated TBI-related death in Oklahoma and might lead to national underreporting. More accurate and detailed completion of death certificates would result in better estimates of the burden of TBI-related death. Educational efforts to improve death certificate completion could substantially increase the accuracy of mortality statistics.	Oklahoma Dept Hlth, Off Sci Affairs, Oklahoma City, OK 73117 USA; Oklahoma Dept Hlth, Injury Prevent Program, Oklahoma City, OK 73117 USA; Oklahoma Chief Med Examiner, Oklahoma City, OK USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA		Rodriguez, SR (corresponding author), Oklahoma Dept Hlth, Communicable Dis Div, 1000 NE 10th St, Oklahoma City, OK 73117 USA.	sara@health.ok.gov			ODCDC CDC HHS [U17/CCU611902] Funding Source: Medline		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ARCHER P, 1996, MMWR-MORBID MORTAL W, V45, P209; Archer PJ, 1998, AM J PREV MED, V15, P83, DOI 10.1016/S0749-3797(98)00054-3; BONNIE RJ, 1999, REDUCING BURDEN INJU, P78; *CDCP, 2005, INSTR CLASS MULT CAU; *CENS BUR, 2003, METR STAT AR COMP; Centers for Disease Control and Prevention, 2003, NAT VIOL DEATH REP S; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P303; [Anonymous], 2001, MMWR Recomm Rep, V50, P1; Chugh SS, 2004, J AM COLL CARDIOL, V44, P1268, DOI 10.1016/j.jacc.2004.06.029; Comstock RD, 2005, INJURY PREV, V11, P58, DOI 10.1136/ip.2004.007567; Coultas DB, 1996, THORAX, V51, P717, DOI 10.1136/thx.51.7.717; CROSS J, 2003, MMWR-MORBID MORTAL W, V52, P276; *DEP LAB, 1995 1999 CHARTB; DIJKHUIS H, 1994, AM J EPIDEMIOL, V139, P637, DOI 10.1093/oxfordjournals.aje.a117053; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Horan JM, 2003, EPIDEMIOL REV, V25, P24, DOI 10.1093/epirev/mxg010; HOYERT DL, 2005, NATL VITAL STAT REP, V523, P1; *INF INC, 2004, LINKPR V301; JORDAN JM, 1993, CLIN INVEST MED, V16, P249; KRAUS JF, 1995, AM J EPIDEMIOL, V141, P973, DOI 10.1093/oxfordjournals.aje.a117364; Lakkireddy DR, 2004, AM J MED, V117, P492, DOI 10.1016/j.amjmed.2004.04.018; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LAPIDUS G, 1994, ACCIDENT ANAL PREV, V26, P535, DOI 10.1016/0001-4575(94)90044-2; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Lyman JM, 2004, DEATH STUD, V28, P659, DOI 10.1080/07481180490476515; Marr A., 2004, CENTRAL NERVOUS SYST; MAUDSLEY G, 1993, J PUBLIC HEALTH MED, V15, P192; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; MOOLENAAR RL, 1995, WESTERN J MED, V163, P431; Myers KA, 1998, CAN MED ASSOC J, V158, P1317; Nelson David E., 1993, Morbidity and Mortality Weekly Report, V42, P29; Pezzotti P, 2003, INT J EPIDEMIOL, V32, P778, DOI 10.1093/ije/dyg202; SAS Institute Inc, 2004, SAS 9 1; Schootman M, 2000, J TRAUMA, V48, P70, DOI 10.1097/00005373-200001000-00012; THURMAN D, 2001, HEAD TRAUMA BASIC PR; Washko RM, 1996, PUBLIC HEALTH REP, V111, P251; Will JC, 2001, J CLIN EPIDEMIOL, V54, P239, DOI 10.1016/S0895-4356(00)00303-6; World Health Organization, 2004, ICD 10 INT STAT CLAS	41	27	27	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-3549	1468-2877		PUBLIC HEALTH REP	Public Health Rep.	MAY-JUN	2006	121	3					282	289		10.1177/003335490612100310			8	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	034HF	WOS:000236919200010	16640151	Green Published			2022-02-06	
J	Tabish, A; Lone, NA; Afzal, WM; Salam, A				Tabish, A; Lone, NA; Afzal, WM; Salam, A			The incidence and severity of injury in children hospitalised for traumatic brain injury in Kashmir	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						head injury; brain injury; head trauma; brain concussion; brain contusion; subdural hematoma; epidural hematoma; skull fractures; subarachnoid hemorrhage; intracerebral hemorrhage; Glasgow Coma Scale; intracranial pressure	HEAD-INJURY; EPIDEMIOLOGY	A large number of people experience traumatic brain injury each year, often with severe consequences. This is a public health problem that requires ongoing surveillance to follow trends in the incidence, risk factors, causes, and outcomes of these injuries. In 2003, a prospective study of all children below 15 years admitted to hospitals with a diagnosis of head injury was conducted in the Accident Et Emergency Department of Sher-e-Kashmir Institute of Medical Sciences, Srinagar (India) to determine the incidence and severity of accidental head injury among children and the circumstances of injury. The highest incidence of head injury was seen at ages 6-10 years. Head injury rates were higher in mates than in females. The leading causes include falls and motor vehicle accidents. More than 50% falls occurred in the age group of 4-6 years. Ninety per cent patients, who recovered, were discharged within 16-24 h after admission. Lack of supervision, non-implementation of safety measures and poor implementation of traffic rules leads to many injuries. The ability of the health care system to deal with increasing trauma in Jammu Et Kashmir is limited. Nevertheless, prevention can be low cost strategy to overcome this problem. The results of epidemiological studies are affected by factors like demography, geographic region and socioeconomic status. This study emphasizes the need for intensified effort for prevention, minimising risk factors, strict legislative measures, observing traffic rules, implementation of safety measures, establishing appropriate trauma care at district level, adult supervision, and creating awareness. (C) 2006 Elsevier Ltd. All rights reserved.	Sher E Kashmir Inst Med Sci, Dept Accid & Emergency, Srinagar 190001, Jammu & Kashmir, India; Sher E Kashmir Inst Med Sci, Dept Neurosurg, Srinagar 190001, Jammu & Kashmir, India; Sher E Kashmir Inst Med Sci, Dept Internal Med, Srinagar 190001, Jammu & Kashmir, India		Tabish, A (corresponding author), Sher E Kashmir Inst Med Sci, Dept Accid & Emergency, POB 826, Srinagar 190001, Jammu & Kashmir, India.	amintabish@rediff.com					ADESUNKAMNI ARK, 1988, TRAUMA, V44, P506; BAKER SP, 1987, J TRAUMA, V27, P343, DOI 10.1097/00005373-198704000-00001; Dawodu ST, TRAUMATIC BRAIN INJU; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; HAUGH RH, 1995, INT J ORAL MAXILLOF, V24, P409; JENNET B, 1998, ARCH DIS CHILD, V78, P1; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KNUDSON MM, 1992, J TRAUMA, V32, P729, DOI 10.1097/00005373-199206000-00009; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MAZUREK AJ, 1994, J ACCID EMERG MED, V11, P9; RAMENOFSKY ML, 1984, J TRAUMA, V24, P818, DOI 10.1097/00005373-198409000-00007; Rohana J, 1998, Med J Malaysia, V53, P217; SHANKS NJ, 1994, PUBLIC HEALTH, V108, P27, DOI 10.1016/S0033-3506(05)80032-0; SHOKUNBI T, 1994, W AFR J MED, P1388; SMITH GS, 1991, EPIDEMIOL REV, V13, P228, DOI 10.1093/oxfordjournals.epirev.a036070; TABISH SA, 2004, JIMSA, V17, P9; TABISH SA, 2004, WALNUT TREE INJURY O; TABISH SA, 2000, J INT MED SCI ACAD, V13, P247; Wesson D, 1995, Semin Pediatr Surg, V4, P83	21	27	28	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAY	2006	37	5					410	415		10.1016/j.injury.2006.01.039			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	037RH	WOS:000237164100008	16569405				2022-02-06	
J	Malec, JF; Moessner, AM				Malec, JF; Moessner, AM			Replicated positive results for the VCC model of vocational intervention after ABI within the social model of disability	BRAIN INJURY			English	Article						vocational rehabilitation; brain injury; disability	TRAUMATIC BRAIN-INJURY; SUPPORTED EMPLOYMENT; OUTCOMES; RETURN; WORK	Primary objective: Replicated evaluation of the Vocational Case Co-ordinator (VCC) Model for vocational rehabilitation after acquired brain injury (ABI). Research design: Referral cohort studied within the social model of disability. Methods and procedures: One hundred and thirty-eight participants with ABI were assisted by a VCC to develop self-directed vocational plans and networks of medical centre and community services. Early intervention, work trials, temporary or long-term supported employment and employer education are fundamental features of the VCC Model. Main outcomes and results: One year after initial placement 80% of participants remained in community-based employment, 56% of the total sample with no support. Better outcomes were associated with earlier intervention but not with initial injury severity. Conclusions: Results replicate original findings of the effectiveness of the VCC Model of vocational rehabilitation after ABI with a different VCC. Implications for social change within the social model of disability are discussed.	Mayo Clin, Coll Med, Generose ME TBI, Rochester, MN 55905 USA		Malec, JF (corresponding author), Mayo Clin, Coll Med, Generose ME TBI, Rochester, MN 55905 USA.	malec.james@mayo.edu					Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; CORTHELL DW, 1985, 12 I REH ISS REH TRA; Corthell DW, 1990, TRAUMATIC BRAIN INJU; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; Malec J. F., 1992, NEURO REHABILITATION, V2, P1, DOI [10.3233/NRE-1992-2303, DOI 10.3233/NRE-1992-2303]; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF, 2005, REHABILITATION TRAUM, P176; MENZ FE, 1990, TRAUMATIC BRAIN INJU; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; THOMAS DF, 1993, COMMUNITY BASED EMPL; Union of the Physically Impaired against Segregation, 1975, FUND PRINC DIS; Wall JR, 1998, BRAIN INJURY, V12, P215; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN P, 1993, COMMUNITY BASED EMPL; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	23	27	28	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2006	20	3					227	236		10.1080/02699050500488124			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400002	16537264				2022-02-06	
J	Wang, XF; Huang, LD; Yu, PP; Hu, JG; Yin, L; Wang, L; Xu, XM; Lu, PH				Wang, XF; Huang, LD; Yu, PP; Hu, JG; Yin, L; Wang, L; Xu, XM; Lu, PH			Upregulation of type I interleukin-1 receptor after traumatic spinal cord injury in adult rats	ACTA NEUROPATHOLOGICA			English	Article						inflammation; spinal cord injury Rat; IL-1; IL-1 receptor	TUMOR-NECROSIS-FACTOR; INDUCED SICKNESS BEHAVIOR; TIME QUANTITATIVE PCR; FACTOR-ALPHA; DEFICIENT MICE; GENE-EXPRESSION; BRAIN-DAMAGE; CELL-DEATH; IL-1-BETA; CYTOKINES	Post-traumatic inflammation response has been implicated in secondary injury mechanisms after spinal cord injury (SCI). Interleukin-1 (IL-1) is a key inflammatory mediator that is increasingly expressed after SCI. The action of IL-1 is mediated through its functional receptor, type I interleukin-1 receptor (IL-1RI). However, whether this receptor is expressed after SCI remains to be elucidated. In the present study, the temporospatial expression of IL-1RI was detected in rats that received a moderate contusive SCI (a 10 g rod dropped at a height of 12.5 mm) at the ninth to tenth thoracic vertebral level using a widely used New York University impact device. Our study demonstrated that IL-1RI was slightly increased at 4 h post-injury compared to the normal or sham-operated controls, reached the peak at 8 h at mRNA level (4.44-fold, P < 0.01) and 1 d at protein level (2.62-fold, P < 0.01). IL-1RI remained at its elevated levels for a relatively long duration (4 h-7 days). Spatially, IL-1RI was observed throughout the entire length of a 10 mm-long cord segment containing the injury epicenter. Colocalization of IL-1RI was found in neurons, oligodendrocytes, astrocytes, and activated microglia. Our results suggest that the elevated expression of IL-1RI after SCI may contribute to posttraumatic inflammation responses of IL-1.	Shanghai Med Univ 2, Dept Neurobiol, Shanghai 200025, Peoples R China; Nantong Univ, Affiliated Hosp, Dept Lab Sci, Nantong 226001, Peoples R China; Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA		Xu, XM (corresponding author), Shanghai Med Univ 2, Dept Neurobiol, 280 S Chong Qing Rd, Shanghai 200025, Peoples R China.	xmxu0001@louisville.edu; peihualua3@yahoo.com.cn	Yu, Panpan/A-4962-2013; Yu, Panpan/M-5718-2019	Xu, Xiao-ming/0000-0002-7229-0081			Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002; Basu A, 2002, J NEUROSCI, V22, P6071; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Blasi F, 1999, BIOL CHEM, V380, P259, DOI 10.1515/BC.1999.034; Bluthe RM, 2000, EUR J NEUROSCI, V12, P4447, DOI 10.1111/j.1460-9568.2000.01348.x; BOSSU P, 1995, AM J PATHOL, V147, P1852; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; BRENNEMAN DE, 1995, INT J DEV NEUROSCI, V13, P187, DOI 10.1016/0736-5748(95)00014-8; CHUNG IY, 1990, J IMMUNOL, V144, P2999; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Cremona S, 1998, NEUROSCI LETT, V246, P101, DOI 10.1016/S0304-3940(98)00238-9; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; Dziegielewska KM, 2000, CELL TISSUE RES, V299, P335; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; GIULIAN D, 1988, J NEUROSCI, V8, P709; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Johnson RW, 1997, COMP BIOCHEM PHYS A, V116, P183, DOI 10.1016/S0300-9629(96)00277-0; Konsman JP, 2002, TRENDS NEUROSCI, V25, P154, DOI 10.1016/S0166-2236(00)02088-9; Labow M, 1997, J IMMUNOL, V159, P2452; LEE SC, 1994, GLIA, V12, P309, DOI 10.1002/glia.440120407; Li CS, 2005, J BIOL CHEM, V280, P26152, DOI 10.1074/jbc.M503262200; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; NORRIS JG, 1994, J IMMUNOL, V152, P841; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Pan JZ, 2002, J NEUROSCI RES, V68, P315, DOI 10.1002/jnr.10215; Parish CL, 2002, J NEUROSCI, V22, P8034; Parker LC, 2002, BRIT J PHARMACOL, V136, P312, DOI 10.1038/sj.bjp.0704715; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.3.CO;2-5; Pinteaux E, 2002, J NEUROCHEM, V83, P754, DOI 10.1046/j.1471-4159.2002.01184.x; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Sung CS, 2004, BRAIN RES, V1015, P145, DOI 10.1016/j.brainres.2004.04.068; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yan P, 2003, EXP NEUROL, V183, P286, DOI 10.1016/S0014-4886(03)00135-3; Yan P, 1999, J NEUROSCI, V19, P9355; Yang LQ, 2005, J CLIN NEUROSCI, V12, P276, DOI 10.1016/j.jocn.2004.06.011; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004	53	27	29	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2006	111	3					220	228		10.1007/s00401-005-0016-x			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	030HA	WOS:000236624000003	16456668				2022-02-06	
J	Kendall, E; Muenchberger, H; Gee, T				Kendall, Elizabeth; Muenchberger, Heidi; Gee, Travis			Vocational rehabilitation following traumatic brain injury: A quantitative synthesis of outcome studies	JOURNAL OF VOCATIONAL REHABILITATION			English	Article						Traumatic brain injury; quantitative synthesis; vocational rehabilitation; return-to-work		This study is a quantitative synthesis of research relating to Traumatic Brain Injury (TBI) and employment outcomes. Using broad inclusion criteria, 26 studies were selected for review. The study comprised a combined sample of 3688 participants aged 16 years and above who had sustained a TBI as an adult. Aggregate results across selected studies indicated that individuals with TBI returned to competitive employment and other productive activities earlier with vocational intervention than without intervention. The current synthesis also demonstrated that the use of a narrow definition of return-to-work (i. e., full-time competitive work only) produced more apparent unemployment than an inclusive definition (i.e., any competitive work or productive activity). Although this finding is not surprising, full-time employed persons seemed more likely to remain 'employed' over time compared to those who were in any type of employment or productive activity. These findings have important implications regarding the timeliness of vocational interventions and highlight the need for competitive employment (full-time) preparation to ensure optimal long-term outcomes following TBI. The definition of employment and the nature of pre-injury employment is crucial to any interpretation of return-to-work in TBI. The current study also highlights the importance of measuring employment outcomes using multiple points over time, rather than single data points or first return-to-work.	[Kendall, Elizabeth; Muenchberger, Heidi; Gee, Travis] Griffith Univ Logan, Ctr Natl Res Disabil & Rehabil Med CONROD, Meadowbrook, Qld 4131, Australia		Kendall, E (corresponding author), Griffith Univ Logan, Ctr Natl Res Disabil & Rehabil Med CONROD, Meadowbrook, Qld 4131, Australia.	e.kendall@griffith.edu.au		Kendall, Elizabeth/0000-0003-2399-1460			Anathousou J., 2003, AUSTR J CAREER DEV, V12, P58; Ashley MJ, 1997, BRAIN INJURY, V11, P677; Australian Bureau of Statistics ABS, 2000, DIS DIS COND; Babineau J L, 1998, Work, V10, P137, DOI 10.3233/WOR-1998-10205; Baldwin ML, 1996, AM J IND MED, V29, P632; Blettner M, 1999, INT J EPIDEMIOL, V28, P1, DOI 10.1093/ije/28.1.1; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Bryant DM, 1996, EVAL PROGRAM PLANN, V19, P121, DOI 10.1016/0149-7189(96)00003-1; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Buys N., 2003, AUST J CAREER DEV, V12, P36; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chmura-Kraemer H., 1989, J CONSULT CLIN PSYCH, V57, P148; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Coetzer B R, 2002, Aust J Rural Health, V10, P229, DOI 10.1046/j.1440-1584.2002.00425.x; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Curl R. M., 1992, REHABILITATION ED, V6, P195; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; Fredric M., 1986, METAANALYSIS QUANTIT; Golden T. P., 1993, J REHABIL, P55; Goran DA, 1997, ARCH CLIN NEUROPSYCH, V12, P691, DOI 10.1016/S0887-6177(97)00004-8; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; GRENVILLE J, 1995, J ADV NURS, V22, P965; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hillier SL, 1997, BRAIN INJURY, V11, P661; Holzberg Emily, 2001, Work, V16, P245; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Kendall E, 1998, J REHABIL, V64, P16; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; Krause JS, 2001, TOP SPINAL CORD INJ, V6, P102; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; MCAWEENEY MJ, 1997, SCI PSYCHOSOCIAL PRO, V10, P58; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pollock G., 2002, INT J SOC RES METHOD, V5, P91, DOI [DOI 10.1080/13645570110062432, 10.1080/13645570110062432]; Possl O, 2001, BRAIN INJURY, V15, P15; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sherer M, 1999, BRAIN INJURY, V13, P973; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Sluis CK, 1998, INJURY, V29, P281, DOI 10.1016/S0020-1383(97)00199-X; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wehman P, 1999, EDUC TRAIN MENT RET, V34, P3; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Wehman P., 1990, COMMUNITY INTEGRATIO; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200	56	27	28	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1052-2263	1878-6316		J VOCAT REHABIL	J. Vocat. Rehabil.		2006	25	3					149	160					12	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V71OP	WOS:000211583800002					2022-02-06	
J	Mottram, L; Donders, J				Mottram, Lisa; Donders, Jacobus			Cluster subtypes on the California verbal learning test-children's version after pediatric traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							STRUCTURAL EQUATION ANALYSIS; HEAD-INJURY; WISC-III; STANDARDIZATION SAMPLE; CVLT-C; MEMORY; PERFORMANCE; ADOLESCENTS; FREQUENCY; PATTERNS	The purpose of this study is to determine the presence of profile subtypes on the California Verbal Learning Test-Children's Version (CVLT-C; Delis, Kramer, Kaplan, & Ober, 1994) in 175 children with traumatic brain injury (TBI). Four key z score variables are used in a 2-stage cluster analysis that reveal 4 reliable subtypes. No meaningful differences among the clusters are found on demographic variables. In contrast, statistically significant differences among the 4 clusters in both level and pattern of performance are found on injury severity parameters and the 4 factor index scores from an independent measure of psychometric intelligence (Wechsler Intelligence Scale for Children-Third Edition; Wechsler, 1991). This study concludes that although no unique profile is found on the CVLT-C after TBI in children, performance on this test is affected strongly by injury severity, with a mediating contribution by speed of information processing.	Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; BJORKLUND DF, 1997, DEV MEMORY CHILDHOOD, P00201; BLASHFIELD RK, 1976, PSYCHOL BULL, V83, P377, DOI 10.1037/0033-2909.83.3.377; BOLL T, 1993, CHILDRENS CATEGORY T; CARTER RL, 1989, PSYCHOMETRIKA, V54, P9, DOI 10.1007/BF02294446; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Cohen M.J., 1997, CHILDRENS MEMORY SCA; DELIS D, 1994, CALIFORNIA VERBAL LE; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 1999, DEV NEUROPSYCHOL, V16, P163, DOI 10.1207/S15326942DN1602_2; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; Fuerst DR, 1995, CHILD NEUROPSYCHOL, V1, P38, DOI 10.1080/09297049508401341; Hair J.F., 2002, READING UNDERSTANDIN, P147; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kail R, 2002, CHILD DEV, V73, P1703, DOI 10.1111/1467-8624.00500; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Meyers JE., 1995, REY COMPLEX FIGURE T; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; MILLIGAN GW, 1980, PSYCHOMETRIKA, V45, P325, DOI 10.1007/BF02293907; MILLIGAN GW, 1985, PSYCHOMETRIKA, V50, P159, DOI 10.1007/BF02294245; MILLIGAN GW, 2003, HDB PSYCHOL RES METH, V2, P165; Mottram L, 2005, PSYCHOL ASSESSMENT, V17, P212, DOI 10.1037/1040-3590.17.2.212; Nesbit-Greene K, 2002, J CLIN EXP NEUROPSYC, V24, P194, DOI 10.1076/jcen.24.2.194.996; Precourt S, 2002, DEV NEUROPSYCHOL, V21, P173, DOI 10.1207/S15326942DN2102_4; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; *SAS I INC, 1990, SAS STAT US GUIDE VE, V1; Saunders CD, 2000, CHILD NEUROPSYCHOL, V6, P129, DOI 10.1076/chin.6.2.129.7057; Schinka JA, 1998, PSYCHOL ASSESSMENT, V10, P171, DOI 10.1037/1040-3590.10.2.171; Sheslow DA, 2003, WIDE RANGE ASSESSMEN; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Verger K, 2001, BRAIN INJURY, V15, P211; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; White DA, 2001, NEUROPSYCHOLOGY, V15, P221, DOI 10.1037/0894-4105.15.2.221; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Williams J, 2001, CHILD NEUROPSYCHOL, V7, P15, DOI 10.1076/chin.7.1.15.3148; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	43	27	27	0	1	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2006	30	3					865	883		10.1207/s15326942dn3003_6			19	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	113OM	WOS:000242607200006	17083297				2022-02-06	
J	Wilson, DJ; Powell, M; Gorham, JL; Childers, MK				Wilson, DJ; Powell, M; Gorham, JL; Childers, MK			Ambulation training with and without partial weighthearing after traumatic brain injury - Results of a randomized, controlled trial	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						gait; partial weight bearing; traumatic brain injury	BODY-WEIGHT SUPPORT; SPINAL-CORD-INJURY; TREADMILL; GAIT; STROKE; WALKING; LOCOMOTION; OUTCOMES	Objective: To test the hypothesis that 8 wks of partial weight-bearing gait retraining improves functional ambulation to a greater extent than traditional physical therapy in individuals after traumatic brain injury. Desiqn: A randomized, open-label, controlled, cohort study was conducted at two inpatient university-based rehabilitation hospitals. A total of 38 adults with a primary diagnosis of traumatic brain injury and significant gait abnormalities received either 8 wks of standard physical therapy or physical therapy supplemented with partial weight-bearing gait training twice weekly. Results: Significant (P < 0.05) improvements were detected in both groups on Functional Ambulation Category, Standing Balance Scale, Rivermead Mobility Index, and FIM (R). However, no differences were found between the treatment groups. Conclusions: Results did not support the hypothesis that 8 wks of partial weight-bearing gait retraining improves functional ambulation to a greater extent than traditional physical therapy in individuals after traumatic brain injury based on common clinical measures.	Missouri State Univ, Exercise & Rehabil Biomech Lab, Dept Hlth Phys Educ & Recreat, Springfield, MO 65897 USA; Missouri Rehabil Ctr, Mt Vernon, MO USA; Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO USA; Univ Missouri, Dept Biomed Sci, Coll Vet Med, Columbia, MO USA		Wilson, DJ (corresponding author), Missouri State Univ, Exercise & Rehabil Biomech Lab, Dept Hlth Phys Educ & Recreat, 121C McDonald Arena,901 S Natl Ave, Springfield, MO 65897 USA.		sahely, ahmad/R-6293-2017	Childers, Martin/0000-0003-4754-0883	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980008] Funding Source: Medline		Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; BOHANNON R W, 1989, Physiotherapy Canada, V41, P198; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Collen F M, 1991, Int Disabil Stud, V13, P50; da Cunha IT, 2002, ARCH PHYS MED REHAB, V83, P1258, DOI 10.1053/apmr.2002.34267; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DITUNNO JF, 1982, J NEUROTRAUMA S1, V9, pS301; Eich HJ, 2004, CLIN REHABIL, V18, P640, DOI 10.1191/0269215504cr779oa; Field-Fote EC, 2001, ARCH PHYS MED REHAB, V82, P818, DOI 10.1053/apmr.2001.23752; Frattali C M, 1993, Disabil Rehabil, V15, P1; Gardner MB, 1998, PHYS THER, V78, P361, DOI 10.1093/ptj/78.4.361; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HESSE S, 1994, ARCH PHYS MED REHAB, V75, P1087, DOI 10.1016/0003-9993(94)90083-3; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; HUNTER D, 1995, J ORTHOP SPORT PHYS, V21, P268, DOI 10.2519/jospt.1995.21.5.268; McNevin NH, 2000, ARCH PHYS MED REHAB, V81, P525, DOI 10.1053/mr.2000.4429; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Miller EW, 2001, NEUROREHABILITATION, V16, P155; Miyai I, 2002, ARCH PHYS MED REHAB, V83, P1370, DOI 10.1053/apmr.2002.34603; Nilsson L, 2001, CLIN REHABIL, V15, P515, DOI 10.1191/026921501680425234; Protas EJ, 2001, ARCH PHYS MED REHAB, V82, P825, DOI 10.1053/apmr.2001.23198; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schindl MR, 2000, ARCH PHYS MED REHAB, V81, P301, DOI 10.1053/apmr.2000.0810301; Seif-Naraghi AH, 1999, J HEAD TRAUMA REHAB, V14, P146, DOI 10.1097/00001199-199904000-00005; SUDARSKY L, 1990, NEW ENGL J MED, V322, P1441; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; VISINTIN M, 1989, CAN J NEUROL SCI, V16, P315, DOI 10.1017/S0317167100029152; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; Wilson DJ, 2002, BRAIN INJURY, V16, P259, DOI 10.1080/02699050110103922	32	27	28	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JAN	2006	85	1					68	74		10.1097/01.phm.0000193507.28759.37			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	996QW	WOS:000234190400010	16357551				2022-02-06	
J	Wrona, RM				Wrona, RM			The use of state workers' compensation administrative data to identify injury scenarios and quantify costs of work-related traumatic brain injuries	JOURNAL OF SAFETY RESEARCH			English	Article						WC data and TBI; cost of work related TBI; industry specific injury scenarios for TBI; occupations and industries with high frequencies of TBI; ANSI Z16.2 Injury Typology	LADDER FALL ACCIDENTS; WASHINGTON-STATE	Problem: Traumatic brain injury (TBI) is a public health problem but little is known about the nature of that problem in the working population. Method: The author used a national definition to identify cases in Washington State from workers' compensation (WC) hospital billing data, quantified the cost of WC insurance benefits using actuarial cost estimates, and identified high risk industries using ANSI Z16.2 typology. Results: There were 928 cases of TBI with a lifetime claim cost of $159 million from the Washington State Fund (1994-2001). Sixty percent of injuries resulted in death or disability. The highest risks of TBI are concentrated in 16 industrial insurance risk classes and the highest costs in 19 North American Industry Classification codes. Injury scenarios were identified for nine industrial insurance risk classes. Conclusions: TBI is a disabling and costly workplace injury in the state of Washington, affecting even teenagers and seniors who are not generally considered to be part of the workforce. Injury typology codes provide useful information for improving workplace safety. Impact on industry: This research provides industry with quantitative information regarding the cost of work-related traumatic brain injury and the usefulness of using workers' compensation claims data to reduce the burden of workplace injury. (c) 2006 National Safety Council and Elsevier Ltd. All rights reserved.	Washington State Dept Labor & Ind, Olympia, WA 98504 USA		Wrona, RM (corresponding author), 3608 Stevens Dr NE, Lacey, WA 98516 USA.	ronwrona@comcast.net	Wrona, Ronald/W-9319-2019		NIOSH CDC HHS [5U01OH07292-01] Funding Source: Medline; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [U01OH007292] Funding Source: NIH RePORTER		Alexander BH, 1999, AM J IND MED, V36, P317, DOI 10.1002/(SICI)1097-0274(199908)36:2<317::AID-AJIM11>3.3.CO;2-I; *ANSI, 1995, ANSI Z 16 2 COD MAN; Bell JL, 2003, AM J IND MED, V44, P502, DOI 10.1002/ajim.10307; *CDCP, 2001, MORBIDITY MORTALITY, V46, P1; COHEN HH, 1991, J SAFETY RES, V22, P21, DOI 10.1016/0022-4375(91)90010-S; COHEN HH, 1991, J SAFETY RES, V22, P31, DOI 10.1016/0022-4375(91)90011-J; COHEN M, 1999, 571 SHARP DEP LAB IN; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Johantgen M, 2004, J SAFETY RES, V35, P309, DOI 10.1016/j.jsr.2004.01.003; Jones Derek, 2003, Work, V20, P179; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; OREILLY JT, 2001, ACCIDENT PREVENTION; Partridge RA, 1998, ACAD EMERG MED, V5, P31, DOI 10.1111/j.1553-2712.1998.tb02571.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1995, PREV INJ DEATHS LOGG; *US OFF MAN BUDG, 2002, N AM IND CLASS SYST; *US OFF MAN BUDG, 2000, STAND OCC CLASS MAN; *US OFF MAN BUDG, 1980, SOURC SOC DAT GEN AP; *WASH DEP LAB IND, 2000, STAT WASH WORK COMP	20	27	28	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4375			J SAFETY RES	J. Saf. Res.		2006	37	1					75	81		10.1016/j.jsr.2005.08.008			7	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	027QT	WOS:000236431000008	16519901				2022-02-06	
J	Campbell, M; Parry, A				Campbell, M; Parry, A			Balance disorder and traumatic brain injury: Preliminary findings of a multi-factorial observational study	BRAIN INJURY			English	Article						TBI; brain injury; balance disorder; postural control; clinical assessment	REHABILITATION; AWARENESS; OUTCOMES	The pathophysiology of TBI suggests that balance disorder in this population may be associated with multi-system dysfunction, but this has not been widely explored in the literature. This study was undertaken to begin to describe the nature of balance disorder across the TBI population. A clinically-based observational design was employed and data gathered by a standardized process of structured observation. Twenty-seven subjects were recruited across a range of injury severities. The sample was skewed towards mild/moderate injury with a mean summated GCS score of 9.6. Deficits were observed across a wide range of domains at both individual and group level and the overall level of balance dysfunction was high. Summary results are reported here and a more detailed analysis of individual cases is underway. Additional cross-disciplinary research is required to further develop understanding of the nature of balance disorder in this population and to develop appropriate methods of clinical assessment.	Sheffield W Primary Care Trust, Sheffield S10 3TG, S Yorkshire, England; Sheffield Hallam Univ, Sheffield S1 1WB, S Yorkshire, England		Campbell, M (corresponding author), Sheffield W Primary Care Trust, Fulwood House,Old Fulwood Rd, Sheffield S10 3TG, S Yorkshire, England.	Maggie.campbell@sheffieldw-pct.nhs.uk					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BELL F, 1998, PRINCIPLES MECH BIOM, P26; Beynon GJ, 1998, CLIN OTOLARYNGOL, V23, P117; BRONSTEIN AM, 1995, J NEUROL NEUROSUR PS, V59, P472, DOI 10.1136/jnnp.59.5.472; Campbell M., 2000, REHABILITATION TRAUM, P17; CARR J, 1998, NEUROLOGICAL REHABIL, P47; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; Di Fabio RP, 1998, ACTA OTO-LARYNGOL, V118, P449, DOI 10.1080/00016489850154540; DIFABIO RP, 1990, PHYS THER, V70, P542, DOI 10.1093/ptj/70.9.542; FLEMING JM, 1996, INT PERSPECTIVES TRA, P438; FUKUDA T, 1959, Acta Otolaryngol, V50, P95, DOI 10.3109/00016485909129172; GENTLEMAN D, 1986, BRIT MED J, V292, P449, DOI 10.1136/bmj.292.6518.449; GillBody KM, 1997, PHYS THER, V77, P534, DOI 10.1093/ptj/77.5.534; HALMAGYI GM, 1988, ARCH NEUROL-CHICAGO, V45, P737, DOI 10.1001/archneur.1988.00520310043015; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Hillier SL, 1997, BRAIN INJURY, V11, P661; HONRUBIA V, 1994, VESTIBULAR REHABILIT, P113; HORAK FB, 1990, EXP BRAIN RES, V82, P167; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; JENNETT B, 1975, LANCET, V1, P480; KARLBERG M, 1995, NECK HUMAN BALANCE C; MANN NR, 1996, MED REHABILITATION T, P479; Nashner L., 1993, HDB BALANCE FUNCTION, P308; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; Newman AC, 2000, BRAIN INJURY, V14, P333; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; NOLTE J, 1999, HUMAN BRAIN, P325; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Roberts TDM, 1995, UNDERSTANDING BALANC; Schumway-Cook A, 2000, VESTIBULAR REHABILIT, P476; Shepard N.T., 1996, PRACTICAL MANAGEMENT, P33; Shepard NT, 1996, PRACTICAL MANAGEMENT; Shumway-Cook A, 2001, MOTOR CONTROL THEORY, V2nd, P163; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; WING AM, 1993, REHABILITATION MOTOR, P87; Winter D.A., 1990, BIOMECHANICS MOTOR C, VVol. 1; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WOOLLACOTT MH, 1990, PHYS THER, V70, P799, DOI 10.1093/ptj/70.12.799; Yardley L, 1994, VERTIGO DIZZINESS	41	27	28	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	13					1095	1104		10.1080/02699050500188898			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	983ZD	WOS:000233270000004	16286323				2022-02-06	
J	Hughes, S; Colantonio, A; Santaguida, PL; Paton, T				Hughes, S; Colantonio, A; Santaguida, PL; Paton, T			Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury	BRAIN INJURY			English	Article						amantadine; brain injury; recovery; coma	SOMATOSENSORY-EVOKED-POTENTIALS; SEVERE HEAD-INJURY; FRONTAL-LOBE DYSFUNCTION; VEGETATIVE STATE; PREDICTION; RECOVERY; SURVIVAL; COMA; MANAGEMENT; PROGNOSIS	Primary objective: To evaluate the association between amantadine and recovery of consciousness from prolonged traumatic coma. Research design: A retrospective cohort study. Methods: Subjects included 123 adults with severe traumatic brain injury (TBI) admitted over a 10-year period who remained in coma despite becoming medically stable. Experimental interventions: Cases received 100-200 mg of amantadine twice daily. Main outcomes and results: 46.4% (13/28) of cases emerged from coma compared to 37.9% (36/95) of controls (p = 0.42). Somatosensory evoked potential (SSEP) was the only significant predictor of emergence from coma (p = 0.02), while SSEP, age and Glasgow Coma Score (GCS) significantly predicted time to emerge from coma (p < 0.05). Conclusions: Although the study and its design do not support the view that amantadine has an effect on recovery of consciousness; it remains safe, inexpensive and has few side effects. The lack of treatment alternatives and anecdotal support for its use may warrant further study. Prospective controlled trials would yield more definitive results.	Sunnybrook & Womens Coll Hlth Sci Ctr, Physiotherapy Serv, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Occupat Therapy, Toronto Rehabil Inst, Toronto, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada		Hughes, S (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Physiotherapy Serv, CG13,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	shari.hughes@sw.ca		Colantonio, Angela/0000-0003-2094-4765			Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; Ansell B. J., 1993, J HEAD TRAUMA REHAB, V8, P88, DOI DOI 10.1097/00001199-199309000-00011; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chandler M C, 1988, Brain Inj, V2, P309; CHEN HSV, 1992, J NEUROSCI, V12, P4427; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/BF01709556; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COWELL LC, 1995, J HEAD TRAUMA REHAB, V10, P91, DOI 10.1097/00001199-199512000-00018; DAVIS CW, 1985, CLIN MANAGEMENT PHYS, V5, P23; DAVIS CW, 1985, CLIN MANAGEMENT PHYS, V5, P16; DAVIS CW, 1985, CLIN MANAGEMENT PHYS, V5, P20; EDBY K, 1983, CHILD NERV SYST, V11, P607; EDWARDS SM, 1987, CLIN MANAGEMENT PHYS, V7, P6; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Gladstone DJ, 2000, CAN J NEUROL SCI, V27, P97; Goldberg G, 1998, J HEAD TRAUMA REHAB, V13, P51, DOI 10.1097/00001199-199802000-00008; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HAGEN C, 1979, REAHBILITATION HEAD; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hall M, 1992, J Neurosci Nurs, V24, P199; HANS P, 1987, BRIT J HOSP MED, V37, P535; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Metman LV, 1998, NEUROLOGY, V50, P1323, DOI 10.1212/WNL.50.5.1323; Meythaler JM, 2003, J HEAD TRAUMA REHAB, V18, P5, DOI 10.1097/00001199-200301000-00004; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Patrick PD, 2000, BEHAV INTERVENT, V15, P225, DOI 10.1002/1099-078X(200007/09)15:3<225::AID-BIN58>3.0.CO;2-8; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Raffaele R, 2002, ARCH GERONTOL GERIAT, P309; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P384; Rudnik A, 1992, Acta Neurochir Suppl (Wien), V55, P33; Schneider WN, 1999, BRAIN INJURY, V13, P863; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Shiller AD, 1999, BRAIN INJURY, V13, P715; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Yamamoto T, 1999, ACT NEUR S, V75, P17; Zafonte RD, 1998, BRAIN INJURY, V12, P617	69	27	29	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	14					1197	1206		10.1080/02699050500309296			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	983ZF	WOS:000233270200003	16286335				2022-02-06	
J	Carne, W; Cifu, DX; Marcinko, P; Baron, M; Pickett, T; Qutubuddin, A; Calabrese, V; Roberge, P; Holloway, K; Mutchler, B				Carne, William; Cifu, David X.; Marcinko, Paul; Baron, Mark; Pickett, Treven; Qutubuddin, Abu; Calabrese, Vincent; Roberge, Peggy; Holloway, Kathryn; Mutchler, Brian			Efficacy of multidisciplinary treatment program on long-term outcomes of individuals with Parkinson's disease	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						disease progression; intervention; levodopa; Movement disorder; multidisciplinary team; neurology; outcomes; Parkinson's disease; rehabilitation; Unified Parkinson's Disease Rating Scale	TRAUMATIC BRAIN-INJURY; CONTROLLED-TRIAL; RANDOMIZED-TRIAL; RATING-SCALE; REHABILITATION; PROGRESSION; LEVODOPA; MANAGEMENT; DISABILITY; PEOPLE	We examined the impact of multidisciplinary clinical management of the Parkinson's Disease Research, Education, and Clinical Center program on Parkinson's disease progression. Initial and follow-up scores on the Part III Motor Examination subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) were examined. Overall, 37 (75.5%) of the 49 patients demonstrated stable or improved UPDRS motor scores at 1- to 3-year follow-up; in the 1-year group (n = 28), 22 patients (78.6%) improved, while 6 (21.4%) worsened. In the 2-year group (n = 15). 10 (66.7%) improved, while 5 (33.3%) worsened. In the 3-year group (n = 6), 5 (83.3%) improved, while 1 (16.7%) worsened. Multidisciplinary interventions included neurology (95.9% of patients), physiatry (93.9%). nursing (87.8%), psychology (42.9%), medication changes (59.2% increases, 18.4% decreases), rehabilitation therapies (physical, occupational, speech-language, 67.3%), functional diagnostic testing (18.4%), support group (16.3%), home exercise instruction (85.7%), and disease and wellness education (81.6%). Improved and worsened patients did not significantly differ on the individual program components. Clinical implications and study limitations are discussed.	PADRECC, Dept Rehabil Med, Hunter Holmes McGuire VAMC, Richmond, VA 23249 USA; VAMC, Hunter Holmes McGuire Dept, SE Parkinsons Dis Res Educ & Clin Ctr, Richmond, VA USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23284 USA		Carne, W (corresponding author), PADRECC, Dept Rehabil Med, Hunter Holmes McGuire VAMC, 1201 Broad Rock Blvd,Room 2C-144, Richmond, VA 23249 USA.	william.carne@med.va.gov		Cifu, David/0000-0003-1600-9387; Holloway, Kathryn/0000-0003-3777-0060			Adler CH, 1997, NEUROLOGY, V49, P393, DOI 10.1212/WNL.49.2.393; Ahlskog JE, 2003, NEUROLOGY, V60, P381, DOI 10.1212/01.WNL.0000044047.58984.2F; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; Cameron IT, 2005, COMPUT-AIDED CHEM EN, V20a-20b, P3; Chan PLS, 2001, ANNU REV PHARMACOL, V41, P625, DOI 10.1146/annurev.pharmtox.41.1.625; Choudhury SR, 2001, J REHABIL RES DEV, V38, P293; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Fahn S, 2004, NEW ENGL J MED, V351, P2498; Fahn S, 1999, ARCH NEUROL-CHICAGO, V56, P529, DOI 10.1001/archneur.56.5.529; FAHN S, 1978, NEUROLOGY, V28, P5, DOI 10.1212/WNL.28.1.5; Fahn S., 1987, RECENT DEV PARKINSON, P153; FAHN S, 1992, SCI BASIS TREATMENT, P89; Growdon JH, 1998, NEUROLOGY, V50, P1327, DOI 10.1212/WNL.50.5.1327; Holloway RG, 2005, ARCH NEUROL-CHICAGO, V62, P430; Holloway RG, 2004, ARCH NEUROL-CHICAGO, V61, P1044; Horn S, 2004, NEUROLOGY, V63, pS7, DOI 10.1212/WNL.63.7_suppl_2.S7; JANKOVIC J, 1990, NEUROLOGY, V40, P1529, DOI 10.1212/WNL.40.10.1529; Jankovic J, 2001, ARCH NEUROL-CHICAGO, V58, P1611, DOI 10.1001/archneur.58.10.1611; Kerr EA, 2004, ANN INTERN MED, V141, P272, DOI 10.7326/0003-4819-141-4-200408170-00007; Kieburtz K, 1996, ANN NEUROL, V40, P99; KORCZYN AD, 1998, STUDY GROUP MOV DISO, V13, P46; MacMahon DG, 1999, NEUROLOGY, V52, pS21; Miszko TA, 2003, J GERONTOL A-BIOL, V58, P171; OLANOW CW, 1994, MOVEMENT DISORD, V9, P40, DOI 10.1002/mds.870090107; Playfer JR, 2002, EUR J NEUROL, V9, P55, DOI 10.1046/j.1468-1331.9.s3.7.x; Poewe WH, 1996, NEUROLOGY, V47, pS146, DOI 10.1212/WNL.47.6_Suppl_3.146S; Reimer J, 2004, J NEUROL NEUROSUR PS, V75, P396, DOI 10.1136/jnnp.2003.022780; RICHARDS M, 1994, MOVEMENT DISORD, V9, P89, DOI 10.1002/mds.870090114; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561; Stocchi F, 2002, BRAIN, V125, P2058, DOI 10.1093/brain/awf214; Trend P, 2002, CLIN REHABIL, V16, P717, DOI 10.1191/0269215502cr545oa; VANHILTEN JJ, 1994, MOVEMENT DISORD, V9, P84, DOI 10.1002/mds.870090113; Wade DT, 2003, J NEUROL NEUROSUR PS, V74, P158, DOI 10.1136/jnnp.74.2.158; 2000, HOSP PHARM, V7, P143	37	27	27	0	17	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	NOV-DEC	2005	42	6					779	786		10.1682/JRRD.2005.03.0054			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	047MQ	WOS:000237883800008	16680615	Bronze			2022-02-06	
J	Kinoshita, T; Moritani, T; Hiwatashi, A; Wang, HZ; Shrier, DA; Numaguchi, Y; Westesson, PLA				Kinoshita, T; Moritani, T; Hiwatashi, A; Wang, HZ; Shrier, DA; Numaguchi, Y; Westesson, PLA			Conspicuity of diffuse axonal injury lesions on. diffusion-weighted MR imaging	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						diffuse axonal injury; magnetic resonance imaging; diffusion	HEAD-INJURY; BRAIN; CHILDREN; TRAUMA	Objective: (1) To detect diffuse axonal injury (DAI) lesions by diffusion-weighted imaging (DWI), as compared with fluid-attenuated inversion recovery (FLAIR) imaging and (2) to evaluate hemorrhagic DAI lesions by b(o) images obtained from DWI, as compared with gradient-echo (GRE) imaging. Methods: We reviewed MR images of 36 patients with a diagnosis of DAI. MR imaging was performed 20 h to 14 days (mean, 3.7 days) after traumatic brain injury. We evaluated: (1) conspicuity of lesions on DWI and FLAIR and (2) conspicuity of hemorrhage in DAI lesions on bo images and GRE imaging. Results: DWI clearly depicted high-signal DAI lesions. The sensitivity of DWI to lesional conspicuity in DAI lesions was almost equal to that of FLAIR. The sensitivity of bo images to identification of hemorrhagic DAI lesions was inferior to that of GRE. Conclusion: DWI is as useful as FLAIR in detecting DAI lesions. GRE imaging is still the superior tool for the evaluation of hemorrhagic DAL (C) 2005 Elsevier Ireland Ltd. All rights reserved.	Univ Rochester, Med Ctr, Dept Radiol, Div Neuroradiol, Rochester, NY 14642 USA		Kinoshita, T (corresponding author), Tottori Univ, Fac Med, Dept Pathophysiol & Therapeut Sci, Div Radiol, Tottori 6838504, Japan.	kino@grape.med.tottori-u.ac.jp					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hiwatashi A, 2003, AM J ROENTGENOL, V181, P1705, DOI 10.2214/ajr.181.6.1811705; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Lin DDM, 2001, AM J NEURORADIOL, V22, P1275; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Maldjian JA, 2001, AM J NEURORADIOL, V22, P112; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; Povlishock JT, 2001, HEAD TRAUMA, P281; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; [No title captured]	19	27	28	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	OCT	2005	56	1					5	11		10.1016/j.ejrad.2005.04.001			7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	974HL	WOS:000232582000002	16168258				2022-02-06	
J	Yeates, KO; Enrile, BG				Yeates, KO; Enrile, BG			Implicit and explicit memory in children with congenital and acquired brain disorder	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		myelomeningocele; traumatic brain injury; implicit memory; explicit memory	ALZHEIMERS-DISEASE; COGNITIVE-DEVELOPMENT; PARKINSONS-DISEASE; DECLARATIVE MEMORY; VISUAL COMPLEXITY; NAME AGREEMENT; HEAD-INJURY; AMNESIA; DISSOCIATION; HYDROCEPHALUS	Implicit and explicit memory were examined in 8- to 15-year-old children with myelomeningocele and shunted hydrocephalus, severe traumatic brain injuries, or orthopedic injuries. Each group included between 22 and 29 children. Children completed a fragmented picture identification task to assess perceptual priming and a semantic decision-making task to assess conceptual priming. Each task also assessed procedural learning as well as explicit recall and recognition. All 3 groups showed significant perceptual and semantic priming of similar magnitude. In contrast, both brain-disordered groups displayed poorer explicit memory than did the comparison group. No group showed significant procedural learning on either task. Age and IQ were stronger predictors of explicit recall than of implicit memory. The findings indicate that implicit memory is relatively intact in many children with congenital and acquired brain disorders, despite deficits in explicit memory, and support the existence of separate memory systems in children.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; Childrens Hosp, Sect Behav & Dev Pediat, Columbus, OH 43205 USA		Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.	yeatesk@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD036680] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03-HD36680] Funding Source: Medline		BERMAN S, 1989, BEHAV RES METH INSTR, V21, P371, DOI 10.3758/BF03202800; Blaxton T A, 1995, J Int Neuropsychol Soc, V1, P112; BLYSMA FW, 1991, NEUROPSYCHOLOGIA, V12, P1213; BONDI MW, 1993, BRAIN COGNITION, V22, P213, DOI 10.1006/brcg.1993.1035; BONDI MW, 1991, J CLIN EXP NEUROPSYC, V13, P339, DOI 10.1080/01688639108401048; BUTTERS N, 1990, B PSYCHONOMIC SOC, V28, P359; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Colvin AN, 2003, J INT NEUROPSYCH SOC, V9, P642, DOI 10.1017/S1355617703940045; Cycowicz YM, 2000, MEMORY, V8, P19, DOI 10.1080/096582100387687; DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666; Dennis M, 1998, MED PEDIATR ONCOL, P25; Dennis M, 2004, BRAIN, V127, P1292, DOI 10.1093/brain/awh154; DIGIULIO DV, 1994, BRAIN COGNITION, V25, P79, DOI 10.1006/brcg.1994.1024; Donders J, 1997, PSYCHOL ASSESSMENT, V9, P15; Doyon J, 2003, NEUROPSYCHOLOGIA, V41, P252, DOI 10.1016/S0028-3932(02)00158-6; Edelstein K, 2004, J INT NEUROPSYCH SOC, V10, P877, DOI 10.1017/S1355617704106085; FLEISCHMAN DA, 1995, NEUROPSYCHOLOGY, V9, P187; Fletcher JM, 1996, ARCH NEUROL-CHICAGO, V53, P549, DOI 10.1001/archneur.1996.00550060093022; FLETCHER JM, IN PRESS INT REV RES; Gabrieli J D, 1995, J Int Neuropsychol Soc, V1, P115; GILBERT JN, 1986, NEUROSURGERY, V18, P559, DOI 10.1227/00006123-198605000-00008; GLISKY EL, 1989, HDB NEUROPSYCHOLOGY, P233; GRAF P, 1990, B PSYCHONOMIC SOC, V28, P353; HEINDEL WC, 1989, J NEUROSCI, V9, P582; KEANE MM, 1991, BEHAV NEUROSCI, V105, P326, DOI 10.1037/0735-7044.105.2.326; KEANE MM, 1995, BRAIN, V118, P1129, DOI 10.1093/brain/118.5.1129; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Levy DA, 2004, PSYCHOL SCI, V15, P680, DOI 10.1111/j.0956-7976.2004.00740.x; LORSBACH TC, 1989, CONTEMP EDUC PSYCHOL, V14, P67, DOI 10.1016/0361-476X(89)90006-4; Mattson SN, 1999, J INT NEUROPSYCH SOC, V5, P462, DOI 10.1017/S1355617799555082; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Mitchell David B., 1993, P171; NAITO M, 1990, J EXP CHILD PSYCHOL, V50, P462, DOI 10.1016/0022-0965(90)90081-I; Naito Mika, 1993, P231; NELSON CA, 1995, DEV PSYCHOL, V31, P723, DOI 10.1037/0012-1649.31.5.723; Parkin Alan J., 1993, P191; PASCUALLEONE A, 1993, ANN NEUROL, V34, P594, DOI 10.1002/ana.410340414; Poldrack RA, 1999, NEUROPSYCHOLOGY, V13, P564, DOI 10.1037/0894-4105.13.4.564; Renner P, 2000, J AUTISM DEV DISORD, V30, P3, DOI 10.1023/A:1005487009889; Rich JB, 1996, J CLIN EXP NEUROPSYC, V18, P148, DOI 10.1080/01688639608408270; ROEDIGER HL, 1989, VARIATIONS MEMORY CO, P00003; RoveeCollier C, 1997, PSYCHOL REV, V104, P467, DOI 10.1037/0033-295X.104.3.467; SAINTCYR JA, 1992, NEUROPSYCHOLOGY MEMO, P188; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schacter DL, 2001, CURR DIR PSYCHOL SCI, V10, P1, DOI 10.1111/1467-8721.00101; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P149, DOI 10.1076/jcen.21.2.149.929; SNODGRASS JG, 1987, BEHAV RES METH INSTR, V19, P270, DOI 10.3758/BF03203798; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; SNODGRASS JG, 1989, IMPLICIT MEMORY, P259; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; VAIDYA CJ, 1995, NEUROPSYCHOLOGY, V9, P580, DOI 10.1037/0894-4105.9.4.580; Vakil E, 1997, J Int Neuropsychol Soc, V3, P327; Verfaellie M, 1996, NEUROPSYCHOLOGY, V10, P517, DOI 10.1037/0894-4105.10.4.517; Vicari S, 2001, Downs Syndr Res Pract, V7, P35; Vicari S, 2001, NEUROPSYCHOLOGIA, V39, P665, DOI 10.1016/S0028-3932(01)00012-4; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; Willingham DB, 1999, PSYCHOL SCI, V10, P531, DOI 10.1111/1467-9280.00201; Wyatt BS, 1998, AM J MENT RETARD, V102, P511; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YEATES KO, 1995, J PEDIATR PSYCHOL, V20, P801, DOI 10.1093/jpepsy/20.6.801; Yonelinas AP, 2002, J MEM LANG, V46, P441, DOI 10.1006/jmla.2002.2864; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	65	27	31	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2005	19	5					618	628		10.1037/0894-4105.19.5.618			11	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology; Neurosciences & Neurology	970HU	WOS:000232296700007	16187880				2022-02-06	
J	Aboy, M; Marquez, OW; McNames, J; Hornero, R; Trong, T; Goldstein, B				Aboy, M; Marquez, OW; McNames, J; Hornero, R; Trong, T; Goldstein, B			Adaptive modeling and spectral estimation of nonstationary biomedical signals based on Kalman filtering	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						intracranial pressure; Kalman filter; linear models; spectral estimation; traumatic brain injury		We describe an algorithm to estimate the instantaneous power spectral density (PSD) of nonstationary signals. The algorithm is based on a dual Kalman filter that adaptively generates an estimate of the autoregressive model parameters at each time instant. The algorithm exhibits superior PSD tracking performance in nonstationary signals than classical nonparametric methodologies, and does not assume local stationarity of the data. Furthermore, it provides better time-frequency resolution, and is robust to model mismatches. We demonstrate its usefulness by a sample application involving PSD estimation of intracranial pressure signals (ICP) from patients with traumatic brain injury (TBI).	Oregon Inst Technol, Dept Elect Engn Technol, Portland, OR 97201 USA; Portland State Univ, Dept Elect & Comp Engn, Biomed Signal Proc Lab, Portland, OR 97201 USA; Univ Vigo, Signal Theory & Commun Dept, ETSI Telecomun, Vigo, Spain; Portland State Univ, Portland, OR 97201 USA; Univ Valladolid, Dept Signal Theory & Commun, ETSI Telecomunicac, Valladolid 47011, Spain; Oregon Hlth & Sci Univ, Dept Biomed Engn, OGI Sch Sci & Engn, Portland, OR 97206 USA; Oregon Hlth & Sci Univ, Dept Pediat, Complex Syst Lab, Portland, OR 97201 USA		Aboy, M (corresponding author), Oregon Inst Technol, Dept Elect Engn Technol, Portland, OR 97201 USA.	mateoaboy@ieee.org	Hornero, Roberto/B-5398-2008; Hornero, Roberto/M-5313-2019; Aboy, Mateo/K-4060-2019	Hornero, Roberto/0000-0001-9915-2570; Hornero, Roberto/0000-0001-9915-2570; Aboy, Mateo/0000-0002-5168-4321			BARTLETT MS, 1948, NATURE, V161, P686, DOI 10.1038/161686a0; BURG J, 1975, THESIS STANFORD U ST; Gelb A., 1974, APPL OPTIMAL ESTIMAT; Grewal M. S., 2001, KALMAN FILTERING THE; Kailath T, 2000, PR H INF SY, pXIX; Kalman R.E., 1960, J BASIC ENG-T ASME, V82, P35, DOI DOI 10.1115/1.3662552; Kay S. M., 1988, MODERN SPECTRAL ESTI; Manolakis D. G., 2000, STAT ADAPTIVE SIGNAL; NELSON AT, 1998, P IEEE INT JOINT C N, V3, P2489; Tukey J.W, 1958, MEASUREMENT POWER SP; Wan EA, 1998, INT CONF ACOUST SPEE, P381, DOI 10.1109/ICASSP.1998.674447; Wan EA, 1997, NEURAL NETWORKS FOR SIGNAL PROCESSING VII, P466, DOI 10.1109/NNSP.1997.622428; WELCH P, 1967, IEEE T AUDIO ELECTOA, V12, P70	13	27	29	0	4	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	AUG	2005	52	8					1485	1489		10.1109/TBME.2005.851465			5	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	946DW	WOS:000230553500014	16119245				2022-02-06	
J	Liao, CC; Lui, TN; Chen, LR; Chuang, CC; Huang, YC				Liao, CC; Lui, TN; Chen, LR; Chuang, CC; Huang, YC			Spinal cord injury without radiological abnormality in preschool-aged children: correlation of magnetic resonance imaging findings with neurological outcomes	JOURNAL OF NEUROSURGERY			English	Article						spinal cord injury; spine; SCIWORA; magnetic resonance imaging; pediatric neurosurgery	RADIOGRAPHIC ABNORMALITY; CERVICAL-SPINE; TRAUMA; SCIWORA	Object. Spinal cord injury without radiological abnormality (SCIWORA) was defined in the era when magnetic resonance (MR) images were not popularly used as diagnostic tools. Although it is generally accepted that MR imaging can effectively illustrate the level and severity of spinal cord injury in the acute phase of trauma, only a few reports of MR imaging studies of SCIWORA have been published. The authors retrospectively reviewed nine preschool-aged patients with SCIWORA to study the correlation between MR imaging findings and the outcomes of neurological deficits, with an elimination of the bias for age. Methods. Clinical manifestations, radiological images, surgical records, and MR imaging studies were reviewed. The pre- and postoperative neurological statuses of the patients were reappraised using American Spinal Injury Association scores and Nurick grades. Nonparametric tests were used to analyze the correlations among the variables of patient characteristics, MR imaging appearances of the injured spinal cord, and neurological outcome. Conclusions. Among the patients with SCIWORA younger than 8 years old, the different patterns of the injured spinal cords could be identified using MR imaging as transection, contusive hemorrhage, traumatic edema, and concussion. The MR imaging patterns of SCIWORA had significant prognostic correlations with the neurological outcomes of these patients; that is, a normal spinal cord appearance was prognostic of a complete recovery of neurological deficits, and intramedullary lesions correlated with permanent deficits with functional disability.	Chang Gung Mem Hosp, Dept Neurosurg, Taoyuan 333, Taiwan; Chang Gung Univ, Dept Neurosurg, Taoyuan, Taiwan; Taoyuan Gen Hosp, Dept Phys Med & Rehabil, Taoyuan, Taiwan		Liao, CC (corresponding author), Chang Gung Mem Hosp, Dept Neurosurg, 5 Fu Shing St, Taoyuan 333, Taiwan.	liao2901@adm.cgmh.org.tw					ARMSTRONG DC, 1999, MAGNETIC RESONANCE I, V3, P1917; BAILEY DK, 1952, RADIOLOGY, V59, P712, DOI 10.1148/59.5.712; BEERS GJ, 1988, J COMPUT ASSIST TOMO, V12, P755, DOI 10.1097/00004728-198809010-00007; Bosch PP, 2002, SPINE, V27, P2788, DOI 10.1097/00007632-200212150-00009; Dare AO, 2002, J NEUROSURG, V97, P33, DOI 10.3171/spi.2002.97.1.0033; DICKMAN CA, 1991, J SPINAL DISORD, V4, P296, DOI 10.1097/00002517-199109000-00006; FLANDERS AE, 1990, RADIOLOGY, V177, P25, DOI 10.1148/radiology.177.1.2399326; GRABB PA, 1994, NEUROSURGERY, V35, P406, DOI 10.1227/00006123-199409000-00007; HADLEY MN, 1988, J NEUROSURG, V68, P18, DOI 10.3171/jns.1988.68.1.0018; HAMILTON MG, 1992, J NEUROSURG, V77, P700, DOI 10.3171/jns.1992.77.5.0700; LAKHANPAL SK, 1999, MAGNETIC RESONANCE I, V3, P1379; LEVENTHAL HR, 1960, J PEDIATR-US, V56, P447, DOI 10.1016/S0022-3476(60)80356-3; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; MATSUMURA A, 1990, SURG NEUROL, V33, P281, DOI 10.1016/0090-3019(90)90049-U; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; MONTEIRO L, 1992, ACTA NEUROL SCAND, V86, P563, DOI 10.1111/j.1600-0404.1992.tb05487.x; NURICK S, 1972, BRAIN, V95, P87; OSENBACH RK, 1992, NEUROSURGERY, V30, P385, DOI 10.1227/00006123-199203000-00012; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; PENNECOT GF, 1984, J PEDIATR ORTHOPED, V4, P346, DOI 10.1097/01241398-198405000-00011; POLLACK IF, 1988, J NEUROSURG, V69, P177, DOI 10.3171/jns.1988.69.2.0177; Proctor MR, 2002, CRIT CARE MED, V30, pS489, DOI 10.1097/00003246-200211001-00014; Selden NR, 1999, NEUROSURGERY, V44, P785, DOI 10.1097/00006123-199904000-00057; WITTENBERG RH, 1990, CLIN ORTHOP RELAT R, P176; ZWIMPFER TJ, 1990, J NEUROSURG, V72, P894, DOI 10.3171/jns.1990.72.6.0894	26	27	30	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2005	103	1		S			17	23		10.3171/ped.2005.103.1.0017			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	955GY	WOS:000231215100005	16122000				2022-02-06	
J	Hu, H; Chen, G; Zhang, JM; Zhang, WP; Zhang, L; Ge, QF; Yao, HT; Ding, W; Chen, Z; Wei, EQ				Hu, H; Chen, G; Zhang, JM; Zhang, WP; Zhang, L; Ge, QF; Yao, HT; Ding, W; Chen, Z; Wei, EQ			Distribution of cysteinyl leukotriene receptor 2 in human traumatic brain injury and brain tumors	ACTA PHARMACOLOGICA SINICA			English	Article						cysteinyl leukotriene receptor 2; brain injuries; brain neoplasms; vascular smooth muscle cell	FOCAL CEREBRAL-ISCHEMIA; CYSLT(2) RECEPTOR; ENDOTHELIAL-CELLS; INFLAMMATION; EXPRESSION; FIBROSIS; INCREASE; RHINITIS; PATHWAY; CLONING	Aim: To determine the distribution of cysteinyl leukotriene receptor 2 (CysLT(2)), one of the cysteinyl leukotriene receptors, in human brains with traumatic injury and tumors. Methods: Brain specimens were obtained from patients who underwent brain surgery. CysLT(2) in brain tissues was examined using immunohistochemical analysis. Results: CysLT(2) was expressed in the smooth muscle cells (not in the endothelial cells) of arteries and veins. CysLT(2) was also expressed in the granulocytes in both vessels and in the brain parenchyma. In addition, CysLT(2) was detected in neuron- and glial-appearing cells in either the late stages of traumatic injury or in the area surrounding the tumors. Microvessels regenerated 8 d after trauma and CysLT(2) expression was recorded in their endothelial cells. Conclusion: CysLT(2) is distributed in vascular smooth muscle cells and granulocytes, and brain trauma and tumor can induce its expression in vascular endothelial cells and in a number of other cells.	Zhejiang Univ, Sch Med, Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China; Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China; Zhejiang Univ, Sch Med, Dept Pathol, Hosp 1, Hangzhou 310003, Peoples R China		Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Borish L, 2002, ANN ALLERG ASTHMA IM, V88, P16, DOI 10.1016/S1081-1206(10)62024-8; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; Evans JF, 2002, PROSTAG OTH LIPID M, V68-9, P587, DOI 10.1016/S0090-6980(02)00057-6; Fujita M, 1999, EUR J PHARMACOL, V369, P349, DOI 10.1016/S0014-2999(99)00037-0; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; Inamura Takanori, 1992, Neurological Research, V14, P405; Kamohara M, 2001, BIOCHEM BIOPH RES CO, V287, P1088, DOI 10.1006/bbrc.2001.5695; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; Lynch KR, 1999, NATURE, V399, P789; Paruchuri S, 2002, J CELL SCI, V115, P1883; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Shinonaga M, 1990, Adv Neurol, V52, P475; Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF; Storms WW, 2003, ANN ALLERG ASTHMA IM, V91, P131, DOI 10.1016/S1081-1206(10)62167-9; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	23	27	33	2	6	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	JUN	2005	26	6					685	690		10.1111/j.1745-7254.2005.00092.x			6	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Pharmacology & Pharmacy	937IL	WOS:000229917700007	15916734	Bronze			2022-02-06	
J	Armstrong, E				Armstrong, E			Language disorder: A functional linguistic perspective	CLINICAL LINGUISTICS & PHONETICS			English	Article						sociolinguistics; semantics; speech pathology; aphasia	TRAUMATIC BRAIN-INJURY; NARRATIVE DISCOURSE; COHESION ANALYSIS; FLUENT; COHERENCE; DEMENTIA; PATTERNS; CHILDREN; PEOPLE; USAGE	This paper explores the issues involved in the linguistic characterisation of disordered discourse and the ways in which a Systemic Functional Linguistic framework addresses these issues. For many years, language disorders were described in terms of formal grammars, with "breakdown'' discussed in terms of one or more of the traditional levels of language, i.e., phonology, syntax, and semantics. While it was acknowledged that an individual could have difficulty at one or more of these levels, each was viewed quite separately, with semantics viewed largely from a referential perspective. More recent approaches using functional grammar have broadened this view of language and have provided a model of language that re-conceptualises the notion of meaning and embraces context as integral to its organisation. Such a model has introduced a different perspective on language into clinical fields, and has enabled researchers and clinicians to explore the skills of speakers with language disorders across a variety of situations and contextual variables, examining the linguistic resources still available to them. This paper introduces principles involved in a functional framework and provides an overview of how these principles have been applied to language disorders to date. In addition, the notion of "disorder'' itself is discussed as it is situated in this alternative model.	Macquarie Univ, Dept Linguist, Sydney, NSW 2109, Australia		Armstrong, E (corresponding author), Macquarie Univ, Dept Linguist, N Ryde, NSW 2010, Australia.	barmstrong@ling.mq.edu.au		Armstrong, Elizabeth/0000-0003-4469-1117			Armstrong E, 2001, APHASIOLOGY, V15, P1029, DOI 10.1080/02687040143000375; ARMSTRONG E, 1995, TREATMENT APHASIA TH, P70; Armstrong E. M, 1993, APHASIA TREATMENT WO, P263; ARMSTRONG EM, 1991, CLIN LINGUIST PHONET, V5, P39, DOI 10.3109/02699209108985501; ARMSTRONG EM, 1997, THESIS MACQUARIE U S; ARMSTRONG EM, 1987, CLIN APHASIOLOGY, P210; Bird H, 1996, J NEUROLINGUIST, V9, P187, DOI 10.1016/0911-6044(96)00006-1; Bower AR, 1997, J NARRAT LIFE HIST, V7, P265, DOI 10.1075/jnlh.7.1-4.33the; Butt D., 1995, USING FUNCTIONAL GRA; CHENERY HJ, 1994, APHASIOLOGY, V8, P159, DOI 10.1080/02687039408248648; CHRISTIANSEN JA, 1995, BRAIN LANG, V51, P291, DOI 10.1006/brln.1995.1062; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Cutler, 1982, SLIPS TONGUE LANGUAG; DUCHAN J, 2001, ADV SPEECH LANGUAGE, V3, P37, DOI DOI 10.3109/14417040109003707; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; FERGUSON A, 1992, J NEUROLINGUIST, V7, P277, DOI 10.1016/0911-6044(92)90019-S; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Halliday M., 2004, INTRO FUNCTIONAL GRA; Halliday M.A.K., 1985, **DROPPED REF**, P3; Halliday M. K., 1976, COHESION ENGLISH; Hartley L. L, 1995, COGNITIVE COMMUNICAT; Hasan R., 1987, NEW DEV SYSTEMIC LIN, P184; Hasan R., 1985, LANGUAGE CONTEXT TEX, P52; HASAN R, 1996, WAYS F SAYING WAYS F, P51; Hasan R., 1994, PERSPECTIVES PEDAGOG, P179, DOI [10.1017/cbo9781139524605.010, DOI 10.1017/CBO9781139524605.010]; HOLLAND A, 1979, RATIONALE ADULT APHA; Labov W, 1993, DISCOURSE NEUROLOGIC, P115; Lemme M.L., 1984, P CLIN APH C SEABR I, P215; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; LILES BZ, 1995, J SPEECH HEAR RES, V38, P415, DOI 10.1044/jshr.3802.415; Lock S, 1997, CLIN LINGUIST PHONET, V11, P299, DOI 10.3109/02699209708985197; Mackenzie C, 2000, INT J LANG COMM DIS, V35, P269, DOI 10.1080/136828200247188; MANOCHIOPINIG S, 1992, APHASIOLOGY, V6, P519, DOI 10.1080/02687039208249489; Martin J. R, 1997, WORKING FUNCTIONAL G; Martin J. R., 2003, WORKING DISCOURSE ME; Martin J. R., 1992, ENGLISH TEXT SYSTEM; Matthiessen C.M.I.M., 1995, LEXICOGRAMMATICAL CA; Matthiessen C. M. I. M., 1997, SYSTEMIC FUNCTIONAL; McKeough A, 1995, J NARRAT LIFE HIST, V5, P21, DOI 10.1075/jnlh.5.1.02con; MORTENSEN L, 1992, J NEUROLINGUIST, V7, P309, DOI 10.1016/0911-6044(92)90021-N; MORTENSEN L, 2003, THESIS MACQUARIE U S; NICHOLAS M, 1985, J SPEECH HEAR RES, V28, P405, DOI 10.1044/jshr.2803.405; NORRIS JA, 1988, J SPEECH HEAR DISORD, V53, P416, DOI 10.1044/jshd.5304.416; Penn C, 1985, S Afr J Commun Disord, V32, P18; PIEHLER MF, 1984, CLIN APHASIOLOGY, P208; RIPICH DN, 1988, J SPEECH HEAR DISORD, V53, P8, DOI 10.1044/jshd.5301.08; SAFFRAN EM, 1989, BRAIN LANG, V37, P440, DOI 10.1016/0093-934X(89)90030-8; Schneider P., 1997, J SPEECH LANGUAGE PA, V21, P8; STUARTSMITH VG, 2003, AUSTR J LANGUAGE LIT, V26, P69; Tannen D., 1994, GENDER DISCOURSE; Thoma GJ, 2003, INT J PHYTOREMEDIAT, V5, P41, DOI 10.1080/16226510390856466; THOMSON J, 2000, THESIS U NEWCASTLE A; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Togher L., 2000, BRAIN DAM B, P1; Ulatowska Hanna K., 1990, DISCOURSE ABILITY BR, P180, DOI 10.1007/978-1-4612-3262-9_8; Ulatowska HK, 2000, BRAIN LANG, V71, P249, DOI 10.1006/brln.1999.2261; VENTOLA E, 1987, STRUCTURE SOCIAL INT; Wilcox MJ, 1983, TOP LANG DISORD, V3, P35; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205	63	27	27	2	17	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9206	1464-5076		CLIN LINGUIST PHONET	Clin. Linguist. Phon.	APR-MAY	2005	19	3					137	153		10.1080/02699200410001698599			17	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	913VC	WOS:000228182300002	15823952				2022-02-06	
J	Agrawal, D; Gowda, NK; Bal, CS; Pant, M; Mahapatra, AK				Agrawal, D; Gowda, NK; Bal, CS; Pant, M; Mahapatra, AK			Is medial temporal injury responsible for pediatric postconcussion syndrome? A prospective controlled study with single-photon emission computerized tomography	JOURNAL OF NEUROSURGERY			English	Article						persistent postconcussion syndrome; minor head injury; mild traumatic brain injury; medial temporal ischemia; medial temporal hypoperfusion	TRAUMATIC BRAIN-INJURY; ENDURING MEMORY IMPAIRMENT; MILD HEAD-INJURY; HIPPOCAMPUS; CONCUSSION; SPECT; LONG; CT	Object. The authors sought to correlate the finding of medial temporal hypoperfusion (MTH) demonstrated on single photon emission computerized tomography (SPECT) with pediatric persistent postconcussion syndrome (PPCS) and to ascertain its usefulness in routine clinical practice. Methods. Thirty consecutive children with minor head injury and features of PPCS underwent SPECT scanning within 72 hours of injury. Those children having MTH on SPECT were included in the test group (14 patients), and the remaining 16 children comprised the control group. At the end of a 3-month period SPECT scanning was repeated and the incidence of PPCS was assessed clinically in both groups. Repeated SPECT scanning at 3 months revealed persisting MTH in 13 children (93%) in the test group; no child developed MTH in the control group. Twelve children were found to have PPCS in the MTH group compared with only two in the control group, and this was highly statistically significant (relative risk 6.86 [95% confidence interval 1.84-25.51], p = 0.0003). Conclusions. There exists significant MTH in pediatric patients with PPCS, which would imply that medial temporal lobe damage (involving the hippocampus and related structures) may occur after minor head injury and could be responsible for the symptoms of PPCS observed in this group of patients. Brain SPECT scans may thus help in the early identification of children prone to develop PPCS, and serial SPECT scanning may serve as a platform for testing the efficacy of various neurobehavioral and pharmacological interventions in these patients.	All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, India; All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India; Univ Coll Med Sci, Dept Community Med, Delhi 110095, India		Mahapatra, AK (corresponding author), All India Inst Med Sci, Dept Neurosurg, New Delhi 110029, India.	akmahapatra_22000@yahoo.com		Agrawal, Deepak/0000-0002-5499-0746			AGRAWAL D, 2003, NEUROSCIENCES TODAY, V7, P33; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARVIGO F, 1985, SURG NEUROL, V24, P211, DOI 10.1016/0090-3019(85)90187-9; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JACOBS A, 1994, J NUCL MED, V35, P942; Jenkins LW, 1999, BRAIN RES, V817, P132, DOI 10.1016/S0006-8993(98)01237-2; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Masdeu J C, 1994, J Neuroimaging, V4, P177; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; RempelClower NL, 1996, J NEUROSCI, V16, P5233; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; TIKOFSKY RS, 1994, J NUCL MED, V35, P947; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; World Health Organization, 2004, ICD 10 INT STAT CLAS; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	26	27	27	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2005	102	2		S			167	171		10.3171/jns.2005.102.2.0167			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	912GR	WOS:000228066100006	16156226				2022-02-06	
J	Adachi, K; Yimin, Y; Satake, K; Matsuyama, Y; Ishiguro, N; Sawada, M; Hirata, Y; Kiuchi, K				Adachi, K; Yimin, Y; Satake, K; Matsuyama, Y; Ishiguro, N; Sawada, M; Hirata, Y; Kiuchi, K			Localization of cyclooxygenase-2 induced following traumatic spinal cord injury	NEUROSCIENCE RESEARCH			English	Article						cyclooxygenase-2; endothelial cells; pia matters; blood vessels; rat; spinal cord injury; weight-drop technique	NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; MESSENGER-RNA; INDUCIBLE CYCLOOXYGENASE; GENE-EXPRESSION; BRAIN; CELLS; INFLAMMATION; INDUCTION; NEURONS	Objective: Up-regulation of cyclooxygenase-2 (COX-2), a key enzyme in the synthesis of prostaglandins (PGs), is postulated to be involved in pathological processes of acute spinal cord injury (SCI). In the present study, we sought to clarify temporal and spatial expression patterns of the COX-2 gene induced in the spinal cord after traumatic insults using a weight-drop technique. Results: Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed that COX-2 transcription in the spinal cord began to increase within 30 min, peaked at 3 h after injury. Western blotting analysis indicated that the deglycosylated COX-2 protein significantly increased 6 h after injury. Double-immunofluorescent staining analysis showed that COX-2 immunoreactivity was present only in endothelial cells of blood vessels, but not in neurons, astrocytes, monocytes, macrophages, or microglia 6 h after injury. Conclusions: The results suggested that COX-2 gene induction seems not to require any new protein synthesis and that its expression in endothelial cells may be a component of an inflammatory process after traumatic SCI. (C) 2004 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.	Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan; Fujita Hlth Univ, Inst Comprehens Med Sci, Joint Res Div Therapies Against Inctractable Dis, Toyoake, Aichi 4701192, Japan; Nagoya Univ, Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4668550, Japan		Kiuchi, K (corresponding author), Gifu Univ, Fac Engn, Dept Biomol Sci, 1-1 Yanagido, Gifu 5011193, Japan.	kiuchi@biomol.gifu-u.ac.jp	Hirata, Yoko/L-3142-2019; Hirata, Yoko/AAG-6798-2020	Hirata, Yoko/0000-0002-7081-4937; 			Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Breder CD, 1996, BRAIN RES, V713, P64, DOI 10.1016/0006-8993(95)01474-8; Chao CC, 1997, NEUROREPORT, V8, P3163, DOI 10.1097/00001756-199709290-00031; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FAN ZH, 1995, AM J CHINESE MED, V23, P279, DOI 10.1142/S0192415X9500033X; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; Guhring H, 2000, J NEUROSCI, V20, P6714, DOI 10.1523/JNEUROSCI.20-17-06714.2000; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; Ichitani Y, 1997, NEUROREPORT, V8, P2949, DOI 10.1097/00001756-199709080-00028; Inoue A, 1999, J NEUROCHEM, V73, P2206; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; Jobin C, 1998, IMMUNOLOGY, V95, P537; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; Madrigal JLM, 2001, J NEUROCHEM, V76, P532, DOI 10.1046/j.1471-4159.2001.00108.x; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nishiya T, 2000, BIOCHEM BIOPH RES CO, V275, P268, DOI 10.1006/bbrc.2000.3293; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Satake K, 2000, NEUROREPORT, V11, P3877, DOI 10.1097/00001756-200011270-00054; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Serou MJ, 1999, J NEUROSCI RES, V58, P593, DOI 10.1002/(SICI)1097-4547(19991115)58:4<593::AID-JNR12>3.3.CO;2-W; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Tanaka M, 2000, BBA-GENE STRUCT EXPR, V1494, P63, DOI 10.1016/S0167-4781(00)00218-9; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tonai T, 1999, J NEUROCHEM, V72, P302, DOI 10.1046/j.1471-4159.1999.0720302.x; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	37	27	29	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102	1872-8111		NEUROSCI RES	Neurosci. Res.	JAN	2005	51	1					73	80		10.1016/j.neures.2004.10.007			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	889HK	WOS:000226433900010	15596243				2022-02-06	
J	Reistetter, TA; Spencer, JC; Trujillo, L; Abreu, BC				Reistetter, TA; Spencer, JC; Trujillo, L; Abreu, BC			Examining the Community Integration Measure (CIM): A replication study with life satisfaction	NEUROREHABILITATION			English	Article						community integration; life satisfaction; measurement; brain injury	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; QUESTIONNAIRE CIQ; REHABILITATION; OUTCOMES; DISABILITY; HANDICAP; RECOVERY	Objective: To examine instrument reliability, validity, factor structure, and conceptual underpinnings of the Community Integration Measure (CIM) with the Community Integration Questionnaire Revised (CIQ-R) and the Satisfaction with Life Scale (SWLS). Design: A replication study. Setting: Community living. Participants: Ninety-one participants: 51 individuals with a brain injury, and 40 without brain injury. Main Outcomes: Internal consistency, criterion validity, construct validity, discriminant validity factor structure. Results: CIM items produced standardized alphas ranging from 0.72 to 0.83. Significant positive correlations were found among the CIM and both the CIQ-R and SWLS, with the CIM performing better with the SWLS than did the CIQ-R. The CIM discriminated between subject samples as well as by living arrangement. The factor loading solution revealed a three-factor model that explained 63.72 percent of the variance. Conclusion: The CIM shows good promise for capturing an individual's perception of community integration. The factor structure supports the original Model of Community Integration. Further research is needed to examine the influence of objective items on the CIM and Model of Community Integration.	Brain Injury & Stroke Program, Inst Rehabil & Res, Houston, TX 77030 USA; Texas Womans Univ, Sch Occupat Therapy, Houston, TX USA; Univ Texas, Med Branch, Sch Occupat Therapy, Div Rehabil Sci, Galveston, TX 77550 USA; Transit Learning Ctr, Galveston, TX USA; E Carolina Univ, Sch Allied Hlth Sci, Dept Occupat Therapy, Greenville, NC USA		Reistetter, TA (corresponding author), Brain Injury & Stroke Program, Inst Rehabil & Res, 1333 Moursand, Houston, TX 77030 USA.	reistt@tirr.tmc.edu					Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; DeVellis R.F., 1991, SCALE DEV; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Karlovits T, 1999, BRAIN INJURY, V13, P845; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; McColl MA, 1999, BRAIN INJURY, V13, P311, DOI 10.1080/026990599121511; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Millis S R, 1994, Int J Neurosci, V79, P165; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ocampo S, 1997, OCCUP THER INT, V4, P161; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Rintala DH, 2002, REHABIL PSYCHOL, V47, P144, DOI 10.1037//0090-5550.47.2.144; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 2007, INT CLASS FUNCT DIS; ZHANG ZT, 2002, ABSTR APPL ANAL, V7, P509	48	27	27	0	10	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2005	20	2					139	148					10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	966EG	WOS:000232001800010	15920306				2022-02-06	
J	Foster, M; Tilse, C; Fleming, J				Foster, M; Tilse, C; Fleming, J			Referral to rehabilitation following traumatic brain injury: practitioners and the process of decision-making	SOCIAL SCIENCE & MEDICINE			English	Article						traumatic brain injury; rehabilitation; professional decision-making; Australia	SEVERE HEAD-INJURY; HEALTH-CARE; PRACTICAL ISSUES; DISCHARGE; CHILDREN; TRANSITION; HOSPITALS; PROVISION; SERVICES; OUTCOMES	The study aimed to examine the factors influencing referral to rehabilitation following traumatic brain injury (TBI) by using social problems theory as a conceptual model to focus on practitioners and the process of decision-making in two Australian hospitals. The research design involved semi-structured interviews with 18 practitioners and observations of 10 team meetings, and was part of a larger study on factors influencing referral to rehabilitation in the same settings. Analysis revealed that referral decisions were influenced primarily by practitioners' selection and their interpretation of clinical and non-clinical patient factors. Further, practitioners generally considered patient factors concurrently during an ongoing process of decision-making, with the combinations and interactions of these factors forming the basis for interpretations of problems and referral justifications. Key patient factors considered in referral decisions included functional and tracheostomy status, time since injury, age, family, place of residence and Indigenous status. However, rate and extent of progress, recovery potential, safety and burden of care, potential for independence and capacity to cope were five interpretative themes, which emerged as the justifications for referral decisions. The subsequent negotiation of referral based on patient factors was in turn shaped by the involvement of practitioners. While multi-disciplinary processes of decision-making were the norm, allied health professionals occupied a central role in referral to rehabilitation, and involvement of medical, nursing and allied health practitioners varied. Finally, the organizational pressures and resource constraints, combined with practitioners' assimilation of the broader efficiency agenda were central factors shaping referral. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia; Griffith Univ, Res Ctr Clin Pract Innovat, Bundall, Qld 9726, Australia; Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4072, Australia		Tilse, C (corresponding author), Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia.	tilsec@social.uq.edu.au	Fleming, Jennifer M/B-4436-2011; Tilse, Cheryl/A-1266-2008; Tilse, Cheryl/AAH-2155-2019	Tilse, Cheryl/0000-0001-5596-9132; 			Abbott A., 1988, SYSTEM PROFESSIONS E; *AIWH, 1998, HLTH RUR REM AUSTR A; Banja J, 1999, BRAIN INJURY, V13, P745, DOI 10.1080/026990599121142; Baumann E. A., 1989, IMAGES ISSUES TYPIFY, P55; BEST J, 1987, SOC PROBL, V34, P101, DOI 10.1525/sp.1987.34.2.03a00010; Best J., 1993, CONSTRUCTIONIST CONT; BEST J, 1995, IMAGES ISSUES TYPIFY, P3; Blades DA, 1997, J REHABIL, V63, P35; Caplan A, 1997, J HEAD TRAUMA REHAB, V12, P29, DOI 10.1097/00001199-199702000-00006; Cavestri R, 1997, ITAL J NEUROL SCI, V18, P9, DOI 10.1007/BF02106224; CHABOYER W, 2003, INTENSIVE CRITICAL C; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; CLARK DO, 1994, J APPL GERONTOL, V13, P267, DOI 10.1177/073346489401300304; CLARK JA, 1991, SOC SCI MED, V32, P853, DOI 10.1016/0277-9536(91)90241-4; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Dillingham TR, 1998, ARCH PHYS MED REHAB, V79, P279, DOI 10.1016/S0003-9993(98)90007-7; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DOMBOVY M, 1996, BRAIN INJURY, V11, P305; Draper M., 1999, HLTH POLICY MARKET S, P131; DUCHENE PA, 1995, J HEAD TRAUMA REHAB, V12, P91; Eker C, 2000, BRAIN INJURY, V14, P605; Fabiano RJ, 1998, J REHABIL, V64, P9; FINCH J, 1999, INTERIM REPORT STATE; Foster M, 2000, BRAIN INJURY, V14, P1035; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; FOSTER M, 2001, THESIS U QUEENSLAND; Foster RL, 1997, ADV NURS SCI, V20, P1; Foster-Barber A, 2002, MENT RETARD DEV D R, V8, P20, DOI 10.1002/mrdd.10009; Freidson Eliot, 1986, PROFESSIONAL POWERS; Fyffe C, 1996, Aust J Rural Health, V4, P232, DOI 10.1111/j.1440-1584.1996.tb00216.x; GRIFFIN SD, 1993, ARCH PHYS MED REHAB, V74, P1087, DOI 10.1016/0003-9993(93)90066-J; GRIFFITHS L, 1994, QUALITATIVE HLTH RES, V4, P385; HAIG AJ, 1995, ARCH PHYS MED REHAB, V76, P341, DOI 10.1016/S0003-9993(95)80659-8; Hancock L., 1999, HLTH POLICY MARKET S, P87; HARRISON S, 1995, BRIT MED BULL, V51, P885, DOI 10.1093/oxfordjournals.bmb.a073003; Hensher M, 1999, BRIT MED J, V319, P845, DOI 10.1136/bmj.319.7213.845; Hill TP, 1996, SOC SCI MED, V43, P783, DOI 10.1016/0277-9536(96)00123-2; Holstein JA, 1993, RECONSIDERING SOCIAL, P151; Hughes D, 1997, SOC SCI MED, V44, P589, DOI 10.1016/S0277-9536(96)00207-9; Humphreys J, 1999, Aust J Rural Health, V7, P60, DOI 10.1046/j.1440-1584.1999.00217.x; HUNTER DJ, 1995, BRIT MED BULL, V51, P876, DOI 10.1093/oxfordjournals.bmb.a073002; IRVINE DH, 1995, BRIT MED BULL, V51, P842, DOI 10.1093/oxfordjournals.bmb.a072999; Jan S, 1996, AUST NZ J PUBL HEAL, V20, P9, DOI 10.1111/j.1467-842X.1996.tb01326.x; Jones H P, 1995, J Rural Health, V11, P122, DOI 10.1111/j.1748-0361.1995.tb00405.x; Keigher SM, 1997, HEALTH SOC WORK, V22, P149, DOI 10.1093/hsw/22.2.149; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Mason J, 1996, QUALITATIVE RES; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McKinlay W W, 1987, Brain Inj, V1, P3, DOI 10.3109/02699058709034438; MCKINNEY MM, 1993, HEALTH SERV RES, V28, P459; McMillan T. M., 1993, CLIN REHABIL, V7, P346; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Patford J., 1999, AUSTR SOCIAL WORK, V52, P3, DOI 10.1080/03124079908414103; Patton MQ., 2015, QUALITATIVE RES EVAL, V4; Potthoff S, 1997, HEALTH CARE FINANC R, V19, P47; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; SCHWARTZ CG, 1983, PSYCHIATRY, V46, P333, DOI 10.1080/00332747.1983.11024208; Sherman SE, 2000, J GEN INTERN MED, V15, P2; Swerissen H, 1997, HLTH POLICY FINANCIN, P13; Tennier LD, 1997, SOC WORK HEALTH CARE, V26, P41, DOI 10.1300/J010v26n01_03; Teram E, 1999, HUM RELAT, V52, P263, DOI 10.1177/001872679905200204; TOBIS JS, 1982, SCAND J REHABIL MED, V14, P83; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Tuzman L, 1992, Health Soc Work, V17, P299; Unsworth C A, 1997, Pediatr Rehabil, V1, P207; Walker WC, 1996, BRAIN INJURY, V10, P65; WILLIAMS S, 1995, AUSTR OCCUPATIONAL T, V42, P143; WRAY LA, 1992, GENERATION, V16, P31; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	71	27	27	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	NOV	2004	59	9					1867	1878		10.1016/j.socscimed.2004.02.017			12	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Biomedical Social Sciences	852CZ	WOS:000223734100008	15312921				2022-02-06	
J	Lachapelle, J; Ouimet, C; Bach, M; Ptito, A; McKerral, M				Lachapelle, J; Ouimet, C; Bach, M; Ptito, A; McKerral, M			Texture segregation in traumatic brain injury - a VEP study	VISION RESEARCH			English	Article						texture segregation; visual evoked potentials; traumatic brain injury; motion; orientation	VISUAL-EVOKED POTENTIALS; HEAD-INJURY; PERCEPTION; MOTION; MILD; ORIENTATION; CORTEX; VISION	Visual evoked potentials (VEPs) were recorded to textures segregated by gradients in orientation or motion. Recordings were obtained in traumatic brain-injured (TBI) subjects and in normal controls. We analyzed both the low-level VEPs (llVEPs) evoked by homogenous stimuli, as well as the components associated with texture segregation (tsVEP) obtained through an appropriate linear combination. Our results suggest that the tsVEP, presumably higher tip in the visual processing chain than the llVEP, is sensitive to TBI and can reveal further information as to the nature of possible information processing deficits after TBI. It could also help quantify cortical damage that is not revealed with more standard clinical tools. (C) 2004 Elsevier Ltd. All rights reserved.	Site Ctr Readaptat Lucie Bruneau, Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ H2H 2N8, Canada; McGill Univ, Dept Neurol Neurosurg, Montreal, PQ H3A 2T5, Canada; Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; Univ Freiburg, Augenklin, Elektrophysiol Lab, D-7800 Freiburg, Germany		McKerral, M (corresponding author), Site Ctr Readaptat Lucie Bruneau, Ctr Rech Interdisciplinaire Readaptat, 2275 Laurier Ave E, Montreal, PQ H2H 2N8, Canada.	mmckerral@videotron.ca	Bach, Michael/A-6637-2010	Bach, Michael/0000-0003-2028-535X	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [42843] Funding Source: Medline		BACH M, 1990, Investigative Ophthalmology and Visual Science, V31, P104; Bach M, 2000, VISION RES, V40, P3559, DOI 10.1016/S0042-6989(00)00195-4; Bach M, 1997, VISION RES, V37, P1409, DOI 10.1016/S0042-6989(96)00322-7; BACH M, 1992, VISION RES, V32, P417, DOI 10.1016/0042-6989(92)90233-9; BACH M, 2000, EP2000 FREIBURG EVOK; BACH M, 2001, 39 INT SOC CLIN EL V; Bertone A, 2003, J COGNITIVE NEUROSCI, V15, P218, DOI 10.1162/089892903321208150; Cohen A H, 1992, J Am Optom Assoc, V63, P530; FRACO RF, 1989, BRIT J OPTOMETRY, V46, P40; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; Harding GFA, 1996, VISION RES, V36, P3567, DOI 10.1016/0042-6989(96)00125-3; JULESZ B, 1983, BELL SYST TECH J, V62, P1619, DOI 10.1002/j.1538-7305.1983.tb03502.x; Kandil FI, 2003, EUR J NEUROSCI, V18, P2874, DOI 10.1111/j.1460-9568.2003.03022.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LACHAPELLE J, 2002, T ANN ASS RES VISION; LAMME VAF, 1992, VISION RES, V32, P797, DOI 10.1016/0042-6989(92)90022-B; LAMME VAF, 1993, VISUAL NEUROSCI, V10, P781, DOI 10.1017/S0952523800006039; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PADULA WV, 1994, BRAIN INJURY, V8, P125, DOI 10.3109/02699059409150964; PAPATHANASOPOULOS P, 1994, EUR NEUROL, V34, P268, DOI 10.1159/000117054; Regan, 1989, HUMAN BRAIN ELECTROP; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; Uzzell B P, 1990, Adv Neurol, V52, P269; Vaina LM, 1996, P ROY SOC B-BIOL SCI, V263, P1225, DOI 10.1098/rspb.1996.0180; Walsh K. W., 1985, UNDERSTANDING BRAIN; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31	31	27	27	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0042-6989	1878-5646		VISION RES	Vision Res.	NOV	2004	44	24					2835	2842		10.1016/j.visres.2004.06.007			8	Neurosciences; Ophthalmology; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Ophthalmology; Psychology	856LL	WOS:000224046600009	15342227	Bronze			2022-02-06	
J	Gagnon, I; Swaine, B; Friedman, D; Forget, R				Gagnon, I; Swaine, B; Friedman, D; Forget, R			Visuomotor response time in children with mild traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the 79th Annual Meeting American-Congress-of-Rehabilitation-Medicine/9th Annual Meeting of the American-Society-of-Neurorehabilitation	OCT 02-06, 2002	PHILADELPHIA, PA	American Congress Rehabilitat Med, American Soc Neurorehabilitat		mild traumatic brain injury; pediatrics; response time	HEAD-INJURY; ATTENTIONAL DEFICITS; PERCEPTION; PERFORMANCE; CONCUSSION; BALANCE	Objective: Compare the visuomotor response times of children after a mild traumatic brain injury (mTBI) with those of noninjured children matched for age, sex, and premorbid level of physical activity. Design: Prospective cohort study. Setting: Pediatric trauma center. Participants: Thirty-eight children aged 7 to 16 years in each group. Children with mTBI had a mean Glasgow Coma Scale score of 14.8 and were considered normal on a neurological assessment carried out at the time of hospital discharge. Noninjured children were friends of those with mTBI. Intervention: Assessments of response time were conducted at 1, 4, and 12 weeks after mTBI and at corresponding time intervals for the control children. Main Outcome Measures: The response speed subtest of the Bruininks-Oseretsky Test of Motor Proficiency (BOTMP); reaction and movement time for upper and lower extremities, for simple, choice, and reversed choice response time paradigms. Results: Over the assessment period, children with mTBI performed worse than the control group only on the response speed subtest of the BOTMP. The mTBI children however tended to have slower movement times 1 week postinjury for the reversed choice response time paradigm for the lower extremities. Conclusions: Some children with mTBI may have some problems in response time persisting until 12 weeks postinjury Further research is required to better identify and understand the severity of these problems and determine their impact, if any, on participation in physical activities.	Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; McGill Univ, Montreal Childrens Hosp, Hlth Ctr, Dept Phys Therapy, Montreal, PQ H3A 2T5, Canada; Inst Readaptat Montreal, Ctr Rehc Interdisciplinaire & Readaptat Montreal, Montreal, PQ, Canada		Gagnon, I (corresponding author), Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada.	Isabelle.gagnon6@sympaticaca.ca		Gagnon, Isabelle/0000-0003-2043-1644			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bruininks, 1978, BRUININKS OSERETSKY; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; Faubert J, 2002, CAN J EXP PSYCHOL, V56, P164, DOI 10.1037/h0087394; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; HARBIN G, 1989, MED SCI SPORT EXER, V21, P258; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KINOQUEBEC, 2000, ACTIVITE PHYS DETERM; Levin HS, 1996, NEUROTRAUMA, P749; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Moss NE., 1994, CLIN REHABIL, V8, P149; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SALLIS JF, 1988, AM J EPIDEMIOL, V127, P933, DOI 10.1093/oxfordjournals.aje.a114896; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Schenk T, 1997, NEUROPSYCHOLOGIA, V35, P1289, DOI 10.1016/S0028-3932(97)00004-3; SCHMIDT RA, 1988, MOTOR CONTROL LEARIN; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; SWAINE B, 2002, ACTA NEURCHIR, V144, pA34; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEEREN AH, 1984, CLOSED HEAD INJURY P; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	33	27	27	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2004	19	5					391	404		10.1097/00001199-200409000-00004			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Rehabilitation	858UB	WOS:000224216300004	15597030				2022-02-06	
J	Larkins, BM; Worrall, LE; Hickson, LM				Larkins, BM; Worrall, LE; Hickson, LM			Stakeholder opinion of functional communication activities following traumatic brain injury	BRAIN INJURY			English	Article								Primary objective : To establish a process whereby assessment of functional communication reflects the authentic communication of the target population. The major functional communication assessments available from the USA may not be as relevant to those who reside elsewhere, nor assessments developed primarily for persons who have had a stroke as relevant for traumatic brain injury rehabilitation. Research design : The investigation used the Nominal Group Technique to elicit free opinion and support individuals who have compromised communication ability. A survey mailed out sampled a larger number of stakeholders to test out differences among groups. Methods and procedures : Five stakeholder groups generated items and the survey determined relative 'importance'. The stakeholder groups in both studies comprised individuals with traumatic brain injury and their families, health professionals, third-party payers, employers, and Maori, the indigenous population of New Zealand. Main outcomes and results : There was no statistically significant difference found between groups for 19 of the 31 items. Only half of the items explicitly appear on a well-known USA functional communication assessment. Conclusions : The present study has implications for whether functional communication assessments are valid across cultures and the type of impairment.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld, Australia		Larkins, BM (corresponding author), 3 Brackendale Pl, Christchurch 8004, New Zealand.	brigette@chch.planet.org.nz	Worrall, Linda/D-2579-2010; Hickson, Louise MH/F-8748-2010	Worrall, Linda/0000-0002-3283-7038; Hickson, Louise MH/0000-0001-6832-4173			*AM SPEECH LANG HE, 1990, P2 ASHA; BAKER R, 1995, AUST J AGEING, V14, P81, DOI 10.1111/j.1741-6612.1995.tb00702.x; Delbecq A.L., 1975, GROUP TECHNIQUES PRO; DRESSER A, 1983, ARCH NEUROL-CHICAGO, V29, P111; Fraterrigo TL, 1999, J BIOL INORG CHEM, V4, P183, DOI 10.1007/s007750050303; FRATTALI CM, 1992, APHASIOLOGY, V6, P63, DOI 10.1080/02687039208248577; Hickson L, 1996, EDUC GERONTOL, V22, P257, DOI 10.1080/0360127960220304; Hochberg J., 1987, MULTIPLE COMP PROCED; Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; Larkins B., 2000, NEUROGENIC COMMUNICA, P206; LARKINS B, 1995, APH S AUSTR BRISB SE; MURDOCH B, 1996, INT PERSPECTIVES TRA, P280; Penn C, 2000, NEUROGENIC COMMUNICA, P103; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P18; World Health Organization, 2007, INT CLASS FUNCT DIS; WORRALL L, 1995, TREATMENT APHASIA TH; Worrall LS, 1990, AUST J HUM COMMUN DI, V18, P53, DOI [10.3109/asl2.1990.18.issue-2.04, DOI 10.3109/ASL2.1990.18.ISSUE-2.04]; YLVISAKER M S, 1990, Seminars in Speech and Language, V11, P215, DOI 10.1055/s-2008-1064254; [No title captured]	19	27	29	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					691	706		10.1080/02699050310001617389			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700006	15204330				2022-02-06	
J	Fujii, D; Ahmed, I; Hishinuma, E				Fujii, D; Ahmed, I; Hishinuma, E			A neuropsychological comparison of psychotic disorder following traumatic brain injury, traumatic brain injury without psychotic disorder, and schizophrenia	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							DORSOLATERAL PREFRONTAL CORTEX; PHYSIOLOGICAL DYSFUNCTION; ALZHEIMERS-DISEASE; EPILEPSY; SECONDARY	Neuropsychological functioning in individuals with psychotic disorder following traumatic brain injury (PDFTBI), traumatic brain injury without psychosis (TBIWP), and schizophrenia were compared against each other and to the means of normal subjects. It was predicted that the PDFTBI group would be similar to the schizophrenic group in patterns of deficits, but milder in severity. Compared to scores from a normal sample, the PDFTBI group scored significantly lower in intelligence, vocabulary, verbal memory, and executive functioning, while the schizophrenic group scored significantly lower in intelligence, working memory, verbal memory, visual spatial abilities, and executive functioning. No differences were found between normal subjects and the TBIWP group. Implications of our findings for the conceptualization of psychotic disorders are discussed.	Hawaii State Hosp, Dept Neuropsychol, Kaneohe, HI 96744 USA; Univ Hawaii, Dept Psychiat, John A Burns Sch Med, Manoa, HI USA		Fujii, D (corresponding author), Hawaii State Hosp, Dept Neuropsychol, 45-710 Keaahala Rd, Kaneohe, HI 96744 USA.	defujii@hsh.health.state.hi.us					ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Ahmed I, 1998, Semin Clin Neuropsychiatry, V3, P23; *AM PSYCH ASS, 1994, DIAGN STAT MANAUL ME; Andreasen NC, 1998, SCHIZOPHRENIA BULL, V24, P203, DOI 10.1093/oxfordjournals.schbul.a033321; Benton AL, 1994, MULTILINGUAL APHASIA; Bilder RM, 2000, AM J PSYCHIAT, V157, P549, DOI 10.1176/appi.ajp.157.4.549; Cantillon, 1998, Semin Clin Neuropsychiatry, V3, P34; CAUTHEN N, 1977, J CLIN PSYCHOL, V34, P456; CUMMINGS JL, 1988, PSYCHOSOMATICS, V29, P16, DOI 10.1016/S0033-3182(88)72418-4; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; Edelstyn NMJ, 1999, INT J GERIATR PSYCH, V14, P48, DOI 10.1002/(SICI)1099-1166(199901)14:1<48::AID-GPS891>3.3.CO;2-S; FLORHENRY P, 1969, EPILEPSIA, V10, P363, DOI 10.1111/j.1528-1157.1969.tb03853.x; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii Daryl, 2002, Cogn Neuropsychiatry, V7, P41, DOI 10.1080/135468000143000131; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P534, DOI 10.1176/appi.neuropsych.13.4.534; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; Fujii DEM, 1999, NEUROPSY NEUROPSY BE, V12, P110; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; JESTE DV, 1996, AM J PSYCHIAT, V53, P90; KOTRLA KJ, 1995, AM J PSYCHIAT, V152, P1470; KOVELMAN JA, 1984, BIOL PSYCHIAT, V19, P1601; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lisanby, 1998, Semin Clin Neuropsychiatry, V3, P12; McCarley RW, 1999, BIOL PSYCHIAT, V45, P1099, DOI 10.1016/S0006-3223(99)00018-9; Mellers JDC, 2000, PSYCHOL MED, V30, P325, DOI 10.1017/S0033291799001786; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Reitan R, 1985, HALSTEAD REITAN NEUR; Sachdev P, 1998, AM J PSYCHIAT, V155, P325, DOI 10.1176/ajp.155.3.325; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Schatzberg AF, 2000, AM J PSYCHIAT, V157, P1095, DOI 10.1176/appi.ajp.157.7.1095; Selemon LD, 1999, BIOL PSYCHIAT, V45, P17, DOI 10.1016/S0006-3223(98)00281-9; Starkstein SE, 1992, NEUROPSY NEUROPSY BE, V5, P114; SULTZER DL, 1995, J NEUROPSYCH CLIN N, V7, P476; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WEICKERT TW, 2000, COGNITION SCHIZOPHRE, P3; WEINBERGER DR, 1995, LANCET, V346, P552, DOI 10.1016/S0140-6736(95)91386-6; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WEINBERGER DR, 1988, ARCH GEN PSYCHIAT, V45, P609; Wright IC, 2000, AM J PSYCHIAT, V157, P16, DOI 10.1176/ajp.157.1.16; YOUNG AW, 1992, PSYCHOL MED, V22, P799, DOI 10.1017/S003329170003823X	44	27	28	0	7	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2004	16	3					306	314		10.1176/appi.neuropsych.16.3.306			9	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	855PN	WOS:000223986300007	15377737				2022-02-06	
J	Otori, T; Friedland, JC; Sinson, G; McIntosh, TK; Raghupathi, R; Welsh, FA				Otori, T; Friedland, JC; Sinson, G; McIntosh, TK; Raghupathi, R; Welsh, FA			Traumatic brain injury elevates glycogen and induces tolerance to ischemia in rat brain	JOURNAL OF NEUROTRAUMA			English	Article						glucose; glycogen; head injury; ischemic tolerance; secondary injury	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION INJURY; HEAD-INJURY; GLUCOSE-UTILIZATION; NEURONAL INJURY; HIPPOCAMPAL CA1; FOCAL ISCHEMIA; MOUSE-BRAIN; HYPOXIA	Previous studies have demonstrated that traumatic brain injury (TBI) increases the vulnerability of the brain to an acute episode of hypoxia-ischemia. The objective of the present study was to determine whether TBI alters the vulnerability of the brain to a delayed episode of ischemia and, if so, to identify contributing mechanisms. Sprague-Dawley rats were subjected to lateral fluid-percussion (FP) brain injury (n = 14) of moderate severity (2.3-2.5 atm), or sham-injury (n = 12). After recovery for 24 h, all animals underwent an 8-min episode of forebrain ischemia, followed by survival for 6 days. Ischemic damage in the hippocampus and cerebral cortex of the FP-injured hemisphere was compared to that in the contralateral hemisphere and to that in sham-injured animals. Remarkably, the number of surviving CA, neurons in the middle and lateral segments of the hippocampus in the FP-injured hemisphere was signficantly greater than that in the contralateral hemisphere and sham-injured animals (p < 0.05). Likewise, in the cerebral cortex the number of damaged neurons tended to be lower in the FP-injured hemisphere than in the contralateral hemisphere. These results suggest that TBI decreased the vulnerability of the brain to a delayed episode of ischemia. To determine whether TBI triggers protective metabolic alterations, glycogen levels were measured in cerebral cortex and hippocampus in additional animals 24 h after FP-injury (n 13) or sham-injury (n = 7). Cortical glycogen levels in the ipsilateral hemisphere increased to 12.9 +/- 6.4 mmol/kg (mean SD), compared to 6.4 +/- 1.8 mmol/kg in the opposite hemisphere and 5.7 +/- 1.3 mmol/kg in sham-injured animals (p < 0.001). Similarly, in the hippocampus glycogen levels in the FP-injured hemisphere increased to 13.4 +/- 4.9 mmol/kg, compared to 8.1 +/- 2.4 mmol/kg in the contralateral hemisphere (p < 0.004) and 6.2 +/- 1.5 mmol/kg in sham-injured animals (P < 0.001). These results demonstrate that TBI triggers a marked accumulation of glycogen that may protect the brain during ischemia by serving as an endogenous source of metabolic energy.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19104 USA		Welsh, FA (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 371 Stemmler Hall,Box 44,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	fwelsh@mail.med.upenn.edu	Raghupathi, Ramesh/AAX-5538-2021		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER		BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; CARDELL M, 1991, J CEREBR BLOOD F MET, V11, P122, DOI 10.1038/jcbfm.1991.14; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Folbergrova J, 1996, J NEUROL SCI, V137, P7, DOI 10.1016/0022-510X(96)82226-X; FRIEDLAND JC, 2002, J NEUROTRAUM, V19, P1357; GATFIELD PD, 1966, J NEUROCHEM, V13, P185, DOI 10.1111/j.1471-4159.1966.tb07512.x; GLAZIER SS, 1994, J CEREBR BLOOD F MET, V14, P545, DOI 10.1038/jcbfm.1994.68; GUTH L, 1968, EXP NEUROL, V22, P590, DOI 10.1016/0014-4886(68)90151-9; HAYMAKER W, 1970, BIBL PSYCHIAT, P71; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; KLATZO I, 1961, J NEUROPATH EXP NEUR, V20, P459, DOI 10.1097/00005072-196120040-00001; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MURAMATSU H, 2003, J CEREB BLOOD FLOW M, V23, P509; OTORI T, 2001, J NEUROTRAUM, V18, P1131; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; PHELPS CH, 1975, J NEUROCYTOL, V4, P479, DOI 10.1007/BF01261377; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; SANDERS JE, 1996, IEEE T REHABIL ENG, V4, P285; SHIMIZU N, 1958, NATURE, V181, P781, DOI 10.1038/181781a0; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; SWANSON RA, 1990, STROKE, V21, P322, DOI 10.1161/01.STR.21.2.322; TAKAHATA Y, 1986, BRAIN RES, V381, P368, DOI 10.1016/0006-8993(86)90091-0; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; WATANABE H, 1974, BRAIN RES, V66, P147, DOI 10.1016/0006-8993(74)90084-5; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WELSH FA, 1983, J CEREBR BLOOD F MET, V3, P486, DOI 10.1038/jcbfm.1983.75; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P459, DOI 10.1038/jcbfm.1991.88; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; Wiegand F, 1999, J CEREBR BLOOD F MET, V19, P1229, DOI 10.1097/00004647-199911000-00007; WOLFE LS, 1962, J NEUROCHEM, V9, P213, DOI 10.1111/j.1471-4159.1962.tb11862.x; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	53	27	28	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					707	718		10.1089/0897715041269623			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600007	15253799				2022-02-06	
J	Grellner, W; Buhmann, D; Giese, A; Gehrke, G; Koops, E; Puschel, K				Grellner, W; Buhmann, D; Giese, A; Gehrke, G; Koops, E; Puschel, K			Fatal and non-fatal injuries caused by crossbows	FORENSIC SCIENCE INTERNATIONAL			English	Article						crossbow; bow and arrow; morphology; homicide; suicide; accident	ARROW WOUNDS; BOLT; SUICIDE; BRAIN	Today in modem times, traumatic injuries caused by crossbows are a rarity. The largest collection of cases so far is presented in this study, consisting of four fatalities (two homicides and two suicides) and two non-fatal injuries (grievous bodily harm and an accident). All the victims were male having an age between 31 and 54. The weapons, which were used, were mainly high-performance precision crossbows with telescopic sights and hunting bolts. The parts of the body involved were the facial/head area in three of the cases and the thorax in three of them. There were either deep or total penetration injuries to the cranium and thorax with the bolt remaining in the wound in four out of six cases. The persons with non-fatal crossbow injuries exhibited comparatively few symptoms, despite the sometimes extensive involvement of the interior of the cranium (cerebrocranial penetration, in one instance). The two cases of suicide favoured the body areas often found with gun-users. The aetiological classification of crossbow injuries may be difficult after the removal of the bolt. The external morphology is strongly dependent on the type of tip used. Multiple-bladed hunting broadheads produce radiating incised wounds, whereas conical field tips produce circular to slitlike defects. Correspondingly, the external injuries can be reminiscent of the effects of a violent attack by sharp force or of a gunshot wound. The possibility, supported by clinical data, that the victim might have the ability to act or even to survive for a period of time, even with penetration of the brain, should be taken into account when the cause of death is being investigated. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Univ Mainz, Inst Forens Med, DE-55131 Mainz, Germany; Univ Saarland, Inst Forens Med, DE-66421 Homburg, Germany; Univ Hamburg, Dept Neurosurg, DE-20246 Hamburg, Germany; Henriettenstift Hannover, Dept Oral & Maxillofacial Surg, DE-30171 Hannover, Germany; Univ Hamburg, Inst Forens Med, DE-22529 Hamburg, Germany		Grellner, W (corresponding author), Univ Mainz, Inst Forens Med, Pulverturm 3, DE-55131 Mainz, Germany.	grellner@uni-mainz.de					Alessi F J, 1976, J La State Med Soc, V128, P231; Besler K, 1998, INT J LEGAL MED, V111, P88, DOI 10.1007/s004140050121; Byard RW, 1999, AM J FOREN MED PATH, V20, P347, DOI 10.1097/00000433-199912000-00007; Cina SJ, 1998, AM J FOREN MED PATH, V19, P102, DOI 10.1097/00000433-199803000-00020; CLAYDON SM, 1993, MED SCI LAW, V33, P349, DOI 10.1177/002580249303300414; DOWNS JCU, 1994, J FORENSIC SCI, V39, P428; Eriksson A, 2000, J FORENSIC SCI, V45, P911; FRADET G, 1988, ANN THORAC SURG, V45, P680, DOI 10.1016/S0003-4975(10)64779-0; GRESHAM GA, 1977, MED SCI LAW, V17, P239, DOI 10.1177/002580247701700403; HAIN JR, 1989, J FORENSIC SCI, V34, P691; Karger B, 1998, J TRAUMA, V45, P495, DOI 10.1097/00005373-199809000-00011; Karger B, 1998, INT J LEGAL MED, V111, P314, DOI 10.1007/s004140050178; MISLIWETZ J, 1985, BEITR GERICHTL MED, V43, P437; MULLAN FJ, 1991, BRIT J SURG, V78, P972, DOI 10.1002/bjs.1800780825; OPESKIN K, 1994, AM J FOREN MED PATH, V15, P14, DOI 10.1097/00000433-199403000-00004; RANDALL B, 1989, J FORENSIC SCI, V34, P579; ROGERS C, 1990, J FORENSIC SCI, V35, P886; SALAM AA, 1990, ARCH EMERG MED, V7, P224; SALVINO CK, 1991, NEUROSURGERY, V28, P904, DOI 10.1227/00006123-199106000-00023; SAW EC, 1973, ARCH SURG-CHICAGO, V106, P721; SIVALOGANATHAN D, 1979, POLICE J, V52, P42; Taupin JM, 1998, J FORENSIC SCI, V43, P205	22	27	29	0	7	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	MAY 28	2004	142	1					17	23		10.1016/j.forsciint.2003.12.021			7	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	820GN	WOS:000221375600003	15110069				2022-02-06	
J	Bellander, BM; Bendel, O; Von Euler, G; Ohlsson, M; Svensson, M				Bellander, BM; Bendel, O; Von Euler, G; Ohlsson, M; Svensson, M			Activation of microglial cells and complement following traumatic injury in rat entorhinal-hippocampal slice cultures	JOURNAL OF NEUROTRAUMA			English	Article						complement; slice cultures; traumatic brain injury	SULFATED GLYCOPROTEIN-2; BRAIN MACROPHAGES; NERVOUS-SYSTEM; MYELIN; ATTACK; PROTEIN; DEGENERATION; RECRUITMENT; INCREASE; NUCLEUS	The complement cascade has been suggested to be involved in development of secondary brain damage following traumatic brain injury (TBI). Previous studies have shown that reactive microglia are involved in activation of the complement cascade following various injuries to the nervous system. Macrophages seem to have a significant role in this process, but it is still unclear whether these cells, as well as the complement components, are derived from reactive microglia or if these biological events only can occur as a result from the influx of plasma and monocytes via a disrupted blood-brain barrier (BBB). The aim of this study was to investigate the response of microglial cells and the complement system in the absence of plasma/blood components following a standardized crush injury in an entorhinal-hippocampal slice culture. There was a clear increase in complement component C1q and C5b-9-IR (Membrane Attack Complex, MAC) in the area near the crush injury. MAC-IR appeared as numerous dots in clusters which co-localized with anti-NeuN labelled neurons in the injury border zone. Complement C1q-IR co-localized with reactive microglia, co-labelled with OX42 antisera. These findings show activation of the complement cascade near the injury zone and in particular, formation of MAC at the surface of neurons in this area. There was a distinct activation of microglial cells (OX42-IR) near the site of injury, as well as an increase in ED-1 expressing macrophages. In the absence of blood and plasma components it is likely that ED-1-labelled cells represent reactive microglia transformed into macrophages. In addition, Neurons (Neun-IR) near the injury were found to co-localize with clusterin-IR indicating upregulation of a defense system to the endogenous complement attack. The present study provides evidence that microglia and complement is activated in the injury border zone of the tissue slice in a similar fashion as in vivo following TBI, despite the absence of plasma/blood products and cells. These findings support the hypothesis that reactive microglia have a key role in complement activation following TBI by local synthesis of complement with a potential impact on development of secondary neuronal insults.	Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden		Bellander, BM (corresponding author), Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, R3-02 Karolinska Vagen, S-17176 Stockholm, Sweden.	bob@ks.se	Ohlsson, Marcus R/H-1395-2011; Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003			AGOSTONI A, 1992, INT J IMMUNOPATH PH, V5, P123, DOI 10.1177/039463209200500207; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; Blumbergs PC, 1997, HEAD INJURY PATHOPHY, P39; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BRUCK W, 1991, J NEUROL SCI, V103, P182, DOI 10.1016/0022-510X(91)90162-Z; CAMPBELL AK, 1981, BIOCHEM J, V194, P551, DOI 10.1042/bj1940551; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; GIULIAN D, 1993, J NEUROSCI, V13, P29; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1993, HEAD INJURY, P91; HANSCH GM, 1992, IMMUNOPHARMACOLOGY, V24, P107, DOI 10.1016/0162-3109(92)90017-7; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; LACHMANN PJ, 1991, IMMUNOL TODAY, V12, P312, DOI 10.1016/0167-5699(91)90005-E; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MICHEL D, 1992, SYNAPSE, V11, P105, DOI 10.1002/syn.890110203; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; OKUSAWA S, 1987, J IMMUNOL, V139, P2635; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Raivich G, 1998, J NEUROSCI, V18, P5804; ROSEN H, 1990, J LEUKOCYTE BIOL, V48, P465, DOI 10.1002/jlb.48.5.465; SCHILLING MT, 1990, IEEE T POWER SYST, V5, P1, DOI 10.1109/59.49079; Soares HD, 1995, J NEUROSCI, V15, P8223; STOLL G, 1991, ANN NEUROL, V30, P147, DOI 10.1002/ana.410300205; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; SVENSSON M, 1992, J NEUROIMMUNOL, V40, P99, DOI 10.1016/0165-5728(92)90217-9; Takayama A, 1996, PHYS PLASMAS, V3, P3, DOI 10.1063/1.871832; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; TODD NV, 1990, ACT NEUR S, V51, P296; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; VANGURI P, 1988, J BIOL CHEM, V263, P7228; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	51	27	29	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					605	615		10.1089/089771504774129937			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900011	15165368				2022-02-06	
J	Heinemann, AW; Corrigan, JD; Moore, D				Heinemann, AW; Corrigan, JD; Moore, D			Case management for traumatic brain injury survivors with alcohol problems	REHABILITATION PSYCHOLOGY			English	Article							COGNITIVE STATUS EXAMINATION; ADDICTION SEVERITY INDEX; HEALTH SURVEY SF-36; SUBSTANCE-ABUSE; VALIDITY; SCALE	Objective: To evaluate a community-based approach to substance abuse using comprehensive case management for persons with traumatic brain injury (TBI). Setting: Two programs that provide case management services (n = 217); a comparison group was recruited that did not receive case management (n = 102). Intervention: Comprehensive case management. Main Outcome Measures: Self-reported substance use, community integration, employment status, health-related quality of life. Results: For those receiving case management, employment at recruitment and early referral were associated with employment 9 months later. Community integration and physical well-being increased for both groups. Earlier program referral was associated with larger gains in physical well-being, employment, and community integration. Conclusions: Case management appears to have beneficial effects for adults with TBI and substance abuse problems in terms of life and family satisfaction as well as to have potential cost savings.	Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA; Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Feinberg Sch Med, Chicago, IL 60611 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Wright State Univ, Dept Community Hlth, Sch Med, Dayton, OH 45435 USA		Heinemann, AW (corresponding author), Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Heinemann, Allen W/K-6283-2012; Corrigan, John D./E-2921-2011; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326			Ashery R S, 1994, J Case Manag, V3, P179; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; Bode R K, 2001, J Appl Meas, V2, P78; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; CARVER MD, 1992, SOC BEHAV PERSONAL, V20, P71, DOI 10.2224/sbp.1992.20.2.71; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; *CTR OUTC MEAS BRA, 2000, CIQ PROP; Doninger NA, 2000, J HEAD TRAUMA REHAB, V15, P683, DOI 10.1097/00001199-200002000-00007; Drake RE, 1996, AM J ORTHOPSYCHIAT, V66, P42, DOI 10.1037/h0080153; Fisher W., 1992, RASCH MEAS T, V6, P238; FORD J, 1995, MAGAZINE, V3, P19; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; LANGLEY M, 1991, WORK WORTH DOING ADV, P251; LANGLEY M, 1992, NEUROREHABILITATION, V2, P65; LEHMAN AF, 1988, NEW DIRECTIONS MENTA, V40, P67; LINACRE JM, 1999, WINSTEPS PC COMPATIB; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; *NAT HEAD INJ FDN, 1988, NAT HEAD INJ FDN SUB; *NO CAL NEUR GROUP, 1988, MAN NEUR COGN STAT E; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Rasch Georg, 1980, PROBABILISTIC MODELS; Ridgely M S, 1994, J Case Manag, V3, P132; SPARADEO F, 1993, STAFF DEV CLIN INTER, P189; SPARADEO FR, 1992, NEUROREHABILITATION, V2, P65; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weisner C, 2000, J SUBST ABUSE TREAT, V19, P103, DOI 10.1016/S0740-5472(99)00103-8; Willenbring M L, 1994, J Case Manag, V3, P150; Willer B., 1993, BRAIN INJURY REHABIL, P355; Wright B, 1982, RATING SCALE ANAL RA; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	40	27	27	0	7	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2004	49	2					156	166		10.1037/0090-5550.49.2.156			11	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	819BS	WOS:000221288800010					2022-02-06	
J	MacKay, RJ				MacKay, RJ			Brain injury after head trauma: pathophysiology, diagnosis, and treatment	VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE			English	Article							BASILAR SKULL FRACTURES; TEMPOROHYOID OSTEOARTHROPATHY; 3 HORSES; RADIOGRAPHIC DIAGNOSIS; OTITIS-MEDIA; MANAGEMENT; DISEASES; TRIAL; CARE	Brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues. In horses, traumatic brain injury occurs in three main settings: (1) poll impact in horses that flip over backwards; (2) frontal/parietal impact in horses that run into a fixed object, and (3) injury to the vestibular apparatus secondary to temporohyoid osteoarthropathy. Distinct forebrain, vestibular, midbrain, hindbrain, or multifocal syndromes may be encountered in horses with traumatic brain injury. The most important components of treatment are those consistent with principles of "evidence-based medicine". Accordingly, secondary brain injury can most effectively be prevented by establishing normal blood pressure, temperature, blood glucose concentration, and tissue oxygenation. Pain must be controlled and brain swelling may be treated with infusions of hypertonic saline or mannitol. Surgical procedures, including unilateral hyoid bone transaction or elevation of skull fracture fragments, are indicated in selected cases. Optional additional treatments include use of antioxidants, conventional doses of corticosteroids, magnesium sulfate and drainage of CSF. There is no indication for the use of massive doses of methyl prednisolone sodium succinate.	Univ Florida, Dept Large Anim Clin Sci, Gainesville, FL 32610 USA		MacKay, RJ (corresponding author), Univ Florida, Dept Large Anim Clin Sci, POB 100136,2015 SW 16th Ave,Room VH-136, Gainesville, FL 32610 USA.	mackayr@mail.vetmed.ufl.edu					Alexander K, 2002, J AM VET MED ASSOC, V220, P297, DOI 10.2460/javma.2002.220.297; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; BLOGG JR, 1990, EQUINE VET J S, V10, P5; BLYTHE LL, 1984, J AM VET MED ASSOC, V185, P775; Blythe LL, 1997, VET CLIN N AM-EQUINE, V13, P21, DOI 10.1016/S0749-0739(17)30253-5; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Braet V, 2002, EMERG MED J, V19, P510; DARIEN BJ, 1991, J AM VET MED ASSOC, V198, P1799; Donaldson J, 2000, Crit Care Nurs Clin North Am, V12, P465; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Foreman JH, 1998, VET CLIN N AM-EQUINE, V14, P205, DOI 10.1016/S0749-0739(17)30220-1; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Johnson PJ, 1996, J AM VET MED ASSOC, V209, P901; Kohn CW, 1999, AM J VET RES, V60, P299; Komaromy AM, 2003, VET OPHTHALMOL, V6, P27, DOI 10.1046/j.1463-5224.2003.00261.x; Kramer GC, 2003, J TRAUMA, V54, pS89, DOI 10.1097/01.TA.0000065609.82142.F1; Lacombe VA, 2001, J VET INTERN MED, V15, P385, DOI 10.1892/0891-6640(2001)015&lt;0385:DVOEIE&gt;2.3.CO;2; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MARTIN L, 1986, EQUINE VET J, V18, P133, DOI 10.1111/j.2042-3306.1986.tb03569.x; MAYHEW IG, 1990, BRIT VET J, V146, P509, DOI 10.1016/0007-1935(90)90054-7; MCKELVEY WAC, 1979, J AM VET MED ASSOC, V175, P295; MCLLWRAITH CWR, 1998, TURNERS EQUINE SURG, P276; Newton SA, 1999, VET REC, V145, P142, DOI 10.1136/vr.145.5.142; RAGLE CA, 1993, VET CLIN N AM-EQUINE, V9, P171, DOI 10.1016/S0749-0739(17)30422-4; Ramirez O, 1998, VET RADIOL ULTRASOUN, V39, P391, DOI 10.1111/j.1740-8261.1998.tb01624.x; Rhoney DH, 2001, NEUROL RES, V23, P237, DOI 10.1179/016164101101198398; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; SINHA AK, 1991, VET REC, V128, P518, DOI 10.1136/vr.128.22.518; STICK JA, 1980, J AM VET MED ASSOC, V176, P228; SWEENEY CR, 1993, J AM VET MED ASSOC, V202, P1129; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; Tietje S, 1996, EQUINE VET J, V28, P98, DOI 10.1111/j.2042-3306.1996.tb01599.x; TYLER CM, 1993, AUST VET J, V70, P445, DOI 10.1111/j.1751-0813.1993.tb00846.x; Walker AM, 2002, J VET INTERN MED, V16, P697, DOI 10.1892/0891-6640(2002)016<0697:TOIH>2.3.CO;2; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003	38	27	27	2	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0739	1558-4224		VET CLIN N AM-EQUINE	Vet. Clin. N. Am.-Equine Pract.	APR	2004	20	1					199	+		10.1016/j.cveq.2003.11.006			19	Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Veterinary Sciences	808QN	WOS:000220583700011	15062465				2022-02-06	
J	Tsai, WC; Chiu, WT; Chiou, HY; Choy, CS; Hung, CC; Tsai, SH				Tsai, WC; Chiu, WT; Chiou, HY; Choy, CS; Hung, CC; Tsai, SH			Pediatric traumatic brain injuries in Taiwan: an 8-year study	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						pediatric; traumatic brain injury; severity; GOS	SEVERE HEAD-INJURY; RISK-FACTORS; CHILDREN; CHILDHOOD; TRENDS; COMA	Background. This study is intended to determine the causes of pediatric traumatic brain injuries (PTBI) in children aged 14 years or less, and to identify various types of craniocerebral damage resulting from different mechanisms of injury. Methods. From July 1, 1993 to June 30, 2001, a survey on PTBI was conducted in Taiwan. The data of patients used in this study were collected from 56 major hospitals among the age group of 0-14 years. The items in the traumatic brain injury survey included sex, age, causes of injuries, severity, and the eventual outcome. Results. A total of 5349 cases were identified. The male-to-female ratio was 1.69:1. The incidence rate was higher in the age groups of 4-9 years and 10-14 years. The main cause of PTBI was traffic injury, which accounted for 2537 of the cases (47.3%), followed by falls, 2160 (40.3%). Of all traffic injuries, motorcycle-related injury had the highest incidence, followed by the pedestrian and bicycle-related injury. This study also showed that 83.2% of the patients had mild injury, 9.8% had moderate injury, and 7.0%, severe injury. Conclusions. The results of this study suggest that it is important to decrease all the risk factors in the environment of homes and public areas as much as possible. Helmet wearing and the development of public transportation are essential for the prevention of head injury. (C) 2003 Elsevier Ltd. All rights reserved.	Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei Municipal Wan Fang Hosp, Taipei 110, Taiwan; Taipei Med Univ, Inst Publ Hlth, Taipei, Taiwan; Taipei Med Univ Hosp, Dept Emergency, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Neurosurg, Taipei, Taiwan		Chiu, WT (corresponding author), Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei Municipal Wan Fang Hosp, 250 Wu Hsing St, Taipei 110, Taiwan.	wtchiu@tmu.edu.tw		Chiou, Hung Yi/0000-0002-4545-9697			Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; CHIU WT, 1992, B T MED COLL, P105; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; Henry P C, 1992, J Neurosci Nurs, V24, P311; HOYERT DL, 1991, MON VITAL STAT REP, V42; JAMISON DL, 1974, ARCH DIS CHILD, V49, P376, DOI 10.1136/adc.49.5.376; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1980, J NEUROSURG, V53, P803; LESCOHIER I, 1993, PEDIATRICS, V91, P721; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; *MED RES COUNC, 1990, INJ REL DEATHS S AFR, P1; *OKL STAT DEP HLTH, 1991, TRAUM BRAIN INJ; PATTINGTON MW, 1960, ARCH DIS CHILD, P215; Runge J W, 1993, Emerg Med Clin North Am, V11, P241; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; WASTON GS, 1981, AM J PUBLIC HEALTH, V71, P297; *WHO, 1997, MAN INT CLASS DIS IN; 1993, HLTH VITAL STAT; 1989, WORLD HLTH STAT ANN	31	27	28	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	FEB	2004	11	2					126	129		10.1016/S0967-5868(03)00156-5			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	779DM	WOS:000189280200003	14732368				2022-02-06	
J	Ivanhoe, CB; Hartman, ET				Ivanhoe, CB; Hartman, ET			Clinical caveats on medical assessment and treatment of pain after TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						botox; deep venous thrombosis; dysautonomia; fracture; headache; heterotopic ossification; intrathecal baclofen; motor point block; neuropathic pain; shoulder subluxation; spastic dystonia; spasticity	TRAUMATIC BRAIN-INJURY; BOTULINUM-TOXIN-A; INTRATHECAL BACLOFEN; HETEROTOPIC OSSIFICATION; VENOUS THROMBOEMBOLISM; SPASTICITY; MANAGEMENT; PATIENT; DYSAUTONOMIA; SHOULDER	The diagnosis and management of pain in the patient with traumatic brain injury (TBI) can be difficult in light of the limitations imposed by the cognitive, language, and behavioral deficits. With patients in the acute rehabilitation setting, one must be vigilant for the often subtle signs and symptoms of pain. Causes more commonly seen in the population with TBI as a consequence of the injury itself include dysautonomia, neuropathic pain, spasticity, and heterotopic ossification. Headaches may be a consequence of TBI or associated with it for other reasons. Sources of pain associated with TBI include deep venous thrombosis and others. The reader is, reminded that patients with TBI are subject to all the causes of pain that affect the general population.	Baylor Coll Med, Inst Rehabil & Res, Dept Phys Med & Rehabil, Houston, TX USA		Ivanhoe, CB (corresponding author), Baylor Coll Med, Inst Rehabil & Res, Dept Phys Med & Rehabil, Houston, TX USA.	ivanhc@tirr.tmc.edu					ACQUANDRO MA, 1994, ANESTHESIOLOGY, V80, P706; ANDERSEN G, 1995, PAIN, V61, P187, DOI 10.1016/0304-3959(94)00144-4; ANDERSEN JT, 1977, INT UROL NEPHROL, V9, P133, DOI 10.1007/BF02082015; BAGLEY SL, 1979, ORTHOPEDIC REV, V8, P113; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Beric A, 1998, NEUROL CLIN, V16, P899, DOI 10.1016/S0733-8619(05)70104-3; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; BONTKE CF, 1989, PHYS MED REHABIL STA, V3, P43; Bowsher D, 1996, J NEUROL NEUROSUR PS, V61, P62, DOI 10.1136/jnnp.61.1.62; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; DECOURVAL LP, 1990, ARCH PHYS MED REHAB, V71, P673; Galer BS, 1998, NEUROL CLIN, V16, P791, DOI 10.1016/S0733-8619(05)70098-0; GARLAND DE, 1978, CLIN ORTHOP RELAT R, P111; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Gellman H, 1996, J HEAD TRAUMA REHAB, V11, P23, DOI 10.1097/00001199-199608000-00005; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; Hammond FM, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199802000-00007; Hanscom DA, 1987, J HEAD TRAUMA REHAB, V2, P1; Hulstyn M J, 1993, Orthop Rev, V22, P425; Ivanhoe CB, 2002, PAIN MANAGEMENT IN REHABILITATION, P101; Keenan MAE, 1996, J HEAD TRAUMA REHAB, V11, P8, DOI 10.1097/00001199-199608000-00004; KOMAN LA, 1994, J PEDIATR ORTHOPED, V14, P299, DOI 10.1097/01241398-199405000-00005; Lang AM, 2003, ARCH PHYS MED REHAB, V84, pS69, DOI 10.1053/apmr.2003.50121; LEHMKUHL LD, 1990, J HEAD TRAUMA REHAB, V5, P23, DOI DOI 10.1097/00001199-199012000-00005; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Mellick GA, 1997, ARCH PHYS MED REHAB, V78, P98, DOI 10.1016/S0003-9993(97)90020-4; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; Merren MD, 1998, SOUTHERN MED J, V91, P739, DOI 10.1097/00007611-199808000-00007; Merskey H, 1994, CLASSIFICATION CHRON, P207; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P1, DOI 10.1016/S0003-9993(96)90210-5; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; On AY, 1999, AM J PHYS MED REHAB, V78, P344, DOI 10.1097/00002060-199907000-00010; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; RIMEL RW, 1983, REHABILITATION HEAD, P9; Samkoff LM, 1997, NEUROLOGY, V49, P304, DOI 10.1212/WNL.49.1.304; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; STRAKOWSKI JA, 2000, PHYSICAL MED REHABIL, P797; Subbarao J V, 1999, J Spinal Cord Med, V22, P273; VANOUWENALLER C, 1986, ARCH PHYS MED REHAB, V67, P23; Welch MJ, 2000, TOXICON, V38, P245, DOI 10.1016/S0041-0101(99)00153-1; Wheeler AH, 2001, J MUSCULOSKELET PAIN, V9, P67, DOI 10.1300/J094v09n01_08; WHYTE J, 1986, J HEAD TRAUMA REHAB, V1, P39; ZUCKERMAN JD, 1991, AM FAM PHYSICIAN, V43, P497; Zuniga RE, 2002, REGION ANESTH PAIN M, V27, P90, DOI 10.1053/rapm.2002.29244	51	27	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					29	39		10.1097/00001199-200401000-00004			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000004	14732829				2022-02-06	
J	Carhuaporna, JR; Gupta, K; Coplin, WM; Muddassir, SM; Meratee, MM				Carhuaporna, JR; Gupta, K; Coplin, WM; Muddassir, SM; Meratee, MM			Treatment of refractory fever in the neurosciences critical care unit using a novel, water-circulating cooling device - A single-center pilot experience	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						fever; acute brain injury	ACUTE ISCHEMIC STROKE; BODY-TEMPERATURE; ACETAMINOPHEN; HYPOTHERMIA; INDUCTION; MORTALITY; SEVERITY; EFFICACY; SAFETY	Fever after acute brain injury affects neuronal function and recovery. Standard therapies have proven to be inadequate in treating hyperthermia in this patient population. We report on safety/efficacy pilot data collected using a noninvasive, novel, water-circulating cooling device in febrile acute brain injury patients. We enrolled patients who developed fever (rectal temperature greater than or equal to38.0degreesC) refractory to pharmacological therapy. The treatment device uses an ice water circulating system embedded in hydrogel-coated, energy transfer pads. Its thermoregulatory feedback control uses cold water (4.0degreesC-42.0degreesC) and was set at 36.5degreesC for this study. We analyzed the temperature response during 600 consecutive minutes of treatment. Six consecutive patients were enrolled and seven episodes of fever were recorded; the mean age of the patients was 59.7 years (range 46-71 years; five male, one female). Diagnoses were as follows: subarachnoid hemorrhage (two), severe traumatic brain injury (two), status epilepticus following massive cerebral infarction (one), and intracerebral/intraventricular hemorrhage (one). Hand warming was applied at treatment onset on all patients; shivering only responsive to meperidine occurred in five of them. Fever of 38.4degreesC (range 38.0degreesC-38.9degreesC) was reduced to 36.9degreesC (range 36.0degreesC-38.0degreesC) after 120 minutes (P < 0.001). Core temperature remained "locked" during the remainder of the treatment (36.6degreesC, P = 0.5; 36.6degreesC P = 0.9; and 36.5degreesC, P = 0.9 at 180, 300, and 600 minutes, respectively). Skin integrity under the pads was preserved in all study subjects. Our results indicate that use of this novel technique is safe, rapidly effective, and able to maintain sustained normothermia following fever in a cohort of critically ill neurologic/neurosurgical patients.	Wayne State Univ, Sch Med, Neurosci Crit Care Program, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI USA		Carhuaporna, JR (corresponding author), Univ Hlth Ctr, Dept Neurol, 8C 4201 St,Antoine Blvd, Detroit, MI 48201 USA.	jcarhuap@med.wayne.edu	Carhuapoma, Juan/AAC-5279-2019; Carhuapoma, Juan/X-9195-2018	Carhuapoma, Juan/0000-0002-5868-7701; 			AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Badjatia N, 2003, CRIT CARE MED, V31, pA20; Boysen G, 2001, STROKE, V32, P413, DOI 10.1161/01.STR.32.2.413; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036; Dippel DWJ, 2001, STROKE, V32, P1607, DOI 10.1161/01.STR.32.7.1607; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Henker R, 2001, Am J Crit Care, V10, P276; Iaizzo PA, 1999, J NEUROSURG ANESTH, V11, P231, DOI 10.1097/00008506-199910000-00002; Inderbitzen B, 2002, NEUROSURGERY, V50, P364, DOI 10.1097/00006123-200202000-00023; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; Koennecke HC, 2002, STROKE, V33, P134; Koennecke HC, 2001, NEUROLOGY, V57, P2301, DOI 10.1212/WNL.57.12.2301; Mateescu R, 1977, Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir, V26, P397; Mayer SA, 2002, CRIT CARE MED, V30, pA5, DOI 10.1097/00003246-200212001-00016; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; ODonnell J, 1997, CLIN INFECT DIS, V24, P1208, DOI 10.1086/513660; Plattner O, 1997, ANESTHESIOLOGY, V87, P1089, DOI 10.1097/00000542-199711000-00013; Powell RM, 2000, ANESTH ANALG, V90, P1423, DOI 10.1097/00000539-200006000-00032; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; Sweney MT, 2001, ANESTHESIOLOGY, V95, P1089, DOI 10.1097/00000542-200111000-00011; Takagi K, 2002, STROKE, V33, P2154, DOI 10.1161/01.STR.0000028803.70874.AA	25	27	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2003	15	4					313	318		10.1097/00008506-200310000-00004			6	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	728HF	WOS:000185711200004	14508172				2022-02-06	
J	O'Connor, C; Heath, DL; Cernak, I; Nimmo, AJ; Vink, R				O'Connor, C; Heath, DL; Cernak, I; Nimmo, AJ; Vink, R			Effects of daily versus weekly testing and pre-training on the assessment of neurologic impairment following diffuse traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cognitive outcome; deficits; motor outcome; neurotrauma; recovery; stress	CLOSED-HEAD INJURY; AXONAL INJURY; MAGNESIUM THERAPY; IMPACT; MODEL; MOTOR; PERFORMANCE; FORELIMB; RECOVERY; STRESS	A number of test paradigms have been used to determine acute and chronic motor and cognitive deficits after experimental traumatic brain injury (TBI). Some involve daily testing of either trained or untrained animals whereas others utilize periodic testing over extended time periods. Which test paradigm is the most appropriate for the assessment of motor and cognitive deficits is, however, unclear. In the current study, we have used both daily and weekly testing in trained and untrained animals to ascertain which assessment protocol is most suited for the detection of functional deficits after diffuse TBI in rats. Animals were subjected to severe injury using the impact-acceleration model of diffuse TBI. An equal number of animals were also prepared surgically but not subject to injury (shams). The rotarod device and the Barnes Maze were used for motor and cognitive assessment respectively, with half of the animals being pre-trained on each test for 10 days prior to injury. The open field test was used to assess spontaneous exploratory activity (stress). Following injury, animals were assessed for neurologic deficits either on a daily basis (for 10 days) or a weekly basis (for 4 weeks). In trained animals, the greatest differences in neurologic outcome between injured and sham animals were observed early after injury. In contrast, in untrained animals, greatest differences between injured and sham animals were observed at later time points. Pre-injury training did not improve the rate of cognitive recover, or the rate of motor recovery in the weekly test paradigm, but did improve the rate of motor recovery in the daily assessment paradigm. Daily assessment promoted rapid functional recovery whereas weekly assessments did not significantly affect outcome in injured animals over the 4-week assessment period. Spontaneous exploratory activity was decreased after TBI and was not influenced by task exposure. These studies demonstrate that the functional assessment paradigm needs to be considered when quantifying functional deficits following diffuse TBI in rats.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia; Georgetown Univ, Dept Neurosci, Washington, DC USA		Vink, R (corresponding author), Univ Adelaide, Dept Pathol, North Terrace, Adelaide, SA 5005, Australia.		Vink, Robert/S-5616-2019; Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X; Nimmo, Alan/0000-0002-0718-7934			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bland ST, 2001, BEHAV BRAIN RES, V126, P33, DOI 10.1016/S0166-4328(01)00243-1; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GIULIAN D, 1975, PHYSIOL BEHAV, V14, P109, DOI 10.1016/0031-9384(75)90150-X; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Vallee M, 1997, J NEUROSCI, V17, P2626; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2	32	27	27	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					985	993		10.1089/089771503770195830			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300007	14588115				2022-02-06	
J	Lacza, Z; Horvath, EM; Komjati, K; Hortobagyi, T; Szabo, C; Busija, DW				Lacza, Z; Horvath, EM; Komjati, K; Hortobagyi, T; Szabo, C; Busija, DW			PARP inhibition improves the effectiveness of neural stem cell transplantation in experimental brain trauma	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						brain trauma; BrDU; cold lesion; neural stem cell transplantation; peroxynitrite; poly (ADP-ribose) polymerase (PARP)	MESENCEPHALIC DOPAMINERGIC-NEURONS; CEREBRAL-ARTERY OCCLUSION; GROWTH-FACTOR PROMOTES; NITRO-L-ARGININE; PARKINSONS-DISEASE; POLY(ADP-RIBOSE) POLYMERASE; NIGRAL TRANSPLANTS; GRAFT-SURVIVAL; RAT MODEL; IN-VITRO	Neural stem cell transplantation is a promising new treatment of ischemic or traumatic brain injury. We have now investigated the involvement of the peroxynitrite - poly(ADP-ribose) polymerase (ONOO- -PARP) activation cascade in brain trauma and neural stem cell transplantation. The forelimb motor cortex of adult male rats was exposed to cold lesion (-60degreesC) and motor function was monitored. Neural stem cells isolated from E14 rat embryos were labeled with brome deoxyuridine (BrDU) and injected into the injured cortex 6 days after the lesion. After another 6 days, the survival and differentiation of the grafted cells were investigated with immunohistochemistry. Increased production of ONOO- revealed by tyrosine nitration was seen in the lesion 2 days after transplantation. Animals treated with the ONOO- decomposition catalyst FP15 or the PARP inhibitor PJ34 had a significantly improved motor score, when compared to vehicle-treated controls. The neurological score further improved following stem cell grafting in the PJ34 treated, but not in the control animals. Six days after transplantation, differentiated BrDU positive cells were found in the cortical penumbra. The majority of these differentiated cells expressed an astrocyte marker and some of the cells expressed oligodendrocyte or neuronal markers. The number of surviving transplanted cells was significantly higher in the PJ34 treated group. Inhibition of the ONOO- - PARP activation cascade significantly improves the effectiveness of neural stem cell transplantation and promotes rapid functional recovery.	Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol Pharmacol, Winston Salem, NC 27157 USA; Semmelweis Univ, Inst Human Physiol & Clin Expt Res, Budapest, Hungary; Inotek Pharmaceut Corp, Beverly, MA USA; Univ Szeged, Dept Pathol, H-6720 Szeged, Hungary		Lacza, Z (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	zlacza@mac.com	Horvath, Eszter/I-9128-2017; Szabo, Csaba/D-1882-2013; Szabo, Csaba/ABG-2644-2021	Horvath, Eszter/0000-0002-0517-1269; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL030260] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-30260, HL-50557] Funding Source: Medline		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Bartlett PF, 1998, IMMUNOL CELL BIOL, V76, P414, DOI 10.1046/j.1440-1711.1998.00762.x; Bjorklund L, 1997, EXP NEUROL, V148, P324, DOI 10.1006/exnr.1997.6655; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P79, DOI 10.1016/0149-7634(95)00063-1; Brundin P, 2000, BRAIN, V123, P1380, DOI 10.1093/brain/123.7.1380; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Brundin P, 2001, NAT MED, V7, P512, DOI 10.1038/87796; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Hortobagyi T, 1998, BRAIN RES BULL, V47, P185, DOI 10.1016/S0361-9230(98)00047-1; Hortobagyi T, 2000, PFLUG ARCH EUR J PHY, V441, P409, DOI 10.1007/s004240000441; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Isacson O, 2001, NAT NEUROSCI, V4, P553, DOI 10.1038/88362; Iwai M, 2002, J CEREBR BLOOD F MET, V22, P411, DOI 10.1097/00004647-200204000-00005; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; Kanelos SK, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199812000-00003; KOVACH AGB, 1992, J PHYSIOL-LONDON, V449, P183, DOI 10.1113/jphysiol.1992.sp019081; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; MAYER E, 1993, NEUROSCIENCE, V56, P389, DOI 10.1016/0306-4522(93)90340-L; MAYER E, 1993, NEUROSCIENCE, V56, P379, DOI 10.1016/0306-4522(93)90339-H; MOKRY J, 1995, MOL CHEM NEUROPATHOL, V25, P235, DOI 10.1007/BF02960916; Mundt-Petersen U, 2000, EXP NEUROL, V164, P112, DOI 10.1006/exnr.2000.7407; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Rosenblad C, 1999, EUR J NEUROSCI, V11, P1554, DOI 10.1046/j.1460-9568.1999.00566.x; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; SCHNEIDER GH, 1994, ACTA NEUROCHIR, P437; Sinclair SR, 1996, NEUROREPORT, V7, P2547, DOI 10.1097/00001756-199611040-00029; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Szabo C, 2002, MOL MED, V8, P571, DOI 10.1007/BF03402167; TAKAYAMA H, 1995, NAT MED, V1, P53, DOI 10.1038/nm0195-53; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	43	27	27	0	3	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	AUG	2003	12	2					153	159					7	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	701AE	WOS:000184142700003	12851710				2022-02-06	
J	Royo, NC; Schouten, JW; Fulp, CT; Stumizu, S; Marklund, N; Graham, DI; McIntosh, TK				Royo, NC; Schouten, JW; Fulp, CT; Stumizu, S; Marklund, N; Graham, DI; McIntosh, TK			From cell death to neuronal regeneration: Building a new brain after traumatic brain injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						apoptosis; cell death; necrosis; neurogenesis; replacement therapy; transplantation; traumatic brain injury	POSTMITOTIC HUMAN NEURONS; EPIDERMAL-GROWTH-FACTOR; CORTICAL IMPACT INJURY; NEUROGENESIS IN-VITRO; STEM-CELLS; SPINAL-CORD; HEAD-INJURY; NEURAL TRANSPLANTATION; MAMMALIAN FOREBRAIN; NEUROTROPHIC FACTOR	During the past decade, there has been accumulating evidence of the involvement of passive and active cell death mechanisms in both the clinical setting and in experimental models of traumatic brain injury (TBI). Traditionally, research for a treatment of TBI consists of strategies to prevent cell death using acute pharmacological therapy. However, to date, encouraging experimental work has not been translated into successful clinical trials. The development of cell replacement therapies may offer an alternative or a complementary strategy for the treatment of TBI. Recent experimental studies have identified a variety of candidate cell lines for transplantation into the injured CNS. Additionally, the characterization of the neurogenic potential of specific regions of the adult mammalian brain and the elucidation of the molecular controls underlying regeneration may allow for the development of neuronal replacement therapies that do not require transplantation of exogenous cells. These novel strategies may represent a new opportunity of great interest for delayed intervention in patients with TBI.	Head Injury Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, TKM, Philadelphia, PA 19104 USA; Univ Glasgow, So Gen Hosp, Dept Neuropathol, Inst Neurol Sci, Glasgow, Lanark, Scotland		McIntosh, TK (corresponding author), Head Injury Ctr, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu		Marklund, Niklas/0000-0002-9797-5626	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS40978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER		Anderson MF, 2002, DEV BRAIN RES, V134, P115; Brezun JM, 2000, HIPPOCAMPUS, V10, P37, DOI 10.1002/(SICI)1098-1063(2000)10:1<37::AID-HIPO4>3.3.CO;2-3; Buki A, 2000, J NEUROSCI, V20, P2825; Cameron HA, 1998, CURR OPIN NEUROBIOL, V8, P677, DOI 10.1016/S0959-4388(98)80099-8; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chisholm A, 1999, CURR OPIN NEUROBIOL, V9, P603, DOI 10.1016/S0959-4388(99)00021-5; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dergham P, 2002, J NEUROSCI, V22, P6570; Emery DL, 2000, J COMP NEUROL, V424, P521; Fowler J, 2002, CLIN NEUROPATHOL, V21, P156; Fritz JL, 2002, DEV BIOL, V252, P46, DOI 10.1006/dbio.2002.0842; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gould E, 1997, DEV BRAIN RES, V103, P91, DOI 10.1016/S0165-3806(97)00079-5; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grandpre T, 2001, NEUROSCIENTIST, V7, P377, DOI 10.1177/107385840100700507; Gray JA, 1999, PHILOS T R SOC B, V354, P1407, DOI 10.1098/rstb.1999.0488; Grunwald IC, 2002, CURR OPIN NEUROBIOL, V12, P250, DOI 10.1016/S0959-4388(02)00323-9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Huber AB, 2000, BIOL CHEM, V381, P407, DOI 10.1515/BC.2000.053; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2002, J NEUROSCI, V22, P5365; Katoh-Semba R, 2002, FASEB J, V16, P1328, DOI 10.1096/fj.02-0143fje; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Larsson E, 2002, EXP NEUROL, V177, P1, DOI 10.1006/exnr.2002.7992; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; Meltzer CC, 2001, NEUROSURGERY, V49, P586, DOI 10.1097/00006123-200109000-00011; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nakagawa S, 2002, J NEUROSCI, V22, P9868; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Radley JJ, 2002, BRAIN RES, V955, P264, DOI 10.1016/S0006-8993(02)03477-7; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RAGHUPATHI R, 2003, IN PRESS EXP NEUROL; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; RINK A, 1995, AM J PATHOL, V147, P1575; Roy M, 1999, TRENDS NEUROSCI, V22, P419, DOI 10.1016/S0166-2236(99)01435-6; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wahl F, 1999, ACT NEUR S, V73, P103; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684; [No title captured]	82	27	32	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	2003	62	8					801	811		10.1093/jnen/62.8.801			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	717LP	WOS:000185091000001	14503636	Bronze			2022-02-06	
J	Alderson, AL; Novack, TA				Alderson, AL; Novack, TA			Reliable serial measurement of cognitive processes in rehabilitation: The cognitive log	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						cognition; neuropsychology; rehabilitation	TRAUMATIC BRAIN INJURY; GALVESTON ORIENTATION; AMNESIA TEST; STATE	Objective: To evaluate the reliability and utility of a brief quantitative measure of cognitive recovery, the Cognitive Log (Cog-Log), developed for daily use with rehabilitation inpatients to provide information about the recovery of higher neurocognitive processes including verbal recall, attention, working memory, motor sequencing, and response inhibition. Design: Descriptive study of the Cog-Log's normative scores, reliability (interrater, internal consistency), and validity as shown by its relationship to standard neuropsychologic measures. Setting: Inpatient rehabilitation hospital affiliated with a large university medical center. Participants: One hundred fifty neurorchabilitation inpatients with acquired brain injury; 83 young adults without acquired brain injury were included to provide normative data. Interventions: Not applicable. Main Outcome Measures: The Cog-Log; standardized neuropsychologic measures of memory (Wechsler Memory Scale-Revised, Rey Auditory Verbal Learning Test), language, attention (Wechsler Adult Intelligence Scale-Revised), and reasoning (Trail Making Test). Results: Reliability analysis showed strong interrater reliability across items (Spearman r,.749-1.0.0) and high internal consistency (Cronbach alpha =.778). Factor an alysis of the Cog-Log using principal components extraction revealed a unitary factor (eigenvalue=3.48). Cog-Log items designed to measure working. memory and immediate and delayed verbal memory were most strongly predictive of performance on similar standardized neuropsychologic measures administered on the same day. Conclusion: The Cog-Log appears to be a reliable and efficient tool for measuring ongoing neurocognitive recovery during inpatient rehabilitation.	Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA		Alderson, AL (corresponding author), Shepherd Ctr, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline		FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Israelian MK, 2000, REHABIL PSYCHOL, V45, P284, DOI 10.1037/0090-5550.45.3.284; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; *NO CAL NEUR GROUP, 1995, COGN NEUR COGN STAT; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635	9	27	27	1	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2003	84	5					668	672		10.1016/S0003-9993(03)04842-6			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	675NF	WOS:000182700900008	12736879				2022-02-06	
J	Ashendorf, L; O'Bryant, SE; McCaffrey, RJ				Ashendorf, L; O'Bryant, SE; McCaffrey, RJ			Specificity of malingering detection strategies in older adults using the CVLT and WCST	CLINICAL NEUROPSYCHOLOGIST			English	Article							VERBAL-LEARNING TEST; CARD SORTING TEST; TRAUMATIC BRAIN-INJURY; PATIENT SAMPLES; HEAD-INJURY; PERFORMANCE	Strategies for the detection of possible malingering have largely taken two forms. First is the development and validation of domain-specific measures of malingering designed specifically for the detection of malingering (e.g., Test Of Memory Malingering, Word Memory Test, and Word Completion Memory Test). The second has been the development and evaluation of performance patterns and cutoff scores applicable to commonly used neuropsychological instruments. Two such instruments that have been examined are the Wisconsin Card Sorting Test (WCST) and the California Verbal Learning Test (CVLT). While several studies propose possible cutoff scores and actuarial judgement strategies for these tests, the specificity of these strategies within older, nonimpaired adults has not been established. Without proper evaluation of potential age-related effects within these strategies, the actual utility of the strategies within suspected malingerers who are older adults is unknown. Therefore, the present study was conducted to evaluate the specificity of the proposed strategies for detecting possible malingering with the WCST and the CVLT in a sample of older, community-dwelling, nonimpaired adults. The results suggest that the currently existing WCST formulas may have limited utility for the detection of malingering with older adults while the CVLT strategies do appear to have potential clinical utility. The potential of these formulas for use with older adults is discussed.	SUNY Albany, Dept Psychol, Albany, NY 12222 USA		Ashendorf, L (corresponding author), SUNY Albany, Dept Psychol, 1400 Washington Ave, Albany, NY 12222 USA.		Ashendorf, Lee/R-7206-2019	O'Bryant, Sid/0000-0003-0582-5266			AXELROD BN, 1992, CLIN NEUROPSYCHOL, V6, P16; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; DELIS D, 1987, CALIFORNIA VERBAL LE; DONDERS J, 1999, J FORENSIC NEUROPSYC, V1, P35; Essig SM, 2001, ARCH CLIN NEUROPSYCH, V16, P271, DOI 10.1016/S0887-6177(99)00065-7; FRIDLUND A, 1987, CVLT ADM SCORING SYS; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; HAYES JS, 1999, EVALUATION TREATMENT; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1997, CALIFORNIA VERBAL LE; *PSYCH ASS RES, 1993, WISC CARD SORT TEST; Ruiz MA, 2002, PROF PSYCHOL-RES PR, V33, P294, DOI 10.1037//0735-7028.33.3.294; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; [No title captured]	24	27	28	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	2003	17	2					255	262		10.1076/clin.17.2.255.16502			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	734PF	WOS:000186065200015	13680433				2022-02-06	
J	Binder, LM; Kelly, MP; Villanueva, MR; Winslow, MM				Binder, LM; Kelly, MP; Villanueva, MR; Winslow, MM			Motivation and neuropsychological test performance following mild head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; DIGIT RECOGNITION TEST; FORCED-CHOICE METHOD; MEMORY TEST; DEFICITS; VALIDITY; IMPAIRMENT; PROSPECTS; AMNESIA; TASK	Effect of motivation on neuropsychological test performance in mild head injury was assessed. Motivation was measured using the Portland Digit Recognition Test. Three groups were compared: (a) mild head injury, financial incentives, good motivation; (b) mild head injury, financial incentives, poor motivation; (c) moderate/severe head injury, good motivation. The neuropsychological battery included measures of sensory function, motor function, attention, intelligence, abstract reasoning, and memory. Mild head injury well motivated patients performed significantly better than the other two groups on some tests. Mild head injury poorly motivated individuals and moderate-severe head injury patients were indistinguishable on many tests. Consistent with previous reports, tactile sensory (finger recognition and Fingertip Number Writing Perception) and recognition memory (Rey Auditory Verbal Learning) tasks were identified as clinically useful measures of poor motivation. On these measures mild head injury well motivated examinees performed no better than moderate-severe patients, with both groups superior to mild head injury poorly motivated examinees. Sensitivity and specificity data are reported. Our measures of tactile sensation and verbal recognition memory were more affected by motivation than by the severity of head injury.	Univ Maryland, Sch Med, Baltimore, MD 21201 USA; So Oregon Neuropsychol Clin LLC, Medford, OR USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA		Binder, LM (corresponding author), 4900 SW Griffith Dr,Suite 244, Beaverton, OR 97005 USA.	PDXLarry@aol.com					ALEXANDER MP, 1987, NEUROBEHAVIORAL RECO, P191; BENTON AL, 1961, ARCH GEN PSYCHIAT, V4, P105; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Cohen J., 2013, STAT POWER ANAL BEHA; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Etcoff LM, 1996, NEUROPSYCHOL REV, V6, P171, DOI 10.1007/BF01874896; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GREIFFENSTEIN MF, 1994, PSYCHOL ASSESSMENT, V8, P218; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton RK, 1991, COMPREHENSIVE NORMS; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Martin J, 2001, J TURBUL, V2, P1; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Orey SA, 2000, ARCH CLIN NEUROPSYCH, V15, P335, DOI 10.1016/S0887-6177(99)00024-4; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; Reitan RM, 1985, HALSTEADREITAN NEURO; Rogers R., 1992, STRUCTURED INTERVIEW; ROSE F, 1995, CLIN NEUROPSYCHOL, V9, P1245; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler, 1997, WECHSLER ADULT INTEL; WECHSLER D, 1987, WECHSCLER MEMORY SCA; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Youngjohn, 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	42	27	27	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2003	25	3					420	430		10.1076/jcen.25.3.420.13806			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	683GX	WOS:000183141200011	12916654				2022-02-06	
J	Filipetti, P; Decq, P				Filipetti, P; Decq, P			Interest of anesthetic blocks for assessment of the spastic patient. A series of 815 motor blocks	NEUROCHIRURGIE			French	Article; Proceedings Paper	53rd Annual Congress of the Societe-De-Neurochirurgie-De-Langue-Francaise	MAY 09-12, 2003	TOZEUR, TUNISIA	Soc Neurochirurgie Langue Francaise		spasticity; local anesthetic block		Background - The purpose of the study was to emphasize the value of anesthetic blocks in the approach to the spastic patient. The report relates our experience concerning 566 patients (ranging in age from 4 to 72 years, mean 48 years) tested by 815 motor blocks performed within a "spasticity and dystonia evaluation" unit. The spasticity was mainly (lute to stroke (56%), cerebral palsy (21%) and traumatic brain injury (14%). Methods. - Motor blocks were performed with standardized procedure (specific needle, neurostimulator, localization technique), analytic and functional assessment. Results. - The anesthetic was mostly 1% non-adrenalized etidocaine, chosen for its onset and duration of action. Re-injections were few and side effects exeptional. Quality and motor blocks results were technique-dependent and required patient cooperation. The spasticity disappeared in blocked muscles. Tardieu and Ashworth modified scale showed constantly decreased spasticity (2 to 3 points) with better sensitivity for the Tardieu modified score. Local anesthetic blocks determined the relative contributions of overactivity and of muscle shortening in the generation of the pathologic posture, the muscle or muscles responsable for the spastic pattern and the level of active performance of the antagonistic muscle. New stability was evaluated by functional assessment of gait posture and prehension. Conclusion. - At the present time, anesthetic motor blocks represent a necessary and decisive stage procedure as regards spastic patient assessment. This method is particularly useful to anticipate a new functional balance and simulate treatment. Motor blocks provide acute knowledge of the pathological pattern and a better adjustment of therapeutic directions.	Hop Henri Mondor, Serv Neurochirurg, Grp Evaluat & Traitement Spast & Dystonie, F-94010 Creteil, France; Ctr Reg Specialise Arche, Le Mans, France		Filipetti, P (corresponding author), Hop Henri Mondor, Serv Neurochirurg, Grp Evaluat & Traitement Spast & Dystonie, F-94010 Creteil, France.						ARENDZEN JH, 1992, SCAND J REHABIL MED, V24, P75; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BONNET F, 1995, ACTUALITE ANESTHESIE, P157; BOYD RN, 1998, DEV MED CHILD NEUROL, V40, P7; DECQ P, 2000, NEUROTOMIES PERIPHER, V3; DUK HS, 2000, ARCH PHYS MED REHAB, V81, P910; FILIPETTI P, 1988, ANN READAPT MED PHYS, V41, P23; GAUTHIERLAFAYE P, 1994, PRECIS ANESTHESIE LO; KHALILI ALIA, 1966, CLIN ORTHOP RELAT RES, V47, P97; LECRON L, 1989, ANESTHESIE LOCO REGI; Liddell EGT, 1924, P R SOC LOND B-CONTA, V96, P212, DOI 10.1098/rspb.1924.0023; Liljestrand G, 1919, PFLUG ARCH GES PHYS, V176, P168, DOI 10.1007/BF01722339; MAHONEY F I, 1965, Md State Med J, V14, P61; PENN RD, 1985, LANCET, V2, P125; PIERROTDESEILLI.E, 2000, CLOSTRIDIUM, V3; PINZUR MS, 1985, J HAND SURG-AM, V10A, P547, DOI 10.1016/S0363-5023(85)80081-2; TARDIEU G., 1964, ARCH FRANC PEDIAT, V21, P25; TARDIEU G, 1954, REV NEUROL, V91, P143; Walshe FMR, 1924, BRAIN, V47, P159, DOI 10.1093/brain/47.2.159; YASUDA I, 1980, BRIT J ANAESTH, V52, P409, DOI 10.1093/bja/52.4.409; Zancolli E., 1979, STRUCTURAL DYNAMIC B	22	27	29	0	4	MASSON EDITEUR	PARIS 06	120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE	0028-3770			NEUROCHIRURGIE	Neurochirurgie	MAY	2003	49	2-3	2				226	238					13	Clinical Neurology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	679JM	WOS:000182917100011	12746697				2022-02-06	
J	Mariak, Z; White, MD; Lyson, T; Lewko, J				Mariak, Z; White, MD; Lyson, T; Lewko, J			Tympanic temperature reflects intracranial temperature changes in humans	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY			English	Article						brain temperature; face fanning; humans; tympanic temperature	SEVERELY HYPERTHERMIC HUMANS; SEVERE HEAD-INJURY; BRAIN TEMPERATURE; BLOOD-FLOW; EXERCISE; HYPOTHERMIA; GRADIENTS; VEINS	The purpose of the study was to identify extracranial locations in which temperature changes in humans reflect those of intracranial temperature in a reliable and repeatable way. This was achieved by subjecting 14 non-anaesthetized patients after neurosurgery to face fanning while intracranial and extracranial temperatures were continuously measured. In all patients the cranium was closed and the group included both febrile and non-febrile as well as hyperthermic and normothermic patients. The patients' faces were fanned for 20-30 min, with a small fan at an air speed of 3.25 m s(-1). This gave intracranial temperature changes measured in the subdural space (T-sd) that were highly and significantly correlated (r = 0.91, P < 0.05, n = 14) with changes in tympanic temperatures (T-ty). A low, statistically insignificant correlation (r = 0.40, P > 0.05, n = 12) was found between T-sd and oesophageal temperatures. In conclusion, intracranial temperature changes, induced by face fanning, were reliably reflected by the changes in T-ty.	Med Univ Bialystok, Dept Neurosurg, PL-15276 Bialystok, Poland; Mem Univ Newfoundland, Sch Human Kinet & Recreat, Lab Exercise & Environm Physiol, St Johns, NF A1C 5S7, Canada		Mariak, Z (corresponding author), Med Univ Bialystok, Dept Neurosurg, Ul M Sklodowskiej Curie 24A, PL-15276 Bialystok, Poland.			Lyson, Tomasz/0000-0002-9757-8276; Mariak, Zenon/0000-0003-4132-9278			BRENGELMANN GL, 1993, FASEB J, V7, P1148, DOI 10.1096/fasebj.7.12.8375613; BRINNEL H, 1989, J THERM BIOL, V14, P47, DOI 10.1016/0306-4565(89)90029-6; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CABANAC M, 1979, J PHYSIOL-LONDON, V286, P255, DOI 10.1113/jphysiol.1979.sp012617; CABANAC M, 1985, EUR J APPL PHYSIOL O, V54, P172, DOI 10.1007/BF02335925; CABANAC M, 1993, PFLUG ARCH EUR J PHY, V424, P367, DOI 10.1007/BF00384366; Cabanac M, 1995, HUMAN SELECTIVE BRAI; CAPUTA M, 1980, J THERM BIOL, V5, P249, DOI 10.1016/0306-4565(80)90029-7; CAPUTA M, 1978, CR ACAD SCI D NAT, V287, P1011; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; HIRASHITA M, 1992, EUR J APPL PHYSIOL, V64, P92, DOI 10.1007/BF00376447; JESSEN C, 1992, J APPL PHYSIOL, V72, P664, DOI 10.1152/jappl.1992.72.2.664; MARIAK Z, 1994, EUR J APPL PHYSIOL O, V69, P545, DOI 10.1007/BF00239873; Mariak Z, 2000, Neurol Neurochir Pol, V34, P509; Mariak Z, 2002, J THERM BIOL, V27, P219, DOI 10.1016/S0306-4565(01)00087-0; Mariak Z, 1998, ACTA NEUROCHIR, V140, P585, DOI 10.1007/s007010050144; MCCAFFREY TV, 1975, J APPL PHYSIOL, V39, P114, DOI 10.1152/jappl.1975.39.1.114; MELLERGARD P, 1995, SURG NEUROL, V43, P91, DOI 10.1016/0090-3019(95)80049-M; NIELSEN B, 1992, PFLUG ARCH EUR J PHY, V422, P168, DOI 10.1007/BF00370416; RASCH W, 1991, J APPL PHYSIOL, V71, P590, DOI 10.1152/jappl.1991.71.2.590; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Shibasaki M, 1998, J APPL PHYSIOL, V85, P921, DOI 10.1152/jappl.1998.85.3.921; SHIRAKI K, 1988, J APPL PHYSIOL, V65, P482, DOI 10.1152/jappl.1988.65.1.482; STONE JG, 1995, ANESTHESIOLOGY, V82, P344, DOI 10.1097/00000542-199502000-00004; YASUDA N, 1991, ANESTHESIOLOGY, V74, P489, DOI 10.1097/00000542-199103000-00017	26	27	28	0	7	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0031-6768			PFLUG ARCH EUR J PHY	Pflugers Arch.	MAY	2003	446	2					279	284		10.1007/s00424-003-1021-3			6	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	687VX	WOS:000183398600019	12739166				2022-02-06	
J	Mills, WJ; Tejwani, T				Mills, WJ; Tejwani, T			Heterotopic ossification after knee dislocation: The predictive value of the injury severity score	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						knee dislocation; heterotopic ossification; ISS	POSTERIOR CRUCIATE LIGAMENTS; ARTHROPLASTY; RECONSTRUCTION; ANTERIOR	Objective: To determine the relationship of multiple variables, including the Injury Severity Score (ISS), closed head injury (CHI), and timing and type of surgery to formation of motion-limiting heterotopic ossification (HO) following knee dislocation. Design: Longitudinal observational study. Setting: University level 1 trauma center. Patients/Participants: Thirty-five consecutive patients with 36 knee dislocations (OTA fracture and dislocation classification 40-D) admitted over a 26-month period. Main Outcome Measurements: Admission ISS, Glascow Coma scale (GCS) scores, CHI, timing (> or < 3 weeks from injury) and type (open or arthroscopic) of surgery, number of cruciate ligaments reconstructed, medial surgical procedure, and eventual presence or absence of motion-limiting HO. Results: A classification system for HO was developed ranging from none (type 0) to ankylosing (type IV) HO. Twenty-nine patients with type 0-III HO recovered an average range of motion of 126degrees at an average of 14 months (group A). Six patients formed ankylosing type IV HO (group B). The ISS in group A ranged from 9 to 26. ISS in group B ranged from 26 to 50 (P < 0.001). Regarding the formation of type IV HO, the sensitivity of an ISS greater than or equal to26 was 100%, the specificity was 97%, and the positive predictive value was 86%. Patients in group B had a greater incidence of documented CHI (P < 0.025). Timing and type of surgery, number of ligaments reconstructed, and whether or not the patient had a medial surgical procedure had no statistical influence on degree of HO formation. Conclusions: An ISS of 26 seems to be a discrete boundary above which patients with knee dislocation are at extremely high risk for type IV HO formation if undergoing surgical reconstruction and below which patients are likely spared this complication. The presence of a CHI is a significant factor in type IV HO formation, although harder to quantify. None of the remaining independent variables studied were significantly related to ankylosing type IV HO formation.	Univ Washington, Harborview Med Ctr, Dept Orthopaed, Seattle, WA 98104 USA; NYU, Dept Orthopaed, New York, NY USA		Mills, WJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Orthopaed, Box 359798,325 9th Ave, Seattle, WA 98104 USA.			Tejwani, Nirmal/0000-0001-8578-6556			Anglen JO, 1996, J ORTHOP TRAUMA, V10, P258, DOI 10.1097/00005131-199605000-00006; AUSTIN KS, 1995, J ARTHROPLASTY, V10, P695, DOI 10.1016/S0883-5403(05)80219-0; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bellemans J, 1999, Acta Orthop Belg, V65, P98; Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; Chidel MA, 2001, J ARTHROPLASTY, V16, P1, DOI 10.1054/arth.2001.16492; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Dedmond B T, 2001, Am J Knee Surg, V14, P33; FRASSICA FJ, 1991, CLIN ORTHOP RELAT R, P200; Freedman E L, 1996, Am J Orthop (Belle Mead NJ), V25, P559; FURIA JP, 1995, J ARTHROPLASTY, V10, P413, DOI 10.1016/S0883-5403(05)80139-1; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P133; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GHALAMBOR N, 1994, CLIN ORTHOP RELAT R, V305, P96; GREEN NE, 1977, J BONE JOINT SURG AM, V59, P236, DOI 10.2106/00004623-197759020-00017; Harwin S F, 1993, J Arthroplasty, V8, P113, DOI 10.1016/S0883-5403(06)80048-3; HELFET DL, 1993, CLIN ORTHOP RELAT R, V292, P26; Horne LT, 1999, J ORTHOP TRAUMA, V13, P385, DOI 10.1097/00005131-199906000-00013; Ibrahim SA, 1999, J BONE JOINT SURG BR, V81B, P987, DOI 10.1302/0301-620X.81B6.9516; Ilahi OA, 1998, ORTHOPEDICS, V21, P265; IPPOLITO E, 1999, CLIN ORTHOP RELAT R, V43, P130; JOHNSON EE, 1994, CLIN ORTHOP RELAT R, V305, P88; KUNDEL K, 1996, CLIN ORTHOP RELAT R, V41, P200; MAYO KA, 1994, CLIN ORTHOP RELAT R, V332, P31; MEYERS MH, 1971, J BONE JOINT SURG AM, VA 53, P16, DOI 10.2106/00004623-197153010-00002; Noyes FR, 1997, AM J SPORT MED, V25, P769, DOI 10.1177/036354659702500608; Patton WC, 2000, AM J SPORT MED, V28, P398, DOI 10.1177/03635465000280032001; Rader GP, 1997, ACTA ORTHOP SCAND, V68, P46, DOI 10.3109/17453679709003974; Roman P D, 1987, Orthop Rev, V16, P917; ROUTT MLC, 1990, J BONE JOINT SURG AM, V72A, P897, DOI 10.2106/00004623-199072060-00016; SHAPIRO MS, 1995, AM J SPORT MED, V23, P580, DOI 10.1177/036354659502300511; SILISKI JM, 1998, MASTER TECHNIQUES OR, P347; TAYLOR A R, 1972, Journal of Bone and Joint Surgery British Volume, V54, P96; Tomaino M, 2000, KNEE SURG SPORT TR A, V8, P163, DOI 10.1007/s001670050208; Twaddle BC, 1996, J BONE JOINT SURG BR, V78B, P573, DOI 10.1302/0301-620X.78B4.0780573; VARNELL RM, 1989, AM SURGEON, V55, P699; WALKER DN, 1994, J TRAUMA, V36, P898, DOI 10.1097/00005373-199406000-00027; Wascher DC, 1997, J ORTHOP TRAUMA, V11, P525, DOI 10.1097/00005131-199710000-00011; Wascher DC, 2000, CLIN SPORT MED, V19, P457, DOI 10.1016/S0278-5919(05)70218-0; Yeh WL, 1999, J TRAUMA, V46, P693, DOI 10.1097/00005373-199904000-00023	41	27	31	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	MAY	2003	17	5					338	345		10.1097/00005131-200305000-00004			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	675AJ	WOS:000182670600004	12759638				2022-02-06	
J	Duperier, T; Mosenthal, A; Swan, KG; Kaul, S				Duperier, T; Mosenthal, A; Swan, KG; Kaul, S			Acute complications associated with Greenfield filter insertion in high-risk trauma patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Greenfield filter; complications; pulmonary embolism; arteriovenous fistula; deep venous thrombosis	VENA-CAVA FILTERS; DEEP VENOUS THROMBOSIS; TERM FOLLOW-UP; PULMONARY-EMBOLISM; PERCUTANEOUS INSERTION; INTERMITTENT COMPRESSION; PLACEMENT; FIBRINOLYSIS; PROPHYLAXIS; EXPERIENCE	Background: Use of Greenfield filters (GFs) to prevent fatal pulmonary embolism (PE) in trauma patients is generally well accepted. Nonetheless, a surprisingly small number of trauma surgeons insert filters in their patients. Among the reasons cited is fear of complications. Methods: We observed three femoral arteriovenous fistulae (AVF) in trauma patients who had inferior vena caval placement of filters for PE prophylaxis in one 12-month period (academic year 1999). In an effort to document the magnitude of this problem, we evaluated trauma patients who had a GF inserted in academic year 2000. Results: During that year, 133 consecutive patients (8.6% of trauma admissions) received 133 GFs through a percutaneous approach. The most common isolated indications for GF insertion included closed head injuries (n = 28), multiple long bone fractures (n = 27), pelvic and acetabular fractures (n 6), spinal cord injuries (n = 16), and vertebral fractures (n = 3). Five patients had documented deep venous thrombosis (DVT) diagnosed by duplex ultrasonography before GF placement, and 11 patients had other indications requiring a filter. There were 37 patients with more than one indication requiring filter placement. Most patients (57%) underwent preinsertion duplex scanning of their lower extremity veins; 77% of patients underwent postinsertion scanning. Filters were inserted an average of 6.8 +/- 0.6 (SE) days after trauma. No AVF were suspected clinically or detected ultrasonographically. No operative or postoperative complications occurred. DVT was observed in 30% of patients despite 92% prophylaxis; there was a 26% incidence of de novo thrombi detected. None of the patients evidenced DVT clinically. Conclusion: Our data indicate that complications of GF insertion for prophylaxis against PE from DVT complicating trauma patients continue to be negligible. In addition, the incidence of insertion-site thrombosis may be lower than expected. Moreover, femoral AVF is a rare complication of this procedure.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA		Swan, KG (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave,Room G-592, Newark, NJ 07103 USA.						ALLENBY F, 1973, LANCET, V2, P1412; Aswad MA, 1996, J VASC SURG, V24, P809, DOI 10.1016/S0741-5214(96)70017-4; BECKER DM, 1992, ARCH INTERN MED, V152, P1985, DOI 10.1001/archinte.152.10.1985; Blebea J, 1999, J VASC SURG, V30, P821, DOI 10.1016/S0741-5214(99)70006-6; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; DORFMAN GS, 1989, RADIOLOGY, V173, P159, DOI 10.1148/radiology.173.1.2675182; ENDERSON BL, 1991, J TRAUMA, V31, P1240, DOI 10.1097/00005373-199109000-00007; Gosin JS, 1997, ANN VASC SURG, V11, P100, DOI 10.1007/s100169900017; GRASSI CJ, 1988, AM J ROENTGENOL, V151, P681, DOI 10.2214/ajr.151.4.681; Greenfield LJ, 2000, J VASC SURG, V32, P490, DOI 10.1067/mva.2000.108636; GREENFIELD LJ, 1977, ANN SURG, V185, P692, DOI 10.1097/00000658-197706000-00012; HIRSCH SB, 1987, J VASC SURG, V6, P609, DOI 10.1067/mva.1987.avs0060609; KANTOR A, 1987, AM J ROENTGENOL, V149, P1065, DOI 10.2214/ajr.149.5.1065; KAPSCH DN, 1984, SURGERY, V95, P473; KHANSARINIA S, 1995, J VASC SURG, V22, P231, DOI 10.1016/S0741-5214(95)70135-4; KNIGHT MTN, 1976, LANCET, V2, P1265; Langan EM, 1999, J VASC SURG, V30, P484, DOI 10.1016/S0741-5214(99)70075-3; LEACH TA, 1994, AM SURGEON, V60, P292; MASTROBATTISTA JM, 1995, GYNECOL ONCOL, V56, P399, DOI 10.1006/gyno.1995.1070; McMurtry AL, 1999, J AM COLL SURGEONS, V189, P314, DOI 10.1016/S1072-7515(99)00137-4; Meissner M H, 1998, Semin Vasc Surg, V11, P274; MEWISSEN MW, 1989, RADIOLOGY, V173, P159; PAIS SO, 1988, J VASC SURG, V8, P460; Patton JH, 1996, J TRAUMA, V41, P231, DOI 10.1097/00005373-199608000-00006; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; Rogers FB, 1998, ARCH SURG-CHICAGO, V133, P406, DOI 10.1001/archsurg.133.4.406; SCHMIDT U, 1992, J TRAUMA, V33, P312, DOI 10.1097/00005373-199208000-00023; Snedecor G.W., 1980, STAT METHODS, V7th; Trousseau A, 1865, CLIN MED HOTEL DIEU, V2nd, P654; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021; Wojcik R, 2000, J TRAUMA, V49, P839, DOI 10.1097/00005373-200011000-00008	33	27	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2003	54	3					545	549		10.1097/00005373-200303000-00018			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	660EA	WOS:000181819800018	12634536				2022-02-06	
J	Yunoki, M; Kawauchi, M; Ukita, N; Sugiura, T; Ohmoto, T				Yunoki, M; Kawauchi, M; Ukita, N; Sugiura, T; Ohmoto, T			Effects of lecithinized superoxide dismutase on neuronal cell loss in CA3 hippocampus after traumatic brain injury in rats	SURGICAL NEUROLOGY			English	Article						neuronal cell loss; superoxide dismutase; traumatic brain injury	POLYETHYLENE-GLYCOL; TIME-COURSE; EDEMA; LINES	BACKGROUND The protective effect of excitatory amino acid antagonists for CA3 hippocampal neuronal loss has been well documentated. From a clinical point of view, however, alternative therapies should also be explored because excitatory amino acid antagonists have relatively deleterious side effects. Administration of lecithinized superoxide dismutase (PC-SOD) has recently been demonstrated to reduce brain edema after traumatic brain injury (TBI) in the cerebral cortex. In this study, we investigated the effectiveness of PC-SOD on CA3 hippocampal cell loss by examining hematoxylin and eosin-stained sections. METHODS Rats were divided at random into three groups. The first group received 1 mL of saline (contusion + saline group, n = 5). Rats of the second group were treated with 3000 IU/kg of PC-SOD (contusion + SOD I group, n = 5), while the third group received 5000 IU/kg of PC-SOD (contusion + SOD 2 group, n = 5). All agents were administered intraperitoneally 1 minute after traumatic insult and every 24 hours until 2 or 3 days post-TBI. Animals were sacrificed 3 or 7 days after contusion injury. RESULTS PC-SOD prevented CA3 neuronal loss 3 days after TBI, and increased the number of surviving CA3 neurons 7 days after TBI. CONCLUSION Our findings suggest that PC-SOD may serve as a pharmacological agent in the treatment of neuronal loss after TBI. (C) 2003 Elsevier Science Inc.	Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 700, Japan		Yunoki, M (corresponding author), Okayama Univ, Sch Med, Dept Neurol Surg, 2-5-1 Shikata Cho, Okayama 700, Japan.						Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; CHOI D, 1981, J NEUROBIOL, V23, P1261; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; FUKUHARA T, 1994, NEUROSURGERY, V35, P924, DOI 10.1227/00006123-199411000-00018; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HE YY, 1993, AM J PHYSIOL, V265, pH252, DOI 10.1152/ajpheart.1993.265.1.H252; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; IGARASHI R, 1994, J PHARMACOL EXP THER, V271, P1672; IGARASHI R, 1992, J PHARMACOL EXP THER, V262, P1214; Iijima T, 1998, J NEUROTRAUM, V15, P277, DOI 10.1089/neu.1998.15.277; KARLSSON K, 1989, LAB INVEST, V60, P659; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAEDA T, 1996, NEUROTRAUMATOLOGY, V19, P162; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Nakauchi K, 1996, J NEUROTRAUM, V13, P573, DOI 10.1089/neu.1996.13.573; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VERONESE FM, 1983, J PHARM PHARMACOL, V35, P757, DOI 10.1111/j.2042-7158.1983.tb02888.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	27	27	27	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	MAR	2003	59	3					156	161		10.1016/S0090-3019(02)01040-6			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	665JA	WOS:000182115400005	12681536				2022-02-06	
J	Cui, X; Kalsotra, A; Robida, AM; Matzilevich, D; Moore, AN; Boehme, CL; Morgan, ET; Dash, PK; Strobel, HW				Cui, X; Kalsotra, A; Robida, AM; Matzilevich, D; Moore, AN; Boehme, CL; Morgan, ET; Dash, PK; Strobel, HW			Expression of cytochromes P4504F4 and 4F5 in infection and injury models of inflammation	BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS			English	Article; Proceedings Paper	12th International Symposium on Cellular Biology of Cytochrome P450 Regulation	SEP, 2001	LA GRANDE MOTTE, FRANCE			regulation of CYP4F expression; inflammation and P450 expression; brain cytochrome P450 distribution; lipopolysaccharide and CYP4F subfamily expression; CYP4F subfamily expression; CYP4F subfamily suppression by inflammation	B-4 OMEGA-HYDROXYLASE; TRAUMATIC BRAIN-INJURY; CDNA CLONING; RAT-BRAIN; PROTEIN EXPRESSION; MOLECULAR-CLONING; GENE-EXPRESSION; INDUCTION; INTERLEUKIN-6; HEPATOCYTES	Lipopolysaccharide (LPS) treatment of rats suppresses CYP 4174 and 4175 expression by 50 and 40%, respectively, in a direct fashion occurring in the liver. This contention is borne out by essentially parallel dose-dependent changes observed upon treatment of rat hepatocyte cultures with LPS. An alternate avenue of triggering the inflammatory cascade is traumatic brain injury by controlled cortical impact. Such injury brings about a dramatic change in the expression of CYP 4174 and 4F5 mRNA which reaches its greatest effect 24 h after impact compared with sham-operated but uninjured controls. At time points after 24 h the expression of both isoforms increases dramatically reaching highest levels at 2 weeks post-injury. These changes in mRNA expression are mirrored by changes in protein expression. The results are consistent with the notion that immediately after injury, concentrations of leukotriene and prostaglandin mediators are elevated by decreased CYP 4F concentrations. As time after injury increases those conditions reverse. Increased CYP 4F expression leads to diminished concentrations of leukotriene and prostaglandin mediators and then to recovery and repair. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA		Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708,6431 Fannin St, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Morgan, Edward/0000-0003-4273-2261; Kalsotra, Auinash/0000-0002-1011-0006	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 46897] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 58297] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM046897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH058297] Funding Source: NIH RePORTER		ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; BARKER CW, 1992, J BIOL CHEM, V267, P8050; BOEHME CL, 2001, J NEUROTOX RES, V3, P329; Bureau F, 2002, J IMMUNOL, V168, P5318, DOI 10.4049/jimmunol.168.10.5318; Bylund J, 1999, BIOCHEM BIOPH RES CO, V261, P169, DOI 10.1006/bbrc.1999.1011; Bylund J, 2001, BIOCHEM BIOPH RES CO, V280, P892, DOI 10.1006/bbrc.2000.4191; CHEN LP, 1993, ARCH BIOCHEM BIOPHYS, V300, P18, DOI 10.1006/abbi.1993.1003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cui XM, 2000, GENOMICS, V68, P161, DOI 10.1006/geno.2000.6276; Cui XM, 2001, J PHARMACOL EXP THER, V296, P542; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRARI L, 1993, J PHARMACOL EXP THER, V264, P1012; FUKUDA Y, 1992, BIOCHEM BIOPH RES CO, V184, P960, DOI 10.1016/0006-291X(92)90684-D; Hofbauer R, 2000, MICROVASC RES, V59, P354, DOI 10.1006/mvre.1999.2220; Kawashima H, 1995, BIOCHEM BIOPH RES CO, V217, P1137, DOI 10.1006/bbrc.1995.2887; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; Kawashima H, 1996, J BIOL CHEM, V271, P28176, DOI 10.1074/jbc.271.45.28176; Kikuta Y, 2000, ARCH BIOCHEM BIOPHYS, V383, P225, DOI 10.1006/abbi.2000.2078; Kikuta Y, 1999, DNA CELL BIOL, V18, P723, DOI 10.1089/104454999315006; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; Kikuta Y, 1998, DNA CELL BIOL, V17, P221, DOI 10.1089/dna.1998.17.221; Kikuta Y, 1999, ARCH BIOCHEM BIOPHYS, V369, P193, DOI 10.1006/abbi.1999.1271; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; LIDDLE C, 1992, ARCH BIOCHEM BIOPHYS, V298, P159, DOI 10.1016/0003-9861(92)90107-8; Liu SB, 1998, INFECT IMMUN, V66, P5089, DOI 10.1128/IAI.66.11.5089-5098.1998; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; MORGAN ET, 1991, BIOCHEM PHARMACOL, V42, P51, DOI 10.1016/0006-2952(91)90680-4; PETERSON TC, 1986, BIOCHEM PHARMACOL, V35, P1491, DOI 10.1016/0006-2952(86)90114-0; Poloyac SM, 2001, DRUG METAB DISPOS, V29, P296; Sabourault C, 1999, BIOCHEM BIOPH RES CO, V258, P155, DOI 10.1006/bbrc.1999.0608; Sewer MB, 1996, DRUG METAB DISPOS, V24, P401; Sewer MB, 1997, J PHARMACOL EXP THER, V280, P1445; Su GL, 1999, J HEPATOL, V31, P435, DOI 10.1016/S0168-8278(99)80034-8; Thomas SC, 1998, FASEB J, V12, P1371, DOI 10.1096/fasebj.12.13.1371; UFKES JG, 1998, BR J EXP PATHOL, V69, P457; WILLIAMS JF, 1991, BIOCHEM BIOPH RES CO, V178, P1049, DOI 10.1016/0006-291X(91)90998-M; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	41	27	28	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0304-4165	1872-8006		BBA-GEN SUBJECTS	Biochim. Biophys. Acta-Gen. Subj.	FEB 17	2003	1619	3					325	331	PII S0304-4165(02)00491-9	10.1016/S0304-4165(02)00491-9			7	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Biophysics	648FW	WOS:000181140200013	12573492				2022-02-06	
J	Baker, AM; Craig, BR; Lonergan, GJ				Baker, AM; Craig, BR; Lonergan, GJ			Homicidal commotio cordis: the final blow in a battered infant	CHILD ABUSE & NEGLECT			English	Article						homicide; commotio cordis; precordial	SUDDEN-DEATH; EXPERIMENTAL-MODEL; SPORTS ACTIVITIES; CARDIAC-ARREST; IMPACT; YOUNG	Objective: This report describes in detail the occurrence of inflicted commotio cordis (cardiac concussion) in a previously abused 7-week-old. Though inflicted commotio cordis has been reported in three toddlers, this is the first report in a young infant. Method: Following documentation of abuse in a living child, the case of a death of a prior sibling-previously regarded as natural-was re-opened for further investigation. Original autopsy materials were reviewed, and the body of the deceased child was exhumed. Results: Exhumation and second autopsy documented more than 50 fractures in the deceased child. When re-interviewed, the children's father admitted to causing the injuries in both children, and gave a textbook description of commotio cordis as the mechanism of death in the fatal case. Conclusions: Commotio cordis is a rare event in which a fatal dysrhythmia-usually ventricular fibrillation-is precipitated by a blow to the precordial chest. Previous reports have indicated that homicidal commotio cordis can occur in small children. This report demonstrates that commotio cordis can occur even in the very young, previously abused infant. Published by Elsevier Science Ltd.	Off Armed Forces Med Examiner, Rockville, MD USA; Armed Forces Ctr Child Protect, Bethesda, MD USA; Armed Forces Inst Pathol, Dept Radiol Pathol, Pediat Radiol Div, Washington, DC USA		Baker, AM (corresponding author), Hennepin Cty Med Examiners Off, 530 Chicago Ave, Minneapolis, MN 55415 USA.						ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; Boglioli LR, 1998, PEDIATR CARDIOL, V19, P436, DOI 10.1007/s002469900347; Denton JS, 2000, J FORENSIC SCI, V45, P734; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; Link M S, 1999, Cardiol Rev, V7, P265, DOI 10.1097/00045415-199909000-00010; Link MS, 1998, NEW ENGL J MED, V338, P1805, DOI 10.1056/NEJM199806183382504; Link MS, 2001, J AM COLL CARDIOL, V37, P649, DOI 10.1016/S0735-1097(00)01142-6; Maron BJ, 1997, AM J CARDIOL, V79, P840, DOI 10.1016/S0002-9149(96)00887-9; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; Maron BJ, 1999, J CARDIOVASC ELECTR, V10, P114, DOI 10.1111/j.1540-8167.1999.tb00648.x; Maron BJ, 2002, AM J CARDIOL, V89, P210, DOI 10.1016/S0002-9149(01)02202-0; Michalodimitrakis EN, 1997, AM J FOREN MED PATH, V18, P282, DOI 10.1097/00000433-199709000-00010; Perron AD, 2001, AM J EMERG MED, V19, P406, DOI 10.1053/ajem.2001.24455	13	27	27	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134			CHILD ABUSE NEGLECT	Child Abuse Negl.	JAN	2003	27	1					125	130	PII S0145-2134(02)00511-2	10.1016/S0145-2134(02)00511-2			6	Family Studies; Psychology, Social; Social Work	Social Science Citation Index (SSCI)	Family Studies; Psychology; Social Work	635VG	WOS:000180419900009	12510035				2022-02-06	
J	Duncan, CC; Kosmidis, MH; Mirsky, AF				Duncan, CC; Kosmidis, MH; Mirsky, AF			Event-related potential assessment of information processing after closed head injury	PSYCHOPHYSIOLOGY			English	Article						closed head injury; information processing; event-related potentials; N200; P300; reaction time	TRAUMATIC BRAIN INJURY; AUDITORY ODDBALL TASK; P300 COMPONENT; REACTION-TIME; DISCRIMINATION TASK; CEREBRAL CONCUSSION; COGNITIVE FUNCTION; VISUAL-ATTENTION; DYSFUNCTION; GENERATORS	We evaluated alterations in information processing after closed head injury as a function of task demands and stimulus modality. Visual and auditory discrimination tasks ere administered to I I survivors of a head injury and 16 matched healthy controls. In auditory tasks. compared with controls the survivors had smaller N100s, smaller and later N200s, a more posterior scalp distribution of N200 and longer P300 and response latencies. Auditors N200 and P300 correlated highly with duration of unconsciousness. In contrast, in visual tasks, only a reduced N200 in the survivors differentiated the groups. Our results indicate that processing of auditory stimuli. including the perception and discrimination Of Stimulus features and the evaluation and categorization of Stimuli, may be impaired after head trauma. Visual sensory processing may be spared but higher-order visual processing involved ill Stimulus classification may be compromised.	Uniformed Serv Univ Hlth Sci, Dept Psychiat, Clin Psychophysiol & Psychopharmacol Lab, Bethesda, MD 20814 USA; NIMH, Sect Clin & Expt Neuropsychol, Bethesda, MD 20892 USA		Kosmidis, MH (corresponding author), MSC 2615,5415 W Cedar Lane,Suite 203B, Bethesda, MD 20892 USA.	connie_duncan@nih.gov	Kosmidis, Mary H/AAN-2104-2021	Kosmidis, Mary/0000-0001-8790-1220	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH000509] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; Alexander JE, 1996, INT J PSYCHOPHYSIOL, V21, P189, DOI 10.1016/0167-8760(95)00047-X; Alexander T, 2000, J CURRICULUM STUD, V32, P467, DOI 10.1080/002202700182664; BARRETT G, 1987, ELECTROEN CLIN NEURO, V66, P409, DOI 10.1016/0013-4694(87)90210-0; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CAMPBELL K, 1986, STUDIES EVENT RELATE, V38, P486; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CAMPBELL KB, 1990, ELECTROEN CLIN NEURO, P202; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; COOPER R, 1984, EVOKED POTENTIAL, V2, P446; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; Curry S H, 1996, Electroencephalogr Clin Neurophysiol Suppl, V46, P283; Curry S H, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P469; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; Deacon-Elliott D L, 1987, Electroencephalogr Clin Neurophysiol Suppl, V40, P664; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DUNCAN CC, 1994, PSYCHOPHYSIOLOGY, V31, P386, DOI 10.1111/j.1469-8986.1994.tb02447.x; DUNCAN CC, 1987, PSYCHOPHARMACOL BULL, V23, P497; DUNCAN CC, 1990, PSYCHIAT WORLD PERSP, V2, P398; DUNCANJOHNSON CC, 1979, PSYCHOPHYSIOLOGY, V16, P53, DOI 10.1111/j.1469-8986.1979.tb01440.x; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; DUNCANJOHNSON CC, 1982, BIOL PSYCHOL, V14, P1, DOI 10.1016/0301-0511(82)90016-3; EGAN MF, 1994, SCHIZOPHR RES, V11, P259, DOI 10.1016/0920-9964(94)90020-5; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; FRIEDMAN A, 1981, J EXP PSYCHOL HUMAN, V7, P1031, DOI 10.1037/0096-1523.7.5.1031; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Holbourn AHS, 1943, LANCET, V2, P438; JOHNSON R, 1993, PSYCHOPHYSIOLOGY, V30, P90; JOHNSON R, 1989, PSYCHOPHYSIOLOGY, V26, P651, DOI 10.1111/j.1469-8986.1989.tb03167.x; JOHNSON R, 1989, PSYCHOPHYSIOLOGY, V26, P633, DOI 10.1111/j.1469-8986.1989.tb03165.x; JOHNSON R, 1991, J PSYCHOPHYSIOL, V5, P11; Kayser J, 1998, PSYCHOPHYSIOLOGY, V35, P576, DOI 10.1017/S0048577298970214; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KOSMIDIS MH, 1993, AM M COGN ERP RES NE; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LINDHOLM E, 1985, INT J PSYCHOPHYSIOL, V3, P121, DOI 10.1016/0167-8760(85)90032-7; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Montirosso R, 1997, INT J PSYCHOPHYSIOL, V25, P48, DOI 10.1016/S0167-8760(97)85471-2; MUNTE TF, 1994, ARCH NEUROL-CHICAGO, V51, P482, DOI 10.1001/archneur.1994.00540170058017; NAATANE R, 1992, ATTENTION BRAIN FUNC; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Naatanen R, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P169; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; NATIV A, 1994, ARCH PHYS MED REHAB, V75, P1322; NOVAK GP, 1990, ELECTROEN CLIN NEURO, V75, P255, DOI 10.1016/0013-4694(90)90105-S; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPO I, 1982, ACTA NEUROCHIR, V62, P47, DOI 10.1007/BF01402210; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1111/1469-8986.3720127; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Pritchard W., 1991, ADV PSYCHOPHYSIOLOGY; Reinvang I, 1999, NEUROPSYCHOL REV, V9, P231, DOI 10.1023/A:1021638723486; Reinvang I, 1998, J CLIN EXP NEUROPSYC, V20, P885, DOI 10.1076/jcen.20.6.885.1106; RITTER W, 1979, SCIENCE, V203, P1358, DOI 10.1126/science.424760; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; RUCHKIN DS, 1995, PSYCHOPHYSIOLOGY, V32, P399, DOI 10.1111/j.1469-8986.1995.tb01223.x; RUGG M, 1986, CEREBRAL PSYCHOPHY S, V38, P273; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; SPITZER RL, 1975, SCHEDULE AFFECTIVE D; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; STRICH SJ, 1961, LANCET, V2, P443; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Watt S, 1999, NEUROPSYCHOLOGY, V13, P338, DOI 10.1037/0894-4105.13.3.338; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6; WRIGHT MJ, 1994, AUST J PSYCHOL, V46, P63, DOI 10.1080/00049539408259475; [No title captured]	92	27	33	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	JAN	2003	40	1					45	59		10.1111/1469-8986.00006			15	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	636KT	WOS:000180455300006	12751803				2022-02-06	
J	Murai, T; Fujimoto, S				Murai, T; Fujimoto, S			Rapid cycling bipolar disorder after left temporal polar damage	BRAIN INJURY			English	Article							BRAIN INJURY; HEAD-INJURY; RESPONSES; VALPROATE; ANGER	The case of a 48-year-old woman with rapid cycling bipolar disorder subsequent to a traumatic brain injury is reported. Both depressive and manic episodes had an average duration of similar to1 month, alternating without stable euthymic periods. Neuroradiological examinations revealed a circumscribed lesion in the left temporal pole. After 1 year without treatment, psychiatric intervention and pharmacotherapy was initiated. Her mood swings were successfully treated with the co-administration of valproate and lithium. Case reports of rapid cycling bipolar disorder after traumatic brain injury are very rare and this case supports the idea that temporal polar dysfunction is a candidate for the neurobiological basis of rapid cycling bipolar disorder.	Kyoto Univ, Fac Med, Dept Psychiat, Kyoto 6068507, Japan		Murai, T (corresponding author), Kyoto Univ, Fac Med, Dept Psychiat, Shogoin Kawaharacho 54, Kyoto 6068507, Japan.		anand, amit/A-7222-2009				American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ARNOLD SE, 1994, ARCH NEUROL-CHICAGO, V51, P145, DOI 10.1001/archneur.1994.00540140051014; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; Dolan RS, 2000, NEUROIMAGE, V11, P203, DOI 10.1006/nimg.2000.0538; Dougherty DD, 1999, BIOL PSYCHIAT, V46, P466, DOI 10.1016/S0006-3223(99)00063-3; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; Monji A, 1999, PSYCHOSOMATICS, V40, P448, DOI 10.1016/S0033-3182(99)71215-6; MORAN MA, 1987, J COMP NEUROL, V256, P88, DOI 10.1002/cne.902560108; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; Royet JP, 2000, J NEUROSCI, V20, P7752; ZWIL AS, 1993, BRAIN INJURY, V7, P147, DOI 10.3109/02699059309008168; [No title captured]	12	27	28	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	4					355	358		10.1080/0269905031000070170			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	660MP	WOS:000181837200008	12637187				2022-02-06	
J	Rush, AJ				Rush, AJ			Toward an understanding of bipolar disorder and its origin	JOURNAL OF CLINICAL PSYCHIATRY			English	Article; Proceedings Paper	Roundtable Discussion on Bipolar Disorder - From Clinical Research to Therapeutic Intervention	JUN 30, 2001	BERLIN, GERMANY				TRAUMATIC BRAIN INJURY; LIFE EVENTS; PERINATAL COMPLICATIONS; PSYCHIATRIC-DISORDERS; SUBSTANCE-ABUSE; SECONDARY MANIA; MOOD DISORDERS; SOCIAL-CLASS; DRUG-ABUSE; SCHIZOPHRENIA	Bipolar disorder, a disease with significant morbidity and mortality, continues to present diagnostic and clinical challenges. Lifetime prevalence of bipolar I disorder has been estimated at 1.3%, with an equal distribution between males and females. Recognition of the illness may take years, but most patients are diagnosed before the age of 30. The role of genetic influences in bipolar disease is supported by family studies and high concordance rates among monozygotic twins. Current speculation proposes a likely interaction between genetic predisposition and environmental influences, including stressful life events. Diagnostic work-up should exclude mania secondary to drug use or general medical causes, particularly in patients whose symptoms begin after age 30 and in those with no family history of bipolar or unipolar disease. Patients with cyclothymia or thyroid dysfunction or postpartum women are at particular risk for bipolar disease. Substance abuse, which is extremely common among patients with bipolar disorder, interferes with diagnosis and can worsen the course of the disease. Alcohol dependence has been reported in approximately one third of those with bipolar I and one fifth of those with bipolar 11 disorder. To facilitate early diagnosis and effective management, clinicians should be aware of the risk factors, possible causes, and comorbidities of bipolar disease.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA		Rush, AJ (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	john.rush@UTSouthwestern.edu		Rush, Augustus/0000-0003-2004-2382			AKISKAL HS, 1977, AM J PSYCHIAT, V134, P1227; Alda M, 1997, CAN J PSYCHIAT, V42, P378, DOI 10.1177/070674379704200404; BAUER MS, 1990, ARCH GEN PSYCHIAT, V47, P427; BEBBINGTON P, 1995, SOC PSYCH PSYCH EPID, V30, P279, DOI 10.1007/BF00805795; Begley CE, 2001, PHARMACOECONOMICS, V19, P483, DOI 10.2165/00019053-200119050-00004; Berrettini WH, 1997, ARCH GEN PSYCHIAT, V54, P27; BRADY KT, 1992, J CLIN PSYCHOPHARM, V12, pS17, DOI 10.1097/00004714-199202001-00004; Brady KT, 2000, J CLIN PSYCHIAT, V61, P32; BRADY KT, 1995, J CLIN PSYCHIAT, V56, P19; Buka SL, 1999, SCHIZOPHR RES, V39, P113, DOI 10.1016/S0920-9964(99)00109-7; CADORET RJ, 1978, AM J PSYCHIAT, V135, P463; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Cassidy F, 2001, BIPOLAR DISORD, V3, P181, DOI 10.1034/j.1399-5618.2001.030403.x; CORYELL W, 1989, AM J PSYCHIAT, V146, P983; Craddock N, 1999, J MED GENET, V36, P585, DOI 10.1136/jmg.36.8.585; EGELAND JA, 1987, NATURE, V325, P783, DOI 10.1038/325783a0; ELLICOTT A, 1990, AM J PSYCHIAT, V147, P1194; Evans DL, 2000, J CLIN PSYCHIAT, V61, P26; Griswold KS, 2000, AM FAM PHYSICIAN, V62, P1343; HAGGERTY JJ, 1990, BIOL PSYCHIAT, V27, P51, DOI 10.1016/0006-3223(90)90019-X; Hendrick V, 2000, J CLIN PSYCHIAT, V61, P393, DOI 10.4088/JCP.v61n0514; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HIRSCHFELD RMA, 2002, 155 ANN M AM PSYCH A; Hultman CM, 1999, BRIT MED J, V318, P421, DOI 10.1136/bmj.318.7181.421; HUNT N, 1992, J AFFECT DISORDERS, V25, P13, DOI 10.1016/0165-0327(92)90088-N; Johnson SL, 2000, J ABNORM PSYCHOL, V109, P721, DOI 10.1037/0021-843X.109.4.721; Johnson SL, 1997, J ABNORM PSYCHOL, V106, P449, DOI 10.1037/0021-843X.106.3.449; Johnson SL, 1999, J ABNORM PSYCHOL, V108, P558, DOI 10.1037/0021-843X.108.4.558; JONES BE, 1986, HOSP COMMUNITY PSYCH, V37, P61; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kinney DK, 1998, J AFFECT DISORDERS, V50, P117; KINNEY DK, 1993, PSYCHIAT RES, V48, P47, DOI 10.1016/0165-1781(93)90112-T; KRAUTHAMMER C, 1978, ARCH GEN PSYCHIAT, V35, P1333; Leibenluft E, 1996, AM J PSYCHIAT, V153, P163; LENZI A, 1993, SOC PSYCH PSYCH EPID, V28, P56, DOI 10.1007/BF00802092; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; LISH JD, 1994, J AFFECT DISORDERS, V31, P281, DOI 10.1016/0165-0327(94)90104-X; Maier W, 1996, BRIT J PSYCHIAT, V168, P93, DOI 10.1192/S0007125000298462; Moller HJ, 2003, J CLIN PSYCHIAT, V64, P23; MUKHERJEE S, 1983, AM J PSYCHIAT, V140, P1571; Oomen HAPC, 1996, CLIN ENDOCRINOL, V45, P215, DOI 10.1046/j.1365-2265.1996.d01-1558.x; Potash JB, 2000, AM J PSYCHIAT, V157, P2048, DOI 10.1176/appi.ajp.157.12.2048; Preisig M, 2001, COMPR PSYCHIAT, V42, P87, DOI 10.1053/comp.2001.21221; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; SCHWARZKOPF SB, 1989, PSYCHIAT RES, V27, P233, DOI 10.1016/0165-1781(89)90139-X; SHULMAN K, 1980, BRIT J PSYCHIAT, V136, P26, DOI 10.1192/bjp.136.1.26; STINE OC, 1995, AM J HUM GENET, V57, P1384; Strakowski SM, 2000, CLIN PSYCHOL REV, V20, P191, DOI 10.1016/S0272-7358(99)00025-2; STRAKOWSKI SM, 1994, INT J PSYCHIAT MED, V24, P305, DOI 10.2190/CM8E-46R5-9AJL-03FN; VERDOUX H, 1995, J AFFECT DISORDERS, V33, P181, DOI 10.1016/0165-0327(94)00087-P; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; Winokur G, 1998, J AFFECT DISORDERS, V50, P81, DOI 10.1016/S0165-0327(98)00108-6; Winokur G, 1996, AM J MED GENET, V67, P197, DOI 10.1002/(SICI)1096-8628(19960409)67:2<197::AID-AJMG10>3.0.CO;2-E; Woods SW, 2000, J CLIN PSYCHIAT, V61, P38; YASSA R, 1988, J AFFECT DISORDERS, V14, P197, DOI 10.1016/0165-0327(88)90035-3	56	27	28	0	11	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry		2003	64			6			4	8					5	Psychology, Clinical; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Psychiatry	677UU	WOS:000182827000002	12720474				2022-02-06	
J	Park, ES; Park, CI; Kim, DY; Kim, YR				Park, ES; Park, CI; Kim, DY; Kim, YR			The effect of spasticity on cortical somatosensory-evoked potentials: Changes of cortical somatosensory-evoked potentials after botulinum toxin type A injection	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						botulinum toxin type A; cerebral palsy; evoked potentials, somatosensory; rehabilitation; spasticity	CEREBRAL-PALSY; CONTRACTION; DYSTONIA; MUSCLE; INHIBITION; RHIZOTOMY; MOVEMENT; CHILDREN; LIMB	Objective: To evaluate the changes in cortical somatosensory-evoked potentials (SEPs) after botulinum toxin type A injection to determine what effect spasticity has on cortical SEPs. Design: Intervention study and before-after trial. Setting: University-affiliated hospital in Korea. Participants: Twelve children with spastic hemiplegic cerebral palsy (CP), 7 children with spastic diplegic CP, and 8 patients with traumatic brain injury. Intervention: All participants had botulinum toxin type A injected into the muscles of the spastic limb. Main Outcome Measures: SEPs were recorded before and 7 days after the botulinum toxin type A injection. Spasticity of the affected spastic limb was also measured. The short latency and amplitude of waves in SEPs were measured. The SEP results were divided into 3 groups: flat (no evoked potential), abnormal (evoked but delayed in latency), and normal (clear waveform with normal latency). Results: The normal response of cortical SEP increased after injection. The SEPs exhibited more frequent improvement in the limbs, with greater improvement of spasticity in grade (>1.0 grade) and in patients of younger age (<3y) after injection (P<.05). Conclusion: The observed improvement of cortical SEPs with associated reduction of spasticity that occurred after the botulinum toxin type A injection indicates that spasticity itself can be considered a factor affecting cortical SEPs.	Yonsei Univ, Coll Med, Dept Rehabil, Seoul 120752, South Korea; Yonsei Univ, Severance Hosp, Rehabil Dept, Coll Med, Seoul 120752, South Korea; Yonsei Univ, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Res Inst Rehabil Med, Seoul 120752, South Korea; Yonsei Univ, Cerebral Palsy & Pediat Sect, Seoul 120752, South Korea		Kim, YR (corresponding author), Yonsei Univ, Severance Hosp, Rehabil Dept, Coll Med, CPO Box 8044, Seoul 120752, South Korea.	221419@hanmail.net	kim, deog young/Q-8498-2019	Park, Eun Sook/0000-0002-9144-3063; kim, deog young/0000-0001-7622-6311			AALFS CM, 1993, ELECTROEN CLIN NEURO, V89, P437, DOI 10.1016/0168-5597(93)90118-9; ABBRUZZESE G, 1981, J NEUROL NEUROSUR PS, V44, P942, DOI 10.1136/jnnp.44.10.942; APPLEGATE C, 1988, EXP BRAIN RES, V71, P183; Aymard C, 2000, BRAIN, V123, P1688, DOI 10.1093/brain/123.8.1688; CAHAN LD, 1987, APPL NEUROPHYSIOL, V50, P459; CHERON G, 1987, ELECTROEN CLIN NEURO, V67, P537, DOI 10.1016/0013-4694(87)90056-3; Chuang TY, 1999, AM J PHYS MED REHAB, V78, P2, DOI 10.1097/00002060-199901000-00002; DUMITRU D, 1993, AM J PHYS MED REHAB, V72, P75, DOI 10.1097/00002060-199304000-00004; FILIPPI GM, 1993, ACTA OTO-LARYNGOL, V113, P400, DOI 10.3109/00016489309135834; GANTCHEV G, 1994, INT J PSYCHOPHYSIOL, V17, P191, DOI 10.1016/0167-8760(94)90062-0; Giladi N, 1997, J NEUROL SCI, V152, P132, DOI 10.1016/S0022-510X(97)00151-2; Halliday A.M, 1993, EVOKED POTENTIALS CL; JONES SJ, 1989, ELECTROEN CLIN NEURO, V74, P36, DOI 10.1016/0168-5597(89)90049-X; Kanovsky P, 1998, MOVEMENT DISORD, V13, P108, DOI 10.1002/mds.870130122; KUNDI M, 1989, ARCH NEUROL-CHICAGO, V46, P524, DOI 10.1001/archneur.1989.00520410058024; Lin YY, 2000, NEUROIMAGE, V11, P334, DOI 10.1006/nimg.1999.0536; Modugno N, 1998, MUSCLE NERVE, V21, P1701, DOI 10.1002/(SICI)1097-4598(199812)21:12<1701::AID-MUS12>3.0.CO;2-K; Morita H, 1998, EXP BRAIN RES, V120, P143, DOI 10.1007/s002210050388; Nishihira Y, 1996, Electromyogr Clin Neurophysiol, V36, P21; Parise M, 1997, STEREOT FUNCT NEUROS, V69, P268, DOI 10.1159/000099886; PFEIFFER FE, 1989, MUSCLE NERVE, V12, P473, DOI 10.1002/mus.880120607; PRIORI A, 1995, BRAIN, V118, P801, DOI 10.1093/brain/118.3.801; Rossini PM, 1996, MUSCLE NERVE, V19, P191, DOI 10.1002/(SICI)1097-4598(199602)19:2<191::AID-MUS11>3.0.CO;2-Y; RUSHTON DN, 1981, BRAIN, V104, P465, DOI 10.1093/brain/104.3.465; Tinazzi M, 1998, NEUROLOGY, V50, P1655, DOI 10.1212/WNL.50.6.1655; Wissel J, 1999, NEUROPEDIATRICS, V30, P120, DOI 10.1055/s-2007-973475; WONG PKH, 1982, ELECTROEN CLIN NEURO, V54, P266, DOI 10.1016/0013-4694(82)90176-6	27	27	30	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2002	83	11					1592	1596		10.1053/apmr.2002.34623			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	612TP	WOS:000179091800016	12422331				2022-02-06	
J	Varma, MR; Dixon, CE; Jackson, EK; Peters, GW; Melick, JA; Griffith, RP; Vagni, VA; Clark, RSB; Jenkins, LW; Kochanek, PM				Varma, MR; Dixon, CE; Jackson, EK; Peters, GW; Melick, JA; Griffith, RP; Vagni, VA; Clark, RSB; Jenkins, LW; Kochanek, PM			Administration of adenosine receptor agonists or antagonists after controlled cortical impact in mice: effects on function and histopathology	BRAIN RESEARCH			English	Article						excitotoxicity; head injury; hippocampus; Morris water maze; neuroprotection; purine; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; HEAD-INJURY; KINDLED SEIZURES; RAT HIPPOCAMPUS; 2-CHLOROADENOSINE; METABOLISM; CELLS; INTRAPERITONEAL	Adenosine is an endogenous neuroprotectant via anti-excitotoxic effects at A(1) receptors, and blood flow promoting and anti-inflammatory effects at A(2a) receptors. Previous studies showed improved motor function after fluid percussion injury (FPI) in rats treated with the broad-spectrum adenosine receptor agonist 2-chloroadenosine (2-CA). We studied the effects of 2-CA, a specific A(1) agonist (2-chloro-N-6-cyclopentyladenosine, CCPA), and a specific A(1) antagonist (8-cyclopentyl-1,3-dipropylxanthine, DPCPX) on motor task and Morris water maze (MWM) performance, and histopathology (contusion volume, hippocampal cell counts) after controlled cortical impact (CCI) in mice. Each agent (12 nmol), or respective vehicle (saline or DMSO) was injected into dorsal hippocampus beneath the contusion immediately after CCI or craniotomy (sham). 2-CA treatment attenuated wire grip deficits after CCI (P<0.05 versus other treatments). DPCPX treatment exacerbated deficits on beam balance (P<0.05 versus sham). No treatment effect was seen on MWM performance, although there was a deleterious effect of the DMSO vehicle used for DPCPX. Contusion volume tended to be attenuated by 2-CA (P=0.08 versus saline) and increased after either DMSO or DPCPX (P<0.05 versus all groups). CA1 and CA3 counts were decreased in all groups versus sham. However, treatment with the selective A(1) agonist CCPA attenuated the CA3 cell loss (P<0.05 versus other treatment). We suggest that the beneficial effect of the broad spectrum adenosine receptor agonist 2-CA on motor function after CCI is not mediated solely by effects at the A(1) receptor. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318, NS 38037] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS038037, P50NS030318, P01NS030318] Funding Source: NIH RePORTER		Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Boison D, 1999, EXP NEUROL, V160, P164, DOI 10.1006/exnr.1999.7209; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; Costenla AR, 1999, EXP EYE RES, V68, P367, DOI 10.1006/exer.1998.0645; DECKERT J, 1988, BRAIN RES, V446, P161, DOI 10.1016/0006-8993(88)91308-X; DEMENDONCA A, 1994, NEUROSCIENCE, V62, P385, DOI 10.1016/0306-4522(94)90373-5; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dunwiddie Thomas V., 1997, P359; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Geiger Jonathan D., 1997, P55; Grant MB, 1999, CIRC RES, V85, P699, DOI 10.1161/01.RES.85.8.699; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAMM RJ, 1992, J NEUROTRAUMA S1, V9, pS173; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; Kaputlu I, 1998, ANAESTHESIA, V53, P496, DOI 10.1046/j.1365-2044.1998.00330.x; Kemp N, 1997, NEUROSCI LETT, V225, P189, DOI 10.1016/S0304-3940(97)00221-8; Kochanek PM, 2001, MAGNET RESON MED, V45, P924, DOI 10.1002/mrm.1123; KOCHANEK PM, 2001, SOC NEUR ABSTR, V27; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Melani A, 1999, STROKE, V30, P2448, DOI 10.1161/01.STR.30.11.2448; Miller LP, 1999, STROKE THERAPY, P131; Mirnajafi-Zadeh J, 2000, BRAIN RES, V858, P48, DOI 10.1016/S0006-8993(99)02425-7; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Navarro JF, 2000, METHOD FIND EXP CLIN, V22, P43, DOI 10.1358/mf.2000.22.1.795830; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Ochiishi T, 1999, J COMP NEUROL, V411, P301; Ongini E, 1997, ANN NY ACAD SCI, V825, P30, DOI 10.1111/j.1749-6632.1997.tb48412.x; Pourgholami MH, 1997, BRAIN RES, V775, P37, DOI 10.1016/S0006-8993(97)00769-5; Pourgholami MH, 1997, BRAIN RES, V751, P259, DOI 10.1016/S0006-8993(96)01406-0; Puccio AM, 2000, CRIT CARE MED, V28, pA205; RUNCKEL DN, 1980, CLIN CHEM, V26, P1745; Sebastiao AM, 1996, PROG NEUROBIOL, V48, P167, DOI 10.1016/0301-0082(95)00035-6; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; VONLUBITZ DKJ, 1997, PURINERGIC APPROACHE, P449; vonLubitz DKJE, 1997, ANN NY ACAD SCI, V825, P49; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Wiesner JB, 1999, J PHARMACOL EXP THER, V289, P1669; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YU L, 1991, BRAIN RES, V540, P307, DOI 10.1016/0006-8993(91)90525-Z	51	27	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 4	2002	951	2					191	201	PII S0006-8993(02)03161-X	10.1016/S0006-8993(02)03161-X			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	602TB	WOS:000178519600006	12270497				2022-02-06	
J	Groswasser, Z; Reider-Groswasser, II; Schwab, K; Ommaya, AK; Pridgen, A; Brown, HR; Cole, R; Salazar, AM				Groswasser, Z; Reider-Groswasser, II; Schwab, K; Ommaya, AK; Pridgen, A; Brown, HR; Cole, R; Salazar, AM			Quantitative imaging in late TBI. Part II: cognition and work after closed and penetrating head injury: a report of the Vietnam head injury study	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; CT FINDINGS; VETERANS; RETURN; SCAN	Context: Functional outcome in relation to CT findings in traumatic brain injured (TBI) patients is not well established in relation to cognitive and vocational outcome. Objective: To investigate the possible correlation between relatively simple quantitative radiological measurements and cognitive and vocational outcome. Design: Retrospective analysis of quantitative assessment of CT studies in relation to post-injury cognitive changes and vocational outcome. Setting: US Army Medical Centre. Patients: 74 penetrating head injured (PHI) and 37 closed head injured (CHI) Vietnam war veterans. Outcome measures: The Armed Forces Qualification Test (AFQT); Disability score; Return to work. Results: Total brain volume loss, third ventricle width (3VW), ventricular score (VS), and septum-caudate distance (SCD) were significantly related to cognitive change and return to work in PHI patients. Volume loss and 3VW were the most valuable radiologic predictors of outcome in multivariate linear and logistic regression models for both CHI and PHI. Conclusion: 3VW on late CT scans following traumatic brain injury is a powerful predictor of overall long-term cognitive outcomes and potential for return to work.	Uniformed Serv Univ Hlth Sci, Dept Brain Injury Rehabil, Loewenstein Rehabil Hosp, HM Jackson Fdn Advancement Med Sci, IL-43100 Raanana, Israel; Def & Vet Head Injury Prog, Raanana, Israel; Tel Aviv Univ, Sect Sackler Fac Med, IL-69978 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Imaging, Tel Aviv, Israel		Groswasser, Z (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Brain Injury Rehabil, Loewenstein Rehabil Hosp, HM Jackson Fdn Advancement Med Sci, 278 Achza St,POB 3, IL-43100 Raanana, Israel.	zeevgros@ccsg.tau.ac.il					EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; GYLDENSTED C, 1977, NEURORADIOLOGY, V14, P183, DOI 10.1007/BF00496982; JONAS BS, 1987, P SECT SURV RES METH; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; Melamed S, 1982, PSYCHOSOCIAL RES REH, P59; Najenson T, 1980, Int Rehabil Med, V2, P17; REIDERGROSWASSE.I, BRAIN INJURY, V16, P517; ReiderGroswasser I, 1997, BRAIN INJURY, V11, P865, DOI 10.1080/026990597122936; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9	19	27	28	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2002	16	8					681	690		10.1080/02699050110119835			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	583GP	WOS:000177399100004	12167193				2022-02-06	
J	Teplicky, R; Law, M; Russell, D				Teplicky, R; Law, M; Russell, D			The effectiveness of casts, orthoses, and splints for children with neurological disorders	INFANTS & YOUNG CHILDREN			English	Article						brain injury; casting; cerebral palsy; lower extremity; orthosis; upper extremity	ANKLE-FOOT ORTHOSES; CEREBRAL-PALSY; NEURODEVELOPMENTAL THERAPY; GAIT; MANAGEMENT; IMPROVEMENT; WALKING; GRASP	Casts. orthoses. and splints are often used for children with neurological conditions to improve limb positioning and increase functional movement. This article reports the results of a critical review of the literature examining the effectiveness of casts. orthoses, and splints for the upper and lower extremity when used for children with cerebral palsy or brain injury. Results indicate that for children with cerebral palsy, hands splints improve grasp, and upper extremity casts lead to increased range of motion and decreased muscle tone. The effects on upper extremity function need to he studied further. For lower extremity casts. orthoses, and splints, there is evidence to support their effectiveness for children with cerebral palsy in improving range of motion At the ankle, leading to changes in the quality of walking. For children with traumatic brain injury, there is less information on the effects of casts, orthoses, and splints for both the upper and lower extremity. Further research in this area is needed.	McMaster Univ, Inst Appl Hlth Sci, Canchild Ctr Childhood Disabil Res, Hamilton, ON L8S 4L8, Canada		Teplicky, R (corresponding author), McMaster Univ, Inst Appl Hlth Sci, Canchild Ctr Childhood Disabil Res, Hamilton, ON L8S 4L8, Canada.						BERTOTI DB, 1986, PHYS THER, V66, P1522, DOI 10.1093/ptj/66.10.1522; BLAIR E, 1995, DEV MED CHILD NEUROL, V37, P544; Brouwer B, 1998, DEV MED CHILD NEUROL, V40, P168; Brouwer B, 2000, J PEDIATR ORTHOPED, V20, P221, DOI 10.1097/00004694-200003000-00017; Buckon CE, 2001, DEV MED CHILD NEUROL, V43, P371, DOI 10.1017/S0012162201000706; Cameron ME, 1998, NZ J PHYS THER, V26, P28; Carlson WE, 1997, AM J PHYS MED REHAB, V76, P219, DOI 10.1097/00002060-199705000-00012; COPLEY J, 1999, MANAGEMENT LIMB HYPE; Corry IS, 1998, J PEDIATR ORTHOPED, V18, P304, DOI 10.1097/00004694-199805000-00006; Cottalorda J, 2000, J BONE JOINT SURG BR, V82B, P541, DOI 10.1302/0301-620X.82B4.10188; Crenshaw S, 2000, J PEDIATR ORTHOPED, V20, P210, DOI 10.1097/00004694-200003000-00015; Dent K., 1996, AUST OCCUP THER J, V43, P39; Evans C, 1994, DEV MED CHILD NE S70, V36, P26; EXNER CE, 1983, OCCUP THER J RES, V3, P75, DOI 10.1177/153944928300300202; FEHLINGS DL, 1998, KEEPING CURRENT; FLEGLE JH, 1988, RES DEV DISABIL, V9, P145, DOI 10.1016/0891-4222(88)90048-0; Flett PJ, 1999, J PAEDIATR CHILD H, V35, P71, DOI 10.1046/j.1440-1754.1999.00330.x; Hainsworth F, 1997, DEV MED CHILD NEUROL, V39, P243; HILL J, 1994, AM J OCCUP THER, V48, P219, DOI 10.5014/ajot.48.3.219; HINDERER KA, 1988, DEV MED CHILD NEUROL, V30, P370; Katz K, 2000, FOOT ANKLE INT, V21, P1011, DOI 10.1177/107110070002101205; LAW M, 1991, DEV MED CHILD NEUROL, V33, P379; Law M, 1997, DEV MED CHILD NEUROL, V39, P664; Law M, 1998, GUIDELINES CRITICAL; MACKAY S, 1996, AUSTR OCCUPATIONAL T, V43, P51; Maltais D, 2001, MED SCI SPORT EXER, V33, P320; MILLS VM, 1984, PHYS THER, V64, P190, DOI 10.1093/ptj/64.2.190; MOSSBERG KA, 1990, ARCH PHYS MED REHAB, V71, P490; OTIS JC, 1985, J PEDIATR ORTHOPED, V5, P682, DOI 10.1097/01241398-198511000-00010; Radtka SA, 1997, PHYS THER, V77, P395, DOI 10.1093/ptj/77.4.395; Reid D T, 1992, Int J Rehabil Res, V15, P15, DOI 10.1097/00004356-199203000-00002; Rethlefsen S, 1999, J PEDIATR ORTHOPED, V19, P470, DOI 10.1097/00004694-199907000-00009; STANGER M, 1997, ORTHOTICS FUNCTIONAL, P246; TARDIEU G, 1982, ARCH PHYS MED REHAB, V63, P103; WATT J, 1986, DEV MED CHILD NEUROL, V28, P480; Wilson H, 1997, J PEDIATR ORTHOPED, V17, P370	36	27	27	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0896-3746	1550-5081		INFANT YOUNG CHILD	Infants Young Child.	JUL	2002	15	1					42	50		10.1097/00001163-200207000-00007			9	Education, Special; Psychology, Developmental; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Psychology; Rehabilitation	566NP	WOS:000176435100007					2022-02-06	
J	Beaulieu, CL				Beaulieu, CL			Rehabilitation and outcome following pediatric traumatic brain injury	SURGICAL CLINICS OF NORTH AMERICA			English	Article							HEAD-INJURY; CHILDREN; PLASTICITY; SEVERITY; RECOVERY; CORTEX; TBI; AGE; ADOLESCENTS	Mounting evidence indicates that children are more vulnerable than adults to the consequences of traumatic brain injuries. The long-term outcome following traumatic brain injuries sustained in childhood must be viewed in the context of development and maturation. The ultimate outcome is determined by the impact on the child's ability to achieve developmental milestones following injury. Although neuronal plasticity provides a potential for neuronal reorganization, neuronal reorganization is generally incomplete and comes at a cost to long-term development. Pediatric rehabilitation is the setting that not only provides the behavioral and environmental demands necessary to stimulate neuronal reorganization, but also sets the stage for meeting the child's long-term recovery and developmental needs.	Brooks Rehabil Hosp, Neuropsychol Serv, Jacksonville, FL 32216 USA		Beaulieu, CL (corresponding author), Brooks Rehabil Hosp, Neuropsychol Serv, 3599 Univ Blvd S, Jacksonville, FL 32216 USA.	cynthia.beaulieu@brookshealth.org					ALS H, 1994, JAMA-J AM MED ASSOC, V272, P853, DOI 10.1001/jama.272.11.853; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2000, SCI PRACT NEUROPSYCH, P117; Bakker K, 1999, Pediatr Rehabil, V3, P149; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Beaulieu CL, 1997, ARCH CLIN NEUROPSYCH, V12, P285, DOI 10.1093/arclin/12.4.285a; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; Braverman SE, 1999, BRAIN INJURY, V13, P405; Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; *COMM ACCR REH FAC, 2001, MED REH STAND MAN JU; Conway TW, 1998, J INT NEUROPSYCH SOC, V4, P608, DOI 10.1017/S1355617798466104; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; DENNIS M, 1993, J PEDIATR PSYCHOL, V18, P639, DOI 10.1093/jpepsy/18.5.639; Dennis M., 1988, MASTER LECT SERIES, V7, P85; EVANS RL, 1991, ARCH PHYS MED REHAB, V72, P685; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; Fraser R, 1998, TRAUMATIC BRAIN INJU, P417; GREENOUGH WT, 1979, BEHAV NEURAL BIOL, V26, P287, DOI 10.1016/S0163-1047(79)91278-0; Hebb DO, 1949, ORG BEHAV NEUROPSYCH; Indredavik B, 1999, STROKE, V30, P1524, DOI 10.1161/01.STR.30.8.1524; JACKSON RD, 1989, ARCH PHYS MED REHAB, V70, P33; James HE, 1999, ACT NEUR S, V73, P85; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; JURASKA JM, 1980, BEHAV NEURAL BIOL, V29, P157, DOI 10.1016/S0163-1047(80)90482-3; Kelly T P, 1999, Pediatr Rehabil, V3, P187; Kilgard MP, 1998, NAT NEUROSCI, V1, P727, DOI 10.1038/3729; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Ludlow L H, 2000, J Outcome Meas, V4, P482; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Osberg J S, 1997, Pediatr Rehabil, V1, P131; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Pittler MH, 1997, ARCH PHYS MED REHAB, V78, P1281, DOI 10.1016/S0003-9993(97)90346-4; Puurunen K, 2001, EXP NEUROL, V167, P348, DOI 10.1006/exnr.2000.7563; Rothi LJ, 1998, APPROACHES TREATMENT, P179; ROTHI LJG, 2000, 20 ANN M NAT AC NEUR; RUSSELL ML, 1998, TRAUMATIC BRAIN INJU, P61; Satz P., 1994, NEUROPSYCHOLOGY, V8, P255, DOI DOI 10.1037/0894-4105.8.2.255; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Szekeres SF, 1998, TRAUMATIC BRAIN INJU, P389; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEUBER H, 1962, Dev Med Child Neurol, V4, P3; Unsworth C A, 1997, Pediatr Rehabil, V1, P207; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; WAALAND PK, 1998, TRAUMATIC BRAIN INJU, P345; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; YEATES KO, 2000, PEDIAT NEUROPSYCHOLO, V8, P85; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P369; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P429; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P125; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P303; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU	67	27	29	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	APR	2002	82	2					393	+	PII S0039-6109(02)00009-9	10.1016/S0039-6109(02)00009-9			17	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	567XZ	WOS:000176513500011	12113374				2022-02-06	
J	Perry, C; Mackay-Sim, A; Feron, F; McGrath, J				Perry, C; Mackay-Sim, A; Feron, F; McGrath, J			The 2000 Ogura Lecture: Olfactory neural cells: An untapped diagnostic and therapeutic resource	LARYNGOSCOPE			English	Article						olfactory neurones; olfactory ensheathing glial cells; paraplegia cure; schizophrenia diagnosis prevention	ENSHEATHING GLIA; REGENERATION	Objective. This is an over-view of the cellular biology of upper nasal mucosal cells that have special characteristics that enable them to be used to diagnose and study congenital neurological diseases and to aid neural repair. Study Design: After mapping the distribution of neural cells in the upper nose, the authors' investigations moved to the use of olfactory neurones to diagnose neurological diseases of development, especially schizophrenia. Olfactory-ensheating glial cells (OEGs) from the cranial cavity promote axonal penetration of the central nervous system and aid spinal cord repair in rodents. The authors sought to isolate these cells from the more accessible upper nasal cavity in rats and in humans and prove they could likewise promote neural regeneration, making these cells suitable for human spinal repair investigations. Methods: The schizophrenia-diagnosis aspect of the study entailed the biopsy of the olfactory areas of 10 schizophrenic patients and 10 control subjects. The tissue samples were sliced and grown in culture medium. The ease of cell attachment to fibronectin (artificial epithelial basement membrane), as well as the mitotic and apoptotic indices, was studied in the presence and absence of dopamine in those cell cultures. The neural repair part of the study entailed a harvesting and insertion of first rat olfactory lamina propria rich in OEGs between cut ends of the spinal cords and then later the microinjection of an OEG-rich suspension into rat spinal cords previously transected by open laminectomy. Further studies were done in which OEG insertion was performed up to 1 month after rat cord transection and also in monkeys. Results: Schizophrenic patients' olfactory tissues do not easily attach to basement membrane compared with control subjects, adding evidence to the theory that cell wall anomalies are part of the schizophrenic "lesion" of neurones. Schizophrenic patient cell cultures had higher mitotic and apoptotic indices compared with control subjects. The addition of dopamine altered these indices enough to allow accurate differentiation of schizophrenics from control patients, leading to, possibly for the first time, an early objective diagnosis of schizophrenia and possible assessment of preventive strategies. OEGs from the nose were shown to be as effective as those from the olfactory bulb in promoting axonal growth across transected spinal cords even when added I month after injury in the rat. These otherwise paraplegic rats grew motor and proprioceptive and fine touch fibers with corresponding behavioral improvement. Conclusions. The tissues of the olfactory mucosa are readily available to the otolaryngologist. Being surface cells, they must regenerate (called "neurogenesis"). Biopsy of this area and amplification of cells in culture gives the scientist a "window to the developing brain," including early diagnosis of schizophrenia. The "Holy Grail" of neurological disease is the cure of traumatic paraplegia and OEGs from the nose promote that repair. The otolaryngologist may become the necessary partner of the neurophysiologist and spinal surgeon to take the laboratory potential of paraplegic cure into the day-to-day realm of clinical reality.	Univ Queensland, Dept Surg, St Lucia, Qld 4067, Australia; Griffith Univ, Ctr Mol Neurobiol, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia; Univ Queensland, Dept Psychiat, St Lucia, Qld 4067, Australia		Perry, C (corresponding author), Watkins Med Ctr, 4th Floor,225 Wickham Terrace, Brisbane, Qld 4000, Australia.		Feron, Francois/A-3947-2010; Feron, Francois/J-5639-2014; McGrath, John J/G-5493-2010; Mackay-Sim, Alan/C-3431-2008	McGrath, John J/0000-0002-4792-6068; Mackay-Sim, Alan/0000-0003-4446-5371			Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Feron F, 1998, ARCH OTOLARYNGOL, V124, P861, DOI 10.1001/archotol.124.8.861; Feron F, 1999, SCHIZOPHR RES, V40, P211, DOI 10.1016/S0920-9964(99)00055-9; Gogos JA, 2000, CELL, V103, P609, DOI 10.1016/S0092-8674(00)00164-1; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Li Y, 1998, J NEUROSCI, V18, P10514; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099	11	27	28	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0023-852X			LARYNGOSCOPE	Laryngoscope	APR	2002	112	4					603	607		10.1097/00005537-200204000-00002			5	Medicine, Research & Experimental; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Otorhinolaryngology	541DU	WOS:000174970600002	12150509				2022-02-06	
J	Dault, MC; Dugas, C				Dault, MC; Dugas, C			Evaluation of a specific balance and coordination programme for individuals with a traumatic brain injury	BRAIN INJURY			English	Article							SWAY	The purpose of this study was to evaluate the effectiveness of an aerobic dancing training, designed to reduce postural imbalance and coordination deficits for individuals who had sustained a traumatic brain injury (TBI). A two group experimental design was conducted. A control group participated in a traditional muscular training (TMT) programme while participants in the experimental group were assigned to an aerobic dancing, Slide(TM) and Step(TM) training programme (specific training group (ST)). Participants were evaluated pre- and post-training. Balance was quantified using a force platform and coordination using a Peak Performance system to compare the velocity profiles of a modified Jumping jack test. Results showed that temporal variables were significantly different pre- and post-training for the ST group, but no changes were found in the TMT group. The results of the balance test indicated a significant reduction of postural sway area in the ST group but not in the TMT group. Overall, the combination workout with Step(TM) and Slide(TM) is more effective in reducing balance and coordination deficits when compared to muscular based training.	Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON K1N 8M5, Canada; Univ Quebec Trois Rivieres, Dept Sci Act Phys, Trois Rivieres, PQ GA9 5H7, Canada		Dault, MC (corresponding author), Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, 451 Smyth Rd, Ottawa, ON K1N 8M5, Canada.	mdault@uottawa.ca					Ashley MJ, 1995, TRAUMATIC BRAIN INJU; BERGEGO C, 1995, NEUROPSYCHOLOGIE TRA; BERROL C, 1990, Brain Injury, V4, P257; BERROL CF, 1985, AM J DANCE THER, V8, P46, DOI 10.1007/BF02251441; Buchner DM, 1997, AGING CLIN EXP RES, V9, P112, DOI 10.1007/BF03340136; Burton A. W., 1990, ADAPTED PHYSICAL ACT, V7, P126; COHADON F, 1988, SCAND J REHABIL MED, P75; DAULT MC, 1999, P 11 INT S AD PHYS E, P59; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; GILLBODY KM, 1997, PHYS THER, V77, P552; HAGAN M, 1992, PROGRAM SLIDE TRAINI; HOPKINS DR, 1990, GERONTOLOGIST, V30, P189, DOI 10.1093/geront/30.2.189; Horak FB, 1997, PHYS THER, V77, P517, DOI 10.1093/ptj/77.5.517; Leahy Patricia, 1994, P491; REESE S, 1991, NSCA J, V13, P22; SCHARFFOLSON M, 1991, MED SCI SPORTS EXERC, V23, P1311; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; VANIER M, 1993, CLINICIEN, V8, P105; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	22	27	27	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2002	16	3					231	244		10.1080/02699050110103300			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	526HP	WOS:000174124800005	11908477				2022-02-06	
J	Szelies, B; Sobesky, J; Pawlik, G; Mielke, R; Bauer, B; Herholz, K; Heiss, WD				Szelies, B; Sobesky, J; Pawlik, G; Mielke, R; Bauer, B; Herholz, K; Heiss, WD			Impaired benzodiazepine receptor binding in peri-lesional cortex of patients with symptomatic epilepsies studied by [C-11]-flumazenil PET	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						flumazenil positron; emission tomography; lesional epilepsy; peri-lesional FMZ binding; positron emission tomography/magnetic resonance imaging coregistration	TEMPORAL-LOBE EPILEPSY; C-11 FLUMAZENIL-PET; POSITRON-EMISSION-TOMOGRAPHY; INTRAOPERATIVE ELECTROCORTICOGRAPHY; FLUORODEOXYGLUCOSE-PET; INTRACTABLE EPILEPSY; MRI; BRAIN; SURGERY; INVIVO	Individual benzodiazepine receptor (BZR) binding of peri-lesional cortex was investigated in symptomatic epilepsies. Eleven patients aged 19-44 years were studied whose diagnosis was established by medical history, clinical, electroencephalographic, and magnetic resonance imaging (MRI) findings. Three-dimensional [C-11]-flumazenil (FMZ) positron emission tomography and MRI scans were obtained and coregistered. Lesions (five low-grade brain tumours, one AV malformation, one cavernoma, one cystic lesion of unknown aetiology, one traumatic brain injury, one post-operative and one post-haemorrhagic defect) were outlined on individual MRI scans. Adjacent to those lesions, and in homologous contralateral structures, FMZ binding was analysed in four pairs of cortical 9 x 9-mm regions of interest (ROIs) placed on transaxial and coronal slices, respectively, as well as in the lesion volume and its mirror region. Percentage asymmetry ratios were calculated and those at or outside the 90-110% range were operationally defined significant. Peri-lesional FMZ binding asymmetries ranged from 70 to 125%, lesional asymmetries from 38 to 82%. Only one patient showed no significant change, whilst nine exhibited significant reductions of FMZ binding in at least one ROI (3 x 1, 4 x 2, 1 x 3, 1 x 4), and significant increases were observed in two ROIs of another patient. Therefore, peri-lesional disturbances of BZR binding are common but variable in location. Because a close correlation between regional decreases in FMZ binding and spiking activity was recently demonstrated in neocortical epilepsies, abnormal peri-lesional FMZ binding may bear some relation to the mechanisms of epileptogenesis in symptomatic epilepsies.	Neurol Univ Klin, D-50931 Cologne, Germany; Max Planck Inst Neurol Res, D-50931 Cologne, Germany		Szelies, B (corresponding author), Neurol Univ Klin, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.						Arnold S, 2000, EPILEPSIA, V41, P818, DOI 10.1111/j.1528-1157.2000.tb00248.x; AWAD IA, 1991, EPILEPSIA, V32, P179, DOI 10.1111/j.1528-1157.1991.tb05242.x; BURDETTE DE, 1995, NEUROLOGY, V45, P934, DOI 10.1212/WNL.45.5.934; ENGEL J, 1993, J CLIN NEUROPHYSIOL, V10, P90, DOI 10.1097/00004691-199301000-00010; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; FREY KA, 1991, ANN NEUROL, V30, P663, DOI 10.1002/ana.410300506; HAGLUND MM, 1992, J NEUROSURG, V77, P209, DOI 10.3171/jns.1992.77.2.0209; HENRY TR, 1993, NEUROLOGY, V43, P1998, DOI 10.1212/WNL.43.10.1998; Juhasz C, 2000, NEUROLOGY, V55, P825, DOI 10.1212/WNL.55.6.825; Juhasz C, 2000, J CLIN NEUROPHYSIOL, V17, P29; Koepp MJ, 1997, NEUROLOGY, V49, P764, DOI 10.1212/WNL.49.3.764; Koepp MJ, 2000, NEUROLOGY, V54, P332, DOI 10.1212/WNL.54.2.332; Koepp MJ, 1998, ANN NEUROL, V43, P618, DOI 10.1002/ana.410430510; Lamusuo S, 2000, NEUROLOGY, V54, P2252, DOI 10.1212/WNL.54.12.2252; Madar I, 1997, ANN NEUROL, V41, P358, DOI 10.1002/ana.410410311; MAZIERE M, 1984, INT J APPL RADIAT IS, V35, P973, DOI 10.1016/0020-708X(84)90215-1; Muzik O, 2000, NEUROLOGY, V54, P171, DOI 10.1212/WNL.54.1.171; Muzik O, 1998, Comput Aided Surg, V3, P74, DOI 10.1002/(SICI)1097-0150(1998)3:2<74::AID-IGS4>3.0.CO;2-H; Nagy F, 1999, J CEREBR BLOOD F MET, V19, P939, DOI 10.1097/00004647-199909000-00001; OLSEN RW, 1990, J CHEM NEUROANAT, V3, P59; PIETRZYK U, 1994, J NUCL MED, V35, P2011; PILCHER WH, 1993, J NEUROSURG, V78, P891, DOI 10.3171/jns.1993.78.6.0891; Richardson MP, 1998, NEUROLOGY, V51, P485, DOI 10.1212/WNL.51.2.485; Richardson MP, 1996, ANN NEUROL, V40, P188, DOI 10.1002/ana.410400210; Ryvlin P, 1999, NEUROLOGY, V53, P1882, DOI 10.1212/WNL.53.8.1882; Ryvlin P, 1998, BRAIN, V121, P2067, DOI 10.1093/brain/121.11.2067; SAVIC I, 1993, J NEUROL NEUROSUR PS, V56, P615, DOI 10.1136/jnnp.56.6.615; SAVIC I, 1988, LANCET, V2, P863, DOI 10.1016/S0140-6736(88)92468-3; Spencer SS, 1996, EPILEPSIA, V37, P807, DOI 10.1111/j.1528-1157.1996.tb00032.x; Szelies B, 2000, EUR J NEUROL, V7, P393, DOI 10.1046/j.1468-1331.2000.00077.x; Szelies B, 1996, NEUROIMAGE, V3, P109, DOI 10.1006/nimg.1996.0013; Tran TA, 1997, EPILEPSIA, V38, P1132, DOI 10.1111/j.1528-1157.1997.tb01203.x; WIENHARD K, 1994, J COMPUT ASSIST TOMO, V18, P110, DOI 10.1097/00004728-199401000-00023; Wolf HK, 1996, ACTA NEUROPATHOL, V91, P376, DOI 10.1007/s004010050439; Wyllie E, 1998, ANN NEUROL, V44, P740, DOI 10.1002/ana.410440507; Zentner J, 1997, NEUROSURGERY, V41, P378, DOI 10.1097/00006123-199708000-00008	36	27	27	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	MAR	2002	9	2					137	142		10.1046/j.1468-1331.2002.00338.x			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	529QW	WOS:000174310900003	11882054				2022-02-06	
J	Thees, C; Scholz, M; Schaller, C; Gass, A; Pavildis, C; Weyland, A; Hoeft, A				Thees, C; Scholz, M; Schaller, C; Gass, A; Pavildis, C; Weyland, A; Hoeft, A			Relationship between intracranial pressure and critical closing pressure in patients with neurotrauma	ANESTHESIOLOGY			English	Article							CEREBRAL PERFUSION-PRESSURE; CEREBROVASCULAR TONE; CIRCULATION; AUTOREGULATION; MANAGEMENT	Background: The driving pressure gradient for cerebral perfusion is the difference between mean arterial pressure (MAP) and critical closing pressure (CCP = zero flow pressure). Therefore, determination of the difference between MAP and CCP should provide an appropriate monitoring of the effective cerebral perfusion pressure (CPPeff). Based on this concept, the authors compared conventional measurements of cerebral perfusion pressure by MAP and intracranial pressure (CPPICP) with CPPeff. Methods: Simultaneous synchronized recordings of pressure waveforms of the radial artery and blood flow velocities of the middle cerebral artery were performed in 70 head trauma patients. CCP was calculated from pressure-flow velocity plots by linear extrapolation to zero flow. Results: Intracranial pressure measured by intraventricular probes and CCP ranged from 3 to 71 and 4 to 70 mmHg, respectively. Linear correlation between ICP and CCP was r = 0.91. CPPICP was 77 +/- 20 mm g and did not differ from CPPeff; linear correlation was r = 0.92. However, limits of agreement were only +/- 16.2 mmHg. Therefore, in 51.4% of the patients, CPPICP overestimated CPPeff by 19.8 mmHg at most. Conclusion: Assuming that CPPeff (MAP - CCP) takes into account more determinants of cerebral downstream pressure, in individual cases, the actual gold standard of CPP determination (MAP - ICP) might overestimate the CPPeff of therapeutic significance.	Univ Bonn, Klin & Poliklin Anaesthesiol & Specielle Intens M, Dept Anesthesia & Intens Care Med, D-53105 Bonn, Germany		Thees, C (corresponding author), Univ Bonn, Klin & Poliklin Anaesthesiol & Specielle Intens M, Dept Anesthesia & Intens Care Med, Sigmund Freud Str 25, D-53105 Bonn, Germany.						Aaslid R., 1986, INTRACRANIAL PRESSUR, P226; Aaslid R, 1992, TRANSCRANIAL DOPPLER, P49; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BURTON AC, 1951, AM J PHYSIOL, V164, P319, DOI 10.1152/ajplegacy.1951.164.2.319; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; Dawson SL, 1999, J APPL PHYSIOL, V86, P675, DOI 10.1152/jappl.1999.86.2.675; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; EARLY CB, 1974, J NEUROSURG, V41, P590, DOI 10.3171/jns.1974.41.5.0590; MICHEL E, 1995, NEUROL RES, V17, P149, DOI 10.1080/01616412.1995.11740304; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; PANERAI RB, 1995, NEUROPEDIATRICS, V26, P168, DOI 10.1055/s-2007-979748; Panerai RB, 1996, IEEE T BIO-MED ENG, V43, P779, DOI 10.1109/10.508541; PERMUTT S, 1963, J APPL PHYSIOL, V18, P924, DOI 10.1152/jappl.1963.18.5.924; Richards HK, 1999, ACTA NEUROCHIR, V141, P1221, DOI 10.1007/s007010050422; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SACHS I, 1997, ANGEW STAT ANWENDUNG, P84; Weyland A, 2000, J NEUROSURG ANESTH, V12, P210, DOI 10.1097/00008506-200007000-00002	19	27	27	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAR	2002	96	3					595	599		10.1097/00000542-200203000-00014			5	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	526NH	WOS:000174136200013	11873033				2022-02-06	
J	Melamed, H; Harris, MB; Awasthi, D				Melamed, Hooman; Harris, Mitchel B.; Awasthi, Deepak			Anatomic Considerations of Superior Laryngeal Nerve During Anterior Cervical Spine Procedures	SPINE			English	Article						superior laryngeal nerve; anterior cervical spine surgery		Study Design. Cadavers were dissected anatomically to identify the course of the superior laryngeal nerve relative to the spinal column. Objective. To illustrate the anatomic relation of the SLN with respect to its vulnerability during anterior cervical spine procedures. Summary of Background Data. There is ample literature referencing the superior laryngeal nerve with respect to head and neck surgery. Detailed descriptions of the anatomy of the recurrent laryngeal nerve are quite extensive in both the spine and head and neck literature. To the authors' best knowledge, no similar reports have delineated the anatomic relation of the superior laryngeal nerve in procedures on the anterior aspect of the cervical spine. Methods. Ten dissections were carried out on human cadavers to show the course of the superior laryngeal nerve. Particular attention was directed to the internal branch of the superior laryngeal nerve to show the overall anatomic relation relative to standard landmarks. These landmarks included the superior laryngeal and superior thyroid arteries, the split of the superior laryngeal nerve, and the intervertebral disc space. Results. The superior laryngeal nerve originates from the vagus nerve in the carotid sheath and bifurcates into internal and external branches. Distally, the internal branch of the superior laryngeal nerve courses in close proximity with the superior laryngeal artery and inserts within 1 cm superior to the superior laryngeal artery into the thyrohyoid membrane. With respect to the cervical spine, the distal of portion of the internal branch of the superior laryngeal nerve is located between the C3 and C4 vertebral bodies. Conclusions. The internal branch of the superior laryngeal nerve supplies innervation to the mucosa of the larynx and has an important sensory reflex that serves to protect the lungs from aspiration. Injury to this nerve can predispose the patient to life-threatening pneumonia. It is therefore imperative for the surgeon to recognize the location and course of this nerve to avoid injuring it. Injury most commonly occurs either by excessive retraction in different planes or by accidental ligation of the nerve.	[Melamed, Hooman] Louisiana State Univ, Dept Orthopaed Surg, New Orleans, LA USA; [Harris, Mitchel B.] Wake Forrest Univ, Dept Orthopaed Surg, Winston Salem, NC 27157 USA; [Awasthi, Deepak] Louisiana State Univ, Dept Neurosurg, New Orleans, LA USA		Harris, MB (corresponding author), Wake Forest Univ, Sch Med, Dept Orthopaed Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	miharris@wfumc.edu					Blumin JH, 1999, LARYNGOSCOPE, V109, P1637, DOI 10.1097/00005537-199910000-00017; Cannon CR, 1999, OTOLARYNG HEAD NECK, V120, P769, DOI 10.1053/hn.1999.v120.a84675; DROULIAS C, 1976, AM SURGEON, V42, P635; DURHAM CF, 1964, SURG GYNECOL OBSTET, V118, P38; Dursun G, 1996, J VOICE, V10, P206, DOI 10.1016/S0892-1997(96)80048-8; Ebraheim NA, 1997, SPINE, V22, P2663; Eckley CA, 1998, J VOICE, V12, P340, DOI 10.1016/S0892-1997(98)80024-6; El-Guindy A, 2000, J LARYNGOL OTOL, V114, P268; HEENEMAN H, 1973, LARYNGOSCOPE, V83, P17, DOI 10.1288/00005537-197301000-00002; Jonas J, 2000, AM J SURG, V179, P234, DOI 10.1016/S0002-9610(00)00308-1; LENNQUIST S, 1987, SURGERY, V102, P999; Lu J, 2000, ORTHOPEDICS, V23, P841; Mortero RF, 2001, ANESTH ANALG, V92, P271; NAGAYAMA I, 1994, J LARYNGOL OTOL, V108, P417, DOI 10.1017/S0022215100126957; Sanders I, 1998, ANAT RECORD, V252, P646, DOI 10.1002/(SICI)1097-0185(199812)252:4<646::AID-AR15>3.0.CO;2-E; SantAmbrogio G, 1996, PULM PHARMACOL THER, V9, P309, DOI 10.1006/pulp.1996.0040; Stephens RE, 1999, CLIN ANAT, V12, P79, DOI 10.1002/(SICI)1098-2353(1999)12:2<79::AID-CA1>3.0.CO;2-W; Weisberg NK, 1997, OTOLARYNG HEAD NECK, V116, P317, DOI 10.1016/S0194-5998(97)70266-3	18	27	29	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	FEB 15	2002	27	4					E83	E86		10.1097/00007632-200202150-00005			4	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	V43MC	WOS:000209684500001	11840114				2022-02-06	
J	Polo, MD; Newton, P; Rogers, D; Escera, C; Butler, S				Polo, MD; Newton, P; Rogers, D; Escera, C; Butler, S			ERPs and behavioural indices of long-term preattentive and attentive deficits after closed head injury	NEUROPSYCHOLOGIA			English	Article						MMN; P1; N165; P3b; RT; TBI	EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY MMN; TRAUMATIC BRAIN INJURY; AUDITORY ODDBALL TASK; ELECTROPHYSIOLOGICAL EVIDENCE; INVOLUNTARY ATTENTION; PERFORMANCE; DISTRACTIBILITY; GENERATORS; HUMANS	Attentional deficits are often reported even years after sustaining a closed head injury (CHI). Disturbance of cognitive attentional functions following CHI has been documented in both behavioural and event-related brain potential (ERP) studies. Recently, the possibility that the sequelae of CHI extend to preattentive processes of attention has been pointed out. We used a paradigm that makes it possible to assess simultaneously the processing of relevant information and involuntary mechanisms of attention to gain further insight in this matter. Eleven patients with CHI greater than I year post-trauma and 14 age-matched control subjects were engaged in the performance of a continuous visual reaction time (RT) discrimination task while ignoring streams of auditory task-irrelevant stimuli. The main characteristic in the paradigm was that all visual stimuli were shortly preceded by an auditory stimulus, which could be a repeated (90%) or a different (deviant) tone. We measured performance on the discrimination task, and ERP indices of preattentive (mismatch negativity MMN) and attentive information processing (P1, N165, P3b). In relation to control subjects, CHI patients showed an attenuation of the MMN evoked by the deviant-tone. In response to the visual stimuli, CHI patients showed a delay of P1, and a reduction of the N165 and P3b components. Moreover, they had slower RT and missed more responses in a visual discrimination task. These results indicate both preattentive and attentive deficits, which is consistent with the typical diffuse axonal injury (DAI) resulting after CHI. (C) 2002 Elsevier Science Ltd. All rights reserved.	Frenchay Hosp, Burden Neurol Inst, Bristol BS16 1JB, Avon, England; Univ Barcelona, Dept Psychiat & Psychobiol, Neurodynam Lab, Barcelona 08035, Catalonia, Spain		Polo, MD (corresponding author), Frenchay Hosp, Burden Neurol Inst, Bristol BS16 1JB, Avon, England.	dolorespolo@hotmail.com	Escera, Carles/A-8658-2010	Escera, Carles/0000-0001-8203-2951			Alain C, 1998, BRAIN RES, V812, P23, DOI 10.1016/S0006-8993(98)00851-8; ALHO K, 1995, EAR HEARING, V16, P38, DOI 10.1097/00003446-199502000-00004; Alho K, 1997, NEUROREPORT, V8, P3233, DOI 10.1097/00001756-199710200-00010; ALHO K, 1994, ELECTROEN CLIN NEURO, V91, P353, DOI 10.1016/0013-4694(94)00173-1; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Barcelo F, 2000, NAT NEUROSCI, V3, P399, DOI 10.1038/73975; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; Deacon-Elliott D., 1987, COGNITIVE REHABILITA, V5, P12; Deouell LY, 1998, PSYCHOPHYSIOLOGY, V35, P355, DOI 10.1017/S0048577298970287; Escera C, 2000, AUDIOL NEURO-OTOL, V5, P151, DOI 10.1159/000013877; Escera C, 1998, J COGNITIVE NEUROSCI, V10, P590, DOI 10.1162/089892998562997; FernandezDuque D, 1997, NEUROPSYCHOLOGIA, V35, P477, DOI 10.1016/S0028-3932(96)00103-0; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; HILLYARD SA, 1973, SCIENCE, V182, P177, DOI 10.1126/science.182.4108.177; JENNETT B, 1975, LANCET, V1, P480; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Kaipio ML, 2001, NEUROREPORT, V12, P1517, DOI 10.1097/00001756-200105250-00043; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; LEVIN HS, 1982, NEUROBEHAVIOURAL CON, P3; LEVIN HS, 1987, HEAD INJURY; MANGUN GR, 1988, ELECTROEN CLIN NEURO, V70, P417, DOI 10.1016/0013-4694(88)90019-3; Martinez A, 1999, NAT NEUROSCI, V2, P364, DOI 10.1038/7274; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Naatanen R, 1992, ATTENTION BRAIN FUNC; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; VANZOMEREN AH, 1984, ATTENTIONAL DEFICITS, P74; Vogenthaler D R, 1987, Brain Inj, V1, P113; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	38	27	27	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2002	40	13					2350	2359	PII S0028-3932(02)00127-6	10.1016/S0028-3932(02)00127-6			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	623RH	WOS:000179716300014	12417464				2022-02-06	
J	Zurita, M; Vaquero, J; Oya, S; Morales, C				Zurita, M; Vaquero, J; Oya, S; Morales, C			Effects of dexamethasone on apoptosis-related cell death after spinal cord injury	JOURNAL OF NEUROSURGERY			English	Article						spinal cord injury; apoptosis; Apostain; dexamethasone; rat	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; HEMORRHAGIC NECROSIS; CEREBRAL-ISCHEMIA; MALIGNANT GLIOMA; NEURONAL DEATH; T-LYMPHOCYTES; GENE-TRANSFER; BRAIN INJURY; ADULT-RAT	Object. The purpose of this study was to analyze the expression of F7-26 (Apostain) in injured spinal cord tissue, and the modifying effects of dexamethasone administration. Methods. A total of 56 adult female Wistar rats were subjected to traumatic spinal cord injury (SCI) to induce complete paraplegia. These rats were divided into two groups according to whether they received dexamethasone (doses of 1 mg/kg daily) post-SCI. Injured spinal cord tissue was studied by means of conventional histological techniques, and Apostain expression was determined by immunohistochemical analysis at 1, 4, 8, 24, and 72 hours, and at 1 and 2 weeks after SCI in all the animals. Apostain-positive cells, mainly neurons and glial cells, were detected 1 hour after injury, peaking at 8 hours, after which the number decreased. One week after injury, apoptosis was limited to a few glial cells, mainly oligodendrocytes, and 2 weeks after injury there was no evidence of Apostain-positive cells. In the group of paraplegic rats receiving post-SCI intraperitoneal dexamethasone, there was a significant decrease in the number of Apostain-positive cells. Conclusions. Analysis of the results indicated that apoptosis plays a role in the early period after SCI and that administration of dexamethasone decreases apoptosis-related cell death in the injured spinal cord tissue.	Univ Autonoma Madrid, Puerta de Hierro Clin, Neurosurg Serv, Madrid 28035, Spain; Mapfre Med Fdn, Neurosci Res Unit, Madrid, Spain		Vaquero, J (corresponding author), Univ Autonoma Madrid, Puerta de Hierro Clin, Neurosurg Serv, San Martin de Porres 4, Madrid 28035, Spain.						Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; ANDERSON TE, 1992, J NEUROTRAUMA S1, V9, P135; BALENTINE JD, 1978, LAB INVEST, V39, P236; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; BLIGHT AR, 1992, J NEUROTRAUM, V9, P147, DOI 10.1089/neu.1992.9.147; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; Crowe M. J., 1995, Society for Neuroscience Abstracts, V21, P232; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; DAWSON VL, 1993, J NEUROSCI, V13, P2651; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Ferlini C, 1997, J IMMUNOL METHODS, V205, P95, DOI 10.1016/S0022-1759(97)00054-9; Frankfurt OS, 1996, EXP CELL RES, V226, P387, DOI 10.1006/excr.1996.0240; Gonzalez SL, 1999, CELL MOL NEUROBIOL, V19, P597, DOI 10.1023/A:1006980301382; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kanellopoulos GK, 1997, ANN THORAC SURG, V64, P1279, DOI 10.1016/S0003-4975(97)00903-X; Kaptanoglu E, 1999, J NEUROSURG, V91, P200, DOI 10.3171/spi.1999.91.2.0200; Katoh K, 1996, NEUROSCI LETT, V216, P9; Katoh O, 1998, CANCER RES, V58, P5565; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KIWERSKI JE, 1993, INJURY, V24, P457, DOI 10.1016/0020-1383(93)90149-Z; KOBRINE AI, 1975, J NEUROSURG, V42, P144, DOI 10.3171/jns.1975.42.2.0144; Lemke M, 1990, J NEUROTRAUM, V7, P41, DOI 10.1089/neu.1990.7.41; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI Y, 1995, AM J PATHOL, V146, P1045; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; NAGAFUJI T, 1995, MOL CHEM NEUROPATHOL, V26, P107, DOI 10.1007/BF02815009; Namura S, 1998, J NEUROSCI, V18, P3659; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Olby N, 1999, J VET INTERN MED, V13, P399, DOI 10.1892/0891-6640(1999)013&lt;0399:CCITMO&gt;2.3.CO;2; Oneda K, 1999, Arerugi, V48, P13; OSTERHOLM JL, 1972, J NEUROSURG, V36, P386, DOI 10.3171/jns.1972.36.4.0386; OSTERHOLM JL, 1972, J NEUROSURG, V36, P395, DOI 10.3171/jns.1972.36.4.0395; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x; Rieger J, 1998, ONCOGENE, V17, P2323, DOI 10.1038/sj.onc.1202154; RINK A, 1995, AM J PATHOL, V147, P1575; Schmidt M, 1999, J IMMUNOL, V163, P3484; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Tacconi MT, 1998, NEUROCHEM RES, V23, P759, DOI 10.1023/A:1022463527474; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TSAI YH, 1975, BIOCHEMISTRY-US, V14, P1257, DOI 10.1021/bi00677a026; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WELLER M, 1995, CANCER RES, V55, P2936; WEN LP, 1997, AM J PHYSIOL, V273, P921; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; Yick LW, 1999, EXP NEUROL, V159, P131, DOI 10.1006/exnr.1999.7134; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Young W, 1985, Cent Nerv Syst Trauma, V2, P109; YOUNG W, 1994, HORMONAL RESTRUCTURI, P241; YOUNG W, 1992, SPINAL CORD TRAUMA H, V17, P399; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zunino SJ, 1996, AM J PATHOL, V149, P653; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257; ZURITA M, 1994, POLYTRAUMATIZED, P343	70	27	33	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2002	96	1		S			83	89		10.3171/spi.2002.96.1.0083			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	509PA	WOS:000173155100014	11795719				2022-02-06	
J	McMahon, MA; Noll, RB; Michaud, LJ; Johnson, JC				McMahon, MA; Noll, RB; Michaud, LJ; Johnson, JC			Sibling adjustment to pediatric traumatic brain injury: A case-controlled pilot study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior; depressive symptoms; pediatric traumatic brain injury; self-concept; siblings	CHILDHOOD-CANCER; CHILDREN; FAMILY; PREDICTORS; ADAPTATION	Objective: To assess depressive symptoms, self-concept, and behavior in non-affected siblings of children with severe pediatric traumatic brain injury (TBI). Design: Cross-sectional study with case controls. Setting: Children's hospital tertiary care center. Participants: Twelve siblings of children consecutively admitted to an inpatient rehabilitation unit after a severe TBI. Case controls were randomly selected from the sibling's classmates. Main Outcome Measures: The Child Behavior Checklist (CBCL), the Teacher's Report Form of the CBCL (TRF-CBCL), the Self-Perception Profile for Children and the Children's Depression Inventory (CDI). Results: No statistical differences were found in depressive symptoms, self-concept, or behavior between the siblings and their classmates 3 to 18 months after injury: Poorer functional outcomes in the child with a TBI were found to correlate significantly with lower self-concept and more symptoms of depression in the siblings. Conclusions: Further research is needed to evaluate the potential impact on sibling adjustment after pediatric TBI.	Childrens Hosp, Med Ctr, Div Pediat Rehabil, Dept Pediat Rehabil, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Dept Hematol Oncol, Div Hematol Oncol, Cincinnati, OH 45229 USA; Univ Missouri, Biostat Off, Integrated Technol Serv, Columbia, MO USA		McMahon, MA (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Rehabil, Dept Pediat Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Johnson, Jane/0000-0002-8825-5926			Achenbach TM, 1986, MANUAL CHILD BEHAV C; AMSTEN A, 1989, EMERGENCE DISCIPLINE; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; CADMAN D, 1988, J DEV BEHAV PEDIATR, V9, P117; Edelbrock C., 1986, MANUAL TEACHERS REPO; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gill D. J., 2000, REHABILITATION NURSI, V25, P48, DOI [10.1002/j.2048-7940.2000.tb01862.x, DOI 10.1002/J.2048-7940.2000.TB01862.X]; Harter S., 1985, MANUAL SELF PERCEPTI; Houtzager BA, 1999, SUPPORT CARE CANCER, V7, P302, DOI 10.1007/s005200050268; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Kovacs M., 1992, MANUAL CHILDRENS DEP; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; NOLL RB, 1995, J PEDIATR PSYCHOL, V20, P165, DOI 10.1093/jpepsy/20.2.165; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [10.1097/00001199-199303000-00010, DOI 10.1097/00001199-199303000-00010]; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; SAHLER OJZ, 1994, J DEV BEHAV PEDIATR, V15, P353; TEASDALE G, 1974, LANCET, V2, P81; *U BUFF, 1998, WEEFIM SYST CLIN GUI; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110	22	27	27	0	1	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2001	16	6					587	594		10.1097/00001199-200112000-00006			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	501AL	WOS:000172660800006	11732973				2022-02-06	
J	Carlotti, APCP; Bohn, D; Rutka, JT; Singh, S; Berry, D; Sharman, A; Cusimano, M; Halperin, ML				Carlotti, APCP; Bohn, D; Rutka, JT; Singh, S; Berry, D; Sharman, A; Cusimano, M; Halperin, ML			A method to estimate urinary electrolyte excretion in patients at risk for developing cerebral salt wasting	JOURNAL OF NEUROSURGERY			English	Article						chloride; hyponatremia; neurosurgery; syndrome of inappropriate antidiuretic hormone secretion; traumatic brain injury	ANTI-DIURETIC HORMONE; TOTAL-BODY WATER; INAPPROPRIATE SECRETION; ACUTE HYPONATREMIA; FLUID VOLUME; SALINE	Object. Two major criteria are necessary to diagnose cerebral salt wasting (CSW): a cerebral lesion and a large urinary excretion of Na+ and Cl- at a time when the extracellular fluid (ECF) volume is contracted. Nevertheless, it is difficult for the physician to confirm from bedside observation that a patient has a contracted ECF volume. Hyponatremia, although frequently present, should not be a criterion for a diagnosis of salt wasting. A contracted ECF volume is unlikely if there are positive balances of Na+ and Cl-. The goal of this study was to assess the accuracy of calculating balances for Na+ plus K+ and of Cl- over 1 to 10 days in an intensive care unit (ICU) setting. Methods. A prospective comparison of measured and estimated quantities of Na+ plus K+ and of Cl- excreted over 1 to 10 days in 10 children and 12 adults who had recently received a traumatic brain injury or undergone recent neurosurgery. Plasma concentrations of electrolytes were recorded at the beginning and end of the study period. The total volumes infused and excreted and the concentrations of Na+, K+, and Cl- in the infusate were obtained from each patient's ICU chart. The electrolytes in the patients' urine were measured and calculated. Correlations between measured and calculated values for excretions of Cl- and of Na+ plus K+ were excellent. Conclusions. Mass balances for Na+ plus K+ and for Cl- can be accurately estimated. These data provide information to support or refute a clinical diagnosis of CSW. The danger of relying on balances for these electrolytes measured within a single day to diagnose CSW is illustrated.	St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1A6, Canada; Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada		Halperin, ML (corresponding author), St Michaels Hosp, Div Nephrol, 38 Shuter St, Toronto, ON M5B 1A6, Canada.	mitchell.halperin@utoronto.ca	Carlotti, Ana PCP/G-4893-2012; Cusimano, Michael/X-4059-2019	Carlotti, Ana PCP/0000-0003-2760-8801; Cusimano, Michael/0000-0002-9989-0650			BURCH GE, 1945, AM J MED SCI, V209, P226, DOI 10.1097/00000441-194502000-00014; CHUNG HM, 1987, AM J MED, V83, P905, DOI 10.1016/0002-9343(87)90649-8; DECAUX G, 1980, AM J MED, V69, P99, DOI 10.1016/0002-9343(80)90506-9; DECAUX G, 1981, NEW ENGL J MED, V304, P329, DOI 10.1056/NEJM198102053040605; Gowrishankar M, 1998, CLIN NEPHROL, V50, P352; Gowrishankar M, 1996, KIDNEY INT, V50, P1490, DOI 10.1038/ki.1996.463; HALPERIN ML, 1985, AM J PHYSIOL, V248, pF607, DOI 10.1152/ajprenal.1985.248.4.F607; HALPERIN ML, 1993, CLIN DETECTIVE STORI, P273; Halperin ML., 1999, FLUID ELECTROLYTE AC, V3; HANTMAN D, 1973, ANN INTERN MED, V78, P870, DOI 10.7326/0003-4819-78-6-870; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; Kamel KS, 1998, KIDNEY INT, V53, P531, DOI 10.1046/j.1523-1755.1998.00803.x; KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001; Laredo S, 1996, J AM SOC NEPHROL, V7, P2527; MacGregor G., 1998, SALT DIET HLTH NEPTU; Mallie JP, 1997, CLIN INVEST MED, V20, P16; McCance RA, 1936, LANCET, V1, P823; MOOREEDE MC, 1977, AM J PHYSIOL, V232, pF128, DOI 10.1152/ajprenal.1977.232.2.F128; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Porzio P, 2000, CRIT CARE MED, V28, P1905, DOI 10.1097/00003246-200006000-00037; QUINTON PM, 1987, KIDNEY INT, V32, pS102; ROBERTSON GL, 2000, KIDNEY PHYSL PATHOPH, V2, P1133; SATO K, 1989, J AM ACAD DERMATOL, V20, P537, DOI 10.1016/S0190-9622(89)70063-3; Schmidt-Nielsen K., 1997, ANIMAL PHYSL ADAPTAT; SPITAL A, 1989, ARCH INTERN MED, V149, P1255, DOI 10.1001/archinte.149.6.1255; Steele A, 1997, ANN INTERN MED, V126, P20, DOI 10.7326/0003-4819-126-1-199701010-00003; Sterns Richard H., 1993, P225; Taubes C, 1998, SCIENCE, V281, P898, DOI 10.1126/science.281.5379.898; WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27; WIJDICKS EFM, 1985, ANN NEUROL, V17, P137, DOI 10.1002/ana.410170206	30	27	28	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2001	95	3					420	424		10.3171/jns.2001.95.3.0420			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	470WP	WOS:000170894600008	11565862				2022-02-06	
J	Schopp, LH; Shigaki, CL; Johnstone, B; Kirkpatrick, HA				Schopp, LH; Shigaki, CL; Johnstone, B; Kirkpatrick, HA			Gender differences in cognitive and emotional adjustment to traumatic brain injury	JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS			English	Article						depression; emotion; traumatic brain injury; neuropsychological testing; gender	SEX-DIFFERENCES; HEAD; INTELLIGENCE; PROGESTERONE	This study examined gender differences in cognitive and emotional status after traumatic brain injury (TBI) among 262 men and 140 women with TBI referred for neuropsychological evaluations. In this cross-sectional study, cognition was measured in terms of both absolute level of functioning (i.e., raw/standard scores) and estimated decline from premorbid levels expressed as z-deficit scores in the following domains: intelligence [Wechsler Adult Intelligence Scale-Revised (WAIS-R)], memory and attention [Wechsler Memory Scale-Revised (WMS-R)], processing speed (Trails A), and cognitive flexibility (Trails B). Emotional functioning was measured in terms of depression (Beck Depression Inventory) and general emotional distress (Brief Symptom Inventory). Kruskal-Wallis nonparametric one-way ANOVAs indicated that women and men differed significantly on 2 of 8 raw/standard cognitive scores [men demonstrated lower WMS-R General Memory (p < .05) and Trails B scores (p < .0001) and 4 of 8 relative decline scores [women demonstrated more estimated change in VIQ (Verbal IQ) [p < .0001], FSIQ (Full Scale IQ) [p < .01], and Attention (p < .01)]; men demonstrated greater estimated z-decline scores on Trails B (p < .01)]. Women reported significantly higher levels of depression (p < .01), but men endorsed significantly greater general psychological distress (p < .05). Research and assessment recommendations are suggested.	Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO 65212 USA		Schopp, LH (corresponding author), Univ Missouri, Sch Med, Dept Phys Med & Rehabil, DC046-00,1 Hosp Dr, Columbia, MO 65212 USA.	schoppl@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			*AG HLTH CAR POL R, 1998, REH TRAUM BRAIN INJ; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; ANDREASEN NC, 1993, AM J PSYCHIAT, V150, P130; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DEROGATIS LR, 1993, ADMINISTRATION SCORI; FARACE E, 2000, DO WOMEN FARE WORSE; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; Gerberich SG, 1997, NEUROEPIDEMIOLOGY, V16, P1, DOI 10.1159/000109665; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HAYES ZL, 1994, CAN J BEHAV SCI, V26, P421, DOI 10.1037/0008-400X.26.3.421; INGLIS J, 1982, CAN J PSYCHOL, V36, P670, DOI 10.1037/h0080670; Jastak S., 1984, WRAT R WIDE RANGE AC; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; JOHNSTONE BJ, 1999, J HEAD TRAUMA REHAB, V14, P10; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Levy J., 1992, SEXUAL DIFFERENTIATI, V11; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Millis Scott R., 1993, Brain Injury, V7, P53, DOI 10.3109/02699059309008156; *NAT CTR INJ PREV, 2000, EP TRAUM BRAIN INJ U; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Reitan R, 1986, TRAIL MAKING TEST MA; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; STEIN DG, 1995, RESTOR NEUROL NEUROS, V8, P105, DOI 10.3233/RNN-1995-81226; *TBI MOD SYST NAT, 1998, TBI FACTS FIG; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Turkheimer E., 1992, PSYCHOL ASSESSMENT, V4, P498; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MANUAL WECHSLER MEMO; WEISSMAN MM, 1993, J AFFECT DISORDERS, V29, P77, DOI 10.1016/0165-0327(93)90025-F; Wilkinson G, 1993, WRAT3 WIDE RANGE ACH; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	40	27	27	0	6	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9583	1573-3572		J CLIN PSYCHOL MED S	J. Clin. Psychol. Med. Settings	SEP	2001	8	3					181	188		10.1023/A:1011369620254			8	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	471FN	WOS:000170918000006					2022-02-06	
J	Shi, R; Qiao, X; Emerson, N; Malcom, A				Shi, R; Qiao, X; Emerson, N; Malcom, A			Dimethylsulfoxide enhances CNS neuronal plasma membrane resealing after injury in low temperature or low calcium	JOURNAL OF NEUROCYTOLOGY			English	Article							MAMMALIAN SPINAL-CORD; CYTOCHEMICAL EVIDENCE; AXONAL DAMAGE; NERVE-FIBERS; BRAIN-INJURY; OPTIC-NERVE; IN-VITRO; HYPOTHERMIA; TRANSECTION; PERMEABILITY	The inability to repair the damaged membrane may be one of the key mechanisms underlying the severe neuronal degeneration and overall functional loss seen in in vivo spinal cord injury and traumatic axonal injury in blunt head trauma. Promoting membrane resealing following damage may therefore constitute a potential effective therapeutic intervention in treating head trauma and spinal cord injuries. In our previous studies, we have shown that the axolemma failed to reseal following transection in clinically related situations, such as low extracellular calcium and low temperature. Our current studies indicate that DMSO is capable of rendering significant improvement in guinea pig axonal membrane resealing following transection in both 0.5 mM [Ca2+](0) and 25degreesC situations. This was demonstrated physiologically by monitoring membrane potential recovery and anatomically by conducting HRP-exclusion assays 60 minutes after injury. Further, we have shown that the addition of DMSO in normal Krebs' solution (2 mM [Ca2+](0) and 37degreesC) resulted in a decrease in membrane repair following injury. This indicates that DMSO-mediated membrane repair is sensitive to temperature and calcium. This study suggests the role of DMSO in axonal membrane resealing in clinically relevant conditions and raises the possibility of using DMSO in combination with other more established therapies in spinal cord injury treatment.	Purdue Univ, Sch Vet Med, Inst Appl Neurol, Dept Basic Med Sci, W Lafayette, IN 47907 USA		Shi, R (corresponding author), Purdue Univ, Sch Vet Med, Inst Appl Neurol, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	riyi@vet.purdue.edu					BADYLAK SF, 1986, AM J EMERG MED, V4, P313, DOI 10.1016/0735-6757(86)90299-8; Brown M, 1988, J Burn Care Rehabil, V9, P22, DOI 10.1097/00004630-198801000-00007; Bruck R, 1999, J HEPATOL, V31, P27, DOI 10.1016/S0168-8278(99)80160-3; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Cochran T, 1983, Curr Surg, V40, P435; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Eddleman CS, 1998, J NEUROSCI, V18, P4029; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; GARRETT RH, 1999, BIOCHEMISTRY; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; GROSS GW, 1987, EXP BRAIN RES, V67, P52, DOI 10.1007/BF00269452; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HANSEBOUT RR, 1984, SPINE, V9, P508, DOI 10.1097/00007632-198407000-00020; HAYES KC, 1993, PARAPLEGIA, V31, P730, DOI 10.1038/sc.1993.115; Heimer L, 1989, NEUROANATOMICAL TRAC; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Kirpatovskii V I, 1995, Urol Nefrol (Mosk), P32; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; LUCAS JH, 1994, J NEUROTRAUM, V11, P35, DOI 10.1089/neu.1994.11.35; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Miyake K, 2001, J CELL SCI, V114, P3487; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; ROEDERER E, 1983, J NEUROSCI, V3, P153; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SANGER JW, 1980, P NATL ACAD SCI-BIOL, V77, P5268, DOI 10.1073/pnas.77.9.5268; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572, DOI 10.1152/jn.1996.76.3.1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763, DOI 10.1152/jn.2000.84.4.1763; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; VINCENT C, 1990, MOL REPROD DEV, V26, P227, DOI 10.1002/mrd.1080260306; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Winckler B, 1999, NATURE, V397, P698, DOI 10.1038/17806; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1985, J NEUROSCI, V5, P1626; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; Yu ZW, 1998, MOL MEMBR BIOL, V15, P59, DOI 10.3109/09687689809027519	51	27	28	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	SEP-OCT	2001	30	9-10					829	839		10.1023/A:1019645505848			11	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	582AX	WOS:000177328500006	12165673				2022-02-06	
J	Lewis, LM; Naunheim, R; Standeven, J; Lauryssen, C; Richter, C; Jeffords, B				Lewis, LM; Naunheim, R; Standeven, J; Lauryssen, C; Richter, C; Jeffords, B			Do football helmets reduce acceleration of impact in blunt head injuries?	ACADEMIC EMERGENCY MEDICINE			English	Article						football helmets; sports injuries; head injuries; acceleration	SOCCER PLAYERS; COLLEGE FOOTBALL; CONCUSSION	Several recent studies suggest that acceleration of the head at impact during sporting activities may have a detrimental effect on cognitive function. Reducing acceleration of impact in these sports could reduce neurologic sequelae. Objective: To measure the effectiveness of a regulation football helmet to reduce acceleration of impact for both low- and moderate-force impacts. Methods: An experimental paired study design was used. Male volunteers between 16 and 30 years of age headed soccer balls traveling approximately 35 miles per hour bareheaded and with a helmet. An intraoral accelerometer worn inside a plastic mouthpiece measured acceleration of the head. The helmet also had an accelerometer placed inside the padding. For more forceful impacts, cadaver heads, both with and without helmets, were instrumented with intraoral (IO) and intracranial (IC) accelerometers and struck with a pendulum device. Simultaneous IO and IC accelerations were measured and compared between helmeted and unhelmeted cadaver heads. The main outcome was mean peak acceleration of the head and/or brain associated with low- and moderate-force impacts with and without protective headgear. Results: Mean peak Gs, measured by the mouthpiece accelerometer, were significantly reduced when the participants heading soccer balls were wearing a helmet (7.7 Gs with vs 19.2 Gs without, p = 0.01). Wearing a helmet also significantly lowered the peak Gs measured intraorally and intracranially in cadavers subjected to moderate-force pendulum impacts: 28.7 Gs with vs 62.6 Gs without, p < 0.001; and 56.4 Gs with vs 81.6 Gs without, p < 0.001, respectively. Conclusions: A regulation football helmet substantially reduced the peak Cs associated with "heading" a soccer ball traveling at moderately high velocities. A helmet was also effective in reducing the peak acceleration both intraorally and intracranially for impacts significantly more forceful than heading a soccer ball.	Washington Univ, Sch Med, Emergency Med Div, St Louis, MO USA; Barnes Jewish Hosp, Human Performance Lab, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO USA		Lewis, LM (corresponding author), Washington Univ, Med Ctr, Div Emergency Med, Washington Univ Phys, Campus Box 8072,660 S Euclid Ave, St Louis, MO 63110 USA.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; *ASTM, 1997, F144697 ASTM, P923; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dietzen C J, 1999, Phys Med Rehabil Clin N Am, V10, P159; GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; LEWIS LM, 1993, ANN EMERG MED, V22, P900; Linn S, 1998, Inj Prev, V4, P122; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MCDERMOTT FT, 1982, MED J AUSTRALIA, V2, P30, DOI 10.5694/j.1326-5377.1982.tb124205.x; MURRAY WA, 1999, 2000 OFFICIAL RULES, P14; *NAT FOOTB LEAG, 1999, OFF RUL NFL, P58; OFFNER PJ, 1992, J TRAUMA, V32, P636, DOI 10.1097/00005373-199205000-00016; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; *US HOCK INC, 1999, 1999 2001 OFF RUL IC, P31; 2000, 2000 OFFICIAL RULES, P39	25	27	27	0	11	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUN	2001	8	6					604	609		10.1111/j.1553-2712.2001.tb00171.x			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	441FM	WOS:000169220400002	11388933	Bronze			2022-02-06	
J	Woertgen, C; Rothoerl, RD; Brawanski, A				Woertgen, C; Rothoerl, RD; Brawanski, A			Neuron-specific enolase serum levels after controlled cortical impact injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						neuron-specific enolase; rat; traumatic brain injury	MINOR HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; S-100 PROTEIN; BRAIN-DAMAGE; CEREBROSPINAL-FLUID; COMPUTED-TOMOGRAPHY; ISCHEMIC STROKE; SERIAL S-100; BLOOD; INDICATORS	The aim of this study was to investigate the time course and the correlation of neuron-specific enolase (NSE) serum levels to the severity of traumatic brain injury in rats, Sixty-five male Wistar rats were subjected to severe cortical impact injury (100 PSI, 2 mm deformation). Blood samples were drawn directly after trauma and after 1, 6, 12, 24, and 48 h in the trauma group. In the sham operated levels animals samples were drawn directly after craniotomy and after 6 and 48 h, Additionally, NSE serum levels after controlled cortical impact at different levels of severity samples (45 PSI, 75 PSI; 2 mm deformity) were compared to sham-operated animals, The severity of the injury was not validated histopathologically, NSE serum levels were estimated with a commercially available enzyme immunoassay (LIA mat Sangtec(R)), The control animals showed a NSE serum level of 8.82 mug/L (mean, n = 10) and the injured animals demonstrated a time-dependent release of NSE into the serum. The highest NSE serum values were detected 6 h after trauma (31.5 mug/L mean, n = 10), In addition, we found a close relationship between NSE serum levels and the severity of traumatic brain injury in the cortical impact model. NSE serum levels reflect in a time-dependent manner the severity of brain trauma induced by cortical impact model in rat.	Univ Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany		Woertgen, C (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.						DIXON CE, 1991, J NEUROSCI METH, V39, P253; FAGNART OC, 1988, CLIN CHEM, V34, P1387; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; UZAN M, 1995, ACTA NEUROCHIR, V135, P141, DOI 10.1007/BF02187758; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977	19	27	46	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					569	573		10.1089/089771501300227378			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000010	11393260				2022-02-06	
J	Wildburger, R; Zarkovic, N; Leb, G; Borovic, S; Zarkovic, K; Tatzber, F				Wildburger, R; Zarkovic, N; Leb, G; Borovic, S; Zarkovic, K; Tatzber, F			Post-traumatic changes in insulin-like growth factor type 1 and growth hormone in patients with bone fractures and traumatic brain injury	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						bone fractures; traumatic brain injury; growth hormone; insulin-like growth factor type 1; heterotopic; ossifications	SEVERE HEAD-INJURY; ENHANCED OSTEOGENESIS; FACTOR-I; IGF-I; CALLUS FORMATION; RATS; EXPRESSION; DENSITY; VITRO; LINK	The aim of the study was to determine whether changes in serum levels of growth hormone (GH) and insulin-like growth factor type 1 (IGF-1) are related to the phenomenon of enhanced osteogenesis in patients with bone fracture combined with traumatic brain injury (TBI), which would also suggest their involvement in posttraumatic stress and their applicability in the promotion of bone fracture healing. GH values were increased during the initial post-traumatic period in all patients (those with bone fractures or TBI alone or combined injury associated with enhanced osteogenesis), declining to normal values afterwards. However, a further increase in GH was only observed in patients with combined injury overlapping with the time of clinically manifested enhanced osteogenesis. Serum levels of IGF-1 were above normal throughout the study period (14 weeks) in patients with TBI only, but not if TBI was combined with bone fractures followed by enhanced osteogenesis. In these patients IGF-1 values increased gradually during fracture healing, as was also the case in patients with bone fractures alone. Thus, different patterns of post-traumatic changes in both GH and IGF-1 were seen in patients with TBI or bone fractures in comparison to those with combined injury, indicating the involvement of these substances in the posttraumatic stress response and in the phenomenon of enhanced osteogenesis in patients with bone fractures and TBI.	Graz Univ, Clin Traumatol, Dept Traumatol, A-8036 Graz, Austria; Graz Univ, Dept Med, A-8036 Graz, Austria; Rudjer Boskovic Inst, Dept Mol Med, Zagreb, Croatia; KBC Rebro, Fac Med, Dept Neuropathol, Zagreb, Croatia; Univ Vienna, Inst Nucl Med, EliTec GMBH, Vienna, Austria		Wildburger, R (corresponding author), Graz Univ, Clin Traumatol, Dept Traumatol, Auenbruggerpl 7A, A-8036 Graz, Austria.		Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			ANDREW JG, 1993, CALCIFIED TISSUE INT, V53, P97, DOI 10.1007/BF01321886; BAGI C, 1995, BONE, V16, P559, DOI 10.1016/8756-3282(95)00078-R; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; CALANDRIELLO B, 1964, Bull Hosp Joint Dis, V25, P170; CANALIS E, 1992, CALCIFIED TISSUE INT, V53, P90; Collins D, 1998, BONE, V23, P13, DOI 10.1016/S8756-3282(98)00066-0; CONOVER CA, 1992, J CLIN ENDOCR METAB, V74, P1355, DOI 10.1210/jc.74.6.1355; DEJERINE MME, 1918, ANN MED, V5, P497; Dore S, 1997, TRENDS NEUROSCI, V20, P326; EHRNBERG A, 1995, ACTA ORTHOP SCAND, V64, P562; Eming SA, 1996, J INVEST DERMATOL, V107, P113, DOI 10.1111/1523-1747.ep12298351; FERRACCIOLI G, 1994, J RHEUMATOL, V21, P1332; Gianotti L, 1998, J ENDOCRINOL INVEST, V21, P115, DOI 10.1007/BF03350325; GILPIN DA, 1994, ANN SURG, V220, P19, DOI 10.1097/00000658-199407000-00004; Hedner E, 1996, J BONE MINER RES, V11, P1952; Jeevanandam M, 1996, NUTRITION, V12, P777, DOI 10.1016/S0899-9007(96)00220-1; MOHAN S, 1991, CLIN ORTHOP RELAT R, P30; Nguyen TT, 1996, ANN SURG, V223, P14, DOI 10.1097/00000658-199601000-00004; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; PETERSEN SR, 1995, J TRAUMA, V39, P295, DOI 10.1097/00005373-199508000-00018; Raff T, 1997, CHIRURG, V68, P995, DOI 10.1007/s001040050309; RAISZ LG, 1993, PHYSL PHARM BONE, P229; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; Sell S, 1998, CALCIFIED TISSUE INT, V62, P51, DOI 10.1007/s002239900394; Sherrard RM, 1997, NEUROREPORT, V8, P3225, DOI 10.1097/00001756-199710200-00008; SMITH R, 1987, J BONE JOINT SURG BR, V69, P518, DOI 10.1302/0301-620X.69B4.3611149; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Sugimoto T, 1997, J BONE MINER RES, V12, P1272, DOI 10.1359/jbmr.1997.12.8.1272; THALLER SR, 1993, ANN PLAS SURG, V31, P429, DOI 10.1097/00000637-199311000-00007; THALLER SR, 1993, ANN PLAS SURG, V31, P421, DOI 10.1097/00000637-199311000-00006; Trippel SB, 1996, J BONE JOINT SURG AM, V78A, P1272, DOI 10.2106/00004623-199608000-00020; Unneberg K, 1997, EUR J SURG, V163, P779; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WILDBURGER R, 1992, ZBL CHIR, V117, P515; Wildburger R, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P305; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; Wildburger R, 1996, UNFALLCHIRURG, V99, P17; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Wildburger R, 2000, WIEN KLIN WOCHENSCHR, V112, P798; WILDBURGER R, 1995, MED SCI RES, V223, P219; WILDBURGER R, 2000, ERSATZ ERGANZUNGSMET, P370	43	27	35	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0043-5325			WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB 15	2001	113	3-4					119	126					8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	405BB	WOS:000167136400010	11253737				2022-02-06	
J	Abraham, KE; McGinty, JF; Brewer, KL				Abraham, KE; McGinty, JF; Brewer, KL			The role of kainic acid/AMPA and metabotropic glutamate receptors in the regulation of opioid mRNA expression and the onset of pain-related behavior following excitotoxic spinal cord injury	NEUROSCIENCE			English	Article						dynorphin; enkephalin; pain; spinal cord injury; 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline; (RS)-1-aminoindan-1,5-dicarboxylic acid	RADIOIMMUNOASSAY TECHNIQUE; TRAUMATIC INJURY; QUISQUALIC ACID; RAT STRIATUM; NMDA; IMMUNOREACTIVITY; AMPHETAMINE; ANTAGONISTS; ALLODYNIA; DYNORPHIN	Intraspinal injection of quisqualic acid. a mixed kainic acid/2-amino-3(3-hydroxy-5-methylisonazol-4-yl) pionic acid and metabotropic glutamate receptor agonist, produces an excitotoxic injury that leads to the onset of both spontaneous and evoked pain behavior as well as changes in spinal and cortical expression of opioid peptide mRNA, preprodynorphin and preproenkephalin. What characteristics of the quisqualic acid-induced injury are attributable to activation of each receptor subtype is unknown. This study attempted to define the role of activation of the kainic acid/2-amino-3(3-hydroxy-5-methylisoxazol-4-yl) acid (AMPA) and metabotropic glutamate receptor subtypes in the regulation of opioid peptide expression and the onset of spontaneous and evoked pain-related behavior following excitotoxic spinal cord injury by comparing quisqualic acid-induced changes with those created by co-injection of quisqualic acid and the kainic acid/AMPA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline, (NBQX) or the metabotropic antagonist, IRS)-1-aminoindan-1,5-dicarboxylic acid (AIDA). Therefore, 42 male Long Evans adult rats were divided into seven treatment groups and received intraspinal microinjections of saline (sham). 0.5% dimethylsulphoxide (sham), quisqualic acid (1.2 mul, 125 mM), NBQX (1.2 mul. 60 muM). AIDA (1.2 mul. 250 muM), quisqualic acid/ NBQX (1.2 mul. 125 mM/60 muM), or quisqualic acid/AIDA (1.2 mul, 125 mM/250 muM) directed at spinal levels thoracic 12-lumbar 2. Behavioral observations of spontaneous and evoked pain responses were completed following surgery. After a 10-day survival period, animals were killed and brain and spinal cord tissues were removed and processed for histologic analysis and in situ hybridization. Both AIDA and NBQX affected the quisqualic acid-induced total lesion volume but only AIDA caused a decrease in the percent tissue damage at the lesion epicenter. Preprodynorphin and preproenkephalin expression is increased in both spinal and cortical areas in quisqualic acid-injected animals versus sham-, NBQX or AIDA-injected animals. NBQX did not affect quisqualic acid-induced spinal or cortical expression of preprodynorphin or preproenkephalin except for a significant decrease in preproenkephalin expression in the spinal cord. In contrast, AIDA significantly decreases quisqualic acid-induced preprodynorphin and preproenkephalin expression within the spinal cord and cortex. AIDA. but not NBQX, significantly reduced the frequency of, and delayed the onset of, quisqualic acid-induced spontaneous pain-related behavior. From these data we suggest that both the kainic acid/AMPA and metabotropic glutamate receptor subtypes are involved in the induction of the excitotoxic cascade responsible for quisqualic acid-induced neuronal damage and changes in opioid peptide mRNA expression, while metabotropic glutamate receptors may play a more significant role in the onset of post-injury pain-related behavior. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Greenville, NC 27858 USA; Shenandoah Univ, Div Phys Therapy, Winchester, VA 22601 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA		Brewer, KL (corresponding author), E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Physicians Quadrangle Bldg M, Greenville, NC 27858 USA.	brewerk@mail.ecu.edu					Abraham KE, 2001, PAIN, V90, P181, DOI 10.1016/S0304-3959(00)00402-4; Abraham KE, 2000, NEUROSCIENCE, V99, P189, DOI 10.1016/S0306-4522(00)00150-0; Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; BREWER KL, 1997, SOC NEUR ABSTR, V23, P437; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Christensen MD, 1996, PAIN, V68, P97, DOI 10.1016/S0304-3959(96)03224-1; EIMERL S, 1994, J NEUROCHEM, V62, P1223; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; GOMEZPINELLA F, EXP NEUROL, V104, P118; HAO JX, 1991, PAIN, V45, P175, DOI 10.1016/0304-3959(91)90186-2; HAO JX, 1992, EXP NEUROL, V118, P143, DOI 10.1016/0014-4886(92)90031-K; Hao JX, 1998, EXP BRAIN RES, V118, P259, DOI 10.1007/s002210050280; HELTON TE, 1993, MOL CELL NEUROSCI, V4, P319, DOI 10.1006/mcne.1993.1042; KOSTERLITZ HW, 1985, PROC R SOC SER B-BIO, V225, P27, DOI 10.1098/rspb.1985.0048; LEES GJ, 1993, BRAIN RES, V628, P1, DOI 10.1016/0006-8993(93)90930-L; LENZ FA, 1991, SYMP PAIN R, P171; LEVITT M, 1985, BRAIN RES REV, V10, P247, DOI 10.1016/0165-0173(85)90027-X; LITTMAN L, 1995, NEUROPHARMACOLOGY, V34, P829, DOI 10.1016/0028-3908(95)00070-M; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; MARTINEZARIZALA A, 1990, EXP NEUROL, V108, P232, DOI 10.1016/0014-4886(90)90128-F; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; Morrow TJ, 2000, EXP NEUROL, V161, P220, DOI 10.1006/exnr.1999.7246; NOGUCHI K, 1991, MOL BRAIN RES, V10, P227, DOI 10.1016/0169-328X(91)90065-6; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PORTER RHP, 1992, BRIT J PHARMACOL, V106, P509, DOI 10.1111/j.1476-5381.1992.tb14366.x; PRZEWLOCKI R, 1988, MOL BRAIN RES, V4, P37, DOI 10.1016/0169-328X(88)90016-2; Ruda MA, 1995, PROG BRAIN RES, V104, P349; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; SHARMA HS, 1992, NEUROSCI RES, V14, P195; SIDDALL P, 1995, NEUROREPORT, V6, P1241, DOI 10.1097/00001756-199506090-00003; SMITH AJW, 1994, MOL BRAIN RES, V21, P359, DOI 10.1016/0169-328X(94)90268-2; Tachibana T, 1998, J NEUROTRAUM, V15, P485, DOI 10.1089/neu.1998.15.485; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; VIERCK CJ, 1991, SYMP PAIN R, P129; WANG JQ, 1995, J PHARMACOL EXP THER, V273, P909; WANG JQ, 1994, SYNAPSE, V18, P343, DOI 10.1002/syn.890180410; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1992, BRAIN RES, V573, P324; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; ZELTSER R, 1994, PROG PAIN RES MANAG, V3, P295	51	27	27	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2001	104	3					863	874		10.1016/S0306-4522(01)00134-8			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	453TT	WOS:000169933100024	11440816				2022-02-06	
J	Adams, J; Frumiento, C; Shatney-Leach, L; Vane, DW				Adams, J; Frumiento, C; Shatney-Leach, L; Vane, DW			Mandatory admission after isolated mild closed head injury in children: Is it necessary?	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	31st Annual Meeting of the American-Pediatric-Surgical-Association	MAY 25-29, 2000	ORLANDO, FLORIDA	Amer Pediat Surg Assoc		concussion; closed head injury; minor head injury	UTILITY; TRAUMA	Background/Purpose: Children with closed head injuries diagnosed as concussion alone or concussion with brief loss of consciousness are admitted routinely for observation despite a normal central nervous system finding, negative computed tomography (CT) scan, and a Glasgow Coma Score (GCS) of 15. Recent studies have questioned the necessity of such an admission. The purpose of this study was to review a large pediatric database and study the length of stay as well as any required procedures or complications in these children. The hypothesis was that routine admission is unnecessary in this population. Methods: The National Pediatric Trauma Registry-Phase II was reviewed for the period from October 1988 to January 1996, Entry criteria included age less than 18 and an isolated closed head injury after blunt trauma with an admission GCS of 15, Variables studied included age, gender, mechanism of injury, length of stay, procedures, and outcome. Results: A total of 1,033 children met criteria for this study. The average age was 8.3 years. Males predominated at 61.9%. Falls, sports, and motor vehicle crashes were the most common mechanisms of injury. The average length of stay was 1.19 days, and 60 children were not admitted. A total of 583 children had no procedures performed, whereas 386 received a CT scan, and 148 had x-rays. None required neurosurgical intervention, and all were discharged alive. Conclusion: These findings indicate that routine admission may not be necessary for children with isolated mild closed head injuries with a negative CT scan and a normal neurologic finding and allows for a prospective randomized trial to confirm this. J Pediatr Surg 36:119-121. Copyright (C) 2001 by W.B. Saunders Company.	Univ Vermont, Coll Med, Div Pediat Surg, Burlington, VT 05401 USA		Vane, DW (corresponding author), Univ Vermont, Coll Med, Div Pediat Surg, 111 Colchester Ave,Fletcher 4,MCHV Campus, Burlington, VT 05401 USA.						Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; KRAUS JF, 1987, PEDIATRICS, V79, P501; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009	7	27	27	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	JAN	2001	36	1					119	121		10.1053/jpsu.2001.20026			3	Pediatrics; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	388KW	WOS:000166180500021	11150449				2022-02-06	
J	Martins, RN; Taddei, K; Kendall, C; Evin, G; Bates, KA; Harvey, AR				Martins, RN; Taddei, K; Kendall, C; Evin, G; Bates, KA; Harvey, AR			Altered expression of apolipoprotein E, amyloid precursor protein and presenilin-1 is associated with chronic reactive gliosis in rat cortical tissue	NEUROSCIENCE			English	Article						Alzheimer's disease; astrocytes; amyloid; cerebral cortex; inflammation; foetal transplants	TRAUMATIC BRAIN-INJURY; CHONDROITIN SULFATE PROTEOGLYCANS; SPORADIC ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; SENILE PLAQUES; MESSENGER-RNA; BETA-PEPTIDE; MICROGLIAL PHAGOCYTOSIS; MISSENSE MUTATIONS; GLIAL RESPONSES	A major characteristic feature of Alzheimer's disease is the formation of compact, extracellular deposits of beta -amyloid (senile plaques). These deposits are surrounded by reactive astrocytes, microglia and dystrophic neurites. Mutations in three genes have been implicated in early-onset familial Alzheimer's disease, However, inflammatory changes and astrogliosis are also believed to play a role in Alzheimer's pathology. What is unclear is the extent to which these factors initiate or contribute to the disease progression. Previous rat studies demonstrated that heterotopic transplantation of foetal cortical tissue onto the midbrain of neonatal hosts resulted in sustained glial reactivity for many months. Similar changes were not seen in cortex-to-cortex grafts. Using this model of chronic cortical gliosis, we have now measured reactive changes in the levels of the key Alzheimer's disease proteins. namely the amyloid precursor protein, apolipoprotein E and presenilin-1. These changes were visualised immunohistochemically and were quantified by western blot analysis. We report here that chronic cortical gliosis in the rat results in a sustained increase in the levels ci apolipoprotein E and total amyloid precursor protein. Reactive astrocytes in heterotopic cortical grafts were immunopositive for both of these proteins. Using a panel of amyloid precursor protein antibodies we demonstrate that chronic reactive gliosis is associated with alternative cleavage of the peptide. No significant changes in apolipoprotein E or amyloid precursor protein expression were seen in non-gliotic cortex-to-cortex transplants. Compared to host cortex, the levels of both N-terminal and C-terminal fragments of presenilin-1 were significantly lower in gliotic heterotopic grafts, The changes described here largely mirror those seen in the cerebral cortex of humans with Alzheimer's disease and are consistent with the proposal that astrogliosis may be an important factor in the pathogenesis of this disease. (C) 2001 IBRO. Published by Elsevier Science Ltd, All rights reserved.	Univ Western Australia, Sir James McCusker Alzheimer Res Unit, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia; Hollywood Private Hosp, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Anat & Human Biol, Perth, WA 6009, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic 3050, Australia		Martins, RN (corresponding author), Univ Western Australia, Sir James McCusker Alzheimer Res Unit, Monash Ave, Nedlands, WA 6009, Australia.		Evin, Genevieve M/E-5891-2013; Bates, Kristyn/C-4245-2011	Martins, Ralph/0000-0002-4828-9363			AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Baskin F, 1997, J NEUROL SCI, V148, P15, DOI 10.1016/S0022-510X(96)05335-X; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Casadei VM, 1999, NEUROLOGY, V53, P1888, DOI 10.1212/WNL.53.8.1888; CHAO CC, 1995, CRIT REV NEUROBIOL, V9, P189; Chauvet N, 1997, J COMP NEUROL, V377, P550; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; CHUI DH, 1994, AM J PATHOL, V145, P771; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; DEWITT DA, 1994, BRAIN RES, V656, P205, DOI 10.1016/0006-8993(94)91386-2; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; Du Y, 2000, NEUROLOGY, V55, P480, DOI 10.1212/WNL.55.4.480; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P454, DOI 10.1001/archneur.57.4.454; Evans RM, 2000, NEUROLOGY, V54, P240, DOI 10.1212/WNL.54.1.240; Frautschy SA, 1998, J NEUROSCI, V18, P8311; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Harvey AR, 1997, NEUROSCI LETT, V228, P58, DOI 10.1016/S0304-3940(97)00341-8; HOKE A, 1994, EXP NEUROL, V130, P56, DOI 10.1006/exnr.1994.1185; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; JAEGER CB, 1980, J COMP NEUROL, V194, P571, DOI 10.1002/cne.901940307; JENKINSON ML, 1989, BRIT J RHEUMATOL, V28, P86; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Licastro F, 1999, NEUROSCI LETT, V270, P129, DOI 10.1016/S0304-3940(99)00468-1; Licastro F, 2000, J NEUROIMMUNOL, V103, P97, DOI 10.1016/S0165-5728(99)00226-X; LUCCA U, 1994, BIOL PSYCHIAT, V36, P854, DOI 10.1016/0006-3223(94)90598-3; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; McMillan PJ, 2000, MOL BRAIN RES, V78, P138, DOI 10.1016/S0169-328X(00)00086-3; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Mouchel Y, 1995, NEUROREPORT, V7, P205; MYLLYKANGASLUOSUJARVI R, 1994, BRIT J RHEUMATOL, V33, P501; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Niquet J, 1996, GLIA, V16, P359, DOI 10.1002/(SICI)1098-1136(199604)16:4<359::AID-GLIA8>3.0.CO;2-V; PANGALOS MN, 1995, J NEUROCHEM, V65, P762; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; REBECK GW, 1993, NEURON, V11, P575; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Roitbak T, 1999, GLIA, V28, P40, DOI 10.1002/(SICI)1098-1136(199910)28:1<40::AID-GLIA5>3.0.CO;2-6; ROTHWELL N, 1995, CYTOKINES NEURODEGEN, P77; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schubert P, 2000, ANN NY ACAD SCI, V903, P24, DOI 10.1111/j.1749-6632.2000.tb06346.x; Schwab SG, 1999, DEMENT GERIATR COGN, V10, P469, DOI 10.1159/000017191; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHIOI J, 1995, J BIOL CHEM, V270, P11839, DOI 10.1074/jbc.270.20.11839; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Sykova E, 1999, NEUROSCIENCE, V91, P783, DOI 10.1016/S0306-4522(98)00603-4; Takami K, 1997, BRAIN RES, V748, P122, DOI 10.1016/S0006-8993(96)01274-7; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Veerhuis R, 1999, EXP NEUROL, V160, P289, DOI 10.1006/exnr.1999.7199; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; Vincent B, 2000, BIOCHEM BIOPH RES CO, V271, P82, DOI 10.1006/bbrc.2000.2581; Weldon DT, 1998, J NEUROSCI, V18, P2161; Yaffe K, 2000, NEUROLOGY, V54, P1949, DOI 10.1212/WNL.54.10.1949; Young MJ, 1999, BRAIN RES BULL, V50, P27, DOI 10.1016/S0361-9230(99)00084-2; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	86	27	28	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2001	106	3					557	569		10.1016/S0306-4522(01)00289-5			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	483NH	WOS:000171640800007	11591456				2022-02-06	
J	McMillan, TM				McMillan, TM			Errors in diagnosing post-traumatic stress disorder after traumatic brain injury	BRAIN INJURY			English	Article							MOTOR-VEHICLE ACCIDENTS; MINOR HEAD-INJURY; FOLLOW-UP; EVENT; EPIDEMIOLOGY; DISASTER; SYMPTOMS; VICTIMS; AMNESIA; IMPACT	Evidence to support the view that post-traumatic stress disorder (PTSD) can occur after traumatic brain injury (TBI) continues to grow. However, the reported incidence of cases with both diagnoses ranges widely, from less than 1% to more than 50%. Given that the incidence of TBI is high, a more precise incidence has to be established if screening and treatment resources are to be considered. Are cases being missed or are they over-diagnosed? The single case report presented here does not definitively answer this question, but illustrates the potential shortcomings of diagnosing PTSD using questionnaire measures alone (Impact of Events Scale, Post-traumatic Stress Diagnostic Scale and General Health Questionnaire) and indicates a need for a conjoint interview which takes into account the common effects of TBI and the symptom overlap between PTSD and TBI.	Univ Glasgow, Dept Psychol Med, Glasgow G12 8QQ, Lanark, Scotland		McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Dept Psychol Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.						*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P424; BADDELEY A, 1991, SPEED CAPACITY LANGU; Beck AT, 1990, BECK ANXIETY INVENTO; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; BURGES C, IN PRESS BRIT J CLIN; Burgess P.W., 1997, HAYLING BRIXTON TEST; COUGHLAN AT, 1985, ASSESSMENT MEMORY IN; DAVIDSON JRT, 1933, POST TRAUMATIC STRES; Edgeworth JA, 1998, BALLOONS TEST TEST V; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; FIELD HJ, 1976, EPIDEMIOLOGY HEAD IN; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JOSEPH S, 1993, BRIT J CLIN PSYCHOL, V32, P327, DOI 10.1111/j.2044-8260.1993.tb01063.x; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Koren D, 1999, AM J PSYCHIAT, V156, P367; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; MALT U, 1988, BRIT J PSYCHIAT, V159, P431; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; MCMILLAN T, 1993, NEUROLOGICAL REHABIL, P437; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Middelboe T., 1992, European Psychiatry, V7, P183; MILLER JD, 1985, LANCET, V1, P1141; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Silver JM, 1997, NEUROCASE, V3, P151, DOI 10.1080/13554799708404048; THOMPSON J, 1994, BRIT J CLIN PSYCHOL, V33, P75, DOI 10.1111/j.2044-8260.1994.tb01096.x; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Wechsler, 1997, WECHSLER ADULT INTEL; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x	47	27	29	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2001	15	1					39	46		10.1080/02699050118030			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	384UF	WOS:000165963600004	11201313				2022-02-06	
J	Radensky, PW; Archer, JW; Dournaux, SF; O'Brien, CF				Radensky, PW; Archer, JW; Dournaux, SF; O'Brien, CF			The estimated cost of managing focal spasticity: A physician practice patterns survey	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						spasticity; stroke; traumatic brain injury; botulinum toxin type A; baclofen	UPPER EXTREMITY SPASTICITY; BOTULINUM TOXIN; PERCEPTIONS; PATIENT; TRIAL	The purpose of this study was to estimate the overall cost of managing focal spasticity after stroke (CVA) and traumatic brain injury (TBI) and the cost impact of individual treatments. Sixty physicians described management strategies over six treatment visits for four focal spasticity case studies (one upper and one lower extremity case for CVA and TBI). Mean and median per-case costs were determined across physicians; median per,case costs of physicians who did or did not report use of specific treatments were compared. Mean per-case costs of managing spasticity are as follows: CVA upper, $5,131; CVA tower, $5,384; TBI upper, $14,615; and TBI lower, $13,966. Median per,case costs for strategies including botulinum toxin type A (BTX-A) were less than those without BTX-A in CVA upper; median costs for strategies including oral baclofen were more than those without baclofen in CVA lower. Fewer total treatments were reported with BTX-A than without; more total treatments were reported with baclofen than without. No individual treatment had a significant impact on median treatment costs in TBI. Physician,reported spasticity management costs are substantial. Despite higher drug costs for BTX-A compared with oral therapies like baclofen, strategies for managing spasticity in CVA that include BTX-A may cost less than those without BTX-A.	McDermott Will & Emery, Miami, FL 33131 USA; Colorado Neurol Inst, Englewood, CO USA		Radensky, PW (corresponding author), McDermott Will & Emery, 201 S Biscayne Blvd,Suite 2200, Miami, FL 33131 USA.						Barnes MP, 1997, EUR J NEUROL, V4, pS33; BRIN MF, 1997, MUSCLE NERVE       S, V6, P146; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; Gracies JM, 1997, MUSCLE NERVE, pS92; Hirth RA, 2000, INT J TECHNOL ASSESS, V16, P35, DOI 10.1017/S0266462300016147; KLAINMAN MD, 1997, TRAUMA, V39, P33; Mayer N, 1996, MED REHABILITATION T, P411; MAYER NH, 1997, MUSCLE NERVE       S, V6, P21; Meschia JF, 1998, CNS DRUGS, V9, P357, DOI 10.2165/00023210-199809050-00003; *NAT CTR HLTH STAT, 1994, NAT HOSP DISCH SURV; *NAT STROK ASS, 2000, BRAIN ATT STAT; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; PEDERSEN E, 1974, ACTA NEUROL SCAND, V50, P665; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; Ryan M, 1996, PHARMACOECONOMICS, V9, P321, DOI 10.2165/00019053-199609040-00005; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Taylor TN, 1997, DRUGS, V54, P51, DOI 10.2165/00003495-199700543-00008; Viriyavejakul Adulya, 1998, Journal of the Medical Association of Thailand, V81, P413; Wallesch CW, 1997, EUR J NEUROL, V4, pS53; Wennberg DE, 1997, J GEN INTERN MED, V12, P172; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	21	27	30	0	0	DEMOS MEDICAL PUBLISHING	NEW YORK	386 PARK AVE SOUTH, STE 201, NEW YORK, NY 10016 USA	0888-4390			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair		2001	15	1					57	68		10.1177/154596830101500108			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	466BH	WOS:000170624100008	11527280				2022-02-06	
J	Dijkstra, S; Geisert, EE; Gispen, WH; Bar, PR; Joosten, EAJ				Dijkstra, S; Geisert, EE; Gispen, WH; Bar, PR; Joosten, EAJ			Up-regulation of CD81 (target of the antiproliferative antibody; TAPA) by reactive microglia and astrocytes after spinal cord injury in the rat	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						gliosis; nerve regeneration; central nervous system; Schwann cells; spinal cord injuries	PROTEIN-TYROSINE PHOSPHORYLATION; CELL-ADHESION; AXONAL REGENERATION; HUMAN PLATELETS; NERVOUS-SYSTEM; ADULT-RAT; IN-VITRO; EXPRESSION; LESION; BRAIN	We examined the expression of CD81 (also known as TAPA, or target of the antiproliferative antibody) after traumatic spinal cord injury in the rat. CD81, a member of the tetraspanin family of proteins, is thought to be involved in reactive gliosis. This is based on the antiproliferative and antiadhesive effects of antibodies against CD81 on cultured astrocytes, as well as its up-regulation after penetrating brain injury. CD81 expression following dorsal hemisection of the spinal cord was determined immunohistochemically at time points ranging from 1 day to 2 months postlesion (p.l.). In the unlesioned cord a low background level of CD81 was observed, with the exception of the ependyma of the central canal and the pia mater, which were strongly CD81-positive. One day p.l., CD81 was diffusely up-regulated in the spinal cord parenchyma surrounding the lesion site. From 3 days onward, intensely CD81-positive round cells entered the lesion site, completely filling it by 7 days p.l. Staining with the microglial markers OX-42 and Iba1 revealed that these cells were reactive microglia/ macrophages. At this time, no significant CD81 expression by GFAP-positive reactive astrocytes was noted. From the second week onward, CD81 was gradually down-regulated; i.e., its spatial distribution became more restricted. The CD81-positive microglia/macrophages disappeared from the lesion site, leaving behind large cavities. After 2 months, astrocytes that formed the wall of these cavities were strongly CD81-positive. In addition, CD81 was present on reactive astrocytes in the dorsal funiculus distal from the lesion in degenerated white matter tracts. In conclusion, the spatiotemporal expression pattern of CD81 by reactive microglia and astrocytes indicates that CD81 is involved in the glial response to spinal cord injury. (C) 2000 Wiley-Liss, Inc.	Univ Utrecht, Med Ctr, Lab Expt Neurol, Dept Expt Neurol,RMI Neurosci, NL-3508 GA Utrecht, Netherlands; Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA		Dijkstra, S (corresponding author), Univ Utrecht, Med Ctr, Lab Expt Neurol, Dept Expt Neurol,RMI Neurosci, Room G02314,POB 85500, NL-3508 GA Utrecht, Netherlands.		bar, peter/A-2897-2009	Dijkstra, Sipke/0000-0003-2535-297X			ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; ANTON ES, 1995, J NEUROSCI, V15, P584; Bartholdi D, 1998, GLIA, V23, P278, DOI 10.1002/(SICI)1098-1136(199807)23:3<278::AID-GLIA10>3.0.CO;2-Q; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Brook GA, 1998, J NEUROSCI RES, V53, P51, DOI 10.1002/(SICI)1097-4547(19980701)53:1<51::AID-JNR6>3.0.CO;2-I; Clarke K, 1998, Mol Vis, V4, P3; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Elkabes S, 1996, J NEUROSCI, V16, P2508; GEISERT EE, 1991, NEUROSCI LETT, V133, P262, DOI 10.1016/0304-3940(91)90584-G; Geisert EE, 1996, J NEUROSCI, V16, P5478; GIELING RG, 1998, EUR J NEUROSCI S, V10; GIULIAN D, 1993, ADV NEUROL, V59, P315; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; Houweling DA, 1998, EXP NEUROL, V153, P49, DOI 10.1006/exnr.1998.6867; IRWIN MH, 1993, NEUROSCI LETT, V154, P57, DOI 10.1016/0304-3940(93)90170-P; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; JOOSTEN EAJ, 1995, J NEUROSCI RES, V41, P481, DOI 10.1002/jnr.490410407; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Miyake M, 1996, CANCER RES, V56, P1244; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; Peduzzi JD, 1999, EXP NEUROL, V160, P460, DOI 10.1006/exnr.1999.7234; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Reier P J, 1988, Adv Neurol, V47, P87; SCHICK MR, 1993, J IMMUNOL, V151, P1918; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Serru V, 2000, BBA-PROTEIN STRUCT M, V1478, P159, DOI 10.1016/S0167-4838(00)00022-4; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sullivan CD, 1998, J COMP NEUROL, V396, P366; Todd SC, 1998, BBA-GENE STRUCT EXPR, V1399, P101, DOI 10.1016/S0167-4781(98)00087-6; Watanabe T, 1999, J NEUROTRAUM, V16, P255, DOI 10.1089/neu.1999.16.255; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; YATOMI Y, 1993, FEBS LETT, V322, P285, DOI 10.1016/0014-5793(93)81587-P	49	27	27	1	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	DEC 11	2000	428	2					266	277		10.1002/1096-9861(20001211)428:2<266::AID-CNE6>3.0.CO;2-0			12	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	371ML	WOS:000165182700006	11064366				2022-02-06	
J	Beschorner, R; Engel, S; Mittelbronn, M; Adjodah, D; Dietz, K; Schluesener, HJ; Meyermann, R				Beschorner, R; Engel, S; Mittelbronn, M; Adjodah, D; Dietz, K; Schluesener, HJ; Meyermann, R			Differential regulation of the monocytic calcium-binding peptides macrophage-inhibiting factor related protein-8 (MRP8/S100A8) and allograft inflammatory factor-1 (AIF-1) following human traumatic brain injury	ACTA NEUROPATHOLOGICA			English	Article						allograft-inflammatory factor-1; microglia response factor-1; macrophage-inhibiting factor related-protein-8/S 100A8; traumatic brain injury; human	FACTOR-I; ACTIVATED MACROPHAGES; MICROGLIAL CELLS; EXPRESSION; LESIONS; MRP14; ENCEPHALOMYELITIS; POLYPEPTIDE; CONTUSION; NEURITIS	Intracellular calcium (Ca2+) has been shown to function as second messenger and to be associated with activation of different cell types including microglia. Previously, in human focal cerebral infarctions an early expression of macrophage-related protein-8 (MRP8/ S100A8), a member of the Ca2+-binding S100-protein family, in microglia has been reported. On the other hand, a delayed activation of microglia was observed following traumatic brain injury (TBI). We therefore examined immunohistochemically microglial expression of MRP8 and allograft inflammatory factor-1 (AIF-1), identical to microglial response factor-1 (mrf-1) and ionized calcium binding adaptor molecule-1 (iba1) in human brains after TBI and in control brains. Both, MRP8 and AIF-1 are Ca2+-binding peptides which have been associated with microglial activation in experimental models and in human cerebral infarctions. Detection of AIF-1 in controls confirmed constitutive expression of this peptide in a subset of microglial cells. After TBI, the density of AIF-1(+) microglia did not increase significantly. Lesional expression of AIF-1 did not significantly differ from other brain regions. Furthermore, following TBI, we found no significant differences in the density of AIF-1+ microglia as compared to controls. Microglial MRP8 expression was not detectable in controls and within the first 3 days post TBI, but increased rapidly after 3 days post TBI, suggesting a subpopulation of microglial cells to be AIF-1(-)/MRP8(+). We conclude that the delayed expression of MRP8 and the lack of AIF-1 up-regulation in microglia after TBI is in contrast to ischemic brain lesions and might reflect different activation cascades of microglia.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Dept Med Biometry, D-72076 Tubingen, Germany		Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwerstr 3, D-72076 Tubingen, Germany.		Dietz, Klaus/R-9268-2016; Beschorner, Rudi/M-6397-2014	Dietz, Klaus/0000-0001-8503-9737; Beschorner, Rudi/0000-0003-1109-915X; Mittelbronn, Michel/0000-0002-2998-052X			Abe M, 1999, J NEUROL, V246, P358, DOI 10.1007/s004150050363; Autieri MV, 1996, BIOCHEM BIOPH RES CO, V228, P29, DOI 10.1006/bbrc.1996.1612; Chen ZW, 1997, P NATL ACAD SCI USA, V94, P13879, DOI 10.1073/pnas.94.25.13879; ENGEL S, 1996, NACTA NEUROCHIR WI S, V66, P89; ENGEL S, 2000, IN PRESS ACTA NEUROP; GILCHRIST JSC, 1994, MOL CELL BIOCHEM, V135, P79, DOI 10.1007/BF00925963; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; LAGASSE E, 1992, BLOOD, V79, P1907; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; Lugering N, 1998, Z GASTROENTEROL, V36, P173; MAHNKE K, 1995, J LEUKOCYTE BIOL, V57, P63, DOI 10.1002/jlb.57.1.63; MATTIACE LA, 1990, AM J PATHOL, V136, P1101; McLarnon JG, 1997, NEUROSCIENCE, V78, P1217, DOI 10.1016/S0306-4522(96)00680-X; Moller T, 1997, J NEUROSCI, V17, P615; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Postler E, 2000, J NEUROIMMUNOL, V104, P85, DOI 10.1016/S0165-5728(99)00222-2; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Schluesener HJ, 1999, ACTA NEUROPATHOL, V97, P119, DOI 10.1007/s004010050964; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; Streit Wolfgang J., 1995, P85; Tanaka S, 1998, J NEUROSCI, V18, P6358; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Utans U, 1996, TRANSPLANTATION, V61, P1387, DOI 10.1097/00007890-199605150-00018; Wege H, 1998, ADV EXP MED BIOL, V440, P437	31	27	27	0	6	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	DEC	2000	100	6					627	634		10.1007/s004010000232			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	365ZY	WOS:000089981400006	11078214	Green Published			2022-02-06	
J	Price, EA; Rush, LR; Perper, JA; Bell, MD				Price, EA; Rush, LR; Perper, JA; Bell, MD			Cardiopulmonary resuscitation-related injuries and homicidal blunt abdominal trauma in children	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						cardiopulmonary resuscitation; homicidal blunt abdominal trauma; child abuse	COMPLICATIONS	Defendants accused of inflicting fatal abdominal injuries to children occasionally raise the defense that the injuries were caused by cardiopulmonary resuscitation (CPR). The purpose of this study is to answer the question: Does closed chest CPR result in fatal blunt abdominal injuries that can be mistaken for homicidal assault? To that end, a retrospective study was conducted of all homicidal blunt abdominal injuries in children 10 years and younger from the Dade, Broward, and Palm Beach Medical Examiner's Offices from 1981 through 1997. These were compared to cases of children who died of natural causes during the same time period in Broward County who had CPR (control group 1) and to children who died of nonvehicular accidental blunt abdominal trauma (control group 2). Children with life-threatening head injuries were excluded. Medical examiner records, autopsy reports, documenting photographs, and clinical records were reviewed. The data analyzed included subject demographics, whether CPR was performed and by whom, and autopsy findings. Thirty-three child homicides with fatal abdominal injuries were reviewed. Twenty-four (73%) of the homicides received CPR. There was no difference in the nature and severity of injuries between the 24 children who received CPR and the 9 who did not. Three hundred and twenty-four cases of pediatric natural deaths were reviewed, all of which had CPR. No traumatic abdominal injuries were found in any of the children who died of natural causes. Only four children who died of natural causes had evidence of extraabdominal trauma related to CPR. No cases of nonvehicular accidental blunt abdominal trauma were identified during the 17-year period, although there were nonvehicular accidental fatalities due to extraabdominal. injuries. The likelihood of CPR-related primary abdominal trauma in child homicides is very low.	Broward Cty Med Examiners Off, Ft Lauderdale, FL 33312 USA		Price, EA (corresponding author), Broward Cty Med Examiners Off, 5301 SW 31 Ave, Ft Lauderdale, FL 33312 USA.						BARRY RC, 1994, CHID MALTREATMENT CL, P57; BEDELL SE, 1986, ARCH INTERN MED, V146, P1725, DOI 10.1001/archinte.146.9.1725; Bush CM, 1996, ANN EMERG MED, V28, P40, DOI 10.1016/S0196-0644(96)70137-3; Custer J R, 1987, Pediatr Emerg Care, V3, P24, DOI 10.1097/00006565-198703000-00007; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; KRISCHER JP, 1987, CHEST, V92, P287, DOI 10.1378/chest.92.2.287; POWNER DJ, 1984, CRIT CARE MED, V12, P54, DOI 10.1097/00003246-198401000-00015; THALER MM, 1962, NEW ENGL J MED, V207, P500; WALDMAN PJ, 1984, AM J EMERG MED, V2, P510, DOI 10.1016/0735-6757(84)90076-7	9	27	28	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-7910			AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2000	21	4					307	310		10.1097/00000433-200012000-00001			4	Medicine, Legal; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine; Pathology	375CW	WOS:000165382800001	11111786				2022-02-06	
J	Solbakk, AK; Reinvang, I; Nielsen, CS				Solbakk, AK; Reinvang, I; Nielsen, CS			ERP indices of resource allocation difficulties in mild head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							EVENT-RELATED POTENTIALS; PREFRONTAL LESIONS; MENTAL CHRONOMETRY; BRAIN POTENTIALS; ATTENTION; P300; TASK; DEFICITS; LATENCY; DISTRACTIBILITY	This study examined the hypothesis that distractibility is a characteristic sequela of mild closed head injury (MHI). The Minnesota Multiphasic Personality Inventory (MMPI-2) was used to study whether comorbid stress-related symptoms are associated with behavioral and electrophysiological indexes of attention. Event-related potentials (ERPs) and performance (reaction time, accuracy) were studied in patients with MHI (n = 20), patients with frontal lesions (n = 14), and healthy controls (n = 20) during a three-tone oddball task. Participants were instructed to detect rare target (2000 Hz) tones, and to withhold responding to equally rare distracter (500 Hz) tones and frequently occurring standard (1000 Hz) tones. All groups distinguished the two classes of deviants as indicated by the larger P3 amplitude to target relative to distracter tones. This indicates that the group with MHI was capable of differential allocation of attentional resources to target and non-target events. However, impaired performance and attenuated ERP amplitudes to both classes of deviants relative to patients with frontal lesions and controls, suggest limited availability, or expenditure of the resources needed for adequate task performance. In the group with MHI, both P3 amplitude acid reaction time (RT) were significantly related to subjectively reported distress. The difference in RT disappeared, whereas the P3 amplitude differences between the patient groups remained when adjusting for level of distress.	Univ Oslo, Inst Psychol, Blindern, Norway; Univ Oslo, Natl Hosp, Dept Psychosomat & Behav Med, Oslo, Norway		Solbakk, AK (corresponding author), Univ Oslo, Inst Psychol, PB 1094, Blindern, Norway.	a.k.solbakk@psykologi.uio.no					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Boller F, 1995, ANN NY ACAD SCI, V769, P23, DOI 10.1111/j.1749-6632.1995.tb38129.x; Butcher J.N., 1989, MMPI 2 MINNESOTA MUL; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, P269; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; Cripe L I, 1996, Appl Neuropsychol, V3, P97, DOI 10.1207/s15324826an0303&4_1; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Gentilini M., 1989, MILD HEAD INJURY; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; JOHNSON R, 1995, HDB NEUROPSYCHOLOGY, P241; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Katayama J, 1998, PSYCHOPHYSIOLOGY, V35, P23, DOI 10.1017/S0048577298961479; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KNIGHT RT, 1981, ELECTROEN CLIN NEURO, V52, P571, DOI 10.1016/0013-4694(81)91431-0; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V504, P338, DOI 10.1016/0006-8993(89)91381-4; KNIGHT RT, 1991, FRONTAL LOBE FUNCTIO; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI; Naatanen R, 1992, ATTENTION BRAIN FUNC; NIELSEN CS, 1997, READPEAK DATA PROGRA; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Reinvang I, 1998, J CLIN EXP NEUROPSYC, V20, P885, DOI 10.1076/jcen.20.6.885.1106; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; Schroger E, 1998, COGNITIVE BRAIN RES, V7, P71, DOI 10.1016/S0926-6410(98)00013-5; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; SQUIRES KC, 1973, PERCEPT PSYCHOPHYS, V14, P265, DOI 10.3758/BF03212388; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STUSS DT, 1991, SELF : INTERDISCIPLINARY APPROACHES, P255; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; Vilkki J, 1995, Appl Neuropsychol, V2, P93, DOI 10.1207/s15324826an0203&4_1; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212	48	27	27	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2000	22	6					743	760		10.1076/jcen.22.6.743.953			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	403QT	WOS:000167054500004	11320433				2022-02-06	
J	Yu, WR; Westergren, H; Farooque, M; Holtz, A; Olsson, Y				Yu, WR; Westergren, H; Farooque, M; Holtz, A; Olsson, Y			Systemic hypothermia following spinal cord compression injury in the rat: an immunohistochemical study on MAP 2 with special reference to dendrite changes	ACTA NEUROPATHOLOGICA			English	Article						hypothermia; immunohistochemistry; microtubule-associated protein 2 (MAP2); rat; spinal cord injury	MICROTUBULE-ASSOCIATED PROTEIN-2; TRAUMATIC BRAIN INJURY; SENSITIVE MARKER; NERVOUS-SYSTEM; BLOOD-FLOW; PEROXIDASE; TEMPERATURE; ISCHEMIA	Systemic hypothermia has been shown to exert neuroprotective effects in experimental ischemic CNS models caused by vascular occlusions. The present study addresses the question as to whether systemic hypothermia has similar neuroprotective qualities following severe spinal cord compression trauma using microtubule-associated protein 2 (MAP2) immunohistochemistry combined with the avidin-biotin-peroxidase complex method as marker to identify neuronal and dendritic lesions. Fifteen rats were randomized into three equally sized groups. One group sustained thoracic laminectomy. the others severe spinal cord compression trauma of the T8-9 segment. The control roup contained laminectomized animals submitted to a hypothermic procedure in which the esophageal temperature was reduced from 38 degrees C to 30 degrees C. The two trauma groups were either submitted to the same hypothermic procedure or kept normothermic during the corresponding time. All animals were sacrificed 24 h following the surgical procedure. The MAP2 immunostaining in the normothermic trauma group indicated marked reductions in MAP2 antigen in the cranial and caudal peri-injury zones (T7 and T10, respectively). This reduction was much less pronounced in the hypothermic trauma group. In fact, the MAP2 antigen was present in almost equally sized areas in both the hypothermic groups independent of previous laminectomy alone or the addition of trauma. Our study thus indicates that hypothermia has a neuroprotective effect on dendrites of rat spinal cords subjected to compression trauma.	Univ Uppsala Hosp, Dept Genet & Pathol, Neuropathol Lab, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Neurosci, Neurosurg Unit, Uppsala, Sweden		Yu, WR (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Neuropathol Lab, S-75185 Uppsala, Sweden.			Westergren, Hans/0000-0002-4052-9692			BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; BRACKEN MB, 1997, JAMA-J AM MED ASSOC, V277, P1591; BRAY D, 1978, P NATL ACAD SCI USA, V75, P5226, DOI 10.1073/pnas.75.10.5226; CACERES A, 1988, MOL BRAIN RES, V3, P233, DOI 10.1016/0169-328X(88)90046-0; CLIFTON GL, 1995, J NEUROSURG ANESTH, V7, P152, DOI 10.1097/00008506-199504000-00023; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Eguchi Y, 1997, J NEUROTRAUM, V14, P109, DOI 10.1089/neu.1997.14.109; GEISLER FH, 1996, PRINCIPLES SPINAL SU, P769; HANCOCK MB, 1984, J HISTOCHEM CYTOCHEM, V32, P311, DOI 10.1177/32.3.6198359; HOLTZ A, 1989, SURG NEUROL, V31, P350, DOI 10.1016/0090-3019(89)90066-9; HOLTZ A, 1993, J NEUROTRAUM, V7, P115; Holtz Anders, 1995, Upsala Journal of Medical Sciences, V100, P93; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; LI GL, 1995, RESTOR NEUROL NEUROS, V8, P189, DOI 10.3233/RNN-1995-8404; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MATUS A, 1994, TRENDS NEUROSCI, V17, P19, DOI 10.1016/0166-2236(94)90030-2; MAUNEY MC, 1995, ANN THORAC SURG, V59, P245, DOI 10.1016/0003-4975(94)00815-O; MIYAWAKI A, 1993, TASK VEG SC, V30, P5; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P460, DOI 10.1111/j.1600-0404.1988.tb03688.x; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 1998, J NEUROTRAUM, V15, P943, DOI 10.1089/neu.1998.15.943; WILBERGER JE, 1996, PRINCIPLES SPINAL SU, P753; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 1999, NEUROPATHOLOGY, V19, P172, DOI 10.1046/j.1440-1789.1999.00227.x	32	27	28	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	NOV	2000	100	5					546	552		10.1007/s004010000206			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	352GK	WOS:000089206800013	11045677				2022-02-06	
J	Franulic, A; Horta, E; Maturana, R; Scherpenisse, J; Carbonell, C				Franulic, A; Horta, E; Maturana, R; Scherpenisse, J; Carbonell, C			Organic personality disorder after traumatic brain injury: cognitive, anatomic and psychosocial factors. A 6 month follow-up	BRAIN INJURY			English	Article							HEAD-INJURY; INDIVIDUALS; SEQUELAE	Objective: The purpose of the study is to describe psychosocial adjustment in patients who present Organic Personality Disorder (OPD) after TBI in relation to patients with TBI without OPD. Method: The group included patients who were admitted as inpatients in the Neurology Service. Exclusion criteria were: previous personality disorders; previous alcohol and drugs addiction, history of head injury and other neurological diseases. For this purpose, a semi-structured interview based on the ICD-10 was applied to the patient or significant other during the 1st or 2nd week after the accident. Selected patients were evaluated with psychological and psychosocial tests and questionnaires 6 months after head injury, among them: WAIS, Benton Test, Rey Osterrieth Test, Wisconsin Cards, Psychosocial Scale and Neurobehavioural Rating Scale (NRS-27). Results: No significant differences were observed in relation to demographic characteristics, type of head injury, GCS, or psychometric results. Significant differences were found in the answers to neurobehavioural and psychosocial questionnaires, showing more impairment in patients with OPD. Conclusions: The results show that, in this group, patients with OPD after TBI present more psychosocial adjustment and emotional problems than patients with TBI without OPD diagnosis. The difference found is independent of cognitive impairments.	Hosp Trabajador Santiago, Mental Hlth Serv, Santiago, Chile; Hosp Trabajador Santiago, Serv Neurol, Santiago, Chile		Franulic, A (corresponding author), Hosp Trabajador Santiago, Mental Hlth Serv, Vicuna Mackenna 200, Santiago, Chile.	ghtrae@gw.achs.cl		Carbonell, Carmen Gloria/0000-0001-9279-1847			[Anonymous], 1994, DIAGNOSTIC STAT MANU; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; BAMRAH JS, 1991, BRIT J PSYCHIAT, V158, P117, DOI 10.1192/bjp.158.1.117; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; BOND M, 1984, PSICHIATRY CLOSED HE; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1984, CLOSED HEAD INJURY P; *CIE 10, 1995, CLAS EST INT ENF PRO; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P260; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Labbate L A, 1997, Ann Clin Psychiatry, V9, P27, DOI 10.3109/10401239709147771; Lannoo E, 1997, J PSYCHOSOM RES, V43, P505, DOI 10.1016/S0022-3999(97)00152-9; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LISHMAN WD, 1987, ORGANIC PSICHIATRY P; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Munoz Cespedes JM., 1997, MAPFRE MED, V8, P41; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; YUDOFSKY SC, 1992, CURRENT OPINION PSYC, V5, P103	24	27	28	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2000	14	5					431	439					9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	316MQ	WOS:000087171500004	10834338				2022-02-06	
J	Frietsch, T; Krafft, P; Piepgras, A; Lenz, C; Kuschinsky, W; Waschke, KF				Frietsch, T; Krafft, P; Piepgras, A; Lenz, C; Kuschinsky, W; Waschke, KF			Relationship between local cerebral blood flow and metabolism during mild and moderate hypothermia in rats	ANESTHESIOLOGY			English	Article						autoradiography; coupling; local cerebral glucose utilization; neuroprotection; pH management; pH-stat	TRAUMATIC BRAIN INJURY; ACID-BASE MANAGEMENT; GLUCOSE-UTILIZATION; CARDIOPULMONARY BYPASS; HIPPOCAMPAL GLUTAMATE; CARBON-DIOXIDE; ALPHA-STAT; PH-STAT; ISCHEMIA; ISOFLURANE	Background: Hypothermia may interfere with the relationship between cerebral blood now (CBF) and metabolism. Because this conclusion was based on the analysis of global values. the question remains whether hypothermic CBF/metabolism uncoupling exists on a local cerebral level. This study investigated the effects of hypothermic anesthesia on local cerebral blood now (LCBF) and local cerebral glucose utilization (LCGU). Methods: Thirty-six rats were anesthetized with isoflurane (1 minimum alveolar concentration) and artificially ventilated to maintain normal arterial carbon dioxide partial pressure (pH-stat). Pericranial temperature was maintained as normothermic (37.5 degrees C, n = 12) or was reduced to 35 degrees C (n = 12) or 32 degrees C (n = 12), Pericranial temperature was maintained constant for 60 min until LCBF or LCGU were measured by autoradiography. Twelve conscious rats served as normothermic controls. Results: Compared with conscious animals, mean CBI: remained unchanged during normothermic anesthesia. Mean CBI: significantly increased during mild hypothermia but was unchanged during moderate hypothermia. During normothermic anesthesia, mean CGU was 45% lower than in conscious controls (P < 0.05), No further CGU reduction was found during mild hypothermia, whereas CGU further decreased during moderate hypothermia (48%; P < 0.05), Local analysis showed a Linear LCBF/LCGU relationship in conscious (r = 0.94) and anesthetized (r = 0.94) normothermic animals, as well as in both hypothermic groups (35 degrees C: r = 0.92; 32 degrees C: r = 0.95; P < 0.05), The LCBF-to-LCGU ratio increased from 1.4 (conscious controls) to 2.4 (normothermic isoflurane) and 3.6 ml/mu mol (mild and moderate hypothermia, P < 0.05), Conclusions: Decrease of mean CGU at unchanged or increased mean CBF during hypothermic anesthesia may not indicate uncoupling. Local analysis shows a maintained linear relationship that is reset to a higher CHF/CGU ratio.	Fac Clin Med Mannheim, Dept Anesthesiol, D-68167 Mannheim, Germany; Fac Clin Med Mannheim, Dept Crit Care Med, D-68167 Mannheim, Germany; Fac Clin Med Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; Univ Heidelberg, Dept Physiol, Heidelberg, Germany		Waschke, KF (corresponding author), Fac Clin Med Mannheim, Dept Anesthesiol & Crit Care Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.		Frietsch, Thomas/ABE-1386-2021				Bacher A, 1998, ANESTHESIOLOGY, V88, P403, DOI 10.1097/00000542-199802000-00019; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; BUSIJA DW, 1987, AM J PHYSIOL, V253, pH869, DOI 10.1152/ajpheart.1987.253.4.H869; CALLAGHAN P, 1961, ANN SURG, V154, P903; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Conroy BP, 1998, ANESTHESIOLOGY, V88, P390, DOI 10.1097/00000542-199802000-00018; FORD I, 1991, J CEREBR BLOOD F MET, V11, pA89, DOI 10.1038/jcbfm.1991.43; FRERICHS KU, 1994, J CEREBR BLOOD F MET, V14, P193, DOI 10.1038/jcbfm.1994.26; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; HARTUNG J, 1994, J NEUROSURG ANESTH, V6, P1; Hindman BJ, 1998, ANESTHESIOLOGY, V89, P5, DOI 10.1097/00000542-199807000-00004; HINDMAN BJ, 1993, ANESTHESIOLOGY, V79, P580, DOI 10.1097/00000542-199309000-00023; Hoffman WE, 1996, NEUROL RES, V18, P185; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; Klementavicius R, 1996, J NEUROSURG, V85, P482, DOI 10.3171/jns.1996.85.3.0482; Kurth CD, 1998, ANESTHESIOLOGY, V89, P110, DOI 10.1097/00000542-199807000-00018; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCULLOCH J, 1982, J NEUROCHEM, V39, P255, DOI 10.1111/j.1471-4159.1982.tb04729.x; MCCULLOCH J, 1982, J CEREBR BLOOD F MET, V2, P487, DOI 10.1038/jcbfm.1982.56; MURKIN JM, 1987, ANESTH ANALG, V66, P825; NAKASHIMA K, 1995, ANESTHESIOLOGY, V82, P1199, DOI 10.1097/00000542-199505000-00015; Niwa K, 1998, BRAIN RES, V789, P68, DOI 10.1016/S0006-8993(98)00013-4; PALMER C, 1989, ANESTHESIOLOGY, V71, P730, DOI 10.1097/00000542-198911000-00017; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; SANO T, 1992, ANESTHESIOLOGY, V76, P221, DOI 10.1097/00000542-199202000-00011; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STEPHAN H, 1992, BRIT J ANAESTH, V69, P51, DOI 10.1093/bja/69.1.51; Thoresen M, 1997, NEUROREPORT, V8, P3359, DOI 10.1097/00001756-199710200-00033; VERHAEGEN MJJ, 1993, STROKE, V24, P407, DOI 10.1161/01.STR.24.3.407; VITEZ TS, 1974, ANESTHESIOLOGY, V41, P80, DOI 10.1097/00000542-197407000-00020; WASCHKE K, 1993, AM J PHYSIOL, V265, pH1243, DOI 10.1152/ajpheart.1993.265.4.H1243	36	27	34	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAR	2000	92	3					754	763		10.1097/00000542-200003000-00019			10	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	289NL	WOS:000085628800017	10719954				2022-02-06	
J	Shum, DHK; Harris, D; O'Gorman, JG				Shum, DHK; Harris, D; O'Gorman, JG			Effects of severe traumatic brain injury on visual memory	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY	The study aimed to clarify the effects of severe traumatic brain injury (TBI) on visual memory. Three groups of participants (14 late-recovery and 14 early-recovery TBI individuals and 18 controls) were administered the following: The Shum Visual Learning Test (SVLT), a test that measures the ability to remember visual patterns, an electronic maze test, a test that measures the ability to remember spatial positions, and the Rey Auditory Verbal Learning Test (RAVLT), a test of verbal memory and learning. The individuals with TBI (late- and early-recovery) were found to be impaired on the SVLT and the RAVLT but not on the electronic maze. Specifically, on the SVLT, they were found to learn at a slower rate and make more false-positive errors than the controls. The advantages of the SVLT over visual memory tests used in previous studies and the significance of findings of the present study were discussed.	Griffith Univ, Neuropsychol Unit, Brisbane, Qld, Australia; Griffith Univ, Sch Appl Psychol, Brisbane, Qld, Australia		Shum, DHK (corresponding author), Griffith Univ, Sch Appl Psychol, Nathan, Qld 4111, Australia.		Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			BOWDEN SC, 1994, AUST PSYCHOL, V29, P34, DOI 10.1080/00050069408257317; BOWDEN SC, 1988, J CLIN EXP NEUROPSYC, V10, P157, DOI 10.1080/01688638808408232; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P224; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CULLUM CM, 1990, TRAUMATIC BRAIN INJU, P129; DELIS DC, 1989, HDB NEUROPSYCHOLOGY, V3, P3; EADIE K, 1995, J CLIN EXP NEUROPSYC, V17, P731, DOI 10.1080/01688639508405163; GEFFEN GM, 1994, BRAIN INJURY, V8, P405, DOI 10.3109/02699059409150992; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HEILBRONNER RL, 1992, CLIN NEUROPSYCHOL, V6, P105; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P48; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LEE GP, 1989, PSYCHOL ASSESS J CON, V1, P192; MAPOU RL, 1992, HDB HEAD TRAUMA EARL, V75, P75; Mayes A., 1992, HDB NEUROPSYCHOLOGIC, P73; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; NEWCOMBE F, 1987, NEUROPSYCHOLOGIA, V25, P149, DOI 10.1016/0028-3932(87)90127-8; Nixon S.J., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [DOI 10.1037/10198-001, https://doi.org/10.1037/10198-001]; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; Rey A., 1964, EXAMEN CLIN PSYCHOL; SHUM DHK, IN PRESS CLIN NEUROP; VANDERPLAS JM, 1959, J EXP PSYCHOL, V57, P147, DOI 10.1037/h0048723; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397; Walsh KW., 1991, UNDERSTANDING BRAIN; Wechsler D, 1987, MEMORY SCALE REVISED; [No title captured]	28	27	27	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2000	22	1					25	39		10.1076/1380-3395(200002)22:1;1-8;FT025			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	287BE	WOS:000085484000003	10649543				2022-02-06	
J	Gerwick, L; Demers, NE; Bayne, CJ				Gerwick, L; Demers, NE; Bayne, CJ			Modulation of stress hormones in rainbow trout by means of anesthesia, sensory deprivation and receptor blockade	COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY			English	Article						stress; anesthesia; antagonist; catecholamine; cortisol; Oncorhynchus; spleen; trout; 2-phenoxyethanol	CORTISOL; PHAGOCYTES; SALMON; BURST	Sympathetic activation leading to increased levels of blood catecholamines, and stimulation of the hypothalamic-pituitary-inter-renal axis leading to increased cortisol, are difficult to avoid when handling animals. Yet, in research on effects of acute stress, elicitation of such responses must be minimized in the control groups. The work examines means to achieve a mimmally disturbed stale in rainbow trout (Oncorhynchus mykiss). Level of arousal was determined by adrenaline and cortisol concentrations in plasma, and by the spleen:somatic index. Fish were prepared for bleeding by rapid capture and concussion, by infusion of anesthetic into the undisturbed home tank, by confinement in black boxes, or by being fed alpha- and P-receptor antagonists. Even when done quickly, netting and concussion yielded fish with ca. 200-pmol adrenaline/ml plasma. Cortisol was elevated(to > 10 ng/ml) within 30 s of stress initiation. Surreptitious infusion of anesthetic (2-phenoxyethanol, PE) into tanks yielded fish with lower adrenaline levels (means 19.34 and 19.58 pmols/ml in home tank and black boxes, respectively). Among fish given phentolamine and propranolol, spleen:somatic indices and plasma adrenaline were higher than in diet controls, whether undisturbed or stressed, indicative of successful receptor blockade. Since careful infusion of 2-PE yielded the lowest adrenaline levels, and requires no special apparatus, it is the method of choice for obtaining minimally stressed fish. (C) 1999 Elsevier Science Inc. All rights reserved.	Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA		Gerwick, L (corresponding author), Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA.	gerwickl@bcc.orst.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES000210, P50ES003850, P30ES003850] Funding Source: NIH RePORTER; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES-03850, ES-00210] Funding Source: Medline		BAYNE CJ, 1991, J LEUKOCYTE BIOL, V50, P554, DOI 10.1002/jlb.50.6.554; BAYNE CJ, 1991, J FISH BIOL, V38, P609, DOI 10.1111/j.1095-8649.1991.tb03147.x; BERNARD C, 1959, HOMEOSTASIS ORIGINS; Cannon WB, 1929, BODILY CHANGES PAIN; Demers NE, 1997, DEV COMP IMMUNOL, V21, P363, DOI 10.1016/S0145-305X(97)00009-8; DEMERS NE, 1994, MODULATORS FISH IMMU, V1; FLORY C M, 1989, Brain Behavior and Immunity, V3, P331, DOI 10.1016/0889-1591(89)90032-9; FLORY CM, 1990, DEV COMP IMMUNOL, V14, P283, DOI 10.1016/0145-305X(90)90019-B; GAMPERL AK, 1994, J FISH BIOL, V45, P313; IWAMA GK, 1989, CAN J ZOOL, V67, P2065, DOI 10.1139/z89-294; KIECOLTGLASER JK, 1992, PSYCHOSOM MED, V54, P680, DOI 10.1097/00006842-199211000-00008; MATTHEWS KA, 1995, PSYCHOSOM MED, V57, P564, DOI 10.1097/00006842-199511000-00009; MAULE AG, 1989, J ENDOCRINOL, V120, P135, DOI 10.1677/joe.0.1200135; NALIBOFF BD, 1995, BRAIN BEHAV IMMUN, V9, P207, DOI 10.1006/brbi.1995.1020; PEARSON MP, 1991, FISH PHYSIOL BIOCHEM, V9, P39, DOI 10.1007/BF01987610; POTTINGER TG, 1993, J FISH BIOL, V43, P121, DOI 10.1006/jfbi.1993.1114; REDDING JM, 1984, GEN COMP ENDOCR, V56, P146, DOI 10.1016/0016-6480(84)90071-6; Ruis MAW, 1997, J AQUAT ANIM HEALTH, V9, P190, DOI 10.1577/1548-8667(1997)009&lt;0190:EOASOB&gt;2.3.CO;2; SCHRECK CB, 1996, FISH IMMUNE SYSTEM, V15; SELYE H, 1973, AM SCI, V61, P692; SELYE H, 1950, BRIT MED J, V1, P1383, DOI 10.1136/bmj.1.4667.1383; THOMAS P, 1990, AM FISHERIES SOC S, P9; Wedemeyer G.A., 1990, P451	23	27	28	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1095-6433	1531-4332		COMP BIOCHEM PHYS A	Comp. Biochem. Physiol. A-Mol. Integr. Physiol.	NOV	1999	124	3					329	334		10.1016/S1095-6433(99)00126-9			6	Biochemistry & Molecular Biology; Physiology; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Physiology; Zoology	264LF	WOS:000084183200009	10665382				2022-02-06	
J	Driesse, MJ; Kros, JM; Avezaat, CJJ; Valerio, D; Vecht, CJ; Bout, A; Smitt, PAES				Driesse, MJ; Kros, JM; Avezaat, CJJ; Valerio, D; Vecht, CJ; Bout, A; Smitt, PAES			Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates	HUMAN GENE THERAPY			English	Article							MONKEY AIRWAY EPITHELIUM; BLOOD-BRAIN-BARRIER; GENE-TRANSFER; IMMUNE-RESPONSE; RAT MODEL; VECTORS; METHOTREXATE; EXPRESSION; THERAPY; LUNG	Gene therapy by administration of vectors into the cerebrospinal fluid (CSF) may be used in treatment of leptomeningeal metastases (cancer gene therapy) as well as in treatment of neurodegenerative disorders, traumatic injury, and chronic pain. Recombinant adenoviruses are attractive vectors for intra-CSF administration because they can efficiently transfer genes into the nonreplicating cells of the central nervous system (CNS). In addition, they can be produced in high titers and, because no producers cells are introduced, the risk of CSF obstruction by clustering cells is circumvented. However, successful application requires favorable distribution dynamics, high transduction efficiency, and long-lasting transgene expression. In this study we examined the distribution of a recombinant adenovirus containing the lacZ gene after administration into the CSF of nonhuman primates. After intraventricular and suboccipital administration, homogeneous distribution of the vector along the meninges covering the brain and spinal cord was obtained, as demonstrated by extensive and intense blue staining of cells, predominantly in the arachnoid and pia mater. In one animal we also found beta-galactosidase activity in the cervical paraspinal fat and in one of the deep cervical lymph nodes, indicating drainage of the vector or vector products with CSF into cervical lymph. This route of vector clearance from the CNS may result in antigenic presentation and an effective immune response and may explain the sixfold higher serum antibody titers after intrathecal injection of adenovirus as compared with intranasal application in Fischer rats. We conclude that distribution dynamics of recombinant adenovirus after intra-CSP administration are excellent. However, because of the immune response elicited by the virus, even after administration to the CNS, development of immunomodulating strategies remains a challenge.	Univ Rotterdam Hosp, Dept Neurooncol, Dept Neurosurg, NL-3008 AE Rotterdam, Netherlands; Univ Rotterdam Hosp, Dept Pathol, NL-3008 AE Rotterdam, Netherlands; Leiden Univ, Dept Mol Cell Biol, NL-2301 CA Leiden, Netherlands; IntroGene BV, NL-2301 CA Leiden, Netherlands		Driesse, MJ (corresponding author), Univ Rotterdam Hosp, Dept Neurooncol, Dept Neurosurg, POB 5201, NL-3008 AE Rotterdam, Netherlands.						BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BLANEY SM, 1995, J CLIN ONCOL, V13, P177, DOI 10.1200/JCO.1995.13.1.177; BOUT A, 1993, EXP LUNG RES, V19, P193, DOI 10.3109/01902149309031719; BOUT A, 1994, GENE THER, V1, P385; BOUT A, 1994, HUM GENE THER, V5, P3, DOI 10.1089/hum.1994.5.1-3; BRADBURY MWB, 1990, FERNS FOUND SERIES, V14, P403; CSERR HF, 1992, J NEUROIMMUNOL, V41, P195, DOI 10.1016/0165-5728(92)90070-2; CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5; DEJONG JC, 1993, J CLIN MICROBIOL, V31, P1562, DOI 10.1128/JCM.31.6.1562-1569.1993; ERLICH SS, 1986, J NEUROSURG, V64, P466, DOI 10.3171/jns.1986.64.3.0466; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fishman R. A., 1992, CEREBROSPINAL FLUID, V2nd; Fortunati E, 1996, BBA-GENE STRUCT EXPR, V1306, P55, DOI 10.1016/0167-4781(95)00217-0; Furlan R, 1998, HUM GENE THER, V9, P2605, DOI 10.1089/10430349850019445; GORDON LB, 1992, J NEUROIMMUNOL, V40, P81, DOI 10.1016/0165-5728(92)90215-7; Gravel C, 1997, NAT MED, V3, P765, DOI 10.1038/nm0797-765; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; LE GLS, 1993, SCIENCE, V259, P988; MCCOMB JG, 1990, FERNS FOUND SERIES, V14, P421; MCCULLY CL, 1990, LAB ANIM SCI, V40, P520; MILHORAT TH, 1970, J NEUROSURG, V32, P522, DOI 10.3171/jns.1970.32.5.0522; Morral N, 1997, HUM GENE THER, V8, P1275, DOI 10.1089/hum.1997.8.10-1275; Ohashi T, 1997, P NATL ACAD SCI USA, V94, P1287, DOI 10.1073/pnas.94.4.1287; Posner JB, 1995, NEUROLOGIC COMPLICAT, P143; PRECIOUS B, 1985, VIROLOGY PRACTICAL A, P157; SHAPIRO WR, 1975, NEW ENGL J MED, V293, P161, DOI 10.1056/NEJM197507242930402; Smith JG, 1998, GENE THERAPY NEUROLO, P147; SNIDER RS, 1961, STEREOTACTIC ATLAS M; Stevenson PG, 1997, J VIROL, V71, P145, DOI 10.1128/JVI.71.1.145-151.1997; Vincent AJPE, 1997, NEUROSURGERY, V41, P442, DOI 10.1097/00006123-199708000-00023; Vincent AJPE, 1996, J NEUROSURG, V85, P648, DOI 10.3171/jns.1996.85.4.0648	33	27	29	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1043-0342			HUM GENE THER	Hum. Gene Ther.	SEP 20	1999	10	14					2347	2354		10.1089/10430349950016997			8	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	239JT	WOS:000082765500008	10515454				2022-02-06	
J	Zubkov, AY; Pilkington, AS; Bernanke, DH; Parent, AD; Zhang, J				Zubkov, AY; Pilkington, AS; Bernanke, DH; Parent, AD; Zhang, J			Posttraumatic cerebral vasospasm: Clinical and morphological presentations	JOURNAL OF NEUROTRAUMA			English	Article						head injury; cerebral vasospasm; posttraumatic vasospasm; computed tomographic angiography; morphology	TRANSCRANIAL DOPPLER ULTRASOUND; BLOOD-FLOW VELOCITY; SEVERE HEAD-INJURY; ARTERIAL SPASM; SUBARACHNOID HEMORRHAGE; ANGIOGRAPHIC FINDINGS; ULTRASONOGRAPHY; TCD	Head injury is one of the leading causes of morbidity and mortality in the young population. Many factors complicate head injury and worsen an outcome. One of these factors is posttraumatic cerebral vasospasm. We studied 75 patients admitted to the University of Mississippi Medical Center with head injury. Their ages ranged from 14 to 67 years (mean 30 years, SD 11.63). Eighty percent of the patients were men, and 20 % were women. Of these patients, 53 (70.6 %) suffered severe blunt trauma, and 4 patients suffered gunshot wounds to the head. Four patients had mild head injury, and 14 had moderate head injury. Posttraumatic vasospasm was detected in 24 (32 %) patients. Among these patients, 19 (79.2 %) had severe closed head injury, 3 patients had moderate head injury, and 2 suffered gunshot wounds. The severity of the patient's respective condition was correlated with the development of posttraumatic cerebral vasospasm: 50 % of the patients with Glasgow Coma Scale (GCS) 3-4 developed PTV, and only 30 % with GCS 9-11, and none of the patients with GCS >12 developed PTV. Overall, posttraumatic vasospasm started earlier and had a shorter course than did aneurysmal vasospasm. Morphologically, posttraumatic vasospasm resembled the features of aneurysmal vasospasm. We found increased corrugation of the internal elastic lamina and increased amounts of connective tissue in the subendothelial layer. These findings show that posttraumatic vasospasm, although clinically more mild, demonstrates the same morphological changes as aneurysmal vasospasm.	Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Surg Intens Care Unit, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Anat, Jackson, MS 39216 USA		Zubkov, AY (corresponding author), Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA.			Zhang, John H./0000-0002-4319-4285	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 S10 RR11321-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR011321] Funding Source: NIH RePORTER		ARSENI C, 1971, ACTA NEUROCHIR, V24, P25, DOI 10.1007/BF01403138; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; BACKMUND H, 1972, NEURORADIOLOGY, V4, P46, DOI 10.1007/BF00344809; BASS A, 1993, STROKE, V24, P520; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, NEUROSURGERY, V30, P697; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; ECHLIN FA, 1980, CEREBRAL ARTERIAL SP, P251; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FRENIDENFELT H, 1963, ACTA RADIOL, V1, P278; GARDNER D, 1986, NURS CLIN N AM, V21, P555; GROLIMUND P, 1988, LANCET, V1, P1173; HAMER J, 1976, NEUROCHIRURGIA, V19, P185; KORDESTANI RK, 1995, NEUROSURG CLIN N AM, V6, P657; LEEDS NE, 1966, ACTA RADIOL DIAGN, V5, P320, DOI 10.1177/02841851660050P135; LEWIN W, 1968, BRIT J SURG, V55, P321, DOI 10.1002/bjs.1800550502; Lindegaard K F, 1986, Acta Radiol Suppl, V369, P96; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Rozsa L, 1989, Radiol Diagn (Berl), V30, P151; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; WILLIAMS AR, 1993, STROKE, V24, P520; Zhang J, 1998, ANAT REC, V253, P58, DOI 10.1002/(SICI)1097-0185(199804)253:2<58::AID-AR9>3.0.CO;2-A; Zubkov AY, 1999, SURG NEUROL, V51, P399, DOI 10.1016/S0090-3019(98)00133-5; ZUBKOV AY, 1998, J NEUROVASC DIS, V3, P257; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X; [No title captured]	35	27	30	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					763	770		10.1089/neu.1999.16.763			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700002	10521136				2022-02-06	
J	Thornton, KE				Thornton, KE			Exploratory investigation into mild brain injury and discriminant analysis with high frequency bands (32-64 Hz)	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; QUANTITATIVE EEG	QEEG variables (five activation, two relationship variables, 19 locations and five bands up to 64 Hertz) were collected under eyes dosed condition (under both 32 and 64 Hertz conditions) on 91 subjects, consisting of 32 mild brain-injured subjects (no loss of consciousness greater than 20 minutes) and 52 normals over the age of 14. An additional seven subjects who were unconscious seater than 20 minutes were available for analysis. Previous discriminant function analysis developed by Thatcher et at. was employed on the eyes closed 32 Hertz condition to ascertain its robustness for time periods greater than 1 year and for significant periods of unconsciousness. A separate discriminant for subjects was developed, employing only frontal high frequency coherence figures. The Thatcher discriminant could reliably (79%) identify all subjects up to 43 years post accident. The high frequency discriminant effectively identified 87% of the brain injured across an time periods (without significant loss of consciousness) and 100% of subjects within 1 year of accident. The combination of the discriminants resulted in a 100% accuracy rate for the 39 brain injured subjects for which discriminate values were available.	Ctr Hlth Psychol, S Plainfield, NJ USA		Thornton, KE (corresponding author), Ctr Hlth Psychol, 24 Highland Ave, Metuchen, NJ 08840 USA.			thornton, kirtley/0000-0002-3303-4747			DUFFY FH, 1994, CLIN ELECTROENCEPHAL, V25, pR6, DOI 10.1177/155005949402500403; HOOSHMAND H, 1989, CLIN ELECTROENCEPHAL, V20, P235, DOI 10.1177/155005948902000411; HUGHES JR, 1999, IN PRESS J NEUROPSYC; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; PAULSON MJ, 1970, J CLIN PSYCHOL, V26, P453, DOI 10.1002/1097-4679(197010)26:4<453::AID-JCLP2270260415>3.0.CO;2-V; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; Roland Per E, 1993, BRAIN ACTIVATION; TABANO MT, 1988, ELECTROENCEPHALOGRAP, V70, P185; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0	10	27	28	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1999	13	7					477	488		10.1080/026990599121395			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	215GT	WOS:000081374100002	10462146				2022-02-06	
J	Tirassa, M				Tirassa, M			Communicative competence and the architecture of the mind/brain	BRAIN AND LANGUAGE			English	Article							CLOSED-HEAD-INJURY; DISCOURSE; COMPREHENSION; REQUESTS; ABILITY; ADULTS	Cognitive pragmatics is concerned with the mental processes involved in intentional communication. I discuss a few issues that may help clarify the relationship between this area and the broader cognitive science and the contribution that they give, or might give, to each other. Rather than dwelling on the many technicalities of the various theories of communication that have been advanced, I focus on the different conceptions of the nature and the architecture of the mind/brain that underlie them. My aims are, first, to introduce and defend mentalist views of communication in general; second, to defend one such view, namely that communication is a cognitive competence, that is, a faculty, and the underlying idea that the architecture of the mind/brain is domain-specific; and, third, to review the (scarce) neuropsychological evidence that bears on these issues. (C) 1999 Academic Press.	Univ Turin, Ctr Cognit Sci, I-10123 Turin, Italy		Tirassa, M (corresponding author), Univ Turin, Ctr Cognit Sci, Via Lagrange 3, I-10123 Turin, Italy.						AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1207/s15516709cog1702_2; AIRENTI G, 1998, P 6 C INT ASS DIAL A; Austin J. L., 1975, DO THINGS WORDS; Bara BG, 1999, BRAIN LANG, V68, P507, DOI 10.1006/brln.1999.2125; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Barkow J.H., 1992, ADAPTED MIND EVOLUTI; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; BOSCO FM, 1998, P 20 ANN C COGN SCI; Bratman M., 1987, INTENTIONS PLANS PRA; BURLING R, 1993, CURR ANTHROPOL, V34, P25, DOI 10.1086/204132; Caplan D., 1992, LANGUAGE STRUCTURE P; Chomsky N., 1980, RULES REPRESENTATION; Churchland P.M., 1984, MATTER CONSCIOUSNESS; Churchland P.S., 1986, NEUROPHILOSOPHY UNIF; CHURCHLAND PM, 1988, BEHAV BRAIN SCI, V11, P507, DOI 10.1017/S0140525X00058647; Clark H. H., 1981, ELEMENTS DISCOURSE U; Clark Herbert H., 1996, USING LANGUAGE; CLEMENTS WA, 1994, COGNITIVE DEV, V9, P377, DOI 10.1016/0885-2014(94)90012-4; Cohen P. R., 1990, INTENTIONS COMMUNICA; COHEN PR, 1990, ARTIF INTELL, V42, P213, DOI 10.1016/0004-3702(90)90055-5; COSMIDES L, 1994, COGNITION, V50, P41, DOI 10.1016/0010-0277(94)90020-5; Cosmides L., 1994, MAPPING MIND DOMAIN; Davis A. G, 1985, ADULT APHASIA REHABI; DAVIS AG, 1981, LANGUAGE INTERVENTIO; DEBLESER R, 1986, PRAGMATICS ED; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; FEYEREISEN P, 1982, BRAIN LANG, V16, P191, DOI 10.1016/0093-934X(82)90083-9; Fodor J.A., 1975, LANGUAGE THOUGHT; FODOR JA, 1988, COGNITION, V28, P3, DOI 10.1016/0010-0277(88)90031-5; Fodor Jerry A., 1983, MODULARITY MIND ESSA; Foldi N.S., 1983, LANGUAGE FUNCTIONS B; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; Gelman S.A, 1994, MAPPING MIND DOMAIN; GRICE HP, 1957, PHILOS REV, V66, P377, DOI 10.2307/2182440; GRICE HP, 1982, MUTUAL KNOWLEDGE; Grice P., 1989, STUDIES WAY WORDS; GUILFORD AM, 1982, J COMMUN DISORD, V15, P337, DOI 10.1016/0021-9924(82)90001-6; HOLLAND AL, 1982, J SPEECH HEAR DISORD, V47, P50, DOI 10.1044/jshd.4701.50; Howard D., 1987, APHASIA THERAPY HIST; James W., 1890, PRINCIPLES PSYCHOL; JOANETTE Y, 1986, BRAIN LANG, V29, P81, DOI 10.1016/0093-934X(86)90035-0; JOANETTE Y, 1991, DISCOURSE ABILITY BR; Johnson-Laird Philip Nicholas, 1983, MENTAL MODELS COGNIT; Karmiloff-Smith A., 1992, MODULARITY DEV PERSP; KASHER A, 1991, J PRAGMATICS, V16, P381, DOI 10.1016/0378-2166(91)90132-H; Kasher A., 1976, LANGUAGE FOCUS FDN M; KASHER A, 1991, PRAGMATICS READER; Kasher Asa, 1991, CHOMSKYAN TURN; Leslie A.M., 1994, MAPPING MIND DOMAIN; Marr D., 1982, VISION COMPUTATIONAL, P428; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Minsky M, 1985, SOC MIND; Newell A., 1972, HUMAN PROBLEM SOLVIN; Newell Allen, 1990, UNIFIED THEORIES COG; PENN C, 1988, BRAIN INJURY, V1, P3; Penn Claire, 1987, APHASIOLOGY, P235, DOI [10.1080/02687038708248840, DOI 10.1080/02687038708248840]; Perner Josef, 1991, UNDERSTANDING REPRES; Pinker S., 1997, MIND WORKS; PLUM F, 1988, LANGUAGE COMMUNICATI; PREMACK D, 1990, COGNITION, V36, P1, DOI 10.1016/0010-0277(90)90051-K; Premack D., 1986, GAVAGAI FUTURE HIST; RAO A, 1992, P KR 92 3 INT C KNOW; Schiffer Stephen R., 1972, MEANING; Searle J. R., 1992, REDISCOVERY MIND; Searle J.R., 1983, INTENTIONALITY ESSAY; Searle J.R., 1979, EXPRESSION MEANING; Searle John R., 1969, SPEECH ACTS ESSAY PH; SHERRATT SM, 1990, APHASIOLOGY, V4, P539, DOI 10.1080/02687039008248506; SPELKE E, 1994, COGNITION, V50, P431, DOI 10.1016/0010-0277(94)90039-6; Sperber D., 1995, RELEVANCE COMMUNICAT; STEMMER B, 1994, BRAIN LANG, V46, P565, DOI 10.1006/brln.1994.1031; Stich S., 1983, FOLK PSYCHOL COGNITI; STRAWSON PF, 1964, PHILOS REV, V73, P439, DOI 10.2307/2183301; TIRASSA M, 1999, BEHAV BRAIN SCI; TIRASSA M, 1997, P 2 EUR C COGN SCI M; TIRASSA M, IN PRESS SPATIAL COG; TIRASSA M, 1994, PSYCOLOQUY, V5; Trevarthen C., 1978, ACTION GESTURE SYMBO; Wellman H. M., 1990, CHILDS THEORY MIND; WEYLMAN ST, 1989, BRAIN LANG, V36, P362; WILCOX MJ, 1978, BRAIN LANG, V6, P362, DOI 10.1016/0093-934X(78)90069-X; WILSON D, 1991, PRAGMATICS READER; Winner E., 1977, BRAIN, V100, P719; WYCKOFF LH, 1984, THESIS U FLORIDA; [No title captured]	87	27	29	0	0	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	1999	68	3					419	441		10.1006/brln.1999.2121			23	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	226TE	WOS:000082037100004	10441187	Green Published			2022-02-06	
J	Zentner, J; Wolf, HK; Helmstaedter, C; Grunwald, T; Aliashkevich, AF; Wiestler, OD; Elger, CE; Schramm, J				Zentner, J; Wolf, HK; Helmstaedter, C; Grunwald, T; Aliashkevich, AF; Wiestler, OD; Elger, CE; Schramm, J			Clinical relevance of amygdala sclerosis in temporal lobe epilepsy	JOURNAL OF NEUROSURGERY			English	Article						corpus amygdaloideum; sclerosis; epilepsy; temporal lobe seizure	STATUS EPILEPTICUS; MEMORY IMPAIRMENT; EMOTIONAL MEMORY; VERBAL MEMORY; NEURON LOSS; HIPPOCAMPUS; LOBECTOMY; CONVULSIONS; RESECTION; DEFICITS	Object. The goal of this study was to define the incidence and clinical significance of amygdala sclerosis (AS) in patients with temporal lobe epilepsy (TLE). Methods. Surgical specimens of the lateral amygdaloid nucleus and the hippocampus excised from 71 patients who were treated for medically intractable TLE were quantitatively evaluated using a computer-assisted image-analysis system and compared with 10 normal autopsy specimens. Densities of neurons and reactive astrocytes in the patients with TLE were correlated with clinical, neuropsychological, and depth-electroencephalography data. The neuron counts of the lateral amygdaloid nucleus did not correlate with various presumed etiological factors of TLE including hereditary seizures, birth complications, febrile convulsions, traumatic brain injury, infections, seizure semiology, and epileptological outcome. However, patient age at surgery was significantly higher (mean difference 10 years) when AS was present, as compared with patients without AS (p < 0.01). Seizure origin, as determined by using amygdalohippocampal depth electrodes, did not correlate with the presence or absence of AS. Neuropsychologically, there was a significant correlation between the neuronal densities of the lateral amygdaloid nucleus and both preoperative visual recognition and postoperative deterioration of short-term verbal memory performance (p < 0.05). Conclusions. Except for the relatively long history of epilepsy, the presence of AS is not associated with specific clinical or electrocorticographic features of mesial TLE. However, patients without AS are particularly at risk for deterioration of short-term verbal memory following amygdalohippocampectomy.	Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany; Univ Bonn, Dept Epileptol, D-5300 Bonn, Germany; Univ Bonn, Dept Neuropathol, D-5300 Bonn, Germany		Zentner, J (corresponding author), Univ Freiburg Klinikum, Dept Neurosurg, Breisacherstr 64, D-79106 Freiburg, Germany.						AICARDI J, 1970, EPILEPSIA, V11, P187, DOI 10.1111/j.1528-1157.1970.tb03880.x; ANDERSEN R, 1978, NEUROPSYCHOLOGIA, V16, P439, DOI 10.1016/0028-3932(78)90067-2; BEHRENS E, 1994, ACTA NEUROCHIR, V128, P84, DOI 10.1007/BF01400656; BLUME WT, 1993, ANN NEUROL, V33, P105, DOI 10.1002/ana.410330118; Brockhaus H, 1940, J PSYCHOL NEUROL, V49, P1; Bruton C., 1988, NEUROPATHOLOGY TEMPO; CAHILL L, 1995, NATURE, V377, P295, DOI 10.1038/377295a0; CAVANAGH JB, 1958, TEMPORAL LOBE EPILEP, P140; CENDES F, 1994, BRAIN, V117, P739, DOI 10.1093/brain/117.4.739; COURVILLE CB, 1958, TEMPORAL LOBE EPILEP, P220; DAM AM, 1980, EPILEPSIA, V21, P617, DOI 10.1111/j.1528-1157.1980.tb04315.x; EARLE KM, 1953, AMA ARCH NEUROL PSY, V69, P27, DOI 10.1001/archneurpsyc.1953.02320250033003; Elger CE, 1997, NEUROPSYCHOLOGIA, V35, P657, DOI 10.1016/S0028-3932(96)00110-8; Engel Jerome Jr., 1993, P609; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FEINDEL W, 1991, CAN J NEUROL SCI, V18, P603; GASTAUT H, 1959, EPILEPSIA, V1, P56, DOI 10.1111/j.1528-1157.1959.tb04249.x; GLOOR P, 1992, P505; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GOLDRING S, 1992, J NEUROSURG, V77, P185, DOI 10.3171/jns.1992.77.2.0185; Helmstaedter C, 1990, Schweiz Arch Neurol Psychiatr (1985), V141, P21; HELMSTAEDTER C, 1991, CORTEX, V27, P547, DOI 10.1016/S0010-9452(13)80004-4; HOSOKAWA J, 1995, EPILEPSY RES, V20, P11, DOI 10.1016/0920-1211(94)00058-5; HUDSON LP, 1993, ANN NEUROL, V33, P622, DOI 10.1002/ana.410330611; JOOMA R, 1995, ACTA NEUROCHIR, V133, P44, DOI 10.1007/BF01404946; KESNER R P, 1992, P379; KIM HI, 1992, STEREOT FUNCT NEUROS, V58, P162, DOI 10.1159/000098990; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; LEDOUX JE, 1993, BEHAV BRAIN RES, V58, P69, DOI 10.1016/0166-4328(93)90091-4; LEE K, 1981, ACTA NEUROL SCAND, V63, P231; LEONARD G, 1991, CAN J NEUROL SCI, V18, P593, DOI 10.1017/S0317167100032777; MALAMUD N, 1958, TEMPORAL LOBE EPILEP, P149; MALDONADO HM, 1988, EPILEPSIA, V29, P420, DOI 10.1111/j.1528-1157.1988.tb03741.x; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MCINTYRE DC, 1982, BRAIN RES, V250, P53, DOI 10.1016/0006-8993(82)90952-0; MEENCKE HJ, 1992, EPILEPSY SURGERY, P705; MEYER A, 1955, J NEUROL NEUROSUR PS, V18, P24, DOI 10.1136/jnnp.18.1.24; MILLER LA, 1994, J NEUROL NEUROSUR PS, V57, P1099, DOI 10.1136/jnnp.57.9.1099; MORRELL F, 1987, SURGICAL TREATMENT E, P701; MURRAY EA, 1984, J NEUROSCI, V4, P2565; MURRAY EA, 1985, SCIENCE, V228, P604, DOI 10.1126/science.3983648; NORMAN RM, 1958, TEMPORAL LOBE EPILEP, P20; OROURKE DM, 1993, NEUROSURGERY, V32, P574, DOI 10.1227/00006123-199304000-00013; Ounsted C., 1966, CLIN DEV MED, V22; PEINADOMANZANO MA, 1990, BEHAV BRAIN RES, V38, P117, DOI 10.1016/0166-4328(90)90010-C; Penfield W, 1954, EPILEPSY FUNCTIONAL; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; SANO K, 1953, AMA ARCH NEUROL PSY, V70, P40, DOI 10.1001/archneurpsyc.1953.02320310046003; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; SAUNDERS RC, 1984, NEUROPSYCHOLOGIA, V22, P785, DOI 10.1016/0028-3932(84)90103-9; SOININEN HS, 1994, NEUROLOGY, V44, P1660, DOI 10.1212/WNL.44.9.1660; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; VanRoost D, 1995, STEREOT FUNCT NEUROS, V64, P101, DOI 10.1159/000098739; WIESER HG, 1988, EPILEPSIA S2, V29, P100; Wieser HG., 1983, ELECTROCLINICAL FEAT; WOLF HK, 1993, J NEUROPATH EXP NEUR, V52, P499, DOI 10.1097/00005072-199309000-00008; Wolf HK, 1997, ACTA NEUROPATHOL, V93, P606, DOI 10.1007/s004010050658; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15; ZENTNER J, 1995, J NEUROL NEUROSUR PS, V58, P666, DOI 10.1136/jnnp.58.6.666; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P1922	61	27	27	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1999	91	1					59	67		10.3171/jns.1999.91.1.0059			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	209PM	WOS:000081057000009	10389881				2022-02-06	
J	Bagley, LJ; Grossman, RI; Galetta, SL; Sinson, GP; Kotapka, M; McGowan, JC				Bagley, LJ; Grossman, RI; Galetta, SL; Sinson, GP; Kotapka, M; McGowan, JC			Characterization of white matter lesions in multiple sclerosis and traumatic brain injury as revealed by magnetization transfer contour plots	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							HEAD-INJURY; MICROSCOPIC DISEASE; TRANSFER CONTRAST; AXONAL INJURY; MR; IMAGES; BURDEN; MILD; MS	BACKGROUND AND PURPOSE: Magnetization transfer imaging provides information about the structural integrity of macromolecular substances, such as myelin, Our objective was to use this imaging technique and contour plotting to characterize and to define the extent of white matter lesions in multiple sclerosis and traumatic brain injury. METHODS: Magnetization transfer imaging was performed of 30 multiple sclerosis plaques and 10 traumatic white matter lesions. Magnetization transfer ratios (MTRs) were calculated for the lesions, for the normal- or abnormal-appearing surrounding white matter, and for remote normal-appearing white matter, MTR contour plots were constructed about these lesions. RESULTS: The contour plot appearance of MS plaques differed from that of traumatic white matter lesions, There was a gradual increase in MTR values at points at increasing distances from the center of the MS plaques; this was true for those lesions with and without surrounding T2 signal abnormality (halos), In contrast, there was an abrupt transition in MTR values between traumatic lesions and normal-appearing surrounding white matter, Additionally, the size of the MTR abnormality exceeded the size of the T2 signal abnormality for the MS plaques. CONCLUSION: MTR contour plots permit characterization and border definition of white matter lesions, Analysis of the contour plots suggests that MS is a centrifugal process with the lowest MTR within the center of the lesion. In contrast, traumatic white matter injuries are discrete lesions with abrupt transitions between the abnormal lesion and normal brain.	Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA		Bagley, LJ (corresponding author), Univ Penn, Med Ctr, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS34353] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS034353, P01NS008803, R29NS034353, P50NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALLEN IV, 1979, J NEUROL SCI, V41, P81, DOI 10.1016/0022-510X(79)90142-4; Allen IV, 1991, MCALPINES MULTIPLE S, P341; ANDERSON DW, 1992, ANN NEUROL, V31, P333, DOI 10.1002/ana.410310317; BAGLEY LJ, 1997, INT SOC MAGN RES MED; BAUMHEFNER RW, 1990, ARCH NEUROL-CHICAGO, V47, P19, DOI 10.1001/archneur.1990.00530010027014; BOORSTEIN JM, 1994, RADIOLOGY, V191, P799, DOI 10.1148/radiology.191.3.8184068; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FARBER M, 1994, SPORTS ILLUSTRATED, V81, P39; FILIPPI M, 1995, NEUROLOGY, V45, P478, DOI 10.1212/WNL.45.3.478; HUBER SJ, 1988, J NEUROL SCI, V86, P1, DOI 10.1016/0022-510X(88)90002-0; Kasner SE, 1997, NEUROLOGY, V48, P534, DOI 10.1212/WNL.48.2.534; Kato Y, 1997, AM J NEURORADIOL, V18, P1541; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; LOEVNER LA, 1995, AM J NEURORADIOL, V16, P1473; MCGOWAN JC, 1994, JMRI-J MAGN RESON IM, V4, P79; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; THOMPSON AJ, 1990, BMJ-BRIT MED J, V600, P631; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TRUYEN L, 1990, J NEUROL SCI, V96, P173, DOI 10.1016/0022-510X(90)90130-F; van Buchem MA, 1998, NEUROLOGY, V50, P1609, DOI 10.1212/WNL.50.6.1609; vanBuchem MA, 1997, AM J NEURORADIOL, V18, P1287; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; WOLFF SD, 1991, RADIOLOGY, V179, P133, DOI 10.1148/radiology.179.1.2006263; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113	34	27	27	0	0	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JUN-JUL	1999	20	6					977	981					5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	224WC	WOS:000081922100007	10445432				2022-02-06	
J	Wiegner, S; Donders, J				Wiegner, S; Donders, J			Performance on the Wisconsin Card Sorting Test after traumatic brain injury	ASSESSMENT			English	Article						Wisconsin Card Sorting Test; traumatic brain injury	CLOSED-HEAD-INJURY; CATEGORY TEST; PATHOLOGY; EDUCATION; SUBTYPES; DAMAGE; SAMPLE; AGE	The performance of 100 patients with traumatic brain injury (TBI) on the Wisconsin Card Sorting Test (WCST) was examined to determine the underlying latent structure as well as profile subtypes. Exploratory factor analysis with oblique rotation identified three factors: response accuracy, learning, and failure to maintain set. Marker variables from each factor were then included in a two-stage cluster analysis, which identified two reliable subtypes. Level of performance differences between these subtypes were meaningfully related to both demographic background and length of coma. It is concluded that interpretation of the WCST results of patients with TBI should consider the multifactorial nature of the instrument in combination with injury severity characteristics and demographic variables.	Mary Free Bed Hosp, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Hosp, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1995, CHILD NEUROPSYCHOL, V1, P19, DOI 10.1080/09297049508401339; DONDERS J, 1991, CLIN NEUROPSYCHOL, V5, P78, DOI DOI 10.1080/13854049108401844; GOLDMAN GS, 1996, ASSESSMENT, V3, P73; Gorsuch R.L., 1983, FACTOR ANAL; Greve KW, 1998, ARCH CLIN NEUROPSYCH, V13, P597; HATCHER L, 1994, STEP BY STEP APPROAC; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 1991, COMPREHENSIVE NORMS; Heaton RK, 1992, COMPREHENSIVE NORMS; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Jones R. D., 1996, P395; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; PANIAK CE, 1992, J CLIN PSYCHOL, V48, P219, DOI 10.1002/1097-4679(199203)48:2<219::AID-JCLP2270480212>3.0.CO;2-K; PAOLO AM, 1995, ARCH CLIN NEUROPSYCH, V10, P463, DOI 10.1016/0887-6177(95)00052-6; PERRINE K, 1993, J CLIN EXP NEUROPSYC, V15, P461, DOI 10.1080/01688639308402571; Reitan R.M., 1993, HALSTEADREITAN NEURO; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P151, DOI 10.1080/13854049508401597; SCHERZER BP, 1993, BRAIN INJURY, V7, P411, DOI 10.3109/02699059309029684; ShuttleworthJordan AB, 1997, CLIN NEUROPSYCHOL, V11, P205, DOI 10.1080/13854049708407053; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; SULLIVAN EV, 1993, PSYCHIAT RES, V46, P175, DOI 10.1016/0165-1781(93)90019-D; TEASDALE G, 1974, LANCET, V2, P81; Vanderploeg RD, 1997, CLIN NEUROPSYCHOL, V11, P210, DOI 10.1080/13854049708407054; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wechsler, 1997, WECHSLER ADULT INTEL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	33	27	27	1	12	PSYCHOLOGICAL ASSESSMENT RESOURCES INC	ODESSA	PO BOX 998, ODESSA, FL 33556 USA	1073-1911			ASSESSMENT	Assessment	JUN	1999	6	2					179	187		10.1177/107319119900600205			9	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	205CF	WOS:000080803200005	10335020				2022-02-06	
J	Bombardier, CH; Rimmele, CT				Bombardier, CH; Rimmele, CT			Motivational interviewing to prevent alcohol abuse after traumatic brain injury: A case series	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; DRINKERS; ISSUES	Objective: Our goal was to test motivational interviewing as a means of preventing return to alcohol abuse after traumatic brain injury.: Participants: Twelve of 15 inpatients (80%) who screened positive for alcoholism were approached about the study. Historical controls were 20 similar but untreated patients with follow-up data. Results: One-year outcome data were obtained on 9 participants (75%). Seventy-six percent were male and an average of 35 years old. Eighty-nine percent of participants and 55% of controls reported drinking no alcohol during atypical week at 1 year after discharge. Conclusion: Motivational interviewing is feasible during inpatient rehabilitation and may reduce drinking after traumatic brain injury. Controlled studies are needed.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Seattle Vet Affairs Med Ctr, Seattle, WA USA		Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359740, Seattle, WA 98104 USA.	chb@u.washington.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283			Allen JP, 1997, J STUD ALCOHOL, V58, P7; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ANTTIPOIKA I, 1988, ALCOHOL ALCOHOLISM, V23, P115; BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; BEIN T, 1992, ADDICTIONS, V88, P315; BOMBARDIER C, 1997, ARCH PHYSICAL MED RE, V7, P592; Bombardier CH, 1997, REHABIL PSYCHOL, V42, P259; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CHICK J, 1985, BRIT MED J, V290, P965, DOI 10.1136/bmj.290.6473.965; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FREEDLAND E, 1993, EMERGENCY MED CLIN N, V11, P255; HEATHER N, 1993, 19 U NEW S WAL NAT D; HUNT WA, 1971, J CLIN PSYCHOL, V27, P355; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; MCLELLAN AT, 1994, J CONSULT CLIN PSYCH, V62, P1141, DOI 10.1037/0022-006X.62.6.1141; Miller W., 1995, DRINKER INVENTORY CO; Miller W, 1992, PROJECT MATCH MONOGR; MILLER WR, 1992, J STUD ALCOHOL, V53, P249, DOI 10.15288/jsa.1992.53.249; MILLER WR, 1991, BRIT J ADDICT, V86, P43; MILLER WR, 1984, MANUAL COMPREHENSIVE; Miller WR, 1987, BRIEF DRINKER PROFIL; Miller WR, 1991, MOTIVATIONAL INTERVI; *NAT HEAD INJ FDN, 1988, SUBST AB TASK FORC W; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Reilly E L, 1986, Adv Psychosom Med, V16, P17; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; SOBELL L, 1996, AM J PUBLIC HEALTH, V84, P966; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	40	27	27	0	12	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FEB	1999	44	1					52	67		10.1037/0090-5550.44.1.52			16	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	178VP	WOS:000079290100005					2022-02-06	
J	Nowell, SA; Leakey, JEA; Warren, JF; Lang, NP; Frame, LT				Nowell, SA; Leakey, JEA; Warren, JF; Lang, NP; Frame, LT			Identification of enzymes responsible for the metabolism of heme in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN INJURY; HUMAN-LIVER; RAT-BRAIN; UDP-GLUCURONOSYLTRANSFERASE; BILIVERDIN REDUCTASE; GILBERTS-SYNDROME; OXYGENASE-1 HO-1; CARBON-MONOXIDE; IN-VIVO; EXPRESSION	The major enzymes involved in the degradation of heme were identified in human platelets. It was determined that heme oxygenase activity levels in umbilical cord blood platelets were higher, whereas biliverdin reductase activity levels were comparable with that found in platelets from adults. In membranes prepared from adenosine diphosphate-activated platelets, UDP-glucuronic acid-dependent bilirubin conjugation was detected, whereas activity was negligible in unactivated platelets and undetected in serum and heat-inactivated platelets, and in platelets prepared from umbilical cord blood. Platelet fractions were analyzed by Western blot and shown to express heme oxygenase, biliverdin reductase, and UDP-glucuronosyltransferases, and there was concordance with known developmental profiles found in other tissues. Heme oxygenase expression was higher, whereas UGT expression was lower, in neonatal compared with adult platelets. These data suggest that platelets are involved in multiple steps of heme and bilirubin metabolism and that developmental regulation of these enzymes may be similar to that in other human tissues.	John L McClellan Mem Vet Affairs Med Ctr, Surg Serv 112LR, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Surg Oncol, Little Rock, AR 72205 USA; Natl Ctr Toxicol Res, Div Microbiol & Chem HFT230, Jefferson, AR 72079 USA; Reece Ctr, Inst Environm & Human Hlth, Lubbock, TX 79416 USA		Lang, NP (corresponding author), John L McClellan Mem Vet Affairs Med Ctr, Surg Serv 112LR, 4300 W 7th St, Little Rock, AR 72205 USA.				NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 58697, CA 55751] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 15722] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA058697, R01CA055751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG015722] Funding Source: NIH RePORTER		BISSELL DM, 1972, BLOOD-J HEMATOL, V40, P812, DOI 10.1182/blood.V40.6.812.812; BROWN AL, 1982, TOPICS LEARNING LEAR, V0002, P00001; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; CASTELLANI R, 1995, BRAIN RES, V696, P268, DOI 10.1016/0006-8993(95)00535-X; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; COUGHTRIE MWH, 1986, ANAL BIOCHEM, V159, P198, DOI 10.1016/0003-2697(86)90328-3; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; DENNERY PA, 1995, FREE RADICAL BIO MED, V19, P395, DOI 10.1016/0891-5849(95)00032-S; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; Hume R, 1996, BLOOD, V87, P762, DOI 10.1182/blood.V87.2.762.bloodjournal872762; JONES AL, 1995, BIOCHEM BIOPH RES CO, V208, P855, DOI 10.1006/bbrc.1995.1414; LANDAW SA, 1970, J CLIN INVEST, V49, P914, DOI 10.1172/JCI106311; LIN JHC, 1989, ARCH BIOCHEM BIOPHYS, V270, P623, DOI 10.1016/0003-9861(89)90545-6; LINCOLN BC, 1988, ANAL BIOCHEM, V170, P485, DOI 10.1016/0003-2697(88)90662-8; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1992, CLIN APPL FUNCTIONS; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; MILLS DCB, 1968, J PHYSIOL-LONDON, V195, P715, DOI 10.1113/jphysiol.1968.sp008484; MORI H, 1991, JPN J CANCER RES, V82, P755, DOI 10.1111/j.1349-7006.1991.tb02698.x; NEUZIL J, 1993, FEBS LETT, V331, P281, DOI 10.1016/0014-5793(93)80353-V; NOWELL S, 1997, 8 N AM ISSX M HILT H, P92; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; PIMSTONE NR, 1971, J CLIN INVEST, V50, P1264; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; RITTER JK, 1991, J BIOL CHEM, V266, P1043; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; Tiribelli C, 1996, HEPATOLOGY, V24, P1296; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vallis KA, 1996, CARCINOGENESIS, V17, P649, DOI 10.1093/carcin/17.4.649; VANROY FP, 1971, CLIN CHIM ACTA, V31, P109, DOI 10.1016/0009-8981(71)90367-6; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WALTERS MI, 1970, MICROCHEM J, V15, P231, DOI 10.1016/0026-265X(70)90045-7; WEBER CM, 1994, J NEUROCHEM, V63, P953; WILLIAMS M, 1994, BBA-LIPID LIPID MET, V1211, P310, DOI 10.1016/0005-2760(94)90155-4; WISHART GJ, 1978, BIOCHEM J, V174, P485, DOI 10.1042/bj1740485; Wu TW, 1994, LIFE SCI, V54, pP477	44	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33342	33346		10.1074/jbc.273.50.33342			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	WOS:000077462500038	9837908	hybrid			2022-02-06	
J	Schreiber, S; Klag, E; Gross, Y; Segman, RH; Pick, CG				Schreiber, S; Klag, E; Gross, Y; Segman, RH; Pick, CG			Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury	INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY			English	Article						psychosis; risperidone; sleep disturbances; traumatic brain injury		Severe disturbances of sleep architecture and circadian rhythms are common in traumatic brain injured patients; however, complete absence of the rapid eye movement sleep stage is very rare. We describe a brain injured patient with cognitive disturbances who developed severe alterations of sleep architecture, accompanied by paranoid and jealousy delusions. Following several trials with conventional antipsychotics his psychotic state stabilized but he continued to complain of insomnia and daytime fatigue. When treated with risperidone 2 mg/day, both his sleep and the delusional thoughts improved markedly and his daytime alertness increased. Severe deterioration of his support system brought about discontinuation of treatment with re-emergence of all symptoms. Int Clin Psychopharmacol 13:273-275 (C) 1998 Lippincott Williams & Wilkins.	Chaim Sheba Med Ctr, Dept Psychiat C, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; Neuropsychol Unit Treatment & Rehabil, Tel Aviv, Israel; Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel; Hadassah Hebrew Univ Med Ctr, Dept Psychiat, Jerusalem, Israel		Schreiber, S (corresponding author), Chaim Sheba Med Ctr, Dept Psychiat C, IL-52621 Tel Hashomer, Israel.		Pick, Chaim/D-4789-2009; Schreiber, Shaul/E-5821-2010; Sanguansri, Luz/B-6630-2011	Schreiber, Shaul/0000-0002-2189-0693; Sanguansri, Luz/0000-0003-1908-7604			ALDRICH MS, 1993, J PSYCHOSOM RES, V37, P3, DOI 10.1016/0022-3999(93)90022-8; CRICK F, 1983, NATURE, V304, P111, DOI 10.1038/304111a0; FADDA P, 1993, PROG NEURO-PSYCHOPH, V17, P269, DOI 10.1016/0278-5846(93)90047-V; JACOBSEN FM, 1995, J CLIN PSYCHIAT, V56, P423; JANSSEN PAJ, 1988, J PHARMACOL EXP THER, V244, P685; LAVIE P, 1984, NEUROLOGY, V34, P118, DOI 10.1212/WNL.34.1.118; Mahowald Mark W., 1996, P285; Schreiber S, 1997, NEUROSCI LETT, V228, P25, DOI 10.1016/S0304-3940(97)00345-5; SCHREIBER S, 1997, J NEUROPSYCHIAT, V9, P640; Staedt J, 1996, EUR ARCH PSY CLIN N, V246, P305, DOI 10.1007/BF02189023; WAUQUIER A, 1985, SLEEP NEUROTRANSMITT	11	27	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0268-1315			INT CLIN PSYCHOPHARM	Int. Clin. Psychopharmacol.	NOV	1998	13	6					273	275		10.1097/00004850-199811000-00006			3	Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Psychiatry	146HW	WOS:000077424100006	9861578				2022-02-06	
J	London, L; Nell, V; Thompson, ML; Myers, JE				London, L; Nell, V; Thompson, ML; Myers, JE			Health status among farm workers in the western cape - Collateral evidence from a study of occupational hazards	SOUTH AFRICAN MEDICAL JOURNAL			English	Article							SOUTH-AFRICA; EXPOSURE	Motivation. Farm workers are a marginalised occupational group whose poor living and working conditions may place them at increased risk for occupational and non-occupational morbidity and mortality. Research into the health status of farm workers has been neglected in the past. Aims and objectives. As part of an investigation into the neurological and neurobehavioural effects of exposure to organophosphate insecticides, this study describes the demographics, life histories, risk factors for chronic illness End selected indicators of general health status among:a group of farm workers in the Western Cape. Study design. Cross-sectional study conducted in the deciduous fruit farming industry in 1993. Subjects. 164 pesticide applicators and 83 non-spraying controls (all men) from 73 farms, frequency matched for age and education. Measurements. A structured questionnaire, venous blood for serum and erythrocyte cholinesterase, albumin, gamma glutamyl transferase and haemoglobin assessment, and weight measurement. Results. Most farm workers were children of farm workers had lived and worked on farms for most of their lives. study found substantial levels of illiteracy (21 - 44%, depending on the definition) and innumeracy (4%) and evidence of a significant morbidity burden: high levels of alcohol intake and ongoing reported application of the 'dop' system, high levels of head injury (70% of subjects) and evidence of substantial adult, undernutrition. Protective equipment was relatively well distributed and used, although certain work activities (such as acting as a human marker) continue to pose substantial exposure hazards. There were no differences in respect of cholinesterase levels between spray applicators and controls, although past poisoning was reported by 9% of subjects. Conclusion. Farm workers appear to be a closed community with a high disease burden. Their health needs pose substantial challenges to the public health authorities.	Univ Cape Town, Occupat & Environm Hlth Res Unit, Dept Community Hlth, ZA-7700 Rondebosch, South Africa; Univ S Africa, Hlth Psychol Unit, Johannesburg, South Africa; Univ Washington, Dept Biostat, Seattle, WA 98195 USA		London, L (corresponding author), Univ Cape Town, Occupat & Environm Hlth Res Unit, Dept Community Hlth, ZA-7700 Rondebosch, South Africa.		London, Leslie/G-6061-2011				Bailie R, 1998, S AFR MED J, V88, P1105; BALL A, 1990, S AFR LAB B, V14, P52; Bourne L T, 1993, Cent Afr J Med, V39, P238; BRIDGEMAN DHM, 1992, S AFRICAS LEADING ED; COYE MJ, 1988, OCCUPATIONAL HLTH RE; DAVIES W, 1990, WE CRY OUR LAND FARM; DEGRAAFF JF, 1990, 14 U STELL RES UN SO; DONALDSON A, 1994, DEV SO AFRICA, V11, P131; DUTOIT A, 1992, FARM FAMILY PATERNAL; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; *FARMW RES RES PRO, 1997, STAT S AFR FARMW 199; GROENEWALD CJ, 1986, COMMUNITY DEV FARMS, V9; KEENAN J, 1987, S AFRICAN REV, V4, P581; KNEDEL M, 1967, KLIN WOCHENSCHR, V45, P325, DOI 10.1007/BF01747115; KRITZINGER A, 1995, LABOUR SITUATION S A; LANZ SH, 1994, WOMEN FARMS REPORT W; LOEWENSEN R, 1990, RES WORKSH PEST SAF; Loewenson R., 1986, Health Policy and Planning, V1, P48, DOI 10.1093/heapol/1.1.48; London L, 1997, ENVIRON RES, V73, P132, DOI 10.1006/enrs.1997.3715; LONDON L, 1995, OCCUP ENVIRON MED, V52, P57, DOI 10.1136/oem.52.1.57; LONDON L, 1994, S AFR MED J, V84, P273; London L, 1995, S AFR J SCI, V91, P515; LONDON L, 1995, EPIDEMIOLOGY S, V6, pS107; LONDON L, 1995, THESIS U CAPE TOWN D; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; Merchant James, 1995, P267; National Center for Health Statistics, 1994, TRAUMA REV, V2, P1; Naude JT, 1998, S AFR MED J, V88, P1102; REES D, 1993, SCAND J WORK ENV HEA, V19, P236, DOI 10.5271/sjweh.1478; *S AFR MED RES COU, 1993, GUID ETH MED RES; Segal Lauren, 1991, BRUTAL HARVEST ROOTS; SEKIMPI DK, 1992, OCCUPATIONAL HLTH DE, P31; SETZER ML, 1971, AM J PSYCHIAT, V127, P1653; STEYN K, 1990, S AFR MED J, V78, P68; WALDMAN PL, 1993, THESIS U CAP TOWN DE; WEIDEPOEL L, 1984, LEARNING LIT PROJECT; WHITTAKER S, 1987, THESIS U CAPE TOWN; *WHO, 1982, DECL HELS PROP INT G; WOLMARANS P, 1988, S AFR MED J, V73, P12	39	27	29	0	2	MED ASSOC S AFRICA	JOHANNESBURG	MED HOUSE CENTRAL SQ 7430 PINELANDS  PRIV BAG X1, JOHANNESBURG, SOUTH AFRICA	0038-2469			S AFR MED J	S. Afr. Med. J.	SEP	1998	88	9					1096	1101					6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131NY	WOS:000076583200035	9798496				2022-02-06	
J	Nagurney, JT; Borczuk, P; Thomas, SH				Nagurney, JT; Borczuk, P; Thomas, SH			Elder patients with closed head trauma: A comparison with nonelder patients	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 19-22, 1997	WASHINGTON, D.C.	Soc Acad Emergency Med		geriatrics; aged; accidents; neurosurgery; head injuries, closed; trauma	COMPUTED-TOMOGRAPHY; BRAIN INJURY	Objective: Little is known about the circumstances surrounding closed head trauma (CHT) in elders, and how they differ from nonelders. The study objective was to compare the 2 populations for outcome (positive cranial CT scan depicting traumatic injury, or the need for neurosurgery), mechanism of injury, and the value of the neurologic examination to predict a CT scan positive for traumatic injury or the need for neurosurgical intervention. Methods: A retrospective study was conducted by collecting a case series of patients with blunt head trauma who underwent CT scanning, and comparing elder (aged greater than or equal to 60 years) with nonelder patients. The setting was the ED of a university-affiliated Level-1 trauma center. Results: Twenty percent of the elders and 13% of the nonelders had CT scans positive for traumatic injury, which conferred a risk ratio of 1.58 (95% CI 1.21-2.05). Older women were more at risk for the need for neurosurgery than were younger ones (3.1 vs 0.3%, RR 10.66, 95% CI 1.26-90.46). Among the elders, falls were the dominant mechanism of closed head trauma, followed by motor vehicle collisions (MVCs), then being struck as a pedestrian. In the nonelders, MVCs, falls, and assaults were the most important mechanisms of injury. A focally abnormal neurologic examination imparted an increased risk for both a CT scan positive for traumatic injury (elder 4.39, 95% CI 2.91-6.62; nonelder 7.75, 95% CI 5.53-10.72) and the need for neurosurgery (elder 35.68, 95% CI 4.58-275.89; nonelder 142.58, 95% CI 19.11-1064.22) in both age groups. Conclusions: Significant differences exist between elder and nonelder victims of CHT with respect to mechanisms of trauma and outcomes (CT scan positive for traumatic injury, or the need for neurosurgery).	Massachusetts Gen Hosp, Clin 117, Dept Emergency Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA		Nagurney, JT (corresponding author), Massachusetts Gen Hosp, Clin 117, Dept Emergency Med, 55 Fruit St, Boston, MA 02114 USA.	nagurney.john@mgh.harvard.edu					Baker SP, 1992, THE INJURY FACT BOOK, VSecond; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; MADDEN C, 1995, ACAD EMERG MED, V2, P248, DOI 10.1111/j.1553-2712.1995.tb03217.x; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOSENTHAL AC, 1995, J TRAUMA, V38, P753, DOI 10.1097/00005373-199505000-00013; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SPAITE DW, 1990, ANN EMERG MED, V19, P1418, DOI 10.1016/S0196-0644(05)82611-3; WEST JG, 1988, TRAUMA	17	27	27	0	1	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUL	1998	5	7					678	684		10.1111/j.1553-2712.1998.tb02485.x			7	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	100KJ	WOS:000074815100006	9678391				2022-02-06	
J	Li, XS; Williams, M; Bartlett, WP				Li, XS; Williams, M; Bartlett, WP			Induction of IGF-1 mRNA expression following traumatic injury to the postnatal brain	MOLECULAR BRAIN RESEARCH			English	Article						brain injury; IGF-1; mRNA; astrogliosis	GROWTH-FACTOR-I; MESSENGER RIBONUCLEIC-ACID; CENTRAL-NERVOUS-SYSTEM; GENE-EXPRESSION; SKELETAL-MUSCLE; RAT-BRAIN; RNA; ASTROCYTES; HIPPOCAMPUS; PROTEIN	A variety of adult, non-neural tissues respond to injury by increasing expression of the gene which encodes for insulin-like growth factor-1 (IGF-1). This response is thought to be a key component in the regenerative capacity of these tissues. In contrast, the central nervous system (CNS) has relatively little regenerative capacity following injury. interestingly, compared to many non-neuronal tissues, little IGF-1 mRNA can be detected in the adult CNS, raising the possibility that its lack of regenerative capacity is related its relative lack of IGF-1 expression. However, in the 2-week-old adolescent CNS IGF-1 mRNA can be detected in numerous brain regions. Therefore, the purpose of this study was to determine the responsiveness of the IGF-1 gene to injury in adolescent CNS tissue, a period in which expression of this gene is relatively abundant. Expression of IGF-1 mRNA was measured by means of a sensitive solution hybridization/RNase protection assay in the parieto-occipital lobes of 2-week-old and adult mice following penetrating injury. Levels of IGF-1 transcript in the injured brains were significantly increased above those of controls in both 2-week-old and adult brains 3-day post injury and remained elevated for 1 week after injury. These observations demonstrate that the adult CNS, like other tissues, can respond to injury by increasing expression of IGF-1 mRNA. (C) 1998 Elsevier Science B.V. All rights reserved.	Texas Womans Univ, Sch Phys Therapy, Houston, TX 77030 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Anat & Neurosci, Hershey, PA 17033 USA		Bartlett, WP (corresponding author), Texas Womans Univ, Sch Phys Therapy, 1130 MD Anderson Blvd, Houston, TX 77030 USA.						AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; BACH M A, 1991, Molecular Brain Research, V10, P43, DOI 10.1016/0169-328X(91)90054-2; BARONVANEVERCOO.A, 1991, J NEUROL RES, V28, P24; BARTLETT WP, 1992, MOL BRAIN RES, V12, P285, DOI 10.1016/0169-328X(92)90131-T; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; BONDY CA, 1991, J NEUROSCI, V11, P3442; Breese CR, 1996, J COMP NEUROL, V369, P388; BURGESS SK, 1987, J BIOL CHEM, V262, P1618; CHEN H, 1993, J NEUROL SCI, V118, P109, DOI 10.1016/0022-510X(93)90099-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLE AJ, 1992, PATHOPHYSIOL MECH; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Del Rio-Hortega P, 1927, B JOHNS HOPKINS HOSP, V41, P278; EDWALL D, 1989, ENDOCRINOLOGY, V124, P820, DOI 10.1210/endo-124-2-820; Eng LF, 1987, PROG BRAIN RES <D>, V71, P439; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; HAN VKM, 1987, J NEUROSCI, V7, P501; HANSSON HA, 1986, ACTA PHYSIOL SCAND, V126, P609, DOI 10.1111/j.1748-1716.1986.tb07862.x; HANSSON HA, 1987, CELL TISSUE RES, V250, P499; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V129, P9, DOI 10.1111/j.1748-1716.1987.tb08034.x; KANJE M, 1989, BRAIN RES, V486, P36; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LENOIR D, 1983, DEV BRAIN RES, V7, P205, DOI 10.1016/0165-3806(83)90177-3; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LINDSAY RM, 1986, ASTROCYTES, V2, P226; LUDWIN SK, 1985, LAB INVEST, V52, P20; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; PHILIPPS AF, 1988, PEDIATR RES, V23, P298, DOI 10.1203/00006450-198803000-00014; RUSSELL WE, 1985, AM J PHYSIOL, V248, P618; SHEMER J, 1987, J BIOL CHEM, V262, P7698; SJOBERG J, 1989, BRAIN RES, V485, P102, DOI 10.1016/0006-8993(89)90671-9; SMITH FE, 1991, P NATL ACAD SCI USA, V88, P6152, DOI 10.1073/pnas.88.14.6152; SUMI SM, 1968, ACTA NEUROPATHOL, V10, P324, DOI 10.1007/BF00690707; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; YAMAGUCHI F, 1991, NEUROSCI LETT, V128, P273, DOI 10.1016/0304-3940(91)90278-2	40	27	27	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JUN 1	1998	57	1					92	96		10.1016/S0169-328X(98)00075-8			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZW068	WOS:000074370700011	9630538				2022-02-06	
J	Zink, BJ; Stern, SA; Wang, X; Chudnofsky, CC				Zink, BJ; Stern, SA; Wang, X; Chudnofsky, CC			Effects of ethanol in an experimental model of combined traumatic brain injury and hemorrhagic shock	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	SAEM Annual Meeting	MAY, 1996	DENVER, COLORADO	Soc Acad Emergency Med		alcohol; ethanol; injury; shock; hemorrhage; brain; trauma	CEREBRAL BLOOD-FLOW; FREE-RADICAL MECHANISMS; NERVOUS-SYSTEM TRAUMA; SEVERE HEAD-INJURIES; OXYGEN DELIVERY; ALCOHOL-INTOXICATION; RESPONSES; METABOLISM; ARTERIOLES; REDUCTION	Objectives: Given that clinical and laboratory studies suggest that ethanol and hemorrhagic shock (HS) potentiate traumatic brain injury (TBI), the authors studied the effects of ethanol in a model of combined TBI and HS. Methods: A controlled porcine model of combined TBI and HS was evaluated for the effect of ethanol on survival time, hemodynamic function, and cerebral tissue perfusion. Anesthetized swine (17-24 kg) were instrumented, splenectomized, and subjected to fluid percussion TBI with concurrent 25-mL/kg graded hemorrhage over 30 minutes. Two groups were studied: control (n = 11) and ethanol (n = 11). Ethanol, 3.5 g/kg intragastric, was given 100 minutes prior to TBI/HS. Systemic and cerebral physiologic and metabolic parameters were monitored for 2 hours without resuscitation. Regional cerebral blood flow (rCBF) and renal blood flow were measured with dye-labeled microspheres. Data were analyzed with 2-sample t-test and repeated-measures ANOVA. Results: Ethanol levels at the time of injury were 162 +/- 68 mg/dL. Average TBI was 2.65 +/- 0.35 atm. Survival time was significantly shorter in the ethanol group (60 +/- 27 min vs 94 +/- 28 min, p = 0.011). The ethanol group had significantly lower mean arterial pressure, cerebral perfusion pressure, and cerebral venous O-2 saturation in the postinjury period. Cerebral O-2 extraction ratios and cerebral venous lactate levels were significantly higher in the ethanol group. A trend toward lower postinjury rCBF in all brain regions was observed in the ethanol group. Conclusion: In this TBI/HS model, ethanol administration decreased survival time, impaired the hemodynamic response, and worsened measures of cerebral tissue perfusion.	Univ Michigan, Med Ctr, Dept Surg, Sect Emergency Med, Ann Arbor, MI 48109 USA		Zink, BJ (corresponding author), Univ Michigan, Med Ctr, Dept Surg, Sect Emergency Med, TC B134,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	bzink@umich.edu			NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [1 KO8 AA00184-01A2] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K08AA000184] Funding Source: NIH RePORTER		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BEARD JD, 1973, Q J STUD ALCOHOL, V34, P1303; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CREWS F, 1993, RES MONOGRAPH, V22, P355; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DILUZIO NR, 1969, EXP MOL PATHOL, V11, P38, DOI 10.1016/0014-4800(69)90069-0; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; DURCAN MJ, 1989, PHARMACOL BIOCHEM BE, V32, P667, DOI 10.1016/0091-3057(89)90015-4; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; EISENHOFER G, 1984, BRIT J CLIN PHARMACO, V18, P581, DOI 10.1111/j.1365-2125.1984.tb02507.x; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FADEN AI, 1989, SCIENCE, V244, P789; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; GOLDSTEIN D, 1983, PHARM ALCOHOL, P164; GORDIS E, 1989, ALCOHOL ALERT NAT I, V3, P1; GORDON EL, 1995, J CEREBR BLOOD F MET, V15, P532, DOI 10.1038/jcbfm.1995.66; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HORTON JW, 1986, SURGERY, V100, P520; ISRAEL RS, 1988, ANN EMERG MED, V17, P560; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KNEUSSL MP, 1986, AM REV RESPIR DIS, V133, P1024; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KUPARI M, 1983, EUR HEART J, V4, P463, DOI 10.1093/oxfordjournals.eurheartj.a061503; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609000-00010; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LIEBER CS, 1984, MED CLIN N AM, V68, P3, DOI 10.1016/S0025-7125(16)31238-X; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARX J, 1990, Emergency Medicine Clinics of North America, V8, P929; Mayhan WG, 1996, ALCOHOL CLIN EXP RES, V20, P538, DOI 10.1111/j.1530-0277.1996.tb01089.x; MAYHAN WG, 1995, STROKE, V26, P2097, DOI 10.1161/01.STR.26.11.2097; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; Mihic S. J., 1996, PHARM TOXIC, P51; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MURR R, 1989, CEREBRAL MICROCIRCUL, V16, P61; NEWSOME HH, 1988, J TRAUMA, V28, P1, DOI 10.1097/00005373-198801000-00001; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; NORDMANN R, 1996, PHARM TOXIC, P329; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PITTS LH, 1990, HDB CLIN NEUROLOGY, V13, P65; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; REVES JG, 1972, Q J STUD ALCOHOL, V33, P464; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCALEA TM, 1994, CRIT CARE MED, V22, P1610; Schmoker JD, 1996, J NEUROTRAUM, V13, P67, DOI 10.1089/neu.1996.13.67; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SELIGMAN ML, 1977, LIPIDS, V12, P945, DOI 10.1007/BF02533316; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SIGGINS GR, 1996, PHARM TOXIC, P175; Smith DH, 1996, NEUROTRAUMA, P1445; Suzuki K., 1990, NAGOYA MED J, V34, P159; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YUAN XQ, 1991, CIRC SHOCK, V35, P231; ZHANG A, 1993, EUR J PHARM-ENVIRON, V248, P229, DOI 10.1016/0926-6917(93)90049-V; ZINK BJ, 1988, ANN EMERG MED, V17, P15, DOI 10.1016/S0196-0644(88)80496-7; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; ZINK BJ, 1988, CIRC SHOCK, V24, P19	70	27	31	0	2	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JAN	1998	5	1					9	17		10.1111/j.1553-2712.1998.tb02568.x			9	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	YQ544	WOS:000071398400003	9444336	Green Submitted, Bronze			2022-02-06	
J	Schmid, I; Wechsler, B				Schmid, I; Wechsler, B			Behaviour of Japanese quail (Coturnix japonica) kept in semi-natural aviaries	APPLIED ANIMAL BEHAVIOUR SCIENCE			English	Article						Japanese quail; housing; time budget; social behaviour; egg laying behaviour	WELFARE	In caged Japanese quail (Coturnix japonica), there are several welfare problems such as head injuries caused by aggressive pecking and head-banging as a consequence of escape responses. The present study is aimed at improving the knowledge of the behaviour elf this farm animal species for the design of adequate housing systems. From May to October, eight groups of eight or nine quails of a domestic strain were housed in aviaries (19.1 m(2)) containing natural soil and vegetation. There were two groups with hens only and six groups of varied sex ratio. A time budget analysis showed that the quails spent 35% of the observation time on passive behaviour, 24% on locomotory behaviour, 8% on exploratory/foraging behaviour, 14% on comfort behaviour and 4% on ingestive behaviour. The percentage of time the quails stayed in cover (average 48%) was significantly higher than the proportion of the floor area that was severed with plants and artificial shelters. On the other hand, the time spent on elevated structures (average 0.5%) was significantly lower than expected. Based on data of spatial proximity 'close relationships' of a given hen with a cock were identified, Most of these relationships broke up after the end of the reproductive period. Aggressive behaviour was rare in groups without cocks. In heterosexual groups, 67% of the aggressive interactions were observed between cocks. The percentage of eggs found in cover (average 91%) was significantly higher than expected. The hens also laid significantly more eggs than expected in the corners and within a zone of 0.1 m along the border of the aviaries. In the discussion, recommendations are made for the design of housing systems that are adapted to the behaviour of domestic quails. (C) 1997 Elsevier Science B.V.	Univ Bern, Inst Zool, Abt Sozial & Nutzierethol, Ethol Stn Hasli, CH-3032 Hinterkappelen, Switzerland		Schmid, I (corresponding author), Univ Bern, Inst Zool, Abt Sozial & Nutzierethol, Ethol Stn Hasli, Wohlenstr 50A, CH-3032 Hinterkappelen, Switzerland.		Wechsler, Beat/D-7897-2013	Wechsler, Beat/0000-0002-9022-5988			ALTMANN J, 1974, BEHAVIOUR, V49, P227, DOI 10.1163/156853974X00534; APPLEBY MC, 1991, WORLD POULTRY SCI J, V47, P109, DOI 10.1079/WPS19910013; BAUMGARTNER J, 1994, WORLD POULTRY SCI J, V50, P227; Cooper D. M., 1987, UFAW HDB CARE MANAGE, P678; DAWKINS MS, 1989, APPL ANIM BEHAV SCI, V24, P77, DOI 10.1016/0168-1591(89)90126-3; GERKEN M, 1987, BRIT POULTRY SCI, V28, P23, DOI 10.1080/00071668708416933; Gerken M, 1993, 4 EUR S POULTR WELF, P158; Kovach, 1974, APPL ANIM ETHOL, V1, P77, DOI [10.1016/0304-3762(74)90010-8, DOI 10.1016/0304-3762(74)90010-8]; Kovach J. K., 1975, The behaviour of domestic animals,, P437; Mason I., 1984, EVOLUTION DOMESTICAT, P319; Nichols C. R., 1992, Gibier Faune Sauvage, V9, P743; ORCUTT FS, 1976, AUK, V93, P135; RATNAMOHAN N, 1985, VET RES COMMUN, V9, P1, DOI 10.1007/BF02215123; SCHEIN MW, 1983, APPL ANIM ETHOL, V10, P375, DOI 10.1016/0304-3762(83)90186-4; STATKIEWICZ WR, 1980, ANIM BEHAV, V28, P462, DOI 10.1016/S0003-3472(80)80053-4; STEVENS VERNON C., 1961, JOUR WILDLIFE MANAGEMENT, V25, P99, DOI 10.2307/3797004; Yamashina Y., 1961, Journal of the Bombay Natural History Society, V58, P216; [No title captured]	18	27	28	4	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-1591			APPL ANIM BEHAV SCI	Appl. Anim. Behav. Sci.	DEC	1997	55	1-2					103	112		10.1016/S0168-1591(97)00039-7			10	Agriculture, Dairy & Animal Science; Behavioral Sciences; Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Agriculture; Behavioral Sciences; Veterinary Sciences	YP628	WOS:000071297800009					2022-02-06	
J	Max, JE; Sharma, A; Qurashi, MI				Max, JE; Sharma, A; Qurashi, MI			Traumatic brain injury in a child psychiatry inpatient population: A controlled study	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children and adolescents; psychiatric inpatients	HEAD-INJURIES; SEQUELAE	Objective: To extend our findings from child psychiatry outpatients to child psychiatry inpatients regarding the similarity of children with a history of traumatic brain injury (TBI), particularly mild TBI, to matched children without such a history. Method: This is a chart review of patients consecutively admitted to a child psychiatry inpatient unit over a 5-year period. Children with TBI were matched by age, sex, race, and social class to children with no history of TBI. Axis I and II diagnoses and diagnostic clusters and use of special education services and IQ scores were compared. Results: Fifty-six (8.1%) of 694 consecutive patients admitted had a definite TBI. Not one of more than 50 variables compared between TBI and control subjects was significantly different. Conclusion: In a child psychiatry inpatient unit, patients with a history of TBI were virtually indistinguishable from matched children without TBI. Caution should be exercised before attributing the child's problems, especially long-term problems, to the TBI unless the injury was severe or the child is exhibiting related phobic or posttraumatic stress symptomatology.	UNIV IOWA,DEPT PSYCHIAT,IOWA CITY,IA 52242								ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BENDER L, 1956, PSYCHOPATHOLOGY CHIL, P66; BLACK P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; MAX JE, 1997, J AM ACAD CHILD ADOL, V36, P96; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; OTTO U, 1960, Acta Paedopsychiatr, V27, P6; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; *SPSS INC, 1995, SPSS WIND PROF STAT; TEASDALE G, 1974, LANCET, V2, P81	17	27	28	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	NOV	1997	36	11					1595	1601		10.1016/S0890-8567(09)66570-9			7	Psychology, Developmental; Pediatrics; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	YC340	WOS:A1997YC34000023	9394945				2022-02-06	
J	Yunoki, M; Kawauchi, M; Ukita, N; Noguchi, Y; Nishio, S; Ono, Y; Asari, S; Ohmoto, T; Asanuma, M; Ogawa, N				Yunoki, M; Kawauchi, M; Ukita, N; Noguchi, Y; Nishio, S; Ono, Y; Asari, S; Ohmoto, T; Asanuma, M; Ogawa, N			Effects of lecithinized superoxide dismutase on traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						superoxide dismutase; lecithinization; reactive oxygen species; traumatic brain injury; mRNA; brain edema	POLYETHYLENE-GLYCOL; LIPID-PEROXIDATION; CELL-LINES; REPERFUSION; INDUCTION; ISCHEMIA; BINDING; TISSUES; ENZYME; EDEMA	Only small amounts of superoxide dismutase (SOD) are present in the extracellular space to scavenge excess amounts of superoxide anions (O2(-)) released after traumatic brain injury (TBI). Experiments were performed in rats with cerebral contusion produced by weight-drop technique. We investigated the effects of exogenous lecithinized SOD (PC-SOD) on accumulation of O2(-) produced in our model, by measuring the level of SOD activity (using the NBT-reducing method) and the expression of copper, zinc-SOD (Cu, Zn-SOD) mRNA (by Northern blot analysis). As determined by tissue-specific gravity, administration of PC-SOD reduced brain edema in the periphery of the lesion 6 h after contusion. SOD activity increased in the peripheral region at 30 min after contusion, but returned to normal levels at 6 h after TBI. Administration of PC-SOD increased SOD activity up to 6 h after TBI. The expression of Cu, Zn-SOD mRNA increased in the core region, peripheral portion, and contralateral hemisphere up to 6 h after TBI, then was suppressed in all three regions by PC-SOD. Our results confirm the important role of O2(-) in the development of brain edema after TBI and indicate that PC-SOD diminishes brain edema through a protective effect against O2(-).	OKAYAMA UNIV,SCH MED,INST MOL & CELLULAR MED,DEPT NEUROSCI,OKAYAMA 700,JAPAN		Yunoki, M (corresponding author), OKAYAMA UNIV,SCH MED,INST MOL & CELLULAR MED,DEPT NEUROL SURG,2-5-1 SHIKATA CHO,OKAYAMA 700,JAPAN.						ASANUMA M, 1995, MOL BRAIN RES, V33, P29, DOI 10.1016/0169-328X(95)00102-X; CHEN LY, 1995, AM HEART J, V129, P211, DOI 10.1016/0002-8703(95)90000-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELABAR JM, 1987, EUR J BIOCHEM, V166, P181, DOI 10.1111/j.1432-1033.1987.tb13500.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; FUKUHARA T, 1994, NEUROSURGERY, V35, P924, DOI 10.1227/00006123-199411000-00018; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [DOI 10.1098/RSPA.1934.0221, 10.1098/rspa.1934.0221]; HE YY, 1993, AM J PHYSIOL, V265, pH252, DOI 10.1152/ajpheart.1993.265.1.H252; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; IGARASHI R, 1994, J PHARMACOL EXP THER, V271, P1672; IGARASHI R, 1992, J PHARMACOL EXP THER, V262, P1214; KARLSSON K, 1989, LAB INVEST, V60, P659; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P135, DOI 10.1038/jcbfm.1993.16; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NADASY GL, 1989, ACTA PHYSIOL HUNG, V74, P267; Nakauchi K, 1996, J NEUROTRAUM, V13, P573, DOI 10.1089/neu.1996.13.573; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; OGAWA N, 1994, BRAIN RES, V646, P337, DOI 10.1016/0006-8993(94)90102-3; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; UYAMA O, 1992, STROKE, V23, P75, DOI 10.1161/01.STR.23.1.75; VERONESE FM, 1983, J PHARM PHARMACOL, V35, P757, DOI 10.1111/j.2042-7158.1983.tb02888.x; YANG YJ, 1991, MOL CHEM NEUROPATHOL, V14, P11, DOI 10.1007/BF03160994	33	27	27	1	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1997	14	10					739	746		10.1089/neu.1997.14.739			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	YE057	WOS:A1997YE05700005	9383092				2022-02-06	
J	Ashley, MJ; Persel, CS; Clark, MC; Krych, DK				Ashley, MJ; Persel, CS; Clark, MC; Krych, DK			Long-term follow-up of post-acute traumatic brain injury rehabilitation: A statistical analysis to test for stability and predictability of outcome	BRAIN INJURY			English	Article							DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; RECOVERY; TELEPHONE; IMPACT; RETURN; WORK; AGE	A high percentage of the estimated 500 000 traumatic brain injuries (TBI) in the US every year occur with young people who will face many years of neurobehavioral and economic consequences. This study examined the long-term stability of outcome after post-acute TBI rehabilitation and possible predictors of long-term outcome based on a 127-item survey of 332 clients up to 14 years post-discharge. Correlational, factor, and multiple regression analysis indicated positive long-term outcome stability following rehabilitation with the exception of vocational status, which decreased over the same time period. A number of possible explanations for this occupational anomaly are suggested. Rating scale scores and latency-to-rehabilitation proved to be better predictors of long-term outcome than demographic data.	CTR NEUROSKILLS,DEPT RES & DEV,BAKERSFIELD,CA 93306; KERN REG CTR DEV DISABLED,BAKERSFIELD,CA; CTR NEUROSKILLS,IRVING,TX								Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Arokiasamy C V, 1994, NeuroRehabilitation, V4, P45, DOI 10.3233/NRE-1994-4107; Ashley M. J., 1993, J HEAD TRAUMA REHAB, V8, P30; BELLINI J, 1995, REHABIL COUNS BULL, V39, P151; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; CRISP R, 1992, J REHABIL, V58, P27; DELEEUW E, 1988, TELEPHONE SURVERY ME; DEVANEY CW, 1991, J HEAD TRAUMA REHAB, V6, P59; EISENBERG H, 1991, J NEUROSURG, V75, pS1; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KORNERBITENSKY N, 1994, ARCH PHYS MED REHAB, V75, P1287; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NARINS P, 1995, KEYWORDS, V56, P6; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Sherron P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, https://doi.org/10.1097/00001199-199109000-00004]; SIEMIATYCKI J, 1979, AM J PUBLIC HEALTH, V69, P238, DOI 10.2105/AJPH.69.3.238; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; Webb C, 1996, BRAIN INJURY, V10, P303, DOI 10.1080/026990596124476	32	27	30	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1997	11	9					677	690					14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	XT726	WOS:A1997XT72600006	9376835				2022-02-06	
J	Isaksson, J; Lewen, A; Hillered, L; Olsson, Y				Isaksson, J; Lewen, A; Hillered, L; Olsson, Y			Up-regulation of intercellular adhesion molecule 1 in cerebral microvessels after cortical contusion trauma in a rat model	ACTA NEUROPATHOLOGICA			English	Article						intercellular adhesion molecule 1; immunohistochemistry; rat; brain; trauma	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD INJURY; BRAIN INJURY; LEUKOCYTE ADHESION; ARTERY OCCLUSION; ISCHEMIC-INJURY; CELL-ADHESION; BLOOD-FLOW; EXPRESSION; ICAM-1	A study was made on the expression of the intercellular adhesion molecule 1 (ICAM-1) in cerebral microvessels after cortical contusion trauma of the rat brain. The trauma was produced by a free-falling weight on the exposed dura of one fronto-parietal lobe. Immunohistochemistry was done on cryostat sections using a monoclonal antibody and the reaction product was visualized using the avidin-biotin-peroxidase complex method. Control and sham-operated rats showed immunostaining of some penetrating arteries of the cerebral cortex, the epithelial cells of the choroid plexus and occasional microvessels of the brain parenchyma. The same pattern of immunostaining was seen in rats that were subjected to trauma and killed after 30 min. All rats with contusion trauma that were allowed to survive for 6-72 h showed a substantial increase in the number of immunostained capillaries throughout the site of the lesion. The ipsilateral hippocampus showed a mild to moderate increase in the number of immunostained microvascular profiles. This phenomenon was also present in the lateral thalamus of some rats. The staining was seen as an uninterrupted line at the position of the endothelial cells, indicating an upregulation of this adhesion molecule after brain trauma. Up-regulation of ICAM-1 is a well-known phenomenon in inflammatory and ischemic lesions of the brain but has not previously been described in detail in traumatic brain injury. ICAM-1 may be involved in the production of several post-traumatic events such as leukocyte adhesion, microcirculatory disturbances and edema formation.	UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN		Isaksson, J (corresponding author), UNIV UPPSALA HOSP,NEUROPATHOL LAB,S-75185 UPPSALA,SWEDEN.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Carlos T. M., 1995, Journal of Neurotrauma, V12, P458; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; DECKERTSCHLUTER M, 1994, J NEUROPATH EXP NEUR, V53, P457, DOI 10.1097/00005072-199409000-00005; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1995, BRAIN PATHOL, V5, P395; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; KUROSE I, 1994, CIRC RES, V74, P336, DOI 10.1161/01.RES.74.2.336; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LINDSBERG PJ, 1995, J CEREB BLOOD FLOW M, V15, pS681; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SOBEL RA, 1990, AM J PATHOL, V136, P1309; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; WASHINGTON R, 1994, ANN NEUROL, V35, P89, DOI 10.1002/ana.410350114; WILCOX CE, 1990, J NEUROIMMUNOL, V30, P43, DOI 10.1016/0165-5728(90)90051-N; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	34	27	31	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JUL	1997	94	1					16	20		10.1007/s004010050666			5	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	XG013	WOS:A1997XG01300003	9224525				2022-02-06	
J	Zafonte, RD; Mann, NR; Millis, SR; Wood, DL; Lee, CY; Black, KL				Zafonte, RD; Mann, NR; Millis, SR; Wood, DL; Lee, CY; Black, KL			Functional outcome after violence related traumatic brain injury	BRAIN INJURY			English	Article							CRANIOCEREBRAL GUNSHOT WOUNDS; GLASGOW-COMA-SCALE; ADULT CIVILIANS; HEAD-INJURY; VIETNAM; POPULATION; MANAGEMENT; MORTALITY; NEUROLOGY; PROGNOSIS	Violent injuries have become an increasingly prevalent cause of traumatic brain injury (TBI). These injuries can be classified as either penetrating or non-penetrating in nature. While much of the research on violence has been within a military population, there exists a marked difference between military and civilian injuries. Prior work has reported relatively poor outcomes for those individuals who have suffered penetrating TBIs, but little has been done to assess specific functional outcome parameters in survivors. We examined 25 subjects that had sustained blunt injuries and 25 cases with penetrating injuries as a result of a violent act. Cases were matched by initial Glasgow Coma Scale (GCS), age and educational level. Mean GCS for this study sample was 8.8. The following outcome variables were assessed at rehabilitation admission and discharge and at 1 year post injury: Disability Rating Scale (DRS), Rancho Los Amigos Scale (LCFS), Functional Independence Measure (FIM) (ambulation, expression items), length of stay, and cost of care. Student's t-tests were performed to assess for differences between the two groups. No significant differences were noted between the groups for any of the outcome variables. Although penetrating injuries may have a higher initial mortality, those who survive to come to rehabilitation appear to have similar outcomes to those patients with nonpenetrating violence related injuries.	WAYNE STATE UNIV,REHABIL INST MICHIGAN,DETROIT,MI								ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; CAREY ME, 1974, J NEUROSURG, V41, P542, DOI 10.3171/jns.1974.41.5.0542; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COWEN T, ARCH PHYSICAL MED RE, V76, P797; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1985, NEUROSURGERY, V16, P754, DOI 10.1227/00006123-198506000-00002; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; MILLIS SR, 1995, BRAIN INJURY, V9, P509, DOI 10.3109/02699059509008210; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1986, NEUROLOGY, V36, P459, DOI 10.1212/WNL.36.4.459; SCHAWB K, 1993, NEUROLOGY, V43, P95; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SWEENEY J, 1983, PHYS THER, V12, P2018	18	27	28	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1997	11	6					403	407					5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	WZ726	WOS:A1997WZ72600002	9171926				2022-02-06	
J	VanderSchaaf, PJ; Kriel, RL; Krach, LE; Luxenberg, MG				VanderSchaaf, PJ; Kriel, RL; Krach, LE; Luxenberg, MG			Late improvements in mobility after acquired brain injuries in children	PEDIATRIC NEUROLOGY			English	Article							PROLONGED UNCONSCIOUSNESS; COHORT	The purpose of this investigation was to describe the late improvements in functional mobility in children who have sustained severe acquired anoxic or traumatic brain injuries, Ninety-eight children from a consecutive series of 199 with acquired brain injuries met inclusion criteria, As expected, children with traumatic injuries had better mobility at time of discharge from rehabilitation than did children with anoxic injury, In addition, children with traumatic injuries improved more in mobility status during the first 2 years after injury than did children with anoxic injury, The children who continued to improve in mobility after discharge were unconscious for a shorter time, Children who became community ambulators during the first year after discharge had higher mobility ratings at discharge, Although children who eventually achieved more functional mobility were admitted to rehabilitation service sooner after injury, discriminant analysis revealed that the duration of unconsciousness, and therefore severity of injury, was more closely correlated with the final mobility status. (C) 1997 by Elsevier Science Inc. All rights reserved.	HENNEPIN CTY MED CTR 867B,MINNEAPOLIS,MN 55415; GILLETTE CHILDRENS SPECIALTY HEALTHCARE,DEPT REHABIL,ST PAUL,MN; GILLETTE CHILDRENS SPECIALTY HEALTHCARE,DEPT NEUROL,ST PAUL,MN; GILLETTE CHILDRENS SPECIALTY HEALTHCARE,DEPT PEDIAT,ST PAUL,MN; HENNEPIN CTY MED CTR,ST PAUL,MN								BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; KRIEL RL, 1994, PEDIATR NEUROL, V10, P207, DOI 10.1016/0887-8994(94)90024-8; Kriel RL, 1995, J NEUROL REHABIL, V9, P145; KRIEL RL, 1989, PEDIATR NEUROL, V25, P296; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201	12	27	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	MAY	1997	16	4					306	310		10.1016/S0887-8994(97)00025-8			5	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	XP128	WOS:A1997XP12800005	9258963				2022-02-06	
J	Furman, JM; Balaban, CD; Pollack, IF				Furman, JM; Balaban, CD; Pollack, IF			Vestibular compensation in a patient with a cerebellar infarction	NEUROLOGY			English	Article							AXIS ROTATIONAL RESPONSES; UNILATERAL LABYRINTHECTOMY; OCULAR REFLEX; FOS EXPRESSION; BRAIN; NYSTAGMUS; FLOCCULUS; NODULUS; RAT; PARAFLOCCULUS	We report the case of a 67-year-old man who suffered a traumatic unilateral peripheral vestibular injury subsequent to an unrelated prior cerebellar infarction that occurred at least 2 years earlier. The patient's clinical course was marked by poor compensation for his peripheral vestibular loss. Four months after his vestibular injury, his symptoms of dizziness had not resolved. He had a spontaneous vestibular nystagmus, and laboratory testing indicated an asymmetric semicircular canal-ocular reflex. The otolith-ocular reflex, tested using off-vertical axis rotation, also was asymmetric but had a preserved modulation component. Visual-vestibular interaction and semicircular canal-otolith interaction were normal. An MRI indicated preservation of the flocculo-nodular lobe but infarction of the pyramis and uvula. Taken together, the findings in this case suggest that despite structural and functional preservation of the flocculo-nodular lobe, an anatomic region often labeled the ''vestibulo-cerebellum,'' a lesion of the cerebellum that can impair CNS compensation for a unilateral peripheral lesion in humans.	UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,PITTSBURGH,PA 15261				Balaban, Carey/O-6586-2019; Balaban, Carey/I-3467-2017	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC02556, DC01791, DC00739] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC001791, R01DC000739, R01DC002556] Funding Source: NIH RePORTER		ANGELAKI DE, 1995, J NEUROPHYSIOL, V73, P1729; BALOH RW, 1986, ADV BIOSCI, V57, P349; CIRELLI C, 1993, ARCH ITAL BIOL, V131, P71; COURJON JH, 1982, BRAIN RES, V239, P251, DOI 10.1016/0006-8993(82)90847-2; Fetter M, 1990, J Vestib Res, V1, P9; Furman JM, 1996, J VESTIBUL RES-EQUIL, V6, P93; FURMAN JMR, 1992, ANN OTO RHINOL LARYN, V101, P643, DOI 10.1177/000348949210100803; FURMAN JMR, 1989, ANN OTO RHINOL LARYN, V98, P551, DOI 10.1177/000348948909800711; FURMAN JMR, 1993, ANN OTO RHINOL LARYN, V102, P137, DOI 10.1177/000348949310200211; GRAFE MR, 1990, AM J NEURORADIOL, V11, P905; HAIN TC, 1988, ACTA OTO-LARYNGOL, V105, P13, DOI 10.3109/00016488809119440; IGARASHI M, 1985, ACTA OTO-LARYNGOL, V99, P452, DOI 10.3109/00016488509108937; Jeannerod M., 1981, LESION INDUCED NEURO, P208; JENKINS HA, 1985, LARYNGOSCOPE, V95, P1224; KAUFMAN GD, 1992, NEUROREPORT, V3, P829, DOI 10.1097/00001756-199210000-00002; Llinas R., 1979, INTEGRATION NERVOUS, P145; LUYTEN WHML, 1986, BRAIN RES, V373, P68, DOI 10.1016/0006-8993(86)90316-1; PATRICKSON JW, 1985, EXP BRAIN RES, V60, P227; PRECHT W, 1966, J NEUROPHYSIOL, V29, P996, DOI 10.1152/jn.1966.29.6.996; SHOTTON JC, 1989, J LARYNGOL OTOL, V103, P263, DOI 10.1017/S0022215100108667; SMITH PF, 1989, BRAIN RES REV, V14, P155, DOI 10.1016/0165-0173(89)90013-1; SOLOMON D, 1994, EXP BRAIN RES, V102, P57; WAESPE W, 1985, SCIENCE, V228, P199, DOI 10.1126/science.3871968; WAESPE W, 1983, EXP BRAIN RES, V50, P9; ZEE DS, 1981, J NEUROPHYSIOL, V46, P878, DOI 10.1152/jn.1981.46.4.878	25	27	27	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology	APR	1997	48	4					916	920		10.1212/WNL.48.4.916			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WU327	WOS:A1997WU32700022	9109877				2022-02-06	
J	Blostein, PA; Jones, SJ; Buechler, CM; Vandongen, S				Blostein, PA; Jones, SJ; Buechler, CM; Vandongen, S			Cognitive screening in mild traumatic brain injuries: Analysis of the neurobehavioral cognitive status examination when utilized during initial trauma hospitalization	JOURNAL OF NEUROTRAUMA			English	Article						cognitive screen; mild traumatic brain injury; neurobehavioral cognitive status exam; Glasgow Coma Scale	MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; CONCUSSION; SYMPTOMS; SEQUELAE; RECOVERY; CAPACITY; MEMORY	Cognitive screening following mild traumatic brain injury (MTBI) remains variable with method of diagnosis, indications for testing, and utilization of results differing between institutions. The Neurobehavioral Cognitive Status Examination (NCSE) was originally developed for use in organic brain dysfunction and central nervous system (CNS) lesions. When attention is given to both the objective cognitive area scores and the ''process features'' component of the exam, it is an effective tool for identifying cognitive deficits associated with MTBI. One hundred seven MTBI patients underwent cognitive screening in the acute care setting. Memory was the function most frequently affected in patients with positive cognitive screens. Several of the NCSE deficits also correlated significantly with each other but not with memory. Age, length of stay, injury severity score (ISS), and cranial computed tomography scan were not associated with cognitive screen results. An admission Glasgow Coma Scale (GCS) of 13 or 14 was significantly associated with a positive cognitive screen, but a GCS of 15 did not predict a negative cognitive screen. All patients with MTBI require cognitive screening to identify deficits, ensure patient and family education, and when necessary facilitate treatment.			Blostein, PA (corresponding author), BRONSON METHODIST HOSP,TRAUMA SURG SERV,252 E LOVELL ST,KALAMAZOO,MI 49007, USA.						Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Marshall LF, 1989, MILD HEAD INJURY, P276; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; NELSON A, 1986, J NERV MENT DIS, V174, P73, DOI 10.1097/00005053-198602000-00002; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHWAMM LH, 1987, ANN INTERN MED, V107, P486, DOI 10.7326/0003-4819-107-4-486; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; VanDongen S, 1993, Rehabil Nurs, V18, P76; Veltman R H, 1993, J Neurosci Nurs, V25, P367; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1989, MILD HEAD INJURY, P245; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004; [No title captured]	31	27	29	2	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1997	14	3					171	177		10.1089/neu.1997.14.171			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WT814	WOS:A1997WT81400005	9104934				2022-02-06	
J	Lam, CH; Montes, J; Farmer, JP; OGorman, AM; MeagherVillemure, K				Lam, CH; Montes, J; Farmer, JP; OGorman, AM; MeagherVillemure, K			Traumatic aneurysm from shaken baby syndrome: Case report	NEUROSURGERY			English	Article						porencephaly; shaken baby syndrome; traumatic aneurysm	INTRACRANIAL ANEURYSMS; ARTERIES; INJURY; BRAIN	OBJECTIVE AND IMPORTANCE: We present a 6-week-old infant who developed a traumatic aneurysm from clearly documented shaken baby syndrome. Despite the theoretical similarity in the mechanism of such injuries, this is the first aneurysm reported that resulted from such a cause. The infant is also the youngest reported patient to have suffered from a traumatic aneurysm. CLINICAL PRESENTATION: Police records documented shaking of the child as well as direct impact on the child's head. Three weeks later, the patient developed an intracerebral hemorrhage, which was revealed by angiography to have resulted from a pericallosal artery aneurysm. TECHNIQUE: The aneurysm was totally resected through a porencephalic cyst, which had developed secondary to ischemic injury to the brain. CONCLUSION: The temporal course, as well as the location of this traumatic aneurysm, is similar to that in older patients.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,DIV NEUROSURG,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,MONTREAL CHILDRENS HOSP,DEPT RADIOL,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,MONTREAL CHILDRENS HOSP,DEPT PATHOL,MONTREAL,PQ H3H 1P3,CANADA								ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; Birrell R G, 1968, Med J Aust, V2, P1023; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; CAFFEY J, 1974, PEDIATRICS, V54, P396; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUTREVOU MD, 1992, NEUROSURGERY, V31, P905, DOI 10.1227/00006123-199211000-00012; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; NAKSTAD P, 1986, NEURORADIOLOGY, V28, P335, DOI 10.1007/BF00333440; NEWTON RW, 1989, ARCH DIS CHILD, V64, P188, DOI 10.1136/adc.64.2.188; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; SENEGOR M, 1991, J NEUROSURG, V75, P475, DOI 10.3171/jns.1991.75.3.0475; SMITH DR, 1970, J NEUROSURG, V32, P357, DOI 10.3171/jns.1970.32.3.0357; SMITH KR, 1968, J NEUROSURG, V29, P551, DOI 10.3171/jns.1968.29.5.0551; SMITH SM, 1974, BMJ-BRIT MED J, V3, P666, DOI 10.1136/bmj.3.5932.666; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163; YAZBAK PA, 1995, PEDIATR NEUROSURG, V22, P15, DOI 10.1159/000121294	16	27	27	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	DEC	1996	39	6					1252	1255		10.1097/00006123-199612000-00041			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VT943	WOS:A1996VT94300093	8938784				2022-02-06	
J	Levin, HS; Fletcher, JM; Kusnerik, L; Kufera, JA; Lilly, MA; Duffy, FF; Chapman, S; Mendelsohn, D; Bruce, D				Levin, HS; Fletcher, JM; Kusnerik, L; Kufera, JA; Lilly, MA; Duffy, FF; Chapman, S; Mendelsohn, D; Bruce, D			Semantic memory following pediatric head injury: Relationship to age, severity of injury, and MRI	CORTEX			English	Article							CHILDREN; ADOLESCENTS; AMNESIA; DISTINCTION; ABILITY	The effects of closed head injury (CHI) severity (mild vs. severe) and age at injury were analyzed in a longitudinal study (3, 12 months postinjury) of semantic memory which used magnetic resonance imaging (MRI) to characterize focal brain lesions. Semantic memory was evaluated by word and category fluency, semantic verification, semantic clustering in word list recall, and vocabulary. Episodic memory was assessed by word list recall. Comparison of normal control (n = 104) data with the patients' data (n = 77) at 3 months postinjury disclosed semantic and episodic memory deficits in the severe CHI patients. Analysis of the longitudinal data revealed significant effects of age at injury for all of the semantic memory measures. The effects of injury severity were confined to the latency of verifying correct statements. Volume of left frontal and extrafrontal lesions was predictive of performance on several semantic memory measures, but less robust for right hemisphere lesions.	UNIV MARYLAND,MED SYST,DIV NEUROSURG,BALTIMORE,MD 21201; UNIV TEXAS,MED BRANCH,DEPT SURG,GALVESTON,TX 77550; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX; UNIV TEXAS,CALLIER CTR COMMUN DISORDERS,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235				fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Baddeley A. D., 1976, PSYCHOL MEMORY; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENTON AL, 1993, MANUAL MULTILINGUAL; CERMAK LS, 1983, NEUROPSYCHOLOGIA, V21, P213, DOI 10.1016/0028-3932(83)90039-8; Cohen N. J., 1984, NEUROPSYCHOLOGY MEMO, P83; COLLINS AM, 1975, PSYCHOL REV, V82, P407, DOI 10.1037/0033-295X.82.6.407; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DAMASIO H, 1991, FRONTAL LOBE FUNCTIO, P99; DELIS DC, 1986, CALIFORNIA VERBAL LE; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; GABRIELI JDE, 1988, BRAIN COGNITION, V7, P157, DOI 10.1016/0278-2626(88)90027-9; GATHERCOLE SE, 1993, MEMORY LANGUAGE; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; Hodges J. R, 1995, HDB MEMORY DISORDERS, P167; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P1871; MCKOON G, 1986, J EXP PSYCHOL LEARN, V12, P295, DOI 10.1037/0278-7393.12.2.295; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; TULVING E, 1986, J EXP PSYCHOL LEARN, V12, P307, DOI 10.1037/0278-7393.12.2.307; Wechsler D., 1974, WECHSLER INTELLIGENC	29	27	27	0	7	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	SEP	1996	32	3					461	478		10.1016/S0010-9452(96)80004-9			18	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	VH618	WOS:A1996VH61800004	8886522				2022-02-06	
J	Ritter, AM; Robertson, CS; Goodman, JC; Contant, CF; Grossman, RG				Ritter, AM; Robertson, CS; Goodman, JC; Contant, CF; Grossman, RG			Evaluation of a carbohydrate-free diet for patients with severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral ischemia; head injury; hyperglycemia	ENERGY PHOSPHATE-METABOLISM; TOTAL PARENTERAL-NUTRITION; TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; VASOGENIC EDEMA; RAT-BRAIN; HYPERGLYCEMIA; INFARCTION; HYPOXIA; CHLORIDE	Hyperglycemia, which may be caused or exacerbated by conventional diets, may worsen the neurological outcome from severe head injury, especially if secondary ischemic insults occur. The purpose of this study was to evaluate an experimental diet intended to replace systemic caloric and protein requirements without producing hyperglycemia. In initial studies in the laboratory, 5 experimental diets were employed in a middle cerebral artery temporary occlusion model. The effects of the diets on blood biochemistry and on infarction volume were compared in fasted animals and in animals fed a control diet. Animals fed the experimental diets had a significantly lower preischemia blood glucose concentration, a higher blood concentration of ketone bodies, and a smaller infarct volume than the animals fed a control diet. One diet chosen from the laboratory study was then evaluated in a clinical study as a randomized, open-label trial. Twenty severely head-injured patients were randomly assigned to be fed the experimental diet, EN-9305, or the control diet, Osmolyte HN, for the first 2 weeks after injury. Both treatment groups had similar blood glucose concentrations, averaging 6.33 +/- 0.21 mu mol/mL (114 +/- 4 mg/dL), on day 1 prior to starting the assigned diet. Blood glucose concentration increased in the control diet group to a peak of 8.37 +/- 0.94 mu mol/mL (151 +/- 17 mg/dL) on day 7 as the infusion rate of the diet was increased to the final rate. In the experimental diet group, the blood glucose concentration remained unchanged from fasting levels as the diet was advanced. Blood lactate concentration was lower, and blood ketone body concentrations were higher in the patients fed the experimental diet. Urinary nitrogen balance was better in the experimental diet group, but measures of visceral protein sparing, including serum albumin, plasma retinol binding protein, and total lymphocyte count, were not significantly different in the 2 treatment groups. Measures of cerebral anaerobic metabolism, including CSF lactate concentration and cerebral lactate production, were not significantly different in the 2 treatment groups. These studies suggest that a carbohydrate-free diet such as EN-9305 might have advantages for patients with severe head injury by replacing systemic caloric and protein requirements without producing hyperglycemia.	BAYLOR COLL MED,DEPT NEUROSURG,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS26716] Funding Source: Medline		BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CHONG WK, 1989, J CHROMATOGR-BIOMED, V487, P147, DOI 10.1016/S0378-4347(00)83017-0; COMBS DJ, 1989, J NEUROSURG, V70, P623, DOI 10.3171/jns.1989.70.4.0623; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KIRSCH JR, 1980, STROKE, V11, P506, DOI 10.1161/01.STR.11.5.506; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LUNDY EF, 1984, STROKE, V15, P547, DOI 10.1161/01.STR.15.3.547; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; MICHAUD LJ, 1991, J TRAUMA, V31, P1365; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MYERS RE, 1976, J NEUROPATH EXP NEUR, V35, P301, DOI 10.1097/00005072-197605000-00011; Pentelenyi T, 1979, Acta Neurochir Suppl (Wien), V28, P103; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON C, 1992, STROKE, V23, P564, DOI 10.1161/01.STR.23.4.564; ROBERTSON CS, 1992, J NEUROTRAUM, V9, P398; Rogers A. E., 1979, LABORATORY RAT, VI, P123, DOI DOI 10.1016/B978-0-12-074901-0.50013-7; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P686; SIEMKOWICZ E, 1981, ACTA NEUROL SCAND, V64, P207; SIEMKOWICZ E, 1978, ACTA NEUROL SCAND, V58, P1; WATERS DC, 1986, J NEUROSURG, V64, P460, DOI 10.3171/jns.1986.64.3.0460; YIP PK, 1991, NEUROLOGY, V67, P76; YOUNG B, 1987, J NEUROSURG, V67, P76, DOI 10.3171/jns.1987.67.1.0076; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	36	27	30	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1996	13	8					473	485		10.1089/neu.1996.13.473			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VH009	WOS:A1996VH00900005	8880611				2022-02-06	
J	Reeder, KP; Rosenthal, M; Lichtenberg, P; Wood, D				Reeder, KP; Rosenthal, M; Lichtenberg, P; Wood, D			Impact of age on functional outcome following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							DISABILITY RATING-SCALE; GLASGOW-COMA-SCALE; IMPAIRED CONSCIOUSNESS; HEAD-INJURY; RELIABILITY; RECOVERY	Objective: To examine whether increasing age is associated with poorer rehabilitation outcome. It was hypothesized that older individuals would benefit less from rehabilitation since increasing age is associated with greater morbidity and mortality. Design: Retrospective analysis of data collected at the beginning and end of inpatient medical rehabilitation. No experimental manipulation was performed. Injury severity, demographic information, initial level of functioning, and age were used in a hierarchical regression analysis to predict level of independent functioning. Setting: inpatient traumatic brain injury units at four model system programs. Patients: 365 patients with traumatic brain injuries (39 mild, 67 moderate, 259 severe; 78% male; mean age = 34 years). Interventions: All subjects participated in a comprehensive rehabilitation program including sen-ices from rehabilitation medicine, neuropsychology, nursing, social work, physical therapy, occupational therapy, speech and language pathology, vocational rehabilitation, and therapeutic recreation. Main Outcome Measures: Functional Independence Measure (FIM) and Disability Rating Scale (DRS). Results: After controlling for injury etiology, injury severity, and other demographic information, age had no statistically significant predictive value for functional outcome. Level of functioning on admission, independent of other factors, was the strongest predictor of functioning at discharge. Conclusions: Although increasing age has been strongly associated with higher rates of morbidity and mortality, it did not affect the level of functional improvement individuals achieved during inpatient rehabilitation. Hence, there does not appear to be justification for limiting access to rehabilitation solely on the: basis of advanced age.	WAYNE STATE UNIV,DEPT PHYS MED & REHABIL,DETROIT,MI 48202		Reeder, KP (corresponding author), REHABIL INST MICHIGAN,261 MACK BLVD,SUITE 555,DETROIT,MI 48201, USA.						Cambria S, 1979, J Neurosurg Sci, V23, P121; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL K, FUNCTIONAL ASSESSMEN; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JENNETT B, 1975, LANCET, V1, P480; JOHNSTONE AJ, 1993, BRAIN INJURY, V7, P501, DOI 10.3109/02699059309008177; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; NOVACK TA, 1992, J HEAD TRAUMA REHAB, V6, P69; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENTHAL M, 1992, NEUROREHABILITATION, V2, P1; ROSENTHAL M, 1993, J HEAD TRAUMA REHABI, V8; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; Tabachnick B. G., 1989, USING MULTIVARIATE S; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; Vollmer DG, 1991, J NEUROSURG S, V75, P37; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	31	27	27	0	18	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1996	11	3					22	31		10.1097/00001199-199606000-00006			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UP774	WOS:A1996UP77400006					2022-02-06	
J	Carnevale, GJ				Carnevale, GJ			Natural-setting behavior management for individuals with traumatic brain injury: Results of a three-year caregiver training program	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior management; community reentry; family training; traumatic brain injury	HEAD	The Natural-Setting Behavior Management Program (NSBM) is a mobile ream approach that is designed to teach persons with traumatic brain injury (TBI) and their caregivers how to implement and sustain home-based behavior management programs. Of 35 families assessed over a 3-year period, 17 were referred for NSBM training and 11 completed the program, including a 1-year follow-up. This group demonstrated an 82% improvement in target behaviors over the course of training, with the greatest improvement occurring during the education phase. These initial results promote the value of family training programs to support community stabilization of persons with TBI who experience behavioral challenges.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103		Carnevale, GJ (corresponding author), KESSLER INST REHABIL,DEPT PSYCHOL NEUROPSYCHOL,240 CENT AVE,E ORANGE,NJ 07018, USA.						BROOKS N, 1984, CLOSED HEAD INJURY P; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; JACOBS H, 1991, HEAD INJURY FAMILY M; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T; JACOBS HE, 1990, NEUROPSYCHOLOGY EVER; JACOBS HE, 1993, BEHAVIOR ANAL GUIDEL; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MUIR CA, 1987, 6TH ANN NAT S SAN DI; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Siegel S., 1956, NONPARAMETRIC STAT B; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1974, SCANDINAVIAN J REHAB, V6, P180	15	27	27	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1996	11	1					27	38		10.1097/00001199-199602000-00005			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	TU021	WOS:A1996TU02100005					2022-02-06	
J	FABIANO, RJ; CREWE, N				FABIANO, RJ; CREWE, N			VARIABLES ASSOCIATED WITH EMPLOYMENT FOLLOWING SEVERE TRAUMATIC BRAIN INJURY	REHABILITATION PSYCHOLOGY			English	Article							SEVERE HEAD-INJURY	The results of a survey of employment outcome and their relationship to psychometric indices indicated that competitive employment following severe traumatic brain injury is an ambitious endeavor. While 98% of the subjects sampled were either employed or in school premorbidly, 43% of the subjects were unemployed post-injury. Psychometric variables were most highly related to employment outcome which suggested a useful role of neuropsychological testing in assisting in vocational rehabilitation planning. Furthermore, the psychometric test results indicated that many subjects who were unemployed may be capable of part-time employment. Future studies are needed to further examine those neuropsychological abilities which subsequently affect employability following severe traumatic brain injury.	MICHIGAN STATE UNIV,E LANSING,MI 48824								BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Denny-Brown D., 1942, NEW ENGL J MED, V227, P771; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; FAHY TJ, 1967, LANCET, V2, P475; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; HEATON RK, 1978, J NERV MENT DIS, V116, P408; KAY T, 1988, HEAD TRAUMA RES PROJ; KAY T, 1988, EXPT DESIGN PROCEDUR, V3, P65; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIMEL RW, 1983, REHABILITATION HEAD; ROWBOTHAM GF, 1954, BRIT MED J, V1, P726, DOI 10.1136/bmj.1.4864.726; SACHS PR, 1993, REHABIL PSYCHOL, V38, P87, DOI 10.1037/h0080294; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; *US DEP LAB EMPL T, 1981, SEL CHAR OCC DEF DIC; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler, 1997, WECHSLER ADULT INTEL; WEHMAN P, 1990, VOCATIONAL REHABILIT; [No title captured]	22	27	27	0	0	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FAL	1995	40	3					223	231		10.1037/0090-5550.40.3.223			9	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	TH449	WOS:A1995TH44900006					2022-02-06	
J	ROBERTS, MA; MANSHADI, FF; BUSHNELL, DL; HINES, ME				ROBERTS, MA; MANSHADI, FF; BUSHNELL, DL; HINES, ME			NEUROBEHAVIORAL DYSFUNCTION FOLLOWING MILD TRAUMATIC BRAIN INJURY IN CHILDHOOD - A CASE-REPORT WITH POSITIVE FINDINGS ON POSITRON EMISSION TOMOGRAPHY (PET)	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; SEQUELAE; CHILDREN; EEG; ANTIDEPRESSANTS; PHENOMENOLOGY; SYMPTOMS; EPILEPSY; SEIZURES; CT	The present case study describes the neurobehavioural, neurodiagnostic, and positron emission tomography (PET) scan findings in a child who sustained a whiplash-type injury in a motor vehicle accident. Although neck and back pain were reported immediately, neurobehavioural symptoms, such as staring spells, gradually increased in frequency over a 2-year period following the accident. At 4 years after the accident the patient's symptoms persisted, as reported by teachers and parents, and more extensive diagnostic work-up was initiated. Standard EEG was normal while two ambulatory EEGs were abnormal and interpreted as epileptiform. A PET scan showed evidence of marked hypometabolism in both temporal lobes. Neuropsychological findings were consistent with PET findings and reflected verbal and visual memory deficits in the context of high average intelligence. Treatment with carbamazepine, verapamil, and fluoxetine greatly improved the patient's symptoms. The present case illustrates an example of a poor outcome in a paediatric case of mild traumatic brain injury, the importance of PET in demonstrating definitive evidence of brain dysfunction, and the child's positive response to anticonvulsant medication.	PHYS MED & REHABIL ASSOCIATES,WATERLOO,IA; UNIV IOWA,COLL MED,DEPT RADIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT VET AFFAIRS MED CTR,COLL MED,DEPT PEDIAT,NUCL MED SERV,IOWA CITY,IA; OTTUMWA REG MED CTR,OTTUMWA,IA 52501					Bushnell, David/0000-0002-2768-396X			ABOUKHALIL BW, 1987, ANN NEUROL, V22, P480, DOI 10.1002/ana.410220407; ADAMEC RE, 1990, BIOL PSYCHIAT, V27, P249, DOI 10.1016/0006-3223(90)90001-I; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BARNHILL LJ, 1989, NEUROPSY NEUROPSY BE, V2, P211; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BIJUR PE, 1990, PEDIATRICS, V86, P337; Engel J, 1991, KINDLING SYNAPTIC PL, P195; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; GORMAN LL, 1990, J CLIN EXP NEUROPSYC, V12, P76; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAAS DC, 1986, BRAIN, V109, P251, DOI 10.1093/brain/109.2.251; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIGUORI G, 1989, CHILD NERV SYST, V5, P160, DOI 10.1007/BF00272119; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; LIU YK, 1984, SPINE, V9, P329, DOI 10.1097/00007632-198405000-00001; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; ROBERTS MA, PEDIATRIC INVENTORY; ROBERTS RJ, 1992, EPILEPSY RES, V13, P167, DOI 10.1016/0920-1211(92)90073-3; ROBERTS RJ, 1991, DICHOTIC WORD LISTEN; ROBERTS RJ, 1992, NEUROPSYCHOLOGY, V4, P65; ROSENSTEIN DL, 1993, J CLIN PSYCHIAT, V54, P289; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Sheslow D., 1990, WIDE RANGE ASSESSMEN; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; THEODORE WH, 1990, NEUROLOGY, V40, P797, DOI 10.1212/WNL.40.5.797; TORRES F, 1961, ARCH NEUROL-CHICAGO, V5, P28, DOI 10.1001/archneur.1961.00450130030005; TUCKER GJ, 1986, J NERV MENT DIS, V174, P348, DOI 10.1097/00005053-198606000-00007; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; Wechsler D., 1974, WECHSLER INTELLIGENC; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004; [No title captured]	40	27	27	0	4	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1995	9	5					427	436		10.3109/02699059509008202			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100001	7550214				2022-02-06	
J	DUNNMEYNELL, AA; LEVIN, BE				DUNNMEYNELL, AA; LEVIN, BE			LATERALIZED EFFECT OF UNILATERAL SOMATOSENSORY CORTEX CONTUSION ON BEHAVIOR AND CORTICAL REORGANIZATION	BRAIN RESEARCH			English	Article						TRAUMATIC BRAIN INJURY; RECOVERY OF FUNCTION; PLASTICITY; BARREL RECEPTOR FIELD; VIBRISSA; MULTIMODALITY; OCCIPITAL CORTEX; VICARIATION	CEREBRAL GLUCOSE-UTILIZATION; RAT BARREL CORTEX; C-14 2-DEOXYGLUCOSE UPTAKE; MOTOR RECOVERY; FUNCTIONAL REORGANIZATION; VIBRISSAL STIMULATION; THROMBOTIC INFARCTION; FACILITATE RECOVERY; LOCUS COERULEUS; LEFT-HEMISPHERE	Previous studies have shown that rats recover function after unilateral somatosensory cortex lesions, possibly by transfer of information processing to other brain areas not normally involved in those functions. In the present study, adult rats underwent unilateral contusions of the somatosensory cortex with ablation of the barrel receptor field. Behavioral testing with modified beam-walking and sensory neglect tasks demonstrated persistent somatosensory deficits in rats with left contusions but no apparent deficits in right injured animals. After 2 months, the [C-14]2-deoxyglucose (2-DG) method was used to show the metabolic activity produced by unilateral stimulation of the facial vibrissae. In left injured animals, cortical metabolic activity rostral and caudal to the injury site was depressed both under basal conditions and during right vibrissal stimulation. On the other hand, comparison of the pattern of [C-14]2-DG uptake in the intact, right cortex revealed changes in the pattern of glucose utilization associated with left injury combined with right vibrissal stimulation. Pattern changes were quantified by measuring the area in which glucose utilization was within the highest 25% of this range (high activity area; HAA). Right vibrissal stimulation in left injured rats caused an expansion of this HAA in the intact occipital/temporal cortex. Also, in the intact somatosensory cortex of left injured rats, there was an enlarged HAA whether or not vibrissal stimulation was performed. Thus, a combination of depressed peri-injury metabolic activity and aberrant activity in remote brain areas occurs following unilateral somatosensory cortex injury. It remains to be shown whether these factors ameliorate or contribute to persistent behavioral deficits.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103		DUNNMEYNELL, AA (corresponding author), DEPT VET AFFAIRS MED CTR,NEUROL SERV 127,E ORANGE,NJ 07018, USA.						ADAMS FS, 1992, BRAIN RES, V597, P114, DOI 10.1016/0006-8993(92)91512-D; AFONSO D, 1993, BRAIN RES BULL, V32, P11, DOI 10.1016/0361-9230(93)90312-Y; BARNEOUD P, 1991, BEHAV BRAIN RES, V44, P87, DOI 10.1016/S0166-4328(05)80242-6; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1993, PHARMACOL BIOCHEM BE, V44, P297, DOI 10.1016/0091-3057(93)90465-6; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1992, PHARMACOL BIOCHEM BE, V43, P771, DOI 10.1016/0091-3057(92)90407-7; BOYESON MG, 1991, RESTOR NEUROL NEUROS, V3, P227, DOI 10.3233/RNN-1991-3501; Boyeson MG, 1991, J NEUROTRAUM, V8, P205, DOI 10.1089/neu.1991.8.205; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; CIRICILLO SP, 1994, NEUROSCIENCE, V59, P975, DOI 10.1016/0306-4522(94)90300-X; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CRAIK R L, 1988, Society for Neuroscience Abstracts, V14, P843; CRAIK RL, 1987, BRAIN RES BULL, V19, P495, DOI 10.1016/0361-9230(87)90154-7; DELACOUR J, 1987, NEUROSCIENCE, V23, P63, DOI 10.1016/0306-4522(87)90271-5; DELACOUR J, 1990, NEUROSCIENCE, V37, P237, DOI 10.1016/0306-4522(90)90209-M; DENENBERG VH, 1978, SCIENCE, V201, P1150, DOI 10.1126/science.684436; Dietrich W. D., 1987, CEREBROVASC DIS, P285; Duvdevani R., 1992, Society for Neuroscience Abstracts, V18, P178; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FUKUSHIMA T, 1979, J COMP NEUROL, V183, P169, DOI 10.1002/cne.901830112; GINSBERG MD, 1992, J CEREB BLOOD FLOW M, V9, P329; GLASSMAN RB, 1994, EXP NEUROL, V125, P125, DOI 10.1006/exnr.1994.1016; GLICK SD, 1981, BRAIN RES, V205, P222, DOI 10.1016/0006-8993(81)90737-X; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GONZALEZ MF, 1985, J COMP NEUROL, V231, P457, DOI 10.1002/cne.902310405; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRABOWSKI M, 1991, BRAIN RES, V547, P249, DOI 10.1016/0006-8993(91)90968-2; GRABOWSKI M, 1993, ANN NEUROL, V34, P362, DOI 10.1002/ana.410340310; GUICROBLES E, 1992, BEHAV BRAIN RES, V48, P145, DOI 10.1016/S0166-4328(05)80150-0; HOVDA DA, 1990, BEHAV BRAIN RES, V37, P119, DOI 10.1016/0166-4328(90)90087-U; Hovda David A., 1992, Brain Dysfunction, V5, P3; HURWITZ BE, 1990, BRAIN RES, V512, P210, DOI 10.1016/0006-8993(90)90628-O; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; HUSTON JP, 1986, EXP NEUROL, V93, P380, DOI 10.1016/0014-4886(86)90198-6; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; KAAS JH, 1983, ANN REV NEUROSCI, V6, P125; KOLB B, 1992, ADV EXP MED BIOL, V325, P169; KOLB B, 1989, PROG NEUROBIOL, V32, P235, DOI 10.1016/0301-0082(89)90023-3; KORALEK KA, 1990, J COMP NEUROL, V299, P133, DOI 10.1002/cne.902990202; KOSSUT M, 1988, J NEUROPHYSIOL, V60, P829, DOI 10.1152/jn.1988.60.2.829; LEVIN BE, 1988, BRAIN RES, V443, P261, DOI 10.1016/0006-8993(88)91620-4; LEVIN BE, 1993, MOL BRAIN RES, V18, P59, DOI 10.1016/0169-328X(93)90173-M; LEVIN BE, 1991, EXP NEUROL, V113, P237, DOI 10.1016/0014-4886(91)90180-K; LEVIN BE, 1993, BRAIN RES; LU SM, 1993, SOMATOSENS MOT RES, V10, P1, DOI 10.3109/08990229309028819; MIKLYAEVA EI, 1993, BEHAV BRAIN RES, V56, P145, DOI 10.1016/0166-4328(93)90032-L; MILLER MW, 1993, J COMP NEUROL, V335, P283, DOI 10.1002/cne.903350211; MITCHELL IJ, 1984, BRAIN RES, V298, P191, DOI 10.1016/0006-8993(84)91168-5; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PAPPIUS HM, 1982, ANN NEUROL, V12, P157, DOI 10.1002/ana.410120205; PESCHANSKI M, 1984, NEUROSCIENCE, V12, P465, DOI 10.1016/0306-4522(84)90066-6; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Ramachandran R., 1993, Society for Neuroscience Abstracts, V19, P1447; ROBINSON RG, 1994, SCIENCE, V205, P707; RODRIGUEZ M, 1993, PHYSIOL BEHAV, V54, P91, DOI 10.1016/0031-9384(93)90048-K; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; SCHALLERT T, 1984, BEHAV NEUROSCI, V3, P518; SCHWARTING RKW, 1990, PHARMACOL BIOCHEM BE, V35, P989, DOI 10.1016/0091-3057(90)90389-Y; SHARP FR, 1984, NEUROLOGY, V34, P1305, DOI 10.1212/WNL.34.10.1305; SHARP JW, 1988, BRAIN RES, V438, P357, DOI 10.1016/0006-8993(88)91363-7; SHERMAN GF, 1980, BRAIN RES, V192, P61, DOI 10.1016/0006-8993(80)91008-2; SIMONS DJ, 1989, J NEUROPHYSIOL, V61, P311, DOI 10.1152/jn.1989.61.2.311; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOKOLOFF L, 1977, J NEUROCHEM, V23, P897; STEINER H, 1989, EXP BRAIN RES, V77, P421, DOI 10.1007/BF00275000; SULLIVAN RM, 1994, BRAIN RES, V637, P114, DOI 10.1016/0006-8993(94)91223-8; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TOLDI J, 1994, NEUROSCI LETT, V167, P1, DOI 10.1016/0304-3940(94)91014-6; TOLDI J, 1990, NEUROSCIENCE, V37, P675, DOI 10.1016/0306-4522(90)90098-O; TRACEY DJ, 1985, RAT NERVOUS SYSTEM, P136; TRUGMAN JM, 1986, BRAIN RES, V379, P264, DOI 10.1016/0006-8993(86)90780-8; VOLGYI B, 1993, NEUROREPORT, V4, P827; Von Monakow C, 1969, BRAIN BEHAVIOR, P27; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; WELKER C, 1971, J COMP NEUROL, V166, P173; WELKER E, 1992, J NEUROSCI, V12, P153; WISE SP, 1976, J COMP NEUROL, V168, P313, DOI 10.1002/cne.901680302; WOLFF JR, 1992, J COMP NEUROL, V317, P187, DOI 10.1002/cne.903170207; ZILLES K, 1985, RAT NERVOUS SYSTEM, V1, P375	92	27	27	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 27	1995	675	1-2					143	156		10.1016/0006-8993(95)00050-Z			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QQ322	WOS:A1995QQ32200019	7796123				2022-02-06	
J	YELON, JA; HARRIGAN, N; EVANS, JT				YELON, JA; HARRIGAN, N; EVANS, JT			BICYCLE TRAUMA - A 5-YEAR EXPERIENCE	AMERICAN SURGEON			English	Article; Proceedings Paper	62nd Annual Scientific Meeting of the Southeastern Surgical Conference	FEB 06-10, 1994	LAKE BUENA VISTA, FL				INJURIES; ACCIDENTS; CHILDHOOD	The medical records of 84 patients who were admitted to the hospital following injuries sustained during bicycle collisions (BC) between January 1986 and December 1991 were retrospectively reviewed. BC most commonly occurred during summer months in the afternoon and early evening. The average patient age was 21.3 years, with more men injured than women (83% vs 17%). Forty-four individuals were struck by a motor vehicle, 36 fell from their cycles, and two were struck by another cyclist. The average ISS for the group was 13.1. Fifteen per cent of the patients had a documented positive toxicology screen; all patients tested positive for ethanol, with an average blood alcohol level of 201 mg/dL. An additional 17% of patients had polychemical intoxication. Orthopedic injuries were the most commonly encountered (59.5%), with lower extremity fractures being most common (52%). Neurologic injuries accounted for 35.7% of injuries, with closed head injuries being most common. Twenty-four patients sustained visceral injuries: 50% thoracic, 25% genitourinary, and 25% abdominal. Of the thoracic injuries, 83% had parenchymal lung injuries, and half had skeletal chest injury. No patient had a vascular lesion within the chest, owing to the minimal deceleration incurred during these injuries. The genitourinary injuries (n = 6) were all urethral injuries that occurred with ejections from the bicycle. No patient had any form of protective gear. The overall average length of stay was 9.15 days, with 30.9% requiring ICU admission. Although bicycling remains a popular recreational activity as well as mode of transportation, few locals mandate protective legislation. Because of the high percentage of orthopedic and CNS injuries, helmets and protective padding might be a reasonable requirement for cyclists in public areas.			YELON, JA (corresponding author), NASSAU CTY MED CTR,DEPT SURG,2201 HEMPSTEAD TURNPIKE,E MEADOW,NY 11554, USA.						BODTKER S, 1990, Ugeskrift for Laeger, V152, P2412; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; GREENSHER J, 1988, PEDIATR ANN, V17, P114, DOI 10.3928/0090-4481-19880201-08; GUCHON DM, 1975, J TRAUMA, V15, P504; ILLINGWORTH CM, 1981, INJURY, V13, P7, DOI 10.1016/0020-1383(81)90083-8; KIBURZ D, 1986, AM J SPORT MED, V14, P416, DOI 10.1177/036354658601400516; KRUSE DL, 1980, AM J SPORT MED, V8, P342, DOI 10.1177/036354658000800509; MCKENNA PJ, 1991, J TRAUMA, V31, P392, DOI 10.1097/00005373-199103000-00015; MELLION MB, 1991, SPORTS MED, V11, P52, DOI 10.2165/00007256-199111010-00004; NIXON J, 1987, BRIT MED J, V294, P1267, DOI 10.1136/bmj.294.6582.1267; PLESS IB, 1987, AM J PUBLIC HEALTH, V77, P358, DOI 10.2105/AJPH.77.3.358; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; 1991, MMWR-MORBID MORTAL W, V36, P269; 1990, NY STATE J MED, V90, P426; 1991, ACCIDENT FACTS, P62	16	27	27	0	3	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	MAR	1995	61	3					202	205					4	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	QM985	WOS:A1995QM98500004	7887529				2022-02-06	
J	HAMMELL, KRW				HAMMELL, KRW			PSYCHOSOCIAL OUTCOME FOLLOWING SPINAL-CORD INJURY	PARAPLEGIA			English	Article						SPINAL CORD INJURIES; HEAD INJURIES; PSYCHOLOGICAL OUTCOME; SOCIAL OUTCOME; QUALITY OF LIFE; REHABILITATION		Studies have indicated that loss of social contact remains the primary complaint of people with head injuries many years after discharge. In an attempt to disentangle specific and nonspecific effects of head injury a study was undertaken to compare a group of 15 men with severe closed head injuries and their wives, with a group of 15 men with complete, traumatic spinal cord injuries and their partners (n = 60). Time since discharge extended from 4 months to several years. This paper focuses primarily upon the results and implication of the responses from the group of men with spinal cord injuries and their partners. The Interview Schedule for Social Interaction was correlated with the Leeds Scale for the Self Assessment of Anxiety and Depression. All groups reported low availability and adequacy of social integration and exhibited high levels of depression. The group of men with spinal cord injuries had the lowest scores for the availability of social integration, indicating that the social isolation which has previously been identified amongst people with head injuries may not be attributable solely to brain damage.1	UNIV SOUTHAMPTON,REHABIL RES UNIT,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND									0	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0031-1758			PARAPLEGIA	Paraplegia	NOV	1994	32	11					771	779					9	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Orthopedics	PV770	WOS:A1994PV77000009	7885720				2022-02-06	
J	MCINTOSH, TK; FERNYAK, S; YAMAKAMI, I; FADEN, AI				MCINTOSH, TK; FERNYAK, S; YAMAKAMI, I; FADEN, AI			CENTRAL AND SYSTEMIC KAPPA-OPIOID AGONISTS EXACERBATE NEUROBEHAVIORAL RESPONSE TO BRAIN INJURY IN RATS	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article						ENDOGENOUS OPIOIDS; FLUID-PERCUSSION	SPINAL-CORD INJURY; DYNORPHIN-RELATED PEPTIDES; EXCITATORY AMINO-ACIDS; GUINEA-PIG BRAIN; RECEPTOR AGONIST; INTRATHECAL INJECTION; NONOPIOID MECHANISMS; HINDLIMB PARALYSIS; ENDOGENOUS OPIOIDS; MOTOR DYSFUNCTION	The endogenous opioid peptide dynorphin has been implicated in the pathophysiology of secondary tissue injury after central nervous system (CNS) trauma. The detrimental effects of dynorphin appear to be mediated through both opioid receptors (probably kappa-receptors) and nonopioid mechanisms. However, both kappa-opioid agonists and antagonists have been reported to improve outcome in models of CNS trauma. To attempt to clarify this controversy, we examined the effects of centrally or systemically administered kappa-opioid agonists on neurological recovery after experimental fluid-percussion brain injury in the rat. Agonists included dynorphin-A-(1-17) [Dyn A-(1-17)], which has actions at both kappa(1)- and kappa(2)-sites, and the selective kappa(1)-agonlsts U-50,488H and U-69,593. des-Tyr-dynorphin A-(2-17) [Dyn A-(2-17)], which is inactive at opioid receptors, was also used. Microinjection of Dyn A-(1-17), but not Dyn A-(2-17) or U-50,488H, into the lateral ventricle 15 min before brain injury significantly worsened motor deficits over a 2-wk period. However, systemic administration of high doses of the kappa-agonists U-50;488H and U-69,593 also significantly worsened neurologi cal outcome. These results fail to demonstrate any protective actions of kappa(1)-agonists in this model of experimental traumatic brain injury and suggest that the opioid-related pathophysiological actions of dynorphin may be mediated by kappa(2)-opioid receptors.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; CHIBA UNIV,DEPT NEUROSURG,CHIBA 28913,JAPAN; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007		MCINTOSH, TK (corresponding author), UNIV PENN,DEPT SURG,DIV NEUROSURG,105 HAYDEN HALL,240 S 33RD ST,PHILADELPHIA,PA 19104, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-27849, R01 NS-26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R01NS027849] Funding Source: NIH RePORTER		ALZHEIMER C, 1990, J PHARMACOL EXP THER, V255, P900; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BAKSHI R, 1990, J NEUROSCI, V10, P3793, DOI 10.1523/JNEUROSCI.10-12-03793.1990; BIRCH PJ, 1991, BRIT J PHARMACOL, V103, P1819, DOI 10.1111/j.1476-5381.1991.tb09869.x; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461; CONTRERAS PC, 1991, BRAIN RES, V546, P79, DOI 10.1016/0006-8993(91)91161-S; DERRICK BE, 1991, BRAIN RES BULL, V27, P219, DOI 10.1016/0361-9230(91)90071-Q; DEVLIN T, 1990, J PHARMACOL EXP THER, V253, P749; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1992, J NEUROSCI, V12, P425; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1985, PEPTIDES, V6, P15, DOI 10.1016/0196-9781(85)90006-3; FADEN AI, 1993, HDB EXPT PHARM, P325; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GANNON RL, 1991, BRAIN RES, V548, P242, DOI 10.1016/0006-8993(91)91127-M; HALL E, 1987, BRAIN RES, V436, P174; HALL E, 1990, STROKE, V21, P327; HAN JS, 1982, LIFE SCI, V31, P1781, DOI 10.1016/0024-3205(82)90209-0; HAYES AG, 1988, J PHARM PHARMACOL, V40, P718, DOI 10.1111/j.2042-7158.1988.tb07002.x; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; HUDSON CJ, 1991, BRAIN RES, V564, P261, DOI 10.1016/0006-8993(91)91462-A; HUNTER JC, 1990, BRIT J PHARMACOL, V101, P183, DOI 10.1111/j.1476-5381.1990.tb12110.x; ISAAC L, 1990, BRAIN RES, V531, P83, DOI 10.1016/0006-8993(90)90760-9; KRUMINS SA, 1985, BIOCHEM BIOPH RES CO, V127, P120, DOI 10.1016/S0006-291X(85)80134-0; KUSUMOTO K, 1992, BRAIN RES, V576, P147, DOI 10.1016/0006-8993(92)90621-F; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LASON W, 1989, BRAIN RES, V482, P333, DOI 10.1016/0006-8993(89)91196-7; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1989, BRAIN RES, V497, P155, DOI 10.1016/0006-8993(89)90982-7; MCFADZEAN I, 1987, NEUROSCIENCE, V20, P231, DOI 10.1016/0306-4522(87)90015-7; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1993, J CEREB BLOOD FLOW S, V11, pS7334; MOISES HC, 1985, EUR J PHARMACOL, V108, P85, DOI 10.1016/0014-2999(85)90286-9; PAXINOS G, 1990, STEREOTAXIC ATLAS RA; PINNOCK RD, 1992, NEUROSCIENCE, V47, P87; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; ROTHMAN RB, 1990, PEPTIDES, V11, P311, DOI 10.1016/0196-9781(90)90088-M; SILVIA RC, 1987, BRAIN RES, V403, P52, DOI 10.1016/0006-8993(87)90121-1; SPAMPINATO S, 1985, EUR J PHARMACOL, V110, P21, DOI 10.1016/0014-2999(85)90024-X; STEVENS CW, 1986, J PHARMACOL EXP THER, V238, P833; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X; VINK R, 1991, AM J PHYSIOL, V261, pR1527, DOI 10.1152/ajpregu.1991.261.6.R1527; VINK R, 1990, J NEUROSCI, V10, P3524; WALKER JM, 1982, SCIENCE, V218, P1136, DOI 10.1126/science.6128791; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	57	27	28	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0002-9513			AM J PHYSIOL	Am. J. Physiol.	SEP	1994	267	3	2				R665	R672		10.1152/ajpregu.1994.267.3.R665			8	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	PH383	WOS:A1994PH38300054	7916537				2022-02-06	
J	OKIYAMA, K; ROSENKRANTZ, TS; SMITH, DH; GENNARELLI, TA; MCINTOSH, TK				OKIYAMA, K; ROSENKRANTZ, TS; SMITH, DH; GENNARELLI, TA; MCINTOSH, TK			(S)-EMOPAMIL ATTENUATES ACUTE REDUCTION IN REGIONAL CEREBRAL BLOOD-FLOW FOLLOWING EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CALCIUM-CHANNEL BLOCKER; ACUTE HEAD-INJURY; ISCHEMIC BRAIN; ARTERY OCCLUSION; ENERGY-METABOLISM; GLUCOSE-UTILIZATION; CONSCIOUS RATS; MICROSPHERES; ANTAGONIST; NIMODIPINE	We examined the effects of (S)-emopamil, a phenylalkylamine calcium channel blocker with serotonin receptor antagonist properties, on regional cerebral blood flow (rCBF) following experimental brain injury in the rat. Animals were subjected to fluid percussion brain injury of moderate severity (2.1 atm), and received (S)-emopamil (20 mg/kg, i.p., n = 10) or saline (n = 10) at 20 minutes postinjury and 2.5 hours after the first injection of the drug. Consecutive rCBF measurements were performed: (1) prior to injury, (2) 15 minutes, (3) 90 minutes, and (4) 4 hours postinjury, using the radiolabeled microsphere technique. Brain injury produced an acute and significant reduction of rCBF at 15 minutes postinjury in all the regions examined (p < 0.05). At 90 minutes postinjury, rCBF remained significantly de-pressed in the forebrain regions. All brain regions showed a recovery of rCBF to normal by 4 hours following injury in saline-treated animals, with the exception of injured left parietal cortex and bilateral hippocampi, where rCBF remained significantly depressed. A significant attenuation of the trauma-induced reduction in rCBF was observed at 70 minutes after the first administration of (S)-emopamil in the forebrain regions and cerebellum (p < 0.05). Following the second (S)-emopamil injection, the significant improvement in rCBF observed in left injured cortex was maintained. These results suggest that (S)-emopamil may be efficacious in reversing post-traumatic alterations in rCBF, which may contribute to the post-traumatic pathophysiologic sequelae.	UNIV PENN, DIV NEUROSURG, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06032 USA				smith, douglas/A-1321-2007		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS 26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803, R55NS026818, P01NS008803] Funding Source: NIH RePORTER		ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; BAER RW, 1984, AM J PHYSIOL, V246, pH418, DOI 10.1152/ajpheart.1984.246.3.H418; BIELENBERG GW, 1987, J CEREBR BLOOD F MET, V7, P480, DOI 10.1038/jcbfm.1987.91; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BUCKBERG GD, 1971, J APPL PHYSIOL, V31, P598, DOI 10.1152/jappl.1971.31.4.598; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEFEUDIS FV, 1989, TRENDS PHARMACOL SCI, V10, P215, DOI 10.1016/0165-6147(89)90262-9; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HARRIS RJ, 1982, STROKE, V13, P759, DOI 10.1161/01.STR.13.6.759; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEISS WD, 1976, ARCH NEUROL-CHICAGO, V33, P813, DOI 10.1001/archneur.1976.00500120017003; HOFFMAN WE, 1981, LIFE SCI, V28, P2167, DOI 10.1016/0024-3205(81)90624-X; HOFMANN HP, 1989, ARZNEIMITTEL-FORSCH, V39-1, P304; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; JACEWICZ M, 1986, J CEREBR BLOOD F MET, V6, P263, DOI 10.1038/jcbfm.1986.48; JACEWICZ M, 1992, J CEREBR BLOOD F MET, V12, P359, DOI 10.1038/jcbfm.1992.53; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; KUSCHINSKY W, 1978, PHYSIOL REV, V58, P656, DOI 10.1152/physrev.1978.58.3.656; LIN BW, 1990, STROKE, V21, P1734, DOI 10.1161/01.STR.21.12.1734; LIU D, 1990, Journal of Neurotrauma, V7, P219, DOI 10.1089/neu.1990.7.219; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYDIC R, 1991, J COMP NEUROL, V304, P517, DOI 10.1002/cne.903040402; MADSEN PL, 1991, J CEREBR BLOOD F MET, V11, P502, DOI 10.1038/jcbfm.1991.94; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; MEMEZAWA H, 1992, EXP BRAIN RES, V89, P67; MENDELOW AD, 1984, STROKE, V15, P704, DOI 10.1161/01.STR.15.4.704; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MOHAMED AA, 1984, J CEREBR BLOOD F MET, V4, P206, DOI 10.1038/jcbfm.1984.29; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PENFIELD W, 1937, RES PUBL ASS NERV ME, V18, P605; PLUM F, 1968, ARCH NEUROL-CHICAGO, V18, P1; RUBANYI GM, 1991, J CELL BIOCHEM, V46, P27, DOI 10.1002/jcb.240460106; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SIESJO BK, 1991, THROMBOLYTIC THERAPY, P60; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOKOLOFF L, 1981, FED PROC, V40, P2311; STANEK KA, 1983, AM J PHYSIOL, V245, pH920, DOI 10.1152/ajpheart.1983.245.6.H920; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1985, BRIT J ANAESTH, V57, P34, DOI 10.1093/bja/57.1.34; SYMON L, 1974, STROKE, V5, P355, DOI 10.1161/01.STR.5.3.355; SZABO L, 1989, ARZNEIMITTEL-FORSCH, V39-1, P309; SZABO L, 1989, ARZNEIMITTELFORSCH, V39-1, P314; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; TSUCHIYA M, 1977, AM J PHYSIOL, V233, pH617, DOI 10.1152/ajpheart.1977.233.5.H617; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; VORSTRUP S, 1986, J CEREBR BLOOD F MET, V6, P222, DOI 10.1038/jcbfm.1986.35; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	76	27	27	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	1994	11	1					83	95		10.1089/neu.1994.11.83			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	NC365	WOS:A1994NC36500005	8201628				2022-02-06	
J	HOVDA, DA; FU, K; BADIE, H; SAMII, A; PINANONG, P; BECKER, DP				HOVDA, DA; FU, K; BADIE, H; SAMII, A; PINANONG, P; BECKER, DP			ADMINISTRATION OF AN OMEGA-CONOPEPTIDE ONE-HOUR FOLLOWING TRAUMATIC BRAIN INJURY REDUCES CA-45 ACCUMULATION	ACTA NEUROCHIRURGICA			English	Article						CALCIUM; BRAIN INJURY; CONCUSSION	CEREBRAL BLOOD-FLOW	The omega-conopeptide, SNX-111 (NEUREX Corporation) was administered to rats 1 hour following a lateral fluid percussion brain injury to determine if the drug could reduced the extent and duration of trauma-induced calcium accumulation. Administration at doses of 3 or 5 mg/kg (i.v.) markedly reduced the extent of calcium accumulation as determined using calcium-45 autoradiography primarily within the cerebral cortex and hippocampus. The reduction of calcium accumulation was particularly event within the parietal cortex beginning as early as 6 hours and lasting out to 48 hours following injury. Although not as effective as in the cerebral cortex, SNX-111 did exhibit a reduction of calcium accumulation within the dorsal hippocampus especially at 24 and 48 hours after the insult. These preliminary results demonstrate that SNX-111 can reduce the injury-induced accumulation of calcium even when administered 1 hour after the insult and offers this compound as a potential therapeutic treatment for traumatic brain injury.	UNIV CALIF LOS ANGELES, SCH MED, INST BRAIN RES, LOS ANGELES, CA 90024 USA		HOVDA, DA (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROSURG, 74-140 CHS, LOS ANGELES, CA 90024 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		FINEMAN I, 1993, IN PRESS BRAIN RES; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	5	27	27	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1994				60			521	523					3	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	NX226	WOS:A1994NX22600143	7976637				2022-02-06	
J	HARMANLI, O; KOYFMAN, Y				HARMANLI, O; KOYFMAN, Y			TRAUMATIC ATLANTO OCCIPITAL DISLOCATION WITH SURVIVAL - A CASE-REPORT AND REVIEW OF THE LITERATURE	SURGICAL NEUROLOGY			English	Article						ATLANTO OCCIPITAL DISLOCATION; MAGNETIC RESONANCE IMAGING	ATLANTOOCCIPITAL DISLOCATION; JUNCTION; INJURIES; CHILDREN; SPINE	The number of patients who have survived traumatic atlanto-occipital dislocation, the usual outcome of which is death from brain stem transection, has increased in the past two decades due to improvements in on-scene resuscitation and transportation. This case of survival after traumatic atlanto-occipital dislocation is of interest because the patient had a complete neurologic recovery and a magnetic resonance imaging (MRI) study was obtained to confirm the diagnosis and rule out associated injuries.	MED CTR DELAWARE,DEPT SURG,NEWARK,DE 19713								ALKER GJ, 1978, ORTHOP CLIN N AM, V9, P1003; Blackwood NJ, 1908, ANN SURG, V47, P654, DOI 10.1097/00000658-190805000-00003; BOOLS JC, 1986, AM J NEURORADIOL, V7, P901; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; CLARK CR, 1988, SPINE, V13, P742, DOI 10.1097/00007632-198807000-00006; COLLATO PM, 1986, J BONE JOINT SURG AM, V61, P1106; DIBENEDETTO T, 1990, SPINE, V15, P595, DOI 10.1097/00007632-199006000-00031; DUBLIN AB, 1980, J NEUROSURG, V52, P541, DOI 10.3171/jns.1980.52.4.0541; EISHMONT FJ, 1978, J BONE JOINT SURG AM, V60, P397; EWARTS CM, 1970, J BONE JOINT SURG AM, V52, P1653; FARTHING J W, 1948, N C Med J, V9, P34; FRUIN AH, 1977, J NEUROSURG, V46, P663, DOI 10.3171/jns.1977.46.5.0663; GABRIELS.TO, 1966, AMER J ROENTGENOL RA, V97, P624, DOI 10.2214/ajr.97.3.624; GOLDBERG AL, 1991, J COMPUT ASSIST TOMO, V15, P174, DOI 10.1097/00004728-199101000-00034; GROBOVSCHEK M, 1983, NEURORADIOLOGY, V25, P173, DOI 10.1007/BF00455738; JEVTICH V, 1989, SPINE, V14, P123, DOI 10.1097/00007632-198901000-00027; KAUFMAN RA, 1987, AM J NEURORADIOL, V8, P995; KAUFMAN RA, 1982, AM J NEURORADIOL, V3, P415; LEE C, 1984, AM J NEURORADIOL, V5, P775; LEE C, 1987, AM J NEURORADIOL, V8, P19; LEVINE AM, 1989, CLIN ORTHOP RELAT R, V239, P53; PAGE CP, 1973, J NEUROSURG, V39, P394, DOI 10.3171/jns.1973.39.3.0394; PANG D, 1980, NEUROSURGERY, V7, P503, DOI 10.1227/00006123-198011000-00017; PAPADOPOULOS SM, 1991, NEUROSURGERY, V28, P574, DOI 10.1227/00006123-199104000-00015; POWERS B, 1979, NEUROSURGERY, V4, P12, DOI 10.1097/00006123-197901000-00004; PUTNAM WE, 1986, J AM OSTEOPATH ASSOC, V86, P798; RAMSAY AH, 1986, INJURY, V17, P412, DOI 10.1016/0020-1383(86)90084-7; RASOOL MN, 1987, S AFR MED J, V72, P295; ROCKSWOLD GL, 1979, MINN MED, V62, P151; TEPPER SL, 1990, AM J FOREN MED PATH, V11, P193, DOI 10.1097/00000433-199009000-00003; TRAYNELIS VC, 1986, J NEUROSURG, V65, P863, DOI 10.3171/jns.1986.65.6.0863; VANDENBOUT AH, 1986, SPINE, V11, P174, DOI 10.1097/00007632-198603000-00017; WATRIDGE CB, 1985, NEUROSURGERY, V17, P345, DOI 10.1227/00006123-198508000-00021; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WHOLEY MH, 1958, RADIOLOGY, V71, P350, DOI 10.1148/71.3.350; WOODRING JH, 1981, AM J ROENTGENOL, V137, P21, DOI 10.2214/ajr.137.1.21	36	27	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0090-3019			SURG NEUROL	Surg. Neurol.	APR	1993	39	4					324	330		10.1016/0090-3019(93)90015-S			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	LD877	WOS:A1993LD87700015	8488454				2022-02-06	
J	CRUZ, J; GENNARELLI, TA; ALVES, WM				CRUZ, J; GENNARELLI, TA; ALVES, WM			CONTINUOUS MONITORING OF CEREBRAL HEMODYNAMIC RESERVE IN ACUTE BRAIN INJURY - RELATIONSHIP TO CHANGES IN BRAIN-SWELLING	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	51ST ANNUAL SESSION OF THE AMERICAN ASSOC FOR THE SURGERY OF TRAUMA	SEP 11-14, 1991	PHILADELPHIA, PA	AMER ASSOC SURG TRAUMA			BLOOD-FLOW; COMATOSE PATIENTS	A new concept of cerebral hemodynamic and metabolic physiology, cerebral hemodynamic reserve (CHR), was evaluated in 20 comatose adults with acute traumatic brain swelling who were undergoing continuous monitoring of the arteriojugular difference in oxyhemoglobin saturation, along with cerebral perfusion pressure and expired PCO2. The CHR was measured as the ratio of relative (percent) changes in cerebral oxygen extraction to relative changes in cerebral perfusion pressure during spontaneous increases in intracranial pressure. In patients with initially severe brain swelling, the CHR was more frequently abnormal (compromised) on the first day, and tended to improve on the second day. In patients with initially moderate brain swelling, the CHR was more frequently normal (preserved) on the first day, but tended to become compromised on the second day if the brain swelling exacerbated. It is concluded that cerebral hemodynamic reserve abnormalities very closely associate with signs of increased intracranial "tightness" on computed tomographic scans of the head. Cerebral hemodynamic reserve could therefore become an important guide in the functional evaluation and management of acute brain swelling (focusing on cerebral oxygenation and perfusion pressure) in a variety of predominantly diffuse acute intracranial disorders.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HEAD INJURY CTR,PHILADELPHIA,PA 19104						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803-19] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR303687-02] Funding Source: Medline		BAELE PL, 1982, ANESTH ANALG, V61, P513; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1992, J TRAUMA, V32, P401, DOI 10.1097/00005373-199203000-00020; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1984, Society for Neuroscience Abstracts, V10, P542; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; CRUZ J, 1984, 52ND ANN M AM ASS NE; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GRUBB RL, 1975, J NEUROSURG, V43, P385, DOI 10.3171/jns.1975.43.4.0385; GUILLAUME J, 1951, REV NEUROL, V84, P131; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Lundberg N, 1960, ACTA PSYCHIAT NEUR S, V36, P149; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; TEASDALE G, 1974, LANCET, V2, P81	18	27	27	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1992	32	5					629	635		10.1097/00005373-199205000-00015			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	HW811	WOS:A1992HW81100015	1588652				2022-02-06	
J	HARTLEY, LL; LEVIN, HS				HARTLEY, LL; LEVIN, HS			LINGUISTIC DEFICITS AFTER CLOSED HEAD-INJURY - A CURRENT APPRAISAL	APHASIOLOGY			English	Article											HARTLEY, LL (corresponding author), GALVESTON INST HUMAN COMMUN,TRANSIT LEARNING COMMUNITY,1528 PO,GALVESTON,TX 77550, USA.							0	27	28	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	JUL-AUG	1990	4	4					353	370		10.1080/02687039008249088			18	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	DT690	WOS:A1990DT69000005					2022-02-06	
J	BROTHERTON, FA; THOMAS, LL; WISOTZEK, IE; MILAN, MA				BROTHERTON, FA; THOMAS, LL; WISOTZEK, IE; MILAN, MA			SOCIAL SKILLS TRAINING IN THE REHABILITATION OF PATIENTS WITH TRAUMATIC CLOSED HEAD-INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article									EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; GEORGIA STATE UNIV, DEPT PSYCHOL, ATLANTA, GA 30303 USA								ANDRASIK F, 1985, HDB SOCIAL SKILLS TR, P418; ASCHER LM, 1980, HDB BEHAV INTERVENTI, P266; Bellack A. S., 1979, RES PRACTICE SOCIAL; Ben-Yishay Y, 1983, REHABILITATION HEAD, P367; CURRAN JP, 1977, PSYCHOL BULL, V84, P140; DEUTSCH RD, 1979, RES COMMUN PSYCH PSY, V4, P415; DUNN M, 1981, BEHAV THER, V12, P153, DOI 10.1016/S0005-7894(81)80068-8; HERSEN M, 1976, J APPL BEHAV ANAL, V9, P239, DOI 10.1901/jaba.1976.9-239; Hersen M., 1976, SINGLE CASE EXPT DES; Jennett B, 1981, MANAGEMENT HEAD INJU; KOLKO DJ, 1985, BEHAV MODIF, V9, P165, DOI 10.1177/01454455850092003; KOLKO DJ, 1981, BEHAV ASSESS, V3, P383; LABATE LL, 1985, HDB SOCIAL SKILLS TR; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIBET JM, 1973, J CONSULT CLIN PSYCH, V40, P304, DOI 10.1037/h0034530; MUIR CA, 1983, REHABILITATION HEAD, P381; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PHILLIPS EL, 1985, HDB SOCIAL SKILLS TR, P3; ROSENTHAL M, 1983, REHABILITATION HEAD; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; ZAHARA DJ, 1984, CLIN PSYCHOL REV, V4, P477, DOI 10.1016/0272-7358(84)90022-9	23	27	27	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1988	69	10					827	832					6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	Q5535	WOS:A1988Q553500001	3178449				2022-02-06	
J	STONE, L; KEENAN, MAE				STONE, L; KEENAN, MAE			PERIPHERAL-NERVE INJURIES IN THE ADULT WITH TRAUMATIC BRAIN INJURY	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article									RANCHO LOS AMIGOS HOSP, ADULT HEAD TRAUMA SERV, DOWNEY, CA 90242 USA; UNIV SO CALIF, SCH MED, DEPT ORTHOPAED SURG, LOS ANGELES, CA 90033 USA		STONE, L (corresponding author), RANCHO LOS AMIGOS HOSP, HEAD TRAUMA SERV, 7601 E IMPERIAL HIGHWAY, DOWNEY, CA 90242 USA.		Keenan, Mary Ann/ABB-1551-2020				ANDERSON DW, 1980, J NEUROSURG, V53, pS1; BOOTH BJ, 1983, PHYS THER, V63, P1960, DOI 10.1093/ptj/63.12.1960; BRAUN RM, 1973, J BONE JOINT SURG AM, VA 55, P580, DOI 10.2106/00004623-197355030-00015; CHAN RC, 1980, NEUROSURGERY, V7, P545, DOI 10.1227/00006123-198012000-00001; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; FEINDEL W, 1958, Can J Surg, V1, P287; FROIMSON AI, 1980, J HAND SURG-AM, V5, P391, DOI 10.1016/S0363-5023(80)80183-3; GARLAND DE, 1978, CLIN ORTHOP RELAT R, P111; GARLAND DE, 1983, PHYS THER, V63, P2004, DOI 10.1093/ptj/63.12.2004; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P243; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; GELBERMAN RH, 1981, J BONE JOINT SURG AM, V63, P380, DOI 10.2106/00004623-198163030-00009; Heiden J.S., 1979, NEURAL TRAUMA, P181; HERBISON GJ, 1983, ARCH PHYS MED REHAB, V64, P201; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KATZ JORDAN, 1967, ARCH PHYS MED REHABIL, V48, P97; KEENAN MAE, 1988, J HAND SURG-AM, V13A, P120, DOI 10.1016/0363-5023(88)90214-6; KEENAN MAE, 1987, J HEAD TRAUMA REHAB, V2, P62; KHALILI AA, 1967, J AMER MED ASSOC, V200, P1155, DOI 10.1001/jama.200.13.1155; KHALILI ALI A., 1964, ARCH PHYS MED REHABIL, V45, P513; KIMURA J, 1983, ELECTRODIAGNOSIS DIS; KINGSTON WJ, 1985, SEMIN NEUROL, V5, P260, DOI 10.1055/s-2008-1041523; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MALKMUS D, 1980, REHABILITATION HEAD, P2; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MOONEY V, 1969, CLIN ORTHOP RELAT R, P122; MORITZ U, 1973, SCAND J REHABIL MED, V5, P160; PHALEN GS, 1970, J AMER MED ASSOC, V212, P1365, DOI 10.1001/jama.212.8.1365; RHOADES ME, 1978, CLIN ORTHOP RELAT R, P104; WILBOURN AJ, 1985, NEUROL CLIN, V3, P511, DOI 10.1016/S0733-8619(18)31019-3; Woltman HW, 1930, AM J MED SCI, V179, P528, DOI 10.1097/00000441-193004000-00008	32	27	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	1988		233					136	144					9	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	P7178	WOS:A1988P717800017	3402119				2022-02-06	
J	CRAGOE, EJ				CRAGOE, EJ			DRUGS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY	MEDICINAL RESEARCH REVIEWS			English	Article											CRAGOE, EJ (corresponding author), MERCK SHARP & DOHME RES LABS, W POINT, PA 19486 USA.						AUEN EL, 1979, ACTA NEUROPATHOL, V47, P175, DOI 10.1007/BF00690544; Avezaat C J, 1979, Acta Neurochir Suppl (Wien), V28, P26; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BARRON KD, 1986, ANN NEUROL, V20, P144; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Becker DP, 1972, INTRACRANIAL PRESSUR, P309; BELOPAVLOVIC M, 1980, ANAESTHESIA, V35, P235, DOI 10.1111/j.1365-2044.1980.tb05090.x; BLACK KL, 1979, CLIN RES, V27, pA714; BOURKE RS, 1976, BRAIN RES, V105, P309, DOI 10.1016/0006-8993(76)90427-3; BOURKE RS, 1978, BRAIN RES, V154, P196, DOI 10.1016/0006-8993(78)91072-7; BOURKE RS, 1969, EXP BRAIN RES, V8, P232; BOURKE RS, 1983, NEUROCHEM RES, V8, P5, DOI 10.1007/BF00965650; BOURKE RS, 1981, J NEUROSURG, V55, P364, DOI 10.3171/jns.1981.55.3.0364; BOURKE RS, 1979, STUDIES FORMATION AS, P108; BOWERS SA, 1980, NEUROSURGERY, V6, P237; Bradbury M.W.B., 1979, CONCEPT BLOOD BRAIN; BURG M, 1973, KIDNEY INT, V4, P301, DOI 10.1038/ki.1973.121; CANDIA OA, 1981, AM J PHYSIOL, V240, pF25, DOI 10.1152/ajprenal.1981.240.1.F25; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CASTANER J, 1978, Drugs of the Future, V3, P229; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; COTTRELL JE, 1977, ANESTHESIOLOGY, V47, P28, DOI 10.1097/00000542-197707000-00006; CRAGOE EJ, 1986, J MED CHEM, V29, P825, DOI 10.1021/jm00155a038; CRAGOE EJ, 1982, J MED CHEM, V25, P567, DOI 10.1021/jm00347a017; CRAGOE EJ, 1986, Patent No. 4579869; CRAGOE EJ, 1903, Patent No. 741068; CRAGOE EJ, 1986, Patent No. 4604396; CRAGOE EJ, 1857, Patent No. 17403; CRAGOE EJ, 1983, DIURETICS CHEM BIOL, P212; CRAGOE EJ, 1982, Patent No. 4316043; CRAGOE EJ, 1984, DIURETICS CHEM PHARM, P12; CROSS PE, 1978, J MED CHEM, V21, P845, DOI 10.1021/jm00207a001; DAVISON C, 1961, J PHARMACOL EXP THER, V133, P161; DODSON RF, 1977, J NEUROL SCI, V33, P161, DOI 10.1016/0022-510X(77)90190-3; Ehrenreich DL, 1961, ARCH NEUROL-CHICAGO, V5, P125; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; GAAB M, 1979, J NEUROL, V220, P185, DOI 10.1007/BF00705536; GARAY RP, 1986, N-S ARCH PHARMACOL, V334, P202, DOI 10.1007/BF00505823; GARCIA JH, 1977, VIRCHOWS ARCH B, V25, P191; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; GRONWALL D, 1974, LANCET, V2, P605; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; JANE JA, 1982, HEAD INJURY BASIC CL, P229; JENNETT B, 1980, TRENDS NEUROSCI, V3, pR1, DOI 10.1016/S0166-2236(80)80059-2; JENNETT B, 1981, MANAGEMENT HEAD INJU, P317; KIMELBERG H K, 1986, Society for Neuroscience Abstracts, V12, P86; KIMELBERG HK, 1986, BIOCHEM PHARMACOL, V35, P2273, DOI 10.1016/0006-2952(86)90451-X; KIMELBERG HK, 1983, CELL MOL NEUROBIOL, V3, P1, DOI 10.1007/BF00734994; KIMELBERG HK, 1979, BRAIN RES, V173, P111; KIMELBERG HK, 1981, BIOCHIM BIOPHYS ACTA, V646, P179, DOI 10.1016/0005-2736(81)90285-6; KIMELBERG HK, 1979, NEURAL TRAUMA, P137; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; KIMELBERG HK, IN PRESS CENTRAL NER; KIMELBERG HK, 1982, HEAD INJURY BASIC CL, P31; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kraus J F, 1978, Adv Neurol, V19, P261; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LONG DM, 1976, HDB CLIN NEUROLOGY 2, V24, P627; LORBER J, 1973, J NEUROSURG, V39, P702, DOI 10.3171/jns.1973.39.6.0702; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MARSHALL LF, 1979, SEMINARS NEUROLOGICA, P347; Meinig G, 1980, Adv Neurol, V28, P471; METZEL E, 1981, NEUROCHIRURGIA, V24, P15; MUYAZAKI Y, 1969, ARZNEI-FORSCHUNG, V19, P1961; NELSON LR, 1979, SEMINARS NEUROLOGICA, P297; NELSON LR, 1981, HEAD INJURY BASIC CL, P117; NELSON LR, 1979, SOC NEUR ABSTR, V5, P516; PARDRIDGE WM, 1986, FASEB J, V45, P2047; PIETRUSZKIEWICZ AM, 1857, Patent No. 17379; POPE A, 1978, DYNAMIC PROPERTIES G, P13; RANDALL WC, 1983, COMMUNICATION; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; ROTIN D, 1987, CANCER RES, V47, P1497; SCHWAM H, 1984, INVEST OPHTHALMOL  S, V25, P181; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TOCCO DJ, 1984, COMMUNICATION; TOTTEN J, 1979, LANCET, V1, P369; WARREN SE, 1981, ARCH INTERN MED, V141, P493, DOI 10.1001/archinte.141.4.493; WILKINSON HA, 1971, J NEUROSURG, V34, P203, DOI 10.3171/jns.1971.34.2part1.0203; WISE BL, 1961, ARCH NEUROL-CHICAGO, V4, P200, DOI 10.1001/archneur.1961.00450080082009; WOLTERSDORF OW, 1977, J MED CHEM, V20, P1400, DOI 10.1021/jm00221a010; WOLTERSDORF OW, 1983, Patent No. 4394385; WOLTERSDORF OW, 1978, ACS SYM SER, V83, P190; YEN JK, 1978, J NEUROL NEUROSUR PS, V41, P1125, DOI 10.1136/jnnp.41.12.1125; YEN JK, 1979, SEMINARS NEUROLOGICA, P329; ZIMMERMAN RA, 1979, SEMINARS NEUROLOGICA, P253; [No title captured]; DHEW PSH791120 PUBL; 1981, MED WORLD NEWS, P56; 1979, UNPUB MORTALITY STAT	92	27	27	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0198-6325	1098-1128		MED RES REV	Med. Res. Rev.	JUL-SEP	1987	7	3					271	305		10.1002/med.2610070302			35	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	J0934	WOS:A1987J093400001	3306216				2022-02-06	
J	FAAS, FH; OMMAYA, AK				FAAS, FH; OMMAYA, AK			BRAIN TISSUE ELECTROLYTES AND WATER CONTENT IN EXPERIMENTAL CONCUSSION IN MONKEY	JOURNAL OF NEUROSURGERY			English	Article																	ALEU FP, 1963, J NEUROPATH EXP NEUR, V22, P403, DOI 10.1097/00005072-196307000-00003; Alexander L, 1938, ARCH NEURO PSYCHIATR, V40, P877, DOI 10.1001/archneurpsyc.1938.02270110031002; BOURKE RS, 1965, AM J PHYSIOL, V208, P682, DOI 10.1152/ajplegacy.1965.208.4.682; BRADBURY BW, 1965, J PHYSIOL-LONDON, V181, P151, DOI 10.1113/jphysiol.1965.sp007752; CAVENESS WF, 1966, HEAD INJURY       ED, P439; CAVENESS WF, 1966, HEAD INJURY       ED, P142; CAVENESS WF, 1966, HEAD INJURY       ED, P444; CAVENESS WF, 1966, HEAD INJURY       ED, P249; CAVENESS WF, 1966, HEAD INJURY       ED, P397; CAVENESS WF, 1966, HEAD INJURY C P   ED, P276; CAVENESS WF, 1966, HEAD INJURY C P   ED, P254; CAVENESS WF, 1966, HEAD INJURY       ED, P448; COTLOVE E, 1963, ANAL CHEM, V35, P101, DOI 10.1021/ac60194a031; COTLOVE E, 1958, J LAB CLIN MED, V51, P461; EICHELBERGER L, 1949, AM J PHYSIOL, V156, P129, DOI 10.1152/ajplegacy.1949.156.1.129; FISHER RG, 1966, HEAD INJURY, P249; Flamm E S, 1966, Surg Forum, V17, P414; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; HERSCHKO.N, 1965, BRAIN, V88, P557, DOI 10.1093/brain/88.3.557; ISHII S, 1966, HEAD INJURY, P276; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KURZE T, 1966, HEAD INJURY C P, P254; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; MCLAURIN RL, 1966, HEAD INJURY C P, P142; Nelson S, 1966, HEAD INJURY, P444; Ommaya A K, 1966, Ann R Coll Surg Engl, V39, P317; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; PAPPIUS H. M., 1965, PROGR BRAIN RES, V15, P135; Pappius HM, 1963, ACTA NEUROPATH BERL, V2, P451; Pilcher C, 1937, ARCH SURG-CHICAGO, V35, P512, DOI 10.1001/archsurg.1937.01190150095009; PILCHER C, 1941, SURG GYNECOL OBSTET, V72, P755; POPE A, 1966, HEAD INJURY, P439; REED DJ, 1964, ARCH NEUROL-CHICAGO, V10, P604, DOI 10.1001/archneur.1964.00460180070007; Shapiro P, 1939, ARCH SURG-CHICAGO, V38, P443, DOI 10.1001/archsurg.1939.01200090048005; SPIEGEL EA, 1946, P ASS RES NERV MENT, V26, P84; STEINWALL O, UNPUBLISHED OBSERVAT; STERN WE, 1964, AM J PHYSIOL, V206, P1, DOI 10.1152/ajplegacy.1964.206.1.1; STERN WE, 1965, NEUROLOGY, V15, P902, DOI 10.1212/WNL.15.10.902; TOWER DB, 1966, HEAD INJURY, P448; VANHARRE.A, 1966, AM J PHYSIOL, V210, P251, DOI 10.1152/ajplegacy.1966.210.2.251; VANHARREVELD A, 1966, HEAD INJURY, P397; VANHARREVELD A, 1966, BRAIN TISSUE ELECTRO; White JC, 1943, ANN SURG, V119, P619, DOI 10.1097/00000658-194310000-00010; WHITE JC, ARCHS SURG CHICAGO, V44, P1	45	27	27	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.		1968	28	2					137	+		10.3171/jns.1968.28.2.0137			1	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	A6851	WOS:A1968A685100008	4966169				2022-02-06	
J	CRAMER, F; PASTER, S; STEPHENSON, C				CRAMER, F; PASTER, S; STEPHENSON, C			CEREBRAL INJURIES DUE TO EXPLOSION WAVES - CEREBRAL BLAST CONCUSSION - A PATHOLOGIC, CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY	ARCHIVES OF NEUROLOGY AND PSYCHIATRY			English	Article																	Abbott WD, 1943, J AMER MED ASSOC, V121, P739, DOI 10.1001/jama.1943.02840100025007; Abbott WD, 1943, J AMER MED ASSOC, V121, P664, DOI 10.1001/jama.1943.02840090034010; AITA J A, 1946, Bull U S Army Med Dep, V6, P411; Ascroft PB, 1943, LANCET, V1, P234; Barrow DW, 1944, J AMER MED ASSOC, V125, P900, DOI 10.1001/jama.1944.02850310020006; Bell R C, 1944, Br Med J, V2, P689; Bernal JD, 1941, NATURE, V147, P594, DOI 10.1038/147594a0; BETTINGTON RHB, 1945, MED J AUSTRALIA, V2, P210; BOLLINGER O, 1891, INT BEITRAGE WEISSEN, P457; Brazier MAB, 1944, J CLIN INVEST, V23, P303, DOI 10.1172/JCI101495; BRUBAKER RE, 1945, B US ARMY M DEP, V87, P110; COHEN H, 1946, ARCH PATHOL, V42, P12; COREY E L, 1946, U S Nav Med Bull, V46, P623; Davis PA, 1941, J NEUROPHYSIOL, V4, P92, DOI 10.1152/jn.1941.4.1.92; DAVISON C, 1946, ARCH NEURO PSYCHIATR, V55, P111, DOI 10.1001/archneurpsyc.1946.02300130037002; DAVISON C, 1946, ARCH NEURO PSYCHIATR, V55, P126, DOI 10.1001/archneurpsyc.1946.02300130052003; DAVISON C, 1946, ARCH NEURO PSYCHIATR, V55, P364, DOI 10.1001/archneurpsyc.1946.02300150068005; DENNYBROWN D, 1943, T AM NEUROL ASSOC, V69, P98; FABING HD, 1947, ARCH NEURO PSYCHIATR, V57, P14, DOI 10.1001/archneurpsyc.1947.02300240030002; FEARNLEY GR, 1945, BMJ-BRIT MED J, V1, P474, DOI 10.1136/bmj.1.4396.474; Fulton J. F., 1942, NEW ENGL J MED, V226, P1; GANADO W, 1943, BMJ-BRIT MED J, V2, P118; GARAI O, 1944, LANCET, V1, P788; Gibbs FA, 1943, ARCH NEURO PSYCHIATR, V50, P111, DOI 10.1001/archneurpsyc.1943.02290200011001; Grinker Roy R, 1943, WAR NEUROSES N AFRIC; GRINKER RR, COMMUNICATION; Groat RA, 1944, AM J PHYSIOL, V141, P0117, DOI 10.1152/ajplegacy.1944.141.1.117; GRUNNAGLE JF, TRAUMATIC INTRACEREB; GUTMAN PE, 1944, AM J SURG, V45, P408; Hamlin H., 1943, U S NAVAL MED BULL, V41, P26; HASSIN GB, 1940, INJURIES SKULL BRAIN, P13; JASPER H, 1945, ASS RES NERV MENT DI, V24, P388; Jefferson G, 1944, BRIT MED J, V1944, P1; JEFFERSON G, 1943, T AM NEUROL A, V69, P13; POLLOCK LJ, 1943, ILLINOIS M J, V83, P165; ROBINSON CS, 1944, EXPLOSIONS THEIR ANA; ROGERS L, 1945, MED J AUSTRALIA, V2, P209; Rowbotham G. F., 1945, ACUTE INJURIES HEAD; STALLARD HB, 1944, BMJ-BRIT MED J, V2, P330; Stewart OW, 1941, LANCET, V1, P172; Sutherland GA, 1940, LANCET, V2, P641; Symonds C.P., 1940, INJURIES SKULL BRAIN, P69; TUNBRIDGE RE, 1945, WAR MED, V7, P3; TURNER EA, 1945, BRAIN, V68, P98, DOI 10.1093/brain/68.2.98; VONSTORCH TJC, 1945, STUDY CEREBRAL CONCU; WAKELEY CPG, 1945, LANCET, V248, P715; WILLIAMS D, 1945, BRAIN, V68, P123, DOI 10.1093/brain/68.2.123; Wilson JV, 1943, BMJ-BRIT MED J, V1943, P470; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; WOOD H, 1946, U S Nav Med Bull, V46, P51; ZUCKERMAN S, 1941, LANCET, V1, P110; 1945, B US ARMY M DEP, V4, P360; 1946, DIGEST NEUROL PSYCHI, V14, P145	54	27	27	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0096-6754			ARCH NEURO PSYCHIATR			1949	61	1					1	20					20	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Psychiatry	UF291	WOS:A1949UF29100001	18108324				2022-02-06	
J	Czeiter, E; Amrein, K; Gravesteijn, BY; Lecky, F; Menon, DK; Mondello, S; Newcombe, VFJ; Richter, S; Steyerberg, EW; Vande Vyvere, T; Verheyden, J; Xu, HY; Yang, ZH; Maas, AIR; Wang, KKW; Buki, A				Czeiter, Endre; Amrein, Krisztina; Gravesteijn, Benjamin Y.; Lecky, Fiona; Menon, David K.; Mondello, Stefania; Newcombe, Virginia F. J.; Richter, Sophie; Steyerberg, Ewout W.; Vande Vyvere, Thijs; Verheyden, Jan; Xu, Haiyan; Yang, Zhihui; Maas, Andrew I. R.; Wang, Kevin K. W.; Buki, Andras		CENTER-TBI Participants	Blood biomarkers on admission in acute traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study	EBIOMEDICINE			English	Article						Traumatic brain injury; Biomarkers; GFAP; Serum; Diagnostic; Computerized tomography; Clinical decision rule; Injury severity	COMPUTED-TOMOGRAPHY; IMPROVE	Background: Serum biomarkers may inform and improve care in traumatic brain injury (TBI). We aimed to correlate serum biomarkers with clinical severity, care path and imaging abnormalities in TBI, and explore their incremental value over clinical characteristics in predicting computed tomographic (CT) abnormalities. Methods: We analyzed six serum biomarkers (S100B, NSE, GFAP, UCH-L1, NFL and t-tau) obtained <24 h post-injury from 2867 patients with any severity of TBI in the Collaborative European NeuroTrauma Effectiveness Research (CENTER-TBI) Core Study, a prospective, multicenter, cohort study. Univariable and multivariable logistic regression analyses were performed. Discrimination was assessed by the area under the receiver operating characteristic curve (AUC) with 95% confidence intervals. Findings: All biomarkers scaled with clinical severity and care path (ER only, ward admission, or ICU), and with presence of CT abnormalities. GFAP achieved the highest discrimination for predicting CT abnormalities (AUC 0.89 [95%CI: 0.87-0.90]), with a 99% likelihood of better discriminating CT-positive patients than clinical characteristics used in contemporary decision rules. In patients with mild TBI, GFAP also showed incremental diagnostic value: discrimination increased from 0.84 [95%CI: 0.83-0.86] to 0.89 [95%CI: 0.87-0.90] when GFAP was included. Results were consistent across strata, and injury severity. Combinations of biomarkers did not improve discrimination compared to GFAP alone. Interpretation: Currently available biomarkers reflect injury severity, and serum GFAP, measured within 24 h after injury, outperforms clinical characteristics in predicting CT abnormalities. Our results support the further development of serum GFAP assays towards implementation in clinical practice, for which robust clinical assay platforms are required.(C) 2020 The Authors. Published by Elsevier B.V.	[Czeiter, Endre; Amrein, Krisztina; Buki, Andras] Univ Pecs, Med Sch, Dept Neurosurg, Ret U 2, H-7623 Pecs, Hungary; [Czeiter, Endre; Amrein, Krisztina; Buki, Andras] Univ Pecs, Szentagothai Res Ctr, Neurotrauma Res Grp, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Czeiter, Endre] MTA PTE Clin Neurosci MR Res Grp, Ret U 2, H-7623 Pecs, Hungary; [Gravesteijn, Benjamin Y.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands; [Lecky, Fiona] Univ Sheffield, Sch Hlth & Related Res ScHARR, Hlth Serv Res Sect, Ctr Urgent & Emergency Care Res CURE, Sheffield S1 4DA, S Yorkshire, England; [Lecky, Fiona] Salford Royal Hosp, Emergency Dept, Salford M6 8HD, Lancs, England; [Menon, David K.; Newcombe, Virginia F. J.; Richter, Sophie] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 0QQ, England; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Via Consolare Valeria 1, I-98125 Messina, Italy; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [Vande Vyvere, Thijs; Verheyden, Jan] Icometrix, Res & Dev, Kolonel Begaultlaan 1b-12, B-3012 Leuven, Belgium; [Vande Vyvere, Thijs] Antwerp Univ Hosp, Dept Radiol, Wijlrijkstr 10, B-2650 Edegem, Belgium; [Vande Vyvere, Thijs; Maas, Andrew I. R.] Univ Antwerp, Wijlrijkstr 10, B-2650 Edegem, Belgium; [Xu, Haiyan; Yang, Zhihui; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Program Neurotrauma Neuroprote & Biomarker Res, Dept Emergency Med, L4-100L 1149 South Newell Dr, Gainesville, FL 32611 USA; [Xu, Haiyan; Yang, Zhihui; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Program Neurotrauma Neuroprote & Biomarker Res, Dept Psychiat & Neurosci, L4-100L 1149 South Newell Dr, Gainesville, FL 32611 USA; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Wijlrijkstr 10, B-2650 Edegem, Belgium; [Wang, Kevin K. W.] Malcom Randall Vet Affairs Med Ctr VAMC, Brain Rehabil Res Ctr, 1601 SW Archer Rd, Gainesville, FL 32608 USA		Czeiter, E (corresponding author), Univ Pecs, Szentagothai Res Ctr, Neurotrauma Res Grp, Ifjusag Utja 20, H-7624 Pecs, Hungary.	endre.czeiter@gmail.com	Castano-Leon, Ana M/ABF-6322-2020; Vande Vyvere, Thijs/AAB-5180-2022; Posti, Jussi P./Y-2908-2019; Mondello, Stefania/A-1813-2012	Castano-Leon, Ana M/0000-0002-7918-5049; Vande Vyvere, Thijs/0000-0003-4032-5443; Posti, Jussi P./0000-0002-5925-5193; Mondello, Stefania/0000-0002-8587-3614; Richter, Sophie/0000-0003-3272-484X; Newcombe, Virginia/0000-0001-6044-9035; Gravesteijn, Benjamin/0000-0001-8096-5803; Czeiter, Endre/0000-0002-9578-6944	European Union 7th Framework program (EC grant) [602150]; Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA); Neurotrauma Sciences (USA)	CENTER-TBI study supported by the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences Corporation (USA) and from Neurotrauma Sciences (USA).	Abdelhak A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00280; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Bossuyt PM, 2020, J CLIN EPIDEMIOL, V117, P29, DOI 10.1016/j.jclinepi.2019.09.017; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Buuren, 2018, FLEXIBLE IMPUTATION; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Foks KA, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3527; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Huie JR, 2021, J NEUROTRAUM, V38, P2514, DOI 10.1089/neu.2019.6762; Maas AIR, 2018, LANCET NEUROL, V17, P737, DOI 10.1016/S1474-4422(18)30275-8; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Minkkinen M, 2019, J NEUROTRAUM, V36, P2904, DOI 10.1089/neu.2018.6351; Mondello Stefania, 2015, Handb Clin Neurol, V127, P245, DOI 10.1016/B978-0-444-52892-6.00016-7; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; National_Clinical_Guideline_C._National_Clinical_Guidance_Centre, 2014, 176 CG NAT CLIN GUID; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Rezaii PG, 2019, J NEUROTRAUM, V36, P2407, DOI 10.1089/neu.2018.6053; Rubin D.B., 2004, MULTIPLE IMPUTATION; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Steyerberg EW, 2015, BIOMETRICAL J, V57, P556, DOI 10.1002/bimj.201300260; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Thelin E, 2019, J NEUROTRAUM, V36, P2850, DOI 10.1089/neu.2019.6375; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; US_Food_and_Drug_Administration, 2019, EV AUT CLASS 3 DES B; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Welch RD, 2017, J NEUROTRAUM, V34, P1957, DOI 10.1089/neu.2016.4772; Yue JK, 2019, LANCET NEUROL, V18, P953, DOI 10.1016/S1474-4422(19)30282-0	31	26	26	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	2352-3964			EBIOMEDICINE	EBioMedicine	JUN	2020	56								102758	10.1016/j.ebiom.2020.102785			11	Medicine, General & Internal; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Research & Experimental Medicine	MM1OY	WOS:000549929200009	32464528	Green Published, gold, Green Accepted			2022-02-06	
J	Bathini, P; Brai, E; Auber, LA				Bathini, Praveen; Brai, Emanuele; Auber, Lavinia Alberi			Olfactory dysfunction in the pathophysiological continuum of dementia	AGEING RESEARCH REVIEWS			English	Article						Olfaction; Smell loss; Olfactory nerve; Aging; Dementia; Alzheimer's disease; Microbes; Inflammation; Olfactory diagnostics	SIMPLEX-VIRUS TYPE-1; MILD COGNITIVE IMPAIRMENT; MEDIODORSAL THALAMIC NUCLEUS; SMELL IDENTIFICATION TEST; BETA-AMYLOID DEPOSITION; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; ORBITOFRONTAL CORTEX; NEUROFIBRILLARY TANGLES	Sensory capacities like smell, taste, hearing, vision decline with aging, but increasing evidence show that sensory dysfunctions are one of the early signs diagnosing the conversion from physiological to pathological brain state. Smell loss represents the best characterized sense in clinical practice and is considered as one of the first preclinical signs of Alzheimer's and Parkinson's disease, occurring a decade or more before the onset of cognitive and motor symptoms. Despite the numerous scientific reports and the adoption in clinical practice, the etiology of sensory damage as prodromal of dementia remains largely unexplored and more studies are needed to resolve the mechanisms underlying sensory network dysfunction. Although both cognitive and sensory domains are progressively affected, loss of sensory experience in early stages plays a major role in reducing the autonomy of demented people in their daily tasks or even possibly contributing to their cognitive decline. Interestingly, the chemosensory circuitry is devoid of a blood brain barrier, representing a vulnerable port of entry for neurotoxic species that can spread to the brain. Furthermore, the exposure of the olfactory system to the external environment make it more susceptible to mechanical injury and trauma, which can cause degenerative neuroinflammation. In this review, we will summarize several findings about chemosensory impairment signing the conversion from healthy to pathological brain aging and we will try to connect those observations to the promising research linking environmental influences to sporadic dementia. The scientific body of knowledge will support the use of chemosensory diagnostics in the presymptomatic stages of AD and other biomarkers with the scope of finding treatment strategies before the onset of the disease.	[Bathini, Praveen; Auber, Lavinia Alberi] Univ Fribourg, Dept Med, Fribourg, Switzerland; [Brai, Emanuele] VIB KU Leuven, Ctr Brain & Dis Res, Lab Res Neurodegenerat Dis, Leuven, Belgium; [Auber, Lavinia Alberi] Swiss Integrat Ctr Human Hlth, Fribourg, Switzerland		Auber, LA (corresponding author), Swiss Integrat Ctr Human Hlth, Fribourg, Switzerland.	lavinia.alberi@unifr.ch		bathini, praveen/0000-0002-4031-8975	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [163470]; Ministry of Science and Education Switzerland (ESKAS) [2017.0480]; Human Brain ProjectUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [SP8.7]	This project is supported by funds of the Swiss National Science Foundation (N.163470; LA), the Ministry of Science and Education Switzerland (ESKAS No. 2017.0480; PB) and the Human Brain Project (SP8.7; LA).	Akimoto H, 2003, SCIENCE, V302, P1716, DOI 10.1126/science.1092666; Anderson AK, 2003, NAT NEUROSCI, V6, P196, DOI 10.1038/nn1001; [Anonymous], 2018, WORLD ALZH REP; Arendt T, 2009, ACTA NEUROPATHOL, V118, P167, DOI 10.1007/s00401-009-0536-x; Arnold SE, 2010, ANN NEUROL, V67, P462, DOI 10.1002/ana.21910; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Attems J, 2006, CLIN NEUROPATHOL, V25, P265; Attems J, 2012, P NATL ACAD SCI USA, V109, P6259, DOI 10.1073/pnas.1203843109; Ayala-Grosso CA, 2015, BRAIN PATHOL, V25, P136, DOI 10.1111/bpa.12169; Bacon AW, 1998, ANN NY ACAD SCI, V855, P723, DOI 10.1111/j.1749-6632.1998.tb10651.x; Bahar-Fuchs A, 2011, INT PSYCHOGERIATR, V23, P1097, DOI 10.1017/S1041610210002371; Baitsch D, 2011, ARTERIOSCL THROM VAS, V31, P1160, DOI 10.1161/ATVBAHA.111.222745; Bakkour A, 2013, NEUROIMAGE, V76, P332, DOI 10.1016/j.neuroimage.2013.02.059; Balin BJ, 1998, MED MICROBIOL IMMUN, V187, P23, DOI 10.1007/s004300050071; Bathini P, 2019, NEUROBIOL AGING, V76, P80, DOI 10.1016/j.neurobiolaging.2018.12.006; Bergmann O, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a018994; Bergmann O, 2012, NEURON, V74, P634, DOI 10.1016/j.neuron.2012.03.030; Biella G, 2000, J NEUROPHYSIOL, V83, P1924, DOI 10.1152/jn.2000.83.4.1924; Biesbroek G., 2013, PLOS PATHOG, V9; Bodewes R, 2011, AM J PATHOL, V179, P30, DOI 10.1016/j.ajpath.2011.03.026; Boelen E, 2007, NEUROBIOL AGING, V28, P524, DOI 10.1016/j.neurobiolaging.2006.02.014; Borders AS, 2007, J COMP NEUROL, V501, P206, DOI 10.1002/cne.21252; Bower JH, 2006, NEUROLOGY, V67, P494, DOI 10.1212/01.wnl.0000227906.99570.cc; BRAAK H, 1991, ACTA NEUROPATHOL, V81, P261, DOI 10.1007/BF00305867; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Braak H, 2015, BRAIN, V138, P2814, DOI 10.1093/brain/awv236; Brodie M, 1934, SCIENCE, V79, P235, DOI 10.1126/science.79.2045.235; Brunjes PC, 2010, J COMP NEUROL, V518, P1603, DOI 10.1002/cne.22293; Budson Andrew E, 2012, Pract Neurol, V12, P88, DOI 10.1136/practneurol-2011-000145; Burgos JS, 2006, J VIROL, V80, P5383, DOI 10.1128/JVI.00006-06; Burt TD, 2008, P NATL ACAD SCI USA, V105, P8718, DOI 10.1073/pnas.0803526105; Calderon-Garciduenas L, 2003, TOXICOL PATHOL, V31, P524, DOI 10.1080/01926230390226645; Calderon-Garciduenas L, 2002, TOXICOL PATHOL, V30, P373, DOI 10.1080/01926230252929954; Calderon-Garciduenas L, 2008, BRAIN COGNITION, V68, P117, DOI 10.1016/j.bandc.2008.04.008; Calderon-Garciduenas L, 2008, TOXICOL PATHOL, V36, P289, DOI 10.1177/0192623307313011; Calderon-Garciduenas L, 2010, EXP TOXICOL PATHOL, V62, P91, DOI 10.1016/j.etp.2009.02.117; Calhoun-Haney R, 2005, BRAIN COGNITION, V58, P178, DOI 10.1016/j.bandc.2004.10.004; Chapuis J, 2013, J NEUROSCI, V33, P13449, DOI 10.1523/JNEUROSCI.1387-13.2013; Chen CR, 2014, J NEUROL SURG PART B, V75, P293, DOI 10.1055/s-0033-1361837; Chen MF, 2017, P NATL ACAD SCI USA, V114, P8089, DOI 10.1073/pnas.1620664114; Chen Pan, 2016, F1000Res, V5, DOI 10.12688/f1000research.7431.1; Cheng SB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017966; Chetelat G, 2005, NEUROIMAGE, V27, P934, DOI 10.1016/j.neuroimage.2005.05.015; Child KM, 2018, J NEUROSCI, V38, P6806, DOI 10.1523/JNEUROSCI.3261-17.2018; Choi R, 2018, LARYNGOSCOPE INVEST, V3, P35, DOI 10.1002/lio2.135; Christen-Zaech S, 2003, CAN J NEUROL SCI, V30, P20, DOI 10.1017/S0317167100002389; Chung SD, 2015, AM J RHINOL ALLERGY, V29, P44, DOI 10.2500/ajra.2015.29.4113; Cleland T.A., 2003, HDB OLFACTION GUSTAT, P165; Cohen NA, 2006, ANN OTO RHINOL LARYN, V115, P20; Costanzo RM, 2005, CHEM SENSES, V30, pI133, DOI 10.1093/chemse/bjh150; Courtiol E, 2014, J NEUROPHYSIOL, V111, P1274, DOI 10.1152/jn.00741.2013; Covington JW, 1999, INT J PSYCHOPHYSIOL, V32, P205, DOI 10.1016/S0167-8760(99)00012-4; Cross DJ, 2013, J NUCL MED, V54, P1278, DOI 10.2967/jnumed.112.116558; DANIELLO A, 1992, BRAIN RES, V592, P44, DOI 10.1016/0006-8993(92)91656-Y; DAVIES DC, 1993, NEUROBIOL AGING, V14, P353, DOI 10.1016/0197-4580(93)90121-Q; de Bont N, 1999, J LIPID RES, V40, P680; De Simone R, 2010, SEIZURE-EUR J EPILEP, V19, P383, DOI 10.1016/j.seizure.2010.04.008; Devanand DP, 2015, NEUROLOGY, V84, P182, DOI 10.1212/WNL.0000000000001132; Devanand DP, 2008, BIOL PSYCHIAT, V64, P871, DOI 10.1016/j.biopsych.2008.06.020; Djordjevic J, 2008, NEUROBIOL AGING, V29, P693, DOI 10.1016/j.neurobiolaging.2006.11.014; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333; Donati D, 2005, J VIROL, V79, P9439, DOI 10.1128/JVI.79.15.9439-9448.2005; Doty RL, 2008, ANN NEUROL, V63, P7, DOI 10.1002/ana.21327; Doty RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00020; DOTY RL, 1987, BRAIN RES BULL, V18, P597, DOI 10.1016/0361-9230(87)90129-8; Doty RL, 2001, LARYNGOSCOPE, V111, P409, DOI 10.1097/00005537-200103000-00008; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Eimer WA, 2018, NEURON, V99, P56, DOI 10.1016/j.neuron.2018.06.030; El-Habashi N, 2010, J NEUROVIROL, V16, P242, DOI 10.3109/13550284.2010.489596; Elisabeth K., 1986, OLFACTORY DYSFUNCTIO, DOI [10.1080/87565648609540332, DOI 10.1080/87565648609540332]; ESKENAZI B, 1986, NEUROPSYCHOLOGIA, V24, P553, DOI 10.1016/0028-3932(86)90099-0; Ezzat K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10192-2; Fahrenhold M, 2018, BRAIN PATHOL, V28, P595, DOI 10.1111/bpa.12564; Falgarone G, 2009, ADV CANCER RES, V104, P139, DOI 10.1016/S0065-230X(09)04008-1; Farbman AI, 1999, J COMP NEUROL, V414, P306, DOI 10.1002/(SICI)1096-9861(19991122)414:3<306::AID-CNE2>3.0.CO;2-#; Federico G, 1999, BRAIN RES, V835, P306, DOI 10.1016/S0006-8993(99)01614-5; Finch CE, 2007, CURR ALZHEIMER RES, V4, P185, DOI 10.2174/156720507780362254; Forster S, 2010, J ALZHEIMERS DIS, V22, P581, DOI 10.3233/JAD-2010-091549; FORTIER I, 1991, AM J IND MED, V20, P495, DOI 10.1002/ajim.4700200405; Francois A, 2016, SCI REP-UK, V6, DOI 10.1038/srep24687; Frenkel D, 2002, P NATL ACAD SCI USA, V99, P5675, DOI 10.1073/pnas.072027199; Friedman JH, 2008, NEUROLOGY, V70, P487, DOI 10.1212/01.wnl.0000279380.25130.ce; Frisoni GB, 2009, J NEUROL, V256, P916, DOI 10.1007/s00415-009-5040-7; FULLER GN, 1990, CLIN NEUROPATHOL, V9, P279; Fulop T, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00362; Gerard HC, 2005, MICROB PATHOGENESIS, V39, P19, DOI 10.1016/j.micpath.2005.05.002; GERMAN DC, 1992, ANN NEUROL, V32, P667, DOI 10.1002/ana.410320510; Geula C, 1996, CEREB CORTEX, V6, P165, DOI 10.1093/cercor/6.2.165; Giannakopoulos Panteleimon, 2009, V24, P20, DOI 10.1159/000197881; Gilbert PE, 2004, J CLIN EXP NEUROPSYC, V26, P779, DOI 10.1080/13803390490509439; Gillet L, 2015, CURR OPIN VIROL, V15, P34, DOI 10.1016/j.coviro.2015.07.007; Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Goncalves Stefania, 2016, Curr Otorhinolaryngol Rep, V4, P115; Gonzalez B, 2017, NEUROL CLIN, V35, P175, DOI 10.1016/j.ncl.2017.01.001; Gordon Brian A, 2018, Alzheimers Dement (Amst), V10, P245, DOI 10.1016/j.dadm.2018.02.003; Gottfried JA, 2006, NEURON, V49, P467, DOI 10.1016/j.neuron.2006.01.007; Gottfried JA, 2005, BRAIN RES REV, V50, P287, DOI 10.1016/j.brainresrev.2005.08.004; Gottfried JA, 2002, J NEUROSCI, V22, P10819; Gottfried JA, 2006, ADV OTO-RHINO-LARYNG, V63, P44, DOI 10.1159/000093750; Gottfried JA, 2010, NAT REV NEUROSCI, V11, P628, DOI 10.1038/nrn2883; Gottlieb S, 2000, BRIT MED J, V321, P1100; Grudzien A, 2007, NEUROBIOL AGING, V28, P327, DOI 10.1016/j.neurobiolaging.2006.02.007; Guzman-Sanchez F, 2012, J ALZHEIMERS DIS, V30, P779, DOI 10.3233/JAD-2012-120070; Gylfe A, 2002, SCAND J INFECT DIS, V34, P922, DOI 10.1080/0036554021000026972; Haas JG, 2018, TRENDS NEUROSCI, V41, P570, DOI 10.1016/j.tins.2018.07.001; Halgren E, 1982, Hum Neurobiol, V1, P251; Han PF, 2018, J NEUROTRAUM, V35, P2632, DOI 10.1089/neu.2017.5393; Harberts E, 2011, P NATL ACAD SCI USA, V108, P13734, DOI 10.1073/pnas.1105143108; Hasegawa-Ishii S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10229-w; Heneka MT, 2015, NAT IMMUNOL, V16, P229, DOI 10.1038/ni.3102; Herbert RP, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-109; Hill JM, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00009; Hishiki T, 2010, J VIROL, V84, P12048, DOI 10.1128/JVI.01063-10; Hoffman HJ, 2016, REV ENDOCR METAB DIS, V17, P221, DOI 10.1007/s11154-016-9364-1; Holbrook EH, 2005, LARYNGOSCOPE, V115, P2144, DOI 10.1097/01.MLG.0000181493.83661.CE; Holbrook EH, 2011, LARYNGOSCOPE, V121, P1687, DOI 10.1002/lary.21856; Hong GH, 2016, J IMMUNOL, V196, P2021, DOI 10.4049/jimmunol.1500747; Huttenbrink KB, 2013, DTSCH ARZTEBL INT, V110, P1, DOI 10.3238/arztebl.2013.0001; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; Hummel T, 2010, J NEUROL SCI, V289, P119, DOI 10.1016/j.jns.2009.08.026; Hussain A, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-49; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; Iannaccone A, 2005, AM J MED GENET A, V132A, P343, DOI 10.1002/ajmg.a.30512; Itzhaki RF, 1997, LANCET, V349, P241, DOI 10.1016/S0140-6736(96)10149-5; Itzhaki RF, 2008, J ALZHEIMERS DIS, V13, P393; Itzhaki RF, 2016, J ALZHEIMERS DIS, V51, P979, DOI 10.3233/JAD-160152; Itzhaki RF, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00202; JAMIESON GA, 1991, J MED VIROL, V33, P224, DOI 10.1002/jmv.1890330403; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; Kalmey J.K., 1998, ANAT REC, DOI [10.1002/(SICI)1097-0185(199807)251:3%3C326::AID-AR7/03E3.0.00;2-T, DOI 10.1002/(SICI)1097-0185(199807)251:3%3C326::AID-AR7/03E3.0.00;2-T]; Kareken DA, 2001, NEUROPSYCHOLOGY, V15, P18, DOI 10.1037//0894-4105.15.1.18; Kattan OM, 2008, J IMMUNOL, V181, P1399, DOI 10.4049/jimmunol.181.2.1399; Kawagoe T, 2007, NEUROREPORT, V18, P683, DOI 10.1097/WNR.0b013e3280bef9a6; KNUPFER L, 1986, International Journal of Geriatric Psychiatry, V1, P3, DOI 10.1002/gps.930010103; Kobayashi M, 2005, CHEM SENSES, V30, pI216, DOI 10.1093/chemse/bjh191; Kondo K, 2010, J COMP NEUROL, V518, P1962, DOI 10.1002/cne.22316; Koskinen K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19438-3; KOSS E, 1988, NEUROLOGY, V38, P1228, DOI 10.1212/WNL.38.8.1228; Kovacs I, 1998, BRAIN RES, V789, P167, DOI 10.1016/S0006-8993(98)00097-3; Kovacs T, 1999, NEUROPATH APPL NEURO, V25, P481; Kril JJ, 2002, ACTA NEUROPATHOL, V103, P370, DOI 10.1007/s00401-001-0477-5; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Kumar DKV, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1059; Lachen-Montes M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09481-x; Lane AP, 2010, J NEUROSCI, V30, P2324, DOI 10.1523/JNEUROSCI.4507-09.2010; LEHERICY S, 1993, J COMP NEUROL, V330, P15, DOI 10.1002/cne.903300103; Leibovitch EC, 2018, P NATL ACAD SCI USA, V115, P11292, DOI 10.1073/pnas.1811974115; LEWIS DA, 1987, J NEUROSCI, V7, P1799; Li W, 2010, PSYCHOL SCI, V21, P1454, DOI 10.1177/0956797610382121; Li W, 2010, BRAIN, V133, P2714, DOI 10.1093/brain/awq209; Little CS, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00304; Little CS, 2004, NEUROBIOL AGING, V25, P419, DOI 10.1016/S0197-4580(03)00127-1; Liu CC, 2017, NEURON, V96, P1024, DOI 10.1016/j.neuron.2017.11.013; Lledo PM, 2004, NEUROSCIENTIST, V10, P292, DOI 10.1177/1073858404263460; Lokensgard JR, 2001, J NEUROVIROL, V7, P208; MACDONALD AB, 1987, HUM PATHOL, V18, P759, DOI 10.1016/S0046-8177(87)80252-6; MANN DMA, 1988, MECH AGEING DEV, V42, P1, DOI 10.1016/0047-6374(88)90058-9; Martin C, 2014, J ALZHEIMERS DIS, V39, P849, DOI 10.3233/JAD-131706; McEwen DP, 2007, P NATL ACAD SCI USA, V104, P15917, DOI 10.1073/pnas.0704140104; MIKLOSSY J, 1994, NEUROREPORT, V5, P1201, DOI 10.1097/00001756-199406020-00010; Miklossy J, 2004, J ALZHEIMERS DIS, V6, P639; MIKLOSSY J, 1996, AZHEIMERS RES, V2, P95; Miklossy J, 2008, J ALZHEIMERS DIS, V13, P381; Miklossy J, 2008, J ALZHEIMERS DIS, V13, P357; Miklossy J, 2016, J ALZHEIMERS DIS, V53, P1459, DOI 10.3233/JAD-160451; Miklossy J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-90; Miklossy Judith, 2008, Handb Clin Neurol, V89, P825, DOI 10.1016/S0072-9752(07)01272-9; Moir RD, 2018, ALZHEIMERS DEMENT, V14, P1602, DOI 10.1016/j.jalz.2018.06.3040; Mori I, 2005, J NEUROVIROL, V11, P129, DOI 10.1080/13550280590922793; Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711; Mossner R, 2000, ADV RES NEURODEGENER, V8, P345; Mouly A.-M., 2011, NEUROBIOLOGY OLFACTI; Mueller A, 2005, J NEURAL TRANSM, V112, P1363, DOI 10.1007/s00702-005-0280-x; Mundinano IC, 2011, ACTA NEUROPATHOL, V122, P61, DOI 10.1007/s00401-011-0830-2; Munster VJ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00736; Murphy C, 1999, PHYSIOL BEHAV, V66, P177, DOI 10.1016/S0031-9384(98)00262-5; MURPHY C, 1990, NEUROBIOL AGING, V11, P465, DOI 10.1016/0197-4580(90)90014-Q; Murphy C., 1994, PSYCHOPHYSICAL ASSES, P609, DOI [10.1007/978-4-431-68355-1_251, DOI 10.1007/978-4-431-68355-1_251]; Murphy C, 2009, ANN NY ACAD SCI, V1170, P647, DOI 10.1111/j.1749-6632.2009.04486.x; Nai Q, 2010, NEUROSCIENCE, V169, P882, DOI 10.1016/j.neuroscience.2010.05.010; Nai Q, 2009, J NEUROPHYSIOL, V101, P2472, DOI 10.1152/jn.91187.2008; Nathan BP, 2005, BRAIN RES, V1041, P87, DOI 10.1016/j.brainres.2005.02.011; Nathan BP, 2007, BRAIN RES, V1137, P78, DOI 10.1016/j.brainres.2006.12.036; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Nicolson GL, 2008, LABMEDICINE, V39, P291, DOI 10.1309/96M3BWYP42L11BFU; Nordin S, 1998, ACTA OTO-LARYNGOL, V118, P226; O'Doherty J, 2003, NEUROPSYCHOLOGIA, V41, P147, DOI 10.1016/S0028-3932(02)00145-8; Okada K., 2014, CELL TISSUE RES, V357, P279; Olofsson JK, 2016, NEUROPSYCHOLOGIA, V85, P1, DOI 10.1016/j.neuropsychologia.2016.03.004; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Parron T, 2011, TOXICOL APPL PHARM, V256, P379, DOI 10.1016/j.taap.2011.05.006; Paskavitz J.F., 1995, J GERIATRIC PSYCNET; Pedro T, 2012, DEMENT GERIATR COGN, V34, P149, DOI 10.1159/000342118; PELOSI P, 1994, CRIT REV BIOCHEM MOL, V29, P199, DOI 10.3109/10409239409086801; Peters JM, 2003, AM J PSYCHIAT, V160, P1995, DOI 10.1176/appi.ajp.160.11.1995; Pisa D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28231-1; Pisa D, 2015, SCI REP-UK, V5, DOI 10.1038/srep15015; Pisa D, 2015, J ALZHEIMERS DIS, V43, P613, DOI 10.3233/JAD-141386; Plailly J, 2008, J NEUROSCI, V28, P5257, DOI 10.1523/JNEUROSCI.5607-07.2008; Plourde JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046605; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Poo C, 2009, NEURON, V62, P850, DOI 10.1016/j.neuron.2009.05.022; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; Poulin SP, 2011, PSYCHIAT RES-NEUROIM, V194, P7, DOI 10.1016/j.pscychresns.2011.06.014; Prinz M, 2017, NAT NEUROSCI, V20, P136, DOI 10.1038/nn.4475; Proskynitopoulos P. J., 2016, SURG NEUROLOGY INT, V7, P263; Purves D., 2001, ODORANT RECEPTORS OL; Purves D., 2001, TRANSDUCTION OLFACTO; Quarmley M, 2017, J ALZHEIMERS DIS, V55, P1497, DOI 10.3233/JAD-160842; Quinn K, 2011, MOL THER, V19, P1990, DOI 10.1038/mt.2011.146; Rahayel S, 2012, BEHAV BRAIN RES, V231, P60, DOI 10.1016/j.bbr.2012.02.047; Readhead B, 2018, NEURON, V99, P64, DOI 10.1016/j.neuron.2018.05.023; Reinvang I., 2012, INT J ALZHEIMERS DIS, DOI [10.1155/2012/936272.2012, DOI 10.1155/2012/936272.2012]; Rennaker RL, 2007, J NEUROSCI, V27, P1534, DOI 10.1523/JNEUROSCI.4072-06.2007; Rey NL, 2018, NEUROBIOL DIS, V109, P226, DOI 10.1016/j.nbd.2016.12.013; Rey NL, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.10.009; Richardson JR, 2014, JAMA NEUROL, V71, P284, DOI 10.1001/jamaneurol.2013.6030; Ridha BH, 2008, J NEUROL, V255, P567, DOI 10.1007/s00415-008-0750-9; Rolls ET, 2003, EUR J NEUROSCI, V18, P695, DOI 10.1046/j.1460-9568.2003.02779.x; RUBERG M, 1986, BRAIN RES, V362, P83, DOI 10.1016/0006-8993(86)91401-0; Rudi A.J., 2014, PET SPECT NEUROLOGY; Saiki K., 1994, OLFACTION TASTE 11, P340, DOI [10.1007/978-4-431-68355-1140, DOI 10.1007/978-4-431-68355-1140]; Saiz-Sanchez D, 2010, EXP NEUROL, V223, P347, DOI 10.1016/j.expneurol.2009.06.010; Saiz-Sanchez D, 2016, EXP NEUROL, V276, P13, DOI 10.1016/j.expneurol.2015.11.009; Saiz-Sanchez D, 2015, BRAIN STRUCT FUNCT, V220, P2011, DOI 10.1007/s00429-014-0771-3; SAPOLSKY RM, 1980, BRAIN BEHAV EVOLUT, V17, P276, DOI 10.1159/000121804; SCHAB FR, 1991, PSYCHOL BULL, V109, P242, DOI 10.1037/0033-2909.109.2.242; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P751, DOI 10.1152/jn.1995.74.2.751; Schrauwen EJA, 2012, J VIROL, V86, P3975, DOI 10.1128/JVI.06828-11; Schubert CR, 2008, J AM GERIATR SOC, V56, P1517, DOI 10.1111/j.1532-5415.2008.01826.x; SCOTT SA, 1992, ANN NEUROL, V32, P555, DOI 10.1002/ana.410320412; Sela L, 2009, J NEUROSCI, V29, P12059, DOI 10.1523/JNEUROSCI.2114-09.2009; Sellati T.J., 1998, J AM ASS IMMNOL; Shi Y, 2018, NAT REV IMMUNOL, V18, P759, DOI 10.1038/s41577-018-0051-1; Shipley SJ, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-48; Simkhovich BZ, 2008, J AM COLL CARDIOL, V52, P719, DOI 10.1016/j.jacc.2008.05.029; SLOTNICK BM, 1990, BRAIN RES, V529, P23, DOI 10.1016/0006-8993(90)90807-N; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Sorg C, 2007, P NATL ACAD SCI USA, V104, P18760, DOI 10.1073/pnas.0708803104; Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Spitzer P, 2016, SCI REP-UK, V6, DOI 10.1038/srep32228; STAUBLI U, 1984, P NATL ACAD SCI-BIOL, V81, P5885, DOI 10.1073/pnas.81.18.5885; Steenland K, 2000, ENVIRON HEALTH PERSP, V108, P293, DOI 10.2307/3454346; Stranahan AM, 2010, NEURAL PLAST, V2010, DOI 10.1155/2010/108190; Strandberg TE, 2003, STROKE, V34, P2126, DOI 10.1161/01.STR.0000086754.32238.DA; Suzuki Y, 2000, EXP NEUROL, V165, P35, DOI 10.1006/exnr.2000.7465; Tabert MH, 2005, ANN NEUROL, V58, P155, DOI 10.1002/ana.20533; Tekin S, 2001, ANN NEUROL, V49, P355, DOI 10.1002/ana.72; TERLAAK HJ, 1994, ALZ DIS ASSOC DIS, V8, P38, DOI 10.1097/00002093-199408010-00007; Tham WWP, 2011, BRAIN COGNITION, V77, P71, DOI 10.1016/j.bandc.2011.05.008; Tham WWP, 2011, NEUROCASE, V17, P148, DOI 10.1080/13554794.2010.504728; Tham WWP, 2009, BRAIN RES REV, V62, P109, DOI 10.1016/j.brainresrev.2009.09.007; Thomann PA, 2009, J ALZHEIMERS DIS, V17, P213, DOI 10.3233/JAD-2009-1036; Tomlinson JJ, 2017, J NEURAL TRANSM, V124, P721, DOI 10.1007/s00702-017-1726-7; Tzeng NS, 2018, NEUROTHERAPEUTICS, V15, P417, DOI 10.1007/s13311-018-0611-x; Van Hoesen GW, 2000, CEREB CORTEX, V10, P243, DOI 10.1093/cercor/10.3.243; Van Oosten MV, 2001, J BIOL CHEM, V276, P8820, DOI 10.1074/jbc.M009915200; van Riel D, 2015, J PATHOL, V235, P277, DOI 10.1002/path.4461; Vasavada MM, 2017, J ALZHEIMERS DIS, V59, P359, DOI 10.3233/JAD-170310; Veldhuizen MG, 2011, CHEM SENSES, V36, P747, DOI 10.1093/chemse/bjr043; Verbeurgt C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096333; VEREECKEN THLG, 1994, NEUROBIOL AGING, V15, P45, DOI 10.1016/0197-4580(94)90143-0; Vogt NM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13601-y; Weinshenker D, 2008, CURR ALZHEIMER RES, V5, P342, DOI 10.2174/156720508784533286; Wesson DW, 2010, J NEUROSCI, V30, P505, DOI 10.1523/JNEUROSCI.4622-09.2010; Wetter S, 2001, NEUROBIOL AGING, V22, P439, DOI 10.1016/S0197-4580(01)00215-9; Wilson DA, 2001, LEARN MEMORY, V8, P279, DOI 10.1101/lm.42601; Wilson DA, 2014, PROG BRAIN RES, V208, P275, DOI 10.1016/B978-0-444-63350-7.00011-5; Wirth S, 1998, BEHAV BRAIN RES, V91, P49, DOI 10.1016/S0166-4328(97)00102-2; Witt M, 2009, MOVEMENT DISORD, V24, P906, DOI 10.1002/mds.22464; Wozniak MA, 2009, J PATHOL, V217, P131, DOI 10.1002/path.2449; Wozniak MA, 2007, NEUROSCI LETT, V429, P95, DOI 10.1016/j.neulet.2007.09.077; Wozniak MA, 2013, J NEUROIMMUNOL, V257, P7, DOI 10.1016/j.jneuroim.2013.01.005; Wozniak MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025152; Xu WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106431; Yang Y, 2001, ACTA NEUROPATHOL, V101, P256; Yasue M, 2015, CURR ALZHEIMER RES, V12, P1006, DOI 10.2174/1567205012666150710105152; Yi HA, 2016, J NEUROL NEUROSUR PS, V87, P425, DOI 10.1136/jnnp-2014-309105; Yin CJ, 2019, NAT MED, V25, P496, DOI 10.1038/s41591-018-0336-8; Yin ZN, 2010, CLIN CHEM LAB MED, V48, P1803, DOI 10.1515/CCLM.2010.354; Yount NY, 2006, BIOPOLYMERS, V84, P435, DOI 10.1002/bip.20543; Zald DH, 1997, P NATL ACAD SCI USA, V94, P4119, DOI 10.1073/pnas.94.8.4119; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001; Zarow C, 2003, ARCH NEUROL-CHICAGO, V60, P337, DOI 10.1001/archneur.60.3.337; Zelano C, 2011, NEURON, V72, P178, DOI 10.1016/j.neuron.2011.08.010; Zhang HL, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/949072; ZIELINSKI BS, 1989, ANAT RECORD, V225, P232, DOI 10.1002/ar.1092250309	294	26	26	2	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1568-1637	1872-9649		AGEING RES REV	Ageing Res. Rev.	NOV	2019	55								100956	10.1016/j.arr.2019.100956			15	Cell Biology; Geriatrics & Gerontology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Cell Biology; Geriatrics & Gerontology	JF8MJ	WOS:000491638300009	31479764	Green Submitted			2022-02-06	
J	Rich, AM; Filben, TM; Miller, LE; Tomblin, BT; Van Gorkom, AR; Hurst, MA; Barnard, RT; Kohn, DS; Urban, JE; Stitzel, JD				Rich, Andrea M.; Filben, Tanner M.; Miller, Logan E.; Tomblin, Brian T.; Van Gorkom, Aaron R.; Hurst, Michael A.; Barnard, Ryan T.; Kohn, Dena S.; Urban, Jillian E.; Stitzel, Joel D.			Development, Validation and Pilot Field Deployment of a Custom Mouthpiece for Head Impact Measurement	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Mouthpiece; Soccer; Pediatric; Subconcussive impacts; Concussion; Instrumentation; Head impact exposure; Head kinematics	ACCELERATION MEASUREMENT; LABORATORY EVALUATION; SYSTEM; CONCUSSIONS; KINEMATICS; MOUTHGUARD; SCENARIO; DEVICE	The objective of this study was to develop a mouthpiece sensor with improved head kinematic measurement for use in non-helmeted and helmeted sports through laboratory validation and pilot field deployment in female youth soccer. For laboratory validation, data from the mouthpiece sensor was compared to standard sensors mounted in a headform at the center of gravity as the headform was struck with a swinging pendulum. Linear regression between peak kinematics measured from the mouthpiece and headform showed strong correlation, with r(2) values of 0.95 (slope = 1.02) for linear acceleration, 1.00 (slope = 1.00) for angular velocity, and 0.97 (slope = 0.96) for angular acceleration. In field deployment, mouthpiece data were collected from four female youth soccer players and time-synchronized with film. Film-verified events (n = 915) were observed over 9 practices and 5 games, and 632 were matched to a corresponding mouthpiece event. This resulted in an overall sensitivity of 69.2% and a positive predictive value of 80.3%. This validation and pilot field deployment data demonstrates that the mouthpiece provides highly accurate measurement of on-field head impact data that can be used to further study the effects of impact exposure in both helmeted and non-helmeted sports.	[Rich, Andrea M.; Filben, Tanner M.; Miller, Logan E.; Tomblin, Brian T.; Van Gorkom, Aaron R.; Barnard, Ryan T.; Kohn, Dena S.; Urban, Jillian E.; Stitzel, Joel D.] Wake Forest Sch Med, Dept Biomed Engn, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27101 USA; [Rich, Andrea M.; Filben, Tanner M.; Miller, Logan E.; Tomblin, Brian T.; Van Gorkom, Aaron R.; Urban, Jillian E.; Stitzel, Joel D.] Wake Forest Univ, Sch Biomed Engn & Sci, Virginia Tech, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27101 USA; [Barnard, Ryan T.] Wake Forest Sch Med, Dept Biostat & Data Sci, 525 Vine St, Winston Salem, NC 27101 USA; [Hurst, Michael A.] Hurst Dent Lab, 946 Brookstown Ave, Winston Salem, NC 27101 USA		Stitzel, JD (corresponding author), Wake Forest Sch Med, Dept Biomed Engn, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27101 USA.	jstitzel@wakehealth.edu		Filben, Tanner/0000-0002-2572-0093; Stitzel, Joel/0000-0001-9762-3033	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091602-01A1, R01NS082453, R01NS094410]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082453, R01NS094410, R01NS091602] Funding Source: NIH RePORTER	The authors thank the Virginia Tech Helmet Lab for their assistance in conducting the laboratory validation tests. They would also like to thank Konstantia Strates for her efforts in study coordination. Special thanks to the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center for providing support for this study. The National Institute of Neurological Disorders and Stroke of the National Institutes of Health, through Award Numbers R01NS091602-01A1, R01NS082453 and R01NS094410, supported members of the research team who contributed to this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The mouthpiece technology presented herein is patent pending.	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Chrisman SPD, 2019, CLIN J SPORT MED, V29, P3, DOI 10.1097/JSM.0000000000000497; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Covassin T, 2003, J ATHL TRAINING, V38, P238; Engineers S. O. A., 1995, INSTR IMP TEST 1; FIFA, 2007, FIFA BIG COUNT 2006 FIFA BIG COUNT 2006; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harriss A, 2019, MUSCULOSKEL SCI PRAC, V40, P53, DOI 10.1016/j.msksp.2019.01.009; Higgins M, 2007, J ATHL TRAINING, V42, P5; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Lamond LC, 2018, J ATHL TRAINING, V53, P115, DOI 10.4085/1062-6050-90-17; Lightman K, 2016, IEEE SPECTRUM, V53, P48, DOI 10.1109/MSPEC.2016.7420400; Mainwaring L, 2018, INT J PSYCHOPHYSIOL, V132, P39, DOI 10.1016/j.ijpsycho.2018.01.007; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Miller L., 2019, RES SPORTS MED, DOI [10.1080/15438627.2019.159083, DOI 10.1080/15438627.2019.159083]; Miller LE, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4039165; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Nevins D, 2015, PROCEDIA ENGINEER, V112, P175, DOI 10.1016/j.proeng.2015.07.195; O'Kane JW, 2016, PHYSICIAN SPORTSMED, V44, P190, DOI 10.1080/00913847.2016.1149423; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Rowson S., 2017, P I MECH ENG P-J SPO, DOI [10.1177/1754337, DOI 10.1177/1754337]; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Self BP, 2006, ENG SPORT 6, V6, P81; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Stewart WF, 2017, NEUROLOGY, V88, P901, DOI 10.1212/WNL.0000000000003657; Triax Technologies, 2014, LAB VAL SIM G HEAD I; Tyson AM, 2018, J APPL BIOMECH, V34, P320, DOI 10.1123/jab.2017-0256; Wu LC, 2016, J BIOMECH, V49, P2918, DOI 10.1016/j.jbiomech.2016.07.004; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153; Yang YT, 2016, JAMA PEDIATR, V170, P413, DOI 10.1001/jamapediatrics.2016.0338; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029	42	26	26	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2019	47	10			SI		2109	2121		10.1007/s10439-019-02313-1			13	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	JQ0HT	WOS:000498636800007	31297724				2022-02-06	
J	Zheng, JJ; Dai, QX; Han, KY; Hong, WD; Jia, DY; Mo, YC; Lv, Y; Tang, HL; Fu, HX; Geng, WJ				Zheng, Jianjian; Dai, Qinxue; Han, Kunyuan; Hong, Wandong; Jia, Danyun; Mo, Yunchang; Lv, Ya; Tang, Hongli; Fu, Hongxing; Geng, Wujun			JNK-IN-8, a c-Jun N-terminal kinase inhibitor, improves functional recovery through suppressing neuroinflammation in ischemic stroke	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article						ischemia brain injury; JNK; JNK-IN-8; neuroinflammation; NF-kappa B	NEGATIVE BREAST-CANCER; INJURY; INFLAMMATION; ACTIVATION; AUTOPHAGY; PATHWAY; CELLS	C-Jun N-terminal kinase (JNK) is a pivotal MAPK (mitogen-activated protein kinase), which activated by ischemia brain injury and plays a fairly crucial function in cerebral ischemic injury. Emerging studies demonstrated that JNK-IN-8 (a JNK inhibitor with high specificity) regulates traumatic brain injury through controlling neuronal apoptosis and inflammation. However, the function of JNK-IN-8 in ischemic stroke and the mechanisms underlying of JNK-IN-8 about neuroprotection are not well understood. In this work, male rats were treated with JNK-IN-8 after transient middle cerebral artery occlusion, and then the modified improved neurological function score (mNSS), the foot-fault test (FFT), interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) levels were assessed. We found that JNK-IN-8-treated rats with MCAO exerted an observable melioration in space learning as tested by the improved mNSS, and showed sensorimotor functional recovery as measured by the FFT. JNK-IN-8 also played anti-inflammatory roles as indicated through decreased activation of microglia and decreased IL-6, IL-1 beta, and TNF-alpha expression. Furthermore, JNK-IN-8 suppressed the activation of JNK and nuclear factor-kappa B (NF-kappa B) signaling as indicated by the decreased level of phosphorylated-JNK and p65. All data demonstrate that JNK-IN-8 inhibits neuroinflammation and improved neurological function by inhibiting JNK/NF-kappa B and is a promising agent for the prevention of ischemic brain injury.	[Zheng, Jianjian] Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Di, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Dai, Qinxue; Han, Kunyuan; Jia, Danyun; Mo, Yunchang; Lv, Ya; Tang, Hongli; Geng, Wujun] Wenzhou Med Univ, Dept Anesthesiol, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China; [Hong, Wandong] Wenzhou Med Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Fu, Hongxing] Wenzhou Med Univ, Sch Pharmaceut, Wenzhou, Zhejiang, Peoples R China		Tang, HL; Geng, WJ (corresponding author), Wenzhou Med Univ, Dept Anesthesiol, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.; Fu, HX (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325000, Zhejiang, Peoples R China.	tanghongli@wzhospital.cn; fuhongxing@wmu.edu.cn; gengwujun@wzhospital.cn		Geng, Wujun/0000-0001-5599-3036	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81603685, 81704180, 81774109, 81973620]; Zhejiang Basic Public Welfare Research Project [GD20H290004]; Wenzhou Science and Technology Plan Project [Y20180496]	National Natural Science Foundation of China, Grant/Award Numbers: 81603685, 81704180, 81774109, 81973620; Zhejiang Basic Public Welfare Research Project, Grant/Award Number: GD20H290004; Wenzhou Science and Technology Plan Project, Grant/Award Number: Y20180496	Amouyel P, 2012, LANCET NEUROL, V11, P931, DOI 10.1016/S1474-4422(12)70235-1; Atochin DN, 2016, NEUROSCI LETT, V618, P45, DOI 10.1016/j.neulet.2016.02.033; Burton MD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-54; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2018, METABOLISM, V83, P256, DOI 10.1016/j.metabol.2018.03.004; Chen YR, 2000, INT J ONCOL, V16, P651; Choudhury S, 2015, FREE RADICAL RES, V49, P1371, DOI 10.3109/10715762.2015.1075016; Ebelt ND, 2017, ONCOTARGET, V8, P104894, DOI 10.18632/oncotarget.20581; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Guan QH, 2006, BRAIN RES, V1092, P36, DOI 10.1016/j.brainres.2006.03.086; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; Jiang J, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00363; Jin R, 2013, J CARDIOVASC TRANSL, V6, P834, DOI 10.1007/s12265-013-9508-6; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Ramesh G., 2014, CELL SIGNAL, V1, pe111, DOI 10.14800/ics.111; Simmons LJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0703-7; Utsugi M, 2003, J IMMUNOL, V171, P628, DOI 10.4049/jimmunol.171.2.628; Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014; Xie X, 2017, ONCOGENE, V36, P2599, DOI 10.1038/onc.2016.417; Yilmaz G, 2008, NEUROL RES, V30, P783, DOI 10.1179/174313208X341085; Yu J, 2018, EXP NEUROL, V307, P12, DOI 10.1016/j.expneurol.2018.05.022; Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhou XG, 2011, BIOCHEM BIOPH RES CO, V411, P271, DOI 10.1016/j.bbrc.2011.06.117; Zhu YP, 2019, EXP PHYSIOL, V104, P837, DOI 10.1113/EP087656	25	26	28	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	MAR	2020	235	3					2792	2799		10.1002/jcp.29183		SEP 2019	8	Cell Biology; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Physiology	OZ4PU	WOS:000487514000001	31541462	Green Published, Green Submitted, hybrid			2022-02-06	
J	Yin, B; Li, DD; Huang, H; Gu, CH; Bai, GH; Hu, LX; Zhuang, JF; Zhang, M				Yin, Bo; Li, Dan-Dong; Huang, Huan; Gu, Cheng-Hui; Bai, Guang-Hui; Hu, Liu-Xun; Zhuang, Jin-Fei; Zhang, Ming			Longitudinal Changes in Diffusion Tensor Imaging Following Mild Traumatic Brain Injury and Correlation With Outcome	FRONTIERS IN NEURAL CIRCUITS			English	Article						mild traumatic brain injury; diffusion tensor imaging; longitudinal changes; fractional anisotropy; neuropsychological test	AXONAL INJURY; MULTIPLE-SCLEROSIS; RECOVERY; SEGMENTATION; DAMAGE; MODEL; TIME	The chronic consequences of traumatic brain injury (TBI) may contribute to the increased risk for early cognitive decline and dementia, primarily due to diffusion axonal injury. Previous studies in mild TBI (mTBI) have been controversial in describing the white matter tract integrity changes occurring at acute and subacute post-injury. In this prospective longitudinal study, we aim to investigate the longitudinal changes of white matter (WM) using diffusion tensor imaging (DTI) and their correlations with neuropsychological tests. Thirty-three patients with subacute mTBI and 31 matched healthy controls were studied with an extensive imaging and clinical battery. Neuroimaging was obtained within 7 days post-injury for acute scans and repeated at 1 and 3 months post-injury. Using a region-of-interest-based approach, tract-based spatial statistics was used to conduct voxel-wise analysis on diffusion changes in mTBI and was compared to those of healthy matched controls, scanned during the same time period and rescanned with an interval similar to that of patients. We found decreased fractional anisotropy (FA) values in the left anterior limb of internal capsule (ALIC) and right inferior fronto-occipital fasciculus (IFOF) during the 7 days post-injury, which showed longitudinal evidence of recovery following 1 month post-injury. Increased FA values in these two tracts at 1 month post-injury were positively associated with better performance on cognitive information processing speed at initial assessment. By contrast, there were also some tracts (right anterior corona radiata, forceps major, and body of corpus callosum) exhibiting the continuing loss of integrity sustaining even beyond 3 months, which can predict the persisting post-concussion syndromes. Continuing loss of structural integrity in some tracts may contribute to the persistent post-concussion syndromes in mTBI patients, suggesting certain tracts providing an objective biomarker for tracking the pathological recovery process following mTBI.	[Yin, Bo; Zhang, Ming] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Imaging, Xian, Shaanxi, Peoples R China; [Yin, Bo; Li, Dan-Dong; Gu, Cheng-Hui; Hu, Liu-Xun] Wenzhou Med Univ, Dept Neurosurg, Affiliated Hosp 2, Wenzhou, Peoples R China; [Yin, Bo; Li, Dan-Dong; Huang, Huan; Gu, Cheng-Hui; Bai, Guang-Hui; Hu, Liu-Xun; Zhuang, Jin-Fei] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China; [Huang, Huan; Bai, Guang-Hui] Wenzhou Med Univ, Dept Radiol, Affiliated Hosp 2, Wenzhou, Peoples R China; [Zhuang, Jin-Fei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Rehabil Med, Wenzhou, Peoples R China		Zhang, M (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Imaging, Xian, Shaanxi, Peoples R China.	zhangming01@mail.xjtu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571640]; Zhejiang Natural Science FoundationNatural Science Foundation of Zhejiang Province [LY15H090016]; Wenzhou Municipal Sci-Tech Bureau [Y20140577]	This research was supported by the National Natural Science Foundation of China under Grant No. 81571640, the Zhejiang Natural Science Foundation (Grant No. LY15H090016), and Wenzhou Municipal Sci-Tech Bureau (Y20140577).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; ARNETT JA, 1995, PSYCHOL ASSESSMENT, V7, P220; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baxendale S, 2005, EPILEPSY BEHAV, V6, P207, DOI 10.1016/j.yebeh.2004.12.009; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Churchill NW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07742-3; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Harman-Smith YE, 2013, J CLIN EXP NEUROPSYC, V35, P785, DOI 10.1080/13803395.2013.824554; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; Khong E, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00156; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Martino J, 2010, CORTEX, V46, P691, DOI 10.1016/j.cortex.2009.07.015; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Meier TB, 2016, HUM BRAIN MAPP, V37, P833, DOI 10.1002/hbm.23072; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valverde S, 2015, NEUROIMAGE-CLIN, V9, P640, DOI 10.1016/j.nicl.2015.10.012; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	50	26	28	2	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5110			FRONT NEURAL CIRCUIT	Front. Neural Circuits	MAY 7	2019	13								28	10.3389/fncir.2019.00028			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HW9DP	WOS:000466991200001	31133818	Green Published, gold			2022-02-06	
J	Morales-Gomez, JA; Garcia-Estrada, E; Leos-Bortoni, JE; Delgado-Brito, M; Flores-Huerta, LE; De la Cruz-Arriaga, AA; Torres-Diaz, LJ; de Leon, ARMP				Morales-Gomez, Jesus A.; Garcia-Estrada, Everardo; Leos-Bortoni, Jorge E.; Delgado-Brito, Miriam; Flores-Huerta, Luis E.; De la Cruz-Arriaga, Adriana A.; Torres-Diaz, Luis J.; Martinez-Ponce de Leon, Angel R.			Cranioplasty with a low-cost customized polymethylmethacrylate implant using a desktop 3D printer	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; custom polymethylmethacrylate mold; 3D printing; surgical technique	PATIENT-SPECIFIC IMPLANTS; POLYETHER ETHER KETONE; LARGE CRANIAL DEFECTS; BONE FLAP; METHACRYLATE CRANIOPLASTY; ACRYLIC CRANIOPLASTY; PMMA CRANIOPLASTY; RECONSTRUCTION	OBJECTIVE Cranioplasty implants should be widely available, low in cost, and customized or easy to mold during surgery. Although autologous bone remains the first choice for repair, it cannot always be used due to infection, fragmentation, bone resorption, or other causes, which led to use of synthetic alternatives. The most frequently used allogenic material for cranial reconstructions with long-term results is polymethylmethacrylate (PMMA). Three-dimensional printing technology has allowed the production of increasingly popular customized, prefabricated implants. The authors describe their method and experience with a customized PMMA prosthesis using a precise and reliable low-cost implant that can be customized at any institution with open-source or low-cost software and desktop 3D printers. METHODS A review of 22 consecutive patients undergoing CT-based, low-cost, customized PMMA cranioplasty over a 1-year period at a university teaching hospital was performed. Preoperative data included patient sex and age; CT modeling parameters, including the surface area of the implant (defect); reason for craniectomy; date(s) of injury and/or resections; the complexity of the defect; and associated comorbidities. Postoperative data included morbiditiy and complications, such as implant exposure, infection, hematoma, seroma, implant failure, and seizures; the cost of the implant; and cosmetic outcome. RESULTS Indications for the primary craniectomy were traumatic brain injury (16, 73%), tumor resection (3, 14%), infection (1, 4%), and vascular (2, 9%). The median interval between previous surgery and PMMA cranioplasty was 12 months. The operation time ranged from 90 to 150 minutes (mean 126 minutes). The average cranial defect measured 65.16 cm(2) (range 29.31-131.06 cm(2)). During the recovery period, there was no sign of infection, implant rejection, or wound dehiscence, and none of the implants had to be removed over a follow-up ranging from 1 to 6 months. The aesthetic appearance of all patients was significantly improved, and the implant fit was excellent. CONCLUSIONS The use of a customized PMMA was associated with excellent patient, family, and surgeon satisfaction at follow-up at a fraction of the cost associated with commercially available implants. This technique could be an attractive option to all patients undergoing cranioplasty.	[Morales-Gomez, Jesus A.; Garcia-Estrada, Everardo; Leos-Bortoni, Jorge E.; Delgado-Brito, Miriam; Flores-Huerta, Luis E.; De la Cruz-Arriaga, Adriana A.; Torres-Diaz, Luis J.; Martinez-Ponce de Leon, Angel R.] Hosp Univ Dr Jose Eleuterio Gonzalez, Dept Neurosurg, Monterrey, Nuevo Leon, Mexico		Morales-Gomez, JA (corresponding author), Hosp Univ Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo Leon, Mexico.	jesus.moralesg@uanl.mx	Garcia-Estrada, Everardo/AAA-7401-2019	Garcia-Estrada, Everardo/0000-0002-8773-1230			Akan M, 2011, J CRANIOFAC SURG, V22, P1236, DOI 10.1097/SCS.0b013e31821c0f34; Anchieta MVM, 2016, INT J COMPUT ASS RAD, V11, P1919, DOI 10.1007/s11548-016-1415-2; Bauermeister AJ, 2016, ANN PLAS SURG, V77, P569, DOI 10.1097/SAP.0000000000000671; Bhargava D, 2010, ACTA NEUROCHIR, V152, P173, DOI 10.1007/s00701-009-0394-2; BONFIELD CM, 2014, NEUROSURG FOCUS, V36; Brandicourt P, 2017, WORLD NEUROSURG, V105, P783, DOI 10.1016/j.wneu.2017.04.049; Caro-Osorio Enrique, 2013, Surg Neurol Int, V4, P136, DOI 10.4103/2152-7806.119535; Chae MP, 2015, FRONT SURG, V2, DOI 10.3389/fsurg.2015.00025; Eppley BL, 2005, J CRANIOFAC SURG, V16, P140, DOI 10.1097/00001665-200501000-00028; Feroze AH, 2015, J NEUROSURG, V123, P1098, DOI 10.3171/2014.11.JNS14622; Fiaschi P, 2016, J NEUROSURG-PEDIATR, V17, P705, DOI 10.3171/2015.10.PEDS15489; Fischer CM, 2012, NEUROL RES, V34, P281, DOI 10.1179/1743132812Y.0000000007; Gurdjian ES, 1943, SURGERY, V14, P876; Hanasono MM, 2009, ANN PLAS SURG, V62, P653, DOI 10.1097/SAP.0b013e318184abc7; Harris DA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13560; Huang GJ, 2015, J CRANIOFAC SURG, V26, P68, DOI 10.1097/SCS.0000000000001315; Jaberi J, 2013, J ORAL MAXIL SURG, V71, pE81, DOI 10.1016/j.joms.2012.09.023; Kung WM, 2012, BRAIN INJURY, V26, P1737, DOI 10.3109/02699052.2012.698361; Lethaus B, 2014, J CRANIO MAXILL SURG, V42, P1948, DOI 10.1016/j.jcms.2014.08.006; Manrique OJ, 2015, J CRANIOFAC SURG, V26, P663, DOI 10.1097/SCS.0000000000001443; Marbacher S, 2013, WORLD NEUROSURG, V79, P124, DOI 10.1016/j.wneu.2011.05.057; Marbacher S, 2012, NEUROSURG REV, V35, P527, DOI 10.1007/s10143-012-0376-3; Naftulin JS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136198; O'Reilly EB, 2015, J PLAST RECONSTR AES, V68, P329, DOI 10.1016/j.bjps.2014.11.001; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenthal G, 2014, NEUROSURGERY, V75, P523, DOI 10.1227/NEU.0000000000000477; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Sharavanan GM, 2015, J MAXILLOFAC ORAL SU, V14, P378, DOI 10.1007/s12663-014-0670-4; Tan ETW, 2016, J NEUROSURG, V124, P1531, DOI 10.3171/2015.5.JNS15119; Unterhofer C, 2017, NEUROL NEUROCHIR POL, V51, P214, DOI 10.1016/j.pjnns.2017.02.007; Werndle MC, 2012, CLIN NEUROL NEUROSUR, V114, P962, DOI 10.1016/j.clineuro.2012.02.019; 2017, WORLD NEUROSURG, V105, P971; 2013, J NEUROSCI RURAL PRA, V4, P471	33	26	26	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2019	130	5					1721	1727		10.3171/2017.12.JNS172574			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HW0VW	WOS:000466401100037	29905512	Bronze			2022-02-06	
J	Voormolen, DC; Polinder, S; von Steinbuechel, N; Vos, PE; Cnossen, MC; Haagsma, JA				Voormolen, Daphne C.; Polinder, Suzanne; von Steinbuechel, Nicole; Vos, Pieter E.; Cnossen, Maryse C.; Haagsma, Juanita A.			The association between post-concussion symptoms and health-related quality of life in patients with mild traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Quality of life; Post-concussion syndrome; Rivermead post-concussion symptoms questionnaire; SF-36	SEVERITY SCORE; PREDICTORS; QUESTIONNAIRE; CONSEQUENCES; MODERATE; ADULTS; IMPACT; DUTCH	A subset of mild traumatic brain injury (mTBI) patients experience post-concussion symptoms. When a cluster of post-concussion symptoms persists for over three months, it is referred to as post-concussion syndrome (PCS). Little is known about the association between PCS and Health-Related Quality of Life (HRQoL) after mTBI. The aims of this study were to assess the implications of PCS on HRQoL six months after mTBI and the relationship between PCS and HRQoL domains. A prospective observational cohort study was conducted among a sample of mTBI patients. Follow-up postal questionnaires at six months after emergency department (ED) admission included socio-demographic information, the Rivermead Post-Concussion Symptoms Questionnaire (RPQ), and HRQoL measured with the 36-item Short-Form Health Survey (SF-36) and the Perceived Quality of Life Scale (PQoL). In total, 731 mTBI patients were included, of whom 38.7% were classified as suffering from PCS. Patients with PCS had significantly lower scores on all SF-36 domains, lower physical and mental component summary scores and lower mean PQoL scores compared to patients without PCS. All items of the RPQ were negatively correlated to all SF-36 domains and PQoL subscale scores, indicating that reporting problems on any of the RPQ symptoms was associated with a decrease on different aspects of an individuals' HRQoL. To conclude, PCS is common following mTBI and patients with PCS have a considerably lower HRQoL. A better understanding of the relationship between PCS and HRQoL and possible mediating factors in this relationship could improve intervention strategies, the recovery process for mTBI patients and benchmarking. (C) 2018 Elsevier Ltd. All rights reserved.	[Voormolen, Daphne C.; Polinder, Suzanne; Cnossen, Maryse C.; Haagsma, Juanita A.] Erasmus Univ, Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands; [von Steinbuechel, Nicole] Georg August Univ, Inst Med Psychol & Med Sociol, Gottingen, Germany; [Vos, Pieter E.] Slingeland Hosp, Dept Neurol, POB 169, NL-7000 AD Doetinchem, Netherlands; [Haagsma, Juanita A.] Erasmus Univ, Med Ctr, Dept Emergency Med, Rotterdam, Netherlands; [von Steinbuechel, Nicole] Univ Med Ctr Gottingen, Inst Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany		Voormolen, DC (corresponding author), Erasmus Univ, Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.voormolen@erasmusmc.nl; s.polinder@erasmusmc.nl; nvsteinbuechel@med.uni-goettingen.de; p.vos@slingeland.nl; m.c.cnossen@erasmusmc.nl; j.haagsma@erasmusmc.nl			European UnionEuropean Commission [602150]; National Institutes of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086090]	The paper has been written in the context of the CENTER-TBI project. CENTER-TBI has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no 602150. TRACK-TBI has received funding from the National Institutes of Neurologic Disorders and Stroke, grant no U01 NS086090. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; American Congress of Rehabilitation Medicine (ACRM), 1993, DEF MILD TRAUM BRAIN; [Anonymous], 2000, AM PSYCH ASS DIAGN S; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Cnossen MC, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0641-9; COHEN J, 1988, APPL PSYCH MEAS, V12, P425, DOI 10.1177/014662168801200410; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hiploylee C., 2016, J NEUROTRAUMA; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; King NS, 2013, BRAIN IMPAIR, V14, P235, DOI 10.1017/BrImp.2013.17; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Scholten AC, 2017, POPUL HEALTH METR, V15, DOI 10.1186/s12963-017-0127-3; Seattle Quality of Life Group, 2008, INF SHEET PERC QUAL; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; von Steinbuechel N, 2016, BEHAV NEUROL, V2016, DOI 10.1155/2016/7928014; Voormolen DC, 2018, J NEUROTRAUM, V35, P1233, DOI 10.1089/neu.2017.5257; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Ware JE, 1994, BOSTON SF 36 PHYS ME; Ware JE, 1993, BOSTON SF 36 HLTH SU; World Health Organization, 1993, ICD 10 CLASS MENT BE; 2010, J NEUROTRAUM, V27, P2173, DOI DOI 10.1089/NEU.2010.1353	40	26	26	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2019	50	5					1068	1074		10.1016/j.injury.2018.12.002			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	HX6UG	WOS:000467538200012	30554897				2022-02-06	
J	Elkin, BS; Gabler, LF; Panzer, MB; Siegmund, GP				Elkin, Benjamin S.; Gabler, Lee F.; Panzer, Matthew B.; Siegmund, Gunter P.			Brain tissue strains vary with head impact location: A possible explanation for increased concussion risk in struck versus striking football players	CLINICAL BIOMECHANICS			English	Article						Football; Brain; Finite element model; Concussion	FINITE-ELEMENT MODEL; PROFESSIONAL FOOTBALL; INJURY; RESPONSES; SEVERITY; VALIDATION; CRITERIA; SPORTS	Background: On-field football helmet impacts over a large range of severities have caused concussions in some players but not in other players. One possible explanation for this variability is the struck player's helmet impact location. Methods: We examined the effect of impact location on regional brain tissue strain when input energy was held constant. Laboratory impacts were performed at 12 locations distributed over the helmet and the resulting head kinematics were simulated in two finite element models of the brain: the Simulated Injury Monitor and the Global Human Body Model Consortium brain model. Findings: Peak kinematics, injury metrics and brain strain varied significantly with impact location. Differences in impact location explained 33 to 37% of the total variance in brain strain for the whole brain and cerebrum, considerably more than the variance explained by impact location for the peak resultant head kinematics (8 to 23%) and slightly more than half of the variance explained by the difference in closing speed (57 to 61%). Both finite element models generated similar strain results, with minor variations for impacts that generated multiaxial rotations, larger variations in brainstem strains for some impact locations and a small bias for the cerebellum. Interpretation: Based on this experimental and computational simulation study, impact location on the football helmet has a large effect on regional brain tissue strain. We also found that the lowest strains consistently occurred in impacts to the crown and forehead, helmet locations commonly associated with the striking player.	[Elkin, Benjamin S.] MEA Forens Engineers & Scientists, Toronto, ON, Canada; [Gabler, Lee F.; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, Charlottesville, VA USA; [Siegmund, Gunter P.] MEA Forens Engineers & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada; [Siegmund, Gunter P.] Univ British Columbia, Sch Kinesiol, Vancouver, BC, Canada; [Elkin, Benjamin S.] MEA Forens Engineers & Scientists Ltd, 22 Voyager Court South, Toronto, ON, Canada; [Gabler, Lee F.; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA		Siegmund, GP (corresponding author), MEA Forens Engineers & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada.	gunter.siegmund@meaforensic.com	Siegmund, Gunter P/B-7003-2013	Siegmund, Gunter/0000-0003-2387-941X			Adams J, 1987, P 31 STAPP CAR CRASH, V96, P1355, DOI DOI 10.4271/872197; Bandak F.A., 1994, SAE T, V103, P1708, DOI DOI 10.4271/942215; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Eckner JT, 2014, AM J SPORT MED, V42, P566, DOI 10.1177/0363546513517869; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hodgson V. R., 1983, 831618 SAE, DOI [10.4271/831618, DOI 10.4271/831618]; Holbourn AHS, 1943, LANCET, V2, P438; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Jin X, 2017, J BIOMECH ENG-T ASME, V139, DOI 10.1115/1.4037399; Kleiven, 2005, P IRCOBI C PRAG CZEC, P21; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; Miller LE, 2017, COMPUT METHOD BIOMEC, V20, P1273, DOI 10.1080/10255842.2017.1340462; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Siegmund GP, 2014, ANN BIOMED ENG, V42, P1834, DOI 10.1007/s10439-014-1052-2; Takhounts E. G., 2011, P 22 ENH SAF VEH C; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viceconti M, 2005, CLIN BIOMECH, V20, P451, DOI 10.1016/j.clinbiomech.2005.01.010; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Wonnacott M., 2010, 2010010136 SAE; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhao W, 2015, IRCOBI C LYON FRANC, P208	40	26	26	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0268-0033	1879-1271		CLIN BIOMECH	Clin. Biomech.	APR	2019	64				SI		49	57		10.1016/j.clinbiomech.2018.03.021			9	Engineering, Biomedical; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Orthopedics; Sport Sciences	HY6ON	WOS:000468249700008	29625747				2022-02-06	
J	Cardoso, MGD; Faleiro, RM; de Paula, JJ; Kummer, A; Caramelli, P; Teixeira, AL; de Souza, LC; Miranda, AS; Silva, AP; Campos, ABB; Costa, CC; Antonio, CP; Loures, DLEM; Ponte, EF; Guarconi, FV; Barbosa, GRM; Miranda, INS; Queiroz, JC; Salomao, LG; Oliveira, MD; Nassif, MCL; Valadao, MB; Moura, MVB; Rodrigues, OF; Leal, PIL; Diamantino, TC; Araujo, LS; Furlan, TD; da Silva, EWM; Roque, IG; da Silva, AN				de Freitas Cardoso, Maira Gloria; Faleiro, Rodrigo Moreira; de Paula, Jonas Jardim; Kummer, Arthur; Caramelli, Paulo; Teixeira, Antonio Lucio; de Souza, Leonardo Cruz; Miranda, Aline Silva; Silva, Ananda Peixoto; Bacilar Campos, Antonio Bernardes; Costa, Camila Carvalhais; Antonio, Christian Pereira; Lanna e Melo Loures, Daniela; Ponte, Eduarda Felix; Guarconi, Felipe Vieira; Mansur Barbosa, Guilherme Ribeiro; Santos Miranda, Ilanna Naoli; Queiroz, Jordana Campos; Salomao, Leonardo Gomes; Oliveira, Monteiro de Souza; Landim Nassif, Maria Cecilia; Valadao, Mariana Braga; Brandao Moura, Millena Vieira; Rodrigues, Otavio Fonseca; Lodde Leal, Pedro Ilenrique; Diamantino, Tatiana Costa; Araujo, Leticia Siqueira; Furlan, Thiago de Oliveira; Machado da Silva, Ewelin Wasner; Roque, Isadora Goncalves; da Silva, Alessandra Noronha		Minas Gerais Traumatic Brain Injur	Cognitive Impairment Following Acute Mild Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; cognitive impairment; loss of consciousness; Brazilian patients; episodic memory	MINI-MENTAL-STATE; NEUROPSYCHOLOGICAL OUTCOMES; CONSCIOUSNESS; ASSOCIATION; CONCUSSION; SYMPTOMS; HISTORY; RESERVE; STRESS	Patients with mild traumatic brain injury (mTBI) may present cognitive deficits within the first 24 h after trauma, herein called "acute phase," which in turn may lead to long-term functional impairment and decrease in quality of life. Few studies investigated cognition in mTBI patients during the acute phase. The objectives of this study were to investigate the cognitive profile of patients with mTBI during the acute phase, compared to controls and normative data, and whether loss of consciousness (LOC), previous TBI and level of education influence cognition at this stage. Fifty-three patients with mTBI (aged 19-64 years) and 28 healthy controls participated in the study. All patients were evaluated at bedside within 24 h post-injury. Demographic and clinical data were registered. Cognitive function was assessed with the Mini-mental state examination (MMSE), the Frontal Assessment Battery (FAB), Digit Span (working memory), and the Visual Memory Test/Brief Cognitive Battery (for episodic memory). The clinical sample was composed mainly by men (58.5%). The mean age was 39 years-old and 64.3% of the patients had more than 8 years of education. The most common causes of mTBI were fall from own height (28.3%), aggression (24.5%), and fall from variable heights (24.5%). Compared to controls, mTBI patients exhibited significantly worse performance on MMSE, FAB, naming, incidental memory, immediate memory, learning, and delayed recall. Compared to normative data, 26.4% of patients had reduced global cognition as measured by the MMSE. Episodic memory impairment (13.2%) was more frequent than executive dysfunction (9.4%). No significant differences were found in cognitive performance when comparing patients with or without LOC or those with or without history of previous TBI. Patients with lower educational level had higher rates of cognitive impairment (VMT naming-28.6 vs. 4.2%; VMT immediate memory-32 vs. 4.2%; VMT learning-39.3 vs. 4.2%, all p < 0.05). In sum, we found significant cognitive impairment in the acute phase of mTBI, which was not associated with LOC or history of TBI, but appeared more frequently in patients with lower educational level.	[de Freitas Cardoso, Maira Gloria] Univ Fed Minas Gerais, Lab Interdisciplinar Invest Med, Neurosci Program, Belo Horizonte, MG, Brazil; [Faleiro, Rodrigo Moreira] Fundacao Hosp Estado Minas Gerais, Fac Ciencias Med Minas Gerais, Belo Horizonte, MG, Brazil; [de Paula, Jonas Jardim] Fac Ciencias Med Minas Gerais, Belo Horizonte, MG, Brazil; [Kummer, Arthur] Eli Lilly & Co Brasil, Lab Interdisciplinar Invest Med, Sao Paulo, Brazil; [Caramelli, Paulo] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Belo Horizonte, MG, Brazil; [Teixeira, Antonio Lucio] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Psychiat & Behav Sci, Santa Casa BH Ensino & Pesquisa Neuropsychiat Pro, Houston, TX 77030 USA; [de Souza, Leonardo Cruz] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Lab Interdisciplinar Invest Med, Belo Horizonte, MG, Brazil; [Miranda, Aline Silva] Univ Fed Minas Gerais, Fac Med, Lab Interdisciplinar Invest Med, Belo Horizonte, MG, Brazil; [Miranda, Aline Silva] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Lab Neurobiol, Belo Horizonte, MG, Brazil		Miranda, AS (corresponding author), Univ Fed Minas Gerais, Fac Med, Lab Interdisciplinar Invest Med, Belo Horizonte, MG, Brazil.; Miranda, AS (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Morfol, Lab Neurobiol, Belo Horizonte, MG, Brazil.	mirandas.aline@gmail.com	Kummer, Arthur/AAU-3317-2020; de Paula, Jonas J/I-8066-2012; CARAMELLI, PAULO/H-9735-2012; de Souza, Leonardo C/C-1833-2016	CARAMELLI, PAULO/0000-0002-4786-6990; de Souza, Leonardo C/0000-0001-5027-9722	Brain & Behavior Research FoundationNARSAD [25414]; FAPEMIGFundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	This work was supported by the 2016 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (grant number 25414), and FAPEMIG to ASM. LCS is supported by CNPq and MGFC is supported by CAPES.	Barker-Collo S, 2015, BRAIN INJURY, V29, P1604, DOI 10.3109/02699052.2015.1075143; Beato Rogério Gomes, 2007, Dement. neuropsychol., V1, P59, DOI 10.1590/S1980-57642008DN10100010; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014; Castro Stephanie, 2009, Dement. neuropsychol., V3, P327, DOI 10.1590/S1980-57642009DN30400011; Cho YE, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00168; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Dall'Acqua P, 2017, J NEUROTRAUM, V34, P3270, DOI 10.1089/neu.2017.5124; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Figueiredo Vera L. M. de, 2007, Psic.: Teor. e Pesq., V23, P313, DOI 10.1590/S0102-37722007000300010; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fonseca Rochele Paz, 2012, Psychol. Neurosci., V5, P183, DOI 10.3922/j.psns.2012.2.08; Gardner AJ, 2016, HAND CLINIC, V138, P207, DOI 10.1016/B978-0-12-802973-2.00012-4; Gauthier S, 2018, J COMMUN DISORD, V73, P77, DOI 10.1016/j.jcomdis.2018.04.003; De la Blanca MAIP, 2018, BRAIN INJURY, V32, P99, DOI 10.1080/02699052.2017.1382716; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Larrabee GJ, 2013, BEHAV SCI LAW, V31, P686, DOI 10.1002/bsl.2087; Leary JB, 2018, J HEAD TRAUMA REHAB, V33, pE28, DOI 10.1097/HTR.0000000000000329; Magalhaes AS., 2017, REV BRAS NEUROL, V53, P15; Massey JS, 2015, NEUROPSYCHOLOGY, V29, P530, DOI 10.1037/neu0000192; Mathias JL, 2015, NEUROSCI BIOBEHAV R, V55, P573, DOI 10.1016/j.neubiorev.2015.06.001; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Mortensen L, 2006, LANG COGNITIVE PROC, V21, P238, DOI 10.1080/01690960444000278; Nelson LD, 2018, J NEUROTRAUM, V35, P249, DOI 10.1089/neu.2017.4988; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; NITRINI R, 1994, ARQ NEURO-PSIQUIAT, V52, P457, DOI 10.1590/S0004-282X1994000400001; Norris JN, 2014, BRAIN INJURY, V28, P1052, DOI 10.3109/02699052.2014.891761; Oldenburg C, 2016, BRAIN INJURY, V30, P146, DOI 10.3109/02699052.2015.1089598; Paolieri D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191656; Paz Fonseca R., 2016, ACTA COLOMB PSICOL, V19, DOI [https://doi.org/10.14718/ACP.2016.19.2.6, DOI 10.14718/ACP.2016.19.2.6]; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rojas N, 2019, APPL NEUROPSYCH-ADUL, V26, P319, DOI 10.1080/23279095.2017.1422506; de Almeida CER, 2016, WORLD NEUROSURG, V87, P540, DOI 10.1016/j.wneu.2015.10.020; Sivak S, 2014, BRAIN INJURY, V28, P341, DOI 10.3109/02699052.2013.865270; Sofko CA, 2016, BRAIN INJURY, V30, P1561, DOI 10.1080/02699052.2016.1199897; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Van Patten R, 2016, J CLIN EXP NEUROPSYC, V38, P12, DOI 10.1080/13803395.2015.1091064; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Yue JK, 2017, J CLIN NEUROSCI, V45, P293, DOI 10.1016/j.jocn.2017.07.022	50	26	27	3	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAR 8	2019	10								198	10.3389/fneur.2019.00198			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HO3FN	WOS:000460805200001	30906278	Green Published, gold			2022-02-06	
J	Hsu, ET; Gangolli, M; Su, S; Holleran, L; Stein, TD; Alvarez, VE; McKee, AC; Schmidt, RE; Brody, DL				Hsu, Eric T.; Gangolli, Mihika; Su, Shiran; Holleran, Laurena; Stein, Thor D.; Alvarez, Victor E.; McKee, Ann C.; Schmidt, Robert E.; Brody, David L.			Astrocytic degeneration in chronic traumatic encephalopathy	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Neurodegeneration; Astrocyte; Glial fibrillary acidic protein	BLOOD-BRAIN-BARRIER; FIBRILLARY ACIDIC PROTEIN; ALZHEIMERS-DISEASE; REACTIVE ASTROCYTES; NEURITE OUTGROWTH; TAU PATHOLOGY; NEUROPATHOLOGY; INJURY; TISSUE; AUTOANTIBODIES	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repeated head traumas. Using immunohistochemistry for glial fibrillary acidic protein as a marker, plus automated quantitative analysis, we examined the characteristics and extent of astrogliosis present in stage III and IV CTE, along with Alzheimer's disease (AD), and frontotemporal dementia (FTD) cases. Astrogliosis in CTE patients was more diffuse compared to that of AD and FTD patients, which was concentrated in the sulcal depths. Of 14 patients with CTE, 10 exhibited signs of a degenerating astrocyte pathology, characterized by beaded, broken astrocytic processes. This astrocytic degeneration was typically found to be diffuse throughout the white matter, although two cases demonstrated astrocytic degeneration in the gray matter. The degeneration was also observed in 2 of 3 AD and 2 of 3 FTD brains, with overall similar characteristics across diseases. There was minimal to no astrocytic degeneration in six age-matched controls with no neurodegenerative disease. We found that the extent of the white matter astrocytic degeneration was strongly correlated with the level of overall astrogliosis in both the white and gray matter. However, astrocytic degeneration was not correlated with the overall extent of tau pathology. Specifically, there was no correlation between levels of p-tau in the sulcal depths and astrocytic degeneration in the white matter adjacent to the sulcal depths. Thus, astrocytic degeneration and overall astrogliosis appear to represent distinct pathological features of CTE. Further investigation into these astroglial pathologies could provide new insights into underlying disease mechanisms and represent a potential target for in vivo assessment of CTE as well as other neurodegenerative disorders.	[Hsu, Eric T.; Holleran, Laurena; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63130 USA; [Gangolli, Mihika; Su, Shiran; Brody, David L.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; [Holleran, Laurena] Natl Univ Ireland, Ctr Neuroimaging & Cognit Genom, Galway, Ireland; [Stein, Thor D.; Alvarez, Victor E.; McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [Stein, Thor D.; Alvarez, Victor E.; McKee, Ann C.] Boston Univ, Sch Med, Boston Univ Alzheimers Dis, Boston, MA 02118 USA; [Stein, Thor D.; Alvarez, Victor E.; McKee, Ann C.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA; [Stein, Thor D.; Alvarez, Victor E.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Schmidt, Robert E.; Brody, David L.] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63130 USA; [Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63130 USA; [Brody, David L.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63130 USA.; Brody, DL (corresponding author), Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA.; Brody, DL (corresponding author), Washington Univ, Dept Pathol & Immunol, St Louis, MO 63130 USA.; Brody, DL (corresponding author), Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63130 USA.; Brody, DL (corresponding author), Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.	e.hsu@wustl.edu; mihika.gangolli@wustl.edu; shiran@wustl.edu; Laurena.holleran@nuigalway.ie; tdstein@bu.edu; valvarez@bu.edu; amckee@bu.edu; reschmidt@wustl.edu; david.brody@usuhs.edu		Hsu, Eric/0000-0002-3232-6131	VA Boston Healthcare SystemUS Department of Veterans Affairs; Washington University Center for Cellular Imaging [P30 NS057105]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UO1 NS086659-02]; US Department of Veterans AffairsUS Department of Veterans Affairs; National Operating Committee on Standards for Athletic Equipment; Concussion Legacy Foundation; Andlinger Family Foundation; WWE; NFL; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER	We would like to thank the donors and their families for the generous brain donation which made this research possible. We would also like to thank VA Boston Healthcare System and Boston University Alzheimer's Disease and CTE Center for sample procurement. The studies presented in this work were carried out, in part, using the Hope Center Alafi Neuroimaging Lab, Washington University in St. Louis and the Washington University Center for Cellular Imaging (P30 NS057105). We would also like to thank Marc Goldfinger, Steve Gentleman, Dan Perl, Thomas J. Esparza, and Andrew Sauerbeck for helpful discussions. This research was funded by the National Institute of Health, and the views expressed are those of the authors. NIH UO1 NS086659-02 (Overall PI: A. McKee, Subproject 3 PI: Brody), the US Department of Veterans Affairs, the National Operating Committee on Standards for Athletic Equipment, the Concussion Legacy Foundation, the Andlinger Family Foundation, the WWE, and the NFL. Additional support was provided by a SURF fellowship from Washington University to E. Hsu.	Alilain WJ, 2011, NATURE, V475, P196, DOI 10.1038/nature10199; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Amadoro G, 2006, P NATL ACAD SCI USA, V103, P2892, DOI 10.1073/pnas.0511065103; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Broe M, 2004, BRAIN, V127, P2214, DOI 10.1093/brain/awh250; Bukhari W, 2012, INT J MOL SCI, V13, P12970, DOI 10.3390/ijms131012970; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Caserta MT, 1998, J NEUROPSYCH CLIN N, V10, P78, DOI 10.1176/jnp.10.1.78; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Dickson D, 2011, J MOL NEUROSCI, V45, P384, DOI 10.1007/s12031-011-9589-0; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Erickson MA, 2013, J CEREBR BLOOD F MET, V33, P1500, DOI 10.1038/jcbfm.2013.135; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Gangolli M, 2017, NEUROIMAGE, V153, P152, DOI 10.1016/j.neuroimage.2017.03.059; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gruden MA, 2007, J NEUROIMMUNOL, V186, P181, DOI 10.1016/j.jneuroim.2007.03.023; Halassa MM, 2007, TRENDS MOL MED, V13, P54, DOI 10.1016/j.molmed.2006.12.005; Hamby ME, 2012, J NEUROSCI, V32, P14489, DOI 10.1523/JNEUROSCI.1256-12.2012; Holleran L, 2017, ACTA NEUROPATHOL, V133, P367, DOI 10.1007/s00401-017-1686-x; Ihara M, 2010, ACTA NEUROPATHOL, V119, P579, DOI 10.1007/s00401-009-0635-8; Khakh BS, 2015, NAT NEUROSCI, V18, P942, DOI 10.1038/nn.4043; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Martin JA, 2001, NEUROBIOL AGING, V22, P195, DOI 10.1016/S0197-4580(00)00231-1; Matthias K, 2003, J NEUROSCI, V23, P1750; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; MILSTED A, 1990, P NATL ACAD SCI USA, V87, P5720, DOI 10.1073/pnas.87.15.5720; Noy S, 2016, J NEUROPATH EXP NEUR, V75, P1145, DOI 10.1093/jnen/nlw092; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Olah M, 2011, CNS NEUROL DISORD-DR, V10, P108, DOI 10.2174/187152711794488575; Omalu B, 2018, NEUROSURGERY, V82, P237, DOI 10.1093/neuros/nyx536; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Papadopoulos MC, 2012, LANCET NEUROL, V11, P535, DOI 10.1016/S1474-4422(12)70133-3; Parratt JDE, 2010, MULT SCLER J, V16, P1156, DOI 10.1177/1352458510382324; Rajkowska G, 2013, CURR DRUG TARGETS, V14, P1225; Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Simpson JE, 2010, NEUROBIOL AGING, V31, P578, DOI 10.1016/j.neurobiolaging.2008.05.015; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Starr JM, 2009, PSYCHIAT RES-NEUROIM, V171, P232, DOI 10.1016/j.pscychresns.2008.04.003; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Tai XY, 2016, BRAIN, V139, P2441, DOI 10.1093/brain/aww187; TANAKA J, 1989, ACTA NEUROL SCAND, V80, P554, DOI 10.1111/j.1600-0404.1989.tb03926.x; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tomimoto H, 1997, ACTA NEUROPATHOL, V94, P146, DOI 10.1007/s004010050686; Turner RC, 2016, BRAIN INJURY, V30, P1279, DOI 10.1080/02699052.2016.1193631; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Wosik K, 2007, J NEUROSCI, V27, P9032, DOI 10.1523/JNEUROSCI.2088-07.2007; Wu JM, 2016, J BIOMED RES, V30, P361, DOI 10.7555/JBR.30.20150131; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	67	26	26	4	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	DEC	2018	136	6					955	972		10.1007/s00401-018-1902-3			18	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	HC7AL	WOS:000451952700009	30194648				2022-02-06	
J	Haarbauer-Krupa, J; Lee, AH; Bitsko, RH; Zhang, XJ; Kresnow-Sedacca, MJ				Haarbauer-Krupa, Juliet; Lee, Akilah Heggs; Bitsko, Rebecca H.; Zhang, Xinjian; Kresnow-Sedacca, Marcie-jo			Prevalence of Parent-Reported Traumatic Brain Injury in Children and Associated Health Conditions	JAMA PEDIATRICS			English	Article							PSYCHIATRIC-DISORDERS; BEHAVIOR PROBLEMS; EARLY-CHILDHOOD; UNITED-STATES; ADOLESCENTS; OUTCOMES; CARE; US; DISABILITY; RECOVERY	IMPORTANCE Traumatic brain injury (TBI) in children results in a high number of emergency department visits and risk for long-term adverse effects. OBJECTIVES To estimate lifetime prevalence of TBI in a nationally representative sample of US children and describe the association between TBI and other childhood health conditions. DESIGN, SETTING, AND PARTICIPANTS Data were analyzed from the 2011-2012 National Survey of Children's Health, a cross-sectional telephone survey of US households with a response rate of 23%. Traumatic brain injury prevalence estimates were stratified by sociodemographic characteristics. The likelihood of reporting specific health conditions was compared between children with and without TBI. Age-adjusted prevalence estimates were computed for each state. Associations between TBI prevalence, insurance type, and parent rating of insurance adequacy were examined. Data analysis was conducted from February 1, 2016, through November 1, 2017. MAIN OUTCOMES AND MEASURES Lifetime estimate of TBI in children, associated childhood health conditions, and parent report of health insurance type and adequacy. RESULTS The lifetime estimate of parent-reported TBI among children was 2.5%(95% CI, 2.3%-2.7%), representing over 1.8 million children nationally. Children with a lifetime history of TBI were more likely to have a variety of health conditions compared with those without a TBI history. Those with the highest prevalence included learning disorders (21.4%; 95% CI, 18.1%-25.2%); attention-deficit/hyperactivity disorder (20.5%; 95% CI, 17.4%-24.0%); speech/language problems (18.6%; 95% CI, 15.8%-21.7%); developmental delay (15.3%; 95% CI, 12.9%-18.1%); bone, joint, or muscle problems (14.2%; 95% CI, 11.6%-17.2%); and anxiety problems (13.2%; 95% CI, 11.0%-16.0%). States with a higher prevalence of childhood TBI were more likely to have a higher proportion of children with private health insurance and higher parent report of adequate insurance. Examples of states with higher prevalence of TBI and higher proportion of private insurance included Maine, Vermont, Pennsylvania, Washington, Montana, Wyoming North Dakota, South Dakota, and Colorado. CONCLUSIONS AND RELEVANCE A large number of US children have experienced a TBI during childhood. Higher TBI prevalence in states with greater levels of private insurance and insurance adequacymay suggest an underrecognition of TBI among children with less access to care. For more comprehensive monitoring, health care professionals should be aware of the increased risk of associated health conditions among children with TBI.	[Haarbauer-Krupa, Juliet] Ctr Dis Control & Prevent, Div Unintent Injury, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS-F62, Atlanta, GA 30341 USA; [Lee, Akilah Heggs] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA; [Bitsko, Rebecca H.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA; [Zhang, Xinjian; Kresnow-Sedacca, Marcie-jo] Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Atlanta, GA 30341 USA		Haarbauer-Krupa, J (corresponding author), Ctr Dis Control & Prevent, Div Unintent Injury, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS-F62, Atlanta, GA 30341 USA.	jhaarbauerkrupa@cdc.gov					Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bramlett Matthew D, 2017, Vital Health Stat 1, P1; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, TRAUM BRAIN INJ CONC; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; DeNavas-Walt C, 2012, US CENSUS BUREAU CUR; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fabio A., 2017, J HLTH DISPAR RES PR, V10, P107; Faul M, TRAUMATIC BRAIN INJU; Glang A, 2008, NEUROREHABILITATION, V23, P477; Haarbauer-Krupa J, 2017, J HEAD TRAUMA REHAB, V32, P367, DOI 10.1097/HTR.0000000000000287; Hansen G, 2015, SAGE OPEN MED, V3, DOI 10.1177/2050312115573817; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Iverson GL, 2016, J NEUROTRAUM, V33, P2077, DOI 10.1089/neu.2014.3424; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Max JE, 2015, J NEUROPSYCH CLIN N, V27, P112, DOI 10.1176/appi.neuropsych.13080190; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Pastor PN, 2006, AMBUL PEDIATR, V6, P38, DOI 10.1016/j.ambp.2005.07.002; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Schell A, 2016, OTOLARYNG HEAD NECK, V154, P175, DOI 10.1177/0194599815609114; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schootman M, 2000, BRAIN INJURY, V14, P373; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Taylor HG, 2015, J HEAD TRAUMA REHAB, V30, P302, DOI 10.1097/HTR.0000000000000106; Vaaramo K, 2014, J NEUROL NEUROSUR PS, V85, P598, DOI 10.1136/jnnp-2012-304457; Waissbluth S, 2016, INT J PEDIATR OTORHI, V84, P106, DOI 10.1016/j.ijporl.2016.02.034; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007	35	26	26	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	NOV	2018	172	11					1078	1086		10.1001/jamapediatrics.2018.2740			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	GZ2LO	WOS:000449215800022	30264150	Green Published, Bronze			2022-02-06	
J	Howell, DR; Zemek, R; Brilliant, AN; Mannix, RC; Master, CL; Meehan, WP				Howell, David R.; Zemek, Roger; Brilliant, Anna N.; Mannix, Rebekah C.; Master, Christina L.; Meehan, William P., III			Identifying Persistent Postconcussion Symptom Risk in a Pediatric Sports Medicine Clinic	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						mild traumatic brain injury; pediatric; recovery; postconcussion syndrome; assessment	ERROR SCORING SYSTEM; CONCUSSION MANAGEMENT; RECOVERY; ADOLESCENTS; DURATION; BALANCE; CHILDREN; ADULTS; ASSOCIATION; POPULATION	Background: Although most children report symptom resolution within a month of a concussion, some patients experience persistent postconcussion symptoms (PPCS) that continues for more than 1 month. Identifying patients at risk for PPCS soon after an injury can provide useful clinical information. Purpose: To determine if the Predicting Persistent Post-concussive Problems in Pediatrics (5P) clinical risk score, an emergency department (ED)-derived and validated tool, is associated with developing PPCS when obtained in a primary care sports concussion setting. Study Design: Cohort study; Level of evidence, 3. Methods: We conducted a study of patients seen at a pediatric sports medicine concussion clinic between May 1, 2013, and October 1, 2017, who were <19 years of age and evaluated within 10 days of a concussion. The main outcome was PPCS, defined as symptoms lasting >28 days. Nine variables were used to calculate the 5P clinical risk score, and we assessed the association between the 5P clinical risk score and PPCS occurrence. The secondary outcome was total symptom duration. Results: We examined data from 230 children (mean age, 14.8 +/- 2.5 years; 50% female; mean time from injury to clinical assessment, 5.6 +/- 2.7 days). In univariable analyses, a greater proportion of those who developed PPCS reported feeling slowed down (72% vs 44%, respectively; P < .001), headache (94% vs 72%, respectively; P < .001), sensitivity to noise (71% vs 43%, respectively; P < .001), and fatigue (82% vs 51%, respectively; P < .001) and committed >= 4 errors in tandem stance (33% vs 7%, respectively; P < .001) than those who did not. Higher 5P clinical risk scores were associated with increased odds of developing PPCS (adjusted odds ratio [OR], 1.62 [95% CI, 1.30-2.02]) and longer symptom resolution times (beta = 8.40 [95% CI, 3.25-13.50]). Among the individual participants who received a high 5P clinical risk score (9-12), the majority (82%) went on to experience PPCS. The area under the curve for the 5P clinical risk score was 0.75 (95% CI, 0.66-0.84). After adjusting for the effect of covariates, fatigue (adjusted OR, 2.93) and >= 4 errors in tandem stance (adjusted OR, 7.40) were independently associated with PPCS. Conclusion: Our findings extend the potential use for an ED-derived clinical risk score for predicting the PPCS risk into the sports concussion clinic setting. While not all 9 predictor variables of the 5P clinical risk score were independently associated with the PPCS risk in univariable or multivariable analyses, the combination of factors used to calculate the 5P clinical risk score was significantly associated with the odds of developing PPCS. Thus, obtaining clinically pragmatic risk scores soon after a concussion may be useful for early treatments or interventions to mitigate the PPCS risk.	[Howell, David R.; Zemek, Roger; Brilliant, Anna N.; Mannix, Rebekah C.; Master, Christina L.; Meehan, William P., III] Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA; [Howell, David R.] Childrens Hosp Colorado, Ctr Sports Med, 13123 East 16th Ave,B060, Aurora, CO 80045 USA; [Howell, David R.] Univ Colorado, Sch Med, Dept Orthoped, Aurora, CO USA; [Howell, David R.; Brilliant, Anna N.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Zemek, Roger] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON, Canada; [Brilliant, Anna N.; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Mannix, Rebekah C.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.; Meehan, William P., III] Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Master, Christina L.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA; [Master, Christina L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA		Howell, DR (corresponding author), Childrens Hosp Colorado, Ctr Sports Med, 13123 East 16th Ave,B060, Aurora, CO 80045 USA.	David.Howell@ucdenver.edu	Mannix, Rebekah/AAD-8702-2020	Master, Christina/0000-0002-6717-4270	National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament; Boston Children's Hospital; Cincinnati Children's Hospital Medical Center; ElMindA	D.R.H. and A.N.B. were supported, in part, through a research contract between Boston Children's Hospital, Cincinnati Children's Hospital Medical Center, and ElMindA. W.P.M. receives royalties from ABC-CLIO for the sale of his books (Kids, Sports, and Concussion: A Guide for Coaches and Parents and Concussions), Springer for the sale of a book (Head and Neck Injuries in Young Athletes), and Wolters Kluwer for working as an author for UpToDate. His research is funded, in part, by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.	Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P848, DOI 10.1136/bjsports-2017-097506; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Houston MN, 2016, BRAIN INJURY, V30, P891, DOI 10.3109/02699052.2016.1146960; Howell DR, 2017, J NEUROTRAUM, V34, P3288, DOI 10.1089/neu.2017.5191; Howell DR, 2017, CLIN J SPORT MED, V27, P444, DOI 10.1097/JSM.0000000000000374; Howell DR, 2016, ACTA PAEDIATR, V105, pE426, DOI 10.1111/apa.13486; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McDevitt J, 2015, BRAIN INJURY, V29, P1674, DOI 10.3109/02699052.2015.1075252; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Oldham JR, 2018, MED SCI SPORT EXER, V50, P1162, DOI 10.1249/MSS.0000000000001540; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Stache S, 2016, CLIN J SPORT MED, V26, P381, DOI 10.1097/JSM.0000000000000270; Worster A, 2004, ACAD EMERG MED, V11, P187, DOI 10.1197/j.aem.2003.03.002; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	32	26	26	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2018	46	13					3254	3261		10.1177/0363546518796830			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	HA5WM	WOS:000450350300021	30265817				2022-02-06	
J	Janulewicz, P; Krengel, M; Quinn, E; Heeren, T; Toomey, R; Killiany, R; Zundel, C; Ajama, J; O'Callaghan, J; Steele, L; Klimas, N; Sullivan, K				Janulewicz, Patricia; Krengel, Maxine; Quinn, Emily; Heeren, Timothy; Toomey, Rosemary; Killiany, Ronald; Zundel, Clara; Ajama, Joy; O'Callaghan, James; Steele, Lea; Klimas, Nancy; Sullivan, Kimberly			The Multiple Hit Hypothesis for Gulf War Illness: Self-Reported Chemical/Biological Weapons Exposure and Mild Traumatic Brain Injury	BRAIN SCIENCES			English	Article						Gulf War Illness; Gulf War; mild traumatic brain injury; chemical weapons; neurotoxicant exposures	MULTISYMPTOM ILLNESS; CYCLOSARIN EXPOSURE; RISK-FACTORS; VETERANS; SYMPTOMS; ETIOLOGY; HISTORY; SARIN; SENSE	The Gulf War Illness Consortium (GWIC) was designed to identify objective biomarkers of Gulf War Illness (GWI) in 1991 Gulf War veterans. The symptoms of GWI include fatigue, pain, cognitive problems, gastrointestinal, respiratory, and skin problems. Neurotoxicant exposures during deployment, such as pesticides, sarin, and pyridostigmine bromide pills have been identified as contributors to GWI. We have also found an association between mild traumatic brain injury (mTBI) and increased rates of GWI. However, the combined impact of these physical and chemical exposures has not yet been explored in GWI. The objective of this study was to examine both self-reported mTBI and exposure to chemical/biological weapons (CBW) as a multiple or two hit model for increased risk of GWI and other chronic health conditions. The study population included 125 Gulf War (GW) veterans from the Boston GWIC. Exposure to CBW was reported in 47.2% of the study population, and 35.2% reported sustaining a mTBI during the war. Results confirmed that those with both exposures (mTBI and CBW) had higher rates of comorbid chronic health conditions while rates of GWI were equivalent for mTBI and CBW or mTBI alone. The timing of exposure to mTBI was found to be strikingly different between those with GWI and those without it. Correspondingly, 42.3% of GWI cases reported experiencing a mTBI during military service while none of the controls did (p = 0.0002). Rates of mTBI before and after the war did not differ between the cases and controls. In addition, 54% of cases compared to 14.3% of controls (p = <0.001) reported being exposed to CBW during military service. The current study examined the relation of the separate and combined effects of exposure to mTBI and CBW in 1991 GW veterans. The findings from this study suggest that both exposure to mTBI and CBW are associated with the development of GWI and multiple chronic health conditions and that combined exposure appears to lead to higher risk of chronic health effects.	[Janulewicz, Patricia; Ajama, Joy; Sullivan, Kimberly] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; [Krengel, Maxine] VA Boston Healthcare Syst, Res Serv, Boston, MA 02130 USA; [Krengel, Maxine] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Quinn, Emily] Boston Univ, Sch Publ Hlth, Biostat & Epidemiol Data Analyt Ctr, Boston, MA 02118 USA; [Heeren, Timothy] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Toomey, Rosemary] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA; [Killiany, Ronald] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Zundel, Clara] Boston Univ, Sch Med, Dept Behav Neurosci, Boston, MA 02118 USA; [O'Callaghan, James] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA; [Steele, Lea] Baylor Coll Med, Dept Psychiat & Behav Sci, Div Neuropsychiat, Houston, TX 77030 USA; [Klimas, Nancy] Miami VA Healthcare Syst, Dept Med, Miami, FL 33125 USA; [Klimas, Nancy] Nova Southeastern Univ, Dept Clin Immunol, Miami, FL 33314 USA		Janulewicz, P (corresponding author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA.	paj@bu.edu; mhk@bu.edu; eq@bu.edu; tch@bu.edu; toomey@bu.edu; killiany@bu.edu; cgzundel@bu.edu; ajamajoy@bu.edu; jdo5@cdc.gov; Lea.Steele@bcm.edu; nklimas@nova.edu; tty@bu.edu	Zundel, Clara/AAV-5775-2020; Killiany, Ronald/Y-7251-2019	Zundel, Clara/0000-0002-1736-2695; Killiany, Ronald/0000-0003-4740-2181; Sullivan, Kimberly/0000-0001-7940-6123; Krengel, Maxine/0000-0001-7632-590X	Congressionally Directed Medical Research Program (CDMRP) through the Gulf War Illness Research Program (GWIRP) [W81XWH-13-2-0072]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This work was supported by the Congressionally Directed Medical Research Program (CDMRP) through the Gulf War Illness Research Program (GWIRP) under Award No. W81XWH-13-2-0072 to Kimberly Sullivan.	Abou-Donia MB, 2017, NEUROTOXICOL TERATOL, V61, P36, DOI 10.1016/j.ntt.2017.03.002; Alhasson F, 2018, REDOX BIOL, V17, P1, DOI 10.1016/j.redox.2018.04.002; Banks CN, 2012, NEUROTOXICOLOGY, V33, P575, DOI 10.1016/j.neuro.2012.02.002; Barnett ML, 2018, NEUROIMAGE-CLIN, V17, P596, DOI 10.1016/j.nicl.2017.11.017; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Chao LL, 2018, MIL MED, V183, pE571, DOI 10.1093/milmed/usy109; Chao LL, 2016, NEUROTOXICOLOGY, V53, P246, DOI 10.1016/j.neuro.2016.02.009; Chao LDL, 2015, NEUROTOXICOLOGY, V48, P239, DOI 10.1016/j.neuro.2015.04.005; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Feigenson KA, 2014, NEUROSCI BIOBEHAV R, V38, P72, DOI 10.1016/j.neubiorev.2013.11.006; Feng L., 2012, THESIS; First M.B., 1996, STRUCTURED CLIN INTE; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Georgopoulos AP, 2017, EXP BRAIN RES, V235, P3217, DOI 10.1007/s00221-017-5050-0; Haley RW, 2013, NEUROEPIDEMIOLOGY, V40, P178, DOI 10.1159/000345124; Institute of Medicine, 2014, CHRON MULT ILLN GULF; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Matzinger P, 2002, ANN NY ACAD SCI, V961, P341, DOI 10.1111/j.1749-6632.2002.tb03118.x; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; O'Callaghan JP, 2016, EBIOMEDICINE, V13, P5, DOI 10.1016/j.ebiom.2016.10.037; Proctor S.P., 2006, DEV STRUCTURED NEURO; Proctor SP, 1998, INT J EPIDEMIOL, V27, P1000, DOI 10.1093/ije/27.6.1000; Proctor SP, 2006, NEUROTOXICOLOGY, V27, P931, DOI 10.1016/j.neuro.2006.08.001; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Rayhan RU, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0058493, 10.1371/journal.pone.0063903]; Research Advisory Committee on Gulf War Veterans' Illnesses, 2014, GULF WAR ILLN HLTH G; Research Advisory Committee on Gulf War Veterans' Illnesses, 2008, GULF WAR ILLN HLTH G; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Seth RK, 2018, TOXICOL APPL PHARM, V350, P64, DOI 10.1016/j.taap.2018.05.006; Smith MA, 2004, NEUROBIOL AGING, V25, pS68, DOI 10.1016/S0197-4580(04)80231-8; Steele L, 2000, AM J EPIDEMIOL, V152, P992, DOI 10.1093/aje/152.10.992; Steele L, 2012, ENVIRON HEALTH PERSP, V120, P112, DOI 10.1289/ehp.1003399; Sullivan K, 2003, J PSYCHOPATHOL BEHAV, V25, P95, DOI 10.1023/A:1023342915425; Sullivan K, 2018, NEUROTOXICOL TERATOL, V65, P1, DOI 10.1016/j.ntt.2017.11.002; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Van Riper SM, 2017, PAIN, V158, P2364, DOI 10.1097/j.pain.0000000000001038; Vynorius KC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00188; White RF, 2001, AM J IND MED, V40, P42, DOI 10.1002/ajim.1070; White RF, 2016, CORTEX, V74, P449, DOI 10.1016/j.cortex.2015.08.022; Wolfe J, 2002, J OCCUP ENVIRON MED, V44, P271, DOI 10.1097/00043764-200203000-00015; Yee MK, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070079; Yee MK, 2016, J HEAD TRAUMA REHAB, V31, P320, DOI 10.1097/HTR.0000000000000173	45	26	26	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2076-3425			BRAIN SCI	Brain Sci.	NOV	2018	8	11							198	10.3390/brainsci8110198			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HB8AS	WOS:000451306300008	30428552	gold, Green Submitted, Green Published			2022-02-06	
J	Bernardo-Colon, A; Vest, V; Clark, A; Cooper, ML; Calkins, DJ; Harrison, FE; Rex, TS				Bernardo-Colon, Alexandra; Vest, Victoria; Clark, Adrienne; Cooper, Melissa L.; Calkins, David J.; Harrison, Fiona E.; Rex, Tonia S.			Antioxidants prevent inflammation and preserve the optic projection and visual function in experimental neurotrauma	CELL DEATH & DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; MOUSE MODEL; BETA-HYDROXYBUTYRATE; NLRP3 INFLAMMASOME; KETOGENIC DIET; VITAMIN-C; AXONOPATHY; ASTROCYTES; STRESS; NEUROINFLAMMATION	We investigated the role of oxidative stress and the inflammasome in trauma-induced axon degeneration and vision loss using a mouse model. The left eyes of male mice were exposed to over-pressure air waves. Wild-type C57Bl/6 mice were fed normal, high-vitamin-E (VitE), ketogenic or ketogenic-control diets. Mice lacking the ability to produce vitamin C (VitC) were maintained on a low-VitC diet. Visual evoked potentials (VEPs) and retinal superoxide levels were measured in vivo. Tissue was collected for biochemical and histological analysis. Injury increased retinal superoxide, decreased SOD2, and increased cleaved caspase-1, IL-1 alpha, IL-1 beta, and IL-18 levels. Low-VitC exacerbated the changes and the high-VitE diet mitigated them, suggesting that oxidative stress led to the increase in IL-1 alpha and activation of the inflammasome. The injury caused loss of nearly 50% of optic nerve axons at 2 weeks and astrocyte hypertrophy in mice on normal diet, both of which were prevented by the high-VitE diet. The VEP amplitude was decreased after injury in both control-diet and low-VitC mice, but not in the high-VitE-diet mice. The ketogenic diet also prevented the increase in superoxide levels and IL-1 alpha, but had no effect on IL-1 beta. Despite this, the ketogenic diet preserved optic nerve axons, prevented astrocyte hypertrophy, and preserved the VEP amplitude. These data suggest that oxidative stress induces priming and activation of the inflammasome pathway after neurotrauma of the visual system. Further, blocking the activation of the inflammasome pathway may be an effective post-injury intervention.	[Bernardo-Colon, Alexandra; Vest, Victoria; Clark, Adrienne; Cooper, Melissa L.; Calkins, David J.; Rex, Tonia S.] Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Vanderbilt Eye Inst, Nashville, TN 37232 USA; [Harrison, Fiona E.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA		Rex, TS (corresponding author), Vanderbilt Univ, Med Ctr, Dept Ophthalmol & Visual Sci, Vanderbilt Eye Inst, Nashville, TN 37232 USA.	tonia.rex@vanderbilt.edu		Calkins, David/0000-0002-8475-9959; Cooper, Melissa/0000-0003-4337-8356	NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01 EY022349]; DoDUnited States Department of Defense [W81XWH-15-1-0096, W81XWH-17-2-0055]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 NS094595]; Potocsnak Discovery Grant in Regenerative Medicine; Ayers Foundation Regenerative Visual Neuroscience Pilot Grant; VAUS Department of Veterans Affairs [I01 CX001610-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EY024997, P30EY008126]; Glaucoma Research Foundation; Stanley Cohen Innovation Fund; Vanderbilt University Medical Center Cell Imaging Shared Resource core facility (Clinical and Translational Science Award Grant from National Center for Research Resources) [UL1 RR024975]; Training Grant in Vision Research [T32 EY021833]; Research Prevent Blindness, Inc.; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY024997, P30EY008126, R01EY021833, R01EY022349, T32EY021453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094595] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001610] Funding Source: NIH RePORTER	We thank Marcus Colyer for valuable input, and Purnima Ghose, John Clifton, Ryan Dahl, and Bohan Kim for their technical assistance. Support was provided by NEI R01 EY022349 (TR), DoD W81XWH-15-1-0096 (TR) and W81XWH-17-2-0055 (TR), NIA R01 NS094595 (TR), Potocsnak Discovery Grant in Regenerative Medicine (TR), Ayers Foundation Regenerative Visual Neuroscience Pilot Grant (TR), VA I01 CX001610-01 (FH), NIH R01EY024997 (DC) and P30EY008126 (DC), the Glaucoma Research Foundation (DC), the Stanley Cohen Innovation Fund (DC), and the Vanderbilt University Medical Center Cell Imaging Shared Resource core facility (Clinical and Translational Science Award Grant UL1 RR024975 from National Center for Research Resources), Training Grant in Vision Research T32 EY021833, Research Prevent Blindness, Inc.	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Bertheloot D, 2017, CELL MOL IMMUNOL, V14, P43, DOI 10.1038/cmi.2016.34; Bond WS, 2016, MOL THER, V24, P230, DOI 10.1038/mt.2015.198; Bricker-Anthony C, 2017, OPTOMETRY VISION SCI, V94, P20, DOI 10.1097/OPX.0000000000000898; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Brown AM, 2005, J NEUROSCI RES, V79, P74, DOI 10.1002/jnr.20335; Chapman KM, 1996, J GERONTOL A-BIOL, V51, pB261, DOI 10.1093/gerona/51A.4.B261; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Cooper ML, 2016, EXP EYE RES, V150, P22, DOI 10.1016/j.exer.2015.11.016; Crish SD, 2010, P NATL ACAD SCI USA, V107, P5196, DOI 10.1073/pnas.0913141107; Dapper JD, 2013, NEUROBIOL DIS, V59, P26, DOI 10.1016/j.nbd.2013.07.001; Goldberg EL, 2017, CELL REP, V18, P2077, DOI 10.1016/j.celrep.2017.02.004; Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x; Harrison FE, 2008, J NEUROCHEM, V106, P1198, DOI 10.1111/j.1471-4159.2008.05469.x; Harrison FE, 2012, J ALZHEIMERS DIS, V29, P711, DOI 10.3233/JAD-2012-111853; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; Hines-Beard J, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0499-5; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Ishaq GM, 2013, J NEUROSCI RURAL PRA, V4, P292, DOI 10.4103/0976-3147.118784; Kashiwaya Y, 2013, NEUROBIOL AGING, V34, P1530, DOI 10.1016/j.neurobiolaging.2012.11.023; Langlois K, 2016, HEALTH REP, V27, P3; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; Lye-Barthel M, 2013, INVEST OPHTH VIS SCI, V54, P909, DOI 10.1167/iovs.12-10109; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; Pearson JF, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080831; Perge JA, 2009, J NEUROSCI, V29, P7917, DOI 10.1523/JNEUROSCI.5200-08.2009; Prins ML, 2014, J LIPID RES, V55, P2450, DOI 10.1194/jlr.R046706; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Sarkies N, 2004, EYE, V18, P1122, DOI 10.1038/sj.eye.6701571; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; STEINSAPIR KD, 1994, SURV OPHTHALMOL, V38, P487, DOI 10.1016/0039-6257(94)90145-7; STOYANOVSKY DA, 1995, CURR EYE RES, V14, P181, DOI 10.3109/02713689509033513; Sun D, 2017, J EXP MED, V214, P1411, DOI 10.1084/jem.20160412; Tekkok SB, 2005, J NEUROSCI RES, V81, P644, DOI 10.1002/jnr.20573; Thaler S, 2010, GRAEF ARCH CLIN EXP, V248, P1729, DOI 10.1007/s00417-010-1425-7; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vlasov Anton, 2015, J Trauma Acute Care Surg, V79, pS210, DOI 10.1097/TA.0000000000000666; Wahls T, 2014, NUTR NEUROSCI, V17, P252, DOI 10.1179/1476830513Y.0000000088; Ward NJ, 2014, J NEUROSCI, V34, P3161, DOI 10.1523/JNEUROSCI.4089-13.2014; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; Yang XJ, 2016, INVEST OPHTH VIS SCI, V57, P2344, DOI 10.1167/iovs.16-19153; Yang XX, 2010, J MOL NEUROSCI, V42, P145, DOI 10.1007/s12031-010-9336-y; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Yu-Wai-Man Patrick, 1800, Taiwan J Ophthalmol, V5, P3; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	47	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	OCT 26	2018	9								1097	10.1038/s41419-018-1061-4			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	GZ5PP	WOS:000449477900003	30367086	Green Published, gold			2022-02-06	
J	Chandran, R; Kim, T; Mehta, SL; Udho, E; Chanana, V; Cengiz, P; Kim, H; Kim, C; Vemuganti, R				Chandran, Raghavendar; Kim, TaeHee; Mehta, Suresh L.; Udho, Eshwar; Chanana, Vishal; Cengiz, Pelin; Kim, HwuiWon; Kim, Chanul; Vemuganti, Raghu			A combination antioxidant therapy to inhibit NOX2 and activate Nrf2 decreases secondary brain damage and improves functional recovery after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Apocynin; brain trauma; combination therapy; oxidative stress; tert-butylhydroquinone	ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR NRF2; INDUCED OXIDATIVE STRESS; NADPH OXIDASE; PERINATAL HYPOXIA; PATHWAY; MICE; MODEL; PRETREATMENT; RESPONSES	Uncontrolled oxidative stress contributes to the secondary neuronal death that promotes long-term neurological dysfunction following traumatic brain injury (TBI). Surprisingly, both NADPH oxidase 2 (NOX2) that increases and transcription factor Nrf2 that decreases reactive oxygen species (ROS) are induced after TBI. As the post-injury functional outcome depends on the balance of these opposing molecular pathways, we evaluated the effect of TBI on the motor and cognitive deficits and cortical contusion volume in NOX2 and Nrf2 knockout mice. Genetic deletion of NOX2 improved, while Nrf2 worsened the post-TBI motor function recovery and lesion volume indicating that decreasing ROS levels might be beneficial after TBI. Treatment with either apocynin (NOX2 inhibitor) or TBHQ (Nrf2 activator) alone significantly improved the motor function after TBI, but had no effect on the lesion volume, compared to vehicle control. Whereas, the combo therapy (apocynin + TBHQ) given at either 5min/24h or 2h/24h improved motor and cognitive function and decreased cortical contusion volume compared to vehicle group. Thus, both the generation and disposal of ROS are important modulators of oxidative stress, and a combo therapy that prevents ROS formation and potentiates ROS disposal concurrently is efficacious after TBI.	[Chandran, Raghavendar; Kim, TaeHee; Mehta, Suresh L.; Kim, HwuiWon; Kim, Chanul; Vemuganti, Raghu] Univ Wisconsin, Dept Neurol Surg, Mail Code CSC 8660 600,Highland Ave, Madison, WI 53792 USA; [Udho, Eshwar; Chanana, Vishal; Cengiz, Pelin] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Vemuganti, Raghu] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA		Vemuganti, R (corresponding author), Univ Wisconsin, Dept Neurol Surg, Mail Code CSC 8660 600,Highland Ave, Madison, WI 53792 USA.	vemuganti@neurosurgery.wisc.edu	Kim, TaeHee/AAS-5541-2020; Chandran, Raghavendar/AAB-9402-2019	Kim, TaeHee/0000-0002-1980-7774; Chandran, Raghavendar/0000-0002-7915-2810	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS083007, NS082957]; US Veterans Administration Merit Review Grant [BX001638]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS088563-01A1]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 HD03352]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD090256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS088563] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partially supported by the National Institutes of Health Grants - NS083007 and NS082957, US Veterans Administration Merit Review Grant (BX001638), K08 NS088563-01A1 from NINDS (Cengiz P) and NIH P30 HD03352 (Waisman Center).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Anilkumar N, 2008, ARTERIOSCL THROM VAS, V28, P1347, DOI 10.1161/ATVBAHA.108.164277; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Boutten A, 2010, EXPERT OPIN THER TAR, V14, P329, DOI 10.1517/14728221003629750; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Calkins MJ, 2009, ANTIOXID REDOX SIGN, V11, P497, DOI [10.1089/ars.2008.2242, 10.1089/ARS.2008.2242]; Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851; Cengiz P, 2011, DEV NEUROSCI-BASEL, V33, P270, DOI 10.1159/000328430; Cengiz P, 2011, ANTIOXID REDOX SIGN, V14, P1803, DOI 10.1089/ars.2010.3468; Chaudhari N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00213; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Cikla U, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0025-15.2015; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coyoy A, 2008, FREE RADICAL BIO MED, V45, P1056, DOI 10.1016/j.freeradbiomed.2008.06.027; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Demaurex N, 2009, NAT NEUROSCI, V12, P819, DOI 10.1038/nn0709-819; Diebold BA, 2015, ANTIOXID REDOX SIGN, V23, P375, DOI 10.1089/ars.2014.5862; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Genovese T, 2011, BRAIN RES, V1372, P92, DOI 10.1016/j.brainres.2010.11.088; Guemez-Gamboa A, 2011, J NEUROPATH EXP NEUR, V70, P1020, DOI 10.1097/NEN.0b013e3182358e4e; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hayes JD, 2006, MOL CELL, V21, P732, DOI 10.1016/j.molcel.2006.03.004; Higashi Y, 2014, J NEUROTRAUM, V31, P1689, DOI 10.1089/neu.2014.3331; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jiang S, 2017, MOL NEUROBIOL, V54, P1440, DOI 10.1007/s12035-016-9707-7; Jin W, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/502564; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kim T, 2016, J NEUROSCI, V36, P7055, DOI 10.1523/JNEUROSCI.1241-16.2016; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li JQ, 2009, EXPERT OPIN THER TAR, V13, P785, DOI 10.1517/14728220903025762; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; Ma MW, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0150-7; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Murotomi K, 2011, MOL CELL NEUROSCI, V46, P681, DOI 10.1016/j.mcn.2011.01.009; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Osier N, 2016, METHODS MOL BIOL, V1462, P177, DOI 10.1007/978-1-4939-3816-2_11; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Stefanska J, 2012, EXP LUNG RES, V38, P90, DOI 10.3109/01902148.2011.649823; Stefanska J, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/106507; Sukumari-Ramesh S, 2016, J MOL NEUROSCI, V58, P525, DOI 10.1007/s12031-016-0722-y; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Uluc K, 2013, CNS NEUROL DISORD-DR, V12, P360, DOI 10.2174/18715273113129990061; von Lohneysen K, 2010, MOL CELL BIOL, V30, P961, DOI 10.1128/MCB.01393-09; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan YP, 2007, J CEREBR BLOOD F MET, V27, P1213, DOI 10.1038/sj.jcbfm.9600432; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yu C, 2017, INT IMMUNOPHARMACOL, V45, P74, DOI 10.1016/j.intimp.2017.01.034; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	67	26	26	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2018	38	10					1818	1827		10.1177/0271678X17738701			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	GV6EM	WOS:000446200600013	29083257	Green Published, Bronze			2022-02-06	
J	Salinsky, M; Rutecki, P; Parko, K; Goy, E; Storzbach, D; O'Neil, M; Binder, L; Joos, S				Salinsky, Martin; Rutecki, Paul; Parko, Karen; Goy, Elizabeth; Storzbach, Daniel; O'Neil, Maya; Binder, Laurence; Joos, Sandra			Psychiatric comorbidity and traumatic brain injury attribution in patients with psychogenic nonepileptic or epileptic seizures: A multicenter study of US veterans	EPILEPSIA			English	Article						psychogenic seizures; PTSD; traumatic brain injury; veterans	POSTTRAUMATIC-STRESS-DISORDER; OUTCOMES; PTSD; IRAQ; DIAGNOSIS; SYMPTOMS; EXPOSURE; HEALTH; PNES	Objective To determine the frequency and severity of psychiatric disorders and attribution of seizures to traumatic brain injury (TBI) in veterans with verified psychogenic nonepileptic seizures (PNES) versus epileptic seizures (ES). Methods Results We studied 333 consecutive admissions to the monitoring units of three Veterans Administration epilepsy centers. All patients underwent continuous video-electroencephalographic recording to define definite PNES or ES. Evaluations included the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th edition, PTSD Checklist, Beck Depression Inventory II, and Patient Seizure Etiology Questionnaire. Interviews and questionnaires were completed prior to final seizure type diagnosis and patient debriefing. The primary outcome measure was a comparison of Axis I psychiatric diagnoses in patients diagnosed with PNES versus ES. A total of 81 patients were diagnosed with PNES, and 70 with ES. PTSD was the most frequent Axis I diagnosis in veterans with PNES (64%, vs 13% of those with ES; P < 0.001). Posttraumatic stress disorder (PTSD) was common regardless of deployment to a war theater or combat exposure. Mood, substance abuse, and anxiety disorders were also more common in the PNES group. TBI was cited as a likely cause of seizures by 47% of veterans with PNES versus 25% of those with ES (P = 0.01). PTSD and attribution of seizures to TBI were found in 30% of veterans with PNES versus 3% of those with ES (P < 0.001). Significance In veterans referred for inpatient seizure evaluation, PTSD was strongly associated with a diagnosis of PNES versus ES. The association of PNES with PTSD, attribution of seizures to TBI, or both, may prompt early consideration of PNES.	[Salinsky, Martin; Goy, Elizabeth; Storzbach, Daniel; O'Neil, Maya; Joos, Sandra] VA Portland Hlth Care Syst, Portland, OR USA; [Salinsky, Martin; Binder, Laurence] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Rutecki, Paul] William S Middleton Mem Vet Affairs Med Ctr, Madison, WI USA; [Parko, Karen] San Francisco VA Med Ctr, San Francisco, CA USA		Salinsky, M (corresponding author), VA Portland Hlth Care Syst, P3ECOE, Epilepsy Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	Salinsky@ohsu.edu			US Department of Veterans AffairsUS Department of Veterans Affairs [5101cx000721-04]	US Department of Veterans Affairs, Grant/Award Number: 5101cx000721-04	Annegers JF, 1996, TREATMENT EPILEPSY P, P166; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Benbadis SR, 1999, EUR NEUROL, V41, P114, DOI 10.1159/000008015; Benbadis SR, 2004, EPILEPSIA, V45, P1150, DOI 10.1111/j.0013-9580.2004.14504.x; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brown RJ, 2016, CLIN PSYCHOL REV, V45, P157, DOI 10.1016/j.cpr.2016.01.003; Department of Veterans Affairs Epilepsy Centers of Excellence, 2016, ANN SUMM; Diprose W, 2016, EPILEPSY BEHAV, V56, P123, DOI 10.1016/j.yebeh.2015.12.037; Dworetzky BA, 2005, EPILEPSIA, V46, P1418, DOI 10.1111/j.1528-1167.2005.13004.x; Ettinger AB, 1999, EPILEPSIA, V40, P1292, DOI 10.1111/j.1528-1157.1999.tb00860.x; Fiszman A, 2004, EPILEPSY BEHAV, V5, P818, DOI 10.1016/j.yebeh.2004.09.002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Josephson CB, 2017, INT REV PSYCHIATR, V29, P409, DOI 10.1080/09540261.2017.1302412; Kansagara D., 2013, COMPLICATIONS MILD T; LaFrance WC, 2008, INT REV NEUROBIOL, V83, P347, DOI 10.1016/S0074-7742(08)00020-2; LaFrance WC, 2014, JAMA PSYCHIAT, V71, P997, DOI 10.1001/jamapsychiatry.2014.817; LaFrance WC, 2013, EPILEPSIA, V54, P2005, DOI 10.1111/epi.12356; LaFrance WC, 2013, EPILEPSIA, V54, P718, DOI 10.1111/epi.12053; LaFrance WC, 2006, EPILEPSY BEHAV, V8, P451, DOI 10.1016/j.yebeh.2006.02.004; McKenzie P, 2010, NEUROLOGY, V74, P64, DOI 10.1212/WNL.0b013e3181c7da6a; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Myers L, 2017, EPILEPSY BEHAV, V66, P86, DOI 10.1016/j.yebeh.2016.10.019; Myers L, 2013, EPILEPSY BEHAV, V28, P121, DOI 10.1016/j.yebeh.2013.03.033; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Reuber M, 2003, ANN NEUROL, V53, P305, DOI 10.1002/ana.3000; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Salinsky M, 2016, EPILEPSY BEHAV, V57, P141, DOI 10.1016/j.yebeh.2016.02.003; Salinsky M, 2015, J HEAD TRAUMA REHAB, V30, pE65, DOI 10.1097/HTR.0000000000000057; Salinsky M, 2012, EPILEPSY BEHAV, V25, P345, DOI 10.1016/j.yebeh.2012.07.013; Salinsky M, 2011, NEUROLOGY, V77, P945, DOI 10.1212/WNL.0b013e31822cfc46; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Sharpe D, 2006, CLIN PSYCHOL REV, V26, P1020, DOI 10.1016/j.cpr.2005.11.011; Storzbach D, 2015, J INT NEUROPSYCH SOC, V21, P353, DOI 10.1017/S1355617715000326; Tellegen, 2008, MINNESOTA MULTIPHASI; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 2004, TOMM TESTS MEMORY MA; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	40	26	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	OCT	2018	59	10					1945	1953		10.1111/epi.14542			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	GZ5TO	WOS:000449491800011	30144027				2022-02-06	
J	Haber, M; James, J; Kim, J; Sangobowale, M; Irizarry, R; Ho, J; Nikulina, E; Grin'kina, NM; Ramadani, A; Hartman, I; Bergold, PJ				Haber, Margalit; James, Jessica; Kim, Justine; Sangobowale, Michael; Irizarry, Rachel; Ho, Johnson; Nikulina, Elena; Grin'kina, Natalia M.; Ramadani, Albana; Hartman, Isabella; Bergold, Peter J.			Minocycline plus N-acteylcysteine induces remyelination, synergistically protects oligodendrocytes and modifies neuroinflammation in a rat model of mild traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Brain trauma; immunohistochemistry; inflammation; microglia; white matter; oligodendrocytes	WHITE-MATTER INJURY; TUMOR-NECROSIS-FACTOR; MICROGLIA/MACROPHAGE POLARIZATION; MULTIPLE-SCLEROSIS; WORKING-MEMORY; NITRIC-OXIDE; CELL-DEATH; ACETYLCYSTEINE; INFLAMMATION; ACTIVATION	Mild traumatic brain injury afflicts over 2 million people annually and little can be done for the underlying injury. The Food and Drug Administration-approved drugs Minocycline plus N-acetylcysteine (MINO plus NAC) synergistically improved cognition and memory in a rat mild controlled cortical impact (mCCI) model of traumatic brain injury.(3) The underlying cellular and molecular mechanisms of the drug combination are unknown. This study addressed the effect of the drug combination on white matter damage and neuroinflammation after mCCI. Brain tissue from mCCI rats given either sham-injury, saline, MINO alone, NAC alone, or MINO plus NAC was investigated via histology and qPCR at four time points (2, 4, 7, and 14 days post-injury) for markers of white matter damage and neuroinflammation. MINO plus NAC synergistically protected resident oligodendrocytes and decreased the number of oligodendrocyte precursor cells. Activation of microglia/macrophages (MP/MG) was synergistically increased in white matter two days post-injury after MINO plus NAC treatment. Patterns of M1 and M2 MP/MG were also altered after treatment. The modulation of neuroinflammation is a potential mechanism to promote remyelination and improve cognition and memory. These data also provide new and important insights into how drug treatments can induce repair after traumatic brain injury.	[Haber, Margalit; James, Jessica; Kim, Justine; Sangobowale, Michael; Irizarry, Rachel; Ho, Johnson; Nikulina, Elena; Grin'kina, Natalia M.; Ramadani, Albana; Hartman, Isabella; Bergold, Peter J.] Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA		Bergold, PJ (corresponding author), Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Box 29,450 Clarkson Ave, Brooklyn, NY 11203 USA.	pbergold@downstate.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1070512]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the NIH grant RO1070512 to P.J.B.	Abdel Baki SG, 2010, PLOS ONE, V5; Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; ALLT G, 1988, ACTA NEUROPATHOL, V75, P456, DOI 10.1007/BF00687132; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Baron W, 2002, EMBO J, V21, P1957, DOI 10.1093/emboj/21.8.1957; Barros MHM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080908; Birch AM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-25; Blakemore WF, 2008, CURR TOP MICROBIOL, V318, P193; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bramow S, 2010, BRAIN, V133, P2983, DOI 10.1093/brain/awq250; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; Burke NN, 2014, BRAIN BEHAV IMMUN, V42, P147, DOI 10.1016/j.bbi.2014.06.015; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Carty ML, 2008, INT J DEV NEUROSCI, V26, P477, DOI 10.1016/j.ijdevneu.2008.02.005; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cikla U, 2016, J NEUROIMMUNOL, V291, P18, DOI 10.1016/j.jneuroim.2015.12.004; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cui JX, 2016, J NEUROPHYSIOL, V116, P2892, DOI 10.1152/jn.00603.2016; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Bundel D, 2011, J NEUROSCI, V31, P5792, DOI 10.1523/JNEUROSCI.5465-10.2011; Dean O, 2011, J PSYCHIATR NEUROSCI, V36, P78, DOI 10.1503/jpn.100057; Drescher KM, 2000, BRAIN PATHOL, V10, P1; Duncan ID, 2009, P NATL ACAD SCI USA, V106, P6832, DOI 10.1073/pnas.0812500106; ELLISON JA, 1994, J NEUROSCI RES, V37, P116, DOI 10.1002/jnr.490370116; Fan LW, 2005, J NEUROSCI RES, V82, P71, DOI 10.1002/jnr.20623; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Grin'kina NM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053775; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hellewell SC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/356494; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Jackson SJ, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-76; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karalija A, 2014, NEUROSCIENCE, V269, P143, DOI 10.1016/j.neuroscience.2014.03.042; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar S, 2013, CLIN NEUROL NEUROSUR, V115, P1326, DOI 10.1016/j.clineuro.2012.12.038; Lampron A, 2015, J EXP MED, V212, P481, DOI 10.1084/jem.20141656; Lechpammer M, 2008, NEUROPATH APPL NEURO, V34, P379, DOI 10.1111/j.1365-2990.2007.00925.x; Lee SM, 2004, J NEUROCHEM, V91, P568, DOI 10.1111/j.1471-4159.2004.02780.x; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li JR, 2008, J NEUROSCI, V28, P5321, DOI 10.1523/JNEUROSCI.3995-07.2008; Licinio J, 1999, MOL MED TODAY, V5, P225, DOI 10.1016/S1357-4310(99)01453-7; Liu MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043924; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Nayak A, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/563784; Patel J, 2012, INT J MOL SCI, V13, P10647, DOI 10.3390/ijms130810647; Peferoen LAN, 2015, J NEUROPATH EXP NEUR, V74, P48, DOI 10.1097/NEN.0000000000000149; Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471-4159.2004.02796.x; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Prins M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083835; Rawji KS, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/948976; Riediger T, 2010, PHARMACOL BIOCHEM BE, V97, P112, DOI 10.1016/j.pbb.2010.04.015; Rojo AI, 2014, ANTIOXID REDOX SIGN, V21, P1766, DOI 10.1089/ars.2013.5745; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Shahripour RB, 2014, BRAIN BEHAV, V4, P108, DOI 10.1002/brb3.208; Simpson JE, 2007, NEUROPATH APPL NEURO, V33, P670, DOI 10.1111/j.1365-2990.2007.00890.x; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; VICK RS, 1992, J NEUROTRAUM, V9, pS93; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Yeo YA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-173; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055	78	26	27	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2018	38	8					1312	1326		10.1177/0271678X17718106			15	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	GP2OQ	WOS:000440674900005	28685618	Green Published, Bronze			2022-02-06	
J	Lee, DJ; Kearns, JC; Wisco, BE; Green, JD; Gradus, JL; Sloan, DM; Nock, MK; Rosen, RC; Keane, TM; Marx, BP				Lee, Daniel J.; Kearns, Jaclyn C.; Wisco, Blair E.; Green, Jonathan D.; Gradus, Jaimie L.; Sloan, Denise M.; Nock, Matthew K.; Rosen, Raymond C.; Keane, Terence M.; Marx, Brian P.			A longitudinal study of risk factors for suicide attempts among Operation Enduring Freedom and Operation Iraqi Freedom veterans	DEPRESSION AND ANXIETY			English	Article						alcoholism/alcohol use disorders; PTSD/posttraumatic stress disorder; suicide/self harm; trauma; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; COGNITIVE-BEHAVIORAL THERAPY; NONSUICIDAL SELF-INJURY; TRAUMATIC BRAIN-INJURY; MILITARY PERSONNEL; ACTIVE-DUTY; PRIMARY-CARE; PREVALENCE; IDEATION	Background: Suicide rates among veterans have increased markedly since the onset of Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF; LeardMann etal., 2013). Identification of factors with the greatest contribution to suicide risk among veterans is needed to inform risk assessment and to identify intervention targets. Methods: This study examined predictors of suicide attempts among participants in the Veterans After-Discharge Longitudinal Registry; a nationwide cohort of OEF/OIF veterans enrolled in Department of Veterans Affairs (VA) services. Veterans with and without probable posttraumatic stress disorder (PTSD) were sampled at a 3:1 ratio, and male and female veterans were sampled at a 1:1 ratio. Participants (N=1,649) were assessed at two time points, roughly 2 years apart (M=28.74 months, SD=8.72). Results: Seventy-four participants (4.49%) attempted suicide during the follow-up period. The strongest predictors of suicide attempts among the full sample were suicidal intent, attempt history, suicide ideation, PTSD symptoms, alcohol use disorder (AUD) symptoms, and depression. Veterans with multiple risk factors were particularly vulnerable; of veterans with 0, 1, 2, 3, or 4 of these risk factors, 0%, 7.81%, 10.31%, 18.45%, and 20.51% made a suicide attempt, respectively. Conclusions: This prospective study identified several strong predictors of suicide attempts among OEF/OIF veterans which may be important targets for suicide prevention efforts. Further, co-occurrence of multiple risk factors was associated with markedly greater risk for suicide attempts; veterans with multiple risk factors appear to be at the highest risk among OEF/OIF veterans enrolled in VA care.	[Lee, Daniel J.; Gradus, Jaimie L.; Sloan, Denise M.; Keane, Terence M.; Marx, Brian P.] Natl Ctr PTSD, Boston, MA USA; [Lee, Daniel J.; Kearns, Jaclyn C.; Green, Jonathan D.; Gradus, Jaimie L.; Sloan, Denise M.; Keane, Terence M.; Marx, Brian P.] VA Boston Healthcare Syst, Boston, MA USA; [Lee, Daniel J.; Green, Jonathan D.; Sloan, Denise M.; Keane, Terence M.; Marx, Brian P.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kearns, Jaclyn C.] Univ Rochester, Dept Clin & Social Sci Psychol, Rochester, NY USA; [Wisco, Blair E.] Univ North Carolina Greensboro, Dept Psychol, Greensboro, NC USA; [Nock, Matthew K.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA; [Rosen, Raymond C.] New England Res Inst Inc, Watertown, MA USA		Marx, BP (corresponding author), 150 South HuntingtonAve 116B-4, Boston, MA 02130 USA.	Brian.Marx@VA.gov	Marx, Brian/AAK-5072-2020; Nock, Matthew/AAE-8330-2019; Keane, Terence/I-8253-2014	Sloan, Denise/0000-0002-0962-478X; Kearns, Jaclyn/0000-0001-9246-9057; Keane, Terence/0000-0002-0482-3149	U.S. Department of DefenseUnited States Department of Defense [W81XWH-08-2-0100/W81XWH-082-0102, W81XWH-12-2-0117/W81XWH-12-20121]	U.S. Department of Defense, Grant/Award Numbers: W81XWH-08-2-0100/W81XWH-082-0102, W81XWH-12-2-0117/W81XWH-12-20121	Benda BB, 2005, SUICIDE LIFE-THREAT, V35, P106, DOI 10.1521/suli.35.1.106.59262; Black SA, 2011, MIL PSYCHOL, V23, P433, DOI 10.1080/08995605.2011.590409; Borges G, 2010, J CLIN PSYCHIAT, V71, P1617, DOI 10.4088/JCP.08m04967blu; Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brown GK, 2005, JAMA-J AM MED ASSOC, V294, P563, DOI 10.1001/jama.294.5.563; Bryan CJ, 2016, DEPRESS ANXIETY, V33, P549, DOI 10.1002/da.22456; Bryan CJ, 2015, SUICIDE LIFE-THREAT, V45, P315, DOI 10.1111/sltb.12127; Bryan CJ, 2014, COMPR PSYCHIAT, V55, P534, DOI 10.1016/j.comppsych.2013.10.006; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; de Klerk S, 2011, J AFFECT DISORDERS, V133, P257, DOI 10.1016/j.jad.2011.03.021; Department of the Army, 2010, HLTH PROM RISK RED S; Enders C. K., 2010, APPL MISSING DATA AN; First MB, 1995, STRUCTURED CLIN INTE; Franklin JC, 2016, J CONSULT CLIN PSYCH, V84, P544, DOI 10.1037/ccp0000093; Gibbons RD, 2012, AM J PUBLIC HEALTH, V102, pS17, DOI 10.2105/AJPH.2011.300491; Gradus JL, 2013, SUICIDE LIFE-THREAT, V43, P574, DOI 10.1111/sltb.12040; Gradus JL, 2013, DEPRESS ANXIETY, V30, P1046, DOI 10.1002/da.22117; Gradus JL, 2013, SUICIDE LIFE-THREAT, V43, P39, DOI 10.1111/j.1943-278X.2012.00126.x; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI 10.1177/1073191104269954; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; Gysin-Maillart A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001968; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Ilgen MA, 2012, J CONSULT CLIN PSYCH, V80, P323, DOI 10.1037/a0028266; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kang HK, 2015, ANN EPIDEMIOL, V25, P96, DOI 10.1016/j.annepidem.2014.11.020; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Kaplan MS, 2007, AM J ORTHOPSYCHIAT, V77, P56, DOI 10.1037/0002-9432.77.1.56; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kimbrel NA, 2016, PSYCHIAT RES, V243, P97, DOI 10.1016/j.psychres.2016.06.011; Kimbrel NA, 2015, PSYCHIAT RES, V227, P360, DOI 10.1016/j.psychres.2015.03.026; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Klonsky ED, 2014, SUICIDE LIFE-THREAT, V44, P1, DOI 10.1111/sltb.12068; Kraemer HC, 1992, EVALUATING MED TESTS; Lambert MT, 1997, J MENT HEALTH ADMIN, V24, P350, DOI 10.1007/BF02832668; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; Maguen S, 2015, J PSYCHIATR RES, V68, P120, DOI 10.1016/j.jpsychires.2015.06.013; Maguen S, 2011, J ANXIETY DISORD, V25, P563, DOI 10.1016/j.janxdis.2011.01.003; May AM, 2016, CLIN PSYCHOL-SCI PR, V23, P5, DOI 10.1111/cpsp.12136; McLean CP, 2017, J AFFECT DISORDERS, V208, P392, DOI 10.1016/j.jad.2016.08.061; Muthen LK, 1998, MPLUS USERS GUIDE, V8th; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Nock MK, 2007, PSYCHOL ASSESSMENT, V19, P309, DOI 10.1037/1040-3590.19.3.309; Nock MK, 2006, J ABNORM PSYCHOL, V115, P616, DOI 10.1037/0021-843X.115.3.616; Nock MK, 2016, DEPRESS ANXIETY, V33, P460, DOI 10.1002/da.22528; Nock MK, 2016, CLIN PSYCHOL-SCI PR, V23, P31, DOI 10.1111/cpsp.12133; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Park S, 2012, PSYCHIAT RES, V198, P509, DOI 10.1016/j.psychres.2012.01.028; Pfeiffer PN, 2009, DEPRESS ANXIETY, V26, P752, DOI 10.1002/da.20583; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Ribeiro JD, 2016, PSYCHOL MED, V46, P225, DOI 10.1017/S0033291715001804; Rosen RC, 2012, INT J METH PSYCH RES, V21, P5, DOI 10.1002/mpr.355; Rudd MD, 2015, AM J PSYCHIAT, V172, P441, DOI 10.1176/appi.ajp.2014.14070843; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Stein DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010574; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tiet QQ, 2006, PSYCHIAT SERV, V57, P107, DOI 10.1176/appi.ps.57.1.107; Ursano RJ, 2015, DEPRESS ANXIETY, V32, P3, DOI 10.1002/da.22317; Weathers F.W., 1993, ANN M INT SOC TRAUM; Wiborg JF, 2013, PSYCHOSOM MED, V75, P800, DOI 10.1097/PSY.0000000000000013; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; [No title captured]	65	26	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269	1520-6394		DEPRESS ANXIETY	Depress. Anxiety	JUL	2018	35	7					609	618		10.1002/da.22736			10	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	GM0RR	WOS:000437763700003	29637667	Bronze			2022-02-06	
J	Dai, WJ; Liu, AZ; Kaminga, AC; Deng, J; Lai, ZW; Yang, JZ; Wen, SW				Dai, Wenjie; Liu, Aizhong; Kaminga, Atipatsa C.; Deng, Jing; Lai, Zhiwei; Yang, Jianzhou; Wen, Shi Wu			Prevalence of acute stress disorder among road traffic accident survivors: a meta-analysis	BMC PSYCHIATRY			English	Article						Acute stress disorder; Road traffic accident; Prevalence; meta-analysis	MOTOR-VEHICLE ACCIDENTS; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS; RANDOMIZED-TRIALS; RISK-FACTORS; CHILDREN; SYMPTOMS; ASSOCIATION; ADOLESCENTS; DEPRESSION	Background: Road traffic accident (RTA), an unexpected traumatic event, may not only lead to death and serious physical injuries, but also could put survivors at an increased risk for a wide range of psychiatric disorders, particularly acute stress disorder (ASD). Early assessment of trauma-related psychological responses is important because acute trauma responses in the early post-traumatic period are among the robust predictors of long-term mental health problems. However, estimates of the prevalence of ASD among RTA survivors varied considerably across studies. Therefore, this meta-analysis aimed to identify the pooled prevalence of ASD among RTA survivors. Methods: A systematic literature search in the databases of PubMed, PsycINFO, PsycARTICLES, Embase and Web of Science was performed from their inception dates to December 2017. Subject headings were used to identify relevant articles, and the search strategy was adjusted across databases. Heterogeneity across studies was evaluated by Cochran's chi(2) test and quantified by the I-2 statistic. Subgroup analyses were performed to identify the pooled prevalence in relation to the country of study, instrument used to identify ASD, age, gender and traumatic brain injury. When significant heterogeneity was observed, the influence of some potential moderators was explored using meta-regression analyses. Results: Thirteen eligible studies conducted in 8 countries were included. A total of 2989 RTA survivors were assessed, of which 287 were identified with ASD. The overall heterogeneity was high across studies (I-2=96.8%, P < 0.001), and the pooled prevalence of ASD among RTA survivors was 15.81% (95% confidence interval: 8.27-25.14%). Subgroup analyses indicated that the prevalence of ASD among RTA survivors differed significantly with regard to the country of study, instrument used to identify ASD, age and gender (P < 0.05). Meta-regression analyses showed that mean age of participants and quality assessment score were significant moderators for heterogeneity (P < 0.05). Conclusions: Nearly one-sixth of RTA survivors suffer from ASD, indicating the need for regular assessment of early trauma responses among RTA survivors, as well as the importance of implementing early psychological interventions.	[Dai, Wenjie; Liu, Aizhong; Kaminga, Atipatsa C.; Deng, Jing; Wen, Shi Wu] Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China; [Dai, Wenjie; Wen, Shi Wu] Univ Ottawa, Dept Obstet & Gynecol, OMNI Res Grp, Fac Med, Ottawa, ON, Canada; [Dai, Wenjie; Wen, Shi Wu] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Dai, Wenjie; Wen, Shi Wu] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Fac Med, Ottawa, ON, Canada; [Kaminga, Atipatsa C.] Mzuzu Univ, Dept Math, Mzuzu, Malawi; [Lai, Zhiwei] Hunan Prov Ctr Dis Control & Prevent, Immunizat Programme Dept, Changsha, Hunan, Peoples R China; [Yang, Jianzhou] Changzhi Med Coll, Dept Prevent Med, Changzhi, Shanxi, Peoples R China		Liu, AZ; Wen, SW (corresponding author), Cent S Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China.; Wen, SW (corresponding author), Univ Ottawa, Dept Obstet & Gynecol, OMNI Res Grp, Fac Med, Ottawa, ON, Canada.; Wen, SW (corresponding author), Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.; Wen, SW (corresponding author), Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Fac Med, Ottawa, ON, Canada.	lazroy@live.cn; swwen@ohri.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [FDN-148438]; Specialized Research Fund for the Doctoral Program of Higher EducationSpecialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [20130162110054]; Natural Science Foundation of Hunan Province, ChinaNatural Science Foundation of Hunan Province [2016JJ2153]; Fundamental Research Funds for the postgraduates of Central South University [2015zzts282]; Applied Basic Research Project of Shanxi Province [2016011092]	This study was supported in part, by the Canadian Institutes of Health Research (FDN-148438), the Specialized Research Fund for the Doctoral Program of Higher Education (20130162110054), the Natural Science Foundation of Hunan Province, China (2016JJ2153), the Fundamental Research Funds for the postgraduates of Central South University (2015zzts282), and the Applied Basic Research Project of Shanxi Province (2016011092).	Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; Alisic E, 2011, CLIN PSYCHOL REV, V31, P736, DOI 10.1016/j.cpr.2011.03.001; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bassuk EL, 2015, J AM ACAD CHILD PSY, V54, P86, DOI 10.1016/j.jaac.2014.11.008; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant B, 2004, PSYCHOL MED, V34, P335, DOI 10.1017/S0033291703001053; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 2003, AUST NZ J PSYCHIAT, V37, P226, DOI 10.1046/j.1440-1614.2003.01130.x; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2011, DEPRESS ANXIETY, V28, P802, DOI 10.1002/da.20737; Dai WJ, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0891-9; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Einsle F, 2012, J PSYCHOSOM RES, V72, P434, DOI 10.1016/j.jpsychores.2012.02.008; Elklit Ask, 2003, Violence Vict, V18, P461, DOI 10.1891/vivi.2003.18.4.461; Fernandez CA, 2017, INT J EPIDEMIOL, V46, P440, DOI 10.1093/ije/dyw094; Fuglsang AK, 2004, NORD J PSYCHIAT, V58, P223, DOI 10.1080/08039480410006278; Griffiths J, 2007, INTENS CARE MED, V33, P1506, DOI 10.1007/s00134-007-0730-z; Haag AC, 2015, EUR J PSYCHOTRAUMATO, V6, DOI 10.3402/ejpt.v6.29074; Hamanaka S, 2006, GEN HOSP PSYCHIAT, V28, P234, DOI 10.1016/j.genhosppsych.2006.02.007; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Kessler RC, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1353383; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; Ladeira Roberto Marini, 2017, Rev. bras. epidemiol., V20, P157, DOI 10.1590/1980-5497201700050013; Li XM, 2017, J AFFECT DISORDERS, V218, P322, DOI 10.1016/j.jad.2017.03.048; Loney P L, 1998, Chronic Dis Can, V19, P170; McKibben JBA, 2008, J BURN CARE RES, V29, P22, DOI 10.1097/BCR.0b013e31815f59c4; Meiser-Stedman R, 2007, J TRAUMA STRESS, V20, P359, DOI 10.1002/jts.20211; Melroy-Greif WE, 2017, TWIN RES HUM GENET, V20, P197, DOI 10.1017/thg.2017.12; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Muldoon OT, 2003, J CHILD PSYCHOL PSYC, V44, P193, DOI 10.1111/1469-7610.00113; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Pailler ME, 2007, GEN HOSP PSYCHIAT, V29, P357, DOI 10.1016/j.genhosppsych.2007.04.003; Roberge MA, 2008, PSYCHOSOM MED, V70, P1028, DOI 10.1097/PSY.0b013e318189a920; Salmon K, 2007, BRIT J CLIN PSYCHOL, V46, P203, DOI 10.1348/014466506X160704; Siqveland J, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00164; Spottswood M, 2017, HARVARD REV PSYCHIAT, V25, P159, DOI 10.1097/HRP.0000000000000136; Staab JP, 1996, ANXIETY, V2, P219, DOI 10.1002/(SICI)1522-7154(1996)2:5<219::AID-ANXI3>3.0.CO;2-H; Swartzman S, 2017, DEPRESS ANXIETY, V34, P327, DOI 10.1002/da.22542; Tousignant B, 2018, NEUROPSYCHOL REHABIL, V28, P429, DOI 10.1080/09602011.2016.1158114; van den Heuvel L, 2016, ANXIETY STRESS COPIN, V29, P616, DOI 10.1080/10615806.2016.1163545; Vasterling JJ, 2018, J INT NEUROPSYCH SOC, V24, P311, DOI 10.1017/S1355617717001059; Williamson V, 2018, AM J GERIAT PSYCHIAT, V26, P534, DOI 10.1016/j.jagp.2017.11.001; Wilson JL, 2017, VET REC, V180, P195, DOI 10.1136/vr.103859; Winston FK, 2005, ARCH PEDIAT ADOL MED, V159, P1074, DOI 10.1001/archpedi.159.11.1074; Winston FK, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e90; Yahav R, 2007, SOC PSYCH PSYCH EPID, V42, P830, DOI 10.1007/s00127-007-0237-5; Yang CS, 2017, TRAFFIC INJ PREV, V18, P724, DOI 10.1080/15389588.2017.1309650; Yasan A, 2009, PSYCHOPATHOLOGY, V42, P236, DOI 10.1159/000218521; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zhang LJ, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1234-1; Zhou PL, 2016, PSYCH J, V5, P206, DOI 10.1002/pchj.136	56	26	26	2	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-244X			BMC PSYCHIATRY	BMC Psychiatry	JUN 13	2018	18								188	10.1186/s12888-018-1769-9			11	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	GJ5GT	WOS:000435410200003	29895273	Green Published, gold			2022-02-06	
J	Ong, LK; Chow, WZ; Tebay, C; Kluge, M; Pietrogrande, G; Zalewska, K; Crock, P; Aberg, D; Bivard, A; Johnson, SJ; Walker, FR; Nilsson, M; Isgaard, J				Ong, Lin Kooi; Chow, Wei Zhen; Tebay, Clifford; Kluge, Murielle; Pietrogrande, Giovanni; Zalewska, Katarzyna; Crock, Patricia; Aberg, David; Bivard, Andrew; Johnson, Sarah J.; Walker, Frederick R.; Nilsson, Michael; Isgaard, Jorgen			Growth Hormone Improves Cognitive Function After Experimental Stroke	STROKE			English	Article						cognition; growth hormone; insulin-like growth factor-1; neuronal plasticity; stroke; vascular endothelial growth factor A; vascular remodeling	TRAUMATIC BRAIN-INJURY; STRESS-INDUCED DISRUPTION; FOCAL CEREBRAL-ISCHEMIA; PHOTOTHROMBOTIC STROKE; SECONDARY NEURODEGENERATION; REPLACEMENT THERAPY; GH REPLACEMENT; MICE; PERFORMANCE; POSTSTROKE	Background and Purpose-Cognitive impairment is a common outcome for stroke survivors. Growth hormone (GH) could represent a potential therapeutic option as this peptide hormone has been shown to improve cognition in various clinical conditions. In this study, we evaluated the effects of peripheral administration of GH at 48 hours poststroke for 28 days on cognitive function and the underlying mechanisms. Methods-Experimental stroke was induced by photothrombotic occlusion in young adult mice. We assessed the associative memory cognitive domain using mouse touchscreen platform for paired-associate learning task. We also evaluated neural tissue loss, neurotrophic factors, and markers of neuroplasticity and cerebrovascular remodeling using biochemical and histology analyses. Results-Our results show that GH-treated stroked mice made a significant improvement on the paired-associate learning task relative to non-GH-treated mice at the end of the study. Furthermore, we observed reduction of neural tissue loss in GH-treated stroked mice. We identified that GH treatment resulted in significantly higher levels of neurotrophic factors (IGF-1 [insulin-like growth factor-1] and VEGF [vascular endothelial growth factor]) in both the circulatory and peri-infarct regions. GH treatment in stroked mice not only promoted protein levels and density of presynaptic marker (SYN-1 [synapsin-1]) and marker of myelination (MBP [myelin basic protein]) but also increased the density and area coverage of 2 major vasculature markers (CD31 and collagen-IV), within the peri-infarct region. Conclusions-These findings provide compelling preclinical evidence for the usage of GH as a potential therapeutic tool in the recovery phase of patients after stroke. Visual Overview-An online visual overview is available for this article.	[Ong, Lin Kooi; Walker, Frederick R.; Nilsson, Michael; Isgaard, Jorgen] Univ Newcastle, Prior Res Ctr Stroke & Brain Injury, Callaghan, NSW, Australia; [Chow, Wei Zhen; Tebay, Clifford; Kluge, Murielle; Pietrogrande, Giovanni; Zalewska, Katarzyna] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia; [Crock, Patricia] Univ Newcastle, John Hunter Childrens Hosp, Prior Res Ctr Grow Well, Dept Paediat Endocrinol & Diabet, Callaghan, NSW, Australia; [Johnson, Sarah J.] Univ Newcastle, Sch Elect Engn & Comp, Callaghan, NSW, Australia; [Bivard, Andrew] Univ Newcastle, John Hunter Hosp, Dept Neurol, Callaghan, NSW, Australia; [Ong, Lin Kooi; Chow, Wei Zhen; Tebay, Clifford; Kluge, Murielle; Pietrogrande, Giovanni; Zalewska, Katarzyna; Bivard, Andrew; Johnson, Sarah J.; Walker, Frederick R.; Nilsson, Michael] Hunter Med Res Inst, New Lambton Hts, NSW 2305, Australia; [Ong, Lin Kooi; Walker, Frederick R.; Nilsson, Michael] Natl Hlth & Med Res Council Ctr Res Excellence St, New Lambton Hts, NSW, Australia; [Isgaard, Jorgen] Univ Gothenburg, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil, Gothenburg, Sweden; [Isgaard, Jorgen] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Internal Med, Gothenburg, Sweden		Ong, LK (corresponding author), Hunter Med Res Inst, New Lambton Hts, NSW 2305, Australia.; Isgaard, J (corresponding author), Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Internal Med, Gothenburg, Sweden.	jorgen.isgaard@medic.gu.se	Aberg, N. David/O-4068-2019; NILSSON, MICHAEL/ABE-7821-2020; Ong, Lin Kooi/H-2797-2012	NILSSON, MICHAEL/0000-0002-8826-1621; Ong, Lin Kooi/0000-0001-8664-0540	Swedish Government [ALFGBG 74 390]; University of Gothenburg; James S. McDonnell Foundation; Hunter Medical Research Institute; Brawn Bequest; Priority Research Centre for Stroke and Brain Injury Research Support Grant; Mary Costello Alzheimer's Pilot Grant; University of Newcastle, Australia	This study was supported by the Swedish Government (ALFGBG 74 390), University of Gothenburg, James S. McDonnell Foundation, Hunter Medical Research Institute, The Brawn Bequest, Priority Research Centre for Stroke and Brain Injury Research Support Grant, Mary Costello Alzheimer's Pilot Grant, and The University of Newcastle, Australia.	Aberg D, 2011, J CLIN ENDOCR METAB, V96, pE1055, DOI 10.1210/jc.2010-2802; Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Balkaya MG, 2018, BEHAV BRAIN RES, V352, P161, DOI 10.1016/j.bbr.2017.07.039; Barnett JH, 2016, CURR TOP BEHAV NEURO, V28, P449, DOI 10.1007/7854_2015_5001; Devesa J, 2016, CLIN MED INSIGHTS-EN, V9, P47, DOI 10.4137/CMEDED.S38201; Devesa J, 2013, HORM BEHAV, V63, P331, DOI 10.1016/j.yhbeh.2012.02.022; Diederich K, 2014, STROKE, V45, P614, DOI 10.1161/STROKEAHA.113.001907; Enhamre-Brolin E, 2013, BEHAV BRAIN RES, V238, P273, DOI 10.1016/j.bbr.2012.10.036; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Horner AE, 2013, NAT PROTOC, V8, P1961, DOI 10.1038/nprot.2013.122; Johnson SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10607; Kluge MG, 2017, GLIA, V65, P1885, DOI 10.1002/glia.23201; Kongsui R, 2015, NEUROSCIENCE, V310, P629, DOI 10.1016/j.neuroscience.2015.09.061; Kuhn HG, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a025981; Labat-gest V, 2013, JOVE-J VIS EXP, DOI 10.3791/50370; Lee DR, 2003, BRAIN RES, V989, P221, DOI 10.1016/S0006-8993(03)03373-0; Lee SC, 2010, EUR J NEUROL, V17, P45, DOI 10.1111/j.1468-1331.2009.02731.x; Levine DA, 2015, JAMA-J AM MED ASSOC, V314, P41, DOI 10.1001/jama.2015.6968; Moreau OK, 2013, J NEUROTRAUM, V30, P998, DOI 10.1089/neu.2012.2705; Nithianantharajah J, 2015, SCI REP-UK, V5, DOI 10.1038/srep14613; Nyberg F, 2013, NAT REV ENDOCRINOL, V9, P357, DOI 10.1038/nrendo.2013.78; Ong LK, 2017, J CEREBR BLOOD F MET, V37, P1338, DOI 10.1177/0271678X16654920; Ong LK, 2017, BRAIN BEHAV IMMUN, V60, P117, DOI 10.1016/j.bbi.2016.10.001; Pathipati P, 2009, BEHAV BRAIN RES, V204, P93, DOI 10.1016/j.bbr.2009.05.023; Reimunde P, 2011, BRAIN INJURY, V25, P65, DOI 10.3109/02699052.2010.536196; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Schmidt A, 2015, STROKE, V46, P1127, DOI 10.1161/STROKEAHA.115.008905; Shepherd A, 2016, J MOL NEUROSCI, V60, P371, DOI 10.1007/s12031-016-0837-1; Song J, 2012, ANN REHABIL MED-ARM, V36, P447, DOI 10.5535/arm.2012.36.4.447; Stochholm K, 2018, CLIN ENDOCRINOL, V88, P515, DOI 10.1111/cen.13502; Sun JH, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.05; Thoren AE, 2005, J CEREBR BLOOD F MET, V25, P440, DOI 10.1038/sj.jcbfm.9600035; Tynan RJ, 2013, ACTA NEUROPATHOL, V126, P75, DOI 10.1007/s00401-013-1102-0; Walker FR, 2014, J CEREBR BLOOD F MET, V34, P208, DOI 10.1038/jcbfm.2013.211; Walser M, 2011, GROWTH HORM IGF RES, V21, P16, DOI 10.1016/j.ghir.2010.11.002; Waters M J, 2011, Pediatr Endocrinol Rev, V9, P549; Weinstein G, 2014, INT J STROKE, V9, P48, DOI 10.1111/ijs.12275; Yanev P, 2017, J CEREBR BLOOD F MET, V37, P2768, DOI 10.1177/0271678X16674737; Zalewska K, 2017, BRAIN BEHAV IMMUN; Zalewska K, 2018, BRAIN BEHAV IMMUN, V69, P210, DOI 10.1016/j.bbi.2017.11.014; Zalewska K, 2017, NEUROSCIENCE, V352, P30, DOI 10.1016/j.neuroscience.2017.03.005; Zhang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108518; Zhao Z, 2017, CEREB BLOOD FLOW MET; Zhao ZD, 2017, J CEREBR BLOOD F MET, V37, P3709, DOI 10.1177/0271678X17696100	46	26	27	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	MAY	2018	49	5					1257	+		10.1161/STROKEAHA.117.020557			23	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	GD7AX	WOS:000430662100043	29636425	Bronze			2022-02-06	
J	Thurman, DJ; Begley, CE; Carpio, A; Helmers, S; Hesdorffer, DC; Mu, J; Toure, K; Parko, KL; Newton, CR				Thurman, David J.; Begley, Charles E.; Carpio, Arturo; Helmers, Sandra; Hesdorffer, Dale C.; Mu, Jie; Toure, Kamadore; Parko, Karen L.; Newton, Charles R.			The primary prevention of epilepsy: A report of the Prevention Task Force of the International League Against Epilepsy	EPILEPSIA			English	Article						central nervous system infection; epidemiology; etiology; perinatal brain injury; prevalence; stroke; traumatic brain injury	ACTIVE CONVULSIVE EPILEPSY; NEW-ONSET EPILEPSY; LONG-TERM RISK; GLOBAL LEVELS; RURAL AREA; PREVALENCE; POPULATION; SEIZURES; NEUROCYSTICERCOSIS; ETIOLOGY	Among the causes of epilepsy are several that are currently preventable. In this review, we summarize the public health burden of epilepsy arising from such causes and suggest priorities for primary epilepsy prevention. We conducted a systematic review of published epidemiologic studies of epilepsy of 4 preventable etiologic categoriesperinatal insults, traumatic brain injury (TBI), central nervous system (CNS) infection, and stroke. Applying consistent criteria, we assessed the quality of each study and extracted data on measures of risk from those with adequate quality ratings, summarizing findings across studies as medians and interquartile ranges. Among higher-quality population-based studies, the median prevalence of active epilepsy across all ages was 11.1 per 1000 population in lower- and middle-income countries (LMIC) and 7.0 per 1000 in high-income countries (HIC). Perinatal brain insults were the largest attributable fraction of preventable etiologies in children, with median estimated fractions of 17% in LMIC and 15% in HIC. Stroke was the most common preventable etiology among older adults with epilepsy, both in LMIC and in HIC, accounting for half or more of all new onset cases. TBI was the attributed cause in nearly 5% of epilepsy cases in HIC and LMIC. CNS infections were a more common attributed cause in LMIC, accounting for about 5% of all epilepsy cases. Among some rural LMIC communities, the median proportion of epilepsy cases attributable to endemic neurocysticercosis was 34%. A large proportion of the overall public health burden of epilepsy is attributable to preventable causes. The attributable fraction for perinatal causes, infections, TBI, and stroke in sum reaches nearly 25% in both LMIC and HIC. Public health interventions addressing maternal and child health care, immunizations, public sanitation, brain injury prevention, and stroke prevention have the potential to significantly reduce the burden of epilepsy.	[Thurman, David J.; Helmers, Sandra] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Begley, Charles E.] Univ Texas Houston, Sch Publ Hlth, Hlth Sci Ctr Houston, Houston, TX USA; [Carpio, Arturo] Univ Cuenca, Fac Med Sci, Cuenca, Ecuador; [Hesdorffer, Dale C.] Columbia Univ, Med Ctr, Gertrude H Sergievsky Ctr, New York, NY USA; [Hesdorffer, Dale C.] Columbia Univ, Med Ctr, Dept Epidemiol, New York, NY USA; [Mu, Jie] Sichuan Univ, Dept Neurol, West China Hosp, Chengdu, Sichuan, Peoples R China; [Toure, Kamadore] Fann Univ Hosp, Dept Neurol, Dakar, Senegal; [Parko, Karen L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Newton, Charles R.] Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Program, Kilifi, Kenya; [Newton, Charles R.] Univ Oxford, Dept Psychiat, Oxford, England		Thurman, DJ (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.	david.j.thurman@emory.edu	Newton, Charles/V-7872-2019; Newton, Charles RJC/B-7578-2014	Newton, Charles/0000-0002-6999-5507; Newton, Charles RJC/0000-0002-6999-5507; Thurman, David/0000-0002-0533-7062; Carpio, Arturo/0000-0002-5821-6379	UCBUCB Pharma SA; Patient-Centered Outcomes Research InstitutePatient-Centered Outcomes Research Institute - PCORI; U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Epilepsy Study Consortium; Wellcome Trust, UKWellcome Trust; Epilepsia; Mount Sinai Injury Control Research Center	D.J.T. receives consultant fees under contract with UCB. D.C.H. serves as an associate editor of Epilepsia (paid), is on the editorial board of Epilepsy and Behavior (unpaid), and is a consultant to the Mount Sinai Injury Control Research Center (paid); she receives grant support from the Patient-Centered Outcomes Research Institute, the U.S. National Institutes of Health, and the Epilepsy Study Consortium. C.R.N. is funded by the Wellcome Trust, UK. None of the other authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.	Ablah E, 2014, EPILEPSY RES, V108, P792, DOI 10.1016/j.eplepsyres.2014.01.001; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Cansu A, 2007, SEIZURE-EUR J EPILEP, V16, P338, DOI 10.1016/j.seizure.2007.02.003; Carpio A, 1998, EPILEPSIA, V39, P1025, DOI 10.1111/j.1528-1157.1998.tb01287.x; Carter JA, 2004, EPILEPSIA, V45, P978, DOI 10.1111/j.0013-9580.2004.65103.x; Chung TT, 2013, EPILEPSY BEHAV, V29, P374, DOI 10.1016/j.yebeh.2013.08.013; Cruz ME, 1999, INT J EPIDEMIOL, V28, P799, DOI 10.1093/ije/28.4.799; Del Brutto OH, 2005, EPILEPSIA, V46, P583, DOI 10.1111/j.0013-9580.2005.36504.x; Ehrenstein V, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-23; Ehrenstein V, 2007, PEDIATRICS, V119, pE554, DOI 10.1542/peds.2006-1308; Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Fernandez-Suarez E, 2015, REV NEUROLOGIA, V60, P535, DOI 10.33588/rn.6012.2015038; Fiest KM, 2017, NEUROLOGY, V88, P296, DOI 10.1212/WNL.0000000000003509; Garcia HH, 2016, NEW ENGL J MED, V374, P2335, DOI [10.1056/NEJMoa1515520, 10.1056/NEJMc1609161]; Gething PW, 2016, NEW ENGL J MED, V375, P2435, DOI 10.1056/NEJMoa1606701; Goel D, 2011, NEUROL INDIA, V59, P37, DOI 10.4103/0028-3886.76855; Guekht A, 2010, EPILEPSY RES, V92, P209, DOI 10.1016/j.eplepsyres.2010.09.011; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Hesdorffer DC, 2004, ARCH GEN PSYCHIAT, V61, P731, DOI 10.1001/archpsyc.61.7.731; Hussain SA, 2006, EPILEPSY RES, V71, P195, DOI 10.1016/j.eplepsyres.2006.06.018; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Imfeld P, 2013, EPILEPSIA, V54, P700, DOI 10.1111/epi.12045; Josipovic-Jelic Z, 2011, EPILEPSY BEHAV, V20, P686, DOI 10.1016/j.yebeh.2011.02.008; Kaiser C, 1998, EPILEPSY RES, V30, P247, DOI 10.1016/S0920-1211(98)00007-2; Kannoth S, 2009, EPILEPSY BEHAV, V16, P58, DOI 10.1016/j.yebeh.2009.07.019; Khedr EM, 2013, EPILEPSY RES, V103, P294, DOI 10.1016/j.eplepsyres.2012.08.006; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Lee ACC, 2013, PEDIATR RES, V74, P50, DOI 10.1038/pr.2013.206; Li XH, 1997, EPILEPSIA, V38, P1216, DOI 10.1111/j.1528-1157.1997.tb01219.x; Ma GY, 2004, CHIN J CLIN REHAB, V8, P3178; Mahendran M, 2017, EPILEPSY BEHAV, V75, P102, DOI 10.1016/j.yebeh.2017.02.034; Mani R, 2011, NEUROSCI LETT, V497, P251, DOI 10.1016/j.neulet.2011.03.010; Martin RC, 2014, EPILEPSIA, V55, P1120, DOI 10.1111/epi.12649; Matuja WBP, 2001, NEUROEPIDEMIOLOGY, V20, P242, DOI 10.1159/000054797; Medina MT, 2011, EPILEPSIA, V52, P1177, DOI 10.1111/j.1528-1167.2010.02945.x; Medina MT, 2005, EPILEPSIA, V46, P124, DOI 10.1111/j.0013-9580.2005.11704.x; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; Moyano LM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002692; Murphy DJ, 2004, AM J OBSTET GYNECOL, V191, P392, DOI 10.1016/j.ajog.2004.03.020; Mwape KE, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003972; Ngoungou EB, 2006, EPILEPSIA, V47, P2147, DOI 10.1111/j.1528-1167.2006.00890.x; Ngugi AK, 2013, LANCET NEUROL, V12, P253, DOI 10.1016/S1474-4422(13)70003-6; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Njamnshi AK, 2007, AFR J NEUROL SCI, V26, P18; Norrving B, 2015, NEUROEPIDEMIOLOGY, V45, P215, DOI 10.1159/000441104; Pugh MJV, 2009, J AM GERIATR SOC, V57, P237, DOI 10.1111/j.1532-5415.2008.02124.x; Rajshekhar V, 2006, NEUROLOGY, V67, P2135, DOI 10.1212/01.wnl.0000249113.11824.64; Ruwe M, 2010, SOC WORK PUBLIC HLTH, V25, P550, DOI 10.1080/19371910903344217; Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709; Sen Wu C, 2008, PEDIATRICS, V122, P1072, DOI 10.1542/peds.2007-3666; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]; Singh G, 2012, EPILEPSIA, V53, P2203, DOI 10.1111/epi.12005; Staton C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144971; Su CL, 1998, ACTA NEUROL TAIWAN, V7, P75; Sun YL, 2006, EPIDEMIOLOGY, V17, P296, DOI 10.1097/01.ede.0000208478.47401.b6; Syvertsen M, 2015, EPILEPSIA, V56, P699, DOI 10.1111/epi.12972; Tabatabaei SS, 2013, NEUROL SCI, V34, P1441, DOI 10.1007/s10072-012-1261-0; Tchalla AE, 2011, EPILEPSIA, V52, P2203, DOI 10.1111/j.1528-1167.2011.03320.x; Tekle AH, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0160-7; Tellez-Zenteno JF, 2017, EPILEPSY BEHAV, V76, P146, DOI 10.1016/j.yebeh.2017.01.030; Thompson K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009900.pub2; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Vestergaard M, 2007, AM J EPIDEMIOL, V165, P911, DOI 10.1093/aje/kwk086; Wagner RG, 2014, EPILEPSY RES, V108, P782, DOI 10.1016/j.eplepsyres.2014.01.004; Whitehead E, 2006, PEDIATRICS, V117, P1298, DOI 10.1542/peds.2005-1660; WHO, 1998, HLTH PROM GLOSS; World Health Organisation, 2008, WORLD REPORT CHILD I; World Health Organization, 2006, NEUR DIS PUBL HLTH C; World Health Organization, 2007, WHO GLOB REP FALLP; World Health Organization Executive Board 136th Session, 2015, GLOB BURD EP NEED CO; Wright J, 2000, SEIZURE-EUR J EPILEP, V9, P309, DOI 10.1053/seiz.2000.0422	71	26	26	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	MAY	2018	59	5					905	914		10.1111/epi.14068			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GE8QB	WOS:000431495200004	29637551	Green Accepted, Green Submitted			2022-02-06	
J	Kim, JA; Boyle, EJ; Wu, AC; Cole, AJ; Staley, KJ; Zafar, S; Cash, SS; Westover, MB				Kim, Jennifer A.; Boyle, Emily J.; Wu, Alexander C.; Cole, Andrew J.; Staley, Kevin J.; Zafar, Sahar; Cash, Sydney S.; Westover, M. Brandon			Epileptiform activity in traumatic brain injury predicts post-traumatic epilepsy	ANNALS OF NEUROLOGY			English	Article							RISK-FACTORS; SEIZURES; EEG; ABNORMALITIES; ADULTS	We hypothesize that epileptiform abnormalities (EAs) in the electroencephalogram (EEG) during the acute period following traumatic brain injury (TBI) independently predict first-year post-traumatic epilepsy (PTE1). We analyze PTE1 risk factors in two cohorts matched for TBI severity and age (n=50). EAs independently predict risk for PTE1 (odds ratio [OR], 3.16 [0.99, 11.68]); subdural hematoma is another independent risk factor (OR, 4.13 [1.18, 39.33]). Differences in EA rates are apparent within 5 days following TBI. Our results suggest that increased EA prevalence identifies patients at increased risk for PTE1, and that EAs acutely post-TBI can identify patients most likely to benefit from antiepileptogenesis drug trials. Ann Neurol 2018;83:858-862	[Kim, Jennifer A.; Boyle, Emily J.; Cole, Andrew J.; Staley, Kevin J.; Zafar, Sahar; Cash, Sydney S.; Westover, M. Brandon] Massachusetts Gen Hosp, Dept Neurol, 15 Parkman St,Wang ACC 739 L, Boston, MA 02114 USA; [Kim, Jennifer A.; Zafar, Sahar] Massachusetts Gen Hosp, Dept Emergency Neurol & Neurocrit Care, Boston, MA 02114 USA; [Wu, Alexander C.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA		Westover, MB (corresponding author), Massachusetts Gen Hosp, Dept Neurol, 15 Parkman St,Wang ACC 739 L, Boston, MA 02114 USA.	mwestover@mgh.harvard.edu		Cole, Andrew/0000-0002-0828-826X	NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743, 1K23NS090900, R01NS086364]; Bee Foundation; Andrew David Heitman Neuroendovascular Research Fund; CDC-NIOSH ERC training-grant [T42 OH008416]; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [T42OH008416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086364, R25NS065743, K23NS090900] Funding Source: NIH RePORTER	J.A.K. received funding from NIH-NINDS (R25NS065743) and the Bee Foundation W. M.B.W. received funding from NIH-NINDS (1K23NS090900) and the Andrew David Heitman Neuroendovascular Research Fund. A.C.W. is supported by the CDC-NIOSH ERC training-grant (T42 OH008416). K.J.S. received funding from NIH-NINDS (R01NS086364).	ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Curia G., 2016, TRANSLATIONAL RES TR; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Klein P, 2017, EPILEPSY BEHAV, V72, P188, DOI 10.1016/j.yebeh.2017.05.024; KOUFEN H, 1978, FORTSCHR NEUROL PSYC, V46, P165; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Piccenna Loretta, 2017, Epilepsia Open, V2, P123, DOI 10.1002/epi4.12049; Ritter AC, 2016, EPILEPSIA, V57, P1968, DOI 10.1111/epi.13582; Ruiz AR, 2017, JAMA NEUROL, V74, P181, DOI 10.1001/jamaneurol.2016.4990; Schmidt D, 2014, NEUROTHERAPEUTICS, V11, P401, DOI 10.1007/s13311-013-0252-z; Shafi MM, 2012, NEUROLOGY, V79, P1796, DOI 10.1212/WNL.0b013e3182703fbc; Terrone G, 2016, PHARMACOL RES, V110, P96, DOI 10.1016/j.phrs.2016.05.009; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Vespa P, 2016, ANN NEUROL, V79, P579, DOI 10.1002/ana.24606; Wang ML, 2016, J NEUROL SCI, V370, P244, DOI 10.1016/j.jns.2016.09.049; Westover MB, 2015, CLIN NEUROPHYSIOL, V126, P463, DOI 10.1016/j.clinph.2014.05.037; Xu T, 2017, EPILEPSY BEHAV, V67, P1, DOI 10.1016/j.yebeh.2016.10.026; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547	19	26	27	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	APR	2018	83	4					858	862		10.1002/ana.25211			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GD7BA	WOS:000430662400021	29537656	Green Accepted			2022-02-06	
J	Cheng, WH; Stukas, S; Martens, KM; Namjoshi, DR; Button, EB; Wilkinson, A; Bashir, A; Robert, J; Cripton, PA; Wellington, CL				Cheng, Wai Hang; Stukas, Sophie; Martens, Kris M.; Namjoshi, Dhananjay R.; Button, Emily B.; Wilkinson, Anna; Bashir, Asma; Robert, Jerome; Cripton, Peter A.; Wellington, Cheryl L.			Age at injury and genotype modify acute inflammatory and neurofilament-light responses to mild CHIMERA traumatic brain injury in wild-type and APP/PS1 mice	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury (TBI); Closed Head Injury; Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA); Ageing; Inflammation; Neurofilament-light; Alzheimer's disease	WHITE-MATTER ABNORMALITIES; AMYLOID-BETA ACCUMULATION; ALZHEIMERS-DISEASE; A-BETA; HEAD-INJURY; INTERSTITIAL FLUID; PRECURSOR-PROTEIN; INDUCED INCREASES; TERM SURVIVORS; MOUSE MODEL	Peak incidence of traumatic brain injury (TBI) occurs in both young and old individuals, and older age at injury is associated with worse outcome and poorer recovery. Moderate-severe TBI is a reported risk factor for dementia, including Alzheimer's disease (AD), but whether mild TBI (mTBI) alters AD pathogenesis is not clear. To delineate how age at injury and predisposition to amyloid formation affect the acute response to mTBI, we used the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model of TBI to induce two mild injuries in wild-type (WT) and APP/PS1 mice at either 6 or 13 months of age and assessed behavioural, histological and biochemical changes up to 14 days post-injury. Age at injury did not alter acute behavioural responses to mTBI, including measures of neurological status, motor performance, spatial memory, fear, or anxiety, in either strain. Young APP/PS1 mice showed a subtle and transient increase in diffuse A beta deposits after injury, whereas old APP/PS1 mice showed decreased amyloid deposits, without significant alterations in total soluble or insoluble A beta levels at either age. Age at injury and genotype showed complex responses with respect to microglial and cytokine outcomes, where post-injury neuroinfiammation is increased in old WT mice but attenuated in old APP/PS1 mice. Intriguingly, silver staining confirmed axonal damage in both strains and ages, yet only young WT and APP/PS1 mice showed neurofilament-positive axonal swellings after mTBI, as this response was almost entirely attenuated in old mice. Plasma neurofilament-light levels were significantly elevated after injury only in young APP/PS1 mice. This study suggests that mild TBI has minimal effects on A beta metabolism, but that age and genotype can each modify acute outcomes related to white matter injury.	[Cheng, Wai Hang; Stukas, Sophie; Martens, Kris M.; Namjoshi, Dhananjay R.; Button, Emily B.; Wilkinson, Anna; Bashir, Asma; Robert, Jerome; Wellington, Cheryl L.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Dept Pathol & Lab Med, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; [Cripton, Peter A.] Univ British Columbia, Dept Mech Engn, Int Collaborat Repair Discoveries, Vancouver, BC, Canada		Wellington, CL (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Dept Pathol & Lab Med, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	wcheryl@mail.ubc.ca	Cripton, Peter Alec/AAC-8268-2020; Robert, Jerome/C-6226-2018	Cripton, Peter Alec/0000-0002-5067-0833; Robert, Jerome/0000-0002-2847-9362; Cheng, Wai Hang/0000-0002-3408-9184; Bashir, Asma/0000-0002-3616-9436	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CIHR MOP 123461]; Weston Brain Institute [TR140070]; Alzheimer Society Research Program Doctoral Award; Comissao Technica de Atribuicao de Bolsas para Estudos Pos Graduados Macao; Canadian Traumatic Brain Injury Research Consortium; CIHR Graduate FellowshipCanadian Institutes of Health Research (CIHR); University of British Columbia Doctoral Fellowship; CIHR Doctoral ScholarshipCanadian Institutes of Health Research (CIHR); BrightFocus Alzheimer's disease award; Weston Brain Institute Rapid Response grant	Operating funding for this project was obtained from the Canadian Institutes of Health Research (CIHR MOP 123461) to C.L.W., and a Transformational Grant from the Weston Brain Institute (TR140070) to C.L.W. and P.A.C. W.H.C. is supported by Alzheimer Society Research Program Doctoral Award and Comissao Technica de Atribuicao de Bolsas para Estudos Pos Graduados Macao. S.S. is supported by an award from the Canadian Traumatic Brain Injury Research Consortium. A.B. is supported by a CIHR Graduate Fellowship and a University of British Columbia Doctoral Fellowship. E.B. is supported by a CIHR Doctoral Scholarship and a University of British Columbia Doctoral Fellowship. JR is supported by a BrightFocus Alzheimer's disease award and a Weston Brain Institute Rapid Response grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2013, J CEREBR BLOOD F MET, V33, P826, DOI 10.1038/jcbfm.2013.24; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Bagnato S., 2017, NEUROREPORT; Bates K, 2014, NEUROBIOL AGING, V35, P1345, DOI 10.1016/j.neurobiolaging.2013.11.020; Bird SM, 2016, NEUROSCI BIOBEHAV R, V64, P215, DOI 10.1016/j.neubiorev.2016.01.004; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Castellani RJ, 2010, DM-DIS MON, V56, P484, DOI 10.1016/j.disamonth.2010.06.001; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gardner RC, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002246; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Graham DI, 1996, ACT NEUR S, V66, P96; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gupta RK, 2016, MOL NEUROBIOL, V53, P3377, DOI 10.1007/s12035-015-9287-y; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Ljungqvist J., 2016, J NEUROTRAUMA; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Marklund N, 2014, J NEUROTRAUM, V31, P42, DOI 10.1089/neu.2013.2964; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; May S., 2011, J NEUROL NEUROSCI, V2; McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Namjoshi D.R., 2017, EXP NEUROL; Namjoshi DR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146540; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Robert J, 2016, BBA-MOL BASIS DIS, V1862, P1027, DOI 10.1016/j.bbadis.2015.10.005; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Sherer M, 2015, REHABIL PSYCHOL, V60, P138, DOI 10.1037/rep0000030; Shibahashi K, 2016, J NEUROTRAUM, V33, P1826, DOI 10.1089/neu.2015.4237; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; TEASDALE G, 1974, LANCET, V2, P81; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00300; Tierney KJ, 2016, J NEUROSURG, V124, P538, DOI 10.3171/2015.4.JNS142440; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	81	26	26	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2018	301		A				26	38		10.1016/j.expneurol.2017.12.007			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FX8EW	WOS:000426325100003	29269117				2022-02-06	
J	Wallace, C; Smirl, JD; Zetterberg, H; Blennow, K; Bryk, K; Burma, J; Dierijck, J; Wright, AD; van Donkelaar, P				Wallace, Colin; Smirl, Jonathan D.; Zetterberg, Henrik; Blennow, Kaj; Bryk, Kelsey; Burma, Joel; Dierijck, Jill; Wright, Alexander David; van Donkelaar, Paul			Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics	BMJ OPEN SPORT & EXERCISE MEDICINE			English	Article								Objectives To determine the effect of heading a soccer ball on serum neurofilament light (NF-L) protein, plasma tau protein and symptom metrics including total number of symptoms reported and symptom severity scores on the Standardized Concussion Assessment Tool- 3rd edition (SCAT3). Methods Eleven male collegiate soccer players were recruited to take part in three experimental conditions including heading, sham and control conditions. Participants were required to perform 40 headers in 20 min in the heading condition, and control 40 soccer balls directed at them with their hands, chest or thigh in the sham condition. No ball contact was made during the control condition. Blood sampling and SCAT3 symptom assessments were completed prior to and 1 hour following conditions. A subset of participants returned 3 weeks following the heading condition for blood sampling. Results NF-L was elevated at 1 hour (p=0.004) and 1 month (p=0.04) following the heading condition, and at 1 hour (p=0.02) following the control condition. Tau levels remained unchanged following all conditions. The total number of symptoms (TS) and symptom severity (SS) scores from the SCAT3 were both elevated following the heading condition (p=0.01 and p=0.03, respectively). Both TS and SS decreased following sham (p=0.04 and p=0.04) and control conditions (p=0.04 and p=0.04). Conclusion An acute bout of soccer heading is associated with increased NF-L concentrations at 1 hour and 1 month following the session and can lead to symptoms commonly reported following sport-related concussion.	[Wallace, Colin] Univ British Columbia, Dept Pathol & Lab Med, Fac Med, Vancouver, BC, Canada; [Wallace, Colin; Smirl, Jonathan D.; Burma, Joel; van Donkelaar, Paul] Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Inst Neurosci & Physiol,Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Bryk, Kelsey] Univ Delaware, Coll Hlth Sci, Newark, DE USA; [Dierijck, Jill] Dalhousie Univ, Fac Hlth, Halifax, NS, Canada; [Wright, Alexander David] Univ British Columbia, Fac Med, Vancouver, BC, Canada		Wallace, C (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Fac Med, Vancouver, BC, Canada.; Wallace, C (corresponding author), Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada.	colin.wallace@alumni.ubc.ca	Burma, Joel/AAL-1073-2021	Burma, Joel/0000-0001-9756-5793; Wallace, Colin/0000-0002-3720-6526; Wright, Alexander D./0000-0001-6442-5583; Smirl, Jonathan/0000-0003-1054-0038	Canadian Institutes for Health Research (CIHR), Canada Foundation for Innovation (CFI); Mitacs; Mitacs Accelerate Programme	This research was funded by grants to PvD from the Canadian Institutes for Health Research (CIHR), Canada Foundation for Innovation (CFI) and Mitacs. CW was supported by the Mitacs Accelerate Programme.	Armstrong S, 2009, J AM COLL HEALTH, V57, P521, DOI 10.3200/JACH.57.5.521-526; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Count FB, 2006, 270 MILLION PEOPLE A; Dorminy M, 2015, BRAIN INJURY, V29, P1158, DOI 10.3109/02699052.2015.1035324; Gill J, 2017, NEUROLOGY, V88, P595, DOI 10.1212/WNL.0000000000003587; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Grinberg LT, 2016, J ALZHEIMERS DIS, V54, P169, DOI 10.3233/JAD-160312; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mehnert Michael J, 2005, Pain Physician, V8, P391; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Rissin DM, 2006, NANO LETT, V6, P520, DOI 10.1021/nl060227d; Shahim P, 2018, NEUROLOGY, V90, pE1780, DOI 10.1212/WNL.0000000000005518; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2015, MOL CELL NEUROSCI, V66, P99, DOI 10.1016/j.mcn.2015.02.003	29	26	26	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2398-9459	2055-7647		BMJ OPEN SPORT EXERC	BMJ Open Sport Exerc. Med.	MAR	2018	4	1							e000433	10.1136/bmjsem-2018-000433			5	Sport Sciences	Emerging Sources Citation Index (ESCI)	Sport Sciences	VJ4QA	WOS:000596798200126	30233810	Green Published, gold			2022-02-06	
J	Yi, Y; Li, E; Sun, G; Yan, HQ; Foley, LM; Andrzejczuk, LA; Attarwala, IY; Hitchens, TK; Kiselyov, K; Dixon, CE; Sun, DD				Yi, Yan; Li, Eric; Sun, George; Yan, Hong Q.; Foley, Lesley M.; Andrzejczuk, Liwia A.; Attarwala, Insiya Y.; Hitchens, T. Kevin; Kiselyov, Kirill; Dixon, C. Edward; Sun, Dandan			Effects of DHA on Hippocampal Autophagy and Lysosome Function After Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Autophagy; Cortical contusion injury; Docosahexaenoic acid; Lysosome; Microglial polarization; Secondary injury	OXIDATIVE STRESS; CELL-SURVIVAL; CATHEPSIN-D; PROTEIN; RAT; BIOSYNTHESIS; BIOGENESIS; EXPRESSION; TRANSIENT; MODEL	Traumatic brain injury (TBI) triggers endoplasmic reticulum (ER) stress and impairs autophagic clearance of damaged organelles and toxic macromolecules. In this study, we investigated the effects of the post-TBI administration of docosahexaenoic acid (DHA) on improving hippocampal autophagy flux and cognitive functions of rats. TBI was induced by cortical contusion injury in Sprague-Dawley rats, which received DHA (16 mg/kg in DMSO, intraperitoneal administration) or vehicle DMSO (1 ml/kg) with an initial dose within 15 min after the injury, followed by a daily dose for 3 or 7 days. First, RT-qPCR reveals that TBI induced a significant elevation in expression of autophagy-related genes in the hippocampus, including SQSTM1/p62 (sequestosome 1), lysosomal-associated membrane proteins 1 and 2 (Lamp1 and Lamp2), and cathepsin D (Ctsd). Upregulation of the corresponding autophagy-related proteins was detected by immunoblotting and immunostaining. In contrast, the DHA-treated rats did not exhibit the TBI-induced autophagy biogenesis and showed restored CTSD protein expression and activity. T-2-weighted images and diffusion tensor imaging (DTI) of ex vivo brains showed that DHA reduced both gray matter and white matter damages in cortical and hippocampal tissues. DHA-treated animals performed better than the vehicle control group on the Morris water maze test. Taken together, these findings suggest that TBI triggers sustained stimulation of autophagy biogenesis, autophagy flux, and lysosomal functions in the hippocampus. Swift post-injury DHA administration restores hippocampal lysosomal biogenesis and function, demonstrating its therapeutic potential.	[Yi, Yan] Dalian Med Univ, Hosp 2, Dept Neurol, Dalian 116027, Peoples R China; [Yi, Yan; Li, Eric; Sun, George; Attarwala, Insiya Y.; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Yan, Hong Q.; Dixon, C. Edward; Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA; [Foley, Lesley M.; Hitchens, T. Kevin] Univ Pittsburgh, Anim Imaging Ctr, Pittsburgh, PA 15213 USA; [Andrzejczuk, Liwia A.; Kiselyov, Kirill] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Hitchens, T. Kevin] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA		Sun, DD (corresponding author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.; Sun, DD (corresponding author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA.	sund@upmc.edu		Andrzejczuk, Livia A./0000-0001-5585-6189	Chinese Dalian Municipal Bureau Study Abroad Research Award; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS089051]; US Department of Veterans Affairs VA [RRD] [B6761R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089051] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health [R01NS089051] (DS) and the US Department of Veterans Affairs VA [RR&D#B6761R] (CED). Y.Y. was supported by the Chinese Dalian Municipal Bureau Study Abroad Research Award.	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Calandria JM, 2015, CELL DEATH DIFFER, V22, P1363, DOI 10.1038/cdd.2014.233; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; Colletti GA, 2012, J BIOL CHEM, V287, P8082, DOI 10.1074/jbc.M111.285536; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Mayurasakorn K, 2011, CURR OPIN CLIN NUTR, V14, P158, DOI 10.1097/MCO.0b013e328342cba5; Nakanishi H, 2001, J NEUROSCI, V21, P7526, DOI 10.1523/JNEUROSCI.21-19-07526.2001; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Park Y, 2015, J NEUROTRAUM, V32, P1449, DOI 10.1089/neu.2014.3694; Pena KA, 2015, BIOCHEM J, V470, P65, DOI 10.1042/BJ20140645; Pettersen K, 2016, FREE RADICAL BIO MED, V90, P158, DOI 10.1016/j.freeradbiomed.2015.11.018; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Schober ME, 2016, J NEUROTRAUM, V33, P390, DOI 10.1089/neu.2015.3945; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Yao XL, 2006, NEUROSCI LETT, V409, P65, DOI 10.1016/j.neulet.2006.09.015; Zhang XZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10938; Zhao Jiang, 2015, Journal of China Agricultural University, V20, P1	30	26	26	0	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAR	2018	55	3					2454	2470		10.1007/s12035-017-0504-8			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FY5TG	WOS:000426897800052	28365875	Green Accepted			2022-02-06	
J	Mahler, B; Carlsson, S; Andersson, T; Tomson, T				Mahler, Benno; Carlsson, Sofia; Andersson, Tomas; Tomson, Torbjoern			Risk for injuries and accidents in epilepsy: A prospective population-based cohort study	NEUROLOGY			English	Article							SEIZURE-RELATED INJURIES; PSYCHIATRIC-DISORDERS; UNPROVOKED SEIZURES; CHILDREN; FRACTURES; FALLS; COMORBIDITIES; PEOPLE; ADULTS	ObjectiveTo study the risk for injuries/accidents in people with newly diagnosed epileptic seizures in relation to comorbidities.MethodsBetween September 1, 2001, and August 31, 2008, individuals in northern Stockholm with incident unprovoked seizures (epilepsy; n = 2,130) were included in a registry. For every epilepsy patient, 8 individuals matched for sex and inclusion year (n = 16,992) were randomly selected as references from the population of the catchment area. Occurrence of injuries/accidents was monitored through the national patient and cause of death registers until December 31, 2013. These registers also provided information on comorbidities (e.g., brain tumor, stroke, psychiatric disease, diabetes mellitus).ResultsInjury/accident was demonstrated in 1,033 epilepsy cases and 6,202 references (hazard ratio [HR] 1.71, 95% confidence interval 1.60-1.83). The excess risk was seen mainly during the first 2 years after diagnosis. Sex and educational status had no significant effect on HR. The risk was normal in children but increased in adults. Highest HR was seen for drowning, poisoning, adverse effect of medication, and severe traumatic brain injury. Compared to references without comorbidities, HR was 1.17 (1.07-1.28) in epilepsy without comorbidities, 4.52 (4.18-4.88) in references with comorbidities, and 7.15 (6.49-7.87) in epilepsy with comorbidities.ConclusionPresence of comorbidities should be considered when counseling patients with newly diagnosed epilepsy concerning risk for injuries/accidents. Early information is important, as the risk is highest during the first 2 years following seizure onset.	[Mahler, Benno; Tomson, Torbjoern] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Mahler, Benno; Carlsson, Sofia] Karolinska Inst, Inst Environm Med, Epidemiol Unit, Stockholm, Sweden; [Andersson, Tomas] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden		Mahler, B (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.; Mahler, B (corresponding author), Karolinska Inst, Inst Environm Med, Epidemiol Unit, Stockholm, Sweden.	benno.mahler@sll.se		carlsson, sofia/0000-0002-9497-2331	Stockholm County Council (ALF)Stockholm County Council; AFA Forsakring	No corporate sponsorship was received, but the study has received grants from the Stockholm County Council (ALF) and AFA Forsakring.	Adelow C, 2012, NEUROLOGY, V78, P396, DOI 10.1212/WNL.0b013e318245f461; Adelow C, 2009, EPILEPSIA, V50, P1094, DOI 10.1111/j.1528-1167.2008.01726.x; Andell E, 2015, EPILEPSY RES, V113, P140, DOI 10.1016/j.eplepsyres.2015.04.002; Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; Appleton RE, 2002, EPILEPSIA, V43, P764, DOI 10.1046/j.1528-1157.2002.41101.x; Arron K, 2011, J INTELL DISABIL RES, V55, P109, DOI 10.1111/j.1365-2788.2010.01337.x; Beghi E, 2002, EPILEPSIA, V43, P1076, DOI 10.1046/j.1528-1157.2002.18701.x; Beghi E, 2009, EXPERT REV NEUROTHER, V9, P291, DOI 10.1586/14737175.9.2.291; Bell GS, 2008, NEUROLOGY, V71, P578, DOI 10.1212/01.wnl.0000323813.36193.4d; Buck D, 1997, EPILEPSIA, V38, P439, DOI 10.1111/j.1528-1157.1997.tb01733.x; Calvin CM, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2708; Chiba Y, 2009, AJIDD-AM J INTELLECT, V114, P225, DOI 10.1352/1944-7558-114.4:225-236; Czernuszenko A, 2009, CLIN REHABIL, V23, P176, DOI 10.1177/0269215508098894; Gedeborg R, 2008, EPIDEMIOLOGY, V19, P860, DOI 10.1097/EDE.0b013e318181319e; Josty IC, 2000, EPILEPSIA, V41, P453, DOI 10.1111/j.1528-1157.2000.tb00188.x; Kearney FC, 2013, DEMENT GERIATR COGN, V36, P20, DOI 10.1159/000350031; Keezer MR, 2016, LANCET NEUROL, V15, P106, DOI 10.1016/S1474-4422(15)00225-2; KIRBY S, 1995, EPILEPSIA, V36, P25, DOI 10.1111/j.1528-1157.1995.tb01660.x; Kirsch R, 2001, J CHILD NEUROL, V16, P100, DOI 10.2310/7010.2001.6916; Kwon C, 2011, NEUROLOGY, V76, P801, DOI 10.1212/WNL.0b013e31820e7b3b; Kwon CS, 2010, EPILEPSIA, V51, P2247, DOI 10.1111/j.1528-1167.2010.02697.x; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; NAKKEN KO, 1993, EPILEPSIA, V34, P836, DOI 10.1111/j.1528-1157.1993.tb02099.x; Neufeld MY, 1999, EPILEPSY RES, V34, P123, DOI 10.1016/S0920-1211(98)00105-3; ORLOWSKI JP, 1982, AM J DIS CHILD, V136, P777, DOI 10.1001/archpedi.1982.03970450019004; Persson HBI, 2002, EPILEPSIA, V43, P768, DOI 10.1046/j.1528-1157.2002.15801.x; Pi HY, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8612143; Nguyen R, 2009, NEUROL INT, V1, P72, DOI 10.4081/ni.2009.e20; RUSSELLJONES DL, 1989, J NEUROL NEUROSUR PS, V52, P659, DOI 10.1136/jnnp.52.5.659; Shadloo B, 2016, IRAN J PUBLIC HEALTH, V45, P623; Souverein PC, 2005, EPILEPSIA, V46, P304, DOI 10.1111/j.0013-9580.2005.23804.x; Stone CA, 2012, J CLIN ONCOL, V30, P2128, DOI 10.1200/JCO.2011.40.7791; Tellez-Zenteno JF, 2008, EPILEPSIA, V49, P954, DOI 10.1111/j.1528-1167.2007.01499.x; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; Tomson T, 2004, EPILEPSY RES, V60, P1, DOI 10.1016/j.eplepsyres.2004.05.004; van den Broek M, 2004, EPILEPSIA, V45, P667, DOI 10.1111/j.0013-9580.2004.33903.x; Vestergaard P, 2005, ACTA NEUROL SCAND, V112, P277, DOI 10.1111/j.1600-0404.2005.00474.x; Wilson DA, 2014, EPILEPSY BEHAV, V32, P42, DOI 10.1016/j.yebeh.2013.12.035; Yau RK, 2013, DIABETES CARE, V36, P3985, DOI 10.2337/dc13-0429	40	26	26	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 27	2018	90	9					E779	+		10.1212/WNL.0000000000005035			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ7WQ	WOS:000427816000007	29386275				2022-02-06	
J	Undurti, A; Colasurdo, EA; Sikkema, CL; Schultz, JS; Peskind, ER; Pagulayan, KF; Wilkinson, CW				Undurti, Arundhati; Colasurdo, Elizabeth A.; Sikkema, Carl L.; Schultz, Jaclyn S.; Peskind, Elaine R.; Pagulayan, Kathleen F.; Wilkinson, Charles W.			Chronic Hypopituitarism Associated with Increased Postconcussive Symptoms Is Prevalent after Blast-Induced Mild Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; blast; concussion; pituitary; military; posttraumatic stress disorder; growth hormone deficiency; veterans	GROWTH-HORMONE DEFICIENCY; QUALITY-OF-LIFE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY DYSFUNCTION; GH DEFICIENCY; LONG-TERM; IGF-I; POSTTRAUMATIC HYPOPITUITARISM; SCREENING-TEST; YOUNG-ADULTS	The most frequent injury sustained by US service members deployed to Iraq or Afghanistan is mild traumatic brain injuries (mTBI), or concussion, by far most often caused by blast waves from improvised explosive devices or other explosive ordnance. TBI from all causes gives rise to chronic neuroendocrine disorders with an estimated prevalence of 25-50%. The current study expands upon our earlier finding that chronic pituitary gland dysfunction occurs with a similarly high frequency after blast-related concussions. We measured circulating hormone levels and accessed demographic and testing data from two groups of male veterans with hazardous duty experience in Iraq or Afghanistan. Veterans in the mTBI group had experienced one or more blast-related concussion. Members of the deployment control (DC) group encountered similar deployment conditions but had no history of blast-related mTBI. 12 of 39 (31%) of the mTBI participants and 3 of 20 (15%) veterans in the DC group screened positive for one or more neuroendocrine disorders. Positive screens for growth hormone deficiency occurred most often. Analysis of responses on self-report questionnaires revealed main effects of both mTBI and hypopituitarism on postconcussive and posttraumatic stress disorder (PTSD) symptoms. Symptoms associated with pituitary dysfunction overlap considerably with those of PTSD. They include cognitive deficiencies, mood and anxiety disorders, sleep problems, diminished quality of life, deleterious changes in metabolism and body composition, and increased cardiovascular mortality. When such symptoms are due to hypopituitarism, they may be alleviated by hormone replacement. These findings suggest consideration of routine post-deployment neuroendocrine screening of service members and veterans who have experienced blast-related mTBI and are reporting postconcussive symptoms.	[Undurti, Arundhati; Peskind, Elaine R.; Pagulayan, Kathleen F.; Wilkinson, Charles W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Colasurdo, Elizabeth A.; Sikkema, Carl L.; Schultz, Jaclyn S.; Wilkinson, Charles W.] US Dept Vet Affairs, VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98174 USA; [Peskind, Elaine R.; Pagulayan, Kathleen F.] US Dept Vet Affairs, VA Puget Sound Hlth Care Syst, VISN Northwest Network Mental Illness Res Educ &, Seattle, WA USA; [Undurti, Arundhati] Vancouver Clin, Vancouver, WA USA		Wilkinson, CW (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.; Wilkinson, CW (corresponding author), US Dept Vet Affairs, VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98174 USA.	wilkinso@uw.edu	Wilkinson, Charles W/N-5969-2017; Pagulayan, Kati/AAR-9225-2020	Wilkinson, Charles/0000-0002-5390-0294	United States Department of Defense Congressionally Directed Medical Research Programs Concept Award [W81XWH-11-1-0278]; United States Department of Veterans Affairs (USDVA) Rehabilitation Research and Development Service Merit Award [5 I01 RX 000509]; USDVA Clinical Science Research and Development Service Career Development Award [IK2CX000516]; USDVA Rehabilitation Research and Development Service Merit Award [B77421]; Geriatric Research, Education and Clinical Center; Research and Development Service of the VA Puget Sound Health Care System; VA Northwest Network Mental Illness Research, Education and Clinical Center; University of Washington Alzheimer's Disease Research CenterUniversity of Washington [NIA AG05136]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001612, I01RX000509, I01RX000521, IK2CX000516] Funding Source: NIH RePORTER	United States Department of Defense Congressionally Directed Medical Research Programs Concept Award Number W81XWH-11-1-0278 and United States Department of Veterans Affairs (USDVA) Rehabilitation Research and Development Service Merit Award #5 I01 RX 000509 to CW, USDVA Clinical Science Research and Development Service Career Development Award #IK2CX000516 to KP, USDVA Rehabilitation Research and Development Service Merit Award #B77421 to EP, the Geriatric Research, Education and Clinical Center, and the Research and Development Service of the VA Puget Sound Health Care System; the VA Northwest Network Mental Illness Research, Education and Clinical Center; and the University of Washington Alzheimer's Disease Research Center NIA AG05136.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Ajmal A, 2014, PSYCHOSOMATICS, V55, P29, DOI 10.1016/j.psym.2013.08.008; American Psychiatric Association, 1994, DSM 4 DIAGN STAT MAN, P828; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Ben-Shlomo A, 2011, PITUITARY, 3RD EDITION, P21, DOI 10.1016/B978-0-12-380926-1.10002-1; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blevins JE, 2015, PHYSIOL BEHAV, V152, P438, DOI 10.1016/j.physbeh.2015.05.023; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Brambilla M, 2016, DRUG DEVELOP RES, V77, P479, DOI 10.1002/ddr.21343; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Campbell A, 2010, PERS SOC PSYCHOL REV, V14, P281, DOI 10.1177/1088868310363594; Campbell I, 2007, STAT MED, V26, P3661, DOI 10.1002/sim.2832; Capozzi A, 2015, GYNECOL ENDOCRINOL, V31, P506, DOI 10.3109/09513590.2015.1017810; Carboni L, 2012, INT J NEUROPSYCHOPH, V15, P645, DOI 10.1017/S1461145711000824; Ceanga M, 2010, NEUROSCI LETT, V477, P15, DOI 10.1016/j.neulet.2010.04.024; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Colao A, 2008, CLIN ENDOCRINOL, V69, P347, DOI 10.1111/j.1365-2265.2008.03292.x; Corneli G, 2008, J ENDOCRINOL INVEST, V31, P689, DOI 10.1007/BF03346416; Corneli G, 2007, EUR J ENDOCRINOL, V157, P701, DOI 10.1530/EJE-07-0384; Detillion CE, 2004, PSYCHONEUROENDOCRINO, V29, P1004, DOI 10.1016/j.psyneuen.2003.10.003; Di Simplicio M, 2016, J PSYCHOPHARMACOL, V30, P1156, DOI 10.1177/0269881116641872; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; First M. B., 2002, STRUCTURED CLIN INTE, P1; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Guerrero AF, 2010, MIL MED, V175, P574, DOI 10.7205/MILMED-D-09-00189; Hadjadj S, 2007, ANN ENDOCRINOL-PARIS, V68, P449, DOI 10.1016/j.ando.2007.08.004; Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hoencamp R, 2014, INJURY, V45, P1028, DOI 10.1016/j.injury.2014.02.012; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Ioachimescu AG, 2015, PITUITARY, V18, P535, DOI 10.1007/s11102-014-0606-5; Juul A, 1997, J CLIN ENDOCR METAB, V82, P1195, DOI 10.1210/jc.82.4.1195; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2014, J NEUROTRAUM, V31, P1161, DOI 10.1089/neu.2013.3212; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2015, EUR J ENDOCRINOL, V172, P753, DOI 10.1530/EJE-14-1069; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Krewer C, 2016, J NEUROTRAUM, V33, P1544, DOI 10.1089/neu.2015.4109; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lagraoui M, 2017, BRAIN BEHAV IMMUN, V61, P96, DOI 10.1016/j.bbi.2016.12.005; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lincoln GA, 2002, J NEUROENDOCRINOL, V14, P36, DOI 10.1046/j.0007-1331.2001.00734.x; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Maghnie M, 2005, EUR J ENDOCRINOL, V152, P589, DOI 10.1530/eje.1.01873; Masel Brent E, 2005, Pituitary, V8, P263, DOI 10.1007/s11102-006-6052-2; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Montgomery J, 2004, J CLIN PSYCHIAT, V65, P1491, DOI 10.4088/JCP.v65n1108; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Naja WJ, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0819-1; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Peuskens J, 2014, CNS DRUGS, V28, P421, DOI 10.1007/s40263-014-0157-3; Pfeifer AC, 2016, SCHMERZ, V30, P457, DOI 10.1007/s00482-016-0164-z; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Richardson J T, 1994, Stat Methods Med Res, V3, P107, DOI 10.1177/096228029400300202; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Romano A, 2016, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00497; Rosario ER, 2013, J HEAD TRAUMA REHAB, V28, P390, DOI 10.1097/HTR.0b013e318250eac6; ROSEN T, 1994, CLIN ENDOCRINOL, V40, P111, DOI 10.1111/j.1365-2265.1994.tb02452.x; Ruxton GD, 2006, BEHAV ECOL, V17, P688, DOI 10.1093/beheco/ark016; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Schultz JS, 2017, SOC BEH NEUR 21 ANN; Silva PPB, 2015, J NEUROTRAUM, V32, P1789, DOI 10.1089/neu.2015.3998; Steward KA, 2017, ARCH CLIN NEUROPSYCH, V32, P98, DOI 10.1093/arclin/acw081; Svensson J, 2007, GROWTH HORM IGF RES, V17, P67, DOI 10.1016/j.ghir.2006.11.002; Szeto A, 2017, AM J PHYSIOL-ENDOC M, V312, pE183, DOI 10.1152/ajpendo.00346.2016; Tanriverdi F, 2011, J ENDOCRINOL INVEST, V34, P541, DOI 10.3275/7805; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2015, NEUROPSYCH DIS TREAT, V11, P1835, DOI 10.2147/NDT.S65814; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; VANCAUTER E, 1992, J CLIN ENDOCR METAB, V74, P1441, DOI 10.1210/jc.74.6.1441; Vanya M, 2017, PSYCHIAT RES, V247, P288, DOI 10.1016/j.psychres.2016.12.007; Venegas J., 2011, ENCY CLIN NEUROPSYCH, P2693, DOI DOI 10.1007/978-0-387-79948-3_1500; Voss JD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0506-z; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilkinson C. W., 2012, FRONT NEUROL, V3, P11, DOI DOI 10.3389/FNEUR.2012.00011; Xin Q, 2017, NEUROCHEM INT, V103, P57, DOI 10.1016/j.neuint.2016.12.021; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089; Zgaljardic DJ, 2011, CLIN ENDOCRINOL, V74, P365, DOI 10.1111/j.1365-2265.2010.03935.x	109	26	27	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	FEB 19	2018	9								72	10.3389/fneur.2018.00072			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FW6HD	WOS:000425418100002	29515515	gold, Green Published			2022-02-06	
J	Zeng, XJ; Li, P; Ning, YL; Zhao, Y; Peng, Y; Yang, N; Zhao, ZA; Chen, JF; Zhou, YG				Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Chen, Jiang-Fan; Zhou, Yuan-Guo			Impaired autophagic flux is associated with the severity of trauma and the role of A(2A)R in brain cells after traumatic brain injury	CELL DEATH & DISEASE			English	Article							RECEPTORS; APOPTOSIS; PATHWAYS; MOUSE; DEATH; NEURODEGENERATION; NEUROPROTECTION; P62/SQSTM1; BLOCKADE; CAFFEINE	Recent studies have shown that after traumatic brain injury (TBI), the number of autophagosomes is markedly increased in brain cells surrounding the wound; however, whether autophagy is enhanced or suppressed by TBI remains controversial. In our study, we used a controlled cortical impact system to establish models of mild, moderate and severe TBI. In the mild TBI model, the levels of autophagy-related protein 6 (Beclin1) and autophagy-related protein 12 (ATG12)-autophagy-related protein 5 (ATG5) conjugates were increased, indicating the enhanced initiation of autophagy. Furthermore, the level of the autophagic substrate sequestosome 1 (SQSTM1) was decreased in the ipsilateral cortex. This result, together with the results observed in tandem mRFP-GFP-LC3 adeno-associated virus (AAV)-infected mice, indicates that autophagosome clearance was also increased after mild TBI. Conversely, following moderate and severe TBI, there was no change in the initiation of autophagy, and autophagosome accumulation was observed. Next, we used chloroquine (CQ) to artificially impair autophagic flux in the injured cortex of the mild TBI model and found that the severity of trauma was obviously exacerbated. In addition, autophagic flux and trauma severity were significantly improved in adenosine A(2A) receptor (A(2A)R) knockout (KO) mice subjected to moderate TBI. Thus, A(2A)R may be involved in regulating the impairment of autophagic flux in response to brain injury. Our findings suggest that whether autophagy is increased after TBI is associated with whether autophagic flux is impaired, and the impairment of autophagic flux exacerbates the severity of trauma. Furthermore, A(2A)R may be a target for alleviating the impairment in autophagic flux after TBI.	[Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Zhou, Yuan-Guo] Third Mil Med Univ, Mol Biol Ctr, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China; [Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Zhou, Yuan-Guo] Third Mil Med Univ, State Key Lab Trauma Burn & Combined Injury, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China; [Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Zhou, Yuan-Guo] Third Mil Med Univ, Res Inst Surg, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China; [Zeng, Xu-Jia; Li, Ping; Ning, Ya-Lei; Zhao, Yan; Peng, Yan; Yang, Nan; Zhao, Zi-Ai; Zhou, Yuan-Guo] Third Mil Med Univ, Daping Hosp, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China; [Chen, Jiang-Fan] Boston Univ, Dept Neurol & Pharmacol, Sch Med, Boston, MA 02118 USA		Zhou, YG (corresponding author), Third Mil Med Univ, Mol Biol Ctr, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.; Zhou, YG (corresponding author), Third Mil Med Univ, State Key Lab Trauma Burn & Combined Injury, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.; Zhou, YG (corresponding author), Third Mil Med Univ, Res Inst Surg, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.; Zhou, YG (corresponding author), Third Mil Med Univ, Daping Hosp, 10 Changjiang Zhilu, Chongqing 400042, Peoples R China.	yuanguo.zhou@gmail.com	Li, ping/J-6507-2019		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471109]	This work was supported by a grant from the National Natural Science Foundation of China (81471109).	Alfinito PD, 2003, J NEUROSCI, V23, P10982; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bao H. J., 2014, NEUROCHEM RES, V40, P29; Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405; Butler D, 2006, AUTOPHAGY, V2, P234, DOI 10.4161/auto.2729; Chen JF, 2014, INT REV NEUROBIOL, V119, P257, DOI 10.1016/B978-0-12-801022-8.00012-X; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cunha GMA, 2006, NEUROSCIENCE, V141, P1775, DOI 10.1016/j.neuroscience.2006.05.024; Dai SS, 2013, J EXP MED, V210, P839, DOI 10.1084/jem.20122196; Dall'lgna OP, 2003, BRIT J PHARMACOL, V138, P1207, DOI 10.1038/sj.bjp.0705185; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Hu QH, 2016, SCI REP-UK, V6, DOI 10.1038/srep18959; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ichimura Y, 2008, AUTOPHAGY, V4, P1063, DOI 10.4161/auto.6826; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Ke JJ, 2015, J CARDIOVASC PHARM, V66, P25, DOI 10.1097/FJC.0000000000000239; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Laurent C, 2016, MOL PSYCHIATR, V21, P97, DOI 10.1038/mp.2014.151; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li W, 2009, EXP NEUROL, V215, P69, DOI 10.1016/j.expneurol.2008.09.012; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu YW, 2016, SCI REP-UK, V6, DOI 10.1038/srep33614; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Martini-Stoica H, 2016, TRENDS NEUROSCI, V39, P221, DOI 10.1016/j.tins.2016.02.002; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Nixon RA, 2011, NEUROBIOL DIS, V43, P38, DOI 10.1016/j.nbd.2011.01.021; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Petullo D, 1999, LIFE SCI, V64, P1099, DOI 10.1016/S0024-3205(99)00038-7; Pierri M, 2005, NEUROPHARMACOLOGY, V48, P517, DOI 10.1016/j.neuropharm.2004.11.009; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shao L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9917; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Simoes AP, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-204; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolfe DM, 2013, EUR J NEUROSCI, V37, P1949, DOI 10.1111/ejn.12169; Zhang Lijuan, 2016, Zhongguo Zhen Jiu, V36, P131; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao MF, 2016, MOL MED REP, V13, P13, DOI 10.3892/mmr.2015.4551	51	26	26	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	FEB 14	2018	9								252	10.1038/s41419-018-0316-4			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	FZ2LP	WOS:000427410000033	29449536	gold, Green Published			2022-02-06	
J	Kuzminski, SJ; Clark, MD; Fraser, MA; Haswell, CC; Morey, RA; Liu, C; Choudhury, KR; Guskiewicz, KM; Petrella, JR				Kuzminski, S. J.; Clark, M. D.; Fraser, M. A.; Haswell, C. C.; Morey, R. A.; Liu, C.; Choudhury, K. R.; Guskiewicz, K. M.; Petrella, J. R.			White Matter Changes Related to Subconcussive Impact Frequency during a Single Season of High School Football	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; CNS VITAL SIGNS; MIXED MODELS; CONCUSSION; DIFFUSION; INJURY; RELIABILITY; INTEGRITY; INFERENCE; EXPOSURE	BACKGROUND AND PURPOSE: The effect of exposing the developing brain of a high school football player to subconcussive impacts during a single season is unknown. The purpose of this pilot study was to use diffusion tensor imaging to assess white matter changes during a single high school football season, and to correlate these changes with impacts measured by helmet accelerometer data and neurocognitive test scores collected during the same period. MATERIALS AND METHODS: Seventeen male athletes (mean age, 16 +/- 0.73 years) underwent MR imaging before and after the season. Changes in fractional anisotropy across the white matter skeleton were assessed with Tract-Based Spatial Statistics and ROI analysis. RESULTS: The mean number of impacts over a 10-g threshold sustained was 414 +/- 291. Voxelwise analysis failed to show significant changes in fractional anisotropy across the season or a correlation with impact frequency, after correcting for multiple comparisons. ROI analysis showed significant (P <.05, corrected) decreases in fractional anisotropy in the fornix-stria terminalis and cingulum hippocampus, which were related to impact frequency. The effects were strongest in the fornix-stria terminalis, where decreases in fractional anisotropy correlated with worsening visual memory. CONCLUSIONS: Our findings suggest that subclinical neurotrauma related to participation in American football may result in white matter injury and that alterations in white matter tracts within the limbic system may be detectable after only 1 season of play at the high school level.	[Kuzminski, S. J.; Liu, C.; Choudhury, K. R.; Petrella, J. R.] Duke Univ, Dept Radiol, Durham, NC 27710 USA; [Haswell, C. C.; Morey, R. A.; Liu, C.; Petrella, J. R.] Duke Univ, Brain Imaging & Anal Ctr, Durham, NC USA; [Morey, R. A.] Duke Univ, Dept Translat Neurosci, Durham, NC USA; [Clark, M. D.; Fraser, M. A.; Guskiewicz, K. M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kuzminski, S. J.] Univ Oklahoma, Hlth Sci Ctr, Dept Radiol Sci, Oklahoma City, OK 73126 USA		Kuzminski, SJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Radiol Sci, POB 2690,Garrison Tower,Suite 4G4250, Oklahoma City, OK 73126 USA.	sam@kuzminskis.com	Morey, Rajendra A/P-3079-2018	Morey, Rajendra A/0000-0002-6517-6969; Roy Choudhury, Kingshuk/0000-0002-0306-2915; Kuzminski, Sam/0000-0002-4963-4376; Clark, Michael/0000-0002-5019-0290; Fraser, Missy/0000-0002-5753-8798; Liu, Chunlei/0000-0001-8816-4832	Department Seed Funding, Department of Radiology, Duke University, Durham, North Carolina; National Institutes of Health under the Ruth L. Kirschstein National Research Service Award from the National Institute of Neurological Disorders and Stroke [F30NS090816]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS090816] Funding Source: NIH RePORTER	This work was supported by Department Seed Funding, Department of Radiology, Duke University, Durham, North Carolina, and the National Institutes of Health under the Ruth L. Kirschstein National Research Service Award F30NS090816 from the National Institute of Neurological Disorders and Stroke.	Acheson A, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.615; Alhilali LM, 2017, AM J NEURORADIOL, V38, P691, DOI 10.3174/ajnr.A5073; Badgeley MA, 2013, J PHYS ACT HEALTH, V10, P160, DOI 10.1123/jpah.10.2.160; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Davis M, 2010, NEUROPSYCHOPHARMACOL, V35, P105, DOI 10.1038/npp.2009.109; Dean CB, 2007, LIFETIME DATA ANAL, V13, P497, DOI 10.1007/s10985-007-9065-x; Detry MA, 2016, JAMA-J AM MED ASSOC, V315, P407, DOI 10.1001/jama.2015.19394; Edlow BL, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-015-0525-8; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lebow MA, 2016, MOL PSYCHIATR, V21, P450, DOI 10.1038/mp.2016.1; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Littleton AC, 2015, SPORTS HEALTH, V7, P443, DOI 10.1177/1941738115586997; MARKOWSKA AL, 1989, EXP BRAIN RES, V74, P187; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Sarkar D., 2017, LINEAR NONLINEAR MIX; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060	29	26	26	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2018	39	2					245	251		10.3174/ajnr.A5489			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	FX2XE	WOS:000425928300007	29269405	Green Accepted, hybrid, Green Published			2022-02-06	
J	Merritt, C; Menon, K; Agus, MSD; Choong, K; McNally, D; O'Hearn, K; Watson, RS; Wong, HR; Duffett, M; Wypij, D; Zimmerman, JJ				Merritt, Courtney; Menon, Kusum; Agus, Michael S. D.; Choong, Karen; McNally, Dayre; O'Hearn, Katie; Watson, R. Scott; Wong, Hector R.; Duffett, Mark; Wypij, David; Zimmerman, Jerry J.			Beyond Survival: Pediatric Critical Care Interventional Trial Outcome Measure Preferences of Families and Healthcare Professionals	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						family preferences; pediatric critical illness interventional trials; outcome measures; study primary end points	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; ORGAN DYSFUNCTION SYNDROME; HOSPITAL CARDIAC-ARREST; FUNCTIONAL STATUS SCALE; TERM-FOLLOW-UP; INTENSIVE-CARE; SEVERE SEPSIS; SEPTIC SHOCK	Objectives: To identify, in addition to survival, preferred outcome measures of PICU family care providers and PICU healthcare professionals for interventional trials enrolling critically ill children, and to describe general attitudes of family care providers and healthcare professionals regarding research in the PICU. Design: Cross-sectional survey examining subject experience with clinical research and personal preferences for outcome measures for a hypothetical interventional clinical trial. Setting: PICUs within four academic children's hospitals in the United States and Canada. Subjects: Two cohorts including family members of critically ill children in PICUs (family care providers) and multidisciplinary staff working in the PICUs (healthcare professionals). Interventions: Administration of a short, deidentified survey. Measurements: Demographic data were collated for the two subject groups. Participants were queried regarding their attitudes related to research conducted in the PICU. In addition to survival, each group was asked to identify their three most important outcomes for an investigation examining whether or not an intervention helps seriously ill children recover. Main Results: Demographics for family care providers (n = 40) and healthcare professionals (n = 53) were similarly distributed. Female respondents (79.8%) predominated. Participants (98.9%) ascertained the importance of conducting research in the PICU, but significant challenges associated with this goal in the high stress PICU environment. Both quality of life and functioning after leaving the hospital were chosen as the most preferred outcome measure, with 77.5% of family care providers and 84.9% of healthcare professionals indicating this choice. Duration of organ dysfunction was identified by 70.0% of family care providers and 40.7% of healthcare professionals as the second most preferred outcome measure. Conclusions: In addition to survival, long-term quality of life/functional status and duration of organ dysfunction represent important interventional trial outcome measures for both families of critically ill children, as well as the multidisciplinary team who provides critical care.	[Merritt, Courtney; Watson, R. Scott; Zimmerman, Jerry J.] Univ Washington, Sch Med, Dept Pediat, Div Pediat Crit Care Med,Seattle Childrens Hosp, Seattle, WA 98195 USA; [Menon, Kusum; McNally, Dayre; O'Hearn, Katie] Univ Ottawa, Childrens Hosp Eastern Ontario, Div Pediat Crit Care, Ottawa, ON, Canada; [Agus, Michael S. D.; Wypij, David] Harvard Med Sch, Boston Childrens Hosp, Div Crit Care Med, Boston, MA USA; [Choong, Karen; Duffett, Mark] McMaster Univ, McMaster Childrens Hosp, Dept Pediat, Hamilton, ON, Canada; [Wong, Hector R.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Crit Care, Cincinnati, OH USA		Zimmerman, JJ (corresponding author), Univ Washington, Sch Med, Dept Pediat, Div Pediat Crit Care Med,Seattle Childrens Hosp, Seattle, WA 98195 USA.	jerry.zimmerman@seattlechildrens.org	Choong, Karen/ABB-7867-2021; Duffett, Mark/B-7524-2019	Choong, Karen/0000-0002-4608-4508; Duffett, Mark/0000-0003-1705-5422	Seattle Children's Hospital Research Institute; Academic Health - Sciences Alternate Funding Plan Innovation Grant; McMaster University; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Seattle Children's Hospital; University of WashingtonUniversity of Washington; PAS; University of Colorado; Society of Critical Care Medicine (SCCM); Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/National Institute of Child Health and Human Development and Immunexpress, Seattle, WA; Elsevier Publishing; SCCM	Supported, in part, by Seattle Children's Hospital Research Institute.; Dr. Choong's institution received funding from Academic Health - Sciences Alternate Funding Plan Innovation Grant, and she received funding from McMaster University. Dr. Watson's institution received funding from a National Institutes of Health (NIH) grant; he received funding for employment from Seattle Children's Hospital and University of Washington; funding for travel to attend meetings/lectures from PAS, University of Colorado, Society of Critical Care Medicine (SCCM), and the Centers for Disease Control; and received funding for honorariums from the NIH and University of Colorado. Dr. Wypij received several NIH grants to support other work unrelated to this. Dr. Zimmerman's institution received funding from NIH/National Institute of Child Health and Human Development and Immunexpress, Seattle, WA; and he received funding from Elsevier Publishing (textbook royalties) and SCCM (reimbursement of travel expenses to attend board meetings). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Agus MSD, 2012, NEW ENGL J MED, V367, P1208, DOI 10.1056/NEJMoa1206044; Aspesberro F, 2016, PEDIATR CRIT CARE ME, V17, pE272, DOI 10.1097/PCC.0000000000000727; Aspesberro F, 2015, INTENS CARE MED, V41, P1235, DOI 10.1007/s00134-015-3780-7; Bennett TD, 2016, PEDIATR CRIT CARE ME, V17, P1147, DOI 10.1097/PCC.0000000000000934; BERNARD GR, 1995, AM J RESP CRIT CARE, V152, P4, DOI 10.1164/ajrccm.152.1.7599855; Bronner MB, 2009, PEDIATR CRIT CARE ME, V10, P636, DOI 10.1097/PCC.0b013e3181ae5c1a; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Buysse CMP, 2008, CRIT CARE MED, V36, P596, DOI 10.1097/01.CCM.0000299740.65484.CA; Campbell I, 2007, STAT MED, V26, P3661, DOI 10.1002/sim.2832; Colville GA, 2013, PEDIATR CRIT CARE ME, V14, pE85, DOI 10.1097/PCC.0b013e3182712997; Cunha F, 2013, PEDIATR CRIT CARE ME, V14, pE8, DOI 10.1097/PCC.0b013e31826012b4; Curley Martha A Q, 2005, Pediatr Crit Care Med, V6, pS150, DOI 10.1097/01.PCC.0000161582.63265.B6; Davies H, 2016, AUST CRIT CARE, V29, P27, DOI 10.1016/j.aucc.2015.04.002; Dinglas V, PRACTICAL RESOURCES; Ebrahim S, 2013, PEDIATR CRIT CARE ME, V14, P10, DOI 10.1097/PCC.0b013e31825b64b3; Epstein D, 2011, PEDIATRICS, V127, pE588, DOI 10.1542/peds.2010-0394; Farris RWD, 2013, PEDIATR CRIT CARE ME, V14, P835, DOI 10.1097/PCC.0b013e3182a551c8; FDA Administration, 2009, GUID IND PAT REP OUT; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hartman ME, 2017, PEDIATR CRIT CARE ME, V18, pE112, DOI 10.1097/PCC.0000000000001062; Holubkov R, 2015, PEDIATR CRIT CARE ME, V16, P1, DOI 10.1097/PCC.0000000000000272; Iwashyna TJ, 2014, JAMA-J AM MED ASSOC, V311, P1295, DOI 10.1001/jama.2014.2639; Jeschke MG, 2010, AM J RESP CRIT CARE, V182, P351, DOI 10.1164/rccm.201002-0190OC; Jones S, 2006, PEDIATRICS, V118, P2101, DOI 10.1542/peds.2006-1455; Kaplan RM., 2001, QUALITY LIFE CHILD A, P89; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Kilburn LS, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-379; Knoester H, 2008, INTENS CARE MED, V34, P1076, DOI 10.1007/s00134-008-1061-4; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Leteurtre S, 2013, CRIT CARE MED, V41, P1761, DOI 10.1097/CCM.0b013e31828a2bbd; Levin M, 2000, LANCET, V356, P961, DOI 10.1016/S0140-6736(00)02712-4; Lin JC, 2017, PEDIATR CRIT CARE ME, V18, P8, DOI 10.1097/PCC.0000000000000978; Marino BS, 2009, PEDIATRICS, V123, pE708, DOI 10.1542/peds.2008-2572; Marshall JC, 2005, CRIT CARE MED, V33, P1708, DOI 10.1097/01.CCM.0000174478.70338.03; Menon K, 2017, PEDIATR CRIT CARE ME, V18, P505, DOI 10.1097/PCC.0000000000001121; Menon K, 2017, PEDIATR CRIT CARE ME, V18, pE146, DOI 10.1097/PCC.0000000000001078; Menon K, 2013, PEDIATR CRIT CARE ME, V14, P462, DOI 10.1097/PCC.0b013e31828a7287; Mesotten D, 2012, JAMA-J AM MED ASSOC, V308, P1641, DOI 10.1001/jama.2012.12424; Moler FW, 2017, NEW ENGL J MED, V376, P318, DOI 10.1056/NEJMoa1610493; Moler FW, 2015, NEW ENGL J MED, V372, P1898, DOI 10.1056/NEJMoa1411480; Morrison Anne L, 2002, Pediatr Crit Care Med, V3, P1, DOI 10.1097/00130478-200201000-00001; Morse J.M, 1991, STRATEGIES SAMPLING, P127; Nadel S, 2007, LANCET, V369, P836, DOI 10.1016/S0140-6736(07)60411-5; Namachivayam P, 2012, PEDIATR CRIT CARE ME, V13, P520, DOI 10.1097/PCC.0b013e31824fb989; Namachivayam P, 2010, PEDIATR CRIT CARE ME, V11, P549, DOI 10.1097/PCC.0b013e3181ce7427; Ong C, 2016, PEDIATR CRIT CARE ME, V17, pE247, DOI 10.1097/PCC.0000000000000706; Pearson GA, 2003, LANCET, V362, P180, DOI 10.1016/S0140-6736(03)13948-7; Pollack MM, 2014, JAMA PEDIATR, V168, P671, DOI 10.1001/jamapediatrics.2013.5316; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Robinson KA, 2007, J CLIN EPIDEMIOL, V60, P757, DOI 10.1016/j.jclinepi.2006.11.023; Stevens KJ, 2012, PEDIATR CRIT CARE ME, V13, P387, DOI 10.1097/PCC.0b013e318238969a; Tilford JM, 2007, NEUROCRIT CARE, V7, P64, DOI 10.1007/s12028-007-0037-5; Typpo KV, 2009, PEDIATR CRIT CARE ME, V10, P562, DOI 10.1097/PCC.0b013e3181a64be1; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Villeneuve A, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0144-6; Vincent JL, 2004, CRIT CARE MED, V32, pS209, DOI 10.1097/01.CCM.0000126124.41743.86; Vincent KB, 2012, INT J MULT RES APPRO, V6, P4406; Visser IHE, 2013, INTENS CARE MED, V39, P942, DOI 10.1007/s00134-013-2857-4; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; Woolard RH, 2004, ACAD EMERG MED, V11, P859, DOI 10.1197/j.aem.2003.09.021	61	26	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	FEB	2018	19	2					E105	E111		10.1097/PCC.0000000000001409			7	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	FY8WT	WOS:000427146900005	29394234				2022-02-06	
J	Parola, A; Berardinelli, L; Bosco, FM				Parola, Alberto; Berardinelli, Laura; Bosco, Francesca M.			Cognitive abilities and theory of mind in explaining communicative pragmatic disorders in patients with schizophrenia	PSYCHIATRY RESEARCH			English	Article						Pragmatics; Communication disorders; Executive functioning; Theory of mind; Mindreading; Schizophrenia	TRAUMATIC BRAIN-INJURY; IMPAIRMENT; COMPREHENSION; COMPLEXITY; CHILDREN; PEOPLE	Patients with schizophrenia usually show an impairment in their communicative-pragmatic performance; they also have difficulties in cognitive functioning and Theory of Mind (ToM). In the literature it has been proposed that ToM and cognitive deficits have a role in explaining the communicative-pragmatic difficulties of patients with schizophrenia. However, the exact interplay of these functions is still not completely clear. The present research investigates the relationship between communicative-pragmatic, ToM and cognitive impairments (i.e. general intelligence, selective attention, speed processing and EF-working memory, inhibition and flexibility-) in a sample of 26 individuals with schizophrenia and matched controls. The linguistic and extralinguistic scales of the Assessment Battery of Communication (ABaCo), and a series of ToM and cognitive tasks were administered to patients and healthy controls. The results showed that individuals with schizophrenia performed less well than controls in all the tasks investigated. However, a hierarchical regression analysis showed that only ToM, and not cognitive functions, seems to be a predictive variable of patients' performance. Finally, a Fisher's exact test showed that there was not a stable significant relationship between ToM or EF and pragmatic impairment.	[Parola, Alberto; Bosco, Francesca M.] Univ Turin, Dept Psychol, Ctr Cognit Sci, Turin, Italy; [Berardinelli, Laura] ASL Citta Torino, Dept Mental Hlth, Turin, Italy; [Bosco, Francesca M.] Inst Neurosci, Turin, Italy		Bosco, FM (corresponding author), Dipartimento Psicol, Via Po 14, I-10123 Turin, Italy.	Francesca.bosco@unito.it	Parola, alberto/AAK-3748-2020; bosco, francesca marina/B-6746-2013	bosco, francesca marina/0000-0001-6101-8587; PAROLA, ALBERTO/0000-0002-6039-0907	MIUR: Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN)Ministry of Education, Universities and Research (MIUR); Project 'The interpretative brain: Understanding and promoting pragmatic abilities across lifespan and in mental illness' [201577HA9M]; MIUR: Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN)Ministry of Education, Universities and Research (MIUR); Project 'The interpretative brain: Understanding and promoting pragmatic abilities across lifespan and in mental illness' [201577HA9M]	The research was funded by MIUR: Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN) 2017. Project 'The interpretative brain: Understanding and promoting pragmatic abilities across lifespan and in mental illness' project code 201577HA9M.	Abu-akel A., 2000, PSYCHOL MED, V303, P735; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andreasen N.C., 1985, CONTROVERSIES SCHIZO, P199; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; Arcara G, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00070; Bambini V, 2016, COMPR PSYCHIAT, V71, P106, DOI 10.1016/j.comppsych.2016.08.012; Bara Bruno, 2010, COGNITIVE PRAGMATICS; Bazin N, 2005, SCHIZOPHR RES, V77, P75, DOI 10.1016/j.schres.2005.01.020; Bloom P, 2000, COGNITION, V77, pB25, DOI 10.1016/S0010-0277(00)00096-2; Bosco F. M., 2016, FRONT PSYCHOL, V7, DOI DOI https://doi.org/10.3389/fpsyg.2016.00566; Bosco FM, 2017, CORTEX, V94, P73, DOI 10.1016/j.cortex.2017.06.010; Bosco FM, 2017, BRAIN LANG, V168, P73, DOI 10.1016/j.bandl.2017.01.007; Bosco FM, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00021; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2014, CONSCIOUS COGN, V24, P84, DOI 10.1016/j.concog.2014.01.003; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Bosco FM, 2009, CONSCIOUS COGN, V18, P306, DOI 10.1016/j.concog.2008.06.006; Bosia M., 2015, STUDI ITALIANI LINGU, VXLIV; Brizio A, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01011; Brune M, 2005, SCHIZOPHR RES, V75, P233, DOI 10.1016/j.schres.2004.11.006; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Champagne-Lavau Maud, 2009, Cogn Neuropsychiatry, V14, P217, DOI 10.1080/13546800903004114; Champagne-Lavau M, 2010, J NEUROLINGUIST, V23, P285, DOI 10.1016/j.jneuroling.2009.08.009; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Corcoran R, 1997, SCHIZOPHR RES, V24, P319, DOI 10.1016/S0920-9964(96)00117-X; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Corcoran Rhiannon, 2003, Cogn Neuropsychiatry, V8, P223, DOI 10.1080/13546800244000319; Cummings L., 2017, RES CLIN PRAGMATICS; Del-Monte J, 2013, PSYCHIAT RES, V210, P29, DOI 10.1016/j.psychres.2013.05.034; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Edwards J, 2002, CLIN PSYCHOL REV, V22, P789, DOI 10.1016/S0272-7358(02)00130-7; Eisenberg DP, 2010, NEUROPSYCHOPHARMACOL, V35, P258, DOI 10.1038/npp.2009.111; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frith C.D., 1992, COGN NEUROPSYCHOL; Frith C. D., 1988, SCHIZOPHRENIA MAJOR, P172; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Frith R C, 1996, Cogn Neuropsychiatry, V1, P305, DOI 10.1080/135468096396460; Gabbatore I, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/1612078; Gavilan JM, 2011, J NEUROLINGUIST, V24, P54, DOI 10.1016/j.jneuroling.2010.07.006; Giora R, 2002, J PRAGMATICS, V34, P487, DOI 10.1016/S0378-2166(01)00045-5; Green MF, 2015, NAT REV NEUROSCI, V16, P620, DOI 10.1038/nrn4005; Haas MH, 2015, J PSYCHOLINGUIST RES, V44, P469, DOI 10.1007/s10936-014-9298-2; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Harrington Leigh, 2005, Cogn Neuropsychiatry, V10, P249, DOI 10.1080/13546800444000056; Honan CA, 2015, BRAIN LANG, V150, P69, DOI 10.1016/j.bandl.2015.08.007; Huber W., 1983, AACHENER APHASIE TES; Jang G, 2013, NEUROIMAGE, V81, P61, DOI 10.1016/j.neuroimage.2013.05.027; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Key-DeLyria SE, 2016, AM J SPEECH-LANG PAT, V25, DOI 10.1044/2015_AJSLP-14-0111; Kupper Z, 2010, SCHIZOPHR RES, V121, P90, DOI 10.1016/j.schres.2010.03.032; Langdon R, 2002, MIND LANG, V17, P68, DOI 10.1111/1468-0017.00189; Lavelle M, 2013, SCHIZOPHRENIA BULL, V39, P1150, DOI 10.1093/schbul/sbs091; Levinson Stephen., 1983, PRAGMATICS; Linscott RJ, 2005, SCHIZOPHR RES, V75, P225, DOI 10.1016/j.schres.2004.10.007; Marini A, 2008, SCHIZOPHR RES, V105, P144, DOI 10.1016/j.schres.2008.07.011; Mazza M, 2001, SCHIZOPHR RES, V47, P299, DOI 10.1016/S0920-9964(00)00157-2; Mazza M, 2008, PSYCHOPATHOLOGY, V41, P254, DOI 10.1159/000128324; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; Meilijson SR, 2004, J SPEECH LANG HEAR R, V47, P695, DOI 10.1044/1092-4388(2004/053); Merrill AM, 2017, PSYCHIAT RES, V249, P172, DOI 10.1016/j.psychres.2016.12.051; Mittal VA, 2011, SCHIZOPHR RES, V130, P164, DOI 10.1016/j.schres.2011.05.007; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mo SL, 2008, PSYCHIAT RES, V157, P21, DOI 10.1016/j.psychres.2006.04.002; Moro A, 2015, NEUROPSYCHOLOGIA, V79, P147, DOI 10.1016/j.neuropsychologia.2015.10.030; Mossaheb N, 2014, COMPR PSYCHIAT, V55, P928, DOI 10.1016/j.comppsych.2013.12.021; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nichols S., 2003, MINDREADING INTEGRAT; Parola A, 2016, J NEUROLINGUIST, V39, P10, DOI 10.1016/j.jneuroling.2015.12.003; PERNER J, 1989, CHILD DEV, V60, P689, DOI 10.2307/1130734; Pesciarelli F, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00799; Pickup GJ, 2008, PSYCHOPATHOLOGY, V41, P206, DOI 10.1159/000125554; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Rapp AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074224; Rapp AM, 2012, NEUROIMAGE, V63, P600, DOI 10.1016/j.neuroimage.2012.06.022; Raven JC, 1956, COLOURED PROGR MATRI; Reichenberg A, 2007, PSYCHOL BULL, V133, P833, DOI 10.1037/0033-2909.133.5.833; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sacco K, 2008, J COGN SCI, V9, P111; Sarfati Y, 1999, PSYCHOL MED, V29, P613, DOI 10.1017/S0033291799008326; Schettino A, 2010, NEUROPSYCHOLOGIA, V48, P1032, DOI 10.1016/j.neuropsychologia.2009.11.030; Spinnler H., 1987, ITAL J NEUROL SCI, V6, P8; Sponheim SR, 2003, SCHIZOPHR RES, V65, P117, DOI 10.1016/S0920-9964(02)00525-X; Tan EJ, 2014, COMPR PSYCHIAT, V55, P693, DOI 10.1016/j.comppsych.2013.10.016; Tavano A, 2008, SCHIZOPHR RES, V102, P53, DOI 10.1016/j.schres.2008.02.008; Tenyi T, 2002, PSYCHOPATHOLOGY, V35, P25, DOI 10.1159/000056212; Thoma P, 2006, NEUROSCI BIOBEHAV R, V30, P1182, DOI 10.1016/j.neubiorev.2006.09.001; Thoma P, 2009, PSYCHIAT RES, V170, P132, DOI 10.1016/j.psychres.2009.01.026; Tirassa M, 2006, COGN SYST RES, V7, P128, DOI 10.1016/j.cogsys.2006.01.002; Varga E, 2014, J NEUROLINGUIST, V29, P1, DOI 10.1016/j.jneuroling.2014.01.001; Varga E, 2013, BRAIN LANG, V126, P231, DOI 10.1016/j.bandl.2013.05.017; Weickert TW, 2000, ARCH GEN PSYCHIAT, V57, P907, DOI 10.1001/archpsyc.57.9.907; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5	94	26	26	2	21	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	FEB	2018	260						144	151		10.1016/j.psychres.2017.11.051			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	FV8RU	WOS:000424855300022	29195166				2022-02-06	
J	Zhou, Y; Cai, W; Zhao, ZL; Hilton, T; Wang, M; Yeon, J; Liu, W; Zhang, FY; Shi, FD; Wu, XP; Thiagarajan, P; Li, M; Zhang, JN; Dong, JF				Zhou, Yuan; Cai, Wei; Zhao, Zilong; Hilton, Tristan; Wang, Min; Yeon, Jason; Liu, Wei; Zhang, Fangyi; Shi, Fu-Dong; Wu, Xiaoping; Thiagarajan, Perumal; Li, Min; Zhang, Jianning; Dong, Jing-fei			Lactadherin promotes microvesicle clearance to prevent coagulopathy and improves survival of severe TBI mice	BLOOD			English	Article							TRAUMATIC BRAIN-INJURY; APOPTOTIC CELLS; PROCOAGULANT ACTIVITY; HUMAN-MILK; PHOSPHATIDYLSERINE; SURFACE; PHAGOCYTOSIS; COAGULATION; EXPOSURE; PROTEIN	Coagulopathy is common in patients with traumatic brain injury (TBI) and predicts poor clinical outcomes. We have shown that brain-derived extracellular microvesicles, including extracellular mitochondria, play a key role in the development of TBI-induced coagulopathy. Here, we further show in mouse models that the apoptotic cell-scavenging factor lactadherin, given at a single dose of 400 mu g/kg 30 minutes before (preconditioning) or 30 minutes after cerebral fluid percussion injury, prevented coagulopathy as defined by clotting time, fibrinolysis, intravascular fibrin deposition, and microvascular bleeding of the lungs. Lactadherin also reduced cerebral edema, improved neurological function, and increased survival. It achieved these protective effects by enhancing the clearance of circulating microvesicles through phosphatidylserine-mediated phagocytosis. Together, these results identify the scavenging system for apoptotic cells as a potential therapeutic target to prevent TBI-induced coagulopathy and improve the outcome of TBI.	[Zhou, Yuan; Zhao, Zilong; Liu, Wei; Shi, Fu-Dong; Zhang, Jianning] Tianjin Inst Neurol, Tianjin, Peoples R China; [Zhou, Yuan; Zhao, Zilong; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin, Peoples R China; [Zhou, Yuan; Hilton, Tristan; Yeon, Jason; Liu, Wei; Wu, Xiaoping; Dong, Jing-fei] Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA; [Cai, Wei; Wang, Min; Li, Min] Lanzhou Univ, Inst Pathol, Sch Basic Med Sci, Lanzhou, Gansu, Peoples R China; [Zhang, Fangyi] Univ Washington, Sch Med, Dept Neurosurg, Seattle, WA USA; [Shi, Fu-Dong] Tianjin Med Univ, Dept Neurol, Gen Hosp, Tianjin, Peoples R China; [Shi, Fu-Dong] St Josephs Hosp, Barrow Neurol Inst, Dept Neurol, Phoenix, AZ USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Thiagarajan, Perumal] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX USA; [Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA		Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin, Peoples R China.; Dong, JF (corresponding author), Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.; Li, M (corresponding author), Lanzhou Univ, Inst Pathol, Sch Basic Med Sci, Lanzhou, Gansu, Peoples R China.	limin@lzu.edu.cn; jianningzhang@hotmail.com; jfdong@psbc.org	Zhao, Zilong/AAZ-2196-2020		National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS087296]; National Institutes of Health, National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL119391]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81271361, 81271359, 81672399]; Biomedical Laboratory Research and Development Award from the Department of Veterans Affairs [BX000502]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000502] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke grant NS087296 and National Institutes of Health, National Heart, Lung, and Blood Institute grant HL119391 (J.-f.D.); Natural Science Foundation of China State Key Program Grant 81330029 (J.Z.) and Research Grants 81271361, 81271359 (J.N.Z.),and 81672399 (M.L.); and the Biomedical Laboratory Research and Development Award BX000502 from the Department of Veterans Affairs (P.T.).	Andersen MH, 2000, BIOCHEMISTRY-US, V39, P6200, DOI 10.1021/bi992221r; Andersen MH, 1997, BIOCHEMISTRY-US, V36, P5441, DOI 10.1021/bi963119m; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Couto JR, 1996, DNA CELL BIOL, V15, P281, DOI 10.1089/dna.1996.15.281; Dasgupta SK, 2008, TRANSFUSION, V48, P2370, DOI 10.1111/j.1537-2995.2008.01841.x; Dasgupta SK, 2005, HAEMATOLOGICA, V90, P1267; Dasgupta SK, 2009, BLOOD, V113, P1332, DOI 10.1182/blood-2008-07-167148; DINI L, 1995, J CELL SCI, V108, P967; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; FOX JEB, 1991, J BIOL CHEM, V266, P13289; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; LAROCCA D, 1991, CANCER RES, V51, P4994; Maani CV, 2009, CURR OPIN ANESTHESIO, V22, P255, DOI 10.1097/ACO.0b013e32832922be; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; NAG S, 1984, ACTA NEUROPATHOL, V63, P276, DOI 10.1007/BF00687333; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Owens AP, 2011, CIRC RES, V108, P1284, DOI 10.1161/CIRCRESAHA.110.233056; SAHAGUN G, 1990, AM J PHYSIOL, V259, pH162, DOI 10.1152/ajpheart.1990.259.1.H162; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; Shi JL, 2003, BLOOD, V101, P2628, DOI 10.1182/blood-2002-07-1951; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; SIMIONESCU N, 1981, J CELL BIOL, V90, P605, DOI 10.1083/jcb.90.3.605; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wu F, 2017, SHOCK, V48, P340, DOI 10.1097/SHK.0000000000000832; Zhao ZL, 2016, BLOOD, V127, P2763, DOI [10.1182/blood-2015-12688838, 10.1182/blood-2015-12-688838]; Zhu JJ, 2018, J CEREBR BLOOD F MET, V38, P1979, DOI 10.1177/0271678X17726062	37	26	30	1	11	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	FEB 1	2018	131	5					563	572		10.1182/blood-2017-08-801738			10	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	FV1QA	WOS:000424338300013	29162596	Bronze, Green Published			2022-02-06	
J	Hazelton, I; Yates, A; Dale, A; Roodselaar, J; Akbar, N; Ruitenberg, MJ; Anthony, DC; Couch, Y				Hazelton, Isla; Yates, Abi; Dale, Ashley; Roodselaar, Jay; Akbar, Naveed; Ruitenberg, Marc J.; Anthony, Daniel C.; Couch, Yvonne			Exacerbation of Acute Traumatic Brain Injury by Circulating Extracellular Vesicles	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; extracellular vesicles; inflammation; microglia; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; ACUTE-PHASE RESPONSE; LEUKOCYTE MOBILIZATION; INFLAMMATORY RESPONSE; FLOW-CYTOMETRY; SPINAL-CORD; MICROPARTICLES; NEUROINFLAMMATION; MICROVESICLES; MODEL	Inflammatory lesions in the brain activate a systemic acute-phase response (APR), which is dependent on the release of extracellular vesicles (EVs) into the circulation. The resulting APR is responsible for regulating leukocyte mobilization and subsequent recruitment to the brain. Factors that either exacerbate or inhibit the APR will also exacerbate or inhibit central nervous system (CNS) inflammation as a consequence and have the potential to influence ongoing secondary damage. Here, we were interested to discover how the circulating EV population changes after traumatic brain injury (TBI) and how manipulation of the circulating EV pool impacts on the outcome of TBI. We found the number of circulating EVs increased rapidly post-TBI, and this was accompanied by an increase in CNS and hepatic leukocyte recruitment. In an adoptive transfer study, we then evaluated the outcomes of TBI after administering EVs derived from either in vitro macrophage or endothelial cell lines stimulated with lipopolysaccharide (LPS), or from murine plasma from an LPS challenge using the air-pouch model. By manipulating the circulating EV population, we were able to demonstrate that each population of transferred EVs increased the APR. However, the characteristics of the response were dependent on the nature of the EVs; specifically, it was significantly increased when animals were challenged with macrophage-derived EVs, suggesting that the cellular origins of EVs may determine their function. Selectively targeting EVs from macrophage/monocyte populations is likely to be of value in reducing the impact of the systemic inflammatory response on the outcome of traumatic CNS injury.	[Hazelton, Isla; Yates, Abi; Dale, Ashley; Roodselaar, Jay; Anthony, Daniel C.] Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England; [Hazelton, Isla; Dale, Ashley; Ruitenberg, Marc J.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Akbar, Naveed] Univ Oxford, RDM Invest Med, Dept Cardiovasc Med, Oxford, England; [Couch, Yvonne] Univ Oxford, RDM Invest Med, Acute Stroke Programme, Oxford, England		Anthony, DC (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	daniel.anthony@pharm.ox.ac.uk	Anthony, Daniel C/F-7765-2010	Anthony, Daniel C/0000-0003-1380-6655; Akbar, Naveed/0000-0003-4620-6373; Ruitenberg, Marc/0000-0002-6917-0708; Roodselaar, Jay/0000-0002-9321-7836	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Lundbeck FoundationLundbeckfonden; Spinal Research - Nathalie Rose Barr Award; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_PC_15029] Funding Source: UKRI	The authors acknowledge the assistance of Dr. Errin Johnson (Bioimaging Facility, Dunn School, University of Oxford) for taking the EM images of our EVs. This work was funded by the Medical Research Council (to Y.C.), the Lundbeck Foundation (to N.A.), and Spinal Research - Nathalie Rose Barr Award (to D.A. and A.Y.).	Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Anthony DC, 2012, BRAIN BEHAV IMMUN, V26, P534, DOI 10.1016/j.bbi.2011.10.011; Antonucci F, 2012, EMBO J, V31, P1231, DOI 10.1038/emboj.2011.489; Balusu S, 2016, EMBO MOL MED, V8, P1162, DOI 10.15252/emmm.201606271; Banks WA, 2005, CURR PHARM DESIGN, V11, P973, DOI 10.2174/1381612053381684; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Campbell SJ, 2008, NEUROPHARMACOLOGY, V55, P780, DOI 10.1016/j.neuropharm.2008.06.074; Campbell SJ, 2008, J NEUROPATH EXP NEUR, V67, P223, DOI 10.1097/NEN.0b013e3181654957; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Campbell SJ, 2007, NEUROBIOL DIS, V27, P151, DOI 10.1016/j.nbd.2007.04.013; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Chapman KZ, 2009, J CEREBR BLOOD F MET, V29, P1764, DOI 10.1038/jcbfm.2009.113; Chivet M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00145; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Couch Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09710-3; Couch Y, 2017, STROKE, V48, P2292, DOI 10.1161/STROKEAHA.117.017236; Couch Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130643; Couch Y, 2014, J NEUROIMMUNOL, V275, P57, DOI 10.1016/j.jneuroim.2014.08.150; Couch Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0178-3; Dickens AM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai7696; Dragovic RA, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.113266; Evans MC, 2013, MOL CELL NEUROSCI, V53, P34, DOI 10.1016/j.mcn.2012.10.008; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Joshi P, 2014, CELL DEATH DIFFER, V21, P582, DOI 10.1038/cdd.2013.180; Kanada M, 2015, P NATL ACAD SCI USA, V112, pE1433, DOI 10.1073/pnas.1418401112; Kox M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034431; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Paul D, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0755-8; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rubartelli A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00099; Stoner SA, 2016, CYTOM PART A, V89A, P196, DOI 10.1002/cyto.a.22787; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Yamamoto S, 2015, SCI REP-UK, V5, DOI 10.1038/srep08505; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zhang B, 2014, EXP NEUROL, V258, P112, DOI 10.1016/j.expneurol.2014.04.007; Zhao ZL, 2017, PROTEIN CELL, V8, P801, DOI 10.1007/s13238-017-0414-6	41	26	26	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2018	35	4					639	651		10.1089/neu.2017.5049		JAN 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	FV3OH	WOS:000419868800001	29149810	Green Submitted			2022-02-06	
J	Balba, NM; Elliott, JE; Weymann, KB; Opel, RA; Duke, JW; Oken, BS; Morasco, BJ; Heinricher, MM; Lim, MM				Balba, Nadir M.; Elliott, Jonathan E.; Weymann, Kris B.; Opel, Ryan A.; Duke, Joseph W.; Oken, Barry S.; Morasco, Benjamin J.; Heinricher, Mary M.; Lim, Miranda M.			Increased Sleep Disturbances and Pain in Veterans With Comorbid Traumatic Brain Injury and Posttraumatic Stress Disorder	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						sleep-wake disturbances; concussion; polytrauma clinical triad; insomnia; headaches; sensory sensitivity	INSOMNIA SEVERITY INDEX; POLYTRAUMA-CLINICAL-TRIAD; LONGITUDINAL RELATIONSHIPS; FUNCTIONAL STATUS; OEF/OIF VETERANS; FREEDOM VETERANS; SOMATIC SYMPTOMS; REPORTED SLEEP; PTSD; PREVALENCE	Study Objectives: Veterans are at an increased risk for traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD), both of which are associated with sleep disturbances and increased pain. Furthermore, sleep disturbances and pain are reciprocally related such that each can exacerbate the other. Although both TBI and PTSD are independently linked to sleep disturbances and pain, it remains unclear whether Veterans with comorbid TBI+PTSD show worse sleep disturbances and pain compared to those with only TBI or PTSD. We hypothesized that sleep and pain would be worse in Veterans with comorbid TBI+PTSD compared to Veterans with only TBI or PTSD. Methods: Veterans (n = 639) from the VA Portland Health Care System completed overnight polysomnography and self-report questionnaires. Primary outcome variables were self-reported sleep disturbances and current pain intensity. Participants were categorized into four trauma-exposure groups: (1) neither: without TBI or PTSD (n = 383); (2) TBI: only TBI (n = 67); (3) PTSD: only PTSD (n = 126); and (4) TBI+PTSD: TBI and PTSD (n = 63). Results: The PTSD and TBI+PTSD groups reported worse sleep compared to the TBI and neither groups. The TBI+PTSD group reported the greatest pain intensity compared to the other groups. Conclusions: These data suggest sleep and pain are worst in Veterans with TBI and PTSD, and that sleep is similarly impaired in Veterans with PTSD despite not having as much pain. Thus, although this is a complex relationship, these data suggest PTSD may be driving sleep disturbances, and the added effect of TBI in the comorbid group may be driving pain in this population.	[Balba, Nadir M.; Elliott, Jonathan E.; Weymann, Kris B.; Opel, Ryan A.; Heinricher, Mary M.; Lim, Miranda M.] VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,Mailcode P3-RD42, Portland, OR 97239 USA; [Balba, Nadir M.; Oken, Barry S.; Heinricher, Mary M.; Lim, Miranda M.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; [Elliott, Jonathan E.; Oken, Barry S.; Lim, Miranda M.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Weymann, Kris B.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA; [Duke, Joseph W.] No Arizona Univ, Dept Biol Sci, Box 5640, Flagstaff, AZ 86011 USA; [Morasco, Benjamin J.] VA Portland Hlth Care Syst, Ctr Improve Vet Involvement Care, Portland, OR 97239 USA; [Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Heinricher, Mary M.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; [Lim, Miranda M.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA; [Lim, Miranda M.] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA		Lim, MM (corresponding author), VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,Mailcode P3-RD42, Portland, OR 97239 USA.	lmir@ohsu.edu			VA Career Development Award [IK2 BX002712]; NIH EXITO Institutional CoreUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1GM118964]; N.I.H.United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 AT 002688]; Department of Defense awardUnited States Department of Defense [D01 W81XWH-17-1-0423]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32AT002688] Funding Source: NIH RePORTER	All authors have seen and approved this manuscript. Work for this study was performed at VA Portland Health Care System, Portland, OR. This material is the result of work supported with resources and the use of facilities at the VA Portland Health Care System, VA Career Development Award #IK2 BX002712, NIH EXITO Institutional Core, #UL1GM118964, and the Portland VA Research Foundation to M.M.L.; N.I.H. T32 AT 002688 to J.E.E.; VA OAA Post-doctoral Nursing Research Fellowship to K.B.W.; and Department of Defense award #D01 W81XWH-17-1-0423 to M.M.H. and M.M.L., awarded and administered through the US Army Medical Research Acquisition Activity, Fort Detrick, MD. Interpretations and conclusions are those of the authors and do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. The authors report no conflicts of interest.	Affleck G, 1996, PAIN, V68, P363, DOI 10.1016/S0304-3959(96)03226-5; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; ASAKURA W, 1992, GEN PHARMACOL, V23, P337, DOI 10.1016/0306-3623(92)90092-X; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Beckham JC, 1997, J PSYCHOSOM RES, V43, P379, DOI 10.1016/S0022-3999(97)00129-3; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blevins CA, 2015, J TRAUMA STRESS, V28, P489, DOI 10.1002/jts.22059; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Burstein R, 2015, J NEUROSCI, V35, P6619, DOI 10.1523/JNEUROSCI.0373-15.2015; Call-Schmidt Tracy Ann, 2003, Pain Manag Nurs, V4, P124, DOI 10.1016/S1524-9042(02)54212-0; Callahan ML, 2018, APPL NEUROPSYCH-ADUL, V25, P126, DOI 10.1080/23279095.2016.1261867; Centers for Disease Control and Prevention, 2016, INJ PREV CONTR TRAUM; Chasens ER, 2009, SLEEP, V32, P915, DOI 10.1093/sleep/32.7.915; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Elliott AM, 1999, LANCET, V354, P1248, DOI 10.1016/S0140-6736(99)03057-3; Elliott JE, 2018, J CLIN SLEEP MED, V14, P1177, DOI 10.5664/jcsm.7220; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; Foley D, 2004, J PSYCHOSOM RES, V56, P497, DOI 10.1016/j.jpsychores.2004.02.010; Foley DJ, 1999, SLEEP, V22, pS366; Geisser ME, 2008, J PAIN, V9, P417, DOI 10.1016/j.jpain.2007.12.006; Geisser ME, 2008, PSYCHOSOMATICS, V49, P235, DOI 10.1176/appi.psy.49.3.235; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Goadsby PJ, 2017, PHYSIOL REV, V97, P553, DOI 10.1152/physrev.00034.2015; Gotlib IH, 2004, J ABNORM PSYCHOL, V113, P127, DOI 10.1037/0021-843X.113.1.121; Grima N, 2016, J CLIN SLEEP MED, V12, P419, DOI 10.5664/jcsm.5598; Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9; HICKS RA, 1978, PERCEPT MOTOR SKILL, V47, P848, DOI 10.2466/pms.1978.47.3.848; HICKS RA, 1979, PERCEPT MOTOR SKILL, V48, P687, DOI 10.2466/pms.1979.48.3.687; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Husain AM, 2001, J CLIN NEUROPHYSIOL, V18, P148, DOI 10.1097/00004691-200103000-00005; Insana SP, 2012, BIOL PSYCHOL, V89, P570, DOI 10.1016/j.biopsycho.2012.01.001; Jaramillo CA, 2016, HEADACHE, V56, P528, DOI 10.1111/head.12726; Johannes CB, 2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002; Kaniecki R, 2004, STANDARDS CARE HEADA, P40; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Khazaie Habibolah, 2016, J Inj Violence Res, V8, P99, DOI 10.5249/jivr.v8i2.808; Khoury S, 2018, PROG NEURO-PSYCHOPH, V87, P224, DOI 10.1016/j.pnpbp.2017.06.007; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lamarche LJ, 2007, J CLIN PSYCHIAT, V68, P1257, DOI 10.4088/JCP.v68n0813; Landy S, 2004, TREATMENT PRIMARY HE; Lang KP, 2014, J HEAD TRAUMA REHAB, V29, P44, DOI 10.1097/HTR.0b013e31829c85d0; Lautenbacher S, 2006, SLEEP MED REV, V10, P357, DOI 10.1016/j.smrv.2005.08.001; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lewin DS, 1999, J DEV BEHAV PEDIATR, V20, P244, DOI 10.1097/00004703-199908000-00007; Macey TA, 2011, PAIN MED, V12, P1502, DOI 10.1111/j.1526-4637.2011.01226.x; Martenson ME, 2016, PAIN, V157, P868, DOI 10.1097/j.pain.0000000000000450; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McDonald J.H., 2009, HDB BIOL STAT, V2; Mellman TA, 2007, J TRAUMA STRESS, V20, P893, DOI 10.1002/jts.20246; Menefee LA, 2000, PAIN MED, V1, P156, DOI 10.1046/j.1526-4637.2000.00022.x; Morasco BJ, 2013, PAIN, V154, P609, DOI 10.1016/j.pain.2013.01.001; Morasco BJ, 2011, PAIN, V152, P488, DOI 10.1016/j.pain.2010.10.009; Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Morin CM, 1998, CLIN J PAIN, V14, P311, DOI 10.1097/00002508-199812000-00007; Mysliwiec V, 2018, SLEEP MED REV, V37, P94, DOI 10.1016/j.smrv.2017.01.004; Mysliwiec V, 2014, J CLIN SLEEP MED, V10, P1143, DOI 10.5664/jcsm.4120; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Newell J, 2012, PSYCHIAT RES, V200, P795, DOI 10.1016/j.psychres.2012.07.045; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Nicassio PM, 2002, PAIN, V100, P271, DOI 10.1016/S0304-3959(02)00300-7; NICASSIO PM, 1992, J ABNORM PSYCHOL, V101, P514, DOI 10.1037/0021-843X.101.3.514; Ohayon MM, 2000, COMPR PSYCHIAT, V41, P469, DOI 10.1053/comp.2000.16568; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omachi TA, 2011, ARTHRIT CARE RES, V63, pS287, DOI 10.1002/acr.20544; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Palermo TM, 2005, J PAIN, V6, P201, DOI 10.1016/j.jpain.2004.12.005; Pigeon WR, 2013, J PSYCHOSOM RES, V75, P546, DOI 10.1016/j.jpsychores.2013.09.004; PITMAN RK, 1989, AM J PSYCHIAT, V146, P667; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Pugh MJV, 2014, MED CARE, V52, P172, DOI 10.1097/MLR.0000000000000059; R Development Core Team, 2016, R LANG ENV STAT COMP; Raymond I, 2001, PAIN, V92, P381, DOI 10.1016/S0304-3959(01)00282-2; ROSZELL DK, 1991, HOSP COMMUNITY PSYCH, V42, P293; Ruff RL, 2012, J REHABIL RES DEV, V49, P1305, DOI 10.1682/JRRD.2011.12.0251; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sandsmark DK, 2017, SLEEP, V40, DOI 10.1093/sleep/zsx044; Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860; Seal KH, 2017, ARCH PHYS MED REHAB, V98, P1636, DOI 10.1016/j.apmr.2017.03.026; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Smith M. T., 2003, ARTHRITIS RHEUMATISM, V49, pS184, DOI DOI 10.1002/ART.11409; Smith MT, 2007, SLEEP, V30, P494, DOI 10.1093/sleep/30.4.494; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; Stojanovic MP, 2016, PAIN MED, V17, P2017, DOI 10.1093/pm/pnw042; Stone AA, 1997, ARTHRIT CARE RES, V10, P185, DOI 10.1002/art.1790100306; Suhnan AP, 2017, INT J AUDIOL, V56, P801, DOI 10.1080/14992027.2017.1346303; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wahbeh H, 2008, NEUROLOGY, V70, P2321, DOI 10.1212/01.wnl.0000314667.16386.5e; Weathers F.W., 1993, 9 ANN C ISTSS; Weaver TE, 1997, SLEEP, V20, P835; Weymann KB, 2017, CURR SLEEP MED REP, V3, P179; Williams SG, 2015, SLEEP BREATH, V19, P175, DOI 10.1007/s11325-014-0984-y; Woodward SH, 2000, BIOL PSYCHIAT, V48, P1081, DOI 10.1016/S0006-3223(00)00917-3; Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030; Wortzel HS, 2014, NEUROREHABILITATION, V34, P613, DOI 10.3233/NRE-141086; Yesavage JA, 2012, AM J GERIAT PSYCHIAT, V20, P199, DOI 10.1097/JGP.0b013e3181e446ea; Young James A, 2007, Phys Med Rehabil Clin N Am, V18, P145, DOI 10.1016/j.pmr.2006.11.008	103	26	27	0	2	AMER ACAD SLEEP MEDICINE	DARIEN	2510 N FRONTAGE RD, DARIEN, IL 60561 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2018	14	11					1865	1878	PII jc-18-00057	10.5664/jcsm.7482			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HP1GS	WOS:000461414800007	30373686	Bronze, Green Published			2022-02-06	
J	Chen, M; Song, HL; Cui, JK; Johnson, CE; Hubler, GK; DePalma, RG; Gu, ZZ; Xia, WM				Chen, Mei; Song, Hailong; Cui, Jiankun; Johnson, Catherine E.; Hubler, Graham K.; DePalma, Ralph G.; Gu, Zezong; Xia, Weiming			Proteomic Profiling of Mouse Brains Exposed to Blast-Induced Mild Traumatic Brain Injury Reveals Changes in Axonal Proteins and Phosphorylated Tau	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; bioinformatics; mild traumatic brain injury; open-field blast; proteomics	NEUROFIBRILLARY TANGLES; MODEL; MICE; EXPRESSION; CSF; ASSOCIATION; BIOMARKERS; CALCIUM; DISEASE; PLASMA	Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by two pathological hallmarks: Tau-containing neurofibrillary tangles and amyloid-beta protein (A beta)-containing neuritic plaques. The goal of this study is to understand mild traumatic brain injury (mTBI)-related brain proteomic changes and tau-related biochemical adaptations that may contribute to AD-like neurodegeneration. We found that both phosphorylated tau (p-tau) and the ratio of p-tau/tau were significantly increased in brains of mice collected at 3 and 24 h after exposure to 82-kPa low-intensity open-field blast. Neurological deficits were observed in animals at 24 h and 7 days after the blast using Simple Neuroassessment of Asymmetric imPairment (SNAP) test, and axon/dendrite degeneration was revealed at 7 days by silver staining. Liquid chromatography-mass spectrometry (LC-MS/MS) was used to analyze brain tissue labeled with isobaric mass tags for relative protein quantification. The results from the proteomics and bioinformatic analysis illustrated the alterations of axonal and synaptic proteins in related pathways, including but not being limited to substantia nigra development, cortical cytoskeleton organization, and synaptic vesicle exocytosis, suggesting a potential axonal damage caused by blast-induced mTBI. Among altered proteins found in brains suffering blast, microtubule-associated protein 1B, stathmin, neurofilaments, actin binding proteins, myelin basic protein, calcium/calmodulin-dependent protein kinase, and synaptotagmin I were representative ones involved in altered pathways elicited by mTBI. Therefore, TBI induces elevated phospho-tau, a pathological feature found in brains of AD, and altered a number of neurophysiological processes, supporting the notion that blast-induced mTBI as a risk factor contributes to AD pathogenesis. LC/MS-based profiling has presented candidate target/pathways that could be explored for future therapeutic development.	[Chen, Mei; Xia, Weiming] Edith Nourse Rogers Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Off Res & Dev, Bedford, MA 01730 USA; [Chen, Mei] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Song, Hailong; Cui, Jiankun; Gu, Zezong] Univ Missouri, Dept Pathol & Anat Sci, Sch Med, Columbia, MO 65212 USA; [Johnson, Catherine E.] Missouri Univ Sci & Technol, Dept Min & Nucl Engn, Rolla, MO USA; [Cui, Jiankun; Gu, Zezong] Truman VA Hosp Res Serv, Columbia, MO USA; [Hubler, Graham K.] Univ Missouri, Sidney Kimmel Inst Nucl Renaissance, Dept Phys & Astron, Columbia, MO 65212 USA; [DePalma, Ralph G.] Dept Vet Affairs, Off Res & Dev, Washington, DC USA; [DePalma, Ralph G.] Uniformed Univ Hlth Sci, Dept Surg, Bethesda, MD USA; [Xia, Weiming] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA		Gu, ZZ (corresponding author), Univ Missouri, Sch Med, Ctr Translat Neurosci, Dept Pathol & Anat Sci, Columbia, MO 65212 USA.; Xia, WM (corresponding author), Edith Nourse Rogers Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Bldg 70,Room 202, Bedford, MA 01730 USA.	guze@health.missouri.edu; weiming.xia@va.gov	DePalma, Ralph/P-1733-2019; Song, Hailong/I-9418-2018	Song, Hailong/0000-0002-4204-6459	Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development [I01BX003527, I21 BX003807]; Cure Alzheimer's Fund; DoD Congressionally Directed Medical Research Programs (CDMRP) for the Peer Reviewed Alzheimer's Research Program Convergence Science Research Award (PRARP-CSRA) [AZ140109]; University of Missouri; Veterans AffairsUS Department of Veterans Affairs [I01BX003527] Funding Source: NIH RePORTER	We thank Dr. Guy Surpris and Benjamin Morris-Eppolito for critical discussions. This study was supported by the award I01BX003527 and I21 BX003807 from the Biomedical Laboratory Research and Development Service of the Veterans Affairs Office of Research and Development (WX) and the Cure Alzheimer's Fund (WX). This publication-was also made possible by funding from the DoD Congressionally Directed Medical Research Programs (CDMRP) for the Peer Reviewed Alzheimer's Research Program Convergence Science Research Award (PRARP-CSRA; AZ140109) and the research funds of the University of Missouri (ZG). The views expressed in this article are those of the authors and do not represent the views of the US Department of Veterans Affairs or the US Government.	Albayram O, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01068-4; Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bourne JN, 2008, ANNU REV NEUROSCI, V31, P47, DOI 10.1146/annurev.neuro.31.060407.125646; Boutte AM, 2012, ELECTROPHORESIS, V33, P3693, DOI 10.1002/elps.201200196; Chen M, 2018, J PROTEOMICS, V182, P21, DOI 10.1016/j.jprot.2018.04.032; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dieterich DC, 2002, EUR J NEUROSCI, V15, P1433, DOI 10.1046/j.1460-9568.2002.01977.x; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Evans Teresa M, 2014, Transl Proteom, V3, P10; Fagan AM, 2007, ARCH NEUROL-CHICAGO, V64, P343, DOI 10.1001/archneur.64.3.noc60123; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodrich JA, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0395-3; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gupta R, 2005, J ORTHOP RES, V23, P1232, DOI 10.1016/j.orthres.2004.12.010; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hutton M, 2000, ANN NY ACAD SCI, V920, P63; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson MC, 2016, ACS OMEGA, V1, P663, DOI 10.1021/acsomega.6b00220; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Lee HK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163072; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Lund LM, 2002, J NEUROSCI RES, V67, P720, DOI 10.1002/jnr.10162; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martinez-Morillo E, 2015, CLIN CHEM LAB MED, V53, P1575, DOI 10.1515/cclm-2014-0908; Menon DK, 2015, NAT REV NEUROL, V11, P71, DOI 10.1038/nrneurol.2014.261; Merriam EB, 2013, J NEUROSCI, V33, P16471, DOI 10.1523/JNEUROSCI.0661-13.2013; Miyasaka T, 2010, FEBS LETT, V584, P3227, DOI 10.1016/j.febslet.2010.06.014; Mouzon B, 2019, J NEUROTRAUM, V36, P576, DOI 10.1089/neu.2018.5720; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Sarkis GA, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0736-z; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; Shaw LM, 2011, ACTA NEUROPATHOL, V121, P597, DOI 10.1007/s00401-011-0808-0; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Song H, 2018, J PROTEOME RES, V17, P858, DOI 10.1021/acs.jproteome.7b00618; Song HL, 2018, BEHAV BRAIN RES, V340, P147, DOI 10.1016/j.bbr.2016.08.037; Song HL, 2018, BEHAV BRAIN RES, V347, P148, DOI 10.1016/j.bbr.2018.03.007; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tortosa E, 2011, J BIOL CHEM, V286, P40638, DOI 10.1074/jbc.M111.271320; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tzekov R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153608; Uchida S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5389; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Yang WJ, 2017, ACTA NEUROL SCAND, V135, P622, DOI 10.1111/ane.12644; Yap YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176997; Zhang MY, 2012, J MOL NEUROSCI, V46, P631, DOI 10.1007/s12031-011-9651-y; Zupanc GKH, 2007, PROTEOM CLIN APPL, V1, P1362, DOI 10.1002/prca.200700420	61	26	26	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2018	66	2					751	773		10.3233/JAD-180726			23	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HB6ZU	WOS:000451224700028	30347620	Green Accepted			2022-02-06	
J	Liang, JW; Wu, SH; Xie, WX; He, HF				Liang, Jinwei; Wu, Shanhu; Xie, Wenxi; He, Hefan			Ketamine ameliorates oxidative stress-induced apoptosis in experimental traumatic brain injury via the Nrf2 pathway	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						traumatic brain injury; ketamine; oxidative stress; Nrf2; apoptosis	PROVIDES NEUROPROTECTION; AUTOPHAGY; RATS; ANTIOXIDANT; PROTECTS	Background: Ketamine can act as a multifunctional neuroprotective agent by inhibiting oxidative stress, cellular dysfunction, and apoptosis. Although it has been proven to be effective in various neurologic disorders, the mechanism of the treatment of traumatic brain injury (TBI) is not fully understood. The aim of this study was to investigate the neuroprotective function of ketamine in models of TBI and the potential role of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in this putative protective effect. Materials and methods: Wild-type male mice were randomly assigned to five groups: Sham group, Sham + ketamine group, TBI group, TBI + vehicle group, and TBI + ketamine group. Marmarou's weight drop model in mice was used to induce TBI, after which either ketamine or vehicle was administered via intraperitoneal injection. After 24 h, the brain samples were collected for analysis. Results: Ketamine significantly ameliorated secondary brain injury induced by TBI, including neurological deficits, brain water content, and neuronal apoptosis. In addition, the levels of malondialdehyde (MDA), glutathione peroxidase (GPx), and superoxide dismutase (SOD) were restored by the ketamine treatment. Western blotting and immunohistochemistry showed that ketamine significantly increased the level of Nrf2. Furthermore, administration of ketamine also induced the expression of Nrf2 pathway-related downstream factors, including hemeoxygenase-1 and quinine oxidoreductase-1, at the pre- and post-transcriptional levels. Conclusion: Ketamine exhibits neuroprotective effects by attenuating oxidative stress and apoptosis after TBI. Therefore, ketamine could be an effective therapeutic agent for the treatment of TBI.	[Liang, Jinwei; Wu, Shanhu; Xie, Wenxi; He, Hefan] Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesiol, 248 East St, Quanzhou, Fujian, Peoples R China		He, HF (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesiol, 248 East St, Quanzhou, Fujian, Peoples R China.	fjhehefan@126.com			Fujian Province Natural Science FoundationNatural Science Foundation of Fujian Province [2016J01520]	This work was supported by grants from the Fujian Province Natural Science Foundation (No 2016J01520 from Professor Hehe Fan).	Bell JD, 2017, ANESTH ANALG, V124, P1237, DOI 10.1213/ANE.0000000000001856; Bergamo P, 2011, MOL NUTR FOOD RES, V55, pS248, DOI 10.1002/mnfr.201100295; Brown BP, 2015, NEUROSCIENCE, V290, P31, DOI 10.1016/j.neuroscience.2014.12.076; Chang LC, 2013, CNS NEUROSCI THER, V19, P390, DOI 10.1111/cns.12077; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Eisenried A, 2017, PAIN, V158, P2181, DOI 10.1097/j.pain.0000000000001019; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gao YY, 2017, AM J TRANSL RES, V9, P887; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Halima B, 2018, J MED FOOD, V21, P70, DOI 10.1089/jmf.2017.0039; Lee DS, 2016, MOL MED REP, V13, P4911, DOI 10.3892/mmr.2016.5129; Lee JM, 2003, BBA-GENE STRUCT EXPR, V1629, P92, DOI 10.1016/j.bbaexp.2003.08.006; Liu ZW, 2017, NEUROCHEM RES, V42, P1375, DOI 10.1007/s11064-017-2186-z; Luggya TS, 2017, AFR HEALTH SCI, V17, P500, DOI 10.4314/ahs.v17i2.25; MARCOUX FW, 1988, BRAIN RES, V452, P329, DOI 10.1016/0006-8993(88)90037-6; Mas MF, 2017, PHYS MED REH CLIN N, V28, P829, DOI 10.1016/j.pmr.2017.06.014; McGirr A, 2017, BRAIN, V140, P2210, DOI 10.1093/brain/awx142; Mollayeva T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018626; Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326; Okonkwo DO, 2017, CRIT CARE MED, V45, P1907, DOI 10.1097/CCM.0000000000002619; Ozay R, 2017, WORLD NEUROSURG, V97, P407, DOI 10.1016/j.wneu.2016.09.115; Park JM, 2015, J CLIN BIOCHEM NUTR, V56, P132, DOI 10.3164/jcbn.14-76; Qin MZ, 2015, INT J CLIN EXP PATHO, V8, P12943; Reus GZ, 2017, PHARMACOL REP, V69, P1094, DOI 10.1016/j.pharep.2017.04.021; Romano R, 2017, J BREATH RES, V12; Sharma S, 2017, PLOS GENET, V13, DOI [10.1371/journal.pgen.1007019, 10.1371/journal.pgen.1006804]; Syatkin SP, 2016, B EXP BIOL MED+, V161, P703, DOI 10.1007/s10517-016-3489-9; Vazquez GH, 2017, CNS NEUROL DISORD-DR, V16, P858, DOI 10.2174/1871527316666170728165648; Xie YL, 2017, BIOMED PHARMACOTHER, V91, P70, DOI 10.1016/j.biopha.2017.04.070; Zanos P, 2016, NATURE, V533, P481, DOI 10.1038/nature17998; Zhai XF, 2016, NEUROIMMUNOMODULAT, V23, P179, DOI 10.1159/000448716; Zhou X, 2014, BIOL PHARM BULL, V37, P1282, DOI 10.1248/bpb.b14-00083; Zhu Min-min, 2007, Zhonghua Yi Xue Za Zhi, V87, P1308	34	26	27	0	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2018	12						845	853		10.2147/DDDT.S160046			9	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	GD2JU	WOS:000430326700001	29713142	Green Published, Green Submitted, gold			2022-02-06	
J	Simon, DW; Aneja, RK; Alexander, H; Bell, MJ; Bayir, H; Kochanek, PM; Clark, RSB				Simon, Dennis W.; Aneja, Rajesh K.; Alexander, Henry; Bell, Michael J.; Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.			Minocycline Attenuates High Mobility Group Box 1 Translocation, Microglial Activation, and Thalamic Neurodegeneration after Traumatic Brain Injury in Post-Natal Day 17 Rats	JOURNAL OF NEUROTRAUMA			English	Article						HMGB1; microglia; minocycline; neuroinflammation; traumatic brain injury	CEREBROSPINAL-FLUID; CYTOCHROME-C; NEUROPROTECTION; CHILDREN; STATES; MICE; DYSAUTONOMIA; IMPAIRMENT; APOPTOSIS; HMGB1	In response to cell injury, the danger signal high mobility group box-1 (HMGB) is released, activating macrophages by binding pattern recognition receptors. We investigated the role of the anti-inflammatory drug minocycline in attenuating HMGB1 translocation, microglial activation, and neuronal injury in a rat model of pediatric traumatic brain injury (TBI). Post-natal day 17 Sprague-Dawley rats underwent moderate-severe controlled cortical impact (CCI). Animals were randomized to treatment with minocycline (90mg/kg, intraperitoneally) or vehicle (saline) at 10min and 20h after injury. Shams received anesthesia and craniotomy. We analyzed HMGB1 translocation (protein fractionation and Western blotting), microglial activation (Iba-1 immunohistochemistry), neuronal death (Fluoro-Jade-B [FJB] immunofluorescence), and neuronal cell counts (unbiased stereology). Behavioral assessments included motor and Morris-water maze testing. Nuclear to cytosolic translocation of HMGB1 in the injured brain was attenuated in minocycline versus vehicle-treated rats at 24h (p<0.001). Treatment with minocycline reduced microglial activation in the ipsilateral cortex, hippocampus, and thalamus (p<0.05 vs. vehicle, all regions); attenuated neurodegeneration (FJB-positive neurons) at seven days (p<0.05 vs. vehicle); and increased thalamic neuronal survival at 14 days (naive 22773 +/- 1012 cells/mm(3), CCI + vehicle 11753 +/- 464, CCI + minocycline 17047 +/- 524; p<0.001). Minocycline-treated rats demonstrated delayed motor recovery early after injury but had no injury effect on Morris-water maze whereas vehicle-treated rats performed worse than sham on the final two days of testing (both p<0.05 vs. vehicle). Minocycline globally attenuated HMGB1 translocation and microglial activation in injured brain in a pediatric TBI model and afforded selective thalamic neuroprotection. The HMGB1 translocation and thalamic injury may represent novel mechanistic and regional therapeutic targets in pediatric TBI.	[Simon, Dennis W.; Aneja, Rajesh K.; Bell, Michael J.; Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Simon, Dennis W.; Aneja, Rajesh K.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; [Bayir, Hulya] Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA; [Alexander, Henry; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Simon, DW (corresponding author), Childrens Hosp Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	dennis.simon2@chp.edu			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, U01 NS081041]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER	Support was received from NINDS grants R01 NS38620 and U01 NS081041; and NICHD T32 HD40686.	Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cascio A, 2004, ANTIMICROB AGENTS CH, V48, P2739, DOI 10.1128/AAC.48.7.2739-2741.2004; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Chhor V, 2017, BRAIN BEHAV IMMUN, V63, P197, DOI 10.1016/j.bbi.2016.11.001; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hu XR, 2010, EUR J PHARMACOL, V638, P84, DOI 10.1016/j.ejphar.2010.03.059; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kikuchi K, 2009, BIOCHEM BIOPH RES CO, V385, P132, DOI 10.1016/j.bbrc.2009.04.041; Kirk KA, 2012, DEV MED CHILD NEUROL, V54, P759, DOI 10.1111/j.1469-8749.2012.04322.x; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lu B, 2013, PROTEIN CELL, V4, P163, DOI 10.1007/s13238-012-2118-2; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Merianda TT, 2015, J NEUROSCI, V35, P5693, DOI 10.1523/JNEUROSCI.3397-14.2015; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Newell E, 2015, PEDIATR CRIT CARE ME, V16, P549, DOI 10.1097/PCC.0000000000000400; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Stackman RW, 2012, J NEUROSCI, V32, P10211, DOI 10.1523/JNEUROSCI.4868-11.2012; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Walko TD, 2014, MOL MED, V20, P612, DOI 10.2119/molmed.2014.00156; Wallisch J. S., 2017, NEUROCRIT CARE; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wiley CA, 2016, J NEUROTRAUM, V33, P1866, DOI 10.1089/neu.2015.4272	47	26	27	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2018	35	1					130	138		10.1089/neu.2017.5093			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	FS1WO	WOS:000419569700015	28699371	Green Published			2022-02-06	
J	Panahi, S; Aram, Z; Jafari, S; Ma, J; Sprott, JC				Panahi, Shirin; Aram, Zainab; Jafari, Sajad; Ma, Jun; Sprott, J. C.			Modeling of epilepsy based on chaotic artificial neural network	CHAOS SOLITONS & FRACTALS			English	Article						Neural network; Epilepsy; Chaos; Bifurcation	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; SEIZURES; DYNAMICS; ADULTS; POPULATION; DISORDER; NEURONS; MEMORY; PEOPLE	Epilepsy is a long-term chronic neurological disorder that is characterized by seizures. One type of epilepsy is simple partial seizures that are localized to one area on one side of the brain, especially in the temporal lobe, but some may spread from there. GABA (gamma-aminobutyric acid) is an inhibitory neurotransmitter that is widely distributed in the neurons of the cortex. Scientists recently discovered the basic role of neurotransmitters in epilepsy. Synaptic reorganizations at GABAergic and glutamatergic synapses not only enable seizure occurrence, they also modify the normal information processing performed by these networks. Based on some physiological facts about epilepsy and chaos, a behavioral model is presented in this paper. This model represents the problem of undesired seizure, and also tries to suggest different valuable predictions about possible causes of epilepsy disorder. The proposed model suggests that there is a possible interaction between the role of excitatory and inhibitory neurotransmitters and epilepsy. The result of these studies might be helpful to discern epilepsy in a different way and give some guidance to predict the occurrence of seizures in patients. (C) 2017 Elsevier Ltd. All rights reserved.	[Panahi, Shirin; Aram, Zainab; Jafari, Sajad] Amirkabir Univ Technol, Biomed Engn Dept, Tehran 158754413, Iran; [Ma, Jun] Lanzhou Univ Technol, Dept Phys, Lanzhou 730050, Gansu, Peoples R China; [Sprott, J. C.] Univ Wisconsin, Dept Phys, 1150 Univ Ave, Madison, WI 53706 USA		Ma, J (corresponding author), Lanzhou Univ Technol, Dept Phys, Lanzhou 730050, Gansu, Peoples R China.	hyperchaos@163.com	Jafari, Sajad/P-7778-2017; Ma, Jun/G-2376-2010	Jafari, Sajad/0000-0002-6845-7539; Ma, Jun/0000-0002-6127-000X			Alhawarat M., 2015, ARXIV150102192; Allen AS, 2013, NATURE, V501, P217, DOI 10.1038/nature12439; Baghdadi G, 2015, COMMUN NONLINEAR SCI, V20, P174, DOI 10.1016/j.cnsns.2014.05.015; Baker GA, 2001, EPILEPSIA, V42, P66, DOI 10.1046/j.1528-1157.2001.042suppl.3066.x; Bannai H, 2009, NEURON, V62, P670, DOI 10.1016/j.neuron.2009.04.023; Basar E, 2012, CHAOS BRAIN FUNCTION; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/ng0501-46; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bernard C, 2010, EPILEPSIA, V51, P42, DOI 10.1111/j.1528-1167.2010.02828.x; Branford D, 1998, SEIZURE-EUR J EPILEP, V7, P473, DOI 10.1016/S1059-1311(98)80005-8; Cossart R, 2001, NAT NEUROSCI, V4, P52, DOI 10.1038/82900; de Boer HM, 2008, EPILEPSY BEHAV, V12, P540, DOI 10.1016/j.yebeh.2007.12.019; de Curtis M, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a022368; Diaz H, 2015, PROCEDIA COMPUT SCI, V55, P1410, DOI 10.1016/j.procs.2015.07.135; Durand E, 2016, BRAIN INJURY, P1; Eid T, 2004, LANCET, V363, P28, DOI 10.1016/S0140-6736(03)15166-5; El Achkar CM, 2015, EPILEPSY BEHAV, V47, P183, DOI 10.1016/j.yebeh.2014.12.022; Engel J, 2012, JAMA-J AM MED ASSOC, V307, P922, DOI 10.1001/jama.2012.220; Englot D, 2015, HDB CLIN NEUROL, V134, P267; Erkaymaz O, 2017, APPL MATH COMPUT, V311, P22, DOI 10.1016/j.amc.2017.05.010; Falahian R, 2015, NONLINEAR DYNAM, V81, P1951, DOI 10.1007/s11071-015-2118-x; Fister I, 2016, NONLINEAR DYNAM, V84, P895, DOI 10.1007/s11071-015-2537-8; Fister I, 2015, APPL MATH COMPUT, V252, P155, DOI 10.1016/j.amc.2014.12.006; Fox CK, 2013, ANN NEUROL, V74, P249, DOI 10.1002/ana.23916; FREEMAN WJ, 1988, IEEE T CIRCUITS SYST, V35, P781, DOI 10.1109/31.1822; FREEMAN WJ, 1987, BIOL CYBERN, V56, P139, DOI 10.1007/BF00317988; Fridley J, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11334; Gaiarsa JL, 2002, TRENDS NEUROSCI, V25, P564, DOI 10.1016/S0166-2236(02)02269-5; Groticke I, 2007, EXP NEUROL, V207, P329, DOI 10.1016/j.expneurol.2007.06.021; Guerrini R, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb05118.x; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Heylighen F, 2012, WORKING PAPERS; Hilborn, 2000, CHAOS NONLINEAR DYNA; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Huang HL, 2015, CELL BIOCHEM BIOPHYS, V73, P7, DOI 10.1007/s12013-015-0603-y; Iasemidis LD, 1996, NEUROSCIENTIST, V2, P118, DOI 10.1177/107385849600200213; JENSEN I, 1977, ACTA NEUROCHIR, V37, P173, DOI 10.1007/BF01402126; Jouny CC, 2012, CLIN NEUROPHYSIOL, V123, P658, DOI 10.1016/j.clinph.2011.08.003; Karsai M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00397; Kim S.-H., 2015, THESIS; Knutson AR, 2012, P NATL ACAD SCI USA, V109, P13106, DOI 10.1073/pnas.1208876109; Kwan P, 2011, NEW ENGL J MED, V365, P919, DOI 10.1056/NEJMra1004418; Kwon OY, 2014, J CLIN NEUROL, V10, P175, DOI 10.3988/jcn.2014.10.3.175; Larter R, 1999, CHAOS, V9, P795, DOI 10.1063/1.166453; Leeman-Markowski BA, 2016, NEUROL CLIN, V34, P183, DOI 10.1016/j.ncl.2015.08.008; Lehnertz K, 2000, CHAOS BRAIN WORLD SC; Li XD, 2017, IEEE T AUTOMAT CONTR, V62, P3618, DOI 10.1109/TAC.2017.2669580; Li XD, 2015, ASIAN J CONTROL, V17, P1678, DOI 10.1002/asjc.984; Li XD, 2013, IEEE T NEUR NET LEAR, V24, P868, DOI 10.1109/TNNLS.2012.2236352; Li XD, 2011, COMMUN NONLINEAR SCI, V16, P885, DOI 10.1016/j.cnsns.2010.05.025; Lim SN, 2016, NEUROMODULATION; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Loup F, 2000, J NEUROSCI, V20, P5401, DOI 10.1523/JNEUROSCI.20-14-05401.2000; Ma J, 2017, NONLINEAR DYNAM, V89, P1569, DOI 10.1007/s11071-017-3565-3; Maccotta L, 2013, NEUROIMAGE-CLIN, V2, P862, DOI 10.1016/j.nicl.2013.06.011; MANFORD M, 1992, NEUROLOGY, V42, P1911; Marquez MF, 2015, INT J CARDIOL, V180, P206, DOI 10.1016/j.ijcard.2014.11.157; Maschio M, 2012, CURR NEUROPHARMACOL, V10, P124, DOI 10.2174/157015912800604470; Mathern GW, 1999, NEUROLOGY, V52, P453, DOI 10.1212/WNL.52.3.453; McGrother CW, 2006, SEIZURE-EUR J EPILEP, V15, P376, DOI 10.1016/j.seizure.2006.04.002; Miles R., 2012, CHLORIDE HOMEOSTASIS; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; Moshe SL, 2015, LANCET, V385, P884, DOI 10.1016/S0140-6736(14)60456-6; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Noebels J., 2012, JASPERS BASIC MECH E; Olsen R W, 1999, Adv Neurol, V79, P499; Pearl PL, 2016, DEV MED CHILD NEUROL, V58, P330, DOI 10.1111/dmcn.13078; Perrodin C, 2014, J NEUROSCI, V34, P2524, DOI 10.1523/JNEUROSCI.2805-13.2014; Picot MC, 2008, EPILEPSIA, V49, P1230, DOI 10.1111/j.1528-1167.2008.01579.x; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Pitkanen A, 2016, LANCET NEUROL, V15, P185, DOI 10.1016/S1474-4422(15)00248-3; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Purves D., 1985, PRINCIPLES NEURAL DE, V1st ed.; Quintas R, 2012, EPILEPSY BEHAV, V25, P60, DOI 10.1016/j.yebeh.2012.05.016; Raiesdana S, 2013, NEUROCOMPUTING, V111, P54, DOI 10.1016/j.neucom.2012.11.033; Schmidt C, 2013, IEEE T BIO-MED ENG, V60, P1378, DOI 10.1109/TBME.2012.2235835; Schmidt D, 2014, BMJ-BRIT MED J, V348, P1136; Serafini R, 2015, CLIN NEUROPHYSIOL, V126, P1117, DOI 10.1016/j.clinph.2014.08.023; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Singh G, 2008, EPILEPSIA, V49, P1, DOI 10.1111/j.1528-1167.2008.01748.x; Sirven JI, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a022848; Sisodiya SM, 2002, BRAIN, V125, P22, DOI 10.1093/brain/awf002; SKARDA CA, 1987, BEHAV BRAIN SCI, V10, P161, DOI 10.1017/S0140525X00047336; Stamova I, 2014, INT J ADAPT CONTROL, V28, P1227, DOI 10.1002/acs.2440; Takeshita D, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.051925; Terry Jr R. S., 2014, EPILEPSY TOPICS TECH, P139, DOI DOI 10.5772/58332); Timofeev I, 2012, NEURONAL SYNCHRONIZA; Trauner DA, 2015, EPILEPSY BEHAV, V47, P163, DOI 10.1016/j.yebeh.2014.10.020; van Blarikom W, 2006, EPILEPSY BEHAV, V9, P14, DOI 10.1016/j.yebeh.2006.04.001; van Straaten ECW, 2013, EUR NEUROPSYCHOPHARM, V23, P7, DOI 10.1016/j.euroneuro.2012.10.010; Vecht CJ, 2014, ONCOLOGIST, V19, P751, DOI 10.1634/theoncologist.2014-0060; Velazquez JLP, 2003, PHYSICA D, V186, P205, DOI 10.1016/j.physd.2003.07.002; Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033; Viscidi EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067797; Voltzenlogel V, 2015, EPILEPSY RES, V115, P126, DOI 10.1016/j.eplepsyres.2015.06.006; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wang Y, 2017, INT J BIFURCAT CHAOS, V27, DOI 10.1142/S0218127417500304; Wieser HG, 2004, EPILEPSIA, V45, P32; Wilson HR, 1999, J THEOR BIOL, V200, P375, DOI 10.1006/jtbi.1999.1002; Wisniewski I, 2012, EPILEPSY BEHAV, V23, P254, DOI 10.1016/j.yebeh.2011.12.006; Wu Y, 2015, NEUROSCIENCE, V287, P175, DOI 10.1016/j.neuroscience.2014.06.046; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547; Yizhar O, 2012, J MOL NEUROSCI, V48, pS128	105	26	26	3	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0779	1873-2887		CHAOS SOLITON FRACT	Chaos Solitons Fractals	DEC	2017	105						150	156		10.1016/j.chaos.2017.10.028			7	Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary; Physics, Mathematical	Science Citation Index Expanded (SCI-EXPANDED)	Mathematics; Physics	FO2TK	WOS:000416642100019					2022-02-06	
J	Zhang, J; Peng, F; Liu, Z; Luan, JL; Liu, XM; Fei, C; Heng, XY				Zhang, Jian; Peng, Fei; Liu, Zhuang; Luan, Jinli; Liu, Xingming; Fei, Chang; Heng, Xueyuan			Cranioplasty with autogenous bone flaps cryopreserved in povidone iodine: a long-term follow-up study	JOURNAL OF NEUROSURGERY			English	Article						autogenous bone flaps; cranioplasty; follow-up; bone resorption; surgical technique	TRAUMATIC BRAIN-INJURY; METHYL-METHACRYLATE CRANIOPLASTY; DECOMPRESSIVE CRANIECTOMY; AUTOLOGOUS BONE; CLINICAL ARTICLE; RISK-FACTORS; RECONSTRUCTION; FROZEN; GRAFT; RESORPTION	OBJECTIVE The aim of this study was to investigate the long-term therapeutic efficacy of cranioplasty with autogenous bone flaps cryopreserved in povidone iodine and explore the risk factors for bone resorption. METHODS Clinical data and follow-up results of 188 patients (with 211 bone flaps) who underwent cranioplasty with autogenous bone flaps cryopreserved in povidone-iodine were retrospectively analyzed. Bone flap resorption was classified into 3 types according to CT features, including bone flap thinning (Type I), reduced bone density (Type II), and osteolysis within the flaps (Type III). The extent of bone flap resorption was graded as mild, moderate, or severe. RESULTS Short-term postoperative complications included subcutaneous or extradural seroma collection in 19 flaps (9.0%), epidural hematoma in 16 flaps (7.6%), and infection in 8 flaps (3.8%). Eight patients whose flaps became infected and had to be removed and 2 patients who died within 2 years were excluded from the follow-up analysis. For the remaining 178 patients and 201 flaps, the follow-up duration was 24-122 months (mean 63.1 months). In 93 (46.3%) of these 201 flaps, CT demonstrated bone resorption, which was classified as Type I in 55 flaps (59.1%), Type II in 11 (11.8%), and Type III in 27 (29.0%). The severity of bone resorption was graded as follows: no bone resorption in 108 (53.7%) of 201 flaps, mild resorption in 66 (32.8%), moderate resorption in 15 (7.5%), and severe resorption in 12 (6.0%). The incidence of moderate or severe resorption was higher in Type III than in Type I (p = 0.0008). The grading of bone flap resorption was associated with the locations of bone flaps (p = 0.0210) and fragmentation (flaps broken into 2 or 3 fragments) (p = 0.0009). The incidence of bone flap collapse due to bone resorption was higher in patients who underwent ventriculoperitoneal (VP) shunt implantation than in those who did not (p = 0.0091). CONCLUSIONS Because of the low incidence rates of infection and severe bone resorption, the authors conclude that cranioplasty with autogenous bone flaps cryopreserved in povidone-iodine solution is safe and effective. The changes characteristic of bone flap resorption became visible on CT scans about 2 months after cranioplasty and tended to stabilize at about 18 months postoperatively. The bone resorption of autogenous bone flap may be classified into 3 types. The rates of moderate and severe resorption were much higher in Type III than in Type I. The grade of bone flap resorption was associated with bone flap locations. Fragmented bone flaps or those implanted in patients treated with VP shunts may have a higher incidence of bone flap collapse due to bone resorption.	[Zhang, Jian; Fei, Chang; Heng, Xueyuan] Linyi Peoples Hosp, Dept Neurosurg, Linyi, Peoples R China; [Peng, Fei; Liu, Zhuang; Luan, Jinli; Liu, Xingming] Weifang Med Univ, Dept Neurosurg, Weifang, Shandong, Peoples R China; [Peng, Fei] Peoples Hosp Xuchang, Dept Neurosurg, Xuchang, Henan, Peoples R China		Zhang, J (corresponding author), Peoples Hosp Linyi City, Dept Neurosurg, Linyi 276000, Shandong, Peoples R China.	honest20699@126.com			Projects of Medical and Health Technology Development Program in Shandong province [2009HW019]; Shandong Province Health Department	This study was supported by the Projects of Medical and Health Technology Development Program in Shandong province (Item Number: 2009HW019 to Chang Fei). We are especially thankful for funds from the Shandong Province Health Department. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrzejak S, 2005, ACTA NEUROCHIR, V147, P973, DOI 10.1007/s00701-005-0581-8; Artico M, 2003, SURG NEUROL, V60, P71, DOI 10.1016/S0090-3019(03)00031-4; Asano Y, 1993, No To Shinkei, V45, P1145; Bhaskar IP, 2014, WORLD NEUROSURG, V82, pE531, DOI 10.1016/j.wneu.2013.01.013; Bhaskar IP, 2011, ANZ J SURG, V81, P137, DOI 10.1111/j.1445-2197.2010.05584.x; Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Brommeland T, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0155-6; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Chen TM, 2008, J TRAUMA, V65, P1321, DOI 10.1097/TA.0b013e3181574edf; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; Fiorot JA, 2008, ARQ NEURO-PSIQUIAT, V66, P204, DOI 10.1590/S0004-282X2008000200012; Garusi C, 2001, MICROSURG, V21, P131, DOI 10.1002/micr.1024; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Greene AK, 2007, PLAST RECONSTR SURG, V120, P1603, DOI 10.1097/01.prs.0000282106.75808.af; HANCOCK DO, 1963, J NEUROSURG, V20, P983, DOI 10.3171/jns.1963.20.11.0983; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Im SH, 2012, J KOREAN NEUROSURG S, V52, P396, DOI 10.3340/jkns.2012.52.4.396; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Kim H, 2013, ACTA NEUROCHIR, V155, P2171, DOI 10.1007/s00701-013-1877-8; KOBAYASHI S, 1987, NEUROSURGERY, V21, P751, DOI 10.1227/00006123-198711000-00032; KREUZ FP, 1951, J BONE JOINT SURG AM, V33-A, P863, DOI 10.2106/00004623-195133040-00005; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; Krishnan P, 2006, NEUROL INDIA, V54, P291; Kurokawa Y, 1995, JPN J NEUROSURG TOKY, V4, P128; Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0; ODOM GL, 1952, J NEUROSURG, V9, P606, DOI 10.3171/jns.1952.9.6.0606; Ozaki F., 1994, J WAKAYAMA MED SOC, V45, P217; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Rajendra Prasad B, 2009, J Emerg Trauma Shock, V2, P89, DOI 10.4103/0974-2700.50742; Sahoo N, 2010, J CRANIOFAC SURG, V21, P79, DOI 10.1097/SCS.0b013e3181c3ba58; Saringer W, 2002, ACTA NEUROCHIR, V144, P1193, DOI 10.1007/s00701-002-0995-5; Schwarz F, 2016, J NEUROSURG, V124, P710, DOI 10.3171/2015.4.JNS159; Sorour M, 2014, ACTA NEUROCHIR, V156, P207, DOI 10.1007/s00701-013-1800-3; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Wang JC, 2012, J CRANIOFAC SURG, V23, P1802, DOI 10.1097/SCS.0b013e318271012a; Yamashita K, 1992, KEISEI GEKA, V35, P1073; Zins JE, 2010, J CRANIOFAC SURG, V21, P1755, DOI 10.1097/SCS.0b013e3181c34675	43	26	28	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2017	127	6					1449	1456		10.3171/2016.8.JNS16204			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FO5KM	WOS:000416895700030	28186447				2022-02-06	
J	Hung, TH; Shyue, SK; Wu, CH; Chen, CC; Lin, CC; Chang, CF; Chen, SF				Hung, Tai-Ho; Shyue, Song-Kun; Wu, Chun-Hu; Chen, Chien-Cheng; Lin, Chao-Chang; Chang, Che-Feng; Chen, Szu-Fu			Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury	ONCOTARGET			English	Article						soluble epoxide hydrolase; traumatic brain injury; microglia; inflammation; AUDA	NITRIC-OXIDE SYNTHASE; N-TERMINAL DOMAIN; P38 MAPK PATHWAYS; SUBARACHNOID HEMORRHAGE; INFLAMMATORY RESPONSES; THERAPEUTIC TARGET; CEREBRAL-ISCHEMIA; CORTICAL IMPACT; PPAR-GAMMA; C-FOS	Traumatic brain injury (TBI) induces a series of inflammatory processes that contribute to neuronal damage. The present study investigated the involvement of soluble epoxide hydrolase (sEH) in neuroinflammation and brain damage in mouse TBI and in microglial cultures. The effects of genetic deletion of sEH and treatment with an sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), on brain damage and inflammatory responses were evaluated in mice subjected to controlled cortical impact. The anti-inflammatory mechanism of sEH inhibition/deletion was investigated in vitro. TBI-induced an increase in sEH protein level in the injured cortex from 1 h to 4 days and sEH was expressed in microglia. Genetic deletion of sEH significantly attenuated functional deficits and brain damage up to 28 days post-TBI. Deletion of sEH also reduced neuronal death, apoptosis, brain edema, and BBB permeability at 1 and 4 day(s). These changes were associated with markedly reduced microglial/macrophage activation, neutrophil infiltration, matrix metalloproteinase-9 activity, inflammatory mediator expression at 1 and 4 day(s), and epoxyeicosatrienoic acid (EET) degradation at 1 and 4 day(s). Administration of AUDA attenuated brain edema, apoptosis, inflammatory mediator upregulation and EET degradation at 4 days. In primary microglial cultures, AUDA attenuated both LPS-or IFN-Upsilon-stimulated nitric oxide (NO) production and reduced LPS-or IFN-Upsilon-induced p38 MAPK and NF-kappa B signaling. Deletion of sEH also reduced IFN-Upsilon-induced NO production. Moreover, AUDA attenuated N2A neuronal death induced by BV2 microglial-conditioned media. Our results suggest that inhibition of sEH may be a potential therapy for TBI by modulating the cytotoxic functions of microglia.	[Hung, Tai-Ho] Chang Gung Univ, Chang Gung Mem Hosp Taipei, Dept Obstet & Gynecol, Taoyuan, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Shyue, Song-Kun] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Chen, Chien-Cheng; Lin, Chao-Chang; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chang, Che-Feng] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Phys, Taipei, Taiwan; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan		Chen, SF (corresponding author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.; Chen, SF (corresponding author), Natl Def Med Ctr, Dept Phys, Taipei, Taiwan.; Chen, SF (corresponding author), Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Hung, Tai-Ho/ABD-1800-2020; Hung, Tai-Ho/C-7584-2011; Shyue, Song-Kun/Q-2583-2018; WU, CHUN-HU/P-3958-2018	Shyue, Song-Kun/0000-0002-1057-8696; WU, CHUN-HU/0000-0001-6851-7936; Chang, Che-Feng/0000-0002-3211-1739; Hung, Tai-Ho/0000-0003-2354-7060	Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST 101-2314-B-350-001-MY3, MOST 103-2314-B-182A-009-MY2]; Cheng Hsin General Hospital Foundation [CHGH104-29, CHGH104-30]	This study was supported by grants from the Ministry of Science and Technology of Taiwan (no. MOST 101-2314-B-350-001-MY3 and MOST 103-2314-B-182A-009-MY2) and Cheng Hsin General Hospital Foundation (no. CHGH104-29 and CHGH104-30).	Batchelor PE, 1999, J NEUROSCI, V19, P1708; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chen CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115694; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Chen XJ, 2016, MOL NEUROBIOL, V53, P1565, DOI 10.1007/s12035-015-9118-1; Cipriani R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0308-6; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cronin A, 2003, P NATL ACAD SCI USA, V100, P1552, DOI 10.1073/pnas.0437829100; Cummins PM, 2012, MOL CELL BIOL, V32, P242, DOI 10.1128/MCB.06029-11; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Gao YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040258; Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249; Haase G, 2008, CURR OPIN NEUROBIOL, V18, P284, DOI 10.1016/j.conb.2008.07.013; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hou HH, 2015, SCI REP-UK, V5, DOI 10.1038/srep13524; Hou HH, 2012, CARDIOVASC RES, V93, P120, DOI 10.1093/cvr/cvr267; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hung YW, 2015, BRAIN BEHAV IMMUN, V43, P118, DOI 10.1016/j.bbi.2014.07.016; Iliff JJ, 2010, PROSTAG OTH LIPID M, V91, P68, DOI 10.1016/j.prostaglandins.2009.06.004; Imig JD, 2009, NAT REV DRUG DISCOV, V8, P794, DOI 10.1038/nrd2875; Jara JH, 2007, J NEUROCHEM, V100, P1407, DOI 10.1111/j.1471-4159.2006.04330.x; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Khan MAH, 2013, HYPERTENSION, V62, P905, DOI 10.1161/HYPERTENSIONAHA.113.01949; Kim JH, 2010, J NEUROCHEM, V115, P1161, DOI 10.1111/j.1471-4159.2010.07004.x; Koistinaho M, 2002, GLIA, V40, P175, DOI 10.1002/glia.10151; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Liu Y, 2005, P NATL ACAD SCI USA, V102, P16747, DOI 10.1073/pnas.0508081102; Liu Y, 2016, J MOL NEUROSCI, V58, P254, DOI 10.1007/s12031-015-0670-y; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Marmarou A, 2003, ACT NEUR S, V86, P7; Martini RP, 2014, J NEUROSURG, V121, P1359, DOI 10.3171/2014.7.JNS131990; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morin C, 2010, AM J RESP CELL MOL, V43, P564, DOI 10.1165/rcmb.2009-0155OC; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Qin XC, 2015, MOL NEUROBIOL, V52, P187, DOI 10.1007/s12035-014-8833-3; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Revermann M, 2010, CURR OPIN PHARMACOL, V10, P173, DOI 10.1016/j.coph.2009.12.002; Sanders WG, 2012, AM J PHYSIOL-CELL PH, V303, pC278, DOI 10.1152/ajpcell.00386.2011; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siler DA, 2015, STROKE, V46, P1916, DOI 10.1161/STROKEAHA.114.008560; Simpkins AN, 2009, AM J PATHOL, V174, P2086, DOI 10.2353/ajpath.2009.080544; Siopi E, 2013, NEUROPHARMACOLOGY, V67, P183, DOI 10.1016/j.neuropharm.2012.11.009; Skovira JW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0769-2; Smith KR, 2005, P NATL ACAD SCI USA, V102, P2186, DOI 10.1073/pnas.0409591102; Srivastava K, 2012, CELL MOL NEUROBIOL, V32, P319, DOI 10.1007/s10571-011-9777-z; Strauss KI, 2013, PROSTAG OTH LIPID M, V104, P18, DOI 10.1016/j.prostaglandins.2012.07.005; Sun J, 2016, J MOL NEUROSCI, V59, P90, DOI 10.1007/s12031-016-0717-8; Svensson C, 2011, BIOCHEM BIOPH RES CO, V406, P488, DOI 10.1016/j.bbrc.2011.02.083; Tanaka H, 2008, BBA-GENE REGUL MECH, V1779, P17, DOI 10.1016/j.bbagrm.2007.11.005; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wu CH, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0524-8; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yuan L, 2016, NEUROPATH APPL NEURO, V42, P607, DOI 10.1111/nan.12291; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang WR, 2008, STROKE, V39, P2073, DOI 10.1161/STROKEAHA.107.508325; Zhang Y, 2017, J NEUROCHEM, V140, P814, DOI 10.1111/jnc.13933; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhou C, 2016, CELL PHYSIOL BIOCHEM, V39, P721, DOI 10.1159/000445663; Zhou DX, 2014, CELL SIGNAL, V26, P192, DOI 10.1016/j.cellsig.2013.11.004; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	72	26	27	1	4	IMPACT JOURNALS LLC	ORCHARD PARK	6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA		1949-2553		ONCOTARGET	Oncotarget	NOV 28	2017	8	61					103236	103260		10.18632/oncotarget.21139			25	Oncology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Cell Biology	FS1TY	WOS:000419562500041	29262558	Green Published, gold, Green Submitted			2022-02-06	
J	Mann, AP; Scodeller, P; Hussain, S; Braun, GB; Molder, T; Toome, K; Ambasudhan, R; Teesalu, T; Lipton, SA; Ruoslahti, E				Mann, Aman P.; Scodeller, Pablo; Hussain, Sazid; Braun, Gary B.; Molder, Tarmo; Toome, Kadri; Ambasudhan, Rajesh; Teesalu, Tambet; Lipton, Stuart A.; Ruoslahti, Erkki			Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease	NATURE COMMUNICATIONS			English	Article							TISSUE GROWTH-FACTOR; CEREBRAL AMYLOID ANGIOPATHY; PLURIPOTENT STEM-CELLS; REACTIVE ASTROCYTES; ENDOTHELIAL-CELLS; INVADING FIBROBLASTS; PARKINSONS-DISEASE; SPINAL-CORD; EXPRESSION; THERAPY	Cerebrovascular changes occur in Alzheimer's disease (AD). Using in vivo phage display, we searched for molecular markers of the neurovascular unit, including endothelial cells and astrocytes, in mouse models of AD. We identified a cyclic peptide, CDAGRKQKC (DAG), that accumulates in the hippocampus of hAPP-J20 mice at different ages. Intravenously injected DAG peptide homes to neurovascular unit endothelial cells and to reactive astrocytes in mouse models of AD. We identified connective tissue growth factor (CTGF), a matricellular protein that is highly expressed in the brain of individuals with AD and in mouse models, as the target of the DAG peptide. We also showed that exogenously delivered DAG homes to the brain in mouse models of glioblastoma, traumatic brain injury, and Parkinson's disease. DAG may potentially be used as a tool to enhance delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation.	[Mann, Aman P.; Scodeller, Pablo; Hussain, Sazid; Braun, Gary B.; Ruoslahti, Erkki] Sanford Burnham Prebys Med Discovery Inst, Canc Res Ctr, La Jolla, CA 92037 USA; [Scodeller, Pablo; Molder, Tarmo; Toome, Kadri; Teesalu, Tambet] Univ Tartu, Inst Biomed & Translat Med, Canc Biol Lab, EE-50411 Tartu, Estonia; [Hussain, Sazid] AivoCode Inc, La Jolla, CA 92037 USA; [Ambasudhan, Rajesh; Lipton, Stuart A.] Scintillon Inst, Neurodegenerat Dis Ctr, San Diego, CA 92121 USA; [Lipton, Stuart A.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Ctr Nanomed, Santa Barbara, CA 93106 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Dept Cell Mol & Dev Biol, Santa Barbara, CA 93106 USA		Ruoslahti, E (corresponding author), Sanford Burnham Prebys Med Discovery Inst, Canc Res Ctr, La Jolla, CA 92037 USA.; Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Ctr Nanomed, Santa Barbara, CA 93106 USA.; Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Dept Cell Mol & Dev Biol, Santa Barbara, CA 93106 USA.	ruoslahti@sbpdiscovery.org	Scodeller, Pablo/AAH-7694-2019	Scodeller, Pablo/0000-0003-0745-2467	NCI GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA30199]; Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-14-1-4010]; European Research CouncilEuropean Research Council (ERC)European Commission [291910]; Wellcome Trust International FellowshipWellcome Trust [WT095077MA]; European Union through the European Regional Development FundEuropean Commission [2014-2020.4.01.15-0012]; NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 HD29587, R01 NS086890, DP1 DA041722, P30 NS076411]; Distinguished Investigator Award of the Brain & Behavior Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD029587] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS076411, R01NS086890, R21NS097867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056259, RF1AG057409, R21AG058013] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [DP1DA041722] Funding Source: NIH RePORTER	We thank Prof. R. Bjerkvig at University of Bergen for sharing the P13 glioma cells, Prof. Lawrence Goldstein at UCSD for AD hiPSCs; Nima Dolatabadi, Daniel Joseph and James Parker at the Scintillon Institute for assistance in studies involving hiPSC differentiation; Tracy Fang Newmeyer for help with animal studies; Venkata R. Kotamraju for peptide synthesis; and the New York Brain Bank at Columbia University for sharing human AD brain tissues. Proteomics analysis and histology was performed by proteomics and histology core respectively at Sanford Burnham Prebys, supported by the NCI Grant, P30 CA30199. This work was supported in part by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement N66001-14-1-4010 (to E.R.). The findings and views expressed are those of the authors and do not reflect the official policy or position of the Department of Defense or the U.S. Government. T.T. was supported by grants from the European Research Council (No. 291910), the Wellcome Trust International Fellowship (WT095077MA), and by European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012). R. A. and S.A.L. were supported by NIH grants P01 HD29587, R01 NS086890, DP1 DA041722, and P30 NS076411, and by a Distinguished Investigator Award of the Brain & Behavior Research Foundation.	Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108; Baloyannis SJ, 2012, J NEUROL SCI, V322, P117, DOI 10.1016/j.jns.2012.07.010; BJERKVIG R, 1990, J NEUROSURG, V72, P463, DOI 10.3171/jns.1990.72.3.0463; Bougnaud S, 2016, ONCOTARGET, V7, P31955, DOI 10.18632/oncotarget.7454; Braun GB, 2014, NAT MATER, V13, P904, DOI [10.1038/NMAT3982, 10.1038/nmat3982]; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Chesselet MF, 2012, NEUROTHERAPEUTICS, V9, P297, DOI 10.1007/s13311-012-0104-2; Conrad S, 2005, J NEUROSURG-SPINE, V2, P319, DOI 10.3171/spi.2005.2.3.0319; Dadosh T, 2009, MATER LETT, V63, P2236, DOI 10.1016/j.matlet.2009.07.042; de la Torre JC, 2002, STROKE, V33, P1152, DOI 10.1161/01.STR.0000014421.15948.67; De Winter P, 2008, GROWTH FACTORS, V26, P80, DOI 10.1080/08977190802025602; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Hoshi A, 2011, EXP NEUROL, V227, P89, DOI 10.1016/j.expneurol.2010.09.016; Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Laske C, 2014, NEW ENGL J MED, V370, P1459, DOI 10.1056/NEJMc1402193; Lin TX, 2009, NAT METHODS, V6, P805, DOI [10.1038/NMETH.1393, 10.1038/nmeth.1393]; Lippmann ES, 2012, NAT BIOTECHNOL, V30, P783, DOI 10.1038/nbt.2247; Mann AP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11980; Marchesi VT, 2011, FASEB J, V25, P5, DOI 10.1096/fj.11-0102ufm; Meyer EP, 2008, P NATL ACAD SCI USA, V105, P3587, DOI 10.1073/pnas.0709788105; Milner E, 2014, STROKE, V45, P3064, DOI 10.1161/STROKEAHA.114.006078; Montagne A, 2015, NEURON, V85, P296, DOI 10.1016/j.neuron.2014.12.032; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Navarro JRG, 2013, ANALYST, V138, P583, DOI 10.1039/c2an36135c; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Ruoslahti E, 2012, ADV MATER, V24, P3747, DOI 10.1002/adma.201200454; Schwab JM, 2000, NEUROPATH APPL NEURO, V26, P434, DOI 10.1046/j.1365-2990.2000.00271.x; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Sengillo JD, 2013, BRAIN PATHOL, V23, P303, DOI 10.1111/bpa.12004; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Simunovic F, 2009, BRAIN, V132, P1795, DOI 10.1093/brain/awn323; Spliet WGM, 2003, ACTA NEUROPATHOL, V106, P449, DOI 10.1007/s00401-003-0741-y; Talantova M, 2013, P NATL ACAD SCI USA, V110, pE2518, DOI 10.1073/pnas.1306832110; Teesalu T, 2012, METHOD ENZYMOL, V503, P35, DOI 10.1016/B978-0-12-396962-0.00002-1; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Ueberham U, 2003, NEUROSCIENCE, V116, P1, DOI 10.1016/S0306-4522(02)00670-X; Verkhratsky A, 2010, NEUROTHERAPEUTICS, V7, P399, DOI 10.1016/j.nurt.2010.05.017; Weller RO, 2009, ACTA NEUROPATHOL, V118, P87, DOI 10.1007/s00401-009-0498-z; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Wright AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059586; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Zhong ZH, 2009, J CLIN INVEST, V119, P3437, DOI 10.1172/JCI38476; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	45	26	26	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	NOV 10	2017	8								1403	10.1038/s41467-017-01096-0			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM2YM	WOS:000414869200002	29123083	Green Published, gold			2022-02-06	
J	Tan, XG; Przekwas, AJ; Gupta, RK				Tan, X. G.; Przekwas, A. J.; Gupta, R. K.			Computational modeling of blast wave interaction with a human body and assessment of traumatic brain injury	SHOCK WAVES			English	Article						Blast waves; Human body; Coupled modeling; Biomechanics; Traumatic brain injury	DIFFRACTION; SIMULATION; RESPONSES	The modeling of human body biomechanics resulting from blast exposure poses great challenges because of the complex geometry and the substantial material heterogeneity. We developed a detailed human body finite element model representing both the geometry and the materials realistically. The model includes the detailed head (face, skull, brain and spinal cord), the neck, the skeleton, air cavities (lungs) and the tissues. Hence, it can be used to properly model the stress wave propagation in the human body subjected to blast loading. The blast loading on the human was generated from a simulated C4 explosion. We used the highly scalable solvers in the multi-physics code CoBi for both the blast simulation and the human body biomechanics. The meshes generated for these simulations are of good quality so that relatively large time-step sizes can be used without resorting to artificial time scaling treatments. The coupled gas dynamics and biomechanics solutions were validated against the shock tube test data. The human body models were used to conduct parametric simulations to find the biomechanical response and the brain injury mechanism due to blasts impacting the human body. Under the same blast loading condition, we showed the importance of inclusion of the whole body.	[Tan, X. G.; Przekwas, A. J.] CFD Res Corp, Huntsville, AL 35806 USA; [Tan, X. G.] US Naval Res Lab, Washington, DC 20375 USA; [Gupta, R. K.] US Army Med Res & Mat Command, Frederick, MD 21702 USA		Tan, XG (corresponding author), CFD Res Corp, Huntsville, AL 35806 USA.; Tan, XG (corresponding author), US Naval Res Lab, Washington, DC 20375 USA.	Gary.Tan@nrl.navy.mil			DoD Blast Injury Research Program Coordinating Office [W81XWH-14-C-0045]; DoD Congressionally Directed Medical Research Programs [W81XWH-09-2-0168]	This work has resulted from the research project "Physics and Physiology Based Human Body Model of Blast Injury and Protection" (Contract # W81XWH-14-C-0045) managed by the DoD Blast Injury Research Program Coordinating Office. The authors would like to express their appreciation to the DoD Congressionally Directed Medical Research Programs (Contract # W81XWH-09-2-0168) for supporting the initial work. The content included in this work does not necessarily reflect the position or policy of the US government. The authors are very grateful to the reviewers and Amit Bagchi for their careful and meticulous reading of the paper. The reviews were helpful to finalize the manuscript. The authors would like to kindly acknowledge them.	Badia S, 2008, J COMPUT PHYS, V227, P7027, DOI 10.1016/j.jcp.2008.04.006; Baeck K, 2014, COMPUT METHOD BIOMEC, V17, P405, DOI 10.1080/10255842.2012.688106; Belytschko T, 2001, NONLINEAR FINITE ELE; Brands DWA, 2002, THESIS; BRYSON AE, 1961, J FLUID MECH, V10, P1, DOI 10.1017/S0022112061000019; Cotton RT, 2016, COMPUT METHOD BIOMEC, V19, P101, DOI 10.1080/10255842.2014.994118; DAWSON SL, 1980, HUM PATHOL, V11, P155, DOI 10.1016/S0046-8177(80)80136-5; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Gayzik FS, 2012, ANN BIOMED ENG, V40, P2019, DOI 10.1007/s10439-012-0546-z; Godunov, 1959, MAT SBORNIK, V47, P271; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gupta R.K., 2015, P ICCM2015 AUCKL NZ; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hallquist JO, 2006, LS DYNA THEORY MANUA; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Horgan T.J., 2008, INT J CRASHWORTHINES, V8, P1, DOI DOI 10.1533/IJCR.2003.0243; Hull J. B, 1995, THESIS; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kannan R, 2014, J PARALLEL DISTR COM, V74, P2808, DOI 10.1016/j.jpdc.2014.05.001; KIEFFER SW, 1977, J GEOPHYS RES, V82, P2895, DOI 10.1029/JB082i020p02895; Kingery C.N., 1984, ARBRLTR02555 US ARM; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Przekwas A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00002; Puso MA, 2012, COMPUT METHOD APPL M, V245, P273, DOI 10.1016/j.cma.2012.07.014; Ripley RC, 2006, COMPUT FLUIDS, V35, P1420, DOI 10.1016/j.compfluid.2005.05.001; Roberts JC, 2007, J BIOMECH, V40, P125, DOI 10.1016/j.jbiomech.2005.11.003; Roberts JC, 2012, J BIOMECH, V45, P2899, DOI 10.1016/j.jbiomech.2012.07.027; SIMO JC, 1991, COMPUT METHOD APPL M, V85, P273, DOI 10.1016/0045-7825(91)90100-K; Sugiyama K, 2011, J COMPUT PHYS, V230, P596, DOI 10.1016/j.jcp.2010.09.032; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tan XG, 2014, PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION, 2013, VOL 3A; Tan X. Gary, 2011, International Journal of Human Factors Modelling and Simulation, V2, P85, DOI 10.1504/IJHFMS.2011.041639; Tan X.G., 2012, P ASME INT MECH ENG; Toro E. F., 1994, Shock Waves, V4, P25, DOI 10.1007/BF01414629; VENKATAKRISHNAN V, 1995, J COMPUT PHYS, V118, P120, DOI 10.1006/jcph.1995.1084; Wallis G. B., 1969, ONE DIMENSIONAL 2 PH; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	41	26	27	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-1287	1432-2153		SHOCK WAVES	Shock Waves	NOV	2017	27	6					889	904		10.1007/s00193-017-0740-x			16	Mechanics	Science Citation Index Expanded (SCI-EXPANDED)	Mechanics	FN4BE	WOS:000415946600007					2022-02-06	
J	Adams, WM; Scarneo, SE; Casa, DJ				Adams, William M.; Scarneo, Samantha E.; Casa, Douglas J.			State-Level Implementation of Health and Safety Policies to Prevent Sudden Death and Catastrophic Injuries Within Secondary School Athletics	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						sudden cardiac death; exertional heat stroke; traumatic head injuries; emergency action plans; preparticipation examination	ASSOCIATION POSITION STATEMENT; TASK-FORCE; PRACTICES RECOMMENDATIONS; CONSENSUS STATEMENT; CARDIAC-ARREST; SPORT; CONCUSSION; MANAGEMENT; PROGRAMS	Background: Sudden death and catastrophic injuries during sport can be attenuated with the implementation of evidence-based health and safety policies. However, the extent of the implementation of these policies within secondary school athletics is unknown. Purpose: To provide an assessment of the implementation of health and safety policies pertaining to the leading causes of sudden death and catastrophic injuries in sport within secondary school athletics in the United States. Study Design: Descriptive epidemiology study. Methods: A rubric for evidence-based practices for preventing the leading causes of death and catastrophic injuries in sport was created. The rubric comprised 5 equally weighted sections for sudden cardiac arrest, head injuries, exertional heat stroke, appropriate medical coverage, and emergency preparedness. State high school athletic association (SHSAA) policies, enacted legislation, and Department of Education policies were extensively reviewed for all 50 states and the District of Columbia. States meeting the specific criteria in the rubric, which required policies to be mandated for all SHSAA member schools, were awarded credit; the weighted scores were tabulated to calculate an aggregate score. States were then ranked from 1 (best) to 51 (worst) based on the aggregate score achieved. Results: The median score on the rubric was 47.1% (range, 23.00%-78.75%). States ranked 1 through 10 (from 78.75% to 56.98%) were North Carolina, Kentucky, Massachusetts, New Jersey, South Dakota, Missouri, Washington, Hawaii, Wisconsin, and Georgia, respectively. States ranked 11 through 20 (from 56.03% to 50.55%) were Arkansas, New York, Mississippi, West Virginia, Oregon, Illinois, Tennessee, Arizona, Texas, and District of Columbia, respectively. States ranked 21 through 30 (from 49.40% to 44.00%) were Virginia, Pennsylvania, Florida, New Mexico, Alabama, Maine, Rhode Island, Indiana, Nevada, and Utah, respectively. States ranked 31 through 40 (from 43.93% to 39.80%) were Ohio, Delaware, Alaska, Vermont, Louisiana, Maryland, Oklahoma, Connecticut, Idaho, and South Carolina, respectively. States ranked 41 through 51 (from 38.73% to 23.00%) were Michigan, North Dakota, Nebraska, New Hampshire, Kansas, Wyoming, Minnesota, Montana, Iowa, California, and Colorado, respectively. Conclusion: State scores ranged from 23.00% to 78.75% for the implementation of evidence-based best practices for preventing the leading causes of sudden death and catastrophic injuries (sudden cardiac arrest, traumatic head injuries, exertional heat stroke, and exertional sickling) in sport. Continued advocacy for the development and implementation of policies at the secondary school level surrounding sudden death and catastrophic injuries is warranted to optimize the health and safety of these student athletes.	[Adams, William M.; Scarneo, Samantha E.; Casa, Douglas J.] Univ Connecticut, Korey Stringer Inst, Dept Kinesiol, 2095 Hillside Rd,Box U-1110, Storrs, CT 06269 USA		Casa, DJ (corresponding author), Univ Connecticut, Korey Stringer Inst, Dept Kinesiol, 2095 Hillside Rd,Box U-1110, Storrs, CT 06269 USA.	douglas.casa@uconn.edu					Adams WM, 2016, J ATHL TRAINING, V51, P358, DOI 10.4085/1062-6050-51.4.14; Adams WM, 2017, J ATHL TRAIN S6, V52, pS103; Adams WM, 2016, J ATHL TRAIN S, V51, pS167; Almeraya A, 2017, J ATHL TRAIN S6, V52, pS50; Andersen JC, 2002, J ATHL TRAINING, V37, P99; Anderson S, 2017, J ATHL TRAINING, V52, P145, DOI 10.4085/1062-6050-52.3.02; Attanasio SM, 2016, J ATHL TRAIN S6, V51, pS; Bernhardt DT, 2010, PPE PREPARTICIPATION; Boden BP, 2013, AM J SPORT MED, V41, P1108, DOI 10.1177/0363546513478572; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Casa DJ, 2015, J ATHL TRAINING, V50, P986, DOI 10.4085/1062-6050-50.9.07; Casa DJ, 2013, J ATHL TRAINING, V48, P546, DOI 10.4085/1062-6050-48.4.12; Casa DJ, 2012, J ATHL TRAINING, V47, P477, DOI 10.4085/1062-6050-47.4.08; Casa DJ, 2012, J ATHL TRAINING, V47, P96; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; Colgate B, 2017, 2017 FOOTBALL RULES; Demartini JK, 2015, MED SCI SPORT EXER, V47, P240, DOI 10.1249/MSS.0000000000000409; Drezner JA, 2007, PREHOSP EMERG CARE, V11, P253, DOI 10.1080/10903120701204839; Drezner JA, 2013, BRIT J SPORT MED, V47, P1179, DOI 10.1136/bjsports-2013-092786; Finn AL, 2017, J ATHL TRAIN S6, V52, pS314; Hopkins B, 2016, 2016 17 NFHS WRESTLI; Kerr ZY, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116648441; Koski M, 2017, 2017 FIELD HOCKEY RU; Lawler EC, 2017, J HEALTH ECON, V52, P45, DOI 10.1016/j.jhealeco.2017.01.002; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; National Athletic Trainers' Association, 2003, APPR MED CAR SEC SCH; National Center for Catastrophic Sport Injury Research, 2015, CAT SPORTS INJ RES 3; National Federation of State High School Associations, 2017, RUL WRIT PROC; National Federation of State High School Associations, 2016, 2014 15 HIGH SCH ATH; Rynkiewicz KM, 2017, J ATHL TRAIN S6, V52, pS77; Scarneo SE, 2017, J ATHL TRAIN S6, V52, pS22; Schuster D, 2016, 2016 17 NFHS ICE HOC; Weaver J, 2017, 2017 NFHS BOYS LACRO	33	26	26	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	SEP 18	2017	5	9							2325967117727262	10.1177/2325967117727262			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	FH5HZ	WOS:000411197600001	28951881	Green Published, gold			2022-02-06	
J	Li, JR; Donangelo, I; Abe, K; Scremin, O; Ke, SJ; Li, F; Milanesi, A; Liu, YY; Brent, GA				Li, Jianrong; Donangelo, Ines; Abe, Kiyomi; Scremin, Oscar; Ke, Sujie; Li, Feng; Milanesi, Anna; Liu, Yan-Yun; Brent, Gregory A.			Thyroid hormone treatment activates protective pathways in both in vivo and in vitro models of neuronal injury	MOLECULAR AND CELLULAR ENDOCRINOLOGY			English	Article						Controlled cortical injury (CCI); Thyroid hormone; Deiodinase; HIF-1 alpha; HIF-2 alpha; Hypoxia-responsive genes; Thyroid hormone responsive genes	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; NEUROBLASTOMA-CELLS; GENE-EXPRESSION; GROWTH-FACTOR; NEUROGENESIS; RECEPTOR; PROLIFERATION; PATHOPHYSIOLOGY; OVEREXPRESSION	Thyroid hormone plays an important role in brain development and adult brain function, and may influence neuronal recovery after Traumatic Brain Injury (TBI). We utilized both animal and cell culture models to determine the effects of thyroid hormone treatment, post TBI or during hypoxia, on genes important for neuronal survival and neurogenesis. We show that TBI in rats is associated with a reduction in serum thyroxine (T4) and triiodothyronine (T3). A single dose of levothyroxine (T4), one hour after injury, increased serum T4 and normalized serum T3 levels. Expression of genes important for thyroid hormone action in the brain, MCT8 and Type 2 deiodinase (Dio2) mRNA, diminished after injury, but were partially restored with T4 treatment. mRNA from the Type 3 deiodinase (Dio3) gene, which inactivates T4 to reverse T3 (Gamma T3), was induced 2.7 fold by TBI, and further stimulated 6.7-fold by T4 treatment. T4 treatment significantly increased the expression of mRNA from Bcl2, VEGFA, Sox2 and neurotrophin, genes important for neuronal survival and recovery. The cortex, compared to the hippo campus and cerebellum, sustained the greatest injury and had the most significant change in gene expression as a result of injury and the greatest response to T4 treatment. We utilized hypoxia to study the effect of neuronal injury in vitro. Neuroblastoma cells were exposed to reduced oxygen tension, 0.2%, and were compared to cells grown at control oxygen levels of 21%. T3 treatment significantly increased hypoxia inducible factor (HIF)-2 alpha protein, but not HIF-1 alpha. In a hypoxia time course exposure, expression of hypoxia-mediated genes (VEGF, Enolase, HIF2 alpha, c-Jun) peaked at least 8 h earlier with T3-treatment, compared to cells grown without T3. The early induction of these genes may promote cellular growth after injury. After hypoxic injury, T3 induced mRNA expression of the genes, KLF9 and hairless, important for T3-mediated brain function. The findings from both in vitro and in vivo studies support a role of thyroid hormone in activating pathways important for neuronal protection and promotion of neuronal recovery after injury. Published by Elsevier Ireland Ltd.	[Li, Jianrong; Donangelo, Ines; Abe, Kiyomi; Ke, Sujie; Li, Feng; Milanesi, Anna; Liu, Yan-Yun; Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Endocrinol Div, Mol Endocrinol Lab,VA Greater Angeles Healthcare, Los Angeles, CA 90095 USA; [Scremin, Oscar; Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; [Li, Jianrong] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China		Liu, YY; Brent, GA (corresponding author), VA Greater Los Angeles Healthcare Syst, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	yyl@ucla.edu; gbrent@mednet.ucla.edu	Abe, Kiyomi/AAM-6036-2021		United States Veteran Administration Merit Review; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08 DK097295]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08DK097295] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003665] Funding Source: NIH RePORTER	This work is supported by the United States Veteran Administration Merit Review to GAB and NIH K08 DK097295 to AM.	Acosta S, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-12; Alonso-Merino E, 2016, P NATL ACAD SCI USA, V113, pE3451, DOI 10.1073/pnas.1506113113; Anderson GW, 2008, CEREBELLUM, V7, P60, DOI 10.1007/s12311-008-0021-4; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bernal J, 2007, NAT CLIN PRACT ENDOC, V3, P249, DOI 10.1038/ncpendmet0424; Bowyer JF, 2012, JOVE-J VIS EXP, DOI 10.3791/4285; Brent GA, 2012, J CLIN INVEST, V122, P3035, DOI 10.1172/JCI60047; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Cayrol F, 2015, BLOOD, V125, P841, DOI 10.1182/blood-2014-07-587337; Chatonnet F, 2013, P NATL ACAD SCI USA, V110, pE766, DOI 10.1073/pnas.1210626110; Crupi R, 2013, PHARMACOL RES, V70, P80, DOI 10.1016/j.phrs.2012.12.009; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dentice M, 2014, CELL METAB, V20, P1038, DOI 10.1016/j.cmet.2014.10.009; Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795; Farwell AP, 2013, CURR OPIN ENDOCRINOL, V20, P478, DOI 10.1097/01.med.0000433069.09294.e8; Fauquier T, 2011, DEV BIOL, V356, P350, DOI 10.1016/j.ydbio.2011.05.657; Fournier NM, 2012, BEHAV BRAIN RES, V227, P440, DOI 10.1016/j.bbr.2011.04.022; Garry PS, 2015, EXP NEUROL, V263, P235, DOI 10.1016/j.expneurol.2014.10.017; Genovese T, 2013, BRAIN RES, V1513, P92, DOI 10.1016/j.brainres.2013.03.001; Gereben B, 2008, ENDOCR REV, V29, P898, DOI 10.1210/er.2008-0019; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hagihara Hideo, 2009, J Vis Exp, DOI 10.3791/1543; Huang SA, 2008, NAT CLIN PRACT ENDOC, V4, P148, DOI 10.1038/ncpendmet0727; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Koibuchi N, 2003, CEREBELLUM, V2, P279, DOI 10.1080/14734220310011920; Kovalevich J, 2013, METHODS MOL BIOL, V1078, P9, DOI 10.1007/978-1-62703-640-5_2; Lebrun C, 2013, MOL CELL NEUROSCI, V54, P9, DOI 10.1016/j.mcn.2012.11.010; Lin JZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052407; Liu F, 2009, J NEUROSCI, V29, P5075, DOI 10.1523/JNEUROSCI.0201-09.2009; Liu YY, 2002, ENDOCRINOLOGY, V143, P2664, DOI 10.1210/en.143.7.2664; Luidens MK, 2010, VASC PHARMACOL, V52, P142, DOI 10.1016/j.vph.2009.10.007; Magnoni S, 2012, CRIT CARE MED, V40, P1785, DOI 10.1097/CCM.0b013e318246bd45; Mayer S, 2014, J CLIN INVEST, V124, P1987, DOI 10.1172/JCI70324; McAllister RM, 2005, J ENDOCRINOL, V185, P111, DOI 10.1677/joe.1.06022; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; O'Driscoll C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012911; Pizzi M, 2009, FEBS J, V276, P27, DOI 10.1111/j.1742-4658.2008.06767.x; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rovet JF, 2014, ENDOCR DEV, V26, P26, DOI 10.1159/000363153; Sadana P, 2015, J NEUROL SCI, V354, P37, DOI 10.1016/j.jns.2015.04.042; Salvatore D, 2014, NAT REV ENDOCRINOL, V10, P206, DOI 10.1038/nrendo.2013.238; Sarnico I, 2009, INT REV NEUROBIOL, V85, P351, DOI 10.1016/S0074-7742(09)85024-1; Schoenmakers N, 2013, BBA-GEN SUBJECTS, V1830, P4004, DOI 10.1016/j.bbagen.2013.03.018; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Serfozo Z, 2008, NEUROCHEM RES, V33, P569, DOI 10.1007/s11064-007-9480-0; Simonides WS, 2008, J CLIN INVEST, V118, P975, DOI 10.1172/JCI32824; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Taylor SR, 2013, J NEUROSURG-PEDIATR, V12, P545, DOI 10.3171/2013.8.PEDS13154; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vieira HLA, 2011, PROG NEUROBIOL, V93, P444, DOI 10.1016/j.pneurobio.2011.01.007; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolahan SM, 2017, NEUROCRIT CARE, V26, P239, DOI 10.1007/s12028-016-0313-3; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yen CC, 2006, J MOL ENDOCRINOL, V36, P9, DOI 10.1677/jme.1.01911	61	26	29	0	26	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0303-7207			MOL CELL ENDOCRINOL	Mol. Cell. Endocrinol.	SEP 5	2017	452	C					120	130		10.1016/j.mce.2017.05.023			11	Cell Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Endocrinology & Metabolism	EZ5YF	WOS:000404794900012	28549992				2022-02-06	
J	Grauwmeijer, E; Heijenbrok-Kal, MH; Haitsma, IK; Ribbers, GM				Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Haitsma, Ian K.; Ribbers, Gerard M.			Employment Outcome Ten Years after Moderate to Severe Traumatic Brain Injury: A Prospective Cohort Study	JOURNAL OF NEUROTRAUMA			English	Article						outcome measures; prospective studies; rehabilitation; traumatic brain injuries	FOLLOW-UP; RETURN; WORK; IMPACT; EPIDEMIOLOGY; POPULATION; PREDICTORS; EUROPE; TBI	The objective of this prospective cohort study was to evaluate the probability of employment and predictors of employment in patients with moderate-to-severe traumatic brain injury (TBI) over 10-year follow-up. One hundred nine patients (18-67 years) were included with follow-up measurements 3, 6, 12, 18, 24, and 36 months and 10 years post-TBI. Potential predictors of employment probability included patient characteristics, injury severity factors, functional outcome measured at discharge from the hospital with the Glasgow Outcome Scale (GOS), Barthel Index (BI), Functional Independence Measure (FIM), and the Functional Assessment Measure (FAM). Forty-eight patients (42%) completed the 10-year followup. Three months post-TBI, 12% were employed, which gradually, but significantly, increased to 57% after 2-years followup (p < 0.001), followed by a significant decrease to 43% (p = 0.041) after 10 years. Ten years post-TBI, we found that employed persons had less-severe TBI, shorter length of hospital stay (LOS), and higher scores on the GOS, BI, FIM, and FAM at hospital discharge than unemployed persons. No significant differences in age, sex, educational level, living with partner/family or not, pre-injury employment, professional category, psychiatric symptoms, or discharge destination were found. Longitudinal multivariable analysis showed that time, pre-injury employment, FAM, and LOS were independent predictors of employment probability. We concluded that employment probability 10 years after moderate or severe TBI is related to injury severity and pre-injury employment. Future studies on vocational rehabilitation should focus on modifiable factors and take into consideration the effects of national legislation and national labor market forces.	[Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Rijndam Rehabil, Rotterdam, Netherlands; [Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Erasmus Univ, Med Ctr, Dept Rehabil Med, Rotterdam, Netherlands; [Haitsma, Ian K.] Erasmus Univ, Med Ctr, Dept Neurosurg, Rotterdam, Netherlands		Grauwmeijer, E (corresponding author), Rijndam Rehabil Ctr, Rotterdam Neurorehabil Res RoNeRes, POB 23181, NL-3001 KD Rotterdam, Netherlands.	egrauwmeijer@rijndam.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019; VARRECCHIA, TIWANA/AAJ-8712-2021	Ribbers, Gerard M/0000-0002-6114-349X; Heijenbrok-Kal, Majanka H./0000-0002-2982-4404	Netherlands Organization for Health Research and DevelopmentNetherlands Organization for Health Research and Development [1435.0020]	This study was financially supported by the Netherlands Organization for Health Research and Development (project no.: 1435.0020). We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated.	Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bogner JA, 2017, J HEAD TRAUMA REHAB, V32, pE1, DOI 10.1097/HTR.0000000000000291; Central Bureau for Statistics, STAT UN 2003 2013; Collin C, 1988, Int Disabil Stud, V10, P61; Cuthbert JP, 2015, ARCH PHYS MED REHAB, V96, P2128, DOI 10.1016/j.apmr.2015.07.020; Dahm J, 2015, BRAIN INJURY, V29, P1539, DOI 10.3109/02699052.2015.1075141; Dahm J, 2015, J REHABIL MED, V47, P932, DOI 10.2340/16501977-2016; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Donker-Cools BHPM, 2016, BRAIN INJURY, V30, P113, DOI 10.3109/02699052.2015.1090014; Forslund MV, 2014, BRAIN INJURY, V28, P980, DOI 10.3109/02699052.2014.888770; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mahoney F. I., 1965, STATE MED J, V14, P61; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Stergiou-Kita M, 2016, ARCH PHYS MED REHAB, V97, pS40, DOI 10.1016/j.apmr.2015.04.008; Van Baalen B, 2007, BRAIN INJURY, V21, P925, DOI 10.1080/02699050701553197; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377	31	26	27	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2017	34	17					2575	2581		10.1089/neu.2016.4846			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	FE6HI	WOS:000408310200011	28447873				2022-02-06	
J	Hao, P; Duan, HM; Hao, F; Chen, L; Sun, M; Fan, KS; Sun, YE; Williams, D; Yang, ZY; Li, XG				Hao, Peng; Duan, Hongmei; Hao, Fei; Chen, Lan; Sun, Min; Fan, Kevin S.; Sun, Yi Eve.; Williams, David; Yang, Zhaoyang; Li, Xiaoguang			Neural repair by NT3-chitosan via enhancement of endogenous neurogenesis after adult focal aspiration brain injury	BIOMATERIALS			English	Article						Aspiration brain injury; Endogenous neurogenesis; Chitosan; NT3; Functional recovery; Microenvironment	FUNCTIONAL RECOVERY; STEM-CELLS; CEREBRAL-CORTEX; MOTOR CORTEX; HEAD-INJURY; NEURONS; NEUROTROPHIN-3; PROLIFERATION; MIGRATION; TRKC	The latent regenerative potential of endogenous neural stem progenitor cells (NSCs) in the adult mammalian brain has been postulated as a likely source for neural repair. However, the inflammatory and inhibitory microenvironment after traumatic brain injury (TBI) prohibits NSCs from generating new functional neurons to restore brain function. Here we report a biodegradable material, chitosan, which, when loaded with neurotrophin-3 (NT3) and injected into the lesion site after TBI, effectively engaged endogenous NSCs to proliferate and migrate to the injury area. NSCs differentiate and mature into functional neurons, forming nascent neural networks that further integrate into existing neural circuits to restore brain function. Three main actions of NT3-chitosan, i.e., pro-neurogenesis, anti -inflammation, and pro-revascularization, elicit significant regeneration after TBI. Our study suggests that through creating an optimal microenvironment, endogenous NSCs are capable of executing neural repair, thus widening the therapeutic strategies to treat TBI and perhaps stroke or other neurological conditions. (C) 2017 Published by Elsevier Ltd.	[Hao, Peng; Duan, Hongmei; Hao, Fei; Chen, Lan; Sun, Min; Yang, Zhaoyang; Li, Xiaoguang] Capital Med Univ, Sch Basic Med Sci, Dept Neurobiol, Beijing 100069, Peoples R China; [Sun, Yi Eve.] Tongji Univ, Sch Med, Dept Regenerat Med, Shanghai 200065, Peoples R China; [Sun, Yi Eve.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Li, Xiaoguang] Beihang Univ, Sch Biol Sci & Med Engn, Dept Biomed Engn, Beijing 100191, Peoples R China; [Fan, Kevin S.] Univ Calif Santa Barbara, Dept Comp Engn, Santa Barbara, CA 93106 USA; [Williams, David] Wake Forest Inst Regenerat Med, Winston Salem, NC 27101 USA		Yang, ZY; Li, XG (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Neurobiol, Beijing 100069, Peoples R China.	wack_lily@163.com; lxgchina@sina.com		Duan, Hongmei/0000-0003-2261-2182; hao, peng/0000-0002-8509-8232	State Key Program of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31130022, 31320103903, 31670988, 31271371]; International Cooperation in Science and Technology Project of the Ministry of Science and Technology of China [2014DFA30640]; National Ministry of Education Special Fund for Excellent Doctoral Dissertation [201356]; Special Fund for Excellent Doctoral Dissertation of Beijing [20111000601]; Special Funds for Beijing Base Construction & Talent Cultivation [Z171100002217066]	We thank Xiaomin Xu for his assistance in some data analyses. This work was supported by the State Key Program of the National Natural Science Foundation of China (Grants 31130022, 31320103903, 31670988 & 31271371), the International Cooperation in Science and Technology Project of the Ministry of Science and Technology of China (Grant 2014DFA30640), the National Ministry of Education Special Fund for Excellent Doctoral Dissertation (Grant 201356), the Special Fund for Excellent Doctoral Dissertation of Beijing (Grant 20111000601), and the Special Funds for Beijing Base Construction & Talent Cultivation (Grant Z171100002217066).	Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Coskun V, 2008, P NATL ACAD SCI USA, V105, P1026, DOI 10.1073/pnas.0710000105; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Cristofaro B, 2010, ARTERIOSCL THROM VAS, V30, P1143, DOI 10.1161/ATVBAHA.109.205468; Diaz F, 2013, J NEUROSCI, V33, P6278, DOI 10.1523/JNEUROSCI.5885-12.2013; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; Duan HM, 2015, P NATL ACAD SCI USA, V112, P13360, DOI 10.1073/pnas.1510176112; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gonzalez CLR, 2004, EUR J NEUROSCI, V20, P3442, DOI 10.1111/j.1460-9568.2004.03751.x; Henion PD, 1995, DEV BIOL, V172, P602, DOI 10.1006/dbio.1995.8054; Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Ibrahim S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21793; Ihrie RA, 2011, NEURON, V70, P674, DOI 10.1016/j.neuron.2011.05.004; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Lawrie G, 2007, BIOMACROMOLECULES, V8, P2533, DOI 10.1021/bm070014y; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Luo YP, 2015, CELL, V161, P1175, DOI 10.1016/j.cell.2015.04.001; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mo LH, 2010, BIOMATERIALS, V31, P2184, DOI 10.1016/j.biomaterials.2009.11.078; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NARHI LO, 1993, J BIOL CHEM, V268, P13309; Ohira K, 2011, CELL MOL LIFE SCI, V68, P1645, DOI 10.1007/s00018-010-0552-y; Oka H, 1999, J NEUROSCI METH, V93, P61, DOI 10.1016/S0165-0270(99)00113-2; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Riedel G, 1999, NAT NEUROSCI, V2, P898, DOI 10.1038/13202; Saha B, 2013, STEM CELL RES, V11, P965, DOI 10.1016/j.scr.2013.06.006; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Takeo C, 2003, BIOCHEM BIOPH RES CO, V305, P400, DOI 10.1016/S0006-291X(03)00770-8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; Villasana LE, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0056-15.2015; Wang JM, 2011, BIOMATERIALS, V32, P7454, DOI 10.1016/j.biomaterials.2011.06.036; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7; Yalvac ME, 2016, GENE THER, V23, P95, DOI 10.1038/gt.2015.67; Yang JX, 2014, MOL THER, V22, P440, DOI 10.1038/mt.2013.241; Yang ZY, 2015, P NATL ACAD SCI USA, V112, P13354, DOI 10.1073/pnas.1510194112; Yang ZY, 2010, BIOMATERIALS, V31, P4846, DOI 10.1016/j.biomaterials.2010.02.015; Yonemori F, 1999, J CEREBR BLOOD F MET, V19, P483, DOI 10.1097/00004647-199905000-00002; Zhang WD, 2000, HIPPOCAMPUS, V10, P512, DOI 10.1002/1098-1063(2000)10:5<512::AID-HIPO2>3.3.CO;2-D; Zhang YQ, 2012, CELLS TISSUES ORGANS, V195, P313, DOI 10.1159/000327724	58	26	28	8	63	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	SEP	2017	140						88	102		10.1016/j.biomaterials.2017.04.014			15	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	FB2KY	WOS:000405973900009	28641124				2022-02-06	
J	Yin, HY; Song, SW; Pan, XD				Yin, Haiyan; Song, Shuwen; Pan, Xudong			Knockdown of miR-155 protects microglia against LPS-induced inflammatory injury via targeting RACK1: a novel research for intracranial infection	JOURNAL OF INFLAMMATION-LONDON			English	Article						Intracranial inflammation; miR-155; Inflammation; Cell injury; Microglia; RACK1	KAPPA-B ACTIVATION; NITRIC-OXIDE; MICRORNAS; ROLES; DYSREGULATION; PATHWAY; DEATH	Background: Intracranial infection, one of the complications of traumatic brain injury, is usually associated with inflammation. Several microRNAs (miRNAs), including miR-155, have been reported to be critical modulators in peripheral and central nervous system inflammation. In this study, we investigated the role of miR-155 in lipopolysaccharide (LPS)-induced inflammatory injury in mouse microglia BV2 cells. Results: The expression level of miR-155 was significantly up-regulated after LPS stimulation in BV2 cells. LPS administration decreased BV2 cell viability, promoted apoptosis and increased the release of pro-inflammatory cytokines; while miR-155 knockdown rescued BV2 cell from LPS-induced injury. RACK1 was a directly target of miR-155. Interestingly, miR-155 knockdown did not attenuate LPS-induced inflammatory injury when RACK1 was knocked down. The mechanistic study indicated that miR-155 knockdown deactivated MAPK/NF-kappa B and mTOR signaling pathways under LPS-treated conditions. Conclusions: Knockdown of miR-155 protected mouse microglia BV2 cells from LPS-induced inflammatory injury via targeting RACK1 and deactivating MAPK/NF-kappa B and mTOR signaling pathways.	[Yin, Haiyan] Jining Med Univ, Affiliated Hosp, Dept Neurol, Jining 272000, Peoples R China; [Song, Shuwen] Jining 1 Peoples Hosp, Dept Infect Dis, Jining 272000, Peoples R China; [Pan, Xudong] Qingdao Univ, Affiliated Hosp, Dept Neurol, 16,Jiangsu Rd, Qingdao 266000, Peoples R China		Pan, XD (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Neurol, 16,Jiangsu Rd, Qingdao 266000, Peoples R China.	panxudong012@126.com					Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beveridge NJ, 2012, NEUROBIOL DIS, V46, P263, DOI 10.1016/j.nbd.2011.12.029; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bi XL, 2005, INT IMMUNOPHARMACOL, V5, P185, DOI 10.1016/j.intimp.2004.08.008; Bluml S, 2011, ARTHRITIS RHEUM-US, V63, P1281, DOI 10.1002/art.30281; Bodea LG, 2014, J NEUROSCI, V34, P8546, DOI 10.1523/JNEUROSCI.5002-13.2014; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Cullen BR, 2009, NATURE, V457, P421, DOI 10.1038/nature07757; Fan K, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0268-x; Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013; Foerster BR, 2007, ACTA RADIOL, V48, P875, DOI 10.1080/02841850701477728; Geaghan M, 2015, BIOL PSYCHIAT, V78, P231, DOI 10.1016/j.biopsych.2014.12.009; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hutchison ER, 2009, NEUROMOL MED, V11, P153, DOI 10.1007/s12017-009-8086-x; Jin HM, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4531; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kiely PA, 2008, J BIOL CHEM, V283, P22952, DOI 10.1074/jbc.M800802200; Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Lin C, 2015, CHIN J TRAUMATOL, V18, P81, DOI 10.1016/j.cjtee.2014.10.007; Jimenez CM, 2013, WORLD NEUROSURG, V79, P749, DOI 10.1016/j.wneu.2012.06.025; Miller BH, 2010, BRAIN RES, V1338, P89, DOI 10.1016/j.brainres.2010.03.035; Mor E, 2011, NUCLEIC ACIDS RES, V39, P3710, DOI 10.1093/nar/gkq1325; Mullins ME, 2011, RADIOL CLIN N AM, V49, P47, DOI 10.1016/j.rcl.2010.08.002; Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952; Russo I, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0449-7; Saugstad JA, 2010, J CEREBR BLOOD F MET, V30, P1564, DOI 10.1038/jcbfm.2010.101; Seddiki N, 2014, IMMUNOLOGY, V142, P32, DOI 10.1111/imm.12227; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Slezak-Prochazka I, 2010, RNA, V16, P1087, DOI 10.1261/rna.1804410; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Syed SAM, 2015, FASEB J, V29, P634; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Weichhart T, 2011, BLOOD, V117, P4273, DOI 10.1182/blood-2010-09-310888; Wu D, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00055; Xin Q, 2015, J IMMUNOL, V194, P5437, DOI 10.4049/jimmunol.1403028; Yao F, 2014, CELL RES, V24, P359, DOI 10.1038/cr.2013.162; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200	42	26	27	8	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1476-9255			J INFLAMM-LOND	J. Inflamm.-Lond.	AUG 9	2017	14								17	10.1186/s12950-017-0162-7			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	FD6FN	WOS:000407624500001	28804270	Green Published, gold			2022-02-06	
J	Dou, Y; Shen, HT; Feng, DX; Li, HY; Tian, XD; Zhang, J; Wang, Z; Chen, G				Dou, Yang; Shen, Haitao; Feng, Dongxia; Li, Haiying; Tian, Xiaodi; Zhang, Jian; Wang, Zhong; Chen, Gang			Tumor necrosis factor receptor-associated factor 6 participates in early brain injury after subarachnoid hemorrhage in rats through inhibiting autophagy and promoting oxidative stress	JOURNAL OF NEUROCHEMISTRY			English	Article						autophagy; E3 ubiquitin ligase activity; early brain injury; oxidative stress; subarachnoid hemorrhage; TRAF6	DELAYED CEREBRAL-ISCHEMIA; NF-KAPPA-B; ATYPICAL UBIQUITINATION; SIGNAL-TRANSDUCTION; PARKINSONS-DISEASE; ENDOTHELIAL-CELLS; TRAF6; ACTIVATION; MODEL; MECHANISMS	Tumor necrosis factor receptor-associated factor 6 (TRAF6) is a member of the TRAF family and an important multifunctional intracellular adaptin of the tumor necrosis factor superfamily and toll/IL-1 receptor (TIR) superfamily. TRAF6 has been studied in several central nervous system diseases, including ischemic stroke, traumatic brain injury, and neurodegenerative diseases, but its role in subarachnoid hemorrhage (SAH) has not been fully illustrated. This study was designed to explore changes of expression level and potential roles and mechanisms of TRAF6 in early brain injury (EBI) after SAH using a Sprague-Dawley rat model of SAH induced in 0.3 mL nonheparinized autologous arterial blood injected into the prechiasmatic cistern. First, compared with the sham group, we found that the expression levels of TRAF6 increased gradually and peaked at 24 h after SAH. Second, the results showed that application of TRAF6 over-expression plasmid and genetic silencing siRNA could increase or decrease expression of TRAF6, respectively, and severely exacerbate or relieve EBI after SAH, including neuronal death, brain edema, and blood-brain barrier injury. Meanwhile, the levels of autophagy and oxidative stress were reduced and increased separately. Finally, GFP-TRAF6-C70A, which is a TRAF6 mutant that lacks E3 ubiquitin ligase activity, was used to explore the mechanism of TRAF6 in SAH, and the results showed that EBI and oxidative stress were reduced, but the levels of autophagy were increased under this condition. Collectively, these results indicated that TRAF6 affected the degree of EBI after SAH by inhibiting autophagy and promoting oxidative stress.	[Dou, Yang; Shen, Haitao; Li, Haiying; Tian, Xiaodi; Zhang, Jian; Wang, Zhong; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China; [Dou, Yang; Shen, Haitao; Li, Haiying; Tian, Xiaodi; Zhang, Jian; Wang, Zhong; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Brain & Nerve Res Lab, Suzhou, Jiangsu, Peoples R China; [Feng, Dongxia] Scott & White Clin Temple, Temple, TX 76508 USA		Zhang, J (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.	nju_neurosurgery@163.com			Suzhou Key Medical Center [Szzx201501]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571121]; Scientific Department of Jiangsu Province [BL2014045]; Education department of Jiangsu Province [16KJB320008]; Suzhou Government [SZS201413, SYS201608]; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by Suzhou Key Medical Center (Szzx201501), grants from the National Natural Science Foundation of China (No. 81571121), Scientific Department of Jiangsu Province (No. BL2014045), Education department of Jiangsu Province (No. 16KJB320008), Suzhou Government (No. SZS201413 and SYS201608), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions. The authors declare that they have no competing interest.	Ayer RE, 2008, J PINEAL RES, V44, P197, DOI 10.1111/j.1600-079X.2007.00508.x; Brathwaite S, 2014, TRANSL STROKE RES, V5, P207, DOI 10.1007/s12975-013-0316-8; Bruneau S, 2012, BIOCHEM BIOPH RES CO, V419, P66, DOI 10.1016/j.bbrc.2012.01.128; Cabal-Hierro L, 2012, CELL SIGNAL, V24, P1297, DOI 10.1016/j.cellsig.2012.02.006; Cahill J, 2009, STROKE, V40, pS86, DOI 10.1161/STROKEAHA.108.533315; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chen CH, 2013, CNS NEUROSCI THER, V19, P566, DOI 10.1111/cns.12114; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Chen JA, 2011, CELL MOL NEUROBIOL, V31, P269, DOI 10.1007/s10571-010-9617-6; Chen Sheng, 2015, Acta Neurochir Suppl, V120, P39, DOI 10.1007/978-3-319-04981-6_7; Chen S, 2014, PROG NEUROBIOL, V115, P64, DOI 10.1016/j.pneurobio.2013.09.002; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Chong ZZ, 2016, REV NEUROSCIENCE, V27, P745, DOI 10.1515/revneuro-2016-0021; Dang BQ, 2015, CRIT CARE MED, V43, pE369, DOI 10.1097/CCM.0000000000001146; Dawson TM, 2006, J NEURAL TRANSM-SUPP, P209; Driessen S, 2015, AUTOPHAGY, V11, P1458, DOI 10.1080/15548627.2015.1067359; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Etminan N, 2015, TRANSL STROKE RES, V6, P167, DOI 10.1007/s12975-015-0398-6; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Ha H., 2009, CURR PROTOC IMMUNOL; Hansen-Schwartz J, 2007, TRENDS PHARMACOL SCI, V28, P252, DOI 10.1016/j.tips.2007.04.002; He AQ, 2016, INFLAMMATION, V39, P172, DOI 10.1007/s10753-015-0236-8; He SY, 2012, AUTOPHAGY, V8, P1621, DOI 10.4161/auto.21561; He ZH, 2012, STROKE, V43, P484, DOI 10.1161/STROKEAHA.111.626432; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Kang CH, 2008, AUTOPHAGY, V4, P82, DOI 10.4161/auto.5154; Kinsella S, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0099-15.2016; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kooijman E, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-2; Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269; Lee NK, 2002, J BIOCHEM MOL BIOL, V35, P61; Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020; Liu ZJ, 2012, BRAIN RES BULL, V88, P379, DOI 10.1016/j.brainresbull.2012.04.003; Lomaga MA, 2000, J NEUROSCI, V20, P7384; Lu Y, 2014, PAIN, V155, P2618, DOI 10.1016/j.pain.2014.09.027; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Meng ZY, 2017, J IMMUNOL, V198, P820, DOI 10.4049/jimmunol.1600334; Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9; Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708; Puyal J, 2009, AUTOPHAGY, V5, P1060, DOI 10.4161/auto.5.7.9728; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Rahib L, 2009, MOL GENET METAB, V96, P106, DOI 10.1016/j.ymgme.2008.11.163; Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rouse Richard J D, 2008, BMC Res Notes, V1, P45, DOI 10.1186/1756-0500-1-45; Rowland MJ, 2012, BRIT J ANAESTH, V109, P315, DOI 10.1093/bja/aes264; Sehba FA, 2011, MOL NEUROBIOL, V43, P27, DOI 10.1007/s12035-010-8155-z; Shen HT, 2015, STROKE, V46, P2607, DOI 10.1161/STROKEAHA.115.009729; Song ZF, 2012, ARTERIOSCL THROM VAS, V32, P50, DOI 10.1161/ATVBAHA.111.238329; Sun SY, 2012, BRAIN RES BULL, V88, P609, DOI 10.1016/j.brainresbull.2012.05.013; Suzuki H, 2015, TRANSL STROKE RES, V6, P1, DOI 10.1007/s12975-014-0380-8; Suzuki H, 2010, STROKE, V41, P1783, DOI 10.1161/STROKEAHA.110.586537; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wang L, 2013, J PHYSIOL-LONDON, V591, P5005, DOI 10.1113/jphysiol.2013.262667; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; Wang Z, 2012, J MOL NEUROSCI, V46, P192, DOI 10.1007/s12031-011-9575-6; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Wu HJ, 2016, J CELL MOL MED, V20, P1770, DOI 10.1111/jcmm.12855; Wu J, 2016, STROKE, V47, P1319, DOI 10.1161/STROKEAHA.115.011552; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yao LL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-23; Zapata JM, 2007, ADV EXP MED BIOL, V597, P1; Zhang J, 2013, BRAIN RES, V1528, P80, DOI 10.1016/j.brainres.2013.06.032; Zheng ZL, 2012, CURR NEUROVASC RES, V9, P310, DOI 10.2174/156720212803530663; Zucchelli S, 2011, J BIOL CHEM, V286, P25108, DOI 10.1074/jbc.M110.187591; Zucchelli S, 2010, HUM MOL GENET, V19, P3759, DOI 10.1093/hmg/ddq290	67	26	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2017	142	3					478	492		10.1111/jnc.14075			15	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	FA9LZ	WOS:000405768400012	28543180	Bronze			2022-02-06	
J	Lamb, DG; Porges, EC; Lewis, GF; Williamson, JB				Lamb, Damon G.; Porges, Eric C.; Lewis, Greg F.; Williamson, John B.			Non-invasive Vagal Nerve Stimulation Effects on Hyperarousal and Autonomic State in Patients with Posttraumatic Stress Disorder and History of Mild Traumatic Brain Injury: Preliminary Evidence	FRONTIERS IN MEDICINE			English	Article						posttraumatic stress disorder; traumatic brain injury; hyperarousal; autonomic; transcutaneous vagal nerve stimulation; vagal; transcutaneous; sympathetic	HEART-RATE-VARIABILITY; PREFRONTAL CORTEX; NORADRENERGIC MODULATION; ATTENTIONAL CONTROL; EXPOSURE THERAPY; CONDITIONED FEAR; DOUBLE-BLIND; EXTINCTION; PTSD; VETERANS	Posttraumatic stress disorder (PTSD) is a reaction to trauma that results in a chronic perception of threat, precipitating mobilization of the autonomic nervous system, and may be reflected by chronic disinhibition of limbic structures. A common injury preceding PTSD in veterans is mild traumatic brain injury (mTBI). This may be due to the vulnerability of white matter in these networks and such damage may affect treatment response. We evaluated transcutaneous vagal nerve stimulation (tVNS), a non-invasive, low-risk approach that may alter the functions of the limbo-cortical and peripheral networks underlying the hyperarousal component of PTSD and thus improve patient health and well-being. In this single visit pilot study evaluating the impact of tVNS in 22 combat veterans, we used a between-subjects design in people with either PTSD with preceding mTBI or healthy controls. Participants were randomized into stimulation or sham groups and completed a posturally modulated autonomic assessment and emotionally modulated startle paradigm. The primary measures used were respiratory sinus arrhythmia (high-frequency heart rate variability) during a tilt-table procedure derived from an electrocardiogram, and skin conductance changes in response to acoustic startle while viewing emotional images (International Affective Picture System). The stimulation was well tolerated and resulted in improvements in vagal tone and moderation of autonomic response to startle, consistent with modulation of autonomic state and response to stress in this population. Our results suggest that tVNS affects systems underlying emotional dysregulation in this population and, therefore, should be further evaluated and developed as a potential treatment tool for these patients.	[Lamb, Damon G.; Williamson, John B.] Malcom Randall VAMC, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA; [Lamb, Damon G.; Porges, Eric C.; Williamson, John B.] Univ Florida, Coll Med, Ctr Cognit Aging & Memory, Gainesville, FL 32611 USA; [Lamb, Damon G.; Williamson, John B.] Univ Florida, Coll Med, Dept Neurol, Ctr Neuropsychol Studies, Gainesville, FL 32611 USA; [Lamb, Damon G.; Porges, Eric C.; Williamson, John B.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA; [Lewis, Greg F.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA; [Lewis, Greg F.] Indiana Univ, Sch Informat & Comp, Intelligent Syst Engn, Bloomington, IN USA; [Lewis, Greg F.] Indiana Univ, Kinsey Inst, Bloomington, IN USA		Williamson, JB (corresponding author), Malcom Randall VAMC, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA.; Williamson, JB (corresponding author), Univ Florida, Coll Med, Ctr Cognit Aging & Memory, Gainesville, FL 32611 USA.; Williamson, JB (corresponding author), Univ Florida, Coll Med, Dept Neurol, Ctr Neuropsychol Studies, Gainesville, FL 32611 USA.; Williamson, JB (corresponding author), Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA.	john.williamson@neurology.ufl.edu			U.S. Department of Veterans Affairs, Rehabilitation Research and Development Office, Brain Rehabilitation Research Center (BRRC) Center [B6793C]; BRRC Innovation Award [0214BRRC-17, IK2RX000707]; Center for Cognitive Aging and Memory at the University of Florida; McKnight Brain Research Foundation; University of Florida Clinical and Translational Science Institute; National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001427]; NIH/NCATS Clinical and Translational Science AwardsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000064, KL2 TR000065]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001427, KL2TR001429] Funding Source: NIH RePORTER	This work was supported by the U.S. Department of Veterans Affairs, Rehabilitation Research and Development Office, Brain Rehabilitation Research Center (BRRC) Center Grant B6793C, and BRRC Innovation Award No. 0214BRRC-17 as well as IK2RX000707 (JBW), the Center for Cognitive Aging and Memory at the University of Florida, the McKnight Brain Research Foundation, the University of Florida Clinical and Translational Science Institute, which is supported in part by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) under Award No. UL1TR001427; NIH/NCATS Clinical and Translational Science Awards Grant Nos. UL1TR000064 and KL2 TR000065 (ECP). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs, the National Institutes of Health or the University of Florida.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Ben-Menachem E, 2015, EUR J NEUROL, V22, P1260, DOI 10.1111/ene.12629; Benedek M, 2010, J NEUROSCI METH, V190, P80, DOI 10.1016/j.jneumeth.2010.04.028; Binici Z, 2011, STROKE, V42, P3196, DOI 10.1161/STROKEAHA.110.607697; Braithwaite J.J., 2015, GUIDE ANAL ELECTRODE; Bryant RA, 2008, J CONSULT CLIN PSYCH, V76, P695, DOI 10.1037/a0012616; Buffalari DM, 2007, J NEUROSCI, V27, P12358, DOI 10.1523/JNEUROSCI.2007-07.2007; Capone F, 2015, J NEURAL TRANSM, V122, P679, DOI 10.1007/s00702-014-1299-7; Clancy JA, 2014, BRAIN STIMUL, V7, P871, DOI 10.1016/j.brs.2014.07.031; Critchley HD, 2000, J PHYSIOL-LONDON, V523, P259, DOI 10.1111/j.1469-7793.2000.t01-1-00259.x; Dale LP, 2009, APPL PSYCHOPHYS BIOF, V34, P299, DOI 10.1007/s10484-009-9111-4; Davidson J, 2006, J CLIN PSYCHOPHARM, V26, P259, DOI 10.1097/01.jcp.0000222514.71390.c1; Davidson JRT, 2006, J CLIN PSYCHIAT, V67, P34; De Martino B, 2008, PSYCHOPHARMACOLOGY, V197, P127, DOI 10.1007/s00213-007-1015-5; Diamond DM, 2016, J NEUROSCI RES, V94, P437, DOI 10.1002/jnr.23684; Dietrich S, 2008, BIOMED TECH, V53, P104, DOI 10.1515/BMT.2008.022; Difede J, 2014, ANNU REV MED, V65, P319, DOI 10.1146/annurev-med-051812-145438; Fallgatter AJ, 2003, J NEURAL TRANSM, V110, P1437, DOI 10.1007/s00702-003-0087-6; Felmingham KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103653; Foa EB, 2009, EFFECTIVE TREATMENTS, V2nd; Foa EB, 2013, PSYCHOL SCI PUBL INT, V14, P65, DOI 10.1177/1529100612468841; HARDY SGP, 1988, EXP BRAIN RES, V73, P249; Kemp AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030777; Kotecha D, 2012, HEART, V98, P395, DOI 10.1136/heartjnl-2011-300033; Kraus T, 2013, BRAIN STIMUL, V6, P798, DOI 10.1016/j.brs.2013.01.011; Lang PJ, 2001, INT AFFECTIVE PICTUR; Lang PJ, 2001, A5 U FLOR CTR RES PS; LOEWY AD, 1991, PROG BRAIN RES, V87, P253; Magruder KM, 2016, J TRAUMA STRESS, V29, P5, DOI 10.1002/jts.22075; McEwen BS, 2003, HORM BEHAV, V43, P2, DOI 10.1016/S0018-506X(02)00024-7; Miller-Archie SA, 2014, PREV MED, V66, P34, DOI 10.1016/j.ypmed.2014.05.016; Mota N, 2016, J CLIN PSYCHIAT, V77, P348, DOI 10.4088/JCP.15m10101; Mueller D, 2010, BEHAV BRAIN RES, V208, P1, DOI 10.1016/j.bbr.2009.11.025; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Norte CE, 2013, J AFFECT DISORDERS, V150, P136, DOI 10.1016/j.jad.2012.11.039; Owens NC, 2001, BRAIN RES, V919, P221, DOI 10.1016/S0006-8993(01)03017-7; Paulus EJ, 2013, J TRAUMA STRESS, V26, P169, DOI 10.1002/jts.21785; Pena DF, 2013, BIOL PSYCHIAT, V73, P1071, DOI 10.1016/j.biopsych.2012.10.021; Pena DF, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00327; Pietrzak RH, 2010, PSYCHIAT RES, V178, P323, DOI 10.1016/j.psychres.2010.04.039; Porges SW, 2007, BIOL PSYCHOL, V74, P116, DOI 10.1016/j.biopsycho.2006.06.009; Resstel LBM, 2004, BRAIN RES, V1015, P136, DOI 10.1016/j.brainres.2004.04.065; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Santini E, 2004, J NEUROSCI, V24, P5704, DOI 10.1523/JNEUROSCI.0786-04.2004; Shah AJ, 2013, BIOL PSYCHIAT, V73, P1103, DOI 10.1016/j.biopsych.2013.01.019; Simon NM, 2008, J CLIN PSYCHIAT, V69, P400, DOI 10.4088/JCP.v69n0309; Stein MB, 2002, AM J PSYCHIAT, V159, P1777, DOI 10.1176/appi.ajp.159.10.1777; TSUJI H, 1994, CIRCULATION, V90, P878, DOI 10.1161/01.CIR.90.2.878; Umhau JC, 2002, PSYCHOPHYSIOLOGY, V39, P117, DOI 10.1017/S0048577201392016; Vaiva G, 2003, BIOL PSYCHIAT, V54, P947, DOI 10.1016/S0006-3223(03)00412-8; Verberne AJM, 1998, PROG NEUROBIOL, V54, P149, DOI 10.1016/S0301-0082(97)00056-7; White SF, 2015, NEUROIMAGE-CLIN, V7, P19, DOI 10.1016/j.nicl.2014.11.012; Williamson JB, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01571; Williamson John B, 2013, Front Neuroeng, V6, P13, DOI 10.3389/fneng.2013.00013; Williamson JB, 2010, AUTON NEUROSCI-BASIC, V156, P60, DOI 10.1016/j.autneu.2010.03.009; Zikopoulos B, 2017, J NEUROSCI, V37, P5051, DOI 10.1523/JNEUROSCI.3940-16.2017; Zohar J, 2002, J CLIN PSYCHOPHARM, V22, P190, DOI 10.1097/00004714-200204000-00013	58	26	27	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		2296-858X		FRONT MED-LAUSANNE	Front. Med.	JUL 31	2017	4								124	10.3389/fmed.2017.00124			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC9CD	WOS:000407137600001	28824913	Green Published, gold			2022-02-06	
J	Cancelliere, C; Coronado, VG; Taylor, CA; Xu, L				Cancelliere, Carol; Coronado, Victor G.; Taylor, Christopher A.; Xu, Likang			Epidemiology of Isolated Versus Nonisolated Mild Traumatic Brain Injury Treated in Emergency Departments in the United States, 2006-2012: Sociodemographic Characteristics	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; brain injuries; epidemiology; hospital emergency service	ADMINISTRATIVE DATA; DIAGNOSIS; ACCURACY; ADULTS; CODES	Objectives: To describe the frequencies and rates of mild traumatic brain injury (mTBI) emergency department (ED) visits, analyze the trend across the years, and compare sociodemographic characteristics of visits by mTBI type (ie, mTBI as the only injury, or present along with other injuries). Design: Population-based descriptive study using data from the Nationwide Emergency Department Sample (2006-2012). Methods: Joinpoint regression was used to calculate the average annual percent changes of mTBI incidence rates. Characteristics between isolated and nonisolated visits were compared, and the odds ratios were reported. Results: The rate per 100 000 population of mTBI ED visits in the United States increased significantly from 569.4 (in 2006) to 807.9 (in 2012). The highest rates were observed in 0-to 4-year-olds, followed by male 15-to 24-year-olds and females 65 years and older; the lowest rates were among 45-to 64-year-olds. The majority (70%) of all visits were nonisolated and occurred more frequently in residents of metropolitan areas. Falls were the leading external cause. Most visits were privately insured or covered by Medicare/Medicaid, and the injury occurred on weekdays in predominantly metropolitan hospitals in the South region. Conclusions: The burden of mTBI in US EDs is high. Most mTBI ED visits present with other injuries. Awareness of sociodemographic factors associated with nonisolated mTBI may help improve diagnosis in US EDs. This information has implications for resource planning and mTBI screening in EDs.	[Cancelliere, Carol] Univ Toronto, Inst Hlth Policy Management & Evaluat, Hlth Sci Bldg,155 Coll St,Ste 425, Toronto, ON, Canada; [Taylor, Christopher A.; Xu, Likang] Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Coronado, Victor G.] Ctr Dis Control & Prevent, Atlanta, GA USA		Cancelliere, C (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Hlth Sci Bldg,155 Coll St,Ste 425, Toronto, ON, Canada.	carol@427health.com	Taylor, Christopher A/D-2067-2013	Taylor, Christopher A/0000-0002-0937-5461	Intramural CDC HHS [CC999999] Funding Source: Medline		Abrams Gary M, 2015, Continuum (Minneap Minn), V21, P188, DOI 10.1212/01.CON.0000461092.86865.a4; Adachi H, 2015, INTERV NEURORADIOL, V21, P719, DOI 10.1177/1591019915609120; Adamson BC, 2015, ARCH PHYS MED REHAB, V96, P1329, DOI 10.1016/j.apmr.2015.01.005; [Anonymous], 2014, JOINP REGR PROGR VER; [Anonymous], 2013, HCUP NEDS DESCR DAT; [Anonymous], 2014, INTR NEDS; Bay E, 2011, ADV EMERG NURS J, V33, P71, DOI 10.1097/TME.0b013e318207e851; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Carlson KF, 2013, BRAIN INJURY, V27, P640, DOI 10.3109/02699052.2013.771795; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Centers for Disease Control and Prevention, HLTH US 2012 IN INJ; Centers for Disease Control and Prevention, 2012, BRIDG RAC POP EST DA; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2010, TRAUM BRAIN INJ FACT; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faul M, 2010, TRAUMATIC BRAIN INJU, P1; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Krainin Benjamin M, 2011, J Spec Oper Med, V11, P38; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Leute PJF, 2015, EUR J TRAUMA EMERG S, V41, P299, DOI 10.1007/s00068-014-0429-0; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Stuart B, 2012, J EMERG NURS, V38, P435, DOI 10.1016/j.jen.2011.04.006; Voss JD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0506-z	33	26	26	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2017	32	4					E37	E46		10.1097/HTR.0000000000000260			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FA2KB	WOS:000405269200005	28489698	Green Accepted			2022-02-06	
J	Vink, R; Gabrielian, L; Thornton, E				Vink, Robert; Gabrielian, Levon; Thornton, Emma			The Role of Substance P in Secondary Pathophysiology after Traumatic Brain injury	FRONTIERS IN NEUROLOGY			English	Article						substance P; traumatic brain injury; edema; intracranial pressure; brain oxygenation; sheep model	GENE-RELATED PEPTIDE; ANGIOTENSIN-CONVERTING ENZYME; PRIMARY SENSORY NEURONS; CENTRAL-NERVOUS-SYSTEM; ACUTE ISCHEMIC-STROKE; SPINAL-CORD-INJURY; NEUROGENIC INFLAMMATION; EDEMA FORMATION; BARRIER BREAKDOWN; NEUROKININ-1 RECEPTOR	It has recently been shown that substance P (SP) plays a major role in the secondary injury process following traumatic brain injury (TBI), particularly with respect to neuroinflammation, increased blood-brain barrier (BBB) permeability, and edema formation. Edema formation is associated with the development of increased intracranial pressure (ICP) that has been widely associated with increased mortality and morbidity after neurotrauma. However, a pharmacological intervention to specifically reduce ICP is yet to be developed, with current interventions limited to osmotic therapy rather than addressing the cause of increased ICP. Given that previous publications have shown that SP, NK1 receptor antagonists reduce edema after TBI, more recent studies have examined whether these compounds might also reduce ICP and improve brain oxygenation after TBI. We discuss the results of these studies, which demonstrate that NK1 antagonists reduce posttraumatic ICP to near normal levels within 4 h of drug administration, as well as restoring brain oxygenation to near normal levels in the same time frame. The improvements in these parameters occurred in association with an improvement in BBB integrity to serum proteins, suggesting that SP-mediated increases in vascular permeability significantly contribute to the development of increased ICP after acute brain injury. NK1 antagonists may therefore provide a novel, mechanistically targeted approach to the management of increased ICP.	[Vink, Robert] Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA, Australia; [Gabrielian, Levon; Thornton, Emma] Univ Adelaide, Adelaide Med Sch, Discipline Anat & Pathol, Adelaide, SA, Australia		Vink, R (corresponding author), Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA, Australia.	robert.vink@unisa.edu.au	Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	National Health and Medical Research Council, AustraliaNational Health and Medical Research Council of Australia	This study was supported by grants to RV from the National Health and Medical Research Council, Australia.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; AZARYAN AV, 1988, J NEUROSCI RES, V19, P268, DOI 10.1002/jnr.490190213; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bergner AJ, 2000, NEUROSCIENCE, V96, P611, DOI 10.1016/S0306-4522(99)00576-X; Black PH, 2002, BRAIN BEHAV IMMUN, V16, P622, DOI 10.1016/S0889-1591(02)00021-1; BLUMBERG S, 1980, BRAIN RES, V192, P477, DOI 10.1016/0006-8993(80)90898-7; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P14, DOI DOI 10.1089/NEU.2007.9994; Byard RW, 2012, J FORENSIC SCI, V57, P973, DOI 10.1111/j.1556-4029.2012.02109.x; Byard Roger W, 2009, Leg Med (Tokyo), V11 Suppl 1, pS128, DOI 10.1016/j.legalmed.2009.02.001; Cabella B, 2017, NEUROCRIT CARE, V27, P103, DOI 10.1007/s12028-016-0319-x; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cook NL, 2009, J NEUROSCI RES, V87, P34, DOI 10.1002/jnr.21846; Corrigan F, 2016, BRIT J PHARMACOL, V173, P703, DOI 10.1111/bph.13155; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Corrigan F, 2012, CNS NEUROSCI THER, V18, P513, DOI 10.1111/j.1755-5949.2012.00332.x; Cyrino LAR, 2002, PHYTOTHER RES, V16, P545, DOI 10.1002/ptr.987; Czosnyka M, 2017, HAND CLINIC, V140, P67, DOI 10.1016/B978-0-444-63600-3.00005-2; Di Maria GU, 1998, EUR RESPIR J, V12, P1454, DOI 10.1183/09031936.98.12061454; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; DUN NJ, 1981, J PHYSIOL-LONDON, V321, P259, DOI 10.1113/jphysiol.1981.sp013982; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Gabrielian L, 2013, THESIS; Gabrielian Levon, 2013, Acta Neurochir Suppl, V118, P201, DOI 10.1007/978-3-7091-1434-6_37; Gabrielian L, 2011, J NEUROTRAUM, V28, P2103, DOI 10.1089/neu.2011.1785; GIBBINS IL, 1987, CELL TISSUE RES, V248, P417; Harford-Wright E, 2010, NEUROSCI LETT, V481, P26, DOI 10.1016/j.neulet.2010.06.044; Harrison JE, 2008, HOSP SEPARATIONS DUE; Harrison S, 2001, INT J BIOCHEM CELL B, V33, P555, DOI 10.1016/S1357-2725(01)00031-0; HELKE CJ, 1982, PEPTIDES, V3, P479, DOI 10.1016/0196-9781(82)90111-5; HELKE CJ, 1982, BRAIN RES, V243, P147, DOI 10.1016/0006-8993(82)91128-3; HEYMANN E, 1978, FEBS LETT, V91, P360, DOI 10.1016/0014-5793(78)81210-1; HOKFELT T, 1975, SCIENCE, V190, P889, DOI 10.1126/science.242075; HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0; Hokfelt T, 2001, J INTERN MED, V249, P27, DOI 10.1046/j.0954-6820.2000.00773.x; HOOPER NM, 1987, BIOCHEM J, V241, P625, DOI 10.1042/bj2410625; Hu DE, 2005, BRIT J PHARMACOL, V146, P576, DOI 10.1038/sj.bjp.0706350; KAGEYAMA T, 1993, EUR J BIOCHEM, V216, P717, DOI 10.1111/j.1432-1033.1993.tb18191.x; KLINTWORTH GK, 1968, ANAT RECORD, V160, P635, DOI 10.1002/ar.1091600312; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; Kubale V, 2007, CELL TISSUE RES, V330, P231, DOI 10.1007/s00441-007-0462-y; LEE Y, 1985, BRAIN RES, V330, P194, DOI 10.1016/0006-8993(85)90027-7; Leeman SE, 2000, NEUROPEPTIDES, V34, P249, DOI 10.1054/npep.2000.0826; Leonard AV, 2014, SPINAL CORD, V52, P17, DOI 10.1038/sc.2013.136; Leonard AV, 2013, J NEUROTRAUM, V30, P1812, DOI 10.1089/neu.2013.2993; Li W, 2015, J CRANIOFAC SURG, V26, P393, DOI 10.1097/SCS.0000000000001339; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lorente L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0911-z; Ma JP, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub4; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; MARKOWITZ S, 1987, J NEUROSCI, V7, P4129, DOI 10.1523/jneurosci.07-12-04129.1987; MARLIER L, 1991, EXP BRAIN RES, V85, P482; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; McCarson KE, 1999, NEUROSCIENCE, V93, P361, DOI 10.1016/S0306-4522(99)00102-5; Meyer BH, 2006, P NATL ACAD SCI USA, V103, P2138, DOI 10.1073/pnas.0507686103; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Monastyrskaya K, 2005, J BIOL CHEM, V280, P7135, DOI 10.1074/jbc.M405806200; NADEL JA, 1991, EUR RESPIR J, V4, P745; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Node Y, 1990, Adv Neurol, V52, P359; NOGUCHI K, 1988, MOL BRAIN RES, V4, P31, DOI 10.1016/0169-328X(88)90015-0; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Prakash R, 2015, CURR OPIN NEUROL, V28, P556, DOI 10.1097/WCO.0000000000000248; PROBERT L, 1987, NEUROSCI LETT, V78, P132, DOI 10.1016/0304-3940(87)90621-5; Rowlands HE, 2007, PAEDIAT CHILD HLTH, V17, P82, DOI DOI 10.1016/J.PAED.2007.01.011; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saffroy M, 2003, NEUROSCIENCE, V116, P761, DOI 10.1016/S0306-4522(02)00748-0; SAKURADA T, 1990, PHARMACOL TOXICOL, V66, P75, DOI 10.1111/j.1600-0773.1990.tb00708.x; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; Seybold VS, 2003, J NEUROSCI, V23, P1816; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SHULTS CW, 1984, PEPTIDES, V5, P1097, DOI 10.1016/0196-9781(84)90177-3; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Skidgel R A, 1987, Agents Actions Suppl, V22, P289; Stein DG, 1998, NEUROSCIENTIST, V4, P435, DOI 10.1177/107385849800400615; STERNINI C, 1995, J COMP NEUROL, V358, P531, DOI 10.1002/cne.903580406; Stumm RK, 2001, J NEUROSCI, V21, P798, DOI 10.1523/JNEUROSCI.21-03-00798.2001; Turner RJ, 2006, ACTA NEUROCHIR SUPPL, V96, P263; Turner RJ, 2012, NEUROSCIENCE, V220, P1, DOI 10.1016/j.neuroscience.2012.06.047; Turner RJ, 2014, NEUROPEPTIDES, V48, P267, DOI 10.1016/j.npep.2014.07.002; Turner RJ, 2011, BRAIN RES, V1393, P84, DOI 10.1016/j.brainres.2011.03.066; Vennekens R, 2012, REV PHYSIOL BIOCH P, V163, P27, DOI 10.1007/112_2012_8; Vink R, 2003, ACT NEUR S, V86, P257; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Vink R, 2008, ACTA NEUROCHIR SUPPL, V102, P189, DOI 10.1007/978-3-211-85578-2_37; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; WANG LH, 1991, PEPTIDES, V12, P1357, DOI 10.1016/0196-9781(91)90220-J; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39	97	26	30	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUN 28	2017	8								304	10.3389/fneur.2017.00304			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EY9PU	WOS:000404331300001	28701994	Green Published, gold, Green Accepted			2022-02-06	
J	Grasman, JM; Kaplan, DL				Grasman, Jonathan M.; Kaplan, David L.			Human endothelial cells secrete neurotropic factors to direct axonal growth of peripheral nerves	SCIENTIFIC REPORTS			English	Article							VOLUMETRIC MUSCLE LOSS; SKELETAL-MUSCLE; MACROPHAGE PHENOTYPE; STEM-CELLS; IN-VITRO; REGENERATION; NEURONS; BRAIN; GUIDANCE; DELIVERY	Understanding how nerves spontaneously innervate tissues or regenerate small injuries is critical to enhance material-based interventions to regenerate large scale, traumatic injuries. During embryogenesis, neural and vascular tissues form interconnected, complex networks as a result of signaling between these tissue types. Here, we report that human endothelial cells (HUVECs) secrete brain-derived neurotrophic factor (BDNF), which significantly stimulated axonal growth from chicken or rat dorsal root ganglia (DRGs). HUVEC-conditioned medium was sufficient to enhance axonal growth, demonstrating that direct cell-cell contact was not required. When BDNF was neutralized, there was a significant reduction in axonal growth when incubated in HUVEC-conditioned medium and in direct co-culture with HUVECs. These data show that HUVECs secrete neurotrophic factors that significantly enhance axonal growth, and can inform future in vivo studies to direct or pattern the angiogenic response in regenerating tissues to encourage re-innervation.	[Grasman, Jonathan M.; Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA		Kaplan, DL (corresponding author), Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.	david.kaplan@tufts.edu		Grasman, Jonathan/0000-0001-8289-9627	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41EB002520, R01-AR055993, F32-DE026058]; WM Keck FoundationW.M. Keck Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR055993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [F32DE026058] Funding Source: NIH RePORTER	The authors thank Siran (Maggie) Wang for her instruction on the isolation of DRGs and Dana M. Cairns for helpful discussions. This research was funded in part by the NIH (P41EB002520, R01-AR055993, and F32-DE026058) and the WM Keck Foundation.	Ai LS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046287; Alexander JK, 2012, EXP NEUROL, V236, P351, DOI 10.1016/j.expneurol.2012.04.018; Allodi I, 2012, PROG NEUROBIOL, V98, P16, DOI 10.1016/j.pneurobio.2012.05.005; Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264; Bell JHA, 2012, TISSUE ENG PART B-RE, V18, P116, DOI [10.1089/ten.teb.2011.0498, 10.1089/ten.TEB.2011.0498]; Blais M, 2013, TISSUE ENG PT A, V19, P1655, DOI 10.1089/ten.tea.2012.0745; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; Deng B, 2012, J IMMUNOL, V189, P3669, DOI 10.4049/jimmunol.1103180; Ehret F, 2015, STEM CELL RES, V15, P514, DOI 10.1016/j.scr.2015.09.010; Faroni A, 2015, ADV DRUG DELIVER REV, V82-83, P160, DOI 10.1016/j.addr.2014.11.010; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; Grasman JM, 2015, ACTA BIOMATER, V25, P2, DOI 10.1016/j.actbio.2015.07.038; Grogan BF, 2011, J AM ACAD ORTHOP SUR, V19, pS35, DOI 10.5435/00124635-201102001-00007; Hobson MI, 1997, BRIT J PLAST SURG, V50, P125, DOI 10.1016/S0007-1226(97)91325-4; Ichihara S, 2008, INJURY, V39, pS29, DOI 10.1016/j.injury.2008.08.029; Israeli D, 2004, J CELL PHYSIOL, V201, P409, DOI 10.1002/jcp.20088; James JM, 2011, SEMIN CELL DEV BIOL, V22, P1019, DOI 10.1016/j.semcdb.2011.09.010; Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087; Liu YM, 2013, NEUROSCI LETT, V551, P79, DOI 10.1016/j.neulet.2013.07.012; Madduri S, 2010, BIOMATERIALS, V31, P2323, DOI 10.1016/j.biomaterials.2009.11.073; Marquardt LM, 2015, TISSUE ENG PT A, V21, P2852, DOI [10.1089/ten.tea.2015.0311, 10.1089/ten.TEA.2015.0311]; Michaelson MD, 1996, DEV BIOL, V179, P251, DOI 10.1006/dbio.1996.0255; Miknyoczki SJ, 2002, CLIN CANCER RES, V8, P1924; Mills CD, 2007, MOL CELL NEUROSCI, V36, P185, DOI 10.1016/j.mcn.2007.06.011; Ming GL, 2001, NEURON, V29, P441, DOI 10.1016/S0896-6273(01)00217-3; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Nectow AR, 2012, TISSUE ENG PART B-RE, V18, P40, DOI [10.1089/ten.TEB.2011.0240, 10.1089/ten.teb.2011.0240]; Nichols CM, 2004, EXP NEUROL, V190, P347, DOI 10.1016/j.expneurol.2004.08.003; Nishiyama M, 2008, NAT NEUROSCI, V11, P762, DOI 10.1038/nn.2130; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Pagel CN, 2014, J CELL COMMUN SIGNAL, V8, P95, DOI 10.1007/s12079-013-0217-3; Plantman S, 2012, NEUROREPORT, V23, P647, DOI 10.1097/WNR.0b013e328355380e; Rabenstein M, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0098-x; Sawada M, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00053; Segura I, 2009, TRENDS MOL MED, V15, P439, DOI 10.1016/j.molmed.2009.08.005; Shvartsman D, 2014, MOL THER, V22, P1243, DOI 10.1038/mt.2014.76; Sivak WN, 2017, J TISSUE ENG REGEN M, V11, P733, DOI 10.1002/term.1970; Villalta SA, 2011, HUM MOL GENET, V20, P790, DOI 10.1093/hmg/ddq523; Wang SR, 2015, J BIOMED MATER RES A, V103, P3339, DOI 10.1002/jbm.a.35465; Wirth MJ, 2005, P NATL ACAD SCI USA, V102, P3064, DOI 10.1073/pnas.0404712102; Wood MD, 2009, ACTA BIOMATER, V5, P959, DOI 10.1016/j.actbio.2008.11.008; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Zhang WW, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052849, 10.1371/journal.pone.0054779]	44	26	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 22	2017	7								4092	10.1038/s41598-017-04460-8			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY3MF	WOS:000403874900075	28642578	Green Published, gold			2022-02-06	
J	Pekic, S; Popovic, V				Pekic, Sandra; Popovic, Vera			DIAGNOSIS OF ENDOCRINE DISEASE Expanding the cause of hypopituitarism	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; LANGERHANS CELL HISTIOCYTOSIS; CENTRAL-NERVOUS-SYSTEM; PITUITARY DYSFUNCTION; GROWTH-HORMONE; SHEEHANS-SYNDROME; SUBARACHNOID HEMORRHAGE; SELLAR GLOMANGIOMA; EXCESS MORTALITY; CASE SERIES	Hypopituitarism is defined as one or more pituitary hormone deficits due to a lesion in the hypothalamic-pituitary region. By far, the most common cause of hypopituitarism associated with a sellar mass is a pituitary adenoma. A high index of suspicion is required for diagnosing hypopituitarism in several other conditions such as other massess in the sellar and parasellar region, brain damage caused by radiation and by traumatic brain injury, vascular lesions, infiltrative/immunological/inflammatory diseases (lymphocytic hypophysitis, sarcoidosis and hemochromatosis), infectious diseases and genetic disorders. Hypopituitarism may be permanent and progressive with sequential pattern of hormone deficiencies (radiation-induced hypopituitarism) or transient after traumatic brain injury with possible recovery occurring years from the initial event. In recent years, there is increased reporting of less common and less reported causes of hypopituitarism with its delayed diagnosis. The aim of this review is to summarize the published data and to allow earlier identification of populations at risk of hypopituitarism as optimal hormonal replacement may significantly improve their quality of life and life expectancy.	[Pekic, Sandra] Univ Belgrade, Sch Med, Internal Med, Belgrade, Serbia; [Popovic, Vera] Univ Belgrade, Sch Med, Belgrade, Serbia; [Pekic, Sandra] Univ Clin Ctr Belgrade, Clin Endocrinol Diabet & Metab Dis, Belgrade, Serbia		Popovic, V (corresponding author), Univ Belgrade, Sch Med, Belgrade, Serbia.	popver@gmail.com	Pekic, Sandra/S-7175-2016		Ministry of Science of Republic of SerbiaMinistry of Education, Science & Technological Development, Serbia [175033]	This study was supported by a grant from the Ministry of Science of Republic of Serbia (Project 175033).	Abele TA, 2012, CLIN RADIOL, V67, P821, DOI 10.1016/j.crad.2012.01.001; Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Al-Aridi R, 2014, PITUITARY, V17, P575, DOI 10.1007/s11102-013-0542-9; Anthony J, 2016, PITUITARY, V19, P19, DOI 10.1007/s11102-015-0678-x; ASA SL, 1984, ULTRASTRUCT PATHOL, V7, P49, DOI 10.3109/01913128409141853; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Bando H, 2015, PEDIATR ENDOCR REV P, V12, P290; Beatrice Anne M, 2013, Indian J Endocrinol Metab, V17, pS608, DOI 10.4103/2230-8210.123546; Berkmann S, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.05.029; Bricaire L, 2015, J CLIN ENDOCR METAB, V100, P2837, DOI 10.1210/jc.2015-2049; Briet C, 2015, ENDOCR REV, V36, P622, DOI 10.1210/er.2015-1042; Carmichael JD, 2012, CURR OPIN ENDOCRINOL, V19, P314, DOI 10.1097/MED.0b013e32835430ed; Caturegli P, 2016, AM J PATHOL, V186, P3225, DOI 10.1016/j.ajpath.2016.08.020; Chemaitilly W, 2015, J CLIN ONCOL, V33, P492, DOI 10.1200/JCO.2014.56.7933; Cheung CC, 2013, J CLIN ENDOCRINOLOGY, V86, P1048, DOI [10.1210/jcem.86.3.7265, DOI 10.1210/JCEM.86.3.7265]; Cives M, 2015, CRIT REV ONCOL HEMAT, V95, P1, DOI 10.1016/j.critrevonc.2015.02.004; Courtillot C, 2016, J CLIN ENDOCR METAB, V101, P304, DOI 10.1210/jc.2015-3357; De Parisot A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000748; Dhanwal DK, 2010, PITUITARY, V13, P304, DOI 10.1007/s11102-010-0234-7; Diri H, 2016, ENDOCRINE, V51, P22, DOI 10.1007/s12020-015-0726-3; Diri H, 2014, EUR J ENDOCRINOL, V171, P311, DOI 10.1530/EJE-14-0244; Ebinu JO, 2011, ENDOCR PATHOL, V22, P218, DOI 10.1007/s12022-011-9179-2; Faje A, 2016, PITUITARY, V19, P82, DOI 10.1007/s11102-015-0671-4; Fleseriu M, 2016, J CLIN ENDOCR METAB, V101, P3888, DOI 10.1210/jc.2016-2118; Golay V, 2014, PITUITARY, V17, P125, DOI 10.1007/s11102-013-0477-1; Hall J, 2015, BRIT J NEUROSURG, V29, P303, DOI 10.3109/02688697.2014.969681; Hamdeh S, 2015, AM J EMERG MED, V33, DOI 10.1016/j.ajem.2015.04.071; Haroche J, 2013, BLOOD, V121, P1495, DOI 10.1182/blood-2012-07-446286; Hautala T, 2002, CLIN INFECT DIS, V35, P96, DOI 10.1086/340859; He WZ, 2015, PITUITARY, V18, P159, DOI 10.1007/s11102-014-0552-2; Heshmati HM, 2001, MAYO CLIN PROC, V76, P789; Higham CE, 2016, LANCET, V388, P2403, DOI 10.1016/S0140-6736(16)30053-8; Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714; Imashuku S, 2011, INT J HEMATOL, V94, P556, DOI 10.1007/s12185-011-0955-z; Iwama S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008002; Joukhadar R, 2012, PITUITARY, V15, P146, DOI 10.1007/s11102-011-0352-x; Kapoor E, 2014, J CLIN ENDOCR METAB, V99, P3988, DOI 10.1210/jc.2014-1962; Kara O, 2013, J PEDIATR ENDOCR MET, V26, P959, DOI 10.1515/jpem-2013-0033; Karaca Z, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.92; Karaca Z, 2016, MINERVA ENDOCRINOL, V41, P390; Karaca Z, 2016, PROG MOL BIOL TRANSL, V138, P167, DOI 10.1016/bs.pmbts.2015.10.010; Karaca Z, 2009, ENDOCR RES, V34, P10, DOI 10.1080/07435800902841306; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Khajeh L, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0205-0; Klose M, 2015, J CLIN MED, V4, P1480, DOI 10.3390/jcm4071480; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kreitschmann-Andermahr Ilonka, 2005, Pituitary, V8, P219, DOI 10.1007/s11102-006-6044-2; Langrand C, 2012, QJM-INT J MED, V105, P981, DOI 10.1093/qjmed/hcs121; Lasolle H, 2016, LANCET DIABETES ENDO, V4, P374, DOI 10.1016/S2213-8587(15)00458-1; Lury Kenneth M, 2005, Top Magn Reson Imaging, V16, P301, DOI 10.1097/01.rmr.0000224686.21748.ea; Miljic D, 2003, J ENDOCRINOL INVEST, V26, P450, DOI 10.1007/BF03345201; Noblett J, 2015, BMJ CASE REPORTS, V25, P2015; Olsson DS, 2017, EUR J ENDOCRINOL, V176, P67, DOI 10.1530/EJE-16-0450; Olsson DS, 2015, J CLIN ENDOCR METAB, V100, P2651, DOI 10.1210/jc.2015-1475; Pappachan JM, 2015, J CLIN ENDOCR METAB, V100, P1405, DOI 10.1210/jc.2014-3787; Partanen T, 2016, CLIN ENDOCRINOL, V84, P85, DOI 10.1111/cen.12863; Patterson BC, 2014, J CLIN ENDOCR METAB, V99, P2030, DOI 10.1210/jc.2013-4159; Pekic S, 2005, ENDOCRINE, V26, P79, DOI 10.1385/ENDO:26:2:079; Pekic S, 2014, HAND CLINIC, V124, P271, DOI 10.1016/B978-0-444-59602-4.00018-6; Pekic S, 2010, LANCET, V375, P432, DOI 10.1016/S0140-6736(09)61835-3; Pekic S, 2008, ENDOCRINE, V34, P11, DOI 10.1007/s12020-008-9109-3; Pepene CE, 2010, PITUITARY, V13, P385, DOI 10.1007/s11102-008-0150-2; Phillips M, 2009, PEDIATR BLOOD CANCER, V52, P97, DOI 10.1002/pbc.21782; Rajagopala S, 2015, QJM-INT J MED, V108, P719, DOI 10.1093/qjmed/hcv011; Rajasekaran S, 2011, CLIN ENDOCRINOL, V74, P9, DOI 10.1111/j.1365-2265.2010.03913.x; Ramiandrasoa C, 2013, EUR J ENDOCRINOL, V169, P431, DOI 10.1530/EJE-13-0279; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Robba C, 2016, PITUITARY, V19, P522, DOI 10.1007/s11102-016-0733-2; Sanchez JE, 2000, REV NEUROLOGIA, V30, P939, DOI 10.33588/rn.3010.99409; Schaefer S, 2008, EUR J ENDOCRINOL, V158, P3, DOI 10.1530/EJE-07-0484; Shalet SM, 1997, J ROY SOC MED, V90, P192, DOI 10.1177/014107689709000404; Sharma MC, 2000, CLIN NEUROL NEUROSUR, V102, P72, DOI 10.1016/S0303-8467(00)00063-9; Spinner CD, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-481; Stojanovic M, 2008, J CLIN ENDOCR METAB, V93, P2722, DOI 10.1210/jc.2008-0311; Tanimoto K, 2015, INTERNAL MED, V54, P1247, DOI 10.2169/internalmedicine.54.3435; Tanriverdi F, 2014, ENDOCRINE, V47, P198, DOI 10.1007/s12020-013-0127-4; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; Tarabay A, 2016, J NEURO-ONCOL, V130, P383, DOI 10.1007/s11060-016-2249-z; Torino F, 2013, EUR J ENDOCRINOL, V169, pR153, DOI 10.1530/EJE-13-0434; Treip C S, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P178; Tsiakalos A, 2010, J CLIN ENDOCR METAB, V95, P3277, DOI 10.1210/jc.2010-0144; Vates GE, 2001, J NEUROSURG, V95, P233, DOI 10.3171/jns.2001.95.2.0233; Yamamoto M, 2011, J CLIN INVEST, V121, P113, DOI 10.1172/JCI44073; Young J, 2007, PRESSE MED, V36, P1319, DOI 10.1016/j.lpm.2007.01.041; Zhang X, 2002, J CLIN PATHOL, V55, P965, DOI 10.1136/jcp.55.12.965	85	26	29	0	7	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	JUN	2017	176	6					R269	R282		10.1530/EJE-16-1065			14	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	EW4OP	WOS:000402481100002	28258131	Bronze			2022-02-06	
J	Compas, BE; Jaser, SS; Reeslund, K; Patel, N; Yarboi, J				Compas, Bruce E.; Jaser, Sarah S.; Reeslund, Kristen; Patel, Niral; Yarboi, Janet			Neurocognitive Deficits in Children With Chronic Health Conditions	AMERICAN PSYCHOLOGIST			English	Article						children; adolescents; chronic health conditions; neurocognitive problems	LONG-TERM SURVIVORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD-CANCER SURVIVOR; CONGENITAL HEART-DISEASE; SICKLE-CELL-DISEASE; WHITE-MATTER VOLUME; ADULT SURVIVORS; EDUCATIONAL-IMPLICATIONS; COGNITIVE FUNCTION; EXECUTIVE FUNCTION	Over 4 million children in the United States suffer from chronic health conditions, including cancer, sickle cell disease, and diabetes. Because of major advances in the early identification and treatment of these conditions, survival rates for these children continue to rise, and the majority now lives into adulthood. However, increases in survival have come with costs related to long-term effects of disease processes and treatments. Foremost among these consequences is impairment in brain development and neurocognitive function that may affect a substantial portion of children with chronic health conditions and follow many into adulthood. Impaired cognitive function may contribute to impairment in educational and occupational attainment, mental health, and quality of life for children with chronic conditions. Despite the significance and scope of this problem, advances in the identification and understanding of neurocognitive problems and the delivery of effective clinical care have been hindered in part because research has been "siloed"-conducted on each chronic condition in isolation. This review examines, for the first time, neurocognitive problems in a selected set of 6 chronic pediatric health conditions-leukemia, brain tumors, sickle cell disease, congenital heart disease, Type 1 diabetes, and traumatic brain injury-to define the magnitude of the problem and identify directions for future research and clinical care. Psychologists from many areas of specialization, including pediatric psychology, educational and school psychology, neuropsychology, behavioral medicine, and adult primary care, are uniquely positioned to contribute to every phase of this work, including research, identification, and intervention.	[Compas, Bruce E.; Reeslund, Kristen; Yarboi, Janet] Vanderbilt Univ, Dept Psychol & Human Dev, Peabody 552, Nashville, TN 37203 USA; [Jaser, Sarah S.; Patel, Niral] Vanderbilt Univ, Dept Pediat, Nashville, TN USA		Compas, BE (corresponding author), Vanderbilt Univ, Dept Psychol & Human Dev, Peabody 552, Nashville, TN 37203 USA.	bruce.compas@vanderbilt.edu	Jaser, Sarah/J-7872-2019	Patel, Niral/0000-0001-9690-4255	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD075005]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA175840]; National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DP3DK097678]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH018921]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD075005] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA175840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH018921] Funding Source: NIH RePORTER	Preparation of this article was supported in part by grants from the National Institute of Child Health and Human Development (R21HD075005; Bruce E. Compas), the National Cancer Institute (R21CA175840; Bruce E. Compas), the National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK097678; Sarah S. Jaser), and a training grant from the National Institute of Mental Health (T32 MH018921).	Allman C, 2013, CHILD NEUROPSYCHOL, V19, P97, DOI 10.1080/09297049.2011.639756; Andreotti C, 2015, J CHILD NEUROL, V30, P1349, DOI 10.1177/0883073814563140; Annett RD, 2015, PEDIATR BLOOD CANCER, V62, pS460, DOI 10.1002/pbc.25749; [Anonymous], 2016, DIABETES CARE, V39, pS1, DOI 10.2337/dc16-S001; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Campbell LK, 2007, PEDIATR BLOOD CANCER, V49, P65, DOI 10.1002/pbc.20860; Carey ME, 2008, AM J NEURORADIOL, V29, P792, DOI 10.3174/ajnr.A0904; Centers for Disease Control and Prevention, 2014, NAT DIAB STAT REP ES; Centers for Disease Control and Prevention (CDC), 2015, CONG HEART DEF CHDS; Cheung YT, 2015, NEUROSCI BIOBEHAV R, V53, P108, DOI 10.1016/j.neubiorev.2015.03.016; Cohen J., 2013, STAT POWER ANAL BEHA; Conklin HM, 2015, J CLIN ONCOL, V33, P3894, DOI 10.1200/JCO.2015.61.6672; Conklin HM, 2010, J CLIN ONCOL, V28, P4465, DOI 10.1200/JCO.2010.28.4026; Cousino MK, 2013, J PEDIATR PSYCHOL, V38, P809, DOI 10.1093/jpepsy/jst049; Cox CL, 2016, J CANCER SURVIV, V10, P743, DOI 10.1007/s11764-016-0520-0; Deary IJ, 2012, ANNU REV PSYCHOL, V63, P453, DOI 10.1146/annurev-psych-120710-100353; Desrocher M, 2004, CHILD NEUROPSYCHOL, V10, P36, DOI 10.1076/chin.10.1.36.26241; Doan SN, 2011, DEV PSYCHOPATHOL, V23, P873, DOI 10.1017/S0954579411000368; Evans GW, 2009, P NATL ACAD SCI USA, V106, P6545, DOI 10.1073/pnas.0811910106; Fisher L, 2014, AM PSYCHOL, V69, P355, DOI 10.1037/a0036101; Graham T.P., 2010, CONGENITAL HEART DEF, P493; Gurney JG, 2009, J CLIN ONCOL, V27, P2390, DOI 10.1200/JCO.2008.21.1458; Halfon N, 2010, JAMA-J AM MED ASSOC, V303, P665, DOI 10.1001/jama.2010.130; Hanson JL, 2012, J NEUROSCI, V32, P7917, DOI 10.1523/JNEUROSCI.0307-12.2012; Hardy KK, 2013, PSYCHO-ONCOLOGY, V22, P1856, DOI 10.1002/pon.3222; Hood KK, 2014, J ADOLESCENT HEALTH, V55, P498, DOI 10.1016/j.jadohealth.2014.03.011; Kadan-Lottick NS, 2010, JNCI-J NATL CANCER I, V102, P881, DOI 10.1093/jnci/djq156; Kamdar KY, 2011, PEDIATR BLOOD CANCER, V57, P454, DOI 10.1002/pbc.23162; Karsdorp PA, 2007, J PEDIATR PSYCHOL, V32, P527, DOI 10.1093/jpepsy/jsl047; Kernan CL, 2012, EPILEPSIA, V53, P2156, DOI 10.1111/j.1528-1167.2012.03706.x; King AA, 2014, AM J HEMATOL, V89, P162, DOI 10.1002/ajh.23604; Kirchhoff AC, 2011, CANCER-AM CANCER SOC, V117, P3033, DOI 10.1002/cncr.25867; Kolb B., 2008, COGNITIVE NEUROREHAB, P6, DOI [10.1017/CBO9781316529898.003, DOI 10.1017/CBO9781316529898.003]; Koller K, 2004, ENVIRON HEALTH PERSP, V112, P987, DOI 10.1289/ehp.6941; Krull KR, 2013, J CLIN ONCOL, V31, P4407, DOI 10.1200/JCO.2012.48.2315; Krull KR, 2013, J CLIN ONCOL, V31, P2182, DOI 10.1200/JCO.2012.46.7944; Krull KR, 2012, J CLIN ONCOL, V30, P3618, DOI 10.1200/JCO.2012.42.6841; Kucera M, 2011, PSYCHOL SCHOOLS, V48, P587, DOI 10.1002/pits.20573; Kunin-Batson A, 2011, PEDIATR BLOOD CANCER, V57, P1197, DOI 10.1002/pbc.22982; Lane DA, 2002, HEART, V88, P71, DOI 10.1136/heart.88.1.71; Liu F, 2015, NEURO-ONCOLOGY, V17, P604, DOI 10.1093/neuonc/nou306; Marino BS, 2012, CIRCULATION, V126, P1143, DOI 10.1161/CIR.0b013e318265ee8a; Mazaika PK, 2016, DIABETES, V65, P476, DOI 10.2337/db15-1242; Ment LR, 2003, JAMA-J AM MED ASSOC, V289, P705, DOI 10.1001/jama.289.6.705; Morton PD, 2015, TRENDS NEUROSCI, V38, P353, DOI 10.1016/j.tins.2015.04.001; Naguib JM, 2009, J PEDIATR PSYCHOL, V34, P271, DOI 10.1093/jpepsy/jsn074; National Institute of Child Health and Human Development, 2014, EK SHRIV NAT I CHILD; Neville HJ, 2013, P NATL ACAD SCI USA, V110, P12138, DOI 10.1073/pnas.1304437110; Nisbett RE, 2012, AM PSYCHOL, V67, P130, DOI 10.1037/a0026699; Olson K, 2016, CHILD NEUROPSYCHOL, V22, P509, DOI 10.1080/09297049.2015.1049941; Pang JWY, 2008, PEDIATR BLOOD CANCER, V50, P104, DOI 10.1002/pbc.21226; Panigrahy A, 2015, NEUROIMAGE-CLIN, V7, P438, DOI 10.1016/j.nicl.2015.01.013; Pavone P, 2001, NEUROLOGY, V56, P1047, DOI 10.1212/WNL.56.8.1047; Perrin JM, 2007, JAMA-J AM MED ASSOC, V297, P2755, DOI 10.1001/jama.297.24.2755; Raver CC, 2013, DEV PSYCHOL, V49, P292, DOI 10.1037/a0028343; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Reddick WE, 2003, CANCER-AM CANCER SOC, V97, P2512, DOI 10.1002/cncr.11355; Riggs L, 2014, J INT NEUROPSYCH SOC, V20, P168, DOI 10.1017/S135561771300129X; Robinson KE, 2015, CHILD NEUROPSYCHOL, V21, P779, DOI 10.1080/09297049.2014.924492; Robinson KE, 2014, NEUROPSYCHOLOGY, V28, P791, DOI 10.1037/neu0000077; Robinson KE, 2010, PEDIATR BLOOD CANCER, V55, P525, DOI 10.1002/pbc.22568; Robinson KE, 2010, PEDIATR BLOOD CANCER, V54, P585, DOI 10.1002/pbc.22362; Robison LL, 2009, J CLIN ONCOL, V27, P2308, DOI 10.1200/JCO.2009.22.3339; Rosoff PM, 2006, NEW ENGL J MED, V355, P1522, DOI 10.1056/NEJMp068168; Schatz J, 2002, J PEDIATR PSYCHOL, V27, P739, DOI 10.1093/jpepsy/27.8.739; Sheehan VA, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.2716.2716; Simko LC, 2006, J CARDIOVASC NURS, V21, P85, DOI 10.1097/00005082-200603000-00003; Studer M, 2014, NEUROLOGY, V82, P784, DOI 10.1212/WNL.0000000000000162; Thies KM, 1999, J SCHOOL HEALTH, V69, P392, DOI 10.1111/j.1746-1561.1999.tb06354.x; Thigpen J. C., 2016, NEUROONCOLOGY PRACTI; U.S. Bureau of the Census, 2011, 2010 CENSUS BRIEFS; van der Lee JH, 2007, JAMA-J AM MED ASSOC, V297, P2741, DOI 10.1001/jama.297.24.2741; VONRHEIN M, 2011, THE JOURNAL OF PEDIA, V158, P984, DOI DOI 10.1016/J.JPEDS.2010.11.040; Wiener L, 2015, PEDIATR BLOOD CANCER, V62, pS419, DOI 10.1002/pbc.25675; Zagorsky JL, 2007, INTELLIGENCE, V35, P489, DOI 10.1016/j.intell.2007.02.003; Zebrack BJ, 2004, J CLIN ONCOL, V22, P999, DOI 10.1200/JCO.2004.06.148	77	26	26	1	17	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0003-066X	1935-990X		AM PSYCHOL	Am. Psychol.	MAY-JUN	2017	72	4					326	338		10.1037/amp0000042			13	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	EU1EO	WOS:000400756800002	28481580	Green Accepted, Bronze			2022-02-06	
J	Liu, ZW; Wang, HD; Shi, XF; Li, LW; Zhou, ML; Ding, H; Yang, YQ; Li, X; Ding, K				Liu, Zhengwei; Wang, Handong; Shi, Xiaofeng; Li, Liwen; Zhou, Mengliang; Ding, Hui; Yang, Youqing; Li, Xiang; Ding, Ke			DL-3-n-Butylphthalide (NBP) Provides Neuroprotection in the Mice Models After Traumatic Brain Injury via Nrf2-ARE Signaling Pathway	NEUROCHEMICAL RESEARCH			English	Article						DL-3-n-Butylphthalide; Neuroprotection; Traumatic brain injury; Nrf2-ARE signaling pathway; Mice model	FOCAL CEREBRAL-ISCHEMIA; CLOSED-HEAD INJURY; OXIDATIVE STRESS; CHIRAL 3-N-BUTYLPHTHALIDE; ANTIOXIDANT ENZYMES; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; UP-REGULATION; MOUSE MODEL; CELL-DEATH	The present study was aimed to evaluate the neuroprotective effects of NBP in the mice models of TBI, as well as the possible role of Nrf2-ARE pathways in the assumptive neuroprotection. In mice,a modified Marmarou's weight-drop model was employed to induce TBI. ICR mice were randomly assigned to four experimental groups: sham, TBI, TBI+vehicle(V) and TBI+NBP. NBP (100 mg/kg) was administered via an intraperitoneal (i.p.) injection at 1 h following TBI. The administration of NBP significantly ameliorated the effects of the brain injury, including neurological deficits, brain water content, and cortical neuronal apoptosis. Furthermore, the level of malondialdehyde and the activity of superoxide dismutase (SOD) paired with glutathione peroxidase (GPx) were restored in the NBP treatment group. NBP promoted the translocation of Nrf2 protein from the cytoplasm to the nucleus markedly, increased the expressions of Nrf2-ARE pathway-related downstream factors, including hemeoxygenase-1(HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1), and prevented the decline of antioxidant enzyme activities, including SOD and GPx. NBP enhanced the translocation of Nrf2 to the nucleus from the cytoplasm,verified by a western blot, immunofluorescence. Additionally, it upregulated the expression of the Nrf2 downstream factors such as HO-1 and NQO1 were also confirmed via a western blot and real-time quantitative polymerase chain reaction. In conclusion, NBP administration may increase the activities of antioxidant enzymes and attenuate brain injury in a TBI model, potentially via the mediation of the Nrf2-ARE pathway.	[Liu, Zhengwei; Wang, Handong; Ding, Hui; Yang, Youqing] Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China; [Liu, Zhengwei; Shi, Xiaofeng] Shenzhen Longgang Cent Hosp, Dept Neurosurg, 6082 Longgangdadao Rd, Shenzhen 518116, Guangdong, Peoples R China; [Li, Liwen; Zhou, Mengliang; Li, Xiang; Ding, Ke] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81571162]	This work was supported by Grants from the National Natural Science Foundation of China (No. 81371357) and National Natural Science Foundation of China (No. 81571162).	Chang Q, 2003, ACTA PHARMACOL SIN, V24, P796; Chong ZZ, 2000, CHINESE MED J-PEKING, V113, P613; Chong ZZ, 1999, ACTA PHARMACOL SIN, V20, P696; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Deng W, 1997, Chin Med Sci J, V12, P102; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Feng XH, 2012, NEUROPHARMACOLOGY, V62, P1004, DOI 10.1016/j.neuropharm.2011.10.009; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Huang JZ, 2010, NEUROSCI LETT, V475, P89, DOI 10.1016/j.neulet.2010.03.053; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Jin W, 2014, INFLAMM RES, V63, P381, DOI 10.1007/s00011-014-0710-z; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Li JM, 2010, BRAIN RES, V1359, P216, DOI 10.1016/j.brainres.2010.08.061; Li L, 2009, BRAIN RES, V1290, P91, DOI 10.1016/j.brainres.2009.07.020; Li LR, 2014, CHEM-BIOL INTERACT, V209, P56, DOI 10.1016/j.cbi.2013.12.005; Liang L, 2013, J AGR FOOD CHEM, V61, P2755, DOI 10.1021/jf304768p; Liu X. G., 1995, Yaoxue Xuebao, V30, P896; Peng Y, 2010, J NEUROSCI, V30, P8180, DOI 10.1523/JNEUROSCI.0340-10.2010; Sun B, 2012, NEUROSCI LETT, V516, P247, DOI 10.1016/j.neulet.2012.04.003; Vriend J, 2015, MOL CELL ENDOCRINOL, V401, P213, DOI 10.1016/j.mce.2014.12.013; Wang CY, 2016, NEUROBIOL AGING, V38, P32, DOI 10.1016/j.neurobiolaging.2015.10.024; Wang FX, 2016, SCI REP-UK, V6, DOI 10.1038/srep19396; Wang HC, 2016, WORLD NEUROSURG, V87, P463, DOI 10.1016/j.wneu.2015.10.010; Wang YG, 2014, ACTA PHYSIOL, V210, P524, DOI 10.1111/apha.12186; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Xiong NA, 2012, NEUROBIOL AGING, V33, P1777, DOI 10.1016/j.neurobiolaging.2011.03.007; Xu HL, 2000, ACTA PHARMACOL SIN, V21, P433; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan CH, 1998, ACTA PHARMACOL SIN, V19, P117; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhang LH, 2012, CURR NEUROVASC RES, V9, P167, DOI 10.2174/156720212801618956; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang T, 2014, NEUROSCIENCE, V263, P130, DOI 10.1016/j.neuroscience.2014.01.012; Zhang T, 2010, NEUROL RES, V32, P390, DOI 10.1179/016164110X12670144526264; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47	39	26	31	0	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	2017	42	5					1375	1386		10.1007/s11064-017-2186-z			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	ES9UD	WOS:000399906000011	28214984				2022-02-06	
J	McCrea, MA; Nelson, LD; Guskiewicz, K				McCrea, Michael A.; Nelson, Lindsay D.; Guskiewicz, Kevin			Diagnosis and Management of Acute Concussion	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Concussion; Mild traumatic brain injury; Acquired brain injury; Sports injuries	COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; EMERGENCY-DEPARTMENT; NCAA CONCUSSION; METAANALYSIS; STATEMENT; RECOVERY; REST	Over the past 2 decades, there have been major advances in the basic and clinical science of concussion and mild traumatic brain injury. These advances now provide a more evidence-informed approach to the definition, diagnosis, assessment, and management of acute concussion. Standardized clinical tools have been developed and validated for assessment of acute concussion across injury settings (eg, civilian, sport, military). Consensus guidelines now provide guidance regarding injury management and approaches to ensure safe return to activity after acute concussion. This article provides a brief, high-level overview of approaches to best practice in diagnosis, assessment, and management of acute concussion.	[McCrea, Michael A.; Nelson, Lindsay D.] Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Guskiewicz, Kevin] Univ North Carolina Chapel Hill, Coll Arts & Sci, Dept Exercise & Sport Sci, 2207 Stallings, Chapel Hill, NC 27599 USA		McCrea, MA (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mmccrea@mcw.edu					Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2014, REP C TRAUM BRAIN IN; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Furger R.E., 2016, CONCUSSION, V1; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	23	26	27	2	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2017	28	2					271	+		10.1016/j.pmr.2016.12.005			17	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	EU5AJ	WOS:000401043700007	28390513				2022-02-06	
J	Olson, EA; Cui, JL; Fukunaga, R; Nickerson, LD; Rauch, SL; Rosso, IM				Olson, Elizabeth A.; Cui, Jiaolong; Fukunaga, Rena; Nickerson, Lisa D.; Rauch, Scott L.; Rosso, Isabelle M.			Disruption of white matter structural integrity and connectivity in posttraumatic stress disorder: A TBSS and tractography study	DEPRESSION AND ANXIETY			English	Article						anterior cingulate cortex; diffusion tensor imaging; inferior longitudinal fasciculus; posttraumatic stress disorder; probabilistic tractography	TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE; HIPPOCAMPAL VOLUME; PTSD; ABNORMALITIES; VETERANS; EXPOSURE; CORTEX; ADULTS; NEUROCIRCUITRY	BackgroundMost studies of brain white matter (WM) in posttraumatic stress disorder (PTSD) have focused on combat trauma, and often were confounded by neurological and substance dependence comorbidity. This study used tract-based spatial statistics (TBSS) and probabilistic tractography to characterize WM microstructure in a mixed-sex community sample of PTSD patients exposed to diverse and multiple traumas, and in trauma-exposed normal comparison (TENC) subjects. MethodsTBSS compared diffusion measures between 20 adults with DSM-IV PTSD and 17 TENC, using a whole-brain voxel-wise approach. Probabilistic tractography using Freesurfer's TRACULA was employed to measure diffusion tensor imaging (DTI) metrics within anatomically defined pathways. DTI metrics were compared between groups and correlated with PTSD symptom severity and trauma load. ResultsControlling for age, sex, and motion, PTSD subjects had significantly reduced fractional anisotropy (FA) in a left frontal lobe cluster compared with TENC, at p < .05, family-wise error corrected. Tractography identified significant group differences in the inferior longitudinal fasciculus (ILF), including lower FA and higher radial diffusivity in PTSD compared with TENC. Within the PTSD group, FA values were not correlated with symptom severity or trauma load. Results remained significant after removing participants using psychotropic medication or those with comorbid major depression. ConclusionsPTSD patients had reduced WM integrity in left hemisphere frontal WM and temporal-occipital WM tracts, compared to trauma-exposed controls. Reduced frontal FA is consistent with compromised top-down attentional control and emotion regulation in PTSD, while reduced ILF FA may be related to sensory processing and gating abnormalities in this disorder.	[Olson, Elizabeth A.; Cui, Jiaolong; Fukunaga, Rena; Rauch, Scott L.; Rosso, Isabelle M.] McLean Hosp, Ctr Depress Anxiety & Stress Res, Belmont, MA 02478 USA; [Olson, Elizabeth A.; Fukunaga, Rena; Nickerson, Lisa D.; Rauch, Scott L.; Rosso, Isabelle M.] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Nickerson, Lisa D.] McLean Hosp, McLean Imaging Ctr, Belmont, MA 02478 USA		Rosso, IM (corresponding author), McLean Hosp, Anxiety & Traumat Stress Disorders Lab, Mailstop 334,115 Mill St, Belmont, MA 02478 USA.	irosso@hms.harvard.edu	Olson, Elizabeth/M-7981-2018; Rosso, Isabelle M/AAA-6166-2019	Olson, Elizabeth/0000-0003-4617-8050; Rosso, Isabelle/0000-0001-6988-3858	Dana Foundation; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5R01MH096987]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH096987] Funding Source: NIH RePORTER	Grant sponsor: Dana Foundation; Grant sponsor: National Institute of Mental Health (5R01MH096987).	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; Adenauer H, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-127; Admon R, 2013, HUM BRAIN MAPP, V34, P2808, DOI 10.1002/hbm.22100; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bierer LM, 2015, PSYCHONEUROENDOCRINO, V51, P567, DOI 10.1016/j.psyneuen.2014.11.007; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Bryant RA, 2008, J PSYCHIATR NEUROSCI, V33, P142; Catani C, 2009, EUR ARCH PSY CLIN N, V259, P340, DOI 10.1007/s00406-009-0006-4; Catani M, 2003, BRAIN, V126, P2093, DOI 10.1093/brain/awg203; Choi J, 2012, NEUROIMAGE, V59, P1071, DOI 10.1016/j.neuroimage.2011.09.033; Clark CR, 2009, CLIN EEG NEUROSCI, V40, P84, DOI 10.1177/155005940904000208; Corbo V, 2005, BIOL PSYCHIAT, V58, P119, DOI 10.1016/j.biopsych.2005.02.032; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI 10.1002/da.22044; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; De Bellis MD, 2015, DEV PSYCHOPATHOL, V27, P1555, DOI 10.1017/S0954579415000942; Durkee CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080952; Fani N, 2012, NEUROPSYCHOPHARMACOL, V37, P2740, DOI 10.1038/npp.2012.146; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Hakamata Y, 2007, NEUROSCI RES, V59, P383, DOI 10.1016/j.neures.2007.08.012; Helpman L, 2016, NEUROIMAGE-CLIN, V12, P715, DOI 10.1016/j.nicl.2016.10.007; Herringa R, 2012, PSYCHIAT RES-NEUROIM, V203, P139, DOI 10.1016/j.pscychresns.2012.02.005; Isaac L, 2015, BIOL PSYCHOL, V105, P20, DOI 10.1016/j.biopsycho.2014.12.011; Jovanovic T, 2010, AM J PSYCHIAT, V167, P648, DOI 10.1176/appi.ajp.2009.09071074; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kennis M, 2015, NEUROPSYCHOPHARMACOL, V40, P2434, DOI 10.1038/npp.2015.94; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kim MJ, 2005, NEUROREPORT, V16, P1049, DOI 10.1097/00001756-200507130-00004; Kim SJ, 2006, NEUROPSYCHOBIOLOGY, V54, P120, DOI 10.1159/000098262; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Li L, 2014, NEUROSCI BIOBEHAV R, V43, P163, DOI 10.1016/j.neubiorev.2014.04.003; Long ZL, 2013, J AFFECT DISORDERS, V150, P798, DOI 10.1016/j.jad.2013.03.004; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Mueller-Pfeiffer C, 2013, NEUROIMAGE-CLIN, V3, P531, DOI 10.1016/j.nicl.2013.08.009; Nardo D, 2010, J PSYCHIATR RES, V44, P477, DOI 10.1016/j.jpsychires.2009.10.014; Neylan TC, 1999, BIOL PSYCHIAT, V46, P1656, DOI 10.1016/S0006-3223(99)00047-5; O'Doherty DCM, 2015, PSYCHIAT RES-NEUROIM, V232, P1, DOI 10.1016/j.pscychresns.2015.01.002; Pineles SL, 2016, PSYCHOPHYSIOLOGY, V53, P1377, DOI 10.1111/psyp.12679; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Roine U, 2015, MOL AUTISM, V6, DOI 10.1186/2040-2392-6-4; Sanjuan PM, 2013, PSYCHIAT RES-NEUROIM, V214, P260, DOI 10.1016/j.pscychresns.2013.09.002; Sarica A, 2014, J NEUROSCI METH, V224, P79, DOI 10.1016/j.jneumeth.2013.12.014; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; SOLOMON SD, 1992, JAMA-J AM MED ASSOC, V268, P633, DOI 10.1001/jama.268.5.633; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sun YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083473; Thomaes K, 2010, J CLIN PSYCHIAT, V71, P1636, DOI 10.4088/JCP.08m04754blu; Woon FL, 2010, PROG NEURO-PSYCHOPH, V34, P1181, DOI 10.1016/j.pnpbp.2010.06.016; Yeatman JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049790; Yendiki A, 2014, NEUROIMAGE, V88, P79, DOI 10.1016/j.neuroimage.2013.11.027; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023; Zhang L, 2011, J AFFECT DISORDERS, V133, P294, DOI 10.1016/j.jad.2011.03.040	60	26	26	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269	1520-6394		DEPRESS ANXIETY	Depress. Anxiety	MAY	2017	34	5					437	445		10.1002/da.22615			9	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	ET5NJ	WOS:000400330100007	28294462	Green Accepted			2022-02-06	
J	Winkler, MKL; Dengler, N; Hecht, N; Hartings, JA; Kang, EJ; Major, S; Martus, P; Vajkoczy, P; Woitzik, J; Dreier, JP				Winkler, Maren K. L.; Dengler, Nora; Hecht, Nils; Hartings, Jed A.; Kang, Eun J.; Major, Sebastian; Martus, Peter; Vajkoczy, Peter; Woitzik, Johannes; Dreier, Jens P.			Oxygen availability and spreading depolarizations provide complementary prognostic information in neuromonitoring of aneurysmal subarachnoid hemorrhage patients	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Spreading depolarization; spreading depression; subarachnoid hemorrhage; vasospasm; stroke; oxygen availability	TRAUMATIC BRAIN-INJURY; HUMAN CEREBRAL-CORTEX; PERIINFARCT DEPOLARIZATIONS; ANOXIC DEPOLARIZATION; NEUROCRITICAL CARE; MALIGNANT STROKE; DEPRESSION; HYPEROXIA; ISCHEMIA; SLICES	Multimodal neuromonitoring in neurocritical care increasingly includes electrocorticography to measure epileptic events and spreading depolarizations. Spreading depolarization causes spreading depression of activity (=isoelectricity) in electrically active tissue. If the depression is long-lasting, further spreading depolarizations occur in still isoelectric tissue where no activity can be suppressed. Such spreading depolarizations are termed isoelectric and are assumed to indicate energy compromise. However, experimental and clinical recordings suggest that long-lasting spreading depolarization-induced depression and isoelectric spreading depolarizations are often recorded outside of the actual ischemic zones, allowing the remote diagnosis of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Here, we analyzed simultaneous electrocorticography and tissue partial pressure of oxygen recording in 33 aneurysmal subarachnoid hemorrhage patients. Multiple regression showed that both peak total depression duration per recording day and mean baseline tissue partial pressure of oxygen were independent predictors of outcome. Moreover, tissue partial pressure of oxygen preceding spreading depolarization was similar and differences in tissue partial pressure of oxygen responses to spreading depolarization were only subtle between isoelectric spreading depolarizations and spreading depressions. This further supports that, similar to clustering of spreading depolarizations, long spreading depolarization-induced periods of isoelectricity are useful to detect energy compromise remotely, which is valuable because the exact location of future developing pathology is unknown at the time when the neurosurgeon implants recording devices.	[Winkler, Maren K. L.; Kang, Eun J.; Major, Sebastian; Dreier, Jens P.] Charite, Ctr Stroke Res Berlin, Berlin, Germany; [Dengler, Nora; Hecht, Nils; Vajkoczy, Peter; Woitzik, Johannes] Charite, Dept Neurosurg, Berlin, Germany; [Hartings, Jed A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Kang, Eun J.; Major, Sebastian; Dreier, Jens P.] Charite, Dept Expt Neurol, Berlin, Germany; [Major, Sebastian; Dreier, Jens P.] Charite, Dept Neurol, Berlin, Germany; [Martus, Peter] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany		Dreier, JP (corresponding author), Charite, Ctr Stroke Res Berlin, Charite Campus Mitte, Charite Pl 1, D-10117 Berlin, Germany.	jens.dreier@charite.de	Major, Sebastian/I-1838-2019	Major, Sebastian/0000-0003-0970-1308; Dengler, Nora F./0000-0001-7783-8053; Woitzik, Johannes/0000-0002-1865-4606; Hartings, Jed/0000-0001-8583-3471	Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin)Federal Ministry of Education & Research (BMBF) [01 EO 0801, BCCN 01GQ1001C B2]; Era-Net Neuron [01EW1212]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG DR 323/5-1]	The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Supported by the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 0801; BCCN 01GQ1001C B2) and Era-Net Neuron 01EW1212 to Dr. Dreier and Deutsche Forschungsgemeinschaft (DFG DR 323/5-1) to Drs. Dreier, Martus, Woitzik and Vajkoczy.	AITKEN PG, 1988, NEUROSCI LETT, V89, P187, DOI 10.1016/0304-3940(88)90379-5; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Bruce DA, 2000, CHILD NERV SYST, V16, P724, DOI 10.1007/s003810000336; Carter RE, 2013, J NEUROCHEM, V125, P673, DOI 10.1111/jnc.12237; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Citerio G, 2015, CURR OPIN CRIT CARE, V21, P113, DOI 10.1097/MCC.0000000000000179; Claassen J, 2013, ANN NEUROL, V74, P53, DOI 10.1002/ana.23859; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Eross L, 2009, J NEUROSURG, V110, P327, DOI 10.3171/2008.6.JNS17611; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Hartings JA, 2006, J CEREBR BLOOD F MET, V26, P696, DOI 10.1038/sj.jcbfm.9600223; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Kager H, 2002, J NEUROPHYSIOL, V88, P2700, DOI 10.1152/jn.00237.2002; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Lindquist BE, 2012, NEUROSCIENCE, V223, P365, DOI 10.1016/j.neuroscience.2012.07.053; Muller M, 1998, BRAIN RES, V812, P1, DOI 10.1016/S0006-8993(98)00812-9; Narotam PK, 2014, J NEUROTRAUM, V31, P630, DOI 10.1089/neu.2013.3104; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2014, NEUROCRIT CARE, V21, P103, DOI 10.1007/s12028-014-0024-6; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; Park S, 2011, NEUROCRIT CARE, V15, P469, DOI 10.1007/s12028-011-9540-9; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Quintard H, 2015, NEUROCRIT CARE, V22, P243, DOI 10.1007/s12028-014-0062-0; Ramakrishna R, 2008, J NEUROSURG, V109, P1075, DOI 10.3171/JNS.2008.109.12.1075; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Sakowitz OW, 2013, STROKE, V44, P220, DOI 10.1161/STROKEAHA.112.672352; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Schatlo B, 2010, NEUROSURGERY, V67, P721, DOI 10.1227/01.NEU.0000378024.70848.8F; Seule M, 2015, NEUROCRIT CARE, V23, P108, DOI 10.1007/s12028-015-0111-3; Sjoberg F, 2013, J INTERN MED, V274, P505, DOI 10.1111/joim.12139; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; STOLTENBURGDIDI.G, 1987, STROKE MICROCIRCULAT, P471; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Vergouwen MDI, 2011, J CEREBR BLOOD F MET, V31, P1545, DOI 10.1038/jcbfm.2011.56; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Wolf Stefan, 2012, Acta Neurochir Suppl, V114, P161, DOI 10.1007/978-3-7091-0956-4_30	61	26	26	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2017	37	5					1841	1856		10.1177/0271678X16641424			16	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	ET8CG	WOS:000400525200021	27025768	Green Published			2022-02-06	
J	Vargas, BB; Shepard, M; Hentz, JG; Kutyreff, C; Hershey, LG; Starling, AJ				Vargas, Bert B.; Shepard, Morgan; Hentz, Joseph G.; Kutyreff, Cherisse; Hershey, L. George; Starling, Amaal J.			Feasibility and accuracy of teleconcussion for acute evaluation of suspected concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; DIAGNOSIS; NEUROLOGY	Objective: To assess the feasibility and accuracy of telemedical concussion evaluations (teleconcussion) for real-time athletic sideline assessment of concussion, as such assessment may address the gap in access some populations of athletes have to providers with expertise in concussion evaluation. Methods: A cohort of 11 consecutive male collegiate football players with suspected concussion was assessed using Standardized Assessment of Concussion (SAC), King-Devick test (K-D), and modified Balance Error Scoring System (mBESS). A remote neurologist assessed each athlete using a telemedicine robot with real-time, 2-way audiovisual capabilities, while a sideline provider performed a simultaneous face-to-face assessment. After the assessment, a remove-from-play (RFP) determination was made. The remote and the face-to-face providers were blinded to each other's examination findings and RFP decision until the end of the assessment. Results: The teleconcussion and face-to-face SAC were in agreement 100% of the time (6/6; 95% confidence interval [CI] 54%-100%). The mean (SD) difference between remote and sideline K-D times was 0.7 (1.4) seconds. Remote and sideline K-D times were within a 3-second difference 100% of the time (11/11; 95% CI 72%-100%). Remote and sideline mBESS scores were within 3 points 100% of the time (6/6; 95% CI 54%-100%). RFP decisions were in agreement 100% of the time (11/11; 95% CI 72%-100%). Conclusions: The aim of this study was to investigate the feasibility of teleconcussion for sideline concussion assessments. These data suggest a high level of agreement between remote and face-to-face providers with regard to examination findings and RFP determinations.	[Vargas, Bert B.] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Shepard, Morgan; Starling, Amaal J.] Mayo Clin Arizona, Dept Neurol, Scottsdale, AZ USA; [Hentz, Joseph G.] Mayo Clin Arizona, Dept Biostat, Scottsdale, AZ USA; [Kutyreff, Cherisse; Hershey, L. George] No Arizona Univ, Dept Sports Med, Flagstaff, AZ USA		Vargas, BB (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA.	bert.vargas@UTSouthwestern.edu			Mayo Clinic Center for Innovation	No governmental sponsorship or funding was used for this study. This study was funded by the Mayo Clinic Center for Innovation.	Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Goodell Roger, 2014, Neurosurgery, V75 Suppl 4, pS119, DOI 10.1227/NEU.0000000000000498; Grosch MC, 2015, PSYCHIAT RES, V225, P734, DOI 10.1016/j.psychres.2014.12.040; Kutcher JS, 2013, BRIT J SPORT MED, V47, P299, DOI 10.1136/bjsports-2013-092257; Mutgi SA, 2015, NEUROLOGY, V84, pE191, DOI 10.1212/WNL.0000000000001634; Ng EMW, 2013, BRAIN INJURY, V27, P548, DOI 10.3109/02699052.2013.766927; Snyder TD, 2015, NCES2015011 US DEP E; Vargas BB, 2012, TELEMED E-HEALTH, V18, P803, DOI 10.1089/tmj.2012.0118; Yurkiewicz IR, 2012, NEUROLOGY, V79, P1237, DOI 10.1212/WNL.0b013e31826aac33	10	26	26	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 18	2017	88	16					1580	1583		10.1212/WNL.0000000000003841			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ES1NF	WOS:000399293600017	28341642	Bronze			2022-02-06	
J	Hagos, FT; Daood, MJ; Ocque, JA; Nolin, TD; Bayir, H; Poloyac, SM; Kochanek, PM; Clark, RSB; Empey, PE				Hagos, Fanuel T.; Daood, Monica J.; Ocque, Jacob A.; Nolin, Thomas D.; Bayir, Hulya; Poloyac, Samuel M.; Kochanek, Patrick M.; Clark, Robert S. B.; Empey, Philip E.			Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine	XENOBIOTICA			English	Article						Antioxidant; inhibitor; n-acetylcysteine; organic anion tranporter; pharmacokinetics; probenecid; transporter	CEREBROSPINAL-FLUID; GLUTATHIONE; PHARMACOKINETICS; BARRIER; MECHANISM; BENZYLPENICILLIN; FEXOFENADINE; ELIMINATION; ZIDOVUDINE; CLEARANCE	1. N-acetylcysteine (NAC) is being investigated as an antioxidant for several conditions including traumatic brain injury, but the mechanism by which it crosses membrane barriers is unknown. We have attempted to understand how the transporter inhibitor, probenecid, affects NAC pharmacokinetics and to evaluate the interaction of NAC with transporters. 2. Juvenile Sprague-Dawley rats were administered NAC alone or in combination with probenecid intraperitoneally. Plasma and brain samples were collected serially and NAC concentrations were measured. Transporter studies were conducted with human embryonic kidney-293 cells that overexpress organic anion transporter (OAT)1 or OAT3 and with human multi-drug resistance-associatedprotein (MRP)1 or MRP4 membrane vesicles. 3. NAC area under the curve was increased in plasma (1.65-fold) and brain (2.41-fold) by probenecid. The apparent plasma clearance was decreased by 65%. Time- and concentration-dependent NAC uptake that was inhibitable by probenecid was observed with OAT1 and OAT3. No uptake of NAC was observed with MRP1 or MRP4. 4. Our results indicate for the first time that NAC is substrate for OAT1 and OAT3 and that probenecid increases NAC plasma and brain exposure in vivo. These data provide insight regarding how NAC crosses biological barriers and suggest a promising therapeutic strategy to increase NAC exposure.	[Hagos, Fanuel T.; Poloyac, Samuel M.] Univ Pittsburgh, Ctr Clin Pharmaceut Sci, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA USA; [Hagos, Fanuel T.; Daood, Monica J.; Ocque, Jacob A.; Nolin, Thomas D.; Poloyac, Samuel M.; Empey, Philip E.] Univ Pittsburgh, Ctr Clin Pharmaceut Sci, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA USA; [Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.] Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA USA		Empey, PE (corresponding author), Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 335 Sutherland Dr,Room 205, Pittsburgh, PA 15261 USA.	pempey@pitt.edu	Empey, Philip/L-9604-2019; Nolin, Thomas/AAB-7311-2020	Empey, Philip/0000-0001-7474-2339; Nolin, Thomas/0000-0003-4339-1382	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS069247, TR000146]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069247] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health NS069247 and TR000146. The authors have no conflicts of interest related to this study.	Atkuri KR, 2007, CURR OPIN PHARMACOL, V7, P355, DOI 10.1016/j.coph.2007.04.005; BORGSTROM L, 1986, EUR J CLIN PHARMACOL, V31, P217, DOI 10.1007/BF00606662; Cotgreave I A, 1997, Adv Pharmacol, V38, P205; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI [10.1517/14728220802517901, 10.1517/14728220802517901 ]; Donovan MD, 2015, J PHARM PHARMACOL, V67, P501, DOI 10.1111/jphp.12341; Erdman AR, 2006, AM J PHYSIOL-RENAL, V290, pF905, DOI 10.1152/ajprenal.00272.2005; Erickson MA, 2012, BRAIN BEHAV IMMUN, V26, P1085, DOI 10.1016/j.bbi.2012.07.003; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Giustarini D, 2012, BIOCHEM PHARMACOL, V84, P1522, DOI 10.1016/j.bcp.2012.09.010; Grandjean EM, 2000, CLIN THER, V22, P209, DOI 10.1016/S0149-2918(00)88479-9; Harada D, 2001, ANAL BIOCHEM, V290, P251, DOI 10.1006/abio.2000.4980; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; HURST GA, 1967, AM REV RESPIR DIS, V96, P962; Kalvass JC, 2013, CLIN PHARMACOL THER, V94, P80, DOI 10.1038/clpt.2013.34; Kikuchi R, 2003, J PHARMACOL EXP THER, V306, P51, DOI 10.1124/jpet.103.049197; Koh AS, 2002, MOL PHARMACOL, V62, P921, DOI 10.1124/mol.62.4.921; Kusuhara Hiroyuki, 2005, NeuroRx, V2, P73, DOI 10.1602/neurorx.2.1.73; LASKIN OL, 1982, ANTIMICROB AGENTS CH, V21, P804, DOI 10.1128/AAC.21.5.804; Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006; Maeda K, 2014, EUR J PHARM SCI, V59, P94, DOI 10.1016/j.ejps.2014.04.004; Margulies S, 2016, J NEUROTRAUM, V33, P101, DOI 10.1089/neu.2014.3855; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; Minematsu T, 2008, DRUG METAB DISPOS, V36, P1496, DOI 10.1124/dmd.107.019828; Neuwelt EA, 2001, CANCER RES, V61, P7868; Offen D, 2004, J NEUROCHEM, V89, P1241, DOI 10.1111/j.1471-4159.2004.02428.x; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; Pombrio JM, 2001, MOL PHARMACOL, V60, P1091, DOI 10.1124/mol.60.5.1091; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; Rushworth GF, 2014, PHARMACOL THERAPEUT, V141, P150, DOI 10.1016/j.pharmthera.2013.09.006; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; SAWCHUK RJ, 1990, PHARMACEUT RES, V7, P332, DOI 10.1023/A:1015854902915; Shimizu M, 2005, DRUG METAB DISPOS, V33, P1477, DOI 10.1124/dmd.105.004622; Tachikawa M, 2012, J NEUROCHEM, V123, P750, DOI 10.1111/jnc.12018; Tahara H, 2006, DRUG METAB DISPOS, V34, P743, DOI 10.1124/dmd.105.008375; Versantvoort CHM, 1995, INT J CANCER, V63, P855, DOI 10.1002/ijc.2910630617; WONG SL, 1993, J PHARMACOL EXP THER, V264, P899; Zhou J, 2015, J PHARM SCI-US, V104, P2619, DOI 10.1002/jps.24482	37	26	28	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0049-8254	1366-5928		XENOBIOTICA	Xenobiotica	APR	2017	47	4					346	353		10.1080/00498254.2016.1187777			8	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	EM5JK	WOS:000395347600009	27278858	Green Accepted			2022-02-06	
J	Kralik, SF; Yasrebi, M; Supakul, N; Lin, C; Netter, LG; Hicks, RA; Hibbard, RA; Ackerman, LL; Harris, ML; Ho, CY				Kralik, S. F.; Yasrebi, M.; Supakul, N.; Lin, C.; Netter, L. G.; Hicks, R. A.; Hibbard, R. A.; Ackerman, L. L.; Harris, M. L.; Ho, C. Y.			Diagnostic Performance of Ultrafast Brain MRI for Evaluation of Abusive Head Trauma	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLINICAL ARTICLE; CHILDREN; INJURY; HYDROCEPHALUS; INFANTS; QUICK; PREDICTION; CHILDHOOD; CT	BACKGROUND AND PURPOSE: MR imaging with sedation is commonly used to detect intracranial traumatic pathology in the pediatric population. Our purpose was to compare nonsedated ultrafast MR imaging, noncontrast head CT, and standard MR imaging for the detection of intracranial trauma in patients with potential abusive head trauma. MATERIALS AND METHODS: A prospective study was performed in 24 pediatric patients who were evaluated for potential abusive head trauma. All patients received noncontrast head CT, ultrafast brain MR imaging without sedation, and standard MR imaging with general anesthesia or an immobilizer, sequentially. Two pediatric neuroradiologists independently reviewed each technique blinded to other modalities for intracranial trauma. We performed interreader agreement and consensus interpretation for standard MR imaging as the criterion standard. Diagnostic accuracy was calculated for ultrafast MR imaging, noncontrast head CT, and combined ultrafast MR imaging and noncontrast head CT. RESULTS: Interreader agreement was moderate for ultrafast MR imaging (K = 0.42), substantial for noncontrast head CT (K = 0.63), and nearly perfect for standard MR imaging (K = 0.86). Forty-two percent of patients had discrepancies between ultrafast MR imaging and standard MR imaging, which included detection of subarachnoid hemorrhage and subdural hemorrhage. Sensitivity, specificity, and positive and negative predictive values were obtained for any traumatic pathology for each examination: ultrafast MR imaging (50%,100%,100%, 31%), noncontrast head CT (25%,100%,100%, 21%), and a combination of ultrafast MR imaging and noncontrast head CT (60%,100%,100%, 33%). Ultrafast MR imaging was more sensitive than noncontrast head CT for the detection of intraparenchymal hemorrhage (P =.03), and the combination of ultrafast MR imaging and noncontrast head CT was more sensitive than noncontrast head CT alone for intracranial trauma (P =.02). CONCLUSIONS: In abusive head trauma, ultrafast MR imaging, even combined with noncontrast head CT, demonstrated low sensitivity compared with standard MR imaging for intracranial traumatic pathology, which may limit its utility in this patient population.	[Kralik, S. F.; Yasrebi, M.; Supakul, N.; Lin, C.; Netter, L. G.; Ho, C. Y.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [Hicks, R. A.; Hibbard, R. A.] Indiana Univ Sch Med, Child Protect Program, Indianapolis, IN 46202 USA; [Ackerman, L. L.] Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Harris, M. L.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA		Ho, CY (corresponding author), Indiana Univ Sch Med, MRI Dept, 705 Riley Hosp Dr, Indianapolis, IN 46202 USA.	cyho@iupui.edu	Ho, Chang Yueh/Y-9228-2019	Ho, Chang Yueh/0000-0002-2358-1851; Supakul, Nucharin/0000-0002-9129-9639; Lin, Chen/0000-0002-6146-7347	SiemensSiemens AG; Department of Child Services; Criminaliustice Institute; Payment for Lectures including Service on Speakers Bureaus; Child First Indiana	Grants/Grants Pending: Siemens.* Ralph A. Hicks UNRELATED: Expert Testimony: University Pediatric Associates Inc,* Comments: Dr Hicks has testified as an expert witness in cases involving suspected child abuse/neglect. Roberta A. Hibbard UNRELATED: Expert Testimony: Department of Child Services, State of Indiana, Comments: child abuse consultation for attorneys and child protection services*; Grants/Grants Pending: Department of Child Services, Criminaliustice Institute*: Payment for Lectures including Service on Speakers Bureaus: Child First Indiana, Comments: child abuse interviewing; Royalties. Elsevier, Comments: child abuse chapter in dental text; Payment for Development of Educational Presentations: Indiana University School of Medicine, Comments: part of grants.* *Money paid to the institution.	Adamsbaum C, 2012, PEDIATR RADIOL, V42, P1298, DOI 10.1007/s00247-012-2434-y; Ashley WW, 2005, J NEUROSURG, V103, P124, DOI 10.3171/ped.2005.103.2.0124; Ba-Ssalamah A, 2000, MAGN RESON IMAGING, V18, P237, DOI 10.1016/S0730-725X(99)00140-X; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Bradford R, 2013, J NEUROSURG-PEDIATR, V12, P110, DOI 10.3171/2013.4.PEDS12596; Chevignard MP, 2014, PEDIATR RADIOL, V44, P548, DOI 10.1007/s00247-014-3169-8; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Forbes KP, 2003, AM J NEURORADIOL, V24, P796; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Ginde AA, 2008, ACAD EMERG MED, V15, P780, DOI 10.1111/j.1553-2712.2008.00192.x; Goske MJ, 2008, AM J ROENTGENOL, V190, P273, DOI 10.2214/AJR.07.3526; Griffiths PD, 2000, ACTA RADIOL, V41, P401, DOI 10.1034/j.1600-0455.2000.041005401.x; Hedlund GL, 2009, FORENSIC SCI MED PAT, V5, P280, DOI 10.1007/s12024-009-9132-6; Hedlund GL, 2012, J AM OSTEOPATH COLL, V1, P23; Iskandar BJ, 2004, J NEUROSURG, V101, P147, DOI 10.3171/ped.2004.101.2.0147; Jaspan T, 2003, CLIN RADIOL, V58, P44, DOI 10.1053/crad.2002.1094; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kemp AM, 2011, ARCH DIS CHILD, V96, P1103, DOI 10.1136/archdischild-2011-300630; Mehta H, 2016, AM J NEURORADIOL, V37, P11, DOI 10.3174/ajnr.A4464; Miller JH, 2010, AM J NEURORADIOL, V31, P430, DOI 10.3174/ajnr.A1866; Missios S, 2008, J NEUROS-PEDIATR, V2, P438, DOI 10.3171/PED.2008.2.12.438; Niederkrotenthaler T, 2013, CHILD ABUSE NEGLECT, V37, P446, DOI 10.1016/j.chiabu.2013.02.002; Patel DM, 2014, J NEUROSURG-PEDIATR, V13, P440, DOI 10.3171/2014.1.PEDS13447; Penzkofer AK, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.2.1790509; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rozovsky K, 2013, J CLIN NEUROSCI, V20, P400, DOI 10.1016/j.jocn.2012.02.048; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sieswerda-Hoogendoorn T, 2012, EUR J PEDIATR, V171, P617, DOI 10.1007/s00431-011-1611-6; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Singh RK, 2003, ACTA RADIOL, V44, P550, DOI 10.1034/j.1600-0455.2003.00118.x; Tanoue K, 2013, ACTA PAEDIATR, V102, P805, DOI 10.1111/apa.12281; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Vazquez E, 2014, PEDIATR RADIOL, V44, P589, DOI 10.1007/s00247-014-3216-5; Yu CK, 2013, F1000RESEARCH, V2, P166, DOI DOI 10.12688/F1000RESEARCH.2-166.V1; Zimmerman RA, 2007, J NEURORADIOLOGY, V34, P109, DOI 10.1016/j.neurad.2007.01.124	39	26	26	0	6	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2017	38	4					807	813		10.3174/ajnr.A5093			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EQ9UD	WOS:000398429800024	28183837	Green Submitted, hybrid, Green Published			2022-02-06	
J	Wofford, KL; Harris, JP; Browne, KD; Brown, DP; Grovola, MR; Mietus, CJ; Wolf, JA; Duda, JE; Putt, ME; Spiller, KL; Cullen, DK				Wofford, Kathryn L.; Harris, James P.; Browne, Kevin D.; Brown, Daniel P.; Grovola, Michael R.; Mietus, Constance J.; Wolf, John A.; Duda, John E.; Putt, Mary E.; Spiller, Kara L.; Cullen, D. Kacy			Rapid neuroinflammatory response localized to injured neurons after diffuse traumatic brain injury in swine	EXPERIMENTAL NEUROLOGY			English	Article						Neuroinflammation; Microglia reactivity; Diffuse traumatic brain injury; Permeabilized neurons; Concussion	AXONAL INJURY; MICROGLIAL RESPONSE; HEAD-INJURY; IN-VIVO; DAMAGE; PERMEABILITY; IMPACT; MICE; DEGENERATION; INFLAMMATION	Despite increasing appreciation of the critical role that neuroinflammatory pathways play in brain injury and neurodegeneration, little is known about acute microglial reactivity following diffuse traumatic brain injury (TBI) - the most common clinical presentation that includes all concussions. Therefore, we investigated acute microglial reactivity using a porcine model of closed-head rotational velocity/acceleration-induced TBI that closely mimics the biomechanical etiology of inertial TBI in humans. We observed rapid microglial reactivity within 15 min of both mild and severe TBI. Strikingly, microglial activation was restrained to regions proximal to individual injured neurons - as denoted by trauma-induced plasma membrane disruption - which served as epicenters of acute reactivity. Single-cell quantitative analysis showed that in areas free of traumatically permeabilized neurons, microglial density and morphology were similar between sham or following mild or severe TBI. However, microglia density increased and morphology shifted to become more reactive in proximity to injured neurons. Microglial reactivity around injured neurons was exacerbated following repetitive TBI, suggesting further amplification of acute neuroinflammatory responses. These results indicate that neuronal trauma rapidly activates microglia in a highly localized manner, and suggest that activated microglia may rapidly influence neuronal stability and/or pathophysiology after diffuse TBI. (C) 2017 Elsevier Inc. All rights reserved.	[Wofford, Kathryn L.; Harris, James P.; Browne, Kevin D.; Brown, Daniel P.; Grovola, Michael R.; Wolf, John A.; Duda, John E.; Cullen, D. Kacy] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Neurotrauma Neurodegenerat & Restorat, 3900 Woodland Ave, Philadelphia, PA 19104 USA; [Wofford, Kathryn L.; Spiller, Kara L.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA; [Wofford, Kathryn L.; Harris, James P.; Browne, Kevin D.; Brown, Daniel P.; Grovola, Michael R.; Mietus, Constance J.; Wolf, John A.; Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA; [Duda, John E.] Univ Penn, Dept Neurol, 300 Dulles Bldg,3400 Spruce St, Philadelphia, PA 19104 USA; [Putt, Mary E.] Hosp Univ Penn, Dept Biostat & Epidemiol, 621 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA		Cullen, DK (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	kate.wofford@drexel.edu; jph18@case.edu; kbrowne@mail.med.upenn.edu; dbrow@mail.med.upenn.edu; mgrovola@mail.med.upenn.edu; mietusc@gmail.com; wolfjo@upenn.edu; john.duda@va.gov; mputt@mail.med.upenn.edu; kls35@drexel.edu; dkacy@mail.med.upenn.edu	Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303; Wofford, Kathryn/0000-0002-0391-2641; Grovola, Michael/0000-0003-4125-9329; Harris, James/0000-0002-8458-5434	Department of Veterans Affairs(RR&D Merit Review and RR&D Career Development Award) [B1097-I, 1K2-RX001479]; National Institutes of Health(NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32-NS043126, U54-HD086984]; Penn's University Research Foundation [02202014]; National Science Foundation STEM GK-12 program "Catalyzing STEM Education via the NAE Engineering Grand Challenges" through Drexel University [DGE-0947936]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54-HD086984]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD086984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2RX001479, I01RX001097] Funding Source: NIH RePORTER	The authors thank Dr. Victoria Johnson and Carolyn Keating for their technical assistance and guidance. This work was made possible through financial support provided by the Department of Veterans Affairs (RR&D Merit Review #B1097-I and RR&D Career Development Award #1K2-RX001479), the National Institutes of Health (NINDS T32-NS043126; NICHD U54-HD086984), and Penn's University Research Foundation (#02202014). KL. Wofford was supported by a fellowship from the National Science Foundation STEM GK-12 program "Catalyzing STEM Education via the NAE Engineering Grand Challenges", grant #DGE-0947936 through Drexel University. None of the funding sources aided in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. The authors have no conflicts of interest related to this work to disclose.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Clark J. Derrell, 1997, ILAR J, V38, P41; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cullen DK, 2016, METHODS MOL BIOL, V1462, P289, DOI 10.1007/978-1-4939-3816-2_17; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Faul M, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Fitzmaurice G.M., 2004, APPL LONGITUDINAL AN, Ved; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Harris J. P., 2015, J NEUROTRAUMA C P, V32; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hovens IB., 2014, NEUROIMMUNOL NEUROIN, V1, P82; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 2009, IEEE ENG MED BIO, P1113, DOI 10.1109/IEMBS.2009.5334457; Lee M, 2013, CURR PROTEIN PEPT SC, V14, P21, DOI 10.2174/1389203711314010005; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Meaney D. F., 1995, J NEUROTRAUMA, V12; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; R Development Core Team, 2016, R LANG ENV STAT COMP; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shankaran M, 2007, J NEUROSCI RES, V85, P2374, DOI 10.1002/jnr.21389; Simon CM, 2009, J NEUROTRAUM, V26, P563, DOI 10.1089/neu.2008.0523; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Wolf JA, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00043	49	26	27	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2017	290						85	94		10.1016/j.expneurol.2017.01.004			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EM5QR	WOS:000395368000008	28081963	Green Accepted, Bronze			2022-02-06	
J	Fernandez-Calle, R; Vicente-Rodriguez, M; Gramage, E; Pita, J; Perez-Garcia, C; Ferrer-Alcon, M; Uribarri, M; Ramos, MP; Herradon, G				Fernandez-Calle, Rosalia; Vicente-Rodriguez, Marta; Gramage, Esther; Pita, Jimena; Perez-Garcia, Carmen; Ferrer-Alcon, Marcel; Uribarri, Maria; Ramos, Maia P.; Herradon, Gonzalo			Pleiotrophin regulates microglia-mediated neuroinflammation	JOURNAL OF NEUROINFLAMMATION			English	Article						Microgliosis; Microglia activation; Midkine; Neuroimmune response; Neuroinflammation; Pleiotrophin; TLR4	TOLL-LIKE RECEPTORS; STRIATAL DOPAMINERGIC DENERVATION; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; PARKINSONS-DISEASE; SIGNALING PATHWAY; MIDKINE; OVEREXPRESSION; NEUROTOXICITY; INACTIVATION	Background: Pleiotrophin (PTN) is a cytokine found highly upregulated in the brain in different disorders characterized by overt neuroinflammation such as neurodegenerative diseases, drug addiction, traumatic injury, and ischemia. In the present work, we have explored whether PTN modulates neuroinflammation and if Toll-like receptor 4 (TLR4), crucial in the initiation of an immune response, is involved. Methods: In immunohistochemistry assays, we studied lipopolysaccharide (LPS, 7.5 mg/kg i.p.)-induced changes in glial fibrillary acidic protein (GFAP, astrocyte marker) and ionized calcium-binding adaptor molecule 1 (Iba1, microglia marker) expression in the prefrontal cortex (PFC) and striatum of mice with transgenic PTN overexpression in the brain (PTN-Tg) and in wild-type (WT) mice. Cytokine protein levels were assessed in the PFC by X-MAP technology. The influence of TLR4 signaling in LPS effects in both genotypes was assessed by pretreatment with the TLR4 antagonist (TAK-242, 3.0 mg/kg i.p.). Murine BV2 microglial cells were treated with PTN (0.5 mu g/ml) and LPS (1.0 mu g/ml) and assessed for the release of nitric oxide (NO). Results: We found that LPS-induced microglial activation is significantly increased in the PFC of PTN-Tg mice compared to that of WT mice. The levels of TNF-alpha, IL-6, and MCP-1 in response to LPS were significantly increased in the PFC of PTN-Tg mice compared to that of WT mice. Pretreatment with TAK-242 efficiently blocked increases in cytokine contents in a similar manner in both genotypes. Concomitant incubation of BV2 cells with LPS and PTN significantly potentiated the production of NO compared to cells only treated with LPS. Conclusions: Our findings identify for the first time that PTN is a novel and potent regulator of neuroinflammation. Pleiotrophin potentiates LPS-stimulated microglia activation. Our results suggest that regulation of the PTN signaling pathways may constitute new therapeutic opportunities particularly in those neurological disorders characterized by increased PTN cerebral levels and neuroinflammation.	[Fernandez-Calle, Rosalia; Vicente-Rodriguez, Marta; Gramage, Esther; Perez-Garcia, Carmen; Herradon, Gonzalo] Univ CEU San Pablo, Fac Farm, Dept Pharmaceut & Hlth Sci, Pharmacol Lab, Urb Monteprincipe, Madrid 28668, Spain; [Pita, Jimena; Uribarri, Maria] Univ CEU San Pablo, Fac Farm, Dept Chem & Biochem, Biochem & Mol Biol Lab, Madrid, Spain; [Ferrer-Alcon, Marcel; Uribarri, Maria] SL, BRAINco Biopharma, Bizkaia Technology Pk, Vizcaya, Spain		Herradon, G (corresponding author), Univ CEU San Pablo, Fac Farm, Dept Pharmaceut & Hlth Sci, Pharmacol Lab, Urb Monteprincipe, Madrid 28668, Spain.	herradon@ceu.es	Perez-Garcia, Carmen/K-2377-2014; Herradon, Gonzalo/C-8305-2012; Ramos-Alvarez, M.Pilar/B-6359-2011; Fernandez Calle, Rosalia/ABG-1620-2021; Rodriguez, Marta Vicente/K-2354-2014; Gramage, Esther/K-6441-2014	Perez-Garcia, Carmen/0000-0003-4441-0071; Herradon, Gonzalo/0000-0002-1578-3744; Ramos-Alvarez, M.Pilar/0000-0002-7727-7783; Gramage, Esther/0000-0002-5134-1273; Vicente-Rodriguez, Marta/0000-0002-4426-5161	Ministerio de Economia y Competitividad of SpainSpanish Government [SAF2014-56671-R]; National Plan on Drug abuse, Ministerio de Sanidad of Spain [PNSD001I2015]; Universidad CEU San Pablo and Banco de Santander [USP-BS-APP03/2014]	SAF2014-56671-R (Ministerio de Economia y Competitividad of Spain), PNSD001I2015 (National Plan on Drug abuse, Ministerio de Sanidad of Spain), and USP-BS-APP03/2014 (Universidad CEU San Pablo and Banco de Santander).	Achour A, 2008, BIOCHIMIE, V90, P1791, DOI 10.1016/j.biochi.2008.04.010; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Akira S, 2004, CR BIOL, V327, P581, DOI 10.1016/j.crvi.2004.04.002; Alguacil Luis F, 2015, Recent Pat CNS Drug Discov, V10, P28; Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233; Asari A, 2010, J BIOL CHEM, V285, P24751, DOI 10.1074/jbc.M110.104950; Barbierato M, 2013, CNS NEUROL DISORD-DR, V12, P608; Caroni P, 1997, J NEUROSCI METH, V71, P3, DOI 10.1016/S0165-0270(96)00121-5; Cheng ZQ, 2016, JOURNAL PRACT, V10, P744, DOI [10.1111/jnc.13062, 10.1080/17512786.2015.1063079]; Clark KH, 2013, NEUROTOX RES, V23, P174, DOI 10.1007/s12640-012-9334-7; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Curtin K, 2015, DRUG ALCOHOL DEPEN, V146, P30, DOI 10.1016/j.drugalcdep.2014.10.027; Ezquerra L, 2008, GROWTH FACTORS, V26, P44, DOI 10.1080/08977190801987711; Ferrer-Alcon M, 2012, NEW NONCLASSICAL TRA; Frey D, 2015, NEUROPEDIATRICS, V46, P321, DOI 10.1055/s-0035-1562924; Gramage E, 2011, NEUROSCIENCE, V190, P307, DOI 10.1016/j.neuroscience.2011.06.014; Gramage E, 2010, NEUROSCIENCE, V170, P308, DOI 10.1016/j.neuroscience.2010.06.078; Gramage E, 2011, CURR PHARM DESIGN, V17, P449, DOI 10.2174/138161211795164103; Gramage E, 2010, ADDICT BIOL, V15, P403, DOI 10.1111/j.1369-1600.2009.00202.x; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Herradon G, 2014, BRIT J PHARMACOL, V171, P837, DOI 10.1111/bph.12312; Herradon G, 2009, MINI-REV MED CHEM, V9, P440, DOI 10.2174/138955709787847895; Hida H, 2003, EUR J NEUROSCI, V17, P2127, DOI 10.1046/j.1460-9568.2003.02661.x; Himburg HA, 2010, NAT MED, V16, P475, DOI 10.1038/nm.2119; Hwang Onyou, 2013, Exp Neurobiol, V22, P11, DOI 10.5607/en.2013.22.1.11; Lastres-Becker I, 2016, ANTIOXID REDOX SIGN, V25, P61, DOI 10.1089/ars.2015.6549; Le Greves P, 2005, BRAIN RES BULL, V65, P529, DOI 10.1016/j.brainresbull.2005.03.010; Luo XL, 2016, EUR J PHARMACOL, V774, P135, DOI 10.1016/j.ejphar.2016.02.013; MAILLEUX P, 1994, NEUROSCI LETT, V175, P25, DOI 10.1016/0304-3940(94)91069-3; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Marchionini DM, 2007, BRAIN RES, V1147, P77, DOI 10.1016/j.brainres.2007.02.028; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Miao JY, 2012, NEUROSCI RES, V74, P269, DOI 10.1016/j.neures.2012.09.001; Moratalla R, 2015, PROG NEUROBIOL, DOI [10.1016/j.pneurobio.2015.09.011, DOI 10.1016/J.PNEUROBIO.2015.09.011.]; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Nimmo Alan J, 2009, Recent Pat CNS Drug Discov, V4, P86; O'Neill LA, 2003, CURR OPIN PHARMACOL, V3, P396, DOI 10.1016/S1471-4892(03)00080-8; Panicker N, 2015, J NEUROSCI, V35, P10058, DOI 10.1523/JNEUROSCI.0302-15.2015; Pariser H, 2005, BIOCHEM BIOPH RES CO, V332, P664, DOI 10.1016/j.bbrc.2005.05.007; Peria FM, 2007, J NEURO-ONCOL, V84, P255, DOI 10.1007/s11060-007-9379-2; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Silva AP, 2003, CURR DRUG ABUSE REV, V3, P239; Silver K, 2012, GROWTH FACTORS, V30, P258, DOI 10.3109/08977194.2012.693920; Torika N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155823; Vicente-Rodriguez M, 2016, EUR NEUROPSYCHOPHARM, V26, P1794, DOI 10.1016/j.euroneuro.2016.09.002; Vicente-Rodriguez M, 2015, CHEM RES TOXICOL, V28, P1443, DOI 10.1021/acs.chemrestox.5b00130; Vicente-Rodriguez M, 2014, J NEUROCHEM, V131, P688, DOI 10.1111/jnc.12841; Vicente-Rodriguez M, 2014, BEHAV BRAIN RES, V274, P258, DOI 10.1016/j.bbr.2014.08.023; Wisniewski T, 1996, NEUROREPORT, V7, P667, DOI 10.1097/00001756-199601310-00068	49	26	26	1	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 4	2017	14								46	10.1186/s12974-017-0823-8			10	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	EP1NI	WOS:000397151200001	28259175	Green Published, gold			2022-02-06	
J	Kaushal, M; Oni-Orisan, A; Chen, G; Li, WJ; Leschke, J; Ward, BD; Kalinosky, B; Budde, MD; Schmit, BD; Li, SJ; Muqeet, V; Kurpad, SN				Kaushal, Mayank; Oni-Orisan, Akinwunmi; Chen, Gang; Li, Wenjun; Leschke, Jack; Ward, B. Douglas; Kalinosky, Benjamin; Budde, Matthew D.; Schmit, Brian D.; Li, Shi-Jiang; Muqeet, Vaishnavi; Kurpad, Shekar N.			Evaluation of Whole-Brain Resting-State Functional Connectivity in Spinal Cord Injury: A Large-Scale Network Analysis Using Network-Based Statistic	JOURNAL OF NEUROTRAUMA			English	Article						neural injury; neuroplasticity; traumatic SCI	REORGANIZATION; MRI; CORTEX; RECOVERY; MONKEYS; STROKE; PAIN	Large-scale network analysis characterizes the brain as a complex network of nodes and edges to evaluate functional connectivity patterns. The utility of graph-based techniques has been demonstrated in an increasing number of restingstate functional MRI (rs-fMRI) studies in the normal and diseased brain. However, to our knowledge, graph theory has not been used to study the reorganization pattern of resting-state brain networks in patients with traumatic complete spinal cord injury (SCI). In the present analysis, we applied a graph-theoretical approach to explore changes to global brain network architecture as a result of SCI. Fifteen subjects with chronic (> 2 years) complete (American Spinal Injury Association [ASIA] A) cervical SCI and 15 neurologically intact controls were scanned using rs-fMRI. The data were preprocessed followed by parcellation of the brain into 116 regions of interest (ROI) or nodes. The average time series was extracted at each node, and correlation analysis was performed between every pair of nodes. A functional connectivity matrix for each subject was then generated. Subsequently, the matrices were averaged across groups, and network changes were evaluated between groups using the network-based statistic (NBS) method. Our results showed decreased connectivity in a subnetwork of the whole brain in SCI compared with control subjects. Upon further examination, increased connectivity was observed in a subnetwork of the sensorimotor cortex and cerebellum network in SCI. In conclusion, our findings emphasize the applicability of NBS to study functional connectivity architecture in diseased brain states. Further, we show reorganization of large-scale resting-state brain networks in traumatic SCI, with potential prognostic and therapeutic implications.	[Kaushal, Mayank; Kalinosky, Benjamin; Schmit, Brian D.] Marquette Univ, Dept Biomed Engn, Milwaukee, WI 53233 USA; [Oni-Orisan, Akinwunmi; Kurpad, Shekar N.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Chen, Gang; Li, Wenjun; Ward, B. Douglas; Budde, Matthew D.; Li, Shi-Jiang] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; [Leschke, Jack] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Muqeet, Vaishnavi] Clement J Zablocki Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Milwaukee, WI USA		Kaushal, M (corresponding author), Marquette Univ, Dept Biomed Engn, Milwaukee, WI 53233 USA.; Oni-Orisan, A (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.	mayank.kaushal@marquette.edu	Li, Shi-Jiang/M-2534-2017; Kaushal, Mayank/AAK-7667-2020; Kurpad, Shekar/V-2188-2019	Kaushal, Mayank/0000-0002-4121-6751; 	Marquette University; Bryon Riesch Paralysis Foundation; Falk Foundation	The authors thank Moriah Iverson, MS, and Judeen Richlen, RN, (research coordination); Dana Seslija, MD, MS, William Waring, MD, and Merle Orr, MD, (patient recruitment support); and Yu Liu, MS (MRI technical support). This study was funded by the Research Administration Committee of the Department of Physical Medicine and Rehabilitation at the Medical College of Wisconsin, Marquette University; Bryon Riesch Paralysis Foundation; and The Falk Foundation.	BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Carter AR, 2010, ANN NEUROL, V67, P365, DOI 10.1002/ana.21905; Castellanos NP, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00090; Chen GY, 2011, BRAIN CONNECT, V1, P195, DOI 10.1089/brain.2011.0025; Choe AS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00290; Cox RW, 1999, MAGNET RESON MED, V42, P1014, DOI 10.1002/(SICI)1522-2594(199912)42:6<1014::AID-MRM4>3.0.CO;2-F; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Hou JM, 2014, NEUROSCIENCE, V277, P446, DOI 10.1016/j.neuroscience.2014.07.045; Liu YO, 2011, J NEUROL SCI, V304, P127, DOI 10.1016/j.jns.2011.01.023; Min YS, 2015, J NEUROTRAUM, V32, P1422, DOI 10.1089/neu.2014.3661; Min YS, 2015, ANN REHABIL MED-ARM, V39, P374, DOI 10.5535/arm.2015.39.3.374; Nardone R, 2013, BRAIN RES, V1504, P58, DOI 10.1016/j.brainres.2012.12.034; Oni-Orisan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150351; Park CH, 2011, STROKE, V42, P1357, DOI 10.1161/STROKEAHA.110.596155; Rao JS, 2016, ACTA PHYSIOL, V217, P164, DOI 10.1111/apha.12645; Rao JS, 2015, MAGN RESON IMAGING, V33, P1156, DOI 10.1016/j.mri.2015.06.011; Rao JS, 2014, MAGN RESON IMAGING, V32, P482, DOI 10.1016/j.mri.2014.02.001; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Seminowicz DA, 2012, J NEUROSCI, V32, P15843, DOI 10.1523/JNEUROSCI.2927-12.2012; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wrigley PJ, 2009, PAIN, V141, P52, DOI 10.1016/j.pain.2008.10.007; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	24	26	29	2	28	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2017	34	6					1278	1282		10.1089/neu.2016.4649			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EN7ZR	WOS:000396221200015	27937140	Green Published			2022-02-06	
J	Abdallah, CG; Wrocklage, KM; Averill, CL; Akiki, T; Schweinsburg, B; Roy, A; Martini, B; Southwick, SM; Krystal, JH; Scott, JC				Abdallah, C. G.; Wrocklage, K. M.; Averill, C. L.; Akiki, T.; Schweinsburg, B.; Roy, A.; Martini, B.; Southwick, S. M.; Krystal, J. H.; Scott, J. C.			Anterior hippocampal dysconnectivity in posttraumatic stress disorder: a dimensional and multimodal approach	TRANSLATIONAL PSYCHIATRY			English	Article							ADMINISTERED PTSD SCALE; FUNCTIONAL CONNECTIVITY; BRAIN NETWORKS; PREFRONTAL CORTEX; SCHIZOPHRENIA; MODEL; NEUROBIOLOGY; METAANALYSIS; KETAMINE; ANXIETY	The anterior hippocampus (aHPC) has a central role in the regulation of anxiety-related behavior, stress response, emotional memory and fear. However, little is known about the presence and extent of aHPC abnormalities in posttraumatic stress disorder (PTSD). In this study, we used a multimodal approach, along with graph-based measures of global brain connectivity (GBC) termed functional GBC with global signal regression (f-GBCr) and diffusion GBC (d-GBC), in combat-exposed US Veterans with and without PTSD. Seed-based aHPC anatomical connectivity analyses were also performed. A whole-brain voxel-wise data-driven investigation revealed a significant association between elevated PTSD symptoms and reduced medial temporal f-GBCr, particularly in the aHPC. Similarly, aHPC d-GBC negatively correlated with PTSD severity. Both functional and anatomical aHPC dysconnectivity measures remained significant after controlling for hippocampal volume, age, gender, intelligence, education, combat severity, depression, anxiety, medication status, traumatic brain injury and alcohol/substance comorbidities. Depression-like PTSD dimensions were associated with reduced connectivity in the ventromedial and dorsolateral prefrontal cortex. In contrast, hyperarousal symptoms were positively correlated with ventromedial and dorsolateral prefrontal connectivity. We believe the findings provide first evidence of functional and anatomical dysconnectivity in the aHPC of veterans with high PTSD symptomatology. The data support the putative utility of aHPC connectivity as a measure of overall PTSD severity. Moreover, prefrontal global connectivity may be of clinical value as a brain biomarker to potentially distinguish between PTSD subgroups.	[Abdallah, C. G.; Wrocklage, K. M.; Averill, C. L.; Akiki, T.; Schweinsburg, B.; Roy, A.; Martini, B.; Southwick, S. M.; Krystal, J. H.] US Dept Vet Affairs, Clin Neurosci Div, VA Natl Ctr PTSD, West Haven, CT 06516 USA; [Abdallah, C. G.; Wrocklage, K. M.; Averill, C. L.; Akiki, T.; Schweinsburg, B.; Roy, A.; Martini, B.; Southwick, S. M.; Krystal, J. H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Scott, J. C.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; [Scott, J. C.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA		Abdallah, CG (corresponding author), US Dept Vet Affairs, Clin Neurosci Div, VA Natl Ctr PTSD, West Haven, CT 06516 USA.; Abdallah, CG (corresponding author), Yale Univ, Sch Med, Dept Psychiat, 950 Campbell Ave,151E, West Haven, CT 06516 USA.	chadi.abdallah@yale.edu	Abdallah, Chadi/M-9969-2017; Averill, Christopher L./R-4036-2019; Akiki, Teddy J./D-4502-2019	Abdallah, Chadi/0000-0001-5783-6181; Averill, Christopher L./0000-0001-7575-6142; Akiki, Teddy J./0000-0003-1988-9201; Scott, J. Cobb/0000-0001-6538-9043	U.S. Department of Veterans Affairs National Center for PTSD and NIH [MH-101498]; Department of Veterans Affairs Career Development AwardUS Department of Veterans Affairs [IK2CX000772]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH101498] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2CX000772] Funding Source: NIH RePORTER	The authors thank the Veterans who participated in this study for their invaluable contribution. Funding support was provided by the U.S. Department of Veterans Affairs National Center for PTSD and NIH (MH-101498). Dr. Scott's participation was supported by a Department of Veterans Affairs Career Development Award (IK2CX000772). The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	Abdallah CG, 2017, NEUROPSYCHOPHARMACOL, V42, P1210, DOI 10.1038/npp.2016.186; Abdallah CG, 2015, ANNU REV MED, V66, P509, DOI 10.1146/annurev-med-053013-062946; Abdallah CG, 2012, NEUROSCI LETT, V530, P103, DOI 10.1016/j.neulet.2012.09.054; Admon R, 2013, TRENDS COGN SCI, V17, P337, DOI 10.1016/j.tics.2013.05.005; Anticevic A, 2015, BIOL PSYCHIAT, V77, P569, DOI 10.1016/j.biopsych.2014.07.022; Anticevic A, 2014, BIOL PSYCHIAT, V75, P595, DOI 10.1016/j.biopsych.2013.10.021; Anticevic A, 2013, BIOL PSYCHIAT, V73, P565, DOI 10.1016/j.biopsych.2012.07.031; Beck A. T., 1996, MANUAL BECK DEPRESSI, V1, P82; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bonne O, 2008, J CLIN PSYCHIAT, V69, P1087, DOI 10.4088/JCP.v69n0707; Brown VM, 2014, NEUROPSYCHOPHARMACOL, V39, P351, DOI 10.1038/npp.2013.197; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Chen AC, 2013, NEUROPSYCHOPHARMACOL, V38, P1889, DOI 10.1038/npp.2013.122; Chowdhury GMI, 2017, MOL PSYCHIATR, V22, P120, DOI 10.1038/mp.2016.34; Cole MW, 2012, J NEUROSCI, V32, P8988, DOI 10.1523/JNEUROSCI.0536-12.2012; Cole MW, 2011, BIOL PSYCHIAT, V70, P43, DOI 10.1016/j.biopsych.2011.02.010; Coplan JD, 2016, J AFFECT DISORDERS, V192, P167, DOI 10.1016/j.jad.2015.11.049; Driesen NR, 2013, MOL PSYCHIATR, V18, P1199, DOI 10.1038/mp.2012.194; Driesen NR, 2013, NEUROPSYCHOPHARMACOL, V38, P2613, DOI 10.1038/npp.2013.170; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Hirshhorn M, 2012, NEUROPSYCHOLOGIA, V50, P3094, DOI 10.1016/j.neuropsychologia.2012.08.008; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennis M, 2015, HUM BRAIN MAPP, V36, P99, DOI 10.1002/hbm.22615; Kheirbek MA, 2013, NEURON, V77, P955, DOI 10.1016/j.neuron.2012.12.038; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; Koch SBJ, 2016, DEPRESS ANXIETY, V33, P592, DOI 10.1002/da.22478; Kuhn S, 2013, BIOL PSYCHIAT, V73, P70, DOI 10.1016/j.biopsych.2012.06.029; Lanius RA, 2015, EUR J PSYCHOTRAUMATO, V6, DOI 10.3402/ejpt.v6.27313; Liang X, 2013, P NATL ACAD SCI USA, V110, P1929, DOI 10.1073/pnas.1214900110; Liberzon I, 2016, NEURON, V92, P14, DOI 10.1016/j.neuron.2016.09.039; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; McEwen BS, 2015, NAT NEUROSCI, V18, P1353, DOI 10.1038/nn.4086; Milad MR, 2012, ANNU REV PSYCHOL, V63, P129, DOI 10.1146/annurev.psych.121208.131631; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Murrough JW, 2016, HUM BRAIN MAPP, V37, P3214, DOI 10.1002/hbm.23235; O'Doherty DCM, 2015, PSYCHIAT RES-NEUROIM, V232, P1, DOI 10.1016/j.pscychresns.2015.01.002; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Steer, 1990, MANUAL BECK ANXIETY; Strange BA, 2014, NAT REV NEUROSCI, V15, P655, DOI 10.1038/nrn3785; Thomaes K, 2014, J PSYCHIATR RES, V50, P1, DOI 10.1016/j.jpsychires.2013.11.002; Vythilingam M, 2005, PSYCHIAT RES-NEUROIM, V139, P89, DOI 10.1016/j.pscychresns.2005.04.003; WechslerD, 2001, WECHSLER TEST ADULT; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023	52	26	26	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	FEB 28	2017	7								e1045	10.1038/tp.2017.12			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	EP2LT	WOS:000397215300002	28244983	gold, Green Published			2022-02-06	
J	Nguyen, TV; Lew, J; Albaugh, MD; Botteron, KN; Hudziak, JJ; Fonov, VS; Collins, DL; Ducharme, S; McCracken, JT				Tuong-Vi Nguyen; Lew, Jimin; Albaugh, Matthew D.; Botteron, Kelly N.; Hudziak, James J.; Fonov, Vladimir S.; Collins, D. Louis; Ducharme, Simon; McCracken, James T.			Sex-specific associations of testosterone with prefrontal-hippocampal development and executive function	PSYCHONEUROENDOCRINOLOGY			English	Article						Gonadarche; Androgen; Cognition; Puberty; Adolescents; Human brain	VERBAL-LEARNING-TEST; BEHAVIOR RATING INVENTORY; TRAUMATIC BRAIN-INJURY; MEDIAL TEMPORAL-LOBE; ADULT MALE RATS; SALIVARY TESTOSTERONE; CORTICAL MATURATION; CONSTRUCT-VALIDITY; CHILDRENS-VERSION; HORMONE LEVELS	Testosterone is thought to play a crucial role in mediating sexual differentiation of brain structures. Examinations of the cognitive effects of testosterone have also shown beneficial and potentially sex-specific effects on executive function and mnemonic processes. Yet these findings remain limited by an incomplete understanding of the critical timing and brain regions most affected by testosterone, the lack of documented links between testosterone-related structural brain changes and cognition, and the difficulty in distinguishing the effects of testosterone from those of related sex steroids such as of estradiol and dehydroepiandrosterone (DHEA). Here we examined associations between testosterone, corticohippocampal structural covariance, executive function (Behavior Rating Inventory of Executive Function) and verbal memory (California Verbal Learning Test-Children's Version), in a longitudinal sample of typically developing children and adolescents 6-22 yo, controlling for the effects of estradiol, DHEA, pubertal stage, collection time, age, handedness, and total brain volume. We found prefrontal-hippocampal covariance to vary as a function of testosterone levels, but only in boys. Boys also showed a specific association between positive prefrontal-hippocampal covariance (as seen at higher testosterone levels) and lower performance on specific components of executive function (monitoring the action process and flexibly shifting between actions). We also found the association between testosterone and a specific aspect of executive function (monitoring) to be significantly mediated by prefrontal-hippocampal structural covariance. There were no significant associations between testosterone-related cortico-hippocampal covariance and verbal memory. Taken together, these findings highlight the developmental importance of testosterone in supporting sexual differentiation of the brain and sex-specific executive function. (C) 2016 Elsevier Ltd. All rights reserved.	[Tuong-Vi Nguyen] McGill Univ, Dept Psychiat, Ctr Hlth, Royal Victoria Hosp Glen Site, Montreal, PQ H4A 3J1, Canada; [Tuong-Vi Nguyen] McGill Univ, Dept Obstet Gynecol, Ctr Hlth, Royal Victoria Hosp Glen Site, Montreal, PQ H4A 3J1, Canada; [Lew, Jimin] McGill Univ, Dept Psychol, Montreal, PQ H4A 3J1, Canada; [Albaugh, Matthew D.; Hudziak, James J.] Univ Vermont, Coll Med, Burlington, VT 05405 USA; [Botteron, Kelly N.] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Fonov, Vladimir S.; Collins, D. Louis; Ducharme, Simon] Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada; [Ducharme, Simon] McGill Univ, Ctr Hlth, Dept Psychiat, Montreal, PQ H3A 1A1, Canada; [Ducharme, Simon] McGill Univ, Ctr Hlth, Dept Neurol & Neurosurg, Montreal, PQ H3A 1A1, Canada; [McCracken, James T.] Univ Calif Los Angeles, Dept Child & Adolescent Psychiat, Los Angeles, CA 90024 USA		Nguyen, TV (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp Glen Site, 1001 Decarie C6-1188-4, Montreal, PQ H4A 3J1, Canada.	tuong.v.nguyen@mcgill.ca	Fonov, Vladimir/AAG-9572-2019; Albaugh, Matthew/ABB-5839-2020; Albaugh, Matthew D/R-4349-2016; Collins, D. Louis/ABD-7708-2021	Fonov, Vladimir/0000-0003-3402-7749; Albaugh, Matthew/0000-0002-5971-6658; Collins, D. Louis/0000-0002-8432-7021	Brain Development Cooperative Group; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [N01HD023343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [N01MH090002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092315, N01NS092317, N01NS092316, N01NS092320, N01NS092319, N01NS092314] Funding Source: NIH RePORTER	The funding primarily served to support the Brain Development Cooperative Group and was dedicated to protocol development, data collection and image processing.	ABDELGADIR SE, 1994, ENDOCRINOLOGY, V135, P395, DOI 10.1210/en.135.1.395; Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bhasin S, 2001, AM J PHYSIOL-ENDOC M, V281, pE1172, DOI 10.1152/ajpendo.2001.281.6.E1172; Biegon A, 2015, J NUCL MED, V56, P580, DOI 10.2967/jnumed.114.150383; Biegon A, 2010, SYNAPSE, V64, P801, DOI 10.1002/syn.20791; Blakemore SJ, 2010, HUM BRAIN MAPP, V31, P926, DOI 10.1002/hbm.21052; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Brambilla DJ, 2009, J CLIN ENDOCR METAB, V94, P907, DOI 10.1210/jc.2008-1902; Bramen JE, 2011, CEREB CORTEX, V21, P636, DOI 10.1093/cercor/bhq137; Burgess P., 1997, THEORY METHODOLOGY E; Cattie JE, 2012, CLIN NEUROPSYCHOL, V26, P288, DOI 10.1080/13854046.2011.653404; Cherrier MM, 2005, NEUROLOGY, V64, P290, DOI 10.1212/01.WNL.0000149639.25136.CA; Collins DL, 2010, NEUROIMAGE, V52, P1355, DOI 10.1016/j.neuroimage.2010.04.193; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; DABBS JM, 1990, PHYSIOL BEHAV, V48, P83, DOI 10.1016/0031-9384(90)90265-6; Edinger KL, 2004, BEHAV NEUROSCI, V118, P1352, DOI 10.1037/0735-7044.118.6.1352; Evans AC, 2006, NEUROIMAGE, V30, P184, DOI 10.1016/j.neuroimage.2005.09.068; Fernandez G, 2003, J NEUROSCI, V23, P3790; Foradori CD, 2008, FRONT NEUROENDOCRIN, V29, P169, DOI 10.1016/j.yfrne.2007.10.005; Foradori CD, 2007, NEUROSCIENCE, V149, P155, DOI 10.1016/j.neuroscience.2007.06.054; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Gioia GA, 2001, BRAIN COGNITION, V47, P203; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Goldman-Rakic P.S., 1987, CIRCUITRY PRIMATE PR; Goodman AM, 1999, CLIN NEUROPSYCHOL, V13, P274, DOI 10.1076/clin.13.3.274.1748; Granger DA, 2004, PSYCHONEUROENDOCRINO, V29, P1229, DOI 10.1016/j.psyneuen.2004.02.005; Haren MT, 2005, MATURITAS, V50, P124, DOI 10.1016/j.maturitas.2004.05.002; Hill BD, 2012, APPL NEUROPSYCH-ADUL, V19, P198, DOI 10.1080/09084282.2011.643960; Hu SY, 2013, NEUROIMAGE, V74, P276, DOI 10.1016/j.neuroimage.2013.02.032; Huang G, 2015, J ENDOCRINOL INVEST, V38, P455, DOI 10.1007/s40618-014-0213-3; Ishunina TA, 2005, NEUROBIOL AGING, V26, P173, DOI 10.1016/j.neurobiolaging.2004.03.010; Jacobs ML, 2008, ARCH CLIN NEUROPSYCH, V23, P113, DOI 10.1016/j.acn.2007.09.003; Janowsky JS, 2006, TRENDS COGN SCI, V10, P77, DOI 10.1016/j.tics.2005.12.010; KHANDAWOOD FS, 1984, AM J OBSTET GYNECOL, V148, P441; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Koolschijn PCMP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083929; Kritzer MF, 2001, HORM BEHAV, V39, P167, DOI 10.1006/hbeh.2001.1645; McGivern RF, 2002, BRAIN COGNITION, V50, P73, DOI 10.1016/S0278-2626(02)00012-X; Mottram L, 2005, PSYCHOL ASSESSMENT, V17, P212, DOI 10.1037/1040-3590.17.2.212; Muir-Broaddus JE, 2002, ARCH CLIN NEUROPSYCH, V17, P671, DOI 10.1016/S0887-6177(01)00170-6; Muller M, 2005, NEUROLOGY, V64, P866, DOI 10.1212/01.WNL.0000153072.54068.E3; Nakamura N, 2002, NEUROSCIENCE, V109, P473, DOI 10.1016/S0306-4522(01)00513-9; Neufang S, 2009, CEREB CORTEX, V19, P464, DOI 10.1093/cercor/bhn100; Paus T, 2010, HORM BEHAV, V57, P63, DOI 10.1016/j.yhbeh.2009.08.004; Peper JS, 2011, NEUROSCIENCE, V191, P28, DOI 10.1016/j.neuroscience.2011.02.014; PETERSEN AC, 1988, J YOUTH ADOLESCENCE, V17, P117, DOI 10.1007/BF01537962; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Pruessner JC, 2001, J NEUROSCI, V21, P194, DOI 10.1523/JNEUROSCI.21-01-00194.2001; Raznahan A, 2010, P NATL ACAD SCI USA, V107, P16988, DOI 10.1073/pnas.1006025107; Redoute J, 2005, PSYCHONEUROENDOCRINO, V30, P461, DOI 10.1016/j.psyneuen.2004.12.003; Roselli CE, 2001, J STEROID BIOCHEM, V79, P247, DOI 10.1016/S0960-0760(01)00141-8; Sasano H, 1998, CLIN ENDOCRINOL, V48, P325, DOI 10.1046/j.1365-2265.1998.00390.x; Sellers JG, 2007, J RES PERS, V41, P126, DOI 10.1016/j.jrp.2006.02.004; Shallice T., 1991, HIGHER ORDER COGNITI; Shultz S, 2010, J COMP PSYCHOL, V124, P252, DOI 10.1037/a0018894; Sotomayor-Zarate R, 2011, FERTIL STERIL, V96, P1490, DOI 10.1016/j.fertnstert.2011.09.011; Stanczyk FZ, 2006, SEMIN REPROD MED, V24, P78, DOI 10.1055/s-2006-939566; Steckelbroeck S, 1999, J CLIN ENDOCR METAB, V84, P2795, DOI 10.1210/jc.84.8.2795; Stoffel-Wagner B, 1999, J STEROID BIOCHEM, V70, P237, DOI 10.1016/S0960-0760(99)00114-4; Nguyen TV, 2016, PSYCHONEUROENDOCRINO, V63, P109, DOI 10.1016/j.psyneuen.2015.09.021; Nguyen TV, 2013, J NEUROSCI, V33, P10840, DOI 10.1523/JNEUROSCI.5747-12.2013; Nguyen TV, 2013, CEREB CORTEX, V23, P1424, DOI 10.1093/cercor/bhs125; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Witte AV, 2010, NEUROIMAGE, V49, P1205, DOI 10.1016/j.neuroimage.2009.09.046; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P413, DOI 10.1016/j.acn.2006.06.002; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; WORTHMAN CM, 1990, CLIN CHEM, V36, P1769; Yoon T, 2008, LEARN MEMORY, V15, P97, DOI 10.1101/lm.850808; Zuloaga DG, 2008, HORM BEHAV, V53, P613, DOI 10.1016/j.yhbeh.2008.01.013	71	26	27	1	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	FEB	2017	76						206	217		10.1016/j.psyneuen.2016.12.005			12	Endocrinology & Metabolism; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	EK1YL	WOS:000393723600027	27984812	Green Accepted			2022-02-06	
J	Duclos, C; Dumont, M; Arbour, C; Paquet, J; Blais, H; Menon, DK; De Beaumont, L; Bernard, F; Gosselin, N				Duclos, Catherine; Dumont, Marie; Arbour, Caroline; Paquet, Jean; Blais, Helene; Menon, David K.; De Beaumont, Louis; Bernard, Francis; Gosselin, Nadia			Parallel recovery of consciousness and sleep in acute traumatic brain injury	NEUROLOGY			English	Article							WAKE DISTURBANCES; ACTIGRAPHY; PLASTICITY; COMA; POLYSOMNOGRAPHY; CLASSIFICATION; WAKEFULNESS; DEFINITION; DISRUPTION; MEMORY	Objective: To investigate whether the progressive recuperation of consciousness was associated with the reconsolidation of sleep and wake states in hospitalized patients with acute traumatic brain injury (TBI). Methods: This study comprised 30 hospitalized patients (age 29.1 +/- 6 13.5 years) in the acute phase of moderate or severe TBI. Testing started 21.0 +/- 6 13.7 days postinjury. Consciousness level and cognitive functioning were assessed daily with the Rancho Los Amigos scale of cognitive functioning (RLA). Sleep and wake cycle characteristics were estimated with continuous wrist actigraphy. Mixed model analyses were performed on 233 days with the RLA (fixed effect) and sleep-wake variables (random effects). Linear contrast analyses were performed in order to verify if consolidation of the sleep and wake states improved linearly with increasing RLA score. Results: Associations were found between scores on the consciousness/cognitive functioning scale and measures of sleep-wake cycle consolidation (p < 0.001), nighttime sleep duration (p = 0.018), and nighttime fragmentation index (p < 0.001). These associations showed strong linear relationships (p, 0.01 for all), revealing that consciousness and cognition improved in parallel with sleep-wake quality. Consolidated 24-hour sleep-wake cycle occurred when patients were able to give context-appropriate, goal-directed responses. Conclusions: Our results showed that when the brain has not sufficiently recovered a certain level of consciousness, it is also unable to generate a 24-hour sleep-wake cycle and consolidated nighttime sleep. This study contributes to elucidating the pathophysiology of severe sleepwake cycle alterations in the acute phase of moderate to severe TBI.	[Duclos, Catherine; Dumont, Marie; Arbour, Caroline; Paquet, Jean; Blais, Helene; De Beaumont, Louis; Gosselin, Nadia] Hop Sacre Coeur, Ctr Adv Res Sleep Med, Montreal, PQ, Canada; [Bernard, Francis] Hop Sacre Coeur, Traumatol Program, Montreal, PQ, Canada; [Duclos, Catherine; Dumont, Marie] Univ Montreal, Dept Psychiat, Montreal, PQ, Canada; [Arbour, Caroline; Gosselin, Nadia] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Bernard, Francis] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada		Gosselin, N (corresponding author), Hop Sacre Coeur, Ctr Adv Res Sleep Med, Montreal, PQ, Canada.	nadia.gosselin@umontreal.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [115172]; Fonds pour la Recherche du Quebec-Sante [24742]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This study was supported by the Canadian Institutes of Health Research (grant no. 115172) and by the Fonds pour la Recherche du Quebec-Sante (grant no. 24742).	Bagnato S, 2010, CLIN NEUROPHYSIOL, V121, P274, DOI 10.1016/j.clinph.2009.11.008; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; Blume C, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00105; Chiu HY, 2013, J FORMOS MED ASSOC, V112, P545, DOI 10.1016/j.jfma.2013.06.007; Cruse D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-18; de Biase S, 2014, SLEEP MED, V15, P393, DOI 10.1016/j.sleep.2013.09.026; Dowling G A, 1985, J Neurosurg Nurs, V17, P129; Duclos C, 2014, PATHOL BIOL, V62, P252, DOI 10.1016/j.patbio.2014.05.014; Duclos C, 2014, NEUROREHAB NEURAL RE, V28, P472, DOI 10.1177/1545968313517756; Gabor JY, 2003, AM J RESP CRIT CARE, V167, P708, DOI 10.1164/rccm.2201090; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hagen C, 1972, RANCHO LOS AMIGOS LE; Han HJ, 2003, J KOREAN NEUROL ASS, V21, P156; Holcomb EM, 2016, J HEAD TRAUMA REHAB, V31, P108, DOI 10.1097/HTR.0000000000000206; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; Kamper JE, 2016, J HEAD TRAUMA REHAB, V31, P117, DOI 10.1097/HTR.0000000000000215; Kreutzmann JC, 2015, NEUROSCIENCE, V309, P173, DOI 10.1016/j.neuroscience.2015.04.053; Littell RC, 2000, STAT MED, V19, P1793, DOI 10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.0.CO;2-Q; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin JL, 2011, CHEST, V139, P1514, DOI 10.1378/chest.10-1872; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Olden JD, 2001, MAR BIOL, V138, P1063, DOI 10.1007/s002270000517; Olson E, 2016, J NEUROTRAUM, V33, P734, DOI 10.1089/neu.2015.4085; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Sabir M, 2015, BRAIN BEHAV IMMUN, V47, P118, DOI 10.1016/j.bbi.2014.12.023; Skopin MD, 2015, J NEUROTRAUM, V32, P289, DOI 10.1089/neu.2014.3664; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; TEASDALE G, 1974, LANCET, V2, P81; Tononi G, 2014, NEURON, V81, P12, DOI 10.1016/j.neuron.2013.12.025; Walker MP, 2006, ANNU REV PSYCHOL, V57, P139, DOI 10.1146/annurev.psych.56.091103.070307; Wang D, 2008, J CLIN SLEEP MED, V4, P450	36	26	26	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 17	2017	88	3					268	275		10.1212/WNL.0000000000003508			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	EO2YS	WOS:000396562600012	28003503	Green Submitted, Green Published			2022-02-06	
J	Cui, CM; Cui, JZ; Jin, F; Cui, Y; Li, R; Jiang, XH; Tian, YX; Wang, KJ; Jiang, P; Gao, JL				Cui, Changmeng; Cui, Jianzhong; Jin, Feng; Cui, Ying; Li, Ran; Jiang, Xiaohua; Tian, Yanxia; Wang, Kaijie; Jiang, Pei; Gao, Junling			Induction of the Vitamin D Receptor Attenuates Autophagy Dysfunction-Mediated Cell Death Following Traumatic Brain Injury	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Traumatic brain injury; Vitamin D; Calcitriol; Autophagy; Apoptosis; Function recovery	SPINAL-CORD-INJURY; RAT MODEL; D METABOLISM; D HORMONE; NEUROPROTECTION; ACTIVATION; PROGESTERONE; PATHOGENESIS; COMBINATION; MYOCARDIUM	Background/Aims: Traumatic brain injury (TBI) is a major public health problem in the world and causes high rates of mortality and disability. Recent evidence suggests that vitamin D (VD) has neuroprotective actions and can promote function recovery after TBI. In vitro and in vivo studies have demonstrated that autophagy could be enhanced following supplementation with an active metabolite of VD (calcitriol). However, it is unclear whether autophagy participates in the protective effects of calcitriol after TBI. To test this hypothesis, we examined the protective effects of calcitriol on TBI-induced neurological impairment and further investigated whether calcitriol could modulate autophagy dysfunction-mediated cell death in the cortex region of rat brain. Methods: Eighty-five male rats (250-280 g) were randomly assigned to sham (n = 15), TBI model (TBI, n = 35) and calcitriol treatment (calcitriol, n = 35) groups. Rats were injected intraperitoneally with calcitriol (1 mu g/kg) at 30 min, 24 h and 48 h post-TBI in the calcitriol group. The lysosomal inhibitor, chloroquine (CQ), was used to evaluate autophagic flux in the TBI and calcitriol groups. Neurological functions were evaluated via the modified neurological severity score test at 1-7 days after TBI or sham operation, and the terminal deoxynucleotidyl transferase-mediated FITC-dUTP nick-end labeling method was used to evaluate the ability of calcitriol to inhibit apoptosis. The expression of VDR, LC3 and p62 proteins was measured by western blot analysis at 1, 3 and 7 days post-injury. Results: Calcitriol treatment attenuated mNSS at 2-7 days post-TBI (P < 0.05 versus TBI group). Calcitriol dramatically increased VDR protein expression compared with the untreated counterparts at 1, 3 and 7 days post-TBI (P < 0.05). The rate of apoptotic cells in calcitriol-treated rats was significantly reduced compared to that observed in the TBI group (P < 0.05). The LC3II/LC3I ratio was decreased in the cortex region at 1, 3 and 7 days post-TBI in rats treated with calcitriol (p < 0.05 versus TBI group), and the p62 expression was also attenuated (p < 0.05 versus TBI group). The LC3II/LC3I ratio in the calcitriol group was significantly increased when pretreated with CQ (P < 0.05). Conclusion: Calcitriol treatment activated VDR protein expression and attenuated neurological deficits in this rat TBI model. The protective effects might be associated with the restoration of autophagy flux and the decrease in apoptosis in the cortex region of rat brain. (C) 2017 The Author(s) Published by S. Karger AG, Basel	[Cui, Changmeng; Jin, Feng] Jining Med Univ, Affiliated Hosp, Dept Neurosurg, Jining, Peoples R China; [Cui, Changmeng; Jiang, Pei] Jining Med Univ, Jining Peoples Hosp 1, Inst Clin Pharm & Pharmacol, Jining 272000, Shandong, Peoples R China; [Cui, Jianzhong; Cui, Ying; Wang, Kaijie] Tangshan Gongren Hosp, Tangshan, Peoples R China; [Li, Ran; Jiang, Xiaohua; Tian, Yanxia; Gao, Junling] North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Li, Ran; Jiang, Xiaohua; Tian, Yanxia; Gao, Junling] Tangshan Key Lab Preclin & Basic Res Chron Dis, Hebei Key Lab Chron Dis, Tangshan, Peoples R China		Jiang, P; Gao, JL (corresponding author), Jining Med Univ, Jining Peoples Hosp 1, Inst Clin Pharm & Pharmacol, Jining 272000, Shandong, Peoples R China.; Jiang, P; Gao, JL (corresponding author), North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China.	jiangpeicsu@sina.com; jlgaodr2001@163.com		Jiang, Pei/0000-0002-8360-7427			Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Feng Y.C., 2016, CORROS ENG SCI TECHN, P1; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Fu J, 2013, MOL MED REP, V8, P1708, DOI 10.3892/mmr.2013.1734; Galluzzi L, 2016, NAT REV NEUROSCI, V17, P467, DOI 10.1038/nrn.2016.51; He XJ, 2016, CELL PHYSIOL BIOCHEM, V40, P743, DOI 10.1159/000453135; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Jiang P, 2014, PSYCHOPHARMACOLOGY, V231, P3445, DOI 10.1007/s00213-014-3440-6; Jiang P, 2013, PSYCHONEUROENDOCRINO, V38, P2091, DOI 10.1016/j.psyneuen.2013.03.017; Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kalueff AV, 2004, BIOCHEMISTRY-MOSCOW+, V69, P738, DOI 10.1023/B:BIRY.0000040196.65686.2f; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; Lawrence DW, 2016, BRAIN INJURY, V30, P960, DOI 10.3109/02699052.2016.1147081; Mustafa G, 2016, NEUROPHARMACOLOGY, V107, P27, DOI 10.1016/j.neuropharm.2016.03.016; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Sheng R, 2010, AUTOPHAGY, V6, P482, DOI 10.4161/auto.6.4.11737; Somjen D, 2017, J STEROID BIOCHEM, V174, P9, DOI 10.1016/j.jsbmb.2017.05.007; Tang H., 2015, BRAIN INJURY, P1; Tung YT, 2012, J BIOSCIENCES, V37, P157, DOI 10.1007/s12038-011-9176-0; Wang P., 2017, OXID MED CELL LONGEV, V2017, DOI DOI 10.1155/2017/1020357; Wang RC, 2011, J INVEST DERMATOL, V131, P990, DOI 10.1038/jid.2010.423; Yan F, 2014, NEUROSCI LETT, V563, P160, DOI 10.1016/j.neulet.2014.01.058; Yao TB, 2015, ANTIOXID REDOX SIGN, V22, P633, DOI 10.1089/ars.2014.5887; Zanatta AP, 2017, BASIC CLIN ANDROL, V27, DOI 10.1186/s12610-017-0053-z; Zhou KL, 2016, SPINAL CORD, V54, P510, DOI 10.1038/sc.2015.217	36	26	29	1	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2017	42	5					1888	1896		10.1159/000479571			9	Cell Biology; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Physiology	FL2EB	WOS:000414026500015	28772270	gold			2022-02-06	
J	Cui, CM; Song, SX; Cui, JZ; Feng, Y; Gao, JL; Jiang, P				Cui, Changmeng; Song, Sixin; Cui, Jianzhong; Feng, Yan; Gao, Junling; Jiang, Pei			Vitamin D Receptor Activation Influences NADPH Oxidase (NOX2) Activity and Protects against Neurological Deficits and Apoptosis in a Rat Model of Traumatic Brain Injury	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article							1,25-DIHYDROXYVITAMIN D-3; BCL-2 FAMILY; D HORMONE; CALCITRIOL; PROTEINS; INVOLVEMENT; PREVALENCE; EXPRESSION; PREVENTION; CALCIUM	Traumatic brain injury (TBI) is a worldwide phenomenon which results in significant neurological and cognitive deficits in humans. Vitamin D (VD) is implicated as a therapeutic strategy for various neurological diseases now. Recently, inhibition of the NADPH oxidase (NOX2) was reported to protect against oxidative stress (ROS) production. However, whether alterations in NOX2 expression and NOX activity are associated with calcitriol (active metabolite of VD) treatment following TBI remains unclear. In the present study, rats were randomly assigned to the sham, TBI, and calcitriol-treated groups. Calcitriol was administered intraperitoneally (2 mu g/kg) at 30 min, 24 h, and 48 h after TBI insult. We observed that calcitriol treatment alleviated neurobehavioral deficits and brain edema following TBI. At the molecular levels, administration of calcitriol activated the expression of VDR and downregulated NOX2 as well as suppressed apoptosis cell rate in the hippocampus CA1 region of TBI rats. In conclusion, our findings indicate that the protective effects of calcitriol may be related to the modulation of NADPH oxidase and thereby ultimately inhibited the progression of apoptosis. Calcitriol may be promising as a protective intervention following TBI, and more study is warranted for its clinical testing in the future.	[Cui, Changmeng] Jining Med Univ, Affiliated Hosp, Dept Neurosurg, Jining 272000, Shandong, Peoples R China; [Cui, Changmeng; Gao, Junling] North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Cui, Changmeng; Cui, Jianzhong] Tangshan Gongren Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China; [Song, Sixin] Taishan Med Univ, Affiliated Hosp, Dept Neurosurg, Tai An 271000, Shandong, Peoples R China; [Feng, Yan] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China; [Jiang, Pei] Jining Med Univ, Jining Peoples Hosp 1, Inst Clin Pharm & Pharmacol, Jining 272000, Shandong, Peoples R China		Gao, JL (corresponding author), North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China.; Jiang, P (corresponding author), Jining Med Univ, Jining Peoples Hosp 1, Inst Clin Pharm & Pharmacol, Jining 272000, Shandong, Peoples R China.	jlgaodr2001@163.com; jiangpeicsu@sina.com		Jiang, Pei/0000-0002-8360-7427	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81602846]; Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	This work was supported by the National Natural Science Foundation of China (Grant no. 81602846) and the Natural Science Foundation of Hebei Province (Grant no. H2014105079).	Ano Y, 2010, NEUROSCI LETT, V469, P39, DOI 10.1016/j.neulet.2009.11.040; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Baroni E, 2008, REGUL TOXICOL PHARM, V52, P332, DOI 10.1016/j.yrtph.2008.09.002; Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Chabas JF, 2008, J NEUROTRAUM, V25, P1247, DOI 10.1089/neu.2008.0593; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Dang RL, 2015, EUR NEUROPSYCHOPHARM, V25, P1239, DOI 10.1016/j.euroneuro.2015.04.028; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Dong JH, 2012, EUR HEART J, V33, P2980, DOI 10.1093/eurheartj/ehr459; Evatt ML, 2008, ARCH NEUROL-CHICAGO, V65, P1348, DOI 10.1001/archneur.65.10.1348; Eyles DW, 2013, FRONT NEUROENDOCRIN, V34, P47, DOI 10.1016/j.yfrne.2012.07.001; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Feng Y, 2017, CELL MOL NEUROBIOL, V37, P155, DOI 10.1007/s10571-016-0356-1; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Finnie J. W., VET RES COMMUNICATIO, V38, P297; Fu J, 2013, MOL MED REP, V8, P1708, DOI 10.3892/mmr.2013.1734; Hellman P, 1999, INT J MOL MED, V3, P355; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Hwang JH, 2013, INT J MOL MED, V32, P1394, DOI 10.3892/ijmm.2013.1506; Imazeki I, 2006, BIOMED RES-TOKYO, V27, P1, DOI 10.2220/biomedres.27.1; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jia J, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/893516; Jiang P, 2014, NUTRIENTS, V6, P6048, DOI 10.3390/nu6126048; Jiang P, 2014, PSYCHOPHARMACOLOGY, V231, P3445, DOI 10.1007/s00213-014-3440-6; Jorde R, 2015, J NEUROL SCI, V355, P155, DOI 10.1016/j.jns.2015.06.009; Kalueff AV, 2004, BIOCHEMISTRY-MOSCOW+, V69, P738, DOI 10.1023/B:BIRY.0000040196.65686.2f; Kozlowski C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031814; Kutuzova GD, 2004, ARCH BIOCHEM BIOPHYS, V432, P152, DOI 10.1016/j.abb.2004.09.004; Liu J., 2009, BMC BIOINFORMATICS, V10, P9; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580; McGuire TF, 2001, J BIOL CHEM, V276, P26365, DOI 10.1074/jbc.M010101200; Oshima Y, 2008, J BIOL CHEM, V283, P26499, DOI 10.1074/jbc.M800933200; Pittas AG, 2007, DIABETES CARE, V30, P980, DOI 10.2337/dc06-1994; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Segaert S, 2000, BIOCHEM BIOPH RES CO, V279, P89, DOI 10.1006/bbrc.2000.3892; Shinpo K, 2000, J NEUROSCI RES, V62, P374, DOI 10.1002/1097-4547(20001101)62:3<374::AID-JNR7>3.0.CO;2-7; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Thakkar R, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8309031; Tortosa A, 1997, NEUROSCI LETT, V238, P78, DOI 10.1016/S0304-3940(97)00837-9; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wang P., 2017, OXID MED CELL LONGEV, V2017, DOI DOI 10.1155/2017/1020357; Wirrell E, 2010, PEDIATR NEUROL, V42, P394, DOI 10.1016/j.pediatrneurol.2010.02.001; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	52	26	27	1	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.		2017	2017								9245702	10.1155/2017/9245702			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	FR4SN	WOS:000419056100001	29410737	Green Published, gold			2022-02-06	
J	Formisano, R; Azicnuda, E; Sefid, MK; Zampolini, M; Scarponi, F; Avesani, R				Formisano, Rita; Azicnuda, Eva; Sefid, Maryam Khan; Zampolini, Mauro; Scarponi, Federico; Avesani, Renato			Early rehabilitation: benefits in patients with severe acquired brain injury	NEUROLOGICAL SCIENCES			English	Article						Early rehabilitation; Outcome; Severe acquired brain injury	SEVERE HEAD-INJURY	Establish the best time to start rehabilitation by means of scientific evidence. Observational study in patients with a diagnosis of Severe Brain Injury who received intensive inpatient rehabilitation after acute care. 1470 subjects enrolled: 651 with Traumatic Brain Injury (TBI) and 819 with Non-TBI. Male gender was prevalent in the population study, but sex distribution was not different among groups, with a prevalence of male gender in both populations. This project involved 29 rehabilitation facilities for Severe ABI. The registry was an electronic database, remained active only during the period of data collection. The patients were divided into three different categories according to the time interval from brain injury to inpatient rehabilitation admission and demographic and clinical data were collected. Etiology, time interval from injury to inpatient rehabilitation, disability severity, the presence of tracheostomy at admission to the rehabilitation facility, rehabilitation length of stay and transfer back to acute care wards because of medical, surgical or neurosurgical complications. The interval from brain injury to rehabilitation facilities admission increases along with age, brain injury severity according to DRS scores, the presence of a tracheal tube and the percentage of transfers back to acute care wards from rehabilitation facilities, because of medical, surgical or neurosurgical complications. The better recovery and more positive outcomes, reported as resulting from early rehabilitation, may be due more to less severity of brain injury and fewer complications in the acute and post-acute phase than to when the rehabilitation starts.	[Formisano, Rita; Azicnuda, Eva] IRCCS Santa Lucia Fdn, Postcoma Unit, Via Ardeatina 306, I-00179 Rome, Italy; [Sefid, Maryam Khan; Avesani, Renato] Sacro Cuore Don Calabria Hosp, Rehabil Dept, Negrar, Italy; [Zampolini, Mauro; Scarponi, Federico] ASL 3, Dept Rehabil, Perugia, Italy		Formisano, R (corresponding author), IRCCS Santa Lucia Fdn, Postcoma Unit, Via Ardeatina 306, I-00179 Rome, Italy.	r.formisano@hsantalucia.it	Azicnuda, Eva/K-9010-2016; mandala, giorgio/AAC-1842-2019; Scarponi, Federico/K-5714-2018	mandala, giorgio/0000-0002-4384-8672; Scarponi, Federico/0000-0001-9683-8104			Actis MV, 2001, G ITAL MED RIABIL, V15, P49; Avesani R, 2013, EUR J PHYS REHAB MED, V49, P611; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Derrikson JG, 1989, APTA NEUROL REP, V13, P10; Hu MH, 2010, DISABIL REHABIL, V32, P1251, DOI 10.3109/09638280903464448; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Morgan AS, 1988, 1 ANN C E ASS SURG T; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118	9	26	27	0	7	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	JAN	2017	38	1					181	184		10.1007/s10072-016-2724-5			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EK9AZ	WOS:000394217500024	27696274				2022-02-06	
J	Haarbauer-Krupa, J; Taylor, CA; Yue, JK; Winkler, EA; Pirracchio, R; Cooper, SR; Burke, JF; Stein, MB; Manley, GT				Haarbauer-Krupa, Juliet; Taylor, Christopher A.; Yue, John K.; Winkler, Ethan A.; Pirracchio, Romain; Cooper, Shelly R.; Burke, John F.; Stein, Murray B.; Manley, Geoffrey T.		TRACK-TBI Investigators	Screening for Post-Traumatic Stress Disorder in a Civilian Emergency Department Population with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						emergency department screening; post-traumatic stress disorder; traumatic brain injury	COMMON DATA ELEMENTS; GLASGOW OUTCOME SCALE; RISK-FACTORS; HEAD-INJURY; SYMPTOMS; RECOMMENDATIONS; SATISFACTION; VIOLENCE; HEALTH; IMPACT	Post-traumatic stress disorder (PTSD) is a condition associated with traumatic brain injury (TBI). While the importance of PTSD and TBI among military personnel is widely recognized, there is less awareness of PTSD associated with civilian TBI. We examined the incidence and factors associated with PTSD 6 months post-injury in a civilian emergency department population using measures from the National Institute of Neurological Disorders and Stroke TBI Common Data Elements Outcome Battery. Participants with mild TBI (mTBI) from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot study with complete 6-month outcome batteries (n = 280) were analyzed. Screening for PTSD symptoms was conducted using the PTSD Checklist-Civilian Version. Descriptive measures are summarized and predictors for PTSD were examined using logistic regression. Incidence of screening positive for PTSD was 26.8% at 6 months following mTBI. Screening positive for PTSD was significantly associated with concurrent functional disability, post-concussive and psychiatric symptomatology, decreased satisfaction with life, and decreased performance in visual processing and mental flexibility. Multi-variable regression showed injury mechanism of assault (odds ratio [OR] 3.59; 95% confidence interval [CI] 1.69-7.63; p = 0.001) and prior psychiatric history (OR 2.56; 95% CI 1.42-4.61; p = 0.002) remained significant predictors of screening positive for PTSD, while education (per year OR 0.88; 95% CI 0.79-0.98; p = 0.021) was associated with decreased odds of PTSD. Standardized data collection and review of pre-injury education, psychiatric history, and injury mechanism during initial hospital presentation can aid in identifying patients with mTBI at risk for developing PTSD symptoms who may benefit from closer follow-up after initial injury care.	[Haarbauer-Krupa, Juliet; Taylor, Christopher A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury, Atlanta, GA USA; [Yue, John K.; Winkler, Ethan A.; Cooper, Shelly R.; Burke, John F.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Pirracchio, Romain] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Yue, John K.; Winkler, Ethan A.; Cooper, Shelly R.; Burke, John F.; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Cooper, Shelly R.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr BASIC, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015; Taylor, Christopher A/D-2067-2013	Yue, John K/0000-0001-9694-7722; Taylor, Christopher A/0000-0002-0937-5461; Cooper, Shelly/0000-0003-0026-6688; Burke, John/0000-0002-6190-5116	One Mind for Research; National Science FoundationNational Science Foundation (NSF) [DGE-1143954];  [NIH RC2 NS069409];  [NIH RC2 NS064909-02S1];  [NIH U01 NS086090-01];  [DOD W81XWH-13-1-0441];  [DOD W81XWH-14-2-0176]	This study was supported by the following grants: NIH RC2 NS069409, NIH RC2 NS064909-02S1, NIH U01 NS086090-01, DOD W81XWH-13-1-0441, DOD W81XWH-14-2-0176 (Manley), and One Mind for Research.; This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1143954.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2002, DIAGN STAT MAN MENT, V4th; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Browne AL, 2013, DISABIL REHABIL, V35, P1149, DOI 10.3109/09638288.2012.721047; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Combs HL, 2015, J NEUROTRAUM, V32, P956, DOI 10.1089/neu.2014.3585; Delis D.C., 2000, CALIFORNIA VERBAL LE; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Gros DF, 2012, PSYCHIAT RES, V196, P267, DOI 10.1016/j.psychres.2011.10.022; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Han X., 2014, J SLEEP DISORDERS TH, V3, P164; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kaloupek DG, 2010, ARCH PHYS MED REHAB, V91, P1684, DOI 10.1016/j.apmr.2010.06.032; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim H, 2013, DISABIL REHABIL, V35, P2213, DOI 10.3109/09638288.2013.774063; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; TEASDALE G, 1974, LANCET, V2, P81; Weathers F. W., 1993, 9 ANN CONV INT SOC T; Weathers F.W., 2013, PTSD CHECKLIST DSM 5; Wechsler D., 2008, WECHSLER ADULT INTEL; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zatzick DF, 2006, J AM ACAD CHILD PSY, V45, P1188, DOI 10.1097/01.chi.0000231975.21096.45; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	52	26	27	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					50	58		10.1089/neu.2015.4158			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100007	26936513	Green Published			2022-02-06	
J	Janak, JC; Cooper, DB; Bowles, AO; Alamgir, AH; Cooper, SP; Gabriel, KP; Perez, A; Orman, JA				Janak, Jud C.; Cooper, Douglas B.; Bowles, Amy O.; Alamgir, Abul H.; Cooper, Sharon P.; Gabriel, Kelley P.; Perez, Adriana; Orman, Jean A.			Completion of Multidisciplinary Treatment for Persistent Postconcussive Symptoms Is Associated With Reduced Symptom Burden	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast injuries; mild traumatic brain injury; military personnel; posttraumatic stress disorder; rehabilitation; treatment	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILITARY SERVICE MEMBERS; GOOD-OLD-DAYS; OPERATION IRAQI FREEDOM; MILD TBI; COMBAT VETERANS; PSYCHOMETRIC PROPERTIES; COMPENSATION SEEKING; NATIONAL-GUARD	Objective: To investigate the pre- to posttreatment changes in both posttraumatic stress disorder (PTSD) and persistent postconcussive symptoms (PPCSs). Setting and Participants: We studied 257 active-duty patients with a history of mild traumatic brain injury (mTBI) who completed multidisciplinary outpatient treatment at Brooke Army Medical Center TBI Clinic from 2008 to 2013. This treatment program included cognitive rehabilitation; vestibular interventions; headache management; and integrated behavioral healthcare to address co-occurring psychiatric conditions such as PTSD, depression, and sleep disturbance. Design: A 1-group; preexperimental, pre- to posttreatment study. Main Measures: The Neurobehavioral Symptom Inventory (NSI) was used to assess PPCSs, and the PTSD Checklist-Military Version (PCL-M) was used to asses PTSD symptoms. Results: Global PPCS resolution (mean NSI: 35.0 pre vs 23.8 post; P < .0001; d = 0.72) and PTSD symptom resolution (mean PCL-M: 43.2 pre vs 37.7 post; P < .0001; d = 0.34) were statistically significant. Compared with those with only mTBI, patients with mTBI and PTSD reported greater global PPCS impairment both pretreatment (mean NSI: 48.7 vs 27.9; P < .0001) and posttreatment (mean NSI: 36.2 vs 17.4; P < .0001). After adjusting for pretreatment NSI scores, patients with comorbid PTSD reported poorer PPCS resolution than those with mTBI alone (mean NSI: 27.9 pre vs 21.7 post; P = .0009). Conclusion: We found a reduction in both self-reported PPCSs and PTSD symptoms; however, future studies are needed to identify specific components of care associated with symptom reduction.	[Janak, Jud C.] US Army, Oak Ridge Inst Sci & Educ, San Antonio, TX USA; [Cooper, Douglas B.] Def & Vet Brain Injury Ctr, San Antonio, TX USA; [Bowles, Amy O.] Brooke Army Med Ctr, San Antonio, TX USA; [Orman, Jean A.] US Army, Inst Surg Res, Stat & Epidemiol, San Antonio, TX USA; [Cooper, Douglas B.; Alamgir, Abul H.] Univ Texas San Antonio, Sch Publ Hlth San Antonio, San Antonio, TX USA; [Gabriel, Kelley P.; Perez, Adriana] Univ Texas Austin, Sch Publ Hlth Austin, Austin, TX 78712 USA		Janak, JC (corresponding author), US Army, Inst Surg Res, Oak Ridge Inst Sci & Educ, 3698 Chambers Pass,Bldg 3611, San Antonio, TX 78234 USA.	judson.c.janak.vol@mail.mil		Perez, Adriana/0000-0002-6859-9916	National Institute of Occupational and Environmental Health/Centers for Disease Control and Prevention [5T42OH008421]; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [T42OH008421] Funding Source: NIH RePORTER	Support and funding for this study was provided by grant No. 5T42OH008421 from the National Institute of Occupational and Environmental Health/Centers for Disease Control and Prevention to the Southwest Center for Occupational and Environmental Health. In addition, this project was supported in part by an appointment to the Internship/Research Participation Program at the United States Army Institute of Surgical Research, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the Environmental Protection Agency. The authors thank the staff at Brooke Army Medical Center Traumatic Brain Injury Clinic for their hard work and dedication. The authors also thank both the service members and their families for their service to the United States.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cernich AN, 2012, J HEAD TRAUMA REHAB, V27, P253, DOI 10.1097/HTR.0b013e3182585cd5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Department of Defense, 2015, DOD WORLDW NUMB TBI; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 2003, PSYCHIATR SERV, V54, P84, DOI 10.1176/appi.ps.54.1.84; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hoge CW, 2014, JAMA-J AM MED ASSOC, V312, P1685, DOI 10.1001/jama.2014.6670; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge C, 2015, JAMA INTERN MED, V175, P53, DOI 10.1001/jamainternmed.2014.3375; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jones ML, 2013, ARCH PHYS MED REHAB, V94, pS49, DOI 10.1016/j.apmr.2012.04.038; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Management of Concussion/ mTBI Working Group, 2009, J REHABIL RES DEV, V46, pCP1; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Marshall S, 2012, CAN FAM PHYSICIAN, V58, pE128; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Moye L. A., 2006, STAT REASONING MED I; National Center for PTSD US Department of Veterans Affairs, 2014, US PTSD CHECKL DSM 4; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rosner B, 2010, FUNDAMENTALS BIOSTAT; Ryan PB, 2011, BRAIN INJURY, V25, P1019, DOI 10.3109/02699052.2011.597044; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Silver JM, 2011, TXB TRAUMATIC BRAIN, VSecond; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Weathers F.W., 1993, 9 ANN C ISTSS; Whyte J, 2009, NEUROPSYCHOL REHABIL, V19, P807, DOI 10.1080/09602010903031146; Wicklund Alissa H, 2013, Surg Neurol Int, V4, P50, DOI 10.4103/2152-7806.110150; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Yang CC, 2014, J CLIN EXP NEUROPSYC, V36, P399, DOI 10.1080/13803395.2014.903899	74	26	27	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2017	32	1					1	15		10.1097/HTR.0000000000000202			15	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EI2GH	WOS:000392304400001	26709579				2022-02-06	
J	Jiang, C; Zuo, FF; Wang, YJ; Lu, H; Yang, QW; Wang, J				Jiang, Chao; Zuo, Fangfang; Wang, Yuejuan; Lu, Hong; Yang, Qingwu; Wang, Jian			Progesterone Changes VEGF and BDNF Expression and Promotes Neurogenesis After Ischemic Stroke	MOLECULAR NEUROBIOLOGY			English	Article						Brain-derived neurotrophic factor; Cerebral ischemia; Neurogenesis; Progesterone; Vascular endothelial growth factor	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC FACTOR EXPRESSION; NEURAL STEM-CELLS; ADULT-RAT; AGED RATS; INTRACEREBRAL HEMORRHAGE; STIMULATES NEUROGENESIS; INFLAMMATORY RESPONSE	Studies have shown that progesterone enhances functional recovery after ischemic stroke, but the underlying mechanisms are not completely understood. Therefore, we investigated the effect of progesterone on vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), and neurogenesis in a rodent stroke model. Rats underwent permanent middle cerebral artery occlusion (pMCAO) and then received intraperitoneal injections of progesterone (15 mg/kg) or vehicle at 1 h followed by subcutaneous injections at 6, 24, and 48 h. We examined VEGF and BDNF expression by Western blotting and/or immunostaining and microvessel density by lectin immunostaining. Neurogenesis in the subventricular zone was determined by immunostaining of Ki67 and doublecortin, and double BrdU/Nestin immunostaining. We calculated brain water content with the wet-dry weight method on day 3 and assessed neurologic deficits with the modified neurological severity score on days 1, 3, 7, and 14. Progesterone-treated rats showed a significant decrease in VEGF expression, but an increase in BDNF expression, compared with that of vehicle-treated pMCAO rats on day 3 post-occlusion. Progesterone did not alter the microvessel density, but it reduced brain water content compared with that in vehicle-treated rats on day 3 post-occlusion. Progesterone treatment increased the numbers of newly generated neurons in the subventricular zone and doublecortin-positive cells in the peri-infarct region on day 7 post-occlusion. In addition, progesterone improved neurologic function on days 7 and 14 post-occlusion. Our data suggest that the enhancement of endogenous BDNF and subsequent neurogenesis could partially underlie the neuroprotective effects of progesterone.	[Jiang, Chao; Zuo, Fangfang; Wang, Yuejuan] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China; [Jiang, Chao; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21205 USA; [Lu, Hong] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450000, Peoples R China; [Yang, Qingwu] Third Mil Med Univ, Xinqiao Hosp, Dept Neurol, Chongqing 400044, Peoples R China		Jiang, C (corresponding author), Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China.; Jiang, C; Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21205 USA.	chaojzzu@126.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81301006]; American Heart AssociationAmerican Heart Association [13GRNT15730001]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078026, R01AT007317]	This work was supported by grants from the National Natural Science Foundation of China (81301006), American Heart Association grant 13GRNT15730001, and the National Institutes of Health (R01NS078026, R01AT007317). We thank Claire Levine for assistance with this manuscript.	Cekic M, 2012, RESTOR NEUROL NEUROS, V30, P115, DOI 10.3233/RNN-2011-0628; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Chen K, 2007, MOL CELL NEUROSCI, V36, P108, DOI 10.1016/j.mcn.2007.06.004; Coughlan T, 2009, INT J NEUROSCI, V119, P1718, DOI 10.1080/00207450903116430; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fournier NM, 2012, BEHAV BRAIN RES, V227, P440, DOI 10.1016/j.bbr.2011.04.022; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Greenberg ME, 2009, J NEUROSCI, V29, P12764, DOI 10.1523/JNEUROSCI.3566-09.2009; Ishrat T, 2012, NEUROSCIENCE, V210, P442, DOI 10.1016/j.neuroscience.2012.03.008; Jiang C, 2013, BEHAV BRAIN RES, V250, P222, DOI 10.1016/j.bbr.2013.05.011; Jiang C, 2011, INT IMMUNOPHARMACOL, V11, P1925, DOI 10.1016/j.intimp.2011.08.001; Jiang C, 2009, INFLAMM RES, V58, P619, DOI 10.1007/s00011-009-0032-8; Jiang SZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086407; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Khaibullina AA, 2004, DEV BRAIN RES, V148, P59, DOI 10.1016/j.devbrainres.2003.09.022; Klein RL, 1999, NEUROSCIENCE, V90, P815, DOI 10.1016/S0306-4522(98)00537-5; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Lacroix-Fralish ML, 2006, NEURON GLIA BIOL, V2, P227, DOI 10.1017/S1740925X07000385; Li J, 2011, J CEREBR BLOOD F MET, V31, P413, DOI 10.1038/jcbfm.2010.181; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Minnerup J, 2012, INT J MOL SCI, V13, P11753, DOI 10.3390/ijms130911753; Morita K, 2008, J MOL NEUROSCI, V34, P193, DOI 10.1007/s12031-007-9034-6; Moyse E, 2006, AUTON NEUROSCI-BASIC, V126, P50, DOI 10.1016/j.autneu.2006.03.006; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Stein DG, 2012, HORM BEHAV, DOI [10.1016/j.yhbeh.2012.1005.1004, DOI 10.1016/J.YHBEH.2012.1005.1004]; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Vandromme M, 2008, CRIT CARE, V12, DOI 10.1186/cc6899; Wang JP, 2015, BRAIN BEHAV IMMUN, V45, P98, DOI 10.1016/j.bbi.2014.12.015; Wang JP, 2010, BEHAV BRAIN RES, V209, P119, DOI 10.1016/j.bbr.2010.01.026; Wojtal K, 2006, PHARMACOL REP, V58, P335; Won S, 2014, J CEREBR BLOOD F MET, V34, P72, DOI 10.1038/jcbfm.2013.163; Wu H, 2015, NEUROBIOL AGING, V36, P1439, DOI 10.1016/j.neurobiolaging.2014.12.029; Wu T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-22; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yao RQ, 2009, BRAIN RES BULL, V79, P69, DOI 10.1016/j.brainresbull.2008.12.010; Yousuf S, 2014, J CEREBR BLOOD F MET, V34, P297, DOI 10.1038/jcbfm.2013.198; Zan L, 2014, NEUROSCIENCE, V262, P118, DOI 10.1016/j.neuroscience.2013.12.060; Zan LK, 2011, NEUROCHEM INT, V58, P872, DOI 10.1016/j.neuint.2011.02.014; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011	58	26	27	3	20	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JAN	2017	54	1					571	581		10.1007/s12035-015-9651-y			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EI0AO	WOS:000392133900047		Green Accepted			2022-02-06	
J	Yeh, PH; Guan Koay, C; Wang, BQ; Morissette, J; Sham, E; Senseney, J; Joy, D; Kubli, A; Yeh, CH; Eskay, V; Liu, W; French, LM; Oakes, TR; Riedy, G; Ollinger, J				Yeh, Ping-Hong; Guan Koay, Cheng; Wang, Binquan; Morissette, John; Sham, Elyssa; Senseney, Justin; Joy, David; Kubli, Alex; Yeh, Chen-Haur; Eskay, Victora; Liu, Wei; French, Louis M.; Oakes, Terrence R.; Riedy, Gerard; Ollinger, John			Compromised Neurocircuitry in Chronic Blast-Related Mild Traumatic Brain Injury	HUMAN BRAIN MAPPING			English	Article						mild traumatic brain injury; blast injury; cognition; concussion; post-traumatic stress disorder; diffusion tensor imaging; tractography; neurocircuitry	WHITE-MATTER INTEGRITY; DIFFUSE AXONAL INJURY; TENSOR; MEMORY; MRI; TRACTOGRAPHY; SYMPTOMS; EXPOSURE; CONCUSSION; COMPLAINTS	The aim of this study was to apply recently developed automated fiber segmentation and quantification methods using diffusion tensor imaging (DTI) and DTI-based deterministic and probabilistic tractography to access local and global diffusion changes in blast-induced mild traumatic brain injury (bmTBI). Two hundred and two (202) male active US service members who reported persistent post-concussion symptoms for more than 6 months after injury were recruited. An additional forty (40) male military controls were included for comparison. DTI results were examined in relation to post-concussion and post-traumatic stress disorder (PTSD) symptoms. No significant group difference in DTI metrics was found using voxel-wise analysis. However, group comparison using tract profile analysis and tract specific analysis, as well as single subject analysis using tract profile analysis revealed the most prominent white matter microstructural injury in chronic bmTBI patients over the frontal fiber tracts, that is, the front-limbic projection fibers (cingulum bundle, uncinate fasciculus), the fronto-parieto-temporal association fibers (superior longitudinal fasciculus), and the fronto-striatal pathways (anterior thalamic radiation). Effects were noted to be sensitive to the number of previous blast exposures, with a negative association between fractional anisotropy (FA) and time since most severe blast exposure in a subset of the multiple blast-exposed group. However, these patterns were not observed in the subgroups classified using macrostructural changes (T2 white matter hyperintensities). Moreover, post-concussion symptoms and PTSD symptoms, as well as neuropsychological function were associated with low FA in the major nodes of compromised neurocircuitry. Hum Brain Mapp 38:352-369, 2017. (c) 2016 Wiley Periodicals, Inc.	[Yeh, Ping-Hong; Wang, Binquan] Henry Jackson Fdn Adv Mil Med, Rockledge, MD USA; [Yeh, Ping-Hong; Guan Koay, Cheng; Morissette, John; Sham, Elyssa; Senseney, Justin; Joy, David; Kubli, Alex; Yeh, Chen-Haur; Eskay, Victora; Liu, Wei; French, Louis M.; Oakes, Terrence R.; Riedy, Gerard; Ollinger, John] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [French, Louis M.; Riedy, Gerard] Uniformed Serv Univ Hlth Sci, CNRM, Bethesda, MD 20814 USA		Yeh, PH (corresponding author), Walter Reed Natl Mil Med Ctr, 8901 Wisconsin Ave,Bldg 51,Room 1128, Bethesda, MD 20889 USA.	pinghongyeh@gmail.com	Koay, Cheng Guan/AAH-8017-2020; french, louis/AAB-2083-2020	Koay, Cheng Guan/0000-0002-4343-8040; Joy, David/0000-0001-9941-9538; french, louis/0000-0002-9451-0604	CDMRPUnited States Department of Defense [PT074437]; NARSAD, Brain Behavior Research Fund [18317]	Contract grant sponsors: CDMRP to USUHS (CNRM) Grant PT074437 (G.R.) and NARSAD, Brain Behavior Research Fund Grant 18317 (P-H. Y.).	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Ashley M. J., 2004, TRAUMATIC BRAIN INJU, V2nd; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Battaglini M, 2008, NEUROIMAGE, V40, P583, DOI 10.1016/j.neuroimage.2007.10.067; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Charlton RA, 2010, CORTEX, V46, P474, DOI 10.1016/j.cortex.2009.07.005; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Connell S, 2011, J NEUROTRAUM, V28, P1229, DOI 10.1089/neu.2011.1832; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI 10.1002/da.22044; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; French LM, 2014, J REHABIL RES DEV, V51, P933, DOI 10.1682/JRRD.2013.10.0226; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Gouw AA, 2011, J NEUROL NEUROSUR PS, V82, P126, DOI 10.1136/jnnp.2009.204685; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Heilbronner SR, 2014, J NEUROSCI, V34, P10041, DOI 10.1523/JNEUROSCI.5459-13.2014; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jbabdi S, 2007, NEUROIMAGE, V37, P116, DOI 10.1016/j.neuroimage.2007.04.039; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubicki M, 2009, BRAIN IMAGING BEHAV, V3, P191, DOI 10.1007/s11682-009-9061-8; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Kvickstrom P, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-13; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Nestor PG, 2004, NEUROPSYCHOLOGY, V18, P629, DOI 10.1037/0894-4105.18.4.629; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Ruff Robert L, 2010, F1000 Med Rep, V2, P64, DOI 10.3410/M2-64; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Skranes J, 2007, BRAIN, V130, P654, DOI 10.1093/brain/awm001; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Teipel SJ, 2009, J ALZHEIMERS DIS, V17, P571, DOI 10.3233/JAD-2009-1077; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038; Widjaja E, 2013, EPILEPSIA, V54, P1065, DOI 10.1111/epi.12208; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yeatman JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049790; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023; YLIKOSKI A, 1995, STROKE, V26, P1171, DOI 10.1161/01.STR.26.7.1171; Yushkevich PA, 2008, NEUROIMAGE, V41, P448, DOI 10.1016/j.neuroimage.2008.01.013; Zhang H, 2005, LECT NOTES COMPUT SC, V3749, P172	97	26	27	0	46	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JAN	2017	38	1					352	369		10.1002/hbm.23365			18	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EF3XY	WOS:000390259700025	27629984	Green Published			2022-02-06	
J	Daley, M; Dekaban, G; Bartha, R; Brown, A; Stewart, TC; Doherty, T; Fischer, L; Holmes, J; Menon, RS; Rupar, CA; Shoemaker, JK; Fraser, DD				Daley, Mark; Dekaban, Greg; Bartha, Robert; Brown, Arthur; Stewart, Tanya Charyk; Doherty, Timothy; Fischer, Lisa; Holmes, Jeff; Menon, Ravi S.; Rupar, C. Anthony; Shoemaker, J. Kevin; Fraser, Douglas D.			Metabolomics profiling of concussion in adolescent male hockey players: a novel diagnostic method	METABOLOMICS			English	Article						Concussion; Diagnosis; Biomarker; Metabolomics; Adolescents; Ice hockey	SPORTS-RELATED CONCUSSION; TRANSLATIONAL RESEARCH; BRAIN-INJURY; METABOLISM; STATEMENT; CHILDREN	Introduction Concussions are a major health concern as they cause significant acute symptoms and in some athletes, long-term neurologic dysfunction. Diagnosis of concussion can be difficult, as are the decisions to stop play. Objective To determine if concussions in adolescent male hockey players could be diagnosed using plasma metabolomics profiling. Methods Plasma was obtained from 12 concussed and 17 non-concussed athletes, and assayed for 174 metabolites with proton nuclear magnetic resonance and direct injection liquid chromatography tandem mass spectrometry. Data were analysed with multivariate statistical analysis and machine learning. Results The estimated time from concussion occurrence to blood draw at the first clinic visit was 2.3 +/- 0.7 days. Using principal component analysis, the leading 10 components, each containing 9 metabolites, were shown to account for 82 % of the variance between cohorts, and relied heavily on changes in glycerophospholipids. Cross-validation of the classifier using a leave-one out approach demonstrated a 92 % accuracy rate in diagnosing a concussion (P < 0.0001). The number of metabolites required to achieve the 92 % diagnostic accuracy was minimized from 174 to as few as 17 metabolites. Receiver operating characteristic analyses generated an area under the curve of 0.91, indicating excellent concussion diagnostic potential. Conclusion Metabolomics profiling, together with multivariate statistical analysis and machine learning, identified concussed athletes with >90 % certainty. Metabolomics profiling represents a novel diagnostic method for concussion, and may be amenable to point-of-care testing.	[Daley, Mark] Univ Western Ontario, Dept Comp Sci, London, ON, Canada; [Dekaban, Greg] Univ Western Ontario, Mol Med, Robarts Res Inst, London, ON, Canada; [Bartha, Robert; Menon, Ravi S.] Univ Western Ontario, Dept Med Biophys, London, ON, Canada; [Brown, Arthur; Fraser, Douglas D.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Stewart, Tanya Charyk] Univ Western Ontario, Dept Surg, London, ON, Canada; [Doherty, Timothy] Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada; [Fischer, Lisa] Univ Western Ontario, Dept Family Med, London, ON, Canada; [Holmes, Jeff] Univ Western Ontario, Dept Occupat Therapy, London, ON, Canada; [Rupar, C. Anthony] Univ Western Ontario, Dept Biochem, London, ON, Canada; [Rupar, C. Anthony] Univ Western Ontario, Dept Pathol & Lab Med, London, ON, Canada; [Shoemaker, J. Kevin] Univ Western Ontario, Sch Kinesiol, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Pediat, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Paediat Crit Care Med, Childrens Hosp, London Hlth Sci Ctr, Room C2-846,800 Commissioners Rd East, London, ON N6A 5W9, Canada		Fraser, DD (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.; Fraser, DD (corresponding author), Univ Western Ontario, Dept Pediat, London, ON, Canada.; Fraser, DD (corresponding author), Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada.; Fraser, DD (corresponding author), Univ Western Ontario, Paediat Crit Care Med, Childrens Hosp, London Hlth Sci Ctr, Room C2-846,800 Commissioners Rd East, London, ON N6A 5W9, Canada.	douglas.fraser@lhsc.on.ca	Shoemaker, Joel Kevin/L-2682-2013; Daley, Mark/AAS-7366-2020; Menon, Ravi S/K-5500-2013; Menon, Ravi/ABA-8654-2020; Dekaban, Gregory/L-1987-2013; Fischer, Lisa K/H-3999-2015; Bartha, Robert/K-3611-2013; Brown, Arthur/K-8328-2013	Shoemaker, Joel Kevin/0000-0002-6794-5979; Daley, Mark/0000-0002-6939-9772; Menon, Ravi S/0000-0002-7916-0263; Menon, Ravi/0000-0002-7916-0263; Dekaban, Gregory/0000-0002-3087-4660; Fischer, Lisa K/0000-0001-5992-0176; Bartha, Robert/0000-0002-7118-9096; Brown, Arthur/0000-0002-8725-3195	Children's Health Foundation	We thank Ms. Christy Barreira and Ms. Sandra Shaw for excellent technical support, and Ms. Kathryn Manning and Mr. Kevin Blackney for assistance with data. We graciously acknowledge analytic support from The Metabolomics Innovation Centre at the University of Alberta, Edmonton, AB (Ms. Rupasri Mandal, Ms. Jennifer D. Reid and Dr. David Wishart). This study was supported by the Children's Health Foundation (http://childhealth.ca/) grant to DDF.	Braverman NE, 2012, BBA-MOL BASIS DIS, V1822, P1442, DOI 10.1016/j.bbadis.2012.05.008; Brisson AR, 2012, PEDIATRICS, V129, P153, DOI 10.1542/peds.2011-0134; Bujak R, 2015, J PHARMACEUT BIOMED, V113, P108, DOI 10.1016/j.jpba.2014.12.017; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6; Gillio-Meina C, 2013, PEDIATRICS, V131, P754, DOI 10.1542/peds.2012-1181; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Lehmann R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011519; Lovell MR, 2013, J PEDIATR-US, V163, P1192, DOI 10.1016/j.jpeds.2013.05.061; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Morrison Gavin, 2013, Pathophysiology, V20, P49, DOI 10.1016/j.pathophys.2012.02.006; OBRIEN JS, 1965, J LIPID RES, V6, P537; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Saude EJ, 2006, METABOLOMICS, V2, P113, DOI 10.1007/s11306-006-0023-5; Shouval R, 2014, BONE MARROW TRANSPL, V49, P332, DOI 10.1038/bmt.2013.146; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Vitali C, 2014, CARDIOVASC RES, V103, P405, DOI 10.1093/cvr/cvu148; Yudkoff M, 1997, GLIA, V21, P92, DOI 10.1002/(SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W; Zhu W., 2010, NE SAS US GROUP P	32	26	26	0	30	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1573-3882	1573-3890		METABOLOMICS	Metabolomics	DEC	2016	12	12							185	10.1007/s11306-016-1131-5			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	EE4VS	WOS:000389604300010					2022-02-06	
J	Yang, LY; Greig, NH; Huang, YN; Hsieh, TH; Tweedie, D; Yu, QS; Hoffer, BJ; Luo, Y; Kao, YC; Wang, JY				Yang, Ling-Yu; Greig, Nigel H.; Huang, Ya-Ni; Hsieh, Tsung-Hsun; Tweedie, David; Yu, Qian-Sheng; Hoffer, Barry J.; Luo, Yu; Kao, Yu-Chieh; Wang, Jia-Yi			Post-traumatic administration of the p53 inactivator pifithrin-alpha, oxygen analogue reduces hippocampal neuronal loss and improves cognitive deficits after experimental traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury (TBI); p53; Pifithrin-alpha (PFT-alpha); PFT-alpha oxygen analogue (PFT-alpha (o)); Apoptosis; Motor and cognitive deficits; Puma; Controlled cortical impact (CCI)	FLUORO-JADE-C; PEPTIDE-1 RECEPTOR AGONIST; TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; CELL-DEATH; FUNCTIONAL OUTCOMES; UNITED-STATES; UP-REGULATION; HEAD-INJURY; EXPRESSION	Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Neuronal apoptosis in the hippo campus has been detected after TBI. The hippocampal dysfunction may result in cognitive deficits in learning, memory, and spatial information processing. Our previous studies demonstrated that a p53 inhibitor, pifithrin-alpha oxygen analogue (PFT-alpha (O)), significantly reduced cortical cell death, which is substantial following controlled cortical impact (CCI) TBI, and improved neurological functional outcomes via anti-apoptotic mechanisms. In the present study, we examined the effect of PFT-alpha (O) on CCI TBI-induced hippocampal cellular pathophysiology in light of this brain region's role in memory. To investigate whether p53-dependent apoptosis plays a role in hippocampal neuronal loss and associated cognitive deficits and to define underlying mechanisms, SD rats were subjected to experimental CCI TBI followed by the administration of PFT-alpha or PFT-alpha (O) (2 mg/kg, i.v.) or vehicle at 5 h after TBI. Magnetic resonance imaging (MRI) scans were acquired at 24 h and 7 days post-injury to assess evolving structural hippocampal damage. Fluoro-Jade C was used to stain hippocampal sub-regions, including CA1 and dentate gyrus (DG), for cellular degeneration. Neurological functions, including motor and recognition memory, were assessed by behavioral tests at 7 days post injury. p53, p53 upregulated modulator of apoptosis (PUMA), 4-hydroxynonenal (4-HNE), cyclooxygenase-IV (COX IV), annexin V and NeuN were visualized by double immunofluorescence staining with cell-specific markers. Levels of mRNA encoding for caspase-3, p53, PUMA, Bcl-2, Bcl-2-associated X protein (BAX) and superoxide dismutase (SOD) were measured by RT-qPCR. Our results showed that post-injury administration of PFT-alpha and, particularly, PFT-alpha (O) at 5 h dramatically reduced injury volumes in the ipsilateral hippocampus, improved motor outcomes, and ameliorated cognitive deficits at 7 days after TBI, as evaluated by novel object recognition and open-field test. PFT-alpha and especially PFT-alpha (O) significantly reduced the number of FJC-positive cells in hippocampus CA1 and DG subregions, versus vehicle treatment, and significantly decreased caspase-3 and PUMA mRNA expression. PFT-alpha (O), but not PFT-alpha, treatment significantly lowered p53 and elevated SOD2 mRNA expression. Double immunofluorescence staining demonstrated that PFT-alpha (O) treatment decreased p53, annexin V and 4-HNE positive neurons in the hippocampal CA1 region. Furthermore, PUMA co-localization with the mitochondrial maker COX IV, and the upregulation of PUMA were inhibited by PFT-alpha (O) after TBI. Our data suggest that PFT-alpha and especially PFT-alpha (O) significantly reduce hippocampal neuronal degeneration, and ameliorate neurological and cognitive deficits in vivo via antiapoptotic and antioxidative properties. (C) 2016 Published by Elsevier Inc.	[Yang, Ling-Yu; Huang, Ya-Ni; Wang, Jia-Yi] Taipei Med Univ, Grad Inst Med Sci, Coll Med, 250 Wu Hsing St, Taipei 110, Taiwan; [Greig, Nigel H.; Tweedie, David; Yu, Qian-Sheng] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Huang, Ya-Ni] Hsin Sheng Jr Coll Med Care & Management, Dept Nursing, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Coll Med, Dept Phys Therapy, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Coll Med, Grad Inst Rehabil Sci, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Taipei Med Univ, Grad Inst Neural Regenerat Med, Taipei, Taiwan; [Hoffer, Barry J.; Luo, Yu] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Kao, Yu-Chieh] Taipei Med Univ, Sch Med, Translat Imaging Res Ctr, Taipei, Taiwan; [Kao, Yu-Chieh] Taipei Med Univ, Sch Med, Dept Radiol, Taipei, Taiwan; [Wang, Jia-Yi] Taipei Med Univ, Sch Med, Dept Physiol, Coll Med, Taipei, Taiwan		Wang, JY (corresponding author), Taipei Med Univ, Grad Inst Med Sci, Coll Med, 250 Wu Hsing St, Taipei 110, Taiwan.	jywang2010@tmu.edu.tw	Kao, Yu-Chieh Jill/AAW-7050-2020; Hsieh, Tung-Hsun/AAZ-5010-2020	Kao, Yu-Chieh Jill/0000-0001-7416-759X; Hsieh, Tung-Hsun/0000-0002-1794-7941; Luo, Yu/0000-0002-7939-5505; Wang, Jia-Yi/0000-0002-9106-3351	Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [MOST104-2923-B-038-001-MY3 (1-3 2-3)]; National Institutes of Health NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094152]; Intramural Research Program, National Institute on Aging, National Institutes of Health NINDS, USA [R01NS094152]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000994] Funding Source: NIH RePORTER	This study was supported in part by grants from (i) the Ministry of Science and Technology (MOST104-2923-B-038-001-MY3 (1-3 & 2-3) (ii) National Institutes of Health NINDS grant R01NS094152 and by (iii) the Intramural Research Program, National Institute on Aging, National Institutes of Health NINDS grant R01NS094152, USA. The authors thank the Translational Imaging Research Center at Taipei Medical University for technical support in relation to animal setup and MRI imaging. For information relating to PFT-alpha. (O) contact NHG <Greign@mail.nih.gov.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bralic M, 2012, COLLEGIUM ANTROPOL, V36, P1319; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chidlow G, 2009, EXP EYE RES, V88, P426, DOI 10.1016/j.exer.2008.10.015; Chiu WT, 2011, JAMA-J AM MED ASSOC, V306, P267, DOI 10.1001/jama.2011.989; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cregan SP, 2004, J NEUROSCI, V24, P10003, DOI 10.1523/JNEUROSCI.2114-04.2004; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dong XX, 2012, NEUROSCIENCE, V207, P52, DOI 10.1016/j.neuroscience.2012.01.018; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; Engel T, 2010, FASEB J, V24, P853, DOI 10.1096/fj.09-145870; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Gupta S, 2007, Indian J Physiol Pharmacol, V51, P62; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hong MY, 2012, CHINESE MED J-PEKING, V125, P2019, DOI 10.3760/cma.j.issn.0366-6999.2012.11.032; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Leker RR, 2004, EXP NEUROL, V187, P478, DOI 10.1016/j.expneurol.2004.01.030; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lin JW, 2008, ACT NEUR S, V101, P113; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luo Y, 2009, ANN NEUROL, V65, P520, DOI 10.1002/ana.21592; Martin LJ, 2009, CEREB CORTEX, V19, P1273, DOI 10.1093/cercor/bhn167; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; Merchant-Borna K., 2016, ANN BIOMED ENG; Mugwagwa Andrew T, 2015, J Neurodegener Dis, V2015, P242505, DOI 10.1155/2015/242505; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Niizuma K, 2009, STROKE, V40, P618, DOI 10.1161/STROKEAHA.108.524447; Nijboer CH, 2011, ANN NEUROL, V70, P255, DOI 10.1002/ana.22413; Nijboer CHA, 2008, STROKE, V39, P2129, DOI 10.1161/STROKEAHA.107.504175; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tomasevic G, 2010, J NEUROSCI RES, V88, P3414, DOI 10.1002/jnr.22491; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Uo T, 2007, J NEUROSCI, V27, P12198, DOI 10.1523/JNEUROSCI.3222-05.2007; Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005; Wang DB, 2014, BBA-MOL BASIS DIS, V1842, P1186, DOI 10.1016/j.bbadis.2013.12.015; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015; Yonekura I, 2006, J CEREBR BLOOD F MET, V26, P1332, DOI 10.1038/sj.jcbfm.9600293; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	85	26	28	2	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2016	96						216	226		10.1016/j.nbd.2016.08.012			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	EC3WX	WOS:000388058900020	27553877	Green Accepted			2022-02-06	
J	Haar, CV; Lam, FCW; Adams, WK; Riparip, LK; Kaur, S; Muthukrishna, M; Rosi, S; Winstanley, CA				Haar, Cole Vonder; Lam, Frederick C. W.; Adams, Wendy K.; Riparip, Lara-Kirstie; Kaur, Sukhbir; Muthukrishna, Michael; Rosi, Susanna; Winstanley, Catharine A.			Frontal Traumatic Brain Injury in Rats Causes Long-Lasting Impairments in Impulse Control That Are Differentially Sensitive to Pharmacotherapeutics and Associated with Chronic Neuroinflammation	ACS CHEMICAL NEUROSCIENCE			English	Article						Controlled cortical impact; impulsivity; amphetamine; prelimbic; cytokine	CONTROLLED CORTICAL IMPACT; REACTION-TIME-TASK; COGNITIVE DYSFUNCTION; METHYLPHENIDATE TREATMENT; INFLAMMATORY RESPONSE; ORBITOFRONTAL CORTEX; HEAD-INJURY; ATTENTION; MODERATE; DEFICITS	Traumatic brain injury (TBI) affects millions yearly, and is increasingly associated with chronic neuropsychiatric symptoms. We assessed the long-term effects of different bilateral frontal controlled cortical impact injury severities (mild, moderate, and severe) on the five-choice serial reaction time task, a paradigm with relatively independent measurements of attention, motor impulsivity, and motivation. Moderately-and severely injured animals exhibited impairments across all cognitive domains that were still evident 14 weeks postinjury, while mild-injured animals only demonstrated persistent deficits in impulse control. However, recovery of function varied considerably between subjects such that some showed no impairment ("TBI-resilient"), some demonstrated initial deficits that recovered ("TBI-vulnerable"), and some never recovered ("chronically-impaired"). Three clinically relevant treatments for impulse-control or TBI, amphetamine, atomoxetine, and amantadine, were assessed for efficacy in treating injury-induced deficits. Susceptibility to TBI affected the response to pharmacological challenge with amphetamine. Whereas sham and TBI-resilient animals showed characteristic impairments in impulse control at higher doses, amphetamine had the opposite effect in chronically impaired rats, improving task performance. In contrast, atomoxetine and amantadine reduced premature responding but increased omissions, suggesting psychomotor slowing. Analysis of brain tissue revealed that generalized neuroinflammation was associated with impulsivity even when accounting for the degree of brain damage. This is one of the first studies to characterize psychiatric-like symptoms in experimental TBI. Our data highlight the importance of testing pharmacotherapies in TBI models in order to predict efficacy, and suggest that neuroinflammation may represent a treatment target for impulse control problems following injury.	[Haar, Cole Vonder; Lam, Frederick C. W.; Adams, Wendy K.; Kaur, Sukhbir; Winstanley, Catharine A.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; [Haar, Cole Vonder; Lam, Frederick C. W.; Adams, Wendy K.; Muthukrishna, Michael; Winstanley, Catharine A.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z3, Canada; [Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Haar, Cole Vonder] West Virginia Univ, Injury & Recovery Lab, Dept Psychol, Morgantown, WV USA		Winstanley, CA (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.; Haar, CV (corresponding author), Dept Psychol, 53 Campus Dr, Morgantown, WV 26506 USA.	cole.vonderhaar@mail.wvu.edu; cwinstanley@psych.ubc.ca	Muthukrishna, Michael/Z-1655-2019	Muthukrishna, Michael/0000-0002-7079-5166; Vonder Haar, Cole/0000-0001-7949-2068	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458] Funding Source: NIH RePORTER	This work was supported by the Canadian Institutes for Health Research, the Michael Smith Foundation for Health Research, and the National Institute of Neurological Disorders and Stroke (R21NS087458).	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; CARLI M, 1983, BEHAV BRAIN RES, V9, P361, DOI 10.1016/0166-4328(83)90138-9; Coccaro EF, 2014, JAMA PSYCHIAT, V71, P158, DOI 10.1001/jamapsychiatry.2013.3297; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Comeau WL, 2014, EUR J NEUROSCI, V40, P3078, DOI 10.1111/ejn.12671; Courtet P., 2016, WORLD J BIOL PSYCHIA, P1; Davidson J, 2015, NEUROSCIENTIST, V21, P424, DOI 10.1177/1073858414543150; Diaz-Arrastia R., 2014, TRAUMATIC BRAIN INJU, P183; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donegan JJ, 2014, J NEUROSCI, V34, P953, DOI 10.1523/JNEUROSCI.3968-13.2014; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Greve KW, 2001, BRAIN INJURY, V15, P255; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Leeds PR, 2014, ACS CHEM NEUROSCI, V5, P422, DOI 10.1021/cn500040g; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Martens KM, 2012, J NEUROTRAUM, V29, P2505, DOI 10.1089/neu.2012.2388; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Navarra R, 2008, PROG NEURO-PSYCHOPH, V32, P34, DOI 10.1016/j.pnpbp.2007.06.017; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Reeves RR, 2011, J PSYCHOSOC NURS MEN, V49, P42, DOI 10.3928/02793695-20110201-03; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rosenblat JD, 2015, J AFFECT DISORDERS, V188, P149, DOI 10.1016/j.jad.2015.08.058; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Shim SS, 2016, J NEUROTRAUM, V33, P2065, DOI 10.1089/neu.2015.4177; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Sun HS, 2012, PSYCHOPHARMACOLOGY, V219, P285, DOI 10.1007/s00213-011-2419-9; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; van der Staay FJ, 2006, BRAIN RES REV, V52, P131, DOI 10.1016/j.brainresrev.2006.01.006; Vonder Haar C, 2016, J NEUROTRAUM, V33, P1892, DOI 10.1089/neu.2015.4276; Vonder Haar C, 2014, J NEUROTRAUM, V31, P1711, DOI 10.1089/neu.2014.3459; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Winstanley CA, 2010, BEHAV BRAIN RES, V210, P263, DOI 10.1016/j.bbr.2010.02.044; Yan H, 2012, CHINESE MED J-PEKING, V125, P1618, DOI 10.3760/cma.j.issn.0366-6999.2012.09.018; Yu G, 2016, J CHILD ADOL PSYCHOP, V26, P314, DOI 10.1089/cap.2015.0137; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	54	26	26	0	9	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	NOV	2016	7	11					1531	1542		10.1021/acschemneuro.6b00166			12	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	EC9AA	WOS:000388433000009	27525447	Green Accepted			2022-02-06	
J	Tapia-Perez, JH; Karagianis, D; Zilke, R; Koufuglou, V; Bondar, I; Schneider, T				Tapia-Perez, J. H.; Karagianis, D.; Zilke, R.; Koufuglou, V.; Bondar, I.; Schneider, T.			Assessment of systemic cellular inflammatory response after spontaneous intracerebral hemorrhage	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Intracerebral hemorrhage; Inflammation; Interleukin 6; Neutrophils	BRAIN-INJURY; INTERLEUKIN-6; NEUROTOXICITY; MECHANISMS; CORRELATE; SEVERITY; PROTECTS	Objective: After spontaneous intracerebral hemorrhage (ICH) a local and systemic inflammatory response is activated. Interleukin-6 (IL) is one of most relevant orchestrators of inflammatory responses in the brain and is released from multiple immune cells, including neutrophils. Herby we assessed the relevance of systemic inflammation in patients suffering ICH. Methods: From October 2010 to October 2011 we included in our routine of laboratory investigations besides to C-reactive protein (CRP), the addition of IL-6 and an analysis of the subpopulation of circulating blood cells. Values at admission, at 3rd and 7th day after admission were evaluated. We analyzed 43 patients with non-traumatic ICH; stroke-related ICH or tumor associated hemorrhage were excluded. Outcome variables were 30 and 90-day mortality and NIHSS at discharge. A natural logarithmic transformation of IL-6, lymphocytes, and monocytes was used. Results: 8.6% died within 30-days and mortality increased to 39.5% at 90th day. Total leukocytes and neutrophils as well as IL-6 at admission were statistically significant increased among patients who died within 30 days after ICH onset (p = 0.002). IL-6 and CRP in follow-up (3rd and 7th day) were higher among patients with poor outcome (NIHSS >15). The number of circulating lymphocytes and monocytes was not different in measurement. Leukocytes and neutrophils at 3rd day after admission were augmented in patients with respiratory infection and CRP in follow-up increased if some kind of infection was clinically or microbiologically detected. IL-6 at admission and in follow-up and monocytes at 7th day were related to ICH volume. CRP-values at 3rd or 7th day but not at admission were associated to bigger ICH-volume. The values of IL-6 were highly correlated to 30-day mortality and volume of ICH as CRP only with ICH volume. Conclusion: After ICH onset a systemic activation of immune system seems to be induced and may be influencing outcome. Peripheral recruitment of leukocytes, especially neutrophils could be a target for future therapeutic interventions. Because of the tighter correlation of IL-6 at admission, it might be more accurate for prognostic issues than CRP. (C) 2016 Elsevier B.V. All rights reserved.	[Tapia-Perez, J. H.; Karagianis, D.; Zilke, R.; Koufuglou, V.; Bondar, I.; Schneider, T.] Otto Von Guericke Univ, Dept Neurosurg, Magdeburg, Germany; [Tapia-Perez, J. H.] Univ Marburg, Dept Neurosurg, Marburg, Germany; [Tapia-Perez, J. H.] Univ Wurzburg, Dept Neurol, Wurzburg, Germany		Tapia-Perez, JH (corresponding author), Josef Schneider Str 11, D-97080 Wurzburg, Germany.	jhtapiap@gmail.com					Adeoye O, 2014, J STROKE CEREBROVASC, V23, pE107, DOI 10.1016/j.jstrokecerebrovasdis.2013.09.006; Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Brunswick AS, 2012, J NEUROL SCI, V321, P1, DOI 10.1016/j.jns.2012.06.008; Conroy SM, 2004, J NEUROIMMUNOL, V155, P43, DOI 10.1016/j.jneuroim.2004.06.014; Diedler J, 2009, CEREBROVASC DIS, V27, P272, DOI 10.1159/000199465; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200; Illanes S, 2011, NEUROSCI LETT, V490, P170, DOI 10.1016/j.neulet.2010.11.065; Islam O, 2009, MOL BIOL CELL, V20, P188, DOI 10.1091/mbc.E08-05-0463; Loftspring MC, 2009, J CEREBR BLOOD F MET, V29, P137, DOI 10.1038/jcbfm.2008.114; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Peng YP, 2005, NEUROSCI LETT, V374, P192, DOI 10.1016/j.neulet.2004.10.069; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Sarrafzadeh A, 2010, NEUROCRIT CARE, V13, P339, DOI 10.1007/s12028-010-9432-4; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tapia-Perez JH, 2013, NEUROSURG REV, V36, P279, DOI 10.1007/s10143-012-0431-0; Teng WY, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/473276; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woo D, 2002, NEUROSURG CLIN N AM, V13, P265, DOI 10.1016/S1042-3680(02)00011-6; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zhou Y, 2013, OXID MED CELL LONGEV, V2013, P2013, DOI DOI 10.1371/J0URNAL.P0NE.0057558	28	26	27	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	NOV	2016	150						72	79		10.1016/j.clineuro.2016.07.010			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EA5EN	WOS:000386642300013	27611984				2022-02-06	
J	Vedantam, A; Yamal, JM; Rubin, ML; Robertson, CS; Gopinath, SP				Vedantam, Aditya; Yamal, Jose-Miguel; Rubin, Maria Laura; Robertson, Claudia S.; Gopinath, Shankar P.			Progressive hemorrhagic injury after severe traumatic brain injury: effect of hemoglobin transfusion thresholds	JOURNAL OF NEUROSURGERY			English	Article						severe traumatic brain injury; progressive hemorrhagic injury; hemoglobin transfusion threshold; secondary brain injury	ACUTE SUBDURAL-HEMATOMA; HEAD TRAUMA; DECOMPRESSIVE CRANIECTOMY; OXYGEN DELIVERY; BLOOD; CRANIOTOMY; AGE	OBJECTIVE There is limited literature available to guide transfusion practices for patients with severe traumatic brain injury (TBI). Recent studies have shown that maintaining a higher hemoglobin threshold after severe TBI offers no clinical benefit. The present study aimed to determine if a higher transfusion threshold was independently associated with an increased risk of progressive hemorrhagic injury (PHI), thereby contributing to higher rates of morbidity and mortality. METHODS The authors performed a secondary analysis of data obtained from a recently performed randomized clinical trial studying the effects of erythropoietin and blood transfusions on neurological recovery after severe TBI. Assigned hemoglobin thresholds (10 g/dl vs 7 g/dl) were maintained with packed red blood cell transfusions during the acute phase after injury. PHI was defined as the presence of new or enlarging intracranial hematomas on CT as long as 10 days after injury. A severe PHI was defined as an event that required an escalation of medical management or surgical intervention. Clinical and imaging parameters and transfusion thresholds were used in a multivariate Cox regression analysis to identify independent risk factors for PHI. RESULTS Among 200 patients enrolled in the trial, PHI was detected in 61 patients (30.5%). The majority of patients with PHI had a new, delayed contusion (n = 29) or an increase in contusion size (n = 15). The mean time interval between injury and identification of PHI was 17.2 +/- 15.8 hours. The adjusted risk of severe PHI was 2.3 times higher for patients with a transfusion threshold of 10 g/dl (95% confidence interval 1.1-4.7; p = 0.02). Diffuse brain injury was associated with a lower risk of PHI events, whereas higher initial intracranial pressure increased the risk of PHI (p < 0.001). PHI was associated with a longer median length of stay in the intensive care unit (18.3 vs 14.4 days, respectively; p = 0.04) and poorer Glasgow Outcome Scale scores (42.9% vs 25.5%, respectively; p = 0.02) at 6 months. CONCLUSIONS A higher transfusion threshold of 10 g/dl after severe TBI increased the risk of severe PHI events. These results indicate the potential adverse effect of using a higher hemoglobin transfusion threshold after severe TBI.	[Vedantam, Aditya; Robertson, Claudia S.; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA; [Yamal, Jose-Miguel; Rubin, Maria Laura] Univ Texas Houston, Sch Publ Hlth, Dept Biostat, Houston, TX USA		Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA.	shankarg@bcm.tmc.edu			National Institute of Neurological Disorders and Stroke, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM074902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This study was supported by grant no. P01-NS38660 (National Institute of Neurological Disorders and Stroke, NIH).	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Boutin A, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-66; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chen SH, 2011, J TRAUMA, V71, P1632, DOI 10.1097/TA.0b013e3182367b3c; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hosmer JDW, 2013, APPL LOGISTIC REGRES, V3rd; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Morisaki H, 2004, CRIT CARE CLIN, V20, P213, DOI 10.1016/j.ccc.2003.12.003; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Yamal JM, 2015, J NEUROTRAUM, V32, P1239, DOI 10.1089/neu.2014.3752; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	25	26	30	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2016	125	5					1229	1234		10.3171/2015.11.JNS151515			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DZ8FK	WOS:000386106100023	26943843	Green Accepted			2022-02-06	
J	Govindarajan, KA; Narayana, PA; Hasan, KM; Wilde, EA; Levin, HS; Hunter, JV; Miller, ER; Patel, VKS; Robertson, CS; McCarthy, JJ				Govindarajan, Koushik A.; Narayana, Ponnada A.; Hasan, Khader M.; Wilde, Elisabeth A.; Levin, Harvey S.; Hunter, Jill V.; Miller, Emmy R.; Patel, Vipul Kumar S.; Robertson, Claudia S.; McCarthy, James J.			Cortical Thickness in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cortical thickness; FreeSurfer; longitudinal analysis; mTBI; orthopedic injury	VETERANS; ACCURATE; MODELS; SYSTEM	Magnetic resonance imaging data were acquired at approximate to 24h and approximate to 3 months post-injury on mild traumatic brain injury (mTBI; n=75) and orthopedic injury (n=60) cohorts. The mTBI subjects were randomly assigned to a treatment group with atorvastatin or a non-treatment mTBI group. The treatment group was further divided into drug and placebo subgroups. FreeSurfer software package was used to compute cortical thickness based on the three dimensional T1-weighted images at both time-points. Cross-sectional analysis was carried out to compare cortical thickness between the mTBI and control groups. Longitudinal unbiased templates were generated for all subjects and cortical thickness measurements were compared between baseline and follow-up scans in the mTBI group. At baseline, significant reduction in cortical thickness was observed in the left middle temporal and the right superior parietal regions in the mTBI group, relative to the control group (p=0.01). At follow-up, significant cortical thinning was again observed in the left middle temporal cortex in the mTBI group. Further analysis revealed significant cortical thinning only in the non-treatment group relative to the control group. In the follow-up, small regions with significant but subtle cortical thinning and thickening were seen in the frontal, temporal, and parietal lobes in the left hemisphere in the non-treatment group only. Our results indicate that cortical thickness could serve as a useful measure in identifying subtle changes in mTBI patients.	[Govindarajan, Koushik A.; Narayana, Ponnada A.; Hasan, Khader M.; Patel, Vipul Kumar S.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Miller, Emmy R.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA		Narayana, PA (corresponding author), Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St, Houston, TX 77030 USA.	ponnada.a.narayana@uth.tmc.edu	Govindarajan, Koushik Athreya/L-9758-2019; Hasan, Khader M./ABB-5767-2020	Govindarajan, Koushik/0000-0001-8397-1360			Assistant Secretary of Defense for Health Affairs, 2007, HLTH AFF MEM TRAUM B; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Corbo V, 2014, PSYCHIAT RES-NEUROIM, V223, P53, DOI 10.1016/j.pscychresns.2014.04.013; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Iscan Z, 2015, HUM BRAIN MAPP, V36, P3472, DOI 10.1002/hbm.22856; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keightley M., 2014, ARCH PHYS MED REHAB, V95, pe68; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Narayana PA, 2013, NEUROIMAGE-CLIN, V2, P120, DOI 10.1016/j.nicl.2012.11.009; Reuter M., 2012, LONGITUDINAL FREESUR; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Wang X, 2015, J NEUROTRAUM, V32, P455, DOI 10.1089/neu.2014.3492; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763	27	26	26	2	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2016	33	20					1809	1817		10.1089/neu.2015.4253			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EA6YO	WOS:000386775300001	26959810	Green Published			2022-02-06	
J	Armstead, WM; Riley, J; Vavilala, MS				Armstead, William M.; Riley, John; Vavilala, Monica S.			Norepinephrine Protects Cerebral Autoregulation and Reduces Hippocampal Necrosis after Traumatic Brain Injury via Blockade of ERK MAPK and IL-6 in Juvenile Pigs	JOURNAL OF NEUROTRAUMA			English	Article						age; brain injury; cerebral autoregulation; histopathology; sex; signal transduction; vasopressor	TRANSIENT HYPEREMIC RESPONSE; NITROUS-OXIDE; UP-REGULATION; CHILDREN; HYPOTENSION; IMPAIRMENT; PREDICTORS; NEWBORN; PHENYLEPHRINE; INTERLEUKIN-6	Traumatic brain injury (TBI) contributes to morbidity in children, and boys are disproportionately represented. Cerebral autoregulation is impaired after TBI, contributing to poor outcome. Cerebral perfusion pressure (CPP) is often normalized by use of vasoactive agents to increase mean arterial pressure (MAP). In prior studies of 1-to 5-day-old newborn piglets, we observed that norepinephrine (NE) preferentially protected cerebral autoregulation and prevented hippocampal necrosis in females but not males after fluid percussion injury (FPI). The ERK isoform of mitogen activated protein kinase (MAPK) produces hemodynamic impairment after FPI, but less is known about the role of the cytokine interleukin-6 (IL-6). We investigated whether NE protects autoregulation and limits histopathology after FPI in older juvenile (4-week-old) pigs and the role of ERK and IL-6 in that outcome by sex. Results show that NE significantly protects autoregulation and prevents reduction in cerebral blood flow (CBF) in both male and female juvenile pigs after FPI; co-administration of the ERK antagonist U 0126 with NE fully protects both indices of outcome. Papaverine induced dilation was unchanged by FPI and NE. NE blunted ERK MAPK and IL-6 upregulation in both males and females after FPI. NE attenuated loss of neurons in CA1 and CA3 hippocampus of males and females after FPI. These data indicate that NE protects autoregulation and limits hippocampal neuronal cell necrosis via blockade of ERK and IL-6 after FPI in both male and female juvenile pigs. These data suggest that use of NE to improve outcome after TBI is both sex and age dependent.	[Armstead, William M.; Riley, John] Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA		Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090998] Funding Source: NIH RePORTER		Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2016, PEDIATR CRIT CARE ME, V17, pe130, DOI 10.1097/PCC.0000000000000603; Armstead WM, 2013, PEDIATR CRIT CARE ME, V14, pE103, DOI 10.1097/PCC.0b013e3182712b44; Armstead WM, 2012, J NEUROTRAUM, V29, P1794, DOI 10.1089/neu.2012.2328; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead William M., 2016, ANESTHESIOLOGY CLIN, V34, P465; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1080/713773978; Bedford NM, 1999, ANESTH ANALG, V89, P170; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Dobbing J., 1981, SCI F PAEDIATRICS, P744; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Girling KJ, 1999, ANESTH ANALG, V89, P175, DOI 10.1097/00000539-199907000-00031; Ishikawa S, 2009, ANESTH ANALG, V108, P1631, DOI 10.1213/ane.0b013e31819d94e3; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Newacheck PW, 2004, PEDIATRICS, V114, P79, DOI 10.1542/peds.114.1.79; Oto J, 2008, J ANESTH, V22, P207, DOI 10.1007/s00540-008-0639-x; Sharma D, 2010, J NEUROSURG ANESTH, V22, P132, DOI 10.1097/ANA.0b013e3181c9fbf1; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Tibble RK, 2001, ANESTH ANALG, V93, P171; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037	27	26	28	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2016	33	19					1761	+		10.1089/neu.2015.4290			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DY8KP	WOS:000385379100004	26597684	Green Published			2022-02-06	
J	Gale, SC; Kocik, JF; Creath, R; Crystal, JS; Dombrovskiy, VY				Gale, Stephen C.; Kocik, Jurek F.; Creath, Robert; Crystal, Jessica S.; Dombrovskiy, Viktor Y.			A comparison of initial lactate and initial base deficit as predictors of mortality after severe blunt trauma	JOURNAL OF SURGICAL RESEARCH			English	Article						Lactate; Base deficit; Blunt trauma; Metabolic acidosis; Shock; Resuscitation	INTENSIVE-CARE-UNIT; SERUM LACTATE; ARTERIAL LACTATE; BLOOD LACTATE; CLEARANCE; ACIDOSIS; UTILITY; INJURY; SEPSIS; SHOCK	Background: After injury, base deficit (BD) and lactate are common measures of shock. Lactate directly measures anaerobic byproducts, whereas BD is calculated and multifactorial. Although recent studies suggest superiority for lactate in predicting mortality, most were small or analyzed populations with heterogeneous injury severity. Our objective was to compare initial BD with lactate as predictors of inhospital mortality in a large cohort of blunt trauma patients all presenting with hemorrhagic shock. Materials and methods: The Glue Grant multicenter prospective cohort database was queried; demographic, injury, and physiologic parameters were compiled. Survivors, early deaths (<= 24 h), and late deaths were compared. Profound shock (lactate >= 4 mmol/L) and severe traumatic brain injury subgroups were identified a priori. Chi-square, t-test, and analysis of variance were used as appropriate for analysis. Multivariable logistic regression and area under the receiver operating characteristic curve analysis assessed survival predictors. P < 0.05 was significant. Results: A total of 1829 patients met inclusion; 289 (15.8%) died. Both BD and lactate were higher for nonsurvivors (P < 0.00001). After multivariable regression, both lactate (odds ratio [OR] 1.17; 95% confidence interval [CI]: 1.12-1.23; P < 0.00001) and BD (OR 1.04; 95% CI: 1.01-1.07; P < 0.005) predicted overall mortality. However, when excluding early deaths (n = 77), only lactate (OR 1.12 95% CI: 1.06-1.19; P < 0.0001) remained predictive but not BD (OR 1.00 95% CI: 0.97-1.04; P = 0.89). For the shock subgroup, (n = 915), results were similar with lactate, but not BD, predicting both early and late deaths. Findings also appear independent of traumatic brain injury severity. Conclusions: After severe blunt trauma, initial lactate better predicts inhospital mortality than initial BD. Initial BD does not predict mortality for patients who survive > 24 h. (C) 2016 Elsevier Inc. All rights reserved.	[Gale, Stephen C.; Kocik, Jurek F.] East Texas Med Ctr, Trauma Serv, Dept Surg, Tyler, TX USA; [Creath, Robert] East Texas Med Ctr, Dept Emergency Med, Tyler, TX USA; [Crystal, Jessica S.; Dombrovskiy, Viktor Y.] Rutgers RWJMS, Dept Surg, New Brunswick, NJ USA		Gale, SC (corresponding author), East Texas Med Ctr, Ctr Trauma, Elmer G Ellis Level 1,1020 E Idel St, Tyler, TX 75701 USA.	scgale@etmc.org		Gale, Stephen/0000-0002-6454-4686	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM062119]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM062119] Funding Source: NIH RePORTER	The authors would like to acknowledge the contribution of Inflammation and the Host Response to Injury investigators in the Large-Scale Collaborative Research Program, supported by the National Institute of General Medical Sciences (U54GM062119). Also, they are grateful for the influence and mentorship of Ms. Susette Coyle, RN, and Drs Stephen Lowry (deceased), Siobhan Corbett, and Steven Calvano-all from the Robert Wood Johnson Medical School, a Glue Grant "participating institution." They were instrumental in understanding the potential that this data set holds for clinical investigation and in helping formulate the questions investigated in this and other studies. Finally, they thank Mr Elmer G. Ellis for institutional support at East Texas Medical Center in Tyler, Texas.	ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Callaway DW, 2009, J TRAUMA, V66, P1040, DOI 10.1097/TA.0b013e3181895e9e; Casserly B, 2015, CRIT CARE MED, V43, P567, DOI 10.1097/CCM.0000000000000742; Davis JW, 2006, J TRAUMA, V60, P587; Davis JW, 1998, J TRAUMA, V44, P114, DOI 10.1097/00005373-199801000-00014; Dezman ZDW, 2015, J TRAUMA ACUTE CARE, V79, P580, DOI 10.1097/TA.0000000000000810; Galkova K, 2013, BRATISL MED J, V114, P637, DOI 10.4149/BLL_2013_136; Husain FA, 2003, AM J SURG, V185, P485, DOI 10.1016/S0002-9610(03)00044-8; Kincaid EH, 1998, J AM COLL SURGEONS, V187, P384, DOI 10.1016/S1072-7515(98)00202-6; Lavery RF, 2000, J AM COLL SURGEONS, V190, P656, DOI 10.1016/S1072-7515(00)00271-4; Li K, 2015, INT J CLIN EXP MED, V8, P6578; Martin MJ, 2006, AM J SURG, V191, P625, DOI 10.1016/j.amjsurg.2006.02.014; Marty P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-3; McNelis J, 2001, AM J SURG, V182, P481, DOI 10.1016/S0002-9610(01)00755-3; Mikulaschek A, 1996, J TRAUMA, V40, P218, DOI 10.1097/00005373-199602000-00008; Neville AL, 2011, AM SURGEON, V77, P1337; Odom SR, 2013, J TRAUMA ACUTE CARE, V74, P999, DOI 10.1097/TA.0b013e3182858a3e; Ouellet JF, 2012, J TRAUMA ACUTE CARE, V72, P1532, DOI 10.1097/TA.0b013e318256dd5a; Pal JD, 2006, J TRAUMA, V60, P583, DOI 10.1097/01.ta.0000205858.82575.55; Paladino L, 2008, RESUSCITATION, V77, P363, DOI 10.1016/j.resuscitation.2008.01.022; Regnier MA, 2012, ANESTHESIOLOGY, V117, P1276, DOI 10.1097/ALN.0b013e318273349d; Trauma Related Database (TRDB), 2011, INFL HOST RESP INJ	22	26	27	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2016	205	2					446	455		10.1016/j.jss.2016.06.103			10	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	EC2VG	WOS:000387981700025	27664895				2022-02-06	
J	Hill, JL; Kobori, N; Zhao, J; Rozas, NS; Hylin, MJ; Moore, AN; Dash, PK				Hill, Julia L.; Kobori, Nobuhide; Zhao, Jing; Rozas, Natalia S.; Hylin, Michael J.; Moore, Anthony N.; Dash, Pramod K.			Traumatic brain injury decreases AMP-activated protein kinase activity and pharmacological enhancement of its activity improves cognitive outcome	JOURNAL OF NEUROCHEMISTRY			English	Article						glucose metabolism; hippocampus; memory retention; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBOSIDE; ENERGY HOMEOSTASIS; CYCLOSPORINE-A; RAT; GLUCOSE; METFORMIN; REDUCTION; METABOLISM	Prolonged metabolic suppression in the brain is a well-characterized secondary pathology of both experimental and clinical traumatic brain injury (TBI). AMP-activated kinase (AMPK) acts as a cellular energy sensor that, when activated, regulates various metabolic and catabolic pathways to decrease ATP consumption and increase ATP synthesis. As energy availability after TBI is suppressed, we questioned if increasing AMPK activity after TBI would improve cognitive outcome. TBI was delivered using the electromagnetic controlled cortical impact model on male Sprague-Dawley rats (275-300g) and C57BL/6 mice (20-25g). AMPK activity within the injured parietal cortex and ipsilateral hippocampus was inferred by western blots using phospho-specific antibodies. The consequences of acute manipulation of AMPK signaling on cognitive function were assessed using the Morris water maze task. We found that AMPK activity is decreased as a result of injury, as indicated by reduced AMPK phosphorylation and corresponding changes in the phosphorylation of its downstream targets: ribosomal protein S6 and Akt Substrate of 160kDa (AS160). Increasing AMPK activity after injury using the drugs 5-amino-1--d-ribofuranosyl-imidazole-4-carboxamide or metformin did not affect spatial learning, but significantly improved spatial memory. Taken together, our results suggest that decreased AMPK activity after TBI may contribute to the cellular energy crisis in the injured brain, and that AMPK activators may have therapeutic utility.	[Hill, Julia L.; Kobori, Nobuhide; Zhao, Jing; Rozas, Natalia S.; Hylin, Michael J.; Moore, Anthony N.; Dash, Pramod K.] McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA; [Hylin, Michael J.] Southern Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA		Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston UTHlth, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019	Hill, Julia/0000-0003-4744-0532; Rozas, Natalia/0000-0003-0848-0478; Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS086301, NS090935]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086301, R01NS101686, R01NS090935] Funding Source: NIH RePORTER	The authors thank Sara Orsi and Kimberly Hood for their technical help, and Dr John Redell for his critical reading of the manuscript. This work was supported by a grant from NIH (NS086301, NS090935). The authors do not have any conflicts of interest to declare.	Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Ashabi G, 2015, METAB BRAIN DIS, V30, P747, DOI 10.1007/s11011-014-9632-2; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Blum S, 1999, J NEUROSCI, V19, P3535; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Chen KH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106554; Cheng XL, 2013, J CHROMATOGR B, V915, P64, DOI 10.1016/j.jchromb.2012.12.020; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FABIANOWSKAMAJEWSKA K, 1994, BIOCHEM PHARMACOL, V48, P897, DOI 10.1016/0006-2952(94)90360-3; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guerrieri D, 2015, ONCOTARGET, V6, P18293, DOI 10.18632/oncotarget.4715; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hattori N, 2003, J NUCL MED, V44, P1709; Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Jin XS, 2007, STRUCTURE, V15, P1285, DOI 10.1016/j.str.2007.07.017; Karagounis LG, 2009, INT J BIOCHEM CELL B, V41, P2360, DOI 10.1016/j.biocel.2009.07.004; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kokiko-Cochran ON, 2008, NEUROSCI LETT, V436, P27, DOI 10.1016/j.neulet.2008.02.046; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Li J, 2007, STROKE, V38, P2992, DOI 10.1161/STROKEAHA.107.490904; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; MARANGOS PJ, 1990, EPILEPSIA, V31, P239, DOI 10.1111/j.1528-1157.1990.tb05371.x; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Moro N, 2011, NEUROSCI LETT, V491, P158, DOI 10.1016/j.neulet.2011.01.029; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Park HG, 2011, PROG NEURO-PSYCHOPH, V35, P1933, DOI 10.1016/j.pnpbp.2011.09.008; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Rena G, 2013, DIABETOLOGIA, V56, P1898, DOI 10.1007/s00125-013-2991-0; Rousset CI, 2015, J NEUROCHEM, V133, P242, DOI 10.1111/jnc.13034; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Treebak JT, 2006, DIABETES, V55, P2051, DOI 10.2337/db06-0175; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Weisova P, 2009, J NEUROSCI, V29, P2997, DOI 10.1523/JNEUROSCI.0354-09.2009; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Xing GQ, 2012, NEUROSCI LETT, V525, P140, DOI 10.1016/j.neulet.2012.07.055; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhao YH, 2016, STEM CELLS, V34, P1263, DOI 10.1002/stem.2310; Zhou L, 2000, Zhongguo Zhong Xi Yi Jie He Za Zhi, V20, P356	76	26	27	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2016	139	1					106	119		10.1111/jnc.13726			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	DX8RT	WOS:000384657500010	27379837	Bronze, Green Accepted			2022-02-06	
J	van der Ploeg, T; Nieboer, D; Steyerberg, EW				van der Ploeg, Tjeerd; Nieboer, Daan; Steyerberg, Ewout W.			Modern modeling techniques had limited external validity in predicting mortality from traumatic brain injury	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Prediction models; Modeling techniques; Internal validation; External validation; Discrimination; Calibration	LOGISTIC-REGRESSION; VALIDATION; RISK; PERFORMANCE; SIMULATION; PROGNOSIS; DESIGN	Background and Objective: Prediction of medical outcomes may potentially benefit from using modern statistical modeling techniques. We aimed to externally validate modeling strategies for prediction of 6 -month mortality of patients suffering from traumatic brain injury (TBI) with predictor sets of increasing complexity. Methods: We analyzed individual patient data from 15 different studies including 11,026 TBI patients. We consecutively considered a core set of predictors (age, motor score, and pupillary reactivity), an extended set with computed tomography scan characteristics, and a further extension with two laboratory measurements (glucose and hemoglobin). With each of these sets, we predicted 6-month mortality using default settings with five statistical modeling techniques: logistic regression (LR), classification and regression trees, random forests (RFs), support vector machines (SVM) and neural nets. For external validation, a model developed on one of the 15 data sets was applied to each of the 14 remaining sets. This process was repeated 15 times for a total of 630 validations. The area under the receiver operating characteristic curve (AUC) was used to assess the discriminative ability of the models. Results: For the most complex predictor set, the LR models performed best (median validated AUC value, 0.757), followed by RF and support vector machine models (median validated AUC value, 0.735 and 0.732, respectively). With each predictor set, the classification and regression trees models showed poor performance (median validated AUC value, <0.7). The variability in performance across the studies was smallest for the RF-and LR-based models (inter quartile range for validated AUC values from 0.07 to 0.10). Conclusion: In the area of predicting mortality from TBI, nonlinear and nonadditive effects are not pronounced enough to make modern prediction methods beneficial. (C) 2016 Elsevier Inc. All rights reserved.	[van der Ploeg, Tjeerd] Med Ctr Alkmaar, Dept Sci, Wilhelminalaan 12, NL-1815 JD Alkmaar, Netherlands; [van der Ploeg, Tjeerd] Inholland Univ, Dept Sci, Bergerweg 200, NL-1817 MN Alkmaar, Netherlands; [van der Ploeg, Tjeerd; Nieboer, Daan; Steyerberg, Ewout W.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands		van der Ploeg, T (corresponding author), Med Ctr Alkmaar, Dept Sci, Wilhelminalaan 12, NL-1815 JD Alkmaar, Netherlands.; van der Ploeg, T (corresponding author), Inholland Univ, Dept Sci, Bergerweg 200, NL-1817 MN Alkmaar, Netherlands.; van der Ploeg, T (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	tvdploeg@quicknet.nl		van der Ploeg, Tjeerd/0000-0003-0429-6753			Austin PC, 2013, STAT MED, V32, P661, DOI 10.1002/sim.5598; Bleeker SE, 2003, J CLIN EPIDEMIOL, V56, P826, DOI 10.1016/S0895-4356(03)00207-5; Breiman L., 1984, CLASSIFICATION REGRE, V19; Collins GS, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-40; Colombet I, 2000, J AM MED INFORM ASSN, P156; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Ecke TH, 2012, ISRN UROL, V2012; Eftekhar Behzad, 2005, BMC Med Inform Decis Mak, V5, P3; Ennis M, 1998, STAT MED, V17, P2501; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell FE Jr, 2017, REGRESSION MODELING; Hastie T., 2009, ELEMENTS STAT LEARNI, V2; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1976, LANCET, V1, P1031; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Konig IR, 2007, STAT MED, V26, P5499, DOI 10.1002/sim.3069; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Maroco Joao, 2011, BMC Res Notes, V4, P299, DOI 10.1186/1756-0500-4-299; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; R Development Core Team, 2011, R LANG ENV STAT COMP, DOI 10.1007/978-3-540-74686-7; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Siontis GCM, 2015, J CLIN EPIDEMIOL, V68, P25, DOI 10.1016/j.jclinepi.2014.09.007; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.3.CO;2-S; Steyerberg EW, 2009, CLIN PREDICTION MODE, V19; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Terrin N, 2003, J CLIN EPIDEMIOL, V56, P721, DOI 10.1016/S0895-4356(03)00120-3; Tuffery S., 2011, DATA MINING STAT DEC; van der Ploeg T, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-137; van der Ploeg T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100234; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Young NH, 2008, PLOS MED, V5, P1186, DOI 10.1371/journal.pmed.0050168	38	26	26	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	OCT	2016	78						83	89		10.1016/j.jclinepi.2016.03.002			7	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services; Public, Environmental & Occupational Health	EE4ZV	WOS:000389615400011	26987507				2022-02-06	
J	Faul, M; Xu, LK; Sasser, SM				Faul, Mark; Xu, Likang; Sasser, Scott M.			HOSPITALIZED TRAUMATIC BRAIN INJURY: LOW TRAUMA CENTER UTILIZATION AND HIGH INTERFACILITY TRANSFERS AMONG OLDER ADULTS	PREHOSPITAL EMERGENCY CARE			English	Article						TBI; Traumatic Brain Injury; Field triage; Brain Trauma Foundation Guidelines; Field Triage Guidelines; ambulance; transport; older adults; children	LEVEL I; DIRECT TRANSPORT; OUTCOMES; GUIDELINES; IMPACT; MORTALITY; TRENDS; TRIAGE	Objective: Guidelines suggest that Traumatic Brain Injury (TBI) related hospitalizations are best treated at Level I or II trauma centers because of continuous neurosurgical care in these settings. This population-based study examines TBI hospitalization treatment paths by age groups. Methods: Trauma center utilization and transfers by age groups were captured by examining the total number of TBI hospitalizations from National Inpatient Sample (NIS) and the number of TBI hospitalizations and transfers in the Trauma Data Bank National Sample Population (NTDB-NSP). TBI cases were defined using diagnostic codes. Results: Of the 351,555 TBI related hospitalizations in 2012, 47.9% (n = 168,317) were directly treated in a Level I or II trauma center, and an additional 20.3% (n = 71,286) were transferred to a Level I or II trauma center. The portion of the population treated at a trauma center (68.2%) was significantly lower than the portion of the U.S. population who has access to a major trauma center (90%). Further, nearly half of all transfers to a Level I or II trauma center were adults aged 55 and older (p < 0.001) and that 20.2% of pediatric patients arrive by non-ambulatory means. Conclusion: Utilization of trauma center resources for hospitalized TBIs may be low considering the established lower mortality rate associated with treatment at Level I or II trauma centers. The higher transfer rate for older adults may suggest rapid decline amid an unrecognized initial need for a trauma center care. A better understanding of hospital destination decision making is needed for patients with TBI.	[Faul, Mark] Ctr Dis Control & Prevent, 4770 Buford Highway, Atlanta, GA 30341 USA; Greenville Hlth Syst, Dept Emergency Med, Greenville, SC USA		Faul, M (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Highway, Atlanta, GA 30341 USA.	mfaul@cdc.gov		Faul, Mark/0000-0002-7683-0348	Intramural CDC HHS [CC999999] Funding Source: Medline		American College of Surgeons, 2006, RES OPT CAR INJ PAT; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barber MA, 2012, J TRAUMA ACUTE CARE, V73, P558, DOI 10.1097/TA.0b013e318265cb75; Berlot G, 2009, EUR J EMERG MED, V16, P312, DOI 10.1097/MEJ.0b013e32832d3aa1; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chisholm KM, 2010, AM J FOREN MED PATH, V31, P350, DOI 10.1097/PAF.0b013e3181f69c87; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; Dillingham TR, 1998, ARCH PHYS MED REHAB, V79, P279, DOI 10.1016/S0003-9993(98)90007-7; Esposito TJ, 2006, J TRAUMA, V61, P1380, DOI 10.1097/01.ta.0000242862.68899.04; Faul M, 2010, TRAUMATIC BRAIN INJU; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Faul M, 2015, WEST J EMERG MED, V16, P98, DOI 10.5811/westjem.2014.10.22837; Garwe T, 2011, J TRAUMA, V70, P1118, DOI 10.1097/TA.0b013e3181e243b8; Goble S, 2009, J TRAUMA, V67, P637, DOI 10.1097/TA.0b013e3181b84294; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Joosse P, 2012, J TRAUMA ACUTE CARE, V72, P487, DOI 10.1097/TA.0b013e318226ed59; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lane P, 2003, ACAD EMERG MED, V10, P244, DOI 10.1197/aemj.10.3.244; Mahapatra AK, 2012, TXB TRAUMATIC BRAIN, P40; Mann NC, 1999, J TRAUMA, V47, pS25, DOI 10.1097/00005373-199909001-00007; Marion DW, 1997, NE J MED, V336, P541; Newgard CD, 2014, PREHOSP EMERG CARE, V18, P461, DOI 10.3109/10903127.2014.912707; Pitts LH, 1998, J TRAUMA, V44, P989; Qato DM, 2008, JAMA-J AM MED ASSOC, V300, P2867, DOI 10.1001/jama.2008.892; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Roudsari B, 2012, AM J ROENTGENOL, V198, P985, DOI 10.2214/AJR.11.6976; Ryb GE, 2011, J TRAUMA, V71, P742, DOI 10.1097/TA.0b013e31822ba010; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SAS Institute Inc, 2013, SAS VERS 9 3; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Scheetz LJ, 2012, J EMERG MED, V43, P1020, DOI 10.1016/j.jemermed.2011.09.036; Smith NL, 1999, ARCH INTERN MED, V159, P1574, DOI 10.1001/archinte.159.14.1574; Staudenmayer KL, 2013, J AM COLL SURGEONS, V217, P569, DOI 10.1016/j.jamcollsurg.2013.06.017; Tauber M, 2009, J TRAUMA, V67, P521, DOI 10.1097/TA.0b013e3181a7c184; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	42	26	26	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	SEP-OCT	2016	20	5					594	600		10.3109/10903127.2016.1149651			7	Emergency Medicine; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Public, Environmental & Occupational Health	DW8OI	WOS:000383915000007	26986195	Green Accepted			2022-02-06	
J	Madsen, PM; Clausen, BH; Degn, M; Thyssen, S; Kristensen, LK; Svensson, M; Ditzel, N; Finsen, B; Deierborg, T; Brambilla, R; Lambertsen, KL				Madsen, Pernille M.; Clausen, Bettina H.; Degn, Matilda; Thyssen, Stine; Kristensen, Lotte K.; Svensson, Martina; Ditzel, Nicholas; Finsen, Bente; Deierborg, Tomas; Brambilla, Roberta; Lambertsen, Kate L.			Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Tumor necrosis factor; microglia; macrophages; neuroprotection; behavior; cytokines; chemokines	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MICROGLIAL-MACROPHAGE SYNTHESIS; FACTOR-ALPHA GENE; TNF RECEPTOR 2; ARTERY OCCLUSION; INFLAMMATORY RESPONSES; TRANSMEMBRANE TNF; INFARCT VOLUME; DEFICIENT MICE	Microglia respond to focal cerebral ischemia by increasing their production of the neuromodulatory cytokine tumor necrosis factor, which exists both as membrane-anchored tumor necrosis factor and as cleaved soluble tumor necrosis factor forms. We previously demonstrated that tumor necrosis factor knockout mice display increased lesion volume after focal cerebral ischemia, suggesting that tumor necrosis factor is neuroprotective in experimental stroke. Here, we extend our studies to show that mice with intact membrane-anchored tumor necrosis factor, but no soluble tumor necrosis factor, display reduced infarct volumes at one and five days after stroke. This was associated with improved functional outcome after experimental stroke. No changes were found in the mRNA levels of tumor necrosis factor and tumor necrosis factor-related genes (TNFR1, TNFR2, TACE), pro-inflammatory cytokines (IL-1, IL-6) or chemokines (CXCL1, CXCL10, CCL2); however, protein expression of TNF, IL-1, IL-6 and CXCL1 was reduced in membrane-anchored tumor necrosis factor(/) compared to membrane-anchored tumor necrosis factor(wt/wt) mice one day after experimental stroke. This was paralleled by reduced MHCII expression and a reduction in macrophage infiltration in the ipsilateral cortex of membrane-anchored tumor necrosis factor(/) mice. Collectively, these findings indicate that membrane-anchored tumor necrosis factor mediates the protective effects of tumor necrosis factor signaling in experimental stroke, and therapeutic strategies specifically targeting soluble tumor necrosis factor could be beneficial in clinical stroke therapy.	[Madsen, Pernille M.; Clausen, Bettina H.; Thyssen, Stine; Kristensen, Lotte K.; Finsen, Bente; Lambertsen, Kate L.] Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, Winsloewpk 25,2, DK-5000 Odense C, Denmark; [Madsen, Pernille M.; Brambilla, Roberta] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA; [Degn, Matilda] Glostrup Cty Hosp, Dept Diagnost, Mol Sleep Lab, Glostrup, Denmark; [Svensson, Martina; Deierborg, Tomas] Lund Univ, Dept Expt Med Sci, Expt Neuroinflammat Lab, Lund, Sweden; [Ditzel, Nicholas] Odense Univ Hosp, KMEB, Mol Endocrinol, Odense, Denmark		Lambertsen, KL (corresponding author), Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, Winsloewpk 25,2, DK-5000 Odense C, Denmark.; Brambilla, R (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	r.brambilla@miami.edu; klambertsen@health.sdu.dk	Deierborg, Tomas/P-6345-2015; Lambertsen, Kate L./I-8676-2014	Deierborg, Tomas/0000-0002-3651-3444; Lambertsen, Kate L./0000-0001-9276-4902; Clausen, Bettina Hjelm/0000-0003-3302-2022; Finsen, Bente/0000-0002-8323-9329; Degn, Matilda/0000-0003-3093-3525; Madsen, pernille/0000-0003-0558-2460	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS084303-01A1]; Miami Project To Cure Paralysis; Lundbeck FoundationLundbeckfonden [R67-A6383, R54-A5539]; Carlsberg FoundationCarlsberg Foundation [2007_01_0176]; Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited [R153-A12550, R168-A14120]; Fonden til Laegevidenskabens Fremme; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094522] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institute of Health grant NS084303-01A1 (RB); The Miami Project To Cure Paralysis (RB); The Lundbeck Foundation (BHC (R67-A6383) and KLL (R54-A5539)); The Carlsberg Foundation (2007_01_0176), The Novo Nordisk Foundation (R153-A12550 & R168-A14120), and Fonden til Laegevidenskabens Fremme (KLL).	Alexopoulou L, 2006, EUR J IMMUNOL, V36, P2768, DOI 10.1002/eji.200635921; Ando T, 1999, NEUROIMMUNOMODULAT, V6, P319, DOI 10.1159/000026391; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Bach A, 2012, P NATL ACAD SCI USA, V109, P3317, DOI 10.1073/pnas.1113761109; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Barker V, 2001, NAT NEUROSCI, V4, P1194, DOI 10.1038/nn755; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Baune BT, 2008, AM J MED GENET B, V147B, P1056, DOI 10.1002/ajmg.b.30712; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brambilla R, 2011, BRAIN, V134, P2736, DOI 10.1093/brain/awr199; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Cabal-Hierro L, 2012, CELL SIGNAL, V24, P1297, DOI 10.1016/j.cellsig.2012.02.006; Castellanos M, 2002, STROKE, V33, P982, DOI 10.1161/hs0402.105339; Chen ZG, 2013, BRAIN BEHAV IMMUN, V30, P45, DOI 10.1016/j.bbi.2013.01.083; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clausen BH, 2006, EXP BRAIN RES, V175, P60, DOI 10.1007/s00221-006-0526-3; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Clausen BH, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0203-6; Clausen BH, 2005, NEUROSCIENCE, V132, P879, DOI 10.1016/j.neuroscience.2005.01.031; Cui GL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-235; Cunningham CL, 2013, J NEUROSCI, V33, P4216, DOI 10.1523/JNEUROSCI.3441-12.2013; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/S0304-3940(96)13116-5; Dziewulska D, 2003, CLIN NEUROPATHOL, V22, P35; Edelblum KL, 2008, J BIOL CHEM, V283, P29485, DOI 10.1074/jbc.M801269200; Fischer R, 2014, GLIA, V62, P272, DOI 10.1002/glia.22605; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Gimsa U, 2012, CYTOKINE, V59, P72, DOI 10.1016/j.cyto.2012.04.001; Golan H, 2004, SYNAPSE, V53, P6, DOI 10.1002/syn.20032; Golan H, 2004, CEREB CORTEX, V14, P97, DOI 10.1093/cercor/bhg108; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Gu L, 2013, AM J MED SCI, V345, P227, DOI 10.1097/MAJ.0b013e31825f92da; Gu L, 2013, INT J NEUROSCI, V123, P1, DOI 10.3109/00207454.2012.725118; Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363; Hill JK, 1999, BRAIN RES, V820, P45, DOI 10.1016/S0006-8993(98)01140-8; Holtmann MH, 2004, CURR MOL MED, V4, P439, DOI 10.2174/1566524043360636; Intiso D, 2004, NEUROL SCI, V24, P390, DOI 10.1007/s10072-003-0194-z; Lambertsen KL, 2007, NEUROSCIENCE, V144, P934, DOI 10.1016/j.neuroscience.2006.10.046; Lambertsen KL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-123; Lambertsen KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047744; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Lambertsen KL, 2004, J NEUROPATH EXP NEUR, V63, P942, DOI 10.1093/jnen/63.9.942; Lambertsen KL, 2002, J CEREBR BLOOD F MET, V22, P785, DOI 10.1097/00004647-200207000-00004; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lewitus GM, 2014, J NEUROSCI, V34, P6146, DOI 10.1523/JNEUROSCI.3481-13.2014; Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; LIU T, 1993, NEUROSCI LETT, V164, P125, DOI 10.1016/0304-3940(93)90873-J; Lyck L, 2007, EUR J NEUROSCI, V26, P1749, DOI 10.1111/j.1460-9568.2007.05763.x; Maier O, 2013, BIOCHEM BIOPH RES CO, V440, P336, DOI 10.1016/j.bbrc.2013.09.083; Mazzotta G, 2004, EUR J NEUROL, V11, P377, DOI 10.1111/j.1468-1331.2004.00798.x; McAfoose J, 2009, PSYCHONEUROENDOCRINO, V34, P615, DOI 10.1016/j.psyneuen.2008.10.006; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; MOLLER A, 1995, NEUROL RES, V17, P353; Naude PJW, 2014, BEHAV BRAIN RES, V258, P43, DOI 10.1016/j.bbr.2013.10.006; Novrup HG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0159-6; Olleros ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031469; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Patel A, 2010, BRAIN BEHAV IMMUN, V24, P1276, DOI 10.1016/j.bbi.2010.05.005; Patel JR, 2012, ACTA NEUROPATHOL, V124, P847, DOI 10.1007/s00401-012-1034-0; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Pradillo JM, 2005, J CEREBR BLOOD F MET, V25, P193, DOI 10.1038/sj.jcbfm.9600019; Probert L, 2015, NEUROSCIENCE, V302, P2, DOI 10.1016/j.neuroscience.2015.06.038; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; Saunders BM, 2005, J IMMUNOL, V174, P4852, DOI 10.4049/jimmunol.174.8.4852; Simen BB, 2006, BIOL PSYCHIAT, V59, P775, DOI 10.1016/j.biopsych.2005.10.013; Sotgiu S, 2006, EUR J NEUROL, V13, P505, DOI 10.1111/j.1468-1331.2006.01280.x; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Sumbria RK, 2012, J CEREBR BLOOD F MET, V32, P1933, DOI 10.1038/jcbfm.2012.97; Taoufik E, 2008, NEURODEGENER DIS, V5, P32, DOI 10.1159/000109936; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Taoufik E, 2007, J NEUROSCI, V27, P6633, DOI 10.1523/JNEUROSCI.1091-07.2007; Taoufik E, 2011, BRAIN, V134, P2722, DOI 10.1093/brain/awr203; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Torres D, 2005, AM J PATHOL, V167, P1677, DOI 10.1016/S0002-9440(10)61250-3; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; Veroni C, 2010, MOL CELL NEUROSCI, V45, P234, DOI 10.1016/j.mcn.2010.06.014; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; Wang XK, 1998, J NEUROCHEM, V71, P1194; Wirenfeldt M, 2007, AM J PATHOL, V171, P617, DOI 10.2353/ajpath.2007.061044; Yamada K, 2000, J NEUROIMMUNOL, V111, P131, DOI 10.1016/S0165-5728(00)00375-1; Zaremba J, 2001, Folia Morphol (Warsz), V60, P91; Zaremba J, 2001, ACTA NEUROL SCAND, V104, P288, DOI 10.1034/j.1600-0404.2001.00053.x	95	26	26	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2016	36	9					1553	1569		10.1177/0271678X15610339			17	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	DV5UU	WOS:000382996800007	26661199	Green Submitted, Green Published, Bronze			2022-02-06	
J	Wang, Q; Fan, WJ; Cai, Y; Wu, QL; Mo, LD; Huang, ZW; Huang, HL				Wang, Qin; Fan, Weijia; Cai, Ying; Wu, Qiaoli; Mo, Lidong; Huang, Zhenwu; Huang, Huiling			Protective effects of taurine in traumatic brain injury via mitochondria and cerebral blood flow	AMINO ACIDS			English	Article						Traumatic brain injury; Taurine; Mitochondrion; Cerebral blood flow	ENDOPLASMIC-RETICULUM STRESS; ANTIOXIDANT ACTIVITY; DYSFUNCTION; METABOLISM; RESUSCITATION; INFLAMMATION; MORPHOLOGY; MECHANISM; APOPTOSIS; CALCIUM	In mammalian tissues, taurine is an important natural component and the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. This study is to examine the taurine's protective effects on neuronal ultrastructure, the function of the mitochondrial respiratory chain complex, and on cerebral blood flow (CBF). The model of traumatic brain injury (TBI) was made for SD rats by a fluid percussion device, with taurine (200 mg/kg) administered by tail intravenous injection once daily for 7 days after TBI. It was found that CBF was improved for both left and right brain at 30 min and 7 days post-injury by taurine. Reaction time was prolonged relative to the TBI-only group. Neuronal damage was prevented by 7 days taurine. Mitochondrial electron transport chain complexes I and II showed greater activity with the taurine group. The improvement by taurine of CBF may alleviate edema and elevation in intracranial pressure. Importantly taurine improved the hypercoagulable state.	[Wang, Qin; Huang, Zhenwu] Chinese Ctr Dis Control & Prevent, Natl Inst Nutr & Hlth, 27 Nanwei Rd, Beijing 100050, Peoples R China; [Wang, Qin; Fan, Weijia; Cai, Ying; Wu, Qiaoli; Mo, Lidong; Huang, Huiling] Tianjin Huanhu Hosp, Tianjin Neurol Inst, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, 6 Jizhao Rd, Tianjin 300350, Peoples R China		Huang, HL (corresponding author), Tianjin Huanhu Hosp, Tianjin Neurol Inst, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, 6 Jizhao Rd, Tianjin 300350, Peoples R China.	huanghuiling@126.com		, Qin/0000-0002-5891-9621	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973089, 81571216]	The authors would like to thank support from the National Natural Science Foundation of China (Grant Nos. 30973089 and 81571216).	Aly HAA, 2014, FOOD CHEM TOXICOL, V64, P1, DOI 10.1016/j.fct.2013.11.007; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Curtis L, 2014, J NEUROSURG SCI, V58, P151; Dagal A, 2011, CURR OPIN ANESTHESIO, V24, P131, DOI 10.1097/ACO.0b013e3283445898; El Idrissi A, 2008, AMINO ACIDS, V34, P321, DOI 10.1007/s00726-006-0396-9; Gharibani PM, 2013, ADV EXP MED BIOL, V776, P241, DOI 10.1007/978-1-4614-6093-0_23; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; Guan WH, 2011, TRANSL STROKE RES, V2, P80, DOI 10.1007/s12975-010-0050-4; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155; Johansson PI, 2013, TRANSFUSION, V53, P3088, DOI 10.1111/trf.12214; Jong CJ, 2015, AMINO ACIDS, V47, P2609, DOI 10.1007/s00726-015-2053-7; Jong CJ, 2012, AMINO ACIDS, V42, P2223, DOI 10.1007/s00726-011-0962-7; Kallakuri S, 2015, J CLIN IMAG SCI, V5, DOI 10.4103/2156-7514.166354; Keelan J, 1999, BRAIN RES, V821, P124, DOI 10.1016/S0006-8993(99)01084-7; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kim C, 2014, AMINO ACIDS, V46, P89, DOI 10.1007/s00726-013-1545-6; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Luddington RJ, 2005, CLIN LAB HAEMATOL, V27, P81, DOI 10.1111/j.1365-2257.2005.00681.x; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Menzie J, 2014, AMINO ACIDS, V46, P31, DOI 10.1007/s00726-012-1382-z; Nakajima Y, 2010, J NEUROTRAUM, V27, P403, DOI 10.1089/neu.2009.1044; Pan CL, 2012, AMINO ACIDS, V43, P845, DOI 10.1007/s00726-011-1141-6; Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1; Peterson EC, 2011, INT J VASC MED, V2011, DOI 10.1155/2011/823525; Prentice H, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964518; Rak K, 2014, NEUROREPORT, V25, P1250, DOI 10.1097/WNR.0000000000000254; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Rosca AE, 2013, BLOOD COAGUL FIBRIN, V24, P256, DOI 10.1097/MBC.0b013e32835b7611; Schaffer S, 2000, AMINO ACIDS, V19, P527, DOI 10.1007/s007260070004; Schaffer S, 2016, AMINO ACIDS, V48, P549, DOI 10.1007/s00726-015-2110-2; Schaffer SW, 2014, AMINO ACIDS, V46, P1147, DOI 10.1007/s00726-014-1708-0; Schaffer SW, 2014, AMINO ACIDS, V46, P21, DOI 10.1007/s00726-012-1378-8; Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6; Setyarani M, 2014, EUR J NUTR, V53, P929, DOI 10.1007/s00394-013-0596-5; Shimada K, 2015, ADV EXP MED BIOL, V803, P581, DOI 10.1007/978-3-319-15126-7_47; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Sun M, 2015, J NEUROTRAUM, V32, P66, DOI 10.1089/neu.2012.2432; Sun M, 2012, AMINO ACIDS, V42, P1735, DOI 10.1007/s00726-011-0885-3; Sun M, 2011, AMINO ACIDS, V40, P1419, DOI 10.1007/s00726-010-0751-8; Sun QR, 2014, BIOCHEM BIOPH RES CO, V447, P485, DOI 10.1016/j.bbrc.2014.04.019; Tapia NM, 2013, J TRAUMA ACUTE CARE, V74, P378, DOI 10.1097/TA.0b013e31827e20e0; Vlodavsky E, 2017, J CEREBR BLOOD F MET, V37, P166, DOI 10.1177/0271678X15621068; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang YJ, 2013, ACTA BIOCH BIOPH SIN, V45, P359, DOI 10.1093/abbs/gmt034; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zhou F, 2006, ADV EXP MED BIOL, V583, P353; Zhu KJ, 2014, WORLD J GASTROENTERO, V20, P9585, DOI 10.3748/wjg.v20.i28.9585	57	26	26	2	13	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0939-4451	1438-2199		AMINO ACIDS	Amino Acids	SEP	2016	48	9					2169	2177		10.1007/s00726-016-2244-x			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DU1XR	WOS:000382004500007	27156064				2022-02-06	
J	Mustafa, G; Hou, JM; Tsuda, S; Nelson, R; Sinharoy, A; Wilkie, Z; Pandey, R; Caudle, RM; Neubert, JK; Thompson, FJ; Bose, P				Mustafa, Golam; Hou, Jiamei; Tsuda, Shigeharu; Nelson, Rachel; Sinharoy, Ankita; Wilkie, Zachary; Pandey, Rahul; Caudle, Robert M.; Neubert, John K.; Thompson, Floyd J.; Bose, Prodip			Trigeminal neuroplasticity underlies allodynia in a preclinical model of mild closed head traumatic brain injury (cTBI)	NEUROPHARMACOLOGY			English	Article						Closed head TBI; Facial allodynia; Trigeminal sensitization; Operant conditioning	SUBSTANCE-P; SPINAL-CORD; LOCUS-COERULEUS; NEUROKININ-1 RECEPTOR; GABAERGIC NEURONS; OROFACIAL PAIN; POSTTRAUMATIC HEADACHES; FUNCTIONAL NEUROANATOMY; CENTRAL SENSITIZATION; DOWN-REGULATION	Post-traumatic headache (PTH) following TBI is a common and often persisting pain disability. PTH is often associated with a multimodal central pain sensitization on the skin surface described as allodynia. However, the particular neurobiology underlying cTBI-induced pain disorders are not known. These studies were performed to assess trigeminal sensory sensitization and to determine if sensitization measured behaviorally correlated with detectable changes in portions of the trigeminal sensory system (TSS), particularly trigeminal nucleus, thalamus, and sensory cortex. Thermal stimulation is particularly well suited to evaluate sensitization and was used in these studies. Recent advances in the use of reward/conflict paradigms permit use of operant measures of behavior, versus reflex-driven response behaviors, for thermal sensitization studies. Thus, to quantitate facial thermal sensitization (allodynia) in the setting of acute TBI, the current study utilized an operant orofacial pain reward/conflict testing paradigm to assess facial thermal sensitivity in uninjured control animals compared with those two weeks after cTBI in a rodent model. Significant reductions in facial contact/lick behaviors were observed in the TBI animals using either cool or warm challenge temperatures compared with behaviors in the normal animals. These facial thermal sensitizations correlated with detectable changes in multiple levels of the TSS. The immunohistochemical (IHC) studies revealed significant alterations in the expression of the serotonin (5 HT), neurokinin 1 receptor (NK1R), norepinephrine (NE), and gamma-aminobutyric acid (GABA) in the caudal trigeminal nucleus, thalamic VPL/VPM nucleus, and sensory cortex of the orofacial pain pathways. There was a strong correlation between increased expression of certain IHC markers and increased behavioral markers for facial sensitization. The authors conclude that TBI-induced changes observed in the TSS are consistent with the expression of generalized facial allodynia following cTBI. To our knowledge, this is the first report of orofacial sensitization correlated with changes in selected neuromodulators/neurotransmitters in the TSS following experimental mild TBI. Published by Elsevier Ltd.	[Mustafa, Golam; Hou, Jiamei; Nelson, Rachel; Sinharoy, Ankita; Wilkie, Zachary; Pandey, Rahul; Thompson, Floyd J.; Bose, Prodip] North Florida South Georgia Vet Hlth Syst, Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr Excellence, Gainesville, FL 32608 USA; [Mustafa, Golam; Hou, Jiamei; Tsuda, Shigeharu; Thompson, Floyd J.; Bose, Prodip] Univ Florida, Coll Vet Med, Dept Physiol Sci, Gainesville, FL 32610 USA; [Thompson, Floyd J.] Univ Florida, Coll Med, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA; [Caudle, Robert M.] Univ Florida, Coll Dent, Dept Oral & Maxillofacial Surg, Gainesville, FL 32610 USA; [Neubert, John K.] Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL 32610 USA; [Bose, Prodip] Univ Florida, Coll Med, Dept Neurol, McKnight Brain Inst, Gainesville, FL 32610 USA		Bose, P (corresponding author), North Florida South Georgia Vet Hlth Syst, Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr Excellence, Gainesville, FL 32608 USA.	pkbose@ufl.edu		Sinharoy, Ankita/0000-0002-6911-196X; Wilkie, Zachary/0000-0002-4331-9770; Caudle, Robert/0000-0002-2394-4114	United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service [B6570R, B78071, B1005-R]; Veterans AffairsUS Department of Veterans Affairs [I01RX001005] Funding Source: NIH RePORTER	This work was supported by Merit Review Award # B6570R, B78071, B1005-R, from the United States (U.S.) Department of Veterans Affairs Rehabilitation Research and Development Service.	Abbadie C, 1997, J NEUROSCI, V17, P8049; Aicher SA, 2012, J CHEM NEUROANAT, V43, P103, DOI 10.1016/j.jchemneu.2011.11.002; Alwis DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052169; Anderson EM, 2013, JOVE-J VIS EXP, DOI 10.3791/50336; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Awawdeh LA, 2002, EUR J ORAL SCI, V110, P185, DOI 10.1034/j.1600-0447.2002.21236.x; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bernstein AI, 2013, TOXICOL LETT, V219, P93, DOI 10.1016/j.toxlet.2013.03.003; Bernstein AI, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-2; BERVOETS K, 1990, EUR J PHARMACOL, V191, P185, DOI 10.1016/0014-2999(90)94146-O; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bose P, 2005, EXP NEUROL, V191, P13, DOI 10.1016/j.expneurol.2004.08.028; Bose P, 2013, J NEUROTRAUM, V30, P1177, DOI 10.1089/neu.2012.2740; Bose PK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00258; Boulenguez P, 2010, NAT MED, V16, P302, DOI 10.1038/nm.2107; Bowles WR, 2003, J ENDODONT, V29, P265, DOI 10.1097/00004770-200304000-00009; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burstein R, 2010, ANN NEUROL, V68, P81, DOI 10.1002/ana.21994; Cai YQ, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-70; Chai BY, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-78; CHERYCROZE S, 1983, PAIN, V17, P109, DOI 10.1016/0304-3959(83)90137-9; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Cook GA, 2014, MIL MED, V179, P1083, DOI 10.7205/MILMED-D-13-00435; Couto LB, 2006, J CHEM NEUROANAT, V32, P28, DOI 10.1016/j.jchemneu.2006.03.003; Cramer SW, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-36; Defrin R, 2002, BRAIN, V125, P501, DOI 10.1093/brain/awf055; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Denadai-Souza A, 2009, EUR J PAIN, V13, P812, DOI 10.1016/j.ejpain.2008.09.012; DOUGHERTY PM, 1991, PAIN, V47, P85, DOI 10.1016/0304-3959(91)90015-P; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Egea J, 2012, PFLUG ARCH EUR J PHY, V463, P449, DOI 10.1007/s00424-011-1063-x; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Faul M, 2010, TRAUMATIC BRAIN INJU; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Guven H, 2013, NEUROL SCI, V34, P1397, DOI 10.1007/s10072-012-1249-9; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Haggman-Henrikson B, 2011, SWED DENT J, V35, P123; Hirata A, 2006, J NEUROSCI, V26, P4426, DOI 10.1523/JNEUROSCI.5298-05.2006; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Holzer P, 2004, EUR J PHARMACOL, V500, P231, DOI 10.1016/j.ejphar.2004.07.028; Hou JM, 2014, J NEUROTRAUM, V31, P1088, DOI 10.1089/neu.2013.3096; Jasmin L, 2002, P NATL ACAD SCI USA, V99, P1029, DOI 10.1073/pnas.012598599; Jensen O K, 2001, Ugeskr Laeger, V163, P5029; JONES BE, 1991, PROG BRAIN RES, V88, P15; Lagraize SC, 2010, NEUROSCIENCE, V171, P1341, DOI 10.1016/j.neuroscience.2010.09.040; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Lazarov N. E., 2012, NEUROCHEMICAL ANATOM; Lee M, 2011, GLIA, V59, P152, DOI 10.1002/glia.21087; Lipton JW, 2008, NEUROPHARMACOLOGY, V55, P851, DOI 10.1016/j.neuropharm.2008.06.062; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Mansikka H, 2000, EXP NEUROL, V162, P343, DOI 10.1006/exnr.1999.7336; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCCORMICK DA, 1991, J PHYSIOL-LONDON, V442, P235, DOI 10.1113/jphysiol.1991.sp018791; Millan MJ, 1995, BEHAV BRAIN RES, V73, P69; MILLHORN DE, 1988, BRAIN RES, V461, P169, DOI 10.1016/0006-8993(88)90736-6; Miremami JD, 2014, SOMATOSENS MOT RES, V31, P127, DOI 10.3109/08990220.2014.897602; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Murphy Niall P, 2014, Curr Top Behav Neurosci, V20, P121, DOI 10.1007/7854_2014_332; Mustafa G, 2013, PAIN, V154, P2547, DOI 10.1016/j.pain.2013.07.041; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Neubert JK, 2005, PAIN, V116, P386, DOI 10.1016/j.pain.2005.05.011; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Okubo M, 2013, J NEUROSCI, V33, P5152, DOI 10.1523/JNEUROSCI.3390-12.2013; Perez CT, 2013, J NEUROPHYSIOL, V110, P286, DOI 10.1152/jn.01006.2012; Pinal CS, 1998, PERSPECT DEV NEUROBI, V5, P109; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Rodd HD, 2000, EUR J ORAL SCI, V108, P467, DOI 10.1034/j.1600-0722.2000.00924.x; Samuels ER, 2008, CURR NEUROPHARMACOL, V6, P254, DOI 10.2174/157015908785777193; SASA M, 1986, BRAIN RES, V377, P337, DOI 10.1016/0006-8993(86)90877-2; SASA M, 1979, J PHARMACOL EXP THER, V210, P311; SASA M, 1974, BRAIN RES, V80, P443, DOI 10.1016/0006-8993(74)91029-4; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Song BB, 2007, BRAIN RES, V1158, P57, DOI 10.1016/j.brainres.2007.05.006; STAMP JA, 1995, BRAIN RES, V677, P39, DOI 10.1016/0006-8993(95)00119-B; Sterling M, 2003, PAIN, V104, P509, DOI 10.1016/S0304-3959(03)00078-2; TAIWO YO, 1992, NEUROSCIENCE, V48, P485, DOI 10.1016/0306-4522(92)90508-Y; Takeda M, 2005, PAIN, V116, P375, DOI 10.1016/j.pain.2005.05.007; Takeda M, 2012, J PERIPHER NERV SYST, V17, P169, DOI 10.1111/j.1529-8027.2012.00404.x; Teodoro FC, 2013, NEUROPEPTIDES, V47, P199, DOI 10.1016/j.npep.2012.10.005; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Tsuruoka M, 2003, BRAIN RES, V993, P146, DOI 10.1016/j.brainres.2003.09.023; Vierck CJ, 2015, NEUROSCI BIOBEHAV R, V51, P223, DOI 10.1016/j.neubiorev.2015.01.022; Viggiano A, 2004, EUR J PHARMACOL, V496, P87, DOI 10.1016/j.ejphar.2004.06.019; Wasner GL, 2008, CLIN NEUROPHYSIOL, V119, P2389, DOI 10.1016/j.clinph.2008.07.223; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; Wu LA, 2009, NEUROSCI LETT, V457, P36, DOI 10.1016/j.neulet.2009.03.107; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Zhang H, 2007, J NEUROSCI, V27, P12067, DOI 10.1523/JNEUROSCI.0496-07.2007	89	26	26	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	AUG	2016	107						27	39		10.1016/j.neuropharm.2016.03.016			13	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	DQ1HZ	WOS:000378953400004	26972829	Green Accepted			2022-02-06	
J	Zador, Z; Sperrin, M; King, AT				Zador, Zsolt; Sperrin, Matthew; King, Andrew T.			Predictors of Outcome in Traumatic Brain Injury: New Insight Using Receiver Operating Curve Indices and Bayesian Network Analysis	PLOS ONE			English	Article							HEAD-INJURY; VALIDATION; MORTALITY; DESIGN; MODELS; CRASH; COMA	Background Traumatic brain injury remains a global health problem. Understanding the relative importance of outcome predictors helps optimize our treatment strategies by informing assessment protocols, clinical decisions and trial designs. In this study we establish importance ranking for outcome predictors based on receiver operating indices to identify key predictors of outcome and create simple predictive models. We then explore the associations between key outcome predictors using Bayesian networks to gain further insight into predictor importance. Methods We analyzed the corticosteroid randomization after significant head injury (CRASH) trial database of 10008 patients and included patients for whom demographics, injury characteristics, computer tomography (CT) findings and Glasgow Outcome Scale (GCS) were recorded (total of 13 predictors, which would be available to clinicians within a few hours following the injury in 6945 patients). Predictions of clinical outcome (death or severe disability at 6 months) were performed using logistic regression models with 5-fold cross validation. Predictive performance was measured using standardized partial area (pAUC) under the receiver operating curve (ROC) and we used Delong test for comparisons. Variable importance ranking was based on pAUC targeted at specificity (pAUC(SP)) and sensitivity (pAUC(SE)) intervals of 90-100%. Probabilistic associations were depicted using Bayesian networks. Results Complete AUC analysis showed very good predictive power (AUC = 0.8237, 95% CI: 0.8138-0.8336) for the complete model. Specificity focused importance ranking highlighted age, pupillary, motor responses, obliteration of basal cisterns/3rd ventricle and midline shift. Interestingly when targeting model sensitivity, the highest-ranking variables were age, severe extracranial injury, verbal response, hematoma on CT and motor response. Simplified models, which included only these key predictors, had similar performance (pAUC(SP) = 0.6523, 95% CI: 0.6402-0.6641 and pAUC(SE) = 0.6332, 95% CI: 0.62-0.6477) compared to the complete models (pAUC(SP) = 0.6664, 95% CI: 0.6543-0.679, pAUC(SE) = 0.6436, 95% CI: 0.6289-0.6585, de Long p value 0.1165 and 0.3448 respectively). Bayesian networks showed the predictors that did not feature in the simplified models were associated with those that did. Conclusion We demonstrate that importance based variable selection allows simplified predictive models to be created while maintaining prediction accuracy. Variable selection targeting specificity confirmed key components of clinical assessment in TBI whereas sensitivity based ranking suggested extracranial injury as one of the important predictors. These results help refine our approach to head injury assessment, decision-making and outcome prediction targeted at model sensitivity and specificity. Bayesian networks proved to be a comprehensive tool for depicting probabilistic associations for key predictors giving insight into why the simplified model has maintained accuracy.	[Zador, Zsolt; King, Andrew T.] Salford Royal Fdn Trust, Dept Neurosurg, Salford, Greater Manches, England; [Zador, Zsolt] Univ Manchester, Ctr Vasc & Stroke Res, Inst Cardiovasc Sci, Manchester, Lancs, England; [Sperrin, Matthew] Univ Manchester, Manchester Acad Hlth Sci Ctr, Hlth eRes Ctr, Farr Inst, Manchester, Lancs, England		Zador, Z (corresponding author), Salford Royal Fdn Trust, Dept Neurosurg, Salford, Greater Manches, England.; Zador, Z (corresponding author), Univ Manchester, Ctr Vasc & Stroke Res, Inst Cardiovasc Sci, Manchester, Lancs, England.	zadzso@gmail.com	King, Andrew/AAR-1656-2020	Sperrin, Matthew/0000-0002-5351-9960; Zador, Zsolt/0000-0001-9767-3372; King, Andrew/0000-0002-6546-7248	National Institute for Health and Research; University of Manchester's Health eResearch Centre (HeRC) - Medical Research Council Grant [MR/K006665/1]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/K006665/1] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_13042, MR/K006665/1] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2014-06-004] Funding Source: researchfish	ZZ is an Academic Clinical Lecturer Funded by the National Institute for Health and Research. MS is supported by the University of Manchester's Health eResearch Centre (HeRC) funded by the Medical Research Council Grant MR/K006665/1.	Akaike H., 1973, P 2 INT S INF THEOR, V1973, P267, DOI 10.1007/978-1-4612-1694-0; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Bateman DE, 2001, J NEUROL NEUROSUR PS, V71, P13; Cai ZQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120805; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Edwards P, 2005, LANCET, V365, P1957; Faul M, 2010, TRAUMATIC BRAIN INJU; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Kehoe A, 2016, EMERG MED J, V33, P381, DOI 10.1136/emermed-2015-205180; KORB K, 2011, BAYESIAN ARTIFICIAL; Lecky F, 2015, EMERG MED J, V32, P906, DOI 10.1136/emermed-2015-205460; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marion DW, 2006, NEUROSURGERY, V58, P655; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Nagarajan R, 2013, BAYESIAN NETWORKS R; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; R Core Team, 2016, R LANG ENV STAT COMP; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sesen MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082349; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; TEASDALE G, 1974, LANCET, V2, P81; The CRASH trial management group, 2001, BMC Emerg Med, V1, P1; Turck N, 2010, INTENS CARE MED, V36, P107, DOI 10.1007/s00134-009-1641-y; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Wong George K C, 2011, J Emerg Trauma Shock, V4, P346, DOI 10.4103/0974-2700.83861; Wong GKC, 2013, J CLIN NEUROSCI, V20, P1693, DOI 10.1016/j.jocn.2012.12.032	39	26	26	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2016	11	7							e0158762	10.1371/journal.pone.0158762			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR3OC	WOS:000379811500043	27388421	Green Submitted, gold, Green Published			2022-02-06	
J	Lyon, DE; Cohen, R; Chen, HH; Kelly, DL; Starkweather, A; Ahn, HC; Jackson-Cook, CK				Lyon, Debra E.; Cohen, Ronald; Chen, Huaihou; Kelly, Debra L.; Starkweather, Angela; Ahn, Hyo-Chol; Jackson-Cook, Colleen K.			The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY			English	Article						Breast cancer; Cognition; Memory; Adjuvant; Chemotherapy	TRAUMATIC BRAIN-INJURY; ADJUVANT CHEMOTHERAPY; ENDOCRINE THERAPY; WORKING-MEMORY; FATIGUE; IMPAIRMENT; SURVIVORS; ASSOCIATION; DYSFUNCTION; IMPACT	Cognitive dysfunction in women with breast cancer continues to be an area of intense research interest. The prevalence, severity, timing, and cognitive domains that are most affected, as well as the contribution of cancer and its treatments to cognition, remain unresolved. Thus, longitudinal studies are needed that examine cognitive function during different stages of breast cancer treatment and survivorship. This longitudinal trial followed women with early-stage breast cancer, prior to chemotherapy through 2 years survivorship. In women with early-stage breast cancer (N = -75), performance-based assessment of nine cognitive domains was performed at five time points beginning prior to chemotherapy and finishing 24 months after initial chemotherapy. Linear mixed effects models were used to examine the temporal changes in cognitive performance domains, while adjusting for cofactors, including those related to individuals, tumor attributes, chemotherapy (adjuvant or neoadjuvant), radiation, endocrine therapy, and concurrent symptoms. At baseline, scores on reaction time, complex attention, cognitive flexibility, executive function, and visual memory were lower than 90. At 2 years, all domains improved except for the memory domains (verbal, visual, and composite). Scores on six domains (psychomotor speed, reaction time, complex attention, cognitive flexibility, and visual memory) remained lower than 100 at 2 years. Neoadjuvant chemotherapy and fatigue had strong inverse relationship with cognitive functioning at multiple time points. The low performance-based cognitive scores at baseline and over time warrant further study. Although most scores improved over time, memory did not improve. In all, the level of cognitive function is lower than expected for a majority college-educated sample. Thus, future studies are warranted to replicate these findings and to develop methods for identifying women with cognitive dysfunction pretreatment and into survivorship.	[Lyon, Debra E.; Cohen, Ronald; Chen, Huaihou; Kelly, Debra L.; Ahn, Hyo-Chol] Univ Florida, Gainesville, FL USA; [Starkweather, Angela] Univ Connecticut, Storrs Hall,Room 112B,231 Glenbrook Rd,Unit 4026, Storrs, CT 06269 USA; [Jackson-Cook, Colleen K.] Virginia Commonwealth Univ, Sch Med, 1101 E Marshall St, Richmond, VA 23298 USA		Lyon, DE (corresponding author), Univ Florida, Gainesville, FL USA.	delyon@ufl.edu	Lyon, Deb/ABF-7547-2021	Ahn, Hyochol/0000-0002-9998-4876	National Institute of Nursing Research (MPI) [R01 NR012667]; NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG037986, R01 NR013932]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013932, R01NR012667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG037986] Funding Source: NIH RePORTER	This research was supported by the National Institute of Nursing Research (Jackson-Cook/Lyon; MPI; R01 NR012667). Dr. Jackson-Cook (NIH/NIA R01AG037986) and Dr. A. Starkweather (R01 NR013932) are currently receiving grants. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research (NINR), National Institute on Aging (NIA), or the National Institutes of Health (NIH).	Aboalela N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133380; Ahles TA, 2012, PSYCHO-ONCOLOGY, V21, P1141, DOI 10.1002/pon.3196; Ahles TA, 2012, J CLIN ONCOL, V30, P3675, DOI 10.1200/JCO.2012.43.0116; Alosco ML, 2014, OBESITY, V22, P32, DOI 10.1002/oby.20494; Alosco ML, 2013, PSYCHOGERIATRICS, V13, P35, DOI 10.1111/j.1479-8301.2012.00424.x; Andreotti C, 2016, PSYCHO-ONCOLOGY, V25, P43, DOI 10.1002/pon.3799; Arpino G, 2015, BREAST CANCER RES TR, V154, P127, DOI 10.1007/s10549-015-3586-x; Bakoyiannis I, 2016, CLIN DRUG INVEST, V36, P109, DOI 10.1007/s40261-015-0364-9; Barker-Collo S, 2015, BRAIN INJURY, V29, P1604, DOI 10.3109/02699052.2015.1075143; Bender CM, 2015, CANCER-AM CANCER SOC, V121, P2627, DOI 10.1002/cncr.29393; Bower JE, 2000, J CLIN ONCOL, V18, P743, DOI 10.1200/JCO.2000.18.4.743; Breckenridge LM, 2012, PSYCHO-ONCOLOGY, V21, P43, DOI 10.1002/pon.1860; Buchanan ND, 2015, AM J PREV MED, V49, pS498, DOI 10.1016/j.amepre.2015.08.013; Calvio L, 2010, J OCCUP ENVIRON MED, V52, P219, DOI 10.1097/JOM.0b013e3181d0bef7; Cheung YT, 2015, ANN ONCOL, V26, P1446, DOI 10.1093/annonc/mdv206; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S., 1988, SOCIAL PSYCHOL HLTH, P123; Crawford RD, 2016, J ADV NURS, V72, P1409, DOI 10.1111/jan.12755; Fan HGM, 2005, J CLIN ONCOL, V23, P8025, DOI 10.1200/JCO.2005.01.6550; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gunstad J, 2013, EAT WEIGHT DISORD-ST, V11, pe15; Henneghan A, 2016, SUPPORT CARE CANCER, V24, P481, DOI 10.1007/s00520-015-2927-y; Hermelink K, 2007, CANCER, V109, P1905, DOI 10.1002/cncr.22610; Hermelink Kerstin, 2015, Journal of the National Cancer Institute Monographs, P67, DOI 10.1093/jncimonographs/lgv009; Jansen CE, 2011, SUPPORT CARE CANCER, V19, P1647, DOI 10.1007/s00520-010-0997-4; Jenkins V, 2006, BRIT J CANCER, V94, P828, DOI 10.1038/sj.bjc.6603029; Kesler SR, 2016, JAMA ONCOL, V2, P185, DOI 10.1001/jamaoncol.2015.4333; Kool M, 2015, BREAST, V24, P224, DOI 10.1016/j.breast.2015.01.010; Kyranou M, 2014, CANCER NURS, V37, P406, DOI 10.1097/NCC.0000000000000131; Lyon D, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1151-z; Mandelblatt JS, 2014, J CLIN ONCOL, V32, P1909, DOI 10.1200/JCO.2013.54.2050; McDonald BC, 2012, J CLIN ONCOL, V30, P2500, DOI 10.1200/JCO.2011.38.5674; McDonald BC, 2010, BREAST CANCER RES TR, V123, P819, DOI 10.1007/s10549-010-1088-4; Meeske K, 2007, QUAL LIFE RES, V16, P947, DOI 10.1007/s11136-007-9215-3; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Meskal I, 2015, J NEURO-ONCOL, V121, P617, DOI 10.1007/s11060-014-1679-8; Myers JS, 2012, ONCOL NURS FORUM, V39, P1; Ono M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00059; Opdebeeck C, 2015, REV CLIN GERONTOL, V25, P181, DOI 10.1017/S0959259815000155; Perez S, 2014, J TRAUMA STRESS, V27, P224, DOI 10.1002/jts.21901; Ramaiah Ramesh, 2009, Anesthesiol Clin, V27, P485, DOI 10.1016/j.anclin.2009.07.011; Rele S, 2015, PRIM CARE COMPANION, V17, DOI [10.4088/PCC.4014m01734, DOI 10.4088/PCC.4014M01734]; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Scherling C, 2012, J CLIN EXP NEUROPSYC, V34, P543, DOI 10.1080/13803395.2012.666227; Scherling C, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00122; Schrepf A, 2015, BRAIN BEHAV IMMUN, V49, P1, DOI 10.1016/j.bbi.2015.04.010; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Theadom A, 2015, J NEUROTRAUM, V32, P674, DOI 10.1089/neu.2014.3579; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Wefel JS, 2011, LANCET ONCOL, V12, P703, DOI 10.1016/S1470-2045(10)70294-1; Zwart W, 2015, NAT REV CLIN ONCOL, V12, P597, DOI 10.1038/nrclinonc.2015.124; Zygouris S, 2015, AM J ALZHEIMERS DIS, V30, P13, DOI 10.1177/1533317514522852	52	26	27	1	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0171-5216	1432-1335		J CANCER RES CLIN	J. Cancer Res. Clin. Oncol.	JUL	2016	142	7					1461	1474		10.1007/s00432-016-2163-y			14	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	DN9VS	WOS:000377429400007	27102492	Green Accepted			2022-02-06	
J	Santoro, A; Raso, GM; Taliani, S; Da Pozzo, E; Simorini, F; Costa, B; Martini, C; Laneri, S; Sacchi, A; Cosimelli, B; Calignano, A; Da Settimo, F; Meli, R				Santoro, Anna; Raso, Giuseppina Mattace; Taliani, Sabrina; Da Pozzo, Eleonora; Simorini, Francesca; Costa, Barbara; Martini, Claudia; Laneri, Sonia; Sacchi, Antonia; Cosimelli, Barbara; Calignano, Antonio; Da Settimo, Federico; Meli, Rosaria			TSPO-ligands prevent oxidative damage and inflammatory response in C6 glioma cells by neurosteroid synthesis	EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						N,N-dialkyl-2-phenylindol-3-ylglyoxylamides; Pregnenolone; Aminoglutethimide; Oxidative stress; Inflammation; C6 glioma cells	PERIPHERAL BENZODIAZEPINE-RECEPTOR; TRANSLOCATOR-PROTEIN TSPO; ACUTE REGULATORY PROTEIN; 18 KDA TSPO; TRAUMATIC BRAIN-INJURY; CHOLESTEROL TRANSPORT; NERVOUS-SYSTEM; GLIAL-CELLS; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION	Translocator protein 18 kDa (TSPO) is predominantly located in the mitochondrial outer membrane, playing an important role in steroidogenesis, inflammation, cell survival and proliferation. Its expression in central nervous system, mainly in glial cells, has been found to be upregulated in neuropathology, and brain injury. In this study, we investigated the anti-oxidative and anti-inflammatory effects of a group of TSPO ligands from the N, N-dialkyl-2-phenylindol-3-ylglyoxylamide class (PIGAs), highlighting the involvement of neurosteroids in their pharmacological effects. To this aim we used a well-known in vitro model of neurosteroidogenesis: the astrocytic C6 glioma cell line, where TSPO expression and localization, as well as cell response to TSPO ligand treatment, have been established. All PIGAs reduced L-buthionine-(S, R)-sulfoximine (BSO)-driven cell cytotoxicity and lipid peroxidation. Moreover, an anti-inflammatory effect was observed due to the reduction of inducible nitric oxide synthase and cyclooxygenase-2 induction in LPS/IFN gamma challenged cells. Both effects were blunted by aminoglutethimide (AMG), an inhibitor of pregnenolone synthesis, suggesting neurosteroids' involvement in PIGA protective mechanism. Finally, pregnenolone evaluation in PIGA exposed cells revealed an increase in its synthesis, which was prevented by AMG pre-treatment. These findings indicate that these TSPO ligands reduce oxidative stress and pro-inflammatory enzymes in glial cells through the de novo synthesis of neurosteroids, suggesting that these compounds could be potential new therapeutic tools for the treatment of inflammatory-based neuropathologies with beneficial effects possibly comparable to steroids, but potentially avoiding the negative side effects of long-term therapies with steroid hormones. (C) 2016 Elsevier B.V. All rights reserved.	[Santoro, Anna; Raso, Giuseppina Mattace; Laneri, Sonia; Sacchi, Antonia; Cosimelli, Barbara; Calignano, Antonio; Meli, Rosaria] Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy; [Santoro, Anna; Raso, Giuseppina Mattace; Laneri, Sonia; Sacchi, Antonia; Cosimelli, Barbara; Calignano, Antonio; Meli, Rosaria] Univ Pisa, I-56126 Pisa, Italy; [Taliani, Sabrina; Da Pozzo, Eleonora; Simorini, Francesca; Costa, Barbara; Martini, Claudia; Da Settimo, Federico] Univ Pisa, Dept Pharm, I-56126 Pisa, Italy		Meli, R (corresponding author), Univ Naples Federico II, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy.	meli@unina.it	Martini, Claudia/AAC-4089-2019; Calignano, Antonio/K-2542-2018; Da Pozzo, Eleonora/AAW-8186-2020; TALIANI, SABRINA/AAO-7850-2020	Martini, Claudia/0000-0001-9379-3027; Da Pozzo, Eleonora/0000-0003-4762-8949; SIMORINI, Francesca/0000-0002-6745-6489; Santoro, Anna/0000-0002-2276-5659; COSTA, BARBARA/0000-0002-7598-1275; Mattace Raso, Giuseppina/0000-0002-5254-139X; Meli, Rosaria/0000-0002-6246-6813			Agis-Balboa RC, 2006, P NATL ACAD SCI USA, V103, P14602, DOI 10.1073/pnas.0606544103; Akk G, 2007, MOL PHARMACOL, V71, P461, DOI 10.1124/mol.106.029942; Austin CJD, 2013, INT J BIOCHEM CELL B, V45, P1212, DOI 10.1016/j.biocel.2013.03.004; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Barresi E, 2015, J MED CHEM, V58, P6081, DOI 10.1021/acs.jmedchem.5b00689; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013; Batarseh A, 2010, MOL CELL ENDOCRINOL, V327, P1, DOI 10.1016/j.mce.2010.06.013; Beinlich A, 2000, BIOCHEM PHARMACOL, V60, P397, DOI 10.1016/S0006-2952(00)00325-7; Belelli D, 2006, NEUROSCIENCE, V138, P821, DOI 10.1016/j.neuroscience.2005.07.021; BESSLER H, 1992, J NEUROIMMUNOL, V38, P19, DOI 10.1016/0165-5728(92)90086-Z; Biggio G, 2007, PHARMACOL THERAPEUT, V116, P140, DOI 10.1016/j.pharmthera.2007.04.005; Borowicz Kinga K, 2011, Front Endocrinol (Lausanne), V2, P50, DOI 10.3389/fendo.2011.00050; Bose HS, 2002, ENDOCR RES, V28, P295, DOI 10.1081/ERC-120016800; Cagnin A, 2001, BRAIN, V124, P2014, DOI 10.1093/brain/124.10.2014; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; Chelli B, 2004, BIOCHEM PHARMACOL, V68, P125, DOI 10.1016/j.bcp.2004.03.008; Chelli B, 2005, CHEMBIOCHEM, V6, P1082, DOI 10.1002/cbic.200400350; Chen C, 2014, ENDOCRINOLOGY, V155, P2976, DOI 10.1210/en.2013-1844; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Choi HB, 2002, J NEUROCHEM, V83, P546, DOI 10.1046/j.1471-4159.2002.01122.x; Costa B, 2011, PSYCHONEUROENDOCRINO, V36, P463, DOI 10.1016/j.psyneuen.2010.07.021; Da Pozzo E, 2015, BIOCHEM SOC T, V43, P559, DOI 10.1042/BST20150028; Da Settimo F, 2008, J MED CHEM, V51, P5798, DOI 10.1021/jm8003224; Ding Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2236; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Esposito E, 2010, N-S ARCH PHARMACOL, V381, P93, DOI 10.1007/s00210-009-0466-0; Gavish M, 1999, PHARMACOL REV, V51, P629; Gazouli M, 2002, J PHARMACOL EXP THER, V303, P627, DOI 10.1124/jpet.102.039388; Girard C, 2008, P NATL ACAD SCI USA, V105, P20505, DOI 10.1073/pnas.0811201106; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/0736-5748(96)00026-3; Guennoun R, 2015, J STEROID BIOCHEM, V146, P48, DOI 10.1016/j.jsbmb.2014.09.001; Hauet T, 2005, MOL ENDOCRINOL, V19, P540, DOI 10.1210/me.2004-0307; Hauet T, 2002, ENDOCR RES, V28, P395, DOI 10.1081/ERC-120016814; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Jung-Testas I, 1998, J STEROID BIOCHEM, V65, P243, DOI 10.1016/S0960-0760(97)00191-X; Kannan S, 2009, J CHILD NEUROL, V24, P1190, DOI 10.1177/0883073809338063; Keller EA, 2004, DEV BRAIN RES, V153, P13, DOI 10.1016/j.devbrainres.2004.07.009; Klegeris A, 2000, BIOCHEM PHARMACOL, V59, P1305, DOI 10.1016/S0006-2952(00)00252-5; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Leaver KR, 2012, ACS CHEM NEUROSCI, V3, P114, DOI 10.1021/cn200099e; Li W, 2007, BIOCHEM PHARMACOL, V73, P491, DOI 10.1016/j.bcp.2006.10.025; Liu GJ, 2014, BRAIN PATHOL, V24, P631, DOI 10.1111/bpa.12196; Madrigal Jose L. M., 2006, CNS & Neurological Disorders-Drug Targets, V5, P561; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; MANGOURA D, 1989, NEUROCHEM RES, V14, P941, DOI 10.1007/BF00965927; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Mathieu AP, 2002, J MOL ENDOCRINOL, V29, P327, DOI 10.1677/jme.0.0290327; Meli R, 2001, J NEUROCHEM, V79, P556, DOI 10.1046/j.1471-4159.2001.00617.x; Midzak A, 2015, BIOCHEM SOC T, V43, P572, DOI 10.1042/BST20150061; Nogawa S, 1997, J NEUROSCI, V17, P2746; Papadopoulos V, 2006, NEUROSCIENCE, V138, P749, DOI 10.1016/j.neuroscience.2005.05.063; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Papadopoulos V, 2007, MOL CELL ENDOCRINOL, V265, P59, DOI 10.1016/j.mce.2006.12.004; Papadopoulos V, 2015, MOL CELL ENDOCRINOL, V408, P90, DOI 10.1016/j.mce.2015.03.014; Papadopoulos V, 2012, BEST PRACT RES CL EN, V26, P771, DOI 10.1016/j.beem.2012.05.002; PARKER KK, 1980, SCIENCE, V208, P179, DOI 10.1126/science.6102413; Primofiore G, 2004, J MED CHEM, V47, P1852, DOI 10.1021/jm030973k; Raso GM, 2011, J NEUROENDOCRINOL, V23, P591, DOI 10.1111/j.1365-2826.2011.02152.x; Raso GM, 2006, NEUROSCI LETT, V396, P121, DOI 10.1016/j.neulet.2005.11.022; Repalli Jayanthi, 2014, Curr Aging Sci, V7, P168; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010; Sasso O, 2010, EUR NEUROPSYCHOPHARM, V20, P195, DOI 10.1016/j.euroneuro.2009.09.003; Selleri S, 2005, BIOORGAN MED CHEM, V13, P4821, DOI 10.1016/j.bmc.2005.05.015; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Taliani S, 2007, J MED CHEM, V50, P404, DOI 10.1021/jm061137o; Taliani S, 2011, CURR TOP MED CHEM, V11, P860, DOI 10.2174/156802611795165142; Thomson M, 2003, BIOESSAYS, V25, P252, DOI 10.1002/bies.10243; Torres SR, 2000, EUR J PHARMACOL, V408, P199, DOI 10.1016/S0014-2999(00)00760-3; Veenman L, 2012, CURR MOL MED, V12, P398; Veenman L, 2008, J BIOENERG BIOMEMBR, V40, P199, DOI 10.1007/s10863-008-9142-1; Veenman L, 2007, CURR PHARM DESIGN, V13, P2385; Veiga S, 2005, J NEUROSCI RES, V80, P129, DOI 10.1002/jnr.20430; Venneti S, 2006, PROG NEUROBIOL, V80, P308, DOI 10.1016/j.pneurobio.2006.10.002; Wilms H, 2003, NEUROBIOL DIS, V14, P417, DOI 10.1016/j.nbd.2003.07.002	82	26	26	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0928-0987	1879-0720		EUR J PHARM SCI	Eur. J. Pharm. Sci.	JUN 10	2016	88						124	131		10.1016/j.ejps.2016.04.006			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	DM9AI	WOS:000376655200011	27094781	Green Submitted			2022-02-06	
J	Douiri, S; Bandoudi, S; Hamdi, Y; Cubi, R; Basille, M; Fournier, A; Vaudry, H; Tonon, MC; Amri, M; Vaudry, D; Masmoudi-Kouki, O				Douiri, Salma; Bandoudi, Seyma; Hamdi, Yosra; Cubi, Roger; Basille, Magali; Fournier, Alain; Vaudry, Hubert; Tonon, Marie-Christine; Amri, Mohamed; Vaudry, David; Masmoudi-Kouki, Olfa			Involvement of endogenous antioxidant systems in the protective activity of pituitary adenylate cyclase-activating polypeptide against hydrogen peroxide-induced oxidative damages in cultured rat astrocytes	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; astroglial cells; catalase; oxidative stress; PACAP; superoxide dismutase	CEREBELLAR GRANULE NEURONS; STRESS-INDUCED APOPTOSIS; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; NERVE GROWTH-FACTOR; SUPEROXIDE-DISMUTASE; NEURODEGENERATIVE DISEASES; SIGNALING PATHWAYS; GENE-EXPRESSION; FOCAL ISCHEMIA	Astroglial cells possess an array of cellular defense mechanisms, including superoxide dismutase (SOD) and catalase antioxidant enzymes, to prevent damages caused by oxidative stress. Nevertheless, astroglial cell viability and functionality can be affected by significant oxidative stress. We have previously shown that pituitary adenylate cyclase-activating polypeptide (PACAP) is a potent glioprotective agent that prevents hydrogen peroxide (H2O2)-induced apoptosis in cultured astrocytes. The purpose of this study was to investigate the potential protective effect of PACAP against oxidative-generated alteration of astrocytic antioxidant systems. Incubation of cells with subnanomolar concentrations of PACAP inhibited H2O2-evoked reactive oxygen species accumulation, mitochondrial respiratory burst, and caspase-3 mRNA level increase. PACAP also stimulated SOD and catalase activities in a concentration-dependent manner, and counteracted the inhibitory effect of H2O2 on the activity of these two antioxidant enzymes. The protective action of PACAP against H2O2-evoked inhibition of antioxidant systems in astrocytes was protein kinase A, PKC, and MAP-kinase dependent. In the presence of H2O2, the SOD blocker NaCN and the catalase inhibitor 3-aminotriazole, both suppressed the protective effects of PACAP on SOD and catalase activities, mitochondrial function, and cell survival. Taken together, these results indicate that the anti-apoptotic effect of PACAP on astroglial cells can account for the activation of endogenous antioxidant enzymes and reduction in respiration rate, thus preserving mitochondrial integrity and preventing caspase-3 expression provoked by oxidative stress. Considering its powerful anti-apoptotic and anti-oxidative properties, the PACAPergic signaling system should thus be considered for the development of new therapeutical approaches to cure various pathologies involving oxidative neurodegeneration.	[Douiri, Salma; Bandoudi, Seyma; Hamdi, Yosra; Amri, Mohamed; Masmoudi-Kouki, Olfa] Univ Tunis El Manar, Fac Sci Tunis, Dept Biol Sci, Lab Funct Neurophysiol & Pathol,Res Unit UR 11ES0, Tnis 2092, Tunisia; [Bandoudi, Seyma; Cubi, Roger; Basille, Magali; Vaudry, Hubert; Tonon, Marie-Christine; Vaudry, David] Univ Rouen, IRIB, INSERM, U982,Lab Neuronal & Neuroendocrine Commun & Diffe, F-76128 Mont St Aignan, France; [Basille, Magali; Vaudry, Hubert; Tonon, Marie-Christine; Vaudry, David] Univ Rouen, Inst Biomed Res & Innovat, Reg Platform Cell Imaging Normandie PRIMACEN, Mont St Aignan, France; [Fournier, Alain] Inst Armand Frappier, INRS, Laval, PQ, Canada; [Fournier, Alain] Inst Armand Frappier, Lab Int Associe Samuel de Champlain, Laval, PQ, Canada; [Fournier, Alain; Vaudry, Hubert; Vaudry, David] Univ Rouen, Int Associated Lab Samuel de Champlain, Mont St Aignan, France		Masmoudi-Kouki, O (corresponding author), Univ Tunis El Manar, Fac Sci Tunis, Dept Biol Sci, Lab Funct Neurophysiol & Pathol,Res Unit UR 11ES0, Tnis 2092, Tunisia.; Vaudry, D (corresponding author), Univ Rouen, IRIB, INSERM, U982,Lab Neuronal & Neuroendocrine Commun & Diffe, F-76128 Mont St Aignan, France.; Vaudry, D (corresponding author), Univ Rouen, Inst Biomed Res & Innovat, Reg Platform Cell Imaging Normandie PRIMACEN, Mont St Aignan, France.	david.vaudry@univ-rouen.fr; olfa.masmoudi@fst.rnu.tn	VAUDRY, David/M-1454-2018	VAUDRY, David/0000-0003-3567-7452; Amri, Mohamed/0000-0001-5309-7633; Cubi, Roger/0000-0003-2762-9928	University of Tunis El Manar; France-Tunisia exchange program Inserm-DGRS; CMCU-Utique program [UR/11ES09, 07G0822]; Inserm-DGRS program [M10/M]; InsermInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission [U982]; Institute for Medical Research and Innovation (IRIB); Normandy region; PeReNE Interreg project	Salma Douiri and Seyma Bandoudi were recipients of fellowships from the University of Tunis El Manar and a France-Tunisia exchange program Inserm-DGRS. This study was supported by the Research Unit UR/11ES09, a CMCU-Utique program (to Mohamed Amri and Marie-Christine Tonon; grant number 07G0822), an Inserm-DGRS program (to Mohamed Amri and Marie-Christine Tonon; grant number M10/M), Inserm (U982), the Institute for Medical Research and Innovation (IRIB) and the Normandy region, and the Normandy region and the PeReNE Interreg project. Authors declare that they have no conflict of interest.	Baraibar MA, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/919832; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Botia B, 2008, J MOL NEUROSCI, V36, P61, DOI 10.1007/s12031-008-9075-5; Bourgault S, 2011, CURR PHARM DESIGN, V17, P1002, DOI 10.2174/138161211795589337; Cabezas R, 2012, NEUROSCI RES, V74, P80, DOI 10.1016/j.neures.2012.07.008; Chen YM, 2001, GLIA, V33, P343, DOI 10.1002/1098-1136(20010315)33:4<343::AID-GLIA1033>3.0.CO;2-H; Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432; Dasuri K, 2013, FREE RADICAL BIO MED, V62, P170, DOI 10.1016/j.freeradbiomed.2012.09.016; Dejda A, 2005, PHARMACOL REP, V57, P307; Dokic I, 2012, GLIA, V60, P1785, DOI 10.1002/glia.22397; Dumont M, 2009, FASEB J, V23, P2459, DOI 10.1096/fj.09-132928; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Fang KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015299; Feeney CJ, 2008, BRAIN RES, V1198, P1, DOI 10.1016/j.brainres.2007.12.049; Fernandez-Fernandez S, 2012, BIOCHEM J, V443, P3, DOI 10.1042/BJ20111943; Ferrero-Gutierrez A, 2008, FREE RADICAL BIO MED, V44, P1806, DOI 10.1016/j.freeradbiomed.2008.01.029; Gaspar T, 2008, J CEREBR BLOOD F MET, V28, P1090, DOI 10.1038/sj.jcbfm.9600611; Gyulkhandanyan AV, 2003, J NEUROCHEM, V87, P448, DOI 10.1046/j.1471-4159.2003.02029.x; Hamdi Y, 2015, PEPTIDES, V71, P56, DOI 10.1016/j.peptides.2015.06.010; Hamdi Yosra, 2012, Front Endocrinol (Lausanne), V3, P138, DOI 10.3389/fendo.2012.00138; Hamdi Y, 2011, J NEUROCHEM, V118, P416, DOI 10.1111/j.1471-4159.2011.07315.x; Harmar AJ, 2012, BRIT J PHARMACOL, V166, P4, DOI 10.1111/j.1476-5381.2012.01871.x; HSU MJ, 2009, BIOCHIM BIOPHYS ACTA, V1800, P290; Huang WC, 2001, CLIN EXP PHARMACOL P, V28, P822, DOI 10.1046/j.1440-1681.2001.03529.x; Jolivel V, 2009, NEUROSCIENCE, V160, P434, DOI 10.1016/j.neuroscience.2009.02.028; Kaddour H, 2013, J NEUROCHEM, V125, P620, DOI 10.1111/jnc.12140; Kupershmidt L, 2011, NEUROSCIENCE, V189, P345, DOI 10.1016/j.neuroscience.2011.03.040; Lamine A, 2016, NEUROPHARMACOLOGY, V108, P440, DOI 10.1016/j.neuropharm.2015.05.014; Leem YH, 2009, J NEUROSCI RES, V87, P2561, DOI 10.1002/jnr.22075; Liu JB, 2013, NEUROSCI LETT, V555, P91, DOI 10.1016/j.neulet.2013.09.011; Mao XY, 2014, NEUROL SCI, V35, P1261, DOI 10.1007/s10072-014-1695-7; Masmoudi O, 2005, J NEUROCHEM, V94, P561, DOI 10.1111/j.1471-4159.2005.03076.x; Masmoudi O, 2003, FASEB J, V17, P17, DOI 10.1096/fj.02-0317com; Masmoudi-Kouki O, 2007, PEPTIDES, V28, P1753, DOI 10.1016/j.peptides.2007.05.015; Masmoudi-Kouki O, 2011, J NEUROCHEM, V117, P403, DOI 10.1111/j.1471-4159.2011.07185.x; Mei Y, 1999, HEARING RES, V135, P169, DOI 10.1016/S0378-5955(99)00103-3; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; Miyama A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027883; Miyamoto K, 2014, J MOL NEUROSCI, V54, P370, DOI 10.1007/s12031-014-0309-4; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Mullenbrock S, 2011, J BIOL CHEM, V286, P45131, DOI 10.1074/jbc.M111.274076; Lopez MVN, 2007, BBA-GEN SUBJECTS, V1770, P1308, DOI 10.1016/j.bbagen.2007.06.008; Negre-Salvayre A, 2010, FREE RADICAL RES, V44, P1125, DOI 10.3109/10715762.2010.498478; Ouyang YB, 2004, NEUROCHEM INT, V45, P371, DOI 10.1016/j.neuint.2003.07.006; Peng TI, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/159567; Priyanka HP, 2013, NEUROCHEM RES, V38, P141, DOI 10.1007/s11064-012-0902-2; Quesada A, 2011, J NEUROSCI RES, V89, P394, DOI 10.1002/jnr.22543; Radjendirane V., 1998, ONCOGENE, V17, P3145; Ramalingam M, 2014, FREE RADICAL RES, V48, P347, DOI 10.3109/10715762.2013.869588; Ravni A, 2006, J NEUROCHEM, V98, P321, DOI 10.1111/J.1471-4159.2006.03884.X; Reglodi D, 2006, NEUROPEPTIDES, V40, P265, DOI 10.1016/j.npep.2006.06.001; Resch JM, 2014, SYNAPSE, V68, P604, DOI 10.1002/syn.21772; Saito A, 2003, J NEUROSCI, V23, P1710; Sanders LH, 2013, FREE RADICAL BIO MED, V62, P111, DOI 10.1016/j.freeradbiomed.2013.01.003; Schuessel K, 2005, NEUROBIOL DIS, V18, P89, DOI 10.1016/j.nbd.2004.09.003; Seaborn T, 2011, CURR PHARM DESIGN, V17, P204, DOI 10.2174/138161211795049679; Shibata Noriyuki, 2008, Brain and Nerve (Tokyo), V60, P157; Smith PS, 2007, FREE RADICAL BIO MED, V42, P787, DOI 10.1016/j.freeradbiomed.2006.11.032; Steele M. L., 2010, NEUROBIOL AGING, V33, pe421; Stetler RA, 2010, P NATL ACAD SCI USA, V107, P3204, DOI 10.1073/pnas.1000030107; Stumm R, 2007, J NEUROCHEM, V103, P1666, DOI 10.1111/j.1471-4159.2007.04895.x; Sun GY, 2014, MOL NEUROBIOL, V50, P6, DOI 10.1007/s12035-014-8662-4; Suzuki R, 2003, MOL BRAIN RES, V115, P10, DOI 10.1016/S0169-328X(03)00172-4; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Takuma K, 2001, YAKUGAKU ZASSHI, V121, P663, DOI 10.1248/yakushi.121.663; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 1998, NEUROSCIENCE, V84, P801, DOI 10.1016/S0306-4522(97)00545-9; Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Wang JF, 2014, NEUROCHEM INT, V64, P37, DOI 10.1016/j.neuint.2013.11.002; Yang SF, 2006, J PHARMACOL EXP THER, V319, P595, DOI 10.1124/jpet.106.102236; Zhou YC, 2015, INT J MOL MED, V36, P43, DOI 10.3892/ijmm.2015.2205; Zhu H, 2012, EXP BIOL MED, V237, P143, DOI 10.1258/ebm.2011.011152	74	26	26	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2016	137	6					913	930		10.1111/jnc.13614			18	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	DS0BZ	WOS:000380261500009	26991551	Green Accepted, Bronze			2022-02-06	
J	Fahlstedt, M; Halldin, P; Kleiven, S				Fahlstedt, Madelen; Halldin, Peter; Kleiven, Svein			The protective effect of a helmet in three bicycle accidents-A finite element study	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Helmet; Head injuries; Bicycle; Accident reconstruction; Finite element analysis; Injury prevention	TRAUMATIC BRAIN-INJURIES; HEAD-INJURY; DAMAGE; RISK; EFFICACY; MODEL	There is some controversy regarding the effectiveness of helmets in preventing head injuries among cyclists. Epidemiological, experimental and computer simulation studies have suggested that helmets do indeed have a protective effect, whereas other studies based on epidemiological data have argued that there is no evidence that the helmet protects the brain. The objective of this study was to evaluate the protective effect of a helmet in single bicycle accident reconstructions using detailed finite element simulations. Strain in the brain tissue, which is associated with brain injuries, was reduced by up to 43% for the accident cases studied when a helmet was included. This resulted in a reduction of the risk of concussion of up to 54%. The stress to the skull bone went from fracture level of 80 MPa down to 13-16 MPa when a helmet was included and the skull fracture risk was reduced by up to 98% based on linear acceleration. Even with a 10% increased riding velocity for the helmeted impacts, to take into account possible increased risk taking, the risk of concussion was still reduced by up to 46% when compared with the unhelmeted impacts with original velocity. The results of this study show that the brain injury risk and risk of skull fracture could have been reduced in these three cases if a helmet had been worn. (C) 2016 Elsevier Ltd. All rights reserved.	[Fahlstedt, Madelen; Halldin, Peter; Kleiven, Svein] KTH Royal Inst Technol, Sch Technol & Hlth, Neuron Engn, Stockholm, Sweden		Fahlstedt, M (corresponding author), Alfred Nobels Alle 10, SE-14152 Huddinge, Sweden.	madelenf@kth.se			Lansforsakringarnas Cooperation Research fund	This study was partly financed by Lansforsakringarnas Cooperation Research fund.	Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; Adams J, 2001, Inj Prev, V7, P343, DOI 10.1136/ip.7.4.343; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Amoros Emmanuelle, 2011, BMC Public Health, V11, P653, DOI 10.1186/1471-2458-11-653; [Anonymous], 2012, EN1078; [Anonymous], 2001, 327 COST EUR COMM; [Anonymous], 2008, 20632008 ASNZS; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Beusenberg M, 2001, P INT RES COUNC BIOM; Bourdet N, 2014, INT J CRASHWORTHINES, V19, P222, DOI 10.1080/13588265.2013.805293; Bourdet N, 2012, P I MECH ENG P-J SPO, V226, P282, DOI 10.1177/1754337112442326; Chan P., 2007, J CHEM INF MODEL, V53, P1689; Ching RP, 1997, ACCIDENT ANAL PREV, V29, P555, DOI 10.1016/S0001-4575(97)00008-0; CPSC, 1998, FED REGISTER, V63, P11711; Curnow WJ, 2007, ACCIDENT ANAL PREV, V39, P433, DOI 10.1016/j.aap.2006.09.013; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Ebrahimi I, 2015, TRAFFIC INJ PREV, V16, P404, DOI 10.1080/15389588.2014.937804; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Fahlstedt M., 2015, J BIOMECH; Fahlstedt M., 2014, P INT CYCL SAF C 201; Forero Rueda M. A., 2009, THESIS U COLL DUBLIN; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; Ghajari M, 2013, ACCIDENT ANAL PREV, V50, P263, DOI 10.1016/j.aap.2012.04.016; Giordano C., 2014, STAPP CAR CRASH J, V58, p14S; Holbourn AHS, 1943, LANCET, V2, P438; Ito D., 2014, P INT RES COUNC BIOM, P119; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Klug C., 2015, TESTING BICYCLE HELM, P136; Livermore software technology corporation (LSTC), 2014, LS DYNA KEYW US MAN, VII; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; McIntosh A, 1998, ACCIDENT ANAL PREV, V30, P161, DOI 10.1016/S0001-4575(97)00089-4; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; McNally DS, 2013, ACCIDENT ANAL PREV, V60, P15, DOI 10.1016/j.aap.2013.07.011; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; OECD/ITF, 2014, ROAD SAF ANN REP 201; Otte D, 2014, SAE INT J TRANSP SAF, V2, P257, DOI 10.4271/2014-01-0517; Povey LJ, 1999, ACCIDENT ANAL PREV, V31, P763, DOI 10.1016/S0001-4575(99)00033-0; Pucher J, 2011, TRANSPORT RES A-POL, V45, P451, DOI 10.1016/j.tra.2011.03.001; Rizzi M, 2013, P INT RES COUNC BIOM; ROBINSON DL, 2006, BMJ-BRIT MED J, V332, P722; Scholten AC, 2015, ACCIDENT ANAL PREV, V81, P51, DOI 10.1016/j.aap.2015.04.022; SMITH TA, 1994, ACCIDENT ANAL PREV, V26, P795, DOI 10.1016/0001-4575(94)90055-8; Thompson D., 1999, COCHRANE DB SYST REV, P1; Verschueren P., 2009, THESIS KU LEUVEN LEU; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5	51	26	28	3	33	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	JUN	2016	91						135	143		10.1016/j.aap.2016.02.025			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	DK8FP	WOS:000375162900015	26974030				2022-02-06	
J	Moriarty, H; Winter, L; Robinson, K; Piersol, CV; Vause-Earland, T; Iacovone, DB; Newhart, B; True, G; Fishman, D; Hodgson, N; Gitlin, LN				Moriarty, Helene; Winter, Laraine; Robinson, Keith; Piersol, Catherine Verrier; Vause-Earland, Tracey; Iacovone, Delores Blazer; Newhart, Brian; True, Gala; Fishman, Deborah; Hodgson, Nancy; Gitlin, Laura N.			A Randomized Controlled Trial to Evaluate the Veterans' In-home Program for Military Veterans With Traumatic Brain Injury and Their Families: Report on Impact for Family Members	PM&R			English	Article							CAREGIVER BURDEN; NEUROPSYCHIATRIC SEQUELAE; SOCIAL SUPPORT; INTERVENTION; REHABILITATION; DEPRESSION; INDIVIDUALS; HEALTH; CARE; DEMENTIA	Background: Traumatic brain injury (TBI) creates many challenges for families as well as for patients. Few intervention studies have considered both the needs of the person with TBI and his or her family and included both in the intervention process. To address this gap, we designed an innovative intervention for veterans with TBI and families-the Veterans' In-home Program (VIP)-targeting veterans' environment, delivered in veterans' homes, and involving their families. Objectives: To determine whether the VIP is more effective than standard outpatient clinic care in improving family members' well-being in 3 domains (depressive symptoms, burden, and satisfaction) and to assess its acceptability to family members. Design: In this randomized controlled trial, 81 dyads (veteran/family member) were randomly assigned to VIP or an enhanced usual care control condition. Randomization occurred after the baseline interview. Follow-up interviews occurred 3-4 months after baseline, and the interviewer was blinded to group assignment. Setting: Interviews and intervention sessions were conducted in veterans' homes or by telephone. Participants: A total of 81 veterans with TBI recruited from a Veterans Affairs (VA) polytrauma program and a key family member for each participated. Of the 81 family members, 63 completed the follow-up interview. Intervention: The VIP, guided by the person-environment fit model, consisted of 6 home visits and 2 telephone calls delivered by occupational therapists over a 3- to 4-month period. Family members were invited to participate in the 6 home sessions. Main Outcome Measures: Family member well-being was operationally defined as depressive symptomatology, caregiver burden, and caregiver satisfaction 3- 4 months after baseline. Acceptability was operationally defined through 3 indicators. Results: Family members in the VIP showed significantly lower depressive symptom scores and lower burden scores when compared to controls at follow-up. Satisfaction with caregiving did not differ between groups. Family members' acceptance of the intervention was high. Conclusions: VIP represents the first evidence-based intervention that considers both the veteran with TBI and the family. VIP had a significant impact on family member well-being and thus addresses a large gap in previous research and services for families of veterans with TBI.	[Moriarty, Helene] Villanova Univ, Coll Nursing, 800 Lancaster Ave,Driscoll Hall, Villanova, PA 19085 USA; [Moriarty, Helene; Winter, Laraine; Fishman, Deborah] Corporal Michael J Crescenz Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA USA; [Winter, Laraine] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia Res & Educ Fdn, Philadelphia, PA USA; [Robinson, Keith; Iacovone, Delores Blazer; Newhart, Brian] Corporal Michael J Crescenz Vet Affairs Med Ctr, Rehabil Med Serv, Polytrauma Network Site Vet Integrated Serv Netwo, Philadelphia, PA USA; [Robinson, Keith; True, Gala] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Piersol, Catherine Verrier; Vause-Earland, Tracey] Thomas Jefferson Univ, Jefferson Coll Hlth Profess, Philadelphia, PA 19107 USA; [True, Gala] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA; [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Ctr Innovat Care Aging, Sch Nursing, Baltimore, MD USA		Moriarty, H (corresponding author), Villanova Univ, Coll Nursing, 800 Lancaster Ave,Driscoll Hall, Villanova, PA 19085 USA.; Moriarty, H (corresponding author), Corporal Michael J Crescenz Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA USA.	helene.moriarty@villanova.edu		Piersol, Catherine/0000-0003-4992-8988	Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD068857-01]	The project described was supported by Award Number R21 HD068857-01 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health.	ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Asher I. E., 2007, OCCUPATIONAL THERAPY; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bay EH, 2012, J MARITAL FAM THER, V38, P556, DOI 10.1111/j.1752-0606.2011.00231.x; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Brain Trauma Foundation, TRAUM BRAIN INJ STAT; Carnevale GJ, 2006, ARCH PHYS MED REHAB, V87, P1289, DOI 10.1016/j.apmr.2006.06.010; Centers for Disease Control and Prevention, TRAUMATIC BRAIN INJU; Chokshi DA, 2014, NEW ENGL J MED, V371, P297, DOI 10.1056/NEJMp1406868; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Defense and Veteran Brain Injury Center, DOD WORLDW NUMB TBI; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Folkman S., 1984, STRESS; Ford JH, 2014, J REHABIL RES DEV, V51, P1311, DOI 10.1682/JRRD.2014.03.0066; Foster AM, 2012, DISABIL REHABIL, V34, P1855, DOI 10.3109/09638288.2012.670028; Friedemann-Sanchez G, 2008, REHABIL NURS, V33, P206, DOI 10.1002/j.2048-7940.2008.tb00229.x; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Gitlin LN, 2008, AM J GERIAT PSYCHIAT, V16, P229, DOI 10.1097/JGP.0b013e318160da72; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2010, JAMA-J AM MED ASSOC, V304, P983, DOI 10.1001/jama.2010.1253; Gitlin LN, 2010, J AM GERIATR SOC, V58, P1465, DOI 10.1111/j.1532-5415.2010.02971.x; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; Glynn SM, 2013, CLIN CHILD FAM PSYCH, V16, P410, DOI 10.1007/s10567-013-0153-z; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hanks RA, 2012, ARCH PHYS MED REHAB, V93, P1297, DOI 10.1016/j.apmr.2012.04.027; Herzberg PA, 1983, PRINCIPLES STAT; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hsiao CY, 2014, NURS RES, V63, P260, DOI 10.1097/NNR.0000000000000047; Josman N, 1999, Can J Occup Ther, V66, P33; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KINNEY JM, 1995, J APPL GERONTOL, V14, P3, DOI 10.1177/073346489501400101; KINNEY JM, 1989, PSYCHOL AGING, V4, P402, DOI 10.1037/0882-7974.4.4.402; Kizer KW, 2014, NEW ENGL J MED, V371, P295, DOI 10.1056/NEJMp1406852; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Landau J., 2008, FAMILIES SYSTEMS HLT, V26, P69, DOI [10.1037/1091-7527.26.1.69, DOI 10.1037/1091-7527.26.1.69]; LAWTON MP, 1983, GERONTOLOGIST, V23, P349, DOI 10.1093/geront/23.4.349; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lerner D, 2008, J OCCUP ENVIRON MED, V50, P401, DOI 10.1097/JOM.0b013e31816bae50; Lewin, 1935, DYNAMIC THEORY PERS; Lopez J, 2005, ARCH GERONTOL GERIAT, V41, P81, DOI 10.1016/j.archger.2004.12.001; Loss Boss P., 2005, LOSS TRAUMA RESILIEN; Lui MHL, 2005, STROKE, V36, P2514, DOI 10.1161/01.STR.0000185743.41231.85; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Minuchin S., 1974, FAMILIES FAMILY THER; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Oddy M, 2003, NEUROPSYCHOL REHABIL, V13, P259, DOI 10.1080/09602010244000345; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pollard D, 2005, ALLENS COGNITIVE LEV; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rietdijk R, 2012, J REHABIL MED, V44, P913, DOI 10.2340/16501977-1058; Riley GA, 2007, CLIN REHABIL, V21, P82, DOI 10.1177/0269215506071279; RIVERA PA, 2003, TOP SPINAL CORD INJ, V9, P53, DOI DOI 10.1310/G82F-BR2R-T69L-3QX8; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rodgers ML, 2007, AM J PHYS MED REHAB, V86, P482, DOI 10.1097/PHM.0b013e31805c00a1; Roitman DM, 1997, PHYS OCCUP THER GERI, V14, P43; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Roth DL, 2015, J GERONTOL B-PSYCHOL, V70, P813, DOI 10.1093/geronb/gbv034; Sander AM, 2009, J HEAD TRAUMA REHAB, V24, P248, DOI 10.1097/HTR.0b013e3181ad593a; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Steger MF, 2009, J COUNS PSYCHOL, V56, P289, DOI 10.1037/a0015416; Stejskal TM, 2012, NEUROREHABILITATION, V31, P75, DOI 10.3233/NRE-2012-0776; Stevens LF, 2012, NEUROREHABILITATION, V31, P443, DOI 10.3233/NRE-2012-00815; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; U.S. Department of Veterans Affairs Public Health, VA HLTH CAR UT REC V; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Williamson GM, 1998, HEALTH PSYCHOL, V17, P152, DOI 10.1037/0278-6133.17.2.152; Winter L, 2015, 2015 NAT CAP AR TBI; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303	90	26	26	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2016	8	6					495	509		10.1016/j.pmrj.2015.10.008			15	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	DO6OX	WOS:000377904100001	26514790				2022-02-06	
J	Iyyathurai, J; Decuypere, JP; Leybaert, L; D'hondt, C; Bultynck, G				Iyyathurai, Jegan; Decuypere, Jean-Paul; Leybaert, Luc; D'hondt, Catheleyne; Bultynck, Geert			Connexins: substrates and regulators of autophagy	BMC CELL BIOLOGY			English	Article; Proceedings Paper	International Gap Junction Conference	MAR 28-APR 02, 2015	Valparaiso, CHILE			Autophagy; Connexins; Degradation; Regulation	JUNCTION PROTEIN CONNEXIN43; INOSITOL TRISPHOSPHATE RECEPTOR; ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; GAP-JUNCTIONS; CELL-DEATH; ENDOPLASMIC-RETICULUM; DOWN-REGULATION; CONNEXIN43-INTERACTING PROTEIN; INTERCELLULAR COMMUNICATION	Connexins mediate intercellular communication by assembling into hexameric channel complexes that act as hemichannels and gap junction channels. Most connexins are characterized by a very rapid turn-over in a variety of cell systems. The regulation of connexin turn-over by phosphorylation and ubiquitination events has been well documented. Moreover, different pathways have been implicated in connexin degradation, including proteasomal and lysosomal-based pathways. Only recently, autophagy emerged as an important connexin-degradation pathway for different connexin isoforms. As such, conditions well known to induce autophagy have an immediate impact on the connexin-expression levels. This is not only limited to experimental conditions but also several pathophysiological conditions associated with autophagy (dys) function affect connexin levels and their presence at the cell surface as gap junctions. Finally, connexins are not only substrates of autophagy but also emerge as regulators of the autophagy process. In particular, several connexin isoforms appear to recruit pre-autophagosomal autophagy-related proteins, including Atg16 and PI3K-complex components, to the plasma membrane, thereby limiting their availability and capacity for regulating autophagy.	[Iyyathurai, Jegan; D'hondt, Catheleyne; Bultynck, Geert] Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Cellular & Mol Med, Campus Gasthuisberg O-N-I Bus 802,Herestr 49, B-3000 Leuven, Belgium; [Decuypere, Jean-Paul] Katholieke Univ Leuven, Lab Membrane Trafficking, Dept Human Genet, Campus Gasthuisberg,O-N-4,7-159,Herestr 49, B-3000 Leuven, Belgium; [Decuypere, Jean-Paul] VIB Ctr Biol Dis, Campus Gasthuisberg,O-N-4,7-159,Herestr 49, B-3000 Leuven, Belgium; [Leybaert, Luc] Univ Ghent, Physiol Grp, Dept Basic Med Sci, B-9000 Ghent, Belgium		Bultynck, G (corresponding author), Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Cellular & Mol Med, Campus Gasthuisberg O-N-I Bus 802,Herestr 49, B-3000 Leuven, Belgium.	geert.bultynck@med.kuleuven.be	Leybaert, Luc/F-4079-2015	Leybaert, Luc/0000-0001-6452-6982; Bultynck, Geert/0000-0002-5968-4828			Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Barsoum IB, 2014, CANCER RES, V74, P7185, DOI 10.1158/0008-5472.CAN-14-2598; Bejarano E, 2014, NAT CELL BIOL, V16, P401, DOI 10.1038/ncb2934; Bejarano E, 2012, MOL BIOL CELL, V23, P2156, DOI 10.1091/mbc.E11-10-0844; Berthoud VA, 2004, CARDIOVASC RES, V62, P256, DOI 10.1016/j.cardiores.2003.12.021; Bray K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041831; Brisset AC, 2009, ANTIOXID REDOX SIGN, V11, P267, DOI 10.1089/ars.2008.2115; Carette D, 2015, BIOL CELL, V107, P218, DOI 10.1111/boc.201400048; Cochrane K, 2013, CELL COMMUN ADHES, V20, P53, DOI 10.3109/15419061.2013.784745; Criollo A, 2007, CELL DEATH DIFFER, V14, P1029, DOI 10.1038/sj.cdd.4402099; Criollo A, 2007, AUTOPHAGY, V3, P350, DOI 10.4161/auto.4077; Czaja MJ, 2013, AUTOPHAGY, V9, P1131, DOI 10.4161/auto.25063; Czyz J, 2012, NAT REV UROL, V9, P274, DOI 10.1038/nrurol.2012.14; D'hondt C, 2009, BIOESSAYS, V31, P953, DOI 10.1002/bies.200800236; Decrock E, 2012, CELL DEATH DIFFER, V19, P947, DOI 10.1038/cdd.2011.176; Decrock E, 2009, CELL DEATH DIFFER, V16, P524, DOI 10.1038/cdd.2008.196; Decrock E, 2013, BBA-MOL CELL RES, V1833, P1772, DOI 10.1016/j.bbamcr.2012.12.016; Decrock E, 2011, CELL CALCIUM, V50, P310, DOI 10.1016/j.ceca.2011.05.007; Decuypere JP, 2014, AM J TRANSPLANT, V14, P1464, DOI 10.1111/ajt.12717; Decuypere JP, 2015, AM J KIDNEY DIS, V66, P699, DOI 10.1053/j.ajkd.2015.05.021; Decuypere JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061020; Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284; Decuypere JP, 2011, AUTOPHAGY, V7, P1472, DOI 10.4161/auto.7.12.17909; Decuypere JP, 2011, CELL CALCIUM, V50, P242, DOI 10.1016/j.ceca.2011.04.001; Driscoll JJ, 2012, CANCER LETT, V325, P147, DOI 10.1016/j.canlet.2012.06.016; Dumit VI, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00043; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; Elias LAB, 2007, NATURE, V448, P901, DOI 10.1038/nature06063; Falk MM, 2014, FEBS LETT, V588, P1221, DOI 10.1016/j.febslet.2014.01.031; Falk MM, 2012, J MEMBRANE BIOL, V245, P465, DOI 10.1007/s00232-012-9464-0; Falk MM, 2009, MOL BIOL CELL, V20, P3342, DOI 10.1091/mbc.E09-04-0288; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Fong JT, 2012, AUTOPHAGY, V8, P794, DOI 10.4161/auto.19390; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Garcia-Dorado D, 2002, CARDIOVASC RES, V55, P456, DOI 10.1016/S0008-6363(02)00441-8; Gilleron J, 2012, CRIT REV BIOCHEM MOL, V47, P407, DOI 10.3109/10409238.2012.683482; Girao H, 2009, EXP CELL RES, V315, P3587, DOI 10.1016/j.yexcr.2009.10.003; Green DR, 2015, EMBO REP, V16, P674, DOI 10.15252/embr.201540470; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Gump JM, 2014, NAT CELL BIOL, V16, P47, DOI 10.1038/ncb2886; Gumpert AM, 2008, FEBS LETT, V582, P2887, DOI 10.1016/j.febslet.2008.07.024; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hesketh GG, 2010, CIRC RES, V106, P1153, DOI 10.1161/CIRCRESAHA.108.182147; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kar R, 2013, J BONE MINER RES, V28, P1611, DOI 10.1002/jbmr.1917; Kelly JJ, 2015, CELL TISSUE RES, V360, P701, DOI 10.1007/s00441-014-2024-4; Kelly SM, 2007, MOL BIOL CELL, V18, P4279, DOI 10.1091/mbc.E07-05-0487; Kheloufi M, 2015, HEPATOLOGY, V62, P657, DOI 10.1002/hep.27597; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kopanic JL, 2015, BIOCHEM J, V466, P571, DOI 10.1042/BJ20141042; Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laing JG, 1998, CARDIOVASC RES, V38, P711, DOI 10.1016/S0008-6363(98)00060-1; Laird DW, 2014, FEBS LETT, V588, P1339, DOI 10.1016/j.febslet.2013.12.022; Laird DW, 2005, BBA-BIOMEMBRANES, V1711, P172, DOI 10.1016/j.bbamem.2004.09.009; Lamb CA, 2013, BIOESSAYS, V35, P34, DOI 10.1002/bies.201200130; Lan Z, 2005, BIOCHEMISTRY-US, V44, P2385, DOI 10.1021/bi048306w; Leithe E, 2004, J BIOL CHEM, V279, P50089, DOI 10.1074/jbc.M402006200; Leithe E, 2007, J MEMBRANE BIOL, V217, P43, DOI 10.1007/s00232-007-9050-z; Leithe Edward, 2006, Critical Reviews in Oncogenesis, V12, P225; Leithe E, 2009, J CELL SCI, V122, P3883, DOI 10.1242/jcs.053801; Leybaert L, 2012, PHYSIOL REV, V92, P1359, DOI 10.1152/physrev.00029.2011; Leykauf K, 2006, J CELL SCI, V119, P3634, DOI 10.1242/jcs.03149; Li XL, 2008, J BIOL CHEM, V283, P5748, DOI 10.1074/jbc.M709288200; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liaw NY, 2013, AM J PHYSIOL-REG I, V305, pR1171, DOI 10.1152/ajpregu.00198.2013; Lichtenstein A, 2011, J CELL SCI, V124, P910, DOI 10.1242/jcs.073072; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Ma S, 2015, BBA-MOL BASIS DIS, V1852, P271, DOI 10.1016/j.bbadis.2014.05.010; Maes M, 2015, TRANSL RES, V166, P332, DOI 10.1016/j.trsl.2015.05.005; Mancuso M, 2011, ONCOGENE, V30, P4601, DOI 10.1038/onc.2011.176; Mari Muriel, 2011, F1000 Biol Rep, V3, P25, DOI 10.3410/B3-25; Martins-Marques T, 2015, BIOCHEM J, V467, P231, DOI 10.1042/BJ20141370; Minogue PJ, 2013, J BIOL CHEM, V288, P20427, DOI 10.1074/jbc.M113.452847; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Molica F, 2014, BIOL CELL, V106, P269, DOI 10.1111/boc.201400038; Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Orellana JA, 2012, REV NEUROSCIENCE, V23, P163, DOI 10.1515/revneuro-2011-0065; Orellana JA, 2011, J NEUROSCI, V31, P4962, DOI 10.1523/JNEUROSCI.6417-10.2011; Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471-4159.2011.07210.x; Parys JB, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-17; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Piehl M, 2007, MOL BIOL CELL, V18, P337, DOI 10.1091/mbc.E06-06-0487; Polson HEJ, 2010, AUTOPHAGY, V6, P506, DOI 10.4161/auto.6.4.11863; Reed AM, 2014, AM J PHYSIOL-GASTR L, V307, pG24, DOI 10.1152/ajpgi.00010.2014; Retamal MA, 2007, J NEUROSCI, V27, P13781, DOI 10.1523/JNEUROSCI.2042-07.2007; Rubinsztein DC, 2015, J EXP MED, V212, P979, DOI 10.1084/jem.20150956; Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Siebert AP, 2013, J BIOL CHEM, V288, P6140, DOI 10.1074/jbc.M112.409789; Sin WC, 2012, BBA-BIOMEMBRANES, V1818, P2058, DOI 10.1016/j.bbamem.2011.10.022; Solan JL, 2014, FEBS LETT, V588, P1423, DOI 10.1016/j.febslet.2014.01.049; Stehberg J, 2012, FASEB J, V26, P3649, DOI 10.1096/fj.11-198416; Su V, 2014, FEBS LETT, V588, P1212, DOI 10.1016/j.febslet.2014.01.013; Su V, 2014, BIOCHEM J, V458, P57, DOI 10.1042/BJ20131247; Su V, 2012, J MEMBRANE BIOL, V245, P389, DOI 10.1007/s00232-012-9461-3; Su V, 2010, J BIOL CHEM, V285, P40979, DOI 10.1074/jbc.M110.170753; Su V, 2009, CELL MOL LIFE SCI, V66, P2819, DOI 10.1007/s00018-009-0048-9; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Sun LQ, 2015, BEHAV BRAIN RES, V291, P315, DOI 10.1016/j.bbr.2015.05.049; Tittarelli A, 2015, J BIOL CHEM, V290, P23670, DOI 10.1074/jbc.M115.651547; VanSlyke JK, 2005, MOL BIOL CELL, V16, P5247, DOI 10.1091/mbc.E05-05-0415; VanSlyke JK, 2002, J CELL BIOL, V157, P381, DOI 10.1083/jcb.200111045; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34; Vinken M, 2012, BBA-BIOMEMBRANES, V1818, P2002, DOI 10.1016/j.bbamem.2011.06.011; Wang N, 2013, BBA-BIOMEMBRANES, V1828, P35, DOI 10.1016/j.bbamem.2012.07.002; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Xu HY, 2015, J BONE MINER RES, V30, P550, DOI 10.1002/jbmr.2374; Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061; Yonekawa T, 2015, EMBO REP, V16, P700, DOI 10.15252/embr.201439496; Zhong WQ, 2015, HISTOPATHOLOGY, V66, P798, DOI 10.1111/his.12569; Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101	125	26	26	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2121			BMC CELL BIOL	BMC Cell Biol.	MAY 24	2016	17			1					20	10.1186/s12860-016-0093-9			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Cell Biology	DT4GC	WOS:000381437200011	27229147	Green Published, gold			2022-02-06	
J	Rowe, RK; Ellis, GI; Harrison, JL; Bachstetter, AD; Corder, GF; Van Eldik, LJ; Taylor, BK; Marti, F; Lifshitz, J				Rowe, Rachel K.; Ellis, Gavin I.; Harrison, Jordan L.; Bachstetter, Adam D.; Corder, Gregory F.; Van Eldik, Linda J.; Taylor, Bradley K.; Marti, Francesc; Lifshitz, Jonathan			Diffuse traumatic brain injury induces prolonged immune dysregulation and potentiates hyperalgesia following a peripheral immune challenge	MOLECULAR PAIN			English	Article						Traumatic brain injury; pain; hyperalgesia; regulatory T cells; immunology	REGULATORY T-CELLS; NECROSIS-FACTOR-ALPHA; CHRONIC PAIN; NEUROPATHIC PAIN; P38-ALPHA MAPK; RETINOIC ACID; UP-REGULATION; ACTIVATION; MECHANISMS; NEUROINFLAMMATION	Background: Nociceptive and neuropathic pain occurs as part of the disease process after traumatic brain injury (TBI) in humans. Central and peripheral inflammation, a major secondary injury process initiated by the traumatic brain injury event, has been implicated in the potentiation of peripheral nociceptive pain. We hypothesized that the inflammatory response to diffuse traumatic brain injury potentiates persistent pain through prolonged immune dysregulation. Results: To test this, adult, male C57BL/6 mice were subjected to midline fluid percussion brain injury or to sham procedure. One cohort of mice was analyzed for inflammation-related cytokine levels in cortical biopsies and serum along an acute time course. In a second cohort, peripheral inflammation was induced seven days after surgery/injury with an intraplantar injection of carrageenan. This was followed by measurement of mechanical hyperalgesia, glial fibrillary acidic protein and Iba1 immunohistochemical analysis of neuroinflammation in the brain, and flow cytometric analysis of T-cell differentiation in mucosal lymph. Traumatic brain injury increased interleukin-6 and chemokine ligand 1 levels in the cortex and serum that peaked within 1-9 h and then resolved. Intraplantar carrageenan produced mechanical hyperalgesia that was potentiated by traumatic brain injury. Further, mucosal T cells from brain-injured mice showed a distinct deficiency in the ability to differentiate into inflammation-suppressing regulatory T cells (Tregs). Conclusions: We conclude that traumatic brain injury increased the inflammatory pain associated with cutaneous inflammation by contributing to systemic immune dysregulation. Regulatory T cells are immune suppressors and failure of T cells to differentiate into regulatory T cells leads to unregulated cytokine production which may contribute to the potentiation of peripheral pain through the excitation of peripheral sensory neurons. In addition, regulatory T cells are identified as a potential target for therapeutic rebalancing of peripheral immune homeostasis to improve functional outcome and decrease the incidence of peripheral inflammatory pain following traumatic brain injury.	[Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Phoenix Veteran Affairs Healthcare Syst, Phoenix, AZ USA; [Ellis, Gavin I.] Univ Kentucky, Coll Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY USA; [Harrison, Jordan L.; Lifshitz, Jonathan] Arizona State Univ, Tempe, AZ USA; [Bachstetter, Adam D.; Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Bachstetter, Adam D.; Van Eldik, Linda J.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Corder, Gregory F.; Taylor, Bradley K.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY USA		Lifshitz, J (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA.	jlifshitz@email.arizona.edu		Rowe, Rachel/0000-0002-9034-3159; Bachstetter, Adam/0000-0003-4646-6757	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K02 DA19656, R01 DA037621, R01 NS065052, F31 NS09092]; Bisgrove Scholar Award from Science Foundation Arizona; Diane and Bruce Halle Foundation; Office of the Vice President for Research; Markey Cancer Center; NIH Shared Instrument ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10 RR026827]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR026827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA037621, K02DA019656] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by NIH grants K02 DA19656 and R01 DA037621 (BKT) and R01 NS065052 (JL). Dr. Rowe is funded by a Bisgrove Scholar Award from Science Foundation Arizona. Mr. Harrison was partially supported by the Diane and Bruce Halle Foundation and NIH F31 NS09092. Flow cytometry was carried out at the University of Kentucky Flow Cytometry and Cell Sorting Core Facility, which is supported in part by the Office of the Vice President for Research, the Markey Cancer Center and a grant from the NIH Shared Instrument Program (S10 RR026827).	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Austin PJ, 2012, PAIN, V153, P1916, DOI 10.1016/j.pain.2012.06.005; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Beggs S, 2013, NEUROSCI LETT, V557, P37, DOI 10.1016/j.neulet.2013.08.037; Bosco MA, 2013, HEADACHE, V53, P1518, DOI 10.1111/head.12172; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carson WF, 2010, EUR J IMMUNOL, V40, P998, DOI 10.1002/eji.200939739; Corder G, 2013, SCIENCE, V341, P1394, DOI 10.1126/science.1239403; Cunha F Q, 1992, Mediators Inflamm, V1, P397, DOI 10.1155/S0962935192000607; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; DePaolo RW, 2011, NATURE, V471, P220, DOI 10.1038/nature09849; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Eakin K, 2015, BRAIN NEUROTRAUMA MO, P1; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128; Ellis GI, 2012, JOVE-J VIS EXP, DOI 10.3791/3738; Feliciano DP, 2014, NEUROSCI LETT, V583, P55, DOI 10.1016/j.neulet.2014.09.030; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Hall JA, 2011, IMMUNITY, V34, P435, DOI 10.1016/j.immuni.2011.03.003; Harrison JL, 2015, BRAIN BEHAV IMMUN, V47, P131, DOI 10.1016/j.bbi.2015.01.001; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Huang H, 2013, J IMMUNOL, V191, P1136, DOI 10.4049/jimmunol.1201899; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Liu ZM, 2015, CELL MOL IMMUNOL, V12, P553, DOI 10.1038/cmi.2014.133; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Murphy TJ, 2005, J IMMUNOL, V174, P2957, DOI 10.4049/jimmunol.174.5.2957; Myers RR, 2006, DRUG DISCOV TODAY, V11, P8, DOI 10.1016/S1359-6446(05)03637-8; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; NAPOLITANO LM, 1994, ARCH SURG-CHICAGO, V129, P1276; NAPOLITANO LM, 1995, J TRAUMA, V39, P104, DOI 10.1097/00005373-199507000-00014; Old EA, 2015, HANDB EXP PHARMACOL, V227, P145, DOI 10.1007/978-3-662-46450-2_8; Posadas I, 2004, BRIT J PHARMACOL, V142, P331, DOI 10.1038/sj.bjp.0705650; Reichling DB, 2009, TRENDS NEUROSCI, V32, P611, DOI 10.1016/j.tins.2009.07.007; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Sandkuhler J, 2009, PHYSIOL REV, V89, P707, DOI 10.1152/physrev.00025.2008; Schafers M, 2003, J NEUROSCI, V23, P2517; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007; Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; Zelenka M, 2005, PAIN, V116, P257, DOI 10.1016/j.pain.2005.04.018; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	56	26	26	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		1744-8069		MOL PAIN	Mol. Pain	MAY 13	2016	12								1744806916647055	10.1177/1744806916647055			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DM9YY	WOS:000376722800001	27178244	Green Published, gold			2022-02-06	
J	Chaturvedi, J; Botta, R; Prabhuraj, AR; Shukla, D; Bhat, DI; Devi, BI				Chaturvedi, Jitender; Botta, Ragasudha; Prabhuraj, A. R.; Shukla, Dhaval; Bhat, Dahnanjay I.; Devi, B. Indira			Complications of cranioplasty after decompressive craniectomy for traumatic brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						complications; cranioplasty; decompressive craniectomy	MULTICENTER	Introduction. Decompressive craniectomy (DC)a potentially life-saving intervention following traumatic brain injury (TBI) with medically refractory brain swellingonce performed, surviving patients, more often than not, undergo a second procedure with cranioplasty (CP) in the future. This study analyzes complications following CP after DC, as the beneficial effects of the DC can't be extrapolated in long run over a population unless one adds into it the complications associated with the CP in the survivors of TBI. Materials and methods. An observational study was performed retrospectively, with the review of case records. Demographic, clinical, and outcome data were collected, and complications were studied for any predictive parameters. A multivariate analysis was performed to identify factors that influenced these complications. Results. Data were collected for a total of 74 patients who underwent CP with a median age of 32, and a mean follow-up time of 2 years and 8 months. The mortality rate was 1.35% and overall complication rate 31%. The most significant factor determining complications were operating time more than 90 min Odds ratio (OR) 4.77 (1.61-14.20); timing of CP less than 3 months after craniectomy, OR 2.86 (1.48-8.11); age more than 20 years, OR 2.59 (1.20-6.53); and female gender, OR 1.91 (1.13-4.17). Conclusions. Although considered as a straight-forward procedure, the risks associated with this elective procedure should be kept in mind by the surgeon so that the patients and families can be apprised judiciously. It should be ascertained that patient and/or family consents for the procedure after being appropriately informed about the benefits and risks associated with the procedure.	[Chaturvedi, Jitender; Prabhuraj, A. R.; Shukla, Dhaval; Bhat, Dahnanjay I.; Devi, B. Indira] NIMHANS, Dept Neurosurg, Bengaluru 560029, Karnataka, India; [Botta, Ragasudha] NIMHANS, Dept Clin Neurosci, Bengaluru 560029, Karnataka, India		Chaturvedi, J (corresponding author), NIMHANS, Dept Neurosurg, Bengaluru 560029, Karnataka, India.	drjittu28@gmail.com					Bobinski L, 2013, CLIN NEUROL NEUROSUR, V115, P1788, DOI 10.1016/j.clineuro.2013.04.013; Broughton E, 2014, BRIT J NEUROSURG, V28, P34, DOI 10.3109/02688697.2013.815319; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Heo J, 2014, J NEUROSURG, V121, P313, DOI 10.3171/2014.2.JNS131480; Joffe J, 1999, BRIT J NEUROSURG, V13, P576, DOI 10.1080/02688699943088; Klinger DR, 2014, WORLD NEUROSURG, V82, pE525, DOI 10.1016/j.wneu.2013.08.005; Lee MK, 2010, J CRANIO MAXILL SURG, V38, P494, DOI 10.1016/j.jcms.2010.02.001; Shaffrey ME, 1993, BRAIN SURG COMPLICAT, V1, P1373; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	16	26	27	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	MAY 3	2016	30	2					264	268		10.3109/02688697.2015.1054356			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DI3LK	WOS:000373399900019	26083136				2022-02-06	
J	Jagannatha, AT; Sriganesh, K; Devi, BI; Rao, GSU				Jagannatha, Aniruddha Tekkatte; Sriganesh, Kamath; Devi, Bhagavatula Indira; Rao, Ganne Sesha Umamaheswara			An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Brain Trauma Foundation; Hypertonic saline; Intracranial hypertension; Mannitol; Outcome; Traumatic brain injury	20-PERCENT MANNITOL; SODIUM-CHLORIDE; WATER-CONTENT; PRESSURE; FUROSEMIDE; TRIAL	The impact of hypertonic saline (HTS) on long term control of intracranial hypertension (ICH) is yet to be established. The current prospective randomized controlled study was carried out in 38 patients with severe traumatic brain injury (TBI). Over 450 episodes of refractory ICH were treated with equiosmolar boluses of 20% mannitol in 20 patients and 3.0% HTS in 18 subjects. Intracranial pressure (ICP) was monitored for 6 days. ICP and cerebral perfusion pressure (CPP) were comparable between the groups. The mannitol group had a progressive increase in the ICP over the study period (p = 0.01). A similar increase was not seen in the HTS group (p = 0.1). The percentage time for which the ICP remained below a threshold of 20 mmHg on day 6 was higher in the HTS group (63% versus 49%; p = 0.3). The duration of inotrope requirement in the HTS group was less compared to the mannitol group (p = 0.06). The slope of fall in ICP in response to a bolus dose at a given baseline value of ICP was higher with HTS compared to mannitol (p = 0.0001). In-hospital mortality tended to be lower in the HTS group (3 versus 10; p = 0.07) while mortality at 6 months was not different between the groups (6 versus 10; p = 0.41). Dichotomized Glasgow Outcome Scale scores at 6 months were comparable between the groups (p = 0.21). To conclude, immediate physiological advantages seen with HTS over mannitol did not translate into long term benefit on ICP/CPP control or mortality of patients with TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Devi, Bhagavatula Indira] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore, Karnataka, India; [Sriganesh, Kamath; Rao, Ganne Sesha Umamaheswara] Natl Inst Mental Hlth & Neurosci NIMHANS, Neuroctr, Dept Neuroanaesthesia, 3rd Floor,Fac Block,Hosur Rd, Bangalore 560029, Karnataka, India; [Jagannatha, Aniruddha Tekkatte] MS Ramaiah Med Coll, Dept Neurosurg, Bangalore, Karnataka, India		Rao, GSU (corresponding author), Natl Inst Mental Hlth & Neurosci NIMHANS, Neuroctr, Dept Neuroanaesthesia, 3rd Floor,Fac Block,Hosur Rd, Bangalore 560029, Karnataka, India.	gsuma123@yahoo.com					Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERGER S, 1994, ACT NEUR S, V60, P494; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Celli P, 1997, Minerva Chir, V52, P1467; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Himmelseher S, 2007, CURR OPIN ANESTHESIO, V20, P414, DOI 10.1097/ACO.0b013e3282eff9ea; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Kalita J, 2003, NEUROL INDIA, V51, P104; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Mayzler O, 2006, J NEUROSURG ANESTH, V18, P24, DOI 10.1097/01.ana.0000188358.41284.cb; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Strandvik GF, 2009, ANAESTHESIA, V64, P990, DOI 10.1111/j.1365-2044.2009.05986.x; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wang LC, 2013, ANESTHESIOLOGY, V118, P903, DOI 10.1097/ALN.0b013e31828156ff; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	23	26	29	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	MAY	2016	27						68	73		10.1016/j.jocn.2015.08.035			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DK0LZ	WOS:000374605600013	26924183				2022-02-06	
J	Kreutzer, JS; Marwitz, JH; Sima, AP; Bergquist, TF; Johnson-Greene, D; Felix, ER; Whiteneck, GG; Dreer, LE				Kreutzer, Jeffrey S.; Marwitz, Jennifer H.; Sima, Adam P.; Bergquist, Thomas F.; Johnson-Greene, Douglas; Felix, Elizabeth R.; Whiteneck, Gale G.; Dreer, Laura E.			Resilience Following Traumatic Brain Injury: A Traumatic Brain Injury Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation; Resilience; psychological	CONNOR-DAVIDSON RESILIENCE; PSYCHOLOGICAL RESILIENCE; POSITIVE EMOTIONS; REHABILITATION; PREDICTORS; SCALE; SATISFACTION; INTERVIEW; PEOPLE	Objective: To examine resilience at 3 months after traumatic brain injury (TBI). Design: Cross-sectional analysis of an ongoing observational cohort. Setting: Five inpatient rehabilitation centers, with 3-month follow-up conducted primarily by telephone. Participants: Persons with TBI (N=160) enrolled in the resilience module of the TBI Model System study with 3-month follow-up completed. Interventions: Not applicable. Main Outcome Measure: Connor-Davidson Resilience Scale. Results: Resilience scores were lower than those of the general population. A multivariable regression model, adjusting for other predictors, showed that higher education, absence of preinjury substance abuse, and less anxiety at follow-up were significantly related to greater resilience. Conclusions: Analysis suggests that lack of resilience may be an issue for some individuals after moderate to severe TBI. Identifying persons most likely at risk for low resilience may be useful in planning clinical interventions. (C) 2016 by the American Congress of Rehabilitation Medicine	[Kreutzer, Jeffrey S.; Marwitz, Jennifer H.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA; [Sima, Adam P.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Dept Phys Med & Rehabil, Rochester, MN USA; [Johnson-Greene, Douglas; Felix, Elizabeth R.] Univ Miami, Miller Sch Med, Dept Phys Med & Rehabil, Miami, FL 33136 USA; [Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA		Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Box 980542, Richmond, VA 23298 USA.	jhmarwit@vcu.edu	Felix, Elizabeth/AAD-6356-2021	Felix, Elizabeth/0000-0002-6239-715X; Sima, Adam/0000-0001-8426-9987	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90DP0030, 90DP0033, 90DP0034, H133A120096, H133A120099]	Supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR; grant nos. 90DP0030, 90DP0033, 90DP0034, H133A120096, H133A120099). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this manuscript do not necessarily represent the policy of NIDILRR, ACL, HHS, and you should not assume endorsement by the Federal Government.	Bertisch H, 2014, NEUROREHABILITATION, V34, P573, DOI 10.3233/NRE-141059; Brown SA, 2001, AM J PHYS MED REHAB, V80, P196, DOI 10.1097/00002060-200103000-00009; Campbell-Sills L, 2006, BEHAV RES THER, V44, P585, DOI 10.1016/j.brat.2005.05.001; Campbell-Sills L, 2007, J TRAUMA STRESS, V20, P1019, DOI 10.1002/jts.20271; Campbell-Sills L, 2009, J PSYCHIATR RES, V43, P1007, DOI 10.1016/j.jpsychires.2009.01.013; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Connor KM, 2006, J CLIN PSYCHIAT, V67, P46; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Curtis WJ, 2003, DEV PSYCHOPATHOL, V15, P773, DOI 10.1017/S0954579403000373; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dowrick C, 2008, HEALTH-LONDON, V12, P439, DOI 10.1177/1363459308094419; Edward K, 2005, J AM PSYCHIAT NURSES, V11, P101; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Karoly P, 2006, PAIN, V123, P90, DOI 10.1016/j.pain.2006.02.014; Lefebvre H., 2006, ILLNESS CRISIS LOSS, V14, P337, DOI DOI 10.1177/105413730601400403; Losoi H, 2015, J HEAD TRAUMA REHAB, V30, pE24, DOI 10.1097/HTR.0000000000000055; Lukow HR, 2015, J HEAD TRAUMA REHAB, V30, P241, DOI 10.1097/HTR.0000000000000137; Malec JF, 2012, ARCH PHYS MED REHAB, V93, P1603, DOI 10.1016/j.apmr.2012.04.003; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Newman R, 2005, PROF PSYCHOL-RES PR, V36, P227, DOI 10.1037/0735-7028.36.3.227; Norris FH, 2009, SOC SCI MED, V68, P2190, DOI 10.1016/j.socscimed.2009.03.043; Ong AD, 2006, J PERS SOC PSYCHOL, V91, P730, DOI 10.1037/0022-3514.91.4.730; Pavot W, 2009, SOC INDIC RES SER, V39, P101, DOI 10.1007/978-90-481-2354-4_5; Pooley JA, 2010, AUST COMMUNITY PSYCH, V22, P30; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Sullivan KA, 2015, REHABIL PSYCHOL, V60, P147, DOI 10.1037/rep0000037; Tonks J, 2011, BRAIN INJURY, V25, P870, DOI 10.3109/02699052.2011.581641; Tugade MM, 2004, J PERS SOC PSYCHOL, V86, P320, DOI 10.1037/0022-3514.86.2.320; Tulsky DS, 2016, J HEAD TRAUMA REHAB, V31, P40, DOI 10.1097/HTR.0000000000000131; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; White B, 2010, REHABIL PSYCHOL, V55, P23, DOI 10.1037/a0018451; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P540, DOI 10.1016/j.apmr.2010.12.002	41	26	26	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2016	97	5					708	713		10.1016/j.apmr.2015.12.003			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	DL4UM	WOS:000375633300007	26707459				2022-02-06	
J	Pakkanen, T; Virkkunen, I; Kamarainen, A; Huhtala, H; Silfvast, T; Virta, J; Randell, T; Yli-Hankala, A				Pakkanen, Toni; Virkkunen, Ilkka; Kamarainen, Antti; Huhtala, Heini; Silfvast, Tom; Virta, Janne; Randell, Tarja; Yli-Hankala, Arvi			Pre-hospital severe traumatic brain injury - comparison of outcome in paramedic versus physician staffed emergency medical services	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Pre-hospital Emergency Care (MeSH); Emergency Medical Services (MeSH); Critical Care (MeSH); Traumatic Brain Injury (MeSH); Airway Management (MeSH); Endotracheal Intubation (MeSH); Patient Outcome Assessment (MeSH); Glasgow Outcome Scale (MeSH)	RAPID-SEQUENCE INTUBATION; SEVERE HEAD-INJURY; PRACTICAL SCALE; CARE; IMPACT; TRIAL	Background: Traumatic brain injury (TBI) is one of the leading causes of death and permanent disability. Emergency Medical Services (EMS) personnel are often the first healthcare providers attending patients with TBI. The level of available care varies, which may have an impact on the patient's outcome. The aim of this study was to evaluate mortality and neurological outcome of TBI patients in two regions with differently structured EMS systems. Methods: A 6-year period (2005 - 2010) observational data on pre-hospital TBI management in paramedic-staffed EMS and physician-staffed EMS systems were retrospectively analysed. Inclusion criteria for the study were severe isolated TBI presenting with unconsciousness defined as Glasgow coma scale (GCS) score <= 8 occurring either on-scene, during transportation or verified by an on-call neurosurgeon at admission to the hospital. For assessment of one-year neurological outcome, a modified Glasgow Outcome Score (GOS) was used. Results: During the 6-year study period a total of 458 patients met the inclusion criteria. One-year mortality was higher in the paramedic-staffed EMS group: 57 % vs. 42 %. Also good neurological outcome was less common in patients treated in the paramedic-staffed EMS group. Discussion: We found no significant difference between the study groups when considering the secondary brain injury associated vital signs on-scene. Also on arrival to ED, the proportion of hypotensive patients was similar in both groups. However, hypoxia was common in the patients treated by the paramedic-staffed EMS on arrival to the ED, while in the physician-staffed EMS almost none of the patients were hypoxic. Prehospital intubation by EMS physicians probably explains this finding. Conclusion: The results suggest to an outcome benefit from physician-staffed EMS treating TBI patients.	[Pakkanen, Toni; Virkkunen, Ilkka] FinnHEMS Ltd, Res & Dev Unit, Vantaa, Finland; [Pakkanen, Toni; Yli-Hankala, Arvi] Tampere Univ Hosp, Dept Anaesthesia, Tampere, Finland; [Kamarainen, Antti; Virta, Janne] Tampere Univ Hosp, FinnHEMS 30, Tays Emergency Med Serv, Tampere, Finland; [Huhtala, Heini] Univ Tampere, Sch Hlth Sci, FIN-33101 Tampere, Finland; [Silfvast, Tom; Randell, Tarja] Univ Helsinki, Helsinki Univ Hosp, Dept Anaesthesia & Intens Care, Helsinki, Finland; [Yli-Hankala, Arvi] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland		Pakkanen, T (corresponding author), FinnHEMS Ltd, Res & Dev Unit, Vantaa, Finland.; Pakkanen, T (corresponding author), Tampere Univ Hosp, Dept Anaesthesia, Tampere, Finland.	toni.pakkanen@fimnet.fi		Yli-Hankala, Arvi/0000-0002-5029-9181; Kamarainen, Antti/0000-0002-2299-3918	VTR Study Grant from Special State Allocation via Tampere University Hospital [9N088]; FinnHEMS ltd, Research and development unit	This study was supported by a VTR Study Grant #9N088 from Special State Allocation via Tampere University Hospital and FinnHEMS ltd, Research and development unit.	Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DF, 2008, CURR OPIN CRIT CARE, V14, P142, DOI 10.1097/MCC.0b013e3282f63c40; Davis DP, 2008, RESUSCITATION, V76, P333, DOI 10.1016/j.resuscitation.2007.08.004; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Garner A, 2001, INJURY, V32, P455, DOI 10.1016/S0020-1383(01)00013-4; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; TEASDALE G, 1974, LANCET, V2, P81; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008	20	26	27	1	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	APR 29	2016	24								62	10.1186/s13049-016-0256-x			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	DM1AK	WOS:000376077200001	27130216	gold, Green Published			2022-02-06	
J	Tsushima, WT; Geling, O; Arnold, M; Oshiro, R				Tsushima, William T.; Geling, Olga; Arnold, Monica; Oshiro, Ross			Are There Subconcussive Neuropsychological Effects in Youth Sports? An Exploratory Study of High- and Low-Contact Sports	APPLIED NEUROPSYCHOLOGY-CHILD			English	Article						contact; subconcussive neuropsychological effects; youth sports	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL; CONCUSSION INCIDENCE; WHITE-MATTER; IMPACT; RECOVERY; PLAY	This exploratory study was designed to examine the neuropsychological effects of sports-related head traumaspecifically, repetitive subconcussive impacts or head blows that do not result in a diagnosable concussion. The researchers compared the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) neurocognitive test scores of 2 groups of nonconcussed youth athletes (n=282), grouped according to the frequency of concussions in their respective sports, with the assumption that more subconcussive impacts occur in sports in which there are more reported concussions. The results indicated that high-contact-sport (football) athletes had significantly poorer performance in processing speed and reaction time compared with athletes in low-contact sports (wrestling, soccer, baseball, judo, and basketball). This study into the effects of repetitive subconcussive head trauma tentatively raises concern that participation in high-contact sports, even without evidence of a diagnosable concussion, could result in lowered neuropsychological functioning among high school athletes. Limitations of this exploratory research effort are discussed.	[Tsushima, William T.] Straub Clin & Hosp, Dept Psychiat & Psychol, 888 South King St, Honolulu, HI 96813 USA; [Geling, Olga] PPE Solut, Honolulu, HI USA; [Arnold, Monica] Syntactx, New York, NY USA; [Oshiro, Ross] Queens Ctr Sports Med, Honolulu, HI USA		Tsushima, WT (corresponding author), Straub Clin & Hosp, Dept Psychiat & Psychol, 888 South King St, Honolulu, HI 96813 USA.	wtsushima@straub.net	Meijer, Anna/K-5118-2016		Hawaii Pacific Health (HPH)	This work was supported in part by funding from Hawaii Pacific Health (HPH) to Monica Arnold as a participant in the HPH Summer Scholar Research Program.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Datalys Center for Sports Injury Research and Prevention, 2013, NATA NATION PREL CON; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Fainaru-Wada Mark, 2013, LEAGUE DENIAL NFL CO; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lovell M. R., 2006, SPORTS NEUROPSYCHOLO, P193; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Shuttleworth-Edwards Ann B, 2009, Phys Sportsmed, V37, P45, DOI 10.3810/psm.2009.12.1741; Spicer M.A.C.M., 2014, SPORTS RELATED CONCU; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; WEBBE FM, 2006, SPORTS NEUROPSYCHOLO, P45; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	43	26	26	1	28	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2162-2965	2162-2973		APPL NEUROPSYCH-CHIL	Appl. Neuropsychol.-Child	APR 2	2016	5	2					149	155		10.1080/21622965.2015.1052813			7	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	DJ1BG	WOS:000373937500008	26979930				2022-02-06	
J	Gardner, AJ; Iverson, GL; Stanwell, P; Moore, T; Ellis, J; Levi, CR				Gardner, A. J.; Iverson, G. L.; Stanwell, P.; Moore, T.; Ellis, J.; Levi, C. R.			A Video Analysis of Use of the New "Concussion Interchange Rule' in the National Rugby League	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						concussion; video analysis; injury management; return to play	INCIDENT ANALYSIS; PROFESSIONAL FOOTBALL; INJURY; SITUATIONS; MATCH; SPORT	The National Rugby League (NRL) in Australia introduced a new concussion interchange rule' (CIR) in 2014, whereby a player suspected of having sustained a concussion can be removed from play, and assessed, without an interchange being tallied against the player's team. We conducted a video analysis, describing player and injury characteristics, situational factors, concussion signs, and return to play for each CIR event for the 2014 season. There were 167 reported uses of the CIR. Apparent loss of consciousness/unresponsiveness was observed in 32% of cases, loss of muscle tone in 54%, clutching the head in 70%, unsteadiness of gait in 66%, and a vacant stare in 66%. More than half of the players who were removed under the CIR returned to play later in the same match (57%). Most incidences occurred from a hit up (62%) and occurred during a tackle where the initial contact was with the upper body (80%). The new concussion interchange rule has been used frequently during the first season of its implementation. In many cases, there appeared to be video evidence of injury but the athlete was cleared to return to play. More research is needed on the usefulness of video review for identifying signs of concussive injury.	[Gardner, A. J.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Level 5, Waratah 2298, Australia; [Iverson, G. L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Stanwell, P.] Univ Newcastle, Sch Hlth Sci, Callaghan, NSW 2308, Australia; [Moore, T.] Hunter New England Local Hlth Dist, Neuropsychiat Serv, Newcastle, NSW, Australia; [Ellis, J.] Gold Coast Univ Hosp, Dept Med Imaging, Gold Coast, Australia; [Levi, C. R.] Hunter New England Local Hlth Dist, Sports Concuss Program, New Lambton Hts, Australia		Gardner, AJ (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Level 5, Waratah 2298, Australia.	andrew.gardner@neurogard.com.au	Stanwell, Peter/F-9136-2012	Stanwell, Peter/0000-0002-4780-0393; Levi, Christopher/0000-0002-9474-796X; Iverson, Grant/0000-0001-7348-9570; Gardner, Andrew/0000-0001-5031-5586	NSW Sporting Injuries Committee; Brain Foundation, Australia; Hunter Medical Research Institute Life Govenor; Mooney-Reed Charitable Foundation; Australian Football League (AFL); ImPACT(R) Applications Systems	This study was conducted as partial fulfillment for the requirements of a PhD thesis for the first author. A portion of these data was presented at the International Neuropsychological Society Mid-Year Conference, Sydney, Australia. Funding Sources: AJG, PS and CL have received funding support from the NSW Sporting Injuries Committee, and the Brain Foundation, Australia to conduct research in rugby league. AJG also acknowledges support from Jennie Thomas, Hunter Medical Research Institute Life Govenor. GLI acknowledges support from the Mooney-Reed Charitable Foundation. Financial Disclosure: None General Disclosure: AJG has a clinical practice in neuropsychology involving the assessment and management of individuals who have sustained sport-related concussion (including current and former athletes). He has received travel funding from the Australian Football League (AFL) to present at the Concussion in Football Conference in 2013. He also serves in a non-remunerated capacity as a member of the Concussion Advisory Group for the Australian Rugby Union (ARU). GLI has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to MTBI and sport-related concussion at meetings, scientific conferences, and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including athletes). He has received honorariums for serving on research panels that provide scientific peer review of programs. He is a co-investigator, collaborator, or consultant on grants relating to mild TBI funded by several organizations. He has received research support from test publishing companies in the past, including ImPACT (R) Applications Systems (not in the past 5 years).	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Hallgren Kevin A, 2012, Tutor Quant Methods Psychol, V8, P23; Harriss DJ, 2015, INT J SPORTS MED, V36, P1121, DOI 10.1055/s-0035-1565186; Hoskins W, 2006, J SCI MED SPORT, V9, P46, DOI 10.1016/j.jsams.2006.03.013; Hutchison MG, 2013, BRIT J SPORT MED, P1; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; IBM Corp, IBM SPSS STAT MAC VE; King DA, 2010, SPORTS MED, V40, P163, DOI 10.2165/11319740-000000000-00000; Koh JO, 2004, BRAIN INJURY, V18, P1287, DOI 10.1080/02699050410001719907; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Miele VJ, 2007, NEUROSURGERY, V60, P307, DOI 10.1227/01.NEU.0000249247.48299.5B; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158; Savage J, 2013, J SPORTS MED	19	26	27	0	9	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	APR	2016	37	4					267	273		10.1055/s-0035-1565203			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DJ1YZ	WOS:000374002200002	26837928				2022-02-06	
J	Dall'Acqua, P; Johannes, S; Mica, L; Simmen, HP; Glaab, R; Fandino, J; Schwendinger, M; Meier, C; Ulbrich, EJ; Muller, A; Jancke, L; Hanggi, J				Dall'Acqua, Patrizia; Johannes, Soenke; Mica, Ladislav; Simmen, Hans-Peter; Glaab, Richard; Fandino, Javier; Schwendinger, Markus; Meier, Christoph; Ulbrich, Erika J.; Mueller, Andreas; Jaencke, Lutz; Haenggi, Juergen			Connectomic and Surface-Based Morphometric Correlates of Acute Mild Traumatic Brain Injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						mild traumatic brain injury; structural connectome; connectivity analysis; cortical surface area; multimodal MRI; subjective symptoms	POST-CONCUSSION SYMPTOMS; TENSOR IMAGING FINDINGS; HUMAN CEREBRAL-CORTEX; GRAPH-THEORETICAL ANALYSIS; ANTERIOR CINGULATE CORTEX; MAGNETIC-RESONANCE IMAGES; DIFFUSE AXONAL INJURY; POSTCONCUSSION SYMPTOMS; CORTICAL SURFACE; MATTER ABNORMALITIES	Reduced integrity of white matter (WM) pathways and subtle anomalies in gray matter (GM) morphology have been hypothesized as mechanisms in mild traumatic brain injury (mTBI). However, findings on structural brain changes in early stages after mTBI are inconsistent and findings related to early symptoms severity are rare. Fifty-one patients were assessed with multimodal neuroimaging and clinical methods exclusively within 7 days following mTBI and compared to 53 controls. Whole-brain connectivity based on diffusion tensor imaging was subjected to network-based statistics, whereas cortical surface area, thickness, and volume based on T1-weighted MRI scans were investigated using surface-based morphometric analysis. Reduced connectivity strength within a subnetwork of 59 edges located predominantly in bilateral frontal lobes was significantly associated with higher levels of self-reported symptoms. In addition, cortical surface area decreases were associated with stronger complaints in five clusters located in bilateral frontal and postcentral cortices, and in the right inferior temporal region. Alterations in WM and GM were localized in similar brain regions and moderately-to-strongly related to each other. Furthermore, the reduction of cortical surface area in the frontal regions was correlated with poorer attentive-executive performance in the mTBI group. Finally, group differences were detected in both the WM and GM, especially when focusing on a subgroup of patients with greater complaints, indicating the importance of classifying mTBI patients according to severity of symptoms. This study provides evidence that mTBI affects not only the integrity of WM networks by means of axonal damage but also the morphology of the cortex during the initial post-injury period. These anomalies might be greater in the acute period than previously believed and the involvement of frontal brain regions was consistently pronounced in both findings. The dysconnected subnetwork suggests that mTBI can be conceptualized as a dysconnection syndrome. It remains unclear whether reduced WM integrity is the trigger for changes in cortical surface area or whether tissue deformations are the direct result of mechanical forces acting on the brain. The findings suggest that rapid identification of high-risk patients with the use of clinical scales should be assessed acutely as part of the mTBI protocol.	[Dall'Acqua, Patrizia; Johannes, Soenke] Bellikon Rehabil Clin, Bellikon, Switzerland; [Johannes, Soenke; Jaencke, Lutz; Haenggi, Juergen] Univ Zurich, Dept Psychol, Div Neuropsychol, Zurich, Switzerland; [Mica, Ladislav; Simmen, Hans-Peter] Univ Zurich Hosp, Div Trauma Surg, CH-8091 Zurich, Switzerland; [Glaab, Richard] Cantonal Hosp Aarau, Dept Traumatol, Aarau, Switzerland; [Fandino, Javier] Cantonal Hosp Aarau, Dept Neurosurg, Aarau, Switzerland; [Schwendinger, Markus] Baden Cantonal Hosp, Interdisciplinary Emergency Ctr, Baden, Switzerland; [Meier, Christoph] Waid Hosp Zurich, Dept Surg, Zurich, Switzerland; [Ulbrich, Erika J.] Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, CH-8091 Zurich, Switzerland; [Mueller, Andreas] Brain & Trauma Fdn Grison, Chur, Switzerland; [Jaencke, Lutz] Univ Zurich, Int Normal Aging & Plast Imaging Ctr, Zurich, Switzerland; [Jaencke, Lutz] Univ Zurich, Ctr Integrat Human Physiol, Zurich, Switzerland; [Jaencke, Lutz] Univ Zurich, Univ Res Prior Program, Dynam Hlth Aging, Zurich, Switzerland		Dall'Acqua, P (corresponding author), Bellikon Rehabil Clin, Bellikon, Switzerland.	patrizia.dallacqua@rehabellikon.ch		Hanggi, Jurgen/0000-0001-8124-6018; Simmen, Hans-Peter/0000-0002-5201-4549	Research Fund of the Swiss Accident Insurance (SUVA)	This work has been supported by the Research Fund of the Swiss Accident Insurance (SUVA).	Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beck AT, 1993, BECK ANXIETY INVENTO; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; da Costa L, 2015, J NEUROL NEUROSUR PS, V86, P1008, DOI 10.1136/jnnp-2014-308571; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Eagle DM, 2008, PSYCHOPHARMACOLOGY, V199, P439, DOI 10.1007/s00213-008-1127-6; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Floden D, 2006, J COGNITIVE NEUROSCI, V18, P1843, DOI 10.1162/jocn.2006.18.11.1843; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gosselin N, 2012, J NEUROTRAUM, V29, P2625, DOI 10.1089/neu.2012.2312; Hanggi J, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00915; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Hansen K, 2013, ACCIDENT ANAL PREV, V59, P109, DOI 10.1016/j.aap.2013.05.019; Hautzinger M., 2006, BDI 2 BECK DEPRESSIO; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Margraf J, 2007, BAI BECK ANGST INVEN; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Menon V, 2001, HUM BRAIN MAPP, V12, P131, DOI 10.1002/1097-0193(200103)12:3<131::AID-HBM1010>3.0.CO;2-C; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Vink M, 2005, HUM BRAIN MAPP, V25, P336, DOI 10.1002/hbm.20111; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wiebking C, 2014, NEUROIMAGE, V86, P10, DOI 10.1016/j.neuroimage.2013.04.042; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Winkler AM, 2012, NEUROIMAGE, V61, P1428, DOI 10.1016/j.neuroimage.2012.03.026; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Yuan WH, 2015, HUM BRAIN MAPP, V36, P779, DOI 10.1002/hbm.22664; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zalesky A, 2009, IEEE T MED IMAGING, V28, P1023, DOI 10.1109/TMI.2008.2012113; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhan J, 2015, J NERV MENT DIS, V203, P786, DOI 10.1097/NMD.0000000000000368; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhu Y., 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/548392	94	26	26	3	20	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 29	2016	10								127	10.3389/fnhum.2016.00127			15	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	DH6UR	WOS:000372928100001	27065831	Green Accepted, Green Published, gold			2022-02-06	
J	Crupi, R; Impellizzeri, D; Bruschetta, G; Cordaro, M; Paterniti, I; Siracusa, R; Cuzzocrea, S; Esposito, E				Crupi, Rosalia; Impellizzeri, Daniela; Bruschetta, Giuseppe; Cordaro, Marika; Paterniti, Irene; Siracusa, Rosalba; Cuzzocrea, Salvatore; Esposito, Emanuela			Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury	FRONTIERS IN PHARMACOLOGY			English	Article						luteolin; neurogenesis; palmitoylethanolamide; regeneration; spinal cord injury	NEURAL STEM-CELLS; ADULT SUBVENTRICULAR ZONE; TRAUMATIC BRAIN-INJURY; DORSAL VAGAL COMPLEX; NEUROTROPHIC FACTOR; FUNCTIONAL RECOVERY; RAT BRAIN; NEUROGENESIS; MICE; RECEPTOR	Spinal cord injury (SCI) stimulates activation of astrocytes and infiltration of immune cells at the lesion site; however, the mechanism that promotes the birth of new neurons is still under debate. Neuronal regeneration is restricted after spinal cord injury, but can be stimulated by experimental intervention. Previously we demonstrated that treatment co-ultramicronized palmitoylethanolamide and luteolin, namely co-ultraPEALut, reduced inflammation. The present study was designed to explore the neuroregenerative properties of co-ultraPEALut in an estabished murine model of SCI. A vascular clip was applied to the spinal cord dura at T5-18 to provoke injury. Mice were treated with co-ultraPEALut (1 mg/kg, intraperitoneally) daily for 72 h after SCI. Co-ultraPEALut increased the numbers of both bromodeoxyuridine-positive nuclei and doublecortin-immunoreactive cells in the spinal cord of injured mice. To correlate neuronal development with synaptic plasticity a Golgi method was employed to analyze dendritic spine density. Co-ultraPEALut administration stimulated expression of the neurotrophic factors brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, nerve growth factor, and neurotrophin-3. These findings show a prominent effect of co-ultraPEALut administration in the management of survival and differentiation of new neurons and spine maturation, and may represent a therapeutic treatment for spinal cord and other traumatic diseases.	[Crupi, Rosalia; Impellizzeri, Daniela; Bruschetta, Giuseppe; Cordaro, Marika; Paterniti, Irene; Siracusa, Rosalba; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Biol & Environm Sci, Messina, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Manchester Royal Infirm, Sch Med, Manchester Biomed Res Ctr, Manchester M13 9WL, Lancs, England		Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Messina, Italy.; Cuzzocrea, S (corresponding author), Univ Manchester, Manchester Royal Infirm, Sch Med, Manchester Biomed Res Ctr, Manchester M13 9WL, Lancs, England.	salvator@unime.it	Cordaro, Marika/K-7329-2016; Crupi, Rosalia/U-4364-2019; Siracusa, Rosalba/AAC-3110-2022	Cordaro, Marika/0000-0002-3980-0043; Siracusa, Rosalba/0000-0001-7868-2505; Cuzzocrea, Salvatore/0000-0001-6131-3690; Crupi, Rosalia/0000-0002-7629-3132; Impellizzeri, Daniela/0000-0001-9492-3161	Italian Ministry of Instruction, University and Research grants (MIUR)Ministry of Education, Universities and Research (MIUR) [PON01_02512]	This study was supported by the Italian Ministry of Instruction, University and Research grants (MIUR; PON01_02512 grant)	Adhikary S, 2011, J NEUROTRAUM, V28, P2417, DOI 10.1089/neu.2011.1853; Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bauer S, 2005, NEUROSCIENCE, V130, P75, DOI 10.1016/j.neuroscience.2004.08.047; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Berghuis P, 2007, SCIENCE, V316, P1212, DOI 10.1126/science.1137406; BIFFO S, 1995, DEVELOPMENT, V121, P2461; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Butti E, 2012, BRAIN, V135, P3320, DOI 10.1093/brain/aws194; Ceruti S, 2009, BRAIN, V132, P2206, DOI 10.1093/brain/awp147; Chiu WT, 2010, ASIA-PAC J PUBLIC HE, V22, P9, DOI 10.1177/1010539509355470; Choi AY, 2010, NEUROCHEM INT, V57, P143, DOI 10.1016/j.neuint.2010.05.006; Coleman William P, 2004, Spine J, V4, P373, DOI 10.1016/j.spinee.2003.12.006; Crupi R, 2013, CNS NEUROL DISORD-DR, V12, P989, DOI 10.2174/18715273113129990084; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P127, DOI 10.1124/jpet.106.108076; Darian-Smith C, 2009, NEUROSCIENTIST, V15, P149, DOI 10.1177/1073858408331372; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Furutani R, 2012, J NEUROTRAUM, V29, P1266, DOI 10.1089/neu.2010.1630; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Genovese T, 2006, NEUROSCI LETT, V393, P141, DOI 10.1016/j.neulet.2005.09.060; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; Goldshmit Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024636; Goncalves MB, 2008, MOL CELL NEUROSCI, V38, P526, DOI 10.1016/j.mcn.2008.05.001; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Iijima K, 2009, J UROLOGY, V182, P2504, DOI 10.1016/j.juro.2009.07.012; Kazanis I, 2009, BRAIN, V132, P2909, DOI 10.1093/brain/awp237; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Kozlova EN, 2003, EUR J NEUROSCI, V17, P782, DOI 10.1046/j.1460-9568.2003.02518.x; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lin LZ, 2007, J AGR FOOD CHEM, V55, P1321, DOI 10.1021/jf0624796; LoVerme J, 2005, LIFE SCI, V77, P1685, DOI 10.1016/j.lfs.2005.05.012; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Moyse E, 2006, AUTON NEUROSCI-BASIC, V126, P50, DOI 10.1016/j.autneu.2006.03.006; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nishimura Y, 2009, NEUROSCIENTIST, V15, P436, DOI 10.1177/1073858408331375; OKABE S, 1989, P NATL ACAD SCI USA, V86, P4127, DOI 10.1073/pnas.86.11.4127; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-91; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-20; Paterniti I, 2011, EUR J NEUROSCI, V33, P1411, DOI 10.1111/j.1460-9568.2011.07646.x; Pezet S, 2004, EXPERT OPIN THER TAR, V8, P391, DOI 10.1517/14728222.8.5.391; Rioux L, 2003, AM J PSYCHIAT, V160, P149, DOI 10.1176/appi.ajp.160.1.149; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; SHEA TB, 1994, BIOTECHNIQUES, V16, P1126; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Song XY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001707; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Uchida K, 2012, SPINE, V37, P2125, DOI 10.1097/BRS.0b013e3182600ef7; Velayudhan L, 2014, CURR PHARM DESIGN, V20, P2218, DOI 10.2174/13816128113199990434; Vessal M, 2010, J NEUROSCI, V30, P8613, DOI 10.1523/JNEUROSCI.5272-09.2010; Wallace M, 2006, BRAIN RES, V1126, P176, DOI 10.1016/j.brainres.2006.07.064; Xu B, 2010, EUR J PHARMACOL, V627, P99, DOI 10.1016/j.ejphar.2009.10.038; Yuan QJ, 2013, NEUROSCI BULL, V29, P509, DOI 10.1007/s12264-013-1356-5; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176	63	26	26	0	5	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	MAR 8	2016	7								47	10.3389/fphar.2016.00047			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	DF8FF	WOS:000371592100001	27014061	Green Published, gold			2022-02-06	
J	Lucke-Wold, BP; Turner, RC; Logsdon, AF; Nguyen, L; Bailes, JE; Lee, JM; Robson, MJ; Omalu, BI; Huber, JD; Rosen, CL				Lucke-Wold, Brandon P.; Turner, Ryan C.; Logsdon, Aric F.; Nguyen, Linda; Bailes, Julian E.; Lee, John M.; Robson, Matthew J.; Omalu, Bennet I.; Huber, Jason D.; Rosen, Charles L.			Endoplasmic reticulum stress implicated in chronic traumatic encephalopathy	JOURNAL OF NEUROSURGERY			English	Article						chronic traumatic encephalopathy; blast traumatic brain injury; endoplasmic reticulum stress; hyperphosphorylated tau; docosahexaenoic acid; trauma	UNFOLDED PROTEIN RESPONSE; REPETITIVE BRAIN TRAUMA; ER STRESS; CELL-DEATH; TAU; INJURY; DISEASE; MODEL; OMEGA-3-FATTY-ACIDS; ACTIVATION	OBJECTIVE Chronic traumatic encephalopathy is a progressive neurodegenerative disease characterized by neurofibrillary tau tangles following repetitive neurotrauma. The underlying mechanism linking traumatic brain injury to chronic traumatic encephalopathy has not been elucidated. The authors investigate the role of endoplasmic reticulum stress as a link between acute neurotrauma and chronic neurodegeneration. METHODS The authors used pharmacological, biochemical, and behavioral tools to assess the role of endoplasmic reticulum stress in linking acute repetitive traumatic brain injury to the development of chronic neurodegeneration. Data from the authors' clinically relevant and validated rodent blast model were compared with those obtained from postmortem human chronic traumatic encephalopathy specimens from a National Football League player and World Wrestling Entertainment wrestler. RESULTS The results demonstrated strong correlation of endoplasmic reticulum stress activation with subsequent tau hyperphosphorylation. Various endoplasmic reticulum stress markers were increased in human chronic traumatic encephalopathy specimens, and the endoplasmic reticulum stress response was associated with an increase in the tau kinase, glycogen synthase kinase-3 beta. Docosahexaenoic acid, an endoplasmic reticulum stress inhibitor, improved cognitive performance in the rat model 3 weeks after repetitive blast exposure. The data showed that docosahexaenoic acid administration substantially reduced tau hyperphosphorylation (t = 4.111, p < 0.05), improved cognition (t = 6.532, p < 0.001), and inhibited C/EBP homology protein activation (t = 5.631, p < 0.01). Additionally the data showed, for the first time, that endoplasmic reticulum stress is involved in the pathophysiology of chronic traumatic encephalopathy. CONCLUSIONS Docosahexaenoic acid therefore warrants further investigation as a potential therapeutic agent for the prevention of chronic traumatic encephalopathy.	[Lucke-Wold, Brandon P.; Turner, Ryan C.; Rosen, Charles L.] W Virginia Univ, Dept Neurosurg, Sch Med, One Med Ctr Dr,POB 9183 Hlth Sci Ctr, Morgantown, WV 26506 USA; [Lucke-Wold, Brandon P.; Turner, Ryan C.; Logsdon, Aric F.; Nguyen, Linda; Huber, Jason D.; Rosen, Charles L.] W Virginia Univ, Ctr Neurosci, Sch Med, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Nguyen, Linda; Robson, Matthew J.; Huber, Jason D.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Bailes, Julian E.; Lee, John M.] Univ Chicago, Pritzker Sch Med, Dept Neurosurg, NorthShore Univ HealthSyst, Evanston, IL USA; [Robson, Matthew J.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA; [Omalu, Bennet I.] Univ Calif Davis, Med Ctr, Dept Med Pathol & Lab Med, Sacramento, CA USA		Rosen, CL (corresponding author), W Virginia Univ, Dept Neurosurg, Sch Med, One Med Ctr Dr,POB 9183 Hlth Sci Ctr, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu	Lucke-Wold, Brandon/AAW-1881-2021; Lucke-Wold, Brandon/AAW-3525-2021; Robson, Matthew/H-3127-2013; Nguyen, Linda/AAQ-1755-2021	Lucke-Wold, Brandon/0000-0001-6577-4080; Robson, Matthew/0000-0002-3277-3062; Turner, Ryan/0000-0001-5523-0645	West Virginia University Health Sciences Center Office of Research and Graduate Education; West Virginia University Department of Neurosurgery; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM08174, NS007491]; American Foundation of Pharmaceutical Education Predoctoral Grant; American Medical Association Foundation Seed Grant; Neurosurgery Research and Education Foundation Medical Student Summer Research Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942] Funding Source: NIH RePORTER	A Research Funding and Development Grant from the West Virginia University Health Sciences Center Office of Research and Graduate Education supported this work along with the West Virginia University Department of Neurosurgery. Drs. Turner and Robson were supported by NIH training grants (GM08174 and NS007491). Brandon Lucke-Wold was supported by an American Foundation of Pharmaceutical Education Predoctoral Grant, an American Medical Association Foundation Seed Grant, and a Neurosurgery Research and Education Foundation Medical Student Summer Research Fellowship.	Abisambra JF, 2013, J NEUROSCI, V33, P9498, DOI 10.1523/JNEUROSCI.5397-12.2013; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Cavallini A, 2013, J BIOL CHEM, V288, P23331, DOI 10.1074/jbc.M113.463984; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; Dapul HR, 2013, J NEUROTRAUM, V30, P382, DOI 10.1089/neu.2012.2536; DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fonseca ACRG, 2013, BBA-MOL BASIS DIS, V1832, P2191, DOI 10.1016/j.bbadis.2013.08.007; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hetz C, 2014, NAT REV NEUROSCI, V15, P233, DOI 10.1038/nrn3689; Hiramatsu N, 2014, MOL BIOL CELL, V25, P1411, DOI 10.1091/mbc.E13-11-0664; Hoozemans JJM, 2012, INT J BIOCHEM CELL B, V44, P1295, DOI 10.1016/j.biocel.2012.04.023; Kang EB, 2013, APOPTOSIS, V18, P1332, DOI 10.1007/s10495-013-0884-9; Kaufman RJ, 2014, BBA-MOL CELL RES, V1843, P2233, DOI 10.1016/j.bbamcr.2014.03.022; Kester MI, 2014, JAMA NEUROL, V71, P855, DOI 10.1001/jamaneurol.2014.754; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Lebbadi M, 2011, J ALZHEIMERS DIS, V27, P853, DOI 10.3233/JAD-2011-111010; Levi YF, 2014, J INTERN MED, V275, P428, DOI 10.1111/joim.12166; Liu ZC, 2012, J ALZHEIMERS DIS, V29, P727, DOI 10.3233/JAD-2012-111898; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Miyauchi T, 2014, J NEUROTRAUM, V31, P773, DOI 10.1089/neu.2013.3181; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Placido AI, 2015, MOL NEUROBIOL, V51, P571, DOI 10.1007/s12035-014-8819-1; Plattner F, 2006, J BIOL CHEM, V281, P25457, DOI 10.1074/jbc.M603469200; Pooler AM, 2013, EMBO REP, V14, P389, DOI 10.1038/embor.2013.15; Robson MJ, 2014, EXP NEUROL, V254, P180, DOI 10.1016/j.expneurol.2014.01.020; Ron D, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a013177; Rubovitch V, 2011, NEUROCHEM INT, V58, P443, DOI 10.1016/j.neuint.2011.01.009; Sadik G, 2009, J NEUROCHEM, V108, P33, DOI 10.1111/j.1471-4159.2008.05716.x; Shoulders MD, 2013, CELL REP, V3, P1279, DOI 10.1016/j.celrep.2013.03.024; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Song J, 2014, INT J MOL SCI, V15, P2119, DOI 10.3390/ijms15022119; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stutzbach LD, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-31; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Watanabe T, 2010, PM&R, V2, P671, DOI 10.1016/j.pmrj.2010.06.002; Yang CC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/108486; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yokobori S, 2013, TRANSL STROKE RES, V4, P25, DOI 10.1007/s12975-012-0226-1; Zhou SS, 2014, TOXICOL LETT, V227, P113, DOI 10.1016/j.toxlet.2014.03.011; Zhu X, 2014, J BIOL CHEM, V289, P30567, DOI 10.1074/jbc.M114.562868	60	26	26	4	33	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2016	124	3					687	702		10.3171/2015.3.JNS141802			16	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DE8VQ	WOS:000370915200013	26381255	Bronze			2022-02-06	
J	Di Stefano, C; Rinaldesi, ML; Quinquinio, C; Ridolfi, C; Vallasciani, M; Sturiale, C; Piperno, R				Di Stefano, Cristina; Rinaldesi, Maria Luisa; Quinquinio, Cristina; Ridolfi, Chiara; Vallasciani, Massimo; Sturiale, Carmelo; Piperno, Roberto			Neuropsychological changes and cranioplasty: A group analysis	BRAIN INJURY			English	Article						Cognitive changes; Clinical improvement; Cranioplasty; Decompressive craniectomy; Neuropsychological improvement	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; SINKING SKIN FLAP; DECOMPRESSIVE CRANIECTOMY; CRANIAL DEFECTS; CASE SERIES; IMPACT; HEMICRANIECTOMY; REHABILITATION; MULTICENTER	Background: Cranioplasty is the surgical answer to cranial defect due to decompressive craniectomy in order to increase patient's safety and for cosmetic reasons. Two main neurological sequelae of skull breaches have been described and cranioplasty has been suggested as a way to treat these neurological symptoms, but its effects on cognitive and motor functions are still unclear. Materials and methods: In order to better elucidate if and to what extent the cranioplasty affects the whole array of cognitive functions or just some specific domains, 29 patients were studied pre- and post-cranioplasty, with structured assessments of memory, attention, language and executive functioning performed ~ 4 months and 1 month before cranioplasty and 1 month and 6 months after surgery. Results and conclusion: Cranioplasty affects the cognitive profile with a non-specific pattern of change. Timing of the cranioplasty plays a key role to enucleate cognitive improvement, indeed greater cognitive changes were seen in patients who had cranioplasty within 6 months following the injury. Thus, cranioplasty must be considered a key factor in neuropsychological recovery and should be performed as soon as possible following the injury in order to take advantage of the window of opportunity for rehabilitation.	[Di Stefano, Cristina; Piperno, Roberto] Ctr Studi Ric Coma, Bologna, Italy; [Di Stefano, Cristina; Piperno, Roberto] Ausl, Casa Risvegli Luca De Nigris, Dipartimento Emergenza, Bologna, Italy; [Rinaldesi, Maria Luisa; Quinquinio, Cristina; Ridolfi, Chiara; Vallasciani, Massimo] Ist Riabilitaz Santo Stefano, Porto Potenza Picena, Macerata, Italy; [Sturiale, Carmelo] Ausl Bologna, IRCCS, Unita Operat Neurochirurg, Bologna, Italy		Di Stefano, C (corresponding author), Casa Risvegli Luca De Nigris Bologna, Ctr Studi Ric Coma, Via G Gaist 6, I-40100 Bologna, Italy.	c.distefano@ausl.bologna.it	Piperno, Roberto/AAC-3000-2021	Piperno, Roberto/0000-0002-2251-9191	Fondazionedel Monte di Bologna e Ravenna; Centro Studi per la Ricerca sul Coma - Bologna	This work has been supported by a grant from the Fondazionedel Monte di Bologna e Ravenna and Centro Studi per la Ricerca sul Coma - Bologna. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Archavlis E, 2012, NERVENARZT, V83, P751, DOI 10.1007/s00115-011-3424-2; Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972; Chibbaro S, 2013, REV NEUROL-FRANCE, V169, P240, DOI 10.1016/j.neurol.2012.06.016; Cho Hyun, 2006, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V40, P51; CHRISTENSEN L, 1986, BEHAV THER, V17, P305, DOI 10.1016/S0005-7894(86)80060-0; Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Erdogan E, 2003, NEUROL INDIA, V51, P479; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Huang YH, 2013, INT J SURG, V11, P886, DOI 10.1016/j.ijsu.2013.07.013; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Janzen C, 2012, BRAIN INJURY, V26, P101, DOI 10.3109/02699052.2011.635357; Kumar GSS, 2004, NEUROL INDIA, V52, P504; Ng D, 1997, J CLIN NEUROSCI, V4, P346, DOI 10.1016/S0967-5868(97)90103-X; Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008; Piedra Mark P, 2014, Surg Neurol Int, V5, P25, DOI 10.4103/2152-7806.127762; Piedra MP, 2013, J NEUROSURG, V118, P109, DOI 10.3171/2012.10.JNS121037; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sancisi E, 2009, BRAIN INJURY, V23, P163, DOI 10.1080/02699050802660446; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Seo Won-Duck, 2006, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V40, P434; Servadei F, 2015, WORLD NEUROSURG, V83, P133, DOI 10.1016/j.wneu.2014.08.031; Sivaramakrishnan A, 2004, NEUROSURGERY, V55, P1344, DOI 10.1227/01.NEU.0000143612.60114.2D; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43	38	26	26	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN 28	2016	30	2					164	171		10.3109/02699052.2015.1090013			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DF3MM	WOS:000371248400006	26647093				2022-02-06	
J	Elkahloun, AG; Hafko, R; Saavedra, JM				Elkahloun, Abdel G.; Hafko, Roman; Saavedra, Juan M.			An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer's disease	ALZHEIMERS RESEARCH & THERAPY			English	Article						Alzheimer's disease; Neurodegenerative disorders; Glutamate excitotoxicity; Neuroprotection; Angiotensin II receptor blockers; IPA analysis; GEO database; GSEA	AT(1) RECEPTOR BLOCKADE; APOLIPOPROTEIN-E PROTECTS; INNATE IMMUNE-RESPONSE; TRAUMATIC BRAIN-INJURY; METHYL-D-ASPARTATE; FACTOR-KAPPA-B; AMYLOID-BETA; INFLAMMATORY RESPONSE; OXIDATIVE STRESS; AT(1)-RECEPTOR BLOCKER	Background: Alzheimer's disease is the most frequent age-related dementia, and is currently without treatment. To identify possible targets for early therapeutic intervention we focused on glutamate excitotoxicity, a major early pathogenic factor, and the effects of candesartan, an angiotensin receptor blocker of neuroprotective efficacy in cell cultures and rodent models of Alzheimer's disease. The overall goal of the study was to determine whether gene analysis of drug effects in a primary neuronal culture correlate with alterations in gene expression in Alzheimer's disease, thus providing further preclinical evidence of beneficial therapeutic effects. Methods: Primary neuronal cultures were treated with candesartan at neuroprotective concentrations followed by excitotoxic glutamate amounts. We performed genome-wide expression profile analysis and data evaluation by ingenuity pathway analysis and gene set enrichment analysis, compared with alterations in gene expression from two independent published datasets identified by microarray analysis of postmortem hippocampus from Alzheimer's disease patients. Preferential expression in cerebrovascular endothelial cells or neurons was analyzed by comparison to published gene expression in these cells isolated from human cortex by laser capture microdissection. Results: Candesartan prevented glutamate upregulation or downregulation of several hundred genes in our cultures. Ingenuity pathway analysis and gene set enrichment analysis revealed that inflammation, cardiovascular disease and diabetes signal transduction pathways and amyloid beta metabolism were major components of the neuronal response to glutamate excitotoxicity. Further analysis showed associations of glutamate-induced changes in the expression of several hundred genes, normalized by candesartan, with similar alterations observed in hippocampus from Alzheimer's disease patients. Gene analysis of neurons and cerebrovascular endothelial cells obtained by laser capture microdissection revealed that genes up- and downregulated by glutamate were preferentially expressed in endothelial cells and neurons, respectively. Conclusions: Our data may be interpreted as evidence of direct candesartan neuroprotection beyond its effects on blood pressure, revealing common and novel disease mechanisms that may underlie the in vitro gene alterations reported here and glutamate-induced cell injury in Alzheimer's disease. Our observations provide novel evidence for candesartan neuroprotection through early molecular mechanisms of injury in Alzheimer's disease, supporting testing this compound in controlled clinical studies in the early stages of the illness.	[Elkahloun, Abdel G.] NHGRI, Comparat Genom & Canc Genet Branch, NIH, Bethesda, MD 20892 USA; [Hafko, Roman; Saavedra, Juan M.] NIMH, Sect Pharmacol, NIH, Bethesda, MD 20892 USA; [Saavedra, Juan M.] Georgetown Univ, Med Ctr, Dept Pharmacol & Physiol, Med Dent SE402, 3900 Reservoir Rd, Washington, DC 20057 USA		Saavedra, JM (corresponding author), NIMH, Sect Pharmacol, NIH, Bethesda, MD 20892 USA.; Saavedra, JM (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol & Physiol, Med Dent SE402, 3900 Reservoir Rd, Washington, DC 20057 USA.	jms522@georgetown.edu	Saavedra, Juan/AAO-7149-2020	Saavedra, Juan/0000-0002-7238-9647	National Human Genome Research Institute, National Institutes of Health, Bethesda [MD 20892]; National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, USA [MH 002762-16]; Division of Intramural Research ProgramsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL HUMAN GENOME RESEARCH INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [ZICHG200365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH002762] Funding Source: NIH RePORTER	AGE was supported by the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892. RH and JMS were supported by the Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, USA (MH 002762-16).	AbdAlla S, 2013, INT J MOL SCI, V14, P16917, DOI 10.3390/ijms140816917; Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362; Anderson C, 2010, J HYPERTENS, V28, P429, DOI 10.1097/HJH.0b013e3283371355; Ando H, 2004, STROKE, V35, P1726, DOI 10.1161/01.STR.0000129788.26346.18; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Ashabi G, 2013, BASIC CLIN PHARMACOL, V112, P145, DOI 10.1111/bcpt.12000; Ashby EL, 2013, EXPERT OPIN INV DRUG, V22, P1229, DOI 10.1517/13543784.2013.812631; Ben Menachem-Zidon O, 2014, NEUROPSYCHOPHARMACOL, V39, P401, DOI 10.1038/npp.2013.208; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Bian C, 2014, J MOL NEUROSCI, V54, P271, DOI 10.1007/s12031-014-0285-8; Blair LJ, 2013, J CLIN INVEST, V123, P4158, DOI 10.1172/JCI69003; Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100; Bobba A, 2014, BBA-BIOENERGETICS, V1837, P1338, DOI 10.1016/j.bbabio.2014.03.016; CHANG MS, 1994, J BIOL CHEM, V269, P25277; Chen CC, 2014, ONCOGENE, V33, P3648, DOI 10.1038/onc.2013.345; Chrysant SG, 2010, CURR CLIN PHARMACOL, V5, P89, DOI 10.2174/157488410791110742; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; Dandona P, 2003, J CLIN ENDOCR METAB, V88, P4496, DOI 10.1210/jc.2002-021836; Danielyan L, 2010, REJUV RES, V13, P195, DOI 10.1089/rej.2009.0944; Danysz W, 2012, BRIT J PHARMACOL, V167, P324, DOI 10.1111/j.1476-5381.2012.02057.x; Davies NM, 2011, J ALZHEIMERS DIS, V26, P699, DOI 10.3233/JAD-2011-110347; DELACRETAZ E, 1995, HYPERTENSION, V25, P14, DOI 10.1161/01.HYP.25.1.14; Deuss M, 2008, CURR ALZHEIMER RES, V5, P187, DOI 10.2174/156720508783954686; Esposito Z, 2013, CNS NEUROSCI THER, V19, P549, DOI 10.1111/cns.12095; Ewers M, 2010, EXP GERONTOL, V45, P75, DOI 10.1016/j.exger.2009.09.005; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Fogari R, 2004, EUR J CLIN PHARMACOL, V59, P863, DOI 10.1007/s00228-003-0717-9; Frankfurt M, 2015, HORM BEHAV, V74, P28, DOI 10.1016/j.yhbeh.2015.05.004; Gao XM, 1995, BRAIN RES, V703, P63, DOI 10.1016/0006-8993(95)01066-1; Giger T, 2010, GENOME BIOL EVOL, V2, P284, DOI 10.1093/gbe/evq018; Goruppi S, 2010, J BIOL CHEM, V285, P1577, DOI 10.1074/jbc.R109.080887; Ha JS, 2012, NEUROSCI LETT, V526, P112, DOI 10.1016/j.neulet.2012.08.023; Hajjar Ihab, 2009, BMC Geriatr, V9, P48, DOI 10.1186/1471-2318-9-48; Harris LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003964; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; Hokama M, 2014, CEREB CORTEX, V24, P2476, DOI 10.1093/cercor/bht101; Iadecola C, 2013, NEURON, V80, P844, DOI 10.1016/j.neuron.2013.10.008; Igase M, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/320648; Israelsson C, 2010, EUR J NEUROSCI, V31, P852, DOI 10.1111/j.1460-9568.2010.07105.x; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Jin P, 2012, CLIN EXP PHARMACOL P, V39, P852, DOI 10.1111/j.1440-1681.2012.12000.x; Kelleher RJ, 2013, AM J CARDIOVASC DIS, V3, P197; Klohs J, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00032; Konstam MA, 2009, LANCET, V374, P1840, DOI 10.1016/S0140-6736(09)61913-9; Kramer D, 2010, METHODS MOL BIOL, V633, P233, DOI 10.1007/978-1-59745-019-5_17; Lane RM, 2005, J LIPID RES, V46, P949, DOI 10.1194/jlr.M400486-JLR200; Larrayoz IM, 2009, J HYPERTENS, V27, P2365, DOI 10.1097/HJH.0b013e3283314bc7; Latta CH, 2015, NEUROSCIENCE, V302, P103, DOI 10.1016/j.neuroscience.2014.09.061; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Lee CW, 2014, CURR ALZHEIMER RES, V11, P4, DOI 10.2174/1567205010666131119234308; Lee Hae Young, 2009, J Vis Exp, DOI 10.3791/990; Lee HP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0028033, 10.1371/journal.pone.0050296, 10.1371/journal.pone.0044670, 10.1186/1747-597X-7-11]; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465; Liu L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-175; Lyros E, 2014, CURR ALZHEIMER RES, V11, P18, DOI 10.2174/1567205010666131119235254; McArthur S, 2010, J IMMUNOL, V185, P6317, DOI 10.4049/jimmunol.1001095; Medeiros R, 2010, BEHAV BRAIN RES, V209, P165, DOI 10.1016/j.bbr.2010.01.040; Meng PF, 2013, NEUROSCI RES, V75, P94, DOI 10.1016/j.neures.2012.11.007; Michel MC, 2013, PHARMACOL REV, V65, P809, DOI 10.1124/pr.112.007278; Miners JS, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00238; Miyoshi M, 2008, EUR J NEUROSCI, V27, P343, DOI 10.1111/j.1460-9568.2007.06014.x; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morkuniene R, 2015, J NEUROSCI RES, V93, P475, DOI 10.1002/jnr.23510; Mota SI, 2015, BBA-MOL BASIS DIS, V1852, P1428, DOI 10.1016/j.bbadis.2015.03.015; Mullane K, 2013, BIOCHEM PHARMACOL, V85, P289, DOI 10.1016/j.bcp.2012.11.014; Muresanu DF, 2014, CURR NEUROVASC RES, V11, P168, DOI 10.2174/1567202611666140408105333; Nelson L, 2014, J ALZHEIMERS DIS, V41, P331, DOI 10.3233/JAD-140024; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; Oh J, 2014, EXP GERONTOL, V60, P87, DOI 10.1016/j.exger.2014.10.004; Palmer JC, 2012, J ALZHEIMERS DIS, V29, P853, DOI 10.3233/JAD-2012-111760; Pang T, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-102; Pang T, 2012, J HYPERTENS, V30, P87, DOI 10.1097/HJH.0b013e32834dde5f; Perez-Palma E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095413; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Petrone AB, 2014, MOL CELL ENDOCRINOL, V389, P40, DOI 10.1016/j.mce.2013.12.017; Phillips MI, 2008, J MOL MED, V86, P715, DOI 10.1007/s00109-008-0331-5; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; Quintanilla RA, 2004, EXP CELL RES, V295, P245, DOI 10.1016/j.yexcr.2004.01.002; Rincon F, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00024; Rouch L, 2015, CNS DRUGS, V29, P113, DOI 10.1007/s40263-015-0230-6; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001; Savoia C, 2007, CLIN SCI, V112, P375, DOI 10.1042/CS20060247; Shindo T, 2012, BIOL PHARM BULL, V35, P2141, DOI 10.1248/bpb.b12-00387; Sintes J, 2010, J LEUKOCYTE BIOL, V88, P687, DOI 10.1189/jlb.1109756; Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeda S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00171; Talantova M, 2013, P NATL ACAD SCI USA, V110, pE2518, DOI 10.1073/pnas.1306832110; Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003; Tian MJ, 2013, FEBS LETT, V587, P818, DOI 10.1016/j.febslet.2013.01.060; Tian MJ, 2012, FEBS LETT, V586, P3737, DOI 10.1016/j.febslet.2012.09.004; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Trenkwalder P, 2002, J HUM HYPERTENS, V16, pS71, DOI 10.1038/sj.jhh.1001443; Tsukuda K, 2009, HYPERTENSION, V54, P782, DOI 10.1161/HYPERTENSIONAHA.109.136879; de la Torre AV, 2013, PHARMACOL RES, V70, P116, DOI 10.1016/j.phrs.2013.01.007; Villapol S, 2015, AM J HYPERTENS, V28, P289, DOI 10.1093/ajh/hpu197; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Wang F, 2015, NEUROBIOL AGING, V36, P111, DOI 10.1016/j.neurobiolaging.2014.06.029; Wang J, 2014, NEUROPHARMACOLOGY, V79, P249, DOI 10.1016/j.neuropharm.2013.11.022; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Wiesmann M, 2013, J CEREBR BLOOD F MET, V33, P1696, DOI 10.1038/jcbfm.2013.159; Wu X, 2010, BRIT J PHARMACOL, V161, P33, DOI 10.1111/j.1476-5381.2010.00840.x; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Yu X, 2012, BEHAV BRAIN RES, V235, P200, DOI 10.1016/j.bbr.2012.07.045; Zhao W, 2009, J ALZHEIMERS DIS, V16, P49, DOI 10.3233/JAD-2009-0925; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082; Zhou Q, 2015, ANN NEUROL, V77, P637, DOI 10.1002/ana.24361; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003; Zhu DL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016037	115	26	28	0	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1758-9193		ALZHEIMERS RES THER	Alzheimers Res. Ther.	JAN 28	2016	8								5	10.1186/s13195-015-0167-5			18	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DB8HV	WOS:000368758700001	26822027	Green Published, gold			2022-02-06	
J	Talavage, TM; Nauman, EA; Leverenz, LJ				Talavage, Thomas M.; Nauman, Eric A.; Leverenz, Larry J.			The Role of Medical Imaging in the Recharacterization of Mild Traumatic Brain Injury Using Youth Sports as a Laboratory	FRONTIERS IN NEUROLOGY			English	Article						concussion; traumatic brain injury; functional MRI; magnetic resonance imaging; magnetic resonance spectroscopy; subconcussive	HIGH-SCHOOL FOOTBALL; DEFAULT-MODE NETWORK; HEAD IMPACTS; CEREBROVASCULAR REACTIVITY; FUNCTIONAL CONNECTIVITY; WORKING-MEMORY; PROFESSIONAL FOOTBALL; TEMPORAL-LOBE; WHITE-MATTER; CONCUSSION	The short-and long-term impact of mild traumatic brain injury (TBI) is an increasingly vital concern for both military and civilian personnel. Such injuries produce significant social and financial burdens and necessitate improved diagnostic and treatment methods. Recent integration of neuroimaging and biomechanical studies in youth collision-sport athletes has revealed that significant alterations in brain structure and function occur even in the absence of traditional clinical markers of "concussion." While task performance is maintained, athletes exposed to repetitive head accelerations exhibit structural changes to the underlying white matter, altered glial cell metabolism, aberrant vascular response, and marked changes in functional network behavior. Moreover, these changes accumulate with accrued years of exposure, suggesting a cumulative trauma mechanism that may culminate in categorization as "concussion" and long-term neurological deficits. The goal of this review is to elucidate the role of medical imaging in recharacterizing TBI, as a whole, to better identify at-risk individuals and improve the development of preventative and interventional approaches.	[Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Nauman, Eric A.] Purdue Univ, Weldon Sch Biomed Engn, Sch Mech Engn, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA		Talavage, TM (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA.	tmt@purdue.edu	Meijer, Anna/K-5118-2016	Talavage, Thomas/0000-0003-4977-6398	BrainScope, LLC; General Electric HealthcareGeneral ElectricGE Healthcare; Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health	This work was supported in part by grants from BrainScope, LLC; General Electric Healthcare; and the Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Ahmed Niyaz, 2005, Ann Clin Microbiol Antimicrob, V4, P17, DOI 10.1186/1476-0711-4-17; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bailes J, 2015, DEV NEUROPSYCHOL, V40, P59, DOI 10.1080/87565641.2015.1018090; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bartsch A, 2012, J NEUROSURG, V116, P222, DOI 10.3171/2011.9.JNS111059; Baslow MH, 2007, BRAIN LANG, V102, P153, DOI 10.1016/j.bandl.2006.06.119; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Birn RM, 2008, HUM BRAIN MAPP, V29, P740, DOI 10.1002/hbm.20577; BISHOP PJ, 1984, AM J SPORT MED, V12, P233, DOI 10.1177/036354658401200313; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHL TRAIN SPORTS HL, V6, P1; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Cooley J., 2014, IMPACT CODY LEHE; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Graner J, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00016; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Handwerker DA, 2007, HUM BRAIN MAPP, V28, P846, DOI 10.1002/hbm.20307; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hui OY, 2008, J NEUROTRAUM, V25, P19, DOI 10.1089/neu.2007.0340; Ibe O. C., 2005, FUNDAMENTALS APPL PR; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kastrup A, 2001, MAGN RESON IMAGING, V19, P13, DOI 10.1016/S0730-725X(01)00227-2; Kulkarni P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125748; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Liu Y, 2008, BRAIN, V131, P945, DOI 10.1093/brain/awn018; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P69, DOI 10.1080/87565641.2015.1014089; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCabe MA, 2012, AM J NURS, V112, P33, DOI 10.1097/01.NAJ.0000421019.77542.65; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miller JJ, 2011, BIG SCRUM TEDDY ROSS; Mummery CJ, 2000, ANN NEUROL, V47, P36; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ouyang H, 2010, J NEUROTRAUM, V27, P1109, DOI 10.1089/neu.2010.1271; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Ragland JD, 2002, NEUROPSYCHOLOGY, V16, P370, DOI 10.1037//0894-4105.16.3.370; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Shenk TE, 2015, DEV NEUROPSYCHOL, V40, P63, DOI 10.1080/87565641.2015.1014088; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Substance Abuse and Mental Health Services Administration, 2014, RES 2013 NAT SURV DR; Supekar K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000100; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Walcott BP, 2011, NEW ENGL J MED, V365, P860, DOI 10.1056/NEJMc1107891; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	91	26	27	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 19	2016	6								273	10.3389/fneur.2015.00273			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DE2AZ	WOS:000370429900001	26834695	gold, Green Published			2022-02-06	
J	Grinberg, LT; Anghinah, R; Nascimento, CF; Amaro, E; Leite, RP; Martin, MDM; Naslavsky, MS; Takada, LT; Jacob, W; Pasqualucci, CA; Nitrini, R				Grinberg, Lea T.; Anghinah, Renato; Nascimento, Camila Fernandes; Amaro, Edson, Jr.; Leite, Renata P.; Martin, Maria da Graca M.; Naslavsky, Michel S.; Takada, Leonel T.; Jacob Filho, Wilson; Pasqualucci, Carlos A.; Nitrini, Ricardo			Chronic Traumatic Encephalopathy Presenting as Alzheimer's Disease in a Retired Soccer Player	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; autopsy; chronic post-traumatic encephalopathy; dementia; humans; soccer	HIPPOCAMPAL SCLEROSIS; BRAIN-INJURY; PATHOLOGY; DEMENTIA	The relationship between soccer and chronic traumatic encephalopathy (CTE) is not well established. We report clinicopathological correlations in an 83-year-old retired center-back soccer player, with no history of concussion, manifesting typical Alzheimer-type dementia. Examination revealed mixed pathology including widespread CTE, moderate Alzheimer's disease, hippocampal sclerosis, and TDP-43 proteinopathy. This case adds to a few CTE cases described in soccer players. Furthermore, it corroborates that CTE may present clinically as typical Alzheimer-type dementia. Further studies investigating the extent to which soccer is a risk for CTE are needed.	[Grinberg, Lea T.] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94143 USA; [Grinberg, Lea T.; Nascimento, Camila Fernandes; Pasqualucci, Carlos A.] Univ Sao Paulo, Sch Med, Dept Pathol, LIM 22, Sao Paulo, Brazil; [Grinberg, Lea T.] Hosp Albert Einstein, Sao Paulo, Brazil; [Anghinah, Renato; Takada, Leonel T.; Nitrini, Ricardo] Univ Sao Paulo, Sch Med, Dept Neurol, Av Dr 15 Eneas Carvalho Aguiar, BR-05403000 Sao Paulo, SP, Brazil; [Amaro, Edson, Jr.] Univ Sao Paulo, Sch Med, Inst Radiol, Sao Paulo, Brazil; [Leite, Renata P.; Jacob Filho, Wilson] Univ Sao Paulo, Sch Med, Div Geriatr, Sao Paulo, Brazil; [Naslavsky, Michel S.] Univ Sao Paulo, Human Genome Res Ctr, Sao Paulo, Brazil		Nitrini, R (corresponding author), Univ Sao Paulo, Sch Med, Dept Neurol, Av Dr 15 Eneas Carvalho Aguiar, BR-05403000 Sao Paulo, SP, Brazil.	rnitrini@uol.com.br	Nascimento, Camila/ABC-6200-2020; Amaro, Edson/B-6653-2009; Nitrini, Ricardo/B-8703-2013; Naslavsky, Michel S/L-1772-2015; Naslavsky, Michel/U-6595-2019; Takada, Leonel/H-7124-2013	Nascimento, Camila/0000-0002-8170-7635; Amaro, Edson/0000-0002-5889-1382; Nitrini, Ricardo/0000-0002-5721-1525; Naslavsky, Michel S/0000-0002-9068-1713; Naslavsky, Michel/0000-0002-9068-1713; Takada, Leonel/0000-0002-0121-9253	University of Sao Paulo Medical School [LIM-22];  [NIH P01-AG1972403];  [P50-AG023501]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040311, P50AG023501] Funding Source: NIH RePORTER	The authors thank the patient's family for the brain donation and the Brazilian Brain Bank. We also thank Dr. Custodio M. Ribeiro for his help during patient's terminal illness, and Dr. Daniel Perl and Dr. Ann McKee for reviewing the neuropathological slides. LTG is supported by institutional grants NIH P01-AG1972403 and P50-AG023501. This study received funding from LIM-22, University of Sao Paulo Medical School.	Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; Bellini G, 2015, BELLINI 1 CAPIT CAMP; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Carthery-Goulart MT, 2009, REV SAUDE PUBL, V43, P631, DOI 10.1590/S0034-89102009005000031; Fredericks Carolyn A, 2015, Neurol Clin Pract, V5, P475; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; Junge A, 2015, BRIT J SPORT MED, V49, P599, DOI 10.1136/bjsports-2014-094469; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koerte IK, 2016, BRAIN IMAGING BEHAV, V10, P792, DOI 10.1007/s11682-015-9442-0; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Nelson PT, 2013, ACTA NEUROPATHOL, V126, P161, DOI 10.1007/s00401-013-1154-1; Schneider JA, 2007, NEUROLOGY, V69, P2197, DOI 10.1212/01.wnl.0000271090.28148.24; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364	24	26	27	3	32	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	54	1					169	174		10.3233/JAD-160312			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DW7NS	WOS:000383838400017	27472879	Green Accepted, Green Submitted			2022-02-06	
J	Khan, M; Dhammu, TS; Matsuda, F; Annamalai, B; Dhindsa, TS; Singh, I; Singh, AK				Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Annamalai, Balasubramaniam; Dhindsa, Tejbir Singh; Singh, Inderjit; Singh, Avtar K.			Targeting the nNOS/peroxynitrite/calpain system to confer neuroprotection and aid functional recovery in a mouse model of TBI	BRAIN RESEARCH			English	Article						TBI; GSNO; Calpain; Peroxynitrite; nNOS; Neurodegeneration	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; S-NITROSOGLUTATHIONE; EXPERIMENTAL STROKE; RAT MODEL; CYTOSKELETAL DEGRADATION; PEROXYNITRITE FORMATION	Traumatic brain injury (TB!) derails nitric oxide (NO)-based anti-inflammatory and anti-excitotoxicity mechanisms. NO is consumed by superoxide to form peroxynitrite, leading to decreased NO bioavailability for S-nitrosoglutathione (GSNO) synthesis and regulation of neuroprotective pathways. Neuronal peroxynitrite is implicated in neuronal loss and functional deficits following TBI. Using a contusion mouse model of TBI, we investigated mechanisms for the opposed roles of GSNO versus peroxynitrite for neuroprotection and functional recovery. TBI was induced by controlled cortical impact (CCI) in adult male mice. GSNO treatment at 2 h after CCI decreased the expression levels of phospho neuronal nitric oxide synthase (pnNOS), alpha II spectrin degraded products, and 3-NT, while also decreasing the activities of nNOS and calpains. Treatment of TBI with FeTPPS, a peroxynitrite scavenger, had effects similar to GSNO treatment. GSNO treatment of TBI also reduced neuronal degeneration and improved neurobehavioral function in a two-week TB! study. In a cell free system, SIN-1 (a peroxynitrite donor and 3-nitrotyrosinating agent) increased whereas GSNO (an S-nitrosylating agent) decreased calpain activity, and these activities were reversed by, respectively, FeTPPS and mercuric chloride, a cysteine-NO bond cleaving agent. These data indicate that peroxynitrite-mediated activation and GSNO-mediated inhibition of the deleterious nNOS/calpain system play critical roles in the pathobiology of neuronal protection and functional recovery in TBI disease. Given GSNO's safety record in other diseases, its neuroprotective efficacy and promotion of functional recovery in this TBI study make low-dose GSNO a potential candidate for preclinical evaluation. (C) 2015 Elsevier B.V. All rights reserved.	[Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Annamalai, Balasubramaniam; Dhindsa, Tejbir Singh; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan; [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA		Khan, M (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	khanm@musc.edu; dhammu@musc.edu; fumiyo@health.nop.kagoshima-u.ac.jp; annamal@musc.edu; dhindsat@musc.edu; singhi@musc.edu; singha@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511]; VA Merit AwardUS Department of Veterans Affairs [BX001062, BX002829]; NIH from the Extramural Research Facilities Program of the National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018823, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072511] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002829, I01BX001062] Funding Source: NIH RePORTER	This work was supported by grants from NIH (NS-72511) and VA Merit Award (BX001062 and BX002829). This work was also supported by the NIH, Grants C06 RR018823 and No. C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan and Ms. Terry Hope for their technical help and secretarial assistance. We are grateful to Ms. Danielle Lowe (MD/PhD student at the MUSC) for statistical analysis. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing of the manuscript.	Annamalai B, 2015, BIOCHEM BIOPH RES CO, V458, P214, DOI 10.1016/j.bbrc.2015.01.093; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Chiueh CC, 1999, FREE RADICAL RES, V31, P641, DOI 10.1080/10715769900301211; Chou PCT, 2011, J MAGN RESON IMAGING, V33, P1301, DOI 10.1002/jmri.22574; Coert BA, 2003, AM J PHYSIOL-HEART C, V284, pH151, DOI 10.1152/ajpheart.00580.2002; Cook JA, 1996, ANAL BIOCHEM, V238, P150, DOI 10.1006/abio.1996.0268; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dhawan J, 2011, FUTUR NEUROL, V6, P823, DOI 10.2217/FNL.11.55; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Hess DT, 2012, J BIOL CHEM, V287, P4411, DOI 10.1074/jbc.R111.285742; Huang TN, 2014, NAT NEUROSCI, V17, P240, DOI 10.1038/nn.3626; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ju TC, 2005, FREE RADICAL BIO MED, V38, P938, DOI 10.1016/j.freeradbiomed.2004.12.019; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0179-x; Khan M, 2015, DRUG DES DEV THER, V9, P2233, DOI 10.2147/DDDT.S77115; Khan M, 2012, J NEUROCHEM, V123, P86, DOI 10.1111/j.1471-4159.2012.07947.x; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim J., 2013, ANTIOXID REDOX SIGNA; Koh TJ, 2000, AM J PHYSIOL-CELL PH, V279, pC806, DOI 10.1152/ajpcell.2000.279.3.C806; Kruk-Slomka M, 2014, PHARMACOL REP, V66, P638, DOI 10.1016/j.pharep.2014.02.002; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Prasad KN, 2015, BRAIN RES, V1599, P103, DOI 10.1016/j.brainres.2014.12.038; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; Qu ZW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052788; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Rameau GA, 2007, J NEUROSCI, V27, P3445, DOI 10.1523/JNEUROSCI.4799-06.2007; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sakakima H, 2012, RESTOR NEUROL NEUROS, V30, P383, DOI 10.3233/RNN-2012-110209; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Samengo G, 2012, AGING CELL, V11, P1036, DOI 10.1111/acel.12003; Schonhoff CM, 2006, P NATL ACAD SCI USA, V103, P2404, DOI 10.1073/pnas.0507243103; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Shunmugavel A, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-17; SIGNORE P, 1991, PHYSIOL BEHAV, V49, P701, DOI 10.1016/0031-9384(91)90305-8; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; Venna VR, 2014, EUR J NEUROSCI, V39, P2129, DOI 10.1111/ejn.12556; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yoon JS, 2011, NEUROBIOL DIS, V41, P624, DOI 10.1016/j.nbd.2010.11.011; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093334	63	26	26	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 1	2016	1630						159	170		10.1016/j.brainres.2015.11.015			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CZ4YU	WOS:000367109900016	26596859	Green Accepted			2022-02-06	
J	Ma, J; Shui, SF; Han, XW; Guo, D; Li, TF; Yan, L				Ma, Ji; Shui, Shaofeng; Han, Xinwei; Guo, Dong; Li, Tengfei; Yan, Lei			microRNA-22 attenuates neuronal cell apoptosis in a cell model of traumatic brain injury	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Traumatic brain injury; microRNA-22; neuronal cell apoptosis; caspase 3; apoptosis factor	IN-VITRO; BAX/BCL-2 RATIO; UP-REGULATION; DEATH; BCL-2; EXPRESSION; MODERATE; PATHWAY	Traumatic brain injury (TBI) is a major cause of injury-related deaths, and the mechanism of TBI has become a research focus, but little is known about the mechanism of microRNAs in TBI. The aim of this study is the role of microRNA-22 (miR-22) in TBI-induced neuronal cell apoptosis. Rat cortical neurons were cultured and the TBI model was induced by scratch injury in vitro, before which miR-22 level was altered by transfection of agomir or antagomir. Lactate dehydrogenase (LDH) release and TUNEL assays were performed to examine neuronal cell injury and apoptosis. The activity of caspase 3 (CASP3) and level changes of several apoptosis factors including B-cell lymphoma 2 (BCL2), BCL2-associated X protein (BAX), phosphatase and tensin homolog (PTEN) and v-AKT murine thymoma viral oncogene homolog 1 (AKT1) were detected. Results showed that TBI model cells possessed a downregulated miR-22 level (P < 0.001) and more LDH release and apoptotic cells indicating the aggravated neuronal cell injury and apoptosis induced by TBI. miR-22 agomir attenuated neuronal cell injury and apoptosis of the TBI model. It also caused the corresponding changes in CASP3 activity and other apoptosis factors, with cleaved CASP3, BAX and PTEN inhibited and BCL2 and phosphorylated AKT1 promoted, while miR-22 antagomir had the opposite effects. So miR-22 has neuroprotective roles of attenuating neuronal cell injury and apoptosis induced by TBI, which may be associated with its regulation on apoptosis factors. This study reveals miR-22 as a potential approach to TBI treatment and detailed mechanism remains to be uncovered.	[Ma, Ji; Shui, Shaofeng; Han, Xinwei; Guo, Dong; Li, Tengfei; Yan, Lei] Zhengzhou Univ, Affiliated Hosp 1, Dept Intervent Radiol, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China		Han, XW (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Intervent Radiol, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China.	hanxinwei516@126.com					Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fabian MR, 2009, MOL CELL, V35, P868, DOI 10.1016/j.molcel.2009.08.004; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Gong QH, 2007, ACTA PHARMACOL SIN, V28, P1724, DOI 10.1111/j.1745-7254.2007.00666.x; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Jiang H, 2014, MOL MED REP, V9, P2265, DOI 10.3892/mmr.2014.2108; Jovicic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054222; Liu LH, 2010, TOXICOL IN VITRO, V24, P1168, DOI 10.1016/j.tiv.2010.02.016; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Omer AD, 2009, MOL CELL, V35, P739, DOI 10.1016/j.molcel.2009.09.003; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Richman JE, 2007, J BEHAV OPTOMETRY, V18, P149; Roy MJ, 2014, BRIT J PHARMACOL, V171, P1973, DOI 10.1111/bph.12431; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Stechschulte LA, 2014, J BIOL CHEM, V289, P17885, DOI 10.1074/jbc.M113.544072; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Wu B, 2012, ARCH PHARM RES, V35, P543, DOI 10.1007/s12272-012-0318-1; Yang J, 2014, MOL BIOL REP, V41, P555, DOI 10.1007/s11033-013-2891-x; Yu HY, 2015, J CELL BIOCHEM, V116, P233, DOI 10.1002/jcb.24960; Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	30	26	28	0	3	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2016	8	4					1895	1902					8	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	DN5GP	WOS:000377094900009	27186313				2022-02-06	
J	Robinson, C; Apgar, C; Shapiro, LA				Robinson, Clark; Apgar, Christopher; Shapiro, Lee A.			Astrocyte Hypertrophy Contributes to Aberrant Neurogenesis after Traumatic Brain Injury	NEURAL PLASTICITY			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; DENTATE GRANULE CELLS; HILAR BASAL DENDRITES; POSTTRAUMATIC EPILEPSY; SEIZURE SUSCEPTIBILITY; MICROGLIAL ACTIVATION; CIRCUIT MECHANISMS; NEURONS; BORN; INFLAMMATION	Traumatic brain injury (TBI) is a widespread epidemic with severe cognitive, affective, and behavioral consequences. TBIs typically result in a relatively rapid inflammatory and neuroinflammatory response. A major component of the neuroinflammatory response is astrocytes, a type of glial cell in the brain. Astrocytes are important in maintaining the integrity of neuronal functioning, and it is possible that astrocyte hypertrophy after TBIs might contribute to pathogenesis. The hippocampus is a unique brain region, because neurogenesis persists in adults. Accumulating evidence supports the functional importance of these newborn neurons and their associated astrocytes. Alterations to either of these cell types can influence neuronal functioning. To determine if hypertrophied astrocytes might negatively influence immature neurons in the dentate gyrus, astrocyte and newborn neurons were analyzed at 30 days following a TBI in mice. The results demonstrate a loss of radial glial-like processes extending through the granule cell layer after TBI, as well as ectopic growth and migration of immature dentate neurons. The results further show newborn neurons in close association with hypertrophied astrocytes, suggesting a role for the astrocytes in aberrant neurogenesis. Future studies are needed to determine the functional significance of these alterations to the astrocyte/immature neurons after TBI.	[Robinson, Clark; Apgar, Christopher; Shapiro, Lee A.] Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX 76504 USA; [Robinson, Clark; Apgar, Christopher; Shapiro, Lee A.] Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA; [Shapiro, Lee A.] Scott & White Mem Hosp & Clin, Neurosci Res Inst, Dept Neurosurg, Temple, TX 76508 USA		Shapiro, LA (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Surg, Temple, TX 76504 USA.; Shapiro, LA (corresponding author), Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA.; Shapiro, LA (corresponding author), Scott & White Mem Hosp & Clin, Neurosci Res Inst, Dept Neurosurg, Temple, TX 76508 USA.	lshapiro@medicine.tamhsc.edu			Central Texas Veterans Health Care System, Temple, TX, USA	The authors are grateful for the technical contributions of Sanjib Mukherjee, Jessica Kain, and Jaclyn Jenkins. This material is the result of work supported by the use of facilities at the Central Texas Veterans Health Care System, Temple, TX, USA.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Ashton RS, 2012, NAT NEUROSCI, V15, P1399, DOI 10.1038/nn.3212; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Boccazzi M, 2014, GLIA, V62, P428, DOI 10.1002/glia.22614; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Briellmann RS, 2002, NEUROLOGY, V58, P265, DOI 10.1212/WNL.58.2.265; Case M, 2011, EPILEPSIA, V52, P12, DOI 10.1111/j.1528-1167.2011.03225.x; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Diamond ML, 2015, EPILEPSIA, V56, P991, DOI 10.1111/epi.13100; Ehninger D, 2008, CELL TISSUE RES, V331, P243, DOI 10.1007/s00441-007-0478-3; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Foresti ML, 2011, BRAIN RES REV, V66, P115, DOI 10.1016/j.brainresrev.2010.09.002; Foresti ML, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-40; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kuzumaki N, 2010, SYNAPSE, V64, P721, DOI 10.1002/syn.20800; Lagace DC, 2010, P NATL ACAD SCI USA, V107, P4436, DOI 10.1073/pnas.0910072107; Lei ZG, 2012, J NEUROTRAUM, V29, P235, DOI 10.1089/neu.2010.1537; Li Y, 2015, NEUROBIOL DIS, V74, P240, DOI 10.1016/j.nbd.2014.11.021; Liu XS, 2007, J NEUROSCI RES, V85, P2120, DOI 10.1002/jnr.21359; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Mukherjee S., 2014, J NEUROLOGICAL DISOR, V2, P1; Mukherjee S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00028; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Parent JM, 1997, J NEUROSCI, V17, P3727; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Peragine DE, 2014, NEUROSCIENCE, V268, P10, DOI 10.1016/j.neuroscience.2014.02.044; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pierce JP, 2005, EXP NEUROL, V196, P316, DOI 10.1016/j.expneurol.2005.08.007; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ribak CE, 2007, BRAIN RES REV, V55, P390, DOI 10.1016/j.brainresrev.2006.12.005; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Sanchez RM, 2012, EPILEPSIA, V53, P109, DOI 10.1111/j.1528-1167.2012.03481.x; Scharfman H., 2006, DEV NEUROSCIENCE, V29, P14; Scharfman HE, 2003, J NEUROPHYSIOL, V90, P2536, DOI 10.1152/jn.00251.2003; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Shapiro LA, 2006, EPILEPSY RES, V69, P53, DOI 10.1016/j.eplepsyres.2005.12.003; Shapiro LA, 2005, NEUROSCIENCE, V136, P823, DOI 10.1016/j.neuroscience.2005.03.059; Shapiro LA, 2005, BRAIN RES, V1040, P81, DOI 10.1016/j.brainres.2005.01.098; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; Shapiro LA, 2008, EPILEPSIA, V49, P33, DOI 10.1111/j.1528-1167.2008.01491.x; Shapiro LA, 2007, EUR J NEUROSCI, V26, P583, DOI 10.1111/j.1460-9568.2007.05662.x; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Tobin RP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0143-5; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Villasana LE, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0056-15.2015; Vivar C, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00015; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; Yan YP, 2007, J CEREBR BLOOD F MET, V27, P1213, DOI 10.1038/sj.jcbfm.9600432; Yang F, 2010, J NEUROSCI RES, V88, P519, DOI 10.1002/jnr.22224; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020	72	26	27	0	3	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-5904	1687-5443		NEURAL PLAST	Neural. Plast.		2016	2016								1347987	10.1155/2016/1347987			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DM0FN	WOS:000376018600001	27274873	Green Submitted, gold, Green Published			2022-02-06	
J	Shen, WB; Plachez, C; Tsymbalyuk, O; Tsymbalyuk, N; Xu, S; Smith, AM; Michel, SLJ; Yarnell, D; Mullins, R; Gullapalli, RP; Puche, A; Simard, JM; Fishman, PS; Yarowsky, P				Shen, Wei-Bin; Plachez, Celine; Tsymbalyuk, Orest; Tsymbalyuk, Natalya; Xu, Su; Smith, Aaron M.; Michel, Sarah L. J.; Yarnell, Deborah; Mullins, Roger; Gullapalli, Rao P.; Puche, Adam; Simard, J. Marc; Fishman, Paul S.; Yarowsky, Paul			Cell-Based Therapy in TBI: Magnetic Retention of Neural Stem Cells In Vivo	CELL TRANSPLANTATION			English	Article						Traumatic brain injury rat model; Stem cell transplantation; Magnetic stem cell retention; Human neuroprogenitor cells (hNPCs); Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles	TRAUMATIC BRAIN-INJURY; IRON-OXIDE NANOPARTICLES; FUNCTIONAL BENEFIT; IMAGING TRACKING; PROGENITOR CELLS; VASCULAR INJURY; TRANSPLANTATION; MODEL; DELIVERY; REPAIR	Stem cell therapy is under active investigation for traumatic brain injury (TBI). Noninvasive stem cell delivery is the preferred method, but retention of stem cells at the site of injury in TBI has proven challenging and impacts effectiveness. To investigate the effects of applying a magnetic field on cell homing and retention, we delivered human neuroprogenitor cells (hNPCs) labeled with a superparamagnetic nanoparticle into post-TBI animals in the presence of a static magnetic field. We have previously devised a method of loading hNPCs with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles Molday ION Rhodamine B (MIRB (TM)). Labeling of hNPCs (MIRB-hNPCs) does not affect hNPC viability, proliferation, or differentiation. The 0.6 tesla (T) permanent magnet was placed similar to 4 mm above the injured parietal cortex prior to intracarotid injection of 4x 10(4) MIRB-hNPCs. Fluorescence imaging, Perls' Prussian blue histochemistry, immunocytochemistry with SC121, a human-specific antibody, and T2-weighted magnetic resonance imaging ex vivo revealed there was increased homing and retention of MIRB-hNPCs in the injured cortex as compared to the control group in which MIRB-hNPCs were injected in the absence of a static magnetic field. Fluoro-Jade C staining and immunolabeling with specific markers confirmed the viability status of MIRB-hNPCs posttransplantation. These results show that increased homing and retention of MIRB-hNPCs post-TBI by applying a static magnetic field is a promising technique to deliver cells into the CNS for treatment of neurological injuries and neurodegenerative diseases.	[Shen, Wei-Bin; Plachez, Celine; Yarowsky, Paul] Univ Maryland, Sch Med, Dept Pharmacol, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Tsymbalyuk, Orest; Tsymbalyuk, Natalya; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Xu, Su; Mullins, Roger; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol Nucl Med, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Smith, Aaron M.; Michel, Sarah L. J.] Univ Maryland, Sch Med, Dept Pharmaceut Sci, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Yarnell, Deborah; Yarowsky, Paul] VA Maryland Healthcare Syst, Res Serv, Baltimore, MD USA; [Puche, Adam] Univ Maryland, Sch Med, Dept Anat & Neurobiol, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Fishman, Paul S.] Univ Maryland, Sch Med, Dept Neurol, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA; [Simard, J. Marc; Fishman, Paul S.] VA Maryland Healthcare Syst, Baltimore, MD USA; [Plachez, Celine] Hussman Inst Autism, Baltimore, MD USA		Yarowsky, P (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol, 655 W Baltimore St,Rm 4-002,Bressler Res Bldg, Baltimore, MD 21201 USA.	pyarowsky@som.umaryland.edu	Smith, Aaron/AAS-5716-2021	Mullins, Roger/0000-0002-0561-4402; Plachez, Celine/0000-0002-5550-4316; Smith, Aaron/0000-0001-8864-1934	Maryland Stem Cell Research Fund; US Department of Veterans AffairsUS Department of Veterans Affairs; US National Science FoundationNational Science Foundation (NSF) [1306208]	We acknowledge Dr Ernest Groman, BioPAL, for helpful discussions, and Dr. Stephan Vigues for graphics. This work was supported by grants from the Maryland Stem Cell Research Fund (P.Y.), the US Department of Veterans Affairs (P.S.F, P.Y.), and the US National Science Foundation (1306208, S.L.J.M.). The authors declare no conflicts of interest.	Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Arbab AS, 2004, HUM GENE THER, V15, P351, DOI 10.1089/104303404322959506; Arien-Zakay H, 2014, J NEUROTRAUM, V31, P1405, DOI 10.1089/neu.2013.3270; Auriat AM, 2011, TRANSL STROKE RES, V2, P250, DOI 10.1007/s12975-011-0093-1; Berman SMC, 2011, METHODS MOL BIOL, V711, P435, DOI 10.1007/978-1-61737-992-5_22; Brown GC, 2012, TRENDS BIOCHEM SCI, V37, P325, DOI 10.1016/j.tibs.2012.05.002; Carenza E, 2014, NANOMED-NANOTECHNOL, V10, P225, DOI 10.1016/j.nano.2013.06.005; Chen JL, 2013, ACS APPL MATER INTER, V5, P5976, DOI 10.1021/am400249n; Cheng K, 2012, CELL TRANSPLANT, V21, P1121, DOI 10.3727/096368911X627381; Chua JY, 2011, J CEREBR BLOOD F MET, V31, P1263, DOI 10.1038/jcbfm.2010.213; Cohen ME, 2010, J NEUROSCI RES, V88, P936, DOI 10.1002/jnr.22277; Crabbe A, 2010, CELL TRANSPLANT, V19, P919, DOI 10.3727/096368910X494623; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Gutova M, 2013, STEM CELL TRANSL MED, V2, P766, DOI 10.5966/sctm.2013-0049; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Janowski M, 2013, J CEREBR BLOOD F MET, V33, P921, DOI 10.1038/jcbfm.2013.32; Kamei G, 2013, AM J SPORT MED, V41, P1255, DOI 10.1177/0363546513483270; Khurana A, 2013, RADIOLOGY, V269, P186, DOI 10.1148/radiol.13130858; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kyrtatos PG, 2009, JACC-CARDIOVASC INTE, V2, P794, DOI 10.1016/j.jcin.2009.05.014; Landazuri N, 2013, SMALL, V9, P4017, DOI 10.1002/smll.201300570; Li QY, 2013, BIOMATERIALS, V34, P4982, DOI 10.1016/j.biomaterials.2013.03.030; Luciani A, 2009, EUR RADIOL, V19, P1087, DOI 10.1007/s00330-008-1262-9; Lundberg J, 2012, CELL TRANSPLANT, V21, P333, DOI 10.3727/096368911X576036; Lundberg J, 2009, NEURORADIOLOGY, V51, P661, DOI 10.1007/s00234-009-0551-6; Miyaki LAM, 2012, EINSTEIN-SAO PAULO, V10, P189; Matsumoto H, 2008, J CEREBR BLOOD F MET, V28, P149, DOI 10.1038/sj.jcbfm.9600519; Neher JJ, 2014, GLIA, V62, P1463, DOI 10.1002/glia.22693; Nguyen PK, 2014, CELL STEM CELL, V14, P431, DOI 10.1016/j.stem.2014.03.009; Nudi ET, 2015, J NEUROTRAUM, V32, P1117, DOI 10.1089/neu.2014.3618; Oshima S, 2014, J ORTHOP SCI, V19, P478, DOI 10.1007/s00776-014-0548-9; Panizzo RA, 2009, NEUROIMAGE, V44, P1239, DOI 10.1016/j.neuroimage.2008.10.062; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993; Ren ZH, 2011, SCI CHINA LIFE SCI, V54, P981, DOI 10.1007/s11427-011-4239-x; Riegler J, 2013, BIOMATERIALS, V34, P1987, DOI 10.1016/j.biomaterials.2012.11.040; Rosenblum S, 2012, STROKE, V43, P1624, DOI 10.1161/STROKEAHA.111.637884; Sarwar A, 2012, J MAGN MAGN MATER, V324, P742, DOI 10.1016/j.jmmm.2011.09.008; Schafer R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-22; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shen WB, 2013, INT J NANOMED, V8, P4593, DOI 10.2147/IJN.S53012; Shen WB, 2010, ANN NEUROL, V68, P70, DOI 10.1002/ana.22018; Shen YL, 2015, CELL TRANSPLANT, V24, P1981, DOI 10.3727/096368914X685302; Shinozuka K, 2013, BRAIN SCI, V3, P239, DOI 10.3390/brainsci3010239; Silvestrini MT, 2013, STEREOT FUNCT NEUROS, V91, P92, DOI 10.1159/000343213; Song M, 2010, HUM GENE THER, V21, P603, DOI 10.1089/hum.2009.144; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074857; Tian CL, 2013, EXP CLIN TRANSPLANT, V11, P176, DOI 10.6002/ect.2012.0053; Vanecek V, 2012, INT J NANOMED, V7, P3719, DOI 10.2147/IJN.S32824; Wang LN, 2015, CONTRAST MEDIA MOL I, V10, P43, DOI 10.1002/cmmi.1601; Wu HM, 2013, J NEUROTRAUM, V30, P352, DOI 10.1089/neu.2012.2610; Yanai A, 2012, CELL TRANSPLANT, V21, P1137, DOI 10.3727/096368911X627435; Zhu JH, 2006, NEW ENGL J MED, V355, P2376, DOI 10.1056/NEJMc055304	54	26	27	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2016	25	6					1085	1099		10.3727/096368915X689550			15	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	DO5UG	WOS:000377847700007	26395573	Bronze			2022-02-06	
J	Vas, A; Chapman, S; Aslan, S; Spence, J; Keebler, M; Rodriguez-Larrain, G; Rodgers, B; Jantz, T; Martinez, D; Rakic, J; Krawczyk, D				Vas, Asha; Chapman, Sandra; Aslan, Sina; Spence, Jeffrey; Keebler, Molly; Rodriguez-Larrain, Gisella; Rodgers, Barry; Jantz, Tiffani; Martinez, David; Rakic, Jelena; Krawczyk, Daniel			Reasoning training in veteran and civilian traumatic brain injury with persistent mild impairment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain plasticity and repair; CBF; Cognitive training; Gist reasoning; Mild-spectrum TBI in adults; Veterans	COGNITIVE REHABILITATION; WORKING-MEMORY; SUSTAINED-ATTENTION; DEFICITS; DISABILITY; DEPRESSION; NETWORK; ADULTS	Traumatic brain injury (TBI) is a chronic health condition. The prevalence of TBI, combined with limited advances in protocols to mitigate persistent TBI-related impairments in higher order cognition, present a significant challenge. In this randomised study (n=60), we compared the benefits of Strategic Memory Advanced Reasoning Training (SMART, n=31), a strategy-based programme shown to improve cognitive control, versus an active learning programme called Brain Health Workshop (BHW, n=29) in individuals with TBI with persistent mild functional deficits. Outcomes were measured on cognitive, psychological health, functional, and imaging measures. Repeated measures analyses of immediate post-training and 3-month post-training demonstrated gains on the cognitive control domain of gist reasoning (ability to abstract big ideas/goals from complex information/tasks) in the SMART group as compared to BHW. Gains following the SMART programme were also evident on improved executive function, memory, and daily function as well as reduced symptoms associated with depression and stress. The SMART group showed an increase in bilateral precuneus cerebral blood flow (CBF). Improvements in gist reasoning in the SMART group were also associated with an increase in CBF in the left inferior frontal region, the left insula and the bilateral anterior cingulate cortex. These results add to prior findings that the SMART programme provides an efficient set of strategies that have the potential to improve cognitive control performance and associated executive functionsand daily function, to enhance psychological health, and facilitate positive neural plasticity in adults with persistent mild impairment after TBI.	[Vas, Asha; Chapman, Sandra; Aslan, Sina; Spence, Jeffrey; Keebler, Molly; Rodriguez-Larrain, Gisella; Rodgers, Barry; Jantz, Tiffani; Martinez, David; Rakic, Jelena; Krawczyk, Daniel] Univ Texas Dallas, Ctr BrainHlth, 2200 West Mockingbird Lane, Dallas, TX 75235 USA; [Aslan, Sina] Adv MRI LLC, Frisco, TX USA		Chapman, S (corresponding author), Univ Texas Dallas, Ctr BrainHlth, 2200 West Mockingbird Lane, Dallas, TX 75235 USA.	schapman@utdallas.edu		Rodgers, Barry/0000-0003-1673-874X	Meadows Foundation; Dee Wyly Endowed Chair fund; US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) [W81XWH-11-2-0194, W81XWH-11-2-01945]	We would like to thank Lyda Hill, the Meadows Foundation, and Dee Wyly Endowed Chair fund for their support with various aspects of the study including advocacy and recruitments efforts.; This study received funding from the US Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP) [Award W81XWH-11-2-0194 to DCK] and [Award W81XWH-11-2-01945 to SBC]. The funding agency has not had a direct role in the design, data collection, analysis, or interpretation of the data for this study, nor have they had a direct role in the preparation of this manuscript or the decision to submit it.	Alsop DC, 1996, J CEREBR BLOOD F MET, V16, P1236, DOI 10.1097/00004647-199611000-00019; Anand R, 2011, INT J GERIATR PSYCH, V26, P961, DOI 10.1002/gps.2633; Aslan S, 2010, MAGN RESON IMAGING, V28, P928, DOI 10.1016/j.mri.2010.03.037; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barratt W, 2005, BARRATT SIMPLIFIED M; Beck A. T., 1996, MANUAL BECK DEPRESSI, VII; Binder D, 2008, BRAIN HLTH WORKSH; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buck PW, 2011, HEALTH SOC WORK, V36, P299, DOI 10.1093/hsw/36.4.299; Burgess P.W., 1997, HAYLING SENTENCE COM; Buschkuehl M, 2014, COGN AFFECT BEHAV NE, V14, P147, DOI 10.3758/s13415-013-0244-9; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chapman S. B., TEST STRATE IN PRESS; Chapman SB, 2015, CEREB CORTEX, V25, P396, DOI 10.1093/cercor/bht234; Chapman SB, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00069; Chapman Sandra B., 2012, ADOLESCENT BRAIN LEA, P123, DOI DOI 10.1037/13493-005; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Chen JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056733; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cook LG, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00087; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; D'Esposito M, 2006, PROG BRAIN RES, V157, P123, DOI 10.1016/S0079-6123(06)57008-6; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Delis DC., 2001, DELIS KAPLAN EXECUTI; DESPOSITO M, 2006, TXB NEURAL REPAIR RE; Detre JA, 2012, J MAGN RESON IMAGING, V35, P1026, DOI 10.1002/jmri.23581; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Ferguson RJ, 1996, SOURCEBOOK PSYCHOL T, P615; Gabrieli John D E, 2004, Cerebrum, V6, P39; Gamino JF, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00924; Gamino JF, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00188; Gazzaley A, 2005, J COGNITIVE NEUROSCI, V17, P507, DOI 10.1162/0898929053279522; Helgeson S. R., 2010, BRAIN INJURY PROFESS, V7, P18; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Krawczyk DC, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-29; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Lloyd FJ, 2009, JAMA-J AM MED ASSOC, V302, P1332, DOI 10.1001/jama.2009.1383; Marshall S, 2012, CAN FAM PHYSICIAN, V58, pE128; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rutherford GW, 2009, J HEAD TRAUMA REHAB, V24, P421, DOI 10.1097/HTR.0b013e3181c13439; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Soman S., 2014, NEUROLOGY, V82, P329; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Tops M, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00330; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Wechsler D., 2011, WECHSLER ABBREVIATED; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yan XD, 2013, NEUROSCI LETT, V547, P1, DOI 10.1016/j.neulet.2013.04.032; Zwaan RA, 1998, PSYCHOL BULL, V123, P162, DOI 10.1037/0033-2909.123.2.162	64	26	26	2	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2016	26	4					502	531		10.1080/09602011.2015.1044013			30	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	DL8HK	WOS:000375881600003	26018041				2022-02-06	
J	Winkler, EA; Yue, JK; McAllister, TW; Temkin, NR; Oh, SS; Burchard, EG; Hu, DL; Ferguson, AR; Lingsma, HF; Burke, JF; Sorani, MD; Rosand, J; Yuh, EL; Barber, J; Tarapore, PE; Gardner, RC; Sharma, S; Satris, GG; Eng, C; Puccio, AM; Wang, KKW; Mukherjee, P; Valadka, AB; Okonkwo, DO; Diaz-Arrastia, R; Manley, GT				Winkler, Ethan A.; Yue, John K.; McAllister, Thomas W.; Temkin, Nancy R.; Oh, Sam S.; Burchard, Esteban G.; Hu, Donglei; Ferguson, Adam R.; Lingsma, Hester F.; Burke, John F.; Sorani, Marco D.; Rosand, Jonathan; Yuh, Esther L.; Barber, Jason; Tarapore, Phiroz E.; Gardner, Raquel C.; Sharma, Sourabh; Satris, Gabriela G.; Eng, Celeste; Puccio, Ava M.; Wang, Kevin K. W.; Mukherjee, Pratik; Valadka, Alex B.; Okonkwo, David O.; Diaz-Arrastia, Ramon; Manley, Geoffrey T.		TRACK-TBI Investigators	COMT Val (158) Met polymorphism is associated with nonverbal cognition following mild traumatic brain injury	NEUROGENETICS			English	Article						Traumatic brain injury; Genetic factors; Cognitive function; Outcome measures; Human studies	COMMON DATA ELEMENTS; CATECHOL-O-METHYLTRANSFERASE; VERBAL-LEARNING TEST; WORKING-MEMORY; GENE POLYMORPHISMS; PREFRONTAL CORTEX; PERFORMANCE; GENOTYPE; RECOMMENDATIONS; RESILIENCE	Mild traumatic brain injury (mTBI) results in variable clinical outcomes, which may be influenced by genetic variation. A single-nucleotide polymorphism in catechol-o-methyltransferase (COMT), an enzyme which degrades catecholamine neurotransmitters, may influence cognitive deficits following moderate and/or severe head trauma. However, this has been disputed, and its role in mTBI has not been studied. Here, we utilize the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot) study to investigate whether the COMT Val (158) Met polymorphism influences outcome on a cognitive battery 6 months following mTBI-Wechsler Adult Intelligence Test Processing Speed Index Composite Score (WAIS-PSI), Trail Making Test (TMT) Trail B minus Trail A time, and California Verbal Learning Test, Second Edition Trial 1-5 Standard Score (CVLT-II). All patients had an emergency department Glasgow Coma Scale (GCS) of 13-15, no acute intracranial pathology on head CT, and no polytrauma as defined by an Abbreviated Injury Scale (AIS) score of a parts per thousand yen3 in any extracranial region. Results in 100 subjects aged 40.9 (SD 15.2) years (COMT Met (158) /Met (158) 29 %, Met (158) /Val (158) 47 %, Val (158) /Val (158) 24 %) show that the COMT Met (158) allele (mean 101.6 +/- SE 2.1) associates with higher nonverbal processing speed on the WAIS-PSI when compared to Val (158) /Val (158) homozygotes (93.8 +/- SE 3.0) after controlling for demographics and injury severity (mean increase 7.9 points, 95 % CI [1.4 to 14.3], p = 0.017). The COMT Val (158) Met polymorphism did not associate with mental flexibility on the TMT or with verbal learning on the CVLT-II. Hence, COMT Val (158) Met may preferentially modulate nonverbal cognition following uncomplicated mTBI. Registry: ClinicalTrials.gov Identifier NCT01565551.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Yue, John K.; Ferguson, Adam R.; Burke, John F.; Sorani, Marco D.; Yuh, Esther L.; Tarapore, Phiroz E.; Sharma, Sourabh; Satris, Gabriela G.; Mukherjee, Pratik; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Temkin, Nancy R.; Barber, Jason] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy R.; Barber, Jason; Eng, Celeste] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Oh, Sam S.; Burchard, Esteban G.; Hu, Donglei; Eng, Celeste] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94110 USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Rosand, Jonathan; Gardner, Raquel C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94110 USA; [Gardner, Raquel C.] San Francisco Vet Adm Med Ctr, Dept Neurol, San Francisco, CA USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32610 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Burke, John/0000-0002-6190-5116; Gardner, Raquel C./0000-0003-4028-440X; Wang, Kevin/0000-0002-9343-6473; Ferguson, Adam/0000-0001-7102-1608; Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC2 NS069409, RC2 NS069409-02S1, U01 NS086090-01]; DODUnited States Department of Defense [USAMRAAW81XWH-13-1-0441, W81XWH-14-2-0176]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, K23NS095755, U01NS086090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG044281] Funding Source: NIH RePORTER	This work was supported by the following grants: NIH RC2 NS069409, NIH RC2 NS069409-02S1, NIH U01 NS086090-01, DOD USAMRAAW81XWH-13-1-0441, DOD W81XWH-14-2-0176	Agren T, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.5; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen CW, 2011, ACCIDENT ANAL PREV, V43, P823, DOI 10.1016/j.aap.2010.11.001; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Christidi F, 2015, AGING NEUROPSYCHOL C, V22, P667, DOI 10.1080/13825585.2015.1027650; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Davidson J, 2015, NEUROSCIENTIST, V21, P424, DOI 10.1177/1073858414543150; Delis D.C., 2000, CALIFORNIA VERBAL LE; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Faul M, 2010, TRAUMATIC BRAIN INJU; Floresco SB, 2006, PSYCHOPHARMACOLOGY, V188, P567, DOI 10.1007/s00213-006-0404-5; Frenette AJ, 2012, J NEUROTRAUM, V29, P1, DOI 10.1089/neu.2011.1812; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Greer SE, 2010, PERCEPT MOTOR SKILL, V111, P3, DOI 10.2466/03.22.27.PMS.111.4.3-18; Hanninen T, 1997, NEUROLOGY, V48, P148, DOI 10.1212/WNL.48.1.148; Hildebrand F, 2005, INJURY, V36, P293, DOI 10.1016/j.injury.2004.08.012; Hill Shirley Y, 2013, Adv J Mol Imaging, V3, P43; Hong SB, 2015, HUM BRAIN MAPP, V36, P367, DOI 10.1002/hbm.22634; Kang JI, 2013, NEUROPSYCHOBIOLOGY, V68, P174, DOI 10.1159/000353257; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kennedy JE, 2003, CLIN NEUROPSYCHOL, V17, P303, DOI 10.1076/clin.17.3.303.18091; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McAllister, 2004, J NEUROPSYCHIATRY CL, V16, P238; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Monchi O, 2001, J NEUROSCI, V21, P7733, DOI 10.1523/JNEUROSCI.21-19-07733.2001; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slifstein M, 2008, MOL PSYCHIATR, V13, P821, DOI 10.1038/mp.2008.19; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; Stein DJ, 2006, CNS SPECTRUMS, V11, P745, DOI 10.1017/S1092852900014863; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Tunbridge EM, 2006, BIOL PSYCHIAT, V60, P141, DOI 10.1016/j.biopsych.2005.10.024; Tunbridge EM, 2004, J NEUROSCI, V24, P5331, DOI 10.1523/JNEUROSCI.1124-04.2004; van der Heijden P, 2003, ASSESSMENT, V10, P115, DOI 10.1177/1073191103010002001; Wang YJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/293687; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Weaver SM, 2012, NEUROSCIENTIST, V18, P631, DOI 10.1177/1073858411435706; Wechsler D., 2008, WECHSLER ADULT INTEL; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Willmott C, 2014, J NEUROTRAUM, V31, P1507, DOI 10.1089/neu.2013.3308; Willmott C, 2013, BRAIN INJURY, V27, P1281, DOI 10.3109/02699052.2013.809553; Witte AV, 2012, BRAIN RES BULL, V88, P418, DOI 10.1016/j.brainresbull.2011.11.012; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	68	26	27	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1364-6745	1364-6753		NEUROGENETICS	Neurogenetics	JAN	2016	17	1					31	41		10.1007/s10048-015-0467-8			11	Genetics & Heredity; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Genetics & Heredity; Neurosciences & Neurology	DA3KJ	WOS:000367695300005	26576546	Green Submitted, Green Accepted			2022-02-06	
J	dela Pena, I; Borlongan, CV				dela Pena, Ike; Borlongan, Cesar V.			Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke	TRANSLATIONAL STROKE RESEARCH			English	Article						G-CSF; hUCB cells; Stroke; Combination therapy	COLONY-STIMULATING FACTOR; UMBILICAL-CORD BLOOD; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; PROGENITOR CELLS; HEMORRHAGIC TRANSFORMATION; ENDOTHELIAL-CELLS	Among recently investigated stroke therapies, stem cell treatment holds great promise by virtue of their putative ability to replace lost cells, promote endogenous neurogenesis, and produce behavioral and functional improvement through their "bystander effects." Translating stem cell in the clinic, however, presents a number of technical difficulties. A strategy suggested to enhance therapeutic utility of stem cells is combination therapy, i.e., co-transplantation of stem cells or adjunct treatment with pharmacological agents and substrates, which is assumed to produce more profound therapeutic benefits by circumventing limitations of individual treatments and facilitating complementary brain repair processes. We previously demonstrated enhanced functional effects of co-treatment with granulocyte-colony stimulating factor (G-CSF) and human umbilical cord blood cell (hUCB) transplantation in animal models of traumatic brain injury (TBI). Here, we suggest that the aforementioned combination therapy may also produce synergistic effects in stroke. Accordingly, G-CSF treatment may reduce expression of pro-inflammatory cytokines and enhance neurogenesis rendering a receptive microenvironment for hUCB engraftment. Adjunct treatment of G-CSF with hUCB may facilitate stemness maintenance and guide neural lineage commitment of hUCB cells. Moreover, regenerative mechanisms afforded by G-CSF-mobilized endogenous stem cells, secretion of growth factors by hUCB grafts and G-CSF-recruited endothelial progenitor cells (EPCs), as well as the potential graft-host integration that may promote synaptic circuitry re-establishment could altogether produce more pronounced functional improvement in stroked rats subjected to a combination G-CSF treatment and hUCB transplantation. Nevertheless, differences in pathology and repair processes underlying TBI and stroke deserve consideration when testing the effects of combinatorial G-CSF and hUCB cell transplantation for stroke treatment. Further studies are also required to determine the safety and efficacy of this intervention in both preclinical and clinical stroke studies.	[dela Pena, Ike] Loma Linda Univ, Dept Pharmaceut & Adm Sci, Loma Linda, CA 92350 USA; [Borlongan, Cesar V.] Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA		dela Pena, I (corresponding author), Loma Linda Univ, Dept Pharmaceut & Adm Sci, Loma Linda, CA 92350 USA.	idelapena@llu.edu		dela Pena, Ike/0000-0003-2046-522X	National Institutes of Health National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01A1, 1R21NS089851-01]; James and Esther King Biomedical Research Foundation [1KG01-33966]; Loma Linda University School of Pharmacy; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956, R21NS089851] Funding Source: NIH RePORTER	This study was supported, in part, by the National Institutes of Health National Institute of Neurological Disorders and Stroke 1R01NS071956-01A1, 1R21NS089851-01, James and Esther King Biomedical Research Foundation 1KG01-33966, and Loma Linda University School of Pharmacy.	Acosta S. A., 2013, J STEM CELL RES T S4, V1, pS004; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; An CR, 2014, PROG NEUROBIOL, V115, P6, DOI 10.1016/j.pneurobio.2013.12.002; Boltze J, 2012, CELL TRANSPLANT, V21, P723, DOI 10.3727/096368911X586783; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P79, DOI 10.1016/0149-7634(95)00063-1; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689; Buga AM, 2014, FRONT AGING NEUROSCI, V6, DOI [10.3389/fnagi.2014.00044, 10.3389/fnagi.2014.00130]; Chung DJ, 2009, J NEUROSCI RES, V87, P3554, DOI 10.1002/jnr.22162; Copeland N, 2009, CLIN MED, V9, P342, DOI 10.7861/clinmedicine.9-4-342; Cui X, 2012, CELL TRANSPLANT, V21, P845, DOI 10.3727/096368911X627417; Dailey T, 2013, J CLIN MED, V2, P220, DOI 10.3390/jcm2040220; De La Pena I, 2015, CELL TRANSPLANT, V24, P447, DOI 10.3727/096368915X686913; de la Pena I, 2014, REGEN MED, V9, P409, DOI [10.2217/RME.14.32, 10.2217/rme.14.32]; Dela Pena I, 2014, J NEUROSURG SCI, V58, P145; dela Pena IC, 2015, J CEREBR BLOOD F MET, V35, P338, DOI 10.1038/jcbfm.2014.208; Diederich K, 2009, J NEUROSCI, V29, P11572, DOI 10.1523/JNEUROSCI.0453-09.2009; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; Fan CG, 2005, NEUROSCI LETT, V380, P322, DOI 10.1016/j.neulet.2005.01.070; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Graham GD, 2003, STROKE, V34, P2847, DOI 10.1161/01.STR.0000101752.23813.C3; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hafez S, 2014, TRANSL STROKE RES, V5, P442, DOI 10.1007/s12975-014-0336-z; Han JL, 2008, NEUROSCI LETT, V432, P167, DOI 10.1016/j.neulet.2007.07.056; Hayakawa K, 2013, J NEUROCHEM, V125, P273, DOI 10.1111/jnc.12120; Henning RJ, 2008, STEM CELLS DEV, V17, P1207, DOI 10.1089/scd.2008.0023; Ilic D, 2012, BRIT MED BULL, V102, P43, DOI 10.1093/bmb/lds008; Ishikawa H, 2013, STROKE, V44, P3473, DOI 10.1161/STROKEAHA.113.001943; Iskander A, 2013, STEM CELL TRANSL MED, V2, P703, DOI 10.5966/sctm.2013-0066; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Kaneko Y, 2012, CURR PHARM DESIGN, V18, P3731, DOI 10.2174/138161212802002733; Komine-Kobayashi M, 2006, J CEREBR BLOOD F MET, V26, P402, DOI 10.1038/sj.jcbfm.9600195; Koton S, 2014, JAMA-J AM MED ASSOC, V312, P259, DOI 10.1001/jama.2014.7692; Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2; Li L, 2015, EXP NEUROL, VS0014-4886, P00005; Liu XF, 2014, PROG NEUROBIOL, V115, P92, DOI 10.1016/j.pneurobio.2013.11.007; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Ma JH, 2015, NEUROL RES, V37, P50, DOI 10.1179/1743132814Y.0000000399; Matsuda R, 2009, CELL TRANSPLANT, V18, P39, DOI 10.3727/096368909788237122; Metcalf D, 2010, NAT REV CANCER, V10, P425, DOI 10.1038/nrc2843; Minnerup Jens, 2009, Exp Transl Stroke Med, V1, P2, DOI 10.1186/2040-7378-1-2; Nakagomi N, 2009, STEM CELLS, V27, P2185, DOI 10.1002/stem.161; Newman MB, 2006, EXP NEUROL, V199, P201, DOI 10.1016/j.expneurol.2006.04.001; Nishino H, 2000, Prog Brain Res, V127, P461; Pimentel-Coelho PM, 2012, PEDIATR RES, V71, P464, DOI 10.1038/pr.2011.59; PLATZER E, 1985, J EXP MED, V162, P1788, DOI 10.1084/jem.162.6.1788; Popa-Wagner A, 2010, STROKE, V41, P1027, DOI 10.1161/STROKEAHA.109.575621; Ringelstein EB, 2013, STROKE, V44, P2681, DOI 10.1161/STROKEAHA.113.001531; Sanberg PR, 2012, PROG BRAIN RES, V201, P99, DOI 10.1016/B978-0-444-59544-7.00006-8; Sanberg PR, 2012, BRIT MED BULL, V101, P163, DOI 10.1093/bmb/lds001; Sanberg PR, 2005, ANN NY ACAD SCI, V1049, P67, DOI 10.1196/annals.1334.008; Sanchez-Ramos J, 2009, NEUROSCIENCE, V163, P55, DOI 10.1016/j.neuroscience.2009.05.071; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schabitz WR, 2010, STROKE, V41, P2545, DOI 10.1161/STROKEAHA.110.579508; Schneider A, 2005, CELL CYCLE, V4, P1753, DOI 10.4161/cc.4.12.2213; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shahaduzzaman M, 2013, AGE, V35, P2071, DOI 10.1007/s11357-012-9496-5; Shinozuka K, 2013, BRAIN SCI, V3, P239, DOI 10.3390/brainsci3010239; Shyu WC, 2006, CAN MED ASSOC J, V174, P927, DOI 10.1503/cmaj.051322; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Sinden JD, 2012, INT J STROKE, V7, P426, DOI 10.1111/j.1747-4949.2012.00840.x; Sobrino T, 2010, J THROMB HAEMOST, V8, P1567, DOI 10.1111/j.1538-7836.2010.03897.x; Solaroglu I, 2006, NEUROSCIENCE, V143, P965, DOI 10.1016/j.neuroscience.2006.09.014; Solaroglu I, 2009, NEUROL RES, V31, P167, DOI 10.1179/174313209X393582; Sprigg N, 2006, STROKE, V37, P2979, DOI 10.1161/01.STR.0000248763.49831.c3; Stachura DL, 2013, BLOOD, V122, P3918, DOI 10.1182/blood-2012-12-475392; Stone LL, 2013, BRAIN SCI, V3, P599, DOI 10.3390/brainsci3020599; Sullivan R, 2015, EXPERT OPIN BIOL TH, V15, P949, DOI 10.1517/14712598.2015.1043264; The NINDS rt-PA Stroke Study Group, 1997, STROKE, V28, P2109; Toth ZE, 2008, BLOOD, V111, P5544, DOI 10.1182/blood-2007-10-119073; Tsuji T, 1999, GROWTH FACTORS, V16, P225, DOI 10.3109/08977199909002132; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wang XY, 2004, STROKE, V35, P2726, DOI 10.1161/01.STR.0000143219.16695.af; Welte K., 2012, 20 YEARS G CSF MILES, P15; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; World Health Organization ( WHO), 2004, WORLD HLTH REP 2004; Xiao BG, 2007, J CELL MOL MED, V11, P1272, DOI 10.1111/j.1582-4934.2007.00101.x; Xiao J, 2005, STEM CELLS DEV, V14, P722, DOI 10.1089/scd.2005.14.722; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Yip TR, 2007, STROKE, V38, P1952, DOI 10.1161/STROKEAHA.106.479477; Zhang W, 2010, BRAIN RES, V1359, P256, DOI 10.1016/j.brainres.2010.08.072; Zhang XM, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-61; Zhao Li R, 2013, Recent Pat CNS Drug Discov, V8, P2	88	26	27	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2015	6	6					421	429		10.1007/s12975-015-0430-x			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CV3JE	WOS:000364154700003	26482176	Green Accepted			2022-02-06	
J	Delye, H; Clijmans, T; Mommaerts, MY; Sloten, JV; Goffin, J				Delye, Hans; Clijmans, Tim; Mommaerts, Maurice Yves; Sloten, Jos Vander; Goffin, Jan			Creating a normative database of age-specific 3D geometrical data, bone density, and bone thickness of the developing skull: a pilot study	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						finite element model; normative database; skull geometry; skull properties; craniosynostosis; trauma; technique; craniofacial	HALO-PIN PLACEMENT; BEAM COMPUTED-TOMOGRAPHY; VALIDATION IN-VITRO; FETAL CRANIAL BONE; KOREAN ADULTS; 3-DIMENSIONAL CEPHALOMETRY; INTERORBITAL DISTANCE; PEDIATRIC SKULL; PARIETAL BONE; ACCURACY	OBJECT Finite element models (FEMs) of the head are used to study the biomechanics of traumatic brain injury and depend heavily on the use of accurate material properties and head geometry. Any FEM aimed at investigating traumatic head injury in children should therefore use age-specific dimensions of the head, as well as age-specific material properties of the different tissues. In this study, the authors built a database of age-corrected skull geometry, skull thickness, and bone density of the developing skull to aid in the development of an age-specific FEM of a child's head. Such a database, containing age-corrected normative skull geometry data, can also be used for preoperative surgical planning and postoperative long-term follow-up of craniosynostosis surgery results. METHODS Computed tomography data were processed for 187 patients (age range 0-20 years old). A 3D surface model was calculated from segmented skull surfaces. Skull models, reference points, and sutures were processed into a MATLAB-supported database. This process included automatic calculation of 2D measurements as well as 3D measurements: length of the coronal suture, length of the lambdoid suture, and the 3D anterior-posterior length, defined as the sum of the metopic and sagittal suture. Skull thickness and skull bone density calculations were included. RESULTS Cephalic length, cephalic width, intercoronal distance, lateral orbital distance, intertemporal distance, and 3D measurements were obtained, confirming the well-established general growth pattern of the skull. Skull thickness increases rapidly in the first year of life, slowing down during the second year of life, while skull density increases with a fast but steady pace during the first 3 years of life. Both skull thickness and density continue to increase up to adulthood. CONCLUSIONS This is the first report of normative data on 2D and 3D measurements, skull bone thickness, and skull bone density for children aged 0-20 years. This database can help build an age-specific FEM of a child's head. It can also help to tailor preoperative virtual planning in craniosynostosis surgery toward patient-specific normative target values and to perform objective long-term follow-up in craniosynostosis surgery.	[Delye, Hans; Goffin, Jan] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands; [Delye, Hans] Katholieke Univ Leuven, Div Expt Neurosurg & Neuroanat, Brussels, Belgium; [Clijmans, Tim; Sloten, Jos Vander] Katholieke Univ Leuven, Biomech Sect BMe, Brussels, Belgium; [Mommaerts, Maurice Yves] UZ Brussel, Dept Craniomaxillofacial Surg, Brussels, Belgium		Delye, H (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, Huispost 636,Postbus 9101, NL-6500 HB Nijmegen, Netherlands.	hans.delye@radboudumc.nl	Mommaerts, Maurice/N-9287-2014; Delye, H.H.K./L-4265-2015	Mommaerts, Maurice/0000-0002-3522-8879; 	Flemish FWO-Levenslijn grant of the Levenslijn-Kinderfonds - King Baudouin Foundation, Belgium	This work was funded by the Flemish FWO-Levenslijn grant of the Levenslijn-Kinderfonds governed by the King Baudouin Foundation, Belgium.	Axelsson S, 2003, EUR J ORTHODONT, V25, P185, DOI 10.1093/ejo/25.2.185; BROWN WAB, 1984, ANN HUM BIOL, V11, P221, DOI 10.1080/03014468400007091; Cavalcanti MGP, 2004, DENTOMAXILLOFAC RAD, V33, P170, DOI 10.1259/dmfr/13603271; Cavalcanti MGP, 1999, J ORAL MAXIL SURG, V57, P690, DOI 10.1016/S0278-2391(99)90434-2; Citardi MJ, 2001, SKULL BASE-INTERD AP, V11, P5, DOI 10.1055/s-2001-12781; Clumans T, 2008, J CRANIO MAXILL SURG, V36, P66, DOI 10.1016/j.jcms.2007.08.003; Coates D, 1989, J ORAL MAXILLOFAC S1, V47, P124; Connor SEJ, 2007, DENTOMAXILLOFAC RAD, V36, P270, DOI 10.1259/dmfr/90016954; COSTARAS M, 1982, J CRAN GENET DEV BIO, V2, P5; CURREY JD, 1969, J BIOMECH, V2, P1, DOI 10.1016/0021-9290(69)90036-0; Delye H, 2007, J NEUROTRAUM, V24, P1576, DOI 10.1089/neu.2007.0283; Desantis Klinich Kathleen, 2002, Stapp Car Crash J, V46, P165; Ebraheim NA, 2007, SPINE J, V7, P689, DOI 10.1016/j.spinee.2006.09.007; Farkas LG, 1987, ANTHROPOMETRIC FACIA; GARFIN SR, 1986, J PEDIATR ORTHOPED, V6, P434, DOI 10.1097/01241398-198607000-00008; Gelaude F, 2007, COMPUT AIDED SURG, V12, P286, DOI 10.1080/10929080701684762; HILDEBOLT CF, 1990, AM J PHYS ANTHROPOL, V82, P283, DOI 10.1002/ajpa.1330820307; HILDEBOLT CF, 1988, AM J PHYS ANTHROPOL, V76, P497, DOI 10.1002/ajpa.1330760409; Hwang K, 1999, J CRANIOFAC SURG, V10, P395, DOI 10.1097/00001665-199909000-00004; Hwang K, 2000, J CRANIOFAC SURG, V11, P17, DOI 10.1097/00001665-200011010-00004; Hwang K, 1997, J CRANIOFAC SURG, V8, P208, DOI 10.1097/00001665-199705000-00013; Jung YS, 2003, INT J ORAL MAX SURG, V32, P638, DOI 10.1054/ijom.2002.0415; KALENDER WA, 1995, EUR J RADIOL, V20, P83, DOI 10.1016/0720-048X(95)00631-Y; Khechoyan DY, 2014, J PLAST RECONSTR AES, V67, P9, DOI 10.1016/j.bjps.2013.09.009; KRIEWALL TJ, 1981, J BIOMECH, V14, P73, DOI 10.1016/0021-9290(81)90166-4; KRIEWALL TJ, 1982, AM J OBSTET GYNECOL, V143, P707, DOI 10.1016/0002-9378(82)90119-3; LETTS M, 1988, J BONE JOINT SURG BR, V70, P277, DOI 10.1302/0301-620X.70B2.3346303; Lo L J, 2000, Chang Gung Med J, V23, P354; Lo Lun-Jou, 2003, Chang Gung Med J, V26, P1; Loder RT, 1996, J PEDIATR ORTHOPED, V16, P340, DOI 10.1097/01241398-199605000-00009; Lynnerup N, 2001, FORENSIC SCI INT, V117, P45, DOI 10.1016/S0379-0738(00)00447-3; Lynnerup Niels, 2005, Head Face Med, V1, P13, DOI 10.1186/1746-160X-1-13; MAFEE MF, 1986, AM J NEURORADIOL, V7, P265; Marcus JR, 2009, PLAST RECONSTR SURG, V124, P2076, DOI 10.1097/PRS.0b013e3181bf7e1b; Marcus Jeffrey R, 2008, Eplasty, V8, pe20; Mardini S, 2014, J PLAST RECONSTR AES, V67, P336, DOI 10.1016/j.bjps.2013.11.004; MAVES MD, 1986, OTOLARYNG HEAD NECK, V95, P464, DOI 10.1177/019459988609500408; Moerenhout BAMML, 2009, J CRANIO MAXILL SURG, V37, P18, DOI 10.1016/j.jcms.2008.07.006; Mommaerts MY, 2001, J CRANIOFAC SURG, V12, P547, DOI 10.1097/00001665-200111000-00008; Moreira-Gonzalez A, 2006, PLAST RECONSTR SURG, V117, P1964, DOI 10.1097/01.prs.0000209933.78532.a7; Motherway JA, 2009, J BIOMECH, V42, P2129, DOI 10.1016/j.jbiomech.2009.05.030; Olszewski R, 2008, DENTOMAXILLOFAC RAD, V37, P261, DOI 10.1259/dmfr/33343444; Olszewski R, 2007, INT J ORAL MAX SURG, V36, P828, DOI 10.1016/j.ijom.2007.05.022; Olszewski R, 2006, NEURORADIOLOGY, V48, P853, DOI 10.1007/s00234-006-0140-x; Pereira Inês Minniti Rodrigues, 2008, Radiol Bras, V41, P229, DOI 10.1590/S0100-39842008000400006; Roelants M, 2009, ANN HUM BIOL, V36, P680, DOI 10.3109/03014460903049074; ROSS MD, 1976, S AFR MED J, V50, P635; Saber NR, 2012, CHILD NERV SYST, V28, P405, DOI 10.1007/s00381-011-1630-7; Slovis T, 2007, CAFFEYS PEDIAT DIAGN, V11; Swennen GRJ, 2006, AM J ORTHOD DENTOFAC, V130, P410, DOI 10.1016/j.ajodo.2005.11.035; Thilander B, 2005, EUR J ORTHODONT, V27, P370, DOI 10.1093/ejo/cji033; Togashi K, 2002, ANGLE ORTHOD, V72, P513; van Lindert EJ, 2013, CHILD NERV SYST, V29, P1007, DOI 10.1007/s00381-013-2059-y; WAITZMAN AA, 1992, CLEFT PALATE-CRAN J, V29, P118, DOI 10.1597/1545-1569(1992)029<0118:CSMBOC>2.3.CO;2; WONG WB, 1994, SPINE, V19, P1451, DOI 10.1097/00007632-199407000-00005	55	26	26	2	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2015	16	6					687	702		10.3171/2015.4.PEDS1493			16	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CX0FM	WOS:000365372300011	26339957	Bronze			2022-02-06	
J	Quatman-Yates, CC; Bonnette, S; Hugentobler, JA; Mede, B; Kiefer, AW; Kurowski, BG; Riley, MA				Quatman-Yates, Catherine C.; Bonnette, Scott; Hugentobler, Jason A.; Mede, Butovens; Kiefer, Adam W.; Kurowski, Brad G.; Riley, Michael A.			Postconcussion Postural Sway Variability Changes in Youth: The Benefit of Structural Variability Analyses	PEDIATRIC PHYSICAL THERAPY			English	Article						adolescent; analysis of variance; brain concussion/diagnosis; brain concussion/physiopathology; child; female humans; male; mild traumatic brain injury; postural balance	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; CEREBRAL CONCUSSION; NEUROCOGNITIVE FUNCTION; EARLY ADULTHOOD; MANAGEMENT; SYMPTOMS; DYNAMICS; ENTROPY	Purpose: The purpose of this study was to evaluate the utility of postural sway variability as a potential assessment to detect altered postural sway in youth with symptoms related to a concussion. Methods: Forty participants (20 who were healthy and 20 who were injured) aged 10 to 16 years were assessed using the Balance Error Scoring System (BESS) and postural sway variability analyses applied to center-of-pressure data captured using a force plate. Results: Significant differences were observed between the 2 groups for postural sway variability metrics but not for the BESS. Specifically, path length was shorter and Sample and Renyi Entropies were more regular for the participants who were injured compared with the participants who were healthy (P < .05). Conclusion: The results of this study indicate that postural sway variability may be a more valid measure than the BESS to detect postconcussion alterations in postural control in young athletes.	[Quatman-Yates, Catherine C.; Hugentobler, Jason A.] Cincinnati Childrens Hosp Med Ctr, Div Occupat & Phys Therapy, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA; [Quatman-Yates, Catherine C.; Hugentobler, Jason A.; Kiefer, Adam W.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Quatman-Yates, Catherine C.; Kiefer, Adam W.] Univ Cincinnati, Coll Med, Div Pediat, Cincinnati, OH USA; [Quatman-Yates, Catherine C.; Bonnette, Scott; Kiefer, Adam W.; Riley, Michael A.] Univ Cincinnati, Dept Psychol, Ctr Cognit Act & Percept, Cincinnati, OH 45221 USA; [Mede, Butovens] CUNY City Coll, New York, NY 10031 USA		Quatman-Yates, CC (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Occupat & Phys Therapy, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA.	Catherine.quatman@cchmc.org	Quatman-Yates, Catherine/AAK-4507-2021; Kiefer, Adam/F-1756-2018; Quatman-Yates, Catherine/U-9580-2019		Cincinnati Children's Hospital Research In-Patient Services PS2 Mentored Career Grant; University of Cincinnati Research Council; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K23HD074683-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER	The Cincinnati Children's Hospital Research In-Patient Services PS2 Mentored Career Grant, University of Cincinnati Research Council Post-Doctoral Fellow Grant, and NIH grant 1K23HD074683-01A1.	Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bonnette, 2011, SCI MOTRICITE, V74, P5, DOI [10.1051/sm/2011117, DOI 10.1051/SM/2011117]; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Carpenter MG, 2010, NEUROSCIENCE, V171, P196, DOI 10.1016/j.neuroscience.2010.08.030; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Deffeyes JE, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-34; Deffeyes JE, 2009, CLIN BIOMECH, V24, P564, DOI 10.1016/j.clinbiomech.2009.05.004; Dusing SC, 2010, PHYS THER, V90, P1838, DOI 10.2522/ptj.2010033; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Ford KR, 2010, MED SCI SPORT EXER, V42, P1923, DOI 10.1249/MSS.0b013e3181dc99b1; Ford KR, 2010, AM J SPORT MED, V38, P1829, DOI 10.1177/0363546510367425; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldberger AL, 2002, P NATL ACAD SCI USA, V99, P2466, DOI 10.1073/pnas.012579499; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Goldberger AL, 2001, AM J RESP CRIT CARE, V163, P1289, DOI 10.1164/ajrccm.163.6.ed1801a; Goldberger AL, 1997, PERSPECT BIOL MED, V40, P543; Goldfield E. C., 1995, EMERGENT FORMS ORIGI; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Gribble PA, 2004, J ELECTROMYOGR KINES, V14, P641, DOI 10.1016/j.jelekin.2004.05.001; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Haddad JM, 2008, EXP BRAIN RES, V190, P431, DOI 10.1007/s00221-008-1483-9; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harbourne RT, 2009, PHYS THER, V89, P284, DOI 10.2522/ptj.20080130.ar; Harbourne RT, 2009, NONLIN DYNAM PSYCHOL, V13, P123; Harbourne RT, 2003, DEV PSYCHOBIOL, V42, P368, DOI 10.1002/dev.10110; Hewett TE, 2004, J BONE JOINT SURG AM, V86A, P1601, DOI 10.2106/00004623-200408000-00001; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kuznetsov N., 2014, COMPLEX SYSTEMS SPOR, P85; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lee SP, 2014, GAIT POSTURE, V39, P933, DOI 10.1016/j.gaitpost.2013.12.004; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Murnaghan CD, 2011, NEUROSCIENCE, V195, P54, DOI 10.1016/j.neuroscience.2011.08.020; Murnaghan CD, 2013, GAIT POSTURE, V38, P734, DOI 10.1016/j.gaitpost.2013.03.012; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Quatman-Yates CC, 2013, INT J SPORTS PHYS TH, V8, P741; Quatman-Yates CC, 2013, PEDIATR PHYS THER, V25, P271, DOI 10.1097/PEP.0b013e31828e1e9d; Quatman-Yates CC, 2012, BRIT J SPORT MED, V46, P649, DOI 10.1136/bjsm.2010.079616; Ramdani S, 2009, MED ENG PHYS, V31, P1023, DOI 10.1016/j.medengphy.2009.06.004; Renyi A., 1961, 4 BERK S MATH STAT P; Riccio G, 1993, VARIABILITY MOTOR CO, P933; Riley MA, 2002, J MOTOR BEHAV, V34, P99, DOI 10.1080/00222890209601934; Schmit JM, 2006, EXP BRAIN RES, V168, P357, DOI 10.1007/s00221-005-0094-y; Sheehan DP, 2011, MEAS PHYS EDUC EXERC, V15, P234, DOI 10.1080/1091367X.2011.568368; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stergiou N, 2011, HUM MOVEMENT SCI, V30, P869, DOI 10.1016/j.humov.2011.06.002; Takacs J, 2012, J BIOMECH, V45, P2791, DOI 10.1016/j.jbiomech.2012.08.041; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Webber Jr CL, 2005, TUTORIALS CONT NONLI; Winter D., 2005, BIOMECHANICS MOTOR C, V4th	71	26	26	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-5669	1538-005X		PEDIATR PHYS THER	Pediatr. Phys. Ther.	WIN	2015	27	4					316	327		10.1097/PEP.0000000000000193			12	Pediatrics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Rehabilitation	DD1YP	WOS:000369719600003	26397071	Green Accepted			2022-02-06	
J	Kim, DY; O'Leary, M; Nguyen, A; Kaji, A; Bricker, S; Neville, A; Bongard, F; Putnam, B; Plurad, D				Kim, Dennis Yong; O'Leary, Michael; Nguyen, Andrew; Kaji, Amy; Bricker, Scott; Neville, Angela; Bongard, Fred; Putnam, Brant; Plurad, David			The Effect of Platelet and Desmopressin Administration on Early Radiographic Progression of Traumatic Intracranial Hemorrhage	JOURNAL OF NEUROTRAUMA			English	Article						desmopressin; intracranial hemorrhage; platelets; radiographic progression; traumatic brain injury	BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; HEAD TRAUMA; CLOPIDOGREL; TRANSFUSION; PREDICTORS; MORTALITY; ASPIRIN; RISK	Limited data exist regarding the use of hemostatic adjuncts on the progression of traumatic intracranial hemorrhage (tICH). The objective of this study was to examine the impact of platelet transfusion and desmopressin (DDAVP) administration on hemorrhage progression following tICH. We hypothesized that platelet and DDAVP administration would not result in decreased early hemorrhagic progression. We performed a three-year retrospective analysis of a Level 1 trauma center database to identify all adult patents with blunt tICH. The primary outcome was early (4 hours) radiographic hemorrhagic progression. Secondary outcomes included mortality, frequency of operative interventions, and complications. Multiple logistic regression analysis was performed to identify predictors for hemorrhage progression and mortality. A propensity score analysis also was performed to minimize differences and improve comparability between patients who received platelets and DDAVP and those who did not. Of 408 patients with tICH meeting the inclusion criteria, 126 received platelets and DDAVP (P/D [+]) and 282 did not (P/D [-]). Overall, 37% of patients demonstrated early radiographic hemorrhage progression. On univariate analysis, there was no difference in the incidence of hemorrhage progression between groups (43.7% [P/D (+)] vs. 34.2% [P/D (-)]; p = 0.07). On multivariate analyses, platelet and DDAVP administration was not associated with either a decreased risk of hemorrhage progression (odds ratio [OR] = 1.40, confidence interval [CI] = 0.80-2.40; p = 0.2) or mortality (OR = 1.50, CI = 0.60-4.30; p = 0.4). The administration of platelets and DDAVP is not associated with a decreased risk for early radiographic hemorrhage progression in patients with tICH. Further prospective study of these potentially hemostatic adjuncts in patients with tICH is potentially warranted.	[Kim, Dennis Yong; Bricker, Scott; Neville, Angela; Bongard, Fred; Putnam, Brant; Plurad, David] Harbor UCLA Med Ctr, Div Trauma Acute Care Surg Surg Crit Care, Torrance, CA 90509 USA; [O'Leary, Michael; Nguyen, Andrew] Harbor UCLA Med Ctr, Dept Surg, Torrance, CA 90509 USA; [Kaji, Amy] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA		Kim, DY (corresponding author), 1000 W Carson St,Box 42, Torrance, CA 90502 USA.	dekim@dhs.lacounty.gov					Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Anderson CS, 2010, STROKE, V41, P307, DOI 10.1161/STROKEAHA.109.561795; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Batchelor JS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000588; Beshay JE, 2010, J NEUROSURG, V112, P307, DOI 10.3171/2009.7.JNS0982; Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Downey DM, 2009, AM SURGEON, V75, P1100; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Faul M, 2010, TRAUMATIC BRAIN INJU; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2011, NEUROCRIT CARE, V15, P442, DOI 10.1007/s12028-011-9557-0; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Vilahur G, 2007, J THROMB HAEMOST, V5, P82, DOI 10.1111/j.1538-7836.2006.02245.x; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	29	26	26	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1815	1821		10.1089/neu.2014.3728			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500012	25604812				2022-02-06	
J	Iadevaia, C; Roiger, T; Zwart, MB				Iadevaia, Cheree; Roiger, Trevor; Zwart, Mary Beth			Qualitative Examination of Adolescent Health-Related Quality of Life at 1 Year Postconcussion	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; postconcussion recovery; secondary schools	TRAUMATIC BRAIN-INJURY; PARENT-CHILD AGREEMENT; FAMILY BURDEN; CONCUSSION; SPORT; RECOMMENDATIONS; EPIDEMIOLOGY; PERFORMANCE; PEDSQL(TM); INVENTORY	Context: Moderate to severe traumatic brain injuries can negatively influence health-related quality of life (HRQOL) in adolescent patients. The effect of sport-related concussion on adolescent HRQOL remains unclear. Objective: To investigate the perceptions of adolescent student-athletes and their parents regarding the adolescents' HRQOL 1 year after sport-related concussion. Design: Qualitative study. Setting: Secondary school. Patients or Other Participants: Seven adolescent student-athletes (age range, 12-16 years) who sustained a sport-related concussion at least 1 year (15.3 +/- 2.8 months) before the study participated along with their primary care-giving parents (n = 7). Data Collection and Analysis: Fourteen semistructured face-to-face interviews (7 adolescents, 7 parents) were completed. Interviews were transcribed and inductively analyzed by a team of 3 athletic trainers with 32 combined years of professional experience. Themes were negotiated through a consensual review process. Participant checks were completed to ensure trustworthiness of the results. Results: Four major themes emerged from the interviews: (1) significant effect of symptoms, (2) feelings of frustration, (3) influence on school attendance and activities, and (4) nature of interpersonal and team relationships. Participants indicated that the physical symptoms of the concussion substantially affected their emotional and academic function. The influence of the concussion on social interactions seemed to depend on the nature of interpersonal relationships. Conclusions: Sport-related concussion can negatively influence physical and emotional function, academics, and interpersonal interactions as perceived by adolescent student-athletes and their parents. Education of parents and their children, school professionals, coaches, and teammates remains critical to effectively recognize and manage sport-related concussion. Secondary school districts also play a critical role in the concussion-management process by establishing and implementing accommodation policies that alleviate student concerns about falling behind while ensuring a healthy return to normal school routines. Furthermore, adolescent support systems must be considered throughout the recovery process.	[Iadevaia, Cheree; Roiger, Trevor; Zwart, Mary Beth] S Dakota State Univ, Dept Hlth & Nutr Sci, Box 2203 SIM 116, Brookings, SD 57007 USA		Roiger, T (corresponding author), S Dakota State Univ, Dept Hlth & Nutr Sci, Box 2203 SIM 116, Brookings, SD 57007 USA.	trevor.roiger@sdstate.edu			Office of Academic Affairs at South Dakota State University, Brookings, South Dakota	We thank the Office of Academic Affairs at South Dakota State University, Brookings, South Dakota, for financial support of this project.	[Anonymous], LIV BRAIN INJ FAM CA; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cremeens J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-58; Davis A, 2012, J APPL REHABIL COUNS, V43, P3; DeSalvo KB, 2006, J GEN INTERN MED, V21, P267, DOI 10.1111/j.1525-1497.2005.00291.x; EDELBROCK C, 1986, J CHILD PSYCHOL PSYC, V27, P181, DOI 10.1111/j.1469-7610.1986.tb02329.x; Eiser C, 2001, Health Technol Assess, V5, P1; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gauvin-Lepage J, 2010, BRAIN INJURY, V24, P1087, DOI 10.3109/02699052.2010.494593; Goldstein SL, 2008, AM J KIDNEY DIS, V51, P285, DOI 10.1053/j.ajkd.2007.09.021; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Hardy CJ, 1999, PSYCHOL BASES SPORT, V2, P175; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; HODGES K, 1990, J CHILD PSYCHOL PSYC, V31, P427, DOI 10.1111/j.1469-7610.1990.tb01579.x; Kalpinski RJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/102570; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Petitpas A., 1995, Sport psychology interventions., P255; Pope C, 2002, QUAL SAF HEALTH CARE, V11, P148, DOI 10.1136/qhc.11.2.148; Powers SW, 2004, CEPHALALGIA, V24, P120, DOI 10.1111/j.1468-2982.2004.00652.x; Ravens-Sieberer U, 2002, RESTOR NEUROL NEUROS, V20, P151; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Ritchie J, 2003, QUALITATIVE RES PRAC, P251; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Robson C., 2002, REAL WORLD RES RESOU, P289; Roscigno CI, 2011, BRAIN INJURY, V25, P882, DOI 10.3109/02699052.2011.581638; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; TRELEAVEN J, 1994, CEPHALALGIA, V14, P273, DOI 10.1046/j.1468-2982.1994.1404273.x; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110	40	26	26	2	19	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV	2015	50	11					1182	1189		10.4085/1062-6050-50.11.02			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	DK2OO	WOS:000374754500009	26509684	Green Published, Bronze			2022-02-06	
J	Loov, C; Mitchell, CH; Simonsson, M; Erlandsson, A				Loov, Camilla; Mitchell, Claire H.; Simonsson, Martin; Erlandsson, Anna			Slow degradation in phagocytic astrocytes can be enhanced by lysosomal acidification	GLIA			English	Article						phagocytosis; lysosome; digestion; glia; Rab27a; Nox2; pHrodo; nanoparticle	TRAUMATIC BRAIN-INJURY; B7 COSTIMULATORY MOLECULES; T-CELL-ACTIVATION; DENDRITIC CELLS; NADPH OXIDASE; ANTIGEN PRESENTATION; ALZHEIMERS-DISEASE; PHAGOSOME MATURATION; APOPTOTIC CELLS; STEM-CELL	Inefficient lysosomal degradation is central in the development of various brain disorders, but the underlying mechanisms and the involvement of different cell types remains elusive. We have previously shown that astrocytes effectively engulf dead cells, but then store, rather than degrade the ingested material. In the present study we identify reasons for the slow digestion and ways to accelerate degradation in primary astrocytes. Our results show that actin-rings surround the phagosomes for long periods of time, which physically inhibit the phago-lysosome fusion. Furthermore, astrocytes express high levels of Rab27a, a protein known to reduce the acidity of lysosomes by Nox2 recruitment, in order to preserve antigens for presentation. We found that Nox2 colocalizes with the ingested material, indicating that it may influence antigen processing also in astrocytes, as they express MHC class II. By inducing long-time acidification of astrocytic lysosomes using acidic nanoparticles, we could increase the digestion of astrocyte-ingested, dead cells. The degradation was, however, normalized over time, indicating that inhibitory pathways are up-regulated in response to the enhanced acidification.	[Loov, Camilla; Erlandsson, Anna] Uppsala Univ, Uppsala Univ Hosp Ent 85, Dept Neurosci, Uppsala, Sweden; [Mitchell, Claire H.] Univ Penn, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; [Mitchell, Claire H.] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; [Simonsson, Martin] Lulea Univ Technol, SciLifeLab, S-95187 Lulea, Sweden; [Simonsson, Martin] Lulea Univ Technol, Dept Comp Sci Elect & Space Engn, S-95187 Lulea, Sweden; [Erlandsson, Anna] Uppsala Univ, Dept Publ Hlth & Caring Sci, Rudbeck Lab, Uppsala, Sweden		Erlandsson, A (corresponding author), Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden.	anna.erlandsson@pubcare.uu.se			Magnus Bergwall Foundation; Ahlen Foundation; Swedish Medical Society; Tore Nilsson Foundation; Alzheimer Foundation	Grant sponsors: Magnus Bergwall Foundation, Ahlen Foundation, the Swedish Medical Society, the Tore Nilsson Foundation, and the Alzheimer Foundation.	Abramov AY, 2005, J NEUROSCI, V25, P9176, DOI 10.1523/JNEUROSCI.1632-05.2005; Abramov AY, 2005, PHILOS T R SOC B, V360, P2309, DOI 10.1098/rstb.2005.1766; Allan ERO, 2014, J IMMUNOL, V192, P4989, DOI 10.4049/jimmunol.1302896; Aloisi F, 1998, J IMMUNOL, V160, P4671; Appelqvist H, 2013, J MOL CELL BIOL, V5, P214, DOI 10.1093/jmcb/mjt022; Avila-Munoz E, 2014, AGEING RES REV, V18, P29, DOI 10.1016/j.arr.2014.07.004; Aziz Monowar, 2013, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1431s100; Baltazar GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049635; Bryant P, 2004, CURR OPIN IMMUNOL, V16, P96, DOI 10.1016/j.coi.2003.11.011; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chang GHF, 2000, NEURO-ONCOLOGY, V2, P174, DOI 10.1093/neuonc/2.3.174; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; Cornet A, 2000, J NEUROIMMUNOL, V106, P69, DOI 10.1016/S0165-5728(99)00215-5; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Di Malta C, 2012, AUTOPHAGY, V8, P1871, DOI 10.4161/auto.22184; Di Malta C, 2012, P NATL ACAD SCI USA, V109, pE2334, DOI 10.1073/pnas.1209577109; Dolman Nick J, 2013, Curr Protoc Cytom, VChapter 12, DOI 10.1002/0471142956.cy1230s65; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Fellner L, 2013, GLIA, V61, P349, DOI 10.1002/glia.22437; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Guenette SY, 2003, TRENDS MOL MED, V9, P279, DOI 10.1016/S1471-4914(03)00112-6; Hiltbold EM, 2002, CURR OPIN IMMUNOL, V14, P30, DOI 10.1016/S0952-7915(01)00295-3; Hoffmann E, 2012, P NATL ACAD SCI USA, V109, P14556, DOI 10.1073/pnas.1203912109; Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511; Jancic C, 2007, NAT CELL BIOL, V9, P367, DOI 10.1038/ncb1552; Jensen MD, 2009, NEUROCHEM INT, V55, P362, DOI 10.1016/j.neuint.2009.04.002; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jones RS, 2013, J NEUROIMMUNE PHARM, V8, P301, DOI 10.1007/s11481-012-9427-3; Kim SH, 2008, INFECT IMMUN, V76, P5373, DOI 10.1128/IAI.01044-08; Kinchen JM, 2008, NAT REV MOL CELL BIO, V9, P781, DOI 10.1038/nrm2515; Krysko DV, 2006, APOPTOSIS, V11, P1709, DOI 10.1007/s10495-006-9527-8; Liebl D, 2009, J CELL SCI, V122, P2935, DOI 10.1242/jcs.048355; Loov C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033090; Ma D, 2013, J NEUROIMMUNOL, V254, P10, DOI 10.1016/j.jneuroim.2012.08.010; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Magnus T, 2002, J NEUROPATH EXP NEUR, V61, P760, DOI 10.1093/jnen/61.9.760; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Miksa M, 2009, J IMMUNOL METHODS, V342, P71, DOI 10.1016/j.jim.2008.11.019; Nagele RG, 2003, BRAIN RES, V971, P197, DOI 10.1016/S0006-8993(03)02361-8; Nicoll JAR, 2003, TRENDS MOL MED, V9, P281, DOI 10.1016/S1471-4914(03)00109-6; Nielsen HM, 2010, GLIA, V58, P1235, DOI 10.1002/glia.21004; Nielsen HM, 2009, GLIA, V57, P978, DOI 10.1002/glia.20822; Nikcevich KM, 1997, J IMMUNOL, V158, P614; Nixon RA, 2008, AUTOPHAGY, V4, P590, DOI 10.4161/auto.6259; Platt FM, 2012, J CELL BIOL, V199, P723, DOI 10.1083/jcb.201208152; Poon IKH, 2010, CELL DEATH DIFFER, V17, P381, DOI 10.1038/cdd.2009.195; Ravin R, 2008, CELL STEM CELL, V3, P670, DOI 10.1016/j.stem.2008.09.012; Romao S, 2013, J CELL BIOL, V203, P757, DOI 10.1083/jcb.201308173; Savina A, 2007, IMMUNOL REV, V219, P143, DOI 10.1111/j.1600-065X.2007.00552.x; Savina A, 2006, CELL, V126, P205, DOI 10.1016/j.cell.2006.05.035; Savina A, 2009, IMMUNITY, V30, P544, DOI 10.1016/j.immuni.2009.01.013; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Shafer LE, 2001, CHARGING AHEAD INTRO, P81; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sokolowski JD, 2011, BRAIN BEHAV IMMUN, V25, P915, DOI 10.1016/j.bbi.2010.09.021; Soos JM, 1999, INT IMMUNOL, V11, P1169, DOI 10.1093/intimm/11.7.1169; SZABO AG, 1986, PHOTOCHEM PHOTOBIOL, V44, P143, DOI 10.1111/j.1751-1097.1986.tb03578.x; Vardjan N, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-144; Yokoyama K, 2011, J BIOL CHEM, V286, P5375, DOI 10.1074/jbc.M110.171702; Zeinstra E, 2003, J NEUROIMMUNOL, V135, P166, DOI 10.1016/S0165-5728(02)00462-9; Zhou Z, 2008, TRENDS CELL BIOL, V18, P474, DOI 10.1016/j.tcb.2008.08.002; Zhu DH, 2009, BIOCHEM J, V421, P201, DOI 10.1042/BJ20090356	68	26	26	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	NOV	2015	63	11					1997	2009		10.1002/glia.22873			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR2UB	WOS:000361185000008	26095880	Green Accepted			2022-02-06	
J	Dash, PK; Hylin, MJ; Hood, KN; Orsi, SA; Zhao, J; Redell, JB; Tsvetkov, AS; Moore, AN				Dash, Pramod K.; Hylin, Michael J.; Hood, Kimberly N.; Orsi, Sara A.; Zhao, Jing; Redell, John B.; Tsvetkov, Andrey S.; Moore, Anthony N.			Inhibition of Eukaryotic Initiation Factor 2 Alpha Phosphatase Reduces Tissue Damage and Improves Learning and Memory after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CHOP; ER stress; hippocampus; phosphatase; TBI	UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; CONTROLLED CORTICAL IMPACT; AMYOTROPHIC-LATERAL-SCLEROSIS; WATER MAZE PERFORMANCE; ER STRESS; COGNITIVE DEFICITS; TRANSCRIPTION FACTOR; HEMORRHAGIC-SHOCK; NEURONAL INJURY	Patients who survive traumatic brain injury (TBI) are often faced with persistent memory deficits. The hippocampus, a structure critical for learning and memory, is vulnerable to TBI and its dysfunction has been linked to memory impairments. Protein kinase RNA-like ER kinase regulates protein synthesis (by phosphorylation of eukaryotic initiation factor 2 alpha [eIF2]) in response to endoplasmic reticulum (ER) stressors, such as increases in calcium levels, oxidative damage, and energy/glucose depletion, all of which have been implicated in TBI pathophysiology. Exposure of cells to guanabenz has been shown to increase eIF2 phosphorylation and reduce ER stress. Using a rodent model of TBI, we present experimental results that indicate that postinjury administration of 5.0mg/kg of guanabenz reduced cortical contusion volume and decreased hippocampal cell damage. Moreover, guanabenz treatment attenuated TBI-associated motor, vestibulomotor, recognition memory, and spatial learning and memory dysfunction. Interestingly, when the initiation of treatment was delayed by 24h, or the dose reduced to 0.5mg/kg, some of these beneficial effects were still observed. Taken together, these findings further support the involvement of ER stress signaling in TBI pathophysiology and indicate that guanabenz may have translational utility.	[Dash, Pramod K.; Hood, Kimberly N.; Orsi, Sara A.; Zhao, Jing; Redell, John B.; Tsvetkov, Andrey S.; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hylin, Michael J.] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA		Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, POB 20036, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS087149]; Gillson-Longenbaugh Foundation; TIRR Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090935, R01NS087149] Funding Source: NIH RePORTER	This project was made possible by funds provided to P.K.D. by the NIH (NS087149), the Gillson-Longenbaugh Foundation, and the TIRR Foundation.	Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chakrabarti A, 2011, BIOTECHNOL BIOENG, V108, P2777, DOI 10.1002/bit.23282; Chaudhari N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00213; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Colla E, 2012, J NEUROSCI, V32, P3301, DOI 10.1523/JNEUROSCI.5368-11.2012; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; HOLMES B, 1983, DRUGS, V26, P212, DOI 10.2165/00003495-198326030-00003; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jiang HQ, 2014, NEUROSCIENCE, V277, P132, DOI 10.1016/j.neuroscience.2014.03.047; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Lin JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004170; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; McAllister TW, 2011, INT J PSYCHOPHYSIOL, V82, P107, DOI 10.1016/j.ijpsycho.2011.06.022; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Mei Y, 2013, J PHARM BIOMED ANAL, V1, P1; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; Olivari S, 2005, J BIOL CHEM, V280, P2424, DOI 10.1074/jbc.C400534200; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046; Pouzet B, 1999, EUR J NEUROSCI, V11, P123, DOI 10.1046/j.1460-9568.1999.00413.x; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Ron D, 2008, CELL, V132, P24, DOI 10.1016/j.cell.2007.12.017; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Smith CJ, 2012, JOVE-J VIS EXP, DOI 10.3791/4411; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Teske BF, 2011, MOL BIOL CELL, V22, P4390, DOI 10.1091/mbc.E11-06-0510; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tribouillard-Tanvier D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001981; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Tsvetkov AS, 2013, NAT CHEM BIOL, V9, P586, DOI [10.1038/NCHEMBIO.1308, 10.1038/nchembio.1308]; Van Der Vlies D, 2003, ANTIOXID REDOX SIGN, V5, P381, DOI 10.1089/152308603768295113; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang LJ, 2014, NEUROBIOL DIS, V71, P317, DOI 10.1016/j.nbd.2014.08.010; Wang Y, 2000, J BIOL CHEM, V275, P27013; Whishaw IQ, 1997, HIPPOCAMPUS, V7, P361, DOI 10.1002/(SICI)1098-1063(1997)7:4<361::AID-HIPO2>3.0.CO;2-M; Wilson DI, 2013, HIPPOCAMPUS, V23, P352, DOI 10.1002/hipo.22095; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	72	26	27	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2015	32	20					1608	1620		10.1089/neu.2014.3772			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CS6VH	WOS:000362220500009	25843479	Green Published			2022-02-06	
J	Hehar, H; Yeates, K; Kolb, B; Esser, MJ; Mychasiuk, R				Hehar, Harleen; Yeates, Keith; Kolb, Bryan; Esser, Michael J.; Mychasiuk, Richelle			Impulsivity and Concussion in Juvenile Rats: Examining Molecular and Structural Aspects of the Frontostriatal Pathway	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; SEX-DIFFERENCES; INHIBITORY CONTROL; PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS; CHILDREN; ADHD; DOPAMINE	Impulsivity and poor executive control have been implicated in the pathogenesis of many developmental and neuropsychiatric disorders. Similarly, concussions/mild traumatic brain injuries (mTBI) have been associated with increased risk for neuropsychiatric disorders and the development of impulsivity and inattention. Researchers and epidemiologists have therefore considered whether or not concussions induce symptoms of attention-deficit/hyperactivity disorder (ADHD), or merely unmask impulsive tendencies that were already present. The purpose of this study was to determine if a single concussion in adolescence could induce ADHD-like impulsivity and impaired response inhibition, and subsequently determine if inherent impulsivity prior to a pediatric mTBI would exacerbate post-concussion symptomology with a specific emphasis on impulsive and inattentive behaviours. As these behaviours are believed to be associated with the frontostriatal circuit involving the nucleus accumbens (NAc) and the prefrontal cortex (PFC), the expression patterns of 8 genes (Comt, Drd2, Drd3, Drd4, Maoa, Sert, Tph1, and Tph2) from these two regions were examined. In addition, Golgi-Cox staining of medium spiny neurons in the NAc provided a neuroanatomical examination of mTBI-induced structural changes. The study found that a single early brain injury could induce impulsivity and impairments in response inhibition that were more pronounced in males. Interestingly, when animals with inherent impulsivity experienced mTBI, injury-related deficits were exacerbated in female animals. The single concussion increased dendritic branching, but reduced synaptic density in the NAc, and these changes were likely associated with the increase in impulsivity. Finally, mTBI-induced impulsivity was associated with modifications to gene expression that differed dramatically from the gene expression pattern associated with inherent impulsivity, despite very similar behavioural phenotypes. Our findings suggest the need to tailor treatment strategies for mTBI in light of an individual's premorbid characteristics, given significant differences in molecular profiles of the frontostriatal circuits that depend upon sex and the etiology of the behavioural phenotype.	[Hehar, Harleen; Esser, Michael J.; Mychasiuk, Richelle] Univ Calgary, Fac Med, Res Inst, Alberta Childrens Hosp, Calgary, AB, Canada; [Yeates, Keith] Univ Calgary, Dept Psychol, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 1N4, Canada; [Kolb, Bryan] Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Res Inst, Alberta Childrens Hosp, Calgary, AB, Canada.	rmmychas@ucalgary.ca	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	Alberta Children's Hospital Research Institute (ACHRI); Alberta Children's Hospital Foundation; Canadian Institute for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Markin USRP for Health and Wellness	The authors would like to thank the Alberta Children's Hospital Research Institute (ACHRI), the Alberta Children's Hospital Foundation, the Canadian Institute for Health Research (CIHR) and the Markin USRP for Health and Wellness for their financial support.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Bari A, 2008, NAT PROTOC, V3, P759, DOI 10.1038/nprot.2008.41; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136; Biederman J, 2002, AM J PSYCHIAT, V159, P36, DOI 10.1176/appi.ajp.159.1.36; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Clacy A, 2013, OA SPORTS MED, V1, P4; Cortese S, 2012, AM J PSYCHIAT, V169, P1038, DOI 10.1176/appi.ajp.2012.11101521; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dalley JW, 2012, NEUROSCIENCE, V215, P42, DOI 10.1016/j.neuroscience.2012.03.065; Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073; Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020; Dias TGC, 2013, EUR NEUROPSYCHOPHARM, V23, P33, DOI 10.1016/j.euroneuro.2012.10.015; Durston S, 2008, J AM ACAD CHILD PSY, V47, P61, DOI 10.1097/chi.0b013e31815a5f17; Eagle DM, 2008, PSYCHOPHARMACOLOGY, V199, P439, DOI 10.1007/s00213-008-1127-6; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Faul M, 2010, TRAUMATIC BRAIN INJU; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Halperin JM, 2011, NEUROSCI BIOBEHAV R, V35, P621, DOI 10.1016/j.neubiorev.2010.07.006; Hayes DJ, 2011, NEUROSCI BIOBEHAV R, V35, P1419, DOI 10.1016/j.neubiorev.2011.03.005; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Iaboni F, 1997, PSYCHOPHYSIOLOGY, V34, P116, DOI 10.1111/j.1469-8986.1997.tb02422.x; Itohara S, 2015, CURR OPIN BEHAV SCI, V2, P46, DOI 10.1016/j.cobeha.2014.09.002; Johansen EB, 2002, BEHAV BRAIN RES, V130, P37, DOI 10.1016/S0166-4328(01)00434-X; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Konrad KN, 2000, BRAIN INJURY, V14, P859; Martel MM, 2011, J ABNORM CHILD PSYCH, V39, P1, DOI 10.1007/s10802-010-9439-5; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, BRAIN INJURY, V12, P41; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; Mychasiuk R, 2015, NEUROSCIENCE, V288, P145, DOI 10.1016/j.neuroscience.2014.12.034; Mychasiuk R, 2014, JOVE, V8; Mychasiuk R, 2015, BEHAV BRAIN RES, V286, P285, DOI 10.1016/j.bbr.2015.03.010; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Mychasiuk R, 2013, JOVE-J VIS EXP, DOI 10.3791/50694; Palasis S, 2013, J PEDIATR NEURORADIO, V2, P87, DOI 10.3233/PNR-13049; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinto PS, 2012, J NEUROIMAGING, V22, pe18, DOI 10.1111/j.1552-6569.2011.00690.x; Purper-Ouakil D, 2011, PEDIATR RES, V69, p69R, DOI 10.1203/PDR.0b013e318212b40f; Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x; Rommelse NNJ, 2008, AM J MED GENET B, V147B, P1524, DOI 10.1002/ajmg.b.30845; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sagiv SK, 2013, J ATTEN DISORD, V17, P47, DOI 10.1177/1087054711427563; Sanchez F, 2011, SYNAPSE, V65, P198, DOI 10.1002/syn.20837; Scholes KE, 2007, NEUROPSYCHOPHARMACOL, V32, P1600, DOI 10.1038/sj.npp.1301262; Shiloh R, 2002, ATLAS PSYCHIAT PHARM; Simon NW, 2013, EUR J NEUROSCI, V37, P1779, DOI 10.1111/ejn.12191; Sinopoli KJ, 2012, INT J DEV NEUROSCI, V30, P207, DOI 10.1016/j.ijdevneu.2011.08.006; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sonuga-Barke EJS, 2007, J AM ACAD CHILD PSY, V46, P701, DOI 10.1097/chi.0b013e31804659f1; Sonuga-Barke EJS, 2005, BIOL PSYCHIAT, V57, P1231, DOI 10.1016/j.biopsych.2004.09.008; White RD, 2014, SPORTS HEALTH, V6, P149, DOI 10.1177/1941738113484679; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Zilles K., 1985, CORTEX RAT STEREOTAX	57	26	26	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2015	10	10							e0139842	10.1371/journal.pone.0139842			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT0TW	WOS:000362511000058	26448536	Green Published, Green Submitted, gold			2022-02-06	
J	Lu, HY; Kobilo, T; Robertson, C; Tong, S; Celnik, P; Pelled, G				Lu, Hongyang; Kobilo, Tali; Robertson, Courtney; Tong, Shanbao; Celnik, Pablo; Pelled, Galit			Transcranial magnetic stimulation facilitates neurorehabilitation after pediatric traumatic brain injury	SCIENTIFIC REPORTS			English	Article							WORKING-MEMORY; PLASTICITY; TERM; RAT; CHILDREN; MODERATE; OUTCOMES; CORTEX; SAFETY; MOTOR	Traumatic brain injury (TBI) is the leading cause of death and disability among children in the United States. Affected children will often suffer from emotional, cognitive and neurological impairments throughout life. In the controlled cortical impact (CCI) animal model of pediatric TBI (postnatal day 16-17) it was demonstrated that injury results in abnormal neuronal hypoactivity in the non-injured primary somatosensory cortex (S1). It materializes that reshaping the abnormal post-injury neuronal activity may provide a suitable strategy to augment rehabilitation. We tested whether high-frequency, non-invasive transcranial magnetic stimulation (TMS) delivered twice a week over a four-week period can rescue the neuronal activity and improve the long-term functional neurophysiological and behavioral outcome in the pediatric CCI model. The results show that TBI rats subjected to TMS therapy showed significant increases in the evoked-fMRI cortical responses (189%), evoked synaptic activity (46%), evoked neuronal firing (200%) and increases expression of cellular markers of neuroplasticity in the non-injured S1 compared to TBI rats that did not receive therapy. Notably, these rats showed less hyperactivity in behavioral tests. These results implicate TMS as a promising approach for reversing the adverse neuronal mechanisms activated post-TBI. Importantly, this intervention could readily be translated to human studies.	[Lu, Hongyang; Kobilo, Tali; Pelled, Galit] Kennedy Krieger Inst, FM Kirby Res Ctr Funct Brain Imaging, Baltimore, MD 21205 USA; [Lu, Hongyang; Kobilo, Tali; Pelled, Galit] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Lu, Hongyang; Tong, Shanbao] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China; [Robertson, Courtney] Johns Hopkins Univ, Dept Anesthesiol Crit Care Med & Pediat, Sch Med, Baltimore, MD USA; [Celnik, Pablo] Johns Hopkins Univ, Dept Phys Med & Rehabil, Sch Med, Baltimore, MD USA		Pelled, G (corresponding author), Kennedy Krieger Inst, FM Kirby Res Ctr Funct Brain Imaging, Baltimore, MD 21205 USA.	Pelled@kennedykrieger.org		Lu, Hongyang/0000-0002-4077-6802	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072171]; China Scholarship CouncilChina Scholarship Council [201306230041]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072171] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01NS072171 to G.P.). H.L. was supported by the China Scholarship Council (201306230041). The authors thank Dr. Manda Saraswati for technical assistance.	Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Benali A, 2011, J NEUROSCI, V31, P1193, DOI 10.1523/JNEUROSCI.1379-10.2011; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Cantore L, 2012, NEUROREHABILITATION, V30, P225, DOI 10.3233/NRE-2012-0749; Casanova MF, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00851; Celnik PA, 2004, RESTOR NEUROL NEUROS, V22, P261; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen R, 1997, ELECTROMYOGR MOTOR C, V105, P415, DOI 10.1016/S0924-980X(97)00036-2; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Di Battista A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101842; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Frye RE, 2008, J CHILD NEUROL, V23, P79, DOI 10.1177/0883073807307972; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Garvey MA, 2004, EUR J PAEDIATR NEURO, V8, P7, DOI 10.1016/j.ejpn.2003.11.002; Gersner R, 2011, J NEUROSCI, V31, P7521, DOI 10.1523/JNEUROSCI.6751-10.2011; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Konrad KN, 2000, BRAIN INJURY, V14, P859; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Lefaucheur JP, 2004, J NEUROL NEUROSUR PS, V75, P612, DOI 10.1136/jnnp.2003.022236; Leo RJ, 2007, J PAIN, V8, P453, DOI 10.1016/j.jpain.2007.01.009; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Li N, 2014, J MOL NEUROSCI, V53, P553, DOI 10.1007/s12031-013-0221-3; Li N, 2014, J NEUROTRAUM, V31, P395, DOI 10.1089/neu.2013.3059; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Matsumoto JH, 2013, EPILEPSY BEHAV, V27, P233, DOI 10.1016/j.yebeh.2013.01.024; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Mishra AK, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0086852, 10.1371/journal.pone.0095280]; Mueller JK, 2014, NAT NEUROSCI, V17, P1130, DOI 10.1038/nn.3751; Nardone R, 2014, J SPINAL CORD MED, V37, P19, DOI 10.1179/2045772313Y.0000000140; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Niskanen JP, 2013, J NEUROTRAUM, V30, P546, DOI 10.1089/neu.2012.2416; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Pashut T, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00145; Pawela CP, 2008, MAGN RESON MED, V59, P1021, DOI 10.1002/mrm.21524; Ping X., 2015, J NEUROTRAUMA; Popernack ML, 2015, J PEDIATR HEALTH CAR, V29, pE1, DOI 10.1016/j.pedhc.2014.09.003; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Quintana H, 2005, J ECT, V21, P88, DOI 10.1097/01.yct.0000162556.02720.58; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Rosema S, 2015, J NEUROTRAUM, V32, P976, DOI 10.1089/neu.2014.3567; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schulz R, 2013, NEUROPHARMACOLOGY, V64, P579, DOI 10.1016/j.neuropharm.2012.05.016; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Villamar MF, 2012, NEUROMODULATION, V15, P326, DOI 10.1111/j.1525-1403.2012.00474.x; Vlachos A, 2012, J NEUROSCI, V32, P17514, DOI 10.1523/JNEUROSCI.0409-12.2012; Walker PA, 2009, J TRAUMA, V67, pS120, DOI 10.1097/TA.0b013e3181ad323a; Wassermann EM, 1996, ELECTROMYOGR MOTOR C, V101, P412; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yukimasa T, 2006, PHARMACOPSYCHIATRY, V39, P52, DOI 10.1055/s-2006-931542	73	26	27	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 6	2015	5								14769	10.1038/srep14769			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS7PL	WOS:000362276700002	26440604	gold, Green Published			2022-02-06	
J	Sauber-Schatz, EK; Thomas, AM; Cook, LJ				Sauber-Schatz, Erin K.; Thomas, Andrea M.; Cook, Lawrence J.			Motor Vehicle Crashes, Medical Outcomes, and Hospital Charges Among Children Aged 1-12 Years - Crash Outcome Data Evaluation System, 11 States, 2005-2008	MMWR SURVEILLANCE SUMMARIES			English	Article							PASSENGER SAFETY; UNITED-STATES; LINKAGE; SEATS	Problem: Motor vehicle crashes are a leading cause of death among children. Age-and size-appropriate restraint use is an effective way to prevent motor vehicle-related injuries and deaths. However, children are not always properly restrained while riding in a motor vehicle, and some are not restrained at all, which increases their risk for injury and death in a crash. Reporting Period: 2005-2008. Description of the System: The Crash Outcome Data Evaluation System (CODES) is a multistate program facilitated by the National Highway Traffic Safety Administration to probabilistically link police crash reports and hospital databases for traffic safety analyses. Eleven participating states (Connecticut, Georgia, Kentucky, Maryland, Minnesota, Missouri, Nebraska, New York, Ohio, South Carolina, and Utah) submitted data to CODES during the reporting period. Descriptive analysis was used to describe drivers and child passengers involved in motor vehicle crashes and to summarize crash and medical outcomes. Odds ratios and 95% confidence intervals were used to compare a child passenger's likelihood of sustaining specific types of injuries by restraint status (optimal, suboptimal, or unrestrained) and seating location (front or back seat). Because of data constraints, optimal restraint use was defined as car seat or booster seat use for children aged 1-7 years and seat belt use for children aged 8-12 years. Suboptimal restraint use was defined as seat belt use for children aged 1-7 years. Unrestrained was defined as no use of car a seat, booster seat, or seat belt for children aged 1-12 years. Results: Optimal restraint use in the back seat declined with child's age (1 year: 95.9%, 5 years: 95.4%, 7 years: 94.7%, 8 years: 77.4%, 10 years: 67.5%, 12 years: 54.7%). Child restraint use was associated with driver restraint use; 41.3% of children riding with unrestrained drivers also were unrestrained compared with 2.2% of children riding with restrained drivers. Child restraint use also was associated with impaired driving due to alcohol or drug use; 16.4% children riding with drivers suspected of alcohol or drug use were unrestrained compared with 2.9% of children riding with drivers not suspected of such use. Optimally restrained and suboptimally restrained children were less likely to sustain a traumatic brain injury than unrestrained children. The 90th percentile hospital charges for children aged 4-7 years who were in motor vehicle crashes were $1,630.00 and $1,958.00 for those optimally restrained in a back seat and front seat, respectively; $2,035.91 and $3,696.00 for those suboptimally restrained in a back seat and front seat, respectively; and $9,956.60 and $11,143.85 for those unrestrained in a back seat and front seat, respectively. Interpretation: Proper car seat, booster seat, and seat belt use among children in the back seat prevents injuries and deaths, as well as averts hospital charges. However, the number, severity, and cost of injuries among children in crashes who were not optimally restrained or who were seated in a front seat indicates the need for improvements in proper use of age-and size-appropriate car seats, booster seats, and seat belts in the back seat. Public Health Actions: Effective interventions for increasing proper child restraint use could be universally implemented by states and communities to prevent motor vehicle-related injuries among children and their resulting costs.	[Sauber-Schatz, Erin K.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Sauber-Schatz, Erin K.] US PHS, Washington, DC 20201 USA; [Thomas, Andrea M.; Cook, Lawrence J.] Univ Utah, Dept Pediat, Salt Lake City, UT USA		Sauber-Schatz, EK (corresponding author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.	esauberschatz@cdc.gov					[Anonymous], 2015, MOT VEH REL INJ PREV; Arbogast KB, 2009, PEDIATRICS, V124, P1281, DOI 10.1542/peds.2009-0908; Bergen G, 2014, MMWR-MORBID MORTAL W, V63, P894; CDC, 2014, VIT SIGNS FACT SHEET; Choi E-H, 2014, 812037 DOT HS NAT HI; Cook LJ, 2001, METHOD INFORM MED, V40, P196; Durbin DR, 2011, PEDIATRICS, V127, pE1050, DOI 10.1542/peds.2011-0215; Ehiri JE, 2006, COCHRANE DB SYST REV, V1; Eichelberger AH, 2012, TRAFFIC INJ PREV, V13, P631, DOI 10.1080/15389588.2012.660663; [Federal Motor Carrier Safety Administration Governors Highway Safety Association National Highway Traffic Safety Administration Federal Highway Administration], 2012, MMUCC GUID MOD MIN U; Gardner HG, 2011, PEDIATRICS, V127, P788, DOI 10.1542/peds.2011-0213; JARO MA, 1995, STAT MED, V14, P491, DOI 10.1002/sim.4780140510; Kahane C.J., 1986, EVALUATION CHILD PAS; McGlincy MH, 2004, ASA P JOINT STAT M, P4001; Milani J, 2015, ASSESSMENT CHARACTER; National Highway Traffic Safety Administration, 2011, CRASH OUTC DAT EV SY; National Highway Traffic Safety Administration, 2015, PAR CENTR; National Highway Traffic Safety Administration, 2014, NAT AUT SAMPL SYST N; National Highway Traffic Safety Administration, 2013, COUNT WORK HIGHW SAF; NHTSA, 1996, REV EST CHILD RESTR; NHTSA, 2015, TRAFF SAF FACTS 2013; Quinlan K, 2014, PEDIATRICS, V133, P966, DOI 10.1542/peds.2013-2318; Raghunathan T.E., 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186; SAS Institute, 2002, SAS SOFTW; Sauber-Schatz EK, 2014, MMWR-MORBID MORTAL W, V63, P113; Zaza S, 2001, AM J PREV MED, V21, P31, DOI 10.1016/S0749-3797(01)00377-4	26	26	26	0	8	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1545-8636			MMWR SURVEILL SUMM	MMWR Surv. Summ.	OCT 2	2015	64	8					1	32					32	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	CV6NL	WOS:000364386800001	26426527	Bronze			2022-02-06	
J	Hang, B; Babcock, L; Hornung, R; Ho, M; Pomerantz, WJ				Hang, Brian; Babcock, Lynn; Hornung, Richard; Ho, Mona; Pomerantz, Wendy J.			Can Computerized Neuropsychological Testing in the Emergency Department Predict Recovery for Young Athletes With Concussions?	PEDIATRIC EMERGENCY CARE			English	Article						athlete; concussion; ImPACT	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; POSTCONCUSSION SYNDROME; CONSENSUS STATEMENT; FOOTBALL PLAYERS; SYMPTOMS; ADOLESCENTS; CHILDREN	Objective The objective of this study was to determine if computerized neurocognitive testing (Immediate Post-Concussion Assessment and Cognitive Testing [ImPACT]) in the emergency department (ED) can be used as a prognostic tool to detect young athletes at risk of having protracted concussive symptoms. Methods This was a prospective cohort study of athletes aged 11 to 18 years who presented to an ED less than 24 hours after sustaining a sports-related concussion. ImPACT was administered in the ED, and performance was categorized as poor if the athlete had 3 (of 4) or greater low domain scores. Participants completed the Post-Concussion Symptom Scale (PCSS) in the ED and by phone at 1 and 2 weeks after injury. Athletes were symptomatic if their PCSS score was more than 6 in males and more than 8 in females. Results One hundred nine patients were enrolled; 60% and 36% remained symptomatic at 1 and 2 weeks after injury, respectively. Poor ImPACT performance was not particularly useful in predicting athletes with protracted symptoms (at 1 week: positive predictive value, 70.8%; negative predictive value, 43.5%; at 2 weeks: positive predictive value, 47.8%; negative predictive value, 68.9%). In bivariate analysis, a higher ED PCSS score was associated with protracted symptoms (at 1 week: odds ratio, 1.1 [confidence interval, 1.0-1.1]; at 2 weeks: odds ratio, 1.0 [confidence interval, 1.0-1.1]). Conclusions Computerized neurocognitive testing in the ED has limited usefulness in predicting protracted symptoms. Total acute symptom burden may be a useful prognostic tool in the ED evaluation of concussed young athletes, yet further research is necessary.	[Hang, Brian] Ann & Robert Lurie Childrens Hosp Chicago, Div Emergency Med, Pediat Emergency Med, Chicago, IL USA; [Babcock, Lynn; Hornung, Richard; Ho, Mona; Pomerantz, Wendy J.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Babcock, Lynn; Hornung, Richard; Pomerantz, Wendy J.] UC Dept Pediat, Cincinnati, OH USA		Babcock, L (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, 3333 Burnet Ave,ML 2008, Cincinnati, OH 45229 USA.	Lynn.Babcock@cchmc.org	Meijer, Anna/K-5118-2016	Babcock, Lynn/0000-0002-2658-6893	American College of Sports Medicine, Clinical Sports Medicine Research Endowment; Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER	American College of Sports Medicine, Clinical Sports Medicine Research Endowment, 2011; and Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Flahault A, 2005, J CLIN EPIDEMIOL, V58, P859, DOI 10.1016/j.jclinepi.2004.12.009; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Janusz A, 2004, BRIT J SPORT MED, V38, P659; Krol AL, 2011, BRAIN INJURY, V25, P1300, DOI 10.3109/02699052.2011.624571; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell M.R.C.M., 2003, IMMEDIATE POSTCONCUS; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Wiebe DJ, 2012, PEDIATR EMERG CARE, V28, P498, DOI 10.1097/PEC.0b013e3182586f76; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008	26	26	26	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	OCT	2015	31	10					688	693		10.1097/PEC.0000000000000438			6	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	CT3MH	WOS:000362710300002	26430968				2022-02-06	
J	Ojo, JO; Bachmeier, C; Mouzon, BC; Tzekov, R; Mullan, M; Davies, H; Stewart, MG; Crawford, F				Ojo, Joseph O.; Bachmeier, Corbin; Mouzon, Benoit C.; Tzekov, Radouil; Mullan, Michael; Davies, Heather; Stewart, Michael G.; Crawford, Fiona			Ultrastructural Changes in the White and Gray Matter of Mice at Chronic Time Points After Repeated Concussive Head Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal injury; Concussion; Electron microscopy; Microvasculature; Neuroglial activation; Repetitive TBI; Synapses	TRAUMATIC BRAIN-INJURY; MOUSE MODEL; PATHOLOGICAL ALTERATIONS; CEREBRAL VASCULATURE; COGNITIVE DEFICITS; GLIAL ACTIVATION; AXONAL INJURY; ENCEPHALOPATHY; NEUROPATHOLOGY; DEGENERATION	Mild traumatic brain injury is a risk factor for neurodegenerative disease. We recently developed a model of repetitive concussive injury in mice that we have extensively characterized from 24 hours to 24 months after injury. Animals show evidence of progressive spatial memory deficits, thinning of the corpus callosum, axonal injury, and neuroglial activation. Here, we extended our neuropathologic characterization to the ultrastructural level in both a qualitative and a quantitative study. We focused on chronic (3 and 6 months) postinjury time points when the earliest stages of degenerative secondary changes were previously observed. In both C57BL/6 and hTau mice, we found white matter damage typified by axonal degeneration, microglial phagocytosis, and increased neuroglial cell density. In the cerebral cortex, we observed evidence of synaptic degeneration, dark neurons, altered dendritic microfilaments, subtle changes to the microvasculature, a mild augmentation of age-related features such as lipofuscin deposition, and electron-dense inclusions in microglial and perivascular cells. The majority of these ultrastructural features seemed to be more prominent at 3 versus 6 months after injury. Similar patterns were observed in C57BL/6 and hTau mice. These findings further support the relevance of our concussive injury model to the consequences of repetitive mild traumatic brain injury in humans.	[Ojo, Joseph O.; Bachmeier, Corbin; Mouzon, Benoit C.; Tzekov, Radouil; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Dept Neuropathol, Sarasota, FL 34234 USA; [Davies, Heather; Stewart, Michael G.] Open Univ, Dept Life Sci, London, England; [Mouzon, Benoit C.; Tzekov, Radouil; Crawford, Fiona] James A Haley Hosp, Tampa, FL USA		Ojo, JO (corresponding author), Roskamp Inst, Dept Neuropathol, Sarasota, FL 34234 USA.	bojo@roskampinstitute.net		Tzekov, Radouil/0000-0002-3662-9818	Department of DefenseUnited States Department of Defense [W81XWH-13-1-0759]; Roskamp Foundation; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/I020330/1, BB/J021687/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/J021687/1, BB/I020330/1] Funding Source: researchfish	This work was supported by Department of Defense award W81XWH-13-1-0759 (Fiona Crawford) and by the Roskamp Foundation.	ADAMS CWM, 1989, J NEUROL NEUROSUR PS, V52, P600, DOI 10.1136/jnnp.52.5.600; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Bouras C, 1997, EUR NEUROL, V38, P53, DOI 10.1159/000112903; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Castejon OJ, 1997, BRAIN INJURY, V11, P363, DOI 10.1080/026990597123520; CASTEJON OJ, 1985, J SUBMICR CYTOL PATH, V17, P703; Castejon OJ, 2013, ULTRASTRUCT PATHOL, V37, P417, DOI 10.3109/01913123.2013.831157; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Liu J, 2012, NAT NEUROSCI, V15, P1621, DOI 10.1038/nn.3263; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ojo Bunmi, 2013, Neurosci J, V2013, P839535, DOI 10.1155/2013/839535; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Popov VI, 2008, EUR J NEUROSCI, V27, P301, DOI 10.1111/j.1460-9568.2007.06004.x; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Sandell JH, 2003, J COMP NEUROL, V466, P14, DOI 10.1002/cne.10859; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	61	26	26	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	OCT	2015	74	10					1012	1035		10.1097/NEN.0000000000000247			24	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	DC2VQ	WOS:000369076600007	26360375	Bronze			2022-02-06	
J	MacManus, DB; Pierrat, B; Murphy, JG; Gilchrist, MD				MacManus, D. B.; Pierrat, B.; Murphy, J. G.; Gilchrist, M. D.			Dynamic mechanical properties of murine brain tissue using micro-indentation	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain injury (TBI); Cortex; Cerebellum; Sneddon; Finite element analysis	IN-VIVO; HEAD; BIOMECHANICS; COMPRESSION; VALIDATION; MATTER	In the past 50 years significant advances have been made in determining the macro-scale properties of brain tissue in compression, tension, shear and indentation. There has also been significant work done at the nanoscale using the AFM method to characterise the properties of individual neurons. However, there has been little published work on the micro-scale properties of brain tissue using an appropriate indentation methodology to characterise the regional differences at dynamic strain rates. This paper presents the development and use of a novel micro-indentation device to measure the dynamic mechanical properties of brain tissue. The device is capable of applying up to 30/s strain rates with a maximum indentation area of 2500 mu m(2). Indentation tests were carried out to determine the shear modulus of the cerebellum (2.11 +/- 1.26 kPa, 3.15 +/- 1.66 kPa, 3.71 +/- 1.23 kPa) and cortex (4.06 +/- 1.69 kPa, 6.14 +/- 3.03 kPa, 7.05 +/- 3.92 kPa) of murine brain tissue at 5, 15, and 30/s up to 14% strain. Numerical simulations were carried out to verify the experimentally measured force-displacement results. (C) 2015 Elsevier Ltd. All rights reserved.	[MacManus, D. B.; Pierrat, B.; Gilchrist, M. D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 2, Ireland; [Murphy, J. G.] Dublin City Univ, Dept Mech & Mfg Engn, Dublin 9, Ireland		Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 2, Ireland.	david.mac-manus@ucdconnect.ie; baptiste.pierrat@ucd.ie; jeremiah.murphy@dcu.ie; michael.gilchrist@ucd.ie		MacManus, David/0000-0003-2959-698X; Pierrat, Baptiste/0000-0001-8064-8496	Science Foundation IrelandScience Foundation IrelandEuropean Commission [12/IP/1732]	This work was supported by Science Foundation Ireland (Grant no. 12/IP/1732).	Atkin R. J., 1980, INTRO THEORY ELASTIC, P72; Bernick KB, 2011, ACTA BIOMATER, V7, P1210, DOI 10.1016/j.actbio.2010.10.018; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; Faul M, 2010, TRAUMATIC BRAIN INJU; Ferrer I, 2007, J NEUROPATH EXP NEUR, V66, P35, DOI 10.1097/nen.0b013e31802c3e7d; Finan JD, 2014, BIOMECH MODEL MECHAN, V13, P573, DOI 10.1007/s10237-013-0519-7; Fountoulakis M, 2001, EXP NEUROL, V167, P86, DOI 10.1006/exnr.2000.7529; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Haslach HW, 2014, J MECH BEHAV BIOMED, V29, P138, DOI 10.1016/j.jmbbm.2013.08.027; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; Johnson KL, 1985, CONTACT MECH; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mustata M, 2010, J NEUROSCI METH, V186, P35, DOI 10.1016/j.jneumeth.2009.10.021; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; PHARR GM, 1992, J MATER RES, V7, P613, DOI 10.1557/JMR.1992.0613; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Sanborn B, 2012, J BIOMECH, V45, P434, DOI 10.1016/j.jbiomech.2011.12.017; Sharp AA, 2009, IEEE T BIO-MED ENG, V56, P45, DOI 10.1109/TBME.2008.2003261; Sneddon IN, 1965, INT J ENG SCI, V3, P47, DOI [DOI 10.1016/0020-7225(65)90019-4, 10.1016/0020-7225(65)90019-4]; Willinger R, 1999, CR ACAD SCI II B, V327, P125, DOI 10.1016/S1287-4620(99)80021-0; Zhang M., 2014, J APPL MECH, V81, P9	32	26	26	1	33	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 18	2015	48	12					3213	3218		10.1016/j.jbiomech.2015.06.028			6	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	CT8ME	WOS:000363069900039	26189093	Green Submitted			2022-02-06	
J	Cawsey, T; Duflou, J; Weickert, CS; Gorrie, CA				Cawsey, Thomas; Duflou, Johan; Weickert, Cynthia Shannon; Gorrie, Catherine Anne			Nestin-Positive Ependymal Cells Are Increased in the Human Spinal Cord after Traumatic Central Nervous System Injury	JOURNAL OF NEUROTRAUMA			English	Article						postmortem; neural progenitor cells; GFAP; trauma; tanyctye	BETA-APP IMMUNOHISTOCHEMISTRY; NEURAL PRECURSOR CELLS; CNS STEM-CELLS; ADULT-RAT; STEM/PROGENITOR CELLS; CEREBRAL-CORTEX; GLIAL-CELLS; PROLIFERATION; NEUROGENESIS; DIFFERENTIATION	Endogenous neural progenitor cell niches have been identified in adult mammalian brain and spinal cord. Few studies have examined human spinal cord tissue for a neural progenitor cell response in disease or after injury. Here, we have compared cervical spinal cord sections from 14 individuals who died as a result of nontraumatic causes (controls) with 27 who died from injury with evidence of trauma to the central nervous system. Nestin immunoreactivity was used as a marker of neural progenitor cell response. There were significant increases in the percentage of ependymal cells that were nestin positive between controls and trauma cases. When sections from lumbar and thoracic spinal cord were available, nestin positivity was seen at all three spinal levels, suggesting that nestin reactivity is not simply a localized reaction to injury. There was a positive correlation between the percentage of ependymal cells that were nestin positive and post-injury survival time but not for age, postmortem delay, or glial fibrillary acidic protein (GFAP) immunoreactivity. No double-labelled nestin and GFAP cells were identified in the ependymal, subependymal, or parenchymal regions of the spinal cord. We need to further characterize this subset of ependymal cells to determine their role after injury, whether they are a population of neural progenitor cells with the potential for proliferation, migration, and differentiation for spinal cord repair, or whether they have other roles more in line with hypothalamic tanycytes, which they closely resemble.	[Cawsey, Thomas; Gorrie, Catherine Anne] Univ Technol Sydney, Sch Med & Mol Biosci, Sydney, NSW 2007, Australia; [Duflou, Johan] NSW Hlth Pathol, Dept Forens Med, Sydney, NSW, Australia; [Weickert, Cynthia Shannon] Neurosci Res Australia, Sydney, NSW, Australia; [Weickert, Cynthia Shannon] Schizophrenia Res Inst, Sydney, NSW, Australia; [Weickert, Cynthia Shannon] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia		Gorrie, CA (corresponding author), Univ Technol Sydney, Sch Med & Mol Biosci, POB 123, Sydney, NSW 2007, Australia.	catherine.gorrie@uts.edu.au	Duflou, Johan/AAK-2331-2020; Gorrie, Catherine/S-6591-2019	Duflou, Johan/0000-0001-5863-635X; Shannon Weickert, Cynthia/0000-0002-4560-0259; Gorrie, Catherine/0000-0001-5934-2492	University of Maryland, Baltimore, Maryland [HHSN275200900011C, N01-HD-0-0011]; University of Technology, Sydney; Schizophrenia Research Institute from the NSW Ministry of Health; Schizophrenia Research Institute from the Macquarie Group Foundation; University of New South Wales; Neuroscience Research Australia; National Health and Medical Research Council (Australia)National Health and Medical Research Council of Australia	Ethics approval was granted from Sydney Local Health District Human Research Ethics Committee and University of Technology Human Ethics Committees. Human tissue was obtained from Department of Forensic Medicine Sydney, NSW Health Pathology and the NICHD brain and tissue bank for developmental disorders at the University of Maryland, Baltimore, Maryland, contract HHSN275200900011C Ref. No. N01-HD-0-0011. This study was funded by an early career researcher grant to Dr. Catherine Gorrie from the University of Technology, Sydney. Cynthia Shannon Weickert's work was supported by Schizophrenia Research Institute (utilizing infrastructure funding from the NSW Ministry of Health and the Macquarie Group Foundation), the University of New South Wales, and Neuroscience Research Australia. Cynthia Shannon Weickert is a recipient of a National Health and Medical Research Council (Australia) Senior Research Fellowship.	Alfaro-Cervello C, 2012, J COMP NEUROL, V520, P3528, DOI 10.1002/cne.23104; Barnabe-Heider F, 2010, CELL STEM CELL, V7, P470, DOI 10.1016/j.stem.2010.07.014; Blasko J, 2012, CENT EUR J BIOL, V7, P397, DOI 10.2478/s11535-012-0027-2; BRUNI JE, 1987, J ANAT, V152, P55; BRUNI JE, 1985, BRAIN RES REV, V9, P1, DOI 10.1016/0165-0173(85)90016-5; Bruni JE, 1998, MICROSC RES TECHNIQ, V41, P2, DOI 10.1002/(SICI)1097-0029(19980401)41:1<2::AID-JEMT2>3.3.CO;2-T; Cizkova D, 2009, CELL MOL NEUROBIOL, V29, P999, DOI 10.1007/s10571-009-9387-1; Dromard C, 2008, J NEUROSCI RES, V86, P1916, DOI 10.1002/jnr.21646; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Hamilton LK, 2009, NEUROSCIENCE, V164, P1044, DOI 10.1016/j.neuroscience.2009.09.006; Horner PJ, 2000, J NEUROSCI, V20, P2218; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; JORDAN FL, 1987, DEV BRAIN RES, V35, P97, DOI 10.1016/0165-3806(87)90012-5; Kehl LJ, 1997, SCIENCE, V276, P586, DOI 10.1126/science.276.5312.586; Kojima A, 2000, J NEUROPATH EXP NEUR, V59, P687, DOI 10.1093/jnen/59.8.687; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Moreno-Manzano V, 2009, STEM CELLS, V27, P733, DOI 10.1002/stem.24; Mothe AJ, 2005, NEUROSCIENCE, V131, P177, DOI 10.1016/j.neuroscience.2004.10.011; Mothe AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027079; Nakayama D, 2010, EUR J NEUROSCI, V31, P90, DOI 10.1111/j.1460-9568.2009.07043.x; Namiki J, 1999, J NEUROPATH EXP NEUR, V58, P489, DOI 10.1097/00005072-199905000-00008; RAFOLS JA, 1985, ANAT REC, V211, P75, DOI 10.1002/ar.1092110112; Rodriguez EM, 2005, INT REV CYTOL, V247, P89, DOI 10.1016/S0074-7696(05)47003-5; Sakakibara A, 2007, PATHOL INT, V57, P358, DOI 10.1111/j.1440-1827.2007.02108.x; Snethen H, 2008, REGEN MED, V3, P835, DOI 10.2217/17460751.3.6.835; Takahashi M, 2003, J NEUROPATH EXP NEUR, V62, P185, DOI 10.1093/jnen/62.2.185; Takano T, 1997, NEUROPATH APPL NEURO, V23, P3, DOI 10.1046/j.1365-2990.1997.7898078.x; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Tzeng SF, 2002, J BIOMED SCI, V9, P10, DOI 10.1159/000048194; Weiss S, 1996, J NEUROSCI, V16, P7599; Xu RS, 2008, INT J DEV NEUROSCI, V26, P813, DOI 10.1016/j.ijdevneu.2008.06.002; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176	38	26	29	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 15	2015	32	18					1393	1402		10.1089/neu.2014.3575			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CQ8AR	WOS:000360828900002	25599268	Green Published			2022-02-06	
J	Cox, A; Varma, A; Barry, J; Vertegel, A; Banik, N				Cox, April; Varma, Abhay; Barry, John; Vertegel, Alexey; Banik, Naren			Nanoparticle Estrogen in Rat Spinal Cord Injury Elicits Rapid Anti-Inflammatory Effects in Plasma, Cerebrospinal Fluid, and Tissue	JOURNAL OF NEUROTRAUMA			English	Article						spinal cord injury; MCP-1; IL-6; GRO-KC; S100 beta; nanoparticle; estrogen; CSF	TRAUMATIC BRAIN-INJURY; INFLAMMATORY CYTOKINES; CLINICAL-TRIALS; POSTMENOPAUSAL WOMEN; FUNCTIONAL RECOVERY; LOCOMOTOR FUNCTION; SEX STEROIDS; CELL-DEATH; 17-BETA-ESTRADIOL; NEUROPROTECTION	Persons with spinal cord injury (SCI) are in need of effective therapeutics. Estrogen (E2), as a steroid hormone, is a highly pleiotropic agent; with anti-inflammatory, anti-apoptotic, and neurotrophic properties, it is ideal for use in treatment of patients with SCI. Safety concerns around the use of high doses of E2 have limited clinical application, however. To address these concerns, low doses of E2 (25 mu g and 2.5 mu g) were focally delivered to the injured spinal cord using nanoparticles. A per-acute model (6 h after injury) was used to assess nanoparticle release of E2 into damaged spinal cord tissue; in addition, E2 was evaluated as a rapid anti-inflammatory. To assess inflammation, 27-plex cytokine/chemokine arrays were conducted in plasma, cerebrospinal fluid (CSF), and spinal cord tissue. A particular focus was placed on IL-6, GRO-KC, and MCP-1 as these have been identified from CSF in human studies as potential biomarkers in SCI. S100 beta, an additional proposed biomarker, was also assessed in spinal cord tissue only. Tissue concentrations of E2 were double those found in the plasma, indicating focal release. E2 showed rapid anti-inflammatory effects, significantly reducing interleukin (IL)-6, GRO-KC, MCP-1, and S100 beta in one or all compartments. Numerous additional targets of rapid E2 modulation were identified including: leptin, MIP-1 alpha, IL-4, IL-2, IL-10, IFN gamma, tumor necrosis factor-alpha, etc. These data further elucidate the rapid anti-inflammatory effects E2 exerts in an acute rat SCI model, have identified additional targets of estrogen efficacy, and suggest nanoparticle delivered estrogen may provide a safe and efficacious treatment option in persons with acute SCI.	[Cox, April; Varma, Abhay; Banik, Naren] Med Univ S Carolina, Dept Neurol & Neurosurg, Charleston, SC 29425 USA; [Barry, John; Vertegel, Alexey] Clemson Univ, Dept Bioengn, Clemson, SC USA; [Banik, Naren] Ralph H Johnson VA Med Ctr, Charleston, SC USA		Cox, A (corresponding author), Med Univ S Carolina, Dept Neurosci, 96 Jonathan Lucas St,MSC 606, Charleston, SC 29412 USA.	coxaa@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS-RO1 NS-31622, NS-45967]; Office of Research and Development, Medical Research Service, Department of Veterans Affairs, at Ralph H. Johnson VA Medical Center, Charleston, SC, the Department of Neurosurgery, MUSC [1IOBX001262]; South Carolina Spinal Cord Injury Research Fund; National Institutes of Health from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045967, R01NS031622] Funding Source: NIH RePORTER	The funding for this project was provided in part by NIH, NINDS-RO1 NS-31622 and NS-45967; also by 1IOBX001262 from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, at Ralph H. Johnson VA Medical Center, Charleston, SC, the Department of Neurosurgery, MUSC, and South Carolina Spinal Cord Injury Research Fund. This work was conducted in a facility constructed with support from the National Institutes of Health, Grant Number C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We would like to acknowledge Dr. Supriti Samantaray and Nakul Thakore for help in organizing this article.	Ardelt AA, 2012, BRAIN RES, V1461, P76, DOI 10.1016/j.brainres.2012.04.024; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Bank M, 2015, ARCH PHYS MED REHAB, V96, P633, DOI 10.1016/j.apmr.2014.10.021; Bao F, 2011, J NEUROTRAUM, V28, P1035, DOI 10.1089/neu.2010.1575; Bracken MB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001046.pub2; Breslin K, 2012, PEDIATR EMERG CARE, V28, P1238, DOI 10.1097/PEC.0b013e3182724434; Cao F, 2008, J CLIN NEUROSCI, V15, P541, DOI 10.1016/j.jocn.2007.05.014; Cox A, 2015, METAB BRAIN DIS, V30, P473, DOI 10.1007/s11011-014-9547-y; Cuzzocrea S, 2008, SHOCK, V29, P362, DOI 10.1097/shk.0b013e31814545dc; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Eifler AC, 2011, METHODS MOL BIOL, V726, P325, DOI 10.1007/978-1-61779-052-2_21; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Evsen MS, 2013, EUR REV MED PHARMACO, V17, P1869; Fehlings MG, 2005, INJURY, V36, P113, DOI 10.1016/j.injury.2005.06.022; Gatson JW, 2012, J NEUROTRAUM, V29, P2209, DOI 10.1089/neu.2011.2274; Hall ED, 2003, J REHABIL RES DEV, V40, P81, DOI 10.1682/JRRD.2003.08.0081; Perez-Alvarez MJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-157; Kachadroka S, 2010, J NEUROTRAUM, V27, P611, DOI 10.1089/neu.2009.1069; Kipp M, 2012, J NEUROENDOCRINOL, V24, P62, DOI 10.1111/j.1365-2826.2011.02163.x; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kumar S, 2010, BBA-GEN SUBJECTS, V1800, P1127, DOI 10.1016/j.bbagen.2010.04.011; Kwon BK, 2010, SPINE, V35, pS263, DOI 10.1097/BRS.0b013e3181f3286d; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Lammertse DP, 2013, SPINAL CORD, V51, P2, DOI 10.1038/sc.2012.137; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Lee JY, 2012, ENDOCRINOLOGY, V153, P3815, DOI 10.1210/en.2012-1068; Lee YL, 2000, NEUROCHEM INT, V36, P417, DOI 10.1016/S0197-0186(99)00133-3; Lidegaard O, 2002, CONTRACEPTION, V65, P187, DOI 10.1016/S0010-7824(01)00307-9; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2; Ma JJ, 2001, SCAND J PLAST RECONS, V35, P355; Maximov VD, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/26/265103; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Merchenthaler I, 2003, ANN NY ACAD SCI, V1007, P89, DOI 10.1196/annals.1286.009; Mosquera L, 2014, BRAIN RES, V1561, P11, DOI 10.1016/j.brainres.2014.03.002; Neirinckx V, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0150-2; Perot P.L., 1987, J AM PARALYSIS ASS, V4, P149, DOI DOI 10.1089/cns.1987.4.149; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Ritz MF, 2008, BRAIN RES, V1203, P177, DOI 10.1016/j.brainres.2008.01.091; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Saddick SY, 2014, SAUDI J BIOL SCI, V21, P232, DOI 10.1016/j.sjbs.2014.02.004; Samantaray S, 2013, NEUROCHEM RES, V38, P1734, DOI 10.1007/s11064-013-1077-1; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Satishkumar R, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/50/505103; Schroeder GD, 2014, SPINE, V39, P971, DOI 10.1097/BRS.0000000000000297; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Spence RD, 2013, J NEUROSCI, V33, P10924, DOI 10.1523/JNEUROSCI.0886-13.2013; Sribnick EA, 2004, NEUROCHEM RES, V29, P2007, DOI 10.1007/s11064-004-6874-0; Sribnick EA, 2010, J NEUROSCI RES, V88, P1738, DOI 10.1002/jnr.22337; Sribnick EA, 2009, BRAIN RES, V1276, P159, DOI 10.1016/j.brainres.2009.04.022; Stammers AT, 2012, J NEUROSCI RES, V90, P782, DOI 10.1002/jnr.22820; Strom JO, 2008, SCAND J CLIN LAB INV, V68, P806, DOI 10.1080/00365510802254638; Taylor AR, 2014, J NEUROTRAUM, V31, P1561, DOI 10.1089/neu.2014.3405; Tsai EC, 2005, CURR PHARM DESIGN, V11, P1211, DOI 10.2174/1381612053507404; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zlotnik A, 2012, INTENS CARE MED, V38, P137, DOI 10.1007/s00134-011-2401-3	67	26	27	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 15	2015	32	18					1413	1421		10.1089/neu.2014.3730			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CQ8AR	WOS:000360828900004	25845398	Green Published			2022-02-06	
J	Beynon, C; Potzy, A; Sakowitz, OW; Unterberg, AW				Beynon, Christopher; Potzy, Anna; Sakowitz, Oliver W.; Unterberg, Andreas W.			Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: A dangerous combination?	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Anticoagulants; Factor Xa inhibitors; Haemostasis; Intracerebral haemorrhage; Head injury	PROTHROMBIN COMPLEX CONCENTRATE; DABIGATRAN; MANAGEMENT; REVERSAL; ANTICOAGULANTS; PATIENT; COMPLICATIONS; EVENTS	Objectives: Despite several advantages of the novel anticoagulant rivaroxaban compared with vitamin K antagonists (VKA), its lack of specific antidotes to reverse anticoagulant effects may increase the risk profile of patients with bleeding complications. The purpose of this study was to analyze the effects of pre-injury treatment with rivaroxaban on patients with mild traumatic brain injury (TBI) and traumatic intracranial haemorrhage (tICH). Methods: A total of 70 patients with tICH after mild TBI were included in this retrospective analysis and were categorized into three groups: group A (no antithrombotics n = 37), group B (antiplatelet medication n = 22, VKA = 5), and group C (rivaroxaban n = 6). Medical charts were reviewed for baseline characteristics, laboratory values, intracranial haemorrhage, repeated computed tomography (CT) scans, re-haemorrhage, Glasgow Coma Scale (GCS) scores and in-hospital mortality. Results: No significant differences were observed for baseline characteristics. The rate of re-haemorrhage was significantly higher in group C (50%) than in group A (11%) (p < 0.05). Two patients died and both had been treated with rivaroxaban which resulted in a significantly higher mortality rate of 33% in group C compared with groups A (0%) and B (0%). No significant differences were observed for GCS at discharge and length of hospital stay between survivors of groups A-C. Conclusions: Despite major limitations of retrospective design and small patient numbers, our results suggest that rivaroxaban may exacerbate intracranial haemorrhage in patients with mild TBI. Further studies are needed to characterize the risk profile of this drug in patients with tICH. (C) 2015 Elsevier B.V. All rights reserved.	[Beynon, Christopher; Potzy, Anna; Sakowitz, Oliver W.; Unterberg, Andreas W.] Univ Heidelberg Hosp, Dept Neurosurg, D-69120 Heidelberg, Germany		Beynon, C (corresponding author), Univ Heidelberg Hosp, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	christopher.beynon@med.uni-heidelberg.de		Sakowitz, Oliver/0000-0003-3248-6335	CSL Behring	C.B. has received speaker honoraria from CSL Behring and Advisory Board fees from Boehringer Ingelheim. O.W.S. has received speaker honoraria from CSL Behring.	Akwaa Frank, 2013, Curr Treat Options Cardiovasc Med, V15, P288, DOI 10.1007/s11936-013-0238-5; Berger R, 2013, ANN EMERG MED, V61, P475, DOI 10.1016/j.annemergmed.2013.02.008; Beyer-Westendorf J, 2014, BLOOD, V124, P955, DOI 10.1182/blood-2014-03-563577; Bowry R, 2014, STROKE, V45, P880, DOI 10.1161/STROKEAHA.113.004016; Edavettal M, 2014, AM SURGEON, V80, P372; Fawole A, 2013, CLEV CLIN J MED, V80, P443, DOI 10.3949/ccjm.80a.13025; Garber ST, 2012, J NEUROSURG, V116, P1093, DOI 10.3171/2012.2.JNS112132; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kalina M, 2008, AM SURGEON, V74, P858; Karni A, 2001, AM SURGEON, V67, P1098; Lee FMH, 2014, THROMB RES, V133, P705, DOI 10.1016/j.thromres.2014.01.031; Lu GM, 2013, NAT MED, V19, P446, DOI 10.1038/nm.3102; Marlu R, 2012, THROMB HAEMOSTASIS, V108, P217, DOI 10.1160/TH12-03-0179; Maurice-Szamburski A, 2014, J NEUROSURG ANESTH, V26, P183, DOI 10.1097/ANA.0000000000000030; Mega JL, 2013, J AM COLL CARDIOL, V61, P1853, DOI 10.1016/j.jacc.2013.01.066; Melnikova I, 2009, NAT REV DRUG DISCOV, V8, P353, DOI 10.1038/nrd2851; Molina M, 2014, HEMATOL REP, V6, P14, DOI 10.4081/hr.2014.5283; Parra MW, 2013, J NEUROSURG, V119, P760, DOI 10.3171/2013.3.JNS12503; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Pfeilschifter W, 2013, CEREBROVASC DIS, V36, P115, DOI 10.1159/000352062; Piccini JP, 2014, EUR HEART J, V35, P1873, DOI 10.1093/eurheartj/ehu083; Purrucker JC, 2014, AM J EMERG MED, V32, DOI 10.1016/j.ajem.2014.01.042; Samama MM, 2013, THROMB J, V11, DOI 10.1186/1477-9560-11-11; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Stangier J, 2010, CLIN PHARMACOKINET, V49, P259, DOI 10.2165/11318170-000000000-00000; Wassef SN, 2013, NEUROSURGERY, V73, pE368, DOI 10.1227/01.neu.0000430763.95349.5f; Woo CH, 2014, WORLD NEUROSURG, V81, P110, DOI 10.1016/j.wneu.2012.12.002	27	26	26	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	SEP	2015	136						73	78		10.1016/j.clineuro.2015.05.035			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CP4XV	WOS:000359886800015	26070116				2022-02-06	
J	Honeybul, S; Ho, KM; Gillett, G				Honeybul, Stephen; Ho, Kwok Ming; Gillett, Grant			Outcome Following Decompressive Hemicraniectomy for Malignant Cerebral Infarction Ethical Considerations	STROKE			English	Article						brain; decompressive craniectomy; ethics; outcome; stroke	CRANIECTOMY; ARTERY; NEUROTRAUMA		[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6000, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok Ming] Univ Western Australia, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok Ming] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Gillett, Grant] Dunedin Publ Hosp, Div Hlth Sci, Dunedin, New Zealand; [Gillett, Grant] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Hosp Ave, Perth, WA 6000, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Back L, 2015, INTERN MED J, V45, P711, DOI 10.1111/imj.12724; Cooper P R, 1976, Surg Neurol, V5, P25; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; Dworkin R., 1993, DWORKIN R LIFES DOMI, P218; Frank JI, 2014, STROKE, V45, P781, DOI 10.1161/STROKEAHA.113.003200; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2011, J MED ETHICS, V37, P707, DOI 10.1136/medethics-2011-100081; Honeybul S, 2013, NEUROSURGERY, V73, P917, DOI 10.1227/NEU.0000000000000014; Honeybul S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032375; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367; Larach DR, 2009, NEUROCRIT CARE, V11, P106, DOI 10.1007/s12028-008-9180-x; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Puetz V, 2007, LANCET NEUROL, V6, P580, DOI 10.1016/S1474-4422(07)70160-6; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yang MH, 2015, SURG-J R COLL SURG E, V13, P230, DOI 10.1016/j.surge.2014.12.002	27	26	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	SEP	2015	46	9					2695	2698		10.1161/STROKEAHA.115.010078			4	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	CQ9FZ	WOS:000360919700060	26243228	Bronze			2022-02-06	
J	Khaksari, M; Abbasloo, E; Dehghan, F; Soltani, Z; Asadikaram, G				Khaksari, Mohammad; Abbasloo, Elham; Dehghan, Fatemeh; Soltani, Zahra; Asadikaram, Gholamreza			The brain cytokine levels are modulated by estrogen following traumatic brain injury: Which estrogen receptor serves as modulator?	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Article						Estrogen receptors; ICI182 780; Brain cytokines; Traumatic brain injury; Edema	INFLAMMATORY RESPONSE; MEDIATED ATTENUATION; PURE ANTIESTROGEN; STEROID-HORMONES; IMMUNE-RESPONSE; EDEMA FORMATION; ANIMAL-MODELS; YOUNG-ADULT; ICI 182,780; MICROGLIA	The present study was designed to explore whether administration of estrogen affects brain cytokine levels in TBI. We also sought determine which one of type of classical estrogen receptors (ERs) is involved. Ovariectomized female rats were divided in to eight groups. Estrogen or vehicle was administered following TBI (E2 and oil groups). Antagonist of ER(ICI 182, 780) or vehicle was also administered following TBI (ICI and DMSO groups). The ICI or vehicle was administered either before induction of TBI and administration of estrogen (ICI+E2 and DMSO+E2 groups). TBI was induced by Marmarou's method. In addition to brain water content, the levels of brain proinflammatory and anti-inflammatory cytokines were measured 24 hours post-TBI. Present results demonstrated that, estrogen reduced TBI- induced brain edema. The antiedema effect of estrogen was attenuated by ICI. The brain measures of IL-1 beta, IL-6 and TNF-alpha in TBI were also reduced by estrogen. The anti-inflammatory effect of estrogen was attenuated by ICI. The inhibition level of estrogen by ICI was 53.2%, 12.09% and 48.45% for IL-1 beta, IL-6 and INF-alpha, respectively. Estrogen also elevated IL-10 in TBI. ICI inversely controlled the effect of estrogen on IL-10, by 33.84%. This effect was not observed once ICI was used alone. The estrogen administration following TBI probably results in proinflammatoty cytokines reduction, and inversely enhancement of anti-inflammatory cytokines. In our study, the neuroprotective effect of estrogen is proposed to be mediated by both BR alpha and ER alpha, and accordingly the inhibition of neuroprotective effect of estrogen by ICI. (C) 2015 Elsevier B.V. All rights reserved.	[Khaksari, Mohammad] Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran; [Abbasloo, Elham; Dehghan, Fatemeh] Kerman Univ Med Sci, Inst Neuropharmacol, Physiol Res Ctr, Kerman, Iran; [Soltani, Zahra] Kerman Univ Med Sci, Inst Basic & Clin Physiol Sci, Endocrinol & Metab Res Ctr, Kerman, Iran; [Asadikaram, Gholamreza] Kerman Univ Med Sci, Med Sch Afzalipour, Dept Biochem, Kerman, Iran		Khaksari, M (corresponding author), Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran.		Asadikaram, Gholamreza/AAG-4437-2021; Haddad, Mohammad Khaksari/AAB-9025-2019; Soltani, Zahra/AAC-1350-2019	Asadikaram, Gholamreza/0000-0002-9100-0756; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Soltani, Zahra/0000-0002-8423-6189; Asadi karam, Gholamreza/0000-0002-6417-5200	Neuroscience research center of Kerman University of Medical Sciences	We thanked Dr. Mahmoudi of the Department of Biochemistry, Medical School of Afzalipour, Kerman University of Medical Sciences, and Kerman, Iran for providing language. The present study was financially supported by Neuroscience research center of Kerman University of Medical Sciences. We thanked the manager of this center, Prof. Shaibani.	Abdul-Muneer P., 2014, MOL NEUROBIOL, P1; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Cao L, 2007, J NEUROCHEM, V102, P408, DOI 10.1111/j.1471-4159.2007.04588.x; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Castro CC, 2014, NEUROL RES, V36, P198, DOI 10.1179/1743132813Y.0000000286; Cotran R.S., 2003, BASIC PATHOLOGY, P47; Cotroneo MS, 2005, FOOD CHEM TOXICOL, V43, P637, DOI 10.1016/j.fct.2004.12.022; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Di Liberto V, 2012, NEUROPHARMACOLOGY, V62, P1011, DOI 10.1016/j.neuropharm.2011.10.010; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; DUKES M, 1992, J ENDOCRINOL, V135, P239, DOI 10.1677/joe.0.1350239; Ferreira L.C.B., 2014, BRAIN INJURY, P1; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gonzales RJ, 2007, J CEREBR BLOOD F MET, V27, P1841, DOI 10.1038/sj.jcbfm.9600483; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Haour F., 1992, BRAIN INTERLEUKIN 1, P13; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Howell A, 2000, CANCER, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Hsu JT, 2007, J LEUKOCYTE BIOL, V82, P1019, DOI 10.1189/jlb.0607355; Hu R, 2012, CRIT CARE MED, V40, P3230, DOI 10.1097/CCM.0b013e3182657560; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Kawasaki T, 2008, MOL IMMUNOL, V45, P376, DOI 10.1016/j.molimm.2007.06.148; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; Kimura T, 2003, INT IMMUNOPHARMACOL, V3, P1519, DOI 10.1016/S1567-5769(03)00179-6; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Lewis DK, 2008, J NEUROIMMUNOL, V195, P47, DOI 10.1016/j.jneuroim.2008.01.006; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luchetti S, 2014, J NEUROPATH EXP NEUR, V73, P123, DOI 10.1097/NEN.0000000000000037; Miller AP, 2004, CIRCULATION, V110, P1664, DOI 10.1161/01.CIR.0000142050.19488.C7; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nebel D., 2012, FUNCTIONAL IMPORTANC; Nordell VL, 2003, NEUROBIOL AGING, V24, P733, DOI 10.1016/S0197-4580(02)00193-8; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002; Raz L, 2008, NEUROSIGNALS, V16, P140, DOI 10.1159/000111559; Rivera HM, 2010, ENDOCRINOLOGY, V151, P5680, DOI 10.1210/en.2010-0731; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Santos-Galindo M., 2011, BIOL SEX DIFFER, V2; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039-128X(98)00054-3; Suuronen T, 2005, INFLAMM RES, V54, P194, DOI 10.1007/s00011-005-1343-z; Vegeto E, 2006, ENDOCRINOLOGY, V147, P2263, DOI 10.1210/en.2005-1330; WAKELING AE, 1991, CANCER RES, V51, P3867; WAKELING AE, 1995, BIOCHEM PHARMACOL, V49, P1545, DOI 10.1016/0006-2952(94)00528-T; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xing DQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036890; Yang LS, 2006, MOL IMMUNOL, V43, P357, DOI 10.1016/j.molimm.2005.02.012; Yu HP, 2012, CHINESE J PHYSIOL, V55, P229, DOI 10.4077/CJP.2012.BAA023; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zweckberger K, 2011, NEUROSCI LETT, V499, P189, DOI 10.1016/j.neulet.2011.05.059	65	26	26	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-5769	1878-1705		INT IMMUNOPHARMACOL	Int. Immunopharmacol.	SEP	2015	28	1					279	287		10.1016/j.intimp.2015.05.046			9	Immunology; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Pharmacology & Pharmacy	CR5VW	WOS:000361413500036	26112336	Green Accepted			2022-02-06	
J	Mirabelli, MH; Devine, MJ; Singh, J; Mendoza, M				Mirabelli, Mark H.; Devine, Mathew J.; Singh, Jaskaran; Mendoza, Michael			The Preparticipation Sports Evaluation	AMERICAN FAMILY PHYSICIAN			English	Article							HEART-ASSOCIATION COUNCIL; CONSENSUS STATEMENT; ELECTROCARDIOGRAPHIC INTERPRETATION; INTERNATIONAL-CONFERENCE; SCIENTIFIC STATEMENT; PHYSICAL-ACTIVITY; AMERICAN-COLLEGE; ATHLETE; PARTICIPATION; DEATH	The preparticipation physical evaluation is a commonly requested medical visit for amateur and professional athletes of all ages. The overarching goal is to maximize the health of athletes and their safe participation in sports. Although studies have not found that the preparticipation physical evaluation prevents morbidity and mortality associated with sports, it may detect conditions that predispose the athlete to injury or illness and can provide strategies to prevent injuries. Clearance depends on the outcome of the evaluation and the type of sport (and sometimes position or event) in which the athlete participates. All persons undergoing a preparticipation physical evaluation should be questioned about exertional symptoms, presence Of a heart murmur, symptoms of Marfan syndrome, and family history of premature serious cardiac conditions or sudden death. The physical examination should focus on the cardiovascular and musculoskeletal systems. U.S. medical and athletic organizations discourage screening electrocardiography and blood and urine testing in asymptomatic patients. Further evaluation should be considered for persons with heart or lung disease, bleeding disorders, musculoskeletal problems, history of concussion, or other neurologic disorders. Copyright (C) 2015 American Academy of Family Physicians.	[Mirabelli, Mark H.] Univ Rochester, Med Ctr, Dept Orthoped, Rochester, NY 14642 USA; [Mirabelli, Mark H.; Devine, Mathew J.; Singh, Jaskaran; Mendoza, Michael] Univ Rochester, Med Ctr, Dept Family Med, Rochester, NY 14642 USA; [Mirabelli, Mark H.] Univ Rochester, Med Ctr, Dept Phys Med & Rehabil, Rochester, NY 14642 USA		Mirabelli, MH (corresponding author), Univ Rochester, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.	mark_mirabelli@urmc.rochester.edu		Mendoza, Michael/0000-0002-7809-6087			Bernhardt DT, 2010, PPE PREPARTICIPATION; Bille K, 2006, EUR J CARDIOV PREV R, V13, P859, DOI 10.1097/01.hjr.0000238397.50341.4a; Canadian Hemophilia Society, PASSP WELL BEING EMP; Carek PJ, 1999, ARCH FAM MED, V8, P307, DOI 10.1001/archfami.8.4.307; Chaitman BR, 2007, CIRCULATION, V116, P2610, DOI 10.1161/CIRCULATIONAHA.107.711465; Clem KL, 2007, CLIN SPORT MED, V26, P413, DOI 10.1016/j.csm.2007.04.012; Corrado D, 2006, JAMA-J AM MED ASSOC, V296, P1593, DOI 10.1001/jama.296.13.1593; De Souza MJ, 2014, CLIN J SPORT MED, V24, P96, DOI 10.1097/JSM.0000000000000085; Diokno E, 2010, PEDIATR CLIN N AM, V57, P839, DOI 10.1016/j.pcl.2010.03.005; Drezner JA, 2013, BRIT J SPORT MED, V47, P122, DOI 10.1136/bjsports-2012-092067; Fudge J, 2014, BRIT J SPORT MED, V48, P1172, DOI 10.1136/bjsports-2014-093840; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Harmon KG, 2012, BRIT J SPORT MED, V46, P325, DOI 10.1136/bjsports-2011-090896; Harris KM, 2006, ANN INTERN MED, V145, P507, DOI 10.7326/0003-4819-145-7-200610030-00008; Hong G, 2005, CLIN REV ALLERG IMMU, V29, P97, DOI 10.1385/CRIAI:29:2:097; Howard Gregory M, 2004, Curr Sports Med Rep, V3, P15; Klossner D, 2013 14 NCAA SPORTS; Kurowski K, 2000, AM FAM PHYSICIAN, V61, P2683; Ljungqvist A, 2009, BRIT J SPORT MED, V43, P631, DOI 10.1136/bjsm.2009.064394; Lombardo J A, 2001, Clin Cornerstone, V3, P10, DOI 10.1016/S1098-3597(01)90066-3; Maron BJ, 2007, CIRCULATION, V115, P1643, DOI 10.1161/CIRCULATIONAHA.107.181423; Maron BJ, 2014, J AM COLL CARDIOL, V64, P1479, DOI 10.1016/j.jacc.2014.05.006; Maron BJ, 2005, J AM COLL CARDIOL, V45, P1318, DOI 10.1016/j.jacc.2005.02.006; Mayer F, 2012, BRIT J SPORT MED, V46, P524, DOI 10.1136/bjsports-2011-090966; McCambridge Teri M, 2010, Pediatrics, V125, P1287, DOI 10.1542/peds.2010-0658; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Mercer KW, 2005, CLIN SPORT MED, V24, P599, DOI 10.1016/j.csm.2005.03.006; Mick TM, 2004, CLEV CLIN J MED, V71, P587, DOI 10.3949/ccjm.71.7.587; Mitchell JH, 2005, J AM COLL CARDIOL, V45, P1364, DOI 10.1016/j.jacc.2005.02.015; Myerburg RJ, 2007, CIRCULATION, V116, P2616, DOI 10.1161/CIRCULATIONAHA.107.733519; National Hemophilia Foundation, PLAYING IT SAF BLEED; Patel DR, 2010, PEDIATR CLIN N AM, V57, P795, DOI 10.1016/j.pcl.2010.03.002; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Riding NR, 2015, HEART, V101, P384, DOI 10.1136/heartjnl-2014-306437; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Sharma S, 2015, JAMA INTERN MED, V175, P125, DOI 10.1001/jamainternmed.2014.6023; Thompson PD, 2007, CIRCULATION, V115, P2358, DOI 10.1161/CIRCULATIONAHA.107.181485	38	26	26	0	11	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X	1532-0650		AM FAM PHYSICIAN	Am. Fam. Physician	SEP 1	2015	92	5					371	376					6	Primary Health Care; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ7KM	WOS:000360783000008	26371570				2022-02-06	
J	Saika, A; Bansal, S; Philip, M; Devi, BI; Shukla, DP				Saika, Amrit; Bansal, Sonia; Philip, Mariamma; Devi, Bhagavatula Indira; Shukla, Dhaval P.			Prognostic value of FOUR and GCS scores in determining mortality in patients with traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Full Outline Of Unresponsiveness (FOUR) score; Glasgow Coma Scale (GCS); Coma	GLASGOW COMA SCALE; IMPAIRED CONSCIOUSNESS; VALIDATION	Background The Glasgow Coma Scale (GCS) is considered the gold standard for assessment of unconsciousness in patients with traumatic brain injury (TBI) against which other scales are compared. To overcome the disadvantages of GCS, the Full Outline Of Unresponsiveness (FOUR) score was proposed. We aimed to compare the predictability of FOUR score and GCS for early mortality, after moderate and severe TBI. Methods This is a prospective observational study of patients with moderate and severe TBI. Both FOUR and GCS scores were determined at admission. The primary outcome was mortality at the end of 2 weeks of injury. Results A total of 138 (117 males) patients were included in the study. Out of these, 17 (12.3 %) patients died within 2 weeks of injury. The mean GCS and FOUR scores were 9.5 (range, 3-13) and 11 (0-16), respectively. The total GCS and FOUR scores were significantly lower in patients who did not survive. At a cut-off score of 7 for FOUR score, the AUC was 0.97, with sensitivity of 97.5 and specificity of 88.2 % (p<0.0001). For GCS score, AUC was 0.95, with sensitivity of 98.3 % and specificity of 82.4 % with cut-off score of 6 (p<0.0001). The correlation coefficient was 0.753 (p<0.001) between the GCS and FOUR scores. Conclusions The predictive value of the FOUR score on admission of patients with TBI is no better than the GCS score.	[Saika, Amrit; Devi, Bhagavatula Indira; Shukla, Dhaval P.] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore 560029, Karnataka, India; [Bansal, Sonia] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuroanesthesiol & Neurocrit Care, Bangalore 560029, Karnataka, India; [Philip, Mariamma] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Biostat, Bangalore 560029, Karnataka, India		Shukla, DP (corresponding author), Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore 560029, Karnataka, India.	neurodhaval@rediffmail.com	Philip, Mariamma/AAR-4349-2020	Philip, Mariamma/0000-0001-6047-1494			BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; BHATTY GB, 1993, ACTA NEUROCHIR, V120, P132, DOI 10.1007/BF02112031; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Chen BX, 2013, ACTA NEUROCHIR, V155, P2133, DOI 10.1007/s00701-013-1854-2; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Jalali R, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/289803; McNett M, 2014, NEUROCRIT CARE, V21, P52, DOI 10.1007/s12028-013-9947-6; Okasha AS, 2014, NEUROCRIT CARE, V21, P496, DOI 10.1007/s12028-014-9995-6; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Poon WS, 2005, ACT NEUR S, V93, P207; Sadaka F, 2012, NEUROCRIT CARE, V16, P95, DOI 10.1007/s12028-011-9617-5; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Stead LG, 2009, NEUROCRIT CARE, V10, P50, DOI 10.1007/s12028-008-9145-0; TEASDALE G, 1974, LANCET, V2, P81; Widjicks EF, 2015, CRIT CARE MED, V43, P439; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	17	26	28	0	8	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2015	157	8					1323	1328		10.1007/s00701-015-2469-6			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CM9JR	WOS:000358025200008	26077394				2022-02-06	
J	Weersink, CSA; Aries, MJH; Dias, C; Liu, MX; Kolias, AG; Donnelly, J; Czosnyka, M; van Dijk, JMC; Regtien, J; Menon, DK; Hutchinson, PJ; Smielewski, P				Weersink, Corien S. A.; Aries, Marcel J. H.; Dias, Celeste; Liu, Mary X.; Kolias, Angelos G.; Donnelly, Joseph; Czosnyka, Marek; van Dijk, J. Marc C.; Regtien, Joost; Menon, David K.; Hutchinson, Peter J.; Smielewski, Peter			Clinical and Physiological Events That Contribute to the Success Rate of Finding "Optimal" Cerebral Perfusion Pressure in Severe Brain Trauma Patients	CRITICAL CARE MEDICINE			English	Article						cerebral autoregulation; optimal cerebral perfusion pressure; pressure reactivity index; therapy; traumatic brain injury	INTRACRANIAL-PRESSURE; DECOMPRESSIVE CRANIECTOMY; VASCULAR REACTIVITY; WAVE-FORM; AUTOREGULATION; NOREPINEPHRINE; HYPERTENSION; OXYGENATION; PROPOFOL	Objective: Recently, a concept of an individually targeted level of cerebral perfusion pressure that aims to restore impaired cerebral vasoreactivity has been advocated after traumatic brain injury. The relationship between cerebral perfusion pressure and pressure reactivity index normally is supposed to have a U-shape with its minimum interpreted as the value of "optimal" cerebral perfusion pressure. The aim of this study is to investigate the relation between the absence of the optimal cerebral perfusion pressure curve and physiological variables, clinical factors, and interventions. Design: Retrospective analysis of prospectively collected data. Setting: Neurocritical care units in two university centers. Patients: Between May 2012 and December 2013, a total of 48 traumatic brain injury patients were studied with real-time annotation of predefined clinical events. Interventions: None. Measurements and Main Results: All patients had continuous monitoring of arterial blood pressure, intracranial pressure, and cerebral perfusion pressure, with real-time calculations of pressure reactivity index and optimal cerebral perfusion pressure using ICM+ software (Cambridge Enterprise, University of Cambridge, Cambridge, UK). Selected clinical events were inserted on a daily basis, including changes in physiological variables, sedativeanalgesic drugs, vasoactive drugs, and medical/surgical therapies for intracranial hypertension. The collected data were divided into 4-hour periods, with the primary outcome being absence of the optimal cerebral perfusion pressure curve. For every period, mean values (+/- sds) of arterial blood pressure, intracranial pressure, pressure reactivity index, and other physiological variables were calculated; clinical events were organized using predefined scales. In 28% of all 1,561 periods, an optimal cerebral perfusion pressure curve was absent. A generalized linear mixed model with binary logistic regression was fitted. Absence of slow arterial blood pressure waves (odds ratio, 2.7; p < 0.001), higher pressure reactivity index values (odds ratio, 2.9; p < 0.001), lower amount of sedative-analgesic drugs (odds ratio, 1.9; p = 0.03), higher vasoactive medication dose (odds ratio, 3.2; p = 0.02), no administration of maintenance neuromuscular blockers (odds ratio, 1.7; p < 0.01), and following decompressive craniectomy (odds ratio, 1.8; p < 0.01) were independently associated with optimal cerebral perfusion pressure curve absence. Conclusions: This study identified six factors that were independently associated with absence of optimal cerebral perfusion pressure curves.	[Weersink, Corien S. A.; Aries, Marcel J. H.; Liu, Mary X.; Kolias, Angelos G.; Donnelly, Joseph; Czosnyka, Marek; Menon, David K.; Hutchinson, Peter J.; Smielewski, Peter] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Weersink, Corien S. A.; van Dijk, J. Marc C.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosurg, Groningen, Netherlands; [Aries, Marcel J. H.; Regtien, Joost] Univ Groningen, Univ Med Ctr Groningen, Dept Crit Care, Groningen, Netherlands; [Dias, Celeste] Hosp Sao Joao, Neurocrit Care Unit, Dept Intens Care, Oporto, Portugal		Aries, MJH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England.	m.j.h.aries@umcg.nl	van Dijk, J. Marc C./C-1078-2013; Donnelly, Joseph/E-9235-2018; Dias, Celeste/AAD-8711-2019; Donnelly, Joseph/N-6803-2019; Dias, Celeste/AAV-3820-2020	van Dijk, J. Marc C./0000-0002-0814-5680; Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Dias, Celeste/0000-0003-0340-9808; Hutchinson, Peter/0000-0002-2796-1835; Smielewski, Peter/0000-0001-5096-3938; czosnyka, marek/0000-0003-2446-8006; Kolias, Angelos/0000-0003-3992-0587	Marco Polo Fund, Groningen University Fund; Jan Kornelis de Cock Fund; Freemason Lodge "L' Union Provinciale" Groningen; Gates Scholarship; Royal College of Surgeons of England Research Fellowship; NIHR Academic Clinical Fellowship; Sackler Studentship; University of CambridgeUniversity of Cambridge; CenterTBI; Speaker fee BrainLab; National Institute for Health Research (NIHR), United KingdomNational Institute for Health Research (NIHR); NIHR Cambridge Biomedical Centre; NIHR Senior Investigator award; NIHR, United Kingdom; Framework Program 7 of the European Union; Medical Research Council (MRC), United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); NIHRNational Institute for Health Research (NIHR); NIHR Cambridge Biomedical Research Centre grant; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1002277, G9439390, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0600986, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	Dr. Weersink received grant support from the Marco Polo Fund, Groningen University Fund, and Jan Kornelis de Cock Fund (subsidizing study-related stay abroad) and is employed by HagaZiekenhuis Den Haag (from April 2014). Dr. Aries received grant support from Freemason Lodge "L' Union Provinciale" Groningen. Dr. Dias is employed by University Hospital Sao Joao, Porto. Dr. Liu received grant support and received support for travel from the Gates Scholarship. Dr. Kolias is supported by a Royal College of Surgeons of England Research Fellowship, an NIHR Academic Clinical Fellowship, and a Sackler Studentship. Dr. Czosnyka lectured for Inegra Life Science, consulted for Johnson and Johnson and Carag-Switzerland, and received support for article research from the University of Cambridge. Dr. Czosnyka and his institution received other support: licensing fee for ICM+ software. His institution received grant support from CenterTBI. Dr. van Dijk received support for travel from Speaker fee BrainLab (invited educational lecture at RT User meeting Copenhagen [March 2012]). Dr. Menon served as board member (he holds the following directorships on academic/charitable organizations: Co-Chair, European Brain Injury Consortium and Member, Board of Management, Intensive Care National Audit and Research Centre [London], but receives no financial benefit from these). He served as a paid consultant or member of the Data Monitoring Committee for Solvay, GlaxoSmithKline, Brainscope, Ornim Medical, Shire Medical, and Neurovive (not all are current-but all relevant associations for last 5 yr are listed). His contract of employment is with the University of Cambridge and with Addenbrooke's Hospital, Cambridge. He has a patent filed for PET ligand for mitochondrial function (no financial rewards so far); received royalties as Editor of the Textbook of Neuro-anaesthesia and Critical Care; and received support for article research from the National Institute for Health Research (NIHR), United Kingdom; the NIHR Cambridge Biomedical Centre; and an NIHR Senior Investigator award. His institution received grant support from the NIHR, United Kingdom; Framework Program 7 of the European Union; and Medical Research Council (MRC), United Kingdom (Project and Program Grant support); and has pending grants with MRC and NIHR, United Kingdom. Dr. Hutchinson received support for article research from the NIHR, the NIHR Cambridge Biomedical Research Centre grant, and the MRC; provided expert testimony for Medico-Legal; and lectured for J&J. His institution is employed by the NIHR. Dr. Smielewski and his institution received royalties from ICM+ software licensing fees (the author receives part of ICM+ [the software used to collect and partially analyzed data] licensing fees). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Brady KM, 2012, J APPL PHYSIOL, V113, P1362, DOI 10.1152/japplphysiol.00853.2012; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias Celeste, 2015, NEUROCRIT CARE; Feyen BFE, 2012, MINERVA ANESTESIOL, V78, P949; Harrison JM, 1999, BRIT J ANAESTH, V83, P839, DOI 10.1093/bja/83.6.839; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Moppett IK, 2008, BRIT J ANAESTH, V100, P240, DOI 10.1093/bja/aem374; Panerai RB, 2010, J APPL PHYSIOL, V109, P1860, DOI 10.1152/japplphysiol.00857.2010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Sanchez-Porras R, 2012, ACTA NEUROCHIR, V154, P1575, DOI 10.1007/s00701-012-1423-0; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2003, ANESTH ANALG, V97, P572, DOI 10.1213/01.ANE.0000070234.17226.B0; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066	33	26	27	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2015	43	9					1952	1963		10.1097/CCM.0000000000001165			12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC5JH	WOS:000369256800042	26154931				2022-02-06	
J	Petranovich, CL; Wade, SL; Taylor, HG; Cassedy, A; Stancin, T; Kirkwood, MW; Brown, TM				Petranovich, Christine L.; Wade, Shari L.; Taylor, H. Gerry; Cassedy, Amy; Stancin, Terry; Kirkwood, Michael W.; Brown, Tanya Maines			Long-Term Caregiver Mental Health Outcomes Following a Predominately Online Intervention for Adolescents With Complicated Mild to Severe Traumatic Brain Injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						caregiver outcomes; psychopathology; traumatic brain injury	BEHAVIOR PROBLEMS; FAMILY INTERVENTION; RANDOMIZED-TRIAL; CHILDREN; ADAPTATION; PREDICTORS; SYMPTOMS; EPILEPSY; EFFICACY; BURDEN	Objective To examine the efficacy of counselor-assisted problem solving (CAPS) in improving long-term caregiver psychological functioning following traumatic brain injury (TBI) in adolescents. Methods This randomized clinical trial compared CAPS (n = 65), a predominantly online problem-solving intervention, with an Internet resource comparison (n = 67) program. Families of adolescents with TBI completed a baseline assessment and follow-up assessments 6, 12, and 18 months later. General linear mixed models were used to examine longitudinal changes in caregiver global psychological distress, depressive symptoms, and caregiving self-efficacy. Family income and injury severity were examined as moderators of treatment efficacy. Results Family income moderated long-term changes in caregiver psychological distress. For lower-income caregivers, the CAPS intervention was associated with lower levels of psychological distress at 6, 12, and 18 months post baseline. Conclusions These findings support the utility of Web-based interventions in improving long-term caregiver psychological distress, particularly for lower-income families.	[Petranovich, Christine L.] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Petranovich, Christine L.; Wade, Shari L.] Cincinnati Childrens Hosp, Div Phys Med & Rehabil, Med Ctr, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Univ Hosp Case, Med Ctr, Cleveland, OH 44106 USA; [Cassedy, Amy] Cincinnati Childrens Hosp, Div Biostat & Epidemiol, Med Ctr, Cincinnati, OH USA; [Stancin, Terry] Case Western Reserve Univ, MetroHealth Med Ctr, Cleveland, OH 44106 USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Boulder, CO 80309 USA; [Brown, Tanya Maines] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Brown, Tanya Maines] Mayo Clin & Mayo Grad Sch Med, Rochester, MN USA		Petranovich, CL (corresponding author), Univ Cincinnati, Dept Psychol, 1 Edwards Ctr,ML 0376, Cincinnati, OH 45221 USA.	karvercl@mail.uc.edu	Stancin, Terry/L-7993-2019		National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01-MH073764]; National Institute of Disability and Rehabilitation Research [H133G050239]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	This work was supported by grant R01-MH073764 from the National Institute of Mental Health, grant H133G050239 from the National Institute of Disability and Rehabilitation Research, and the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Blaha RZ, 2015, J HEAD TRAUMA REHAB, V30, pE33, DOI 10.1097/HTR.0000000000000059; Bothroyd R, 1997, PRELIMINARY MANUAL C; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Collins C. L., 2014, INJURY EPIDEMIOLOGY, V1, P1; Connell AM, 2002, PSYCHOL BULL, V128, P746, DOI 10.1037//0033-2909.128.5.746; D'Zurilla T. J., 2006, HDB COGNITIVE BEHAV, P211; Deonandan R., 2000, CHRONIC DIS CANADA, V21, P93; Derogatis L. R., 1994, USE PSYCHOL TESTING, P217; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Hastings RP, 2002, AM J MENT RETARD, V107, P222, DOI 10.1352/0895-8017(2002)107<0222:BPOCWA>2.0.CO;2; Hegewald J., 2003, P N E SAS US GROUP W; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Jones TL, 2005, CLIN PSYCHOL REV, V25, P341, DOI 10.1016/j.cpr.2004.12.004; Karver CL, 2014, CHILD NEUROPSYCHOL, V20, P343, DOI 10.1080/09297049.2013.796918; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reeves William C., 2011, Morbidity and Mortality Weekly Report, V60, P1; Stancin T, 2010, J DEV BEHAV PEDIATR, V31, P317, DOI 10.1097/DBP.0b013e3181dbaf32; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Wade SL, 2014, REHABIL PSYCHOL, V59, P1, DOI 10.1037/a0034911; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082	40	26	26	0	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2015	40	7					680	688		10.1093/jpepsy/jsv001			9	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	CP1UH	WOS:000359661200008	25682211	Green Published			2022-02-06	
J	Thibaut, A; Chatelle, C; Wannez, S; Deltombe, T; Stender, J; Schnakers, C; Laureys, S; Gosseries, O				Thibaut, A.; Chatelle, C.; Wannez, S.; Deltombe, T.; Stender, J.; Schnakers, C.; Laureys, S.; Gosseries, O.			Spasticity in disorders of consciousness: a behavioral study	EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE			English	Article; Proceedings Paper	Siz Kine Congress	JUN 14, 2013	Brussels, BELGIUM	Siz		Muscle spasticity; Pain; Therapeutics; Persistent vegetative state; Brain injuries; Nociception	PERSISTENT VEGETATIVE STATE; QUALITY-OF-LIFE; BRAIN-INJURY; STROKE; RECOVERY; SCALE; PATHOPHYSIOLOGY; CONTRACTURE; PAIN; PHYSIOTHERAPY	Background. Spasticity is a frequent complication after severe brain injury, which may impede the rehabilitation process and diminish the patients' quality of life. Aim. We here investigate the presence of spasticity in a population of non-communicative patients with disorders of consciousness. We also evaluate the correlation between spasticity and potential factors of comorbidity, frequency of physical therapy, time since insult, presence of pain, presence of tendon retraction, etiology and diagnosis. Design. Cross-sectional study. Setting. University Hospital of Liege, Belgium. Population. Sixty-five patients with chronic (>3 months post insult) disorders of consciousness were included (22 women; mean age: 44 14 y; 40 with traumatic etiology; 40 in a minimally conscious state; time since insult: 39 37 months). Methods. Spasticity was measured with the Modified Ashworth Scale (MAS) and pain was assessed using the Nociception Coma Scale-Revised (NCS-R). Results. Out of 65 patients, 58 demonstrated signs of spasticity (89%; MAS >= 1), including 40 who showed severe spasticity (61.5%; MAS >= 3). Patients with spasticity receiving anti-spastic medication were more spastic than unmedicated patients. A negative correlation was observed between the severity of spasticity and the frequency of physical therapy. MAS scores correlated positively with time since injury and NCS-R scores. We did not observe a difference of spasticity between the diagnoses. Conclusion. A large proportion of patients with disorders of consciousness develop severe spasticity, possibly affecting their functional recovery and their quality of life. The observed correlation between degrees of spasticity and pain scores highlights the importance of pain management in these patients with altered states of consciousness. Finally, the relationship between spasticity and treatment (i.e., pharmacological and physical therapy) should be further investigated in order to improve clinical care. Clinical Rehabilitation Impact. Managing spasticity at first signs could improve rehabilitation of patients with disorders of consciousness and maximize their chances of recovery. In addition, decreasing this trouble could allow a better quality of life for these non communicative patients.	[Thibaut, A.; Chatelle, C.; Wannez, S.; Laureys, S.; Gosseries, O.] Univ Liege, GIGA Res Cyclotron Res Ctr, Coma Sci Grp, Liege, Belgium; [Thibaut, A.; Chatelle, C.; Wannez, S.; Laureys, S.; Gosseries, O.] Univ Liege, Dept Neurol, Liege, Belgium; [Thibaut, A.; Chatelle, C.; Wannez, S.; Laureys, S.; Gosseries, O.] Univ Hosp Liege, Liege, Belgium; [Chatelle, C.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Deltombe, T.] Catholic Univ Louvain, CHU Dinant Godinne UCL Namur, Phys Med & Rehabil Dept, Yvoir, Belgium; [Stender, J.] Univ Copenhagen, Inst Neurosci & Pharmacol, Copenhagen, Denmark; [Schnakers, C.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA; [Schnakers, C.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA; [Gosseries, O.] Univ Wisconsin, Ctr Sleep & Consciousness, Madison, WI USA; [Gosseries, O.] Univ Wisconsin, Dept Psychiat & Psychol, Postle Lab, Madison, WI USA		Thibaut, A (corresponding author), Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, Allee Six Aout 8, B-4000 Liege, Sart Tilman, Belgium.	athibaut@ulg.ac.be	Gosseries, Olivia/AAB-6469-2020; Thibaut, Aurore/U-8101-2019; Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011	Gosseries, Olivia/0000-0001-9011-7496; Laureys, Steven/0000-0002-3096-3807; Chatelle, Camille/0000-0002-7526-2107	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH064498, MH095984] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH095984, R01MH064498] Funding Source: NIH RePORTER		Ada L, 2006, DISABIL REHABIL, V28, P891, DOI 10.1080/09638280500535165; Ada L, 2005, ARCH PHYS MED REHAB, V86, P230, DOI 10.1016/j.apmr.2004.02.031; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bovend'Eerdt TJ, 2008, ARCH PHYS MED REHAB, V89, P1395, DOI 10.1016/j.apmr.2008.02.015; Brainin M, 2013, NEUROLOGY, V80, pS1, DOI 10.1212/WNL.0b013e3182762379; BROWN GW, 1985, CLIN PEDIATR, V24, P490, DOI 10.1177/000992288502400905; BROWN P, 1994, J NEUROL NEUROSUR PS, V57, P773, DOI 10.1136/jnnp.57.7.773; Chatelle C, 2014, BRAIN INJURY, V28, P1202, DOI 10.3109/02699052.2014.920518; Chatelle C, 2012, J NEUROL NEUROSUR PS, V83, P1233, DOI 10.1136/jnnp-2012-302987; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Dietz V, 2007, LANCET NEUROL, V6, P725, DOI 10.1016/S1474-4422(07)70193-X; Doan QV, 2012, PM&R, V4, P4, DOI 10.1016/j.pmrj.2011.10.001; Elovic EP, 2004, J HEAD TRAUMA REHAB, V19, P155, DOI 10.1097/00001199-200403000-00007; Formisano R, 2014, J HEAD TRAUMA REHAB, V29, P387, DOI 10.1097/HTR.0000000000000027; Formisano R, 2011, FUNCT NEUROL, V26, P15; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gracies JM, 2010, EUR J PHYS REHAB MED, V46, P411; Gracies JM, 2005, MUSCLE NERVE, V31, P535, DOI 10.1002/mus.20284; Gracies JM, 2005, MUSCLE NERVE, V31, P552, DOI 10.1002/mus.20285; Habbal D, 2014, BRAIN INJURY, V28, P1171, DOI 10.3109/02699052.2014.920519; Hart A, 2001, BRIT MED J, V323, P391, DOI 10.1136/bmj.323.7309.391; Hesse S, 2012, CLIN REHABIL, V26, P237, DOI 10.1177/0269215511421355; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P1082; JENNETT B, 1972, LANCET, V1, P734; Kendall MG, 1938, BIOMETRIKA, V30, P81, DOI 10.1093/biomet/30.1-2.81; Kheder Ammar, 2012, Pract Neurol, V12, P289, DOI 10.1136/practneurol-2011-000155; Lance J. W., 1980, SPASTICITY DISORDERS; Lapitskaya N, 2013, BRAIN STIMUL, V6, P590, DOI 10.1016/j.brs.2013.01.002; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leong B, 2002, BRAIN INJURY, V16, P217, DOI 10.1080/02699050110103283; Malhotra S, 2011, CLIN REHABIL, V25, P184, DOI 10.1177/0269215510381620; MCCOMAS AJ, 1994, MED SCI SPORT EXER, V26, P1498; Mehrholz J, 2005, CLIN REHABIL, V19, P751, DOI 10.1191/0269215505cr889oa; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2007, CURR OPIN NEUROL, V20, P620, DOI 10.1097/WCO.0b013e3282f169d9; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Sommerfeld DK, 2004, STROKE, V35, P134, DOI 10.1161/01.STR.0000105386.05173.5E; Stender J, 2014, LANCET IN PRESS; Svensson J, 2014, ACTA NEUROL SCAND, V129, P13, DOI 10.1111/ane.12139; Thibaut A, 2015, BRAIN INJ; Thibaut A, 2013, BRAIN INJURY, V27, P1093, DOI 10.3109/02699052.2013.804202; Urban PP, 2010, STROKE, V41, P2016, DOI 10.1161/STROKEAHA.110.581991; Ward AB, 2012, EUR J NEUROL, V19, P21, DOI 10.1111/j.1468-1331.2011.03448.x; Wheatley-Smith L, 2013, DISABIL REHABIL, V35, P1006, DOI 10.3109/09638288.2012.720355; Wissel J, 2010, J NEUROL, V257, P1067, DOI 10.1007/s00415-010-5463-1; Yeh CY, 2005, ARCH PHYS MED REHAB, V86, P235, DOI 10.1016/j.apmr.2004.03.032; Zorowitz RD, 2013, NEUROLOGY, V80, pS45, DOI 10.1212/WNL.0b013e3182764c86	50	26	28	0	4	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	1973-9087	1973-9095		EUR J PHYS REHAB MED	Eur. J. Phys. Rehabil. Med.	AUG	2015	51	4					389	397					9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation	DB6TW	WOS:000368649500005	25375186				2022-02-06	
J	Jin, YC; Lin, YY; Feng, JF; Jia, F; Gao, GY; Jiang, JY				Jin, Yichao; Lin, Yingying; Feng, Jun-feng; Jia, Feng; Gao, Guo-yi; Jiang, Ji-yao			Moderate Hypothermia Significantly Decreases Hippocampal Cell Death Involving Autophagy Pathway after Moderate Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autophagy; cell death; hippocampus; moderate hypothermia; traumatic brain injury	BCL-X-L; FLUID-PERCUSSION MODEL; CLOSED-HEAD INJURY; BECLIN 1; THERAPEUTIC HYPOTHERMIA; REGULATES AUTOPHAGY; BEHAVIORAL DEFICITS; MILD HYPOTHERMIA; RAT MODEL; APOPTOSIS	Here, we evaluated changes in autophagy after post-traumatic brain injury (TBI) followed by moderate hypothermia in rats. Adult male Sprague-Dawley rats were randomly divided into four groups: sham injury with normothermia group (37 degrees C); sham injury with hypothermia group (32 degrees C); TBI with normothermia group (TNG; 37 degrees C); and TBI with hypothermia group (THG; 32 degrees C). Injury was induced by a fluid percussion TBI device. Moderate hypothermia (32 degrees C) was achieved by partial immersion in a water bath (0 degrees C) under general anesthesia for 4h. All rats were killed at 24h after fluid percussion TBI. The ipsilateral hippocampus in all rats was analyzed with hematoxylin and eosin staining; terminal deoxynucleoitidyl transferase-mediated nick end labeling staining was used to determine cell death in ipsilateral hippocampus. Immunohistochemistry and western blotting of microtubule-associated protein light chain 3 (LC3), Beclin-1, as well as transmission electron microscopy performed to assess changes in autophagy. At 24h after TBI, the cell death index was 27.90 +/- 2.36% in TNG and 14.90 +/- 1.52% in THG. Expression level of LC3 and Beclin-1 were significantly increased after TBI and were further up-regulated after post-TBI hypothermia. Further, ultrastructural observations showed that there was a marked increase of autophagosomes and autolysosomes in ipsilateral hippocampus after post-TBI hypothermia. Our data demonstrated that moderate hypothermia significantly attenuated cell death and increased autophagy in ipsilateral hippocampus after fluid percussion TBI. In conclusion, autophagy pathway may participate in the neuroprotective effect of post-TBI hypothermia.	[Jin, Yichao; Lin, Yingying; Feng, Jun-feng; Jia, Feng; Gao, Guo-yi; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Renji Hosp, Dept Neurosurg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	jiyaojiang@126.com			National Science and Nature grant [81271381]; National Key project [2012CB518100]	This work was supported by grants from a National Science and Nature grant (no. 81271381) and the National Key project (no. 2012CB518100).	Balduini W, 2012, J MATERN-FETAL NEO M, V25, P30, DOI 10.3109/14767058.2012.663176; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Celik SE, 2006, J NEUROTRAUM, V23, P1355, DOI 10.1089/neu.2006.23.1355; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kang R, 2010, AUTOPHAGY, V6, P1209, DOI 10.4161/auto.6.8.13651; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo S, 2007, CELL DEATH DIFFER, V14, P1247, DOI 10.1038/sj.cdd.4402149; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Moore EM, 2011, INJURY, V42, P843, DOI 10.1016/j.injury.2011.03.027; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Son JH, 2012, EXP MOL MED, V44, P89, DOI 10.3858/emm.2012.44.2.031; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Uchiyama Y, 2008, HISTOCHEM CELL BIOL, V129, P407, DOI 10.1007/s00418-008-0406-y; Urbano LA, 2012, CURR NEUROL NEUROSCI, V12, P580, DOI 10.1007/s11910-012-0304-5; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625; Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	43	26	30	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1090	1100		10.1089/neu.2014.3649			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000008	25942484	Green Published			2022-02-06	
J	Aloizos, S; Evodia, E; Gourgiotis, S; Isaia, EC; Seretis, C; Baltopoulos, GJ				Aloizos, Stavros; Evodia, Efimia; Gourgiotis, Stavros; Isaia, Eleni-Christina; Seretis, Charalampos; Baltopoulos, George J.			Neuroprotective Effects of Erythropoietin in Patients with Severe Closed Brain Injury	TURKISH NEUROSURGERY			English	Article						Brain; Injury; Erythropoietin; Mortality; Outcome	RECOMBINANT-HUMAN-ERYTHROPOIETIN; NITRIC-OXIDE; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CONTROLLED-TRIAL; SPATIAL MEMORY; IN-VITRO; RATS; ISCHEMIA; CELLS	AIM: Our research was focused on the neuroprotective function of erythropoietin (Epo) in patients with severe closed traumatic brain injury (TBI). MATERIAL and METHODS: Our model examined the influence of the outcome and neurological recovery in 42 adults with TBI who were admitted to ICU within 6 hours of their injury and were recruited into a randomized controlled study of two groups; only the patients of the intervention group received 10,000 i.u. of Epo for 7 consecutive days. A prognostic model based on CRASH II injury model and outcome was measured by survival and Glasgow Outcome Scale-Extended version (GOS-E) score at 6 months post-injury. RESULTS: Six patients (18.7%) died during the first two weeks; 4 of the control group and 2 of the intervention group. A mortality rate of 22.2% and 8.3% for the control and intervention group respectively was observed. A lower rate of good outcome (GOS-E score >4) at 6 months was mentioned among patients of the control group. CONCLUSION: The study provides evidence of lower mortality and better neurological outcome for the patients who received Epo increasing the possibility that Epo therapy could be used in clinical practice, limiting neuronal damage induced by TBI.	[Aloizos, Stavros; Gourgiotis, Stavros; Isaia, Eleni-Christina; Seretis, Charalampos] 401 Gen Army Hosp Athens, ICU, Athens, Greece; [Evodia, Efimia; Baltopoulos, George J.] Univ Athens, KAT Gen Hosp, Sch Nursing ICU, Athens, Greece		Gourgiotis, S (corresponding author), 401 Gen Army Hosp Athens, ICU, Athens, Greece.	drgourgiotis@yahoo.gr	Gourgiotis, Stavros/AAD-8696-2019	Gourgiotis, Stavros/0000-0002-7923-6395			Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Banerjee D, 2000, KIDNEY INT, V57, P1895, DOI 10.1046/j.1523-1755.2000.00039.x; Bouzat P, 2011, CRIT CARE MED, V39, P2099, DOI 10.1097/CCM.0b013e31821cb7b2; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Campana WM, 1998, INT J MOL MED, V1, P235; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; Casadevall N, 2003, NEPHROL DIAL TRANSPL, V18, P37, DOI 10.1093/ndt/gfg1091; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Edwards P, 2005, LANCET, V365, P1957; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Food and Drug Adminstration, SAF AL HUM MED PROD; Genc S, 2002, NEUROSCI LETT, V321, P73, DOI 10.1016/S0304-3940(02)00041-1; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2001, J Neurosurg Sci, V45, P7; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Haiden N, 2006, PEDIATRICS, V118, P180, DOI 10.1542/peds.2005-2475; Juul SE, 2004, BIOL NEONATE, V85, P138, DOI 10.1159/000074970; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Kellert BA, 2007, PEDIATR RES, V61, P451, DOI 10.1203/pdr.0b013e3180332cec; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Nirula R, 2003, J TRAUMA, V55, P844, DOI 10.1097/01.TA.0000087645.62474.91; Palmer C, 1999, J NEUROSCI RES, V56, P60, DOI 10.1002/(SICI)1097-4547(19990401)56:1<60::AID-JNR8>3.0.CO;2-A; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; STATLER PA, 2007, PEDIATR RES, V61, P1; Sun Y, 2005, STROKE, V36, P1672, DOI 10.1161/01.STR.0000173406.04891.8c; Tsukahara H, 1997, SCAND J CLIN LAB INV, V57, P487, DOI 10.3109/00365519709084598; Ulusal I, 2010, ACTA NEUROCHIR, V152, P2161, DOI 10.1007/s00701-010-0775-6; Vairano M, 2002, EUR J NEUROSCI, V16, P584, DOI 10.1046/j.1460-9568.2002.02125.x; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wu XC, 1999, CLIN SCI, V97, P639, DOI 10.1042/CS19990070	41	26	27	0	2	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	JUL	2015	25	4					552	558		10.5137/1019-5149.JTN.9685-14.4			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CQ0YN	WOS:000360324600007	26242331	Bronze			2022-02-06	
J	Anke, A; Andelic, N; Skandsen, T; Knoph, R; Ader, T; Manskow, U; Sigurdardottir, S; Roe, C				Anke, Audny; Andelic, Nada; Skandsen, Toril; Knoph, Rein; Ader, Tiina; Manskow, Unn; Sigurdardottir, Solrun; Roe, Cecilie			Functional Recovery and Life Satisfaction in the First Year After Severe Traumatic Brain Injury: A Prospective Multicenter Study of a Norwegian National Cohort	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							GLASGOW OUTCOME SCALE; INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; COGNITIVE FUNCTION; DEPRESSION SCALE; HOSPITAL ANXIETY; REHABILITATION; POPULATION; SYMPTOMS; IMPACT	Objectives: (1) To examine the impact of demographic and acute injury-related variables on functional recovery and life satisfaction after severe traumatic brain injury (sTBI) and (2) to test whether postinjury functioning, postconcussive symptoms, emotional state, and functional improvement are related to life satisfaction. Design: Prospective national multicenter study. Setting: Level 1 trauma centers in Norway. Participants: 163 adults with sTBI. Main Measures: Functional recovery between 3 and 12 months postinjury measured with Glasgow Outcome Scale Extended, Rivermead Postconcussion Symptoms Questionnaire, Hospital Anxiety and Depression Scale, and satisfaction with life situation. Results: 60% of cases experienced functional improvement from 3 to 12 months postinjury. Multivariate logistic regression analysis revealed that discharge to a rehabilitation department from acute care (odds ratio [OR] = 2.14; P < .05) and fewer days with artificial ventilation (OR = 1.04; P < .05) were significantly related to improvement. At 12 months postinjury, 85% were independent in daily activities. Most participants (63%) were satisfied with their life situation. Regression analysis revealed that older age (>65 years), low education, better functional outcome, and the absence of depressive and postconcussion symptoms were significant (P < .05) predictors of life satisfaction. Functional improvement was significantly associated with emotional state but not to life satisfaction. Conclusion: Following sTBI, approximately two-thirds of survivors improve between 3 and 12 months postinjury and are satisfied with their life. Direct discharge from acute care to specialized rehabilitation appears to increase functional recovery.	[Anke, Audny; Manskow, Unn] Univ Hosp North Norway, Dept Rehabil, N-9016 Tromso, Troms, Norway; [Anke, Audny] Univ Tromso, Fac Hlth Sci, Dept Clin Med, N-9001 Tromso, Norway; [Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, Fac Med, Trondheim, Norway; [Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Knoph, Rein] Sorlandet Hosp, Dept Phys Med & Rehabil, Kristiansand, Norway; [Ader, Tiina] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Manskow, Unn] Univ Tromso, Fac Hlth Sci, Dept Hlth & Care Sci, N-9001 Tromso, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway		Anke, A (corresponding author), Univ Hosp North Norway, Dept Rehabil, Sykehusveien 1, N-9016 Tromso, Troms, Norway.	audny.anke@uit.no		Andelic, Nada/0000-0002-3719-4406; Anke, Audny/0000-0002-2491-2560	Norwegian Research CouncilResearch Council of NorwayEuropean Commission [185267]	This study was conducted with grants from the Norwegian Research Council, grant number 185267.	Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Fujita F, 2005, J PERS SOC PSYCHOL, V88, P158, DOI 10.1037/0022-3514.88.1.158; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jacobsson LJ, 2011, NEUROPSYCHOL REHABIL, V21, P383, DOI 10.1080/09602011.2011.566711; Ketchum JM, 2012, NEUROREHABILITATION, V30, P23, DOI 10.3233/NRE-2012-0724; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Leon-Carrion J, 2012, J REHABIL MED, V44, P505, DOI 10.2340/16501977-0982; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Livingston DH, 2009, J TRAUMA, V67, P341, DOI 10.1097/TA.0b013e3181a5cc34; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Novack TA, 2000, BRAIN INJURY, V14, P987; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skandsen T, 2013, J REHABIL MED, V45, P734; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Soberg HL, 2013, J REHABIL MED, V45, P785, DOI 10.2340/16501977-1158; Styrke J, 2013, J REHABIL MED, V45, P749, DOI 10.2340/16501977-1215; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Toien K, 2010, J TRAUMA, V69, P1552, DOI 10.1097/TA.0b013e3181e125f3; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; von Wild KRH, 2008, ACT NEUR S, V101, P55; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Wertheimer JC, 2008, ARCH PHYS MED REHAB, V89, P1983, DOI 10.1016/j.apmr.2008.04.010; Williamson OD, 2011, J TRAUMA, V71, P63, DOI 10.1097/TA.0b013e31820e898d; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zampolini M, 2012, BRAIN INJURY, V26, P27, DOI 10.3109/02699052.2011.635358; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	57	26	26	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					E38	E49		10.1097/HTR.0000000000000080			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CM8JB	WOS:000357944800005	25033035				2022-02-06	
J	Cohen, AR; Caruso, P; Duhaime, AC; Klig, JE				Cohen, Ari R.; Caruso, Paul; Duhaime, Ann-Christine; Klig, Jean E.			Feasibility of "rapid" magnetic resonance imaging in pediatric acute head injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							EMERGENCY-DEPARTMENT; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; HYDROCEPHALUS; CT	Objective: The objective was to determine the feasibility of "rapid" magnetic resonance imaging (rMRI) versus noncontrast computed tomography (NCCT) for pediatric patients with possible traumatic brain injury and to compare the populations receiving imaging in an urban tertiary care emergency department ED. Methods: We retrospectively reviewed the electronic medical records of ED patients younger than 19 years with possible traumatic brain injury over 4 years who received an rMRI and then age-matched with NCCT patients. Data collection and analysis included demographic and clinical variables, ED length of stay (LOS), and follow-up outcomes. Results: The final cohort had 45 rMRIs and 45 NCCTs. The mean age was 2.7 years, 63% were male, and 65% sustained a fall. Age, sex, and injury mechanism were similar. Time parameters were longer for rMRI patients: ED arrival to completion of imaging (172 vs 93 minutes, P < .001) and ED LOS (266 vs 225 minutes, P = .008). The NCCT group had higher-acuity patients with higher pediatric intensive care unit admission rates (33% vs 7%, P = .002). No patients returned to the ED within 72 hours. Follow-up was available on 78% patients. No clinically significant intracranial injuries were missed. Conclusions: Rapid MRI may be a viable imaging modality for moderate-risk pediatric head injury. Although rMRI took longer to obtain during this pilot study, scan time was only 3 to 4 minutes; and LOS was only 41 minutes longer. Further integration of rMRI in patient care should decrease time variation. Future study of rMRI reliability and satisfaction is needed. (C) 2015 Elsevier Inc. All rights reserved.	[Cohen, Ari R.; Klig, Jean E.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Caruso, Paul] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Duhaime, Ann-Christine] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA		Cohen, AR (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA.	Acohen7@partners.org	Klig, Jean/N-8505-2019				Ashley WW, 2005, J NEUROSURG, V103, P124, DOI 10.3171/ped.2005.103.2.0124; Bleyer A, 2002, PEDIATR RADIOL, V32, P242, DOI 10.1007/s00247-002-0674-y; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Iskandar BJ, 2004, J NEUROSURG, V101, P147, DOI 10.3171/ped.2004.101.2.0147; Kocher KE, 2011, ANN EMERG MED, V58, P452, DOI 10.1016/j.annemergmed.2011.05.020; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Missios S, 2008, J NEUROS-PEDIATR, V2, P438, DOI 10.3171/PED.2008.2.12.438; Patel DM, 2014, J NEUROSURG-PEDIATR, V13, P440, DOI 10.3171/2014.1.PEDS13447; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Radiology M.G.H.D.o., FACTS RAD IM EX; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Wylie MC, 2014, PEDIATR EMERG CARE, V30, P680, DOI 10.1097/PEC.0000000000000227	13	26	26	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JUL	2015	33	7					887	890		10.1016/j.ajem.2015.03.052			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	CL0BG	WOS:000356602900005	25912791				2022-02-06	
J	Li, SJ; Marks, JA; Eisenstadt, R; Kumasaka, K; Samadi, D; Johnson, VE; Holena, DN; Allen, SR; Browne, KD; Smith, DH; Pascual, JL				Li, Shengjie; Marks, Joshua A.; Eisenstadt, Rachel; Kumasaka, Kenichiro; Samadi, Davoud; Johnson, Victoria E.; Holena, Daniel N.; Allen, Steven R.; Browne, Kevin D.; Smith, Douglas H.; Pascual, Jose L.			Enoxaparin ameliorates post-traumatic brain injury edema and neurologic recovery, reducing cerebral leukocyte endothelial interactions and vessel permeability in vivo	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	28th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 13-17, 2015	Lake Buena Vista, FL	Eastern Assoc Surg Trauma		Enoxaparin; traumatic brain injury; leukocyte; blood-brain barrier; mice	MOLECULAR-WEIGHT HEPARIN; CONTROLLED CORTICAL IMPACT; UNFRACTIONATED HEPARIN; NEUTROPHIL ACTIVATION; HYPERTONIC SALINE; ENDOTOXEMIC RATS; INFARCT SIZE; HEAD-INJURY; INFLAMMATION; MICROCIRCULATION	BACKGROUND Traumatic brain injury (TBI) confers a high risk of venous thrombosis, but early prevention with heparinoids is often withheld, fearing cerebral hematoma expansion. Yet, studies have shown heparinoids not only to be safe but also to limit brain edema and contusion size after TBI. Human TBI data also suggest faster radiologic and clinical neurologic recovery with earlier heparinoid administration. We hypothesized that enoxaparin (ENX) after TBI blunts in vivo leukocyte (LEU) mobilization to injured brain and cerebral edema, while improving neurologic recovery without increasing the size of the cerebral hemorrhagic contusion. METHODS CD1 male mice underwent either TBI by controlled cortical impact (CCI, 1-mm depth, 6 m/s) or sham craniotomy. ENX (1 mg/kg) or vehicle (VEH, 0.9% saline, 1 mL/kg) was administered at 2, 8, 14, 23, and 32 hours after TBI. At 48 hours, intravital microscopy was used to visualize live LEUs interacting with endothelium and microvascular leakage of fluorescein isothiocyanate-albumin. Neurologic function (Neurological Severity Score, NSS), activated clotting time, hemorrhagic contusion size, as well as brain and lung wet-to-dry ratios were evaluated post mortem. Analysis of variance with Bonferroni correction was used for statistical comparisons between groups. RESULTS Compared with VEH, ENX significantly reduced in vivo LEU rolling on endothelium (72.7 28.3 LEU/100 m/min vs. 30.6 +/- 18.3 LEU/100 m/min, p = 0.02) and cerebrovascular albumin leakage (34.5% +/- 8.1% vs. 23.8% +/- 5.5%, p = 0.047). CCI significantly increased ipsilateral cerebral hemisphere edema, but ENX treatment reduced post-CCI edema to near control levels (81.5% +/- 1.5% vs. 77.6% +/- 0.6%, p < 0.01). Compared with VEH, ENX reduced body weight loss at 24 hours (8.7% +/- 1.2% vs. 5.8% +/- 1.1%, p < 0.01) and improved NSS at 24 hours (14.5 +/- 0.5 vs. 16.2 +/- 0.4, p < 0.01) and 48 hours (15.1 +/- 0.4 vs. 16.7 +/- 0.5, p < 0.01) after injury. There were no significant differences in activated clotting time, hemorrhagic contusion size, and lung water content between the groups. CONCLUSION ENX reduces LEU recruitment to injured brain, diminishing visible microvascular permeability and edema. ENX may also accelerate neurologic recovery without increasing cerebral contusion size. Further study in humans is necessary to determine safety, appropriate dosage, and timing of ENX administration early after TBI.	[Li, Shengjie; Marks, Joshua A.; Eisenstadt, Rachel; Kumasaka, Kenichiro; Samadi, Davoud; Holena, Daniel N.; Allen, Steven R.; Pascual, Jose L.] Univ Penn, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, Ctr Brain Injury & Repair,Perelman Sch Med, Philadelphia, PA 19104 USA; [Browne, Kevin D.; Smith, Douglas H.; Pascual, Jose L.] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Perelman Sch Med, Philadelphia, PA 19104 USA; [Li, Shengjie; Johnson, Victoria E.] Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, Tianjin, Peoples R China		Pascual, JL (corresponding author), Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.	Jose.pascual@uphs.upenn.edu	Pascual, Jose/ABI-2291-2020	Pascual, Jose/0000-0002-1613-7912; Holena, Daniel/0000-0003-3424-5754	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS092398] Funding Source: Medline		Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Cavusoglu Erdal, 2005, J Invasive Cardiol, V17, P416; DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012; Dudley RR, 2010, J NEUROTRAUM, V27, P2165, DOI 10.1089/neu.2010.1366; Farooqui A, 2013, J NEUROSURG, V119, P1576, DOI 10.3171/2013.8.JNS13424; Gavins F, 2007, MICROCIRCULATION, V14, P667, DOI 10.1080/10739680701404903; Gikakis N, 1996, CIRCULATION, V94, P341; Gould MK, 2012, CHEST, V141, pE227S, DOI 10.1378/chest.11-2297; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Iba T, 2009, SHOCK, V32, P530, DOI 10.1097/SHK.0b013e3181a2e279; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Kim Luke, 2014, J Emerg Trauma Shock, V7, P141, DOI 10.4103/0974-2700.136846; Knudson M Margaret, 2004, Curr Opin Crit Care, V10, P539, DOI 10.1097/01.ccx.0000144941.09650.9f; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Kubes P, 2000, BRAIN PATHOL, V10, P127; Li LF, 2009, CRIT CARE, V13, DOI 10.1186/cc7949; Libersan D, 1998, CARDIOVASC RES, V37, P656, DOI 10.1016/S0008-6363(97)00292-7; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; Manduteanu I, 2003, EUR J PHARMACOL, V477, P269, DOI 10.1016/j.ejphar.2003.08.016; Manduteanu I, 2002, PHARMACOLOGY, V65, P32, DOI 10.1159/000056183; Marks JA, 2012, J TRAUMA ACUTE CARE, V73, P351, DOI 10.1097/TA.0b013e3182592f76; Mary V, 2001, STROKE, V32, P993, DOI 10.1161/01.STR.32.4.993; McKeating EG, 1998, ACT NEUR S, V71, P200; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Moxon-Emre I, 2011, J NEUROPATH EXP NEUR, V70, P218, DOI 10.1097/NEN.0b013e31820d94a5; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Ouartermain D, 2000, NEUROSCI LETT, V288, P155, DOI 10.1016/S0304-3940(00)01223-4; Pascual JL, 2003, J TRAUMA, V54, pS133, DOI 10.1097/01.TA.0000064526.33647.63; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Pratt J, 1998, HAEMOSTASIS, V28, P78; Quartermain D, 2003, CEREBROVASC DIS, V16, P346, DOI 10.1159/000072556; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Simard JM, 2012, TRANSL STROKE RES, V3, pS155, DOI 10.1007/s12975-012-0166-9; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soares HD, 1995, J NEUROSCI, V15, P8223; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; Tanne D, 2008, NEUROBIOL DIS, V30, P56, DOI 10.1016/j.nbd.2007.12.004; van Buul JD, 2004, ARTERIOSCL THROM VAS, V24, P824, DOI 10.1161/01.ATV.0000122854.76267.5c; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; Whalen MJ, 1998, ACT NEUR S, V71, P212; Yeh YC, 2012, CRIT CARE, V16, DOI 10.1186/cc11303; Zupan Z, 2011, PROG NEURO-PSYCHOPH, V35, P1846, DOI 10.1016/j.pnpbp.2011.08.005	50	26	27	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2015	79	1					78	84		10.1097/TA.0000000000000697			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	CL7LN	WOS:000357153700012	26091318	Green Accepted			2022-02-06	
J	Lu, XY; Wang, HD; Xu, JG; Ding, K; Li, T				Lu, Xin-Yu; Wang, Han-Dong; Xu, Jian-Guo; Ding, Ke; Li, Tao			Deletion of Nrf2 Exacerbates Oxidative Stress After Traumatic Brain Injury in Mice	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Nrf2; NOX2; Oxidative stress	TRANSCRIPTION FACTOR NRF2; NADPH OXIDASE; TERT-BUTYLHYDROQUINONE; INHIBITION; INFLAMMATION; EXPRESSION; PATHWAY; DAMAGE; MODEL; ANTIOXIDANTS	Traumatic brain injury (TBI) is a worldwide public health and medical problem. Oxidative stress is recognized as an important contributing factor in the pathogenesis of TBI. The present study was designed to explore the anti-oxidative effect of Nuclear factor erythroid 2-related factor 2 (Nrf2) on brain damage induced by traumatic injury in a mouse model. Moderate weight-drop impact head injury was induced in adult male mice. The mice were randomly divided into four groups: Nrf2(+/+) sham-operation, Nrf2(-/-) sham-operation, Nrf2(+/+) TBI, and Nrf2(-/-) TBI group. Neurological scores were evaluated 24 h after TBI, followed by collection of the brain specimens. Brain edema was detected by the wet-dry ratio method. The expression of NOX2 protein in the brain specimen was investigated using Western Blot analysis and immunohistochemical staining. In addition, malondialdehyde (MDA) level and superoxide dismutase (SOD) activity were evaluated in the brain tissues. Twenty-four hours after TBI, our results showed Nrf2(+/+) TBI mice have more severe neurological deficits and brain edema than Nrf2(+/+) sham group. On the other hand, the Nrf2(-/-) TBI mice were found to have significantly increased neurological deficits and brain edema, compared to Nrf2(+/+) TBI mice (P < 0.05). At the same time, we found that the expression of NOX2 protein, MDA level were significantly increased in Nrf2(-/-) mice, while SOD activity was considerably decreased after TBI compared to Nrf2(+/+) mice (P < 0.05). We demonstrated that deletion of Nrf2 exacerbates brain injury after TBI in mice, suggesting that Nrf2 may play an important role in protecting brain injury after TBI, possibly by modulating oxidative stress.	[Lu, Xin-Yu; Wang, Han-Dong; Xu, Jian-Guo; Ding, Ke; Li, Tao] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com					Anrather J, 2006, J BIOL CHEM, V281, P5657, DOI 10.1074/jbc.M506172200; Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Cheng ZG, 2013, ASIAN PAC J TROP MED, V6, P305, DOI 10.1016/S1995-7645(13)60061-9; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Ferrer-Sueta G, 2009, ACS CHEM BIOL, V4, P161, DOI 10.1021/cb800279q; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Kahles T, 2012, CELL MOL LIFE SCI, V69, P2345, DOI 10.1007/s00018-012-1011-8; Kalayci M, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-75; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Kerman M, 2012, J MOL HISTOL, V43, P49, DOI 10.1007/s10735-011-9376-9; Kim HJ, 2010, AM J PHYSIOL-RENAL, V298, pF662, DOI 10.1152/ajprenal.00421.2009; Kong XN, 2010, J IMMUNOL, V185, P569, DOI 10.4049/jimmunol.0902315; Li HD, 2013, EUR J APPL PHYSIOL, V113, P1555, DOI 10.1007/s00421-012-2584-5; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lu XY, 2014, J SURG RES, V188, P206, DOI 10.1016/j.jss.2013.11.1106; Mao L, 2011, J SURG RES, V170, pE105, DOI 10.1016/j.jss.2011.05.049; Mao L, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/238321; Marnett LJ, 2001, TRENDS GENET, V17, P214, DOI 10.1016/S0168-9525(01)02239-9; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Reddy PVB, 2012, NEUROCHEM RES, V37, P1697, DOI 10.1007/s11064-012-0779-0; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Titova E, 2007, CLIN EXP PHARMACOL P, V34, P845, DOI 10.1111/j.1440-1681.2007.04664.x; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; Wang JW, 2013, BIOCHEM BIOPH RES CO, V430, P1016, DOI 10.1016/j.bbrc.2012.12.046; WOOLLIAMS JA, 1983, RES VET SCI, V34, P253, DOI 10.1016/S0034-5288(18)32219-7; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Ye QY, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-156; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	46	26	29	0	12	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUL	2015	35	5					713	721		10.1007/s10571-015-0167-9			9	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	CL2JJ	WOS:000356769400012	25732597				2022-02-06	
J	Nusbaum, DM; Wu, SM; Frankfort, BJ				Nusbaum, Derek M.; Wu, Samuel M.; Frankfort, Benjamin J.			Elevated intracranial pressure causes optic nerve and retinal ganglion cell degeneration in mice	EXPERIMENTAL EYE RESEARCH			English	Article						Retina; Retinal ganglion cell; Optic nerve; Intracranial pressure; Intraocular pressure: glaucoma; Visual impairment intracranial pressure; syndrome (VIIP syndrome); Idiopathic intracranial hypertension (IIH)	CEREBROSPINAL-FLUID PRESSURE; OPEN-ANGLE GLAUCOMA; INDUCED OCULAR HYPERTENSION; TRAUMATIC BRAIN-INJURY; INTRAOCULAR-PRESSURE; MOUSE MODEL; RATS; DYSFUNCTION; DIFFERENCE; NEUROPATHY	The purpose of this study was to develop a novel experimental system for the modulation and measurement of intracranial pressure (ICP), and to use this system to assess the impact of elevated ICP on the optic nerve and retinal ganglion cells (RGCs) in CD1 mice. This system involved surgical implantation of an infusion cannula and a radiowave based pressure monitoring probe through the skull and into the subarachnoid space. The infusion cannula was used to increase ICP, which was measured by the probe and transmitted to a nearby receiver. The system provided robust and consistent ICP waveforms, was well tolerated, and was stable over time. ICP was elevated to approximately 30 mmHg for one week, after which we assessed changes in optic nerve structure with transmission electron microscopy in cross section and RGC numbers with antibody staining in retinal flat mounts. ICP elevation resulted in optic nerve axonal loss and disorganization, as well as RGC soma loss. We conclude that the controlled manipulation of ICP in active, awake mice is possible, despite their small size. Furthermore, ICP elevation results in visual system phenotypes of optic nerve and RGC degeneration, suggesting that this model can be used to study the impact of ICP on the visual system. Potentially, this model can also be used to study the relationship between ICP and IOP, as well diseases impacted by ICP variation such as glaucoma, idiopathic intracranial hypertension, and the spaceflight-related visual impairment intracranial pressure syndrome. (C) 2015 Elsevier Ltd. All rights reserved.	[Nusbaum, Derek M.] Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA; [Nusbaum, Derek M.; Frankfort, Benjamin J.] Baylor Coll Med, Ctr Space Med, Houston, TX 77030 USA; [Nusbaum, Derek M.; Wu, Samuel M.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Wu, Samuel M.; Frankfort, Benjamin J.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA		Frankfort, BJ (corresponding author), Baylor Coll Med, Dept Ophthalmol, 6565 Fannin,NC 205, Houston, TX 77030 USA.	benjamin.frankfort@bcm.edu			NASANational Aeronautics & Space Administration (NASA) [NNX 10AK70G]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY021479, EY019908, EY02520]; Retina Research Foundation; Research to Prevent BlindnessResearch to Prevent Blindness (RPB); Oshman Foundation; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [K08EY021479, P30EY002520, R01EY019908] Funding Source: NIH RePORTER	This work was supported byNASA Grant NNX 10AK70G (DMN), NIH Grants EY021479 (BJF), EY019908 (SMW), and EY02520 (Ophthalmology Core Grant to Baylor College of Medicine), the Retina Research Foundation (BJF and SMW), Research to Prevent Blindness (BJF and Baylor College of Medicine), and the Oshman Foundation (BJF). We thank Ralph Nichols for expert assistance with optic nerve preparations, staining, and imaging, and Guofu Shen for helpful discussion.	Acheson JF, 2006, BRIT MED BULL, V79-80, P233, DOI 10.1093/bmb/ldl019; BARTH KNM, 1992, NEUROSURGERY, V30, P138, DOI 10.1227/00006123-199201000-00028; Berdahl JP, 2008, OPHTHALMOLOGY, V115, P763, DOI 10.1016/j.ophtha.2008.01.013; Berdahl JP, 2008, INVEST OPHTH VIS SCI, V49, P5412, DOI 10.1167/iovs.08-2228; Bragin DE, 2013, STROKE, V44, P177, DOI 10.1161/STROKEAHA.112.668293; Buckingham BP, 2008, J NEUROSCI, V28, P2735, DOI 10.1523/JNEUROSCI.4443-07.2008; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen HH, 2011, INVEST OPHTH VIS SCI, V52, P36, DOI 10.1167/iovs.09-5115; Chowdhury UR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082151; Cone FE, 2012, EXP EYE RES, V99, P27, DOI 10.1016/j.exer.2012.04.006; Cone FE, 2010, EXP EYE RES, V91, P415, DOI 10.1016/j.exer.2010.06.018; Crish SD, 2010, P NATL ACAD SCI USA, V107, P5196, DOI 10.1073/pnas.0913141107; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Feiler S, 2010, J NEUROSCI METH, V190, P164, DOI 10.1016/j.jneumeth.2010.05.005; Fleischman David, 2014, Int Ophthalmol Clin, V54, P73, DOI 10.1097/IIO.0b013e3182aabef4; Fleischman D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052664; Frankfort BJ, 2013, INVEST OPHTH VIS SCI, V54, P762, DOI 10.1167/iovs.12-10581; Fu CT, 2010, INVEST OPHTH VIS SCI, V51, P980, DOI 10.1167/iovs.09-4324; Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714; GROSS RL, 2003, T AM OPHTHAL SOC, V101, P169; Gross Ronald L, 2003, Trans Am Ophthalmol Soc, V101, P163; Grozdanic SD, 2003, INVEST OPHTH VIS SCI, V44, P4337, DOI 10.1167/iovs.03-0015; Han Y, 2008, ANN NEUROL, V64, P221, DOI 10.1002/ana.21416; Holcombe DJ, 2008, BRIT J OPHTHALMOL, V92, P683, DOI 10.1136/bjo.2007.133223; Ji JZ, 2005, VISION RES, V45, P169, DOI 10.1016/j.visres.2004.08.008; Kawoos U, 2014, IEEE T BIO-MED ENG, V61, P841, DOI 10.1109/TBME.2013.2291239; Keltner JL, 2014, INVEST OPHTH VIS SCI, V55, P3200, DOI 10.1167/iovs.14-14243; Khan AK, 2015, EXP EYE RES, V130, P29, DOI 10.1016/j.exer.2014.11.007; Kusaka G, 2004, J NEUROSCI METH, V135, P121, DOI 10.1016/j.jneumeth.2003.12.013; Levkovitch-Verbin H, 2002, INVEST OPHTH VIS SCI, V43, P402; Lin JS, 2010, INVEST OPHTH VIS SCI, V51, P5739, DOI 10.1167/iovs.10-5542; Mabuchi F, 2003, INVEST OPHTH VIS SCI, V44, P4321, DOI 10.1167/iovs.03-0138; Mader TH, 2011, OPHTHALMOLOGY, V118, P2058, DOI 10.1016/j.ophtha.2011.06.021; Marzoli SB, 2013, NEUROL SCI, V34, pS143, DOI 10.1007/s10072-013-1373-1; McKinnon SJ, 2009, EXP EYE RES, V88, P816, DOI 10.1016/j.exer.2008.12.002; Monteiro MLR, 2014, EYE, V28, P390, DOI 10.1038/eye.2013.301; MORROW BA, 1990, AM J PHYSIOL, V258, pR1170; Padhye LV, 2013, J NEUROL SCI, V332, P80, DOI 10.1016/j.jns.2013.06.022; Pang JJ, 2015, P NATL ACAD SCI USA, V112, P2593, DOI 10.1073/pnas.1419921112; Pang JJ, 2011, INVEST OPHTH VIS SCI, V52, P4886, DOI 10.1167/iovs.10-5921; Park YS, 2011, CHILD NERV SYST, V27, P903, DOI 10.1007/s00381-011-1398-9; Pease ME, 2011, INVEST OPHTH VIS SCI, V52, P858, DOI 10.1167/iovs.10-5556; Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224; Ren RJ, 2011, GRAEF ARCH CLIN EXP, V249, P1057, DOI 10.1007/s00417-011-1657-1; Ren RJ, 2010, OPHTHALMOLOGY, V117, P259, DOI 10.1016/j.ophtha.2009.06.058; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Ruiz-Ederra J, 2006, EXP EYE RES, V82, P879, DOI 10.1016/j.exer.2005.10.019; Sajjadi SA, 2006, ANN NEUROL, V59, P867, DOI 10.1002/ana.20856; Samsel PA, 2011, INVEST OPHTH VIS SCI, V52, P1671, DOI 10.1167/iovs.09-3921; Samuels BC, 2012, INVEST OPHTH VIS SCI, V53, P7328, DOI 10.1167/iovs.12-10632; Sappington RM, 2010, INVEST OPHTH VIS SCI, V51, P207, DOI 10.1167/iovs.09-3947; Silasi G, 2009, CURR NEUROVASC RES, V6, P62, DOI 10.2174/156720209787466046; Soto I, 2008, J NEUROSCI, V28, P548, DOI 10.1523/JNEUROSCI.3714-07.2008; Wall M, 2014, JAMA NEUROL, V71, P693, DOI 10.1001/jamaneurol.2014.133; Welsbie DS, 2013, P NATL ACAD SCI USA, V110, P4045, DOI 10.1073/pnas.1211284110; Xu H, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-148; Yang DY, 2014, INVEST OPHTH VIS SCI, V55, P3067, DOI 10.1167/iovs.13-13657; Zhang LF, 2014, AVIAT SPACE ENVIR MD, V85, P78, DOI 10.3357/ASEM.3789.2014	58	26	28	1	17	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0014-4835	1096-0007		EXP EYE RES	Exp. Eye Res.	JUL	2015	136						38	44		10.1016/j.exer.2015.04.014			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	CK9LR	WOS:000356562100006	25912998	Green Accepted			2022-02-06	
J	Wang, Z; Wang, Y; Wang, ZY; Zhao, J; Gutkind, JS; Srivatsan, A; Zhang, GF; Liao, HS; Fu, X; Jin, A; Tong, X; Niu, G; Chen, XY				Wang, Zhe; Wang, Yu; Wang, Zhiyong; Zhao, Jun; Gutkind, J. Silvio; Srivatsan, Avinash; Zhang, Guofeng; Liao, Hsien-Shun; Fu, Xiao; Jin, Albert; Tong, Xiao; Niu, Gang; Chen, Xiaoyuan			Polymeric Nanovehicle Regulated Spatiotemporal Real-Time Imaging of the Differentiation Dynamics of Transplanted Neural Stem Cells after Traumatic Brain Injury	ACS NANO			English	Article						stem cells; imaging; traumatic brain injury; differentiation; nanoparticles	DRUG-DELIVERY SYSTEM; ADULT BRAIN; NEUROGENESIS; ANTICANCER; NEURONS; NANOPARTICLES; MODEL; ANTIANGIOGENESIS; NEUROPROTECTION; PRECURSORS	Recent advances in neural stem cell (NSC) transplantation have led to an inspiring progress in alleviating central nervous system (CNS) damages and restoring brain functions from diseases or injuries. One challenge of NSC transplantation is directed differentiation of transplanted NSCs into desired neuronal subtypes, such as neurons, to compensate the adverse impact of brain injury; another challenge lies in the lack of tools to noninvasively monitor the dynamics of NSC differentiation after transplantation in vivo. In this study, we developed a polymer nanovehicle for morphogen sustained release to overcome the drawbacks of conventional methods to realize the long-term directed NSC differentiation in vivo. Moreover, we constructed a bicistronic vector with a unique neuron specific gene tubb3 promoter to drive reporter gene expression for real-time imaging of NSC differentiation and migration. The developed uniform nanovehicle showed efficient NSC uptake and achieved a controlled release of morphogen in cytosol to consistently stimulate NSC differentiation into neurons at a sustainably effective concentration. The spatiotemporal imaging results showed a multiplexed migration, proliferation, differentiation, and apoptosis orchestra of transplanted NSCs regulated by nanovehicles in TBI mice. The imaging results also uncovered the peak time of NSC differentiation in vivo. Although we observed only a handful of NSCs ultimately migrated to the TBI area and differentiated into neurons, those neurons were functional, ameliorating the detrimental impact of TBI. The imaging findings enabled by the nanovehicle and the neuron specific bicistronic vector provide additional understanding of the in vivo behaviors of transplanted NSCs in neuronal regenerative medicine.	[Wang, Zhe; Wang, Yu; Srivatsan, Avinash; Liao, Hsien-Shun; Fu, Xiao; Tong, Xiao; Niu, Gang; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA; [Wang, Zhiyong; Gutkind, J. Silvio] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Zhao, Jun] NIMH, Unit Synapse Dev & Plast, NIH, Bethesda, MD 20892 USA; [Zhang, Guofeng; Liao, Hsien-Shun; Fu, Xiao; Jin, Albert] Natl Inst Biomed Imaging & Bioengn, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD 20892 USA		Chen, XY (corresponding author), Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.	shawn.chen@nih.gov	Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Jin, Albert/0000-0003-3826-1081	Center for Neuroscience and Regenerative Medicine (CNRM) program at the Henry M. Jackson Foundation; Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000073, ZIAEB000015, ZICEB000080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER	This study was supported, in part, by the Center for Neuroscience and Regenerative Medicine (CNRM) program at the Henry M. Jackson Foundation and the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH).	Abematsu M, 2010, J CLIN INVEST, V120, P3255, DOI 10.1172/JCI42957; Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Attardo A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002388; Beal MF, 2001, P NATL ACAD SCI USA, V98, P3, DOI 10.1073/pnas.98.1.3; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Brito C, 2012, METHODS, V56, P452, DOI 10.1016/j.ymeth.2012.03.005; Carbajal KS, 2010, P NATL ACAD SCI USA, V107, P11068, DOI 10.1073/pnas.1006375107; Chanda B, 2013, CELL, V155, P215, DOI 10.1016/j.cell.2013.08.055; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Gaudin A, 2014, NAT NANOTECHNOL, V9, P1054, DOI [10.1038/NNANO.2014.274, 10.1038/nnano.2014.274]; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Gupta N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004373; Hsu YC, 2014, CELL, V157, P935, DOI 10.1016/j.cell.2014.02.057; Hu BY, 2010, METHODS MOL BIOL, V636, P123, DOI 10.1007/978-1-60761-691-7_8; Kokovay E, 2008, NEURON, V60, P420, DOI 10.1016/j.neuron.2008.10.025; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Louis Sharon A, 2013, Methods Mol Biol, V946, P479, DOI 10.1007/978-1-62703-128-8_30; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Okada Y, 2004, DEV BIOL, V275, P124, DOI 10.1016/j.ydbio.2004.07.038; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pollard SM, 2006, CEREB CORTEX, V16, pI112, DOI 10.1093/cercor/bhj167; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Sanberg PR, 2007, P NATL ACAD SCI USA, V104, P11869, DOI 10.1073/pnas.0704704104; Santos T, 2012, ACS NANO, V6, P10463, DOI 10.1021/nn304541h; Stavridis MP, 2010, DEVELOPMENT, V137, P881, DOI 10.1242/dev.043117; Teng YD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004579; Tonge PD, 2010, DIFFERENTIATION, V80, P20, DOI 10.1016/j.diff.2010.04.001; Uchida N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004371; Varga BV, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-89; Wang Z, 2015, STEM CELLS, V33, P456, DOI 10.1002/stem.1878; Wang Z, 2014, ACS NANO, V8, P12386, DOI 10.1021/nn505047n; Wang Z, 2014, PHARM RES-DORDR, V31, P1358, DOI 10.1007/s11095-013-1103-7; Wang Z, 2013, BIOMATERIALS, V34, P6194, DOI 10.1016/j.biomaterials.2013.05.004; Wang Z, 2011, PHARM RES-DORDR, V28, P585, DOI 10.1007/s11095-010-0308-2; Wang Z, 2010, SMALL, V6, P2576, DOI 10.1002/smll.201001122; Wang Z, 2010, BIOMATERIALS, V31, P7115, DOI 10.1016/j.biomaterials.2010.05.075; Wang Z, 2009, PHARM RES-DORDR, V26, P1162, DOI 10.1007/s11095-009-9837-y; Yang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6627; Ziller MJ, 2015, NATURE, V518, P355, DOI 10.1038/nature13990	44	26	26	1	67	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	JUL	2015	9	7					6683	6695		10.1021/acsnano.5b00690			13	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science	CO0EP	WOS:000358823200005	26020550	Green Accepted			2022-02-06	
J	Jiang, Z; Watts, LT; Huang, SL; Shen, Q; Rodriguez, P; Chen, CH; Zhou, CM; Duong, TQ				Jiang, Zhao; Watts, Lora Talley; Huang, Shiliang; Shen, Qiang; Rodriguez, Pavel; Chen, Chunhua; Zhou, Changman; Duong, Timothy Q.			The Effects of Methylene Blue on Autophagy and Apoptosis in MRI-Defined Normal Tissue, Ischemic Penumbra and Ischemic Core	PLOS ONE			English	Article							QUANTITATIVE PERFUSION; CARDIAC-ARREST; STROKE; OXYGEN; REPERFUSION; DIFFUSION; NEUROPROTECTION; BRAIN; RESPONSES; RELEASE	Methylene blue (MB) USP, which has energy-enhancing and antioxidant properties, is currently used to treat methemoglobinemia and cyanide poisoning in humans. We recently showed that MB administration reduces infarct volume and behavioral deficits in rat models of ischemic stroke and traumatic brain injury. This study reports the underlying molecular mechanisms of MB neuroprotection following transient ischemic stroke in rats. Rats were subjected to transient (60-mins) ischemic stroke. Multimodal MRI during the acute phase and at 24hrs were used to define three regions of interest (ROIs): i) the perfusion-diffusion mismatch salvaged by reperfusion, ii) the perfusion-diffusion mismatch not salvaged by reperfusion, and iii) the ischemic core. The tissues from these ROIs were extracted for western blot analyses of autophagic and apoptotic markers. The major findings were: 1) MB treatment reduced infarct volume and behavioral deficits, 2) MB improved cerebral blood flow to the perfusion-diffusion mismatch tissue after reperfusion and minimized harmful hyperperfusion 24hrs after stroke, 3) MB inhibited apoptosis and enhanced autophagy in the perfusion-diffusion mismatch, 4) MB inhibited apoptotic signaling cascades (p53-Bax-Bcl2- Caspase3), and 5) MB enhanced autophagic signaling cascades (p53-AMPK-TSC2-mTOR). MB induced neuroprotection, at least in part, by enhancing autophagy and reducing apoptosis in the perfusion-diffusion mismatch tissue following ischemic stroke.	[Jiang, Zhao; Chen, Chunhua; Zhou, Changman] Peking Univ, Hlth Sci Ctr, Dept Anat & Embryol, Beijing 100871, Peoples R China; [Jiang, Zhao; Watts, Lora Talley; Huang, Shiliang; Shen, Qiang; Rodriguez, Pavel; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA; [Chen, Chunhua] Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, Philadelphia, PA 19104 USA		Duong, TQ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.	DuongT@uthscsa.edu	Shen, Qiang/B-8784-2008; Duong, Tim/AAL-8357-2021	Shen, Qiang/0000-0002-4287-3403; Duong, Tim/0000-0001-6403-2827; jiang, zhao/0000-0002-8192-9908	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS45879]; American Heart AssociationAmerican Heart Association [EIA 0940104N, 12BGIA 9300047]; Translational Technology Resource grant [UL1TR000149]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31271280]; Clinical Translational Science Award Pilot Grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001120, UL1TR000149, KL2TR001118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045879] Funding Source: NIH RePORTER	This work was supported by the NIH (R01-NS45879), the American Heart Association (EIA 0940104N and 12BGIA 9300047), a Clinical Translational Science Award Pilot Grant and a Translational Technology Resource grant (parent grant UL1TR000149) to TQD. This work was also supported in part by the National Natural Science Foundation of China (31271280) to CZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Barbier EL, 2001, J MAGN RESON IMAGING, V13, P496, DOI 10.1002/jmri.1073; Bonova P, 2013, NEUROCHEM INT, V62, P8, DOI 10.1016/j.neuint.2012.10.015; Calamante F, 1999, J CEREBR BLOOD F MET, V19, P701, DOI 10.1097/00004647-199907000-00001; Chen CH, 2013, CNS NEUROSCI THER, V19, P566, DOI 10.1111/cns.12114; Congdon EE, 2012, AUTOPHAGY, V8, P609, DOI 10.4161/auto.19048; Dani KA, 2011, ANN NEUROL, V70, P384, DOI 10.1002/ana.22500; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Duong TQ, 2012, TRANSL STROKE RES, V3, P8, DOI 10.1007/s12975-011-0140-y; Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Geisler BS, 2006, STROKE, V37, P1778, DOI 10.1161/01.STR.0000226738.97426.6f; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Hacke W, 2009, LANCET NEUROL, V8, P141, DOI 10.1016/S1474-4422(08)70267-9; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Huang SL, 2013, NEUROIMAGE, V72, P237, DOI 10.1016/j.neuroimage.2013.01.027; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kidwell CS, 2000, ANN NEUROL, V47, P462, DOI 10.1002/1531-8249(200004)47:4<462::AID-ANA9>3.3.CO;2-P; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kubli DA, 2012, CIRC RES, V111, P1208, DOI 10.1161/CIRCRESAHA.112.265819; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li PA, 2001, BRAIN RES, V896, P69, DOI 10.1016/S0006-8993(01)01997-7; Lin AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046585; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Martijn C, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-27; Peter C, 2000, EUR J CLIN PHARMACOL, V56, P247, DOI 10.1007/s002280000124; Poteet E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048279; Rojas JC, 2012, PROG NEUROBIOL, V96, P32, DOI 10.1016/j.pneurobio.2011.10.007; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; SALARIS SC, 1991, BIOCHEM PHARMACOL, V42, P499, DOI 10.1016/0006-2952(91)90311-R; Santosh C, 2008, J CEREBR BLOOD F MET, V28, P1742, DOI 10.1038/jcbfm.2008.56; Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P887, DOI 10.1097/01.WCB.0000124321.60992.87; Shen Q, 2014, J CEREBR BLOOD F MET, V34, P169, DOI 10.1038/jcbfm.2013.179; Shen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079833; Shen Q, 2011, BRAIN RES, V1425, P132, DOI 10.1016/j.brainres.2011.09.052; Shen Q, 2011, J CEREBR BLOOD F MET, V31, P2076, DOI 10.1038/jcbfm.2011.64; Sun PZ, 2007, J CEREBR BLOOD F MET, V27, P1129, DOI 10.1038/sj.jcbfm.9600424; Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; van der Plaat L W, 2012, Eur Spine J, V21 Suppl 4, pS445, DOI 10.1007/s00586-011-2053-6; Wang P, 2012, AUTOPHAGY, V8, P77, DOI 10.4161/auto.8.1.18274; Watts LT, 2014, J NEUROTRAUM; Wei K, 2012, CNS NEUROSCI THER, V18, P879, DOI 10.1111/cns.12005; Xie LK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00056; Yoo AJ, 2012, J STROKE CEREBROVASC; Yuan JY, 2009, APOPTOSIS, V14, P469, DOI 10.1007/s10495-008-0304-8	53	26	33	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2015	10	6							e0131929	10.1371/journal.pone.0131929			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1BL	WOS:000358150400181	26121129	Green Published, gold, Green Submitted			2022-02-06	
J	Liang, FY; Luo, CM; Xu, GQ; Su, FJ; He, XF; Long, SM; Ren, HX; Liu, YN; Feng, YQ; Pei, Z				Liang, Fengyin; Luo, Chuanming; Xu, Guangqing; Su, Fengjuan; He, Xiaofei; Long, Simei; Ren, Huixia; Liu, Yaning; Feng, Yanqing; Pei, Zhong			Deletion of aquaporin-4 is neuroprotective during the acute stage of micro traumatic brain injury in mice	NEUROSCIENCE LETTERS			English	Article						Aquaporin-4 (AQP4); Micro traumatic brain injury; Acute stage; Cerebral edema	FOCAL CEREBRAL-ISCHEMIA; KNOCKOUT MICE; MOUSE MODEL; EDEMA; BARRIER; EPIDEMIOLOGY; EXPRESSION; PATTERNS; FLUID	Micro traumatic brain injury (TBI) is the most common type of brain injury, but the mechanisms underlying it are poorly understood. Aquaporin-4 (AQP4) is a water channel expressed in astrocyte end-feet, which plays an important role in brain edema. However, little is known about the role of AQP4 in micro TBI. Here, we examined the role of AQP4 in the pathogenesis of micro TBI in a closed-skull brain injury model, using two-photon microscopy. Our results indicate that AQP4 deletion reduced cell death, water content, astrocyte swelling and lesion volume during the acute stage of micro TBI. Our data revealed that astrocyte swelling is a decisive pathophysiological factor in the acute phase of this form of micro brain injury. Thus, treatments that inhibit AQP4 could be used as a neuroprotective strategy for micro TBI. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Liang, Fengyin; Su, Fengjuan; Long, Simei; Liu, Yaning; Feng, Yanqing; Pei, Zhong] Sun Yat Sen Univ, Affiliated Hosp 1,Dept Neurol, Guangdong Key Lab Diag & Treatment Major Neurol D, Natl Key Clin Dept & Key Discipline Neurol, Guangzhou 510080, Guangdong, Peoples R China; [Luo, Chuanming; Ren, Huixia] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China; [Xu, Guangqing; He, Xiaofei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rehabil Med, Guangzhou 510080, Guangdong, Peoples R China		Pei, Z (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1,Dept Neurol, Guangdong Key Lab Diag & Treatment Major Neurol D, Natl Key Clin Dept & Key Discipline Neurol, Guangzhou 510080, Guangdong, Peoples R China.	fyqgz@vip.sina.com; peizhong@mail.sysu.edu.cn			National Key Clinical Department, National Key Discipline, Guangdong Key Laboratory For Diagnosis and Treatment of Major Neurological Diseases [2010A060801005]; Guangdong Science and technology project [2013B051000018]	This study was supported by grants from the National Key Clinical Department, National Key Discipline, Guangdong Key Laboratory For Diagnosis and Treatment of Major Neurological Diseases (No. 2010A060801005), Guangdong Science and technology project (No. 2013B051000018).	Akdemir G, 2014, NEUROSCI LETT, V574, P70, DOI 10.1016/j.neulet.2014.03.073; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Benedek A, 2006, BRAIN RES, V1116, P159, DOI 10.1016/j.brainres.2006.07.123; Cho EE, 2011, J CEREBR BLOOD F MET, V31, P1852, DOI 10.1038/jcbfm.2011.59; Eilert-Olsen M, 2012, GLIA, V60, P432, DOI 10.1002/glia.22277; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Steiner E, 2012, GLIA, V60, P1646, DOI 10.1002/glia.22383; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Wolff RA, 2000, J MOL CELL CARDIOL, V32, P225, DOI 10.1006/jmcc.1999.1074; Yao XM, 2015, NEUROSCI LETT, V584, P368, DOI 10.1016/j.neulet.2014.10.040; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb	23	26	28	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 26	2015	598						29	35		10.1016/j.neulet.2015.05.006			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK9GY	WOS:000356549800006	25957560				2022-02-06	
J	Kilbaugh, TJ; Lvova, M; Karlsson, M; Zhang, Z; Leipzig, J; Wallace, DC; Margulies, SS				Kilbaugh, Todd J.; Lvova, Maria; Karlsson, Michael; Zhang, Zhe; Leipzig, Jeremy; Wallace, Douglas C.; Margulies, Susan S.			Peripheral Blood Mitochondrial DNA as a Biomarker of Cerebral Mitochondrial Dysfunction following Traumatic Brain Injury in a Porcine Model	PLOS ONE			English	Article							RESPONSES	Background Traumatic brain injury (TBI) has been shown to activate the peripheral innate immune system and systemic inflammatory response, possibly through the central release of damage associated molecular patterns (DAMPs). Our main purpose was to gain an initial understanding of the peripheral mitochondrial response following TBI, and how this response could be utilized to determine cerebral mitochondrial bioenergetics. We hypothesized that TBI would increase peripheral whole blood relative mtDNA copy number, and that these alterations would be associated with cerebral mitochondrial bioenergetics triggered by TBI. Methodology Blood samples were obtained before, 6 h after, and 25 h after focal (controlled cortical impact injury: CCI) and diffuse (rapid non-impact rotational injury: RNR) TBI. PCR primers, unique to mtDNA, were identified by aligning segments of nuclear DNA (nDNA) to mtDNA, normalizing values to nuclear 16S rRNA, for a relative mtDNA copy number. Three unique mtDNA regions were selected, and PCR primers were designed within those regions, limited to 25-30 base pairs to further ensure sequence specificity, and measured utilizing qRT-PCR. Results Mean relative mtDNA copy numbers increased significantly at 6 and 25 hrs after following both focal and diffuse traumatic brain injury. Specifically, the mean relative mtDNA copy number from three mitochondrial-specific regions pre-injury was 0.84 +/- 0.05. At 6 and 25 h after diffuse non-impact TBI, mean mtDNA copy number was significantly higher: 2.07 +/- 0.19 (P < 0.0001) and 2.37 +/- 0.42 (P < 0.001), respectively. Following focal impact TBI, relative mtDNA copy number was also significantly higher, 1.35 +/- 0.12 (P < 0.0001) at 25 hours. Alterations in mitochondrial respiration in the hippocampus and cortex post-TBI correlated with changes in the relative mtDNA copy number measured in peripheral blood. Conclusions Alterations in peripheral blood relative mtDNA copy numbers may be a novel biosignature of cerebral mitochondrial bioenergetics with exciting translational potential for non-invasive diagnostic and interventional studies.	[Kilbaugh, Todd J.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Lvova, Maria; Zhang, Zhe; Leipzig, Jeremy; Wallace, Douglas C.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Ctr Mitochondrial & Epigen Med,Dept Pathol & Lab, Philadelphia, PA 19104 USA; [Karlsson, Michael] Lund Univ, Mitochondrial Med, Dept Clin Sci, Lund, Sweden; [Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Kilbaugh, TJ (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA.	kilbaugh@chop.edu	Karlsson, Michael/AAL-8743-2020	Karlsson, Michael/0000-0002-7247-2133; Kilbaugh, Todd/0000-0002-4959-3092; Leipzig, Jeremy/0000-0001-7224-9620	NIH/NINDS grant [U01NS069545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069545, R01NS021328] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS grant: U01NS069545.	Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Chan JK, 2012, J CLIN INVEST, V122, P2711, DOI 10.1172/JCI62423; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Di Filippo M, 2010, J ALZHEIMERS DIS, V20, pS369, DOI 10.3233/JAD-2010-100543; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gnaiger E, 2009, INT J BIOCH CELL BIO; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Jaber SM, 2015, DEV NEUROPSYCHOL, V40, P34, DOI 10.1080/87565641.2014.969733; Karlsson M, 2012, INT J BIOCHEM CELL B, DOI [10.1016/j.biocel.2012.08.008, DOI 10.1016/J.BI0CEL.2012.08.008]; Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282; Lartigue L, 2013, INT J BIOCHEM CELL B, V45, P2052, DOI 10.1016/j.biocel.2013.06.014; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Malik AN, 2013, MITOCHONDRION, V13, P481, DOI 10.1016/j.mito.2012.10.011; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Margulies SS, 2015, BRAIN PATHOL, V25, P289, DOI 10.1111/bpa.12247; Miller AC, 2012, COMMON DATA ELEMENTS; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Walko TD, 2014, SHOCK, V41, P499, DOI 10.1097/SHK.0000000000000160; Weeks D, 2014, J NEUROTRAUM, V31, P206, DOI 10.1089/neu.2013.3113; West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975; Zhang Q, 2010, SHOCK, V34, P55, DOI 10.1097/SHK.0b013e3181cd8c08; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	36	26	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130927	10.1371/journal.pone.0130927			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	WOS:000356835800123	26098565	Green Published, gold, Green Submitted			2022-02-06	
J	Albrecht, JS; Kiptanui, Z; Tsang, Y; Khokhar, B; Liu, XG; Simoni-Wastila, L; Zuckerman, IH				Albrecht, Jennifer S.; Kiptanui, Zippora; Tsang, Yuen; Khokhar, Bilal; Liu, Xinggang; Simoni-Wastila, Linda; Zuckerman, Ilene H.			Depression Among Older Adults After Traumatic Brain Injury: A National Analysis	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article						Depression; older adults; traumatic brain injury	MAJOR DEPRESSION; EPIDEMIOLOGY; COMORBIDITY; ASSOCIATION; DISORDERS; OUTCOMES; ALCOHOL; HEALTH; LIFE	Objective: Sequelae of traumatic brain injury (TBI) include depression, which could exacerbate the poorer cognitive and functional recovery experienced by older adults. The objective of this study was to estimate incidence rates of depression after hospital discharge for TBI among Medicare beneficiaries aged at least 65 years, quantify the increase in risk of depression after TBI, and evaluate risk factors for incident depression post-TBI. Methods: Using a retrospective analysis, the authors studied Medicare beneficiaries at least 65 years old hospitalized for TBI during 2006 to 2010 who survived to hospital discharge and had no documented diagnosis of depression before the study period (N = 67,347). Results: The annualized incidence rate of depression per 1,000 beneficiaries was 62.8 (95% confidence interval [CI]: 61.6, 64.1) pre-TBI and 123.9 (95% CI: 121.6, 126.2) post-TBI. Annualized incidence rates were highest immediately after hospital discharge and declined over the 12 months post-TBI. TBI increased the risk of incident depression in men (hazard ratio: 1.95; 95% CI: 1.84, 2.06; Wald chi(2) = 511.4, df = 1, p < 0.001) and in women (hazard ratio: 1.69; 95% CI: 1.62, 1.77; Wald chi(2) = 589.3, df = 1, p < 0.001). The strongest predictor of depression post-TBI for both men and women was discharge to a skilled nursing facility (men: odds ratio, 1.91; 95% CI, 1.77, 2.06; Wald chi(2) = 277.1, df = 1, p < 0.001; women: odds ratio, 1.72; 95% CI, 1.63, 1.83; Wald chi(2) = 324.2, df = 1, p < 0.001). Conclusion: TBI significantly increased the risk of depression among older adults, especially among men and those discharged to a skilled nursing facility. Results from this study will help increase awareness of the risk of depression post-TBI among older adults.	[Albrecht, Jennifer S.; Kiptanui, Zippora; Tsang, Yuen; Khokhar, Bilal; Liu, Xinggang; Simoni-Wastila, Linda; Zuckerman, Ilene H.] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA; [Liu, Xinggang] Philips Healthcare, Baltimore, MD USA; [Zuckerman, Ilene H.] IMPAQ Int LLC, Columbia, MD USA		Albrecht, JS (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, 220 Arch St,12th Floor, Baltimore, MD 21201 USA.	jalbrecht@rx.umaryland.edu		Albrecht, Jennifer/0000-0003-4838-2274; Kiptanui, Zippora/0000-0003-1212-7642	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AG042768-01, T32AG000262-14]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042768, T32AG000262] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant R21 AG042768-01 (Zuckerman, PI). Dr. Albrecht and Mr. Khokhar are supported by National Institutes of Health grant T32AG000262-14 (Magaziner, PI). The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript or decision to submit the manuscript for publication.	Allison PD, 1995, SURVIVAL ANAL USING; [Anonymous], MED BEN PREV CHRON C; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Beekman ATF, 1997, J AFFECT DISORDERS, V46, P219, DOI 10.1016/S0165-0327(97)00145-6; BLAZER D, 1991, J GERONTOL, V46, pM210, DOI 10.1093/geronj/46.6.M210; Blazer DG, 2003, J GERONTOL A-BIOL, V58, P249; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Centers for Disease Control and Prevention, 2001, RAT TBI REL HOSP AG; Chronic condition warehouse categories, CHRON COND WAR CAT; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul M, TRAUMATIC BRAIN INJU; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fiske A, 2009, ANNU REV CLIN PSYCHO, V5, P363, DOI 10.1146/annurev.clinpsy.032408.153621; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P197, DOI 10.1016/0376-8716(95)01160-4; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034	32	26	28	2	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1064-7481	1545-7214		AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	JUN	2015	23	6					607	614		10.1016/j.jagp.2014.07.006			8	Geriatrics & Gerontology; Gerontology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Psychiatry	CH9EF	WOS:000354338100008	25154547	Green Accepted			2022-02-06	
J	de Kloet, AJ; Lambregts, SAM; Berger, MAM; van Markus, F; Wolterbeek, R; Vlieland, TPMV				de Kloet, Arend J.; Lambregts, Suzanne A. M.; Berger, Monique A. M.; van Markus, Frederike; Wolterbeek, Ron; Vlieland, Thea P. M. Vliet			Family Impact of Acquired Brain Injury in Children and Youth	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article							QUALITY-OF-LIFE; OUTCOME 30 MONTHS; FUNCTIONAL RECOVERY; YOUNG-ADULTS; PREDICTORS; RELIABILITY; VALIDITY; PARTICIPATION; ADOLESCENTS; PEDSQL(TM)	Objective: To assess the parental view on the impact of pediatric traumatic brain injury (TBI) and nontraumatic brain injury (NTBI) on the family and its determinants. Methods: Follow-up study including parents of children with a hospital-based diagnosis of acquired brain injury (ABI) aged 4-20 years at onset of ABI. Parents completed the Pediatric Quality of Life Inventory Family Impact Module (PedsQL FIM), which measures Parent Health-Related Quality of Life, Family Functioning, Communication, and Worry. Additional assessments included the Pediatric Stroke Outcome Measure (PSOM), the Child & Family Follow-up Survey (CFFS), PedsQL General Core and Multiple Fatigue Scales, and sociodemographic and disease characteristics. Results: Parents of 108 patients, median age 13 years (range 5-22), completed the questionnaires 24-30 months after diagnosis. There were 81 patients with TBI of whom 11 (14%) with moderate/severe TBI and 27 patients with NTBI of whom 5 (19%) with moderate/severe NTBI. The median PedsQL FIM Total Scale was 80.4 (SD 16.1). The PedsQL FIM Total Scale and 4 out of 5 Subscale Scores were statistically significantly better in the TBI group than in the NTBI group and in patients with severe NTBI than with mild/moderate NTBI. Moreover, in the total group, there were significant univariate associations between the FIM Total Scale and/or one or more Subscale Scores and age, preinjury patient health problems, and the PSOM, CFFS, PedsQL General Core, and Multiple Fatigue Scales. In the multivariable analysis, the FIM Total Scale was significantly associated with type and severity of injury and preinjury patient health problems. Conclusions: Two years after onset, the parent-reported that impact of ABI on the family as measured by the PedsQL FIM was considerable especially in patients with moderate/severe NTBI.	[de Kloet, Arend J.; Berger, Monique A. M.] Hague Univ Appl Sci, The Hague, Netherlands; [de Kloet, Arend J.; van Markus, Frederike; Vlieland, Thea P. M. Vliet] Sophia Rehabil, NL-2543 SW The Hague, Netherlands; [Lambregts, Suzanne A. M.] Revant Rehabil Ctr, Breda, Netherlands; [Wolterbeek, Ron] Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands; [Vlieland, Thea P. M. Vliet] Leiden Univ, Med Ctr, Dept Orthopaed, Leiden, Netherlands		de Kloet, AJ (corresponding author), Sophia Rehabil, Vrederustlaan 180, NL-2543 SW The Hague, Netherlands.	a.dekloet@sophiarevalidatie.nl	Vlieland, Thea Vliet/AAJ-8119-2020	Vlieland, Thea Vliet/0000-0001-6322-3859	Revalidatiefonds [2010029]; Johanna KinderFonds [0075-1403]; Stichting Kinderrevalidatie Fonds Adriaanstichting [0075-1403]	This study was supported by the Revalidatiefonds (project number 2010029), Johanna KinderFonds (0075-1403), and Stichting Kinderrevalidatie Fonds Adriaanstichting (0075-1403).	Aarsen FK, 2006, CANCER-AM CANCER SOC, V106, P396, DOI 10.1002/cncr.21612; Ab Rahman A, 2011, MALAYS J MED SCI, V18, P63; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bedell GM, 2005, AM J OCCUP THER, V59, P273, DOI 10.5014/ajot.59.3.273; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 2013, STAT POWER ANAL BEHA; de Kloet AJ, 2013, BRAIN INJURY, V27, P843, DOI 10.3109/02699052.2013.775496; de Kloet AJ, 2015, DEV NEUROREHABIL, V18, P357, DOI 10.3109/17518423.2013.850749; Delsing BJP, 2001, PEDIATR NEUROL, V24, P283, DOI 10.1016/S0887-8994(01)00245-4; deVeber GA, 2000, J CHILD NEUROL, V15, P316, DOI 10.1177/088307380001500508; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Galvin J, 2010, AUST OCCUP THER J, V57, P118, DOI 10.1111/j.1440-1630.2009.00822.x; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Green L, 2013, BRAIN INJURY, V27, P872, DOI 10.3109/02699052.2013.775506; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; IBM Corp. Released, 2012, IBM SPSS STAT WIND V; Josie KL, 2008, J HEAD TRAUMA REHAB, V23, P357, DOI 10.1097/01.HTR.0000341431.29133.a8; Kuhlthau KA, 2011, ACAD PEDIATR, V11, P136, DOI 10.1016/j.acap.2010.12.014; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LITTLE RJA, 1993, J AM STAT ASSOC, V88, P125, DOI 10.1080/01621459.1993.10594302; Mano KEJ, 2011, J PEDIATR PSYCHOL, V36, P517, DOI 10.1093/jpepsy/jsp099; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Medrano GR, 2013, QUAL LIFE RES, V22, P2899, DOI 10.1007/s11136-013-0422-9; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Neuner B, 2011, ANN NEUROL, V70, P70, DOI 10.1002/ana.22381; Oakes JM, 2003, SOC SCI MED, V56, P769, DOI 10.1016/S0277-9536(02)00073-4; Pecoraro K, 2010, THESIS U FLORIDA GAI; Prigatano GP, 2007, BRAIN INJURY, V21, P721, DOI 10.1080/02699050701481605; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Scarpelli AC, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-35; Stein REK, 2005, DEV BEHAV PEDIAT, V24, P9; Streiner DL, 2003, HEATH MEASUREMENT SC; TEASDALE G, 1974, LANCET, V2, P81; Varni JW, 2008, QUAL LIFE RES, V17, P105, DOI 10.1007/s11136-007-9282-5; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-1; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Varni JW, 2004, HEALTH QUAL LIFE OUT, V2, P1, DOI DOI https://doi.org/10.1186/1477-7525-2-55; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Walker W, 2005, ED CHILDREN ACQUIRED; Wood, 1997, EVALUATING STRESS BO, P277; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	55	26	26	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-206X	1536-7312		J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	JUN	2015	36	5					342	351		10.1097/DBP.0000000000000169			10	Behavioral Sciences; Psychology, Developmental; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Psychology; Pediatrics	CK5FM	WOS:000356248100006	25961902				2022-02-06	
J	Glenn, TC; Martin, NA; McArthur, DL; Hovda, DA; Vespa, P; Johnson, ML; Horning, MA; Brooks, GA				Glenn, Thomas C.; Martin, Neil A.; McArthur, David L.; Hovda, David A.; Vespa, Paul; Johnson, Matthew L.; Horning, Michael A.; Brooks, George A.			Endogenous Nutritive Support after Traumatic Brain Injury: Peripheral Lactate Production for Glucose Supply via Gluconeogenesis	JOURNAL OF NEUROTRAUMA			English	Article						brain; gluconeogenesis; glucose; glucose homeostasis; glycemia; lactate; mass spectrometry; TBI	SKELETAL-MUSCLE MITOCHONDRIA; TRAINING-INDUCED ALTERATIONS; MODERATE-INTENSITY EXERCISE; MONOCARBOXYLATE TRANSPORTERS; SARCOLEMMAL VESICLES; OXIDATION COMPLEX; HUMANS; MCT1; MEN; METABOLISM	We evaluated the hypothesis that nutritive needs of injured brains are supported by large and coordinated increases in lactate shuttling throughout the body. To that end, we used dual isotope tracer ([6,6-(2)H2]glucose, i.e., D-2-glucose, and [3-C-13]lactate) techniques involving central venous tracer infusion along with cerebral (arterial [art] and jugular bulb [JB]) blood sampling. Patients with traumatic brain injury (TBI) who had nonpenetrating head injuries (n=12, all male) were entered into the study after consent of patients' legal representatives. Written and informed consent was obtained from healthy controls (n=6, including one female). As in previous investigations, the cerebral metabolic rate (CMR) for glucose was suppressed after TBI. Near normal arterial glucose and lactate levels in patients studied 5.7 +/- 2.2 days (range of days 2-10) post-injury, however, belied a 71% increase in systemic lactate production, compared with control, that was largely cleared by greater (hepatic+renal) glucose production. After TBI, gluconeogenesis from lactate clearance accounted for 67.1% of glucose rate of appearance (Ra), which was compared with 15.2% in healthy controls. We conclude that elevations in blood glucose concentration after TBI result from a massive mobilization of lactate from corporeal glycogen reserves. This previously unrecognized mobilization of lactate subserves hepatic and renal gluconeogenesis. As such, a lactate shuttle mechanism indirectly makes substrate available for the body and its essential organs, including the brain, after trauma. In addition, when elevations in arterial lactate concentration occur after TBI, lactate shuttling may provide substrate directly to vital organs of the body, including the injured brain.	[Glenn, Thomas C.; Martin, Neil A.; McArthur, David L.; Hovda, David A.; Vespa, Paul] Univ Calif Los Angeles, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; [Glenn, Thomas C.; Martin, Neil A.] Univ Calif Los Angeles, UCLA Ctr Hlth Sci, Div Neurosurg, Los Angeles, CA 90095 USA; [Johnson, Matthew L.; Horning, Michael A.; Brooks, George A.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA		Glenn, TC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	tglenn@mednet.ucla.edu		Glenn, Thomas/0000-0003-4273-3408; Brooks, George A./0000-0002-1389-1629; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS058489] Funding Source: Medline		Abu Fanne R, 2011, AM J PHYSIOL-REG I, V301, pR668, DOI 10.1152/ajpregu.00058.2011; AHLBORG G, 1982, J CLIN INVEST, V69, P45, DOI 10.1172/JCI110440; Armstead WM, 2011, J NEUROTRAUM, V28, P451, DOI 10.1089/neu.2010.1659; Bergman BC, 2000, AM J PHYSIOL-ENDOC M, V278, pE244, DOI 10.1152/ajpendo.2000.278.2.E244; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684, DOI 10.1152/jappl.1999.87.5.1684; Bergman BC, 1999, AM J PHYSIOL-ENDOC M, V277, pE81, DOI 10.1152/ajpendo.1999.277.1.E81; Bergman BC, 2009, J PHYSIOL-LONDON, V587, P2087, DOI 10.1113/jphysiol.2008.168286; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Bratton S, 2007, J NEUROTRAUM, V24, P7; Brooks GA, 1998, AM J PHYSIOL-REG I, V275, pR1192, DOI 10.1152/ajpregu.1998.275.4.R1192; BROOKS GA, 1992, J APPL PHYSIOL, V72, P2435, DOI 10.1152/jappl.1992.72.6.2435; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/BST0300258; BROOKS GA, 1991, J APPL PHYSIOL, V71, P333, DOI 10.1152/jappl.1991.71.1.333; Brooks GA, 1999, J APPL PHYSIOL, V87, P1713, DOI 10.1152/jappl.1999.87.5.1713; BROOKS GA, 1983, AM J PHYSIOL, V244, pE505, DOI 10.1152/ajpendo.1983.244.5.E505; Brooks GA., 1984, COM PHYSL BIOCH, P208, DOI [10.1007/978-3-642-70610-3_15, DOI 10.1007/978-3-642-70610-3_15]; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Butz CE, 2004, J APPL PHYSIOL, V97, P1059, DOI 10.1152/japplphysiol.00009.2004; Casaer MP, 2014, NEW ENGL J MED, V370, P1227, DOI 10.1056/NEJMra1304623; DONOVAN CM, 1983, AM J PHYSIOL, V244, pE83, DOI 10.1152/ajpendo.1983.244.1.E83; Dubouchaud H, 2000, AM J PHYSIOL-ENDOC M, V278, pE571, DOI 10.1152/ajpendo.2000.278.4.E571; Elustondo PA, 2013, J BIOL CHEM, V288, P25309, DOI 10.1074/jbc.M113.476648; Emhoff CAW, 2013, J APPL PHYSIOL, V114, P297, DOI 10.1152/japplphysiol.01202.2012; Fattor JA, 2005, AM J PHYSIOL-ENDOC M, V288, pE143, DOI 10.1152/ajpendo.00117.2004; Friedlander AL, 1998, J APPL PHYSIOL, V85, P1175, DOI 10.1152/jappl.1998.85.3.1175; Friedlander AL, 1997, J APPL PHYSIOL, V82, P1360, DOI 10.1152/jappl.1997.82.4.1360; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; GERTZ EW, 1981, CIRCULATION, V63, P1273, DOI 10.1161/01.CIR.63.6.1273; GERTZ EW, 1988, J CLIN INVEST, V82, P2017, DOI 10.1172/JCI113822; Glenn T. C., 2014, J NEUROTRAU IN PRESS; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hashimoto T, 2005, J PHYSIOL-LONDON, V567, P121, DOI 10.1113/jphysiol.2005.087411; Hashimoto T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002915; Hashimoto T, 2007, FASEB J, V21, P2602, DOI 10.1096/fj.07-8174com; Hashimoto T, 2006, AM J PHYSIOL-ENDOC M, V290, pE1237, DOI 10.1152/ajpendo.00594.2005; Henderson GC, 2008, AM J CLIN NUTR, V87, P1686, DOI 10.1093/ajcn/87.6.1686; Henderson GC, 2007, AM J PHYSIOL-ENDOC M, V292, pE366, DOI 10.1152/ajpendo.00363.2006; Herzog RI, 2013, J CLIN INVEST, V123, P1988, DOI 10.1172/JCI65105; Hill AV, 1923, Q J MED, V16, P135, DOI 10.1093/qjmed/os-16.62.135; Hintze JL, 1998, AM STAT, V52, P181, DOI 10.2307/2685478; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Jacobs RA, 2013, AM J PHYSIOL-ENDOC M, V304, pE686, DOI 10.1152/ajpendo.00476.2012; Johnson J A, 1972, Adv Metab Disord, V60, P1; Johnson ML, 2012, AM J PHYSIOL-REG I, V302, pR143, DOI 10.1152/ajpregu.00402.2011; Johnson ML, 2011, AM J PHYSIOL-REG I, V301, pR769, DOI 10.1152/ajpregu.00206.2011; MAZZEO RS, 1995, AM J PHYSIOL-REG I, V269, pR201, DOI 10.1152/ajpregu.1995.269.1.R201; MAZZEO RS, 1986, J APPL PHYSIOL, V60, P232, DOI 10.1152/jappl.1986.60.1.232; McClelland GB, 2003, BIOCHEM BIOPH RES CO, V304, P130, DOI 10.1016/S0006-291X(03)00550-3; Messonnier LA, 2013, J APPL PHYSIOL, V114, P1593, DOI 10.1152/japplphysiol.00043.2013; Meyer C, 2002, AM J PHYSIOL-ENDOC M, V282, pE419, DOI 10.1152/ajpendo.00032.2001; Meyerhof O, 1920, PFLUG ARCH GES PHYS, V182, P232, DOI 10.1007/BF01723747; Miller BF, 2002, J PHYSIOL-LONDON, V544, P963, DOI 10.1113/jphysiol.2002.027128; Miller BF, 2002, AM J PHYSIOL-ENDOC M, V283, pE889, DOI 10.1152/ajpendo.00266.2002; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Pellerin L, 2005, J NEUROSCI RES, V79, P55, DOI 10.1002/jnr.20307; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Price NT, 1998, BIOCHEM J, V329, P321; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Richardson RS, 1998, J APPL PHYSIOL, V85, P627, DOI 10.1152/jappl.1998.85.2.627; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P386, DOI 10.1016/0003-9861(90)90506-T; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P377, DOI 10.1016/0003-9861(90)90505-S; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schruth D. M., 2012, CAROLINE COLLECTION; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; Schurr A, 2008, J PHYSIOL-LONDON, V586, P2665, DOI 10.1113/jphysiol.2008.155416; Schurr A, 2012, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00096; STANLEY WC, 1986, J APPL PHYSIOL, V60, P1116, DOI 10.1152/jappl.1986.60.4.1116; STANLEY WC, 1988, METABOLISM, V37, P850, DOI 10.1016/0026-0495(88)90119-9; STANLEY WC, 1985, AM J PHYSIOL, V249, pE595, DOI 10.1152/ajpendo.1985.249.6.E595; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Wilcox R.R., 2012, INTRO ROBUST ESTIMAT; Wolfe R. R., 1982, RADIOACTIVE STABLE I, P81; Yuen K.F., 1985, J ROYAL STAT SOC D, V34, P175; Zhang ZH, 2014, CRIT CARE MED, V42, P2118, DOI 10.1097/CCM.0000000000000405; Zilversmit DB, 1943, J GEN PHYSIOL, V26, P333, DOI 10.1085/jgp.26.3.333	80	26	27	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					811	819		10.1089/neu.2014.3482			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700006	25279664	Green Submitted, Green Published			2022-02-06	
J	Jourdan, C; Bayen, E; Darnoux, E; Ghout, I; Azerad, S; Ruet, A; Vallat-Azouvi, C; Pradat-Diehl, P; Aegerter, P; Weiss, JJ; Azouvi, P				Jourdan, Claire; Bayen, Eleonore; Darnoux, Emmanuelle; Ghout, Idir; Azerad, Sylvie; Ruet, Alexis; Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Aegerter, Philippe; Weiss, Jean-Jacques; Azouvi, Philippe			Patterns of post-acute health care utilization after a severe traumatic brain injury: Results from the PariS-TBI cohort	BRAIN INJURY			English	Article						Brain injuries; cohort studies; health services research; healthcare surveys; rehabilitation; vocational rehabilitation	SERVICE UTILIZATION; MEDICAL-CARE; REHABILITATION; OUTCOMES; HOSPITALIZATION; DISABILITY; VALIDITY; ADULTS; COSTS; NEEDS	Objective: To assess brain injury services utilization and their determinants using Andersen's model. Methods: Prospective follow-up of the PariS-TBI inception cohort. Out of 504 adults with severe traumatic brain injury (TBI), 245 survived and 147 received a 4-year outcome assessment (mean age 33 years, 80% men). Provision rates of medical, rehabilitation, social and re-entry services and their relations to patients' characteristics were assessed. Results: Following acute care discharge, 78% of patients received physiotherapy, 61% speech/cognitive therapy, 50% occupational therapy, 41% psychological assistance, 63% specialized medical follow-up, 21% community re-entry assistance. Health-related need factors, in terms of TBI severity, were the main predictors of services. Provision of each therapy was significantly associated with corresponding speech, motor and psychological impairments. However, care provision did not depend on cognitive impairments and cognitive therapy was related to predisposing and geographical factors. Community re-entry assistance was provided to younger and more independent patients. Conclusions: These quantitative findings illustrate strengths and weaknesses of late brain injury care provision in urban France and highlight the need to improve treatment of cognitive impairments.	[Jourdan, Claire; Ruet, Alexis; Vallat-Azouvi, Claire; Azouvi, Philippe] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, F-92380 Garches, France; [Jourdan, Claire; Ruet, Alexis; Aegerter, Philippe; Azouvi, Philippe] Univ Versailles, EA ECIPSY 4047, St Quentin en Yvelines, France; [Bayen, Eleonore] Univ Paris 09, Lab Econ & Gest Org Sante LEDa LEGOS, Paris, France; [Bayen, Eleonore; Pradat-Diehl, Pascale] Univ Paris 06, Paris, France; [Bayen, Eleonore; Pradat-Diehl, Pascale] Hop Univ Pitie Salpetriere Charles Foix, AP HP, Paris, France; [Darnoux, Emmanuelle; Azerad, Sylvie; Weiss, Jean-Jacques] CRFTC, Paris, France; [Darnoux, Emmanuelle; Ghout, Idir; Azerad, Sylvie; Aegerter, Philippe] Hop Ambroise Pare, AP HP, URC, Boulogne, France; [Vallat-Azouvi, Claire] Hop Raymond Poincare, Antenne UEROS UGECAM IDF SAMSAH92, F-92380 Garches, France		Jourdan, C (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, 104 Bd Raymond Poincare, F-92380 Garches, France.	claire.jourdan@rpc.aphp.fr	AEGERTER, Philippe/AAY-6003-2021; RUET, Alexis/L-8726-2015	AEGERTER, Philippe/0000-0002-9156-5028; RUET, Alexis/0000-0002-5080-5734	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM04084]; AP-HP (Departement de la Recherche Clinique et du Developpement); Institut de Recherche en Sante Publique (IRESP)	The first part of this study was funded by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004, AOM04084) and sponsored by AP-HP (Departement de la Recherche Clinique et du Developpement). The second part of this study was funded by a grant from the Institut de Recherche en Sante Publique (IRESP).	ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J, 1998, STAT POWER ANAL BEHA; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Horn W, 2000, DISABIL REHABIL, V22, P358, DOI 10.1080/096382800296601; INSEE, REV SAL NIV VIE MED; INSEE, REV COMM NIV EC VAR; INSEE, 2007, FRENCH POP IL DE FRA; INSEE, POP POP AG 2007 2040; JENNETT B, 1975, LANCET, V1, P480; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2013, NEUROREHAB NEURAL RE, V27, P35, DOI 10.1177/1545968312440744; Kadushin G, 2004, HEALTH SOC WORK, V29, P219, DOI 10.1093/hsw/29.3.219; Le Gall C., 2007, Annales de Readaptation et de Medecine Physique, V50, P5, DOI 10.1016/j.annrmp.2006.06.007; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; MAHONEY F I, 1965, Md State Med J, V14, P61; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mittelmann M, 1991, J Insur Med, V23, P55; Ordre National des Medecins, ATL DEM MED 2012; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Pradat-Diehl P., 2012, Annals of Physical and Rehabilitation Medicine, V55, P546, DOI 10.1016/j.rehab.2012.07.002; Prang KH, 2012, BRAIN INJURY, V26, P1611, DOI 10.3109/02699052.2012.698790; R Development Core Team, 2012, R LANG ENV STAT COMP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Simpson G, 2005, DISABIL REHABIL, V27, P901, DOI 10.1080/09638280500030589; Soury S., 2005, Annales de Readaptation et de Medecine Physique, V48, P61, DOI 10.1016/j.annrmp.2004.08.007; TEASDALE G, 1974, LANCET, V2, P81; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1016/S0079-6123(09)17707-5; van Buuren S, 2011, MICE MULTIVARIATE IM, P45; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Willemse-van Son AHP, 2009, J REHABIL MED, V41, P59, DOI 10.2340/16501977-0294; Wrona RM, 2010, DISABIL REHABIL, V32, P650, DOI 10.3109/09638280903186327; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	44	26	27	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2015	29	6					701	708		10.3109/02699052.2015.1004646			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CL8RL	WOS:000357241700004	25789712				2022-02-06	
J	Mayhew, J; Beart, PM; Walker, FR				Mayhew, J.; Beart, P. M.; Walker, F. R.			Astrocyte and Microglial Control of Glutamatergic Signalling: A Primer on Understanding the Disruptive Role of Chronic Stress	JOURNAL OF NEUROENDOCRINOLOGY			English	Article; Proceedings Paper	8th International Congress of Neuroendocrinology integrated with the 18th Annual Meeting of the Society for Behavioural Neuroendocrinology	AUG, 2014	Sydney, AUSTRALIA			stress; microglia; astrocyte; glutamate; Chronic stress; depression	FIBRILLARY ACIDIC PROTEIN; LONG-TERM POTENTIATION; MAJOR DEPRESSIVE DISORDER; CHRONIC PSYCHOSOCIAL STRESS; TRAUMATIC BRAIN-INJURY; PREFRONTAL CORTEX; AMINO-ACID; RAT HIPPOCAMPUS; IN-VITRO; EXTRACELLULAR GLUTAMATE	It is now well established that chronic stress can induce significant structural remodelling of astrocytes and microglia. Until recently, however, the full significance of these morphological disturbances has remained unclear. Clues to the significance of astroglial re-organisation following stress are beginning to emerge from a compelling literature describing how astrocytes contribute to glutamatergic neurotransmission. The present review briefly summarises these two fields of research, identifies points of overlap and, in doing so, pin-points future research directions for stress neurobiology. Ultimately, understanding how chronic stress can disrupt the interactions of astrocytes and microglia with neurones has the potential in the future to improve the development of therapeutics designed to treat stress-related illnesses such as depression.	[Mayhew, J.; Walker, F. R.] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Mayhew, J.; Walker, F. R.] Univ Newcastle, Ctr Translat Neurosci, Callaghan, NSW 2308, Australia; [Mayhew, J.; Walker, F. R.] Univ Newcastle, Mental Hlth Res, Callaghan, NSW 2308, Australia; [Mayhew, J.; Walker, F. R.] Hunter Med Res Inst, New Lambton Hts, NSW, Australia; [Beart, P. M.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia		Walker, FR (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.	rohan.walker@newcastle.edu.au			NHMRCNational Health and Medical Research Council of Australia [APP1019833]	FRW acknowledges support from the NHMRC. PMB was supported by NHMRC Research Fellowships APP1019833. The Florey Institute of Neuroscience and Mental Health receives infrastructure support from the Victorian State Government (Australia).	Abraham I, 1996, BRAIN RES, V733, P56; Alfarez DN, 2003, EUR J NEUROSCI, V17, P1928, DOI 10.1046/j.1460-9568.2003.02622.x; Ando RD, 2013, BRAIN RES BULL, V93, P80, DOI 10.1016/j.brainresbull.2012.09.016; Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Bagley J, 1997, NEUROSCIENCE, V77, P65, DOI 10.1016/S0306-4522(96)00435-6; Banasr M, 2010, MOL PSYCHIATR, V15, P501, DOI 10.1038/mp.2008.106; Banasr M, 2008, BIOL PSYCHIAT, V64, P863, DOI 10.1016/j.biopsych.2008.06.008; BARTANUSZ V, 1995, NEUROSCIENCE, V66, P247, DOI 10.1016/0306-4522(95)00084-V; Bechtholt-Gompf AJ, 2010, NEUROPSYCHOPHARMACOL, V35, P2049, DOI 10.1038/npp.2010.74; Beschorner R, 2007, HISTOPATHOLOGY, V50, P897, DOI 10.1111/j.1365-2559.2007.02703.x; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bowley MP, 2002, BIOL PSYCHIAT, V52, P404, DOI 10.1016/S0006-3223(02)01404-X; Bowser DN, 2007, J GEN PHYSIOL, V129, P485, DOI 10.1085/jgp.200709780; Brown DR, 1999, GLIA, V25, P282, DOI 10.1002/(SICI)1098-1136(19990201)25:3<282::AID-GLIA8>3.0.CO;2-N; Cao X, 2013, NAT MED, V19, P773, DOI 10.1038/nm.3162; Cervetto C, 2013, J NEUROCHEM, V124, P821, DOI 10.1111/jnc.12143; Chaouloff F, 2007, J NEUROSCI, V27, P7130, DOI 10.1523/JNEUROSCI.1150-07.2007; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Chretien F, 2002, NEUROPATH APPL NEURO, V28, P410, DOI 10.1046/j.1365-2990.2002.00426.x; Chretien F, 2004, J NEUROPATH EXP NEUR, V63, P1058, DOI 10.1093/jnen/63.10.1058; Cotter D, 2001, ARCH GEN PSYCHIAT, V58, P545, DOI 10.1001/archpsyc.58.6.545; Cotter DR, 2001, BRAIN RES BULL, V55, P585, DOI 10.1016/S0361-9230(01)00527-5; Czeh B, 2006, NEUROPSYCHOPHARMACOL, V31, P1616, DOI 10.1038/sj.npp.1300982; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davis S, 2002, J NEUROL NEUROSUR PS, V73, P556, DOI 10.1136/jnnp.73.5.556; Domin H, 2014, BEHAV BRAIN RES, V273, P23, DOI 10.1016/j.bbr.2014.07.019; Eyo UB, 2014, J NEUROSCI, V34, P10528, DOI 10.1523/JNEUROSCI.0416-14.2014; Fatemi SH, 2004, SCHIZOPHR RES, V69, P317, DOI 10.1016/j.schres.2003.08.014; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973; Fontella FU, 2004, NEUROCHEM RES, V29, P1703, DOI 10.1023/B:NERE.0000035805.46592.6c; FOY MR, 1987, BEHAV NEURAL BIOL, V48, P138, DOI 10.1016/S0163-1047(87)90664-9; GILAD GM, 1990, BRAIN RES, V525, P335, DOI 10.1016/0006-8993(90)90886-G; Gosselin RD, 2009, NEUROSCIENCE, V159, P915, DOI 10.1016/j.neuroscience.2008.10.018; Gourley SL, 2012, PSYCHOPHARMACOLOGY, V219, P805, DOI 10.1007/s00213-011-2403-4; Hascup ER, 2010, J NEUROCHEM, V115, P1608, DOI 10.1111/j.1471-4159.2010.07066.x; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Hughes EG, 2004, MOL BRAIN RES, V124, P114, DOI 10.1016/j.molbrainres.2004.02.021; Jacobsson J, 2006, NEUROSCIENCE, V139, P475, DOI 10.1016/j.neuroscience.2005.12.046; Joels M, 2007, FRONT NEUROENDOCRIN, V28, P72, DOI 10.1016/j.yfrne.2007.04.001; John CS, 2012, NEUROPSYCHOPHARMACOL, V37, P2467, DOI 10.1038/npp.2012.105; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Karst H, 2005, P NATL ACAD SCI USA, V102, P19204, DOI 10.1073/pnas.0507572102; Karst H, 2005, J NEUROPHYSIOL, V94, P3479, DOI 10.1152/jn.00143.2005; Kong H, 2014, CNS NEUROSCI THER, V20, P391, DOI 10.1111/cns.12222; Lau CL, 2010, NEUROCHEM RES, V35, P735, DOI 10.1007/s11064-010-0130-6; Liu RJ, 2008, P NATL ACAD SCI USA, V105, P359, DOI 10.1073/pnas.0706679105; Marcoli M, 2008, J NEUROCHEM, V105, P2330, DOI 10.1111/j.1471-4159.2008.05322.x; Marin-Garcia P, 2008, NEUROSCIENCE, V151, P361, DOI 10.1016/j.neuroscience.2007.10.038; McEwen BS, 2012, NEUROPHARMACOLOGY, V62, P3, DOI 10.1016/j.neuropharm.2011.07.014; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; McNally L, 2008, CNS SPECTRUMS, V13, P501, DOI 10.1017/S1092852900016734; Miguel-Hidalgo JJ, 2000, BIOL PSYCHIAT, V48, P861, DOI 10.1016/S0006-3223(00)00999-9; MOGHADDAM B, 1994, BRAIN RES, V655, P251, DOI 10.1016/0006-8993(94)91622-5; MOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Murugan M, 2013, CNS NEUROL DISORD-DR, V12, P773, DOI 10.2174/18715273113126660174; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Navarrete M, 2008, NEURON, V57, P883, DOI 10.1016/j.neuron.2008.01.029; Ohsawa K, 2007, GLIA, V55, P604, DOI 10.1002/glia.20489; Ohsawa K, 2010, GLIA, V58, P790, DOI 10.1002/glia.20963; Olivenza R, 2000, J NEUROCHEM, V74, P785, DOI 10.1046/j.1471-4159.2000.740785.x; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; Pavlides C, 2002, HIPPOCAMPUS, V12, P245, DOI 10.1002/hipo.1116; Perea G, 2005, J NEUROSCI, V25, P2192, DOI 10.1523/JNEUROSCI.3965-04.2005; Perea G, 2007, SCIENCE, V317, P1083, DOI 10.1126/science.1144640; Persson M, 2005, GLIA, V51, P111, DOI 10.1002/glia.20191; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Reagan LP, 2004, P NATL ACAD SCI USA, V101, P2179, DOI 10.1073/pnas.0307294101; Rodrigues RJ, 2005, J NEUROSCI, V25, P6286, DOI 10.1523/JNEUROSCI.0628-05.2005; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Roumier A, 2004, J NEUROSCI, V24, P11421, DOI 10.1523/JNEUROSCI.2251-04.2004; Roumier A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002595; Sanacora G, 2008, NAT REV DRUG DISCOV, V7, P426, DOI 10.1038/nrd2462; Sanacora G, 2012, NEUROPHARMACOLOGY, V62, P63, DOI 10.1016/j.neuropharm.2011.07.036; Schipke CG, 2001, FASEB J, V15, P255, DOI 10.1096/fj.01-0514fje; Shigeri Y, 2004, BRAIN RES REV, V45, P250, DOI 10.1016/j.brainresrev.2004.04.004; SHORS TJ, 1989, SCIENCE, V244, P224, DOI 10.1126/science.2704997; Si XH, 2004, NEUROPSYCHOPHARMACOL, V29, P2088, DOI 10.1038/sj.npp.1300525; Sieger D, 2012, DEV CELL, V22, P1138, DOI 10.1016/j.devcel.2012.04.012; Siegrist J, 2008, EUR ARCH PSY CLIN N, V258, P115, DOI 10.1007/s00406-008-5024-0; Sperlagh B, 2002, J NEUROCHEM, V81, P1196, DOI 10.1046/j.1471-4159.2002.00920.x; Sullivan SM, 2007, J BIOL CHEM, V282, P29414, DOI 10.1074/jbc.M704152200; Tomasello E, 2000, IMMUNITY, V13, P355, DOI 10.1016/S1074-7613(00)00035-2; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Tynan RJ, 2013, ACTA NEUROPATHOL, V126, P75, DOI 10.1007/s00401-013-1102-0; Vallat-Decouvelaere AV, 2003, J NEUROPATH EXP NEUR, V62, P475, DOI 10.1093/jnen/62.5.475; Venero C, 1999, EUR J NEUROSCI, V11, P2465, DOI 10.1046/j.1460-9568.1999.00668.x; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Vesce S, 1997, FEBS LETT, V411, P107, DOI 10.1016/S0014-5793(97)00674-1; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wang CC, 2009, SYNAPSE, V63, P745, DOI 10.1002/syn.20654; Wang ZY, 2003, VIROLOGY, V312, P60, DOI 10.1016/S0042-6822(03)00181-8; Webster MJ, 2001, BRAIN BEHAV IMMUN, V15, P388, DOI 10.1006/brbi.2001.0646; Whitehead G, 2013, BRAIN, V136, P3753, DOI 10.1093/brain/awt293; Wollmer MA, 2001, J NEUROIMMUNOL, V115, P19, DOI 10.1016/S0165-5728(01)00257-0; Wong TP, 2007, P NATL ACAD SCI USA, V104, P11471, DOI 10.1073/pnas.0702308104; Xu L, 1997, NATURE, V387, P497, DOI 10.1038/387497a0; Yang CH, 2005, J NEUROSCI, V25, P4288, DOI 10.1523/JNEUROSCI.0406-05.2005; Ye YY, 2011, NEUROSCI LETT, V503, P15, DOI 10.1016/j.neulet.2011.07.055; Yuen EY, 2012, NEURON, V73, P962, DOI 10.1016/j.neuron.2011.12.033; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; Zink M, 2010, NEUROPHARMACOLOGY, V58, P465, DOI 10.1016/j.neuropharm.2009.09.005; Zschocke J, 2005, J BIOL CHEM, V280, P34924, DOI 10.1074/jbc.M502581200	113	26	26	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	JUN	2015	27	6			SI		498	506		10.1111/jne.12273			9	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Endocrinology & Metabolism; Neurosciences & Neurology	CJ1HA	WOS:000355233400014	25737228				2022-02-06	
J	Wade, NG; Vogel, DL; Armistead-Jehle, P; Meit, SS; Heath, PJ; Strass, HA				Wade, Nathaniel G.; Vogel, David L.; Armistead-Jehle, Patrick; Meit, Scott S.; Heath, Patrick J.; Strass, Haley A.			Modeling Stigma, Help-Seeking Attitudes, and Intentions to Seek Behavioral Healthcare in a Clinical Military Sample	PSYCHIATRIC REHABILITATION JOURNAL			English	Article						public stigma; self-stigma; help seeking; attitudes; military	NATIONAL-GUARD SOLDIERS; SELF-STIGMA; PSYCHOLOGICAL HELP; COMMITMENT THERAPY; PUBLIC STIGMA; ACTIVE-DUTY; BARRIERS; IMPACT; COMBAT; IRAQ	Objective: This study examined the relationship between public and self-stigma of seeking behavioral health services, and help-seeking attitudes and intent in a sample of active duty military personnel currently being assessed for traumatic brain injuries in a military health center. Although it has been suggested that many military personnel in need of care do not seek services due to concerns with stigma it is not fully clear what role different types of stigma play in the process. Method: Using previously collected data from a clinical sample of 97 military personnel, we conducted path analyses to test the mediation effects of self-stigma on the relationship between public stigma and attitudes toward and intentions to seek behavioral health care. Results: In contrast to a model of military stigma but in line with research with civilian samples, results from this study indicate that self-stigma fully mediates the relationship between public stigma and help-seeking attitudes and intentions. Conclusions and Implications for Practice: These results indicate that programming aimed at increasing mental health care use in the military might best focus on reducing self-stigma associated with seeking mental health services.	[Wade, Nathaniel G.; Vogel, David L.; Heath, Patrick J.; Strass, Haley A.] Iowa State Univ, Dept Psychol, Ames, IA USA; [Armistead-Jehle, Patrick; Meit, Scott S.] Munson Army Hlth Ctr, Dept Behav Hlth, Ft Leavenworth, KS USA		Wade, NG (corresponding author), Iowa State Univ Sci & Technol, Dept Psychol, W112 Lagomarcino Hall, Ames, IA 50011 USA.	nwade@iastate.edu	Heath, Patrick/S-2713-2019; Armistead-Jehle, Patrick/AAU-5741-2020	Heath, Patrick/0000-0002-7939-4916; Armistead-Jehle, Patrick/0000-0002-6784-1432			AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Britt TW, 2007, MIL MED, V172, P157, DOI 10.7205/MILMED.172.2.157; CASH TF, 1975, J COUNS PSYCHOL, V22, P273, DOI 10.1037/h0076730; Cornish M. A., 2012, ANN CONV AM PSYCH AS; Corrigan P, 2004, AM PSYCHOL, V59, P614, DOI 10.1037/0003-066X.59.7.614; Corrigan PW, 2009, WORLD PSYCHIATRY, V8, P75; Efron B, 1993, MONOGRAPHS STAT APPL, V57; FISCHER EH, 1995, J COLL STUDENT DEV, V36, P368; FISCHER EH, 1970, J CONSULT CLIN PSYCH, V35, P79, DOI 10.1037/h0029636; Gould M, 2010, J ROY SOC MED, V103, P148, DOI 10.1258/jrsm.2010.090426; Hammer JH, 2013, PSYCHOL MEN MASCULIN, V14, P65, DOI 10.1037/a0026813; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Kehle SM, 2010, J TRAUMA STRESS, V23, P33, DOI 10.1002/jts.20480; Kim PY, 2010, PSYCHIAT SERV, V61, P582, DOI 10.1176/ps.2010.61.6.582; Komiya N, 2000, J COUNS PSYCHOL, V47, P138, DOI 10.1037/0022-0167.47.1.138; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Lannin D. G., THE COUNSELING PSYCH; Lannin DG, 2013, J COUNS PSYCHOL, V60, P508, DOI 10.1037/a0033789; Ludwikowski WMA, 2009, J COUNS PSYCHOL, V56, P408, DOI 10.1037/a0016180; Luoma JB, 2008, ADDICT RES THEORY, V16, P149, DOI 10.1080/16066350701850295; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Martens MP, 2005, COUNS PSYCHOL, V33, P375, DOI 10.1177/0011000005274598; Masuda A, 2007, BEHAV RES THER, V45, P2764, DOI 10.1016/j.brat.2007.05.008; Mental Health Advisory Team Six, 2009, OP IR FREED 07 09; Mittal D, 2012, PSYCHIAT SERV, V63, P974, DOI 10.1176/appi.ps.201100459; Nash W. P., 2007, COMBAT STRESS INJURY, P70; Nash WP, 2009, PSYCHIAT ANN, V39, P789, DOI 10.3928/00485713-20090728-05; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shrout PE, 2002, PSYCHOL METHODS, V7, P422, DOI 10.1037//1082-989X.7.4.422; Skopp NA, 2012, J CLIN PSYCHOL, V68, P1036, DOI 10.1002/jclp.21889; Stecker T, 2007, PSYCHIAT SERV, V58, P1358, DOI 10.1176/appi.ps.58.10.1358; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Vogel DL, 2007, J COUNS PSYCHOL, V54, P40, DOI 10.1037/0022-0167.54.1.40; Vogel DL, 2006, J COUNS PSYCHOL, V53, P325, DOI 10.1037/0022-0167.53.3.325; Vogel DL, 2013, J COUNS PSYCHOL, V60, P311, DOI 10.1037/a0031889; Vogel DL, 2010, COUNS PSYCHOL, V38, P904, DOI 10.1177/0011000010368297; Wade N. G., 2013, ANN CONV AM PSYCH AS; Warner CH, 2008, MIL MED, V173, P563, DOI 10.7205/MILMED.173.6.563; Westphal RJ, 2007, MIL MED, V172, P1138, DOI 10.7205/MILMED.172.11.1138; Zinzow HM, 2013, MIL PSYCHOL, V25, P514, DOI 10.1037/mil0000015	42	26	26	0	11	CENTER PSYCHIATRIC REHABILITATION	BOSTON	BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA	1095-158X	1559-3126		PSYCHIATR REHABIL J	Psychiatr. Rehabil. J.	JUN	2015	38	2			SI		135	141		10.1037/prj0000131			7	Psychiatry; Rehabilitation	Social Science Citation Index (SSCI)	Psychiatry; Rehabilitation	DE1NE	WOS:000370392900007	25821982				2022-02-06	
J	Cromer, JA; Harel, BT; Yu, K; Valadka, JS; Brunwin, JW; Crawford, CD; Mayes, LC; Maruff, P				Cromer, Jason A.; Harel, Brian T.; Yu, Karen; Valadka, Jaclyn S.; Brunwin, Jack W.; Crawford, Cameron D.; Mayes, Linda C.; Maruff, Paul			Comparison of Cognitive Performance on the Cogstate Brief Battery When Taken In-Clinic, In-Group, and Unsupervised	CLINICAL NEUROPSYCHOLOGIST			English	Article						Computerized testing; Group testing; Baseline testing; Cognition.; Concussion; Remote testing; Unsupervised testing	BASE-LINE; IMPAIRMENT; CONCUSSION; SENSITIVITY; SPORT; IMPACT	Objective: Repeat cognitive assessment comparing post-injury performance to a pre-injury baseline is common in concussion management. Although post-injury tests are typically administered in clinical settings, baseline tests may be conducted individually with one-on-one supervision, in a group with supervision, or without supervision. The extent to which these different test settings affect cognitive performance is not well understood. To assess if performance on the Cogstate Brief Battery (CBB) differs across these settings, tests completed individually with one-on-one supervision were compared to those taken either in a group with supervision or individually but without supervision. Method: A crossover study design was utilized to account for any effect of individual variability or test order to provide an unbiased examination of the effect of test setting on cognitive performance. Young adult participants completed an individually supervised test either before or after also completing a group or unsupervised test. Results: CBB scores from the same individuals were not significantly different across test settings. Effect sizes ranged in magnitude from .09 to .12 for supervised versus unsupervised tests and from .01 to .37 for individual versus group tests across CBB tasks. Conclusion: These results suggest that cognitive testing with the CBB in alternate settings can provide valid cognitive data comparable to data obtained during individually supervised testing.	[Cromer, Jason A.; Harel, Brian T.; Valadka, Jaclyn S.; Brunwin, Jack W.; Mayes, Linda C.] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; [Cromer, Jason A.; Harel, Brian T.; Valadka, Jaclyn S.; Brunwin, Jack W.; Maruff, Paul] Cogstate Ltd, New Haven, CT USA; [Yu, Karen; Valadka, Jaclyn S.; Crawford, Cameron D.] Sewanee Univ South, Dept Psychol, Sewanee, TN USA; [Maruff, Paul] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia		Cromer, JA (corresponding author), 195 Church St,8th Floor, New Haven, CT 06510 USA.	jason.cromer@yale.edu	Maruff, Paul/AAD-2454-2021; Meijer, Anna/K-5118-2016; Maruff, Paul/ABA-1673-2020	Maruff, Paul/0000-0002-6947-9537; 			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P755, DOI 10.1076/jcen.20.5.755.1132; Cromer JA, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00704; Dickinson D., 2011, SCHIZOPHR RES, V125, P284, DOI [10.1016/j.schres.2010.10.023, DOI 10.1016/J.SCHRES.2010.10.023]; Dunlap WP, 1996, PSYCHOL METHODS, V1, P170, DOI 10.1037/1082-989X.1.2.170; Echemendia R. J., 2012, NEUROPSYCHOLOGICAL T; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Hinton-Bayre AD, 2012, CLIN J SPORT MED, V22, P105, DOI 10.1097/JSM.0b013e318248a526; Hinton-Bayre AD, 2010, ARCH CLIN NEUROPSYCH, V25, P244, DOI 10.1093/arclin/acq008; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kivi M, 2014, COGN BEHAV THERAPY, V43, P289, DOI 10.1080/16506073.2014.921834; Klatte M, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00578; Lewis MS, 2011, NEUROUROL URODYNAM, V30, P183, DOI 10.1002/nau.20963; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Liebl A, 2012, APPL ERGON, V43, P424, DOI 10.1016/j.apergo.2011.06.017; Louey AG, 2014, ARCH CLIN NEUROPSYCH, V29, P432, DOI 10.1093/arclin/acu020; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Mayas J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092269; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Olver JS, 2015, STRESS HEALTH, V31, P115, DOI 10.1002/smi.2533; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Spielberg F, 2011, AIDS EDUC PREV, V23, P110, DOI 10.1521/aeap.2011.23.3_supp.110; Tian Ho-Heng, 2011, Asian J Sports Med, V2, P145; Vaughan CG, 2014, AM J SPORT MED, V42, P1716, DOI 10.1177/0363546514531732	37	26	26	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY 19	2015	29	4					542	558		10.1080/13854046.2015.1054437			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	CM8FZ	WOS:000357935100010	26165425				2022-02-06	
J	Chan, S; Kurowski, B; Byczkowski, T; Timm, N				Chan, Steven; Kurowski, Brad; Byczkowski, Terri; Timm, Nathan			Intravenous migraine therapy in children with posttraumatic headache in the ED	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; SEX-DIFFERENCES; PROCHLORPERAZINE; SUMATRIPTAN; SYMPTOMS; COHORT; TRIAL; PAIN	Background: More than 3.8 million children sustain traumatic brain injuries annually. Treatment of posttraumatic headache (PTH) in the emergency department (ED) is variable, and benefits are unclear. Objective: The objective of the study is to determine if intravenous migraine therapy reduces pain scores in children with PTH and factors associated with improved response. Methods: This was a retrospective study of children, 8 to 21 years old, presenting to a tertiary pediatric ED with mild traumatic brain injury (mTBI) and PTH from November 2009 to June 2013. Inclusion criteria were mTBI (defined by diagnosis codes) within 14 days of ED visit, headache, and administration of one or more intravenous medications: ketorolac, prochlorperazine, metoclopramide, chlorpromazine, and ondansetron. Primary outcome was treatment success defined by greater than or equal to 50% pain score reduction during ED visit. Bivariate analysis and logistic regression were used to determine predictors of treatment success: age, sex, migraine or mTBI history, time since injury, ED head computed tomographic (CT) imaging, and pretreatment with oral analgesics. Results: A total of 254 patients were included. Mean age was 13.8 years, 51% were female, 80% were white, mean time since injury was 2 days, and 114 patients had negative head CTs. Eighty-six percent of patients had treatment success with 52% experiencing complete resolution of headache. Bivariate analysis showed that patients who had a head CT were less likely to respond (80% vs 91%; P = .008). Conclusions: Intravenous migraine therapy reduces PTH pain scores for children presenting within 14 days after mTBI. Further prospective work is needed to determine long-term benefits of acute PTH treatment in the ED. (C) 2015 Elsevier Inc. All rights reserved.	[Chan, Steven; Byczkowski, Terri; Timm, Nathan] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Kurowski, Brad] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA		Chan, S (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, 3333 Burnet Ave,ML2008, Cincinnati, OH 45229 USA.	steven.chan@cchmc.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23HD074683-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425, UL1TR000077] Funding Source: NIH RePORTER	Funding from National Institutes of Health grant K23HD074683-01 supported, in part, Brad G. Kurowski's time for participation in the study development and manuscript preparation.	Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Brousseau DC, 2004, ANN EMERG MED, V43, P256, DOI 10.1016/S0196-0644(03)00716-9; Covassin T, 2003, J ATHL TRAINING, V38, P238; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005; Friedman BW, 2008, ANN EMERG MED, V52, P399, DOI 10.1016/j.annemergmed.2007.09.027; GAWEL MJ, 1993, HEADACHE, V33, P96, DOI 10.1111/j.1526-4610.1993.hed3302096.x; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hamalainen ML, 1997, NEUROLOGY, V48, P1100, DOI 10.1212/WNL.48.4.1100; Kabbouche MA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.4.e62; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lay CL, 1999, HEADACHE, V39, P275, DOI 10.1046/j.1526-4610.1999.3904275.x; Leung S, 2013, HEADACHE, V53, P491, DOI 10.1111/head.12042; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; Lumba-Brown A, 2014, PEDIATR EMERG CARE, V30, P139, DOI 10.1097/PEC.0000000000000084; MCBEATH JG, 1994, HEADACHE, V34, P148, DOI 10.1111/j.1526-4610.1994.hed3403148.x; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moreno MA, 2012, ARCH PEDIAT ADOL MED, V166, P296, DOI [10.1001/archpediatrics.2012.8, 10.1001/archpediatrics.2012.79]; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Powers SW, 2003, PEDIATRICS, V112, pE1, DOI 10.1542/peds.112.1.e1; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Trottier ED, 2012, AM J EMERG MED, V30, P456, DOI 10.1016/j.ajem.2010.12.020; Trottier ED, 2010, J EMERG MED, V39, P166, DOI 10.1016/j.jemermed.2008.08.012; von Baeyer CL, 2009, PAIN, V143, P223, DOI 10.1016/j.pain.2009.03.002; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Williams K, 2012, PEDIATRICS, V129, pS153, DOI 10.1542/peds.2012-0055I	35	26	26	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAY	2015	33	5					635	639		10.1016/j.ajem.2015.01.053			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	CH8MX	WOS:000354291600006	25676851	Green Accepted			2022-02-06	
J	Chen, YR; Tymofiyeva, O; Hess, CP; Xu, D				Chen, Yiran; Tymofiyeva, Olga; Hess, Christopher P.; Xu, Duan			Effects of rejecting diffusion directions on tensor-derived parameters	NEUROIMAGE			English	Article						MRI; Brain; DTI; Anisotropy; Motion	TRAUMATIC BRAIN-INJURY; WEIGHTED MRI; FRACTIONAL ANISOTROPY; THEORETICAL-ANALYSIS; FIBER ORIENTATION; ROBUST ESTIMATION; MEAN DIFFUSIVITY; SCHEMES; SPECTROSCOPY; ARCHITECTURE	Diffusion Tensor Imaging (DTI) is adversely affected by subject motion. It is necessary to discard the corrupted images before diffusion parameter estimation. However, the consequences of rejecting those images are not well understood. In this study, we investigated the effects of excluding one or more volumes of diffusion weighted images by analyzing the changes in fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), radial diffusivity (RD) and the primary eigenvector (V1). Based on the full set of diffusion images acquired by the Jones30 diffusion scheme, we generated incomplete sets of at least six in three different ways: random, uniform and clustered rejections. The results showed that MD was not significantly affected by rejecting diffusion directions. In the cases of random rejections, FA, AD, RD and V1 were overestimated more greatly with increasing number of rejections and the overestimations were worse in low FA regions than high FA regions. For uniform rejections, at which the remaining diffusion directions are evenly distributed on a sphere, little change was observed in FA and in V1. Clustered rejections, on the other hand, displayed the most significant overestimation of the parameters, and the resulting accuracy depended on the relative orientation of the underlying fibers with respect to the excluded directions. In practice, if diffusion direction data is excluded, it is important to note the number and location of directions rejected, in order to make a more precise analysis of the data. (C) 2015 Elsevier Inc. All rights reserved.	[Chen, Yiran; Tymofiyeva, Olga; Hess, Christopher P.; Xu, Duan] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA		Xu, D (corresponding author), 1700 4th St,BH102,UCSF Box 2512, San Francisco, CA 94143 USA.	Duan.Xu@ucsf.edu		Xu, Duan/0000-0003-0550-4235	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EB009756, R01HD072074, P01NS082330]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS082330] Funding Source: NIH RePORTER	This study is supported by NIH R01EB009756, R01HD072074 and P01NS082330.	Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Barkovich AJ, 2001, AM J NEURORADIOL, V22, P1786; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Batchelor PG, 2003, MAGN RESON MED, V49, P1143, DOI 10.1002/mrm.10491; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Counsell SJ, 2003, PEDIATRICS, V112, P1, DOI 10.1542/peds.112.1.1; Dietrich O, 2000, NEURORADIOLOGY, V42, P85, DOI 10.1007/s002340050020; Frank LR, 2002, MAGN RESON MED, V47, P1083, DOI 10.1002/mrm.10156; Hasan KM, 2007, MAGN RESON IMAGING, V25, P1196, DOI 10.1016/j.mri.2007.02.011; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; Jiang SZ, 2009, MAGN RESON MED, V62, P645, DOI 10.1002/mrm.22032; Jones DK, 2003, MAGN RESON MED, V49, P7, DOI 10.1002/mrm.10331; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu CL, 2004, MAGN RESON MED, V51, P924, DOI 10.1002/mrm.20071; Lu S, 2003, AM J NEURORADIOL, V24, P937; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; ORDIDGE RJ, 1994, MAGN RESON IMAGING, V12, P455, DOI 10.1016/0730-725X(94)92539-9; Papadakis NG, 2000, MAGN RESON IMAGING, V18, P671, DOI 10.1016/S0730-725X(00)00151-X; Rose SE, 2000, J NEUROL NEUROSUR PS, V69, P528, DOI 10.1136/jnnp.69.4.528; Skare S, 2001, MAGN RESON IMAGING, V19, P1125, DOI 10.1016/S0730-725X(01)00415-5; Skare S, 2000, J MAGN RESON, V147, P340, DOI 10.1006/jmre.2000.2209; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Tuch DS, 2005, PHILOS T R SOC B, V360, P869, DOI 10.1098/rstb.2005.1651; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Tymofiyeva O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063310; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642	33	26	27	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 1	2015	109						160	170		10.1016/j.neuroimage.2015.01.010			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CB9SB	WOS:000349971600016	25585018	Green Accepted			2022-02-06	
J	Krohn, M; Dressler, J; Bauer, M; Schober, K; Franke, H; Ondruschka, B				Krohn, Michael; Dressler, Jan; Bauer, Manfred; Schober, Kristin; Franke, Heike; Ondruschka, Benjamin			Immunohistochemical Investigation of S100 and NSE in Cases of Traumatic Brain Injury and Its Application for Survival Time Determination	JOURNAL OF NEUROTRAUMA			English	Article						NSE; traumatic brain injury; immunohistochemistry; S100; survival time	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; NERVOUS-SYSTEM; HIPPOCAMPAL NEUROGENESIS; GLUCOSE DEPRIVATION; NEUROTROPHIC FACTOR; COGNITIVE RECOVERY; TRANSGENIC MICE; CEREBRAL-CORTEX; GLIAL-CELLS	The availability of markers able to provide insight into protein changes in the central nervous system after fatal traumatic brain injury (TBI) is limited. The present study reports on the semi-quantitative assessments of the immunopositive neuroglial cells (both astrocytes and oligodendrocytes) and neurons for S100 protein (S100), as well as neuronal specific enolase (NSE), in the cerebral cortex, hippocampus, and cerebellum with regard to survival time and cause of death. Brain tissues of 47 autopsy cases with TBI (survival times ranged between several minutes and 34 d) and 10 age- and gender-matched controls (natural deaths) were examined. TBI cases were grouped according to their survival time in acute death after brain injury (ABI, n=25), subacute death after brain injury (SBI, n=18) and delayed death after brain injury (DBI, n=4). There were no significant changes in the percentages of S100-stained astrocytes between TBI and control cases. The percentages of S100-positive oligodendrocytes in the pericontusional zone (PCZ) in cases with SBI were significantly lower than in controls (p<0.05) and in the ABI group (p<0.05). In the hippocampus, S100-positive oligodendrocytes were significantly lower in cases with ABI and SBI (both, p<0.05), compared with controls. It is of particular interest that there were also S100-positive neurons in the PCZ and hippocampus in TBI cases after more than 2 h survival but not in ABI cases or controls. The percentages of NSE-positive neurons in the hippocampus were likewise significantly lower in cases with ABI, compared with controls (p<0.05) but increased in cases with SBI in PCZ (p<0.05). In conclusion, the present findings emphasize that S100 and NSE-immunopositivity might be useful for detecting the cause and process of death due to TBI. Further, S100-positivity in neurons may be helpful to estimate the survival time of fatal injuries in legal medicine.	[Krohn, Michael; Dressler, Jan; Ondruschka, Benjamin] Univ Leipzig, Inst Legal Med, D-04103 Leipzig, Germany; [Bauer, Manfred] Univ Leipzig, Dept Neuropathol, D-04103 Leipzig, Germany; [Franke, Heike] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, D-04103 Leipzig, Germany; [Schober, Kristin] German Air Force Ctr Aerosp Med, Furstenfeldbruck, Germany		Ondruschka, B (corresponding author), Univ Leipzig, Inst Legal Med, Johannisallee 28, D-04103 Leipzig, Germany.	b.ondruschka@medizin.uni-leipzig.de			German Ministry of Defense	This work was partly supported by the German Ministry of Defense. The authors declare that no competing financial interests exist.	Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; AZMITIA EC, 1995, BRAIN RES, V677, P181, DOI 10.1016/0006-8993(95)00051-Q; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Castagna C, 2003, J CHEM NEUROANAT, V25, P195, DOI 10.1016/S0891-0618(03)00009-7; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dmytriyeva O, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2202; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; FISCHER I, 1986, DEV BRAIN RES, V25, P99, DOI 10.1016/0165-3806(86)90156-2; Franke H, 2013, PURINERG SIGNAL, V9, P451, DOI 10.1007/s11302-013-9366-3; Furutani R, 2012, J NEUROTRAUM, V29, P1266, DOI 10.1089/neu.2010.1630; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Gerlach R, 2006, NEUROSCIENCE, V141, P1697, DOI 10.1016/j.neuroscience.2006.05.008; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; Hu JR, 1997, J NEUROCHEM, V69, P2294; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnstone JT, 2013, J NEUROSCI RES, V91, P828, DOI 10.1002/jnr.23208; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P1351, DOI 10.1007/s00701-013-1720-2; Li Dong-Ri, 2006, Legal Medicine, V8, P78, DOI 10.1016/j.legalmed.2005.09.002; Li DR, 2012, LEGAL MED-TOKYO, V14, P84, DOI 10.1016/j.legalmed.2011.12.007; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Mao HJ, 2013, J NEUROTRAUM, V30, P1521, DOI 10.1089/neu.2012.2520; MATSUMOTO M, 1987, MAYO CLIN PROC, V62, P460, DOI 10.1016/S0025-6196(12)65471-8; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Moore CS, 2011, J NEUROSCI RES, V89, P13, DOI 10.1002/jnr.22482; MURRAY GI, 1993, J CLIN PATHOL, V46, P993, DOI 10.1136/jcp.46.11.993; Nobs L, 2013, GLIA, V61, P1443, DOI 10.1002/glia.22533; Nogami M, 1998, ACTA HISTOCHEM, V100, P371, DOI 10.1016/S0065-1281(98)80034-2; Nogami M, 1998, FORENSIC SCI INT, V94, P97, DOI 10.1016/S0379-0738(98)00060-7; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; Ondruschka B, 2013, J NEUROTRAUM, V30, P1862, DOI 10.1089/neu.2013.2895; PELC S, 1986, J NEUROL SCI, V73, P289, DOI 10.1016/0022-510X(86)90153-X; Quintyn JC, 2005, GRAEF ARCH CLIN EXP, V243, P1167, DOI 10.1007/s00417-005-1175-0; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; RICKMANN M, 1995, NEUROSCIENCE, V67, P977, DOI 10.1016/0306-4522(94)00615-C; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Sabattini E, 1998, J CLIN PATHOL, V51, P506, DOI 10.1136/jcp.51.7.506; Savigni DL, 2013, NEUROPHARMACOLOGY, V75, P380, DOI 10.1016/j.neuropharm.2013.07.034; Schiavi Paolo, 2012, Acta Biomed, V83, P5; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Sen J, 2007, J NEUROSCI RES, V85, P1373, DOI 10.1002/jnr.21211; Staffa K, 2012, J NEUROTRAUM, V29, P2716, DOI 10.1089/neu.2011.2246; Steiner J, 2008, NEUROSCIENCE, V154, P496, DOI 10.1016/j.neuroscience.2008.03.060; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; Tiesman HM, 2011, AM J PREV MED, V41, P61, DOI 10.1016/j.amepre.2011.03.007; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; UZAN M, 1995, ACTA NEUROCHIR, V135, P141, DOI 10.1007/BF02187758; VICK RS, 1992, J NEUROTRAUM, V9, pS93; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wajima D, 2013, BRAIN RES, V1519, P127, DOI 10.1016/j.brainres.2013.05.002; Wang S, 2012, CLIN CHEM LAB MED, V50, P525, DOI [10.1515/CCLM.2011.794, 10.1515/cclm.2011.794]; WATANABE M, 1990, DEV BRAIN RES, V53, P89, DOI 10.1016/0165-3806(90)90127-K; Whitaker-Azmitia PM, 1997, BRAIN RES, V776, P51, DOI 10.1016/S0006-8993(97)01002-0; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Xiong Y, 2010, DISCOV MED, V10, P434; Yan EB, 2014, J NEUROTRAUM, V31, P618, DOI 10.1089/neu.2013.3087; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zimmer DB, 2005, CELL MOL BIOL, V51, P201, DOI 10.1170/T620	79	26	30	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					430	440		10.1089/neu.2014.3524			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400003	25211554				2022-02-06	
J	Kuo, CY; Liou, TH; Chang, KH; Chi, WC; Escorpizo, R; Yen, CF; Liao, HF; Chiou, HY; Chiu, WT; Tsai, JT				Kuo, Chia-Ying; Liou, Tsan-Hon; Chang, Kwang-Hwa; Chi, Wen-Chou; Escorpizo, Reuben; Yen, Chia-Feng; Liao, Hua-Fang; Chiou, Hung-Yi; Chiu, Wen-Ta; Tsai, Jo-Ting			Functioning and Disability Analysis of Patients with Traumatic Brain Injury and Spinal Cord Injury by Using the World Health Organization Disability Assessment Schedule 2.0	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Article							QUALITY-OF-LIFE; INTERNATIONAL CLASSIFICATION; PARTICIPATION; REHABILITATION; TAIWAN; SYSTEM; SCALE	The purpose of this study is to compare traumatic brain injuries (TBI) and spinal cord injuries (SCI) patients' function and disability by using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0); and to clarify the factors that contribute to disability. We analyzed data available between September 2012 and August 2013 from Taiwan's national disability registry which is based on the International Classification of Functioning, Disability, and Health (ICF) framework. Of the 2664 cases selected for the study, 1316 pertained to TBI and 1348 to SCI. A larger percentage of patients with TBI compared with those with SCI exhibited poor cognition, self-care, relationships, life activities, and participation in society (all p < 0.001). Age, sex, injury type, socioeconomic status, place of residence, and severity of impairment were determined as factors that independently contribute to disability (all p < 0.05). The WHODAS 2.0 is a generic assessment instrument which is appropriate for assessing the complex and multifaceted disability associated with TBI and SCI. Further studies are needed to validate the WHODAS 2.0 for TBI and SCI from a multidisciplinary perspective.	[Kuo, Chia-Ying; Chiou, Hung-Yi; Chiu, Wen-Ta] Taipei Med Univ, Sch Publ Hlth, Coll Publ Hlth & Nutr, Taipei 11031, Taiwan; [Kuo, Chia-Ying] Taipei Med Univ, Shuang Ho Hosp, Off Med Affairs, New Taipei City 23561, Taiwan; [Liou, Tsan-Hon; Chang, Kwang-Hwa] Taipei Med Univ, Grad Inst Injury Prevent & Control, Coll Publ Hlth & Nutr, Taipei 11031, Taiwan; [Liou, Tsan-Hon] Taipei Med Univ, Shuang Ho Hosp, Dept Phys Med & Rehabil, New Taipei City 23561, Taiwan; [Liou, Tsan-Hon] Taipei Med Univ, Sch Med, Dept Phys Med & Rehabil, Coll Med, Taipei 11031, Taiwan; [Chang, Kwang-Hwa] Taipei Med Univ, Wan Fang Hosp, Dept Phys Med & Rehabil, Taipei 11696, Taiwan; [Chi, Wen-Chou] Chung Shan Med Univ, Sch Occupat Therapy, Taichung 40201, Taiwan; [Escorpizo, Reuben] Univ Vermont, Dept Rehabil & Movement Sci, Coll Nursing & Hlth Sci, Burlington, VT 05401 USA; [Escorpizo, Reuben] Swiss Parapleg Res, CH-6207 Nottwil, Switzerland; [Yen, Chia-Feng] Tzu Chi Univ, Dept Publ Hlth, Hualien 97004, Taiwan; [Liao, Hua-Fang] Chinese Assoc Early Intervent Profess Children De, Hualien 97064, Taiwan; [Liao, Hua-Fang] Natl Taiwan Univ, Sch & Grad Inst Phys Therapy, Coll Med, Taipei 10055, Taiwan; [Tsai, Jo-Ting] Taipei Med Univ, Shuang Ho Hosp, Dept Radiat Oncol, New Taipei City 23561, Taiwan		Chiu, WT (corresponding author), Taipei Med Univ, Sch Publ Hlth, Coll Publ Hlth & Nutr, Taipei 11031, Taiwan.	kuo@s.tmu.edu.tw; peter_liou@s.tmu.edu.tw; chang2773@gmail.com; y6312002@gmail.com; escorpizo.reuben@gmail.com; mapleyeng@gmail.com; hfliao@ntu.edu.tw; hychiou@tmu.edu.tw; wtchiu@tmu.edu.tw; 10576@s.tmu.edu.tw	Escorpizo, Reuben/AAH-4934-2019; Liou, Tsan-Hon/I-8808-2019; chi, danny/AAK-1579-2020	Liou, Tsan-Hon/0000-0002-0959-4023; Chiou, Hung Yi/0000-0002-4545-9697			Adriaansen JJE, 2013, DISABIL REHABIL, V35, P1104, DOI 10.3109/09638288.2012.712196; Chi WC, 2014, INT J ENV RES PUB HE, V11, P12148, DOI 10.3390/ijerph111212148; Chi WC, 2013, J FORMOS MED ASSOC, V112, P473, DOI 10.1016/j.jfma.2013.06.005; Chiu WT, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-416; Chung P, 2014, J REHABIL MED, V46, P108, DOI 10.2340/16501977-1257; De Wolf AC, 2012, J REHABIL MED, V44, P747, DOI 10.2340/16501977-1016; Derrett S, 2012, INJURY PREV, V18, P343, DOI 10.1136/injuryprev-2011-040266; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dryden DM, 2004, SPINAL CORD, V42, P513, DOI 10.1038/sj.sc.3101629; Gupta A, 2012, ANN INDIAN ACAD NEUR, V15, P120, DOI 10.4103/0972-2327.94995; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lin JW, 2008, ACT NEUR S, V101, P113; Magasi SR, 2008, J SPINAL CORD MED, V31, P145, DOI 10.1080/10790268.2008.11760705; Ministry of Health and Welfare, 2010, VIT STAT TAIW; Noonan VK, 2010, TOP SPINAL CORD INJU, V15, P49, DOI DOI 10.1310/SCI1504-49; Stiers W, 2012, J REHABIL RES DEV, V49, P139, DOI 10.1682/JRRD.2010.07.0131; Teng SW, 2013, J FORMOS MED ASSOC, V112, P691, DOI 10.1016/j.jfma.2013.09.007; Toft AMH, 2010, J TRAUMA, V69, P26, DOI 10.1097/TA.0b013e3181d3cbf2; Ustun TB, 2010, B WORLD HEALTH ORGAN, V88, P815, DOI 10.2471/BLT.09.067231; Ustun T, 2010, MEASURING HLTH DISAB; van der Zee CH, 2014, ARCH PHYS MED REHAB, V95, P87, DOI 10.1016/j.apmr.2013.08.236; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; WHO, 2011, HLTH STAT HLTH INF S; Yen CF, 2014, J FORMOS MED ASSOC, V113, P839, DOI 10.1016/j.jfma.2014.08.008	26	26	28	0	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1660-4601			INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	APR	2015	12	4					4116	4127		10.3390/ijerph120404116			12	Environmental Sciences; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	CG7MT	WOS:000353488500045	25874682	Green Submitted, gold, Green Published			2022-02-06	
J	Ramos-Alvarez, I; Mantey, SA; Nakamura, T; Nuche-Berenguer, B; Moreno, P; Moody, TW; Maderdrut, JL; Coy, DH; Jensen, RT				Ramos-Alvarez, Irene; Mantey, Samuel A.; Nakamura, Taichi; Nuche-Berenguer, Bernardo; Moreno, Paola; Moody, Terry W.; Maderdrut, Jerome L.; Coy, David H.; Jensen, Robert T.			A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists	PEPTIDES			English	Article						PACAP; Vasoactive intestinal peptide; Neuroprotection; Stroke; Traumatic brain injury; Structure-function study	CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; INTRACELLULAR CYCLIC-AMP; 4 SPLICE VARIANTS; ADENYLATE-CYCLASE; SIGNAL-TRANSDUCTION; MULTIPLE-MYELOMA; IN-VITRO; RAT; VIP	Pituitary adenylate cyclase-activating polypeptide (PACAP) has widespread physiological/pathophysiological actions and there is increased interest for its use therapeutically, especially in the CNS (neuroprotection). Unfortunately, no selective PACAP-analogs exist for PACAP-preferring PAC1-receptors, primarily because of its high sequence identity to VIP and particularly, because of the inability of structure-function studies to separate the pharmacophore of PAC1-R from VPAC1-R, which has high affinity for PACAP and VIP. The present study attempted to develop PAC1-R-selective agonists primarily by making conformationally restricted PACAP-analogs in positions important for receptor-selectivity/affinity. Forty-six PACAP-related-analogs were synthesized with substitutions in positions 1-4, 14-17, 20-22, 28, 34,38 and receptor-selectivity determined in PAC1-R,VPAC1-R,VPAC2R-transfected or native cells from binding or cAMP-generation experiments. Fifteen PACAP-analogs had 6-78-fold higher affinities for PAC1-R than VPAC1-R and 13 were agonists. Although binding-affinities correlated significantly with agonist potency, the degree of receptor-spareness varied markedly for the different PACAP-analogs, resulting in selective potencies for activating the PAC1 receptor over the VPAC1 receptor from 0- to 103-fold. In addition, a number of PACAP-analogs were identified that had high selectivity for PAC1-R over VPAC2-R as well as PACAP-analogs that could prove more useful therapeutically because of substitutions known to extend their half-lives (substitutions at potential sites of proteolysis and attachment of long-chain fatty acids). This study provides for the first time a separation of the pharmacophores for PAC1-R and VPAC1-R, resulting in PACAP-related analogs that are PAC1-R-preferring. Some of these analogs, or their modifications, could prove useful as therapeutic agents for various diseases. Published by Elsevier Inc.	[Ramos-Alvarez, Irene; Mantey, Samuel A.; Nakamura, Taichi; Nuche-Berenguer, Bernardo; Moreno, Paola; Jensen, Robert T.] NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; [Moody, Terry W.] NCI, Ctr Canc Res, Off Director, NIH, Bethesda, MD 20892 USA; [Maderdrut, Jerome L.; Coy, David H.] Tulane Univ, Hlth Sci Ctr, Peptide Res Lab, Dept Med, New Orleans, LA 70112 USA		Jensen, RT (corresponding author), NIDDK, Digest Dis Branch, NIH, Bldg 10,Room 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov			NIDDK branch of the National Institutes of Health; National Institute of General Medical Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [1 U54 GM104940]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [ZIADK053100, ZIADK053101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104940] Funding Source: NIH RePORTER	This work was supported in part by intramural funds from the NIDDK branch of the National Institutes of Health. This work was also supported in part by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ahren B, 2008, ANN NY ACAD SCI, V1144, P28, DOI 10.1196/annals.1418.003; ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; Banki E, 2013, PEPTIDES, V42, P125, DOI 10.1016/j.peptides.2013.02.002; BANKS WA, 1993, J PHARMACOL EXP THER, V267, P690; Baun M, 2012, CEPHALALGIA, V32, P337, DOI 10.1177/0333102412439354; BENYA RV, 1993, J BIOL CHEM, V268, P20285; Bourgault S, 2009, CURR MED CHEM, V16, P4462, DOI 10.2174/092986709789712899; Bourgault S, 2008, PEPTIDES, V29, P919, DOI 10.1016/j.peptides.2008.01.022; Bourgault S, 2009, J MED CHEM, V52, P3308, DOI 10.1021/jm900291j; Bourgault S, 2008, J MOL NEUROSCI, V36, P260, DOI 10.1007/s12031-008-9081-7; Dickson L, 2006, NEUROPHARMACOLOGY, V51, P1086, DOI 10.1016/j.neuropharm.2006.07.017; Dickson L, 2009, PHARMACOL THERAPEUT, V121, P294, DOI 10.1016/j.pharmthera.2008.11.006; Doan ND, 2011, BIOCHEM PHARMACOL, V81, P552, DOI 10.1016/j.bcp.2010.11.015; Dogrukol-Ak D, 2004, CURR PHARM DESIGN, V10, P1325, DOI 10.2174/1381612043384934; Germano PM, 2001, PEPTIDES, V22, P861, DOI 10.1016/S0196-9781(01)00410-7; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P403, DOI 10.1016/S0196-9781(96)00322-1; Gourlet P, 1996, REGUL PEPTIDES, V62, P125, DOI 10.1016/0167-0115(96)00010-9; Gourlet P, 1998, EUR J PHARMACOL, V348, P95, DOI 10.1016/S0014-2999(98)00133-2; Harmar AJ, 2012, BRIT J PHARMACOL, V166, P4, DOI 10.1111/j.1476-5381.2012.01871.x; Holz GG, 2003, CURR MED CHEM, V10, P2471, DOI 10.2174/0929867033456648; HOU X, 1994, NEUROPHARMACOLOGY, V33, P1189, DOI 10.1016/S0028-3908(05)80009-7; Igarashi H, 2005, J PHARMACOL EXP THER, V315, P370, DOI 10.1124/jpet.105.088823; Igarashi H, 2002, J PHARMACOL EXP THER, V301, P37, DOI 10.1124/jpet.301.1.37; Igarashi H, 2002, J PHARMACOL EXP THER, V303, P445, DOI 10.1124/jpet.102.038075; Inooka H, 2001, NAT STRUCT BIOL, V8, P161, DOI 10.1038/84159; Ito T, 2000, AM J PHYSIOL-GASTR L, V278, pG64, DOI 10.1152/ajpgi.2000.278.1.G64; Kim Y, 2006, J IMMUNOL, V176, P2969, DOI 10.4049/jimmunol.176.5.2969; LERNER EA, 1991, J BIOL CHEM, V266, P11234; Li M, 2008, REGUL PEPTIDES, V145, P24, DOI 10.1016/j.regpep.2007.09.012; Li M, 2007, PEPTIDES, V28, P1891, DOI 10.1016/j.peptides.2007.05.002; Li SY, 2005, INT J ONCOL, V27, P1329; Missig G, 2014, NEUROPHARMACOLOGY, V86, P38, DOI 10.1016/j.neuropharm.2014.06.022; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; Moody TW, 2011, CURR OPIN ENDOCRINOL, V18, P61, DOI 10.1097/MED.0b013e328342568a; Moody TW, 2003, PEPTIDES, V24, P163, DOI 10.1016/S0196-9781(02)00290-5; MUSSO GF, 1988, BIOCHEMISTRY-US, V27, P8174, DOI 10.1021/bi00421a028; Myers SR, 1997, DIABETES, V46, P637, DOI 10.2337/diabetes.46.4.637; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; Onoue S, 2008, N-S ARCH PHARMACOL, V377, P579, DOI 10.1007/s00210-007-0232-0; Pisegna Joseph R, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P58, DOI 10.1097/MED.0b013e328012d605; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; Pisegna JR, 1996, ANN NY ACAD SCI, V805, P54; Reglodi D, 2011, CURR PHARM DESIGN, V17, P962, DOI 10.2174/138161211795589355; Ressler KJ, 2011, NATURE, V470, P492, DOI 10.1038/nature09856; Reubi JC, 2000, CANCER RES, V60, P3105; ROBBERECHT P, 1992, MOL PHARMACOL, V42, P347; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Sun CH, 2007, P NATL ACAD SCI USA, V104, P7875, DOI 10.1073/pnas.0611397104; Uchida D, 1998, ANN NY ACAD SCI, V865, P253, DOI 10.1111/j.1749-6632.1998.tb11185.x; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Ward BP, 2013, MOL METAB, V2, P468, DOI 10.1016/j.molmet.2013.08.008; Waschek JA, 2013, BRIT J PHARMACOL, V169, P512, DOI 10.1111/bph.12181; Wray V, 1998, ANN NY ACAD SCI, V865, P37, DOI 10.1111/j.1749-6632.1998.tb11160.x; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016; Xia M, 1997, J PHARMACOL EXP THER, V281, P229; Yung SL, 2003, J BIOL CHEM, V278, P10273, DOI 10.1074/jbc.M211945200; ZHOU ZC, 1989, AM J PHYSIOL, V256, pG283, DOI 10.1152/ajpgi.1989.256.2.G283	62	26	27	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0196-9781	1873-5169		PEPTIDES	Peptides	APR	2015	66						26	42		10.1016/j.peptides.2015.01.009			17	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	CH1NE	WOS:000353787700005	25698233	Green Accepted			2022-02-06	
J	Ziebell, JM; Adelson, PD; Lifshitz, J				Ziebell, Jenna M.; Adelson, P. David; Lifshitz, Jonathan			Microglia: dismantling and rebuilding circuits after acute neurological injury	METABOLIC BRAIN DISEASE			English	Article						Microglia; Synaptic stripping; Neurological disease; Traumatic brain injury; Epilepsy	TRAUMATIC BRAIN-INJURY; ACTIVATED MICROGLIA; ALZHEIMERS-DISEASE; MULTIPLE ROLES; CELLS; COMPLEMENT; ASTROCYTES; NEUROTOXICITY; FRACTALKINE; SYSTEM	The brain is comprised of neurons and its support system including astrocytes, glial cells and microglia, thereby forming neurovascular units. Neurons require support from glial cells to establish and maintain functional circuits, but microglia are often overlooked. Microglia function as the immune cell of the central nervous system, acting to monitor the microenvironment for changes in signaling, pathogens and injury. More recently, other functional roles for microglia within the healthy brain have been identified, including regulating synapse formation, elimination and function. This review aims to highlight and discuss these alternate microglial roles in the healthy and in contrast, diseased brain with a focus on two acute neurological diseases, traumatic brain injury and epilepsy. In these conditions, microglial roles in synaptic stripping and stabilization as part of neuronal:glial interactions may position them as mediators of the transition between injury-induced circuit dismantling and subsequent reorganization. Increased understanding of microglia roles could identify therapeutic targets to mitigate the consequences of neurological disease.	[Ziebell, Jenna M.; Adelson, P. David; Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA; [Ziebell, Jenna M.; Adelson, P. David; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Adelson, P. David; Lifshitz, Jonathan] Arizona State Univ, Neurosci Program, Tempe, AZ USA; [Lifshitz, Jonathan] Phoenix VA Healthcare Syst, Phoenix, AZ USA		Ziebell, JM (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, 1919 E Thomas Rd, Phoenix, AZ 85016 USA.	jmziebell@email.arizona.edu	Ziebell, Jenna/Y-4496-2019; Adelson, David/W-2083-2019	Ziebell, Jenna/0000-0003-2497-4347	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS065052] Funding Source: Medline		Adalbert R, 2007, TRENDS MOL MED, V13, P135, DOI 10.1016/j.molmed.2007.02.004; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Annunziato L, 2013, J CEREBR BLOOD F MET, V33, P969, DOI 10.1038/jcbfm.2013.44; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8; Benarroch EE, 2013, NEUROLOGY, V81, P1079, DOI 10.1212/WNL.0b013e3182a4a577; Beumer W, 2012, J LEUKOCYTE BIOL, V92, P959, DOI 10.1189/jlb.0212100; Biber K, 2006, CURR DRUG TARGETS, V7, P29, DOI 10.2174/138945006775270196; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Blank T, 2013, GLIA, V61, P62, DOI 10.1002/glia.22372; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boer K, 2006, J NEUROIMMUNOL, V173, P188, DOI 10.1016/j.jneuroim.2006.01.002; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Carthew HL, 2012, NEUROSCIENCE, V214, P78, DOI 10.1016/j.neuroscience.2012.04.028; Chen SK, 2010, CELL, V141, P775, DOI 10.1016/j.cell.2010.03.055; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Dityatev A, 2011, CURR OPIN NEUROBIOL, V21, P353, DOI 10.1016/j.conb.2010.12.006; Drexel M, 2012, NEUROPHARMACOLOGY, V63, P806, DOI 10.1016/j.neuropharm.2012.06.009; Frick LR, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/608654; Goldberg EM, 2013, NAT REV NEUROSCI, V14, P337, DOI 10.1038/nrn3482; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Greer JM, 2002, NEURON, V33, P23, DOI 10.1016/S0896-6273(01)00564-5; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Kalla R, 2001, J COMP NEUROL, V436, P182; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Lazar G, 1996, GLIA, V16, P101; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morris GP, 2013, NEUROBIOL LEARN MEM, V105, P40, DOI 10.1016/j.nlm.2013.07.002; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Pardo CA, 2004, EPILEPSIA, V45, P516, DOI 10.1111/j.0013-9580.2004.33103.x; Perry VH, 2010, ASN NEURO, V2, P281, DOI 10.1042/AN20100024; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; Schafer DP, 2010, BIOCHEM SOC T, V38, P476, DOI 10.1042/BST0380476; Schlegelmilch T, 2011, CURR OPIN NEUROBIOL, V21, P5, DOI 10.1016/j.conb.2010.08.004; Scott DA, 2010, J NEUROSCI, V30, P8083, DOI 10.1523/JNEUROSCI.1091-10.2010; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Siskova Z, 2009, AM J PATHOL, V175, P1610, DOI 10.2353/ajpath.2009.090372; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; SVENSSON M, 1993, EXP NEUROL, V120, P123, DOI 10.1006/exnr.1993.1046; Tambuyzer BR, 2009, J LEUKOCYTE BIOL, V85, P352, DOI 10.1189/jlb.0608385; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Veerhuis R, 1999, EXP NEUROL, V160, P289, DOI 10.1006/exnr.1999.7199; Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003; Vezzani Annamaria, 2012, Handb Clin Neurol, V107, P163, DOI 10.1016/B978-0-444-52898-8.00010-0; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI 10.1016/j.tins.2012.11.007; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wang CC, 1996, J ANAT, V189, P567; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wirenfeldt M, 2009, NEUROBIOL DIS, V34, P432, DOI 10.1016/j.nbd.2009.02.015; Woodruff TM, 2010, NEUROMOL MED, V12, P179, DOI 10.1007/s12017-009-8085-y; Wright GJ, 2001, IMMUNOLOGY, V102, P173, DOI 10.1046/j.1365-2567.2001.01163.x; Yamada J, 2011, NEUROSCIENCE, V182, P1, DOI 10.1016/j.neuroscience.2011.03.030; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Zujovic V, 2000, GLIA, V29, P305, DOI 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.3.CO;2-M	81	26	26	1	12	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	APR	2015	30	2					393	400		10.1007/s11011-014-9539-y			8	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	CD2HA	WOS:000350894800005	24733573	Green Accepted			2022-02-06	
J	Merritt, VC; Rabinowitz, AR; Arnett, PA				Merritt, Victoria C.; Rabinowitz, Amanda R.; Arnett, Peter A.			Injury-related predictors of symptom severity following sports-related concussion	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Headache; Sports injuries; Concussion; Symptom reporting	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC MIGRAINE CHARACTERISTICS; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; PROLONGED RECOVERY; SEX-DIFFERENCES; PERFORMANCE; COLLEGIATE	Introduction: Decisions regarding return to play after sports-related concussion partially revolve around athletes' self-reported symptoms. Given this emphasis on symptoms, it would be beneficial to be able to identify characteristics that could predict which athletes may be susceptible to developing an increase in postconcussion symptoms following head injury. The purpose of this study was to describe the symptoms that athletes endorse immediately following concussion and to determine what impact injury-related characteristics have on the development of postconcussion symptoms within the first week following concussion. Method: Participants included 54 collegiate athletes who sustained concussions and were referred to our concussion management program for postconcussion testing. The main outcome measures included the Post-Concussion Symptom Scale and an interview querying athletes' retrospective symptoms over time, starting immediately postinjury. Results: Descriptive statistics revealed that the most common immediate symptoms following concussion include dizziness (endorsed by 83.6% of the sample), headache (65.5%), feeling in a fog (61.8%), and visual disturbance (60.0%). Logistic regression analyses indicated that retrograde and anterograde amnesia, as well as loss of consciousness, were not significantly predictive of postconcussion symptoms within one week following concussion (p > .05). However, the total symptom score assessed immediately postinjury, in addition to endorsing immediate headache symptoms following concussion, reliably predicted a higher level of symptom reporting in the first week following concussion (p < .05). Finally, receiver-operating characteristic (ROC) curve analysis, using 80% sensitivity to predict the high postconcussion symptom group, established cutoff scores of 7.5 for the immediate total symptom score and 0.5 for immediate headache. Conclusions: These findings demonstrate the importance of evaluating symptoms immediately following concussion. Athletes who endorse more immediate postconcussion symptoms, especially headache symptoms, may be at risk for greater and more severe postconcussion symptoms within the first week following concussion. The present findings have implications for the management and treatment of sports-related concussions.	[Merritt, Victoria C.; Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Rabinowitz, Amanda R.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu		Merritt, Victoria/0000-0001-5683-4168	Penn State Sports Medicine	We would like to thank Dr. Wayne Sebastianelli and Penn State Sports Medicine for their generous support of our research. Also, the authors would like to thank Gray Vargas, Fiona Barwick, Aaron Rosenbaum, and Chris Bailey for their help as project coordinators of the program over the years. Finally, a special thanks to the following individuals for their help with running participants and data entry for this project: Karissa Arthur, Dan Brynien, Saima Farooq, Caitlin Gaffney, Alex Garrison, Briana Hauser, Mark Petusky, Matt Phillips, Jordyn Sessel, Julie Turco, and Steven Yacovelli.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; King J. E, 2008, BINARY LOGISTIC REGR; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lovell M, 2000, IMPACT IMMEDIATE POS; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Peng CYJ, 2002, J EDUC RES, V96, P3, DOI 10.1080/00220670209598786; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	32	26	26	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR 16	2015	37	3					265	275		10.1080/13803395.2015.1004303			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	CI7FV	WOS:000354929200004	25685959				2022-02-06	
J	Mychasiuk, R; Hehar, H; Ma, I; Kolb, B; Esser, MJ				Mychasiuk, R.; Hehar, H.; Ma, I.; Kolb, B.; Esser, M. J.			THE DEVELOPMENT OF LASTING IMPAIRMENTS: A MILD PEDIATRIC BRAIN INJURY ALTERS GENE EXPRESSION, DENDRITIC MORPHOLOGY, AND SYNAPTIC CONNECTIVITY IN THE PREFRONTAL CORTEX OF RATS	NEUROSCIENCE			English	Article						Golgi-Cox; qRT-PCR; telomere; neurodegeneration; pruning; epigenetics	NOGO-A; CORTICAL DEVELOPMENT; ALZHEIMERS-DISEASE; SOCIAL-BEHAVIOR; SEX-DIFFERENCES; ANIMAL-MODEL; CONCUSSION; OXYTOCIN; PLAY; SINGLE	Apart from therapeutic discovery, the study of mild traumatic brain injury (mTBI) has been focused on two challenges: why do a majority of individuals recover with little concern, while a considerable proportion suffer with persistent and often debilitating symptomology; and, how do mild injuries significantly increase risk for an early-onset neurodegeneration? Owing to a lack of observable damage following mTBI, this study was designed to determine if there were changes in neuronal morphology, synaptic connectivity, and epigenetic patterning that could contribute to the manifestation of persistent neurological dysfunction. Prefrontal cortex tissue from male and female rats was used for Golgi-Cox analysis along with the profiling of changes in gene expression (BDNF, DNMT1, FGF2, IGF1, Nogo-A, OXYR, and TERT) and telomere length (TL), following a single mTBI or sham injury in the juvenile period. Golgi-Cox analysis of dendritic branch order, dendritic length, and spine density demonstrate that an early mTBI increases complexity of pyramidal neurons in the mPFC. Furthermore, there are also substantial changes in the expression levels of the seven genes of interest and TL following a single mild injury in this brain region. The results from the neuroanatomical measures and changes in gene expression indicate that the mTBI disrupts normal pruning processes that are typically underway at this point in development. In addition, there are significant interactions between the social environment and epigenetic processes that work in concert to perpetuate neurological dysfunction. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Mychasiuk, R.; Hehar, H.; Ma, I.; Esser, M. J.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Fac Med, Calgary, AB T2N 1N4, Canada; [Kolb, B.] Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Fac Med, Heritage Med Res Bldg Room 274,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Institute, Alberta Children's Hospital Foundation; Markin USRP for Health and Wellness; NSERC of Canada grant	The authors would like to acknowledge Yilin Li and Kehe Xe for their technical assistance with the Golgi-Cox analysis, Dr. Jong Rho and Rose Tobias for organizational support, and the Alberta Children's Hospital Research Institute, Alberta Children's Hospital Foundation, and the Markin USRP for Health and Wellness, and an NSERC of Canada grant to B.K. for their financial contribution.	Andersen SL, 2003, NEUROSCI BIOBEHAV R, V27, P3, DOI 10.1016/S0149-7634(03)00005-8; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bell HC, 2010, BEHAV BRAIN RES, V207, P7, DOI 10.1016/j.bbr.2009.09.029; Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bock J, 2005, CEREB CORTEX, V15, P802, DOI 10.1093/cercor/bhh181; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Bongiorno D, 2010, INT J BIOCHEM CELL B, V42, P1072, DOI 10.1016/j.biocel.2010.02.007; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Ceanga M, 2010, NEUROSCI LETT, V477, P15, DOI 10.1016/j.neulet.2010.04.024; Cheatwood JL, 2008, STROKE, V39, P2091, DOI 10.1161/STROKEAHA.107.507426; Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003; Crews F, 2007, PHARMACOL BIOCHEM BE, V86, P189, DOI 10.1016/j.pbb.2006.12.001; Cruz EMV, 2007, HORM BEHAV, V51, P611, DOI 10.1016/j.yhbeh.2007.02.010; D'Ercole AJ, 2008, ENDOCRINOLOGY, V149, P5958, DOI 10.1210/en.2008-0920; Entringer S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003580; Faul M, 2010, TRAUMATIC BRAIN INJU; FRITH CD, 2003, AUTISM NEURAL BASIS; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Golmirzaei J, 2013, INT J PEDIAT, V2013, DOI 10.1155/2013/953103; Golshani Peyman, 2005, Thalamus & Related Systems, V3, P227, DOI 10.1017/S1472928807000222; Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110; Gordon NS, 2003, NEUROSCI LETT, V341, P17, DOI 10.1016/S0304-3940(03)00158-7; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Heinrichs M, 2008, PROG BRAIN RES, V170, P337, DOI 10.1016/S0079-6123(08)00428-7; Horch HW, 2002, NAT NEUROSCI, V5, P1177, DOI 10.1038/nn927; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Irwin SA, 2001, AM J MED GENET, V98, P161, DOI 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kaufmann WE, 2000, CEREB CORTEX, V10, P981, DOI 10.1093/cercor/10.10.981; KESHAVAN MS, 1994, J PSYCHIATR RES, V28, P239, DOI 10.1016/0022-3956(94)90009-4; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2015, NEUROBIOL DIS, V73, P1, DOI 10.1016/j.nbd.2014.09.003; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Mychasiuk R, 2012, SYNAPSE, V66, P308, DOI 10.1002/syn.21512; Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x; Niblock MM, 2000, J NEUROSCI, V20, P4165; Panossian LA, 2003, NEUROBIOL AGING, V24, P77, DOI 10.1016/S0197-4580(02)00043-X; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Pellis SM, 2007, CURR DIR PSYCHOL SCI, V16, P95, DOI 10.1111/j.1467-8721.2007.00483.x; Pellis SM, 2010, AM J PLAY, V2, P278; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Uvnas-Moberg K, 1998, PSYCHONEUROENDOCRINO, V23, P819, DOI 10.1016/S0306-4530(98)00056-0; Viano DC, 2012, ANN BIOMED ENG, V40, P213, DOI 10.1007/s10439-011-0386-2; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zagrebelsky M, 2010, J NEUROSCI, V30, P13220, DOI 10.1523/JNEUROSCI.1044-10.2010; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x; Zilles K., 1985, CORTEX RAT STEREOTAX	64	26	26	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 12	2015	288						145	155		10.1016/j.neuroscience.2014.12.034			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CA2TD	WOS:000348759600014	25555930				2022-02-06	
J	Fedor, A; Gunstad, J				Fedor, Andrew; Gunstad, John			Limited Knowledge of Concussion Symptoms in College Athletes	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						concussion; knowledge; college; athletes; amnesia	SPORT-RELATED CONCUSSION; SCHOOL FOOTBALL PLAYERS; POSTCONCUSSION SYNDROME; HEAD-INJURY; EPIDEMIOLOGY	Concussions are common in athletes and often go unreported. A likely contributor to underreporting of concussions in athletes is lack of knowledge of concussion-related symptoms. The current study assessed concussion symptom knowledge in 382 Division I athletes and 230 nonathletes. Participants were asked to identify potential symptoms following a concussion from a list of both real symptoms and distractors. Student-athletes expected significantly more total symptoms following a concussion than did nonathletes, and they correctly identified symptoms such as nausea and/or vomiting and being easily upset by loud noises more frequently than controls. However, many student-athletes failed to identify possible emotional symptoms resulting from a concussion, and approximately 70% of student-athletes endorsed the distracter item "forgetting names or faces of people you know well" as being a symptom of concussion. These current findings suggest that student-athletes may have an incomplete understanding of concussion-related symptoms, and future studies are needed to determine whether formal education sessions can improve knowledge for this high-risk population.	[Fedor, Andrew; Gunstad, John] Kent State Univ, Dept Psychol, Kent, OH 44242 USA		Gunstad, J (corresponding author), Kent State Univ, Dept Psychol, 221 Kent Hall, Kent, OH 44242 USA.	jgunstad@kent.edu					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Covassin T, 2003, J ATHL TRAINING, V38, P238; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Edmed SL, 2012, APPL NEUROPSYCH-ADUL, V19, P164, DOI 10.1080/09084282.2011.643961; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2007, IMPACT VERSION 6 0 C; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Pardini D., 2004, BR J SPORTS MED, V38, P661; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; [No title captured]; [No title captured]	25	26	26	1	39	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 4	2015	22	2					108	113		10.1080/23279095.2013.860604			6	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	CC5DR	WOS:000350379400005	25072295				2022-02-06	
J	Roth, RM; Erdodi, LA; McCulloch, LJ; Isquith, PK				Roth, Robert M.; Erdodi, Laszlo A.; McCulloch, Laura J.; Isquith, Peter K.			Much ado about norming: The Behavior Rating Inventory of Executive Function	CHILD NEUROPSYCHOLOGY			English	Article						Assessment; Children; Executive function	WHITE-MATTER ABNORMALITIES; TRAUMATIC BRAIN-INJURY; VELOCARDIOFACIAL SYNDROME; EXTERNALIZING BEHAVIOR; EARLY-CHILDHOOD; WORKING-MEMORY; CHILDREN; ATTENTION; ADOLESCENTS; PERFORMANCE	The Behavior Rating Inventory of Executive Function (BRIEF) is a rating scale designed to assess executive functions in everyday life that is widely used in school and clinical settings and in research studies. It has been recently suggested, however, that the limited geographic stratification of the standardization sample renders the measure overly sensitive. We evaluated this hypothesis by examining BRIEF scores across studies of typically developing children and adolescents. Thirty-nine studies were identified that included at least one of three possible index scores. Mean scores across studies were (a) within one to two T-score units from the standardization sample mean of 50, (b) tended to be slightly lower than 50, and (c) were unrelated to geographic location (US Census regions or internationally). These findings refute recent claims that the BRIEF is overly sensitive and further add to the large body of literature supporting the validity of the measure.	[Roth, Robert M.; Erdodi, Laszlo A.; McCulloch, Laura J.; Isquith, Peter K.] Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Program, Lebanon, NH 03756 USA		Roth, RM (corresponding author), Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Program, One Med Ctr Dr, Lebanon, NH 03756 USA.	robert.m.roth@dartmouth.edu	Isquith, Peter/AAY-4851-2020				Acevedo SF, 2010, PEDIATR RES, V67, P293, DOI 10.1203/PDR.0b013e3181cb8e68; Adamson C, 2013, BRAIN INJURY, V27, P454, DOI 10.3109/02699052.2012.750756; Alloway TP, 2009, CHILD PSYCHIAT HUM D, V40, P353, DOI 10.1007/s10578-009-0131-3; Anderson B, 2009, PEDIATRICS, V123, pE701, DOI 10.1542/peds.2008-1182; Anderson V, 2005, J INT NEUROPSYCH SOC, V11, P817, DOI 10.1017/S1355617705051052; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Antshel KM, 2005, PSYCHIAT RES-NEUROIM, V138, P235, DOI 10.1016/j.pscychresns.2005.02.003; Antshel KM, 2003, NEUROPSYCHOLOGY, V17, P458, DOI 10.1037/0894-4105.17.3.458; Bourke RS, 2011, SLEEP MED, V12, P222, DOI 10.1016/j.sleep.2010.08.011; Brown TM, 2008, CHILD NEUROPSYCHOL, V14, P118, DOI 10.1080/09297040601147605; Chevignard MP, 2012, BRAIN INJURY, V26, P1033, DOI 10.3109/02699052.2012.666366; Clark DB, 2012, ADDICTION, V107, P206, DOI 10.1111/j.1360-0443.2011.03566.x; Duerden EG, 2013, DEV MED CHILD NEUROL, V55, P952, DOI 10.1111/dmcn.12198; Egeland J, 2010, CHILD NEUROPSYCHOL, V16, P326, DOI 10.1080/09297041003601462; Gioia G.A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Goldstein S., 2001, APPL NEUROPSYCHOL, V8, P255, DOI [10.1207/S15324826AN0804_10, DOI 10.1207/S15324826AN0804_10]; Goldweber A, 2011, J CLIN CHILD ADOLESC, V40, P715, DOI 10.1080/15374416.2011.597088; Hughes DM, 2009, INT J LANG COMM DIS, V44, P901, DOI [10.3109/13682820802425693, 10.1080/13682820802425693]; Isquith PK, 2014, APPL NEUROPSYCH-CHIL, V3, P197, DOI 10.1080/21622965.2013.870014; Isquith PK, 2013, APPL NEUROPSYCH-CHIL, V2, P125, DOI 10.1080/21622965.2013.748389; Jarratt KP, 2005, APPL NEUROPSYCHOL, V12, P83, DOI 10.1207/s15324826an1202_4; Kiley-Brabeck K, 2006, APPL NEUROPSYCHOL, V13, P258, DOI 10.1207/s15324826an1304_7; Kral MC, 2004, J PEDIATR PSYCHOL, V29, P185, DOI 10.1093/jpepsy/jsh020; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Lajiness-O'Neill R, 2006, ARCH CLIN NEUROPSYCH, V21, P175, DOI 10.1016/j.acn.2005.09.001; Lande MB, 2010, J PEDIATR-US, V157, P114, DOI 10.1016/j.jpeds.2009.12.053; Lande MB, 2009, J PEDIATR-US, V154, P207, DOI 10.1016/j.jpeds.2008.08.017; Lax ID, 2013, BRAIN STRUCT FUNCT, V218, P575, DOI 10.1007/s00429-012-0417-2; Locascio G, 2010, J LEARN DISABIL-US, V43, P441, DOI 10.1177/0022219409355476; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Memisevic H, 2014, J INTELL DISABIL RES, V58, P830, DOI 10.1111/jir.12098; Naglieri J. A., 2012, COMPREHENSIVE EXECUT; Payne JM, 2011, CHILD NEUROPSYCHOL, V17, P313, DOI 10.1080/09297049.2010.542746; Piper BJ, 2011, PHARMACOL BIOCHEM BE, V98, P432, DOI 10.1016/j.pbb.2011.02.013; Pride NA, 2012, DEV NEUROPSYCHOL, V37, P590, DOI 10.1080/87565641.2012.695831; Pulsipher DT, 2009, EPILEPSIA, V50, P1210, DOI 10.1111/j.1528-1167.2008.01952.x; Reddy LA, 2011, SCHOOL PSYCHOL QUART, V26, P45, DOI 10.1037/a0022585; Rocke K, 2008, AM J OCCUP THER, V62, P528, DOI 10.5014/ajot.62.5.528; Roth R.M., 2014, HDB EXECUTIVE FUNCTI, P301, DOI DOI 10.1007/978-1-4614-8106-5_18; Roy A, 2009, ENVIRON HEALTH PERSP, V117, P1607, DOI 10.1289/ehp.0900625; Semrud-Clikeman M, 2010, J AUTISM DEV DISORD, V40, P1017, DOI 10.1007/s10803-010-0951-9; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Shear PK, 2002, CHILD NEUROPSYCHOL, V8, P285, DOI 10.1076/chin.8.4.285.13511; Shimoni M, 2012, RES DEV DISABIL, V33, P858, DOI 10.1016/j.ridd.2011.12.014; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tarazi RA, 2008, CLIN NEUROPSYCHOL, V22, P585, DOI 10.1080/13854040701425940; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; US Census Bureau, 2010, GEOGR DEF; Viner RM, 2012, LANCET NEUROL, V11, P774, DOI 10.1016/S1474-4422(12)70180-1; Waber DP, 2007, J INT NEUROPSYCH SOC, V13, P729, DOI 10.1017/S1355617707070841; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wang Y, 2012, PSYCHIAT RES-NEUROIM, V202, P245, DOI 10.1016/j.pscychresns.2012.01.005; Yerys BE, 2009, AUTISM RES, V2, P322, DOI 10.1002/aur.103; Ziegler G, 2013, NEUROIMAGE, V82, P284, DOI 10.1016/j.neuroimage.2013.05.088	57	26	26	1	29	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	MAR 4	2015	21	2					225	233		10.1080/09297049.2014.897318			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AW5XO	WOS:000346344500006	24650292				2022-02-06	
J	Cobb, BR; MacAlister, A; Young, TJ; Kemper, AR; Rowson, S; Duma, SM				Cobb, Bryan R.; MacAlister, Anna; Young, Tyler J.; Kemper, Andrew R.; Rowson, Steven; Duma, Stefan M.			Quantitative comparison of Hybrid III and National Operating Committee on Standards for Athletic Equipment headform shape characteristics and implications on football helmet fit	PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART P-JOURNAL OF SPORTS ENGINEERING AND TECHNOLOGY			English	Article						Impact biomechanics; concussion; mild traumatic brain injury; dummy head laboratory testing; sports injury	ICE HOCKEY HELMETS; DYNAMIC IMPACT RESPONSE; TRAUMATIC BRAIN-INJURY; AMERICAN FOOTBALL; PROFESSIONAL FOOTBALL; PERFORMANCE; ACCELERATION; RECONSTRUCTION; CONCUSSION; KINEMATICS	Laboratory tests in which dummy headforms are used to evaluate helmet performance must be representative of real-world conditions to ensure helmets perform well in the field. The objective of this study was to quantify shape differences that may affect helmet fit between two dummy headforms commonly used for football helmet testing. Point-cloud models of a 50th percentile male Hybrid III headform and a medium NOCSAE headform were generated using a coordinate measuring machine. The headforms were optimally aligned and shape comparisons were made in the mid-sagittal plane, three coronal planes, and 3D. Planar and 3D differences were quantified by comparing maximum (MRD) and root-mean-square (RMSD) radial deviations. Minor differences were observed in the upper skull contours of all planar cross-sections, where MRDs were less than 3.5 mm and RMSDs were less than 1.7 mm. Larger deviations were observed in other regions including the jaw in the anterior coronal plane, where the MRD was 6.6 mm and the RMSD deviation was 4.5 mm. Substantial differences were noted between the Hybrid III and NOCSAE at the base of the skull, cheeks, jaw and chin. The headforms were also compared to a head model based on medical imaging of a human subject, which the NOCSAE matched more closely than the Hybrid III. The data presented in this study show that the Hybrid III and NOCSAE headforms have substantial shape differences in several regions that are important for helmet fit, possibly making the NOCSAE a better option for realistic helmet fit.	[Cobb, Bryan R.; MacAlister, Anna; Young, Tyler J.; Kemper, Andrew R.; Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA		Cobb, BR (corresponding author), Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, 440 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	cobb84@vt.edu	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012; Kemper, Andrew/B-4353-2012	Rowson, Steven/0000-0002-3227-0596; Kemper, Andrew/0000-0002-5177-1820			Bartsch A, 2012, J NEUROSURG, V116, P222, DOI 10.3171/2011.9.JNS111059; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Blanco DH, 2014, P I MECH ENG P-J SPO, V228, P95, DOI 10.1177/1754337113518748; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Cormier J, 2010, SAE INT J PASSEN CAR, V3, P842, DOI 10.4271/2010-01-1317; Foster J.K., 1977, P 21 STAPP CAR CRASH; Gayzik FS., 2012, 12 INT LS DYNA US C; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Hertzberg H, 1953, ANTHROPOMETRY FLYING; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hoshizaki TB, 2012, P I MECH ENG P-J SPO, V226, P226, DOI 10.1177/1754337112448765; Hubbard RP, 1973, HUMAN IMPACT RESPONS, P129; HUBBARD RP, 1974, P 18 STAPP CAR CRASH; Kendall M, 2012, P I MECH ENG P-J SPO, V226, P260, DOI 10.1177/1754337112436901; Kroon D. - J., 2011, WAVEFRONT OBJ TOOLBO; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McIntosh AS, 2012, P I MECH ENG P-J SPO, V226, P237, DOI 10.1177/1754337112436628; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2006, STAND LIN IMP TEST M; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2009, STAND PROJ IMP TEST; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; NOCSAE, 2011, STAND PERF SPEC NEWL; NOCSAE (National Operating Committee on Standards for Athletic Equipment), 2011, STAND TEST METH EQ U; Ouckama R, 2012, P I MECH ENG P-J SPO, V226, P185, DOI 10.1177/1754337111435625; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Post A, 2012, P I MECH ENG P-J SPO, V226, P290, DOI 10.1177/1754337112436629; Riddell, FITT INSTR HELM CAR; Rousseau P, 2009, P I MECH ENG P-J SPO, V223, P159, DOI 10.1243/17543371JSET36; Rowson S, 2013, P I MECH ENG P-J SPO, V227, P12, DOI 10.1177/1754337112442620; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Walsh ES, 2012, P I MECH ENG P-J SPO, V226, P220, DOI 10.1177/1754337112442299	37	26	26	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1754-3371	1754-338X		P I MECH ENG P-J SPO	Proc. Inst. Mech. Eng. Part P-J. Sport. Eng. Technol.	MAR	2015	229	1					39	46		10.1177/1754337114548245			8	Engineering, Mechanical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	CC4HA	WOS:000350311900005					2022-02-06	
J	Polak, P; Leddy, JJ; Dwyer, MG; Willer, B; Zivadinov, R				Polak, Paul; Leddy, John J.; Dwyer, Michael G.; Willer, Barry; Zivadinov, Robert			Diffusion Tensor Imaging Alterations in Patients With Postconcussion Syndrome Undergoing Exercise Treatment: A Pilot Longitudinal Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffusion tensor imaging; exercise; mild traumatic brain injury; postconcussion syndrome; potholes analysis; tract-based spatial statistics	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HEAD-INJURY; RELIABILITY; INTEGRITY; VETERANS; RECOVERY; MODERATE; DAMAGE; TIME	Purpose: To investigate diffusion tensor imaging characteristics in patients with postconcussion syndrome (PCS) who received exercise (n = 4) and placebo stretching (n = 4) treatments compared with a group of healthy controls (n = 15). Methods: Subjects diagnosed with PCS obtained a diffusion tensor imaging magnetic resonance image at pretreatment (baseline) and approximately 8 weeks later (follow-up). Analyses included a groupwise comparison using tract-based spatial statistics and a z-score map that investigated localized regional anomalies compared with the healthy control group projected onto the tract-based spatial statistics skeleton. Results: The tract-based spatial statistics analysis detected groupwise differences in the genu of the corpus callosum at both time points with decreased fractional anisotropy and increased radial diffusivity and mean diffusivity values. In contrast, the z-score analysis was more sensitive to heterogeneous changes in fractional anisotropy, with both low-and high-localized areas across various white matter regions, the most prevalent being the corpus callosum, anterior and superior corona radiata, and internal and external capsules. The mean number of voxels different in patients with PCS versus healthy controls was greater in all cases (baseline lower: P < .03 and higher: P < .0001; follow-up lower: P < .0001 and higher: P < .0001). The volume and location of these abnormal regions changed between the 2 diffusion tensor imaging scans, but these did not correlate with the mitigation of symptoms in the patients with PCS. Conclusions: Diffusion tensor imaging revealed spatially varying and heterogeneous localized irregularities in patients with PCS that persisted even as patient symptoms decreased and prognosis improved.	[Polak, Paul; Dwyer, Michael G.; Zivadinov, Robert] SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Dept Neurol, Buffalo, NY 14203 USA; [Leddy, John J.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14203 USA; [Leddy, John J.] SUNY Buffalo, Univ Sports Med, Buffalo, NY 14203 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14203 USA		Zivadinov, R (corresponding author), SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Dept Neurol, 100 High St, Buffalo, NY 14203 USA.	rzivadinov@bnac.net	Zivadinov, Robert/Q-2054-2019	Zivadinov, Robert/0000-0002-7799-1485; Polak, Paul/0000-0002-7719-7572; Dwyer, Michael/0000-0003-4684-4658			Bannister, 2013, AUTONOMIC FAILURE TX; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; DiFiori JP, 2010, CURR SPORT MED REP, V9, P35, DOI 10.1249/JSR.0b013e3181caba67; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Kozlowski KF, 2007, NEUROREHABILITATION, V22, P191; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Oishi K, JHU MNI SS ATLAS; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Schmidt O.I., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014	35	26	27	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2015	30	2					E32	E42		10.1097/HTR.0000000000000037			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CF1MG	WOS:000352309300004	24721808				2022-02-06	
J	Robinson, ME; Shenk, TE; Breedlove, EL; Leverenz, LJ; Nauman, EA; Talavage, TM				Robinson, Meghan E.; Shenk, Trey E.; Breedlove, Evan L.; Leverenz, Larry J.; Nauman, Eric A.; Talavage, Thomas M.			The Role of Location of Subconcussive Head Impacts in fMRI Brain Activation Change	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	2nd Annual Meeting of the CIC/Big Ten/Ivy League Traumatic Brain Injury Summit	JUL 16-17, 2014	Philadelphia, PA				HIGH-SCHOOL FOOTBALL; BIOMECHANICS; CONCUSSION	Monte-Carlo permutation analysis was used to identify sets of head impacts most predictive of functional magnetic resonance imaging (fMRI) changes in football players. The relative distribution of impact location was found to be more predictive of brain activation changes than the number of impacts, suggesting that fMRI changes are related to systematic playing style.	[Robinson, Meghan E.; Shenk, Trey E.; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Robinson, Meghan E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Neuroimaging Res Vet NeRVe Ctr, Boston, MA 02132 USA; [Shenk, Trey E.; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Breedlove, Evan L.; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA		Robinson, ME (corresponding author), VA Boston Healthcare Syst, TRACTS 182, 150 South Huntington Ave, Boston, MA 02132 USA.	meghan.robinson@va.gov		Talavage, Thomas/0000-0003-4977-6398	Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health; National Science FoundationNational Science Foundation (NSF); NDSEG Graduate Research Fellowship Programs	This work was supported by the Indiana Spinal Cord and Brain Injury Research Fund, a part of the Indiana State Department of Health. This work was also partially supported through the National Science Foundation and NDSEG Graduate Research Fellowship Programs.	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHL TRAIN SPORTS HL, V6, P1; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	11	26	26	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	FEB 17	2015	40	2			SI		74	79		10.1080/87565641.2015.1012204			6	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology	CH6UW	WOS:000354172800005	25961589				2022-02-06	
J	Tan, L; Ge, HF; Tang, J; Fu, CH; Duanmu, WS; Chen, YJ; Hu, R; Sui, JF; Liu, X; Feng, H				Tan, Liang; Ge, Hongfei; Tang, Jun; Fu, Chuhua; Duanmu, Wangsheng; Chen, Yujie; Hu, Rong; Sui, Jianfeng; Liu, Xin; Feng, Hua			Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Depression; Dopamine; Amantadine; Nigrostriatal pathway	SUBSTANTIA-NIGRA VULNERABILITY; ANTIDEPRESSANT; RECEPTOR; TRANSPORTER; EXPRESSION; NEURONS; FLUID; PATHOPHYSIOLOGY; PARKINSONISM; RESTORATION	Traumatic brain injury (TBI) often results in multiple neuropsychiatric sequelae, including cognitive, emotional, and behavioral problems. Among them, depression is a common psychiatric symptom, and links to poorer recovery. Amantadine, as an antiparkinsonian, increases dopamine release, and blocks dopamine reuptake, but has recently received attention for its effectiveness as an antidepressant. In the present study, we first induced a post-TBI depression rat model to probe the efficacy of amantadine therapy in reducing post-TBI depression. The DA concentration in the striatum of the injured rats, as well as the degeneration and apoptosis of dopaminergic neurons in the substantia nigra (SN), were checked along with the depression-like behavior. The results showed that amantadine therapy could significantly ameliorate the depression-like behavior, improving the DA level in the striatum and decreasing the degeneration and apoptosis of dopaminergic neurons in the SN. The results indicated that the anti-depression effect may result from the increase of extracellular DA concentration in the striatum and/or the indirect neuroprotection on the dopaminergic neurons in the SN. We conclude that DA plays a critical role in post-TBI depression, and that amantadine shows its potential value in anti-depression treatment for TBI. (C) 2014 Published by Elsevier B.V.	[Tan, Liang; Ge, Hongfei; Tang, Jun; Fu, Chuhua; Duanmu, Wangsheng; Chen, Yujie; Hu, Rong; Liu, Xin; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China; [Tan, Liang; Ge, Hongfei; Tang, Jun; Fu, Chuhua; Duanmu, Wangsheng; Chen, Yujie; Hu, Rong; Liu, Xin; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Key Lab Neurotrauma, Chongqing 400038, Peoples R China; [Sui, Jianfeng] Third Mil Med Univ, Coll Basic Med Sci, Expt Ctr Basic Med, Chongqing 400038, Peoples R China		Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China.	tracy200712@hotmail.com; mudan13868@126.com; juntang881025@sina.com; 87848946@qq.com; 510149003@qq.com; yujiechen6886@foxmail.com; huchrong@aliyun.com; jfsui2003@163.com; shenwai@tmmu.edu.cn; fenghua8888@aliyun.com.cn	Chen, Yujie/AAS-6995-2021; Feng, Hua/AAX-4121-2021; Tan, Liang/AAS-3997-2020	Chen, Yujie/0000-0002-9905-9138; Feng, Hua/0000-0003-4489-9217; 	Natural Basic Research Program of China (973 program)National Basic Research Program of China [SQ2013CB051394]	This study was supported by the Natural Basic Research Program of China (973 program SQ2013CB051394).	Alimoradian A, 2013, IRAN J BASIC MED SCI, V16, P743; [Anonymous], 2006, MMWR, V55, P201; Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130; BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Balasubramani PP, 2014, FRONT COMPUT NEUROSC, V8, DOI 10.3389/fncom.2014.00047; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; BRAESTRUP C, 1975, EUR J PHARMACOL, V34, P181, DOI 10.1016/0014-2999(75)90238-1; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cryan JF, 2002, TRENDS PHARMACOL SCI, V23, P238, DOI 10.1016/S0165-6147(02)02017-5; Dunlop BW, 2007, ARCH GEN PSYCHIAT, V64, P327, DOI 10.1001/archpsyc.64.3.327; Eakin K, 2013, EXP NEUROL, V240, P103, DOI 10.1016/j.expneurol.2012.11.005; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRITSCHY JM, 1992, J COMP NEUROL, V321, P421, DOI 10.1002/cne.903210309; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Harsing L. G, 2008, HDB NEUROCHEMISTRY M, P149, DOI [10.1007/978-0-387-30382-6_7, DOI 10.1007/978-0-387-30382-6_7]; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hu JH, 2013, J NEUROTRAUM, V30, P1755, DOI 10.1089/neu.2013.2857; Hu ZL, 2004, J COMP NEUROL, V476, P301, DOI 10.1002/cne.20230; Huang EYK, 2014, BEHAV BRAIN RES, V267, P156, DOI 10.1016/j.bbr.2014.03.033; Huang EYK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086354; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Kulkarni SK, 2009, EXPERT OPIN INV DRUG, V18, P767, DOI [10.1517/13543780902880850 , 10.1517/13543780902880850]; Lambert G, 2000, ARCH GEN PSYCHIAT, V57, P787, DOI 10.1001/archpsyc.57.8.787; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leggio GM, 2013, EUR J PHARMACOL, V719, P25, DOI 10.1016/j.ejphar.2013.07.022; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Ossola B, 2011, NEUROPHARMACOLOGY, V61, P574, DOI 10.1016/j.neuropharm.2011.04.030; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Park SK, 2005, CELL, V122, P275, DOI 10.1016/j.cell.2005.05.031; Parsons CG, 1996, EUR J NEUROSCI, V8, P446, DOI 10.1111/j.1460-9568.1996.tb01228.x; Patel J, 2003, J NEUROCHEM, V85, P898, DOI 10.1046/j.1471-4159.2003.01732.x; Peeters M, 2002, BRAIN RES, V949, P32, DOI 10.1016/S0006-8993(02)02961-X; Penmatsa A, 2013, NATURE, V503, P85, DOI 10.1038/nature12533; Piotrowska A, 2013, J PHYSIOL PHARMACOL, V64, P493; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rogoz Z, 2007, PHARMACOL REP, V59, P778; Roman A, 2009, PHARMACOL REP, V61, P1069, DOI 10.1016/S1734-1140(09)70169-0; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Shin SS, 2013, J NEUROTRAUM, V30, P259, DOI 10.1089/neu.2012.2462; Stein DJ, 2007, LANCET, V369, P139, DOI 10.1016/S0140-6736(07)60075-0; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tye KM, 2013, NATURE, V493, P537, DOI 10.1038/nature11740; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Wen XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063691; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Wong JC, 2013, CRIT REV CL LAB SCI, V50, P103, DOI 10.3109/10408363.2013.844678; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang QJ, 2010, BRAIN RES, V1312, P127, DOI 10.1016/j.brainres.2009.11.052	60	26	28	0	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 15	2015	279						274	282		10.1016/j.bbr.2014.10.037			9	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	AZ5IO	WOS:000348255200033	25447294				2022-02-06	
J	Whiteside, DM; Kogan, J; Wardin, L; Phillips, D; Franzwa, MG; Rice, L; Basso, M; Roper, B				Whiteside, Douglas M.; Kogan, Julia; Wardin, Lydia; Phillips, Derek; Franzwa, M. Graciela; Rice, Linda; Basso, Michael; Roper, Brad			Language-based embedded performance validity measures in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Boston Naming Test; Performance validity testing; Verbal fluency; Traumatic brain injury	CARD SORTING TEST; CLASSIFICATION ACCURACY; TEST-II; SPECIFICITY; SENSITIVITY; INDICATORS; FLUENCY; SCORES; BIAS	No studies to date have investigated the Boston Naming Test (BNT) as an embedded performance validity test (PVT). This study investigated the classification accuracy of the Boston Naming Test (BNT) and the Verbal Fluency Test (FAS and Animal Fluency), as embedded PVTs in a compensation-seeking mild traumatic brain injury (MTBI) sample (N = 57) compared to a non-compensation-seeking moderate-to-severe TBI (STBI) sample (N = 61). Participants in the MTBI sample who failed two or more PVTs were included, as were STBI participants who passed all PVTs. The classification accuracy of the individual tests and a logistically derived combined (LANGPVT) measure were studied. Results showed significant group differences (p < .05) on BNT, Animal Fluency, and LANGPVT between the MTBI and STBI groups. However, receiver operating characteristic (ROC) analyses indicated that only LANGPVT had acceptable classification accuracy (area under the curve > .70). Setting specificity at approximately .90, the recommended LANGPVT cutoff scores had sensitivity of .26. Results indicated that, similar to other embedded PVTs, these measures had low sensitivity when adequate specificity levels were maintained. However, extremely low scores on these measures are unlikely to occur in non-compensation-seeking, non-language-impaired, STBI cases.	[Whiteside, Douglas M.] Univ Iowa, Dept Psychiat, Iowa City, IA 52245 USA; [Kogan, Julia] Vanderbilt Univ, Nashville, TN 37235 USA; [Kogan, Julia; Wardin, Lydia; Phillips, Derek] Adler Univ, Chicago, IL USA; [Wardin, Lydia] PA Vet Affairs Med Ctr, Coatesville, PA USA; [Franzwa, M. Graciela] Thomson Memory Ctr, Hoffman Estates, IL USA; [Rice, Linda] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Basso, Michael] Univ Tulsa, Dept Psychol, Tulsa, OK 74104 USA; [Roper, Brad] Memphis Vet Affairs Med Ctr, Memphis, TN USA		Whiteside, DM (corresponding author), Univ Iowa, Dept Psychiat, 200 Hawkins Dr, Iowa City, IA 52245 USA.	douglas-whiteside@uiowa.edu	Whiteside, Douglas/AAK-6396-2020; Basso, Michael/S-9587-2019	Basso, Michael/0000-0002-0217-662X; Whiteside, Douglas/0000-0002-8454-4413			Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Benton AL, 1994, MULTILINGUAL APHASIA; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Bodin D., 2012, PEDIAT ADOLESCENT CO; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush, 2012, MILD TRAUMATIC BRAIN; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Heaton R. K., 2004, REVISED COMPREHENSIV; Johnson SC, 2012, CLIN NEUROPSYCHOL, V26, P1230, DOI 10.1080/13854046.2012.709886; Kaplan E, 1983, BOSTON NAMING TEST; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Lemeshow S, 2000, APPL LOGISTIC REGRES; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/09084280152829084; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; Schroeder RW, 2010, CLIN NEUROPSYCHOL, V24, P326, DOI 10.1080/13854040903369441; Silverberg ND, 2008, CLIN NEUROPSYCHOL, V22, P140, DOI 10.1080/13854040601160597; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Whiteside D, 2011, CLIN NEUROPSYCHOL, V25, P287, DOI 10.1080/13854046.2010.538436; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	30	26	26	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB 7	2015	37	2					220	227		10.1080/13803395.2014.1002758			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	CC9IP	WOS:000350682700009	25655924				2022-02-06	
J	Albaugh, MD; Orr, C; Nickerson, JP; Zweber, C; Slauterbeck, JR; Hipko, S; Gonyea, J; Andrews, T; Brackenbury, JC; Watts, R; Hudziak, JJ				Albaugh, Matthew D.; Orr, Catherine; Nickerson, Joshua P.; Zweber, Cole; Slauterbeck, James R.; Hipko, Scott; Gonyea, Jay; Andrews, Trevor; Brackenbury, J. Curtis; Watts, Richard; Hudziak, James J.			Postconcussion Symptoms Are Associated with Cerebral Cortical Thickness in Healthy Collegiate and Preparatory School Ice Hockey Players	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; GEOMETRICALLY ACCURATE; CONCUSSION; SEGMENTATION; PATTERNS; CHILDREN; SPORTS; CORTEX	Objective To investigate the degree to which concussion history and postconcussive symptoms are associated with cortical morphology among male hockey players. Study design Male subjects (n = 29), ranging in age from 14 to 23 years (mean 17.8 years), were recruited from preparatory school and collegiate ice hockey teams and underwent neuroimaging and baseline Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) testing. Cerebral cortical thickness was regressed against ImPACT Total Symptom Score (TSS), concussion history, as well as baseline measures of psychopathology. Reconstruction of surfaces and cortical thickness analysis were conducted with FreeSurfer (version 5.3.0). Results ImPACT TSS was inversely associated with local cortical thickness in widespread brain areas. Associations were revealed in a host of frontal as well as bilateral temporoparietal cortices. Conversely, concussion history was not associated with cortical thickness. An "Age by Concussion History" interaction was associated with thickness in the right ventrolateral and right parietal cortices. Post-hoc analysis revealed that concussed participants did not exhibit age-related cortical thinning in these regions. Conclusion We have identified an association between brain structure and postconcussive symptoms among young, otherwise-healthy male athletes. Postconcussive symptoms and related reductions in cortical thickness may be tied to participation in a full-contact sport that involves frequent blows to the head.	[Albaugh, Matthew D.; Orr, Catherine; Zweber, Cole; Hudziak, James J.] Univ Vermont, Coll Med, Vermont Ctr Children Youth & Families, Div Child Psychiat, Burlington, VT 05401 USA; [Nickerson, Joshua P.; Hipko, Scott; Gonyea, Jay; Andrews, Trevor; Watts, Richard] Univ Vermont, Coll Med, Dept Radiol, Burlington, VT 05401 USA; [Slauterbeck, James R.] Univ Vermont, Coll Med, Dept Orthopaed & Rehabil, Burlington, VT 05401 USA; [Hipko, Scott; Gonyea, Jay; Andrews, Trevor; Watts, Richard] Univ Vermont MRI Ctr Biomed Imaging, Burlington, VT USA; [Andrews, Trevor] Philips Healthcare, Cleveland, OH USA; [Brackenbury, J. Curtis] DC Hybrid Skating, Milwaukee, WI USA		Hudziak, JJ (corresponding author), Univ Vermont, Coll Med, Vermont Ctr Children Youth & Families, Univ Hlth Ctr Campus,1 South Prospect St, Burlington, VT 05401 USA.	james.hudziak@uvm.edu	Albaugh, Matthew D/R-4349-2016; Meijer, Anna/K-5118-2016; Albaugh, Matthew/ABB-5839-2020	Albaugh, Matthew/0000-0002-5971-6658; Andrews, Trevor/0000-0003-0331-1798	Child and Adolescent Psychology Training and Research Foundation	M.A. is funded by the Child and Adolescent Psychology Training and Research Foundation. The authors declare no conflicts of interest.	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Achenbach TM, 2003, MANUAL ASEBA SCH AGE; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Ducharme S, 2014, CEREB CORTEX, V24, P2941, DOI 10.1093/cercor/bht151; Ducharme S, 2012, J AM ACAD CHILD PSY, V51, P18, DOI 10.1016/j.jaac.2011.09.022; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kuperberg GR, 2003, J COGNITIVE NEUROSCI, V15, P272, DOI 10.1162/089892903321208204; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P69; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Petrides M., 2002, PRINCIPLES FRONTAL L, V1, P31, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0003; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Rumsey JM, 2009, NEUROIMAGING IN DEVELOPMENTAL CLINICAL NEUROSCIENCE, P387, DOI 10.1017/CBO9780511757402.030; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schmahmann J.D., 2006, FIBER PATHWAYS BRAIN; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shaw P, 2007, P NATL ACAD SCI USA, V104, P19649, DOI 10.1073/pnas.0707741104; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith AM, 2011, CLIN J SPORT MED, V21, P281, DOI 10.1097/JSM.0b013e318225bc15; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wilde EA, 2012, NEUROREHABILITATION, V31, P245, DOI 10.3233/NRE-2012-0794	40	26	26	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	FEB	2015	166	2					394	+		10.1016/j.jpeds.2014.10.016			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AZ8XY	WOS:000348496200040	25454943				2022-02-06	
J	Jonker, FA; Jonker, C; Scheltens, P; Scherder, EJA				Jonker, Frank A.; Jonker, Cees; Scheltens, Philip; Scherder, Erik J. A.			The role of the orbitofrontal cortex in cognition and behavior	REVIEWS IN THE NEUROSCIENCES			English	Article						behavior disorders; gambling task; orbitofrontal cortex damage; reversal learning; theory of mind (ToM)	VENTROMEDIAL PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE DAMAGE; DECISION-MAKING; RHESUS-MONKEYS; LESIONS; MIND; EMOTION; PSYCHOPATHY; REWARD	The orbitofrontal cortex (OFC) plays a crucial role in behavior and is a common site for damage due to different types of injuries, e.g., closed head injuries, cerebrovascular accidents, tumors, neurosurgical interventions. Despite the (severe) behavioral changes following OFC lesions, persons with damage to the OFC appear to be cognitively intact, i.e., at least when assessed by means of standard neuropsychological tests. Meanwhile, neuropsychological tests addressing reversal learning, gambling, and social cognition show a decline in these patients. The goal of the present review is to link the performance of these latter neuropsychological tests to behavior. The results suggest that in patients with orbitofrontal lesions, reversal learning is more associated with behavioral disinhibition and that impairment in recognition of expressed emotion is more associated with social inappropriate behavior. The faux pas test (theory of mind) appears not to be sensitive to orbitofrontal lesions. Future studies should involve a larger numbers of patients with well-defined locations in the OFC and should integrate specific neuropsychological tests and quantitative behavioral measures to better understand the contribution of the OFC to cognition and behavior.	[Jonker, Frank A.] Vrije Univ Amsterdam, Dept Clin Neuropsychol, Vesalius Ctr Neuropsychiatry Woerden, GGZ Altrecht, NL-3447 GN Woerden, Netherlands; [Jonker, Cees] Vrije Univ Amsterdam Med Ctr, Inst Hlth & Care Res, Dept EMGO, NL-1081 BT Amsterdam, Netherlands; [Scheltens, Philip] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, NL-1007 MB Amsterdam, Netherlands; [Scheltens, Philip] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands; [Scherder, Erik J. A.] Vrije Univ Amsterdam, Dept Clin Neuropsychol, NL-1081 BT Amsterdam, Netherlands		Jonker, FA (corresponding author), Vrije Univ Amsterdam, Dept Clin Neuropsychol, Vesalius Ctr Neuropsychiatry Woerden, GGZ Altrecht, Polanerbaan 2, NL-3447 GN Woerden, Netherlands.	fr.jonker@altrecht.nl	Scheltens, Philip/AAL-9631-2020	Scheltens, Philip/0000-0002-1046-6408; Jonker, Frank/0000-0002-6786-5573	GGZ Altrecht, Vesalius Centre for Neuropsychiatry; Department of Clinical Neuropsychology, VU University; Alzheimer Centre and Department of Neurology, VU University Medical Center	F.A.J. would like to express his deep gratitude to E.J.A. Scherder, C. Jonker, and P. Scheltens, his research supervisors, for their patient guidance, enthusiastic encouragement, and critical revision of the manuscript for important intellectual content. He would also like to thank GGZ Altrecht, Vesalius Centre for Neuropsychiatry; Department of Clinical Neuropsychology, VU University; Alzheimer Centre and Department of Neurology, VU University Medical Center for their financial supporter on this research project.	Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Bachevalier J, 2011, ANN NY ACAD SCI, V1239, P71, DOI 10.1111/j.1749-6632.2011.06211.x; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1999, J NEUROSCI, V19, P5473; Berlin HA, 2005, AM J PSYCHIAT, V162, P2360, DOI 10.1176/appi.ajp.162.12.2360; Berlin HA, 2004, BRAIN, V127, P1108, DOI 10.1093/brain/awh135; Blair RJR, 2007, ANN NY ACAD SCI, V1121, P461, DOI 10.1196/annals.1401.017; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Busemeyer JR, 2002, PSYCHOL ASSESSMENT, V14, P253, DOI 10.1037//1040-3590.14.3.253; Cohen L, 1999, LANCET, V353, P34, DOI 10.1016/S0140-6736(98)09047-3; Cummings JL, 1995, ANN NY ACAD SCI, V769, P1, DOI 10.1111/j.1749-6632.1995.tb38127.x; DAMASIO AR, 1994, SCI AM, V271, P144, DOI 10.1038/scientificamerican1094-144; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; Fellows LK, 2007, ANN NY ACAD SCI, V1121, P421, DOI 10.1196/annals.1401.023; Fellows LK, 2007, CEREB CORTEX, V17, P2669, DOI 10.1093/cercor/bhl176; Fellows LK, 2005, CEREB CORTEX, V15, P58, DOI 10.1093/cercor/bhh108; Floris G, 2008, NEUROCASE, V14, P385, DOI 10.1080/13554790802385418; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Funayama M, 2010, COGN BEHAV NEUROL, V23, P135, DOI 10.1097/WNN.0b013e3181d746ba; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Hahm DS, 2001, NEUROLOGY, V56, P398, DOI 10.1212/WNL.56.3.398; Hanna-Pladdy B, 2007, J Neurol Phys Ther, V31, P119; Izquierdo A, 2004, J NEUROSCI, V24, P7540, DOI 10.1523/JNEUROSCI.1921-04.2004; Kazama A, 2009, J NEUROSCI, V29, P2794, DOI 10.1523/JNEUROSCI.4655-08.2009; Leopold A, 2012, SOC COGN AFFECT NEUR, V7, P871, DOI 10.1093/scan/nsr071; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Mitchell DGV, 2006, NEUROPSYCHOLOGY, V20, P280, DOI 10.1037/0894-4105.20.3.280; Mitchell DGV, 2006, NEUROCASE, V12, P164, DOI 10.1080/13554790600611288; Moll J, 2008, ANN NY ACAD SCI, V1124, P161, DOI 10.1196/annals.1440.005; Namiki C, 2008, NEUROCASE, V14, P474, DOI 10.1080/13554790802459494; Ogai M, 2005, ACTA PSYCHIAT SCAND, V111, P74, DOI 10.1111/j.1600-0447.2004.00395.x; Ohtake H, 2005, J NEUROL NEUROSUR PS, V76, P1309, DOI 10.1136/jnnp.2004.061846; Poletti M, 2010, J NEUROPSYCH CLIN N, V22, pE7, DOI 10.1176/appi.neuropsych.22.2.247-d.e7; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Rudebeck PH, 2013, NAT NEUROSCI, V16, P1140, DOI 10.1038/nn.3440; Rudebeck PH, 2011, ANN NY ACAD SCI, V1239, P1, DOI 10.1111/j.1749-6632.2011.06267.x; Rudebeck PH, 2011, J NEUROSCI, V31, P10569, DOI 10.1523/JNEUROSCI.0091-11.2011; Rushworth MFS, 2007, TRENDS COGN SCI, V11, P168, DOI 10.1016/j.tics.2007.01.004; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Shamay-Tsoory SG, 2006, SOC NEUROSCI-UK, V1, P149, DOI 10.1080/17470910600985589; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Slachevsky A, 2006, BIOL RES, V39, P237, DOI 10.4067/S0716-97602006000200006; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Umeda S, 2010, SOC NEUROSCI-UK, V5, P19, DOI 10.1080/17470910902990584; Volle E, 2002, NEUROLOGY, V58, P488, DOI 10.1212/WNL.58.3.488; Wallis JD, 2007, ANNU REV NEUROSCI, V30, P31, DOI 10.1146/annurev.neuro.30.051606.094334; Walton ME, 2011, ANN NY ACAD SCI, V1239, P14, DOI 10.1111/j.1749-6632.2011.06257.x; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	54	26	29	2	45	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	FEB	2015	26	1					1	11		10.1515/revneuro-2014-0043			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	CC5KE	WOS:000350396700001	25252749				2022-02-06	
J	Addington, CP; Roussas, A; Dutta, D; Stabenfeldt, SE				Addington, Caroline P.; Roussas, Adam; Dutta, Dipankar; Stabenfeldt, Sarah E.			Endogenous Repair Signaling after Brain Injury and Complementary Bioengineering Approaches to Enhance Neural Regeneration	BIOMARKER INSIGHTS			English	Article						stem cells; traumatic brain injury; transplantation; controlled release	FIBROBLAST-GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; MESENCHYMAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; MARROW STROMAL CELLS; ADULT-RAT BRAIN; NEUROTROPHIC FACTORS BDNF; VEGF GENE-TRANSFER	Traumatic brain injury (TBI) affects 5.3 million Americans annually. Despite the many long-term deficits associated with TBI, there currently are no clinically available therapies that directly address the underlying pathologies contributing to these deficits. Preclinical studies have investigated various therapeutic approaches for TBI: two such approaches are stem cell transplantation and delivery of bioactive factors to mitigate the biochemical insult affiliated with TBI. However, success with either of these approaches has been limited largely due to the complexity of the injury microenvironment. As such, this review outlines the many factors of the injury microenvironment that mediate endogenous neural regeneration after TBI and the corresponding bioengineering approaches that harness these inherent signaling mechanisms to further amplify regenerative efforts.	[Addington, Caroline P.; Roussas, Adam; Dutta, Dipankar; Stabenfeldt, Sarah E.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ USA		Stabenfeldt, SE (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ USA.	sarah.stabenfeldt@asu.edu		Dutta, Dipankar/0000-0001-9864-1452; Addington, Caroline/0000-0003-4534-8222	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [DP2HD084067] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [DP2 HD084067] Funding Source: Medline		Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Addington CP, 2014, BIOMATERIALS, V35, P3263, DOI 10.1016/j.biomaterials.2013.12.102; Agasse F, 2007, EUR J NEUROSCI, V26, P3036, DOI 10.1111/j.1460-9568.2007.05915.x; AHMED S, 1995, J NEUROSCI, V15, P5765; Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Alagappan D, 2009, ASN NEURO, V1, DOI 10.1042/AN20090002; Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134; ALTMAN J, 1967, NATURE, V214, P1098, DOI 10.1038/2141098a0; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; Arbour RB, 2013, CRIT CARE NURS CLIN, V25, P297, DOI 10.1016/j.ccell.2013.02.010; Arguello AA, 2009, NEUROSCIENCE, V159, P1003, DOI 10.1016/j.neuroscience.2009.01.020; Bang OY, 2012, CELL MED, V4, P65, DOI 10.3727/215517912X647172; Barone FC, 2006, CLIN NEUROSCI RES, V6, P329, DOI 10.1016/j.cnr.2006.09.010; Basu A, 2002, J NEUROSCI, V22, P6071; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Baumann L, 2012, J CONTROL RELEASE, V162, P68, DOI 10.1016/j.jconrel.2012.04.049; Ben-Hur T, 2003, MOL CELL NEUROSCI, V24, P623, DOI 10.1016/S1044-7431(03)00218-5; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; Berry M, 2011, BRAIN RES BULL, V84, P289, DOI 10.1016/j.brainresbull.2010.08.004; Bertram JP, 2010, PHARM RES-DORDR, V27, P82, DOI 10.1007/s11095-009-0009-x; Bicker J, 2014, EUR J PHARM BIOPHARM, V87, P409, DOI 10.1016/j.ejpb.2014.03.012; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Bovetti S, 2007, J NEUROSCI, V27, P5976, DOI 10.1523/JNEUROSCI.0678-07.2007; Buckwalter MS, 2006, AM J PATHOL, V169, P154, DOI 10.2353/ajpath.2006.051272; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; Cacci E, 2008, GLIA, V56, P412, DOI 10.1002/glia.20616; Calderon TM, 2006, J NEUROIMMUNOL, V177, P27, DOI 10.1016/j.jneuroim.2006.05.003; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Cheng AW, 2003, DEV BIOL, V258, P319, DOI 10.1016/S0012-1606(03)00120-9; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Ching S, 2005, BRAIN BEHAV IMMUN, V19, P127, DOI 10.1016/j.bbi.2004.06.001; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Cook JL, 1998, MOL BRAIN RES, V55, P9, DOI 10.1016/S0169-328X(97)00350-1; Cooke MJ, 2011, BIOMATERIALS, V32, P5688, DOI 10.1016/j.biomaterials.2011.04.032; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cross DP, 2011, PHARM RES-DORDR, V28, P2477, DOI 10.1007/s11095-011-0474-x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cui M, 2011, GLIA, V59, P641, DOI 10.1002/glia.21134; DACUNHA A, 1992, J NEUROIMMUNOL, V36, P157; Delcroix GJR, 2010, BIOMATERIALS, V31, P2105, DOI 10.1016/j.biomaterials.2009.11.084; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Dziegielewska KM, 2000, CELL TISSUE RES, V299, P335; Emerich DF, 2010, NEUROTOX RES, V17, P66, DOI 10.1007/s12640-009-9079-0; Endres M, 2000, J CEREBR BLOOD F MET, V20, P139, DOI 10.1097/00004647-200001000-00018; Faigle R, 2013, BBA-GEN SUBJECTS, V1830, P2435, DOI 10.1016/j.bbagen.2012.09.002; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Filippo TRM, 2013, STEM CELL RES, V11, P913, DOI 10.1016/j.scr.2013.06.003; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Fon D, 2014, BIOMATERIALS, V35, P2692, DOI 10.1016/j.biomaterials.2013.12.016; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Friedman WJ, 2005, MOL NEUROBIOL, V32, P133, DOI 10.1385/MN:32:2:133; Fujio M, 2011, BONE, V49, P693, DOI 10.1016/j.bone.2011.06.024; Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; Galderisi U, 2013, STEM CELL RES, V10, P85, DOI 10.1016/j.scr.2012.09.001; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI [10.1089/neu.2008.0744, 10.1089/neu.2008-0744]; Giraudo E, 1996, J IMMUNOL, V157, P2618; Godbout JP, 2004, J NEUROIMMUNOL, V147, P141, DOI 10.1016/j.jneuroim.2003.10.031; Goldberg JS, 2009, REGEN MED, V4, P879, DOI 10.2217/RME.09.61; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Green HF, 2012, MOL CELL NEUROSCI, V49, P311, DOI 10.1016/j.mcn.2012.01.001; Grigoriadis N, 2011, EXP NEUROL, V230, P78, DOI 10.1016/j.expneurol.2011.02.021; Gritti A, 1996, J NEUROSCI, V16, P1091; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hamann MCJ, 2005, EXP NEUROL, V194, P106, DOI 10.1016/j.expneurol.2005.01.030; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hayamizu TF, 2001, NEUROL RES, V23, P353, DOI 10.1179/016164101101198550; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; He XZ, 2010, INT J PHARMACEUT, V390, P107, DOI 10.1016/j.ijpharm.2009.12.063; Heese K, 1998, J NEUROCHEM, V70, P699; Heffernan J.M., 2014, ANN BIOMED ENG; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Henderson PW, 2011, WOUND REPAIR REGEN, V19, P420, DOI 10.1111/j.1524-475X.2011.00687.x; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Higashino K, 2011, TISSUE ENG PT A, V17, P523, DOI 10.1089/ten.tea.2010.0168; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; Horne MK, 2010, STEM CELLS DEV, V19, P843, DOI 10.1089/scd.2009.0158; Huang F, 2013, NEUROREPORT, V24, P101, DOI 10.1097/WNR.0b013e32835c93c5; Huang YC, 2012, ACTA BIOMATER, V8, P1048, DOI 10.1016/j.actbio.2011.12.009; Iadecola C, 1999, J EXP MED, V189, P719, DOI 10.1084/jem.189.4.719; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jacques TS, 1998, DEVELOPMENT, V125, P3167; Jaerve A, 2012, STEM CELL TRANSL MED, V1, P732, DOI 10.5966/sctm.2012-0068; Jeon O, 2006, BIOMATERIALS, V27, P1598, DOI 10.1016/j.biomaterials.2005.08.030; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kamei N, 2007, SPINE, V32, P1272, DOI 10.1097/BRS.0b013e318059afab; Kawahara N, 1999, J CEREBR BLOOD F MET, V19, P307, DOI 10.1097/00004647-199903000-00009; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; Kokovay E, 2010, CELL STEM CELL, V7, P163, DOI 10.1016/j.stem.2010.05.019; Koo JW, 2008, P NATL ACAD SCI USA, V105, P751, DOI 10.1073/pnas.0708092105; Kopec AM, 2013, LEARN MEMORY, V20, P531, DOI 10.1101/lm.031377.113; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kuldo JM, 2005, AM J PHYSIOL-CELL PH, V289, pC1229, DOI 10.1152/ajpcell.00620.2004; Lachyankar MB, 1997, EXP NEUROL, V144, P350, DOI 10.1006/exnr.1997.6434; LAPCHAK PA, 1993, NEUROSCIENCE, V54, P445, DOI 10.1016/0306-4522(93)90265-H; Lau TT, 2011, EXPERT OPIN BIOL TH, V11, P189, DOI 10.1517/14712598.2011.546338; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223; LEHRMANN E, 1995, EXP NEUROL, V131, P114, DOI 10.1016/0014-4886(95)90013-6; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Li AH, 2013, J MOL NEUROSCI, V51, P1052, DOI 10.1007/s12031-013-0084-7; Li ZW, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-71; Li ZW, 2011, NEUROCHEM INT, V58, P812, DOI 10.1016/j.neuint.2011.03.007; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOGAN A, 1991, ANN NY ACAD SCI, V638, P474, DOI 10.1111/j.1749-6632.1991.tb49073.x; LOGAN A, 1992, J NEUROSCI, V12, P3828; Loganadane LD, 1997, CYTOKINE, V9, P740, DOI 10.1006/cyto.1997.0229; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Ma MM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-117; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2014, J NEUROSURG, V120, P1147, DOI 10.3171/2013.12.JNS131362; Mani N, 2010, J NEUROSCI RES, V88, P248, DOI 10.1002/jnr.22197; Martens DJ, 2002, EUR J NEUROSCI, V16, P1045, DOI 10.1046/j.1460-9568.2002.02181.x; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McPherson CA, 2011, BRAIN BEHAV IMMUN, V25, P850, DOI 10.1016/j.bbi.2010.09.003; Mirzadeh Z, 2008, CELL STEM CELL, V3, P265, DOI 10.1016/j.stem.2008.07.004; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mudo G, 2009, J NEURAL TRANSM, V116, P995, DOI 10.1007/s00702-009-0207-z; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nakaguchi K, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/915160; Nakanishi M, 2007, EUR J NEUROSCI, V25, P649, DOI 10.1111/j.1460-9568.2007.05309.x; Ninomiya M, 2006, NEUROSCI LETT, V403, P63, DOI 10.1016/j.neulet.2006.04.039; Nolan Y, 2004, J NEUROIMMUNOL, V151, P12, DOI 10.1016/j.jneuroim.2004.02.001; Overstreet DJ, 2012, J POLYM SCI POL PHYS, V50, P881, DOI 10.1002/polb.23081; Oyagi A, 2011, NEUROSCIENCE, V185, P116, DOI 10.1016/j.neuroscience.2011.04.034; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Patel T, 2012, ADV DRUG DELIVER REV, V64, P701, DOI 10.1016/j.addr.2011.12.006; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Peng H, 2006, GLIA, V54, P619, DOI 10.1002/glia.20409; Prokoph S, 2012, BIOMATERIALS, V33, P4792, DOI 10.1016/j.biomaterials.2012.03.039; Public Health Economics Program Eric A Finkelstein Senior Health Economist DHSSPRRTI Economist NCIPCCDCPPSCSH Scientist CTRMPR Site Director Pacific Institute for Research Evaluation M, 2006, INC EC BURD INJ US; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Rabbany SY, 2010, CELL TRANSPLANT, V19, P399, DOI 10.3727/096368909X481782; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Ramos-Cejudo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052121; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Robinson R, 2011, ACS NANO, V5, P4392, DOI 10.1021/nn103146p; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Schmidt NO, 2009, BRAIN RES, V1268, P24, DOI 10.1016/j.brainres.2009.02.065; Segers VFM, 2007, CIRCULATION, V116, P1683, DOI 10.1161/CIRCULATIONAHA.107.718718; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shen F, 2008, GENE THER, V15, P30, DOI 10.1038/sj.gt.3303048; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; SIEBERBLUM M, 1991, NEURON, V6, P949, DOI 10.1016/0896-6273(91)90235-R; Silver JM, 2011, TXB TRAUMATIC BRAIN, VSecond; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Skop NB, 2013, ACTA BIOMATER, V9, P6834, DOI 10.1016/j.actbio.2013.02.043; Smith ED, 2014, J BIOL CHEM, V289, P20615, DOI 10.1074/jbc.M114.568659; Snyder EY, 2011, EXP NEUROL, V230, P75, DOI 10.1016/j.expneurol.2011.03.012; Song BW, 2002, J PHARMACOL EXP THER, V301, P605, DOI 10.1124/jpet.301.2.605; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sugiura S, 2005, STROKE, V36, P859, DOI 10.1161/01.STR.0000158905.22871.95; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sun WF, 2014, INFLAMM RES, V63, P287, DOI 10.1007/s00011-013-0699-8; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Suzuki S, 2009, J CEREBR BLOOD F MET, V29, P464, DOI 10.1038/jcbfm.2008.141; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Thau-Zuchman O, 2012, J MOL NEUROSCI, V47, P166, DOI 10.1007/s12031-012-9706-8; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thomsen GM, 2014, STEM CELL RES, V13, P48, DOI 10.1016/j.scr.2014.04.013; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tian YY, 2007, NEUROSCI LETT, V421, P239, DOI 10.1016/j.neulet.2007.05.033; Tong LQ, 2008, NEUROBIOL AGING, V29, P1380, DOI 10.1016/j.neurobiolaging.2007.02.027; Tong LQ, 2012, J NEUROSCI, V32, P17714, DOI 10.1523/JNEUROSCI.1253-12.2012; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Uchida K, 2012, SPINE, V37, P2125, DOI 10.1097/BRS.0b013e3182600ef7; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wachs FP, 2006, J NEUROPATH EXP NEUR, V65, P358, DOI 10.1097/01.jnen.0000218444.53405.f0; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Wang XF, 2007, MOL CELL NEUROSCI, V36, P343, DOI 10.1016/j.mcn.2007.07.005; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Wang Y, 2011, PHARM RES-DORDR, V28, P1406, DOI 10.1007/s11095-011-0452-3; Wang YF, 2013, J CONTROL RELEASE, V172, P1, DOI 10.1016/j.jconrel.2013.07.032; Wang Z, 2015, STEM CELLS, V33, P456, DOI 10.1002/stem.1878; Wang ZT, 2013, J MOL NEUROSCI, V49, P409, DOI 10.1007/s12031-012-9908-0; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Widera D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-64; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Wu DF, 2002, J DRUG TARGET, V10, P239, DOI 10.1080/10611860290022679; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Xu Q, 2007, CLIN EXP PHARMACOL P, V34, P624, DOI 10.1111/j.1440-1681.2007.04619.x; Xue LP, 2014, CELL BIOCHEM BIOPHYS, V70, P1609, DOI 10.1007/s12013-014-0103-5; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yang JP, 2009, NEUROSCI LETT, V461, P212, DOI 10.1016/j.neulet.2009.06.060; Yang JP, 2009, NEUROSCI LETT, V449, P108, DOI 10.1016/j.neulet.2008.10.090; Yao JHS, 2006, BIOCHEM BIOPH RES CO, V342, P1396, DOI 10.1016/j.bbrc.2006.02.100; Yi X, 2014, J CONTROL RELEASE, V190, P637, DOI 10.1016/j.jconrel.2014.06.017; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Yu PP, 2012, METHODS MOL BIOL, V814, P327, DOI 10.1007/978-1-61779-452-0_21; Yu ZH, 2014, J NEUROCHEM, V130, P41, DOI 10.1111/jnc.12710; Zhang HX, 2003, J CELL BIOL, V163, P1375, DOI 10.1083/jcb.200308040; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2009, J CEREBR BLOOD F MET, V29, P1240, DOI 10.1038/jcbfm.2009.55; Zheng J, 2008, J BIOL CHEM, V283, P13280, DOI 10.1074/jbc.M709930200; Zhu Y, 2000, BRAIN RES, V866, P286, DOI 10.1016/S0006-8993(00)02240-X; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	267	26	28	1	9	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1177-2719			BIOMARK INSIGHTS	Biomark. Insights		2015	10			1			43	60		10.4137/BMIMI.S20062			18	Medicine, Research & Experimental	Emerging Sources Citation Index (ESCI)	Research & Experimental Medicine	DB5UQ	WOS:000368579500004	25983552				2022-02-06	
B	Cole, JT		Rajendram, R; Preedy, VR; Patel, VB		Cole, Jeffrey T.			Metabolism BCAAs	BRANCHED CHAIN AMINO ACIDS IN CLINICAL NUTRITION, VOL 1	Nutrition and Health Series		English	Article; Book Chapter						Traumatic brain injury; BCATm; BCKD; Astroglial-neuronal nitrogen cycle; Transamination; Michaelis constant; Nitrogen	BRANCHED-CHAIN AMINOTRANSFERASE; AMINO-ACID-METABOLISM; BCATC MESSENGER-RNA; LEUCINE METABOLISM; NEUROTRANSMITTER METABOLISM; EXPRESSION; BRAIN; ENZYMES; RAT; CELLS		Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Cole, JT (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA.	Jeffrey.cole@usuhs.edu					Berkich DA, 2007, J NEUROSCI RES, V85, P3367, DOI 10.1002/jnr.21500; Bixel MG, 2001, J HISTOCHEM CYTOCHEM, V49, P407, DOI 10.1177/002215540104900314; Bixel MG, 1997, J HISTOCHEM CYTOCHEM, V45, P685, DOI 10.1177/002215549704500506; Brosnan JT, 2006, J NUTR, V136, p207S, DOI 10.1093/jn/136.1.207S; Castellano S, 2007, GENE EXPR PATTERNS, V7, P485, DOI 10.1016/j.modgep.2006.10.010; Castellano S, 2006, BRAIN RES, V1108, P12, DOI 10.1016/j.brainres.2006.06.012; Cole JT, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00018; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; DeSantiago S, 1998, J NUTR, V128, P1165, DOI 10.1093/jn/128.7.1165; Dillon EL, 2013, AMINO ACIDS, V45, P431, DOI 10.1007/s00726-012-1438-0; Drown PM, 2000, BBA-BIOMEMBRANES, V1468, P273, DOI 10.1016/S0005-2736(00)00266-2; FANELLI FR, 1986, GUT, V27, P111, DOI 10.1136/gut.27.Suppl_1.111; Faure M, 2001, J NUTR, V131, P1528, DOI 10.1093/jn/131.5.1528; Garcia-Espinosa MA, 2007, J NEUROCHEM, V100, P1458, DOI 10.1111/j.1471-4159.2006.04332.x; Goichon A, 2013, J PROTEOMICS, V78, P535, DOI 10.1016/j.jprot.2012.10.024; Islam MM, 2007, J BIOL CHEM, V282, P11893, DOI 10.1074/jbc.M700198200; Islam MM, 2010, J BIOL CHEM, V285, P265, DOI 10.1074/jbc.M109.048777; Lang CH, 2003, AM J PHYSIOL-ENDOC M, V285, pE1205, DOI 10.1152/ajpendo.00177.2003; Lang CH, 2010, AM J PHYSIOL-REG I, V299, pR935, DOI 10.1152/ajpregu.00297.2010; Lynch CJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE854, DOI 10.1152/ajpendo.00153.2003; Lynch CJ, 2001, J NUTR, V131, p861S, DOI 10.1093/jn/131.3.861S; MARCHESINI G, 1991, CLIN NUTR, V10, P105, DOI 10.1016/0261-5614(91)90096-U; Mersey BD, 2005, HUM MOL GENET, V14, P3371, DOI 10.1093/hmg/ddi368; PELLETIER V, 1991, AM J CLIN NUTR, V54, P402, DOI 10.1093/ajcn/54.2.402; Perez-Villasefor G, 2005, LIFE SCI, V78, P334, DOI 10.1016/j.lfs.2005.04.079; Purpera MN, 2012, J ENDOCRINOL, V212, P85, DOI 10.1530/JOE-11-0270; Richardson MA, 2004, J CLIN PSYCHIAT, V65, P92; She PX, 2007, AM J PHYSIOL-ENDOC M, V293, pE1552, DOI 10.1152/ajpendo.00134.2007; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Sweatt AJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE64, DOI 10.1152/ajpendo.00276.2003; Yudkoff M, 2005, J NUTR, V135, p1531S, DOI 10.1093/jn/135.6.1531S; Yudkoff M, 1996, J NEUROCHEM, V66, P378; YUDKOFF M, 1994, J NEUROCHEM, V62, P1192	33	26	26	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA			978-1-4939-1923-9; 978-1-4939-1922-2	NUTR HEALTH SER	Nutr. Health Ser.		2015							13	24		10.1007/978-1-4939-1923-9_2	10.1007/978-1-4939-1923-9		12	Nutrition & Dietetics	Book Citation Index – Science (BKCI-S)	Nutrition & Dietetics	BD1EW	WOS:000357985700003					2022-02-06	
J	Echemendia, RJ; Giza, CC; Kutcher, JS				Echemendia, Ruben J.; Giza, Christopher C.; Kutcher, Jeffrey S.			Developing guidelines for return to play: Consensus and evidence-based approaches	BRAIN INJURY			English	Article						Guidelines; mild traumatic brain injury; sports concussion	ASSOCIATION POSITION STATEMENT; COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; CONCUSSION; SPORT; MANAGEMENT; SYMPTOMS; CONSCIOUSNESS	Background: Sports-related concussions are commonplace at all levels of play and across all age groups. The dynamic, evolving nature of this injury coupled with a lack of objective biomarkers creates a challenging management issue for the sports medicine team. Athletes who return to play following a concussion are known to be at higher risk for an additional brain injury, which necessitates a careful, informed return to play (RTP) process. Aim: The goal of this paper is to outline historical attempts at developing RTP guidelines and trace their evolution over time, culminating in a discussion of the process and outcomes of the most recent consensus statements/guidelines published by the international Concussion In Sport Group (CISG), the American Academy of Neurology (AAN), the National Athletic Trainers' Association, and the 2013 Team Physician Consensus Statement Update. Method: An evaluation of the pros and cons of these guidelines is presented along with suggestions for future directions. In addition, the Institute of Medicine recently conducted a comprehensive report outlining the current state of evidence regarding youth concussions, which provides specific recommendations for future research. Conclusions: The different methodologies utilized in the development of consensus statements have distinct advantages and disadvantages, and both approaches add value to the everyday management of sports concussions. Importantly, the overall approach for management of sports concussion is remarkably similar using either consensus-based or formal evidence-based methods, which adds confidence to the current guidelines and allows practitioners to focus on accepted standards of clinical care. Moving forward, careful study designs need to be utilized to avoid bias in selection of research subjects, collection of data, and interpretation of results. Although useful, clinicians must venture beyond consensus statements to examine reviews of the literature that are published in much greater frequency than consensus statements	[Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA 16801 USA; [Echemendia, Ruben J.] Univ Missouri, Univ Orthoped Comprehens Concuss Care, Kansas City, MO 64110 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Kutcher, Jeffrey S.] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA		Echemendia, RJ (corresponding author), Psychol & Neurobehav Associates Inc, 204 East Calder Way,Ste 205, State Coll, PA 16801 USA.	echemendia@panba.com	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NCAA; DODUnited States Department of Defense; Joseph Drown Foundation; ElMindA, Ltd.	The authors report no conflicts of interest. Dr Echemendia serves as a consultant to the NHL, MLS and US Soccer Federation. He is on the Medical Advisory Board for BrainScope, but does not receive financial compensation. He is also a member of the NCAA Concussion Task Force and a member of the US Lacrosse Sports Science Safety Committee. He is involved in Medicolegal cases, primarily regarding brain injury. He was a member of the scientific organizing committee for CISG-IV. Dr Giza serves as a consultant NHL/NHLPA and NFL NCP. He is a member of the MLS Concussion Program Committee, NCAA Concussion Task Force and California State Athletic Commission. He receives research support from NINDS, NCAA, DOD and the Joseph Drown Foundation. He is involved in 1-2 Medicolegal cases annually. Dr Kutcher is the Director of NBA Concussion Program and serves as a consultant to the NHLPA and NFLPA. He is a member of the NCAA Concussion Task Force and receives research support from ElMindA, Ltd.	[Anonymous], 2013, MED SCI SPORT EXER, V45, P1618, DOI 10.1249/MSS.0b013e31829ba437; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; [Anonymous], 2011, CLIN PRACTICE GUIDEL; [Anonymous], 2004, CLIN PRACTICE GUIDEL; Aubry M, 2001, BRIT J SPORT MED, V36, P6, DOI DOI 10.1136/BJSM.36.1.6; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown BB, 1968, DELPHI PROCESS, P1; Brown CN, 2003, J ATHL TRAINING, V38, pS; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Denny-Brown D, 1940, J PHYSL, V99, P2250; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Echemendia RJ, 2011, CLIN NEUROPSYCHOL, V25, P1289, DOI 10.1080/13854046.2011.618466; Erlanger D, 2001, J ATHL TRAINING, V36, P280; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Giza CC, 2013, NEUROLOGY, P1; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011; Herring Stanley A, 2012, Med Sci Sports Exerc, V44, P2446, DOI 10.1249/MSS.0b013e3182750534; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS, 1982, NEUROBEHAVIORAL CONS, P221; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Report of the Sports Medicine Committee, 1990, GUID MAN CONC SPORTS; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SCIARRA D, 1984, MERRITTS TXB NEUROLO, P277; SMITH A, 1961, DIS NERV SYST, V22, P69; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Spicer M.A.C.M., 2014, SPORTS RELATED CONCU; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; [No title captured]	48	26	27	1	38	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	2					185	194		10.3109/02699052.2014.965212			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AZ4OI	WOS:000348201500008	25587745				2022-02-06	
J	Hyde, GA; Savage, SA; Zarzaur, BL; Hart-Hyde, JE; Schaefer, CB; Croce, MA; Fabian, TC				Hyde, Glendon A.; Savage, Stephanie A.; Zarzaur, Ben L.; Hart-Hyde, Jensen E.; Schaefer, Candace B.; Croce, Martin A.; Fabian, Timothy C.			Early tracheostomy in trauma patients saves time and money	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Tracheostomy; Thoracic trauma; Traumatic brain injury; Ventilator associated pneumonia; Medical costs	MECHANICAL VENTILATION; TRACHEOTOMY; METAANALYSIS; COMPLICATIONS; INTUBATION; OUTCOMES; WORK	Introduction: Patients suffering traumatic brain and chest wall injuries are often difficult to liberate from the ventilator yet best timing of tracheostomy remains ill-defined. While prior studies have addressed early versus late tracheostomy, they generally suffer from the use of historical controls, which cannot account for variations in management over time. Propensity scoring can be utilized to identify controls from the same patient population, minimizing impact of confounding variables. The purpose of this study was to determine outcomes associated with early versus late tracheostomy by application of propensity scoring. Methods: Patients requiring intubation within 48 h and receiving tracheostomy from January 2010 to June 2012 were identified. Early tracheostomy (ET) was a tracheostomy performed by the fifth hospital day. ET patients were matched to late tracheostomy patients (LT, tracheostomy after day 5) using propensity scoring and compared for multiple outcomes. Cost for services was calculated using average daily billing rates at our institution. Results: One hundred and six patients were included, 53 each in the ET (mean day tracheostomy = 4) and the LT (mean day tracheostomy = 10) cohorts. The average age was 47 years and 94% suffered blunt injury, with an average NISS of 23.7. Patients in the ET group had significantly shorter TICU LOS (21.4 days vs. 28.6 days, p < 0.0001) and significantly fewer ventilator days (16.7 days vs. 21.9, p < 0.0001) compared to the LT group. ET patients also had significantly less VAP (34% vs. 64.2%, p = 0.0019). Conclusion: In the current era of increased health-care costs, early tracheostomy significantly decreased both pulmonary morbidity and critical care resource utilization. This translates to an appreciable cost savings, at minimum $52,173 per patient and a potential total savings of $2.8 million/year for the entire LT cohort. For trauma patients requiring prolonged ventilator support, early tracheostomy should be performed. (C) 2014 Elsevier Ltd. All rights reserved.	[Savage, Stephanie A.; Hart-Hyde, Jensen E.; Schaefer, Candace B.; Croce, Martin A.; Fabian, Timothy C.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA; [Hyde, Glendon A.] Univ Tennessee, Chattanooga, TN USA; [Zarzaur, Ben L.] Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA		Savage, SA (corresponding author), Univ Tennessee, Hlth Sci Ctr, 910 Madison Ave,Suite 220, Memphis, TN 38163 USA.	ghyde@uthsc.edu; ssavage1@uthsc.edu; bzarzaur@iupui.edu; jhart27@uthsc.edu; cschaefe@uthsc.edu; mcroce@uthsc.edu; tfabian@uthsc.edu	Zarzaur, Ben/S-6572-2019	Zarzaur, Ben/0000-0001-9988-9572			ASTRACHAN DI, 1988, LARYNGOSCOPE, V98, P1165; Bacchetta MD, 2005, ANN THORAC SURG, V79, P1879, DOI 10.1016/j.athoracsur.2004.10.042; Brotfain E, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/156814; Chadha NK, 2011, ARCH OTOLARYNGOL, V137, P30, DOI 10.1001/archoto.2010.228; COLICE GL, 1989, CHEST, V96, P877, DOI 10.1378/chest.96.4.877; Combes A, 2007, CRIT CARE MED, V35, P802, DOI 10.1097/01.CCM.0000256721.60517.B1; Diehl JL, 1999, AM J RESP CRIT CARE, V159, P383, DOI 10.1164/ajrccm.159.2.9707046; Griffiths J, 2005, BMJ-BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0; Higgins KM, 2007, LARYNGOSCOPE, V117, P447, DOI 10.1097/01.mlg.0000251585.31778.c9; Holevar M, 2009, J TRAUMA, V67, P870, DOI 10.1097/TA.0b013e3181b5a960; Moller MG, 2005, AM J SURG, V189, P293, DOI 10.1016/j.amjsurg.2005.01.002; Nieszkowska A, 2005, CRIT CARE MED, V33, P2527, DOI 10.1097/01.CCM.0000186898.58709.AA; Rodriguez JL, 1990, BRIT J SURG, V77, P1406; Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6; Shirawi N, 2006, CRIT CARE, V10, DOI 10.1186/cc3828; Terragni PP, 2010, JAMA-J AM MED ASSOC, V303, P1483, DOI 10.1001/jama.2010.447; Wang F, 2011, CHEST, V140, P1456, DOI 10.1378/chest.11-2024; Wu YK, 2010, CRIT CARE, V14, DOI 10.1186/cc8890	18	26	29	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2015	46	1					110	114		10.1016/j.injury.2014.08.049			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AX1YJ	WOS:000346739600021	25441577				2022-02-06	
J	Neville, C; Ludlow, C; Rieger, B				Neville, Christopher; Ludlow, Caleb; Rieger, Brian			Measuring postural stability with an inertial sensor: validity and sensitivity	MEDICAL DEVICES-EVIDENCE AND RESEARCH			English	Article						balance; concussion; forceplate; posturography; accelerometer		Introduction/purpose: To examine the concurrent validity, and sensitivity, of an inertial sensor for use in the assessment of postural sway. Methods: This was a laboratory-based, repeated-measures design with ten healthy participants. Concurrent validity was tested between an inertial sensor, forceplate, and rigid-body kinematics across three commonly used balance tests. Further, the inertial sensor measures were compared across eight commonly used tests of balance. Variables manipulated include stance position, surface condition, and eyes-open versus eyes-closed. Results: The inertial sensor was correlated to both the forceplate-derived measures (r=0.793) and rigid-body kinematics (r=0.887). Significant differences between the balance tests were observed when tested with the inertial sensor. In general, there was a three-way interactions between the three balance factors (surface, stance, and vision) leading to pairwise comparisons between each balance test. The root-mean-square showed an increase across tasks of greater difficulty ranging from an average of 0.0368 with two legs, eyes-open to 0.911 when tested during tandem stance, eyes-closed tested on a foam pad. Conclusion: The new inertial sensor shows promise for use in the assessment of postural sway. Additionally, the inertial sensor appears sensitive to differences in balance tasks of varying degrees of difficulty when tested in a healthy sample of young adults. This inertial sensor may provide new opportunities for further research in the assessment of balance changes in the mild traumatic brain injury population.	[Neville, Christopher; Ludlow, Caleb] SUNY Upstate Med Univ, Dept Phys Therapy Educ, 2225 Silvermann Hall,750 East Adams St, Syracuse, NY 13210 USA; [Rieger, Brian] SUNY Upstate Med Univ, Upstate Concuss Ctr, Syracuse, NY 13210 USA		Neville, C (corresponding author), SUNY Upstate Med Univ, Dept Phys Therapy Educ, 2225 Silvermann Hall,750 East Adams St, Syracuse, NY 13210 USA.	nevillec@upstate.edu		Neville, Christopher/0000-0002-8601-976X	Upstate Medical University and Motion Intelligence, Inc.	Research reported in this publication was solely the responsibility of the authors. The inertial sensors used in the study were provided by Motion Intelligence, Inc. (Ithaca, NY), and Upstate Medical University and Motion Intelligence, Inc. provided financial support of the clinical research.	Adlerton Anna-Karin, 2003, Physiother Res Int, V8, P187, DOI 10.1002/pri.289; Baltich J, 2014, GAIT POSTURE, V40, P327, DOI 10.1016/j.gaitpost.2014.04.208; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bonfim TR, 2008, NEUROSCI LETT, V441, P257, DOI 10.1016/j.neulet.2008.06.039; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Chang JO, 2014, CLIN J SPORT MED, V24, P256, DOI 10.1097/JSM.0000000000000016; Chaudhry H, 2004, J REHABIL RES DEV, V41, P713, DOI 10.1682/JRRD.2003.09.0140; Cicchetti DV, 2001, J CLIN EXP NEUROPSYC, V23, P695, DOI 10.1076/jcen.23.5.695.1249; Doheny EP, 2012, IEEE ENG MED BIO, P3300, DOI 10.1109/EMBC.2012.6346670; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Jorgensen MG, 2014, DAN MED J, V61; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; MAKI BE, 1994, J GERONTOL, V49, pM72, DOI 10.1093/geronj/49.2.M72; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2012, GAIT POSTURE, V36, P471, DOI 10.1016/j.gaitpost.2012.04.010; McCall Andrew A, 2011, Front Neurol, V2, P88, DOI 10.3389/fneur.2011.00088; McCollum G, 1996, J THEOR BIOL, V180, P257, DOI 10.1006/jtbi.1996.0101; Moe-Nilssen R, 2002, GAIT POSTURE, V16, P60, DOI 10.1016/S0966-6362(01)00200-4; Moe-Nilssen R, 1998, ARCH PHYS MED REHAB, V79, P1377, DOI 10.1016/S0003-9993(98)90231-3; NASHNER LM, 1971, ACTA OTO-LARYNGOL, V72, P429, DOI 10.3109/00016487109122504; O'Sullivan M, 2009, AGE AGEING, V38, P308, DOI 10.1093/ageing/afp009; Palmerini L, 2011, IEEE T INF TECHNOL B, V15, P481, DOI 10.1109/TITB.2011.2107916; Pereira Tiago, 2013, Percept Mot Skills, V117, P1150; Piirtola M, 2006, GERONTOLOGY, V52, P1, DOI 10.1159/000089820; SCHUMANN T, 1995, J BIOMECH, V28, P603, DOI 10.1016/0021-9290(94)00113-I; Seimetz Christina, 2012, Biomed Sci Instrum, V48, P386; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015; WINTER DA, 1990, MED PROG TECHNOL, V16, P31	32	26	26	1	3	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1179-1470			MED DEVICES-EVID RES	MED. DEVICES-EVID. RES.		2015	8						447	454		10.2147/MDER.S91719			8	Engineering, Biomedical	Emerging Sources Citation Index (ESCI)	Engineering	V05TQ	WOS:000213895300048	26604839	gold, Green Published, Green Submitted			2022-02-06	
J	Olivecrona, Z; Bobinski, L; Koskinen, LOD				Olivecrona, Zandra; Bobinski, Lukas; Koskinen, Lars-Owe D.			Association of ICP, CPP, CT findings and S-100B and NSE in severe traumatic head injury. Prognostic value of the biomarkers	BRAIN INJURY			English	Article						CPP; CT classification; ICP targeted therapy; ICP; NSE; prognostication; S-100B; severe traumatic brain injury	NEURON-SPECIFIC ENOLASE; LOW-DOSE PROSTACYCLIN; SERUM S100B LEVELS; BRAIN-INJURY; COMPUTED-TOMOGRAPHY; CEREBROSPINAL-FLUID; OUTCOME PREDICTION; PROTEIN; MARKER; DAMAGE	Objective: The association was studied of intracranial pressure (ICP) and cerebral perfusion pressure (CPP) on S-100B and neuron-specific enolase (NSE) in severe traumatic brain injury (sTBI). The relationship was explored between biomarkers, ICP, CPP, CT-scan classifications and the clinical outcome. Materials and methods: Data were collected prospectively and consecutively in 48 patients with Glasgow Coma Scale score <= 8, age 15-70 years. NSE and S-100B were analysed during 5 consecutive days. The initial and follow-up CT-scans were classified according to the Marshall, Rotterdam and Morris-Marshall classifications. Outcome was evaluated with extended Glasgow outcome scale at 3 months. Results: Maximal ICP and minimal CPP correlated with S-100B and NSE levels. Complex relations between biomarkers and CT classifications were observed. S-100B bulk release (AUC = 0.8333, p = 0.0009), and NSE at 72 hours (AUC = 0.8476, p = 0.0045) had the highest prediction power of mortality. Combining Morris-Marshall score and S-100B bulk release improved the prediction of clinical outcome (AUC = 0.8929, p = 0.0008). Conclusion: Biomarker levels are associated with ICP and CPP and reflect different aspects of brain injury as evaluated by CT-scan. The biomarkers might predict mortality. There are several pitfalls influencing the interpretation of biomarker data in respect to ICP, CPP, CT-findings and clinical outcome.	[Olivecrona, Zandra; Bobinski, Lukas; Koskinen, Lars-Owe D.] Umea Univ, Dept Neurosurg, Inst Pharmacol & Clin Neurosci, SE-90185 Umea, Sweden		Koskinen, LOD (corresponding author), Umea Univ, Dept Neurosurg, Inst Pharmacol & Clin Neurosci, SE-90185 Umea, Sweden.	lars-owe.koskinen@neuro.umu.se	Koskinen, Lars-Owe/AAQ-8957-2020		Department of Pharmacology and Clinical Neuroscience, Umea University; Tore Nilsson Found; Kempe Found; Capio Research Found	The authors report no conflicts of interest. Financial support from the Department of Pharmacology and Clinical Neuroscience, Umea University, Tore Nilsson Found, Kempe Found, and Capio Research Found is acknowledged.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Babcock L, 2012, BRAIN INJURY, V26, P1372, DOI 10.3109/02699052.2012.694565; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Bobinski L, 2012, ACTA NEUROCHIR, V154, P1069, DOI 10.1007/s00701-012-1345-x; Bouzat P, 2009, ANN FR ANESTH, V28, P135, DOI 10.1016/j.annfar.2008.12.019; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; Guan Wei, 2003, Chin J Traumatol, V6, P218; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jung CS, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/560305; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kirchhoff C, 2008, EUR J MED RES, V13, P511; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kofke WA, 2004, ANESTH ANALG, V99, P1323, DOI 10.1213/01.ANE.0000135345.03635.6A; Koskinen LOD, 2015, NEUROCRIT CARE, V22, P26, DOI 10.1007/s12028-014-0030-8; Lesko MM, 2014, BRAIN INJURY, V28, P987, DOI 10.3109/02699052.2014.890743; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marmarou A, 2000, ACT NEUR S, V76, P349; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Moller AD, 1997, AM J PHYSIOL-HEART C, V273, pH200, DOI 10.1152/ajpheart.1997.273.1.H200; Morris GF, 1997, CLIN NEUROL NEURO S1, V99, pS16; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Olivecrona M, 2012, BRAIN INJURY, V26, P67, DOI 10.3109/02699052.2011.635351; Olivecrona M, 2009, J NEUROTRAUM, V26, P1251, DOI [10.1089/neu.2008.0605, 10.1089/neu.2008-0605]; Olivecrona Z, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-33; Olivecrona Z, 2012, ACTA NEUROCHIR, V154, P675, DOI 10.1007/s00701-012-1292-6; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Unden J, 2007, NEUROCRIT CARE, V6, P94, DOI 10.1007/s12028-007-0005-0; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vos PE, 2006, EUR J NEUROL, V13, P632, DOI 10.1111/j.1468-1331.2006.01332.x; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Ytrebo LM, 2000, SCAND J GASTROENTERO, V35, P546	65	26	27	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	4					446	454		10.3109/02699052.2014.989403			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CF8JE	WOS:000352803300005	25518864				2022-02-06	
J	Campolo, M; Esposito, E; Ahmad, A; Di Paola, R; Paterniti, I; Cordaro, M; Bruschetta, G; Wallace, JL; Cuzzocrea, S				Campolo, Michela; Esposito, Emanuela; Ahmad, Akbar; Di Paola, Rosanna; Paterniti, Irene; Cordaro, Marika; Bruschetta, Giuseppe; Wallace, John L.; Cuzzocrea, Salvatore			Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Brain trauma; Hydrogen sulfide; Neurotrophic factor; Inflammation; Motor recovery; Infarct area; Infarct volume; Nitrosative stress; Astrogliosis; Neuroprotection	UP-REGULATION; NITRIC-OXIDE; NEUROTROPHIC FACTOR; GROWTH-FACTOR; SIGNALING MOLECULE; KAPPA-B; EXPRESSION; PROTECTS; H2S; NEURONS	Background: Traumatic brain injury (TBI) induces secondary injury mechanisms, including dynamic interplay between ischemic, inflammatory and cytotoxic processes. We recently reported that administration of ATB-346 (2-(6-methoxynapthalen-2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester), a hydrogen sulfide-releasing cyclooxygenase inhibitor, showed marked beneficial effects in an animal model of spinal cord injury, significantly enhancing recovery of motor function and reducing the secondary inflammation and tissue injury. Methods: Here we evaluated the neuroprotective potential of ATB-346, a hydrogen sulfide-releasing derivative of naproxen, using the controlled cortical impact (CCI) injury model in mice, one of the most common models of TBI. Moreover, the aim of the present study was to carefully investigate molecular pathways and subtypes of glial cells involved in the protective effect of ATB-346 on inflammatory reaction associated with an experimental model of TBI. In these studies, TBI was induced in mice by CCI and mice were orally administered ATB-346, naproxen (both at 30 mu mol/ kg) or vehicle (dimethylsulfoxide: 1% carboxymethylcellulose [5:95] suspension) one and six hours after brain trauma and once daily for 10 days. Results: Results revealed that ATB-346 attenuated TBI-induced brain edema, suppressed TBI-induced neural cell death and improved neurological function. ATB-346 also significantly reduced the severity of inflammation and restored neurotrophic factors that characterized the secondary events of TBI. Conclusions: These data demonstrate that ATB-346 can be efficacious in a TBI animal model by reducing the secondary inflammation and tissue injury. Therefore, ATB-346 could represent an interesting approach for the management of secondary damage following CNS diseases, counteracting behavioral changes and inflammatory process.	[Campolo, Michela; Esposito, Emanuela; Ahmad, Akbar; Di Paola, Rosanna; Paterniti, Irene; Cordaro, Marika; Bruschetta, Giuseppe; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy; [Wallace, John L.] Univ Calgary, Inflammat Res Network, Calgary, AB T2N 4N1, Canada; [Cuzzocrea, Salvatore] Univ Manchester, Manchester Royal Infirm, Sch Med, Manchester Biomed Res Ctr, Manchester M13 9WU, Lancs, England		Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Viale Ferdinando Stagno DAlcontres, I-98166 Messina, Italy.	salvator@unime.it	Cordaro, Marika/K-7329-2016; Campolo, Michela/K-6432-2016; Wallace, John/AAL-3763-2021; di paola, rosanna/U-4356-2019	Cordaro, Marika/0000-0002-3980-0043; di paola, rosanna/0000-0001-6725-8581; Cuzzocrea, Salvatore/0000-0001-6131-3690; Ahmad, Akbar/0000-0003-1841-9670			Altaany Z, 2013, J CELL MOL MED, V17, P879, DOI 10.1111/jcmm.12077; Anisimova I. E., 2004, Sudebno-Meditsinskaya Ekspertiza, V47, P37; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blackman RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029798; Campolo M, 2013, FASEB J, V27, P4489, DOI 10.1096/fj.13-234716; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cui X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080358; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Geng B, 2004, BIOCHEM BIOPH RES CO, V313, P362, DOI 10.1016/j.bbrc.2003.11.130; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hermann DM, 2001, NEUROBIOL DIS, V8, P964, DOI 10.1006/nbdi.2001.0448; Kamat PK, 2013, NEUROSCIENCE, V252, P302, DOI 10.1016/j.neuroscience.2013.07.051; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kimura H, 2005, ANTIOXID REDOX SIGN, V7, P778, DOI 10.1089/ars.2005.7.778; Kimura H, 2002, MOL NEUROBIOL, V26, P13, DOI 10.1385/MN:26:1:013; Kimura H, 2012, ANTIOXID REDOX SIGN, V17, P45, DOI 10.1089/ars.2011.4345; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kondo K, 2013, CIRCULATION, V127, P1116, DOI 10.1161/CIRCULATIONAHA.112.000855; Kram L, 2013, THROMB RES, V132, pE112, DOI 10.1016/j.thromres.2013.07.010; Li L, 2009, FREE RADICAL BIO MED, V47, P103, DOI 10.1016/j.freeradbiomed.2009.04.014; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Lundblad C, 2009, J NEUROTRAUM, V26, P1953, DOI 10.1089/neu.2009.0955; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Pedersen MO, 2009, HISTOL HISTOPATHOL, V24, P573, DOI 10.14670/HH-24.573; Polhemus DJ, 2014, CIRC RES, V114, P730, DOI 10.1161/CIRCRESAHA.114.300505; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; Schomacher M, 2008, BRAIN RES, V1240, P213, DOI 10.1016/j.brainres.2008.09.019; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Wallace JL, 2014, ANTIOXID REDOX SIGNA; Wallace JL, 2007, TRENDS PHARMACOL SCI, V28, P501, DOI 10.1016/j.tips.2007.09.003; Wallace JL, 2007, GASTROENTEROLOGY, V132, P261, DOI 10.1053/j.gastro.2006.11.042; Wallace JL, 2010, BRIT J PHARMACOL, V159, P1236, DOI 10.1111/j.1476-5381.2009.00611.x; WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	46	26	28	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	DEC 4	2014	11								196	10.1186/s12974-014-0196-1			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	AW6LJ	WOS:000346380700001	25472548	Green Published, gold			2022-02-06	
J	Levita, L; Bois, C; Healey, A; Smyllie, E; Papakonstantinou, E; Hartley, T; Lever, C				Levita, Liat; Bois, Catherine; Healey, Andrew; Smyllie, Emily; Papakonstantinou, Evelina; Hartley, Tom; Lever, Colin			The Behavioural Inhibition System, anxiety and hippocampal volume in a non-clinical population	BIOLOGY OF MOOD & ANXIETY DISORDERS			English	Article						Anxiety; Behavioural Inhibition System; Sensitivity to Punishment; Structural MRI; Hippocampus; Amygdala		Background: Animal studies have suggested that the hippocampus may play an important role in anxiety as part of the Behavioural Inhibition System (BIS), which mediates reactivity to threat and punishment and can predict an individual's response to anxiety-relevant cues in a given environment. The aim of the present structural magnetic resonance imaging (MRI) study was to examine the relationship between individual differences in BIS and hippocampal structure, since this has not received sufficient attention in non-clinical populations. Thirty healthy right-handed participants with no history of alcohol or drug abuse, neurological or psychiatric disorders, or traumatic brain injury were recruited (16 male, 14 female, age 18 to 32 years). T1-weighted structural MRI scans were used to derive estimates of total intracranial volume, and hippocampal and amygdala gray matter volume using FreeSurfer. To relate brain structure to Gray's BIS, participants completed the Sensitivity to Punishment questionnaire. They also completed questionnaires assessing other measures potentially associated with hippocampal volume (Beck Depression Inventory, Negative Life Experience Survey), and two other measures of anxiety (Spielberger Trait Anxiety Inventory and the Beck Anxiety Inventory). Results: We found that high scores on the Sensitivity to Punishment scale were positively associated with hippocampal volume, and that this phenomenon was lateralized to the right side. In other words, greater levels of behavioural inhibition (BIS) were positively associated with right hippocampal volume. Conclusions: Our data suggest that hippocampal volume is related to the cognitive and affective dimensions of anxiety indexed by the Sensitivity to Punishment, and support the idea that morphological differences in the hippocampal formation may be associated with behavioural inhibition contributions to anxiety.	[Levita, Liat] Univ Sheffield, Dept Psychol, Western Bank, Sheffield S10 2TN, S Yorkshire, England; [Bois, Catherine; Healey, Andrew; Smyllie, Emily; Papakonstantinou, Evelina; Hartley, Tom] Univ York, Dept Psychol, York YO10 5DD, N Yorkshire, England; [Bois, Catherine] Univ Edinburgh, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland; [Lever, Colin] Univ Durham, Dept Psychol, Durham DH1 3LE, England		Levita, L (corresponding author), Univ Sheffield, Dept Psychol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	l.levita@sheffield.ac.uk	Lever, Colin/B-4860-2008; Hartley, Tom/B-7811-2008	Lever, Colin/0000-0002-8955-2885; Hartley, Tom/0000-0002-4072-6637; Levita, Liat/0000-0001-6002-6817	BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/G01342X/2]; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/G01342X/1] Funding Source: UKRI	The research was funded by a BBSRC (BB/G01342X/2) grant to CL. We would also like to thank the York Neuroimaging Centre for help and assistance while conducting the study.	Adhikari A, 2011, NEURON, V71, P898, DOI 10.1016/j.neuron.2011.07.027; Adhikari A, 2010, NEURON, V65, P257, DOI 10.1016/j.neuron.2009.12.002; Bados A, 2010, J PERS ASSESS, V92, P560, DOI 10.1080/00223891.2010.513295; Bangert M, 2006, NEUROIMAGE, V30, P917, DOI 10.1016/j.neuroimage.2005.10.044; Barnes J, 2010, NEUROIMAGE, V53, P1244, DOI 10.1016/j.neuroimage.2010.06.025; Barros-Loscertales A, 2006, NEUROIMAGE, V33, P1011, DOI 10.1016/j.neuroimage.2006.07.025; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bishop SJ, 2007, TRENDS COGN SCI, V11, P307, DOI 10.1016/j.tics.2007.05.008; Blackhart GC, 2006, BIOL PSYCHOL, V72, P46, DOI 10.1016/j.biopsycho.2005.06.010; Brambilla P, 2012, PSYCHOL MED, V42, P427, DOI 10.1017/S0033291711001255; Brown ES, 2008, BIOL PSYCHIAT, V63, P705, DOI 10.1016/j.biopsych.2007.09.014; Brown ES, 2004, BIOL PSYCHIAT, V55, P538, DOI 10.1016/j.biopsych.2003.09.010; Campbell S, 2004, J PSYCHIATR NEUROSCI, V29, P417; CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319; Cherbuin N, 2008, SOC COGN AFFECT NEUR, V3, P262, DOI 10.1093/scan/nsn018; Cools R, 2005, PSYCHOPHARMACOLOGY, V180, P670, DOI 10.1007/s00213-005-2215-5; Cornwell BR, 2012, HIPPOCAMPUS, V22, P1848, DOI 10.1002/hipo.22019; Davidson R.J., 1990, INT J PERSONALITY SO, V58, P330, DOI DOI 10.1037/0022-3514.58.2.330; DAVIDSON RJ, 1990, J CLIN EXP NEUROPSYC, V12, P62; Duvernoy HM, 1991, HUMAN BRAIN SURCACE; Engin E, 2008, NEUROSCIENCE, V157, P666, DOI 10.1016/j.neuroscience.2008.09.037; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ermer E, 2012, J ABNORM PSYCHOL, V121, P649, DOI 10.1037/a0026371; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fuentes P, 2012, COGN AFFECT BEHAV NE, V12, P491, DOI 10.3758/s13415-012-0099-5; GRAY JA, 1982, BEHAV BRAIN SCI, V5, P469, DOI 10.1017/S0140525X00013066; Gray JA., 2000, NEUROPSYCHOLOGY ANXI; Gros DF, 2007, PSYCHOL ASSESSMENT, V19, P369, DOI 10.1037/1040-3590.19.4.369; Hahn T, 2010, BIOL PSYCHIAT, V68, P459, DOI 10.1016/j.biopsych.2010.04.033; Heller W, 1998, COGNITION EMOTION, V12, P421; Lang P. J., 1968, RES PSYCHOTHERAPY, P90, DOI [DOI 10.1037/10546-004, 10.1037/10546-004]; Leyfer OT, 2006, J ANXIETY DISORD, V20, P444, DOI 10.1016/j.janxdis.2005.05.004; Li W, 2012, HUM BRAIN MAPP; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; Maack DJ, 2012, J ANXIETY DISORD, V26, P689, DOI 10.1016/j.janxdis.2012.05.005; Mathews A, 2004, J COGNITIVE NEUROSCI, V16, P1683, DOI 10.1162/0898929042947810; May A, 2007, CEREB CORTEX, V17, P205, DOI 10.1093/cercor/bhj138; McEwen BS, 2000, BIOL PSYCHIAT, V48, P721, DOI 10.1016/S0006-3223(00)00964-1; McNaughton N, 2004, NEUROSCI BIOBEHAV R, V28, P285, DOI 10.1016/j.neubiorev.2004.03.005; McNaughton N, 2007, BEHAV PHARMACOL, V18, P329, DOI 10.1097/FBP.0b013e3282ee82e3; Mogg K, 2002, BEHAV RES THER, V40, P1403, DOI 10.1016/S0005-7967(02)00017-7; Nelson MD, 1998, ARCH GEN PSYCHIAT, V55, P433, DOI 10.1001/archpsyc.55.5.433; Nitschke JB, 1999, PSYCHOPHYSIOLOGY, V36, P628, DOI 10.1017/S0048577299972013; Oler JA, 2010, NATURE, V466, P864, DOI 10.1038/nature09282; Pavic L, 2007, PSYCHIAT RES-NEUROIM, V154, P191, DOI 10.1016/j.pscychresns.2006.08.005; Peper JS, 2007, HUM BRAIN MAPP, V28, P464, DOI 10.1002/hbm.20398; Qiu AQ, 2009, NEUROIMAGE, V47, P1221, DOI 10.1016/j.neuroimage.2009.05.054; Rao U, 2010, BIOL PSYCHIAT, V67, P357, DOI 10.1016/j.biopsych.2009.10.017; REIMAN EM, 1984, NATURE, V310, P683, DOI 10.1038/310683a0; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Risbrough V, 2010, CURR TOP BEHAV NEURO, V2, P205, DOI 10.1007/7854_2009_11; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; SARASON IG, 1978, J CONSULT CLIN PSYCH, V46, P932, DOI 10.1037/0022-006X.46.5.932; Seidenbecher T, 2003, SCIENCE, V301, P846, DOI 10.1126/science.1085818; Shackman AJ, 2009, PSYCHOL SCI, V20, P1500, DOI 10.1111/j.1467-9280.2009.02476.x; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Spielberger C.D., 1989, STATE TRAIT ANXIETY; Spielberger CD., 1983, STATE TRAIT ANXIETY; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Sutton SK, 1997, PSYCHOL SCI, V8, P204, DOI 10.1111/j.1467-9280.1997.tb00413.x; Taubert M, 2012, NEUROSCIENTIST, V18, P320, DOI 10.1177/1073858411419048; Torrubia R, 2001, PERS INDIV DIFFER, V31, P837, DOI 10.1016/S0191-8869(00)00183-5; TORRUBIA R, 1984, PERS INDIV DIFFER, V5, P371, DOI 10.1016/0191-8869(84)90078-3; TURNER SM, 1984, J BEHAV ASSESS, V6, P265, DOI 10.1007/BF01321321; van Tol MJ, 2010, ARCH GEN PSYCHIAT, V67, P1002, DOI 10.1001/archgenpsychiatry.2010.121; Vervoort L, 2010, PERS INDIV DIFFER, V48, P629, DOI 10.1016/j.paid.2009.12.021; Wager TD, 2003, NEUROIMAGE, V19, P513, DOI 10.1016/S1053-8119(03)00078-8; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wells CE, 2013, J NEUROSCI, V33, P8650, DOI 10.1523/JNEUROSCI.5040-12.2013; Winter H, 2004, AM J PSYCHIAT, V161, P2194, DOI 10.1176/appi.ajp.161.12.2194; Woollett K, 2011, CURR BIOL, V21, P2109, DOI 10.1016/j.cub.2011.11.018; Wright L, 2009, PERS INDIV DIFFER, V46, P20, DOI 10.1016/j.paid.2008.08.019; Yeung M, 2012, NEUROPHARMACOLOGY, V62, P155, DOI 10.1016/j.neuropharm.2011.06.011; Zaidel DW, 1999, INT J PSYCHOPHYSIOL, V34, P187, DOI 10.1016/S0167-8760(99)00076-8	75	26	28	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	2045-5380			BIOL MOOD ANXIETY DI	Biol. Mood Anxiety Disord.	DEC	2014	4	1								10.1186/2045-5380-4-4			10	Behavioral Sciences	Emerging Sources Citation Index (ESCI)	Behavioral Sciences	V30GP	WOS:000215551400004	24607258	Green Accepted, Green Published, hybrid			2022-02-06	
J	Larrabee, GJ				Larrabee, Glenn J.			Minimizing False Positive Error With Multiple Performance Validity Tests: Response to Bilder, Sugar, and Hellemann (2014 this issue)	CLINICAL NEUROPSYCHOLOGIST			English	Article						False positive rate.; Performance and symptom validity tests; Multiple scores	TRAUMATIC BRAIN-INJURY; INADEQUATE EFFORT; CLINICAL-SAMPLE; TEST FAILURE; HEAD-INJURY; INTELLIGENCE; VALIDATION; INDICATORS; SCALE	Bilder, Sugar, and Hellemann (2014 this issue) contend that empirical support is lacking for use of multiple performance validity tests (PVTs) in evaluation of the individual case, differing from the conclusions of Davis and Millis (2014), and Larrabee (2014), who found no substantial increase in false positive rates using a criterion of failure of >= 2 PVTs and/or Symptom Validity Tests (SVTs) out of multiple tests administered. Reconsideration of data presented in Larrabee (2014) supports a criterion of >= 2 out of up to 7 PVTs/SVTs, as keeping false positive rates close to and in most cases below 10% in cases with bona fide neurologic, psychiatric, and developmental disorders. Strategies to minimize risk of false positive error are discussed, including (1) adjusting individual PVT cutoffs or criterion for number of PVTs failed, for examinees who have clinical histories placing them at risk for false positive identification (e.g., severe TBI, schizophrenia), (2) using the history of the individual case to rule out conditions known to result in false positive errors, (3) using normal performance in domains mimicked by PVTs to show that sufficient native ability exists for valid performance on the PVT(s) that have been failed, and (4) recognizing that as the number of PVTs/SVTs failed increases, the likelihood of valid clinical presentation decreases, with a corresponding increase in the likelihood of invalid test performance and symptom report.			Larrabee, GJ (corresponding author), 2650 Bahia Vista St,Suite 308, Sarasota, FL 34239 USA.	glarrabee@aol.com					BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Binder LM, 2003, J CLIN EXP NEUROPSYC, V25, P420, DOI 10.1076/jcen.25.3.420.13806; Boone K., 2002, B TEST MANUAL; Boone K. B., 2002, DOT COUNTING TEST MA; Boone K.B., 2007, ASSESSMENT FEIGNED C; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heaton R. K., 2004, REVISED COMPREHENSIV; Larrabee, 2007, ASSESSMENT MALINGERE, P334; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Pearson, 2009, ADV CLIN SOLUTIONS U; Pella RD, 2012, ARCH CLIN NEUROPSYCH, V27, P45, DOI 10.1093/arclin/acr090; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Silverberg N, 2005, J CLIN EXP NEUROPSYC, V27, P907, DOI 10.1080/13803390490919326; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682	33	26	26	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2014	28	8					1230	1242		10.1080/13854046.2014.988754			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AY0KY	WOS:000347286600003	25491180				2022-02-06	
J	Doig, RLO; Bartlett, CA; Maghzal, GJ; Lam, M; Archer, M; Stocker, R; Fitzgerald, M				Doig, Ryan L. O'Hare; Bartlett, Carole A.; Maghzal, Ghassan J.; Lam, Magdalena; Archer, Michael; Stocker, Roland; Fitzgerald, Melinda			Reactive species and oxidative stress in optic nerve vulnerable to secondary degeneration	EXPERIMENTAL NEUROLOGY			English	Article						Neurotrauma; Secondary degeneration; Oxidative stress; Reactive species; Antioxidant enzymes; Oxidative damage; Mitophagy	SPINAL-CORD-INJURY; CELL-DEATH; IN-VIVO; LIPID-PEROXIDATION; WHITE-MATTER; CALCIUM; DAMAGE; BRAIN; PEROXYNITRITE; OXYGEN	Secondary degeneration contributes substantially to structural and functional deficits following traumatic injury to the CNS. While it has been proposed that oxidative stress is a feature of secondary degeneration, contributing reactive species and resultant oxidized products have not been clearly identified in vivo. The study is designed to identify contributors to, and consequences of, oxidative stress in a white matter tract vulnerable to secondary degeneration. Partial dorsal transection of the optic nerve (ON) was used to model secondary degeneration in ventral nerve unaffected by the primary injury. Reactive species were assessed using fluorescent labelling and liquid chromatography/tandem mass spectroscopy (LC/MS/MS). Antioxidant enzymes and oxidized products were semi-quantified immunohistochemically. Mitophagy was assessed by electron microscopy. Fluorescent indicators of reactive oxygen and/or nitrogen species increased at 1, 3 and 7 days after injury, in ventral ON. LC/MS/MS confirmed increases in reactive species linked to infiltrating microglia/macrophages in dorsal ON. Similarly, immunoreactivity for glutathione peroxidase and haem oxygenase-1 increased in ventral ON at 3 and 7 days after injury, respectively. Despite increased antioxidant immunoreactivity, DNA oxidation was evident from 1 day, lipid oxidation at 3 days, and protein nitration at 7 days after injury. Nitrosative and oxidative damage was particularly evident in CC1-positive oligodendrocytes, at times after injury at which structural abnormalities of the Node of Ranvier/paranode complex have been reported. The incidence of mitochondrial autophagic profiles was also significantly increased from 3 days. Despite modest increases in antioxidant enzymes, increased reactive species are accompanied by oxidative and nitrosative damage to DNA, lipid and protein, associated with increasing abnormal mitochondria, which together may contribute to the deficits of secondary degeneration. (C) 2014 Elsevier Inc. All rights reserved.	[Doig, Ryan L. O'Hare; Bartlett, Carole A.; Archer, Michael; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Maghzal, Ghassan J.; Lam, Magdalena; Stocker, Roland] Victor Chang Cardiac Res Inst, Vasc Biol Div, Darlinghurst, NSW, Australia; [Maghzal, Ghassan J.; Stocker, Roland] Univ New S Wales, Sydney, NSW 2052, Australia		Fitzgerald, M (corresponding author), Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia.	lindy.fitzgerald@uwa.edu.au	maghzal, ghassan/A-9692-2015; Fitzgerald, Melinda/C-4235-2011; Doig, Ryan O'Hare/AAG-7585-2019; Stocker, Roland/AAV-4489-2021	Fitzgerald, Melinda/0000-0002-4823-8179; Lam, Magdalena/0000-0002-5350-8006	Neurotrauma Research Program of Western Australia; Road Safety Council of Western Australia; Road Trauma Trust Account, Western Australia; Australian Research Council Discovery ProjectAustralian Research Council [DP 110102135]; National Health & Medical Research Council of Australia (NHMRC) ProjectNational Health and Medical Research Council of Australia [1037879]; NHMRC Senior Principal Research FellowshipNational Health and Medical Research Council of Australia	We are grateful to Elora Bartlett and Conor McCarthy for technical assistance with mitochondrial quantification and Ivan Lozic for the schematic diagram. We acknowledge financial support from the Neurotrauma Research Program of Western Australia, an initiative of the Road Safety Council of Western Australia. This project is funded through the Road Trauma Trust Account, Western Australia, but does not reflect views or recommendations of the Road Safety Council. This work was partly supported by an Australian Research Council Discovery Project Grant DP 110102135 (to G.J.M.) and a National Health & Medical Research Council of Australia (NHMRC) Project Grant 1037879 (to R.S.). R.S. is supported by a NHMRC Senior Principal Research Fellowship.	Aldini G, 2006, CHEMMEDCHEM, V1, P1045, DOI 10.1002/cmdc.200600075; Back SA, 2005, ANN NEUROL, V58, P108, DOI 10.1002/ana.20530; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Bodeutsch N, 1999, J NEUROBIOL, V38, P116, DOI 10.1002/(SICI)1097-4695(199901)38:1<116::AID-NEU9>3.0.CO;2-F; BONGARZONE ER, 1995, J NEUROSCI RES, V41, P213, DOI 10.1002/jnr.490410209; Camello-Almaraz MC, 2006, J CELL PHYSIOL, V206, P487, DOI 10.1002/jcp.20498; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI 10.1089/neu.2008-0870; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Crow JP, 1997, J NEUROCHEM, V69, P1945; Cummins N, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-98; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Dasgupta A, 2013, ASN NEURO, V5, P99, DOI 10.1042/AN20120088; Denicola A, 2005, TOXICOLOGY, V208, P273, DOI 10.1016/j.tox.2004.11.023; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Ferguson AR, 2008, J NEUROSCI, V28, P11391, DOI 10.1523/JNEUROSCI.3708-08.2008; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; French HM, 2009, J NEUROSCI RES, V87, P3076, DOI 10.1002/jnr.22139; Fuss B, 2000, DEV BIOL, V218, P259, DOI 10.1006/dbio.1999.9574; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goldberg JA, 2012, NAT NEUROSCI, V15, P1414, DOI 10.1038/nn.3209; GRIOT C, 1990, FREE RADICAL RES COM, V11, P181, DOI 10.3109/10715769009088915; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Higgins GC, 2009, CELL MOL LIFE SCI, V66, P2773, DOI 10.1007/s00018-009-0079-2; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001; Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Li ZS, 2010, FEBS LETT, V584, P2291, DOI 10.1016/j.febslet.2010.03.040; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Ma F, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-31; Maghzal GJ, 2014, J BIOL CHEM, V289, P5580, DOI 10.1074/jbc.M113.539486; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; Min KJ, 2006, J NEUROSCI, V26, P1880, DOI 10.1523/JNEUROSCI.3696-05.2006; Moreira PI, 2005, ANN NY ACAD SCI, V1043, P545, DOI 10.1196/annals.1333.062; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Payne SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065710; Payne SC, 2012, INVEST OPHTH VIS SCI, V53, P6093, DOI 10.1167/iovs.12-10080; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Pryde KR, 2011, J BIOL CHEM, V286, P18056, DOI 10.1074/jbc.M110.186841; Reynolds MR, 2005, BIOCHEMISTRY-US, V44, P1690, DOI 10.1021/bi047982v; Schlieve CR, 2006, INVEST OPHTH VIS SCI, V47, P3878, DOI 10.1167/iovs.05-1010; Schneider C, 2008, J BIOL CHEM, V283, P15539, DOI 10.1074/jbc.R800001200; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; Sultana R, 2006, ANTIOXID REDOX SIGN, V8, P2021, DOI 10.1089/ars.2006.8.2021; Szymanski CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066448; Tang EHC, 2008, J PHARMACOL EXP THER, V327, P148, DOI 10.1124/jpet.108.140046; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003; Tretter L, 2007, J NEUROSCI RES, V85, P3471, DOI 10.1002/jnr.21405; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; VACA CE, 1988, MUTAT RES, V195, P137, DOI 10.1016/0165-1110(88)90022-X; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Yu HB, 2005, CHEM RES TOXICOL, V18, P1849, DOI 10.1021/tx050146h; Zielonka J, 2008, FREE RADICAL BIO MED, V44, P835, DOI 10.1016/j.freeradbiomed.2007.11.013; Zielonka J, 2008, NAT PROTOC, V3, P8, DOI 10.1038/nprot.2007.473; Zielonka J, 2010, FREE RADICAL BIO MED, V48, P983, DOI 10.1016/j.freeradbiomed.2010.01.028	69	26	26	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2014	261						136	146		10.1016/j.expneurol.2014.06.007			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR4AX	WOS:000343531500014	24931225	Green Submitted			2022-02-06	
J	Yanamadala, V; Walcott, BP; Fecci, PE; Rozman, P; Kumar, JI; Nahed, BV; Swearingen, B				Yanamadala, Vijay; Walcott, Brian P.; Fecci, Peter E.; Rozman, Peter; Kumar, Jay I.; Nahed, Brian V.; Swearingen, Brooke			Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Fresh frozen plasma; Intracranial hemorrhage; Prothrombin complex concentrate; Subdural hematoma; Warfarin	PLASMA	Warfarin-associated intracranial hemorrhage is associated with a high mortality rate. Ongoing coagulopathy increases the likelihood of hematoma expansion and can result in catastrophic hemorrhage if surgery is performed without reversal. The current standard of care for emergency reversal of warfarin is with fresh frozen plasma (FFP). In April 2013, the USA Food and Drug Administration approved a new reversal agent, 4-factor prothrombin complex concentrate (PCC), which has the potential to more rapidly correct coagulopathy. We sought to determine the feasibility and outcomes of using PCC for neurosurgical patients. A prospective, observational study of all patients undergoing coagulopathy reversal for intracranial hemorrhage from April 2013 to December 2013 at a single, tertiary care center was undertaken. Thirty three patients underwent emergent reversal of coagulopathy using either FFP or FCC at the discretion of the treating physician. Intracranial hemorrhage included subdural hematoma, intraparenchymal hematoma, and subarachnoid hemorrhage. FFP was used in 28 patients and FCC was used in five patients. International normalized ratio at presentation was similar between groups (FFP 2.9, PCC 3.1, p = 0.89). The time to reversal was significantly shorter in the PCC group (FFP 256 minutes, PCC 65 minutes, p < 0.05). When operations were performed, the time delay to perform operations was also significantly shorter in the PCC group (FFP 307 minutes, PCC 159 minutes, p <0.05). In this preliminary experience, FCC appears to provide a rapid reversal of coagulopathy. Normalization of coagulation parameters may prevent further intracranial hematoma expansion and facilitate rapid surgical evacuation, thereby improving neurological outcomes. (C) 2014 Elsevier Ltd. All rights reserved.	[Walcott, Brian P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA		Walcott, BP (corresponding author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA.	walcott.brian@mgh.harvard.edu	; Nahed, Brian/E-4239-2014	Fecci, Peter/0000-0002-2912-8695; Nahed, Brian/0000-0001-8537-106X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25 NS065743] Funding Source: Medline		Awad AJ, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS1323; Bershad EM, 2008, J NEUROSURG, V109, P664, DOI 10.3171/JNS/2008/109/10/0664; Hickey M, 2013, CIRCULATION, V128, P360, DOI 10.1161/CIRCULATIONAHA.113.001875; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; RADBERG JA, 1991, STROKE, V22, P571, DOI 10.1161/01.STR.22.5.571; Rossi E., 2009, ROSSIS PRINCIPLES TR; Sarode R, 2013, CIRCULATION, V128, P1234, DOI 10.1161/CIRCULATIONAHA.113.002283; Zubkov AY, 2008, ARCH NEUROL-CHICAGO, V65, P1320, DOI 10.1001/archneur.65.10.1320	10	26	26	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	NOV	2014	21	11					1881	1884		10.1016/j.jocn.2014.05.001			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU4TK	WOS:000345604100007	24953825	Green Accepted			2022-02-06	
J	Wang, JW; Zou, DH; Li, ZD; Huang, P; Li, DR; Shao, Y; Wang, HJ; Chen, YJ				Wang, Jiawen; Zou, Donghua; Li, Zhengdong; Huang, Ping; Li, Dongri; Shao, Yu; Wang, Huijun; Chen, Yijiu			Mechanical Properties of Cranial Bones and Sutures in 1-2-Year-Old Infants	MEDICAL SCIENCE MONITOR			English	Article						Cranial Sutures; Fractures, Bone; Head Injuries, Closed; Infant	FINITE-ELEMENT MODEL; CRANIOFACIAL SUTURES; BRAIN-INJURY; HEAD-INJURY; SKULL; VALIDATION; SIMULATION; IMPACT; FALLS	Background: The mechanical properties of 1-2-year-old pediatric cranial bones and sutures and their influential factors were studied to better understand how the pediatric calvarium reacts to loading. Material/Methods: Cranial bone and suture specimens were extracted from seven fresh-frozen human infant cadavers (1.5 +/- 0.5 years old). Eight specimens were obtained from each subject: two frontal bones, two parietal bones, two sagittal suture samples, and two coronal suture samples. The specimens were tested in a three-point bend setup at 1.5 mm/s. The mechanical properties, such as ultimate stress, elastic modulus, and ultimate strain, were calculated for each specimen. Results: The ultimate stress and elastic modulus of the frontal bone were higher than those of the parietal bone (P<0.05). No differences were found between the coronal and sagittal sutures in ultimate stress, elastic modulus, or ultimate strain (P>0.05). The ultimate stress and elastic modulus of the frontal and parietal bones were higher than those of the sagittal and coronal sutures (P<0.05), whereas the opposite ultimate strain findings were revealed (P<0.05). Conclusions: There was no significant difference in ultimate stress, elastic modulus, or ultimate strain between the sagittal and coronal sutures. However, there were significant differences in ultimate stress, elastic modulus, and ultimate strain between the frontal and parietal bones as well as between the cranial bones and sutures.	[Wang, Jiawen; Li, Dongri; Wang, Huijun; Chen, Yijiu] Southern Med Univ, Coll Med, Dept Forens Sci, Guangzhou, Guangdong, Peoples R China; [Wang, Jiawen; Zou, Donghua; Li, Zhengdong; Huang, Ping; Shao, Yu; Chen, Yijiu] Minist Justice, Inst Forens Sci, Shanghai Key Lab Forens Med, Shanghai, Peoples R China; [Wang, Jiawen] Foshan Univ, Basic Med Coll, Dept Pathol Teaching, Foshan, Peoples R China; [Wang, Jiawen] Foshan Univ, Basic Med Coll, Res Sect, Foshan, Peoples R China		Chen, YJ (corresponding author), Southern Med Univ, Coll Med, Dept Forens Sci, Guangzhou, Guangdong, Peoples R China.	hjwang@smu.edu.cn; yijiuchen@aliyun.com	Huang, Ping/L-1193-2019		12th Five-year National Plan for Science and Technology [2012BAK16B02]; Council of National Science Foundation of China [81273338-81102300]; Scientific and Technological Key Project of Shanghai Municipality [14231202500-14DZ2271500]; Shanghai Postdoctoral Scientific Program [14R21423000]	The 12th Five-year National Plan for Science and Technology (No. 2012BAK16B02), the Council of National Science Foundation of China (No. 81273338-81102300), the Scientific and Technological Key Project of Shanghai Municipality (No. 14231202500-14DZ2271500), the Shanghai Postdoctoral Scientific Program (No. 14R21423000)	Baumer TG, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.4000081; Coats B, 2008, J NEUROSURG-PEDIATR, V2, P321, DOI 10.3171/PED.2008.2.11.321; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Davis C, 2010, PLAST RECONSTR SURG, V125, P1111, DOI 10.1097/PRS.0b013e3181d0abcf; Davis MT, 2012, J BIOMECH, V45, P2493, DOI 10.1016/j.jbiomech.2012.07.001; Delille R, 2007, INT J CRASHWORTHINES, V12, P101, DOI 10.1080/13588260701433081; Desantis Klinich Kathleen, 2002, Stapp Car Crash J, V46, P165; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Herring S W, 2005, Orthod Craniofac Res, V8, P174, DOI 10.1111/j.1601-6343.2005.00328.x; Jasinoski SC, 2012, J BIOMECH, V45, P2050, DOI 10.1016/j.jbiomech.2012.05.007; Jasinoski SC, 2010, J BIOMECH, V43, P3104, DOI 10.1016/j.jbiomech.2010.08.007; JASLOW CR, 1990, J BIOMECH, V23, P313, DOI 10.1016/0021-9290(90)90059-C; Lapeer RJ, 2001, J BIOMECH, V34, P1125, DOI 10.1016/S0021-9290(01)00070-7; Li ZG, 2013, COMPUT METH PROG BIO, V112, P309, DOI 10.1016/j.cmpb.2013.05.008; Li ZG, 2011, ANN BIOMED ENG, V39, P2984, DOI 10.1007/s10439-011-0409-z; Maloul A, 2014, J BIOMECH, V47, P245, DOI 10.1016/j.jbiomech.2013.09.009; Maloul A, 2013, J BIOMECH, V46, P912, DOI 10.1016/j.jbiomech.2012.12.016; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; McLaughlin E, 2000, CLEFT PALATE-CRAN J, V37, P590, DOI 10.1597/1545-1569(2000)037<0590:TLDCON>2.0.CO;2; Moazen M, 2013, ANAT REC, V296, P198, DOI 10.1002/ar.22629; Moazen M, 2009, P ROY SOC B-BIOL SCI, V276, P39, DOI 10.1098/rspb.2008.0863; Motherway J, 2009, Leg Med (Tokyo), V11 Suppl 1, pS220, DOI 10.1016/j.legalmed.2009.01.072; Motherway JA, 2009, J BIOMECH, V42, P2129, DOI 10.1016/j.jbiomech.2009.05.030; Peterson J, 2003, ANAT REC PART A, V274A, P785, DOI 10.1002/ar.a.10096; Peterson J, 2002, ANAT REC, V268, P7, DOI 10.1002/ar.10131; Pierce MC, 2008, ANNU REV BIOMED ENG, V10, P85, DOI 10.1146/annurev.bioeng.9.060906.151907; Rafferty KL, 1999, J MORPHOL, V242, P167, DOI 10.1002/(SICI)1097-4687(199911)242:2<167::AID-JMOR8>3.3.CO;2-T; Roark R.J., 1986, FORMULAS STRESS STRA; Roth S, 2010, COMPUT METH PROG BIO, V99, P25, DOI 10.1016/j.cmpb.2009.10.004; Roth S, 2009, COMPUT METH PROG BIO, V93, P32, DOI 10.1016/j.cmpb.2008.08.001; Timoshenko S., 1970, THEORY ELASTICITY; Wang Q, 2012, ANAT REC, V295, P278, DOI 10.1002/ar.21532; Wang QA, 2010, ANAT REC, V293, P1477, DOI 10.1002/ar.21203	33	26	32	2	18	INT SCIENTIFIC LITERATURE, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	OCT 3	2014	20						1808	1813					6	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	AQ3ET	WOS:000342673100002	25279966	Green Published			2022-02-06	
J	Radic, JAE; Chou, SHY; Du, R; Lee, JW				Radic, Julia Anne Elisabeth; Chou, Sherry H-Y.; Du, Rose; Lee, Jong Woo			Levetiracetam Versus Phenytoin: A Comparison of Efficacy of Seizure Prophylaxis and Adverse Event Risk Following Acute or Subacute Subdural Hematoma Diagnosis	NEUROCRITICAL CARE			English	Article						Antiepileptic drug; Seizure; Subdural hematoma	TRAUMATIC BRAIN-INJURY; POSTOPERATIVE SEIZURES; CLINICAL ARTICLE; PREVENTION; TUMORS; TRIAL	Although both levetiracetam and phenytoin are used for seizure prophylaxis in subdural hematomas (SDHs), there is little data on their comparative efficacies. We compared the efficacy and risk of using levetiracetam versus phenytoin for seizure prophylaxis following acute or subacute SDH diagnosis. In this retrospective cohort study, the clinical data registry at a tertiary care hospital was searched for all cases of acute or subacute SDHs that were admitted to hospital in 2002, 2003, or 2011. Risk of clinical and/or electrographic seizures, and risk of adverse drug events were compared between the two exposure arms. 124 subjects in the phenytoin arm and 164 subjects in the levetiracetam arm were included. There was no significant difference in clinical and/or electrographic seizure risk, though there was a decreased risk of adverse events in the levetiracetam arm (p < 0.001). In subjects with midline shift > 0 mm, levetiracetam was associated with an increased risk of electrographic seizures during hospitalization (p = 0.028) and a decreased risk of adverse drug effects (p = 0.001), compared with phenytoin use. Levetiracetam generally appears to have a similar efficacy to phenytoin in preventing clinical and/or electrographic seizures following acute/subacute SDH diagnosis, though patients with midline shift > 0 mm may have associated with a higher risk of electrographic seizures on levetiracetam compared with patients on phenytoin. Levetiracetam is associated with a lower risk of adverse drug effects. A prospective, randomized study would more definitively determine any difference in efficacy and risk between phenytoin and levetiracetam.	[Radic, Julia Anne Elisabeth; Chou, Sherry H-Y.; Du, Rose; Lee, Jong Woo] Brigham & Womens Hosp, Edward B Bromfield Epilepsy Program, Dept Neurol, Boston, MA 02115 USA; [Radic, Julia Anne Elisabeth] Dalhousie Univ, Div Neurosurg, Halifax, NS, Canada; [Chou, Sherry H-Y.] Dept Neurol, Boston, MA USA; [Du, Rose] Dept Neurosurg, Boston, MA USA		Lee, JW (corresponding author), Brigham & Womens Hosp, Edward B Bromfield Epilepsy Program, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.	jar334@mail.harvard.edu; schou1@partners.org; rdu@partners.org; jlee38@partners.org	Lee, Jongwoo/AAI-3617-2020; Radic, Julia/AAV-4075-2020; Du, Rose/AAJ-2873-2020; Chou, Sherry/G-5779-2015; Du, Rose/I-5402-2012	Lee, Jongwoo/0000-0001-5283-7476; Chou, Sherry/0000-0002-5483-2908; Du, Rose/0000-0003-2641-6496	UCB, Inc.UCB Pharma SA; Sunovion, Inc.	Julia A. E. Radic declares that she has no conflict of interest. Rose Du declares that she has no conflict of interest. Sherry H-Y. Chou declares that she has no conflict of interest. Jong Woo Lee has received research grants from UCB, Inc. and Sunovion, Inc.	Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chen CW, 2004, J CLIN NEUROSCI, V11, P706, DOI 10.1016/j.jocn.2004.03.019; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; JONES GL, 1983, MED RES REV, V3, P383, DOI 10.1002/med.2610030403; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Kern K, 2012, J CLIN NEUROSCI, V19, P99, DOI 10.1016/j.jocn.2011.07.021; Messe S, 2009, NEUROCRIT CARE, V11, P38, DOI 10.1007/s12028-009-9207-y; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; Nalichowski R, 2006, BETH ANN S P AMIA S, P1044; OHNO K, 1993, J NEUROL NEUROSUR PS, V56, P1231, DOI 10.1136/jnnp.56.11.1231; Rabinstein AA, 2010, J NEUROSURG, V112, P455, DOI 10.3171/2009.7.JNS09392; Ramael S, 2006, EPILEPSIA, V47, P1128, DOI 10.1111/j.1528-1167.2006.00586.x; SABO RA, 1995, SURG NEUROL, V43, P579, DOI 10.1016/0090-3019(95)00155-7; Schierhout G, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000173; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Varelas PN, 2013, NEUROCRIT CARE, V19, P4, DOI 10.1007/s12028-013-9840-3; Wiedemayer H, 2002, BRAIN INJURY, V16, P323, DOI 10.1080/02699050110102077; Wu AS, 2013, J NEUROSURG, V118, P873, DOI 10.3171/2012.12.JNS111970; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30	21	26	28	0	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2014	21	2					228	237		10.1007/s12028-013-9951-x			10	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AQ9AR	WOS:000343132900009	24549935				2022-02-06	
J	Liu, SF; Mok, K; Neelavalli, J; Cheng, YCN; Tang, J; Ye, YQ; Haacke, EM				Liu, Saifeng; Mok, Karen; Neelavalli, Jaladhar; Cheng, Yu-Chung N.; Tang, Jin; Ye, Yongquan; Haacke, E. Mark			Improved MR Venography Using Quantitative Susceptibility-Weighted Imaging	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						susceptibility-weighted imaging; quantitative susceptibility mapping; phase imaging	MAGNETIC-SUSCEPTIBILITY; OXYGEN-SATURATION; PHASE DATA; BRAIN; FIELD; MAP; RECONSTRUCTION; MULTIPLE	Purpose: To remove the geometry dependence of phase-based susceptibility weighting masks in susceptibility-weighted imaging (SWI) and to improve the visualization of the veins and microbleeds. Materials and Methods: True SWI (tSWI) was generated using susceptibility-based masks. Simulations were used to evaluate the influence of the characteristic parameters defining the mask. In vivo data from three healthy adult human volunteers were used to compare the contrast-to-noise-ratios (CNRs) of the right septal vein and the left internal cerebral vein as measured from both tSWI and SWI data. A traumatic brain injury (TBI) patient dataset was used to illustrate qualitatively the proper visualization of microbleeds using tSWI. Results: Compared with conventional SWI, tSWI improved the CNR of the two selected veins by a factor of greater than three for datasets with isotropic resolution and greater than 30% for datasets with anisotropic resolution. Veins with different orientations can be properly enhanced in tSWI. Furthermore, the blooming artifact due to the strong dipolar phase of microbleeds in conventional SWI was reduced in tSWI for the TBI case. Conclusion: The use of tSWI overcomes the geometric limitations of using phase and provides better visualization of the venous system, especially for data collected with isotropic resolution.	[Liu, Saifeng; Mok, Karen; Haacke, E. Mark] McMaster Univ, Sch Biomed Engn, Hamilton, ON, Canada; [Neelavalli, Jaladhar; Cheng, Yu-Chung N.; Ye, Yongquan; Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI USA; [Tang, Jin; Haacke, E. Mark] MRI Inst Biomed Res, Detroit, MI USA		Neelavalli, J (corresponding author), HUH MR Res G030 Radiol,3990 John R St, Detroit, MI 48201 USA.	jaladhar@wayne.edu	Liu, Saifeng/I-1242-2019	NEELAVALLI, JALADHAR/0000-0002-9513-337X; Liu, Saifeng/0000-0002-3642-8282; Cheng, Yu-Chung/0000-0001-5870-6653	National Institutes of Health (NIH) (STTR) [1R42HL112580-01A1]; Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0522]; Perinatal Research Initiative of the Wayne State University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R42HL112580] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health (NIH) (STTR); Contract grant number: 1R42HL112580-01A1; Contract grant sponsor: Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC); Contract grant number: W81XWH-12-1-0522; Contract grant sponsor: Perinatal Research Initiative of the Wayne State University. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official government position, policy, or decision unless so designated by other documentation.	Abdul-Rahman HS, 2007, APPL OPTICS, V46, P6623, DOI 10.1364/AO.46.006623; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haacke EM, 2011, SUSCEPTIBILIY WEIGHT; Jain V, 2012, MAGN RESON MED, V68, P863, DOI 10.1002/mrm.23282; Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082; Liu T, 2011, NMR BIOMED, V24, P1129, DOI 10.1002/nbm.1670; Liu T, 2009, MAGN RESON MED, V61, P196, DOI 10.1002/mrm.21828; Marques JP, 2005, CONCEPT MAGN RESON B, V25B, P65, DOI 10.1002/cmr.b.20034; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Schweser F, 2012, NEUROIMAGE, V62, P2083, DOI 10.1016/j.neuroimage.2012.05.067; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Shmueli K, 2009, MAGN RESON MED, V62, P1510, DOI 10.1002/mrm.22135; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Venkatesan, 1999, MAGNETIC RESONANCE I; Wharton S, 2010, NEUROIMAGE, V53, P515, DOI 10.1016/j.neuroimage.2010.06.070; Xu YB, 2006, MAGN RESON IMAGING, V24, P155, DOI 10.1016/j.mri.2005.10.030; Xu YB, 2008, MAGN RESON IMAGING, V26, P1406, DOI 10.1016/j.mri.2008.04.008; Zwanenburg JJM, 2011, NEUROIMAGE, V56, P1902, DOI 10.1016/j.neuroimage.2011.03.046	21	26	28	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	SEP	2014	40	3					698	708		10.1002/jmri.24413			11	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	AN4DQ	WOS:000340538200025	24923249	Green Accepted			2022-02-06	
J	Ohnishi, M; Monda, A; Takemoto, R; Fujimoto, Y; Sugitani, M; Iwamura, T; Hiroyasu, T; Inoue, A				Ohnishi, Masatoshi; Monda, Ayaka; Takemoto, Ryoko; Fujimoto, Yukina; Sugitani, Mitsumasa; Iwamura, Takahiro; Hiroyasu, Takashi; Inoue, Atsuko			High-mobility group box 1 up-regulates aquaporin 4 expression via microglia-astrocyte interaction	NEUROCHEMISTRY INTERNATIONAL			English	Article						Aquaporin 4; Astrocyte; High-mobility group box 1; Interleukin-1 beta; Microglia; Nuclear factor-kappa B	TRAUMATIC BRAIN-INJURY; C-DEPENDENT PATHWAY; INTRACEREBRAL HEMORRHAGE; CHROMATIN PROTEIN; WATER CHANNELS; IN-VITRO; EDEMA; RAT; HMGB1; MICE	To clarify the mechanism of high-mobility group box (HMGB) 1-induced brain edema formation, this study focused on the effect of HMGB1 on aquaporin (AQP) 4, a water channel, in rat brain. Treatments for 6 h with 100-1000 ng/ml HMGB1, not showing self-toxicity, of primary-cultured rat astrocytes didnot increase AQP4 mRNA, unexpectedly. In contrast, intracerebroventricular (i.c.v.) injection of 300 ng of HMGB1 significantly increased AQP4 protein after 8 h and formed edema after 24 h in vivo. Thus, we investigated the roles of microglia as well as astrocytes. HMGB1 (1000 ng/ml) drastically increased interleukin (IL)-1 beta in the primary-cultured rat microglia after 2 h. The exposure of microglia to conditioned medium with HMGB1 and 3 mM adenosine 5'-triphosphate for 6 h significantly increased AQP4 mRNA in astrocytes after 6 h. Although 1000 ng/ml HMGB1 didnot induce transfer of nuclear factor (NF)-kappa B into the nucleus in astrocytes after 1 h, the conditioned medium containing IL-1 beta led to its nuclear import. As factors likely to be involved in the nuclear import of NF-kappa B besides IL-1 beta, nitric oxide and tumor necrosis factor-alpha didnot contribute under these conditions. Finally, i.c.v. injection of 30 nmol parthenolide, an NF-kappa B inhibitor, reversed 300 ng of HMGB1 injection-induced AQP4 protein increase after 8 h in vivo. The effect of parthenolide and the outcomes obtained so far suggest that HMGB1 indirectly up-regulates AQP4 expression through diffusible factor(s) such as IL-1 beta from microglia since HMGB1 by itself didnot affect NF-kappa B intracellular localization in astrocytes. (C) 2014 Elsevier Ltd. All rights reserved.	[Ohnishi, Masatoshi; Monda, Ayaka; Takemoto, Ryoko; Fujimoto, Yukina; Sugitani, Mitsumasa; Iwamura, Takahiro; Hiroyasu, Takashi; Inoue, Atsuko] Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Dept Pharmacotherapeut, Fukuyama, Hiroshima 7290292, Japan		Ohnishi, M (corresponding author), Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Dept Pharmacotherapeut, 985-1 Sanzo,Higashimura Cho, Fukuyama, Hiroshima 7290292, Japan.	ohnishi@fupharm.fukuyama-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	This work was supported by the Strategic Support Project of Research Infrastructure Formation for Private Universities from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Castaneyra-Ruiz L, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-18; Fazzina G, 2010, J NEUROTRAUM, V27, P453, DOI 10.1089/neu.2008.0782; Gea-Sorli S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041933; Hu HC, 2011, J SURG RES, V168, pE181, DOI 10.1016/j.jss.2011.02.019; Inoue A, 2012, J MOL NEUROSCI, V48, P541, DOI 10.1007/s12031-012-9747-z; Ishibashi K, 2009, CLIN EXP NEPHROL, V13, P107, DOI 10.1007/s10157-008-0118-6; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Laird MD, 2013, GLIA; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Leclerc P, 2013, SCAND J IMMUNOL, V77, P350, DOI 10.1111/sji.12041; Lo Pizzo M, 2013, NEUROL SCI, V34, P1309, DOI 10.1007/s10072-012-1233-4; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Ohnishi M, 2013, NEUROSCIENCE, V232, P45, DOI 10.1016/j.neuroscience.2012.11.057; Ohnishi M, 2007, EXP NEUROL, V206, P43, DOI 10.1016/j.expneurol.2007.03.030; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Spooren A, 2011, BIOCHEM PHARMACOL, V81, P1004, DOI 10.1016/j.bcp.2011.01.019; Taguchi T, 2006, J ENDOCRINOL, V188, P321, DOI 10.1677/joe.1.06418; Tang YP, 2007, J MOL NEUROSCI, V31, P83, DOI 10.1007/BF02686120; Tourdias T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-143; Unemura K, 2012, J PHARMACOL SCI, V119, P30, DOI 10.1254/jphs.12047FP; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Zhou Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/142458; Zhu SM, 2009, ANESTH ANALG, V109, P1493, DOI 10.1213/ANE.0b013e3181b893f3	33	26	26	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	SEP	2014	75						32	38		10.1016/j.neuint.2014.05.007			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AN8JZ	WOS:000340851800005	24893328				2022-02-06	
J	Semple, BD; Noble-Haeusslein, LJ; Kwon, YJ; Sam, PN; Gibson, AM; Grissom, S; Brown, S; Adahman, Z; Hollingsworth, CA; Kwakye, A; Gimlin, K; Wilde, EA; Hanten, G; Levin, HS; Schenk, AK				Semple, Bridgette D.; Noble-Haeusslein, Linda J.; Kwon, Yong Jun; Sam, Pingdewinde N.; Gibson, A. Matt; Grissom, Sarah; Brown, Sienna; Adahman, Zahra; Hollingsworth, Christopher A.; Kwakye, Alexander; Gimlin, Kayleen; Wilde, Elisabeth A.; Hanten, Gerri; Levin, Harvey S.; Schenk, A. Katrin			Sociosexual and Communication Deficits after Traumatic Injury to the Developing Murine Brain	PLOS ONE			English	Article							MOUSE ULTRASONIC VOCALIZATIONS; SCENT MARKING BEHAVIOR; MICE MUS-DOMESTICUS; SOCIAL COGNITION; C57BL/6J MICE; HOUSE MICE; VOCAL COMMUNICATION; COPULATORY-BEHAVIOR; CORPUS-CALLOSUM; SEXUAL-BEHAVIOR	Despite the life-long implications of social and communication dysfunction after pediatric traumatic brain injury, there is a poor understanding of these deficits in terms of their developmental trajectory and underlying mechanisms. In a well-characterized murine model of pediatric brain injury, we recently demonstrated that pronounced deficits in social interactions emerge across maturation to adulthood after injury at postnatal day (p) 21, approximating a toddler-aged child. Extending these findings, we here hypothesized that these social deficits are dependent upon brain maturation at the time of injury, and coincide with abnormal sociosexual behaviors and communication. Age-dependent vulnerability of the developing brain to social deficits was addressed by comparing behavioral and neuroanatomical outcomes in mice injured at either a pediatric age (p21) or during adolescence (p35). Sociosexual behaviors including social investigation and mounting were evaluated in a resident-intruder paradigm at adulthood. These outcomes were complemented by assays of urine scent marking and ultrasonic vocalizations as indices of social communication. We provide evidence of sociosexual deficits after brain injury at p21, which manifest as reduced mounting behavior and scent marking towards an unfamiliar female at adulthood. In contrast, with the exception of the loss of social recognition in a three-chamber social approach task, mice that received TBI at adolescence were remarkably resilient to social deficits at adulthood. Increased emission of ultrasonic vocalizations (USVs) as well as preferential emission of high frequency USVs after injury was dependent upon both the stimulus and prior social experience. Contrary to the hypothesis that changes in white matter volume may underlie social dysfunction, injury at both p21 and p35 resulted in a similar degree of atrophy of the corpus callosum by adulthood. However, loss of hippocampal tissue was greater after p21 compared to p35 injury, suggesting that a longer period of lesion progression or differences in the kinetics of secondary pathogenesis after p21 injury may contribute to observed behavioral differences. Together, these findings indicate vulnerability of the developing brain to social dysfunction, and suggest that a younger age-at-insult results in poorer social and sociosexual outcomes.	[Semple, Bridgette D.; Noble-Haeusslein, Linda J.; Sam, Pingdewinde N.; Gimlin, Kayleen] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Semple, Bridgette D.] Univ Melbourne, Dept Med, Melbourne Brain Ctr, Royal Melbourne Hosp, Parkville, Vic 3052, Australia; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil, San Francisco, CA 94143 USA; [Kwon, Yong Jun; Gibson, A. Matt; Grissom, Sarah; Brown, Sienna; Adahman, Zahra; Hollingsworth, Christopher A.; Kwakye, Alexander; Schenk, A. Katrin] Randolph Coll, Dept Phys, Lynchburg, VA USA; [Sam, Pingdewinde N.] San Francisco State Univ, San Francisco, CA 94132 USA; [Wilde, Elisabeth A.; Hanten, Gerri; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hanten, Gerri; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA		Semple, BD (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	Bridgette.Semple@ucsf.edu	Tercovich, Kayleen/I-8941-2018	Tercovich, Kayleen/0000-0003-0450-8912; Adahman, Zahra/0000-0001-6306-6486	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159, NS077767]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1052505]; Randolph College start-up funds; Division Of Human Resource DevelopmentNational Science Foundation (NSF)NSF- Directorate for Education & Human Resources (EHR) [1302873] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T34GM008574, R25GM059298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159, R01NS077767] Funding Source: NIH RePORTER	Funding was provided by National Institutes of Health/National Institute of Neurological Disorders and Stroke (http://www.ninds.nih.gov/), R01 #NS050159 and #NS077767 (awarded to LJNH), a CJ Martin Overseas Biomedical Postdoctoral Fellowship from the National Health and Medical Research Council of Australia (https://www.nhmrc.gov.au/) #1052505(awarded to BDS), and Randolph College start-up funds (AKS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acerini CL, 2007, PITUITARY, V10, P373, DOI 10.1007/s11102-007-0052-8; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Arakawa H, 2008, BEHAV BRAIN RES, V190, P97, DOI 10.1016/j.bbr.2008.02.009; Arakawa H, 2007, BEHAV BRAIN RES, V182, P73, DOI 10.1016/j.bbr.2007.05.007; Arriaga G, 2013, BRAIN LANG, V124, P96, DOI 10.1016/j.bandl.2012.10.002; BEAN NJ, 1982, PHYSIOL BEHAV, V28, P31, DOI 10.1016/0031-9384(82)90097-X; BEAN NJ, 1981, BRAIN RES BULL, V6, P109, DOI 10.1016/S0361-9230(81)80033-0; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Bigler ED, 2013, NEUROREHABILITATION, V32, P707, DOI 10.3233/NRE-130896; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Bruell JH, 2006, ANN NY ACAD SCI, V159, P825; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chabout J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029401; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chen CY, 2013, DEV NEUROSCI-BASEL, V35, P474, DOI 10.1159/000355874; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; Crawley JN, 2007, BRAIN PATHOL, V17, P448, DOI 10.1111/j.1750-3639.2007.00096.x; Didus E, 1999, Pediatr Rehabil, V3, P177; Downing MG, 2013, J HEAD TRAUMA REHAB, V28, P171, DOI 10.1097/HTR.0b013e31828b4f63; Duvoisin RM, 2011, BEHAV BRAIN RES, V221, P50, DOI 10.1016/j.bbr.2011.02.049; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2012, INT J DEV NEUROSCI, V30, P247, DOI 10.1016/j.ijdevneu.2011.07.004; Fairless AH, 2012, BEHAV BRAIN RES, V228, P299, DOI 10.1016/j.bbr.2011.12.001; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Fischer J, 2011, GENES BRAIN BEHAV, V10, P17, DOI 10.1111/j.1601-183X.2010.00610.x; Frith CD, 2007, PHILOS T R SOC B, V362, P671, DOI 10.1098/rstb.2006.2003; Fyrberg A, 2007, INT J REHABIL RES, V30, P153; GEYER LA, 1978, J COMP PHYSIOL PSYCH, V92, P447, DOI 10.1037/h0077487; Giannantoni A, 2011, ARCH PHYS MED REHAB, V92, P1134, DOI 10.1016/j.apmr.2011.02.013; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; Hammerschmidt K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041133; Hanson JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040782; Heyes SB, 2012, DEV SOCIAL NEUROSCIE, P325; Hoang TX, 2006, J NEUROSCI, V26, P8672, DOI 10.1523/JNEUROSCI.1259-06.2006; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hurst JL, 2004, BIOESSAYS, V26, P1288, DOI 10.1002/bies.20147; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Kennedy BC, 2011, BEHAV PHARMACOL, V22, P147, DOI 10.1097/FBP.0b013e328343d7dd; Kennedy Sidney H, 2008, Dialogues Clin Neurosci, V10, P271; Kim S, 2012, NMR BIOMED, V25, P104, DOI 10.1002/nbm.1722; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6; Kumar M, 2012, BRAIN RES, V1455, P56, DOI 10.1016/j.brainres.2012.03.041; Lehmann ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069822; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; MAGGIO JC, 1983, PHYSIOL BEHAV, V31, P269, DOI 10.1016/0031-9384(83)90186-5; Mahrt EJ, 2013, J NEUROSCI, V33, P5573, DOI 10.1523/JNEUROSCI.5054-12.2013; Manzo J, 2002, PHYSIOL BEHAV, V75; Matsumoto YK, 2012, NEUROREPORT, V23, P676, DOI 10.1097/WNR.0b013e3283557eea; McCall C, 2012, NAT NEUROSCI, V15, P681, DOI 10.1038/nn.3084; McDonald S., 2012, DEV SOCIAL NEUROSCIE, P325; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P528, DOI 10.1017/S1355617713000039; McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; McKinlay A, 2013, J HEAD TRAUMA REHABI; Moreau OK, 2012, J NEUROTRAUM, V29, P81, DOI 10.1089/neu.2011.2048; Moy SS, 2008, MOL PSYCHIATR, V13, P4, DOI 10.1038/sj.mp.4002082; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Musolf K, 2010, ANIM BEHAV, V79, P757, DOI 10.1016/j.anbehav.2009.12.034; NYBY J, 1976, BEHAV BIOL, V18, P285, DOI 10.1016/S0091-6773(76)92198-2; NYBY J, 1983, BEHAV NEURAL BIOL, V38, P32, DOI 10.1016/S0163-1047(83)90354-0; NYBY J, 1992, HORM BEHAV, V26, P24, DOI 10.1016/0018-506X(92)90029-U; NYBY J, 1978, NEUROSCI BIOBEHAV R, V2, P1, DOI 10.1016/0149-7634(78)90003-9; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Paul LK, 2007, NAT REV NEUROSCI, V8, P287, DOI 10.1038/nrn2107; Pobbe RLH, 2012, PHYSIOL BEHAV, V107, P641, DOI 10.1016/j.physbeh.2012.02.024; Pobbe RLH, 2012, HORM BEHAV, V61, P436, DOI 10.1016/j.yhbeh.2011.10.010; POMERANTZ SM, 1983, PHYSIOL BEHAV, V31, P91, DOI 10.1016/0031-9384(83)90101-4; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Ponsford JL, 2013, J HEAD TRAUMA REHAB, V28, P195, DOI 10.1097/HTR.0b013e31828b4f7b; Portfors CV, 2007, J AM ASSOC LAB ANIM, V46, P28; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Richmond E, 2014, ENDOCRINE, V45, P3, DOI 10.1007/s12020-013-0049-1; Rose SR, 2012, PITUITARY, V15, P267, DOI 10.1007/s11102-011-0360-x; Rosema S, 2014, J NEUROTRAUM, V13, P13; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Roullet FI, 2011, BEHAV BRAIN RES, V216; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; SALES GD, 1972, ANIM BEHAV, V20, P88, DOI 10.1016/S0003-3472(72)80177-5; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P1331, DOI 10.1016/j.apmr.2012.03.037; Scattoni ML, 2011, GENES BRAIN BEHAV, V10, P44, DOI 10.1111/j.1601-183X.2010.00623.x; Scattoni ML, 2009, NEUROSCI BIOBEHAV R, V33, P508, DOI 10.1016/j.neubiorev.2008.08.003; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Sigurdardottir S, 2013, J REHABIL MED, V45, P808, DOI 10.2340/16501977-1156; Simpson GK, 2013, J HEAD TRAUMA REHAB, V28, P202, DOI 10.1097/HTR.0b013e31828dc5ae; SIPOS ML, 1992, BEHAV NEURAL BIOL, V58, P138, DOI 10.1016/0163-1047(92)90375-E; Slifer KJ, 2009, DEV DISABIL RES REV, V15, P144, DOI 10.1002/ddrr.60; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Sullivan JR, 2010, APPL NEUROPSYCHOL, V17, P93, DOI 10.1080/09084281003708852; Terranova ML, 2005, CURR PROT TOXICOL; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; van der Kooij MA, 2012, NEUROSCI BIOBEHAV R, V36, P1763, DOI 10.1016/j.neubiorev.2011.10.006; Veenema AH, 2012, HORM BEHAV, V61, P304, DOI 10.1016/j.yhbeh.2011.12.002; Wei L, 2011, J NEUROSCI, V31, P14335, DOI 10.1523/JNEUROSCI.1333-11.2011; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; White NR, 1998, PHYSIOL BEHAV, V63, P467, DOI 10.1016/S0031-9384(97)00484-8; WHITNEY G, 1973, J COMP PHYSIOL PSYCH, V84, P445, DOI 10.1037/h0034899; Whitney G, 1979, AM ZOOL, V19; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Willott J.F, 2001, HDB MOUSE AUDITORY R; Wohr M, 2011, GENES BRAIN BEHAV, V10, P35, DOI 10.1111/j.1601-183X.2010.00582.x; Wohr M, 2013, BEHAV BRAIN RES, V251, P5, DOI 10.1016/j.bbr.2013.05.047; Wohr M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020631; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yang M, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00159; Yang M, 2012, J NEUROSCI, V32, P6525, DOI 10.1523/JNEUROSCI.6107-11.2012; Yang Mu, 2011, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0826s56; Yang M, 2009, EUR J NEUROSCI, V29, P1663, DOI 10.1111/j.1460-9568.2009.06714.x; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007; Young DM, 2010, P NATL ACAD SCI USA, V107, P11074, DOI 10.1073/pnas.1005620107	133	26	26	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2014	9	8							e103386	10.1371/journal.pone.0103386			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	AR0CG	WOS:000343231900011	25106033	Green Published, gold, Green Submitted			2022-02-06	
J	Walter, KH; Dickstein, BD; Barnes, SM; Chard, KM				Walter, Kristen H.; Dickstein, Benjamin D.; Barnes, Sean M.; Chard, Kathleen M.			Comparing Effectiveness of CPT to CPT-C Among US Veterans in an Interdisciplinary Residential PTSD/TBI Treatment Program	JOURNAL OF TRAUMATIC STRESS			English	Article							COGNITIVE-PROCESSING THERAPY; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CLINICAL-TRIAL; SCALE; VICTIMS	Cognitive processing therapy (CPT) is a leading cognitive-behavioral treatment for posttraumatic stress disorder (PTSD) and a front-line intervention according to the U.S. Department of Veterans Affairs treatment guidelines. The original CPT protocol entails the creation of a written trauma account and use of cognitive therapy. Cognitive processing therapy-cognitive therapy only (CPT-C) does not involve a written account and in a previous study resulted in faster symptom improvement and fewer dropouts than standard CPT. This study sought to replicate these findings by comparing the effectiveness of CPT to CPT-C in a sample of 86 U. S. male veterans receiving treatment in a PTSD residential program for individuals with a history of traumatic brain injury. CPT and CPT-C were delivered in a combined individual and group format as part of a comprehensive, interdisciplinary treatment program. Outcomes were self-and clinician-reported PTSD and self-reported depression symptoms. Multilevel analysis revealed no significant difference for PTSD symptoms, but did show a greater decrease in depression at posttreatment (d = 0.63) for those receiving CPT. When an experiment-wise a correction was applied, this effect did not remain significant.	[Walter, Kristen H.; Dickstein, Benjamin D.; Chard, Kathleen M.] Cincinnati VA Med Ctr, Trauma Recovery Ctr, Cincinnati, OH USA; [Barnes, Sean M.] VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Barnes, Sean M.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA; [Chard, Kathleen M.] Univ Cincinnati, Sch Med, Dept Psychiat, Cincinnati, OH USA		Walter, KH (corresponding author), Vet Med Res Fdn, 3350 La Jolla Village Dr 111-N1,Bldg 13, San Diego, CA 92161 USA.	Kristen.Walter@va.gov	Walter, Kristen H/S-1827-2019				Alvarez J, 2011, J CONSULT CLIN PSYCH, V79, P590, DOI 10.1037/a0024466; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890423349, 10.1176/appi.books.9780890423349]; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Chard K. M., 2009, COGNITIVE PROCESSING; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Chard KM, 2005, J CONSULT CLIN PSYCH, V73, P965, DOI 10.1037/0022-006X.73.5.965; First M.B., 1996, STRUCTURED CLIN INTE; Foa E.B., 2007, PROLONGED EXPOSURE T; Foa E.B., 2008, EFFECTIVE TREATMENTS; Forbes D, 2012, J ANXIETY DISORD, V26, P442, DOI 10.1016/j.janxdis.2012.01.006; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Heck RH, 2010, QUANT METH SER, P1; Hox J.J., 2002, MULTILEVEL ANAL TECH; Institute of Medicine, 2008, TREATM PTSD ASS EV; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; McCarthy E, 2011, J TRAUMA STRESS, V24, P474, DOI 10.1002/jts.20660; McIlvain SM, 2013, COGN BEHAV PRACT, V20, P375, DOI 10.1016/j.cbpra.2012.09.002; Monson C. M., 2007, COGNITIVE PROCESSING; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Shear MK, 2000, AM J PSYCHIAT, V157, P581, DOI 10.1176/appi.ajp.157.4.581; SPSS, 2008, SPSS STAT BAS 17 0 U; Suris A, 2013, J TRAUMA STRESS, V26, P28, DOI 10.1002/jts.21765; Twamley E. W., 2008, COGNITIVE SYMP UNPUB; U. S. Department of Veterans Affairs, 2010, VHA HDB; U. S. Department of Veterans Affairs & U. S. Department of Defense, 2004, VA DOD CLIN PRACT GU; United States Department of Veterans Affairs & Department of Defense, 2009, VA DOD CLIN PRACT GU; Weathers F. W., 1993, ANN M INT SOC TRAUMA; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029	32	26	26	0	21	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	AUG	2014	27	4					438	445		10.1002/jts.21934			8	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	AO2ZQ	WOS:000341198000008	25158637				2022-02-06	
J	Sahuquillo, J; Merino, MA; Sanchez-Guerrero, A; Arikan, F; Vidal-Jorge, M; Martinez-Valverde, T; Rey, A; Riveiro, M; Poca, MA				Sahuquillo, Juan; Merino, Maria-Angels; Sanchez-Guerrero, Angela; Arikan, Fuat; Vidal-Jorge, Marian; Martinez-Valverde, Tamara; Rey, Anna; Riveiro, Marilyn; Poca, Maria-Antonia			Lactate and the Lactate-to-Pyruvate Molar Ratio Cannot Be Used as Independent Biomarkers for Monitoring Brain Energetic Metabolism: A Microdialysis Study in Patients with Traumatic Brain Injuries	PLOS ONE			English	Article							SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL PERFUSION-PRESSURE; FLUID-PERCUSSION INJURY; INTRACRANIAL-PRESSURE; MITOCHONDRIAL DYSFUNCTION; NORMOBARIC HYPEROXIA; TISSUE-OXYGENATION; INSPIRED OXYGEN	Background: For decades, lactate has been considered an excellent biomarker for oxygen limitation and therefore of organ ischemia. The aim of the present study was to evaluate the frequency of increased brain lactate levels and the LP ratio (LPR) in a cohort of patients with severe or moderate traumatic brain injury (TBI) subjected to brain microdialysis monitoring to analyze the agreement between these two biomarkers and to indicate brain energy metabolism dysfunction. Methods: Forty-six patients with an admission Glasgow coma scale score of <= 13 after resuscitation admitted to a dedicated 10-bed Neurotraumatology Intensive Care Unit were included, and 5305 verified samples of good microdialysis data were analyzed. Results: Lactate levels were above 2.5 mmol/L in 56.9% of the samples. The relationships between lactate and the LPR could not be adequately modeled by any linear or non-linear model. Neither Cohen's kappa nor Gwet's statistic showed an acceptable agreement between both biomarkers to classify the samples in regard to normal or abnormal metabolism. The dataset was divided into four patterns defined by the lactate concentrations and the LPR. A potential interpretation for these patterns is suggested and discussed. Pattern 4 (low pyruvate levels) was found in 10.7% of the samples and was characterized by a significantly low concentration of brain glucose compared with the other groups. Conclusions: Our study shows that metabolic abnormalities are frequent in the macroscopically normal brain in patients with traumatic brain injuries and a very poor agreement between lactate and the LPR when classifying metabolism. The concentration of lactate in the dialysates must be interpreted while taking into consideration the LPR to distinguish between anaerobic metabolism and aerobic hyperglycolysis.	[Sahuquillo, Juan; Arikan, Fuat; Poca, Maria-Antonia] Univ Autonoma Barcelona, Dept Neurosurg, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Sahuquillo, Juan; Merino, Maria-Angels; Sanchez-Guerrero, Angela; Arikan, Fuat; Vidal-Jorge, Marian; Martinez-Valverde, Tamara; Riveiro, Marilyn; Poca, Maria-Antonia] Univ Autonoma Barcelona, Neurotraumatol & Neurosurg Res Unit UNINN, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Rey, Anna; Riveiro, Marilyn] Univ Autonoma Barcelona, Neurotraumatol Intens Care Unit, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain		Sahuquillo, J (corresponding author), Univ Autonoma Barcelona, Dept Neurosurg, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain.	sahuquillo@neurotrauma.net	Sahuquillo, Juan/B-3577-2008; Perez, Anna Rey/AAF-8420-2019; Vidal-Jorge, Marian/D-4402-2017; Riveiro, Marilyn/S-5242-2016; Poca, Maria A./B-8475-2008; Arikan, Fuat/F-8900-2016	Sahuquillo, Juan/0000-0003-0713-5875; Perez, Anna Rey/0000-0001-6014-3829; Vidal-Jorge, Marian/0000-0002-3459-9336; Riveiro, Marilyn/0000-0002-1645-3720; Poca, Maria A./0000-0002-3831-0536; Arikan, Fuat/0000-0002-9459-0915	Fondo de Investigacion Sanitaria (Instituto de Salud Carlos III)Instituto de Salud Carlos III; European Regional Development FundEuropean Commission [PI10/00302, PI11/00700]; Fundacion Mutua MadrilenaInstituto de Salud Carlos III [FMM-2010-10]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [FI12/00074, FI11/00195]	This study has been supported by the Fondo de Investigacion Sanitaria (Instituto de Salud Carlos III-http://www.isciii.es/) with grants PI10/00302 and PI11/00700, which were co-financed by the European Regional Development Fund and awarded to MP and JS, respectively. This work has also been partially supported by the Fundacion Mutua Madrilena (http://www.fundacionmutua.es/) with grant FMM-2010-10 given to JS. AS and TM are the recipients of two pre-doctoral grants from the Instituto de Salud Carlos III (grants number FI12/00074 and FI11/00195, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Debray FG, 2007, CLIN CHEM, V53, P916, DOI 10.1373/clinchem.2006.081166; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Fox J., 2019, R COMPANION APPL REG, V3 rd; Gerdle B, 2010, J REHABIL MED, V42, P679, DOI 10.2340/16501977-0581; Gladden LB, 2001, P NATL ACAD SCI USA, V98, P395, DOI 10.1073/pnas.98.2.395; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Horn T, 2010, NEUROCHEM INT, V57, P940, DOI 10.1016/j.neuint.2010.09.014; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Jones AE, 2010, JAMA-J AM MED ASSOC, V303, P739, DOI 10.1001/jama.2010.158; Leen WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042745; Lourido J, 2002, SCAND J CLIN LAB INV, V62, P285, DOI 10.1080/003655102760145843; Mader JK, 2012, DIABETES RES CLIN PR, V97, P112, DOI 10.1016/j.diabres.2012.02.010; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marmarou A, 2005, ACT NEUR S, V95, P149; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Massabuau JC, 2001, RESP PHYSIOL, V128, P249, DOI 10.1016/S0034-5687(01)00305-X; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Merino MA, 2010, NEUROCIRUGIA, V21, P289; Nelson DW, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-21; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P229, DOI 10.1111/j.1399-6576.2012.02783.x; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Poca MA, 2002, J NEUROTRAUM, V19, P439, DOI 10.1089/08977150252932398; Poca MA, 2006, J NEUROTRAUM, V23, P1510, DOI 10.1089/neu.2006.23.1510; R Core Team, 2013, LANGUAGE ENV STAT CO, DOI DOI 11/44679/INDEX.HTM; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rieger A, 1997, NEUROSURGERY, V41, P462, DOI 10.1097/00006123-199708000-00027; RStudio, 2013, RSTUDIO INT DEV ENV; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Sahuquillo J, 1994, INTRACRANIAL PRESSUR, P48; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sanchez Jose J, 2013, Acta Neurochir Suppl, V118, P223, DOI 10.1007/978-3-7091-1434-6_42; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; SIGGAARDANDERSEN O, 1995, CRIT CARE MED, V23, P1284, DOI 10.1097/00003246-199507000-00020; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; Suistomaa M, 2000, SHOCK, V14, P8, DOI 10.1097/00024382-200014010-00002; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Viera AJ, 2005, FAM MED, V37, P360; Vilalta A, 2011, J NEUROTRAUM, V28, P1139, DOI 10.1089/neu.2010.1720; Wacharasint P, 2012, SHOCK, V38, P4, DOI 10.1097/SHK.0b013e318254d41a; WASSERMAN K, 1964, AM J CARDIOL, V14, P844, DOI 10.1016/0002-9149(64)90012-8; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989; Wongpakaran N, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-61; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	59	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2014	9	7							e102540	10.1371/journal.pone.0102540			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6RN	WOS:000339992400085		Green Published, Green Submitted, gold			2022-02-06	
J	Almolda, B; Villacampa, N; Manders, P; Hidalgo, J; Campbell, IL; Gonzalez, B; Castellano, B				Almolda, Beatriz; Villacampa, Nadia; Manders, Peter; Hidalgo, Juan; Campbell, Iain L.; Gonzalez, Berta; Castellano, Bernardo			Effects of astrocyte-targeted production of interleukin-6 in the mouse on the host response to nerve injury	GLIA			English	Article						lymphocytes; microglia; facial nerve axotomy; osteopontin; CD44; transgenic animal	FACIAL MOTOR NUCLEUS; APPEARING WHITE-MATTER; SPINAL-CORD-INJURY; OSTEOPONTIN EXPRESSION; TRANSGENIC MICE; UP-REGULATION; IN-VIVO; MEDIATED NEUROPROTECTION; MACROPHAGE INFILTRATION; LYMPHOCYTE RECRUITMENT	Interleukin-6 (IL-6) is a pleiotropic cytokine with a key role in the control of inflammatory/immune responses. In the central nervous system (CNS), an increase in IL-6 occurs in a wide range of pathological conditions such as excitotoxicity and traumatic brain injury. We evaluated the effects of astrocyte-targeted production of IL-6 in the CNS in the sterile-nerve injury model of facial nerve axotomy. To accomplish this, facial nerve transection was performed in transgenic mice (glial fibrillary acidic protein [GFAP]-IL6Tg) with IL-6 production under the GFAP promoter. Neuronal death, glial activation, lymphocyte recruitment, and integrin expression were evaluated by immunohistochemistry and flow cytometry from 3 to 28 days postinjury. Our findings revealed an increase in motor neuron cell death in GFAP-IL6Tg mice correlating with changes in the microglial activation pattern, characterized principally by less attachment to neurons and reduced expression of both CD11b and CD18. We also found a higher CD4(+) T-lymphocyte recruitment in GFAP-IL6Tg mice. In addition, changes in the expression pattern of different integrins and their receptors were observed in transgenic animals. Specifically, alterations in osteopontin expression in motor neurons and its receptors CD44 and CD49e in lymphocytes and microglia, respectively, which may account for the variations related to glial reactivity and lymphocyte infiltration. In conclusion, our results indicated that forced local production of IL-6 has a direct impact on the outcome of nerve injury in the CNS inducing an increase in neurodegeneration, changes in glial response, and lymphocyte recruitment as well as in the expression of different integrins and their receptors. GLIA 2014;62:1142-1161	[Almolda, Beatriz; Villacampa, Nadia; Hidalgo, Juan; Gonzalez, Berta; Castellano, Bernardo] Univ Autonoma Barcelona, Inst Neurosci, Dept Cell Biol Physiol & Immunol, Bellaterra 08193, Spain; [Manders, Peter; Campbell, Iain L.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia		Almolda, B (corresponding author), Univ Autonoma Barcelona, Unitat Histol, Torre M5, Bellaterra 08193, Spain.	beatriz.almolda@uab.cat	Almolda, Beatriz/L-6920-2014; Hidalgo, Juan/C-9082-2011; Castellano, Bernardo/G-1428-2010; Villacampa, Dr Nadia/K-5304-2014; Gonzalez, Berta/G-1428-2010	Almolda, Beatriz/0000-0001-6631-4385; Hidalgo, Juan/0000-0003-0921-1122; Castellano, Bernardo/0000-0003-1976-971X; Villacampa, Dr Nadia/0000-0001-6513-0250; Gonzalez, Berta/0000-0002-1860-3980	Spanish Ministry of Science and InnovationSpanish Government [BFU2011-27400]; SAF [2008-00435, 2011-23272]; NHMRC projectNational Health and Medical Research Council of Australia [632754]	Grant sponsor: Spanish Ministry of Science and Innovation; Grant numbers: BFU2011-27400 (to BC); Grant sponsor: SAF; Grant numbers: 2008-00435 and 2011-23272 (to JH); Grant sponsor: NHMRC project; Grant number: 632754 (to ILC).	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Almolda Beatriz, 2013, Methods Mol Biol, V1041, P243, DOI 10.1007/978-1-62703-520-0_22; Almolda B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027473; Almolda B, 2010, J NEUROIMMUNOL, V223, P39, DOI 10.1016/j.jneuroim.2010.03.021; Almolda B, 2009, J NEUROIMMUNOL, V209, P65, DOI 10.1016/j.jneuroim.2009.01.026; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Borges K, 2008, EPILEPSIA, V49, P1675, DOI 10.1111/j.1528-1167.2008.01613.x; Brunello AG, 2000, AM J PATHOL, V157, P1485, DOI 10.1016/S0002-9440(10)64787-6; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cao ZX, 2006, J NEUROSCI, V26, P5565, DOI 10.1523/JNEUROSCI.0815-06.2006; Carecchio M, 2011, J ALZHEIMERS DIS, V25, P179, DOI 10.3233/JAD-2011-102151; CASTELLANO B, 1991, J COMP NEUROL, V311, P434, DOI 10.1002/cne.903110312; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Choi JS, 2007, BRAIN RES, V1151, P195, DOI 10.1016/j.brainres.2007.03.016; Conroy SM, 2004, J NEUROIMMUNOL, V155, P43, DOI 10.1016/j.jneuroim.2004.06.014; Dauer DJ, 2011, BRAIN BEHAV IMMUN, V25, P77, DOI 10.1016/j.bbi.2010.08.005; Deboy CA, 2006, EXP NEUROL, V201, P212, DOI 10.1016/j.expneurol.2006.04.028; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Fisher J, 2001, J NEUROIMMUNOL, V119, P1, DOI 10.1016/S0165-5728(01)00342-3; Fu YF, 2004, ACTA NEUROPATHOL, V107, P8, DOI 10.1007/s00401-003-0775-1; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; Giachelli CM, 1998, AM J PATHOL, V152, P353; Giralt M, 2013, GLIA, V61, P587, DOI 10.1002/glia.22457; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Ha GK, 2006, J NEUROIMMUNOL, V172, P1, DOI 10.1016/j.jneuroim.2005.10.012; Ha GK, 2008, J NEUROIMMUNOL, V199, P18, DOI 10.1016/j.jneuroim.2008.04.027; Hao HP, 2007, J NEUROSCI RES, V85, P2196, DOI 10.1002/jnr.21357; Hashimoto M, 2003, J NEUROTRAUM, V20, P287, DOI 10.1089/089771503321532879; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Iczkiewicz J, 2005, EUR J NEUROSCI, V21, P1911, DOI 10.1111/j.1460-9568.2005.04009.x; Ikeda K, 1996, J NEUROL SCI, V135, P109, DOI 10.1016/0022-510X(95)00263-2; Jin JK, 2006, BRAIN RES, V1072, P227, DOI 10.1016/j.brainres.2005.12.013; Jones KJ, 2005, BRAIN BEHAV IMMUN, V19, P12, DOI 10.1016/j.bbi.2004.05.004; Jones LL, 1997, EUR J NEUROSCI, V9, P1854, DOI 10.1111/j.1460-9568.1997.tb00752.x; Kalla R, 2001, J COMP NEUROL, V436, P182; Kazanecki CC, 2007, J CELL BIOCHEM, V102, P912, DOI 10.1002/jcb.21558; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim SY, 2002, MOL CELLS, V13, P429; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Krady JK, 2008, J NEUROSCI RES, V86, P1538, DOI 10.1002/jnr.21620; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Lee JY, 2010, ACTA NEUROBIOL EXP, V70, P1; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; Makwana M, 2010, J COMP NEUROL, V518, P699, DOI 10.1002/cne.22240; Milner R, 2006, MOL CELL NEUROSCI, V33, P429, DOI 10.1016/j.mcn.2006.09.004; Moran LB, 2004, BRAIN RES REV, V44, P154, DOI 10.1016/j.brainresrev.2003.11.004; Mukaino M, 2010, EXP NEUROL, V224, P403, DOI 10.1016/j.expneurol.2010.04.020; MURABE Y, 1981, CELL TISSUE RES, V216, P557, DOI 10.1007/BF00238651; Murphy PG, 1999, J NEUROSCI, V19, P3791; Nakamura M, 2005, CLIN REV ALLERG IMMU, V28, P197, DOI 10.1385/CRIAI:28:3:197; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Pekny M, 2014, NEUROSCI LETT S, VS0304-3940, DOI 00008-00001; Petito CK, 2003, J NEUROVIROL, V9, P36, DOI 10.1080/13550280390173391; Quintana A, 2013, BRAIN BEHAV IMMUN, V27, P162, DOI 10.1016/j.bbi.2012.10.011; Quintana A, 2009, J IMMUNOL, V183, P2079, DOI 10.4049/jimmunol.0900242; Raivich G, 1998, J NEUROSCI, V18, P5804; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Sander LE, 2008, J IMMUNOL, V181, P3586, DOI 10.4049/jimmunol.181.5.3586; Selvaraju R, 2004, MOL CELL NEUROSCI, V25, P707, DOI 10.1016/j.mcn.2003.12.014; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.3.CO;2-3; Serpe CJ, 1999, J NEUROSCI, V19; Shin SL, 1999, NEUROSCI LETT, V273, P73, DOI 10.1016/S0304-3940(99)00516-9; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Shin T, 2004, NEUROSCI LETT, V356, P72, DOI 10.1016/j.neulet.2003.11.023; Sinclair C, 2005, NEUROPATH APPL NEURO, V31, P292, DOI 10.1111/j.1365-2990.2004.00638.x; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Stanke M, 2006, DEVELOPMENT, V133, P141, DOI 10.1242/dev.02189; Suzuki S, 2009, J CEREBR BLOOD F MET, V29, P464, DOI 10.1038/jcbfm.2008.141; Suzuki T, 2012, CELL MOL NEUROBIOL, V32, P1265, DOI 10.1007/s10571-012-9851-1; SVENSSON M, 1993, EXP NEUROL, V120, P123, DOI 10.1006/exnr.1993.1046; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tilgner J, 2001, GLIA, V35, P234, DOI 10.1002/glia.1088; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; van Horssen J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-156; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Villacampa Nadia, 2013, Methods Mol Biol, V1041, P261, DOI 10.1007/978-1-62703-520-0_23; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Werner A, 1998, J NEUROCYTOL, V27, P219, DOI 10.1023/A:1006928830251; Wung JK, 2007, CURR ALZHEIMER RES, V4, P67, DOI 10.2174/156720507779939869; Zhong J, 1999, J NEUROSCI, V19, P4305	94	26	28	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2014	62	7					1142	1161		10.1002/glia.22668			20	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AH3DF	WOS:000336001100010	24691898				2022-02-06	
J	Gouveia, TLF; Scorza, FA; Iha, HA; Frangiotti, MIB; Perosa, SR; Cavalheiro, EA; Silva, JA; Feliciano, RS; de Almeida, AC; Naffah-Mazzacoratti, MG				Gouveia, T. L. F.; Scorza, F. A.; Iha, H. A.; Frangiotti, M. I. B.; Perosa, S. R.; Cavalheiro, E. A.; Silva, J. A., Jr.; Feliciano, R. S.; de Almeida, A. C.; Naffah-Mazzacoratti, M. G.			Lovastatin decreases the synthesis of inflammatory mediators during epileptogenesis in the hippocampus of rats submitted to pilocarpine-induced epilepsy	EPILEPSY & BEHAVIOR			English	Article						Lovastatin; Pilocarpine; Epileptogenesis; Cytokines; Temporal lobe epilepsy	TEMPORAL-LOBE EPILEPSY; TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; STATUS-EPILEPTICUS; KININ B1; REDUCTASE INHIBITORS; NEURONAL DEATH; B2 RECEPTORS; CELL-DEATH	Statins may act on inflammatory responses, decreasing oxidative stress and also reducing brain inflammation in several brain disorders. Epileptogenesis is a process in which a healthy brain becomes abnormal and predisposed to generating spontaneous seizures. We previously reported that lovastatin could prevent neuroinflammation in pilocarpine-induced status epilepticus (SE). In this context, this study investigated the long-lasting effects of lovastatin on mRNA expression of proinflammatoty cytokines (interleukin-1 beta, tumor necrosis factor alpha, interleukin-6) and the antiinflammatoty cytokine IL-10 in the hippocampus during epileptogenesis by immunohistochemistry and real time polymerase chain reaction (RT-PCR) during the latent and chronic phases in the epilepsy model induced by pilocarpine in rats. For these purposes, four groups of rats were employed: saline (CONTROL), lovastatin (LOVA), pilocarpine (PILO), and pilocarpine plus lovastatin (PILO + LOVA). After pilocarpine injection (350 mg/kg, i.p.), the rats were treated with 20 mg/kg of lovastatin via an esophagic probe 2 h after SE onset All surviving rats were continuously treated during 15 days, twice/day. The pilocarpine plus lovastatin group showed a significant decrease in the levels of IL-1 beta, TNF-alpha, and IL-6 during the latent phase and a decreased expression of IL-1 beta and TNF-alpha in the chronic phase when compared with the PILO group. Moreover, lovastatin treatment also induced an increased expression of the antiinflammatory cytokine, IL-10, in the PILO + LOVA group when compared with the PILO group in the chronic phase. Thus, our data suggest that lovastin may reduce excitotoxicity during epileptogenesis induced by pilocarpine by increasing the synthesis of IL-10 and decreasing proinflammatory cytokines in the hippocampus. (C) 2014 Elsevier Inc All rights reserved.	[Gouveia, T. L. F.; Scorza, F. A.; Iha, H. A.; Frangiotti, M. I. B.; Perosa, S. R.; Cavalheiro, E. A.; Naffah-Mazzacoratti, M. G.] Univ Fed Sao Paulo UNIFESP, Dept Neurol & Neurosurg, Sao Paulo, Brazil; [Silva, J. A., Jr.; Feliciano, R. S.] Univ Nave Julho, Rehabil Dept, Sao Paulo, Brazil; [de Almeida, A. C.] Univ Fed Sao Joao del Rei, Dept Biomed Engn, Sao Joao Del Rei, Brazil; [Naffah-Mazzacoratti, M. G.] Univ Fed Sao Paulo UNIFESP, Dept Biochem, Sao Paulo, Brazil		Naffah-Mazzacoratti, MG (corresponding author), Rua Pedro de Toledo 669,04039-032 Vila Clementino, Sao Paulo, Brazil.	naffahmazz.nexp@epm.br	ALMEIDA, ANTONIO-CARLOS G/B-8028-2008; Cavalheiro, Esper A/I-3084-2016; Cavalheiro, Esper A/F-4325-2014; Scorza, Carla Alessandra/C-4199-2013; Cavalheiro, Esper/N-3985-2019; Silva, Jose Antonio/AAA-8100-2019; da Graca Naffah Mazzacoratti, Maria/N-9934-2014; Scorza, Fulvio/C-7048-2013	ALMEIDA, ANTONIO-CARLOS G/0000-0003-4893-338X; Cavalheiro, Esper A/0000-0002-0854-3582; Cavalheiro, Esper A/0000-0002-0854-3582; Scorza, Carla Alessandra/0000-0001-7810-4748; Cavalheiro, Esper/0000-0002-0854-3582; Silva, Jose Antonio/0000-0001-6904-9185; da Graca Naffah Mazzacoratti, Maria/0000-0002-3468-360X; Scorza, Fulvio/0000-0002-0694-8674; Iha, Higor/0000-0002-7034-6678	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Ministerio da Ciencia e Tecnologia, Instituto Nacional de Neurociencia Translacional (INNT); Cooperacao Interinstitucional de Apoio a Pesquisa sobre o Cerebro (CInAPCe), Brazil	This research was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Ministerio da Ciencia e Tecnologia, Instituto Nacional de Neurociencia Translacional (INNT), and Cooperacao Interinstitucional de Apoio a Pesquisa sobre o Cerebro (CInAPCe), Brazil.	Agnello D, 2000, BRAIN RES, V869, P241, DOI 10.1016/S0006-8993(00)02392-1; Arganaraz GA, 2004, BRAIN RES, V1013, P30, DOI 10.1016/j.brainres.2004.03.046; Arganaraz GA, 2004, BRAIN RES, V1006, P114, DOI 10.1016/j.brainres.2003.12.050; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; Chen CP, 2005, DRUG METAB DISPOS, V33, P537, DOI 10.1124/dmd.104.002477; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Choi H, 2008, JAMA-J AM MED ASSOC, V300, P2497, DOI 10.1001/jama.2008.771; Cimino M, 2007, NEUROSCIENTIST, V13, P208, DOI 10.1177/1073858406297121; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; Dolga AM, 2008, J ALZHEIMERS DIS, V13, P111; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Gouveia TLF, 2011, EPILEPSY BEHAV, V20, P1, DOI 10.1016/j.yebeh.2010.10.001; Ginsberg HN, 1998, AM J CARDIOL, V81, p32B, DOI 10.1016/S0002-9149(98)00035-6; Griffin JL, 2006, PHARMACOGENOMICS, V7, P1095, DOI 10.2217/14622416.7.7.1095; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Hering H, 2003, J NEUROSCI, V23, P3262; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; Li G, 2007, NEUROLOGY, V69, P878, DOI 10.1212/01.wnl.0000277657.95487.1c; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; McTaggart F, 2001, AM J CARDIOL, V87, p28B; Neuhaus O, 2004, LANCET NEUROL, V3, P369, DOI 10.1016/S1474-4422(04)00770-7; Pahan K, 2000, J NEUROCHEM, V75, P576, DOI 10.1046/j.1471-4159.2000.0750576.x; Perosa SR, 2007, HIPPOCAMPUS, V17, P26, DOI 10.1002/hipo.20239; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Ravizza T, 2006, NEUROSCIENCE, V137, P301, DOI 10.1016/j.neuroscience.2005.07.063; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; Sewnath ME, 2001, J IMMUNOL, V166, P6323, DOI 10.4049/jimmunol.166.10.6323; Silva JA, 2008, INT IMMUNOPHARMACOL, V8, P197, DOI 10.1016/j.intimp.2007.09.003; Strle K, 2002, J NEUROIMMUNOL, V122, P9, DOI 10.1016/S0165-5728(01)00444-1; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Varella PPV, 2011, ARQ NEURO-PSIQUIAT, V69, P91, DOI 10.1590/S0004-282X2011000100018; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Wang Y, 2010, APOPTOSIS, V15, P1382, DOI 10.1007/s10495-010-0481-0; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	42	26	32	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	JUL	2014	36						68	73		10.1016/j.yebeh.2014.04.009			6	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	AL4WW	WOS:000339136500014	24857811				2022-02-06	
J	Zupan, B; Neumann, D				Zupan, Barbra; Neumann, Dawn			Affect Recognition in Traumatic Brain Injury: Responses to Unimodal and Multimodal Media	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						affect recognition; media; multimodal; traumatic brain injury; unimodal	FACIAL AFFECT RECOGNITION; EMOTION RECOGNITION; HEAD-INJURY; PERCEPTION; EXPRESSION; COMMUNICATION; DEFICITS; FACES; COMPREHENSION; IMPAIRMENTS	Objectives: To compare affect recognition by people with and without traumatic brain injury (TBI) for (1) unimodal and context-enriched multimodal media; (2) positive (happy) and negative emotions; and (3) neutral multimodal stimuli. Participants: A total of 60 people with moderate to severe TBI and 60 matched controls. Measures: (1) facial affect, (2) vocal affect, and (3) multimodal affect. Results: Compared with controls, people with TBI scored significantly lower on both unimodal measures but not on the multimodal measure. Within-group comparisons for people with TBI revealed that they were better at recognizing affect from multimodal than unimodal stimuli. As a group, participants with TBI who were categorized as having impaired facial/vocal affect recognition were less accurate at recognizing all emotions, including happy, than unimpaired participants. Neutral stimuli were more poorly identified by participants with TBI than by those with controls. Conclusion: Context-enriched multimodal stimuli may enhance affect recognition for people with TBI. People with TBI who have impaired affect recognition may have problems identifying both positive (happy) and negative expressions. Furthermore, people with TBI may perceive affect when there is none.	[Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada; [Neumann, Dawn] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indiana, PA USA; [Neumann, Dawn] Rehabil Hosp Indiana, Indiana, PA USA		Zupan, B (corresponding author), Brock Univ, Dept Appl Linguist, 500 Glenridge Ave, St Catharines, ON L2S 3A1, Canada.	bzupan@brocku.ca		Barbra, Zupan/0000-0002-4603-333X	Humanities Research Institute at Brock University in St. Catharines, Ontario; Cannon Research Center at Carolinas Rehabilitation in Charlotte, North Carolina	This work was funded through the Humanities Research Institute at Brock University in St. Catharines, Ontario, and by the Cannon Research Center at Carolinas Rehabilitation in Charlotte, North Carolina.	Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Biele C, 2006, EXP BRAIN RES, V171, P1, DOI 10.1007/s00221-005-0254-0; Busselle R, 2008, COMMUN THEOR, V18, P255, DOI 10.1111/j.1468-2885.2008.00322.x; CARRERALEVILLAIN P, 1994, J NONVERBAL BEHAV, V18, P281, DOI 10.1007/BF02172290; Collignon O, 2008, BRAIN RES, V1242, P126, DOI 10.1016/j.brainres.2008.04.023; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Cunningham DW, 2009, J VISION, V9, DOI 10.1167/9.13.7; Dimoska A, 2010, J INT NEUROPSYCH SOC, V16, P369, DOI 10.1017/S1355617709991445; Dobel C, 2008, PSYCHOL RES-PSYCH FO, V72, P580, DOI 10.1007/s00426-007-0132-4; Duke M.P., 2008, MANUAL RECEPTIVE TES; Ekman P., 1976, PICTURES FACIAL AFFE; Frank MG, 2001, J PERS SOC PSYCHOL, V80, P75, DOI 10.1037/0022-3514.80.1.75; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; GROSS JJ, 1995, COGNITION EMOTION, V9, P87, DOI 10.1080/02699939508408966; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Koelsch S, 2006, HUM BRAIN MAPP, V27, P239, DOI 10.1002/hbm.20180; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; LaBar KS, 2003, CEREB CORTEX, V13, P1023, DOI 10.1093/cercor/13.10.1023; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; Mayes AK, 2009, BRAIN TOPOGR, V22, P145, DOI 10.1007/s10548-009-0106-5; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S., 2002, AWARENESS SOCIAL INF; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Neumann D, 2013, J HEAD TRAUMA REHABI; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Rottenberg J., 2007, HDB EMOTION ELICITAT; RUSSELL JA, 1994, PSYCHOL BULL, V115, P102, DOI 10.1037/0033-2909.115.1.102; Scherer KR, 2003, SPEECH COMMUN, V40, P227, DOI 10.1016/S0167-6393(02)00084-5; Schultz J, 2009, EXP BRAIN RES, V194, P465, DOI 10.1007/s00221-009-1721-9; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Walbott HG, 1986, J PERS SOC PSYCHOL, V51, P690; WIERZBICKA A, 1992, COGNITIVE SCI, V16, P539, DOI 10.1207/s15516709cog1604_4; Wild-Wall N, 2008, BIOL PSYCHOL, V77, P138, DOI 10.1016/j.biopsycho.2007.10.001; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; Zagalo N., 2004, P ACM WORKSH STOR RE; Zupan B, 2009, J COMMUN DISORD, V42, P1, DOI 10.1016/j.jcomdis.2008.06.001	44	26	26	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					E1	E12		10.1097/HTR.0b013e31829dded6			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300001	23982789				2022-02-06	
J	George, EO; Roys, S; Sours, C; Rosenberg, J; Zhuo, JC; Shanmuganathan, K; Gullapalli, RP				George, Elijah O.; Roys, Steve; Sours, Chandler; Rosenberg, Joseph; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			Longitudinal and Prognostic Evaluation of Mild Traumatic Brain Injury: A 1H-Magnetic Resonance Spectroscopy Study	JOURNAL OF NEUROTRAUMA			English	Article						longitudinal study; magnetic resonance spectroscopy; mTBI; neuropsychological tests	PROTON-MAGNETIC-RESONANCE; DIFFUSE AXONAL INJURY; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; POSTTRAUMATIC-STRESS-DISORDER; APPEARING WHITE-MATTER; N-ACETYL-ASPARTATE; MITOCHONDRIAL DYSFUNCTION; MR SPECTROSCOPY; METABOLIC-CHANGES; HEAD-INJURY	In the majority of patients with mild traumatic brain injury (mTBI), brain tissue impairment is undetectable by computed tomography and/or structural magnetic resonance imaging. Even in confirmed cases of head injury, conventional neuroimaging methods lack sensitivity in predicting neuropsychological outcomes of patients. The objectives of this study were to (1) cross-sectionally determine deviations in the neurometabolic profile of patients with mTBI from healthy controls at different stages of mTBI using tightly controlled examination windows, and (2) determine associations between acute neurometabolic markers of mTBI and chronic neurocognitive performance. Patients were examined at the early subacute (n = 43; 5.44 +/- 3.15 days post-injury (DPI)), late subacute (n = 33; 37.00 +/- 12.26 DPI) and chronic (n = 27; 195.30 +/- 19.60 DPI) stages of mTBI. Twenty-one neurologically intact subjects were used as controls. Proton magnetic resonance spectroscopy imaging (H-1-MRSI) was used to obtain metabolic measurements from different brain regions. The Automated Neuropsychological Assessment Metrics (ANAM) was used for cognitive evaluation of patients at the chronic stage of mTBI. Measurements in the thalamus and centrum semiovale (CSV) emerged as the most indicative of injury and were used to predict neurocognitive outcome. The major findings of this study are (1) decreases in Cho/Cre (choline-to-creatine ratio) measured in the thalamus (p = 0.042) and CSV (p = 0.017) at the late subacute stage of mTBI; (2) positive associations of early subacute Cre measurements in the CSV with chronic ANAM scores measuring performance in delayed (r = 0.497, p = 0.019) and immediate (r = 0.391, p = 0.072) code substitution. These findings show that metabolic measurements in the thalamus and CSV can potentially serve as diagnostic and prognostic markers of mTBI.	[George, Elijah O.; Roys, Steve; Sours, Chandler; Rosenberg, Joseph; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [George, Elijah O.; Gullapalli, Rao P.] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA; [Sours, Chandler; Gullapalli, Rao P.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA		Gullapalli, RP (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	rgullapalli@umm.edu			US ArmyUnited States Department of Defense [W81XWH-08-1-0725, W81XWH-12-1-0098]	The authors would like to thank the Adam Cowley Shock Trauma Core team for their help with patient recruitment, George Makris for help with data acquisition, and Jacqueline Janowich for assistance with neuropsychological assessments. This study was supported by US Army awards W81XWH-08-1-0725 and W81XWH-12-1-0098.	Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Bay E, 2012, BRAIN INJURY, V26, P941, DOI 10.3109/02699052.2012.666365; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bendszus M, 2001, AM J NEURORADIOL, V22, P1926; Berman JI, 2004, J NEUROSURG, V101, P66, DOI 10.3171/jns.2004.101.1.0066; Bizzi A, 2001, AM J NEURORADIOL, V22, P1125; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Chang L, 1996, LIFE SCI, V58, P2049, DOI 10.1016/0024-3205(96)00197-X; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; DAVIE CA, 1993, LANCET, V341, P630, DOI 10.1016/0140-6736(93)90390-3; Demougeot C, 2003, J CEREBR BLOOD F MET, V23, P482, DOI 10.1097/01.WCB.0000050066.57184.60; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Durazzo TC, 2004, ALCOHOL CLIN EXP RES, V28, P1849, DOI 10.1097/01.ALC.0000148112.92525.AC; Freeman TW, 1998, MAGNET RESON MED, V40, P66, DOI 10.1002/mrm.1910400110; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; GRAHAM GD, 1993, STROKE, V24, P1891, DOI 10.1161/01.STR.24.12.1891; Greco T, 2013, J CHILD NEUROL, V28, P983, DOI 10.1177/0883073813487594; Greenfield J., 2008, GREENFIELDS NEUROPAT, V1; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Hattingen E, 2009, BRAIN, V132, P3285, DOI 10.1093/brain/awp293; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2003, MAGNET RESON MED, V50, P190, DOI 10.1002/mrm.10481; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Kamada Kyousuke, 1994, Neurologia Medico-Chirurgica, V34, P676, DOI 10.2176/nmc.34.676; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Ongur D, 2010, MAGN RESON MED, V63, P1, DOI 10.1002/mrm.22148; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Parks MH, 2002, ALCOHOL CLIN EXP RES, V26, P1368, DOI 10.1097/01.ALC.0000029598.07833.2D; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Renshaw PF, 1997, BIOL PSYCHIAT, V41, P837, DOI 10.1016/S0006-3223(96)00256-9; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; SBARRA AJ, 1959, J BIOL CHEM, V234, P1355; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Spelman JF, 2012, J GEN INTERN MED, V27, P1200, DOI 10.1007/s11606-012-2061-1; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tartaglia MC, 2002, J NEUROL, V249, P1382, DOI 10.1007/s00415-002-0846-6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toblin RL, 2012, J AFFECT DISORDERS, V136, P469, DOI 10.1016/j.jad.2011.10.048; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wu A, 2013, NEUROSCIENCE, V248, P655, DOI 10.1016/j.neuroscience.2013.06.041; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	88	26	28	2	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2014	31	11					1018	1028		10.1089/neu.2013.3224			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AJ7RS	WOS:000337895300004	24467391				2022-02-06	
